PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Gaynor, JW; Kim, DS; Arrington, CB; Atz, AM; Bellinger, DC; Burt, AA; Ghanayem, NS; Jacobs, JP; Lee, TM; Lewis, AB; Mahle, WT; Marino, BS; Miller, SG; Newburger, JW; Pizarro, C; Ravishankar, C; Santani, AB; Wilder, NS; Jarvik, GP; Mital, S; Russell, MW				Gaynor, J. William; Kim, Daniel Seung; Arrington, Cammon B.; Atz, Andrew M.; Bellinger, David C.; Burt, Amber A.; Ghanayem, Nancy S.; Jacobs, Jeffery P.; Lee, Teresa M.; Lewis, Alan B.; Mahle, William T.; Marino, Bradley S.; Miller, Stephen G.; Newburger, Jane W.; Pizarro, Christian; Ravishankar, Chitra; Santani, Avni B.; Wilder, Nicole S.; Jarvik, Gail P.; Mital, Seema; Russell, Mark W.			Validation of association of the apolipoprotein E epsilon 2 allele with neurodevelopmental dysfunction after cardiac surgery in neonates and infants	JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY			English	Article							E GENOTYPE; CHILDREN; OUTCOMES; APOE; DISEASE; AGE; POPULATION	Objective: Apolipoprotein E (APOE) genotype is a determinant of neurologic recovery after brain ischemia and traumatic brain injury. The APOE epsilon 2 allele has been associated with worse neurodevelopmental (ND) outcome after repair of congenital heart defects (CHD) in infancy. Replication of this finding in an independent cohort is essential to validate the observed genotype- phenotype association. Methods: The association of APOE genotype with ND outcomes was assessed in a combined cohort of patients with single- ventricle CHD enrolled in the Single Ventricle Reconstruction and Infant Single Ventricle trials. ND outcome was assessed at 14 months using the Psychomotor Development Index (PDI) and Mental Development Index (MDI) of the Bayley Scales of Infant Development- II. Stepwise multivariable regression was performed to develop predictive models for PDI and MDI scores. Results: Complete data were available for 298 of 435 patients. After adjustment for preoperative and postoperative covariates, the APOE epsilon 2 allele was associated with a lower PDI score (P =038). Patients with the epsilon 2 allele had a PDI score approximately 6 points lower than those without the risk allele, explaining 1.04% of overall PDI variance, because the epsilon 2 allele was present in only 11% of the patients. There was a marginal effect of the epsilon 2 allele on MDI scores (P - .058). Conclusions: These data validate the association of the APOE epsilon 2 allele with adverse early ND outcomes after cardiac surgery in infants, independent of patient and operative factors. Genetic variants that decrease neuroresilience and impair neuronal repair after brain injury are important risk factors for ND dysfunction after surgery for CHD.	[Gaynor, J. William] Childrens Hosp Philadelphia, Div Cardiothorac Surg, Philadelphia, PA 19104 USA; [Kim, Daniel Seung; Jarvik, Gail P.] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA; [Kim, Daniel Seung; Jarvik, Gail P.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA USA; [Arrington, Cammon B.] Primary Childrens Med Ctr, Salt Lake City, UT 84103 USA; [Atz, Andrew M.] Med Univ S Carolina, Div Pediat Cardiol, Charleston, SC 29425 USA; [Bellinger, David C.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA; [Bellinger, David C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Burt, Amber A.] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA; [Ghanayem, Nancy S.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Jacobs, Jeffery P.] Univ S Florida, All Childrens Hosp, Johns Hopkins Childrens Heart Inst, St Petersburg, FL 33701 USA; [Jacobs, Jeffery P.] Florida Hosp Children, St Petersburg, FL USA; [Lee, Teresa M.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY USA; [Lewis, Alan B.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; [Mahle, William T.] Childrens Healthcare Atlanta, Atlanta, GA USA; [Marino, Bradley S.] Cincinnati Childrens Hosp Med Ctr, Ann & Robert F Lurie Childrens Hosp Chicago, Cincinnati, OH 45229 USA; [Miller, Stephen G.] Duke Univ, Med Ctr, Div Pediat Oncol, Durham, NC USA; [Newburger, Jane W.] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA; [Pizarro, Christian] Alfred I Dupont Hosp Children, Nemours Cardiac Ctr, Wilmington, DE USA; [Ravishankar, Chitra] Childrens Hosp Philadelphia, Div Pediat Cardiol, Philadelphia, PA 19104 USA; [Santani, Avni B.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Wilder, Nicole S.] Univ Michigan, Sch Med, Dept Anesthesia, Ann Arbor, MI USA; [Mital, Seema] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Russell, Mark W.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Div Pediat Cardiol, Ann Arbor, MI USA	Gaynor, JW (corresponding author), Childrens Hosp Philadelphia, Div Cardiothorac Surg, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	gaynor@email.chop.edu	Pizarro, Christian/AAO-9546-2021; Atz, Andrew/J-9196-2015	Atz, Andrew/0000-0002-4744-3832; Kim, Daniel/0000-0003-2971-1909	Daniel M. Tabas Endowed Chair in Pediatric Cardiothoracic Surgery at The Children's Hospital of Philadelphia; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1F31MH101905-01]; National Heart, Lung, and Blood Institute grants (NHLBI) [HL068269, HL068270, HL068279, HL068281, HL068285, HL068292, HL068290, HL068288, HL085057]; Food and Drug Administration's Office of Orphan Products Development; Harvard Catalyst/The Harvard Clinical and Translational Science Center (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 RR 025758]; Harvard Catalyst/The Harvard Clinical and Translational Science Center (Harvard University and its affiliated academic health care centers); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL068292, U01HL068281, U01HL085057, U10HL109816, U10HL109743, U01HL068285, U10HL068270, U01HL068270, U01HL068279, U01HL068269, U10HL109673, U01HL068290, U01HL068288, U10HL109778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH101905] Funding Source: NIH RePORTER	This study was supported by the Daniel M. Tabas Endowed Chair in Pediatric Cardiothoracic Surgery at The Children's Hospital of Philadelphia. D.S. Kim was funded by a grant from the National Institute of Mental Health (1F31MH101905-01).; The Infant Single Ventricle (ISV) trial was supported by the National Heart, Lung, and Blood Institute grants (NHLBI; HL068269, HL068270, HL068279, HL068281, HL068285, HL068292, HL068290, HL068288, and HL085057) and the Food and Drug Administration's Office of Orphan Products Development.; The Single Ventricle Reconstruction (SVR) trial was supported by grants HL068269, HL068270, HL068279, HL068281, HL068285, HL068288, HL068290, HL068292, and HL085057 from the National Heart, Lung, and Blood Institute; and with support from Harvard Catalyst/The Harvard Clinical and Translational Science Center (NIH Award UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centers).	Aboud O, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-35; Ades AM, 2010, CARDIOL YOUNG, V20, P8, DOI 10.1017/S1047951109991909; Ballweg JA, 2006, PEDIAT CARDIOL, V28, P1450; Bayley N., 2006, BAYLEY SCALES INFANT; Braga LW, 2010, DEV MED CHILD NEUROL, V52, P666, DOI 10.1111/j.1469-8749.2009.03465.x; Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Fuller S, 2009, EUR J CARDIO-THORAC, V36, P40, DOI 10.1016/j.ejcts.2009.02.047; Gaynor JW, 2007, J THORAC CARDIOV SUR, V133, P1344, DOI 10.1016/j.jtcvs.2006.10.087; Gaynor JW, 2003, J THORAC CARDIOV SUR, V126, P1736, DOI 10.1016/S0022-5223(03)01188-7; Gelfand AA, 2013, PEDIATR NEUROL, V48, P36, DOI 10.1016/j.pediatrneurol.2012.09.016; Hsu DT, 2010, CIRCULATION, V122, P333, DOI 10.1161/CIRCULATIONAHA.109.927988; Igl BW, 2009, HUM HERED, V67, P66, DOI 10.1159/000164400; Koch W, 2002, CLIN CHEM LAB MED, V40, P1123, DOI 10.1515/CCLM.2002.197; Konig IR, 2011, BRIEF BIOINFORM, V12, P253, DOI 10.1093/bib/bbq074; Kuroda MM, 2007, PEDIATRICS, V119, P306, DOI 10.1542/peds.2006-1083; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Marino BS, 2012, CIRCULATION, V126, P1143, DOI 10.1161/CIR.0b013e318265ee8a; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Mital S, 2011, CIRCULATION, V123, P2353, DOI 10.1161/CIRCULATIONAHA.110.004341; Newburger JW, 2012, CIRCULATION, V125, P2081, DOI 10.1161/CIRCULATIONAHA.111.064113; O'Callaghan ME, 2012, PEDIATRICS, V129, pE414, DOI 10.1542/peds.2011-0739; Ohye RG, 2010, NEW ENGL J MED, V362, P1980, DOI 10.1056/NEJMoa0912461; Oria RB, 2010, BRAZ J MED BIOL RES, V43, P249, DOI 10.1590/S0100-879X2010007500003; Oria RB, 2005, PEDIATR RES, V57, P310, DOI 10.1203/01.PDR.0000148719.82468.CA; Oria RB, 2007, MED HYPOTHESES, V68, P1099, DOI 10.1016/j.mehy.2006.09.036; Ravishankar C, 2013, J PEDIATR-US, V162, P250, DOI 10.1016/j.jpeds.2012.07.048; Roses AD, 1997, NEUROBIOL DIS, V4, P170, DOI 10.1006/nbdi.1997.0161; Roses AD, 1997, ANN NY ACAD SCI, V826, P200, DOI 10.1111/j.1749-6632.1997.tb48471.x; Shillingford AJ, 2008, PEDIATRICS, V121, pE759, DOI 10.1542/peds.2007-1066; Strittmatter WJ, 2002, CURR OPIN LIPIDOL, V13, P119, DOI 10.1097/00041433-200204000-00002; Tabbutt S, 2012, CURR OPIN CARDIOL, V27, P82, DOI 10.1097/HCO.0b013e328350197b; Trachtenberg AJ, 2012, NEUROIMAGE, V59, P565, DOI 10.1016/j.neuroimage.2011.07.059; Westlye LT, 2012, NEUROLOGY, V79, P1961, DOI 10.1212/WNL.0b013e3182735c9c; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Wu YW, 2011, PEDIATR RES, V70, P642, DOI 10.1203/PDR.0b013e31823240dd	35	31	33	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-5223	1097-685X		J THORAC CARDIOV SUR	J. Thorac. Cardiovasc. Surg.	DEC	2014	148	6					2560	2566		10.1016/j.jtcvs.2014.07.052			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	AU6BD	WOS:000345686100033	25282659	Green Accepted, Bronze			2021-06-18	
J	Raasakka, A; Kursula, P				Raasakka, Arne; Kursula, Petri			The myelin membrane-associated enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase: on a highway to structure and function	NEUROSCIENCE BULLETIN			English	Article						2 ',3 '-cyclic nucleotide 3 '-phosphodiesterase; calmodulin; central nervous system; cytoskeleton; myelin proteins; RNA	CENTRAL-NERVOUS-SYSTEM; BRAIN 2',3'-CYCLIC-NUCLEOTIDE 3'-PHOSPHODIESTERASE; MULTIPLE-SCLEROSIS PATIENTS; TRANSFER-RNA LIGASE; N-TERMINAL DOMAIN; MESSENGER-RNA; CHROMOSOMAL LOCALIZATION; SUSCEPTIBILITY GENE; CONVERGENT EVIDENCE; BINDING PROTEIN	The membrane-anchored myelin enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) was discovered in the early 1960s and has since then troubled scientists with its peculiar catalytic activity and high expression levels in the central nervous system. Despite decades of research, the actual physiological relevance of CNPase has only recently begun to unravel. In addition to a role in myelination, CNPase is also involved in local adenosine production in traumatic brain injury and possibly has a regulatory function in mitochondrial membrane permeabilization. Although research focusing on the CNPase phosphodiesterase activity has been helpful, several open questions concerning the protein function in vivo remain unanswered. This review is focused on past research on CNPase, especially in the fields of structural biology and enzymology, and outlines the current understanding regarding the biochemical and physiological significance of CNPase, providing ideas and directions for future research.	[Raasakka, Arne; Kursula, Petri] Univ Oulu, Dept Biochem, Oulu, Finland; [Raasakka, Arne; Kursula, Petri] Univ Oulu, Bioctr Oulu, Oulu, Finland; [Kursula, Petri] Univ Hamburg, Dept Chem, Hamburg, Germany	Kursula, P (corresponding author), Univ Oulu, Dept Biochem, Oulu, Finland.	petri.kursula@oulu.fi	Kursula, Petri/AAF-4563-2020; Raasakka, Arne/AAA-5251-2020	Kursula, Petri/0000-0001-8529-3751; Raasakka, Arne/0000-0002-9443-9959	Department of Biochemistry, University of Oulu; Sigrid Juselius Foundation (Finland)Sigrid Juselius Foundation; Academy of FinlandAcademy of FinlandEuropean Commission; Hamburg Research and Science Foundation (Germany)	This review was supported by grants from the Department of Biochemistry, University of Oulu, the Sigrid Juselius Foundation (Finland), the Academy of Finland, and the Hamburg Research and Science Foundation (Germany). We are grateful to Dr. Matti Myllykoski for building up the CNPase project in our laboratory and his deep insight into this enigmatic protein.	Aggarwal S, 2011, TRENDS CELL BIOL, V21, P585, DOI 10.1016/j.tcb.2011.06.004; Aggarwal S, 2011, DEV CELL, V21, P445, DOI 10.1016/j.devcel.2011.08.001; AGRAWAL HC, 1990, J BIOL CHEM, V265, P11849; Azarashvili T, 2009, AM J PHYSIOL-CELL PH, V296, pC1428, DOI 10.1152/ajpcell.00006.2009; Bankston AN, 2013, NEUROSCI BULL, V29, P216, DOI 10.1007/s12264-013-1321-3; Barley K, 2009, SCHIZOPHR RES, V112, P54, DOI 10.1016/j.schres.2009.04.019; Berggard T, 2006, J PROTEOME RES, V5, P669, DOI 10.1021/pr050421l; Bifulco M, 2002, P NATL ACAD SCI USA, V99, P1807, DOI 10.1073/pnas.042678799; BRAUN PE, 1990, ANN NY ACAD SCI, V605, P55, DOI 10.1111/j.1749-6632.1990.tb42380.x; BRAUN PE, 1991, J NEUROSCI RES, V30, P540, DOI 10.1002/jnr.490300311; Carson JH, 2005, BIOL CELL, V97, P51; de Monasterio-Schrader P, 2012, CELL MOL LIFE SCI, V69, P2879, DOI 10.1007/s00018-012-0958-9; DEANGELIS DA, 1994, J NEUROSCI RES, V39, P386, DOI 10.1002/jnr.490390405; DeAngelis DA, 1996, J NEUROCHEM, V67, P943; DeAngelis DA, 1996, J NEUROCHEM, V66, P2523; Donohoe G, 2007, BIOL PSYCHIAT, V61, p189S; DOUGLAS AJ, 1992, ANN HUM GENET, V56, P243, DOI 10.1111/j.1469-1809.1992.tb01149.x; Dracheva S, 2006, NEUROBIOL DIS, V21, P531, DOI 10.1016/j.nbd.2005.08.012; DRUMMOND G, 1961, J BIOL CHEM, V236, P1126; DRUMMOND GI, 1962, J BIOL CHEM, V237, P3535; Esposito C, 2008, BIOCHEMISTRY-US, V47, P308, DOI 10.1021/bi701474t; Georgieva L, 2006, P NATL ACAD SCI USA, V103, P12469, DOI 10.1073/pnas.0603029103; Gravel M, 2000, J NEUROCHEM, V75, P1940, DOI 10.1046/j.1471-4159.2000.0751940.x; GRAVEL M, 1994, J NEUROSCI RES, V38, P243, DOI 10.1002/jnr.490380302; Gravel M, 1996, MOL CELL NEUROSCI, V7, P453, DOI 10.1006/mcne.1996.0033; Gravel M, 2009, J NEUROSCI RES, V87, P1069, DOI 10.1002/jnr.21939; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; Hagemeyer N, 2012, EMBO MOL MED, V4, P528, DOI 10.1002/emmm.201200230; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hartline DK, 2008, NEURON GLIA BIOL, V4, P153, DOI 10.1017/S1740925X09990263; Heaton PA, 1996, NUCLEIC ACIDS RES, V24, P850, DOI 10.1093/nar/24.5.850; Hinman JD, 2008, GLIA, V56, P118, DOI 10.1002/glia.20595; Hobson GM, 2012, SEMIN NEUROL, V32, P62, DOI 10.1055/s-0032-1306388; Jackson EK, 2011, AM J PHYSIOL-RENAL, V301, pF1160, DOI 10.1152/ajprenal.00450.2011; KOONIN EV, 1990, FEBS LETT, V268, P231, DOI 10.1016/0014-5793(90)81015-G; Kozlov G, 2003, J BIOL CHEM, V278, P46021, DOI 10.1074/jbc.M305176200; Kozlov G, 2007, FEBS J, V274, P1600, DOI 10.1111/j.1742-4658.2007.05707.x; KURIHARA T, 1992, NEUROSCI LETT, V138, P49, DOI 10.1016/0304-3940(92)90469-N; KURIHARA T, 1990, BIOCHEM BIOPH RES CO, V170, P1074, DOI 10.1016/0006-291X(90)90502-E; Kursula P, 2008, AMINO ACIDS, V34, P175, DOI 10.1007/s00726-006-0479-7; Kursula P, 2001, INT J MOL MED, V8, P475; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Le-Niculescu H, 2007, AM J MED GENET B, V144B, P129, DOI 10.1002/ajmg.b.30481; Lee J, 2006, MOL CELL NEUROSCI, V31, P446, DOI 10.1016/j.mcn.2005.10.017; Lee J, 2005, J CELL BIOL, V170, P661, DOI 10.1083/jcb.200411047; Lee J, 2001, J BIOL CHEM, V276, P14804, DOI 10.1074/jbc.M009434200; Li J, 2013, MOL NEUROBIOL, V47, P673, DOI 10.1007/s12035-012-8370-x; Lovato L, 2008, MOL CELL PROTEOMICS, V7, P2337, DOI 10.1074/mcp.M700277-MCP200; Ma H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080769; Mazumder R, 2002, NUCLEIC ACIDS RES, V30, P5229, DOI 10.1093/nar/gkf645; Mirshafiey A, 2013, IRAN J ALLERGY ASTHM, V12, P292; Mitkus SN, 2008, SCHIZOPHR RES, V98, P129, DOI 10.1016/j.schres.2007.09.032; MONOH K, 1993, GENE, V129, P297, DOI 10.1016/0378-1119(93)90283-9; Muraro PA, 2002, J NEUROIMMUNOL, V130, P233, DOI 10.1016/S0165-5728(02)00229-1; Myllykoski M, 2010, BMC RES NOTES, V3, P1; Myllykoski M, 2013, J MOL BIOL, V425, P4307, DOI 10.1016/j.jmb.2013.06.012; Myllykoski M, 2012, J NEUROCHEM, V123, P515, DOI 10.1111/jnc.12000; Myllykoski M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032336; Myllykoski M, 2012, AMINO ACIDS, V42, P1467, DOI 10.1007/s00726-011-0911-5; Nasr F, 2000, NUCLEIC ACIDS RES, V28, P1676, DOI 10.1093/nar/28.8.1676; OLAFSON RW, 1969, CAN J BIOCHEM CELL B, V47, P961, DOI 10.1139/o69-151; ONeill RC, 1997, J NEUROSCI RES, V50, P248; Peirce TR, 2006, ARCH GEN PSYCHIAT, V63, P18, DOI 10.1001/archpsyc.63.1.18; Peirce TR, 2004, AM J MED GENET B, V130B, P81; Popow J, 2012, CELL MOL LIFE SCI, V69, P2657, DOI 10.1007/s00018-012-0944-2; Quarles RH, 2002, CELL MOL LIFE SCI, V59, P1851, DOI 10.1007/PL00012510; Radtke C, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/608496; Rosener M, 1997, J NEUROIMMUNOL, V75, P28, DOI 10.1016/S0165-5728(96)00230-5; Sakamoto Y, 2005, J MOL BIOL, V346, P789, DOI 10.1016/j.jmb.2004.12.024; Schwer B, 2008, RNA, V14, P204, DOI 10.1261/rna.858108; Stingo S, 2007, CHEM BIOL DRUG DES, V70, P502, DOI 10.1111/j.1747-0285.2007.00592.x; Tang FL, 2007, NEUROSCI LETT, V416, P113, DOI 10.1016/j.neulet.2007.01.054; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; Toyama BH, 2013, CELL, V154, P971, DOI 10.1016/j.cell.2013.07.037; TRAPP BD, 1988, J NEUROCHEM, V51, P859, DOI 10.1111/j.1471-4159.1988.tb01822.x; Usui H, 2006, SCHIZOPHR RES, V88, P245, DOI 10.1016/j.schres.2006.07.019; Verrier J, 2012, J NEUROTRAUM, V29, pA168; Verrier JD, 2013, GLIA, V61, P1595, DOI 10.1002/glia.22523; Verrier JD, 2012, J NEUROCHEM, V122, P115, DOI 10.1111/j.1471-4159.2012.07705.x; Verrier JD, 2011, J NEUROCHEM, V118, P979, DOI 10.1111/j.1471-4159.2011.07392.x; Vlkolinsky R, 2001, NEUROBIOL AGING, V22, P547, DOI 10.1016/S0197-4580(01)00218-4; Voineskos AN, 2008, PSYCHIAT GENET, V18, P143, DOI 10.1097/YPG.0b013e3282fa1874; Voineskos AN, 2007, BIOL PSYCHIAT, V61, p209S; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Walsh MJ, 1998, J CLIN INVEST, V101, P1923, DOI 10.1172/JCI1983; Wilson SJ, 2012, CELL HOST MICROBE, V12, P585, DOI 10.1016/j.chom.2012.08.012; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; Yamamoto T, 2013, CONGENIT ANOM, V53, P3, DOI 10.1111/cga.12005; Yin X, 1997, J NEUROSCI RES, V50, P238, DOI 10.1002/(SICI)1097-4547(19971015)50:2<238::AID-JNR12>3.0.CO;2-4; ZHANG Z, 2006, CALCIUM BINDING PROT, V1, P125	90	31	31	0	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1673-7067	1995-8218		NEUROSCI BULL	Neurosci. Bull.	DEC	2014	30	6					956	966		10.1007/s12264-013-1437-5			11	Neurosciences	Neurosciences & Neurology	AU6ZO	WOS:000345750500007	24807122	Green Published			2021-06-18	
J	Sandhir, R; Gregory, E; Berman, NEJ				Sandhir, Rajat; Gregory, Eugene; Berman, Nancy E. J.			Differential response of miRNA-21 and its targets after traumatic brain injury in aging mice	NEUROCHEMISTRY INTERNATIONAL			English	Article						Aging; miR-21; PDCD4; PTEN; RECK; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; MICRORNA EXPRESSION; HIPPOCAMPUS; BIOMARKERS; REGULATORS; ISCHEMIA; NEURONS; DISEASE; DEATH	The present study investigated the possible role of miR-21, a miRNA that has known prosurvival function, in poor outcomes in the elderly following traumatic brain injury compared to adults. Controlled cortical impact injury was induced in adult (5-6 months) and aged (22-24 months) C57/BL6 mice. miR-21 and four of its targets (PDCD4, TIMP3, RECK, PTEN) were analyzed at 1, 3, 7 days post injury in samples of injured cortex using real-time PCR analysis. Basal miR-21 expression was higher in the aged brain than in the adult brain. In the adult brain, miR-21 expression increased in response to injury, with the maximum increase 24 hours after injury followed by a gradual decrease, returning to baseline 7 days post-injury. In contrast, in aged mice, miR21 showed no injury response, and expression of miR-21 target genes (PTEN, PDCD4, RECK, TIMP3) was up-regulated at all post injury time points, with a maximal increase at 24 hours post injury. Based on these results, we conclude that the diminished miR21 injury response in the aged brain leads to up-regulation of its targets, with the potential to contribute to the poor prognosis following TBI in aging brain. Therefore, strategies aimed at up-regulation of miR-21 and/or down regulation of its targets might be useful in improving outcomes in the elderly following TBI. (C) 2014 Elsevier Ltd. All rights reserved.	[Sandhir, Rajat; Gregory, Eugene; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA	Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Mail Stop 3038,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	nberman@kumc.edu			National Institute of Aging, University of Kansas Alzheimer's Disease Center and Steve Palermo Endowment; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG035982, R01AG031140] Funding Source: NIH RePORTER	This work was supported by the National Institute of Aging, University of Kansas Alzheimer's Disease Center and Steve Palermo Endowment.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI [10.1089/neu.2008.0765, 10.1089/neu.2008-0765]; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Bi YJ, 2009, J CELL PHYSIOL, V218, P467, DOI 10.1002/jcp.21639; Brase JC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-306; Brattelid T, 2011, PHYSIOL GENOMICS, V43, P604, DOI 10.1152/physiolgenomics.00131.2010; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Chen Y, 2008, CANCER LETT, V272, P197, DOI 10.1016/j.canlet.2008.06.034; Delay C, 2012, NEUROBIOL DIS, V46, P285, DOI 10.1016/j.nbd.2012.01.003; Ding J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080429; Filatova EV, 2012, BIOCHEMISTRY-MOSCOW+, V77, P813, DOI 10.1134/S0006297912080020; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Guay C, 2013, NAT REV ENDOCRINOL, V9, P513, DOI 10.1038/nrendo.2013.86; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Im HI, 2012, TRENDS NEUROSCI, V35, P325, DOI 10.1016/j.tins.2012.01.004; Jacobs David G, 2003, Curr Opin Crit Care, V9, P535, DOI 10.1097/00075198-200312000-00012; Lee P, 2012, EXP NEUROL, V234, P50, DOI 10.1016/j.expneurol.2011.12.016; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Tran N, 2013, ESSAYS BIOCHEM, V54, P17, DOI [10.1042/bse0540017, 10.1042/BSE0540017]; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Petri R, 2014, EXP CELL RES, V321, P84, DOI 10.1016/j.yexcr.2013.09.022; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Rao P, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00039; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Shi ZD, 2013, CANCER RES, V73, P5519, DOI 10.1158/0008-5472.CAN-13-0280; Strickland IT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023423; Van Wynsberghe PM, 2011, METHOD CELL BIOL, V106, P219, DOI 10.1016/B978-0-12-544172-8.00008-6; Wang HA, 2010, J NEUROCHEM, V115, P385, DOI 10.1111/j.1471-4159.2010.06933.x; Wang T, 2012, AM J PATHOL, V181, P1911, DOI 10.1016/j.ajpath.2012.08.022; Xu Y, 2013, GENE, V530, P278, DOI 10.1016/j.gene.2013.07.055; Yin KJ, 2014, NEUROCHEM INT, V77, P9, DOI 10.1016/j.neuint.2014.03.013; Zhang XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034688; Zhao J, 2013, NEUROSCIENCE, V238, P242, DOI 10.1016/j.neuroscience.2013.02.046	40	31	32	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2014	78						117	121		10.1016/j.neuint.2014.09.009			5	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AY3RY	WOS:000347501400014	25277076	Green Accepted			2021-06-18	
J	Wiggins-Dohlvik, K; Merriman, M; Shaji, CA; Alluri, H; Grimsley, M; Davis, ML; Smith, RW; Tharakan, B				Wiggins-Dohlvik, Katie; Merriman, Morgan; Shaji, Chinchusha A.; Alluri, Himakarnika; Grimsley, Marcene; Davis, Matthew L.; Smith, Randall W.; Tharakan, Binu			Tumor necrosis factor-alpha disruption of brain endothelial cell barrier is mediated through matrix metalloproteinase-9	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	66th Annual Meeting of the Southwestern-Surgical-Congress	APR 13-16, 2014	Scottsdale, AZ	SW Surg Congress		Traumatic brain injury; Blood brain barrier; Matrix metalloproteinase; Gelatinase B; Tumor necrosis factor; Caspase-3	INJURY; PATHOPHYSIOLOGY; INHIBITOR	Traumatic brain injuries cause vascular hyperpermeability. Tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-9 (MMP-9), and caspase-3 may be important in these processes but the relationship between them has not been investigated. We hypothesized that TNF-alpha regulates caspase-3-mediated hyperpermeability and blood brain barrier damage and hyperpermeability directly or indirectly via activation of MMP-9. To test this, rat brain microvascular endothelial cells were treated with TNF-alpha with or without inhibition of MMP-9. Monolayer permeability was measured, zonula occludens-1 and F-actin configuration were examined, and MMP-9 and caspase-3 activities were quantified. TNF-alpha increased monolayer permeability, damaged zonula occludens-1, induced filamentousactin stress fiber formation, and increased both MMP-9 and caspase-3 activities. Inhibition of MMP-9 attenuated these changes. These data highlight a novel link between TNF-alpha and MMP-9 and show that TNF-alpha regulated caspase-3-mediated hyperpermeability and vascular damage may be linked to MMP-9 in vitro. These findings augment the understanding of traumatic brain injury and pave the way for improved treatment. (C) 2014 Elsevier Inc. All rights reserved.	[Wiggins-Dohlvik, Katie; Merriman, Morgan; Shaji, Chinchusha A.; Alluri, Himakarnika; Grimsley, Marcene; Davis, Matthew L.; Smith, Randall W.; Tharakan, Binu] Baylor Scott & White Hlth, Dept Surg, Temple, TX 76508 USA; [Wiggins-Dohlvik, Katie; Merriman, Morgan; Shaji, Chinchusha A.; Alluri, Himakarnika; Grimsley, Marcene; Davis, Matthew L.; Smith, Randall W.; Tharakan, Binu] Texas A&M Univ Hlth Sci Ctr, Coll Med, Dept Surg, Temple, TX USA	Tharakan, B (corresponding author), Baylor Scott & White Hlth, Dept Surg, Temple, TX 76508 USA.	btharakan@sw.org					Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Centers for Disease Control, 2010, NAT HOSP DISCH SURV; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Hellewell SC, 2012, MEDIAT INFLAMM, V2012, P1; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kim J, 2011, KEDI J EDUC POLICY, V8, P3; Lee IT, 2010, J CELL PHYSIOL, V224, P454, DOI 10.1002/jcp.22142; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li W, 2010, BIOL REPROD, V83, P481, DOI 10.1095/biolreprod.109.082578; Lin Y, 2013, INT J MED SCI, V10, P515, DOI 10.7150/ijms.5423; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Qiu LB, 2011, TOXICOLOGY, V285, P31, DOI 10.1016/j.tox.2011.03.019; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tsai CL, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-12; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vermeer PD, 2009, AM J PHYSIOL-LUNG C, V296, pL751, DOI 10.1152/ajplung.90578.2008; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Yamada H, 2013, BIOCHEM PHARMACOL, V85, P1770, DOI 10.1016/j.bcp.2013.04.006; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375	28	31	32	0	2	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	DEC	2014	208	6					954	960		10.1016/j.amjsurg.2014.08.014			7	Surgery	Surgery	AW2LU	WOS:000346120300023	25312844				2021-06-18	
J	Zhang, Z; Yan, R; Zhang, Q; Li, J; Kang, XK; Wang, HN; Huan, LC; Zhang, L; Li, F; Yang, SY; Zhang, JN; Ren, XL; Yang, XY				Zhang, Zhen; Yan, Rong; Zhang, Qi; Li, Jia; Kang, Xiaokui; Wang, Haining; Huan, Linchun; Zhang, Lin; Li, Fan; Yang, Shuyuan; Zhang, Jianning; Ren, Xinliang; Yang, Xinyu			Hes1, a Notch signaling downstream target, regulates adult hippocampal neurogenesis following traumatic brain injury	BRAIN RESEARCH			English	Article						Hes1; Notch signaling; Adult neurogenesis; Dentate gyrus; Traumatic brain injury	BHLH GENE HES1; STEM-CELL DIFFERENTIATION; DENTATE GYRUS; RNA INTERFERENCE; EXPRESSION; PROLIFERATION; ROLES; CONTRIBUTES; MAINTENANCE; NEURONS	Hairy and enhancer of split 1 (Hes1), a downstream target of Notch signaling, has long been recognized as crucial in inhibiting neuronal differentiation. However, the role of Hes1 following traumatic brain injury (TBI) in adult neurogenesis in the mouse dentate gyms (DG) remains partially understood. Here, we investigate the role of Hes1 in regulating neurogenesis in the DG of the adult hippocampus after TBI by up- or downregulating Hes1 expression. First, adenovirus-mediated gene transfection was employed to upregulate Hes1 in vivo. The mice were then subjected to TBI, and the hippocampal tissue was collected for Western blot analysis at designated times, pre- and post-injury. Moreover, the brain slices were stained for BrdU and doublecortin (Dcx). We show that enhancing Hes1 inhibits the proliferation and differentiation of neural precursor cells (NPCs) in the DG of the hippocampus soon after TBI. Second, downregulation of Hes1 via RNA interference (RNAi) results in a significant increase in neuronal production and promotes the differentiation of NPCs into mature neurons in the DG, as assessed by BrdU and NeuN double staining. Furthermore, a Morris water maze (MWM) test clearly confirmed that the knockdown of Hes1 improves the spatial learning and memory capacity of adult mice following injury. Taken together, these observations suggest that Hes1 represents a negative regulator of adult neurogenesis post-TBI and that the precise space-time regulation of Hes1 expression in the DG may promote the recovery of neural function following TBI. (C) 2014 Elsevier B.V. All rights reserved.	[Zhang, Zhen; Li, Jia; Kang, Xiaokui; Wang, Haining; Yang, Shuyuan; Zhang, Jianning; Yang, Xinyu] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Zhang, Zhen; Li, Jia; Kang, Xiaokui; Wang, Haining; Yang, Shuyuan; Zhang, Jianning; Yang, Xinyu] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin Neurol Inst, Tianjin 300052, Peoples R China; [Li, Fan; Ren, Xinliang] Changzhi Med Coll, Heji Hosp, Dept Neurosurg, Changzhi 046000, Peoples R China; [Huan, Linchun] Linyi Peoples Hosp, Dept Neurosurg, Linyi 276000, Peoples R China; [Zhang, Qi] Binzhou Med Univ Hosp, Dept Neurosurg, Binzhou 256603, Peoples R China; [Yan, Rong; Zhang, Lin] Tianjin 5th Cent Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China	Ren, XL (corresponding author), Changzhi Med Coll, Heji Hosp, Dept Neurosurg, 271 Taihang East Rd, Changzhi 046000, Peoples R China.	paperzzhang@gmail.com; rongy198628@163.com; dake413@163.com; lijiacdmc@163.com; xiaokuikang@163.com; Ryyouu@sina.com; uqqc@163.com; zhang_lin1985@126.com; 76484906@qq.com; 18622000583@163.com; jianningzhang@hotmail.com; 76484906@qq.com; yangxinyu@tijmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30973090]; Natural Science Foundation of TianjinNatural Science Foundation of Tianjin [10JCYBJC25700]; Natural Science Foundation of ShanxiNatural Science Foundation of Shanxi Province [2014011041-8]	We thank Prof. Ryoichiro Kageyama (Institute for Virus Research, Kyoto University, Kyoto, Japan) and Prof. Naihe Jing (Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Shanghai, China) for their kindly gifts of the Hes1 plasmids. This work was supported by the National Natural Science Foundation of China No. 30973090, Natural Science Foundation of Tianjin No. 10JCYBJC25700 and Natural Science Foundation of Shanxi No. 2014011041-8.	Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Baek JH, 2006, DEVELOPMENT, V133, P2467, DOI 10.1242/dev.02403; Bai G, 2007, DEV CELL, V13, P283, DOI 10.1016/j.devcel.2007.05.014; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Carre A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016752; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Christie KJ, 2013, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00070; Dhingra D, 2012, ADV PHARMACOL SCI, V2012, DOI 10.1155/2012/357368; Faulkner RL, 2008, P NATL ACAD SCI USA, V105, P14157, DOI 10.1073/pnas.0806658105; Fountaine TM, 2005, CURR GENE THER, V5, P399, DOI 10.2174/1566523054546206; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Harada K, 2013, J CLIN PATHOL, V66, P386, DOI 10.1136/jclinpath-2012-201273; Hatakeyama J, 2006, DEV NEUROSCI-BASEL, V28, P92, DOI 10.1159/000090756; Hatakeyama J, 2004, DEVELOPMENT, V131, P5539, DOI 10.1242/dev.01436; Imayoshi I, 2010, J NEUROSCI, V30, P3489, DOI 10.1523/JNEUROSCI.4987-09.2010; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kabadi S.V., 2014, J CEREB BLOOD FLOW M; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kageyama R, 2007, DEVELOPMENT, V134, P1243, DOI 10.1242/dev.000786; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kitagawa M, 2013, MECH DEVELOP, V130, P458, DOI 10.1016/j.mod.2013.07.001; Kobayashi T, 2010, GENES CELLS, V15, P689, DOI 10.1111/j.1365-2443.2010.01413.x; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ouatas T, 1998, INT J DEV BIOL, V42, P1159; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Peters M, 2009, GENES BRAIN BEHAV, V8, P320, DOI 10.1111/j.1601-183X.2009.00474.x; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Reinecke K, 2013, BEHAV BRAIN RES, V245, P88, DOI 10.1016/j.bbr.2013.02.013; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Rochais F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006267; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Schmidt A, 2007, STEM CELLS, V25, P2910, DOI 10.1634/stemcells.2007-0238; Shimojo H, 2008, NEURON, V58, P52, DOI 10.1016/j.neuron.2008.02.014; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Takatsuka K, 2004, BRAIN RES, V1004, P148, DOI 10.1016/j.brainres.2004.01.045; Tan SL, 2012, GENES CELLS, V17, P952, DOI 10.1111/gtc.12009; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wojtowicz JM, 2006, NAT PROTOC, V1, P1399, DOI 10.1038/nprot.2006.224; Yan R, 2012, J VIROL METHODS, V186, P1, DOI 10.1016/j.jviromet.2012.07.012; Yang XY, 2009, BRAIN INJURY, V23, P830, DOI 10.1080/02699050903196670; Zhang L, 2013, INT J MOL MED, V32, P867, DOI 10.3892/ijmm.2013.1456; Zhou XZ, 2013, STEM CELLS, V31, P1511, DOI 10.1002/stem.1426; Zhu MY, 2013, GENE EXPR PATTERNS, V13, P78, DOI 10.1016/j.gep.2012.12.001	56	31	34	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 2	2014	1583						65	78		10.1016/j.brainres.2014.07.037			14	Neurosciences	Neurosciences & Neurology	AR1PP	WOS:000343357400007	25084035				2021-06-18	
J	Kim, J; Parker, D; Whyte, J; Hart, T; Pluta, J; Ingalhalikar, M; Coslett, HB; Verma, R				Kim, Junghoon; Parker, Drew; Whyte, John; Hart, Tessa; Pluta, John; Ingalhalikar, Madhura; Coslett, H. B.; Verma, Ragini			Disrupted Structural Connectome Is Associated with Both Psychometric and Real-World Neuropsychological Impairment in Diffuse Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Graph theory; Diffusion tensor imaging; Observational rating scales; Frontal Systems Behavior Scale; Executive function; Verbal learning	WHITE-MATTER INTEGRITY; HUMAN CEREBRAL-CORTEX; TENSOR TRACTOGRAPHY; CORTICAL NETWORKS; AXONAL INJURY; CONNECTIVITY; NEUROPATHOLOGY; ORGANIZATION; RECOVERY; SYSTEM	Traumatic brain injury (TBI) is likely to disrupt structural network properties due to diffuse white matter pathology. The present study aimed to detect alterations in structural network topology in TBI and relate them to cognitive and real-world behavioral impairment. Twenty-two people with moderate to severe TBI with mostly diffuse pathology and 18 demographically matched healthy controls were included in the final analysis. Graph theoretical network analysis was applied to diffusion tensor imaging (DTI) data to characterize structural connectivity in both groups. Neuropsychological functions were assessed by a battery of psychometric tests and the Frontal Systems Behavior Scale (FrSBe). Local connection-wise analysis demonstrated reduced structural connectivity in TBI arising from subcortical areas including thalamus, caudate, and hippocampus. Global network metrics revealed that shortest path length in participants with TBI was longer compared to controls, and that this reduced network efficiency was associated with worse performance in executive function and verbal learning. The shortest path length measure was also correlated with family-reported FrSBe scores. These findings support the notion that the diffuse form of neuropathology caused by TBI results in alterations in structural connectivity that contribute to cognitive and real-world behavioral impairment.	[Kim, Junghoon; Whyte, John; Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Parker, Drew; Pluta, John; Ingalhalikar, Madhura; Verma, Ragini] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Pluta, John; Coslett, H. B.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA	Kim, J (corresponding author), CUNY City Coll, Sophie Davis Sch Biomed Educ, Dept Physiol Pharmacol & Neurosci, 160 Convent Ave, New York, NY 10031 USA.	jkim@med.cuny.edu	Kim, Junghoon John/I-6702-2019	Kim, Junghoon John/0000-0001-5729-8993; Whyte, John/0000-0002-4381-1474	Pennsylvania Department of Health; NINDS, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS065980-02]; NIMH, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1R01MH092862]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH092862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065980] Funding Source: NIH RePORTER	The authors declare no competing financial interests. This work was funded by a grant with the Pennsylvania Department of Health (PI: J.W.). The department specifically disclaims responsibility for any analyses, interpretations, or conclusions. Part of the funding also came from grant 5R01NS065980-02 (PI: J.K.) from the NINDS, NIH and 1R01MH092862 (PI: R.V.) from the NIMH, NIH. The authors thank John Slattery, Grayce Selig, and Tincy Philip for their assistance in data collection and analysis.	Adnan A, 2013, BRAIN INJURY, V27, P1415, DOI 10.3109/02699052.2013.823659; Bassett DS, 2008, J NEUROSCI, V28, P9239, DOI 10.1523/JNEUROSCI.1929-08.2008; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bennett IJ, 2010, HUM BRAIN MAPP, V31, P378, DOI 10.1002/hbm.20872; Benton AL, 1983, MULTILINGUAL APHASIA; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Burzynska AZ, 2010, NEUROIMAGE, V49, P2104, DOI 10.1016/j.neuroimage.2009.09.041; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Collette F, 2006, NEUROSCIENCE, V139, P209, DOI 10.1016/j.neuroscience.2005.05.035; Delis DC, 2000, CALIFORNIA VERBAL LE; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Edlow BL, 2012, SEMIN NEUROL, V32, P374, DOI 10.1055/s-0032-1331810; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Gong GL, 2009, J NEUROSCI, V29, P15684, DOI 10.1523/JNEUROSCI.2308-09.2009; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; Hagmann P, 2010, P NATL ACAD SCI USA, V107, P19067, DOI 10.1073/pnas.1009073107; He Y, 2010, CURR OPIN NEUROL, V23, P341, DOI 10.1097/WCO.0b013e32833aa567; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Kim J, 2005, J INT NEUROPSYCH SOC, V11, P434, DOI 10.1017/S1355617705050563; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Levine B, 2013, NEUROIMAGE-CLIN, V2, P534, DOI 10.1016/j.nicl.2013.03.015; Li Y, 2013, HUM BRAIN MAPP, V34, P3376, DOI 10.1002/hbm.22158; Lo CY, 2010, J NEUROSCI, V30, P16876, DOI 10.1523/JNEUROSCI.4136-10.2010; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; QUADE D, 1967, J AM STAT ASSOC, V62, P1187, DOI 10.2307/2283769; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Schwartz MF, 2005, ARCH PHYS MED REHAB, V86, P1807, DOI 10.1016/j.apmr.2005.03.009; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; SIMPSON EH, 1951, J ROY STAT SOC B, V13, P238; Stam Cornelis J, 2007, Nonlinear Biomed Phys, V1, P3, DOI 10.1186/1753-4631-1-3; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	53	31	32	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	OCT	2014	20	9					887	896		10.1017/S1355617714000812			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	AT4YD	WOS:000344947600002	25287217	Green Accepted			2021-06-18	
J	Kobelt, LJ; Wilkinson, AE; McCormick, AM; Willits, RK; Leipzig, ND				Kobelt, Liza J.; Wilkinson, Ashley E.; McCormick, Aleesha M.; Willits, Rebecca Kuntz; Leipzig, Nic D.			Short Duration Electrical Stimulation to Enhance Neurite Outgrowth and Maturation of Adult Neural Stem Progenitor Cells	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Neural stem progenitor cells; Electrical stimulation; Direct current; Neural differentiation; Neurons; Axons; Neurites; Calcium	GROWTH CONE; NERVOUS-SYSTEM; CALCIUM; FIELDS; GRADIENTS; NEURONS; VOLTAGE; DIFFERENTIATION; GALVANOTAXIS; MECHANISMS	New therapies are desperately needed for human central nervous system (CNS) regeneration to circumvent the lack of innate regenerative ability following traumatic injuries. Previously attempted therapies have been stymied by barriers to CNS regeneration largely because of protective mechanisms such as the blood brain barrier, inhibitory molecules, and glial scar formation. The application of electric stimulation (ES) has shown promise for enhancing peripheral nervous system regeneration, but is in its infancy in CNS regeneration. The objective of this study is to better understand how short duration ES can be harnessed to direct adult neural stem progenitor cell (NSPC) neurogenesis, neurite extension, and maturation. Herein, NSPCs were exposed to physiological levels of electrical stimulation of 0.53 or 1.83 V/m (applied power supply setting of 1.2 and 2.5 V) of direct current (DC) for 10 min/days for 2 days with a total differentiation time of 3 days. Culturing conditions consisted of either mitogenic growth factors or the neuronal differentiation factor interferon-gamma (IFN-gamma). Stimulated NSPCs showed lengths that were over five times longer than unstimulated controls (112.0 +/- A 88.8 mu m at 0.53 V/m vs. 21.3 +/- A 8.5 mu m for 0 V/m with IFN-gamma) with the longest neurites reaching up to 600 A mu m. Additionally, ES resulted in mature neuronal morphologies and signs of differentiation through positive beta III tubulin, neuronal nuclei (NeuN), and better organized filamentous-actin (f-actin) staining with growth cone formation. Additionally, the neurites and soma of stimulated NSPCs showed increases in intracellular Ca2+ during stimulation, signifying the presence of functional neurons capable of electrical conductance and communication with other cells. Our study demonstrates that short stimulation times (10 min/ day) result in significant neurite extension of stem cells in a quick time frame (3 days). This ES modality is potentially advantageous for promoting axon re-growth at an injury site using delivered adult stem cells; however, significant work still remains to understand both the delivery approach of cells as well as ES application in vivo.	[Kobelt, Liza J.; Wilkinson, Ashley E.; McCormick, Aleesha M.; Leipzig, Nic D.] Univ Akron, Dept Chem & Biomol Engn, Akron, OH 44325 USA; [Willits, Rebecca Kuntz; Leipzig, Nic D.] Univ Akron, Dept Biomed Engn, Akron, OH 44325 USA	Leipzig, ND (corresponding author), Univ Akron, Dept Chem & Biomol Engn, 200 East Buchtel Common,Whitby Hall 211, Akron, OH 44325 USA.	nl21@uakron.edu	Willits, Rebecca/B-5017-2010; Leipzig, Nic D/AAM-6654-2021	Willits, Rebecca/0000-0002-1866-6789; Leipzig, Nic D/0000-0002-6356-7691; Severs, Liza/0000-0002-9470-8186	University of Akron	We would like to thank The University of Akron for the funding that supported this work.	ANGLISTER L, 1982, DEV BIOL, V94, P351, DOI 10.1016/0012-1606(82)90353-0; Ariza CA, 2010, STEM CELL REV REP, V6, P585, DOI 10.1007/s12015-010-9171-0; Babona-Pilipos R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023808; BOLSOVER SR, 1986, J NEUROSCI, V6, P1934; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; Chang KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018738; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; CORK RJ, 1994, J NEUROBIOL, V25, P1509, DOI 10.1002/neu.480251204; Craig CG, 1996, J NEUROSCI, V16, P2649; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Felaco M, 1999, MOL CELL BIOCHEM, V201, P49, DOI 10.1023/A:1007004316433; Feng JF, 2012, STEM CELLS, V30, P349, DOI 10.1002/stem.779; Fitch M., 1999, J NEUROSCI, V19; FREEMAN JA, 1985, J NEUROSCI RES, V13, P257, DOI 10.1002/jnr.490130118; Frohlich F, 2010, NEURON, V67, P129, DOI 10.1016/j.neuron.2010.06.005; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Haugland R. P., HDB GUIDE FLUORESCEN, P1126; HOTARY KB, 1990, DEV BIOL, V140, P149, DOI 10.1016/0012-1606(90)90062-N; JIMBO Y, 1993, IEEE T BIO-MED ENG, V40, P804, DOI 10.1109/10.238465; KATER SB, 1991, J NEUROSCI, V11, P891; Koppes AN, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046023; Kuhn HG, 1997, J NEUROSCI, V17, P5820; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; Leipzig ND, 2011, BIOMATERIALS, V32, P57, DOI 10.1016/j.biomaterials.2010.09.031; Leipzig ND, 2010, J BIOMED MATER RES A, V93A, P625, DOI 10.1002/jbm.a.32573; Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048824; Li Li, 2011, Front Med, V5, P40, DOI 10.1007/s11684-011-0108-z; Li XF, 2002, J VASC RES, V39, P391, DOI 10.1159/000064517; LIPTON SA, 1986, P NATL ACAD SCI USA, V83, P9774, DOI 10.1073/pnas.83.24.9774; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Matos MA, 2010, BIOTECHNOL PROGR, V26, P664, DOI 10.1002/btpr.389; MCCAIG CD, 1991, EXP PHYSIOL, V76, P473, DOI 10.1113/expphysiol.1991.sp003514; McCaig CD, 2009, J CELL SCI, V122, P4267, DOI 10.1242/jcs.023564; Mycielska ME, 2004, J CELL SCI, V117, P1631, DOI 10.1242/jcs.01125; National Spinal Cord Injury Statistical Center, 2013, FACTS FIG GLANC; PATEL N, 1982, J NEUROSCI, V2, P483; Pullar CE, 2011, BIOL EFF ELECTROMAGN, P1; RAPP B, 1988, EUR BIOPHYS J BIOPHY, V16, P313, DOI 10.1007/BF00254068; REHDER V, 1992, J NEUROSCI, V12, P3175; Rollwitz J, 2004, BBA-GEN SUBJECTS, V1674, P231, DOI 10.1016/j.bbagen.2004.06.024; Schmidt CE, 1997, P NATL ACAD SCI USA, V94, P8948, DOI 10.1073/pnas.94.17.8948; Sheridan DM, 1996, J INVEST DERMATOL, V106, P642, DOI 10.1111/1523-1747.ep12345456; SHI RY, 1995, DEV DYNAM, V202, P101, DOI 10.1002/aja.1002020202; SISKEN BF, 1989, BRAIN RES, V485, P309, DOI 10.1016/0006-8993(89)90575-1; Wan LD, 2010, NEURAL REGEN RES, V5, P1256, DOI 10.3969/j.issn.1673-5374.2010.16.010; Whittemore SR, 1999, EXP CELL RES, V252, P75, DOI 10.1006/excr.1999.4621; Wilkinson A. E., 2011, SYNTH LECT TISSUE EN, V8, P1; Wood M, 2006, BIOELECTROMAGNETICS, V27, P328, DOI 10.1002/bem.20214; Yang G, 2008, INT CONF BIOMED, P548, DOI 10.1109/BMEI.2008.130; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zahir T, 2008, CELL TRANSPLANT, V17, P245, DOI 10.3727/096368908784153887; Zhao M, 2004, J CELL SCI, V117, P397, DOI 10.1242/jcs.00868	52	31	32	1	35	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2014	42	10					2164	2176		10.1007/s10439-014-1058-9			13	Engineering, Biomedical	Engineering	AP2NF	WOS:000341908500015	24957636				2021-06-18	
J	Mutschler, M; Paffrath, T; Wolfl, C; Probst, C; Nienaber, U; Schipper, IB; Bouillon, B; Maegele, M				Mutschler, M.; Paffrath, T.; Woelfl, C.; Probst, C.; Nienaber, U.; Schipper, I. B.; Bouillon, B.; Maegele, M.			The ATLS (R) classification of hypovolaemic shock: A well established teaching tool on the edge?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						ATLS; Shock; Blood loss; Trauma; Vital signs	TRAUMA LIFE-SUPPORT; BASE DEFICIT; HYPOTENSION	Uncontrolled bleeding is the leading cause of shock in trauma patients and delays in recognition and treatment have been linked to adverse outcomes. For prompt detection and management of hypovolaemic shock, ATLS (R) suggests four shock classes based upon vital signs and an estimated blood loss in percent. Although this classification has been widely implemented over the past decades, there is still no clear prospective evidence to fully support this classification. In contrast, it has recently been shown that this classification may be associated with substantial deficits. A retrospective analysis of data derived from the TraumaRegister DGU (R) indicated that only 9.3% of all trauma patients could be allocated into one of the ATLS (R) shock classes when a combination of the three vital signs heart rate, systolic blood pressure and Glasgow Coma Scale was assessed. Consequently, more than 90% of all trauma patients could not be classified according to the ATLS (R) classification of hypovolaemic shock. Further analyses including also data from the UK-based TARN registry suggested that ATLS (R) may overestimate the degree of tachycardia associated with hypotension and underestimate mental disability in the presence of hypovolaemic shock. This finding was independent from pre-hospital treatment as well as from the presence or absence of a severe traumatic brain injury. Interestingly, even the underlying trauma mechanism (blunt or penetrating) had no influence on the number of patients who could be allocated adequately. Considering these potential deficits associated with the ATLS (R) classification of hypovolaemic shock, an online survey among 383 European ATLS (R) course instructors and directors was performed to assess the actual appreciation and confidence in this tool during daily clinical trauma care. Interestingly, less than half (48%) of all respondents declared that they would assess a potential circulatory depletion within the primary survey according to the ATLS (R) classification of hypovolaemic shock. Based on these observations, a critical reappraisal of the current ATLS (R) classification of hypovolaemic seems warranted. (C) 2014 Elsevier Ltd. All rights reserved.	[Mutschler, M.; Paffrath, T.; Probst, C.; Bouillon, B.; Maegele, M.] Private Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Orthoped Trauma & Sportsmed, D-51109 Cologne, Germany; [Woelfl, C.] BG Hosp Ludwigshafen, Dept Trauma & Orthoped Surg, Ludwigshafen, Germany; [Nienaber, U.] Acad Trauma Surg AUC, Berlin, Germany; [Schipper, I. B.] Leiden Univ, Med Ctr, Dept Trauma Surg, Leiden, Netherlands	Mutschler, M (corresponding author), Private Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Orthoped Trauma & Sports Med, Campus Cologne Merheim,Ostmerheimer Str 200, D-51109 Cologne, Germany.	manuelmutschler@web.de					Brasel KJ, 2007, J TRAUMA, V62, P812, DOI 10.1097/TA.0b013e31803245a1; Committee on Trauma American College of Surgeons, 2008, ADV TRAUM LIF SUPP D; Evans JA, 2010, WORLD J SURG, V34, P158, DOI 10.1007/s00268-009-0266-1; Guly HR, 2011, RESUSCITATION, V82, P556, DOI 10.1016/j.resuscitation.2011.01.013; Guly HR, 2010, RESUSCITATION, V81, P1142, DOI 10.1016/j.resuscitation.2010.04.007; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Ley EJ, 2009, J TRAUMA, V67, P1051, DOI 10.1097/TA.0b013e3181bba222; Mutschler M, 2013, RESUSCITATION, V84, P309, DOI 10.1016/j.resuscitation.2012.07.012; Mutschler M, 2013, EMERG MED J; Mutschler M, 2014, EMERG MED J, V31, P35, DOI 10.1136/emermed-2012-202130; Mutschler M, 2013, CRIT CARE, V17, DOI 10.1186/cc12555; Parks JK, 2006, AM J SURG, V192, P727, DOI 10.1016/j.amjsurg.2006.08.034; Privette AR, 2013, CRIT CARE, V17, DOI 10.1186/cc12513; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Victorino GP, 2003, J AM COLL SURGEONS, V196, P679, DOI 10.1016/S1072-7515(03)00128-5	16	31	31	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	OCT	2014	45			3			S35	S38		10.1016/j.injury.2014.08.015			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AR0DP	WOS:000343237400008	25284231				2021-06-18	
J	Stover, JF; Belli, A; Boret, H; Bulters, D; Sahuquillo, J; Schmutzhard, E; Zavala, E; Ungerstedt, U; Schinzel, R; Tegtmeier, F				Stover, John F.; Belli, Antonio; Boret, Henry; Bulters, Diederik; Sahuquillo, Juan; Schmutzhard, Erich; Zavala, Elisabeth; Ungerstedt, Urban; Schinzel, Reinhard; Tegtmeier, Frank		NOSTRA Investigators	Nitric Oxide Synthase Inhibition with the Antipterin VAS203 Improves Outcome in Moderate and Severe Traumatic Brain Injury: A Placebo-Controlled Randomized Phase IIa Trial (NOSTRA)	JOURNAL OF NEUROTRAUMA			English	Article						clinical trial; microdialysis; NO-synthase inhibition; traumatic brain injury	METABOLITES; FLUID; INOS	Traumatic brain injury (TBI) is an important cause of death and disability. Safety and pharmacodynamics of 4-amino-tetrahydrobiopterin (VAS203), a nitric oxide (NO)-synthase inhibitor, were assessed in TBI in an exploratory Phase IIa study (NOSynthase Inhibition in TRAumatic brain injury = NOSTRA). The study included 32 patients with TBI in six European centers. In a first open Cohort, eight patients received three 12-h intravenous infusions of VAS203 followed by a 12-h infusion-free interval over 3 days (total dose 15 mg/kg). Patients in Cohorts 2 and 3 (24) were randomized 2: 1 to receive either VAS203 or placebo as an infusion for 48 or 72 h, respectively (total dose 20 and 30 mg/kg). Effects of VAS203 on intracranial pressure (ICP), cerebral perfusion pressure (CPP), brain metabolism using microdialysis, and the therapy intensity level (TIL) were end points. In addition, exploratory analysis of the extended Glasgow Outcome Score (eGOS) after 6 months was performed. Metabolites of VAS203 were detected in cerebral microdialysates. No significant differences between treatment and placebo groups were observed for ICP, CPP, and brain metabolism. TIL on day 6 was significantly decreased (p < 0.04) in the VAS203 treated patients. The eGOS after 6 months was significantly higher in treated patients compared with placebo (p < 0.01). VAS203 was not associated with hepatic, hematologic, or cardiac toxic effects. At the highest dose administered, four of eight patients receiving VAS203 showed transitory acute kidney injury (stage 2-3). In conclusion, the significant improvement in clinical outcome indicates VAS203-mediated neuroprotection after TBI. At the highest dose, VAS203 is associated with a risk of acute kidney injury.	[Stover, John F.] Univ Hosp Zuerich, Zurich, Switzerland; [Belli, Antonio; Bulters, Diederik] Southampton Univ Hosp, Southampton, Hants, England; [Boret, Henry] HIA St Anne, Toulon, France; [Sahuquillo, Juan] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain; [Schmutzhard, Erich] Med Univ Innsbruck, A-6020 Innsbruck, Austria; [Zavala, Elisabeth] Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Spain; [Ungerstedt, Urban] Karolinska Inst, Stockholm, Sweden; [Schinzel, Reinhard; Tegtmeier, Frank] Vasopharm GmbH, D-97076 Wurzburg, Germany	Schinzel, R (corresponding author), Vasopharm GmbH, Friedrich Bergius Ring 15, D-97076 Wurzburg, Germany.	schinzel@vasopharm.de	Torne, Ramon/ABI-3299-2020; Martinez-Ricarte, Fran/AAI-6846-2020; Bulters, Diederik/ABH-3573-2020; Martinez-Ricarte, Fran/J-4729-2017; Poca, Maria A./B-8475-2008; Belli, Antonio/I-3799-2015; Sahuquillo, Juan/B-3577-2008; Shtaya, Anan/AAX-2494-2020	Torne, Ramon/0000-0001-7932-2528; Martinez-Ricarte, Fran/0000-0003-4567-0828; Martinez-Ricarte, Fran/0000-0003-4567-0828; Poca, Maria A./0000-0002-3831-0536; Belli, Antonio/0000-0002-3211-9933; Sahuquillo, Juan/0000-0003-0713-5875; Shtaya, Anan/0000-0001-7459-8437; Bulters, Diederik/0000-0001-9884-9050	EBIC	The study plan was developed with support from the EBIC.	Ahmed SB, 2007, CLIN J AM SOC NEPHRO, V2, P926, DOI 10.2215/CJN.00110107; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guzik TJ, 2002, HYPERTENSION, V39, P1088, DOI 10.1161/01.HYP.0000018041.48432.B5; Heemskerk S, 2009, NAT REV NEPHROL, V5, P629, DOI 10.1038/nrneph.2009.155; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Terpolilli NA, 2009, J NEUROTRAUM, V26, P1963, DOI 10.1089/neu.2008.0853; Tisdall MM, 2013, NEUROCRIT CARE, V19, P65, DOI 10.1007/s12028-011-9633-5; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; Wang T, 2002, AM J PHYSIOL-RENAL, V283, pF658, DOI 10.1152/ajprenal.00243.2001; Weinstein JR, 2010, ADV CHRONIC KIDNEY D, V17, P302, DOI 10.1053/j.ackd.2010.05.002; Werner ER, 2000, HANDB EXP PHARMACOL, V143, P137; Werner ER, 1996, BIOCHEM J, V320, P93; Woitzik J, 2001, ANAL BIOCHEM, V289, P10, DOI 10.1006/abio.2000.4893	21	31	31	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2014	31	19					1599	1606		10.1089/neu.2014.3344			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AP5VI	WOS:000342146400001	24831445				2021-06-18	
J	Alural, B; Duran, GA; Tufekci, KU; Allmer, J; Onkal, Z; Tunali, D; Genc, K; Genc, S				Alural, Begum; Duran, Gizem Ayna; Tufekci, Kemal Ugur; Allmer, Jens; Onkal, Zeynep; Tunali, Dogan; Genc, Kursad; Genc, Sermin			EPO mediates neurotrophic, neuroprotective, anti-oxidant and anti-apoptotic effects via downregulation of miR-451 and miR-885-5p in SH-SY5Y neuron-like cells	FRONTIERS IN IMMUNOLOGY			English	Article						erythropoietin; miRNAs; cell death; proliferation; apoptosis; migration; neurite outgrowth; oxidative stress	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM; RECOMBINANT ERYTHROPOIETIN; GENE-EXPRESSION; MICRORNAS; RECEPTOR; MODEL; DIFFERENTIATION; PROLIFERATION; PLASTICITY	Erythropoietin (EPO) is a neuroprotective cytokine, which has been applied in several animal models presenting neurological disorders. One of the proposed modes of action resulting in neuroprotection is post-transcriptional gene expression regulation. This directly brings to mind microRNAs (miRNAs), which are small non-coding RNAs that regulate gene expression at the post-transcriptional level. It has not yet been evaluated whether miRNAs participate in the biological effects of EPO or whether it, inversely, modulates specific miRNAs in neuronal cells. In this study, we employed miRNA and mRNA arrays to identify how EPO exerts its biological function. Notably, miR-451 and miR-885-5p are downregulated in EPO-treated SH-SY5Y neuronal-like cells. Accordingly, target prediction and transcriptome analysis of cells treated with EPO revealed an alteration of the expression of genes involved in apoptosis, cell survival, proliferation, and migration. Low expression of miRNAs in SHSY5Y was correlated with high expression of their target genes, vascular endothelial growth factor A, matrix metallo peptidase 9 (MMP9), cyclin-dependent kinase 2 (CDK2), erythropoietin receptor, Mini chromosome maintenance complex 5 (MCM5), B-cell lymphoma 2 (BCL2), and Galanin (GAL). Cell viability, apoptosis, proliferation, and migration assays were carried out for functional analysis after transfection with miRNA mimics, which inhibited some biological actions of EPO such as neuroprotection, anti-oxidation, anti-apoptosis, and migratory effects. In this study, we report for the first time that EPO downregulates the expression of miRNAs (miR-451 and miR-885-5p) in SH-SY5Y neuronal-like cells. The correlation between the over-expression of miRNAs and the decrease in EPO-mediated biological effects suggests that miR-451 and miR-885-5p may play a key role in the mediation of biological function.	[Alural, Begum; Tufekci, Kemal Ugur; Genc, Sermin] Dokuz Eylul Univ, Adv Biomed Res Ctr, TR-35340 Izmir, Turkey; [Alural, Begum; Duran, Gizem Ayna; Tufekci, Kemal Ugur; Onkal, Zeynep; Tunali, Dogan; Genc, Kursad; Genc, Sermin] Dokuz Eylul Univ, Hlth Sci Inst, Dept Neurosci, TR-35340 Izmir, Turkey; [Allmer, Jens] Izmir Inst Technol, Dept Mol Biol & Genet, Urla, Turkey	Genc, K (corresponding author), Dokuz Eylul Univ, Hlth Sci Inst, Dept Neurosci, TR-35340 Izmir, Turkey.	kemal.genc@deu.edu.tr	Allmer, Jens/E-2335-2016; Genc, Kemal Kursad/AAC-6920-2019; Tufekci, Kemal Ugur/A-2850-2014; Genc, Sermin/AAG-5348-2019	Allmer, Jens/0000-0002-2164-7335; Genc, Kemal Kursad/0000-0003-2120-091X; Tufekci, Kemal Ugur/0000-0003-0935-1360; Genc, Sermin/0000-0001-6126-7460	Dokuz Eylul UniversityDokuz Eylul University [2009-KB-SAG-46, 2009-KB-SAG-78]	The research was supported by grants from the Dokuz Eylul University (2009-KB-SAG-46 and 2009-KB-SAG-78).	Afanasyeva EA, 2011, CELL DEATH DIFFER, V18, P974, DOI 10.1038/cdd.2010.164; Anderson GD, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00129; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brines M, 2012, MOL MED, V18, P486, DOI 10.2119/molmed.2011.00414; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Chong ZZ, 2013, EXPERT OPIN THER TAR, V17, P707, DOI 10.1517/14728222.2013.780599; D'Eustachio P, 2011, METHODS MOL BIOL, V694, P49, DOI 10.1007/978-1-60761-977-2_4; Chamorro ME, 2013, BBA-MOL CELL RES, V1833, P1960, DOI 10.1016/j.bbamcr.2013.04.006; Ferracin M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-130; Follert P, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00005; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Hellewell SC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-156; Hobson SA, 2008, CELL MOL LIFE SCI, V65, P1806, DOI 10.1007/s00018-008-8154-7; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Hu Guoku, 2012, Frontiers in Genetics, V3, P56, DOI 10.3389/fgene.2012.00056; Jelkmann W, 2013, TRANSFUS MED HEMOTH, V40, P302, DOI 10.1159/000356193; Juul SE, 2008, DEV NEUROSCI-BASEL, V30, P231, DOI 10.1159/000110348; Juul SE, 2009, PEDIATR RES, V65, P485, DOI 10.1203/PDR.0b013e31819d90c8; Keller A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007440; Kosaka N, 2008, BRIT J HAEMATOL, V142, P293, DOI 10.1111/j.1365-2141.2008.07151.x; Kumral A, 2011, BRAIN DEV-JPN, V33, P632, DOI 10.1016/j.braindev.2010.10.014; Lee K, 2012, J NEUROSCI, V32, P5678, DOI 10.1523/JNEUROSCI.6471-11.2012; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Maiese K, 2012, INT J MOL SCI, V13, P11102, DOI 10.3390/ijms130911102; Maurer MH, 2002, NEUROSCI LETT, V327, P181, DOI 10.1016/S0304-3940(02)00425-1; Mengozzi M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00115; Mengozzi M, 2012, P NATL ACAD SCI USA, V109, P9617, DOI 10.1073/pnas.1200554109; Nairz M, 2012, MICROBES INFECT, V14, P238, DOI 10.1016/j.micinf.2011.10.005; Ogunshola Omolara O, 2013, Methods Mol Biol, V982, P13, DOI 10.1007/978-1-62703-308-4_2; Patz S, 2013, J NEUROTRAUM, V30, P1232, DOI 10.1089/neu.2012.2596; Pregi N, 2006, BBA-MOL CELL RES, V1763, P238, DOI 10.1016/j.bbamcr.2005.12.011; Qiu J, 2013, MOL MED REP, V7, P1955, DOI 10.3892/mmr.2013.1431; Renzi MJ, 2002, MOL BRAIN RES, V104, P86, DOI 10.1016/S0169-328X(02)00323-6; Rosenstein JM, 2010, ORGANOGENESIS, V6, P107, DOI 10.4161/org.6.2.11687; Sargin D, 2010, BEST PRACT RES-CLIN, V24, P573, DOI 10.1016/j.bpa.2010.10.005; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Stachurska A, 2013, MOL NUTR FOOD RES, V57, P504, DOI 10.1002/mnfr.201200456; Tufekci KU, 2014, METHODS MOL BIOL, V1107, P15, DOI 10.1007/978-1-62703-748-8_2; Um M, 2007, CELL SIGNAL, V19, P634, DOI 10.1016/j.cellsig.2006.08.014; Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161; Wenker SD, 2013, FEBS J, V280, P1630, DOI 10.1111/febs.12172; Yuen CM, 2010, J INVEST MED, V58, P893, DOI 10.231/JIM.0b013e3181e80c40; Zeng L, 2014, GENE THER, V21, P37, DOI 10.1038/gt.2013.55	44	31	34	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2014	5								475	10.3389/fimmu.2014.00475			17	Immunology	Immunology	CI0TZ	WOS:000354452400001	25324845	DOAJ Gold, Green Published			2021-06-18	
J	Zhu, XX; Park, J; Golinski, J; Qiu, JH; Khuman, J; Lee, CCH; Lo, EH; Degterev, A; Whalen, MJ				Zhu, Xiaoxia; Park, Juyeon; Golinski, Julianne; Qiu, Jianhua; Khuman, Jugta; Lee, Christopher C. H.; Lo, Eng H.; Degterev, Alexei; Whalen, Michael J.			Role of Akt and mammalian target of rapamycin in functional outcome after concussive brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Akt; concussion; mice; necrostatin-1; rapamycin; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SYNAPTIC PLASTICITY; MTOR; PHOSPHORYLATION; KINASE; ACTIVATION; SURVIVAL; MEMORY; DAMAGE; ALPHA	Akt (protein kinase B) and mammalian target of rapamycin (mTOR) have been implicated in the pathogenesis of cell death and cognitive outcome after cerebral contusion in mice; however, a role for Akt/mTOR in. concussive brain injury has not been well characterized. In a mouse closed head injury (CHI) concussion traumatic brain injury (TBI) model, phosphorylation of Akt (p-Akt), mTOR (p-mTOR), and S6RP (p-S6RP) was increased by 24 hours in cortical and hippocampal brain homogenates (P<0.05 versus sham for each), and p-S6RP was robustly induced in IBA-1 + microglia and glial fibrillary acidic protein-positive (GFAP+) astrocytes. Pretreatment with inhibitors of Akt or mTOR individually by the intracerebroventricular route reduced phosphorylation of their respective direct substrates FOXO1 (P<0.05) or S6RP (P<0.05) after CHI, confirming the activity of inhibitors. Rapamycin pretreatment significantly worsened hidden platform (P<0.01) and probe trial (P<0.05) performance in CHI mice. Intracerebroventricular administration of necrostatin-1 (Nec-1) before CHI increased hippocampal Akt and S6RP phosphorylation and improved place learning (probe trials, P<0.001 versus vehicle), whereas co-administration of rapamycin or Akt inhibitor with Nec-1 eliminated improved, probe trial performance. These data suggest a beneficial role for Akt/mTOR signaling after concussion TBI independent of cell death that may contribute to improved outcome by Nec-1.	[Zhu, Xiaoxia; Park, Juyeon; Golinski, Julianne; Qiu, Jianhua; Khuman, Jugta; Lee, Christopher C. H.; Lo, Eng H.; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA; [Zhu, Xiaoxia; Park, Juyeon; Golinski, Julianne; Qiu, Jianhua; Khuman, Jugta; Lee, Christopher C. H.; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Zhu, Xiaoxia] Fudan Univ, Huashan Hosp, Dept Rheumatol, Shanghai 200433, Peoples R China; [Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Degterev, Alexei] Tufts Univ, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA	Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA.	mwhalen@partners.org			Harvard Catalyst; Harvard University; affiliated academic health care centers [1UL1 TR001102-01]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS047447]; National Football League Players Association; Harvard Catalyst [1UL1 TR001102-01]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447, P01NS055104] Funding Source: NIH RePORTER	This work was conducted with support from Harvard Catalyst and financial contributions from Harvard University and its affiliated academic health care centers, grant number 1UL1 TR001102-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health. This work was supported by a grant from NINDS 5RO1NS047447 (MJW), a grant from the National Football League Players Association, and Harvard Catalyst (1UL1 TR001102-01). Authors have no disclosures or conflict of interest to report.	Troca-Marin JA, 2014, CNS NEUROL DISORD-DR, V13, P34, DOI 10.2174/18715273113126660184; Troca-Marin JA, 2012, PROG NEUROBIOL, V96, P268, DOI 10.1016/j.pneurobio.2012.01.005; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Centers for Disease C Prevention, 2011, MMWR-MORBID MORTAL W, V60, P1337; Chao CC, 2007, J NEUROSCI, V27, P6243, DOI 10.1523/JNEUROSCI.1531-07.2007; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Don ASA, 2012, DRUG DISCOV TODAY, V17, P861, DOI 10.1016/j.drudis.2012.04.010; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Gipson TT, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/486402; Graber TE, 2013, LEARN MEMORY, V20, P518, DOI 10.1101/lm.027664.112; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hoeffer CA, 2012, GENES BRAIN BEHAV, V11, P332, DOI 10.1111/j.1601-183X.2012.00768.x; Hoeffer CA, 2010, TRENDS NEUROSCI, V33, P67, DOI 10.1016/j.tins.2009.11.003; Huganir RL, 2013, NEURON, V80, P704, DOI 10.1016/j.neuron.2013.10.025; Ji K, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/627325; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Man HY, 2003, NEURON, V38, P611, DOI 10.1016/S0896-6273(03)00228-9; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McNamara CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056576; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Sanchez-Perez AM, 2006, NEUROCHEM INT, V49, P351, DOI 10.1016/j.neuint.2006.02.005; Santello M, 2012, ADV EXP MED BIOL, V970, P307, DOI 10.1007/978-3-7091-0932-8_14; Sharma A, 2010, J NEUROSCI, V30, P694, DOI 10.1523/JNEUROSCI.3696-09.2010; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Vivarelli MS, 2004, J EXP MED, V200, P399, DOI 10.1084/jem.20040446; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238	39	31	31	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2014	34	9					1531	1539		10.1038/jcbfm.2014.113			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AO4WT	WOS:000341342800014	24938400	Bronze, Green Published			2021-06-18	
J	Shein, SL; Shellington, DK; Exo, JL; Jackson, TC; Wisniewski, SR; Jackson, EK; Vagni, VA; Bayir, H; Clark, RSB; Dixon, CE; Janesko-Feldman, KL; Kochanek, PM				Shein, Steven L.; Shellington, David K.; Exo, Jennifer L.; Jackson, Travis C.; Wisniewski, Stephen R.; Jackson, Edwin K.; Vagni, Vincent A.; Bayir, Huelya; Clark, Robert S. B.; Dixon, C. Edward; Janesko-Feldman, Keri L.; Kochanek, Patrick M.			Hemorrhagic Shock Shifts the Serum Cytokine Profile from Pro- to Anti-Inflammatory after Experimental Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						blast injury; chemokine; head injury; hypotension; interleukin; polytrauma; resuscitation	CLOSED-HEAD INJURY; MONOCYTE CHEMOATTRACTANT PROTEIN-1; GROWTH-FACTOR PRODUCTION; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; IN-SITU DETECTION; CEREBROSPINAL-FLUID; MODERATE HYPOTHERMIA; NEUROLOGICAL DEFICIT; MULTIPLEX ASSESSMENT	Secondary insults, such as hemorrhagic shock (HS), worsen outcome from traumatic brain injury (TBI). Both TBI and HS modulate levels of inflammatory mediators. We evaluated the addition of HS on the inflammatory response to TBI. Adult male C57BL6J mice were randomized into five groups (n = 4 [naive] or 8/group): naive; sham; TBI (through mild-to-moderate controlled cortical impact [CCI] at 5 m/sec, 1-mm depth), HS; and CCI + HS. All non-naive mice underwent identical monitoring and anesthesia. HS and CCI + HS underwent a 35-min period of pressure-controlled hemorrhage (target mean arterial pressure, 25-27 mm Hg) and a 90-min resuscitation with lactated Ringer's injection and autologous blood transfusion. Mice were sacrificed at 2 or 24 h after injury. Levels of 13 cytokines, six chemokines, and three growth factors were measured in serum and in five brain tissue regions. Serum levels of several proinflammatory mediators (eotaxin, interferon-inducible protein 10 [IP-10], keratinocyte chemoattractant [KC], monocyte chemoattractant protein 1 [MCP-1], macrophage inflammatory protein 1alpha [MIP-1 alpha], interleukin [IL]-5, IL-6, tumor necrosis factor alpha, and granulocyte colony-stimulating factor [G-CSF]) were increased after CCI alone. Serum levels of fewer proinflammatory mediators (IL-5, IL-6, regulated upon activation, normal T-cell expressed, and secreted, and G-CSF) were increased after CCI + HS. Serum level of anti-inflammatory IL-10 was significantly increased after CCI + HS versus CCI alone. Brain tissue levels of eotaxin, IP-10, KC, MCP-1, MIP-1a, IL-6, and G-CSF were increased after both CCI and CCI + HS. There were no significant differences between levels after CCI alone and CCI + HS in any mediator. Addition of HS to experimental TBI led to a shift toward an anti-inflammatory serum profile-specifically, a marked increase in IL-10 levels. The brain cytokine and chemokine profile after TBI was minimally affected by the addition of HS.	[Shein, Steven L.; Shellington, David K.; Exo, Jennifer L.; Jackson, Travis C.; Vagni, Vincent A.; Bayir, Huelya; Clark, Robert S. B.; Dixon, C. Edward; Janesko-Feldman, Keri L.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Shein, Steven L.; Shellington, David K.; Exo, Jennifer L.; Jackson, Travis C.; Bayir, Huelya; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Bayir, Huelya; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Shellington, David K.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Exo, Jennifer L.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Shein, Steven/I-7763-2019	Kochanek, Patrick M/0000-0002-2627-913X; Shein, Steven/0000-0003-3382-5159; Jackson, Edwin/0000-0002-8101-6009; Wisniewski, Stephen/0000-0002-3877-9860	DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-10-C2124]; United States ArmyUnited States Department of Defense [W81XWH-09-2-0187]; U.S. ArmyUnited States Department of Defense [W81XWH-09-2-0187]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040686];  [T32HD040686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER	Support: DARPA N66001-10-C2124 (PMK), the United States Army W81XWH-09-2-0187 (PMK), and T32HD040686 (SLS, JLE).; The authors thank DARPA (N66001-10-C2124; to P. M. K.) and the U.S. Army (W81XWH-09-2-0187; to P. M. K.), and the NICHD (T32 HD040686; to S. L. S.) for support. The views, opinions, and/or findings contained in this article/presentation are those of the authors/presenters and should not be interpreted as representing the official views or policies, either expressed or implied, of the Defense Advanced Research Projects Agency or the Department of Defense. This article has been approved for public release (distribution unlimited).	Akkose S, 2007, ADV THER, V24, P955, DOI 10.1007/BF02877699; Alam HB, 2004, RESUSCITATION, V60, P91, DOI 10.1016/j.resuscitation.2003.08.006; Beeton CA, 2004, J BONE JOINT SURG BR, V86B, P912, DOI 10.1302/0301-620x.86b6.14176; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Black KL, 2002, J HEAD TRAUMA REHAB, V17, P489, DOI 10.1097/00001199-200212000-00001; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clendenen Tess V, 2010, BMC Res Notes, V3, P302, DOI 10.1186/1756-0500-3-302; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Denker SP, 2007, J NEUROCHEM, V100, P893, DOI 10.1111/j.1471-4159.2006.04162.x; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hensler T, 2003, SHOCK, V20, P497, DOI 10.1097/01.shk.0000095058.62263.1f; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Park KW, 2007, EXP MOL MED, V39, P812, DOI 10.1038/emm.2007.88; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; Perrin FE, 2005, BRAIN, V128, P854, DOI 10.1093/brain/awh407; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Rancan M, 2004, J CEREBR BLOOD F MET, V24, P1110, DOI 10.1097/01.WCB.0000133470.91843.72; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Takamiya M, 2007, J NEUROTRAUM, V24, P1833, DOI 10.1089/neu.2007.0336; Valles A, 2006, NEUROBIOL DIS, V22, P312, DOI 10.1016/j.nbd.2005.11.015; Watters JM, 2004, SHOCK, V22, P283, DOI 10.1097/01.shk.0000135288.54535.8a; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Widera D, 2004, EUR J CELL BIOL, V83, P381, DOI 10.1078/0171-9335-00403; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yokoyama Y, 2004, AM J PHYSIOL-GASTR L, V286, pG942, DOI 10.1152/ajpgi.00502.2003; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056	74	31	32	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2014	31	16					1386	1395		10.1089/neu.2013.2985			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AN4DB	WOS:000340536700002	24773520	Green Published			2021-06-18	
J	Atmaca, N; Atmaca, HT; Kanici, A; Anteplioglu, T				Atmaca, Nurgul; Atmaca, Hasan Tarik; Kanici, Ayse; Anteplioglu, Tugce			Protective effect of resveratrol on sodium fluoride-induced oxidative stress, hepatotoxicity and neurotoxicity in rats	FOOD AND CHEMICAL TOXICOLOGY			English	Article						Fluoride toxicity; Oxidative stress; Liver; Brain; Resveratrol; Rats	TRAUMATIC BRAIN-INJURY; DNA-DAMAGE; ANTIOXIDANT PROPERTIES; HISTOPATHOLOGICAL CHANGES; LIPID-PEROXIDATION; BLACK BERRY; TOXICITY; ACID; PARAMETERS; FLUOROSIS	Protective effect of resveratrol on sodium fluoride-induced oxidative stress, hepatotoxicity and neurotoxicity were studied in rats. A total of 28 Wistar albino male rats were used. Four study groups were randomly formed with seven animals in each. The groups were treated for 21 days with distilled water (control group), with water containing 100 ppm fluoride (fluoride group), with resveratrol (12.5 mg/kg i.p., resveratrol group), or with 100 ppm fluoride + 12.5 mg/kg resveratrol i.p. (fluoride + resveratrol group). At the end of the trial, blood samples were collected by cardiac puncture and tissue samples were taken simultaneously. The total antioxidant and oxidant status in plasma and tissues as well as plasma 8-hydroxydeoxyguanosine levels were measured. Histopathological analyses of rat liver and brain tissues were performed in all groups to identify any changes. In the fluoride group, the total oxidant levels increased in plasma, liver and brain and total antioxidant levels decreased, as did the plasma 8-hydroxy-deoxyguanosine levels. These changes were prevented by co-administration of resveratrol. In addition, fluoride-associated severe histopathological changes in brain and liver tissues were not observed in the fluoride + resveratrol group. Consequently, these data suggested that resveratrol had beneficial effects in alleviating fluoride-induced oxidative stress. (C) 2014 Elsevier Ltd. All rights reserved.	[Atmaca, Nurgul] Kirikkale Univ, Fac Vet Med, Dept Physiol, Kirikkale, Turkey; [Atmaca, Hasan Tarik; Anteplioglu, Tugce] Kirikkale Univ, Fac Vet Med, Dept Pathol, Kirikkale, Turkey; [Kanici, Ayse] Kafkas Univ, Fac Vet Med, Dept Pharmacol & Toxicol, Kars, Turkey	Atmaca, N (corresponding author), Kirikkale Univ, Fac Vet Med, Dept Physiol, TR-71450 Kirikkale, Turkey.	nurgulzengin@yahoo.com; ht_atmaca@yahoo.com; akanici@hotmail.com; tugceanteplioglu@gmail.com	Das, Kusal/E-8167-2011; , HTA/AAG-2944-2019; TARHANE, Ayse KANICI/ABI-4581-2020	Das, Kusal/0000-0002-3641-2117; ATMACA, HASAN TARIK/0000-0001-8379-4114	Kirikkale University Research FundKirikkale University [2011/44]	Financial support for this Project (Project No: 2011/44) was provided by the Kirikkale University Research Fund.	Agha FE, 2012, LIFE SCI J, V9, P1260; de la Lastra CA, 2006, OXIDAT STRESS DIS, V20, P33; ARICHI H, 1982, CHEM PHARM BULL, V30, P1766; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Barbier O, 2010, CHEM-BIOL INTERACT, V188, P319, DOI 10.1016/j.cbi.2010.07.011; Bastianetto S, 2000, BRIT J PHARMACOL, V131, P711, DOI 10.1038/sj.bjp.0703626; Bharti VK, 2009, BIOL TRACE ELEM RES, V130, P131, DOI 10.1007/s12011-009-8320-2; Bouaziz H, 2006, PESTIC BIOCHEM PHYS, V86, P124, DOI 10.1016/j.pestbp.2006.02.004; Burkhardt S, 2001, INT J BIOCHEM CELL B, V33, P775, DOI 10.1016/S1357-2725(01)00052-8; CARLSON CH, 1960, P SOC EXP BIOL MED, V104, P235; Chlubek D, 2003, FLUORIDE, V36, P217; Dalaklioglu S, 2013, HUM EXP TOXICOL, V32, P662, DOI 10.1177/0960327112468178; Edmunds WM, 1996, GEOL SOC SP, P91, DOI 10.1144/GSL.SP.1996.113.01.08; Eraslan G, 2007, PESTIC BIOCHEM PHYS, V88, P273, DOI 10.1016/j.pestbp.2007.01.002; Erel O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/j.clinbiochem.2003.11.015; Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008; Flora SJS, 2009, J NEUROL SCI, V285, P198, DOI 10.1016/j.jns.2009.07.001; GEERAERTS F, 1986, FLUORIDE, V19, P108; GruckaMamczar E, 1997, FLUORIDE, V30, P157; Gulcin I, 2010, INNOV FOOD SCI EMERG, V11, P210, DOI 10.1016/j.ifset.2009.07.002; Guo L, 2007, J AGR FOOD CHEM, V55, P5881, DOI 10.1021/jf070440a; Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S; Hassan HA, 2010, FOOD CHEM TOXICOL, V48, P1999, DOI 10.1016/j.fct.2010.05.018; Hassan HA, 2009, FOOD CHEM TOXICOL, V47, P2332, DOI 10.1016/j.fct.2009.06.023; Ignatowicz E, 2001, POL J PHARMACOL, V53, P557; Inkielewicz-Stepniak I, 2010, FOOD CHEM TOXICOL, V48, P1607, DOI 10.1016/j.fct.2010.03.033; KAPOOR V, 1993, FLUORIDE, V26, P105; Karadeniz A, 2008, FLUORIDE, V41, P67; Karaoz E., 2003, TURK KLIN TIP BILIM, V23, P129; Kasdallah-Grissa A, 2007, LIFE SCI, V80, P1033, DOI 10.1016/j.lfs.2006.11.044; KESSABI M, 1986, VET HUM TOXICOL, V28, P300; Kolouchova-Hanzlikova I, 2004, FOOD CHEM, V87, P151, DOI 10.1016/j.foodchem.2004.01.028; Leonard SS, 2003, BIOCHEM BIOPH RES CO, V309, P1017, DOI 10.1016/j.bbrc.2003.08.105; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; Lu KT, 2008, J AGR FOOD CHEM, V56, P6910, DOI 10.1021/jf8007212; Mittal M, 2006, CHEM-BIOL INTERACT, V162, P128, DOI 10.1016/j.cbi.2006.05.018; Mokni M, 2007, NEUROCHEM RES, V32, P981, DOI 10.1007/s11064-006-9255-z; MULLENIX PJ, 1995, NEUROTOXICOL TERATOL, V17, P169, DOI 10.1016/0892-0362(94)00070-T; Nabavi SF, 2013, IND CROP PROD, V44, P50, DOI 10.1016/j.indcrop.2012.10.024; Nabavi SM, 2012, FOOD CHEM, V132, P931, DOI 10.1016/j.foodchem.2011.11.070; Panneerselvam L, 2013, BIOL TRACE ELEM RES, V151, P85, DOI 10.1007/s12011-012-9534-2; Reddy GB, 2003, TOXICOL SCI, V72, P363, DOI 10.1093/toxsci/kfg030; Rzeuski R, 1998, FLUORIDE, V31, P43; Shanthakumari D, 2004, TOXICOLOGY, V204, P219, DOI 10.1016/j.tox.2004.06.058; Shashi A, 2003, FLUORIDE, V36, P95; Shashi A, 2001, FLUORIDE, V34, P34; Silan C, 2007, BIOL PHARM BULL, V30, P79, DOI 10.1248/bpb.30.79; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Tatlidede E, 2009, FREE RADICAL RES, V43, P195, DOI 10.1080/10715760802673008; Trivedi MH, 2012, FLUORIDE, V45, P13; Tunali-Akbay T, 2010, J PHARM PHARM SCI, V13, P303, DOI 10.18433/J30K5Q; USNRC, 1993, HLTH EFF ING FLUOR; Vani ML, 2000, FLUORIDE, V33, P17; Wang AG, 2004, FLUORIDE, V37, P107; Wang Y, 2002, J AGR FOOD CHEM, V50, P431, DOI 10.1021/jf010812u; WATSON BD, 1993, PROG BRAIN RES, V96, P69; Whitford G M, 1983, Dent Hyg (Chic), V57, P16; Yan Y, 2012, FOOD CHEM TOXICOL, V50, P168, DOI 10.1016/j.fct.2011.10.046; Zhang WQ, 2013, FOOD CHEM TOXICOL, V51, P87, DOI 10.1016/j.fct.2012.09.023; Zini R, 1999, DRUG EXP CLIN RES, V25, P87	62	31	33	1	27	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-6915	1873-6351		FOOD CHEM TOXICOL	Food Chem. Toxicol.	AUG	2014	70						191	197		10.1016/j.fct.2014.05.011			7	Food Science & Technology; Toxicology	Food Science & Technology; Toxicology	AM1IO	WOS:000339599800025	24857819				2021-06-18	
J	Effgen, GB; Vogel, EW; Lynch, KA; Lobel, A; Hue, CD; Meaney, DF; Bass, CR; Morrison, B				Effgen, Gwen B.; Vogel, Edward W., III; Lynch, Kimberly A.; Lobel, Ayelet; Hue, Christopher D.; Meaney, David F.; Bass, Cameron R.; Morrison, Barclay, III			Isolated Primary Blast Alters Neuronal Function with Minimal Cell Death in Organotypic Hippocampal Slice Cultures	JOURNAL OF NEUROTRAUMA			English	Article						blast; hippocampus; in vitro; neuron; shock tube	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; RISK-ASSESSMENT; RAT; DEPRESSION; STRETCH; MODEL	An increasing number of U.S. soldiers are diagnosed with traumatic brain injury (TBI) subsequent to exposure to blast. In the field, blast injury biomechanics are highly complex and multi-phasic. The pathobiology caused by exposure to some of these phases in isolation, such as penetrating or inertially driven injuries, has been investigated extensively. However, it is unclear whether the primary component of blast, a shock wave, is capable of causing pathology on its own. Previous in vivo studies in the rodent and pig have demonstrated that it is difficult to deliver a primary blast (i.e., shock wave only) without rapid head accelerations and potentially confounding effects of inertially driven TBI. We have previously developed a well-characterized shock tube and custom in vitro receiver for exposing organotypic hippocampal slice cultures to pure primary blast. In this study, isolated primary blast induced minimal hippocampal cell death (on average, below 14% in any region of interest), even for the most severe blasts tested (424 kPa peak pressure, 2.3 ms overpressure duration, and 248 kPa*ms impulse). In contrast, measures of neuronal function were significantly altered at much lower exposures (336 kPa, 0.84 ms, and 86.5 kPa*ms), indicating that functional changes occur at exposures below the threshold for cell death. This is the first study to investigate a tolerance for primary blast-induced brain cell death in response to a range of blast parameters and demonstrate functional deficits at subthreshold exposures for cell death.	[Effgen, Gwen B.; Vogel, Edward W., III; Lynch, Kimberly A.; Lobel, Ayelet; Hue, Christopher D.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Bass, Cameron R.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC 8904 1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Meaney, David/0000-0002-0954-4122	NDSEG; Multi-disciplinary University Research Initiative from the Army Research Office [W911MF-10-1-05026]	This work was supported by an NDSEG Graduate Fellowship (EV) and Multi-disciplinary University Research Initiative from the Army Research Office (W911MF-10-1-05026). The authors thank Charles J. Levin for his skilled technical assistance in experimental setup, operation, and characterization of the shock tube as well as Lamia Ateshian for her skilled technical assistance with experimental setup, imaging, and image analysis. Additionally, the authors thank Garrett Wood for his skilled technical assistance in blast level scaling and CONWEP analysis.	Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bowen I., 1968, DASA2113; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Connell S, 2011, J NEUROTRAUM, V28, P1229, DOI 10.1089/neu.2011.1832; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Kodama T, 2000, BIOPHYS J, V79, P1821, DOI 10.1016/S0006-3495(00)76432-0; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Muller M, 1999, J NEUROPHYSIOL, V82, P1818, DOI 10.1152/jn.1999.82.4.1818; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Pun P, 2011, FRONT NEUROL, V2, P1; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Shridharani J. K., 2012, PERS AM SYST S SEPT; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; U.S. Department of Health, 2009, BLAST INJ TRAUM BRAI; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wood G., 2013, J NEUROTRAUMA UNPUB; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009	39	31	31	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1202	1210		10.1089/neu.2013.3227			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500009	24558968				2021-06-18	
J	Martin, RC; Faught, E; Richman, J; Funkhouser, E; Kim, Y; Clements, K; Pisu, M				Martin, Roy C.; Faught, Edward; Richman, Joshua; Funkhouser, Ellen; Kim, Yongin; Clements, Kay; Pisu, Maria			Psychiatric and neurologic risk factors for incident cases of new-onset epilepsy in older adults: Data from US Medicare beneficiaries	EPILEPSIA			English	Article						Cerebrovascular disease; Dementia; Depression; Psychosis; Substance abuse	SEIZURES; DEPRESSION; DISORDERS	Objective: Neurologic diseases such as stroke are risk factors for new-onset epilepsy in older adults. Recent evidence suggests that psychiatric disorders independently predict epilepsy in older male veterans. Our aim was to examine the relationship between these disorders in a population-based study of older adults that also included women and minorities. Methods: Weused a national 5% random sample of 2005 Medicare beneficiaries including all 50 US states and Washington, DC. Beneficiaries were 65 years of age or older, with continuous Medicare Part A and Part B coverage and not in managed care plans. Epilepsy cases were identified from claims for physician visits, hospitalizations, and outpatient procedures. We used logistic regressions for the overall sample and stratified by gender to determine whether risk of new-onset epilepsy was associated with prior history of psychiatric (i.e., depression, psychosis, bipolar disorder, schizophrenia, posttraumatic stress disorder (PTSD), adjustment disorder, and substance abuse/dependence) and neurologic conditions (i.e., cerebrovascular disease, dementia, traumatic brain injury, brain tumor, metastatic cancer). Results: Preexisting psychiatric disorders were significantly associated with new-onset epilepsy in the study population as were the neurologic conditions evaluated. Five of the seven psychiatric disorders examined were independently associated with new-onset epilepsy; substance abuse, psychosis, bipolar disorder, schizophrenia, and depression. Gender interaction effects were found for substance abuse/dependence and brain tumors. Significance: Both neurologic and psychiatric factors significantly predicted new-onset epilepsy in a population-based sample of male and female older adults. These results support earlier findings and extend the understanding of risk models for new-onset epilepsy in broader older adult populations.	[Martin, Roy C.] UAB, Dept Neurol, Birmingham, AL 35294 USA; [Faught, Edward] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; [Richman, Joshua] UAB, Dept Surg, Birmingham, AL 35294 USA; [Funkhouser, Ellen; Kim, Yongin; Pisu, Maria] UAB, Div Prevent Med, Birmingham, AL 35294 USA; [Clements, Kay] UAB, Dept Hlth Serv Adm, Birmingham, AL 35294 USA	Pisu, M (corresponding author), UAB, Div Prevent Med, 1530 1720 2nd Ave S,Med Towers 636, Birmingham, AL 35294 USA.	mpisu@uab.edu	Faught, Raymond Edward/F-7767-2010		Centers for Disease Control and Prevention through the Association of American Medical CollegesUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U36/CCU319276, MM-1042-08/08]	This project was supported under a cooperative agreement from the Centers for Disease Control and Prevention through the Association of American Medical Colleges, grant number U36/CCU319276, AAMC ID number MM-1042-08/08. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.	Adachi N, 2011, EPILEPSIA, V52, P1239, DOI 10.1111/j.1528-1167.2011.03039.x; Adelow C, 2012, NEUROLOGY, V78, P396, DOI 10.1212/WNL.0b013e318245f461; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Desai SD, 2010, EPILEPSY BEHAV, V19, P301, DOI 10.1016/j.yebeh.2010.07.005; Ettinger AB, 2010, EPILEPSY BEHAV, V17, P70, DOI 10.1016/j.yebeh.2009.10.010; Faught E, 2012, NEUROLOGY, V78, P448, DOI 10.1212/WNL.0b013e3182477edc; Hesdorffer DC, 2012, ANN NEUROL, V72, P184, DOI 10.1002/ana.23601; Hesdorffer DC, 2006, ANN NEUROL, V59, P35, DOI 10.1002/ana.20685; Hesdorffer DC, 2000, ANN NEUROL, V47, P246, DOI 10.1002/1531-8249(200002)47:2<246::AID-ANA17>3.0.CO;2-E; Holden E Wayne, 2005, Dis Manag, V8, P1, DOI 10.1089/dis.2005.8.1; HORNIG CR, 1990, EUR ARCH PSY CLIN N, V239, P379, DOI 10.1007/BF01734546; Irizarry MC, 2012, ARCH NEUROL-CHICAGO, V69, P368, DOI 10.1001/archneurol.2011.830; Kanner AM, 2011, EPILEPSIA, V52, P21, DOI 10.1111/j.1528-1167.2010.02907.x; Karouni M, 2010, EUR J CLIN PHARMACOL, V66, P1151, DOI 10.1007/s00228-010-0861-y; Pisu M, 2012, EPILEPSIA, V53, P2186, DOI 10.1111/j.1528-1167.2012.03640.x; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Schumock GT, 2013, MINISENTINEL METHODS; St Germaine-Smith C, 2012, NEUROLOGY, V79, P1049, DOI 10.1212/WNL.0b013e3182684707; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; Townsend L, 2010, MINISENTINEL SYSTEMA	20	31	31	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUL	2014	55	7					1120	1127		10.1111/epi.12649			8	Clinical Neurology	Neurosciences & Neurology	AN4YI	WOS:000340595500026	24902475				2021-06-18	
J	Brucken, A; Kurnaz, P; Bleilevens, C; Derwall, M; Weis, J; Nolte, K; Rossaint, R; Fries, M				Bruecken, Anne; Kurnaz, Pinar; Bleilevens, Christian; Derwall, Matthias; Weis, Joachim; Nolte, Kay; Rossaint, Rolf; Fries, Michael			Dose dependent neuroprotection of the noble gas argon after cardiac arrest in rats is not mediated by K-ATP-Channel opening	RESUSCITATION			English	Article						Cardiopulmonary resuscitation; Hypoxia-ischaemia; Brain; Reperfusion injury; Argon; Neuroprotective agents	TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; NEONATAL ASPHYXIA; HYPOTHERMIA COMBINE; CEREBRAL-ISCHEMIA; POTASSIUM CHANNEL; XENON; PIGS; ANESTHESIA; NEURONS	Purpose: Argon at a dosage of 70% is neuroprotective when given 1 h after cardiac arrest (CA) in rats. In a rodent model, we investigated if the neuroprotective effects of argon are dose dependent and mediated by adenosine triphosphate dependent potassium (K-ATP) channels. Methods: Forty-seven male Sprague-Dawley rats were subjected to 7 min of CA and 3 min of cardiopulmonary resuscitation (CPR). In protocol I animals were randomized to receive either 70% or 40% argon ventilation 1 h after successful CPR or no argon-treatment. Animals of the second protocol also received 1 h of 70% argon ventilation or no argon treatment but were randomized to a group receiving the KATP channel blocker 5-hydroxydecanoate (5-HD). For all animals a neurological deficit score (NDS) was calculated daily for seven days following the experiment before the animals were killed and the brains harvested for histopathological analyses. Results: All animals survived. Control animals exhibited severe neurologic dysfunction at all points in time as measured with the NDS. Argon treated animals showed significant improvements in the NDS through all postoperative days in a dose dependent fashion. This was paralleled by a significant reduction in the neuronal damage index in the neocortex and the hippocampal CA 3/4 region. Administration of 5-HD neither abolished the positive effects on functional recovery nor on histopathologic changes observed in the argon group. Conclusion: Our study demonstrates a dose dependent neuroprotective effect of argon administration in this rodent model, which is not mediated via ATP dependent potassium channels. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Bruecken, Anne; Kurnaz, Pinar; Bleilevens, Christian; Derwall, Matthias; Rossaint, Rolf; Fries, Michael] Univ Hosp RWTH Aachen, Dept Anaesthesiol, D-52074 Aachen, Germany; [Weis, Joachim; Nolte, Kay] Univ Hosp RWTH Aachen, Inst Neuropathol, D-52074 Aachen, Germany	Brucken, A (corresponding author), Univ Hosp RWTH Aachen, Dept Anaesthesiol, Pauwelsstr 30, D-52074 Aachen, Germany.	abruecken@ukaachen.de	Weis, Joachim/G-1984-2014; Bleilevens, Christian/AAG-8034-2020	Weis, Joachim/0000-0003-3280-6773; Bleilevens, Christian/0000-0002-2104-1843			Bantel C, 2010, ANESTHESIOLOGY, V112, P623, DOI 10.1097/ALN.0b013e3181cf894a; Bantel C, 2009, ANESTHESIOLOGY, V110, P986, DOI 10.1097/ALN.0b013e31819dadc7; Brucken A, 2013, BRIT J ANAESTH, V110, P106, DOI 10.1093/bja/aes509; Chakkarapani E, 2010, ANN NEUROL, V68, P330, DOI 10.1002/ana.22016; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; David HN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030934; Derwall M, 2009, MINERVA ANESTESIOL, V75, P37; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Fahlenkamp AV, 2012, EUR J PHARMACOL, V674, P104, DOI 10.1016/j.ejphar.2011.10.045; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Fries M, 2008, CRIT CARE MED, V36, P2420, DOI 10.1097/CCM.0b013e3181802874; Fries M, 2012, CRIT CARE MED, V40, P1297, DOI 10.1097/CCM.0b013e31823c8ce7; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Harris K, 2013, ANESTHESIOLOGY, V119, P1137, DOI 10.1097/ALN.0b013e3182a2a265; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Idris AH, 1996, RESUSCITATION, V33, P69, DOI 10.1016/S0300-9572(96)01055-6; Jawad N, 2009, NEUROSCI LETT, V460, P232, DOI 10.1016/j.neulet.2009.05.069; Laver S, 2004, INTENS CARE MED, V30, P2126, DOI 10.1007/s00134-004-2425-z; Loetscher PD, 2009, CRIT CARE, V13, DOI 10.1186/cc8214; Luo Y, 2008, ANESTHESIOLOGY, V109, P782, DOI 10.1097/ALN.0b013e3181895f88; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; NEUMAR RW, 1995, RESUSCITATION, V29, P249, DOI 10.1016/0300-9572(94)00827-3; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Robin E, 2011, BRAIN RES, V1375, P137, DOI 10.1016/j.brainres.2010.12.054; Ryang YM, 2011, CRIT CARE MED, V39, P1448, DOI 10.1097/CCM.0b013e31821209be; Sanders RD, 2003, BRIT J ANAESTH, V91, P709, DOI 10.1093/bja/aeg232; Schmidt M, 2005, ANESTHESIOLOGY, V102, P929, DOI 10.1097/00000542-200505000-00011; STARK RA, 1981, J APPL PHYSIOL, V51, P1355; Yarin YM, 2005, HEARING RES, V201, P1, DOI 10.1016/j.heares.2004.09.015; Zarch AV, 2009, INT J NEUROSCI, V119, P1346, DOI 10.1080/00207450802338721; Zhuang L, 2012, CRIT CARE MED, V40, P1724, DOI 10.1097/CCM.0b013e3182452164	32	31	31	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUN	2014	85	6					826	832		10.1016/j.resuscitation.2014.02.014			7	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	AJ0GY	WOS:000337329600035	24582739				2021-06-18	
J	Sibener, L; Zaganjor, I; Snyder, HM; Bain, LJ; Egge, R; Carrillo, MC				Sibener, Leslie; Zaganjor, Ibrahim; Snyder, Heather M.; Bain, Lisa J.; Egge, Robert; Carrillo, Maria C.			Alzheimer's Disease prevalence, costs, and prevention for military personnel and veterans	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's disease; Military medicine; Traumatic brain injury; Posttraumatic stress disorder; Healthcare costs	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; COGNITIVE FUNCTION; UNITED-STATES; OLDER-ADULTS; DEMENTIA; RISK; ATHEROSCLEROSIS; ENCEPHALOPATHY; EPIDEMIOLOGY	By 2050, more than 13 million Americans of all ages are estimated to be living with Alzheimer's disease (AD), and the aggregate costs of care will swell to approximately $1.2 trillion. The rapidly climbing number of those affected with AD includes a growing population of aging military veterans affected who may have an added risk for the disease as a consequence of traumatic brain injury, posttraumatic stress disorder, and/or service-related injuries. The increasing number of individuals, the long duration of disability, and the rising cost of care for AD and other dementia to our society are important public health challenges facing many older adults. These challenges are further compounded by a burgeoning military veteran population that is much younger, with an increased risk of AD and other dementia, and who may experience decades-long periods of disability and care. This outlook underscores the critical need for investments in research at the federal and international levels to accelerate the pace of progress in developing breakthrough discoveries that will change the trajectory of AD and related dementia. (C) 2014 The Alzheimer's Association. All rights reserved.	[Sibener, Leslie; Zaganjor, Ibrahim; Snyder, Heather M.; Carrillo, Maria C.] Alzheimers Assoc, Med & Sci Relat Div, Chicago, IL 60631 USA; [Egge, Robert] Alzheimers Assoc, Publ Policy & Advocacy Div, Washington, DC USA	Carrillo, MC (corresponding author), Alzheimers Assoc, Med & Sci Relat Div, Chicago, IL 60631 USA.	mcarrillo@alz.org	MUNOZ, ROSA ANA/H-3964-2018	MUNOZ, ROSA ANA/0000-0002-7504-2163	United States Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	Publication of this article was supported by the United States Army Medical Research and Materiel Command.	Ahmadi N, 2011, AM J CARDIOL, V108, P29, DOI 10.1016/j.amjcard.2011.02.340; Alzheimer's Association, 2014, ALZHEIMERS DEMENT, V10, P47, DOI [10.1016/j.jalz.2010.01.009, DOI 10.1016/J.JALZ.2014.02.001]; Barnes DE, 2009, NEUROLOGY, V73, P173, DOI 10.1212/WNL.0b013e3181a81636; Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59; Bremner JD, 2007, NEUROIMAG CLIN N AM, V17, P523, DOI 10.1016/j.nic.2007.07.003; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Byers AL, 2012, AM J GERIAT PSYCHIAT, V20, P664, DOI 10.1097/JGP.0b013e31822001c1; Bynum J, 2011, UNPUBLISHED TABULATI; Carrillo MC, 2013, ALZHEIMERS DEMENT, V9, P123, DOI 10.1016/j.jalz.2012.12.004; Cohen BE, 2013, J CLIN PSYCHIAT, V74, P1063, DOI 10.4088/JCP.12m08291; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Department of Defense, 2011, CONT TRACK SYST NUMB; Department of Veterans Affairs, 2003, VHA VIS 2020; Eichler HG, 2013, NEW ENGL J MED, V369, P1577, DOI 10.1056/NEJMp1310771; Fischer H., 2010, US MILITARY CASUALTY, P1; Gao Y, 2013, INT J GERIATR PSYCH, V28, P441, DOI 10.1002/gps.3845; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Higgins GA, 1997, PHARMACOL BIOCHEM BE, V56, P675, DOI 10.1016/S0091-3057(96)00420-0; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Loef M, 2013, OBESITY, V21, pE51, DOI 10.1002/oby.20037; Lukaschek K, 2013, J PSYCHOSOM RES, V74, P340, DOI 10.1016/j.jpsychores.2012.12.011; MacKnight C, 2002, DEMENT GERIATR COGN, V14, P77, DOI 10.1159/000064928; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; MARTLAND HS, 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; MAYEUX R, 1991, ARCH NEUROL-CHICAGO, V48, P269, DOI 10.1001/archneur.1991.00530150037014; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Metropolitan Life Insurance Company, 2012, 2012 METLIFE MARK SU; Moore MJ, 2001, J GERONTOL B-PSYCHOL, V56, pS219, DOI 10.1093/geronb/56.4.S219; National Council on Disability, 2009, INV WOUNDS SERV SERV; Nowinski C, 2006, HEAD GAMES FOOTBALLS; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; Reiman EM, 2011, J ALZHEIMERS DIS, V26, P321, DOI 10.3233/JAD-2011-0059; Roses AD, 2012, ALZHEIMERS DEMENT S4, V8, pS753; Rytwinski NK, 2013, J TRAUMA STRESS, V26, P299, DOI 10.1002/jts.21814; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; U. S. Census Bureau, 2012, US CENS BUR 2008 201; van Oijen M, 2007, ANN NEUROL, V61, P403, DOI 10.1002/ana.21073; Weiner MW, 2013, ALZHEIMERS DEMENT, V9, P445, DOI [10.1016/j.jalz.2013.05.1769, 10.1016/j.jalz.2013.03.005]; Yaffe K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7051; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Ziegler-Graham K, 2008, ALZHEIMERS DEMENT, V4, P316, DOI 10.1016/j.jalz.2008.05.2479	52	31	31	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUN	2014	10	3		1			S105	S110		10.1016/j.jalz.2014.04.011			6	Clinical Neurology	Neurosciences & Neurology	CP8GM	WOS:000360130700006	24924663	Other Gold			2021-06-18	
J	Zheng, P; Shultz, SR; Hovens, CM; Velakoulis, D; Jones, NC; O'Brien, TJ				Zheng, Ping; Shultz, Sandy R.; Hovens, Chris M.; Velakoulis, Dennis; Jones, Nigel C.; O'Brien, Terence J.			Hyperphosphorylated Tau is Implicated in Acquired Epilepsy and Neuropsychiatric Comorbidities	MOLECULAR NEUROBIOLOGY			English	Article						Hyperphosphorylated tau; Acquired epilepsy; Traumatic brain injury; Post-status epilepticus; Neuropsychiatric comorbidities	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; NEURODEGENERATIVE DISEASES; PROTEIN PHOSPHATASES; MULTIPLE-SCLEROSIS; NEURONAL LOSS; OKADAIC ACID; RISK-FACTOR	Epilepsy is a common group of neurological diseases. Acquired epilepsy can be caused by brain insults, such as trauma, infection or tumour, and followed by a latent period from several months to years before the emergence of recurrent spontaneous seizures. More than 50 % of epilepsy cases will develop chronic neurodegenerative, neurocognitive and neuropsychiatric comorbidities. It is important to understand the mechanisms by which a brain insult results in acquired epilepsy and comorbidities in order to identify targets for novel therapeutic interventions that may mitigate these outcomes. Recent studies have implicated the hyperphosphorylated tubulin-associated protein (tau) in rodent models of epilepsy and Alzheimer's disease, and in experimental and clinical studies of traumatic brain injury. This potentially represents a novel target to mitigate epilepsy and associated neurocognitive and psychiatric disorders post-brain injury. This article reviews the potential role of tau-based mechanisms in the pathophysiology of acquired epilepsy and its neurocognitive and neuropsychiatric comorbidities, and the potential to target these for novel disease-modifying treatments.	[Zheng, Ping; Shultz, Sandy R.; Jones, Nigel C.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia; [Hovens, Chris M.] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Melbourne, Vic 3050, Australia; [Velakoulis, Dennis] Royal Melbourne Hosp, Melbourne Neuropsychiat Ctr, Melbourne, Vic 3050, Australia	Zheng, P (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, 4th Floor,Clin Sci Bldg, Melbourne, Vic 3050, Australia.	zhp@student.unimelb.edu.au	O'Brien, Terence J/L-8102-2013; Velakoulis, Dennis/A-4778-2008	Velakoulis, Dennis/0000-0002-8842-8479; Shultz, Sandy/0000-0002-2525-8775; Hovens, Christopher/0000-0002-0610-1289; Jones, Nigel/0000-0002-1080-8439; O'Brien, Terence/0000-0002-7198-8621			Adams SJ, 2008, BRIT J PSYCHIAT, V192, P464, DOI 10.1192/bjp.bp.107.046664; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Bouilleret V, 2009, NEUROIMAGE, V45, P267, DOI 10.1016/j.neuroimage.2008.12.019; Braithwaite SP, 2012, PROG MOL BIOL TRANSL, V106, P343, DOI 10.1016/B978-0-12-396456-4.00012-2; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Brunden KR, 2009, NAT REV DRUG DISCOV, V8, P783, DOI 10.1038/nrd2959; Corcoran NM, 2010, RSC DRUG DISCOV, V2, P195; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; Deters N, 2009, BIOCHEM BIOPH RES CO, V379, P400, DOI 10.1016/j.bbrc.2008.12.140; Dickey AS, 2011, J NEUROSCI, V31, P15716, DOI 10.1523/JNEUROSCI.3159-11.2011; Engel T, 2006, J NEUROCHEM, V99, P1445, DOI 10.1111/j.1471-4159.2006.04139.x; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Foster CA, 2007, J PHARMACOL EXP THER, V323, P469, DOI 10.1124/jpet.107.127183; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gendron TF, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-13; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; Guillozet AL, 2003, ARCH NEUROL-CHICAGO, V60, P729, DOI 10.1001/archneur.60.5.729; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hanger DP, 2009, TRENDS MOL MED, V15, P112, DOI 10.1016/j.molmed.2009.01.003; Hanyu Y, 2009, GENES CELLS, V14, P539, DOI 10.1111/j.1365-2443.2009.01290.x; Helmstaedter C, 2009, BRAIN, V132, P2822, DOI 10.1093/brain/awp182; Hesdorffer DC, 2010, EPILEPSY CURR, V10, P55, DOI 10.1111/j.1535-7511.2010.01355.x; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Honig A, 1999, INT CLIN PSYCHOPHARM, V14, P167, DOI 10.1097/00004850-199905030-00003; Hung C, 2012, CURR TREAT OPTION NE, V14, P293, DOI 10.1007/s11940-012-0178-5; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Irizarry MC, 2012, ARCH NEUROL-CHICAGO, V69, P368, DOI 10.1001/archneurol.2011.830; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jensen FE, 2011, EPILEPSIA, V52, P1, DOI 10.1111/j.1528-1167.2010.02904.x; Jeong HS, 2012, MOL CELL BIOCHEM, V367, P43, DOI 10.1007/s11010-012-1317-8; Johnston MV, 2005, BRAIN PATHOL, V15, P234; Jones NC, 2012, NEUROBIOL DIS, V45, P897, DOI 10.1016/j.nbd.2011.12.005; Jupp B, 2012, EPILEPSIA, V53, P1233, DOI 10.1111/j.1528-1167.2012.03525.x; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lee SM, 2011, J ALZHEIMERS DIS, V26, P355, DOI 10.3233/JAD-2011-102016; Leroy K, 2010, J ALZHEIMERS DIS, V19, P705, DOI [10.3233/JAD-2009-1276, 10.3233/JAD-2010-1276]; Liang ZH, 2009, J ALZHEIMERS DIS, V17, P531, DOI 10.3233/JAD-2009-1069; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu XP, 2012, GLIA, V60, P1279, DOI 10.1002/glia.22347; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Martin L, 2011, NEUROCHEM INT, V58, P458, DOI 10.1016/j.neuint.2010.12.023; Mazanetz MP, 2007, NAT REV DRUG DISCOV, V6, P464, DOI 10.1038/nrd2111; McIntosh AM, 2004, BRAIN, V127, P2018, DOI 10.1093/brain/awh221; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medders KE, 2011, J NEUROIMMUNE PHARM, V6, P202, DOI 10.1007/s11481-011-9260-0; Morris M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029257; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102; Pachet AK, 2003, PSYCHOPHARMACOLOGY, V170, P225, DOI 10.1007/s00213-003-1592-x; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Ramirez-Munguia N, 2003, NEUROCHEM RES, V28, P1517, DOI 10.1023/A:1025670308663; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Rockhill CM, 2012, J NEUROTRAUM, V29, P1038, DOI 10.1089/neu.2010.1562; Schoch KM, 2012, NEUROTHERAPEUTICS, V9, P323, DOI 10.1007/s13311-012-0107-z; Sereno L, 2009, NEUROBIOL DIS, V35, P359, DOI 10.1016/j.nbd.2009.05.025; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Sontag E, 2004, J NEUROPATH EXP NEUR, V63, P287, DOI 10.1093/jnen/63.4.287; Tian FF, 2010, CLIN LAB, V56, P127; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vogelsberg-Ragaglia V, 2001, EXP NEUROL, V168, P402, DOI 10.1006/exnr.2001.7630; Walaas SI, 2011, FRONT NEUROANAT, V5, DOI 10.3389/fnana.2011.00050; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Wu PR, 2011, CELL DEATH DIFFER, V18, P1507, DOI 10.1038/cdd.2011.2; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu YH, 2008, MOL CELL, V31, P873, DOI 10.1016/j.molcel.2008.08.006; Yang TH, 2010, J NEUROL SCI, V296, P1, DOI 10.1016/j.jns.2010.06.002; Yang Y, 2012, J CELL BIOCHEM, V113, P1314, DOI 10.1002/jcb.24003; Zhang Z, 2010, BRAIN RES, V1359, P233, DOI 10.1016/j.brainres.2010.08.077; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025	82	31	33	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUN	2014	49	3					1532	1539		10.1007/s12035-013-8601-9			8	Neurosciences	Neurosciences & Neurology	AG8KE	WOS:000335666500030	24323428				2021-06-18	
J	Anbari, F; Khalili, MA; Bahrami, AR; Khoradmehr, A; Sadeghian, F; Fesahat, F; Nabi, A				Anbari, Fatemeh; Khalili, Mohammad Ali; Bahrami, Ahmad Reza; Khoradmehr, Arezoo; Sadeghian, Fatemeh; Fesahat, Farzaneh; Nabi, Ali			Intravenous transplantation of bone marrow mesenchymal stem cells promotes neural regeneration after traumatic brain injury	NEURAL REGENERATION RESEARCH			English	Article						nerve regeneration; bone marrow mesenchymal stem cells; traumatic brain injury; intravenous administration; cell differentiation; neurologic function, cerebral cortex; rats; neural regeneration	STROMAL CELLS; THERAPEUTIC BENEFIT; FUNCTIONAL RECOVERY; RATS; NEUROGENESIS; TRANSMIGRATE; STROKE; MODEL	To investigate the supplement of lost nerve cells in rats with traumatic brain injury by intravenous administration of allogenic bone marrow mesenchymal stem cells, this study established a Wistar rat model of traumatic brain injury by weight drop impact acceleration method and administered 3 x 106 rat bone marrow mesenchymal stem cells via the lateral tail vein. At 14 days after cell transplantation, bone marrow mesenchymal stem cells differentiated into neurons and astrocytes in injured rat cerebral cortex and rat neurological function was improved significantly. These findings suggest that intravenously administered bone marrow mesenchymal stem cells can promote nerve cell regeneration in injured cerebral cortex, which supplement the lost nerve cells.	[Anbari, Fatemeh; Khalili, Mohammad Ali; Khoradmehr, Arezoo; Sadeghian, Fatemeh; Fesahat, Farzaneh; Nabi, Ali] Shahid Sadoughi Univ Med Sci, Res & Clin Ctr Infertil, Yazd, Iran; [Bahrami, Ahmad Reza] Ferdowsi Univ Mashhad, Inst Biotechnol, Mashhad, Iran	Khalili, MA (corresponding author), Shahid Sadoughi Univ Med Sci, Res & Clin Ctr Infertil, Yazd, Iran.	khalili59@hotmail.com	fesahat, farzaneh/AAF-4822-2020; Nabi, Ali/R-9349-2017; Bahrami, Ahmad Reza/AAA-4090-2020	Nabi, Ali/0000-0002-3794-6073; Bahrami, Ahmad Reza/0000-0001-9122-7216; Sadeghian-Nodoushan, Fatemeh/0000-0003-2767-7882	Shahid Sadoughi University of Medical Sciences, Yazd, Iran	This study was supported by research center from Shahid Sadoughi University of Medical Sciences, Yazd, Iran.	Azari MF, 2010, CURR NEUROPHARMACOL, V8, P316, DOI 10.2174/157015910793358204; Bonilla C, 2009, BRAIN INJURY, V23, P760, DOI 10.1080/02699050903133970; Brodhun M, 2004, EXP TOXICOL PATHOL, V56, P103, DOI 10.1016/j.etp.2004.04.004; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Collins TR, 2013, NEUROL TODAY, V13, P1; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Hamano K, 2000, CELL TRANSPLANT, V9, P439, DOI 10.1177/096368970000900315; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Joers VL, 2010, ILAR J, V51, P24, DOI 10.1093/ilar.51.1.24; Karaoz E, 2009, HISTOCHEM CELL BIOL, V132, P533, DOI 10.1007/s00418-009-0629-6; Khalili Mohammad Ali, 2014, Exp Neurobiol, V23, P77, DOI 10.5607/en.2014.23.1.77; Khalili MA, 2012, J STROKE CEREBROVASC, V21, P445, DOI 10.1016/j.jstrokecerebrovasdis.2010.10.005; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee DH, 2013, CHILD NERV SYST, V29, P403, DOI 10.1007/s00381-012-1969-4; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Liu KM, 2008, MICROVASC RES, V75, P59, DOI 10.1016/j.mvr.2007.06.003; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Marquez-Curtis LA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/561098; Matsushita T, 2011, NEUROSCI LETT, V502, P41, DOI 10.1016/j.neulet.2011.07.021; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Opydo-Chanek M, 2007, ACTA NEUROBIOL EXP, V67, P187; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pitkanen A, 2006, DRUG DISCOV TODAY, V2, P409; Reitz M, 2012, STEM CELL TRANSL MED, V1, P866, DOI 10.5966/sctm.2012-0045; Schmidt A, 2006, EUR J CELL BIOL, V85, P1179, DOI 10.1016/j.ejcb.2006.05.015; Vaquero J, 2011, PROG NEUROBIOL, V93, P341, DOI 10.1016/j.pneurobio.2010.12.002; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890	35	31	33	0	12	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	1673-5374	1876-7958		NEURAL REGEN RES	Neural Regen. Res.	MAY	2014	9	9					919	923		10.4103/1673-5374.133133			5	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	AI7KH	WOS:000337068600005	25206912	DOAJ Gold, Green Published			2021-06-18	
J	Lamberty, GJ; Nakase-Richardson, R; Farrell-Carnahan, L; McGarity, S; Bidelspach, D; Harrison-Felix, C; Cifu, DX				Lamberty, Greg J.; Nakase-Richardson, Risa; Farrell-Carnahan, Leah; McGarity, Suzanne; Bidelspach, Douglas; Harrison-Felix, Cindy; Cifu, David X.			Development of a Traumatic Brain Injury Model System Within the Department of Veterans Affairs Polytrauma System of Care	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Veterans; traumatic brain injury; NIDRR; longitudinal databases; OEF/OIF; model systems; polytrauma; VA	CONSCIOUSNESS	Background: In 2008, the Department of Veterans Affairs Polytrauma Rehabilitation Centers partnered with the National Institute on Disability and Rehabilitation Research to establish a Model Systems program of research that would closely emulate the civilian Traumatic Brain Injury (TBI) Model Systems Centers Program established in 1987. Objective: To describe the development of a TBI Model Systems program within the Department of Veterans Affairs Polytrauma System of Care. Methods: Enrollment criteria and data collection/data quality efforts for the newly established Department of Veterans Affairs sites are reviewed. Results: Significant progress has been made in the establishment of a Model Systems program for the Polytrauma System of Care. Data collection has moved forward and program-specific modifications have been implemented. Conclusion: The Veterans Affairs TBI Model System program is established and growing, with many projects underway and a strong working relationship with the civilian TBI Model System programs.	[Lamberty, Greg J.] Minneapolis VA Hlth Care Syst, Phys Med & Rehabil Serv, Minneapolis, MN USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Neuropsychol Sect MHBS, Tampa, FL 33612 USA; [McGarity, Suzanne] James A Haley Vet Hosp, Polytrauma Psychol Serv, Tampa, FL 33612 USA; [Farrell-Carnahan, Leah; Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA; [Bidelspach, Douglas] Lebanon VAMC, Rehabil & Prosthet Serv, Lebanon, PA USA; [Harrison-Felix, Cindy] Craig Hosp, Res Dept, Englewood, CO USA	Lamberty, GJ (corresponding author), Minneapolis VA Hlth Care Syst 4K TBI, Phys Med & Rehabil Serv, One Vet Dr, Minneapolis, MN 55417 USA.	gregory.lamberty@va.gov		Cifu, David/0000-0003-1600-9387	Department of Veterans AffairsUS Department of Veterans Affairs; Department of Education, National Institute on Disability and Rehabilitation Research	The Polytrauma Rehabilitation Center Traumatic Brain Injury Model System collaboration is funded through an Interagency Agreement between the Department of Veterans Affairs and the Department of Education, National Institute on Disability and Rehabilitation Research. The views expressed in this article are those of the authors and do not necessarily reflect the policy or position of the Department of Veterans Affairs, the Department of Education, the US government, or affiliated universities.	CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Defense and Veterans Brain Injury Center, 2012, DOD WORLDWIDE NUMBER; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; McCrea MA, 2007, MILD TRAUMATIC BRAIN; McNamee S, 2012, J HEAD TRAUMA REHAB, V27, P244, DOI 10.1097/HTR.0b013e31825e12c8; Nakase-Richardson R, ARCH PHYS M IN PRESS; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	17	31	31	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2014	29	3					E1	E7		10.1097/HTR.0b013e31829a64d1			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AG9SE	WOS:000335759100001	23835876				2021-06-18	
J	Zhang, YM; Yang, YY; Tang, H; Sun, WJ; Xiong, XX; Smerin, D; Liu, JC				Zhang, Yongming; Yang, Yanyan; Tang, Hong; Sun, Wenjiang; Xiong, Xiaoxing; Smerin, Daniel; Liu, Jiachuan			Hyperbaric Oxygen Therapy Ameliorates Local Brain Metabolism, Brain Edema and Inflammatory Response in a Blast-Induced Traumatic Brain Injury Model in Rabbits	NEUROCHEMICAL RESEARCH			English	Article						Brain injury; Explosive injury; Rabbit Magnetic resonance spectrum; Hyperbaric oxygen	MAGNETIC-RESONANCE-SPECTROSCOPY; FOCAL CEREBRAL-ISCHEMIA; RAT MODEL; TISSUE; INHIBITION; EXPRESSION; PRINCIPLES; DISEASE; BARRIER	Many studies suggest that hyperbaric oxygen therapy (HBOT) can provide some clinically curative effects on blast-induced traumatic brain injury (bTBI). The specific mechanism by which this occurs still remains unknown, and no standardized time or course of hyperbaric oxygen treatment is currently used. In this study, bTBI was produced by paper detonators equivalent to 600 mg of TNT exploding at 6.5 cm vertical to the rabbit's head. HBO (100 % O-2 at 2.0 absolute atmospheres) was used once, 12 h after injury. Magnetic resonance spectroscopy was performed to investigate the impact of HBOT on the metabolism of local injured nerves in brain tissue. We also examined blood-brain barrier (BBB) integrity, brain water content, apoptotic factors, and some inflammatory mediators. Our results demonstrate that hyperbaric oxygen could confer neuroprotection and improve prognosis after explosive injury by promoting the metabolism of local neurons, inhibiting brain edema, protecting BBB integrity, decreasing cell apoptosis, and inhibiting the inflammatory response. Furthermore, timely intervention within 1 week after injury might be more conducive to improving the prognosis of patients with bTBI.	[Zhang, Yongming; Yang, Yanyan; Tang, Hong; Sun, Wenjiang; Liu, Jiachuan] Anhui Med Univ, Dept Neurosurg, Hosp PLA 105, Hefei 230031, Peoples R China; [Zhang, Yongming; Xiong, Xiaoxing] Stanford Univ, Dept Neurosurg, Stanford, CA 94306 USA; [Smerin, Daniel] Stanford Univ, Sch Med, Stanford, CA 94306 USA	Liu, JC (corresponding author), Anhui Med Univ, Dept Neurosurg, Hosp PLA 105, Hefei 230031, Peoples R China.	zymhf2966@163.com; zym_105sjw@163.com		Xiong, Xiaoxing/0000-0001-6983-8547	Nature Science Youth Funding of Anhui Province [1208085QH171]; Nanjing Military Region Fund Project [10MB009]	This study was supported by research Grants from the Nature Science Youth Funding of Anhui Province (1208085QH171) and Nanjing Military Region Fund Project (10MB009). We also thank Professor Bingchang Li (Institute of Battle Surgical Research, Third Military Medicine University) for his support while creating our animal model and Daniel Smerin for his manuscript editing.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Brugger S, 2011, BIOL PSYCHIAT, V69, P495, DOI 10.1016/j.biopsych.2010.10.004; Chamorro A, 2006, STROKE, V37, P291, DOI 10.1161/01.STR.0000200561.69611.f8; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4; Edwards ML, 2010, J VET EMERG CRIT CAR, V20, P289, DOI 10.1111/j.1476-4431.2010.00535_1.x; Edwards ML, 2010, J VET EMERG CRIT CAR, V20, P284, DOI 10.1111/j.1476-4431.2010.00535.x; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Harch PG, 2007, BRAIN RES, V1174, P120, DOI 10.1016/j.brainres.2007.06.105; Hedges JC, 2000, AM J RESP CELL MOL, V23, P86, DOI 10.1165/ajrcmb.23.1.4014; Hollin S A, 1968, Prog Brain Res, V30, P479; Huang E, 2013, BRAIN RES, V1529, P125, DOI 10.1016/j.brainres.2013.06.042; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kang GH, 2012, J NEUROL SCI, V318, P25, DOI 10.1016/j.jns.2012.04.013; Lee JH, 2013, NEUROCHEM RES, V38, P2276, DOI 10.1007/s11064-013-1136-7; Li CX, 2008, NEUROCHEM RES, V33, P2342, DOI 10.1007/s11064-008-9739-0; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Liu Zhan, 2006, Chin J Traumatol, V9, P168; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0; McLean MA, 2009, BRIT J NEUROSURG, V23, P5, DOI 10.1080/02688690802491673; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Qian JC, 2013, NEUROCHEM RES, V38, P208, DOI 10.1007/s11064-012-0910-2; Ren CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003851; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rosenthal RE, 2003, STROKE, V34, P1311, DOI 10.1161/01.STR.0000066868.95807.91; Samson Y, 2005, REV NEUROL-FRANCE, V161, P1177; Sidaros Annette, 2007, Ugeskr Laeger, V169, P214; Soares DP, 2009, CLIN RADIOL, V64, P12, DOI 10.1016/j.crad.2008.07.002; Tang XQ, 2010, BRAIN RES, V1348, P174, DOI 10.1016/j.brainres.2010.05.082; Voigt C, 2008, ACTA NEUROCHIR SUPPL, V102, P441, DOI 10.1007/978-3-211-85578-2_86; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Wright JK, 2009, UNDERSEA HYPERBAR M, V36, P391; Yang DY, 2007, NEUROL RES, V29, P274, DOI 10.1179/016164107X159171; Yong-Ming Z, 2012, AFR HEALTH SCI, V12, P552, DOI 10.4314/ahs.v12i4.24	44	31	34	0	6	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	2014	39	5					950	960		10.1007/s11064-014-1292-4			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AG1HF	WOS:000335165200017	24682753				2021-06-18	
J	Park, J; Zheng, LX; Marquis, A; Walls, M; Duerstock, B; Pond, A; Vega-Alvarez, S; Wang, H; Ouyang, Z; Shi, RY				Park, Jonghyuck; Zheng, Lingxing; Marquis, Andrew; Walls, Michael; Duerstock, Brad; Pond, Amber; Vega-Alvarez, Sasha; Wang, He; Ouyang, Zheng; Shi, Riyi			Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-mediated damage	JOURNAL OF NEUROCHEMISTRY			English	Article						acrolein scavenger; aldehyde; lipid peroxidation; oxidative stress	AXONAL MEMBRANE DISRUPTION; LIPID-PEROXIDATION; ALPHA,BETA-UNSATURATED ALDEHYDES; CYSTIC DEGENERATION; SECONDARY INJURY; CONDUCTION LOSS; PC12 CELLS; METHYLPREDNISOLONE; BRAIN; INFLAMMATION	Acrolein, an alpha,beta-unsaturated aldehyde and a reactive product of lipid peroxidation, has been suggested as a key factor in neural post-traumatic secondary injury in spinal cord injury (SCI), mainly based on in vitro and ex vivo evidence. Here, we demonstrate an increase of acrolein up to 300%; the elevation lasted at least 2 weeks in a rat SCI model. More importantly, hydralazine, a known acrolein scavenger can provide neuroprotection when applied systemically. Besides effectively reducing acrolein, hydralazine treatment also resulted in significant amelioration of tissue damage, motor deficits, and neuropathic pain. This effect was further supported by demonstrating the ability of hydralazine to reach spinal cord tissue at a therapeutic level following intraperitoneal application. This suggests that hydralazine is an effective neuroprotective agent not only in vitro, but in a live animal model of SCI as well. Finally, the role of acrolein in SCI was further validated by the fact that acrolein injection into the spinal cord caused significant SCI-like tissue damage and motor deficits. Taken together, available evidence strongly suggests a critical causal role of acrolein in the pathogenesis of spinal cord trauma. Since acrolein has been linked to a variety of illness and conditions, we believe that acrolein-scavenging measures have the potential to be expanded significantly ensuring a broad impact on human health.	[Park, Jonghyuck; Zheng, Lingxing; Marquis, Andrew; Walls, Michael; Duerstock, Brad; Pond, Amber; Vega-Alvarez, Sasha; Shi, Riyi] Purdue Univ, Coll Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Park, Jonghyuck; Zheng, Lingxing; Duerstock, Brad; Wang, He; Ouyang, Zheng; Shi, Riyi] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA	Shi, RY (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	riyi@purdue.edu		Pond, Amber/0000-0002-2836-889X	Indiana State Department of Health [204200]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS073636]; Indiana CTSI Collaboration in Biomedical Translational Research (CBR/CTR) Pilot Program Grant [RR025761]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073636] Funding Source: NIH RePORTER	This study was supported by the Indiana State Department of Health (Grant # 204200 to RS), National Institutes of Health (Grant # NS073636 to RS), and Indiana CTSI Collaboration in Biomedical Translational Research (CBR/CTR) Pilot Program Grant (Grant # RR025761 to RS). The authors thank Melissa Tully and Jessica Page for critical reading of the manuscript and Michel Schweinsberg for illustration drawing. There is not a conflict of interest for any of the authors.	ANDERSON DK, 1994, BRAIN RES, V637, P119, DOI 10.1016/0006-8993(94)91224-6; Barger SW, 2007, J NEUROCHEM, V101, P1205, DOI 10.1111/j.1471-4159.2007.04487.x; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; Burcham PC, 2000, REDOX REP, V5, P47, DOI 10.1179/rer.2000.5.1.47; Burcham PC, 2004, MOL PHARMACOL, V65, P655, DOI 10.1124/mol.65.3.655; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; COLE RA, 1960, AM J PSYCHIAT, V117, P361, DOI 10.1176/ajp.117.4.361; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DEMEDIUK P, 1989, J NEUROSCI RES, V23, P95, DOI 10.1002/jnr.490230113; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Facchinetti F, 2007, AM J RESP CELL MOL, V37, P617, DOI 10.1165/rcmb.2007-0130OC; Feng ZH, 2006, P NATL ACAD SCI USA, V103, P15404, DOI 10.1073/pnas.0607031103; Fitch MT, 1999, J NEUROSCI, V19, P8182; GEORGE ER, 1995, AM SURGEON, V61, P659; Ghilarducci DP, 1995, REV ENVIRON CONTAM T, V144, P95; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2008, J NEUROCHEM, V104, P708, DOI 10.1111/j.1471-4159.2007.05002.x; Hamann K, 2009, J NEUROCHEM, V111, P1348, DOI 10.1111/j.1471-4159.2009.06395.x; Hesterberg TW, 2008, ENVIRON SCI TECHNOL, V42, P6437, DOI 10.1021/es071718i; Hulsebosch CE, 2008, EXP NEUROL, V214, P6, DOI 10.1016/j.expneurol.2008.07.016; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Jones TB, 2005, CURR PHARM DESIGN, V11, P1223, DOI 10.2174/1381612053507468; Kaminskas LM, 2004, J PHARMACOL EXP THER, V310, P1003, DOI 10.1124/jpet.104.067330; Kehrer JP, 2000, TOXICOL SCI, V57, P6, DOI 10.1093/toxsci/57.1.6; KHAN MA, 1953, BMJ-BRIT MED J, V1, P27, DOI 10.1136/bmj.1.4800.27; Leung G, 2011, NEUROSCIENCE, V173, P150, DOI 10.1016/j.neuroscience.2010.11.018; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P209, DOI 10.1002/jnr.20863; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P219, DOI 10.1002/jnr.20862; Lovell MA, 2000, FREE RADICAL BIO MED, V29, P714, DOI 10.1016/S0891-5849(00)00346-4; Lovell MA, 2001, NEUROBIOL AGING, V22, P187, DOI 10.1016/S0197-4580(00)00235-9; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; Moretto N, 2009, AM J PHYSIOL-LUNG C, V296, pL839, DOI 10.1152/ajplung.90570.2008; MUDGE K, 1984, SPINE, V9, P253, DOI 10.1097/00007632-198404000-00005; MURPHY EJ, 1994, MOL CHEM NEUROPATHOL, V23, P13, DOI 10.1007/BF02858504; Newcomer JW, 1999, NEUROPSYCHOPHARMACOL, V20, P106, DOI 10.1016/S0893-133X(98)00067-0; NURICK S, 1970, BRAIN, V93, P211, DOI 10.1093/brain/93.1.211; Park YS, 2008, ANN NY ACAD SCI, V1126, P185, DOI 10.1196/annals.1433.034; Peasley MA, 2003, J NEUROL SCI, V216, P23, DOI 10.1016/S0022-510X(03)00201-6; Pereira JE, 2009, EXP NEUROL, V220, P71, DOI 10.1016/j.expneurol.2009.07.030; Picklo MJ, 2001, BBA-MOL BASIS DIS, V1535, P145, DOI 10.1016/S0925-4439(00)00093-4; REECE PA, 1981, MED RES REV, V1, P73, DOI 10.1002/med.2610010105; Reier PJ, 1983, SPINAL CORD RECONSTR, P163; Rooney GE, 2009, J NEUROSURG-SPINE, V11, P432, DOI 10.3171/2009.4.SPINE08784; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Schurch B, 1996, J NEUROL NEUROSUR PS, V60, P61, DOI 10.1136/jnnp.60.1.61; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R., 2006, APPL NEUROL, V2, P22; Shi RY, 2011, MOL NUTR FOOD RES, V55, P1320, DOI 10.1002/mnfr.201100217; Shi YZ, 2011, J NEUROCHEM, V117, P554, DOI 10.1111/j.1471-4159.2011.07226.x; Shibuta S, 2006, BRIT J ANAESTH, V97, P517, DOI 10.1093/bja/ael192; Smith KJ, 1999, BRAIN PATHOL, V9, P69; Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Wang H, 2011, ANAL CHEM, V83, P1197, DOI 10.1021/ac103150a; White FA, 2005, NAT REV DRUG DISCOV, V4, P834, DOI 10.1038/nrd1852; White FA, 2007, P NATL ACAD SCI USA, V104, P20151, DOI 10.1073/pnas.0709250104; Wood PL, 2006, BRAIN RES, V1122, P184, DOI 10.1016/j.brainres.2006.09.003; Zheng LX, 2013, J NEUROTRAUM, V30, P1334, DOI 10.1089/neu.2013.2888	68	31	32	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2014	129	2					339	349		10.1111/jnc.12628			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AE1GE	WOS:000333716700033	24286176	Green Accepted			2021-06-18	
J	DiTommaso, C; Hoffman, JM; Lucas, S; Dikmen, S; Temkin, N; Bell, KR				DiTommaso, Craig; Hoffman, Jeanne M.; Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy; Bell, Kathleen R.			Medication Usage Patterns for Headache Treatment After Mild Traumatic Brain Injury	HEADACHE			English	Article						post-traumatic headache; mild traumatic brain injury; headache; concussion; migraine	POSTTRAUMATIC HEADACHES	ObjectiveTo describe patient self-report of headache treatment in the first year following mild traumatic brain injury (TBI). BackgroundAn understanding of appropriate management of symptoms after mild TBI is crucial for improving acute care and long-term outcomes. This is particularly true for post-traumatic headaches as recent studies suggest that headaches after mild TBI are common with multiple phenotypes. In addition, symptoms such as headache after mild TBI are often managed by primary care providers without specialty training, and often in medically underserved areas. Outside of previous opinion papers, few studies have guided the treatment or examined the effectiveness of the interventions for post-traumatic headache. MethodsOne hundred sixty-seven participants admitted to a level 1 trauma hospital with mild TBI who were prospectively enrolled and reported new or worse headache at 3, 6, or 12 months after injury. ResultsParticipants were primarily male (75%), white (75%), injured in vehicle crashes (62%), and had completed high school (83%). The majority of headaches met International Classification of Headache Disorders - 2nd edition criteria for migraine/probable migraine, followed by tension-type headache. Despite the diverse nature of headaches, more than 70% of those with headache at each time period used acetaminophen or a nonsteroidal anti-inflammatory drug for headache control. Only 8% of those with the migraine/probable migraine phenotype used triptans. Of those individuals who used medication, 26% of those with migraine/probable migraine phenotype and 70% of those with tension headache phenotype endorsed complete relief (vs partial or no relief) because of medication use. The majority of individuals with tension headache reported never taking medication. ConclusionsHeadaches after mild TBI are frequent and are not optimally treated. Results suggest that many individuals with mild TBI may be self-treating their headaches by utilizing over-the-counter pain relief medications. These medications, however, are only providing effective treatment for a minority of this population. Further research must be conducted to develop evidence-guided treatment and educate providers.	[DiTommaso, Craig; Hoffman, Jeanne M.; Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy; Bell, Kathleen R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Lucas, Sylvia] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA	DiTommaso, C (corresponding author), Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.	craig.ditommaso@gmail.com		Bell, Kathleen/0000-0002-0928-2046	Department of Education, National Institute on Disability and Rehabilitation Research [H133G090022]; NIDRR; Department of DefenseUnited States Department of Defense; Wadsworth Foundation; St. Jude Medical Inc.St. Jude Medical; BiogenIdecBiogen; Zogenix; MAP; AllerganAbbVieAllergan; GenzymeSanofi-AventisGenzyme Corporation; NovartisNovartis; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Dr. DiTommaso has no conflicts of interest to disclose. Dr. Hoffman receives research funding from NIDRR and Department of Defense. Dr. Lucas receives funding from NIDRR, Department of Defense, the Wadsworth Foundation, St. Jude Medical Inc., and BiogenIdec. She has received consulting fees or honoraria from Zogenix, MAP, Allergan, BiogenIdec, Genzyme, and Novartis. Dr. Dikmen receives research funding from NIDRR, Department of Defense, and NIH. Dr. Temkin receives research funding from NIDRR, Department of Defense, and NIH. Dr. Bell receives research funding from NIDRR and Department of Defense.; This study was funded by the Department of Education, National Institute on Disability and Rehabilitation Research, grant number H133G090022. The Department of Education provided funding, but had no role in the study design, data collection, or writing of the paper.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bigal M, 2009, HEADACHE, V49, P1028, DOI 10.1111/j.1526-4610.2009.01410.x; D'Amico D, 2011, NEUROL SCI, V32, pS181, DOI 10.1007/s10072-011-0528-1; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Erickson Jay C, 2010, Continuum (Minneap Minn), V16, P55, DOI 10.1212/01.CON.0000391453.37923.83; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Lainez MJA, 2011, CURR PAIN HEADACHE R, V15, P467, DOI 10.1007/s11916-011-0220-4; Lerman B, 2011, J NEUROTRAUM, V28, pA16; Lieba-Samal D, 2011, CEPHALALGIA, V31, P1618, DOI 10.1177/0333102411428954; Lipton RB, 2007, NEUROLOGY, V68, P343, DOI 10.1212/01.wnl.0000252808.97649.21; Lipton RB, 2012, HEADACHE, V53, P81; Lucas S, 2013, CEPHALALGIA; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Lucas S, 2011, PM&R, V3, pS406, DOI 10.1016/j.pmrj.2011.07.016; National Center for Injury Prevention and Control, 2008, WHAT IS TRAUM BRAIN; Seng EK, 2013, HEADACHE, V53, P1312, DOI 10.1111/head.12155; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Theeler BJ, 2012, CEPHALALGIA, V32, P589, DOI 10.1177/0333102412445220; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003	22	31	32	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	MAR	2014	54	3					511	519		10.1111/head.12254			9	Clinical Neurology	Neurosciences & Neurology	AC0AL	WOS:000332156900009	24741687				2021-06-18	
J	Li, N; Yang, Y; Glover, DP; Zhang, JY; Saraswati, M; Robertson, C; Pelled, G				Li, Nan; Yang, Ya; Glover, David P.; Zhang, Jiangyang; Saraswati, Manda; Robertson, Courtney; Pelled, Galit			Evidence for Impaired Plasticity after Traumatic Brain Injury in the Developing Brain	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; development; magnetic resonance imaging; plasticity; somatosensory cortex; magnetic resonance imaging	IMMATURE RAT; CHRONIC STROKE; SOMATOSENSORY CORTEX; CONTRALATERAL HAND; CORPUS-CALLOSUM; MOTOR RECOVERY; NERVE INJURY; DEAFFERENTATION; REORGANIZATION; ANESTHESIA	The robustness of plasticity mechanisms during brain development is essential for synaptic formation and has a beneficial outcome after sensory deprivation. However, the role of plasticity in recovery after acute brain injury in children has not been well defined. Traumatic brain injury (TBI) is the leading cause of death and disability among children, and long-term disability from pediatric TBI can be particularly devastating. We investigated the altered cortical plasticity 2-3 weeks after injury in a pediatric rat model of TBI. Significant decreases in neurophysiological responses across the depth of the noninjured, primary somatosensory cortex (S1) in TBI rats, compared to age-matched controls, were detected with electrophysiological measurements of multi-unit activity (86.4% decrease), local field potential (75.3% decrease), and functional magnetic resonance imaging (77.6% decrease). Because the corpus callosum is a clinically important white matter tract that was shown to be consistently involved in post-traumatic axonal injury, we investigated its anatomical and functional characteristics after TBI. Indeed, corpus callosum abnormalities in TBI rats were detected with diffusion tensor imaging (9.3% decrease in fractional anisotropy) and histopathological analysis (14% myelination volume decreases). Whole-cell patch clamp recordings further revealed that TBI results in significant decreases in spontaneous firing rate (57% decrease) and the potential to induce long-term potentiation in neurons located in layer V of the noninjured S1 by stimulation of the corpus callosum (82% decrease). The results suggest that post-TBI plasticity can translate into inappropriate neuronal connections and dramatic changes in the function of neuronal networks.	[Li, Nan; Yang, Ya; Glover, David P.; Pelled, Galit] FM Kirby Res Ctr Funct Brain Imaging, Kennedy Krieger Inst, Baltimore, MD USA; [Li, Nan; Yang, Ya; Zhang, Jiangyang; Pelled, Galit] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [Saraswati, Manda; Robertson, Courtney] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Robertson, Courtney] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Pelled, G (corresponding author), Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, FM Kirby Ctr Funct Brain Imaging, Sch Med,Kennedy Krieger Inst,Div MR Res, 707 N Broadway, Baltimore, MD 21205 USA.	Pelled@kennedykrieger.org	Li, Nan/K-7767-2015	Li, Nan/0000-0002-4751-2252; Zhang, Jiangyang/0000-0003-0740-2662; Zhang, Jiangyang/0000-0003-4146-8163	Johns Hopkins Brain Science InstituteJohns Hopkins University; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072171]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072171] Funding Source: NIH RePORTER	This work was supported by Johns Hopkins Brain Science Institute and the National Institutes of Health/National Institute of Neurological Disorders and Stroke (grant no. R01NS072171).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Aggarwal M, 2010, MAGN RESON MED, V64, P249, DOI 10.1002/mrm.22426; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bjorkman A, 2005, SCAND J PLAST RECONS, V39, P234, DOI 10.1080/0284431051006493; Bjorkman A, 2005, NEUROREPORT, V16, P517; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Card JP, 2005, J NEUROTRAUM, V22, P989, DOI 10.1089/neu.2005.22.989; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510; DURHAM D, 1984, J COMP NEUROL, V223, P424, DOI 10.1002/cne.902230308; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Floel A, 2004, ANN NEUROL, V56, P206, DOI 10.1002/ana.20170; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Han Y, 2013, NEUROREHAB NEURAL RE, V27, P664, DOI 10.1177/1545968313484811; Isaac JTR, 1996, J PHYSIOLOGY-PARIS, V90, P299, DOI 10.1016/S0928-4257(97)87901-6; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; KALASKA J, 1979, J NEUROPHYSIOL, V42, P618; Karl A, 2001, J NEUROSCI, V21, P3609, DOI 10.1523/JNEUROSCI.21-10-03609.2001; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Li N, 2011, P NATL ACAD SCI USA, V108, P8838, DOI 10.1073/pnas.1100815108; Pelled G, 2007, NEUROIMAGE, V37, P262, DOI 10.1016/j.neuroimage.2007.03.069; Pelled G, 2009, P NATL ACAD SCI USA, V106, P14114, DOI 10.1073/pnas.0903153106; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Rosen B, 2006, J HAND SURG-BRIT EUR, V31B, P126, DOI 10.1016/j.jhsb.2005.10.017; ROSEN GD, 1990, J NEUROSCI METH, V35, P115, DOI 10.1016/0165-0270(90)90101-K; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Schaechter JD, 2006, BRAIN, V129, P2722, DOI 10.1093/brain/awl214; Schaechter JD, 2012, NEUROREHAB NEURAL RE, V26, P325, DOI 10.1177/1545968311421613; SIMONS DJ, 1992, EXP BRAIN RES, V91, P259; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Talelli P, 2007, CLIN NEUROPHYSIOL, V118, P333, DOI 10.1016/j.clinph.2006.10.014; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; Voller B, 2006, ANN NEUROL, V59, P385, DOI 10.1002/ana.20689; Wechsler B, 2005, J TRAUMA, V58, P940, DOI 10.1097/01.TA.0000162630.78386.98; Werhahn KJ, 2002, BRAIN, V125, P1402, DOI 10.1093/brain/awf140; Werhahn KJ, 2003, ANN NEUROL, V54, P464, DOI 10.1002/ana.10686; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zhao FQ, 2008, NEUROIMAGE, V39, P248, DOI 10.1016/j.neuroimage.2007.07.063	59	31	32	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2014	31	4					395	403		10.1089/neu.2013.3059			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AA7PY	WOS:000331290600012	24050267	Green Published			2021-06-18	
J	Bulstrode, H; Nicoll, JAR; Hudson, G; Chinnery, PF; Di Pietro, V; Belli, A				Bulstrode, Harry; Nicoll, James A. R.; Hudson, Gavin; Chinnery, Patrick F.; Di Pietro, Valentina; Belli, Antonio			Mitochondrial DNA and traumatic brain injury	ANNALS OF NEUROLOGY			English	Article							TEMPORAL WINDOW; POLYMORPHISMS; IMPACT; LONGEVITY; ALLELE; RISK; CLASSIFICATION; VULNERABILITY; DYSFUNCTION; CONCUSSIONS	Objective Traumatic brain injury (TBI) is a multifactorial pathology with great interindividual variability in response to injury and outcome. Mitochondria contain their own DNA (mtDNA) with genomic variants that have different physiological and pathological characteristics, including susceptibility to neurodegeneration. Given the central role of mitochondria in the pathophysiology of neurological injury, we hypothesized that its genomic variants may account for the variability in outcome following TBI. Methods We undertook an analysis of mitochondrial haplogroups in a large, well-characterized cohort of 1,094 TBI patients. A proportional odds model including age, brain computed tomography characteristics, injury severity, pupillary reactivity, mitochondrial haplogroups, and APOE was applied to Glasgow Outcome Score (GOS) data. Results mtDNA had a significant association with 6-month GOS (p = 0.008). Haplogroup K was significantly associated with favorable outcome (odds ratio = 1.64, 95% confidence interval = 1.08-2.51, p = 0.02). There was also a significant interaction between mitochondrial genome and age (p = 0.002), with a strong protective effect of both haplogroups T (p = 0.015) and K (p = 0.017) with advancing age. We also found a strong interaction between APOE and mitochondrial haplogroups (p = 0.001), indicating a protective effect of haplogroup K in carriers of the APOE epsilon 4 allele. Interpretation These findings reveal an interplay between mitochondrial DNA, pathophysiology of TBI, and aging. Haplogroups K and T, which share a common maternal ancestor, are shown as protective in TBI. The data also suggest that the APOE pathways interact with genetically regulated mitochondrial functions in the response to acute injury, as previously reported in Alzheimer disease. Ann Neurol 2014;75:186-195	[Bulstrode, Harry] UCL, Inst Canc, London, England; [Nicoll, James A. R.] Univ Southampton, Div Clin & Expt Sci, Southampton, Hants, England; [Hudson, Gavin; Chinnery, Patrick F.] Newcastle Univ, Wellcome Ctr Mitochondrial Res, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Di Pietro, Valentina; Belli, Antonio] Univ Birmingham, Div Neurotrauma & Neurodegenerat, Birmingham B15 2TT, W Midlands, England; [Belli, Antonio] Univ Hosp Birmingham, Natl Inst Hlth Res, Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England	Belli, A (corresponding author), Univ Birmingham, Div Neurotrauma & Neurodegenerat, Sch Clin & Expt Med, Coll Med & Dent Sci,Inst Biomed Res West, Birmingham B15 2TT, W Midlands, England.	a.belli@bham.ac.uk	Hudson, Gavin/E-7117-2017; Belli, Antonio/I-3799-2015; Nicoll, James/I-9253-2017	Belli, Antonio/0000-0002-3211-9933; Di Pietro, Valentina/0000-0001-9430-4723; Chinnery, Patrick/0000-0002-7065-6617; Nicoll, James/0000-0002-9444-7246; Bulstrode, Harry/0000-0002-3480-108X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9601296N]; National Institute for Health ResearchNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/K000608/1] Funding Source: researchfish; Parkinson&quot;s UKParkinson&apos;s UK [F-1202] Funding Source: researchfish	The APOE study was funded by the Medical Research Council (G9601296N). A.B. is funded by the National Institute for Health Research.	Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463; Conley YP, 2014, J NEUROTRAUM, V31, P34, DOI 10.1089/neu.2013.2855; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Gomez-Duran A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246; Jofre-Monseny L, 2008, MOL NUTR FOOD RES, V52, P131, DOI 10.1002/mnfr.200700322; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Khusnutdinova E, 2008, ANN NY ACAD SCI, V1147, P1, DOI 10.1196/annals.1427.001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; McDonald RPA, 1999, NEUROREPORT, V10, P1875, DOI 10.1097/00001756-199906230-00014; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417; Rose G, 2001, EUR J HUM GENET, V9, P701, DOI 10.1038/sj.ejhg.5200703; Ross OA, 2001, EXP GERONTOL, V36, P1161, DOI 10.1016/S0531-5565(01)00094-8; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Torroni A, 1996, GENETICS, V144, P1835; Tranah GJ, 2011, MITOCHONDRION, V11, P855, DOI 10.1016/j.mito.2011.04.005; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wallace DC, 2013, J CLIN INVEST, V123, P1405, DOI 10.1172/JCI61398; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	40	31	32	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	FEB	2014	75	2					186	195		10.1002/ana.24116			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AD1PD	WOS:000333005000006	24523223	Green Published, Green Accepted, Other Gold			2021-06-18	
J	Kainerstorfer, JM; Sassaroli, A; Hallacoglu, B; Pierro, ML; Fantini, S				Kainerstorfer, Jana M.; Sassaroli, Angelo; Hallacoglu, Bertan; Pierro, Michele L.; Fantini, Sergio			Practical Steps for Applying a New Dynamic Model to Near-Infrared Spectroscopy Measurements of Hemodynamic Oscillations and Transient Changes: Implications for Cerebrovascular and Functional Brain Studies	ACADEMIC RADIOLOGY			English	Article						Hemodynamic model; near-infrared spectroscopy; cerebral autoregulation; cerebral blood flow; metabolic rate of oxygen	CONSUMPTION FOLLOWING ACTIVATION; BLOOD-FLOW; CEREBRAL AUTOREGULATION; CAPILLARY RECRUITMENT; BOLD SIGNAL; OXYGEN; VOLUME; CORTEX; TIME; DIFFUSION	Rationale and Objectives: Perturbations in cerebral blood volume (CBV), blood flow (CBF), and metabolic rate of oxygen (CMRO2) lead to associated changes in tissue concentrations of oxy- and deoxy-hemoglobin (Delta O and Delta D), which can be measured by near-infrared spectroscopy (NIRS). A novel hemodynamic model has been introduced to relate physiological perturbations and measured quantities. We seek to use this model to determine functional traces of cbv(t) and cbf(t) - cmro(2)(t) from time-varying NIRS data, and cerebrovascular physiological parameters from oscillatory NIRS data (lowercase letters denote the relative changes in CBV, CBF, and CMRO2 with respect to baseline). Such a practical implementation of a quantitative hemodynamic model is an important step toward the clinical translation of NIRS. Materials and Methods: In the time domain, we have simulated O(t) and D(t) traces induced by cerebral activation. In the frequency domain, we have performed a new analysis of frequency-resolved measurements of cerebral hemodynamic oscillations during a paced breathing paradigm. Results: We have demonstrated that cbv(t) and cbf(t) - cmro(2)(t) can be reliably obtained from O(t) and D(t) using the model, and that the functional NIRS signals are delayed with respect to cbf(t) - cmro(2)(t) as a result of the blood transit time in the microvasculature. In the frequency domain, we have identified physiological parameters (e.g., blood transit time, cutoff frequency of autoregulation) that can be measured by frequency-resolved measurements of hemodynamic oscillations. Conclusions: The ability to perform noninvasive measurements of cerebrovascular parameters has far-reaching clinical implications. Functional brain studies rely on measurements of CBV, CBF, and CMRO2, whereas the diagnosis and assessment of neurovascular disorders, traumatic brain injury, and stroke would benefit from measurements of local cerebral hemodynamics and autoregulation.	[Kainerstorfer, Jana M.; Sassaroli, Angelo; Hallacoglu, Bertan; Pierro, Michele L.; Fantini, Sergio] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA	Kainerstorfer, JM (corresponding author), Tufts Univ, Dept Biomed Engn, 4 Colby St, Medford, MA 02155 USA.	jana.kainerstorfer@tufts.edu			National Science FoundationNational Science Foundation (NSF) [IIS-1065154]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-CA154774]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA154774] Funding Source: NIH RePORTER	This research is supported by the National Science Foundation (Award No. IIS-1065154) and National Institutes of Health (Grant no. R01-CA154774). Drs. Kainstorfer and Sassaroli contributed equally to the work.	Aaslid R, 2007, STROKE, V38, P1465, DOI 10.1161/STROKEAHA.106.473462; Baumgartl H., 1983, POLAROGRAPHIC OXYGEN; Blaber AP, 1997, STROKE, V28, P1686, DOI 10.1161/01.STR.28.9.1686; Buxton RB, 2012, NEUROIMAGE, V62, P953, DOI 10.1016/j.neuroimage.2012.01.012; Cassot F, 2006, MICROCIRCULATION, V13, P1, DOI 10.1080/10739680500383407; CHEN JL, 1994, MICROVASC RES, V48, P190, DOI 10.1006/mvre.1994.1049; Cheng R, 2012, NEUROIMAGE, V62, P1445, DOI 10.1016/j.neuroimage.2012.05.069; Choi J, 2004, J BIOMED OPT, V9, P221, DOI 10.1117/1.1628242; Claassen JAHR, 2009, J APPL PHYSIOL, V106, P153, DOI 10.1152/japplphysiol.90822.2008; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Dunn AK, 2005, NEUROIMAGE, V27, P279, DOI 10.1016/j.neuroimage.2005.04.024; Fantini S, 2002, PHYS MED BIOL, V47, pN249, DOI 10.1088/0031-9155/47/18/402; Fantini S, 2014, PHYSIOL MEAS, P35; Fantini S, 2014, NEUROIMAGE, V85, P202, DOI 10.1016/j.neuroimage.2013.03.065; Ferrari M, 2012, NEUROIMAGE, V63, P921, DOI 10.1016/j.neuroimage.2012.03.049; Friston KJ, 1998, MAGNET RESON MED, V39, P41, DOI 10.1002/mrm.1910390109; Gagnon L, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2982524; Gatto R, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2804705; Glover GH, 1999, NEUROIMAGE, V9, P416, DOI 10.1006/nimg.1998.0419; GOBEL U, 1989, J CEREBR BLOOD F MET, V9, P491; Gommer ED, 2010, MED BIOL ENG COMPUT, V48, P1243, DOI 10.1007/s11517-010-0706-y; Goutte C, 2000, IEEE T MED IMAGING, V19, P1188, DOI 10.1109/42.897811; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; Hallacoglu B, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.8.081406; Hillman EMC, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2789693; Jones M, 2001, NEUROIMAGE, V13, P1002, DOI 10.1006/nimg.2001.0808; Kasischke KA, 2011, J CEREBR BLOOD F MET, V31, P68, DOI 10.1038/jcbfm.2010.158; Kida I, 2007, J CEREBR BLOOD F MET, V27, P690, DOI 10.1038/sj.jcbfm.9600409; KUSCHINSKY W, 1992, CEREBROVAS BRAIN MET, V4, P261; Leff DR, 2011, NEUROIMAGE, V54, P2922, DOI 10.1016/j.neuroimage.2010.10.058; Leung TS, 2009, PHYSIOL MEAS, V30, P1, DOI 10.1088/0967-3334/30/1/001; Lindquist MA, 2007, HUM BRAIN MAPP, V28, P764, DOI 10.1002/hbm.20310; Lindquist MA, 2009, NEUROIMAGE, V45, pS187, DOI 10.1016/j.neuroimage.2008.10.065; Mandeville JB, 1999, MAGN RESON MED, V42, P944, DOI 10.1002/(SICI)1522-2594(199911)42:5<944::AID-MRM15>3.0.CO;2-W; Masamoto K, 2004, BRAIN RES, V995, P66, DOI 10.1016/j.brainres.2003.09.055; Masamoto K, 2007, J APPL PHYSIOL, V103, P1352, DOI 10.1152/japplphysiol.01433.2006; Mayhew J, 2001, NEUROIMAGE, V13, P975, DOI 10.1006/nimg.2001.0807; Mayhew J, 2001, NEUROIMAGE, V13, P540, DOI 10.1006/nimg.2001.0753; Mayhew J, 2000, NEUROIMAGE, V12, P664, DOI 10.1006/nimg.2000.0656; Medvedev AV, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3533266; Mintun MA, 2001, P NATL ACAD SCI USA, V98, P6859, DOI 10.1073/pnas.111164398; Ohmae E, 2006, NEUROIMAGE, V29, P697, DOI 10.1016/j.neuroimage.2005.08.008; Pardridge WM, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-7; Pierro ML, 2014, NEUROIMAGE, V85, P222, DOI 10.1016/j.neuroimage.2013.03.037; Pierro ML, 2013, J BIOMED OPT; Pries AR, 2008, HANDBOOK OF PHYSIOLOGY: MICROCIRCULATION, 2ND EDITION, P3; Quaresima V, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1851512; Reinhard M, 2006, J NEUROL SCI, V250, P103, DOI 10.1016/j.jns.2006.07.011; Roche-Labarbe N, 2014, NEUROIMAGE, V85, P279, DOI 10.1016/j.neuroimage.2013.01.035; Sassaroli A, 2006, NEUROIMAGE, V33, P505, DOI 10.1016/j.neuroimage.2006.07.006; VILLRINGER A, 1994, CIRC RES, V75, P55, DOI 10.1161/01.RES.75.1.55; Villringer A, 2012, NEUROIMAGE, V62, P995, DOI 10.1016/j.neuroimage.2012.01.113; Yucel MA, 2012, NEUROIMAGE, V61, P1268, DOI 10.1016/j.neuroimage.2012.04.036; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zoccoli G, 1996, J CEREBR BLOOD F MET, V16, P1312, DOI 10.1097/00004647-199611000-00028	55	31	33	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1076-6332	1878-4046		ACAD RADIOL	Acad. Radiol.	FEB	2014	21	2			SI		185	196		10.1016/j.acra.2013.10.012			12	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	298PH	WOS:000330336200008	24439332	Green Accepted			2021-06-18	
J	Perman, SM; Goyal, M; Neumar, RW; Topjian, AA; Gaieski, DF				Perman, Sarah M.; Goyal, Munish; Neumar, Robert W.; Topjian, Alexis A.; Gaieski, David F.			Clinical Applications of Targeted Temperature Management	CHEST			English	Article							TRAUMATIC BRAIN-INJURY; AMERICAN-HEART-ASSOCIATION; MILD THERAPEUTIC HYPOTHERMIA; HOSPITAL CARDIAC-ARREST; MODERATE HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; SYSTEMIC HYPOTHERMIA; COMATOSE SURVIVORS; CARE; GUIDELINES	Targeted temperature management (TTM) has been investigated experimentally and used clinically for over 100 years. The initial rationale for the clinical application of TTM, historically referred to as therapeutic hypothermia, was to decrease the metabolic rate, allowing the injured brain time to heal. Subsequent research demonstrated the temperature dependence of diverse cellular mechanisms including endothelial dysfunction, production of reactive oxygen species, and apoptosis. Consequently, modern use of TTM centers on neuroprotection following focal or global neurologic injury. Despite a solid basic science rationale for applying TTM in a variety of disease processes, including cardiac arrest, traumatic brain injury, ischemic stroke, neonatal ischemic encephalopathy, sepsis-induced encephalopathy, and hepatic encephalopathy, human efficacy data are limited and vary greatly from disease to disease. Ten years ago, two landmark investigations yielded high-quality data supporting the application of TTM in comatose survivors of out-of-hospital cardiac arrest. Additionally, TTM has been demonstrated to improve outcomes for neonatal patients with anoxic brain injury secondary to hypoxic ischemic encephalopathy. Trials are currently under way, or have yielded conflicting results in, examining the utility of TTM for the treatment of ischemic stroke, traumatic brain injury, and acute myocardial infarction. In this review, we place TTM in historic context, discuss the pathophysiologic rationale for its use, review the general concept of a TTM protocol for the management of brain injury, address some of the common side effects encountered when lowering human body temperature, and examine the data for its use in diverse disease conditions with in-depth examination of TTM for postarrest care and pediatric applications.	[Perman, Sarah M.; Gaieski, David F.] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Perman, Sarah M.; Gaieski, David F.] Univ Penn, Dept Emergency Med, Ctr Resuscitat Sci, Perelman Sch Med, Philadelphia, PA 19104 USA; [Topjian, Alexis A.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA 19104 USA; [Goyal, Munish] Washington Hosp Healthcare Syst, Medstar Hlth Syst, Dept Emergency Med, Washington, DC USA; [Neumar, Robert W.] Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI USA	Gaieski, DF (corresponding author), Univ Penn, Dept Emergency Med, Perelman Sch Med, 34th & Spruce St, Philadelphia, PA 19104 USA.	gaieskid@uphs.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS075363, T32NS061779] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS075363, T32 NS061779] Funding Source: Medline		Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Beurskens CJP, 2012, CRIT CARE MED, V40, P919, DOI 10.1097/CCM.0b013e3182373174; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Castren M, 2010, CIRCULATION, V122, P729, DOI 10.1161/CIRCULATIONAHA.109.931691; Che DF, 2011, CRIT CARE MED, V39, P1423, DOI 10.1097/CCM.0b013e318212020a; Chi OZ, 2001, ANESTHESIOLOGY, V95, P933, DOI 10.1097/00000542-200110000-00023; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; De Keyser J, 2005, ACTA NEUROL BELG, V105, P144; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; Doherty DR, 2009, CIRCULATION, V119, P1492, DOI 10.1161/CIRCULATIONAHA.108.791384; Dougherty D, 2008, JAMA-J AM MED ASSOC, V299, P2319, DOI 10.1001/jama.299.19.2319; Fay T, 1940, NY STATE J MED, V40, P1351; Fink EL, 2010, PEDIATR CRIT CARE ME, V11, P66, DOI 10.1097/PCC.0b013e3181c58237; Gaieski DF, 2009, RESUSCITATION, V80, P418, DOI 10.1016/j.resuscitation.2008.12.015; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gotberg M, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-7; Grines CL, ICEIT1; Guluma KZ, 2006, ACAD EMERG MED, V13, P820, DOI 10.1197/j.aem.2006.03.559; Haugk M, 2011, CRIT CARE, V15, DOI 10.1186/cc10116; Haugk M, 2010, RESUSCITATION, V81, P1704, DOI 10.1016/j.resuscitation.2010.08.033; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jalan R, 2004, GASTROENTEROLOGY, V127, P1338, DOI 10.1053/j.gastro.2004.08.005; Jalan R, 2003, TRANSPLANTATION, V75, P2034, DOI 10.1097/01.TP.0000066240.42113.FF; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; Jauch EC, 2010, CIRCULATION, V122, pS818, DOI 10.1161/CIRCULATIONAHA.110.971044; JURKOVICH GJ, 1988, J SURG RES, V44, P514, DOI 10.1016/0022-4804(88)90156-4; Kleinman ME, 2010, CIRCULATION, V122, pS876, DOI 10.1161/CIRCULATIONAHA.110.971101; Kremens Karol, 2011, Conn Med, V75, P203; Leon K, 2012, CRIT CARE MED, V40, P912, DOI 10.1097/CCM.0b013e3182373134; LISS HP, 1986, ANN EMERG MED, V15, P65, DOI 10.1016/S0196-0644(86)80490-5; Lundbye JB, 2012, RESUSCITATION, V83, P202, DOI 10.1016/j.resuscitation.2011.08.005; Ly HQ, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.200502.049; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Merchant RM, 2006, CRIT CARE MED, V34, pS490, DOI 10.1097/01.CCM.0000246016.28679.36; Merchant RM, 2006, CRIT CARE MED, V34, P1935, DOI 10.1097/01.CCM.0000220494.90290.92; Mooney MR, 2011, CIRCULATION, V124, P206, DOI 10.1161/CIRCULATIONAHA.110.986257; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAFAR P, 1964, J Iowa Med Soc, V54, P629; Schortgen F, 2012, AM J RESP CRIT CARE, V185, P1088, DOI 10.1164/rccm.201110-1820OC; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Testori C, 2011, RESUSCITATION, V82, P1162, DOI 10.1016/j.resuscitation.2011.05.022; VILLAR J, 1993, RESUSCITATION, V26, P183, DOI 10.1016/0300-9572(93)90178-S; WILLIAMS GR, 1958, ANN SURG, V148, P462, DOI 10.1097/00000658-195809000-00014; Wolff B, 2009, INT J CARDIOL, V133, P223, DOI 10.1016/j.ijcard.2007.12.039; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174	60	31	34	1	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0012-3692			CHEST	Chest	FEB	2014	145	2					386	393		10.1378/chest.12-3025			8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	AA2WO	WOS:000330955100031	24493510	Green Published			2021-06-18	
J	Schroeppel, TJ; Sharpe, JP; Magnotti, LJ; Weinberg, JA; Clement, LP; Croce, MA; Fabian, TC				Schroeppel, Thomas J.; Sharpe, John P.; Magnotti, Louis J.; Weinberg, Jordan A.; Clement, L. Paige; Croce, Martin A.; Fabian, Timothy C.			Traumatic brain injury and beta-blockers: Not all drugs are created equal	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Trauma; propranolol; dysautonomia	BLUNT HEAD-INJURY; SUBARACHNOID HEMORRHAGE; IMPROVED OUTCOMES; NERVOUS-SYSTEM; CATECHOLAMINES; BLOCKADE; PROPRANOLOL; EPIDEMIOLOGY; MODULATION; EXPOSURE	BACKGROUND: Dysautonomia in traumatic brain injury patients may contribute to secondary injury. We hypothesize that propranolol is the best beta-blocker (BB) to block the excess catecholamines and improve mortality in this patient population. METHODS: Patients with traumatic brain injury admitted during a 48-month period who received BB were compared with those who did not after excluding patients who received preinjury BB, deaths within 48 hours, and head Abbreviated Injury Scale (AIS) score of less than 3 or greater than 5. In addition, propranolol was also compared with all other BBs. RESULTS: A total of 1,755 patients with traumatic brain injury were identified during the study period after exclusions. Patients who received BB (427) were older (49 years vs. 40 years; p < 0.0001), were more severely injured (Injury Severity Score [ISS], 30 vs. 24; p < 0.001), and had a more severe head injury (head AIS score, 4.2 vs. 4.0; p < 0.001). By univariate analysis, BB patients had a higher mortality (13% vs. 6%; p < 0.001); after adjusted analysis, no difference was identified (adjusted odds ratio, 0.850; 95% confidence interval, 0.536-1.348). Seventy-eight patients (18%) received propranolol during the study period. Propranolol patients were younger (30 years vs. 53 years; p G 0.001) but more severely injured (ISS, 33 vs. 29; p = 0.01; head AIS, 4.5 vs. 4.2; p < 0.001), with longer stay (44 days vs. 26 days, p G 0.001). Mortality was less in the propranolol group (3% vs. 15%, p = 0.002). Adjusted analysis confirmed the protective effect of propranolol (adjusted odds ratio, 0.199; 95% confidence interval, 0.043-0.920). CONCLUSION: Propranolol is the best BB to limit secondary injury and decrease mortality in patients with traumatic brain injury. Copyright (C) 2014 by Lippincott Williams & Wilkins	Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Reg Med Ctr Memphis, Dept Pharm, Memphis, TN USA	Schroeppel, TJ (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Surg, 910 Madison Bldg,Ste 220, Memphis, TN 38163 USA.	tschroep@uthsc.edu					Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; [Anonymous], TBI STAT; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Bukur M, 2012, J TRAUMA ACUTE CARE, V72, P1013, DOI 10.1097/TA.0b013e318241bc5b; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Deng JP, 2004, AM J PHYSIOL-CELL PH, V287, pC730, DOI 10.1152/ajpcell.00562.2003; ELENKOV IJ, 1995, J NEUROIMMUNOL, V61, P123, DOI 10.1016/0165-5728(95)00080-L; Freibel JH, 1981, ANN NEUROL, V9, P340; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HAWKINS WE, 1971, CARDIOVASC RES, V5, P524, DOI 10.1093/cvr/5.4.524; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; JAATTELA A, 1975, BRIT J SURG, V62, P177, DOI 10.1002/bjs.1800620303; Kalinichenko VV, 1999, J IMMUNOL, V163, P2492; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; MCLEOD AA, 1982, BRIT HEART J, V47, P221; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; NEILDWYER G, 1981, BRIT J CLIN PHARMACO, V11, P549, DOI 10.1111/j.1365-2125.1981.tb01169.x; NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990; NEILDWYER G, 1985, EUR J CLIN PHARMACOL, V28, P25, DOI 10.1007/BF00543706; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Randell T, 1999, J NEUROSURG ANESTH, V11, P163, DOI 10.1097/00008506-199907000-00001; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Schroeppel TJ, 2010, J TRAUMA, V69, P776, DOI 10.1097/TA.0b013e3181e981b8; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WEIR BK, 1978, J NEUROSURG, V49, P502, DOI 10.3171/jns.1978.49.4.0502; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899	39	31	32	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2014	76	2					504	509		10.1097/TA.0000000000000104			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AH8KG	WOS:000336386100038	24458058				2021-06-18	
J	Weigl, W; Milej, D; Gerega, A; Toczylowska, B; Kacprzak, M; Sawosz, P; Botvvicz, M; Maniewski, R; Mayzner-Zawadzka, E; Liebert, A				Weigl, W.; Milej, D.; Gerega, A.; Toczylowska, B.; Kacprzak, M.; Sawosz, P.; Botvvicz, M.; Maniewski, R.; Mayzner-Zawadzka, E.; Liebert, A.			Assessment of cerebral perfusion in post-traumatic brain injury patients with the use of ICG-bolus tracking method	NEUROIMAGE			English	Article						Traumatic brain injury; TBI; Brain perfusion; Bolus tracking; Time-resolved near-infrared measurements; Diffuse reflectance; Fluorescence; lndocyanine green; ICG	NEAR-INFRARED SPECTROSCOPY; DIFFUSE OPTICAL TOMOGRAPHY; ARTERIAL INPUT FUNCTION; CLOSED-HEAD INJURY; ADULT HUMAN BRAIN; INDOCYANINE GREEN; BLOOD-FLOW; NONINVASIVE MEASUREMENT; SUBARACHNOID HEMORRHAGE; CARDIOPULMONARY BYPASS	The aim of this study was to verify the usefulness of the time-resolved optical method utilizing diffusely reflected photons and fluorescence signals combined with intravenous injection of indocyanine green (ICG) in the assessment of brain perfusion in post-traumatic brain injury patients. The distributions of times of flight (DTOFs) of diffusely reflected photons were acquired together with the distributions of times of arrival (DTAs) of fluorescence photons. The data analysis methodology was based on the observation of delays between the signals of statistical moments (number of photons, mean time of flight and variance) of DTOFs and DTAs related to the inflow of ICG to the extra- and intracerebral tissue compartments. Eleven patients with brain hematoma, 15 patients with brain edema and a group of 9 healthy subjects were included in this study. Statistically significant differences between parameters obtained in healthy subjects and patients with brain hematoma and brain edema were observed. The best optical parameter to differentiate patients and control group was variance of the DTOFs or DTAs. Results of the study suggest that time-resolved optical monitoring of inflow of the ICG seems to be a promising tool for detecting cerebral perfusion insufficiencies in critically ill patients. (C) 2013 Elsevier Inc. All rights reserved.	[Weigl, W.] Med Univ Warsaw, Dept Anesthesia & Intens Care 1, Warsaw, Poland; [Weigl, W.] Warsaw Praski Hosp, Dept Anaesthesia & Intens Care, Warsaw, Poland; [Milej, D.; Gerega, A.; Toczylowska, B.; Kacprzak, M.; Sawosz, P.; Botvvicz, M.; Maniewski, R.; Liebert, A.] Polish Acad Sci, Nalecz Inst Biocybernet & Biomed Engn, Warsaw, Poland; [Mayzner-Zawadzka, E.] Univ Warmia & Mazury, Dept Anaesthesia & Intens Care, Olsztyn, Poland	Weigl, W (corresponding author), Med Univ Warsaw, Dept Anesthesia & Intens Care 1, Warsaw, Poland.	wojciech.weigl@gmail.com	Milej, Daniel/B-6729-2014; Liebert, Adam/D-7654-2011; Gerega, Anna/AAR-1496-2021; Weigl, Wojciech/B-4294-2015	Milej, Daniel/0000-0003-3173-0834; Gerega, Anna/0000-0002-9809-6041; Weigl, Wojciech/0000-0001-5184-6602; Liebert, Adam/0000-0003-1643-7568; Toczylowska, Beata/0000-0002-5031-6228; Kacprzak, Michal/0000-0002-3149-837X	EC Seventh Framework ProgrammeEuropean Commission [201076]; Polish National Centre of Science [2011/03/N/ST7/02598]; European Social Fund, Human Capital Operational Programme [UDA-POKL.08.02.01-14-041/09]	Studies were financed by the EC Seventh Framework Programme under grant agreement no. 201076 project nEUROPt "Non-invasive imaging of brain function and disease by pulsed near infrared light". This work has been also supported by the Polish National Centre of Science under grant agreement 2011/03/N/ST7/02598 and by a scholarship from the European Social Fund, Human Capital Operational Programme for the execution of the project "Support for bio tech med scientists in technology transfer"; (UDA-POKL.08.02.01-14-041/09).	Aletti F, 2012, COMPUT BIOL MED, V42, P282, DOI 10.1016/j.compbiomed.2011.06.001; Becker W., 2010, ADV TIME CORRELATED; Bein B, 2006, CRIT CARE, V10, DOI 10.1186/cc3980; Brawanski A, 2002, J CEREBR BLOOD F MET, V22, P605, DOI 10.1097/00004647-200205000-00012; Brown DW, 2002, PEDIATR RES, V51, P564, DOI 10.1203/00006450-200205000-00004; Budohoski KP, 2012, BRIT J ANAESTH, V108, P89, DOI 10.1093/bja/aer324; Coles JP, 2007, BRIT J ANAESTH, V99, P49, DOI 10.1093/bja/aem141; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; COPE M, 1988, MED BIOL ENG COMPUT, V26, P289, DOI 10.1007/BF02447083; Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5; Diop M, 2011, BIOMED OPT EXPRESS, V2, P2068, DOI 10.1364/BOE.2.002068; Diop M, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3488626; Diop M, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3123347; Ducros N, 2009, PHYS MED BIOL, V54, P7107, DOI 10.1088/0031-9155/54/23/005; Ducros N, 2009, PHYS MED BIOL, V54, P7089, DOI 10.1088/0031-9155/54/23/004; Dunham CM, 2002, J TRAUMA, V52, P40, DOI 10.1097/00005373-200201000-00009; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Elliott JK, 2010, TLS-TIMES LIT SUPPL, P15; Elliott JT, 2013, BIOMED OPT EXPRESS, V4, P206, DOI 10.1364/BOE.4.000206; Gerega A, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.8.087001; Gerega A, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3593386; Gora F, 2002, J NEUROSURG ANESTH, V14, P218, DOI 10.1097/00008506-200207000-00008; Habermehl C, 2011, OPT EXPRESS, V19, P18636, DOI 10.1364/OE.19.018636; Heilmann M, 2007, MAGN RESON MATER PHY, V20, P193, DOI 10.1007/s10334-007-0082-2; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529; Hopton P, 1999, J APPL PHYSIOL, V87, P1981; Jelzow A, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.5.057003; Kacprzak M, 2010, OPTO-ELECTRON REV, V18, P37, DOI 10.2478/s11772-009-0027-6; Kacprzak M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2743964; Kastrup A, 1999, J NEUROL SCI, V166, P91, DOI 10.1016/S0022-510X(99)00121-5; Keller E, 2003, NEUROIMAGE, V20, P828, DOI 10.1016/S1053-8119(03)00315-X; Keller E, 2002, J NEUROSCI METH, V117, P23, DOI 10.1016/S0165-0270(02)00044-4; Keller E, 2001, J NEUROSURG ANESTH, V13, P43, DOI 10.1097/00008506-200101000-00008; Kim DH, 2006, NEUROCRIT CARE, V4, P83, DOI 10.1385/NCC:4:1:083; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kim MN, 2014, NEUROCRIT CARE, V20, P443, DOI 10.1007/s12028-013-9849-7; Kim MN, 2010, NEUROCRIT CARE, V12, P173, DOI 10.1007/s12028-009-9305-x; Kohl-Bareis M, 2002, J BIOMED OPT, V7, P464, DOI 10.1117/1.1482719; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kuebler WM, 1998, J CEREBR BLOOD F MET, V18, P445, DOI 10.1097/00004647-199804000-00013; Kusaka T, 2001, NEUROIMAGE, V13, P944, DOI 10.1006/nimg.2001.0755; LANDSMAN MLJ, 1976, J APPL PHYSIOL, V40, P575; Leal-Noval SR, 2010, INTENS CARE MED, V36, P1309, DOI 10.1007/s00134-010-1920-7; Leung TS, 2004, PEDIATR RES, V55, P134, DOI 10.1203/01.PDR.0000099775.87684.FB; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; Liebert A, 2006, NEUROIMAGE, V31, P600, DOI 10.1016/j.neuroimage.2005.12.046; Liebert A, 2005, NEUROIMAGE, V24, P426, DOI 10.1016/j.neuroimage.2004.08.046; Liebert A, 2004, APPL OPTICS, V43, P3037, DOI 10.1364/AO.43.003037; Liebert A, 2003, APPL OPTICS, V42, P5785, DOI 10.1364/AO.42.005785; Liebert A, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.5.057005; Liebert A, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3574018; Lin PY, 2013, JOVE-J VIS EXP, DOI 10.3791/4379; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mesquita RC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037322; Milej D, 2010, OPTO-ELECTRON REV, V18, P208, DOI 10.2478/s11772-010-0013-z; Milej D, 2012, PHYS MED BIOL, V57, P6725, DOI 10.1088/0031-9155/57/20/6725; Milej D, 2010, ADV INTEL SOFT COMPU, V69, P85; Mordon S, 1998, MICROVASC RES, V55, P146, DOI 10.1006/mvre.1998.2068; Mulvey JM, 2004, NEUROCRIT CARE, V1, P391, DOI 10.1385/NCC:1:3:391; Nabavi DG, 2001, STROKE, V32, P175, DOI 10.1161/01.STR.32.1.175; Nabavi DG, 2001, NEURORADIOLOGY, V43, P7, DOI 10.1007/s002340000434; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Ohmae E, 2006, NEUROIMAGE, V29, P697, DOI 10.1016/j.neuroimage.2005.08.008; Patel J, 1998, PEDIATR RES, V43, P34, DOI 10.1203/00006450-199801000-00006; Petrella JR, 2000, AM J ROENTGENOL, V175, P207, DOI 10.2214/ajr.175.1.1750207; Port RE, 2001, MAGNET RESON MED, V45, P1030, DOI 10.1002/mrm.1137; Reekers M, 2009, ANESTH ANALG, V109, P441, DOI 10.1213/ane.0b013e3181a8d81f; Roberts HC, 2002, AM J NEURORADIOL, V23, P828; Roberts IG, 1998, J THORAC CARDIOV SUR, V115, P94, DOI 10.1016/S0022-5223(98)70447-7; Sawosz P, 2012, PHYS MED BIOL, V57, P7973, DOI 10.1088/0031-9155/57/23/7973; Schytz HW, 2009, EUR J NEUROL, V16, P461, DOI 10.1111/j.1468-1331.2008.02398.x; Selb J, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1852553; Selb J, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2337320; Sheikh K, 2009, AM J ROENTGENOL, V192, pW321, DOI 10.2214/AJR.07.3677; Springett R, 2001, PHYS MED BIOL, V46, P2209, DOI 10.1088/0031-9155/46/8/312; St Lawrence K, 2013, PHYS MED BIOL, V58, P1591, DOI 10.1088/0031-9155/58/5/1591; Steinbrink J, 2008, NEURODEGENER DIS, V5, P296, DOI 10.1159/000135614; Steinbrink J, 2001, PHYS MED BIOL, V46, P879, DOI 10.1088/0031-9155/46/3/320; Steinbrink J, 2006, J THORAC CARDIOV SUR, V132, P1172, DOI 10.1016/j.jtcvs.2006.05.065; Steinkellner O., 2010, BIOMEDICAL OPTICS; Steinkellner O, 2012, BIOCYBERN BIOMED ENG, V32, P3, DOI 10.1016/S0208-5216(12)70028-1; Steinkellner O, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3505009; Ter Minassian A, 1999, ANESTHESIOLOGY, V91, P985; Terborg C, 2004, J NEUROL NEUROSUR PS, V75, P38; The Brain Trauma Foundation, 2007, J NEUROTRAUM, V24, P7; van Osch MJP, 2001, MAGN RESON MED, V45, P477, DOI 10.1002/1522-2594(200103)45:3<477::AID-MRM1063>3.0.CO;2-4; Verdecchia K, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.2.027007; VILLRINGER A, 1993, NEUROSCI LETT, V154, P101, DOI 10.1016/0304-3940(93)90181-J; Wabnitz H, 2010, ADV EXP MED BIOL, V662, P143, DOI 10.1007/978-1-4419-1241-1_20; Wintermark M, 2005, J NEURORADIOLOGY, V32, P294, DOI 10.1016/S0150-9861(05)83159-1; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824	93	31	31	1	31	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 15	2014	85		1		SI		555	565		10.1016/j.neuroimage.2013.06.065			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	278DQ	WOS:000328869700053	23831529				2021-06-18	
J	Elliott, M; Parente, F				Elliott, Madison; Parente, Frederick			Efficacy of memory rehabilitation therapy: A meta-analysis of TBI and stroke cognitive rehabilitation literature	BRAIN INJURY			English	Article						Cognitive rehabilitation; memory; meta-analysis; neurorehabilitation; remediation; stroke; TBI; working memory	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; MODERATE; REMEDIATION; PERFORMANCE	Objective: To examine the efficacy of cognitive rehabilitation strategies specifically designed to improve memory after traumatic brain injury (TBI) and stroke vs. memory improvement with the passage of time. Design and methods: A meta-analysis was performed on 26 studies of memory retraining and recovery that were published between the years of 1985 and 2013. Effect sizes (ESs) from each study were calculated and converted to Pearson's r and then analysed to assess the overall effect size and the relationship among the ESs, patient demographics and treatment interventions. Results: Results indicated a significant average ES (r = 0.51) in the treatment intervention conditions, as well as a significant average ES (r = 0.31) in the control conditions, in which participants did not receive any treatment. The largest ESs occurred in studies of stroke patients and studies concerning working memory rehabilitation. Conclusions: Results showed that memory rehabilitation was an effective therapeutic intervention, especially for stroke patients and for working memory as a treatment domain. However, the results also indicated that significant memory improvement occurred spontaneously over time.	[Elliott, Madison; Parente, Frederick] Towson Univ, Towson, MD 21252 USA	Elliott, M (corresponding author), Towson Univ, Dept Psychol, 8000 York Rd, Towson, MD 21252 USA.	mellio4@students.towson.edu	Parente, Frederick/W-2570-2019	Parente, Frederick/0000-0002-2784-3433			Anderson JW, 2009, J CLIN EXP NEUROPSYC, V31, P425, DOI 10.1080/13803390802232667; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; [Anonymous], SEV BRAIN INJ; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; Bergquist T, 2009, BRAIN INJURY, V23, P790, DOI 10.1080/02699050903196688; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Cooper H., 1994, HDB RES SYNTHESIS; Couillet J, 2010, NEUROPSYCHOL REHABIL, V20, P321, DOI 10.1080/09602010903467746; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Evans J, 1996, CLIN REHABIL, V6, P75; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; Goldstein G, 1996, CLIN NEUROPSYCHOL, V10, P66, DOI 10.1080/13854049608406664; Goldstein G, 1998, CLIN NEUROPSYCHOL, V2, P251; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hildebrandt H, 2011, J CLIN EXP NEUROPSYC, V33, P257, DOI 10.1080/13803395.2010.511471; Katz I, 2006, COGNITIVE REHABILITA; Kay T, 2003, J HEAD TRAUMA REHAB, V8, P74; Kerner M, 1985, COGNIT REHABIL, V11, P26; Kim D, 2006, EUROPEAN J PHARM, V542, P29; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krause M, 2009, BRAIN INJURY, V23, P965, DOI 10.3109/02699050903373485; Livengood M, 2010, BRAIN INJURY, V24, P598, DOI 10.3109/02699051003652815; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Mar J, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-46; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Milders M, 1998, MEMORY, V6, P21, DOI 10.1080/741941597; Nadar MS, 2008, CLIN REHABIL, V22, P847, DOI 10.1177/0269215508091874; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Planas AM, 2012, TRANSLATIONAL MED, V44, P318; Robey RR, 1998, J SPEECH LANG HEAR R, V41, P172, DOI 10.1044/jslhr.4101.172; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rosenthal R, 2001, ANNU REV PSYCHOL, V52, P59, DOI 10.1146/annurev.psych.52.1.59; SCHACTER DL, 1985, J CLIN EXP NEUROPSYC, V7, P79, DOI 10.1080/01688638508401243; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; Smania N, 2011, J HEAD TRAUMA REHAB, V15, P45; Stringer AY, 2011, BRAIN INJURY, V25, P169, DOI 10.3109/02699052.2010.541894; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wolfe CDA, 2000, BRIT MED BULL, V56, P275, DOI 10.1258/0007142001903120	51	31	31	0	25	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	12					1610	1616		10.3109/02699052.2014.934921			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AR6UD	WOS:000343717700013	25058353				2021-06-18	
J	Lehrner, A; Yehuda, R				Lehrner, Amy; Yehuda, Rachel			PTSD IN THE MILITARY: PREVALENCE, PATHOPHYSIOLOGY, TREATMENT Biomarkers of PTSD: military applications and considerations	EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY			English	Article						Posttraumatic stress disorder; biomarkers; clinical utility; ethics; translation	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; COGNITIVE-BEHAVIORAL THERAPY; PREDICTS TREATMENT RESPONSE; EXTREME STRESS; ANTERIOR CINGULATE; MAJOR DEPRESSION; NATIONAL-SURVEY; CORTISOL; PSYCHOTHERAPY	Background: Although there are no established biomarkers for posttraumatic stress disorder (PTSD) as yet, biological investigations of PTSD have made progress identifying the pathophysiology of PTSD. Given the biological and clinical complexity of PTSD, it is increasingly unlikely that a single biomarker of disease will be identified. Rather, investigations will more likely identify different biomarkers that indicate the presence of clinically significant PTSD symptoms, associate with risk for PTSD following trauma exposure, and predict or identify recovery. While there has been much interest in PTSD biomarkers, there has been less discussion of their potential clinical applications, and of the social, legal, and ethical implications of such biomarkers. Objective: This article will discuss possible applications of PTSD biomarkers, including the social, legal, and ethical implications of such biomarkers, with an emphasis on military applications. Method: Literature on applications of PTSD biomarkers and on potential ethical and legal implications will be reviewed. Results: Biologically informed research findings hold promise for prevention, assessment, treatment planning, and the development of prophylactic and treatment interventions. As with any biological indicator of disorder, there are potentially positive and negative clinical, social, legal, and ethical consequences of using such biomarkers. Conclusions: Potential clinical applications of PTSD biomarkers hold promise for clinicians, patients, and employers. The search for biomarkers of PTSD should occur in tandem with an interdisciplinary discussion regarding the potential implications of applying biological findings in clinical and employment settings.	[Lehrner, Amy; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA; [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA	Lehrner, A (corresponding author), James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA.	amy.lehrner@va.gov					American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Aupperle RL, 2013, PSYCHIAT RES-NEUROIM, V214, P48, DOI 10.1016/j.pscychresns.2013.05.001; Baker DG, 2012, NEUROPHARMACOLOGY, V62, P663, DOI 10.1016/j.neuropharm.2011.02.027; Barsaglini A, 2014, PROG NEUROBIOL, V114, P1, DOI 10.1016/j.pneurobio.2013.10.006; Baum M, 2013, BIOPREDICTION BIOMAR, P12; Bomyea J, 2012, CLIN PSYCHOL REV, V32, P630, DOI 10.1016/j.cpr.2012.06.008; Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552; Bottalico B, 2012, INT J LAW PSYCHIAT, V35, P112, DOI 10.1016/j.ijlp.2011.12.001; Brady KT, 2000, J CLIN PSYCHIAT, V61, P22; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Bryant RA, 2008, PSYCHOL MED, V38, P555, DOI 10.1017/S0033291707002231; Bryant RA, 2008, J PSYCHIATR NEUROSCI, V33, P142; Caux C, 2007, SOC SCI MED, V65, P344, DOI 10.1016/j.socscimed.2007.03.041; Cisler JM, 2014, J PSYCHIATR RES, V48, P47, DOI 10.1016/j.jpsychires.2013.09.013; Cloitre M, 2013, EUR J PSYCHOTRAUMATO, V4, DOI 10.3402/ejpt.v4i0.20706; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; Dalenberg CJ, 2012, DEPRESS ANXIETY, V29, P671, DOI 10.1002/da.21926; Delahanty DL, 2005, PSYCHONEUROENDOCRINO, V30, P121, DOI 10.1016/j.psyneuen.2004.06.004; Delahanty DL, 2000, BIOL PSYCHIAT, V48, P940, DOI 10.1016/S0006-3223(00)00896-9; Delahanty DL, 2013, CNS SPECTRUMS, V18, P103, DOI 10.1017/S1092852913000096; DiGangi JA, 2013, CLIN PSYCHOL REV, V33, P728, DOI 10.1016/j.cpr.2013.05.002; Dyer C, 2002, BRIT MED J, V324, P563, DOI 10.1136/bmj.324.7337.563; Falconer E, 2013, J CLIN PSYCHIAT, V74, P895, DOI 10.4088/JCP.12m08020; Farrow TFD, 2005, PSYCHIAT RES-NEUROIM, V140, P45, DOI 10.1016/j.pscychresns.2005.05.012; Felmingham K, 2007, PSYCHOL SCI, V18, P127, DOI 10.1111/j.1467-9280.2007.01860.x; Forbes D, 2010, J TRAUMA STRESS, V23, P340, DOI 10.1002/jts.20526; Ford JD, 1999, J CONSULT CLIN PSYCH, V67, P3, DOI 10.1037/0022-006X.67.1.3; Ford JD, 1998, J TRAUMA STRESS, V11, P743, DOI 10.1023/A:1024497400891; Friedman MJ, 2011, DEPRESS ANXIETY, V28, P750, DOI 10.1002/da.20767; Fuzery AK, 2013, CLIN PROTEOM, V10, DOI 10.1186/1559-0275-10-13; Gauthier S, 2013, PROG NEUROBIOL, V110, P102, DOI 10.1016/j.pneurobio.2013.01.003; Hampel H., 2011, PROGR NEUROBIOLOGY, V95, P517, DOI [10.1016/j.pneurobio.2011.11.009, DOI 10.1016/J.PNEUR0BIO.2011.11.009]; Heber R, 2002, J CLIN PSYCHOL, V58, P1521, DOI 10.1002/jclp.10102; HERMAN JL, 1992, J TRAUMA STRESS, V5, P377, DOI 10.1002/jts.2490050305; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Illes J, 2007, ANN NY ACAD SCI, V1097, P278, DOI 10.1196/annals.1379.030; Institute of Medicine (IOM), 2008, TREATM POSTTR STRESS; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kilpatrick DG, 2003, J CONSULT CLIN PSYCH, V71, P692, DOI 10.1037/0022-006X.71.4.692; Lakhan Shaheen E, 2010, Int Arch Med, V3, P1, DOI 10.1186/1755-7682-3-1; Lanius RA, 2010, AM J PSYCHIAT, V167, P640, DOI 10.1176/appi.ajp.2009.09081168; Lindauer RJL, 2008, PSYCHOL MED, V38, P543, DOI 10.1017/S0033291707001432; Mechelli A, 2010, MED HYPOTHESES, V75, P594, DOI 10.1016/j.mehy.2010.07.042; Mickleborough MJS, 2011, J PSYCHIATR NEUROSCI, V36, P6, DOI 10.1503/jpn.080188; Miller AH, 2008, BIOL PSYCHIAT, V64, P263, DOI 10.1016/j.biopsych.2008.05.018; Morris MC, 2012, CLIN PSYCHOL REV, V32, P301, DOI 10.1016/j.cpr.2012.02.002; Olff M, 2007, PSYCHONEUROENDOCRINO, V32, P619, DOI 10.1016/j.psyneuen.2007.04.001; Otlowski M, 2012, ANNU REV GENOM HUM G, V13, P433, DOI 10.1146/annurev-genom-090711-163800; Pelcovitz D, 1997, J TRAUMA STRESS, V10, P3, DOI 10.1002/jts.2490100103; Peres JFP, 2007, PSYCHOL MED, V37, P1481, DOI 10.1017/S003329170700997X; Peres JFP, 2011, J PSYCHIATR RES, V45, P727, DOI 10.1016/j.jpsychires.2010.11.004; Perlis RH, 2011, MOL PSYCHIATR, V16, P1076, DOI 10.1038/mp.2011.63; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Roy MJ, 2010, ANN NY ACAD SCI, V1208, P142, DOI 10.1111/j.1749-6632.2010.05689.x; Schmidt U, 2013, DIS MARKERS, V2013, P43, DOI 10.1155/2013/835876; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Silver K, 2006, J OCCUP ENVIRON MED, V48, P434, DOI 10.1097/01.jom.0000200878.16077.3b; Singh I, 2009, NATURE, V460, P202, DOI 10.1038/460202a; Slats D., 2010, J NEUROL NEUROSUR PS, V81, P124, DOI [10.1136/jnnp.2009.176412, DOI 10.1136/4NNP.2009.176412]; Steudte S, 2013, BIOL PSYCHIAT, V74, P639, DOI 10.1016/j.biopsych.2013.03.011; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; van der Kolk B., 2002, TREATING TRAUMA SURV, P127; van der Kolk BA, 2005, J TRAUMA STRESS, V18, P389, DOI 10.1002/jts.20047; van Zuiden M, 2013, BRAIN BEHAV IMMUN, V30, P12, DOI 10.1016/j.bbi.2012.08.015; Wolf EJ, 2012, ARCH GEN PSYCHIAT, V69, P698, DOI 10.1001/archgenpsychiatry.2011.1574; Wolf EJ, 2010, J ABNORM PSYCHOL, V119, P320, DOI 10.1037/a0019035; Yehuda R, 1998, BIOL PSYCHIAT, V44, P1305, DOI 10.1016/S0006-3223(98)00276-5; Yehuda R, 2013, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00118; Yehuda R, 2013, PSYCHONEUROENDOCRINO, V38, P1912, DOI 10.1016/j.psyneuen.2013.06.009; Yehuda R, 2009, EXPERT REV NEUROTHER, V9, P1113, DOI 10.1586/ERN.09.79; Yehuda R, 2009, PSYCHONEUROENDOCRINO, V34, P1304, DOI 10.1016/j.psyneuen.2009.03.018; Zohar J, 2011, EUR NEUROPSYCHOPHARM, V21, P796, DOI 10.1016/j.euroneuro.2011.06.001; Zoladz PR, 2013, NEUROSCI BIOBEHAV R, V37, P860, DOI 10.1016/j.neubiorev.2013.03.024	74	31	31	1	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2000-8198	2000-8066		EUR J PSYCHOTRAUMATO	Eur. J. Psychotraumatol.		2014	5								23797	10.3402/ejpt.v5.23797			11	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	AO2HF	WOS:000341138600001	25206945	DOAJ Gold, Green Published			2021-06-18	
J	Seifman, MA; Gomes, K; Nguyen, PN; Bailey, M; Rosenfeld, JV; Cooper, DJ; Morganti-Kossmann, MC				Seifman, Marc A.; Gomes, Keith; Nguyen, Phuong N.; Bailey, Michael; Rosenfeld, Jeffrey V.; Cooper, David J.; Morganti-Kossmann, Maria Cristina			Measurement of serum melatonin in intensive care unit patients: changes in traumatic brain injury, trauma, and medical conditions	FRONTIERS IN NEUROLOGY			English	Article						melatonin; TBI; trauma; intensive care unit; circadian		Melatonin is an endogenous hormone mainly produced by the pineal gland whose dysfunction leads to abnormal sleeping patterns. Changes in melatonin have been reported in acute traumatic brain injury (TBI); however, the impact of environmental conditions typical of the intensive care unit (ICU) has not been assessed. The aim of this study was to compare daily melatonin production in three patient populations treated at the ICU to differentiate the role of TBI versus ICU conditions. Forty-five patients were recruited and divided into severe TBI, trauma without TBI, medical conditions without trauma, and compared to healthy volunteers. Serum melatonin levels were measured at four daily intervals at 0400 h, 1000 h, 1600 h, and 2200 h for 7 days post-ICU admission by commercial enzyme linked immunosorbent assay. The geometric mean concentrations (95% confidence intervals) of melatonin in these groups showed no difference being 8.3 (6.3-11.0), 9.3 (70-12.3), and 8.9 (6.6-11.9) pg/mL, respectively, in TBI, trauma, and intensive care cohorts. All of these patient groups demonstrated decreased melatonin concentrations when compared to control patients. This study suggests that TBI as well as ICU conditions, may have a role in the dysfunction of melatonin. Monitoring and possibly substituting melatonin acutely in these settings may assist in ameliorating long-term sleep dysfunction in all of these groups, and possibly contribute to reducing secondary brain injury in severe TBI.	[Seifman, Marc A.; Gomes, Keith; Nguyen, Phuong N.] The Alfred, Natl Trauma Res Inst, Melbourne, Vic, Australia; [Seifman, Marc A.; Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Seifman, Marc A.; Gomes, Keith; Rosenfeld, Jeffrey V.] The Alfred, Dept Neurosurg, Melbourne, Vic, Australia; [Bailey, Michael; Cooper, David J.; Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Epidemiol, Melbourne, Vic 3004, Australia; [Bailey, Michael; Cooper, David J.; Morganti-Kossmann, Maria Cristina] Australian New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Cooper, David J.] The Alfred, Intens Care Unit, Melbourne, Vic, Australia; [Morganti-Kossmann, Maria Cristina] Univ Arizona, Dept Child Hlth, Barrow Neurol Inst, Phoenix, AZ USA	Morganti-Kossmann, MC (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, 99 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@monash.edu	Bailey, Michael J/A-4499-2012; Cooper, D. James/G-7961-2013	Bailey, Michael J/0000-0002-5551-1401; Cooper, D. James/0000-0002-5872-9051; Morganti-Kossmann, Cristina/0000-0002-0807-2063			Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Ates O, 2006, INT J DEV NEUROSCI, V24, P357, DOI 10.1016/j.ijdevneu.2006.08.003; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Barlow KM, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-271; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Gorgulu AK, 2001, NEUROSURGERY, V49, P1434; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Lewy A, 2006, CHRONOBIOL INT, V23, P403, DOI 10.1080/07420520500545862; Longoni B, 1998, LIFE SCI, V62, P853, DOI 10.1016/S0024-3205(98)00002-2; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rajaratnam SMW, 2009, SLEEP MED CLIN, V4, P179, DOI 10.1016/j.jsmc.2009.02.007; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; Rizzo V, 2002, J CHROMATOGR B, V774, P17, DOI 10.1016/S1570-0232(02)00168-X; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shilo L, 1999, AM J MED SCI, V317, P278, DOI 10.1097/00000441-199905000-00002; Shilo L, 2000, CHRONOBIOL INT, V17, P71, DOI 10.1081/CBI-100101033	25	31	32	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								237	10.3389/fneur.2014.00237			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QW	WOS:000209629300223	25477861	DOAJ Gold, Green Published			2021-06-18	
J	Sinclair, E; Radford, K; Grant, M; Terry, J				Sinclair, Emma; Radford, Kathryn; Grant, Mary; Terry, Jane			Developing stroke-specific vocational rehabilitation: a soft systems analysis of current service provision	DISABILITY AND REHABILITATION			English	Article						Mapping; soft systems analysis; stroke; vocational rehabilitation	TRAUMATIC BRAIN-INJURY; WORK; RETURN	Purpose: This study aimed to clarify the existing service provision of stroke-specific vocational rehabilitation (VR) in one English county, in order to facilitate future service development. Method: Using soft systems methodology, services in Health, Social Care, Department of Work and Pensions, the voluntary and private sectors, which were identified as supporting return to work after stroke, were mapped using a mixed-methodology approach. Results: A lack of a sanctioned VR pathway meant access to support relied on brokered provision and tacit knowledge. The timing of an intervention was complex and there was a substantial degree of unmet need for mild stroke patients. VR was seen as "non-essential" due to competing commissioning priorities. Service providers from all sectors lacked training and cross-sector partnerships were tenuous and provider roles unclear. Conclusions: Stroke-specific VR should be delivered by an integrated, cross-sector multi-disciplinary team and integrated commissioning between health and other sectors is necessary. Although early intervention is important, support later on in the recovery process is also necessary. Service providers need adequate training to meet the needs of stroke survivors wishing to return to work and better awareness of best practice guidelines. Business cases which demonstrate the efficacy and cost-effectiveness of VR are vital.	[Sinclair, Emma; Radford, Kathryn; Grant, Mary] Univ Nottingham, Div Rehabil & Ageing, Nottingham NG7 2RD, England; [Terry, Jane] Nottingham CityCare Partnership, Community Stroke Team, Nottingham, England	Radford, K (corresponding author), Queens Med Ctr, Med Sch B102, Div Rehabil & Ageing, Nottingham NG7 2UH, England.	kate.radford@nottingham.ac.uk	Radford, Kate A/F-8571-2013	Radford, Kate A/0000-0001-6246-3180	National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care for Nottinghamshire, Derbyshire and Lincolnshire (NIHR CLAHRC NDL)	This research was funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care for Nottinghamshire, Derbyshire and Lincolnshire (NIHR CLAHRC NDL). The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Barker G, 2006, GETTING BACK WORK ST; Bedekar Y., 2009, INT J STROKE, V4, P1; Black C, 2008, WORKING HLTH TOMORRO; Black C.D., 2011, HLTH WORK INDEPENDEN; British Society of Rehabilitation Medicine, 2008, NEUR REH BRIEF PAP C; British Society of Rehabilitation Medicine, 2009, BSRM STAND REH SERV; Care Quality Commission, 2011, SUPP LIF STROK REV S; Checkland P, 1999, SOFT SYSTEMS METHODO; Daniel K, 2009, STROKE, V40, pE431, DOI [10.1161/STROKEAHA.108.534487, 10.1161/STROKEAHA.108.535088]; Department of Health, 2007, NAT STROK STRAT; Department of Health, 2005, NAT SERV FRAM LONG T; Department of Health, 2010, EQ EXC LIB NHS; Department of Health, 2010, NHS OUTC FRAM 2011 1; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Lock S, 2005, DISABIL SOC, V20, P33, DOI 10.1080/0968759042000283629; *NAT AUD OFF, 2005, RED BRAIN DAM FAST A; Playford E., 2011, MAPPING VOCATIONAL R; Radford KA, 2012, BRAIN INJURY, V26, P600; Radford KA, HLTH SERV R IN PRESS; SAEKI S, 1995, STROKE, V26, P399, DOI 10.1161/01.STR.26.3.399; Saeki S, 2010, J REHABIL MED, V42, P254, DOI 10.2340/16501977-0503; Saka O, 2009, AGE AGEING, V38, P27, DOI 10.1093/ageing/afn281; Scottish Intercollegiate Guidelines Network, 2010, MAN PAT STROK REH PR; The Royal College of Physicians Intercollegiate Stroke Working Party, 2008, NAT CLIN GUID STROK; Turner-Stokes L, 2001, CLIN REHABIL, V15, P611, DOI 10.1191/0269215501cr455oa; Tyerman A, 2004, VOCATIONAL ASSESSMEN; van Eeden M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-122; Vestling M, 2003, J REHABIL MED, V35, P127, DOI 10.1080/16501970310010475; Waddell G., 2006, IS WORK GOOD YOUR HL	29	31	32	0	23	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2014	36	5					409	417		10.3109/09638288.2013.793410			9	Rehabilitation	Rehabilitation	AC4HF	WOS:000332481100009	23692389	Green Accepted, Green Published			2021-06-18	
J	Thal, SC; Timaru-Kast, R; Wilde, F; Merk, P; Johnson, F; Frauenknecht, K; Sebastiani, A; Sommer, C; Staib-Lasarzik, I; Werner, C; Engelhard, K				Thal, Serge C.; Timaru-Kast, Ralph; Wilde, Florian; Merk, Philipp; Johnson, Frederik; Frauenknecht, Katrin; Sebastiani, Anne; Sommer, Clemens; Staib-Lasarzik, Irina; Werner, Christian; Engelhard, Kristin			Propofol Impairs Neurogenesis and Neurologic Recovery and Increases Mortality Rate in Adult Rats After Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						mortality; neurogenesis; neurologic function; outcome; propofol; traumatic brain injury	HIPPOCAMPAL NEUROGENESIS; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; UP-REGULATION; INFARCT SIZE; PROLIFERATION; MEMORY; ANESTHESIA; DIFFERENTIATION; INHIBITION	Objective: Limited data are available on the influence of sedation for critical care therapy with the widely used anesthetic propofol on recovery from acute traumatic brain injury. To establish the influence of propofol on endogenous neurogenesis and functional recovery after traumatic brain injury, rats were sedated with propofol either during or 2 hours after experimental traumatic brain injury. Design: Randomized controlled animal study. Setting: University research laboratory. Subjects: One hundred sixteen male Sprague Dawley rats. Interventions: Mechanical brain lesion by controlled cortical impact. Measurements and Main Results: This study investigated the dose-dependent influence of propofol (36 or 72mg/kg/hr) either during controlled cortical impact induction or in a delayed application protocol 2 hours after experimental traumatic brain injury. Infusion of propofol resulted in 1) aggravation of neurologic dysfunction, 2) increased 28-day mortality rate, and 3) impaired posttraumatic neurogenesis (5-bromo-2-deoxyuridine + NeuN-positive cells). Application of propofol during trauma induction afforded a significant stronger effect in the high-dose group compared with low-dose propofol. In the posttrauma protocol, animals were sedated with sevoflurane during the controlled cortical impact injury, and propofol was given after an awake phase. In these animals, propofol increased mortality rate and impaired neurologic function and neurogenesis compared with animals without delayed propofol anesthesia. Conclusions: The results show that propofol may prevent or limit reparative processes in the early-phase postinjury. The results therefore indicate that anesthetics may be potentially harmful not only in very young mammalians but also in adult animals following acute cerebral injuries. The results provide first evidence for an altered sensitivity for anesthesia-related negative effects on neurogenesis, functional outcome, and survival in adult rats with brain lesions.	[Thal, Serge C.; Timaru-Kast, Ralph; Wilde, Florian; Merk, Philipp; Johnson, Frederik; Sebastiani, Anne; Staib-Lasarzik, Irina; Werner, Christian; Engelhard, Kristin] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, D-55122 Mainz, Germany; [Frauenknecht, Katrin; Sommer, Clemens] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Neuropathol, D-55122 Mainz, Germany	Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, D-55122 Mainz, Germany.	thal@uni-mainz.de	Frauenknecht, Katrin/AAF-1638-2020; Thal, Serge/D-6593-2011	Frauenknecht, Katrin/0000-0002-1372-3297; Thal, Serge/0000-0002-1222-8729	Else Kroner Fresenius Stiftung (Germany) [P19/07//A07/07]; Focus Program Translational Neurosciences of the Johannes Gutenberg University	Dr. Thal received a grant from Else Kroner Fresenius Stiftung (Germany; P19/07//A07/07) and the Focus Program Translational Neurosciences of the Johannes Gutenberg University. The remaining authors have disclosed that they do not have any potential conflicts of interest.	ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Brown J, 2003, EUR J NEUROSCI, V17, P2042, DOI 10.1046/j.1460-9568.2003.02647.x; CARMICHAEL FJ, 1993, ANESTHESIOLOGY, V79, P1051, DOI 10.1097/00000542-199311000-00024; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eberspacher E, 2006, ANESTH ANALG, V103, P1527, DOI 10.1213/01.ane.0000247803.30582.2d; Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016; Engelhard K, 2007, ANESTH ANALG, V104, P898, DOI 10.1213/01.ane.0000255730.73018.31; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fuss M, 2000, STRAHLENTHER ONKOL, V176, P573, DOI 10.1007/PL00002327; Gelb AW, 2002, ANESTHESIOLOGY, V96, P1183, DOI 10.1097/00000542-200205000-00023; Hernandez-Rabaza V, 2009, NEUROSCIENCE, V159, P59, DOI 10.1016/j.neuroscience.2008.11.054; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kawai T, 2004, J CEREBR BLOOD F MET, V24, P548, DOI 10.1097/00004647-200405000-00009; KOCHS E, 1992, ANESTHESIOLOGY, V76, P245, DOI 10.1097/00000542-199202000-00014; Kulkarni VA, 2002, EUR J NEUROSCI, V16, P2008, DOI 10.1046/j.1460-9568.2002.02268.x; Lasarzik I, 2009, ANESTHESIOLOGY, V110, P529, DOI 10.1097/ALN.0b013e318195b4fe; Liu SH, 2003, J NEUROSCI, V23, P732; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Pittman JE, 1997, ANESTHESIOLOGY, V87, P1139, DOI 10.1097/00000542-199711000-00018; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rossaint J, 2009, CRIT CARE, V13, DOI 10.1186/cc7795; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; Shulga A, 2012, J NEUROSCI, V32, P1757, DOI 10.1523/JNEUROSCI.3282-11.2012; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Taupin P, 2006, CR BIOL, V329, P465, DOI 10.1016/j.crvi.2006.04.001; Thal SC, 2008, J NEUROL SCI, V268, P150, DOI 10.1016/j.jns.2007.12.002; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tsai Y C, 1994, Acta Anaesthesiol Sin, V32, P99; Tung A, 2008, ANESTH ANALG, V106, P1772, DOI 10.1213/ane.0b013e31816f2004; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2010, DISCOV MED, V10, P434; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015	39	31	33	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2014	42	1					129	141		10.1097/CCM.0b013e3182a639fd			13	Critical Care Medicine	General & Internal Medicine	274OK	WOS:000328615600035	24126440				2021-06-18	
J	Varotto, G; Fazio, P; Sebastiano, DR; Duran, D; D'Incerti, L; Parati, E; Sattin, D; Leonardi, M; Franceschetti, S; Panzica, F				Varotto, Giulia; Fazio, Patrik; Sebastiano, Davide Rossi; Duran, Dunja; D'Incerti, Ludovico; Parati, Eugenio; Sattin, Davide; Leonardi, Matilde; Franceschetti, Silvana; Panzica, Ferruccio			Altered resting state effective connectivity in long-standing vegetative state patients: An EEG study	CLINICAL NEUROPHYSIOLOGY			English	Article						Effective connectivity; Partial directed coherence; Disorders of consciousness; EEG; Vegetative state	MINIMALLY CONSCIOUS STATES; PARTIAL DIRECTED COHERENCE; FUNCTIONAL CONNECTIVITY; BRAIN-INJURY; COMA; DYNAMICS; RECOVERY; MODULATION; DISORDERS; MODEL	Objective: Recent evidence mainly based on hemodynamic measures suggests that the impairment of functional connections between different brain areas may help to clarify the neuronal dysfunction occurring in patients with disorders of consciousness (DOC). Objective: The aim of this study was to evaluate effective EEG connectivity in a cohort of 18 patients in a chronic vegetative state (VS) observed years after the occurrence of hypoxic (eight) and traumatic or hemorrhagic brain insult. Methods: we analysed the EEG signals recorded under resting conditions using a frequency domain linear index of connectivity (partial directed coherence: PDC) estimated from a multivariate autoregressive model. The results were compared with those obtained in ten healthy controls. Results: Our findings indicated significant connectivity changes in EEG activities in delta and alpha bands. The VS patients showed a significant and widespread decrease in delta band connectivity, whereas the alpha activity was hyper-connected in the central and posterior cortical regions. Conclusion: These changes suggest the occurrence of severe circuitry derangements probably due to the loose control of the subcortical connections. The alpha hyper-synchronisation may be due to simplified networks mainly involving the short-range connections between intrinsically oscillatory cortical neurons that generate aberrant EEG alpha sources. This increased connectivity may be interpreted as a reduction in information capacity, implying an increasing prevalence of stereotypic activity patterns. Significance: Our observations suggest a remarkable rearrangement of connectivity in patients with long-standing VS. We hypothesize that in persistent VS, after a first period characterized by a breakdown of cortical connectivity, neurodegenerative processes, largely independent from the type of initial insult, lead to cortex de-afferentation and to a severe reduction of possible cortical activity patterns and states. (C) 2013 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Varotto, Giulia; Fazio, Patrik; Sebastiano, Davide Rossi; Duran, Dunja; Franceschetti, Silvana; Panzica, Ferruccio] IRCCS Fdn Carlo Besta Neurol Inst, Dept Neurophysiol & Diagnost Epileptol, Milan, Italy; [D'Incerti, Ludovico] IRCCS Fdn Carlo Besta Neurol Inst, Dept Neuroradiol, Milan, Italy; [Sattin, Davide; Leonardi, Matilde] IRCCS Fdn Carlo Besta Neurol Inst, Disabil Unit, Neurol Unit, Milan, Italy; [Fazio, Patrik] Univ Ferrara, Neurol Sect, Dept Med & Surg Sci Commun & Behav, I-44100 Ferrara, Italy; [Sattin, Davide; Leonardi, Matilde] IRCCS Fdn Carlo Besta Neurol Inst, Coma Res Ctr, Milan, Italy; [Parati, Eugenio] IRCCS Fdn Carlo Besta Neurol Inst, Dept Cerebrovasc Dis, Milan, Italy	Panzica, F (corresponding author), C Besta Fdn Neurol Inst, Dept Neurophysiol & Diagnost Epileptol, Via Celoria 11, I-20133 Milan, Italy.	panzica@istituto-besta.it	leonardi, matilde/J-9997-2018; Sebastiano, Davide Rossi/G-8541-2016; Sattin, Davide/K-5963-2016; Panzica, Ferruccio/K-6711-2016; Varotto, Giulia/K-5352-2016; Duran, Dunja/K-5844-2016; Franceschetti, Silvana/K-3438-2016; Sattin, Davide/AAX-4083-2020; Parati, Eugenio Agostino/AAN-5893-2021	leonardi, matilde/0000-0003-0552-8923; Sebastiano, Davide Rossi/0000-0003-3698-8615; Sattin, Davide/0000-0001-7736-4337; Panzica, Ferruccio/0000-0002-0105-943X; Varotto, Giulia/0000-0001-8849-0398; Duran, Dunja/0000-0002-7232-4018; Franceschetti, Silvana/0000-0002-1921-6755; Sattin, Davide/0000-0001-7736-4337; Parati, Eugenio Agostino/0000-0001-5020-6523; Fazio, Patrik/0000-0002-1863-1922; D'Incerti, Ludovico/0000-0002-4092-9290	Regione LombardiaRegione Lombardia [IX/000407, 05/08/20109]	The project 2CRC, "Coma Research Centre'' was supported by Grant No. No IX/000407 (05/08/20109 awarded by Regione Lombardia.	Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900; AICARDI J, 1979, BRAIN, V102, P727, DOI 10.1093/brain/102.4.727; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Baccala LA, 2001, BIOL CYBERN, V84, P463, DOI 10.1007/PL00007990; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Boly M, 2011, CURR OPIN NEUROL, V24, P394, DOI 10.1097/WCO.0b013e328347da94; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Box G. E. P, 1970, TIME SERIES ANAL FOR; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; DASILVA FL, 1991, ELECTROEN CLIN NEURO, V79, P81, DOI 10.1016/0013-4694(91)90044-5; Demertzi A, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2010.00245; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; Fingelkurts AA, 2012, CONSCIOUS COGN, V21, P149, DOI 10.1016/j.concog.2011.10.004; Friston K. J., 2001, BRAIN CONNECTIVITY, V1, P13; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Gosseries O, 2011, FUNCT NEUROL, V26, P25; Gugino LA, 2001, BRIT J ANAESTH, V87, P421, DOI 10.1093/bja/87.3.421; Hudetz AG, 2012, BRAIN CONNECT, V2, P291, DOI 10.1089/brain.2012.0107; Husain AM, 2006, J CLIN NEUROPHYSIOL, V23, P208, DOI 10.1097/01.wnp.0000220094.60482.b5; JENNETT B, 1972, LANCET, V1, P734; JOHNSEN SJ, 1978, GEOPHYSICS, V43, P681, DOI 10.1190/1.1440846; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Laureys S, 2008, NAT CLIN PRACT NEURO, V4, P544, DOI 10.1038/ncpneuro0887; Lehembre R, 2012, FUNCT NEUROL, V27, P41; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Moosmann M, 2003, NEUROIMAGE, V20, P145, DOI 10.1016/S1053-8119(03)00344-6; Niedermeyer E, 1997, INT J PSYCHOPHYSIOL, V26, P31, DOI 10.1016/S0167-8760(97)00754-X; Pollonini L, 2010, BRAIN TOPOGR, V23, P221, DOI 10.1007/s10548-010-0139-9; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Schloegl A., 2007, BRAIN COMPUTER INTER, P347; SHAUL Y, 1986, EMBO J, V5, P1967, DOI 10.1002/j.1460-2075.1986.tb04451.x; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; Stam CJ, 2009, BRAIN, V132, P213, DOI 10.1093/brain/awn262; Steriade M, 2003, FRONT BIOSCI-LANDMRK, V8, pD878, DOI 10.2741/1043; Steriade M., 2000, NEURO CEREB CORTEX, V10, P1185; Supp GG, 2011, CURR BIOL, V21, P1988, DOI 10.1016/j.cub.2011.10.017; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Timofeev I, 2000, CEREB CORTEX, V10, P1185, DOI 10.1093/cercor/10.12.1185; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Varotto G, 2012, EPILEPSIA, V53, P359, DOI 10.1111/j.1528-1167.2011.03352.x; Wu DY, 2011, CLIN NEUROPHYSIOL, V122, P1956, DOI 10.1016/j.clinph.2011.03.018; Wu DY, 2011, CLIN NEUROPHYSIOL, V122, P490, DOI 10.1016/j.clinph.2010.05.036; ZETTERBERG LH, 1969, ELECTROEN CLIN NEURO, V26, P338; Zoubir A. M., 2004, BOOTSTRAP TECHNIQUES, DOI [10.1017/CBO9780511536717, DOI 10.1017/CBO9780511536717]	50	31	32	0	25	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JAN	2014	125	1					63	68		10.1016/j.clinph.2013.06.016			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	272ZD	WOS:000328501200010	23927942				2021-06-18	
J	Hasebe, N; Fujita, Y; Ueno, M; Yoshimura, K; Fujino, Y; Yamashita, T				Hasebe, Noriko; Fujita, Yuki; Ueno, Masaki; Yoshimura, Kazuhiro; Fujino, Yuji; Yamashita, Toshihide			Soluble beta-amyloid Precursor Protein Alpha Binds to p75 Neurotrophin Receptor to Promote Neurite Outgrowth	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; NERVE GROWTH-FACTOR; ALZHEIMERS-DISEASE; CELL-DEATH; APP BINDS; NEURONS; P75(NTR); MICE; RHO; EXPRESSION	Background: The cleavage of beta-amyloid precursor protein (APP) generates multiple proteins: Soluble beta-amyloid Precursor Protein Alpha (sAPP alpha), sAPP beta, and amyloid beta (A beta). Previous studies have shown that sAPP alpha and sAPP beta possess neurotrophic properties, whereas A beta is neurotoxic. However, the underlying mechanism of the opposing effects of APP fragments remains poorly understood. In this study, we have investigated the mechanism of sAPP alpha-mediated neurotrophic effects. sAPP alpha and sAPP beta interact with p75 neurotrophin receptor (p75(NTR)), and sAPP alpha promotes neurite outgrowth. Methods and Findings: First, we investigated whether APP fragments interact with p75(NTR), because full-length APP and A beta have been shown to interact with p75(NTR) in vitro. Both sAPP alpha and sAPP beta were co-immunoprecipitated with p75(NTR) and co-localized with p75(NTR) on COS-7 cells. The binding affinity of sAPP alpha and sAPP beta for p75(NTR) was confirmed by enzyme-linked immunosorbent assay (ELISA). Next, we investigated the effect of sAPP alpha on neurite outgrowth in mouse cortical neurons. Neurite outgrowth was promoted by sAPP alpha, but sAPP alpha was uneffective in a knockdown of p75(NTR). Conclusion: We conclude that p75(NTR) is the receptor for sAPP alpha to mediate neurotrophic effects.	[Hasebe, Noriko; Fujita, Yuki; Ueno, Masaki; Yoshimura, Kazuhiro; Yamashita, Toshihide] Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Osaka, Japan; [Hasebe, Noriko; Fujino, Yuji] Osaka Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Osaka, Japan; [Hasebe, Noriko; Fujita, Yuki; Ueno, Masaki; Yamashita, Toshihide] Japan Sci & Technol Agcy JST, CREST, Tokyo, Japan; [Ueno, Masaki] Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; [Yoshimura, Kazuhiro] Osaka Univ, Grad Sch Med, Dept Neurosurg, Osaka, Japan	Yamashita, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Osaka, Japan.	yamashita@molneu.med.osaka-u.ac.jp	Ueno, Masaki/J-1216-2019	Yamashita, Toshihide/0000-0003-4559-7018	JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [25221309]	This work was supported by a Grant-in-Aid for Scientific Research (S) from JSPS (25221309) to T.Y. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akar CA, 1998, MOL BRAIN RES, V56, P125, DOI 10.1016/S0169-328X(98)00037-0; Ben-Zvi A, 2007, J NEUROSCI, V27, P13000, DOI 10.1523/JNEUROSCI.3373-07.2007; Chasseigneaux S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016301; Clarris HJ, 1997, J NEUROCHEM, V68, P1164; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Fombonne J, 2009, ANN NEUROL, V65, P294, DOI 10.1002/ana.21578; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Guenette S, 2006, EMBO J, V25, P420, DOI 10.1038/sj.emboj.7600926; Hartmann D, 1999, CURR BIOL, V9, P719, DOI 10.1016/S0960-9822(99)80331-5; Hashimoto Y, 2004, J NEUROSCI RES, V75, P417, DOI 10.1002/jnr.10861; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Higuchi H, 2003, BIOCHEM BIOPH RES CO, V301, P804, DOI 10.1016/S0006-291X(03)00029-9; JIN LW, 1994, J NEUROSCI, V14, P5461; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kim D, 2009, CELL, V137, P997, DOI 10.1016/j.cell.2009.05.042; Knowles JK, 2009, J NEUROSCI, V29, P10627, DOI 10.1523/JNEUROSCI.0620-09.2009; Kobayashi S, 2010, NEUROCHEM INT, V56, P387, DOI 10.1016/j.neuint.2009.11.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LOFFLER J, 1992, J NEUROCHEM, V59, P1316, DOI 10.1111/j.1471-4159.1992.tb08443.x; Luo JJ, 2001, J NEUROSCI RES, V63, P410, DOI 10.1002/1097-4547(20010301)63:5<410::AID-JNR1036>3.0.CO;2-B; Mattson MP, 1997, PHYSIOL REV, V77, P1081; Morishima Y, 2001, J NEUROSCI, V21, P7551; Nakazawa H, 2012, J NEUROSCI, V32, P12712, DOI 10.1523/JNEUROSCI.0989-12.2012; Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767; NINOMIYA H, 1994, J NEUROCHEM, V63, P495; Rossner S, 1998, J NEUROCHEM, V71, P757; SALBAUM JM, 1994, J EXP ZOOL, V269, P116, DOI 10.1002/jez.1402690205; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; SMALL DH, 1994, J NEUROSCI, V14, P2117; Sotthibundhu A, 2008, J NEUROSCI, V28, P3941, DOI 10.1523/JNEUROSCI.0350-08.2008; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Ueno M, 2013, NAT NEUROSCI, V16, P543, DOI 10.1038/nn.3358; Wallace WC, 1997, MOL BRAIN RES, V52, P201, DOI 10.1016/S0169-328X(97)00258-1; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Yaar M, 2007, NEUROPATH APPL NEURO, V33, P533, DOI 10.1111/j.1365-2990.2007.00844.x; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Yoshimura K, 2011, NEUROSCI RES, V71, P266, DOI 10.1016/j.neures.2011.07.1830	41	31	32	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2013	8	12							e82321	10.1371/journal.pone.0082321			9	Multidisciplinary Sciences	Science & Technology - Other Topics	276GD	WOS:000328735700057	24358169	DOAJ Gold, Green Published			2021-06-18	
J	Walder, B; Haller, G; Rebetez, MML; Delhumeau, C; Bottequin, E; Schoettker, P; Ravussin, P; Maeder, MB; Stover, JF; Zurcher, M; Haller, A; Wackelin, A; Haberthur, C; Fandino, J; Haller, CS; Osterwalder, J				Walder, Bernhard; Haller, Guy; Rebetez, Marie My Lien; Delhumeau, Cecile; Bottequin, Ezra; Schoettker, Patrick; Ravussin, Patrick; Maeder, Monika Brodmann; Stover, John F.; Zuercher, Mathias; Haller, Alois; Waeckelin, Adrian; Haberthuer, Christoph; Fandino, Javier; Haller, Chiara Simone; Osterwalder, Joseph			Severe Traumatic Brain Injury in a High-Income Country: An Epidemiological Study	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; geriatric brain injury; head trauma; TBI	SEVERE HEAD-INJURY; PROGNOSTIC VALUE; MORTALITY; SCALE; IMPACT; MULTICENTER; POPULATION; ADMISSION; OUTCOMES; COHORT	This adult cohort determined the incidence and patients' short-term outcomes of severe traumatic brain injury (sTBI) in Switzerland and age-related differences. A prospective cohort study with a follow-up at 14 days was performed. Patients 16 years of age sustaining sTBI and admitted to 1 of 11 trauma centers were included. sTBI was defined by an Abbreviated Injury Scale of the head (HAIS) score >3. The centers participated from 6 months to 3 years. The results are presented as percentages, medians, and interquartile ranges (IQRs). Subgroup analyses were performed for patients <= 65 years (younger) and >65 (elderly). sTBI was observed in 921 patients (median age, 55 years; IQR, 33-71); 683 (74.2%) were male. Females were older (median age, 67 years; IQR, 42-80) than males (52; IQR, 31-67; p < 0.00001). The estimated incidence was 10.58 per 100,000 inhabitants per year. Blunt trauma was observed in 879 patients (95.4%) and multiple trauma in 283 (30.7%). Median Glasgow Coma Score (GCS) on the scene was 9 (IQR 4-14; 8 in younger, 12 in elderly) and in emergency departments 5 (IQR, 3-14; 3 in younger, 8 in elderly). Trauma mechanisms included the following: 484 patients with falls (52.6%; younger, 242 patients [50.0%]; elderly, 242 [50.0%]), 291 with road traffic accidents (31.6%; younger, 237 patients [81.4%]; elderly, 54 [18.6%]), and 146 with others (15.8%). Mortality was 30.2% (24.5% in younger, 40.9% in elderly). Median GCS at 14 days was 15 (IQR, 14-15) without differences among subgroups. Estimated incidence of sTBI in Switzerland was low, age was high, and mortality considerable. The elderly had higher initial GCS and a higher death rate, but high GCS at 14 days.	[Walder, Bernhard; Haller, Guy; Rebetez, Marie My Lien; Delhumeau, Cecile; Bottequin, Ezra] Univ Hosp Geneva, Div Anesthesiol, CH-1211 Geneva 14, Switzerland; [Haller, Guy] Univ Hosp Geneva, Div Clin Epidemiol, CH-1211 Geneva 14, Switzerland; [Schoettker, Patrick] Univ Hosp Ctr Lausanne CHUV, Dept Anaesthesiol, Lausanne, Switzerland; [Ravussin, Patrick] Hosp Sion, Dept Anaesthesiol, Sion, Switzerland; [Maeder, Monika Brodmann] Inselspital Bern, Dept Emergency Med, CH-3010 Bern, Switzerland; [Stover, John F.] Fresenius Kabi Switzerland, Oberdorf, Switzerland; [Zuercher, Mathias] Univ Hosp Basel USB, Dept Anaesthesia & Intens Care Med, Basel, Switzerland; [Haller, Alois] Kantonsspital Winterthur, Div Surg Intens Care, Winterthur, Switzerland; [Waeckelin, Adrian] Kantonsspital Graubunden, Div Intens Care, Chur, Switzerland; [Haberthuer, Christoph] Kantonsspital Luzern, Div Surg Intens Care, Luzern, Switzerland; [Fandino, Javier] Kantonsspital Aarau, Aarau, Switzerland; [Haller, Chiara Simone] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Psychiat, Boston, MA 02215 USA; [Haller, Chiara Simone] Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr, Boston, MA 02115 USA; [Haller, Chiara Simone] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; [Osterwalder, Joseph] Kantonsspital, Emergency Dept, St Gallen, Switzerland	Walder, B (corresponding author), Univ Hosp Geneva, Dept APSI, Div Anesthesiol, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland.	bernhard.walder@hcuge.ch	Schoettker, Patrick/AAE-4462-2020	Schoettker, Patrick/0000-0001-5370-048X; Brodmann Maeder, Monika Maria/0000-0001-5608-7887	Bangerter-Rhyner-Foundation; Swiss Accident Insurance Foundation	This study was funded by the Bangerter-Rhyner-Foundation and the Swiss Accident Insurance Foundation. The funding sources had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data. He was also responsible for the final decision making, which eventually led to the submission of the present material for publication.	Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Bayen E., 2012, J HEAD TRAUMA REHAB, DOI [10.1016/j.rehab.2011.07.745, DOI 10.1016/J.REHAB.2011.07.745.[]; Bhattacharyya T, 2001, J TRAUMA, V51, P118, DOI 10.1097/00005373-200107000-00019; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Cadotte DW, 2011, J NEUROSURG, V114, P1502, DOI 10.3171/2010.12.JNS10808; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; Dick W F, 1999, Eur J Emerg Med, V6, P369; Farin A, 2004, ACT NEUR S, V89, P101; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Gargett S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-270; Garthe E, 1999, J TRAUMA, V47, P309, DOI 10.1097/00005373-199908000-00016; Hanselmann H., 2011, DECISION CONCERNANT; Ivins BJ, 2010, NEUROREHABILITATION, V26, P199, DOI 10.3233/NRE-2010-0556; Kim YJ, 2011, J EMERG NURS, V37, P328, DOI 10.1016/j.jen.2010.04.017; Kim YJ, 2010, J CLIN NURS, V19, P2763, DOI 10.1111/j.1365-2702.2009.03024.x; Kool B, 2012, NEUROEPIDEMIOLOGY, V38, P179, DOI 10.1159/000337261; Landman AB, 2011, PREHOSP EMERG CARE, V15, P149, DOI 10.3109/10903127.2010.534235; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lesko MM, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-72; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Mosconi P, 2011, PATIENT, V4, P55, DOI 10.2165/11535550-000000000-00000; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Pielmaier L, 2011, BRAIN INJURY, V25, P259, DOI 10.3109/02699052.2010.542429; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Prang KH, 2012, BRAIN INJURY, V26, P1611, DOI 10.3109/02699052.2012.698790; Reischies FM, 2001, EUR ARCH PSY CLIN N, V251, P99, DOI 10.1007/s004060170041; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Schneider EB, 2012, J SURG RES, V177, P295, DOI 10.1016/j.jss.2012.06.022; Soreide K, 2010, SCAND J SURG, V99, P235, DOI 10.1177/145749691009900411; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Switzer JA, 2012, STROKE, V43, P2500, DOI 10.1161/STROKEAHA.112.661454; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; von Elm E, 2008, SWISS MED WKLY, V138, P327, DOI 2008/23/smw-12025; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	49	31	33	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2013	30	23					1934	1942		10.1089/neu.2013.2955			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AI0FA	WOS:000336520400002	23822874				2021-06-18	
J	Junger, WG; Rhind, SG; Rizoli, SB; Cuschieri, J; Baker, AJ; Shek, PN; Hoyt, DB; Bulger, EM				Junger, Wolfgang G.; Rhind, Shawn G.; Rizoli, Sandro B.; Cuschieri, Joseph; Baker, Andrew J.; Shek, Pang N.; Hoyt, David B.; Bulger, Eileen M.			PREHOSPITAL HYPERTONIC SALINE RESUSCITATION ATTENUATES THE ACTIVATION AND PROMOTES APOPTOSIS OF NEUTROPHILS IN PATIENTS WITH SEVERE TRAUMATIC BRAIN INJURY	SHOCK			English	Article						Hypertonic saline; resuscitation fluids; hemorrhage; neutrophils; adhesion molecules; inflammation; multi-organ failure; oxidative burst; apoptosis	RANDOMIZED CONTROLLED-TRIAL; HEMORRHAGIC-SHOCK; INTRACRANIAL HYPERTENSION; RECEPTOR EXPRESSION; THERMAL-INJURY; INFLAMMATION; PATHOPHYSIOLOGY; ADENOSINE; INHIBITION; MORTALITY	Background: Activation of polymorphonuclear neutrophils (PMNs) is thought to contribute to traumatic brain injury (TBI). Since hypertonic fluids can inhibit PMN activation, we studied whether hypertonic fluid resuscitation can reduce excessive PMN activation in TBI patients. Methods: Trauma patients with severe TBI were resuscitated with 250 mL of either 7.5% hypertonic saline (HS; n = 22), HS + 6% dextran-70 (HSD; n = 22), or 0.9% normal saline (NS; n = 39), and blood samples were collected on hospital admission and 12 and 24 h after resuscitation. Polymorphonuclear neutrophil activation (CD11b, CD62L, CD64) and degranulation (CD63, CD66b, CD35) markers and oxidative-burst activity, as well as spontaneous PMN apoptosis were measured by flow cytometry. Results: Relative to healthy controls, TBI patients showed increased PMN activation and decreased apoptosis of PMNs. In the HS group, but not in the HSD group, markers of PMN adhesion (CD11b, CD64) and degranulation (CD35, CD66b) were significantly lower than those in the NS group. These effects were particularly pronounced 12 h after resuscitation. Treatment with HS and HSD inhibited PMN oxidative burst responses compared with NS-treated patients. Hypertonic saline alone partially restored delayed PMN apoptosis. Despite these differences, the groups did not differ in clinical outcome parameters such as mortality and Extended Glasgow Outcome Scale. Conclusions: This study demonstrates that prehospital resuscitation with HS can partially restore normal PMN activity and the apoptotic behavior of PMNs, whereas resuscitation with HSD was largely ineffective. Although the results are intriguing, additional research will be required to translate these effects of HS into treatment strategies that improve clinical outcome in TBI patients.	[Junger, Wolfgang G.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; [Junger, Wolfgang G.] Ludwig Boltzmann Inst Expt & Clin Traumatol, Vienna, Austria; [Rhind, Shawn G.; Shek, Pang N.] Def Res & Dev Canada, Toronto Res Ctr, Toronto, ON, Canada; [Rizoli, Sandro B.] Univ Toronto, St Michaels Hosp, Dept Surg, Toronto, ON, Canada; [Rizoli, Sandro B.] Univ Toronto, St Michaels Hosp, Dept Crit Care Med, Toronto, ON, Canada; [Cuschieri, Joseph; Bulger, Eileen M.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; [Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Cara Phelan Ctr Trauma Res Keenan Res Ctr, Brain Injury Lab,Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Hoyt, David B.] Univ Calif Irvine, Dept Surg, Amer Coll Surg, Irvine, CA 92717 USA	Junger, WG (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave, Boston, MA 02215 USA.	wjunger@bidmc.harvard.edu		Rhind, Shawn/0000-0003-2300-0620	National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077885, HL077887, HL077873, HL077865]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM-51477, GM-60475, AI-072287, AI-080582]; Congressionally Directed Medical Research ProgramUnited States Department of Defense [PR043034]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); US Army Medical Research & Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Canadian Institutes of Health Research-Institute of Circulatory and Respiratory HealthCanadian Institutes of Health Research (CIHR); Defence Research and Development Canada; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077867, U01HL077866, U01HL077865, U01HL077887, U01HL077863, U01HL077885, U01HL077873, U01HL077881, U01HL077871, U01HL077908, U01HL077872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI072287, R01AI080582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R29GM051477, R01GM051477, R01GM060475] Funding Source: NIH RePORTER	The Resuscitation Outcome Consortium is supported by a series of cooperative agreements with 10 regional clinical centers and one data coordinating center (5U01 HL077863, HL077881, HL077871 HL077872, HL077866, HL077908, HL077867, HL077885, HL077887, HL077873, HL077865) from the National Heart, Lung and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, US Army Medical Research & Material Command, The Canadian Institutes of Health Research-Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, and the Heart and Stroke Foundation of Canada. In addition, this work was funded in part by grants from the National Institutes of Health, GM-51477, GM-60475, AI-072287, AI-080582, and the Congressionally Directed Medical Research Program PR043034.	Angle N, 1998, J TRAUMA, V45, P7, DOI 10.1097/00005373-199807000-00002; Bahrami S, 2006, SHOCK, V25, P283, DOI 10.1097/01.shk.0000208808.03148.ea; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Bulger Eileen M, 2012, Adv Surg, V46, P73; Bulger EM, 2011, SHOCK, V36, P435, DOI 10.1097/SHK.0b013e318231ee2e; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Chen Y, 2006, AM J PHYSIOL-CELL PH, V290, pC1051, DOI 10.1152/ajpcell.00216.2005; Chen Y, 2004, J LEUKOCYTE BIOL, V76, P245, DOI 10.1189/jlb.0204066; COLOTTA F, 1992, BLOOD, V80, P2012; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cuschieri J, 2002, J IMMUNOL, V168, P1389, DOI 10.4049/jimmunol.168.3.1389; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hu Z, 2003, AM J PHYSIOL-CELL PH, V288, pC1171; Hu ZH, 2004, AM J PHYSIOL-CELL PH, V286, pC170, DOI 10.1152/ajpcell.00187.2003; Inoue Y, 2008, CRIT CARE MED, V36, P2569, DOI 10.1097/CCM.0b013e3181841a91; Inoue Y, 2011, SHOCK, V35, P178, DOI 10.1097/SHK.0b013e3181f221fb; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; Junger WG, 2012, SHOCK, V38, P341, DOI 10.1097/SHK.0b013e3182635aca; Junger WG, 2011, NAT REV IMMUNOL, V11, P201, DOI 10.1038/nri2938; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kim JY, 2012, J SURG RES, V178, P401, DOI 10.1016/j.jss.2012.01.055; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mangat Halinder S, 2012, Continuum (Minneap Minn), V18, P532, DOI 10.1212/01.CON.0000415426.76524.e1; Nakagawa K, 2012, J CLIN ANESTH, V24, P318, DOI 10.1016/j.jclinane.2011.10.011; Nolan B, 2000, J TRAUMA, V48, P599, DOI 10.1097/00005373-200004000-00004; Orlic T, 2002, AM J PHYSIOL-CELL PH, V282, pC1261, DOI 10.1152/ajpcell.00479.2001; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Riffl WL, 2003, SURGERY, V134, P86, DOI 10.1067/msy.2003.178; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Rizoli SB, 1998, J IMMUNOL, V161, P6288; Ropper AH, 2012, NEW ENGL J MED, V367, P746, DOI 10.1056/NEJMct1206321; Rossi AG, 2006, NAT MED, V12, P1056, DOI 10.1038/nm1468; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Shukla A, 2004, SHOCK, V21, P391, DOI 10.1097/00024382-200405000-00001; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Smania N, 2013, J HEAD TRAUMA REHAB, V28, P131, DOI 10.1097/HTR.0b013e31823c0127; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Vaughan KR, 2007, J IMMUNOL, V179, P8544, DOI 10.4049/jimmunol.179.12.8544; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Weed LH, 1919, AM J PHYSIOL, V48, P531; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xu YF, 2010, P NATL ACAD SCI USA, V107, P2950, DOI 10.1073/pnas.0912717107; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005	51	31	35	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	NOV	2013	40	5					366	374		10.1097/SHK.0000000000000038			9	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	297HS	WOS:000330247100004	24088993	Green Accepted			2021-06-18	
J	Shen, XF; Li, AP; Zhang, YL; Dong, XM; Shan, T; Wu, Y; Jia, J; Hu, YS				Shen, Xiafeng; Li, Aiping; Zhang, Yuling; Dong, XiaoMin; Shan, Tian; Wu, Yi; Jia, Jie; Hu, Yongshan			The Effect of Different Intensities of Treadmill Exercise on Cognitive Function Deficit Following a Severe Controlled Cortical Impact in Rats	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						controlled cortical impact; treadmill running; spatial memory; intensity; BDNF	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; VOLUNTARY EXERCISE; NEUROTROPHIC FACTOR; CONTUSION INJURY; UP-REGULATION; IMPAIRMENT; PLASTICITY; MICE; NEUROGENESIS	Exercise has been proposed for the treatment of traumatic brain injury (TBI). However, the proper intensity of exercise in the early phase following a severe TBI is largely unknown. To compare two different treadmill exercise intensities on the cognitive function following a severe TBI in its early phase, rats experienced a controlled cortical impact (CCI) and were forced to treadmill exercise for 14 days. The results revealed that the rats in the low intensity exercise group had a shorter latency to locate a platform and a significantly better improvement in spatial memory in the Morris water maze (MWM) compared to the control group (p < 0.05). The high intensity exercise group showed a longer latency and a mild improvement in spatial memory compared to the control group rats in the MWM; however, this difference was not statistically significant (p > 0.05). The brain-derived neurotrophic factor (BDNF) and p-CREB protein levels in the contralateral hippocampus were increased significantly in the low intensity exercise group. Our results suggest that 2 weeks of low intensity of treadmill exercise is beneficial for improving cognitive function and increasing hippocampal BDNF expression after a severe TBI in its early phase.	[Shen, Xiafeng; Zhang, Yuling; Shan, Tian; Wu, Yi; Jia, Jie; Hu, Yongshan] Fudan Univ, Huashan Hosp, Dept Rehabil, Shanghai 200040, Peoples R China; [Li, Aiping; Dong, XiaoMin] Nanjing Mil Reg Sanat Hangzhou, Rehabil Med Ctr, Hangzhou 310007, Zhejiang, Peoples R China; [Shen, Xiafeng] Shanghai Yangpu Dist Geriatr Hosp, Dept Rehabil, Shanghai 200090, Peoples R China	Li, AP (corresponding author), Nanjing Mil Reg Sanat Hangzhou, Rehabil Med Ctr, Hangzhou 310007, Zhejiang, Peoples R China.	shenxiafeng@aliyun.com; drliap@163.com; zhangyuling1982@hotmail.com; dongxiaomin2013@163.com; shantian2008@hotmail.com; wuyi4000@163.com; shannonjj@126.com; drhuys@sina.com			Nanjing Military Area Command Medical Science Innovation Foundation [09Z037]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81272169]	This study was supported by both the Key Research Project of Nanjing Military Area Command Medical Science Innovation Foundation (No. 09Z037) and the National Natural Science Foundation of China (No. 81272169).	Abbott RD, 2004, JAMA-J AM MED ASSOC, V292, P1447, DOI 10.1001/jama.292.12.1447; Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Blustein JE, 2006, PHYSIOL BEHAV, V89, P582, DOI 10.1016/j.physbeh.2006.07.017; Bruunsgaard H, 1997, MED SCI SPORT EXER, V29, P1176, DOI 10.1097/00005768-199709000-00009; Burnfield JM, 2013, PHYS THER, V93, P1331, DOI 10.2522/ptj.20120500; Carek PJ, 2011, INT J PSYCHIAT MED, V41, P15, DOI 10.2190/PM.41.1.c; Cassilhas RC, 2012, NEUROSCIENCE, V202, P309, DOI 10.1016/j.neuroscience.2011.11.029; Chytrova G, 2008, EUR J NEUROSCI, V27, P1, DOI 10.1111/j.1460-9568.2007.05982.x; Dik MG, 2003, J CLIN EXP NEUROPSYC, V25, P643, DOI 10.1076/jcen.25.5.643.14583; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Franckeviciute Egle, 2006, Medicina (Kaunas), V42, P732; Gibson AS, 2013, SPORTS MED, V43, P413, DOI 10.1007/s40279-013-0044-y; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hansson AC, 2006, J NEUROENDOCRINOL, V18, P104, DOI 10.1111/j.1365-2826.2005.01390.x; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Hoffman-Goetz L, 2008, BRAIN BEHAV IMMUN, V22, P195, DOI 10.1016/j.bbi.2007.07.002; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Kurayama T, 2013, GAIT POSTURE, V37, P402, DOI 10.1016/j.gaitpost.2012.08.009; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lima FD, 2009, BRAIN RES, V1279, P147, DOI 10.1016/j.brainres.2009.04.052; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; Miles SC, 2013, ALTERN THER HEALTH M, V19, P38; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Moraska A, 2000, AM J PHYSIOL-REG I, V279, pR1321; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Schaaf M J, 2000, Stress, V3, P201, DOI 10.3109/10253890009001124; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Szabo Z, 2010, BRAIN RES, V1341, P25, DOI 10.1016/j.brainres.2009.01.035; Taylor AN, 2010, J NEUROTRAUM, V27, P1081, DOI 10.1089/neu.2009.1252; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Triolo RJ, 2013, ARCH PHYS MED REHAB, V94, P1997, DOI 10.1016/j.apmr.2013.04.010; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Zhang Pengyue, 2012, Front Biosci (Elite Ed), V4, P2476	56	31	35	1	32	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	NOV	2013	14	11					21598	21612		10.3390/ijms141121598			15	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	274RR	WOS:000328624400025	24185909	DOAJ Gold, Green Published			2021-06-18	
J	Agarwal, N; Chaudhari, A; Hansberry, DR; Tomei, KL; Prestigiacomo, CJ				Agarwal, Nitin; Chaudhari, Amit; Hansberry, David R.; Tomei, Krystal L.; Prestigiacomo, Charles J.			A comparative analysis of neurosurgical online education materials to assess patient comprehension	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Internet; Neurosurgery; Patient education; Readability	READABILITY FORMULA; HEALTH INFORMATION; INTERNET; WEB; LITERACY	Americans have increasingly utilized the internet as a first-line resource for a variety of information, including healthcare-oriented materials. Therefore, these online resources should be written at a level the average American can understand. Patient education resources specifically written for and available to the public were downloaded from the American Association of Neurological Surgeons website and assessed for their level of readability using the Flesch Reading Ease, Flesch-Kincaid Grade Level, Simple Measure of Gobbledygook Grading, Coleman-Liau Index, and Gunning-Fog Index. A total of 71 subsections from different neurosurgical specialties were reviewed, including Cerebrovascular, Spine and Peripheral Nerves, Neurotrauma and Critical Care, Pain, Pediatric, Stereotactic and Functional, and Tumor material. All neurosurgical subspecialty education material provided on the American Association of Neurological Surgeons website was uniformly written at a level that was too high, as assessed by all modalities. In order to reach a larger patient population, patient education materials on the American Association of Neurological Surgeons website should be revised with the goal of simplifying readability. (C) 2013 Elsevier Ltd. All rights reserved.	[Agarwal, Nitin; Chaudhari, Amit; Hansberry, David R.; Tomei, Krystal L.; Prestigiacomo, Charles J.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07101 USA; [Prestigiacomo, Charles J.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, Newark, NJ 07101 USA; [Prestigiacomo, Charles J.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07101 USA	Prestigiacomo, CJ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol Surg, 90 Bergen St,Suite 8100, Newark, NJ 07101 USA.	c.prestigiacomo@umdnj.edu	Prestigiacomo, Charles J/B-3911-2018	Prestigiacomo, Charles J/0000-0002-5979-2378			Badarudeen S, 2008, J BONE JOINT SURG AM, V90A, P199, DOI 10.2106/JBJS.G.00347; COLEMAN M, 1975, J APPL PSYCHOL, V60, P283, DOI 10.1037/h0076540; Diaz JA, 2002, J GEN INTERN MED, V17, P180, DOI 10.1046/j.1525-1497.2002.10603.x; Flesch R. F., 1979, WRITE PLAIN ENGLISH; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; Friedman DB, 2006, MED INFORM INTERNET, V31, P67, DOI 10.1080/14639230600628427; Gunning R., 1952, TECHNIQUE CLEAR WRIT; Lauder B., 2008, HOME HEALTHCARE NURS, V26, P253; Matter B, 2009, J SPINAL CORD MED, V32, P545, DOI 10.1080/10790268.2009.11754556; MCLAUGHLIN GH, 1969, J READING, V12, P639; National Institutes of Health, WRIT EAS READ HLTH M; Parker R, 2000, HEALTH PROMOT INT, V15, P277, DOI 10.1093/heapro/15.4.277; Rice RE, 2006, INT J MED INFORM, V75, P8, DOI 10.1016/j.ijmedinf.2005.07.032; Sabharwal S, 2008, CLIN ORTHOP RELAT R, V466, P1245, DOI 10.1007/s11999-008-0193-8; Schmitt PJ, 2011, WORLD NEURO IN PRESS; The Health Literacy of America>s Adults, 2006, HLTH LIT AM AD RES 2; Vives M, 2009, SPINE, V34, P2826, DOI 10.1097/BRS.0b013e3181b4bb0c; Walsh TM, 2008, RESP CARE, V53, P1310	18	31	31	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	OCT	2013	20	10					1357	1361		10.1016/j.jocn.2012.10.047			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	244XC	WOS:000326422500005	23809099				2021-06-18	
J	Spitz, G; Bigler, ED; Abildskov, T; Maller, JJ; O'Sullivan, R; Ponsford, JL				Spitz, Gershon; Bigler, Erin D.; Abildskov, Tracy; Maller, Jerome J.; O'Sullivan, Richard; Ponsford, Jennie L.			Regional cortical volume and cognitive functioning following traumatic brain injury	BRAIN AND COGNITION			English	Article						Traumatic brain injury; MRI; Neuropsychology; Cognition	SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; WORKING-MEMORY; TEMPORAL-LOBE; WHITE-MATTER; LONGITUDINAL CHANGES; DIFFUSION-TENSOR; HEAD-INJURY; CONNECTIVITY; ATROPHY	There has been limited examination of the effect of brain pathology on subsequent function. The current study examined the relationships between regional variation in grey matter volume, age and cognitive impairment using a semi-automated image analysis tool. This study included 69 individuals with mild-to-severe TBI, 41 of whom also completed neuropsychological tests of attention, working memory, processing speed, memory and executive functions. A widespread reduction in grey matter volume was associated with increasing age. Regional volumes that were affected also related to the severity of injury, whereby the most severe TBI participants displayed the most significant pathology. Poorer retention of newly learned material was associated with reduced cortical volume in frontal, parietal, and occipital brain regions. In addition, poorer working memory and executive control performance was found for individuals with lower cortical volume in temporal, parietal, and occipital regions. These findings are largely in line with previous literature, which suggests that frontal, temporal, and parietal regions are integral for the encoding of memories into long-term storage, memory retrieval, and working memory. The present study suggests that automated image analysis methods may be used to explore the relationships between regional variation in grey matter volume and cognitive function following TBI. (c) 2013 Elsevier Inc. All rights reserved.	[Spitz, Gershon; Ponsford, Jennie L.] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Spitz, Gershon; Ponsford, Jennie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA; [Abildskov, Tracy] Brigham Young Univ, Dept Psychol Sci, Provo, UT 84602 USA; [Maller, Jerome J.] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Maller, Jerome J.] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia; [O'Sullivan, Richard] Epworth Med Fdn, Healthcare Imaging Serv, Melbourne, Vic, Australia	Spitz, G (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	Gershon.Spitz@monash.edu	Spitz, Gershon/H-7755-2014; Maller, Jerome J/H-4963-2014	Spitz, Gershon/0000-0002-7810-1480; Maller, Jerome J/0000-0003-4685-1508			ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; [Anonymous], 2009, EC COST SPINAL CORD, P1; Arenivas A., 2012, BRAIN IMAGING BEHAV, V13, P1; Axmacher N, 2007, J NEUROSCI, V27, P7807, DOI 10.1523/JNEUROSCI.0962-07.2007; Baddeley A, 1994, DOORS PEOPLE; Beer AL, 2011, EXP BRAIN RES, V213, P299, DOI 10.1007/s00221-011-2715-y; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benton A., 1994, MULTILINGUAL APHASIA; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Coughhlan AK, 2007, BIRT MEMORY INFORM P; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Dewey J, 2010, NEUROIMAGE, V51, P1334, DOI 10.1016/j.neuroimage.2010.03.033; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Eichenbaum H, 2007, ANNU REV NEUROSCI, V30, P123, DOI 10.1146/annurev.neuro.30.051606.094328; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hudak A, 2011, PSYCHIAT RES-NEUROIM, V191, P160, DOI 10.1016/j.pscychresns.2010.10.003; Hutton C, 2009, NEUROIMAGE, V48, P371, DOI 10.1016/j.neuroimage.2009.06.043; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kirchhoff BA, 2000, J NEUROSCI, V20, P6173, DOI 10.1523/JNEUROSCI.20-16-06173.2000; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Makris N., 2012, BRAIN STRUCTURE FUNC; Matsumoto R, 2004, BRAIN, V127, P2316, DOI 10.1093/brain/awh246; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; Morey RA, 2009, NEUROIMAGE, V45, P855, DOI 10.1016/j.neuroimage.2008.12.033; Morris RG, 1997, COGN NEUROPSYCHOL, V14, P1007, DOI 10.1080/026432997381330; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Olson IR, 2006, J NEUROSCI, V26, P4596, DOI 10.1523/JNEUROSCI.1923-05.2006; Owen AM, 1996, BRAIN, V119, P1597, DOI 10.1093/brain/119.5.1597; Park H, 2011, BRAIN CONNECT, V1, P460, DOI 10.1089/brain.2011.0046; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Reitan R., 1988, HALSTEAD REITAN NEUR; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Shallice, 1997, HAYLING BRIXTON TEST; Shen L, 2010, BRAIN IMAGING BEHAV, V4, P86, DOI 10.1007/s11682-010-9088-x; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith A., 1973, SYMBOL DIGIT MODALIT; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Squire LR, 2011, ANNU REV NEUROSCI, V34, P259, DOI 10.1146/annurev-neuro-061010-113720; Strangman G. E., 2010, FRONT HUM NEUROSCI, V4, P181; Sullivan EV, 2007, BRIT J RADIOL, V80, pS99, DOI 10.1259/bjr/22893432; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Todd JJ, 2004, NATURE, V428, P751, DOI 10.1038/nature02466; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Vannorsdall TD, 2010, J NEUROPSYCH CLIN N, V22, P173, DOI 10.1176/appi.neuropsych.22.2.173; Wagner AD, 2005, TRENDS COGN SCI, V9, P445, DOI 10.1016/j.tics.2005.07.001; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Yonelinas AP, 2005, J NEUROSCI, V25, P3002, DOI 10.1523/JNEUROSCI.5295-04.2005; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc	86	31	32	0	35	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	OCT	2013	83	1					34	44		10.1016/j.bandc.2013.06.007			11	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	210UK	WOS:000323860000005	23872098				2021-06-18	
J	Yeh, CC; Wang, HH; Chou, YC; Hu, CJ; Chou, WH; Chen, TL; Liao, CC				Yeh, Chun-Chieh; Wang, Hwang-Huei; Chou, Yi-Chun; Hu, Chaur-Jong; Chou, Wan-Hsin; Chen, Ta-Liang; Liao, Chien-Chang			High Risk of Gastrointestinal Hemorrhage in Patients With Epilepsy: A Nationwide Cohort Study	MAYO CLINIC PROCEEDINGS			English	Article							TRAUMATIC BRAIN-INJURY; GENERAL-POPULATION; UNPROVOKED SEIZURES; COMORBIDITY; DISEASE; HOSPITALIZATION; EPIDEMIOLOGY; DEPRIVATION; COAGULATION; PREVALENCE	Objective: To examine the association between epilepsy and gastrointestinal hemorrhage. Patients and Methods: We conducted a nationwide retrospective cohort study by using data from Taiwan's National Health Insurance Research Database. Patients 20 years and older newly diagnosed as having epilepsy and nonepileptic adults were identified between January 1, 2000, and December 31, 2003, and were observed through December 31, 2008. Cox proportional hazards models were performed to calculate adjusted hazard ratios (HRs) and 95% CIs of gastrointestinal hemorrhage associated with epilepsy. Results: Compared with the nonepileptic group (n=449,541), epileptic patients (n=1412) had a higher incidence of gastrointestinal hemorrhage (13.4 vs 2.9 per 1000 person-years), with an HR of 2.97 (95% CI, 2.49-3.53). The HRs of gastrointestinal hemorrhage for patients with generalized epilepsy, inpatient care, emergency care, and frequent outpatient visits for epilepsy were 3.50 (95% CI, 2.59-4.72), 3.96 (95% CI, 2.85-5.50), 4.35 (95% CI, 3.15-6.01), and 4.96 (95% CI, 3.97-6.21), respectively. Risks were significantly higher in epileptic patients with mental disorders (HR, 3.20; 95% CI, 2.55-4.01), aged 70 years and older (HR, 4.08; 95% CI, 2.89-5.77), and in the first year after epilepsy (HR, 4.81; 95%, CI, 3.14-7.34). Conclusion: Epilepsy is an independent determinant for gastrointestinal hemorrhage in a chronological and severity-dependent pattern. We urge the development of an adequate surveillance policy and strategy for the early prevention of gastrointestinal hemorrhage in epileptic patients. (c) 2013 Mayo Foundation for Medical Education and Research	[Yeh, Chun-Chieh] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Yeh, Chun-Chieh] China Med Univ, Sch Med, Taichung, Taiwan; [Wang, Hwang-Huei] China Med Univ, Grad Inst Integrated Med, Coll Chinese Med, Taichung, Taiwan; [Yeh, Chun-Chieh] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Chou, Yi-Chun] China Med Univ Hosp, Dept Phys Med & Rehabil, Taichung, Taiwan; [Hu, Chaur-Jong] Taipei Med Univ, Sch Med, Dept Neurol, Taipei 110, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ, Sch Med, Taipei 110, Taiwan; [Chou, Wan-Hsin; Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ Hosp, Ctr Hlth Policy Res, Taipei, Taiwan	Liao, CC (corresponding author), Taipei Med Univ, Sch Med, 250 Wu Xing St, Taipei 110, Taiwan.	ccliao@tmu.edu.tw	Yeh, Chun Chieh/Y-3304-2019; Yeh, Chun Chieh/I-4893-2019	Yeh, Chun Chieh/0000-0001-6753-7564	Foundation for Anesthesia Education and Research fellowship; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH102-TD-B-111-004]	This research was supported by a Foundation for Anesthesia Education and Research fellowship grant to Taipei Medical University and in part by the Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004).	ANNEGERS JF, 1989, EPILEPSIA, V30, P348, DOI 10.1111/j.1528-1157.1989.tb05308.x; Berry JD, 2012, NEW ENGL J MED, V366, P321, DOI 10.1056/NEJMoa1012848; Chang CC, 2012, EPILEPSIA, V53, P987, DOI 10.1111/j.1528-1167.2012.03448.x; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; Dallal H, 2001, BRIT MED J, V323, P1115, DOI 10.1136/bmj.323.7321.1115; Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140-6736(06)68477-8; Edwards T, 2008, LANCET NEUROL, V7, P50, DOI 10.1016/S1474-4422(07)70292-2; El Beshlawy Amal, 2004, Pediatr Crit Care Med, V5, P163, DOI 10.1097/01.PCC.0000113261.13338.C3; Gaitatzis A, 2004, EPILEPSIA, V45, P1613, DOI 10.1111/j.0013-9580.2004.17504.x; Heaney DC, 2002, BMJ-BRIT MED J, V325, P1013, DOI 10.1136/bmj.325.7371.1013; Hermann B, 2008, LANCET NEUROL, V7, P151, DOI 10.1016/S1474-4422(08)70018-8; Hesdorffer DC, 1996, NEUROLOGY, V46, P727, DOI 10.1212/WNL.46.3.727; Hesdorffer DC, 1996, EPILEPSIA, V37, P736, DOI 10.1111/j.1528-1157.1996.tb00644.x; Hsu YC, 2012, HEPATOLOGY, V56, P698, DOI 10.1002/hep.25684; Hung CR, 2000, LIFE SCI, V66, P2337, DOI 10.1016/S0024-3205(00)00564-6; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Janszky I, 2009, BRAIN, V132, P2798, DOI 10.1093/brain/awp216; Kaplan RC, 2002, PREV MED, V34, P455, DOI 10.1006/pmed.2002.1008; Kasperaviciute D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023182; Kessler RC, 2012, MOL PSYCHIATR, V17, P748, DOI 10.1038/mp.2011.56; Lewis JD, 2002, AM J GASTROENTEROL, V97, P2540; Liao CC, 2012, J TRAUMA ACUTE CARE, V73, P1327, DOI 10.1097/TA.0b013e31826fc87f; Liao CC, 2012, J NEUROL NEUROSUR PS, V83, P1186, DOI 10.1136/jnnp-2012-302337; Liao CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031527; Majeed Azeem, 2004, Health Stat Q, P5; Morgan CLI, 2000, J NEUROL NEUROSUR PS, V69, P13, DOI 10.1136/jnnp.69.1.13; OTTMAN R, 1994, NEUROLOGY, V44, P2105, DOI 10.1212/WNL.44.11.2105; Pacione D, 2011, J NEUROSURG-PEDIATR, V7, P654, DOI 10.3171/2011.3.PEDS10559; Reid AY, 2012, EPILEPSIA, V53, P291, DOI 10.1111/j.1528-1167.2011.03353.x; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Tellez-Zenteno JF, 2005, EPILEPSIA, V46, P1955, DOI 10.1111/j.1528-1167.2005.00344.x; Tseng CH, 2004, DIABETES CARE, V27, P1605, DOI 10.2337/diacare.27.7.1605; Viviane A, 2008, VALUE HEALTH, V11, P1, DOI 10.1111/j.1524-4733.2007.00208.x; YUEN AWC, 1992, LANCET, V340, P618, DOI 10.1016/0140-6736(92)92159-D	35	31	32	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0025-6196	1942-5546		MAYO CLIN PROC	Mayo Clin. Proc.	OCT	2013	88	10					1091	1098		10.1016/j.mayocp.2013.06.024			8	Medicine, General & Internal	General & Internal Medicine	232DR	WOS:000325470800014	24012412	Bronze			2021-06-18	
J	Miller, LS; Colella, B; Mikulis, D; Maller, J; Green, REA				Miller, Lesley S.; Colella, Brenda; Mikulis, David; Maller, Jerome; Green, Robin E. A.			Environmental enrichment may protect against hippocampal atrophy in the chronic stages of traumatic brain injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						traumatic brain injury; environmental enrichment; subacute atrophy; adult; moderate to severe	DEFAULT MODE NETWORK; COGNITIVE RESERVE; LIFE-STYLE; AGED BRAIN; PLASTICITY; VOLUME; NEUROGENESIS; EXPERIENCE; DECLINE; NEURONS	Objective: To examine the relationship between environmental enrichment (EE) and hippocampal atrophy in the chronic stages of moderate to severe traumatic brain injury (TBI). Design: Retrospective analysis of prospectively collected data; obervational, within-subjects. Participants: Patients (N = 25) with moderate to severe TBI. Measures: Primary predictors: (1) An aggregate of self-report rating of EE (comprising hours of cognitive, physical, and social activities) at 5 months post-injury years of education as a proxy for pre-morbid EE (or cognitive reserve). Primary outcome: bilateral hippocampal volume change from 5 to 28 months post-injury. Results: As predicted, self-reported EE was significantly negatively correlated with bilateral hippocampal atrophy (p < 0.05), with greater EE associated with less atrophy from 5 to 28 months. Contrary to prediction, years of education (a proxy for cognitive reserve) was not significantly associated with atrophy. Conclusion: Post-injury EE may serve as a buffer against hippocampal atrophy in the chronic stages of moderate-severe TBI. Clinical application of EE should be considered for optimal maintenance of neurological functioning in the chronic stages of moderate-severe TBI.	[Miller, Lesley S.] Univ Toronto, Ontario Inst Studies Educ, Appl Psychol & Human Dev, Toronto, ON, Canada; [Colella, Brenda; Green, Robin E. A.] Toronto Rehab Univ Hlth Network, Res Dept, Cognit Neurorehabil Sci Lab, Toronto M5A 2G2, ON, Canada; [Mikulis, David] Univ Hlth Network, Toronto Western Res Inst, Div Appl & Intervent Res, fMRI Lab, Toronto, ON, Canada; [Mikulis, David] Univ Toronto, Fac Med, Dept Med Imaging, Toronto, ON, Canada; [Maller, Jerome] Alfred Hosp, Monash Alfred Psychiatry Res Ctr, Brain Stimulat & Neuroimaging Lab, Melbourne, Vic, Australia; [Green, Robin E. A.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada	Green, REA (corresponding author), Toronto Rehab Univ Hlth Network, Res Dept, Cognit Neurorehabil Sci Lab, 550 Univ Ave, Toronto M5A 2G2, ON, Canada.	robin.green@uhn.ca	Mikulis, David J/H-5167-2019; Maller, Jerome J/H-4963-2014	Maller, Jerome J/0000-0003-4685-1508; Green, Robin/0000-0001-9451-3963; Mikulis, David/0000-0003-3956-0892	Ontario Neurotrauma foundation; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Canada Research Chair and Physicians' Services Incorporated foundation	The study was supported by funding from the Ontario Neurotrauma foundation, Canadian Institutes for Health Research, Canada Research Chair and Physicians' Services Incorporated foundation.	Adnan A., BRAIN INJUR IN PRESS; Amaral David G., 1995, P443; Amato MP, 2013, NEUROLOGY, V80, P1728, DOI 10.1212/WNL.0b013e3182918c6f; Beck A.T., 1987, BECK DEPRESSION INVE; Beck AT., 1990, BECK ANXIETY INVENTO; Berlucchi G, 2011, NEUROPSYCHOL REHABIL, V21, P560, DOI 10.1080/09602011.2011.573255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Blake DT, 2006, NEURON, V52, P371, DOI 10.1016/j.neuron.2006.08.009; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bosma H, 2002, Z GERONTOL GERIATR, V35, P575, DOI 10.1007/s00391-002-0080-y; CORKIN S, 1989, J NEUROSCI, V9, P3876; Corral M, 2006, DEV NEUROPSYCHOL, V29, P479, DOI 10.1207/s15326942dn2903_6; CSIKSZENTMIHALYI M, 1987, J NERV MENT DIS, V175, P526, DOI 10.1097/00005053-198709000-00004; Curlik DM, 2011, J COGNITIVE NEUROSCI, V23, P2159, DOI 10.1162/jocn.2010.21597; Diamond MC, 2001, AN ACAD BRAS CIENC, V73, P211, DOI 10.1590/S0001-37652001000200006; Draganski B, 2006, J NEUROSCI, V26, P6314, DOI 10.1523/JNEUROSCI.4628-05.2006; Duvernoy HM, 2005, HUMAN HIPPOCAMPUS FU; Elkins JS, 2006, NEUROLOGY, V67, P435, DOI 10.1212/01.wnl.0000228246.89109.98; Evans J. J., 2008, NEUROPSYCHOL REHABIL, V18, P372, DOI [10.1080/09602010801909153, DOI 10.1080/09602010801909153]; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Frasca Diana, 2013, Front Hum Neurosci, V7, P31, DOI 10.3389/fnhum.2013.00031; Fritsch T, 2007, GERONTOLOGIST, V47, P307, DOI 10.1093/geront/47.3.307; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; JACOBS B, 1993, J COMP NEUROL, V327, P97, DOI 10.1002/cne.903270108; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kasai H, 2010, TRENDS NEUROSCI, V33, P121, DOI 10.1016/j.tins.2010.01.001; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Kempermann G, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00189; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kolb B, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00204; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Lee T, 2009, NEUROREPORT, V20, P1554, DOI 10.1097/WNR.0b013e328332bb09; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; Maller JJ, 2007, HIPPOCAMPUS, V17, P1023, DOI 10.1002/hipo.20339; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mohammed AH, 2002, PROG BRAIN RES, V138, P109, DOI 10.1016/S0079-6123(02)38074-9; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Nithianantharajah J, 2009, PROG NEUROBIOL, V89, P369, DOI 10.1016/j.pneurobio.2009.10.001; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Petcu EB, 2008, GERONTOLOGY, V54, P6, DOI 10.1159/000112845; Popa-Wagner A, 2007, CURR NEUROVASC RES, V4, P216; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Richards M, 2003, SOC SCI MED, V56, P785, DOI 10.1016/S0277-9536(02)00075-8; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Salthouse TA, 2002, PSYCHOL AGING, V17, P548, DOI 10.1037//0882-7974.17.4.548; Sandrone S, 2012, J NEUROSCI, V32, P1915, DOI 10.1523/JNEUROSCI.5637-11.2012; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Scarmeas N, 2003, J CLIN EXP NEUROPSYC, V25, P625, DOI 10.1076/jcen.25.5.625.14576; Shors TJ, 2012, BEHAV BRAIN RES, V227, P450, DOI 10.1016/j.bbr.2011.04.023; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 2006, ALZ DIS ASSOC DIS, V20, P112, DOI 10.1097/01.wad.0000213815.20177.19; Studenski S., 2006, SCI AGING KNOWLEDGE, V10, P21, DOI DOI 10.1126/SAGEKE.2006.10.PE21; Surget A, 2011, MOL PSYCHIATR, V16, P1177, DOI 10.1038/mp.2011.48; Tanti A, 2013, HIPPOCAMPUS, V23, P797, DOI 10.1002/hipo.22134; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Taub E, 2006, Eura Medicophys, V42, P241; Taylor VA, 2013, SOC COGN AFFECT NEUR, V8, P4, DOI 10.1093/scan/nsr087; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tombaugh TN, 1996, TEST MEMORY MALINGER; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Watson C, 1997, ARCH NEUROL-CHICAGO, V54, P67, DOI 10.1001/archneur.1997.00550130049015; Wechsler D., 2001, WECHSLER TEST ADULT; Willis KJ, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00013; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	76	31	31	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	SEP 24	2013	7								506	10.3389/fnhum.2013.00506			8	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	223IM	WOS:000324797900001	24093011	DOAJ Gold, Green Published			2021-06-18	
J	Sigurdardottir, S; Andelic, N; Roe, C; Schanke, AK				Sigurdardottir, Solrun; Andelic, Nada; Roe, Cecilie; Schanke, Anne-Kristine			DEPRESSIVE SYMPTOMS AND PSYCHOLOGICAL DISTRESS DURING THE FIRST FIVE YEARS AFTER TRAUMATIC BRAIN INJURY: RELATIONSHIP WITH PSYCHOSOCIAL STRESSORS, FATIGUE AND PAIN	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; depression; anxiety; psychosocial; fatigue; pain	PSYCHIATRIC-DISORDERS; HOSPITAL ANXIETY; SCALE; OUTCOMES; REHABILITATION; CHALLENGES; FREQUENCY; RATES; RISK	Objective: To determine the prevalence of depressive symptoms among individuals with traumatic brain injury and to identify predictors of depressive symptoms and psychological distress. Design: A longitudinal study with assessments at 3 months, 1 year and 5 years after injury. Subjects: A total of 118 individuals (29% females; mean age 32.5; range 16-55 years) with mild-to-severe traumatic brain injury who were hospitalized in the Trauma Referral Centre from 2005 to 2007. Methods: Self-report assessments using the Hospital Anxiety and Depression Scale, the Symptom Checklist 90-Revised and the Fatigue Severity Scale. Injury severity, trauma scores, pain, fatigue, substance abuse and demographic characteristics were also recorded. Results: The prevalence of depressive symptoms was 18% at 3 months, 13% at 1 year and 18% at 5 years after injury. Only 4% had persistent depressive symptoms at all time-points. At 1 year post-injury, anxiety, age, ongoing stressors and employment status predicted depressive symptoms (R-2=0.43, p<0.001), and ongoing stressors, employment status, fatigue and pain predicted psychological distress (R-2=0.45, p<0.001). Conclusion: Psychosocial stressors and employment status contributed to depressive symptoms and psychological distress, whereas injury severity did not have any predictive value. The prevalence of depressive symptoms remained stable over time, emphasizing the importance of recognizing and treating depression early after the injury.	[Sigurdardottir, Solrun; Schanke, Anne-Kristine] Sunnaas Rehabil Hosp, Dept Res, NO-1450 Nesoddtangen, Norway; [Sigurdardottir, Solrun; Andelic, Nada; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway; [Schanke, Anne-Kristine] Univ Oslo, Dept Psychol, Fac Social Sci, Oslo, Norway	Sigurdardottir, S (corresponding author), Sunnaas Rehabil Hosp, NO-1450 Nesoddtangen, Norway.	solrun.sigurdardottir@sunnaas.no		Andelic, Nada/0000-0002-3719-4406	South-Eastern Norway Regional Health Authority	The authors are grateful to all the persons for their participation. The study was supported by grants from the South-Eastern Norway Regional Health Authority. Thanks to Morten Hestnes and Nils Oddvar Skaga from the Oslo University Hospital's Trauma Registry, for the extraction of trauma scores, and Tone Jerstad, neuroradiologist, for the CT and MRI assessments.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borg J, 2011, AM J PHYS MED REHAB, V90, P65, DOI 10.1097/PHM.0b013e3181fc80e7; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cosco TD, 2012, J PSYCHOSOM RES, V72, P180, DOI 10.1016/j.jpsychores.2011.06.008; Derogatis L.R., 1983, SCL90R CLIN PSYCH RE; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2005, APPL NEUROPSYCHOL, V12, P30, DOI 10.1207/s15324826an1201_6; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kringlen E, 2001, AM J PSYCHIAT, V158, P1091, DOI 10.1176/appi.ajp.158.7.1091; Lerdal A, 2005, SCAND J PUBLIC HEALT, V33, P123, DOI 10.1080/14034940410028406; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Quale AJ, 2009, INJURY, V40, P498, DOI 10.1016/j.injury.2008.11.006; Schanke HK, 1997, DISABIL REHABIL, V19, P108, DOI 10.3109/09638289709166835; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Steel JL, 2011, INJURY, V42, P288, DOI 10.1016/j.injury.2010.11.045; Taylor C.A., 1998, SEMINARS CLIN NEUROP, V3, P224; TEASDALE G, 1974, LANCET, V2, P81; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa	40	31	32	0	8	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					808	814		10.2340/16501977-1156			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500017	24002318	DOAJ Gold			2021-06-18	
J	Fowler, A; Forsman, L; Eriksson, M; Wickstrom, R				Fowler, Asa; Forsman, Lea; Eriksson, Margareta; Wickstrom, Ronny			Tick-Borne Encephalitis Carries a High Risk of Incomplete Recovery in Children	JOURNAL OF PEDIATRICS			English	Article							FOLLOW-UP; CLINICAL-COURSE; SEVERE FORMS; HEAD-INJURY; CHILDHOOD; QUESTIONNAIRE; PATHOGENESIS; CONCUSSION; SYMPTOMS; SWEDEN	Objective To examine long-term outcome after tick-borne encephalitis (TBE) in children. Study design In this population-based cohort, 55 children with TBE with central nervous system involvement infected during 2004-2008 were evaluated 2-7 years later using the Rivermead post-concussion symptoms questionnaire (n = 42) and the Behavior Rating Inventory of Executive Functioning for parents and teachers (n = 32, n = 22, respectively). General cognitive ability was investigated in a subgroup (n = 20) using the Wechsler Intelligence Scale for Children, 4th edition. Results At long-term follow-up, two-thirds of the children experienced residual problems, the main complaints being cognitive problems, headache, fatigue, and irritability. More than one-third of the children were reported by parents or teachers to have problems with executive functioning on the Behavior Rating Inventory of Executive Functioning, mainly in areas involving initiating and organizing activities and working memory. Children who underwent Wechsler Intelligence Scale for Children, 4th edition testing had a significantly lower working memory index compared with reference norms. Conclusion A large proportion of children experience an incomplete recovery after TBE with central nervous system involvement. Cognitive problems in areas of executive function and working memory are the most prevalent. Even if mortality and severe sequelae are low in children after TBE, all children should be followed after TBE to detect cognitive deficits.	[Fowler, Asa; Forsman, Lea; Wickstrom, Ronny] Karolinska Inst, Neuropediat Unit, Stockholm, Sweden; [Eriksson, Margareta] Karolinska Inst, Dept Womens & Childrens Hlth, Pediat Infect Dis Unit, Stockholm, Sweden	Fowler, A (corresponding author), Karolinska Univ Hosp, Astrid Lindgrens Childrens Hosp, Neuropediat Unit, Q2 07, S-17176 Stockholm, Sweden.	asa.fowler@ki.se			The Jerring Foundation; Stiftelsen Samariten; Sallskapet Barnavard; Linnea and Josef Carlsson's Foundation; Swedish Insurance Association; Karolinska InstitutetKarolinska Institutet	Supported by The Jerring Foundation, Stiftelsen Samariten, Sallskapet Barnavard, Linnea and Josef Carlsson's Foundation, the Swedish Insurance Association, and Karolinska Institutet. The authors declare no conflicts of interest.	Arnez M, 2009, EXPERT REV ANTI-INFE, V7, P1251, DOI 10.1586/ERI.09.99; Barkhash AV, 2012, ANTIVIR RES, V93, P64, DOI 10.1016/j.antiviral.2011.10.017; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Cizman M, 1999, WIEN KLIN WOCHENSCHR, V111, P484; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Engman ML, 2012, PEDIATR INFECT DIS J, V31, P570, DOI 10.1097/INF.0b013e31824f23c0; Fowler A, 2010, PEDIATRICS, V126, pE828, DOI 10.1542/peds.2009-3188; Fritsch P, 2008, ACTA PAEDIATR, V97, P535, DOI 10.1111/j.1651-2227.2008.00763.x; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gritsun TS, 2003, ANTIVIR RES, V57, P129, DOI 10.1016/S0166-3542(02)00206-1; Gunther G, 1997, J NEUROL, V244, P230, DOI 10.1007/s004150050077; Haglund M, 2003, VACCINE, V21, pS11, DOI 10.1016/S0264-410X(02)00811-3; Kaiser R, 2012, WIEN MED WOCHENSCHR, V162, P239, DOI 10.1007/s10354-012-0105-0; Kindberg E, 2011, J INFECT DIS, V203, P523, DOI 10.1093/infdis/jiq082; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lesnicar G, 2003, PEDIATR INFECT DIS J, V22, P612, DOI 10.1097/00006454-200307000-00009; Logar M, 2000, INFECTION, V28, P74, DOI 10.1007/s150100050050; Lundkvist A, 2011, EUROSURVEILLANCE, V2011, P16; Meyer PM, 2010, EUR J PEDIATR, V169, P767, DOI 10.1007/s00431-009-1097-7; Ruzek D, 2010, TRAVEL MED INFECT DI, V8, P223, DOI 10.1016/j.tmaid.2010.06.004; Schmolck H, 2005, J CHILD NEUROL, V20, P500, DOI 10.1177/08830738050200060601; Simpkins JW, 2012, NEUROENDOCRINOLOGY, V96, P119, DOI 10.1159/000338409; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Stjernberg L, 2008, SCAND J INFECT DIS, V40, P4, DOI 10.1080/00365540701522934; Suss J, 2011, TICKS TICK-BORNE DIS, V2, P2, DOI 10.1016/j.ttbdis.2010.10.007; Wechsler D., 2003, WECHSLER INTELLIGENC	28	31	31	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	AUG	2013	163	2					555	560		10.1016/j.jpeds.2013.01.037			6	Pediatrics	Pediatrics	198YG	WOS:000322959500050	23452585				2021-06-18	
J	Imam, AM; Jin, G; Duggan, M; Sillesen, M; Hwabejire, JO; Jepsen, CH; DePeralta, D; Liu, BL; Lu, J; deMoya, MA; Socrate, S; Alam, HB				Imam, Ayesha M.; Jin, Guang; Duggan, Michael; Sillesen, Martin; Hwabejire, John O.; Jepsen, Cecilie H.; DePeralta, Danielle; Liu, Baoling; Lu, Jennifer; deMoya, Marc A.; Socrate, Simona; Alam, Hasan B.			Synergistic effects of fresh frozen plasma and valproic acid treatment in a combined model of traumatic brain injury and hemorrhagic shock	SURGERY			English	Article							DIFFERENT RESUSCITATION STRATEGIES; SEVERE HEAD-INJURY; HISTONE DEACETYLASE; FLUID RESUSCITATION; INTRACRANIAL-PRESSURE; OXYGEN DELIVERY; RODENT MODEL; BLOOD-LOSS; DEATH; AGE	Introduction. Traumatic brain injury (TBI) and hemorrhagic shock (HS) are major causes of trauma-related deaths and are especially lethal as a combined insult. Previously, we showed that early administration of fresh frozen plasma (FFP) decreased the size of the brain lesion and associated swelling in a swine model of combined TBI+HS. We have also shown separately that addition of valproic acid (VPA) to the resuscitation protocol attenuates inflammatory markers in the brain as well as the degree of TBI. The current study was performed to determine whether a combined FFP+VPA treatment strategy would exert a synergistic effect. Methods. Yorkshire swine (42-50 kg) were instrumented to measure hemodynamic parameters, intracranial pressure, and brain tissue oxygenation. TBI was created through a 20-mm craniotomy using a computer-controlled cortical impactor: 15-mm cylindrical tip impactor at 4 m/s velocity, 100 ms dwell time, and 12-mm penetration depth. The TBI was synchronized with the initiation of volume-controlled hemorrhage (40 +/- 5% of total blood volume). After a 2-hour period of shock, animals were randomized to 1 of 3 resuscitation groups (n = 5 per group): (1) 0.9% saline (NS); (2) FFP; and (3) FFP and VPA 300 mg/kg (FFP+VPA). The resuscitative volume for FFP was equivalent to the shed blood, whereas NS was 3 times this volume. VPA treatment was started 1 hour after hemorrhage. Animals were monitored for 6 hours post-resuscitation. At this time the brains were harvested, sectioned into 5-mm slices, and stained with 2,3,5-triphenyltetrazolium chloride to quantify the lesion size (mm(3)) and brain swelling (percent change compared with the uninjured side). Results. The combined TBI+HS model resulted in a highly reproducible brain injury. Lesion size and brain swelling (mean value +/- standard error of the mean) in the FFP+VPA group (1,459 +/- 218 mm(3) and 13 +/- 1%, respectively) were less than the NS group (3,285 +/- 131 mm(3) [P < .001] and 37 +/- 2% [P < .001], respectively), and the FFP alone group (2,160 +/- 203 mm(3) [P < .05] and 22 +/- 1% [P < .001], respectively). Conclusion. In a large animal model of TBI+HS, early treatment with a combination of FFP and VPA decreases the size of brain lesion and the associated swelling.	[Imam, Ayesha M.; Jin, Guang; Duggan, Michael; Sillesen, Martin; Hwabejire, John O.; Jepsen, Cecilie H.; DePeralta, Danielle; Liu, Baoling; Lu, Jennifer; deMoya, Marc A.; Alam, Hasan B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Trauma Emergency Surg & Surg Crit C, Boston, MA USA; [Socrate, Simona] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Jin, Guang; Liu, Baoling; Alam, Hasan B.] Univ Michigan Hosp, Dept Surg, Ann Arbor, MI 48109 USA	Alam, HB (corresponding author), Univ Michigan Hosp, Taubman Ctr 5331 2920, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Sillesen, Martin/0000-0001-9494-5475	US Army Medical Research Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]	Funded by a grant from the US Army Medical Research Material Command GRANTT00521959 (to HBA).	Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851; Aucar John A, 2009, Am J Surg, V198, P900, DOI 10.1016/j.amjsurg.2009.05.034; Baker AJ, 2008, J TRAUMA, V64, P348, DOI 10.1097/01.ta.0000245973.71929.db; Bilotta F, 2007, NEW ENGL J MED, V357, P2635; Bourguignon PR, 1998, ARCH SURG-CHICAGO, V133, P390, DOI 10.1001/archsurg.133.4.390; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Centers for Disease Control and Prevention, INJ LEAD CAUS DEATH, P1; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Fukudome EY, 2010, J SURG RES, V163, P118, DOI 10.1016/j.jss.2010.04.013; Gonzales ER, 2008, J TRAUMA, V65, P554, DOI 10.1097/TA.0b013e31818233ef; GUNNAR W, 1988, SURGERY, V103, P398; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; Ichiyama T, 2000, BRAIN RES, V857, P246, DOI 10.1016/S0006-8993(99)02439-7; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Jin G, 2010, TRANSL STROKE RES, V1, P65, DOI 10.1007/s12975-009-0009-5; Jin G, 2009, EXP NEUROL, V217, P165, DOI 10.1016/j.expneurol.2009.02.004; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kim K, 2012, RESUSCITATION, V83, P243, DOI 10.1016/j.resuscitation.2011.07.029; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lheureux PER, 2005, CRIT CARE, V9, P431, DOI 10.1186/cc3742; Li YQ, 2008, J TRAUMA, V64, P863, DOI 10.1097/TA.0b013e318166b822; Lin T, 2006, SURGERY, V139, P365, DOI 10.1016/j.surg.2005.08.022; Lin T, 2007, SURGERY, V141, P784, DOI 10.1016/j.surg.2007.01.014; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Myburgh J, 2007, NEW ENGL J MED, V357, P874; O'Connell KM, 2013, BIOL RES NURS; Offner PJ, 2004, CRIT CARE, V8, pS24, DOI 10.1186/cc2405; Peiniger S, 2011, CRIT CARE, V15, DOI 10.1186/cc10048; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Purdy FR, 1997, CAN J ANAESTH, V44, P1256, DOI 10.1007/BF03012772; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; Shults C, 2008, J TRAUMA, V64, P629, DOI 10.1097/TA.0b013e3181650ff3; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Sondeen JL, 2011, TRANSFUSION, V51, P779, DOI 10.1111/j.1537-2995.2010.02928.x; Stern SA, 2000, J NEUROSURG, V93, P305, DOI 10.3171/jns.2000.93.2.0305; Takano K, 1997, STROKE, V28, P1255, DOI 10.1161/01.STR.28.6.1255; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408; Zacharias N, 2011, RESUSCITATION, V82, P105, DOI 10.1016/j.resuscitation.2010.09.469; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	47	31	32	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	AUG	2013	154	2					388	396		10.1016/j.surg.2013.05.008			9	Surgery	Surgery	196UB	WOS:000322801800031	23889966				2021-06-18	
J	Zou, YY; Kan, EM; Lu, J; Ng, KC; Tan, MH; Yao, LL; Ling, EA				Zou, Ying-Ying; Kan, Enci Mary; Lu, Jia; Ng, Kian Chye; Tan, Mui Hong; Yao, Linli; Ling, Eng-Ang			Primary blast injury-induced lesions in the retina of adult rats	JOURNAL OF NEUROINFLAMMATION			English	Article						Blast; Retina; Nitric oxide synthase; Vascular endothelial growth factor; Aquaporin-4; Inflammation; Apoptosis	TRAUMATIC BRAIN-INJURY; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; MULLER GLIAL-CELLS; VASCULAR-PERMEABILITY; AQUAPORIN 4; EXPRESSION; DEGENERATION; INFLAMMATION; OVERPRESSURE	Background: The effect of primary blast exposure on the brain is widely reported but its effects on the eye remains unclear. Here, we aim to examine the effects of primary blast exposure on the retina. Methods: Adult male Sprague-Dawley rats were exposed to primary blast high and low injury and sacrificed at 24 h, 72 h, and 2 weeks post injury. The retina was subjected to western analysis for vascular endothelial growth factor (VEGF), aquaporin-4 (AQP4), glutamine synthethase (GS), inducible nitric oxide synthase (NOS), endothelial NOS, neuronal NOS and nestin expression; ELISA analysis for cytokines and chemokines; and immunofluorescence for glial fibrillary acidic protein (GFAP)/VEGF, GFAP/AQP4, GFAP/nestin, GS/AQP4, lectin/iNOS, and TUNEL. Results: The retina showed a blast severity-dependent increase in VEGF, iNOS, eNOS, nNOS, and nestin expression with corresponding increases in inflammatory cytokines and chemokines. There was also increased AQP4 expression and retinal thickness after primary blast exposure that was severity-dependent. Finally, a significant increase in TUNEL+ and Caspase-3+ cells was observed. These changes were observed at 24 h post-injury and sustained up to 2 weeks post injury. Conclusions: Primary blast resulted in severity-dependent pathological changes in the retina, manifested by the increased expression of a variety of proteins involved in inflammation, edema, and apoptosis. These changes were observed immediately after blast exposure and sustained up to 2 weeks suggesting acute and chronic injury mechanisms. These changes were most obvious in the astrocytes and Muller cells and suggest important roles for these cells in retina pathophysiology after blast.	[Zou, Ying-Ying] Kunming Med Univ, Fac Basic Med Sci, Dept Pathol, Kunming 650500, Peoples R China; [Zou, Ying-Ying; Yao, Linli; Ling, Eng-Ang] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore; [Kan, Enci Mary; Lu, Jia; Ng, Kian Chye; Tan, Mui Hong] DSO Natl Labs, Def Med & Environm Res Inst, Singapore 117560, Singapore	Lu, J (corresponding author), DSO Natl Labs, Def Med & Environm Res Inst, 27 Med Dr, Singapore 117560, Singapore.	ljia@dso.org.sg; antlea@nus.edu.sg			National University of SingaporeNational University of Singapore [R-181-000-140-592]; DSO National LaboratoriesDSO National Laboratories [20080102]; Youth Science Foundation of National Natural Science Foundation of China [81200840]	This study was supported by grants number R-181-000-140-592 (EAL), National University of Singapore and 20080102, DSO National Laboratories; and partially supported by Youth Science Foundation of National Natural Science Foundation of China; Grant number 81200840 (YYZ).	Abbotts R, 2007, J R Army Med Corps, V153, P119; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Alam M, 2012, J PAK MED ASSOC, V62, P138; Bates DO, 2002, VASC PHARMACOL, V39, P225, DOI 10.1016/S1537-1891(03)00011-9; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; BROWN GC, 1995, NEUROSCI LETT, V193, P201, DOI 10.1016/0304-3940(95)11703-Y; Chalioulias K, 2007, J R Army Med Corps, V153, P124; Chavko M, 2009, SHOCK, V32, P325, DOI 10.1097/SHK.0b013e31819c38f1; Cheung SSF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026184; Delyfer MN, 2005, MOL VIS, V11, P688; Dinet V, 2012, AGING CELL, V11, P683, DOI 10.1111/j.1474-9726.2012.00834.x; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Hartani D, 2006, J FR OPHTALMOL, V29, P32, DOI 10.1016/S0181-5512(06)73744-5; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JANIGRO D, 1994, CIRC RES, V75, P528, DOI 10.1161/01.RES.75.3.528; Jozkowicz A, 2001, CARDIOVASC RES, V51, P773, DOI 10.1016/S0008-6363(01)00344-3; Kaur C, 2007, J PATHOL, V212, P429, DOI 10.1002/path.2195; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kim JE, 2009, NEUROSCIENCE, V163, P781, DOI 10.1016/j.neuroscience.2009.07.028; Konstantinova T. S., 2012, Biofizika, V57, P325; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; Lamoke F, 2011, EXP EYE RES, V93, P350, DOI 10.1016/j.exer.2011.02.007; Li CR, 2010, INT J OPHTHALMOL-CHI, V3, P224, DOI 10.3980/j.issn.2222-3959.2010.03.10; Liu XQ, 2007, MOL VIS, V13, P309; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Matsuoka Y, 1997, NEUROCHEM INT, V30, P533, DOI 10.1016/S0197-0186(96)00125-8; Morley MG, 2010, DISASTER MED PUBLIC, V4, P154, DOI 10.1001/dmp.v4n2.hra10003; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sajja Venkata Siva Sai S, 2012, Biomed Sci Instrum, V48, P374; Shen F, 2004, INVEST OPHTH VIS SCI, V45, P3107, DOI 10.1167/iovs.03-0948; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; Wang YQ, 2010, INJURY, V41, P707, DOI 10.1016/j.injury.2009.12.003; Xue LP, 2006, NEUROSCIENCE, V143, P117, DOI 10.1016/j.neuroscience.2006.07.044; Xue LP, 2006, NEUROSCIENCE, V139, P723, DOI 10.1016/j.neuroscience.2005.12.032; Zou YY, 2009, NEUROSCIENCE, V160, P698, DOI 10.1016/j.neuroscience.2009.03.007	39	31	32	0	10	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUL 2	2013	10								79	10.1186/1742-2094-10-79			20	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	180HD	WOS:000321583700001	23819902	DOAJ Gold, Green Published			2021-06-18	
J	de Kloet, AJ; Hilberink, SR; Roebroeck, ME; Catsman-Berrevoets, CE; Peeters, E; Lambregts, SAM; van Markus-Doornbosch, F; Vlieland, TPMV				de Kloet, A. J.; Hilberink, S. R.; Roebroeck, M. E.; Catsman-Berrevoets, C. E.; Peeters, E.; Lambregts, S. A. M.; van Markus-Doornbosch, F.; Vlieland, T. P. M. Vliet			Youth with acquired brain injury in The Netherlands: A multi-centre study	BRAIN INJURY			English	Article						ABI; adolescents; causes; children; epidemiology; incidence; non-traumatic brain injury; NTBI; TBI; traumatic brain injury; young adults; young ones; youth	UNITED-STATES; COMPREHENSIVE MODEL; CHILDREN; REHABILITATION; PERFORMANCE; INFANTS; SCHOOL; ABUSE; CARE	Aim: To describe the occurrence and causes of acquired brain injury (ABI), including traumatic brain injury (TBI) and non-traumatic brain injury (NTBI), among Dutch youth and estimate incidence rates from the data. Patients: Aged 1 month-24 years, hospital diagnosed with ABI in 2008 or 2009. Methods: In three major hospitals in the southwest region of the Netherlands patients with ABI were retrospectively identified by means of diagnosis codes and specific search terms. Results: One thousand eight hundred and ninety-two patients were included: 1476 with TBI and 416 with NTBI. Causes of TBI and NTBI varied among the age groups 0-4, 5-14 and 15-24 years, with accidents (in traffic or at home) being the most common cause of TBI and hypoxic-ischemic events for NTBI, in all groups. The estimated yearly incidence rates per 100 000 for mild-moderate-severe TBI were 271.2-15.4-2.3 (0-14 years) and 261.6-27.0-7.9 (15-24 years), for mild-moderate-severe NTBI they were 95.7-11.8-1.3 (0-14 years) and 73.8-6.1-1.6 (15-24 years), respectively. Conclusion: More than 15% of TBI and NTBI in children and youth is classified as moderate or severe, with causes of TBI and NTBI varying among age groups. Based on the occurrence of ABI in three hospitals, the estimated incidence of ABI in children and youth in the southwest region of the Netherlands is substantial.	[de Kloet, A. J.; Roebroeck, M. E.; van Markus-Doornbosch, F.; Vlieland, T. P. M. Vliet] Sophia Rehabil, NL-2543 SW The Hague, Netherlands; [de Kloet, A. J.] Hague Univ Appl Sci, The Hague, Netherlands; [Hilberink, S. R.; Roebroeck, M. E.] Erasmus MC Univ Med Ctr, Dept Rehabil Med & Phys Therapy, Rotterdam, Netherlands; [Catsman-Berrevoets, C. E.] Sophia Childrens Univ Hosp, Erasmus MC Univ Med Ctr, Dept Paediat Neurol, Rotterdam, Netherlands; [Peeters, E.] Haga Hosp, The Hague, Netherlands; [Peeters, E.] Med Ctr Haaglanden, Dept Paediat Neurol, The Hague, Netherlands; [Lambregts, S. A. M.] Revant Rehabil Ctr Breda, Breda, Netherlands; [Vlieland, T. P. M. Vliet] Leiden Univ, Med Ctr, Dept Orthopaed, Leiden, Netherlands	de Kloet, AJ (corresponding author), Sophia Rehabil, Vrederustlaan 180, NL-2543 SW The Hague, Netherlands.	a.dekloet@sophiarevalidatie.nl	Vlieland, Thea Vliet/AAJ-8119-2020	Vlieland, Thea Vliet/0000-0001-6322-3859	Revalidatiefonds [2010/0029]; Johanna Kinder Fonds; Kinderrevalidatie Fonds Adriaan [2009/0075-1403]	This study was financially supported by the Revalidatiefonds (Grant 2010/0029), Johanna Kinder Fonds and Kinderrevalidatie Fonds Adriaan (Grant 2009/0075-1403). The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Andersson EE, 2010, DEV NEUROREHABIL, V13, P346, DOI 10.3109/17518423.2010.503671; Barrera M, 2008, J PSYCHOSOC ONCOL, V26, P1, DOI 10.1300/J077v26n01_01; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; BONITA R, 1988, STROKE, V19, P1497, DOI 10.1161/01.STR.19.12.1497; BRODERICK J, 1993, J CHILD NEUROL, V8, P250, DOI 10.1177/088307389300800308; Bunin G, 2000, PEDIATR NEUROSURG, V32, P321, DOI 10.1159/000028961; Cancer Research UK, POP BAS FIG; Chevignard M, 2010, CHILD CARE HLTH DEV, V36, P31, DOI 10.1111/j.1365-2214.2009.00949.x; Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408; Chung B, 2004, PEDIATRICS, V114, P206; De Guise E, 2009, BRAIN INJURY, V23, P853, DOI 10.1080/02699050903283221; Dunning J, 2004, ARCH DIS CHILD, V89, P763, DOI 10.1136/adc.2003.042523; Falk Ann-Charlotte, 2007, Dev Neurorehabil, V10, P49, DOI 10.1080/13638490600864066; Galvin J, 2011, DEV NEUROREHABIL, V14, P67, DOI 10.3109/17518423.2010.547241; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Gillett J, 2004, NEUROREHABILITATION, V19, P207; GIROUD M, 1995, J CLIN EPIDEMIOL, V48, P1343, DOI 10.1016/0895-4356(95)00039-9; Gordon W, 2008, BRAIN INJURY PROFESS, V5, P8; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Javouhey E, 2006, EUR J PEDIATR, V165, P519, DOI 10.1007/s00431-006-0118-z; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leventhal JM, 2012, PEDIATRICS, V130, P847, DOI 10.1542/peds.2012-0922; Meerhoff S R, 2000, Ned Tijdschr Geneeskd, V144, P1915; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Statistical Package for the Social Studies, 2008, STAT PACK SOC STUD V; Statistics Netherlands, POP BAS FIG; Statistics Rotterdam, POP BAS FIG; TEASDALE G, 1974, LANCET, V2, P81; Todis B, 2008, J HEAD TRAUMA REHAB, V23, P252, DOI 10.1097/01.HTR.0000327257.84622.bc; van Pelt ED, 2011, EUR J PAEDIATR NEURO, V15, P519, DOI 10.1016/j.ejpn.2011.05.005; Ventsel G, 2008, NEUROEPIDEMIOLOGY, V30, P20, DOI 10.1159/000113302; World Health Organization [WHO], 2007, INT CLASS FUNCT DIS	38	31	31	0	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					843	849		10.3109/02699052.2013.775496			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200011	23758314				2021-06-18	
J	Norris, JN; Carr, W; Herzig, T; Labrie, W; Sams, R				Norris, Jacob N.; Carr, Walter; Herzig, Thomas; Labrie, Walter; Sams, Richard			ANAM4 TBI Reaction Time-Based Tests Have Prognostic Utility for Acute Concussion	MILITARY MEDICINE			English	Article							NEUROPSYCHOLOGICAL ASSESSMENT METRICS; SPORT-RELATED CONCUSSION; HEAD-INJURY; FOOTBALL PLAYERS; HIGH-SCHOOL; RETURN; PERFORMANCE; RECOVERY	The Concussion Restoration Care Center has used the Automated Neuropsychological Assessment Metrics version 4 Traumatic Brain Injury (ANAM4 TBI) battery in clinical assessment of concussion. The study's aim is to evaluate the prognostic utility of the ANAM4 TBI. In 165 concussed active duty personnel (all ultimately returned to duty) seen and tested on the ANAM4 TBI on days 3 and 5 (median times) from their injury, Spearman's rho statistics showed that all performance subtests (at day 5) were associated with fewer days return-to-duty (RTD) time, whereas concussion history or age did not. Kruskal Wallis statistics showed that ANAM4 TBI, loss of consciousness, and post-traumatic amnesia were associated with increased RTD time; ANAM4 TBI reaction time-based subtests, collectively, showed the largest effect sizes. A survival analysis using a Kaplan-Meier plot showed that the lowest 25% on the reaction time-based subtests had a median RTD time of 19 days, whereas those in the upper 25% had a median RTD time of approximately 7 days. Results indicate that until validated neurocognitive testing is introduced, the ANAM4 TBI battery, especially reaction time-based tests, has prognostic utility.	[Norris, Jacob N.; Carr, Walter] Naval Med Res Ctr, Neurotrauma Dept, Silver Spring, MD 20904 USA; [Herzig, Thomas] Naval Hlth Res Ctr, Warfighter Performance Dept, San Diego, CA 92106 USA; [Labrie, Walter] Naval Med Ctr Portsmouth, Dept Mental Hlth, Portsmouth, VA 23708 USA; [Sams, Richard] Kings Bay Branch Hlth Clin, Kings Bay, GA USA	Norris, JN (corresponding author), Naval Med Res Ctr, Neurotrauma Dept, 503 Robert Grant Ave, Silver Spring, MD 20904 USA.			Sams, Richard/0000-0003-3264-9616	Navy Bureau of Medicine and Surgery, under Work Unit [N24LB]	The authors thank CAPT Jack Tsao, CAPT Tara Zieber, CDR Peter Lunblad, and CDR Earl Frantz for their support and feedback on drafts of the manuscript. This report was supported by Navy Bureau of Medicine and Surgery, under Work Unit No. N24LB.	Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Department of Defense, DOD POL GUID MAN MIL; Eonta SE, 2011, AVIAT SPACE ENVIR MD, V82, P34, DOI 10.3357/ASEM.2799.2011; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Friedl KE, 2007, ARCH CLIN NEUROPSYCH, V22, pS7, DOI 10.1016/j.acn.2006.10.002; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Kelly MP, 2012, ARCH CLIN NEUROPSYCH, V27, P375, DOI 10.1093/arclin/acs036; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lowe M, 2007, ARCH CLIN NEUROPSYCH, V22, pS89, DOI 10.1016/j.acn.2006.10.010; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; Murphy P. J., 2002, FATIGUE MANAGEMENT O; Office of the Surgeon General, 2011, DOD ANAM PROGR CRIT; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; Torg J, 1991, ATHLETIC INJURIES HE; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vincent AS, 2012, MIL MED, V177, P256, DOI 10.7205/MILMED-D-11-00289; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	34	31	31	0	5	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	JUL	2013	178	7					767	774		10.7205/MILMED-D-12-00493			8	Medicine, General & Internal	General & Internal Medicine	AN7UA	WOS:000340805300012	23820351	Other Gold			2021-06-18	
J	Olsen, AB; Hetz, RA; Xue, H; Aroom, KR; Bhattarai, D; Johnson, E; Bedi, S; Cox, CS; Uray, K				Olsen, A. B.; Hetz, R. A.; Xue, H.; Aroom, K. R.; Bhattarai, D.; Johnson, E.; Bedi, S.; Cox, C. S., Jr.; Uray, K.			Effects of traumatic brain injury on intestinal contractility	NEUROGASTROENTEROLOGY AND MOTILITY			English	Article						brain injury; inflammation; intestinal contractility	CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE; INFLAMMATORY RESPONSE; TNF-ALPHA; CELLS; RATS; INTERLEUKIN-1-BETA; DYSFUNCTION; INTOLERANCE; METABOLISM	Background Patients with traumatic brain injury (TBI) often suffer from gastrointestinal dysfunction including intolerance to enteral feedings. However, it is unclear how TBI affects small intestinal contractile activity. The purpose of this study was to determine if TBI affects intestinal smooth muscle function. Methods Sprague-Dawley rats were subjected to controlled cortical impact injury (TBI). Sham animals underwent a similar surgery but no injury (SHAM). Animals were sacrificed 1, 3, and 7days after TBI and intestinal smooth muscle tissue was collected for measurement of contractile activity and transit, NF-kB activity, and cytokine levels. Brains were collected after sacrifice to determine volume loss due to injury. Key Results Contractile activity decreased significantly in ileum, but not jejunum, in the TBI group 7days after injury compared with SHAM. Brain volume loss increased significantly 7days after injury compared with 3days and correlated significantly with the contractile activity 1day after injury. In the intestinal smooth muscle, NF-kB activity increased significantly in the TBI group 3 and 7days after injury vs SHAM. Wet to dry weight ratio, indicating edema, also increased significantly in the TBI group. Interleukin-1, -1, and -17 increased significantly in the TBI group compared with SHAM. Conclusions & Inferences Traumatic brain injury causes a delayed but significant decrease in intestinal contractile activity in the ileum leading to delayed transit. The decreased intestinal contractile activity is attributed to secondary inflammatory injury as evidenced by increased NF-kB activity, increased edema, and increased inflammatory cytokines in the intestinal smooth muscle.	[Olsen, A. B.; Hetz, R. A.; Xue, H.; Bhattarai, D.; Bedi, S.; Cox, C. S., Jr.; Uray, K.] Univ Texas Houston, Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Hetz, R. A.; Xue, H.; Aroom, K. R.; Cox, C. S., Jr.] Univ Texas Houston, Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Johnson, E.] Univ Texas Houston, Med Sch Houston, Dept Internal Med, Houston, TX 77030 USA; [Uray, K.] Texas A&M Univ, Michael E DeBakey Inst, College Stn, TX USA	Uray, K (corresponding author), Univ Texas Houston, Med Sch Houston, Dept Pediat Surg, MSB 5-230,6431 Fannin St, Houston, TX 77030 USA.	Karen.l.davis@uth.tmc.edu		Uray, Karen/0000-0001-6997-459X	Brown Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK056338] Funding Source: NIH RePORTER	This study was supported by funding from Brown Foundation.	Akiho H, 2002, AM J PHYSIOL-GASTR L, V282, pG226; Akiho Hirotada, 2011, World J Gastrointest Pathophysiol, V2, P72; Akiho Hirotada, 2010, World J Gastrointest Pathophysiol, V1, P97, DOI 10.4291/wjgp.v1.i3.97; Anthony DC, 2012, BRAIN BEHAV IMMUN, V26, P534, DOI 10.1016/j.bbi.2011.10.011; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; CHIU CJ, 1970, ARCH SURG-CHICAGO, V101, P478; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Conti AC, 1998, J NEUROSCI, V18, P5663; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Engel DR, 2010, NAT MED, V16, P1407, DOI 10.1038/nm.2255; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hu WH, 2008, BIOCHEM J, V412, P35, DOI 10.1042/BJ20080042; Hu WH, 2007, AM J PHYSIOL-CELL PH, V293, pC1991, DOI 10.1152/ajpcell.00300.2007; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kinoshita K, 2003, AM J PHYSIOL-GASTR L, V285, pG483, DOI 10.1152/ajpgi.00038.2003; Koda M, 2002, J NEUROTRAUM, V19, P777, DOI 10.1089/08977150260139147; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Martinez GJ, 2008, ANN NY ACAD SCI, V1143, P188, DOI 10.1196/annals.1443.021; McConnell EL, 2008, J PHARM PHARMACOL, V60, P63, DOI 10.1211/jpp.60.1.0008; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; Ohama T, 2007, AM J PHYSIOL-GASTR L, V292, pG1429, DOI 10.1152/ajpgi.00315.2006; Pavlov VA, 2004, CELL MOL LIFE SCI, V61, P2322, DOI 10.1007/s00018-004-4102-3; Pazdrak K, 2004, GASTROENTEROLOGY, V127, P1096, DOI 10.1053/j.gastro.2004.07.008; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Tan M, 2011, BRIT J NEUROSURG, V25, P2, DOI 10.3109/02688697.2010.522745; TEASDALE G, 1974, LANCET, V2, P81; Uray KS, 2006, CRIT CARE MED, V34, P2630, DOI 10.1097/01.CCM.0000239195.06781.8C; Uray KS, 2010, CRIT CARE MED, V38, P861, DOI 10.1097/CCM.0b013e3181ce4aaa; Van Oudenhove L, 2004, BEST PRACT RES CL GA, V18, P663, DOI 10.1016/j.bpg.2004.04.010; Wang YB, 2011, WORLD J GASTROENTERO, V17, P657, DOI 10.3748/wjg.v17.i5.657; Zhao AP, 2008, GASTROENTEROLOGY, V135, P217, DOI 10.1053/j.gastro.2008.03.077	44	31	34	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1350-1925	1365-2982		NEUROGASTROENT MOTIL	Neurogastroenterol. Motil.	JUL	2013	25	7								10.1111/nmo.12121			10	Gastroenterology & Hepatology; Clinical Neurology; Neurosciences	Gastroenterology & Hepatology; Neurosciences & Neurology	164GL	WOS:000320397100011	23551971	Green Accepted			2021-06-18	
J	Zhou, TF; Yu, JG				Zhou, Ting-Fa; Yu, Jin-Gui			Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3 signaling in experimental endotoxemia	JOURNAL OF SURGICAL RESEARCH			English	Article						Apoptosis; Sepsis; rhEPO; Learning and memory; JAK2/STAT3; Hippocampus; Neuronal cultures; Cecal ligation and peroration	TRAUMATIC BRAIN-INJURY; MEDIATED NEUROPROTECTION; ENHANCES NEUROGENESIS; SEPSIS; RATS; PROTECTS; DISEASE; ENCEPHALOPATHY; DYSFUNCTION; ACTIVATION	Background: Septic encephalopathy is characterized by changes in mental status and an increase in neuronal apoptosis. Accumulating evidence has shown that recombinant human erythropoietin (rhEPO) protects brain against ischemia and hypoxia injury. However, whether rhEPO exerts neuroprotective effects on septic encephalopathy remains unclear. We designed the current study to evaluate possible neuroprotection of rhEPO in a model of sepsis. Methods: For this in vitro study, we determined hippocampal neuronal apoptosis by lactate dehydrogenase release, cell counting kit-8 assay, and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling staining after treatment with lipopolysaccharide. We transfected the signal transducer and activator of transcription 3 (STAT3) short hairpin RNA at 14 d in vitro for 48 h. For the in vivo study, we performed cecal ligation and peroration surgery. We detected the expression of phospho-Janus-activated kinase 2 (JAK2), total JAK2, phospho-STAT3, total STAT3, Bax and Bcl-XL by Western blot, and examined behavior using the Morris water maze. Results: Treatment with rhEPO reduces apoptosis and increases cell viability in lipopolysaccharide-treated neuronal cultures. In cecal ligation and peroration rats, rhEPO attenuated the inhibition of phospho-JAK2 and phospho-STAT3. In addition, rhEPO enhanced the expression of Bcl-XL, but depressed Bax, which was abolished by additional administration of inhibitor of JAK2/STAT3 signaling 2-cyano-3-(3,4-dihydroxyphenyl)-N-(benzyl)-2-propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide or (E)-3(6-bromopyridin-2-yl)-2-cyano-N-([S0-1-phenylethyl]acrylamide) in vivo, and was ameliorated by STAT3 short hairpin RNA transfection in vitro. Alternatively, we confirmed the neuronal protective effect of rhEPO by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelingstaining. For the Morris water maze study, rhEPO improved learning and memory disorders without an alternation in locomotor activity. Conclusions: These results indicated that rhEPO improves brain dysfunction by reducing neuronal apoptosis, and JAK2/STAT3 signaling is likely to be involved. Application of rhEPO may serve as a potential therapy for the treatment of septic encephalopathy. (C) 2013 Elsevier Inc. All rights reserved.	[Zhou, Ting-Fa; Yu, Jin-Gui] Shandong Univ, Dept Anesthesiol, Qilu Hosp, Jinan 250000, Peoples R China	Yu, JG (corresponding author), Shandong Univ, Dept Anesthesiol, Qilu Hosp, 107 Western Wenhua Rd, Jinan 250000, Peoples R China.	yujingui68@yahoo.com.cn					Aher S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004868.pub2; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Aoshiba K, 2009, CRIT CARE MED, V37, P889, DOI 10.1097/CCM.0b013e31819b8371; Assaraf MI, 2007, J NEUROPATH EXP NEUR, V66, P389, DOI 10.1097/nen.0b013e3180517b28; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Chiba T, 2009, MOL PSYCHIATR, V14, P206, DOI 10.1038/mp.2008.105; Chiba T, 2009, EXPERT OPIN THER TAR, V13, P1155, DOI 10.1517/14728220903213426; Comim CM, 2008, MITOCHONDRION, V8, P313, DOI 10.1016/j.mito.2008.07.002; d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Haiden N, 2006, PEDIATRICS, V118, P180, DOI 10.1542/peds.2005-2475; Iacobone Emanuele, 2009, Crit Care Med, V37, pS331, DOI 10.1097/CCM.0b013e3181b6ed58; Kaech S, 2006, NAT PROTOC, V1, P2406, DOI 10.1038/nprot.2006.356; Kanaan NM, 2006, BRAIN RES, V1068, P221, DOI 10.1016/j.brainres.2005.10.078; Kao R, 2007, CRIT CARE, V11, DOI 10.1186/cc5920; Koroglu TF, 2006, PHYSIOL RES, V55, P309; Kretz A, 2005, MOL CELL NEUROSCI, V29, P569, DOI 10.1016/j.mcn.2005.04.009; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; McPherson RJ, 2008, INT J DEV NEUROSCI, V26, P103, DOI 10.1016/j.ijdevneu.2007.08.012; Mitra A, 2007, NEPHROL DIAL TRANSPL, V22, P2349, DOI 10.1093/ndt/gfm216; Nicolas CS, 2012, NEURON, V73, P374, DOI 10.1016/j.neuron.2011.11.024; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Ritter C, 2004, CRIT CARE MED, V32, P342, DOI 10.1097/01.CCM.0000109454.13145.CA; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Siami S, 2008, CRIT CARE CLIN, V24, P67, DOI 10.1016/j.ccc.2007.10.001; Wang GS, 2010, J NEUROCHEM, V114, P1039, DOI [10.1111/j.1471-4159.2010.00817.x, 10.1111/j.1471-4159.2010.06817.x]; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Weberpals M, 2009, J NEUROSCI, V29, P14177, DOI 10.1523/JNEUROSCI.3238-09.2009; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656	36	31	35	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUL	2013	183	1					304	312		10.1016/j.jss.2012.11.035			9	Surgery	Surgery	166ZK	WOS:000320599600045	23236988				2021-06-18	
J	Choe, AS; Belegu, V; Yoshida, S; Joel, S; Sadowsky, CL; Smith, SA; van Zijl, PCM; Pekar, JJ; McDonald, JW				Choe, Ann S.; Belegu, Visar; Yoshida, Shoko; Joel, Suresh; Sadowsky, Cristina L.; Smith, Seth A.; van Zijl, Peter C. M.; Pekar, James J.; McDonald, John W.			Extensive neurological recovery from a complete spinal cord injury: a case report and hypothesis on the role of cortical plasticity	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						spinal cord injury; trauma; diffusion tensor imaging; magnetization transfer imaging; resting state fMRI; plasticity	PRINCIPAL EIGENVECTOR MEASUREMENTS; MAGNETIZATION-TRANSFER; MULTIPLE-SCLEROSIS; INDEPENDENT COMPONENTS; FRACTIONAL ANISOTROPY; RADIAL DIFFUSIVITY; MEAN DIFFUSIVITY; NERVOUS-SYSTEM; MOTOR CORTEX; WHITE-MATTER	Neurological recovery in patients with severe spinal cord injury (SCI) is extremely rare. We have identified a patient with chronic cervical traumatic SCI, who suffered a complete loss of motor and sensory function below the injury for 6 weeks after the injury, but experienced a progressive neurological recovery that continued for 17 years. The extent of the patient's recovery from the severe trauma-induced paralysis is rare and remarkable. A detailed study of this patient using diffusion tensor imaging (DTI), magnetization transfer imaging (MTI), and resting state fMRI (rs-fMRI) revealed structural and functional changes in the central nervous system that may be associated with the neurological recovery. Sixty-two percent cervical cord white matter atrophy was observed. DTI-derived quantities, more sensitive to axons, demonstrated focal changes, while MTI-derived quantity, more sensitive to myelin, showed a diffuse change. No significant cortical structural changes were observed, while rs-fMRI revealed increased brain functional connectivity between sensorimotor and visual networks. The study provides comprehensive description of the structural and functional changes in the patient using advanced MR imaging technique. This multimodal MR imaging study also shows the potential of rs-fMRI to measure the extent of cortical plasticity	[Choe, Ann S.; Belegu, Visar; McDonald, John W.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Choe, Ann S.; Belegu, Visar; Sadowsky, Cristina L.; McDonald, John W.] Kennedy Krieger Inc, Hugo W Moser Res Inst, Int Ctr Spinal Cord Injury, Baltimore, MD USA; [Choe, Ann S.; Joel, Suresh; van Zijl, Peter C. M.; Pekar, James J.] Kennedy Krieger Inst, FM Kirby Res Ctr Funct Brain Imaging, Baltimore, MD USA; [Yoshida, Shoko; Joel, Suresh; van Zijl, Peter C. M.; Pekar, James J.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [Sadowsky, Cristina L.; McDonald, John W.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; [Smith, Seth A.] Vanderbilt Univ, Dept Radiol & Radiol Sci, Inst Imaging Sci, Nashville, TN 37235 USA	McDonald, JW (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.	mcdonaldj@kennedykrieger.org	AS, Choe/I-2637-2019; Van Zijl, Peter C/ABF-3732-2020	AS, Choe/0000-0001-7352-1489; Belegu, Visar/0000-0002-1361-4517; Pekar, James/0000-0002-9830-0655	DODUnited States Department of Defense [W81XWH-08-1-0192]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 EB006120-01A2, P41 EB015909]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015909, R21EB006120, K01EB009120] Funding Source: NIH RePORTER	The authors would like to thank Dr. Jeffrey D. Rothstein for helpful discussion and advice. This work was supported in part by grants from the DOD (W81XWH-08-1-0192) and NIH (R21 EB006120-01A2 and P41 EB015909).	Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Beg MF, 2005, INT J COMPUT VISION, V61, P139, DOI 10.1023/B:VISI.0000043755.93987.aa; Belegu V, 2007, NEUROSURG CLIN N AM, V18, P143, DOI 10.1016/j.nec.2006.10.012; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Choe AS, 2012, NMR BIOMED, V25, P900, DOI 10.1002/nbm.1810; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; Cohen-Adad J, 2013, AMYOTROPH LAT SCL FR, V14, P30, DOI 10.3109/17482968.2012.701308; Crawley AP, 2004, BRAIN RES, V1028, P19, DOI 10.1016/j.brainres.2004.08.060; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Endo T, 2007, BRAIN, V130, P2951, DOI 10.1093/brain/awm237; Faria AV, 2011, NEUROIMAGE, V54, P1854, DOI 10.1016/j.neuroimage.2010.09.061; Faria AV, 2010, NEUROIMAGE, V52, P415, DOI 10.1016/j.neuroimage.2010.04.238; Farrell JAD, 2008, MAGN RESON MED, V59, P1079, DOI 10.1002/mrm.21563; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Farrell JAD, 2010, MAGN RESON MED, V63, P1323, DOI 10.1002/mrm.22389; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; Fountas KN, 1998, SPINE, V23, P1513, DOI 10.1097/00007632-199807150-00001; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Furkiewicz MT, 2007, NEUROREHAB NEURAL RE, V21, P527, DOI 10.1177/1545968307301872; Gilmore CP, 2005, ARCH NEUROL-CHICAGO, V62, P1859, DOI 10.1001/archneur.62.12.1859; Henderson LA, 2011, J NEUROSCI, V31, P2630, DOI 10.1523/JNEUROSCI.2717-10.2011; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Joel SE, 2011, MAGN RESON MED, V66, P644, DOI 10.1002/mrm.22818; Jurkiewicz MT, 2010, NEUROREHAB NEURAL RE, V24, P136, DOI 10.1177/1545968309347680; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kalra L, 1997, STROKE, V28, P1386, DOI 10.1161/01.STR.28.7.1386; Kameyama T, 1996, SPINE, V21, P1285, DOI 10.1097/00007632-199606010-00001; Kirshblum S, 2004, ARCH PHYS MED REHAB, V85, P1811, DOI 10.1016/j.apmr.2004.03.015; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; Ko HY, 2004, SPINAL CORD, V42, P35, DOI 10.1038/sj.sc.3101538; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Landman BA, 2011, NEUROIMAGE, V54, P2854, DOI 10.1016/j.neuroimage.2010.11.047; Landman BA, 2010, NMR BIOMED, V23, P152, DOI 10.1002/nbm.1437; Levesque IR, 2010, MAGN RESON MED, V63, P633, DOI 10.1002/mrm.22244; Li YO, 2007, HUM BRAIN MAPP, V28, P1251, DOI 10.1002/hbm.20359; Loy DN, 2007, J NEUROTRAUM, V24, P979, DOI 10.1089/neu.2006.0253; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Maes F, 1999, Med Image Anal, V3, P373, DOI 10.1016/S1361-8415(99)80030-9; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; Naismith RT, 2009, NEUROLOGY, V72, P589, DOI 10.1212/01.wnl.0000335766.22758.cd; NATHAN PW, 1994, BRAIN, V117, P337, DOI 10.1093/brain/117.2.337; Oishi K, 2011, NEUROIMAGE, V56, P8, DOI 10.1016/j.neuroimage.2011.01.051; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Schmithorst VJ, 2004, J MAGN RESON IMAGING, V19, P365, DOI 10.1002/jmri.20009; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Seitz RJ, 1999, RESTOR NEUROL NEUROS, V14, P25; Sigmund EE, 2012, NMR BIOMED, V25, P891, DOI 10.1002/nbm.1809; Smith SA, 2005, MAGN RESON MED, V54, P201, DOI 10.1002/mrm.20553; Smith SA, 2010, NMR BIOMED, V23, P207, DOI 10.1002/nbm.1447; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stevens MC, 2009, BRAIN COGNITION, V70, P1, DOI 10.1016/j.bandc.2008.12.009; Vazquez Xoan Miguens, 2008, J Forensic Leg Med, V15, P20, DOI 10.1016/j.jflm.2007.06.003; White LE, 1997, CEREB CORTEX, V7, P31, DOI 10.1093/cercor/7.1.31; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Zackowski KM, 2009, BRAIN, V132, P1200, DOI 10.1093/brain/awp032	66	31	34	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	JUN 25	2013	7								290	10.3389/fnhum.2013.00290			15	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	172FD	WOS:000320984500001	23805087	DOAJ Gold, Green Published			2021-06-18	
J	Muehlschlegel, S; Carandang, R; Ouillette, C; Hall, W; Anderson, F; Goldberg, R				Muehlschlegel, Susanne; Carandang, Raphael; Ouillette, Cynthia; Hall, Wiley; Anderson, Fred; Goldberg, Robert			Frequency and Impact of Intensive Care Unit Complications on Moderate-Severe Traumatic Brain Injury: Early Results of the Outcome Prognostication in Traumatic Brain Injury (OPTIMISM) Study	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Adult brain injury; Functional outcome; Intensive care unit complications; Medical complications	ISCHEMIC-STROKE PATIENTS; HEAD-INJURY; PERSISTENT HYPERGLYCEMIA; VALIDATION; PROGNOSIS; PREDICTORS; CRASH; TRIAL	Known predictors of adverse outcomes in patients with moderate-severe TBI (msTBI) explain only a relatively small proportion of patient-related outcomes. The frequency and impact of intensive care unit complications (ICU-COMPL) on msTBI-associated outcomes are poorly understood. In 213 consecutive msTBI patients admitted to a Level I Trauma Center neuro trauma ICU, twenty-eight ICU-COMPL (21 medical and 7 neurological) were prospectively collected and adjudicated by group consensus, using pre-defined criteria. We determined frequencies, and explored associations of ICU-COMPL and hospital discharge outcomes using multivariable logistic regression. The average age of the study sample was 53 years, and the median presenting Glasgow Coma Scale and Injury Severity Scores were 5 and 27, respectively. Hyperglycemia (79 %), fever (62 %), systemic inflammatory response syndrome (60 %), and hypotension requiring vasopressors (42 %) were the four most common medical ICU-COMPL. Herniation (39 %), intracranial rebleed (39 %), and brain edema requiring osmotherapy (37 %) were the three most common neurological ICU-COMPL. After adjusting for admission variables, duration of ventilation, and ICU length-of-stay, patients with brain edema (OR 5.8; 95 % CI 2, 16.7) had a significantly increased odds for dying during hospitalization whereas patients with hospital-acquired urinary tract infection (UTI) had a decreased odds (OR 0.05; 95 % CI 0.005, 0.6). Sensitivity analysis revealed that UTI occurred later, suggesting a non-causal association with survival. Brain herniation (OR 15.7; 95 % CI 2.6, 95.4) was associated with an unfavorable functional status (GOS 1-3). ICU-COMPL are very common after msTBI, have a considerable impact on short-term outcomes, and should be considered in the prognostication of these high risk patients. Survival associations of time-dependent complications warrant cautious interpretation.	[Muehlschlegel, Susanne; Carandang, Raphael; Ouillette, Cynthia; Hall, Wiley] Univ Massachusetts, Sch Med, Dept Neurol, Div Neurocrit Care, Worcester, MA 01605 USA; [Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Anesthesia Crit Care, Div Neurocrit Care, Worcester, MA USA; [Muehlschlegel, Susanne; Carandang, Raphael; Hall, Wiley] Univ Massachusetts, Sch Med, Dept Surg, Div Neurocrit Care, Worcester, MA USA; [Anderson, Fred] Univ Massachusetts, Sch Med, Dept Surg, Ctr Outcomes Res, Worcester, MA USA; [Anderson, Fred] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Ctr Outcomes Res, Worcester, MA USA; [Goldberg, Robert] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA	Muehlschlegel, S (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol, Div Neurocrit Care, Worcester, MA 01605 USA.	susanne.muehlschlegel@umassmemorial.org	Viani, Rafael/V-1196-2018				Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; Edwards P, 2005, LANCET, V365, P1957; Fuentes B, 2010, STROKE, V41, P2362, DOI 10.1161/STROKEAHA.110.591529; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Heinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; JENNETT B, 1975, LANCET, V1, P480; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kase CS, 2001, NEUROLOGY, V57, P1603, DOI 10.1212/WNL.57.9.1603; King C, 2012, J HOSP INFECT, V82, P219, DOI 10.1016/j.jhin.2012.05.004; Kourbeti IS, 2011, BRIT J NEUROSURG, V25, P9, DOI 10.3109/02688697.2010.500411; Leigh R, 2004, STROKE, V35, P1903, DOI 10.1161/01.STR.0000132571.77987.4c; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Meier R, 2008, CRIT CARE, V12, DOI 10.1186/cc6974; Melo JRT, 2010, ACTA NEUROCHIR, V152, P1559, DOI 10.1007/s00701-010-0680-z; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Salim A, 2009, AM SURGEON, V75, P25; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Wartenberg KE, 2006, CRIT CARE MED, V34, pA124, DOI 10.1097/00003246-200612002-00426; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Yuan F, 2012, J TRAUMA ACUTE CARE, V73, P137, DOI 10.1097/TA.0b013e31824b00ac; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	34	31	32	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2013	18	3					318	331		10.1007/s12028-013-9817-2			14	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	147II	WOS:000319159600006	23377884				2021-06-18	
J	Ng, EMW; Polatajko, HJ; Marziali, E; Hunt, A; Dawson, DR				Ng, Edith M. W.; Polatajko, Helene J.; Marziali, Elsa; Hunt, Anne; Dawson, Deirdre R.			Telerehabilitation for addressing executive dysfunction after traumatic brain injury	BRAIN INJURY			English	Article						Community integration; cognitive orientation to daily occupational performance	QUALITY-OF-LIFE; SCHEDULED TELEPHONE INTERVENTION; COGNITIVE REHABILITATION; PERFORMANCE; INDIVIDUALS; AWARENESS; PROGRAM; STROKE; ADULTS; CARE	Primary objective: To investigate the feasibility of implementing the Cognitive Orientation to daily Occupational Performance approach (CO-OP) in a telerehabilitation format and to examine its impact on community integration and executive dysfunction for adults with traumatic brain injury (TBI). Research design: A pilot series of three case studies with 3-month follow-up was conducted. Methods and procedures: Three adults (all males, >10 years post-TBI) and their significant others were recruited. The CO-OP intervention, a meta-cognitive approach, was delivered through videoconferencing via Internet to train three of five participant-identified goals. Two goals were not trained to allow examination of transfer. Outcome measures included the Canadian Occupational Performance Measure, the Mayo-Portland Adaptability Inventory-4 Participation Index, and the Dysexecutive Questionnaire. Descriptive statistical analysis was used. Main outcomes and results: The CO-OP approach administered in a telerehabilitation format was found to be feasible. All participants indicated self-reported improvement in both trained and untrained goals. Trends toward fewer symptoms of executive dysfunction and greater community integration were demonstrated. All participants expressed satisfaction with the Internet delivery method. Conclusions: Telerehabilitation shows promise as a way to deliver the CO-OP approach and may help promote community integration of individuals living with TBI. Further study is warranted.	[Ng, Edith M. W.; Dawson, Deirdre R.] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Ng, Edith M. W.; Polatajko, Helene J.; Dawson, Deirdre R.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Polatajko, Helene J.; Hunt, Anne; Dawson, Deirdre R.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Marziali, Elsa] Univ Toronto, Fac Social Work, Toronto, ON M5S 1A1, Canada; [Marziali, Elsa] Univ Toronto, Fac Med, Dept Psychiat, Toronto, ON M5S 1A1, Canada; [Marziali, Elsa; Hunt, Anne; Dawson, Deirdre R.] Baycrest Hosp, Rotman Res Inst, Toronto, ON, Canada	Ng, EMW (corresponding author), Univ Hlth Network, Acquired Brain Injury Serv, Toronto Rehabil Inst, 550 Univ Ave,Room 11-075, Toronto, ON M5G 2A2, Canada.	edith.ng@uhn.ca	Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121	Canadian Occupational Therapy Foundation; Toronto Rehabilitation InstituteUniversity of Toronto; Ontario Ministry of Health and Long Term Care through the Ontario Research Coalition of Research Institutes/Centres on Health and Aging; Ontario Neurotrauma Foundation; Quebec Rehabilitation Research Network (ONF-REPAR); Ontario Rehabilitation Research Advisory Network	The authors report no conflicts of interest. The researchers and organizations involved in this study had no affiliation with Logitech (R), Skype (TM), or Pamela for Skype (TM). This study was conducted by the primary author while she was an MSc student in the Graduate Department of Rehabilitation Science at the University of Toronto. Personnel funding for her graduate studies was received from the Canadian Occupational Therapy Foundation, the Toronto Rehabilitation Institute and the Ontario Ministry of Health and Long Term Care through the Ontario Research Coalition of Research Institutes/Centres on Health and Aging. The study was supported by a grant to D. Dawson from the Ontario Neurotrauma Foundation in collaboration with the Quebec Rehabilitation Research Network (ONF-REPAR) and a grant to D. Dawson from the Ontario Rehabilitation Research Advisory Network.	Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bell KR, 2011, ARCH PHYS MED REHAB, V92, P1552, DOI 10.1016/j.apmr.2011.05.018; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Bergquist T, 2008, BRAIN INJURY, V22, P891, DOI 10.1080/02699050802405487; Bergquist T, 2009, BRAIN INJURY, V23, P790, DOI 10.1080/02699050903196688; Berson T., 2005, SKYPE SECURITY EVALU; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bodenburg S, 2008, J NERV MENT DIS, V196, P75, DOI 10.1097/NMD.0b013e31815faa2b; Boelen DHE, 2011, J NEUROPSYCHOL, V5, P73, DOI 10.1348/174866410X516434; Boelen DHE, 2009, NEUROPSYCHOL REHABIL, V19, P625, DOI 10.1080/09602010802613853; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Brandt J., 2001, HOPKINS VERBAL LEARN; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Burckhardt C.S., 2003, HLTH QUAL LIFE OUTCO, V23, P1; Burgess PW, 2007, TRENDS COGN SCI, V11, P290, DOI 10.1016/j.tics.2007.05.004; Burton CL, 2002, CLIN NEUROPSYCHOL, V16, P264, DOI 10.1076/clin.16.3.264.13854; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Dawson D, 2010, BRAIN INJURY, V24, P380; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Dawson DR, 2009, CAN J OCCUP THER, V76, P74; Doig E, 2011, BRAIN INJURY, V25, P1114, DOI 10.3109/02699052.2011.607788; Erez ABH, 2009, AM J OCCUP THER, V63, P634; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; Hermens H, 2008, ANN I SUPER SANITA, V44, P154; Huijgen BCH, 2008, J TELEMED TELECARE, V14, P249, DOI 10.1258/jtt.2008.080104; Jenkinson N, 2007, BRAIN INJURY, V21, P1283, DOI 10.1080/02699050701739531; Kairy D, 2009, DISABIL REHABIL, V31, P427, DOI 10.1080/09638280802062553; Keightley ML, 2009, BRAIN INJURY, V23, P250, DOI 10.1080/02699050902748331; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Laurent S., 2002, RURAL CANADA ACCESS; Law M, 1998, CANADIAN OCCUPATIONA; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2005, MANUAL MAYO PORTLAND; Man DWK, 2006, NEUROREHABILITATION, V21, P205; McBrinn J, 2008, BRAIN INJURY, V22, P765, DOI 10.1080/02699050802372208; McEwen SE, 2010, NEUROPSYCHOL REHABIL, V20, P541, DOI 10.1080/09602011003638194; McEwen SE, 2009, BRAIN INJURY, V23, P1041, DOI 10.3109/02699050903421107; McGrath N, 2008, J HEAD TRAUMA REHAB, V23, P388, DOI 10.1097/01.HTR.0000341434.74875.c8; Meichenbaum D., 1977, COGNITIVE BEHAV MODI; Mrazik M, 2010, ARCH CLIN NEUROPSYCH, V25, P236, DOI 10.1093/arclin/acq006; Polatajko H. J., 2004, ENABLING OCCUPATION; Rodger S, 2009, AUST OCCUP THER J, V56, P41, DOI 10.1111/j.1440-1630.2008.00739.x; Romanow Roy J., 2002, BUILDING VALUES FUTU; Skidmore ER, 2011, NEUROPSYCHOL REHABIL, V21, P208, DOI 10.1080/09602011.2011.552559; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Spreen O., 1998, COMPENDIUM NEUROPSYC; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Tam Sing-Fai, 2003, Occup Ther Int, V10, P20, DOI 10.1002/oti.175; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; Tulsky D., 1997, WAIS 3 WMS 3 TECHNIC; WHO, 2010, INCREASING ACCESS TO HEALTH WORKERS IN REMOTE AND RURAL AREAS THROUGH IMPROVED RETENTION: GLOBAL POLICY RECOMMENDATIONS, P1; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wressle E., 1999, SCAND J OCCUP THER, V6, P84, DOI DOI 10.1080/110381299443771; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005	64	31	32	3	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2013	27	5					548	564		10.3109/02699052.2013.766927			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	124UK	WOS:000317493000005	23472964				2021-06-18	
J	Sajja, VSSS; Galloway, M; Ghoddoussi, F; Kepsel, A; VandeVord, P				Sajja, Venkata Siva Sai Sujith; Galloway, Matthew; Ghoddoussi, Farhad; Kepsel, Andrea; VandeVord, Pamela			Effects of blast-induced neurotrauma on the nucleus accumbens	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						nucleus accumbens; blast; neurotrauma; 1H-MRS; cognition; inflammation	TRAUMATIC BRAIN-INJURY; DOPAMINE; SEROTONIN; GLUTAMATE; BEHAVIOR; AMYGDALA; PRESSURE; IMPACT	Blast-induced neurotrauma (BINT) leads to deterioration at the cellular level, with adverse cognitive and behavioral outcomes. The nucleus accumbens (NAC) plays an important role in reward, addiction, aggression, and fear pathways. To identify the molecular changes and pathways affected at an acute stage in the NAC, this study focused on a time course analysis to determine the effects of blast on neurochemical and apoptotic pathways. By using a rodent model of BINT, acute damage to the NAC was assessed by proton magnetic resonance spectroscopy (1H-MRS), high-performance liquid chromatography, immunohistochemistry, and Western blotting. The results demonstrated ongoing neuroprotective effects from elevated levels of Bcl-2, an antiapoptotic marker, at 24 hr and N-acetyl aspartate glutamate at 48 hr following blast exposure. Selective loss of serotonin levels at 24 hr, increased levels of inflammation (elevated glycerophosphocholine at 48 and 72 hr), and increased levels of glial fibrillary acidic protein were also observed at 24 and 48 hr, leading to disruptive energy status. Furthermore, active cell death was indicated by the increased levels of the apoptotic marker Bax, decreased actin levels, and signs excitotoxicity (glutamate/creatine). In addition, increased evels of caspase-3, an apoptotic marker, confirm active cell death in NAC. It is hypothesized that blast overpressure causes inflammation and neurochemical changes that trigger apoptosis in NAC. This cascade of events may lead to stress-related behavioral outcomes and psychiatric sequelae. (c) 2013 Wiley Periodicals, Inc.	[Sajja, Venkata Siva Sai Sujith; VandeVord, Pamela] Virginia Polytech & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24060 USA; [Galloway, Matthew; Ghoddoussi, Farhad] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI USA; [Galloway, Matthew; Ghoddoussi, Farhad] Wayne State Univ, Dept Anesthesiol, Detroit, MI USA; [Kepsel, Andrea; VandeVord, Pamela] John D Dingell VA Med Ctr, Detroit, MI USA	VandeVord, P (corresponding author), Virginia Polytech & State Univ, Sch Biomed Engn & Sci, 447 ICTAS Bldg,Stanger St, Blacksburg, VA 24060 USA.	pvord@vt.edu	Kepsel, Andrea/U-1596-2019; Sajja, Sujith/I-5289-2019	Kepsel, Andrea/0000-0002-9651-6700; Sajja, Sujith/0000-0002-1992-9501; Galloway, Matthew/0000-0002-7856-9606	Thomas C. Rumble Fellowship; National Institute of Drug Abuse (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01-DA16736]; Joe Young Research Fund in Psychiatry; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA016736] Funding Source: NIH RePORTER	Contract grant sponsor: Thomas C. Rumble Fellowship; Contract grant sponsor: National Institute of Drug Abuse (NIDA); Contract grant number: R01-DA16736; Contract grant sponsor: Joe Young Research Fund in Psychiatry.	Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Belujon P, 2011, ANN NY ACAD SCI, V1216, P114, DOI 10.1111/j.1749-6632.2010.05896.x; Benarroch EE, 2008, NEUROLOGY, V70, P1353, DOI 10.1212/01.wnl.0000311267.63292.6c; Blum K, 2010, MED HYPOTHESES, V74, P513, DOI 10.1016/j.mehy.2009.10.008; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Commons KG, 2010, BRAIN RES, V1314, P175, DOI 10.1016/j.brainres.2009.11.014; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Edden RAE, 2007, MAGN RESON MED, V57, P977, DOI 10.1002/mrm.21234; Effie CR, 2012, J REHABIL RES DEV, V46, P851; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; GALLOWAY MP, 1990, SYNAPSE, V6, P63, DOI 10.1002/syn.890060108; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Haan C, 2007, J IMMUNOL METHODS, V318, P11, DOI 10.1016/j.jim.2006.07.027; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Helfer TM, 2011, AM J AUDIOL, V20, P33, DOI 10.1044/1059-0889(2011/10-0033); Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jessen F, 2011, SCHIZOPHRENIA B; Kim EM, 2004, BRAIN RES, V1029, P135, DOI 10.1016/j.brainres.2004.10.001; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Kosten TA, 2008, NEUROPSYCHOPHARMACOL, V33, P1545, DOI 10.1038/sj.npp.1301527; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacManus D, 2012, PSYCHOL MED, V42, P1663, DOI 10.1017/S0033291711002327; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; Moore Gregory J, 2002, Psychopharmacol Bull, V36, P5; Qi Z, 2011, PHARMACOPSYCHIATRY, V44, pS62, DOI 10.1055/s-0031-1273707; Quinlan JD, 2010, AM FAM PHYSICIAN, V82, P43; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ryding E, 2008, PROG BRAIN RES, V172, P307, DOI 10.1016/S0079-6123(08)00915-1; Sah P, 2003, PHYSIOL REV, V83, P803, DOI 10.1152/physrev.00002.2003; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Sesack SR, 2010, NEUROPSYCHOPHARMACOL, V35, P27, DOI 10.1038/npp.2009.93; Stetler RA, 2010, PROG NEUROBIOL, V92, P184, DOI 10.1016/j.pneurobio.2010.05.002; Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas AG, 2001, EUR J PHARMACOL, V426, P35, DOI 10.1016/S0014-2999(01)01198-0; Thompson JM, 2008, CAN FAM PHYSICIAN, V54, P1549; van Erp AMM, 2000, J NEUROSCI, V20, P9320; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Walter A, 2004, NEUROBIOL AGING, V25, P1299, DOI 10.1016/j.neurobiolaging.2004.02.016; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427	48	31	31	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2013	91	4					593	601		10.1002/jnr.23179			9	Neurosciences	Neurosciences & Neurology	090IT	WOS:000314973400014	23335267				2021-06-18	
J	Zhang, MY; Shan, HY; Wang, T; Liu, WL; Wang, YQ; Wang, L; Zhang, L; Chang, P; Dong, WW; Chen, XP; Tao, LY				Zhang, Mingyang; Shan, Haiyan; Wang, Tao; Liu, Weili; Wang, Yaoqi; Wang, Long; Zhang, Lu; Chang, Pan; Dong, Wenwen; Chen, Xiping; Tao, Luyang			Dynamic Change of Hydrogen Sulfide After Traumatic Brain Injury and its Effect in Mice	NEUROCHEMICAL RESEARCH			English	Article						Hydrogen sulfide; Cystathionine beta-synthase; Traumatic brain injury; Mice	CYSTATHIONINE-BETA-SYNTHASE; ISCHEMIA-REPERFUSION INJURY; INDUCED CELL-DEATH; OXIDATIVE STRESS; GAMMA-LYASE; PC12 CELLS; PROTECTS NEURONS; NMDA RECEPTOR; RAT; MECHANISMS	Hydrogen sulfide (H2S) is a lipid-soluble, endogenously produced gaseous messenger molecule collectively known as gasotransmitter. Over the last several decades, gasotransmitters have emerged as potent cytoprotective mediators in various models of tissue and cellular injury. In this study, we performed a weight-drop traumatic brain injury (TBI) model in adult mice and investigated changes of H2S and its possible role in the pathogenesis after TBI. Expression of Cystathionine-beta-synthase (CBS) mRNA as H2S-producing enzymes in mouse brain was determined by reverse transcriptase-polymerase chain reaction (RT-PCR). From the results of RT-PCR, it was found that the expression of CBS was down-regulated in mouse brain cortex and hippocampus after brain injury. Western blot analysis revealed that CBS was present in normal mouse brain cortex and the hippocampus. It gradually decreased, reached its lowest level and then increased. Hydrogen sulfide in the cortex and hippocampus exhibited dynamic changes after brain injury, in parallel with CBS mRNA and protein expression. Moreover, pretreatment with the H2S donor (NaHS) could protect the neuron against the injury induced by TBI. Noticeably, the H2S donor NaHS could reduce TBI-induced injury assessed with lesion volume. These data suggested that H2S may have a therapeutic potential against neuron damage.	[Zhang, Mingyang; Wang, Tao; Liu, Weili; Wang, Yaoqi; Wang, Long; Zhang, Lu; Chang, Pan; Dong, Wenwen; Chen, Xiping; Tao, Luyang] Soochow Univ, Inst Forens Sci, Suzhou 215123, Jiangsu, Peoples R China; [Zhang, Mingyang] Nantong Univ, Coll Med, Dept Forens Sci, Nantong 226001, Jiangsu, Peoples R China; [Shan, Haiyan] North Dist Suzhou Municipal Hosp, Dept Obstet & Gynecol, Suzhou 215008, Jiangsu, Peoples R China	Chen, XP (corresponding author), Soochow Univ, Inst Forens Sci, Suzhou 215123, Jiangsu, Peoples R China.	xiping.chen@163.com; luyang.tao@163.com	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237; Zhang, Mingyang/0000-0003-1612-0763	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30872666, 81172911, 81271379]; Natural Science Foundation of Medical College of Nantong University [Y201003]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Colleges and Universities in Jiangsu Province Plans to Graduate Research and Innovation [CXLX12_0824]	This work was supported by the National Natural Science Foundation of China (No. 30872666, No. 81172911 and No. 81271379); Natural Science Foundation of Medical College of Nantong University (No. Y201003); The Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); The Colleges and Universities in Jiangsu Province Plans to Graduate Research and Innovation (CXLX12_0824).	Abe K, 1996, J NEUROSCI, V16, P1066; AWATA S, 1995, BIOCHEM MOL BIOL INT, V35, P1331; AWATA S, 1993, BIOCHEM MOL BIOL INT, V31, P185; Banerjee R, 2005, ARCH BIOCHEM BIOPHYS, V433, P144, DOI 10.1016/j.abb.2004.08.037; Bian JS, 2006, J PHARMACOL EXP THER, V316, P670, DOI 10.1124/jpet.105.092023; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Enokido Y, 2005, FASEB J, V19, P1854, DOI 10.1096/fj.05-3724fje; Eto K, 2002, J NEUROSCI, V22, P3386; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Geng B, 2004, BIOCHEM BIOPH RES CO, V318, P756, DOI 10.1016/j.bbrc.2004.04.094; GOLDSTEIN JL, 1972, J CLIN INVEST, V51, P1034, DOI 10.1172/JCI106863; GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Han Y, 2005, NEUROSCI RES, V53, P216, DOI 10.1016/j.neures.2005.07.002; Hu LF, 2009, MOL PHARMACOL, V75, P27, DOI 10.1124/mol.108.047985; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Ignoul S, 2005, AM J PHYSIOL-CELL PH, V289, pC1369, DOI 10.1152/ajpcell.00282.2005; Ishigami M, 2009, ANTIOXID REDOX SIGN, V11, P205, DOI 10.1089/ARS.2008.2132; Ji Y, 2008, EUR J PHARMACOL, V587, P1, DOI 10.1016/j.ejphar.2008.03.044; Kimura H, 2000, BIOCHEM BIOPH RES CO, V267, P129, DOI 10.1006/bbrc.1999.1915; Kimura H, 2010, ANTIOXID REDOX SIGN, V12, P1111, DOI 10.1089/ars.2009.2919; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kimura Y, 2006, ANTIOXID REDOX SIGN, V8, P661, DOI 10.1089/ars.2006.8.661; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Lee M, 2009, NEUROBIOL AGING, V30, P1523, DOI 10.1016/j.neurobiolaging.2009.06.001; Lee SW, 2006, GLIA, V54, P116, DOI 10.1002/glia.20362; Liu YY, 2011, NEUROCHEM INT, V58, P591, DOI 10.1016/j.neuint.2011.01.023; Liu YY, 2010, J ALZHEIMERS DIS, V22, P1189, DOI 10.3233/JAD-2010-101002; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Maclean KN, 2002, HUM MUTAT, V19, P641, DOI 10.1002/humu.10089; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; Meng JL, 2011, CLIN EXP PHARMACOL P, V38, P42, DOI 10.1111/j.1440-1681.2010.05462.x; Nagai Y, 2004, FASEB J, V18, P557, DOI 10.1096/fj.03-1052fje; Osipov RM, 2009, J CARDIOVASC PHARM, V54, P287, DOI 10.1097/FJC.0b013e3181b2b72b; Plesnila N, 1999, J NEUROTRAUM, V16, P831, DOI 10.1089/neu.1999.16.831; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qu K, 2006, STROKE, V37, P889, DOI 10.1161/01.STR.0000204184.34946.41; Quintana Miguel, 2004, Am J Cardiovasc Drugs, V4, P159, DOI 10.2165/00129784-200404030-00003; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Ren CL, 2010, BRAIN RES, V1345, P197, DOI 10.1016/j.brainres.2010.05.017; Renga Barbara, 2011, Inflammation & Allergy Drug Targets, V10, P85; Rhoads AR, 1997, FASEB J, V11, P331; Robert K, 2003, J HISTOCHEM CYTOCHEM, V51, P363, DOI 10.1177/002215540305100311; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Schreier SM, 2010, NEUROTOX RES, V17, P249, DOI 10.1007/s12640-009-9099-9; Shao JL, 2011, J MOL NEUROSCI, V43, P453, DOI 10.1007/s12031-010-9464-4; Shibuya N, 2009, ANTIOXID REDOX SIGN, V11, P703, DOI 10.1089/ARS.2008.2253; Shono Y, 2010, CELL MOL NEUROBIOL, V30, P453, DOI 10.1007/s10571-009-9470-7; Sodha NR, 2008, EUR J CARDIO-THORAC, V33, P906, DOI 10.1016/j.ejcts.2008.01.047; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tang BQ, 2010, NUTRITION, V26, P1170, DOI 10.1016/j.nut.2009.10.006; Tang XQ, 2010, NEUROSCI RES, V68, P241, DOI 10.1016/j.neures.2010.07.2039; Tay AS, 2010, NEUROSCIENCE, V167, P277, DOI 10.1016/j.neuroscience.2010.02.006; Tyagi N, 2009, ANTIOXID REDOX SIGN, V11, P25, DOI 10.1089/ars.2008.2073; Vitvitsky V, 2006, J BIOL CHEM, V281, P35785, DOI 10.1074/jbc.M602799200; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xie L, 2012, AM J PHYSIOL-CELL PH, V303, pC81, DOI 10.1152/ajpcell.00281.2011; Yin WL, 2009, LIFE SCI, V85, P269, DOI 10.1016/j.lfs.2009.05.023; Zhang MY, 2012, J MOL NEUROSCI, V46, P631, DOI 10.1007/s12031-011-9651-y; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858; Zhong WX, 2012, J BIOL CHEM, V287, P34189, DOI 10.1074/jbc.M112.383646	69	31	35	0	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	APR	2013	38	4					714	725		10.1007/s11064-013-0969-4			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	109JB	WOS:000316361900005	23325453				2021-06-18	
J	McDonald, S; Darke, S; Kaye, S; Torok, M				McDonald, Skye; Darke, Shane; Kaye, Sharlene; Torok, Michelle			Deficits in social perception in opioid maintenance patients, abstinent opioid users and non-opioid users	ADDICTION			English	Article						Emotion perception; opioid users; social perception	TRAUMATIC BRAIN-INJURY; FACIAL EXPRESSIONS; FRONTOTEMPORAL DEMENTIA; COGNITIVE IMPAIRMENT; EMOTION RECOGNITION; OPIATE DEPENDENCE; NEURAL BASIS; MIND; SCHIZOPHRENIA; DEPRESSION	Aims This study aimed to compare emotion perception and social inference in opioid maintenance patients with abstinent ex-users and non-heroin-using controls, and determine whether any deficits in could be accounted for by cognitive deficits and/or risk factors for brain damage. Design Casecontrol. Setting Sydney, Australia. Participants A total of 125 maintenance patients (MAIN), 50 abstinent opiate users (ABST) and 50 matched controls (CON). Measurements The Awareness of Social Inference Test (TASIT) was used to measure emotion perception and social inference. Measures were also taken of executive function, working memory, information processing speed, verbal/non-verbal learning and psychological distress. Findings After adjusting for age, sex, pre-morbid IQ and psychological distress, the MAIN group was impaired relative to CON (=0.19, P<0.05) and ABST (=0.19, P<0.05) on emotion perception and relative to CON (=0.25, P<0.001) and ABST (=0.24, P<0.01) on social inference. In neither case did the CON and ABST groups differ. For both emotion perception (P<0.001) and social inference (P<0.001), pre-morbid IQ was a significant independent predictor. Cognitive function was a major predictor of poor emotion perception (=0.44, P<0.001) and social inference (=0.48, P<0.001). Poor emotion recognition was also predicted by number of heroin overdoses (=0.14, P<0.05). Neither time in treatment or type of maintenance medication (methadone or buprenorphine) were related to performance. Conclusions People in opioid maintenance treatment may have an impaired capacity for emotion perception and ability to make inferences about social situations.	[McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Darke, Shane; Kaye, Sharlene; Torok, Michelle] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014; Torok, Michelle/R-3231-2018	McDonald, Skye/0000-0003-0723-6094; Torok, Michelle/0000-0003-3741-8075; Kaye, Sharlene/0000-0002-7657-5105	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	This research was funded by the National Health and Medical Research Council of Australia. SM is an author on The Awareness of Social Inference Test and received royalties based upon sales.	Blair RJR, 2002, J ABNORM PSYCHOL, V111, P682, DOI 10.1037//0021-843X.111.4.682; Botting N, 2008, BRIT J DEV PSYCHOL, V26, P281, DOI 10.1348/026151007X235891; Braun M, 2005, BRAIN COGNITION, V58, P193, DOI 10.1016/j.bandc.2004.11.003; Caine D, 2000, J INT NEUROPSYCH SOC, V6, P86, DOI 10.1017/S1355617700611116; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Couture SM, 2006, SCHIZOPHRENIA BULL, V32, pS44, DOI 10.1093/schbul/sbl029; Cusi AM, 2012, J PSYCHIATR NEUROSCI, V37, P154, DOI 10.1503/jpn.100179; Darke S, 2000, ADDICTION, V95, P687, DOI 10.1046/j.1360-0443.2000.9556874.x; Darke S., 2011, LIFE HEROIN USER TYP; Darke S., 2012, ADDICT THEO IN PRESS, DOI [10.3109/16066359.2012.672600, DOI 10.3109/16066359.2012.672600]; Darke S, 2012, DRUG ALCOHOL DEPEN, V126, P309, DOI 10.1016/j.drugalcdep.2012.05.032; Davis PE, 2002, DRUG ALCOHOL DEPEN, V67, P105, DOI 10.1016/S0376-8716(02)00012-1; Ersche KD, 2006, NEUROPSYCHOPHARMACOL, V31, P1036, DOI 10.1038/sj.npp.1300889; Ersche KD, 2005, PSYCHOPHARMACOLOGY, V180, P612, DOI 10.1007/s00213-005-2205-7; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fernandez-Duque D, 2005, NEUROPSYCHOLOGIA, V43, P1673, DOI 10.1016/j.neuropsychologia.2005.01.005; Foisy ML, 2005, J STUD ALCOHOL, V66, P673, DOI 10.15288/jsa.2005.66.673; Henry JD, 2008, NEUROPSYCHOLOGIA, V46, P1363, DOI 10.1016/j.neuropsychologia.2007.12.012; Joormann J, 2006, J ABNORM PSYCHOL, V115, P705, DOI 10.1037/0021-843X.115.4.705; Karch SB, 2009, KARCHS PATHOLOGY DRU; Kipps CM, 2009, BRAIN, V132, P592, DOI 10.1093/brain/awn314; Kohler CG, 2005, AM J GERIAT PSYCHIAT, V13, P926, DOI 10.1176/appi.ajgp.13.11.926; Kornreich C, 2003, PSYCHIAT RES, V119, P251, DOI 10.1016/S0165-1781(03)00130-6; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Mandal MK, 1998, SCHIZOPHRENIA BULL, V24, P399, DOI 10.1093/oxfordjournals.schbul.a033335; Martin L, 2006, ADDICTION, V101, P1598, DOI 10.1111/j.1360-0443.2006.01574.x; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S., 2011, AWARENESS SOCIAL INF; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Meyers J., 1995, REY COMPLEX FIGURE T; Mintzer MZ, 2005, DRUG ALCOHOL DEPEN, V78, P225, DOI 10.1016/j.drugalcdep.2004.10.008; Mintzer MZ, 2002, DRUG ALCOHOL DEPEN, V67, P41, DOI 10.1016/S0376-8716(02)00013-3; Monnot M, 2002, J NEUROPSYCH CLIN N, V14, P321, DOI 10.1176/appi.neuropsych.14.3.321; Naranjo C, 2011, J AFFECT DISORDERS, V128, P243, DOI 10.1016/j.jad.2010.06.039; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Shallice, 1997, HAYLING BRIXTON TEST; Shamay-Tsoory SG, 2010, CORTEX, V46, P668, DOI 10.1016/j.cortex.2009.04.008; Sparks A, 2010, SCHIZOPHR RES, V122, P172, DOI 10.1016/j.schres.2010.06.011; SPSS Inc, 2010, PSAW 19 0; Uekermann J, 2008, J INT NEUROPSYCH SOC, V14, P55, DOI 10.1017/S1355617708080016; Uekermann J, 2007, ADDICTION, V102, P232, DOI 10.1111/j.1360-0443.2006.01656.x; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weschler D., 2007, WESCHLER TEST ADULT; Wilson BA, 1996, BEHAV ASSESSMENT DYS	50	31	31	0	30	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0965-2140			ADDICTION	Addiction	MAR	2013	108	3					566	574		10.1111/add.12040			9	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	093HS	WOS:000315182900022	23164063				2021-06-18	
J	Badgeley, MA; McIlvain, NM; Yard, EE; Fields, SK; Comstock, RD				Badgeley, Marcus A.; McIlvain, Natalie M.; Yard, Ellen E.; Fields, Sarah K.; Comstock, R. Dawn			Epidemiology of 10,000 High School Football Injuries: Patterns of Injury by Position Played	JOURNAL OF PHYSICAL ACTIVITY & HEALTH			English	Article						surveillance; sports; concussion; knee	UNITED-STATES; SPORTS; PREVENTION; ATHLETICS	Background: With more than 1.1 million high school athletes playing annually during the 2005-06 to 2009-10 academic years, football is the most popular boys' sport in the United States. Methods: Using an internet-based data collection tool, RIO, certified athletic trainers (ATs) from 100 nationally representative US high schools reported athletic exposure and football injury data during the 2005-06 to 2009-10 academic years. Results: Participating ATs. reported 10,100 football injuries corresponding to an estimated 2,739,187 football-related injuries nationally. The injury rate was 4.08 per 1000 athlete-exposures (AEs) overall. Offensive lineman collectively (center, offensive guard, offensive tackle) sustained 18.3% of all injuries. Running backs (16.3%) sustained more injuries than any other position followed by linebackers (14.9%) and wide receivers (11.9%). The leading mechanism of injury was player-player contact (64.0%) followed by player-surface contact (13.4%). More specifically, injury occurred most commonly when players were being tackled (24.4%) and tackling (21.8%). Conclusions: Patterns of football injuries vary by position. Identifying such differences is important to drive development of evidence-based, targeted injury prevention efforts.	[Badgeley, Marcus A.; McIlvain, Natalie M.; Yard, Ellen E.; Comstock, R. Dawn] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH USA; [Fields, Sarah K.] Ohio State Univ, Dept Phys Act & Educ Serv, Columbus, OH 43210 USA	Badgeley, MA (corresponding author), Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH USA.			Badgeley, Marcus/0000-0001-8064-9050	NCIPC CDC HHS [R49/CE000674-01, R49/CE001172-01] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674, R49CE001172] Funding Source: NIH RePORTER		Adickes MS, 2004, SPORTS MED, V34, P201, DOI 10.2165/00007256-200434030-00005; Binkley HM, 2002, J ATHL TRAINING, V37, P329; Casa DJ, 2009, J ATHL TRAINING, V44, P332, DOI 10.4085/1062-6050-44.3.332; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; CULPEPPER MI, 1983, SOUTHERN MED J, V76, P873, DOI 10.1097/00007611-198307000-00014; DELEE JC, 1992, AM J SPORT MED, V20, P575, DOI 10.1177/036354659202000515; Dick R, 2007, J ATHL TRAINING, V42, P221; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Maughan RJ, 2010, SCAND J MED SCI SPOR, V20, P117, DOI 10.1111/j.1600-0838.2010.01221.x; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mueller FO, 1982, CATASTROPHIC SPORTS; National Federation of State High School Associations, 2009, 2009 10 HIGH SCH ATH; Peterson L, 2000, AM J SPORT MED, V28, pS51; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; Ramirez M, 2006, AM J SPORT MED, V34, P1147, DOI 10.1177/0363546505284385; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Shirreffs SM, 2010, SCAND J MED SCI SPOR, V20, P90, DOI 10.1111/j.1600-0838.2010.01213.x; Sporting Goods Manufacturers Association, ORG SPORTS ATTR MILL; Stocker B D, 1997, J Ky Med Assoc, V95, P458; THOMPSON N, 1987, AM J SPORT MED, V15, P117, DOI 10.1177/036354658701500204; United States Census Bureau, CENS REG US; Weistroffer JK, 2011, AM J SPORT MED, V39, P632, DOI 10.1177/0363546510388901; Wham GS, 2010, J ATHL TRAINING, V45, P75, DOI 10.4085/1062-6050-45.1.75; Yard EE, 2010, J SAFETY RES, V41, P471, DOI 10.1016/j.jsr.2010.09.001	25	31	31	0	25	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1543-3080			J PHYS ACT HEALTH	J. Phys. Act. Health	FEB	2013	10	2					160	169		10.1123/jpah.10.2.160			10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	098PD	WOS:000315560300004	22821941				2021-06-18	
J	Lv, QS; Fan, XY; Xu, GL; Liu, Q; Tian, LL; Cai, XY; Sun, WS; Wang, XM; Cai, QK; Bao, YF; Zhou, LL; Zhang, Y; Ge, L; Guo, RB; Liu, XF				Lv, Qiushi; Fan, Xinying; Xu, Gelin; Liu, Qian; Tian, Lili; Cai, Xiaoyi; Sun, Wenshan; Wang, Xiaomeng; Cai, Qiankun; Bao, Yuanfei; Zhou, Lulu; Zhang, Yao; Ge, Liang; Guo, Ruibing; Liu, Xinfeng			Intranasal delivery of nerve growth factor attenuates aquaporins-4-induced edema following traumatic brain injury in rats	BRAIN RESEARCH			English	Article						TBI; Cerebral edema; AQP4; NGF; Inflammatory Cytokine; NF-kappa B	NF-KAPPA-B; INTRACRANIAL HYPERTENSION; SODIUM-SALICYLATE; WATER TRANSPORT; CELLULAR EDEMA; PROTEIN-KINASE; GLIAL-CELLS; AQUAPORIN-4; BARRIER; EXPRESSION	Traumatic brain injury (TBI) remains the leading cause of injury-related death and disability. Brain edema, one of the most major complications of TBI, contributes to elevated intracranial pressure, and poor prognosis following TBI. Nerve growth factor (NGF) appears to be a viable strategy to treat brain edema and TBI. Unfortunately, due to its poor blood-brain barrier (BBB) permeability, the clinical application of NGF has been greatly limited. We previously demonstrated that intranasal NGF could bypass the BBB and distribute throughout the brain. Here we further studied whether intranasal NGF could attenuate TBI-induced brain edema and its putative mechanisms. TBI was produced by a modified weight-drop model. We found that intranasal administration of NGF (5 mu g/d) attenuated the brain edema, as assayed by hemisphere water content, at 12 h, 24 h and 72 h after TBI induction. This attenuation was associated with a prominent decrease of the content of aquaporin-4, which plays a pivotal role in the formation of brain edema. By the use of RT-PCR and ELISA, we showed that intranasal NGF markedly inhibited the transcription and expression of pro-inflammatory cytokines including IL-1 beta and TNF-alpha. An electrophoretic mobility shift assay (EMSA) displayed a significant activation of nuclear factor-kappa B following TB!, which was, however, much lowered in the NGF-treated rats. Furthermore, upon intranasal NGF supplementation, mitochondria-mediated apoptosis following TBI was minimized, as indicated by upregulation of Bcl-2 and downregulation of caspase-3. Collectively, our findings suggested that intranasal NGF may be a promising strategy to treat brain edema and TBI. (C) 2012 Elsevier B.V. All rights reserved.	[Lv, Qiushi; Fan, Xinying; Xu, Gelin; Liu, Qian; Sun, Wenshan; Wang, Xiaomeng; Cai, Qiankun; Bao, Yuanfei; Zhou, Lulu; Zhang, Yao; Ge, Liang; Guo, Ruibing; Liu, Xinfeng] Nanjing Univ, Sch Med, Dept Neurol, Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China; [Tian, Lili] Peoples Hosp Fuyang, Dept Neurol, Fuyang, Anhui, Peoples R China; [Cai, Xiaoyi] Nanjing Univ, Sch Med, Dept Pediat, Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China	Guo, RB (corresponding author), Nanjing Univ, Sch Med, Dept Neurol, Jinling Hosp, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	grb1995@yahoo.com.cn; xfliu2@yahoo.com.cn		Liu, Qian/0000-0002-1937-0568; Xu, Gelin/0000-0002-6194-0341	Nature Science Foundation of China (CNSF)National Natural Science Foundation of China (NSFC) [31171016]; Jinling Hospital Foundation [2012005]	This work was supported by the grant from Nature Science Foundation of China to X.L (CNSF #31171016) and Jinling Hospital Foundation to R.G (#2012005). We are thankful for the excellent technical assistance of Genbao Peng.	AGRE P, 1993, AM J PHYSIOL, V265, pF463; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Collins MA, 2012, NEUROTOX RES, V21, P70, DOI 10.1007/s12640-011-9276-5; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Frey WH, 1997, DRUG DELIV, V4, P87, DOI 10.3109/10717549709051878; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Iacovetta C, 2012, VET CLIN PATH, V41, P32, DOI 10.1111/j.1939-165X.2011.00390.x; Iseri SO, 2008, REGUL PEPTIDES, V146, P73, DOI 10.1016/j.regpep.2007.08.014; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1994, ACTA NEUROCHIR, P3; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kruttgen A, 2006, BRAIN PATHOL, V16, P304, DOI 10.1111/j.1750-3639.2006.00037.x; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Liu XF, 2001, J NEUROL SCI, V187, P91, DOI 10.1016/S0022-510X(01)00532-9; Lopez NE, 2012, J NEUROTRAUM, V29, P385, DOI 10.1089/neu.2011.2053; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Mao L, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/238321; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Nielsen S, 1997, J NEUROSCI, V17, P171; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Qi X, 2008, J CLIN INVEST, V118, P173, DOI 10.1172/JCI32636; Qin ZH, 2000, MOL BRAIN RES, V80, P111, DOI 10.1016/S0169-328X(00)00147-9; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; Saragovi HU, 2000, TRENDS PHARMACOL SCI, V21, P93, DOI 10.1016/S0165-6147(99)01444-3; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Song YS, 2004, NEUROSCI RES, V49, P69, DOI 10.1016/j.neures.2004.01.010; Stover JF, 2004, ACTA NEUROCHIR, V146, P819, DOI 10.1007/s00701-004-0281-9; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; Warth A, 2007, J NEUROSCI RES, V85, P1336, DOI 10.1002/jnr.21224; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M; Yoshioka K, 1998, J VET MED SCI, V60, P257, DOI 10.1292/jvms.60.257	56	31	32	0	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 1	2013	1493						80	89		10.1016/j.brainres.2012.11.028			10	Neurosciences	Neurosciences & Neurology	082FC	WOS:000314376700008	23183041				2021-06-18	
J	Yokobori, S; Gajavelli, S; Mondello, S; Mo-Seaney, J; Bramlett, HM; Dietrich, WD; Bullock, MR				Yokobori, Shoji; Gajavelli, Shyam; Mondello, Stefania; Mo-Seaney, Jixiang; Bramlett, Helen M.; Dietrich, W. Dalton; Bullock, M. Ross			Neuroprotective effect of preoperatively induced mild hypothermia as determined by biomarkers and histopathological estimation in a rat subdural hematoma decompression model	JOURNAL OF NEUROSURGERY			English	Article						ischemia/reperfusion injury; hypothermia; rat; traumatic brain injury; microdialysis; biomarker; neuronal degeneration	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; CENTRAL-NERVOUS-SYSTEM; THERAPEUTIC HYPOTHERMIA; CARDIAC-ARREST; SERUM-LEVELS; HEAD-INJURY; BARRIER DISRUPTION	Object. In patients who have sustained a traumatic brain injury (TBI), hypothermia therapy has not shown efficacy in multicenter clinical trials. Armed with the post hoc data from the latest clinical trial (National Acute Brain Injury Study: Hypothermia II), the authors hypothesized that hypothermia may be beneficial in an acute subdural hematoma (SDH) rat model by blunting the effects of ischemia/reperfusion injury. The major aim of this study was to test the efficacy of temperature management in reducing brain damage after acute SDH. Methods. The rats were induced with acute SDH and placed into 1 of 4 groups: 1) normothermia group (37 degrees C); 2) early hypothermia group, head and body temperature reduced to 33 degrees C 30 minutes prior to craniotomy; 3) late hypothermia group, temperature lowered to 33 degrees C 30 minutes after decompression; and 4) sham group, no acute SDH (only craniotomy with normothermia). To assess for neuronal and glial cell damage, the authors analyzed microdialysate concentrations of GFAP and ubiquitin carboxyl-terminal hydrolase-L1 (UCH-L1) by using a 100-kD probe. Fluoro-Jade B positive neurons and injury volume with 2,3,5-triphenyltetrazolium chloride staining were also measured. Results. In the early phase of reperfusion (30 minutes, 2.5 hours after decompression), extracellular UCH-L1 in the early hypothermia group was significantly lower than in the normothermia group (early, 4.9 +/- 1.0 ng/dl; late, 35.2 +/- 12.1 ng/dl; normothermia, 50.20 +/- 28.3 ng/dl; sham, 3.1 +/- 1.3 ng/dl; early vs normothermia, p < 0.01; sham vs normothermia, p < 0.01, analyzed using ANOVA followed by a post hoc Bonferroni test). In the late phase of reperfusion (>2.5 hours after decompression), extracellular GFAP in the early hypothermia group was also lower than in the normothermia and late hypothermia groups (early, 5.5 +/- 2.9 ng/dl; late, 7.4 +/- 3.4 ng/dl; normothermia, 15.3 8.4 ng/dl; sham, 3.3 +/- 1.0 ng/dl; normothermia vs sham; p < 0.01). The number of Fluoro-Jade B positive cells in the early hypothermia group was significantly smaller than that in the normothermia group (normothermia vs early: 774,588 +/- 162,173 vs 180,903 +/- 42,212, p < 0.05). Also, the injury area and volume were smaller in the early hypothermia group in which hypothermia was induced before craniotomy and cerebral reperfusion (early, 115.2 15.4 mm(3); late, 344.7 +/- 29.1 mm(3); normothermia, 311.2 +/- 79.2 mm(3); p < 0.05). Conclusions. The data suggest that early, preoperatively induced hypothermia could mediate the reduction of neuronal and glial damage in the reperfusion phase of ischemia/reperfusion brain injury. (http://thejns.org/doi/abs/10.3171/2012.10.JNS12725)	[Yokobori, Shoji; Gajavelli, Shyam; Bramlett, Helen M.; Dietrich, W. Dalton; Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Mondello, Stefania; Mo-Seaney, Jixiang] Banyan Biomarkers Inc, Alachua, FL USA; [Mondello, Stefania] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Mondello, Stefania] Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; [Yokobori, Shoji] Nippon Med Sch, Dept Emergency & Crit Care Med, Tokyo 113, Japan	Yokobori, S (corresponding author), Univ Miami, Miller Sch Med, Dept Neurosurg, 1095 NW 14th Terrace, Miami, FL 33136 USA.	SYokobori@med.miami.edu	Gajavelli, Shyam/AAI-1374-2019; Mondello, Stefania/A-1813-2012	Gajavelli, Shyam/0000-0002-5947-6973; Mondello, Stefania/0000-0002-8587-3614	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 042133]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133] Funding Source: NIH RePORTER	Dr. Mondello and Jiaxing Mo-Seaney are employees of Banyan Biomarkers, Inc. This work was supported by funds from NINDS R01 NS 042133 and the Miami Project to Cure Paralysis.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arnaoutakis GJ, 2011, J THORAC CARDIOV SUR, V142, P902, DOI 10.1016/j.jtcvs.2011.06.027; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; BOLLI R, 1989, CIRC RES, V65, P607, DOI 10.1161/01.RES.65.3.607; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Burger R, 2004, NEUROSURGERY, V54, P701, DOI 10.1227/01.NEU.0000108784.80585.EE; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Di X, 1996, J NEUROSURG, V85, P655, DOI 10.3171/jns.1996.85.4.0655; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Fu ES, 2005, CURR OPIN ANESTHESIO, V18, P181, DOI 10.1097/01.aco.0000162838.56344.88; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Honeybul S, 2011, LANCET NEUROL, V10, P405, DOI 10.1016/S1474-4422(11)70086-2; Janata A, 2009, PROG CARDIOVASC DIS, V52, P168, DOI 10.1016/j.pcad.2009.07.001; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; Jiang JY, 2009, J NEUROTRAUM, V26, P399, DOI 10.1089/neu.2008.0525; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Johnsson P, 2003, ANN THORAC SURG, V75, P162, DOI 10.1016/S0003-4975(02)04318-7; Jonsson H, 2003, RESTOR NEUROL NEUROS, V21, P151; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; Kawai N, 2000, ACT NEUR S, V76, P529; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; KHALID MA, 1993, CIRC RES, V72, P725, DOI 10.1161/01.RES.72.4.725; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; KURODA Y, 1992, NEUROSURGERY, V30, P687; Kwon TH, 2005, J NEUROSURG, V103, P724, DOI 10.3171/jns.2005.103.4.0724; Kwon TH, 2003, J NEUROTRAUM, V20, P337, DOI 10.1089/089771503765172291; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Larach DB, 2011, NEUROCRIT CARE, V15, P609, DOI 10.1007/s12028-011-9517-8; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Mar J, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-46; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Neumar RW, 2000, ANN EMERG MED, V36, P483, DOI 10.1067/mem.2000.110995; Nichol AD, 2011, LANCET NEUROL, V10, P405, DOI 10.1016/S1474-4422(11)70085-0; Nielsen TH, 2011, NEUROCRIT CARE, V15, P585, DOI 10.1007/s12028-011-9563-2; Okauchi M, 2002, J NEUROTRAUM, V19, P741, DOI 10.1089/08977150260139110; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Polderman KH, 2011, LANCET NEUROL, V10, P404, DOI 10.1016/S1474-4422(11)70084-9; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; Shao ZH, 2010, AM J PHYSIOL-HEART C, V298, pH2164, DOI 10.1152/ajpheart.00994.2009; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Takeuchi S, 2011, LANCET NEUROL, V10, P404, DOI 10.1016/S1474-4422(11)70083-7; Timmons SD, 2010, CRIT CARE MED, V38, pS431, DOI 10.1097/CCM.0b013e3181ec57ab; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tuttolomondo A, 2009, CURR TOP MED CHEM, V9, P1317, DOI 10.2174/156802609789869646; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Voloboueva LA, 2007, J NEUROCHEM, V102, P1383, DOI 10.1111/j.1471-4159.2007.04634.x; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Xu LJ, 2001, EXP NEUROL, V169, P416, DOI 10.1006/exnr.2001.7678; Yang D, 2009, FEBS LETT, V583, P2500, DOI 10.1016/j.febslet.2009.07.006; Yokobori S, 2011, J TRAUMA, V71, P1235, DOI 10.1097/TA.0b013e3182140dd7	80	31	36	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2013	118	2					370	380		10.3171/2012.10.JNS12725			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	076DY	WOS:000313937900022	23140154	Green Accepted			2021-06-18	
J	Dulin, JN; Karoly, ED; Wang, Y; Strobel, HW; Grill, RJ				Dulin, Jennifer N.; Karoly, Edward D.; Wang, Ying; Strobel, Henry W.; Grill, Raymond J.			Licofelone Modulates Neuroinflammation and Attenuates Mechanical Hypersensitivity in the Chronic Phase of Spinal Cord Injury	JOURNAL OF NEUROSCIENCE			English	Article							CENTRAL NEUROPATHIC PAIN; INFLAMMATORY RESPONSE; SECONDARY INJURY; CONTUSION INJURY; IN-VIVO; RAT; EXPRESSION; BRAIN; METABOLOMICS; GLUTATHIONE	Inflammation is a major factor shaping outcome during the early, acute phase of traumatic spinal cord injury (SCI). It is known that pro-inflammatory signaling within the injured spinal cord drives pathological alterations in neurosensory processing and shapes functional outcome early after injury. However, it is unclear whether inflammation persists into the chronic phase of injury or shapes sensory processing long after injury. To investigate these possibilities, we have performed biochemical and behavioral assessments 9 months after moderate thoracic spinal contusion injury in the rat. We have found that levels of the pro-inflammatory lipid mediators leukotriene B4 and prostaglandin E2 are elevated in the chronic spinal cord lesion site. Additionally, using metabolomic profiling, we have detected elevated levels of pro-oxidative and inflammatory metabolites, along with alterations in multiple biological pathways within the chronic lesion site. We found that 28 d treatment of chronically injured rats with the dual COX/5-LOX inhibitor licofelone elevated levels of endogenous anti-oxidant and anti-inflammatory metabolites within the lesion site. Furthermore, licofelone treatment reduced hypersensitivity of hindpaws to mechanical, but not thermal, stimulation, indicating that mechanical sensitivity is modulated by pro-inflammatory signaling in the chronic phase of injury. Together, these findings provide novel evidence of inflammation and oxidative stress within spinal cord tissue far into the chronic phase of SCI, and demonstrate a role for inflammatory modulation of mechanical sensitivity in the chronic phase of injury.	[Dulin, Jennifer N.; Grill, Raymond J.] Univ Texas Med Sch Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Karoly, Edward D.] Metabolon Inc, Durham, NC 27713 USA; [Wang, Ying; Strobel, Henry W.] Univ Texas Med Sch Houston, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Grill, RJ (corresponding author), Univ Texas Med Sch Houston, Dept Integrat Biol & Pharmacol, 6431 Fannin St,Med Sch Bldg 4-110, Houston, TX 77030 USA.	Raymond.J.Grill@uth.tmc.edu		Dulin, Jennifer/0000-0001-5767-4290	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 49409, NS 44174, MH 70054]; Paralyzed Veterans of America [2511]; Gillson-Longenbaugh Foundation; Institute for Rehabilitation and Research Foundation; University of Texas Center for Clinical and Translational Sciences; NIH from the National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1 RR024147]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024148, TL1RR024147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH070054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044174, R01NS049409] Funding Source: NIH RePORTER	This work is supported by grants from the National Institutes of Health (NIH) (NS 49409 to R.J.G., NS 44174 and MH 70054 to H.W.S.); Paralyzed Veterans of America (#2511 to R.J.G.); The Gillson-Longenbaugh Foundation (R.J.G.); Mission Connect, a project of The Institute for Rehabilitation and Research Foundation (R.J.G.); and the University of Texas Center for Clinical and Translational Sciences, funded by NIH Clinical and Translational Award (TL1 RR024147 to J.N.D.) from the National Center for Research Resources (NCRR). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the views of the NCRR or the NIH. We gratefully acknowledge Drs. Robyn Crook and Olivera Nesic-Taylor for assistance with behavioral analysis.	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Aimone JB, 2004, EXP NEUROL, V189, P204, DOI 10.1016/j.expneurol.2004.05.042; Alexander JK, 2009, PROG BRAIN RES, V175, P125, DOI 10.1016/S0079-6123(09)17508-8; Baastrup C, 2008, CNS DRUGS, V22, P455, DOI 10.2165/00023210-200822060-00002; Baker M, 2011, NAT METHODS, V8, P117, DOI 10.1038/nmeth0211-117; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Bedi SS, 2010, J NEUROSCI, V30, P14870, DOI 10.1523/JNEUROSCI.2428-10.2010; Benowitz LI, 2011, CURR OPIN NEUROL, V24, P577, DOI 10.1097/WCO.0b013e32834c208d; Buczynski MW, 2010, J NEUROCHEM, V114, P981, DOI 10.1111/j.1471-4159.2010.06815.x; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Carlton SM, 2009, PAIN, V147, P265, DOI 10.1016/j.pain.2009.09.030; Cartagena CM, 2008, J NEUROTRAUM, V25, P1087, DOI 10.1089/neu.2007.0444; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Cheng O, 2010, NEUROSCIENCE, V166, P1101, DOI 10.1016/j.neuroscience.2010.01.024; Cicero AFG, 2007, CLIN INTERV AGING, V2, P73, DOI 10.2147/ciia.2007.2.1.73; DeHaven CD, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-9; DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9; Dulin JN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016456; Dunn WB, 2011, CHEM SOC REV, V40, P387, DOI 10.1039/b906712b; ERIKSSON B, 1967, ACTA CHEM SCAND, V21, P1304, DOI 10.3891/acta.chem.scand.21-1304; Farooqui AA, 2007, J NEUROCHEM, V101, P577, DOI 10.1111/j.1471-4159.2006.04371.x; Finnerup NB, 2001, SPINAL CORD, V39, P256, DOI 10.1038/sj.sc.3101161; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Foyer CH, 2011, PLANT PHYSIOL, V155, P2, DOI 10.1104/pp.110.167569; Fujieda Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043152; Genovese T, 2008, BRIT J PHARMACOL, V153, P568, DOI 10.1038/sj.bjp.0707577; Genovese T, 2005, J NEUROIMMUNOL, V166, P55, DOI 10.1016/j.jneuroim.2005.05.009; Hains BC, 2006, J NEUROSCI, V26, P4308, DOI 10.1523/JNEUROSCI.0003-06.2006; Hains BC, 2003, J NEUROSCI, V23, P8881; Hains BC, 2001, J NEUROTRAUM, V18, P409, DOI 10.1089/089771501750170994; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Herrera JJ, 2010, J NEUROTRAUM, V27, P423, DOI 10.1089/neu.2009.0997; Huang WL, 2009, J NEUROTRAUM, V26, P1429, DOI 10.1089/neu.2008-0835; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Kaddurah-Daouk R, 2008, ANNU REV PHARMACOL, V48, P653, DOI 10.1146/annurev.pharmtox.48.113006.094715; Kwon BK, 2011, J NEUROTRAUM, V28, P1545, DOI 10.1089/neu.2009.1149; Lin CR, 2006, J PHARMACOL EXP THER, V319, P1096, DOI 10.1124/jpet.106.105569; Liu NK, 2010, MOL NEUROBIOL, V41, P197, DOI 10.1007/s12035-010-8101-0; Morales JR, 2008, CIRCULATION, V118, P1450, DOI 10.1161/CIRCULATIONAHA.108.782300; Nesic O, 2005, J NEUROCHEM, V95, P998, DOI 10.1111/j.1471-4159.2005.03462.x; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Noguchi K, 2011, BIOL PHARM BULL, V34, P1163, DOI 10.1248/bpb.34.1163; Okubo M, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-57; Reitman ZJ, 2011, P NATL ACAD SCI USA, V108, P3270, DOI 10.1073/pnas.1019393108; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Saiwai H, 2010, AM J PATHOL, V176, P2352, DOI 10.2353/ajpath.2010.090839; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SHARMA HS, 1993, NEUROSCIENCE, V57, P443, DOI 10.1016/0306-4522(93)90076-R; Singh Vijay Pal, 2005, Indian Journal of Experimental Biology, V43, P247; Singh VP, 2006, FUND CLIN PHARMACOL, V20, P65, DOI 10.1111/j.1472-8206.2005.00387.x; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Velardo MJ, 2004, J NEUROSCI, V24, P8562, DOI 10.1523/JNEUROSCI.3316-04.2004; Wishart DS, 2009, NUCLEIC ACIDS RES, V37, pD603, DOI 10.1093/nar/gkn810; Wu YJ, 2012, BASIC CLIN PHARMACOL, V111, P166, DOI 10.1111/j.1742-7843.2012.00882.x; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; Yoshida Y, 2005, BIOFACTORS, V24, P7, DOI 10.1002/biof.5520240102; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007	61	31	32	0	13	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 9	2013	33	2					652	664		10.1523/JNEUROSCI.6128-11.2013			13	Neurosciences	Neurosciences & Neurology	071EN	WOS:000313569600027	23303944	Bronze, Green Published, Green Accepted			2021-06-18	
J	Dennis, M; Agostino, A; Taylor, HG; Bigler, ED; Rubin, K; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Dennis, Maureen; Agostino, Alba; Taylor, H. Gerry; Bigler, Erin D.; Rubin, Kenneth; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Emotional Expression and Socially Modulated Emotive Communication in Children with Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Emotion; Facial expression; Theory of mind; Closed head injury; Test; language comprehension; Social emotional communication	FACIAL EXPRESSION; RECOGNITION; MILD; NEUROSCIENCE; INTEGRATION; PERCEPTION; ABILITIES; DISORDER; DEFICITS; OUTCOMES	Facial emotion expresses feelings, but is also a vehicle for social communication. Using five basic emotions (happiness, sadness, fear, disgust, and anger) in a comprehension paradigm, we studied how facial expression reflects inner feelings (emotional expression) but may be socially modulated to communicate a different emotion from the inner feeling (emotive communication, a form of affective theory of mind). Participants were 8- to 12-year-old children with TBI (n = 78) and peers with orthopedic injuries (n = 56). Children with mild-moderate or severe TBI performed more poorly than the OI group, and chose less cognitively sophisticated strategies for emotive communication. Compared to the OI and mild-moderate TBI groups, children with severe TBI had more deficits in anger, fear, and sadness; neutralized emotions less often; produced socially inappropriate responses; and failed to differentiate the core emotional dimension of arousal. Children with TBI have difficulty understanding the dual role of facial emotions in expressing feelings and communicating socially relevant but deceptive emotions, and these difficulties likely contribute to their social problems. (JINS, 2013, 19, 34-43)	[Dennis, Maureen] Hosp Sick Children, Dept Psychol, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Agostino, Alba] Ryerson Univ, Dept Psychol, Toronto, ON, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Stancin, Terry] Rainbow Babies & Childrens Hosp, Dept Pediat, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Rubin, Kenneth] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Nationwide Childrens Hosp, Ctr Biobehav Hlth, Res Inst, Columbus, OH USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Pediat, Cleveland, OH USA	Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol, Program Neurosci & Mental Hlth, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	maureen.dennis@sickkids.ca	Gerhardt, Cynthia/E-3109-2011; Rubin, Kenneth H/M-5276-2018; Vannatta, Kathryn/E-4237-2011; Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Rubin, Kenneth H/0000-0002-2608-2484; Yeates, Keith/0000-0001-7680-2892; Agostino, Alexandra/0000-0001-8739-0061	National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 RO1 HD 04946]	This paper was supported by National Institute of Neurological Diseases and Stroke Grant 1 RO1 HD 04946, "Social Outcomes in Pediatric Traumatic Brain Injury.'' The information presented in this manuscript has never been published either electronically or in print elsewhere. No conflicts of interest exist regarding this manuscript.	Adams RB, 2006, MOTIV EMOTION, V30, P179, DOI 10.1007/s11031-006-9020-2; Bennett DS, 2002, INFANCY, V3, P97, DOI 10.1207/S15327078IN0301_5; Berkman ET, 2009, SOC PERSONAL PSYCHOL, V3, P475, DOI 10.1111/j.1751-9004.2009.00186.x; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Cunningham W.A., 2007, SOC NEUROSCI-UK, P227; DAVIDSON RJ, 1992, BRAIN COGNITION, V20, P125, DOI 10.1016/0278-2626(92)90065-T; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; GRAY JA, 1990, COGNITION EMOTION, V4, P269, DOI 10.1080/02699939008410799; Green MJ, 2003, COGNITION EMOTION, V17, P779, DOI 10.1080/02699930302282; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hauser RM, 1997, SOCIOL METHODOL, V27, P177, DOI 10.1111/1467-9531.271028; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Howard I, 2005, ETHNIC DIS, V15, pS51; Huang L, 2011, SOC PSYCHOL PERS SCI, V2, P351, DOI 10.1177/1948550610391677; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Pessoa L, 2008, NAT REV NEUROSCI, V9, P148, DOI 10.1038/nrn2317; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; RUSSELL JA, 1979, J PERS SOC PSYCHOL, V37, P345, DOI 10.1037/0022-3514.37.3.345; SAARNI C, 1984, CHILD DEV, V55, P1504, DOI 10.2307/1130020; Satpute AB, 2006, BRAIN RES, V1079, P86, DOI 10.1016/j.brainres.2006.01.005; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Schrammel F, 2009, PSYCHOPHYSIOLOGY, V46, P922, DOI 10.1111/j.1469-8986.2009.00831.x; Shackman AJ, 2011, NAT REV NEUROSCI, V12, P154, DOI 10.1038/nrn2994; Sinopoli KJ, 2012, INT J DEV NEUROSCI, V30, P207, DOI 10.1016/j.ijdevneu.2011.08.006; Sinopoli KJ, 2011, J CLIN EXP NEUROPSYC, V33, P805, DOI 10.1080/13803395.2011.562864; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; TEASDALE G, 1974, LANCET, V2, P81; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tonks J, 2008, BRAIN INJURY, V22, P325, DOI 10.1080/02699050801968303; Tonks J, 2007, BRAIN INJURY, V21, P623, DOI 10.1080/02699050701426865; Wechsler D., 2011, WECHLSER ABBREVIATED; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	45	31	31	0	26	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2013	19	1					34	43		10.1017/S1355617712000884			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	063NB	WOS:000313005400004	23158960				2021-06-18	
J	Golub, A; Bennett, AS				Golub, Andrew; Bennett, Alex S.			Prescription Opioid Initiation, Correlates, and Consequences Among a Sample of OEF/OIF Military Personnel	SUBSTANCE USE & MISUSE			English	Article						drug use disorder; minority; pain management; military personnel; veterans; reintegration; mental health	SUBSTANCE USE; DRUG-USERS; UNITED-STATES; BEHAVIOR; ABUSE; RECRUITMENT; DISORDERS; VETERANS; ALCOHOL; TRENDS	Prescription opioid (PO) misuse represents a major health risk for many service members and veterans. This paper examines the pathways to misuse among a sample of US veterans who recently returned from Iraq and Afghanistan to low-income, predominately minority sections of New York City. Recreational PO misuse was not common on deployment. Most PO misusers initiated use subsequent to PO use for pain management, an iatrogenic pathway. However, most PO users did not misuse them. Veterans that misused POs were more likely to have other reintegration problems including drug and alcohol use disorders, traumatic brain injury (TBI), unemployment, and homelessness.	[Golub, Andrew; Bennett, Alex S.] Natl Dev & Res Inst Inc, New York, NY USA	Golub, A (corresponding author), Natl Dev & Res Inst Inc, 47 Prospect Pkwy, Burlington, VT 05401 USA.	golub@ndri.org			National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA020178]; Peter F. McManus Charitable Trust; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA020178] Funding Source: NIH RePORTER	This research was supported by grants from the National Institute on Alcohol Abuse and Alcoholism (R01 AA020178) and from the Peter F. McManus Charitable Trust. Points of view expressed in this paper do not necessarily represent the official position of the U. S. Government, NIAAA, the McManus Trust or NDRI. The authors express their deep appreciation to the project interviewers-Mr. Gary Huggins (U. S. Marines, retired), Mr. Atiba Marson-Quinones (U. S. Navy Reserves), and Ms. Morgan Cooley (U. S. Army, retired)-to the data manager, Dr. Peter Vazan, and all of the veterans who participated in the study.	Abdul-Quader AS, 2006, AIDS BEHAV, V9, P403; Barrett F. J., 1996, GENDER WORK ORG, V3, P129, DOI DOI 10.1111/J.1468-0432.1996.TB00054.X; Bennett Alex S., 2012, ADDICTION SYNDROME H, P195; Bergen-Cico DK, 2011, WAR DRUGS ROLE MILIT; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bohnert ASB, 2010, DRUG ALCOHOL DEPEN, V110, P183, DOI 10.1016/j.drugalcdep.2010.03.010; Bray R.M., 2012, PAIN SYNDROMES RECRU, P3; Bray RM, 2006, 2005 DEP DEFENSE SUR; Bray RM, 2007, ADDICTION, V102, P1092, DOI 10.1111/j.1360-0443.2007.01841.x; Bray RM, 2010, MIL MED, V175, P390, DOI 10.7205/MILMED-D-09-00132; CDCP, 2011, PRESCR PAINK OV US V; Courtwright D., 2001, DARK PARADISE HIST O; Ender M.G., 2009, AM SOLDIERS IRAQ MCS; Finley Erin, 2011, FIELDS COMBAT UNDERS; Goebel JR, 2011, J PAIN SYMPTOM MANAG, V41, P848, DOI 10.1016/j.jpainsymman.2010.07.009; Golub A, 2004, J DRUG ISSUES, V34, P361, DOI 10.1177/002204260403400206; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Harocopos A, 2009, INT J DRUG POLICY, V20, P317, DOI 10.1016/j.drugpo.2008.06.003; Heckathorn D., 2012, RESPONDENT DRIVEN SA; Heckathorn D.D., 2003, CHANGING BEAT STUDY, VVol. 3, P48; Heckathorn DD, 2002, SOC PROBL, V49, P11, DOI 10.1525/sp.2002.49.1.11; Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI 10.1525/sp.1997.44.2.03x0221m; Heckathorn DD, 2007, SOCIOL METHODOL, V37, P151, DOI 10.1111/j.1467-9531.2007.00188.x; Heltemes KJ, 2011, MIL MED, V176, P147, DOI 10.7205/MILMED-D-10-00191; Holyfield Lori, 2011, VETERANS JOURNEYS HO; Iguchi MY, 2009, J URBAN HEALTH, V86, pS5, DOI 10.1007/s11524-009-9365-4; Institute of Medicine, 2012, SUBST US DIS US ARM; International Narcotics Control Board, 2009, REP INT NARC CONTR B; Johnson CV, 2009, AM J PUBLIC HEALTH, V99, pS187, DOI 10.2105/AJPH.2007.127464; Karney B.R., 2008, INVISIBLE WOUNDS PRE; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lansky A, 2007, PUBLIC HEALTH REP, V122, P48, DOI 10.1177/00333549071220S108; Larance B, 2011, DRUG ALCOHOL REV, V30, P236, DOI 10.1111/j.1465-3362.2010.00283.x; Madaus JW, 2009, J POSTSECOND EDUC DI, V22, P10; Manchikanti L, 2008, PAIN PHYSICIAN, V11, pS63; Manchikanti Laxmaiah, 2007, Pain Physician, V10, P399; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; ONDCP, 2011, EP RESP AM PRESCR DR; Poehlman JA, 2011, MIL MED, V176, P397, DOI 10.7205/MILMED-D-10-00240; Rusch ML, 2009, J URBAN HEALTH, V86, P760, DOI 10.1007/s11524-009-9377-0; SAMHSA, 2010, 2009 NAT SURV DRUG U; Shahmanesh M, 2009, AM J PUBLIC HEALTH, V99, P1239, DOI 10.2105/AJPH.2008.149930; Sherman SG., 2002, INT J DRUG POLICY, V13, P113, DOI [10.1016/S0955-3959(02)00010-5, DOI 10.1016/S0955-3959(02)00010-5]; Skidmore WC, 2011, SOC WORK HEALTH CARE, V50, P85, DOI 10.1080/00981389.2010.522913; U.S. Army, 2010, ARM HLTH PROM RISK R; U.S. Army, 2012, ARM 2020 GEN HLTH DI; US Department of Defense, 2008, ENH POSTD HLTH ASS P; Wang JC, 2007, ADDICT BEHAV, V32, P924, DOI 10.1016/j.addbeh.2006.06.031; Warner M, 2011, NCHS DATA BRIEF; Wattana W, 2007, DRUG ALCOHOL DEPEN, V90, P228, DOI 10.1016/j.drugalcdep.2007.03.013; Wejnert C, 2008, SOCIOL METHOD RES, V37, P105, DOI 10.1177/0049124108318333; Wu Phipson C, 2010, J Opioid Manag, V6, P133; Zinberg NE., 1986, DRUG SET SETTING BAS	53	31	31	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1082-6084	1532-2491		SUBST USE MISUSE	Subst. Use Misuse		2013	48	10					811	820		10.3109/10826084.2013.796988			10	Substance Abuse; Psychiatry; Psychology	Substance Abuse; Psychiatry; Psychology	186ES	WOS:000322025400003	23869455	Green Accepted			2021-06-18	
J	Juengst, S; Skidmore, E; Arenth, PM; Niyonkuru, C; Raina, KD				Juengst, Shannon; Skidmore, Elizabeth; Arenth, Patricia M.; Niyonkuru, Christian; Raina, Ketki D.			Unique Contribution of Fatigue to Disability in Community-Dwelling Adults With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Fatigue; Rehabilitation	MINOR HEAD-INJURY; QUALITY-OF-LIFE; REHABILITATION; IMPACT; PREDICTORS; DEPRESSION; PATTERNS; SEQUELAE; DEFICITS; OUTCOMES	Objective: To examine the unique contribution of fatigue to self-reported disability in community-dwelling adults with traumatic brain injury (TBI). Design: A cross-sectional cohort design. Setting: Community dwellings. Participants: Adults (N=50) with a history of mild to severe TBI were assessed. Intervention: Not applicable. Main Outcome Measures: This study assessed the contribution of fatigue (Modified Fatigue Impact Scale) to disability (Mayo-Portland Adaptability Inventory), controlling for executive functions (Frontal Systems Behavior Scale), depression status (major depression in partial remission/current major depression/depressive symptoms or no history of depression), and initial injury severity (uncomplicated mild, complicated mild, moderate, or severe). Results: Fatigue was found to contribute uniquely to the variance in self-reported disability (beta=.47, P<.001) after controlling for injury severity, executive functions, and depression status. The overall model was significant (F-4,F-45=17.32, P<001) and explained 61% of the variance in self-reported disability, with fatigue alone accounting for 12% of the variance in self-reported disability (F-1,F-45=13.97, P<.001). Conclusions: Fatigue contributes uniquely to disability status among community-dwelling adults with chronic TBI, independent of injury severity, executive functions, and depression. Addressing fatigue through targeted interventions may help to improve self-perceived disability in this population. Archives of Physical Medicine and Rehabilitation 2013;94:74-9 (C) 2013 by the American Congress of Rehabilitation Medicine	[Juengst, Shannon; Skidmore, Elizabeth; Raina, Ketki D.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Occupat Therapy, Pittsburgh, PA 15260 USA; [Skidmore, Elizabeth; Arenth, Patricia M.; Niyonkuru, Christian] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA	Juengst, S (corresponding author), Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Occupat Therapy, 5012 Forbes Tower, Pittsburgh, PA 15260 USA.	sbj7@pitt.edu	Juengst, Shannon B/AAC-5891-2019	Juengst, Shannon/0000-0003-4709-545X	School of Health and Rehabilitation Science Research Development Fund, School and Health of Rehabilitation Science, University of Pittsburgh; National Institutes of Health (NIH) National Center for Medical Rehabilitation Research (NCMRR)/National Institute of Neurological Disorders and Stroke (NINDS) [KI2 HD 055931]; U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W8IXWH-10-1-0920]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD055931] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER	Supported in part by the School of Health and Rehabilitation Science Research Development Fund, School and Health of Rehabilitation Science, University of Pittsburgh; the National Institutes of Health (NIH) National Center for Medical Rehabilitation Research (NCMRR)/National Institute of Neurological Disorders and Stroke (NINDS) (grant no. KI2 HD 055931); and the U.S. Army Medical Research and Material Command (award no. W8IXWH-10-1-0920).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P25, DOI 10.1097/01.HTR.0000308718.88214.bb; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; Deb S, 1999, AM J PSYCHIAT, V156, P374; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fisk J., 1994, CLIN INFECT DIS, V8, pS79; Flachenecker P, 2002, MULT SCLER J, V8, P523, DOI 10.1191/1352458502ms839oa; Fleming JM, 1996, BRAIN INJURY, V10, P1; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hicks E, 2007, COCHRANE DB SYST REV; Hillier SL, 1997, BRAIN INJURY, V11, P661; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF., 2005, The Mayo-Portland Adaptability Inventory; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Tellez N, 2005, MULT SCLER J, V11, P198, DOI 10.1191/1352458505ms1148oa; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	40	31	31	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2013	94	1					74	79		10.1016/j.apmr.2012.07.025			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	067PV	WOS:000313308500011	22885286	Green Accepted			2021-06-18	
J	Kammersgaard, LP; Linnemann, M; Tibaek, M				Kammersgaard, Lars Peter; Linnemann, Mia; Tibaek, Maiken			Hydrocephalus following severe traumatic brain injury in adults. Incidence, timing, and clinical predictors during rehabilitation	NEUROREHABILITATION			English	Article						Brain injury; traumatic; hydrocephalus; rehabilitation; prediction	POSTTRAUMATIC HYDROCEPHALUS; PRACTICAL SCALE; RISK-FACTORS; HEAD-INJURY	OBJECTIVE: To investigate timing and clinical predictors that might predict hydrocephalus emerging during rehabilitation until 1 year following severe traumatic brain injury (TBI). BACKGROUND: Posttraumatic hydrocephalus (PTH) may lead to clinical deterioration and poor outcome if untreated. However, PTH can be successfully treated if detected. Nevertheless, PTH is easily overlooked during rehabilitation, particularly in severe cases. METHOD: We prospectively followed all patients (n = 444) in Eastern Denmark (population 2.5 mill) sustaining severe TBI, who required lengthy rehabilitation between 2000 and 2010. All patients with PTH were tracked retrospectively. Demographics, surgery, injury severity, consciousness level, and disability were compared for patients with versus without PTH. Independent predictors of PTH during rehabilitation were identified through multiple logistic regression models. RESULTS: PTH occurred in 14.2% and 3/4 emerged during rehabilitation. Patients with PTH were older, had more severe brain injuries, were more frequently in vegetative state, and needed longer rehabilitation stays. After adjusted analyses, however, only older age and low level of consciousness were independently associated with PTH. CONCLUSION: Most cases of PTH emerge during rehabilitation. Therefore, attention towards this complication should be present also beyond the acute stage after TBI, particularly among older patients and patients with severe disordered consciousness.	[Kammersgaard, Lars Peter; Linnemann, Mia; Tibaek, Maiken] Copenhagen RUBRIC, Res Unit Brain Injury Rehabil, Copenhagen, Denmark; [Kammersgaard, Lars Peter; Linnemann, Mia; Tibaek, Maiken] Univ Copenhagen, Dept Neurorehabil, TBI Unit, Copenhagen, Denmark; [Kammersgaard, Lars Peter; Linnemann, Mia; Tibaek, Maiken] Glostrup Cty Hosp, Glostrup, Denmark	Kammersgaard, LP (corresponding author), Copenhagen Univ Hosp, TBI Unit, Dept Neurorehabil, Res Unit Brain Injury Rehabil,Copenhagen RUBRIC, Kettegard Alle 30, DK-2650 Hvidovre, Denmark.	kammersgaard@dadlnet.dk					ADAMS RD, 1965, NEW ENGL J MED, V273, P117, DOI 10.1056/NEJM196507152730301; [Anonymous], 1999, JAMA, V282, P974; Bauer DF, 2011, NEUROSURGERY, V68, P85, DOI 10.1227/NEU.0b013e3181fd85f4; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Denes Z, 2011, INT J REHABIL RES, V34, P222, DOI 10.1097/MRR.0b013e328346e87d; Giacino JT, 1997, J HEAD TRAUMA REHABI, V12; Groswasser Z, 1988, Brain Inj, V2, P267, DOI 10.3109/02699058809150897; Guyot LL, 2000, NEUROL RES, V22, P25; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Licata C, 2001, J Neurosurg Sci, V45, P141; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Phuenpathom Nakornchai, 1999, Journal of the Medical Association of Thailand, V82, P46; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Tian HL, 2008, SURG NEUROL, V69, P241, DOI 10.1016/j.surneu.2007.02.032	22	31	35	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	33	3					473	480		10.3233/NRE-130980			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	252DY	WOS:000326986400014	23949078				2021-06-18	
J	Kleindienst, A; Dunbar, JG; Glisson, R; Marmarou, A				Kleindienst, Andrea; Dunbar, Jana G.; Glisson, Renee; Marmarou, Anthony			The role of vasopressin V-1A receptors in cytotoxic brain edema formation following brain injury	ACTA NEUROCHIRURGICA			English	Article						AQP4 water channel; Vasopressin V-1A receptors; Brain edema; Experimental; Traumatic brain injury; Ischemic brain injury	CEREBRAL-ARTERY OCCLUSION; CORTICAL IMPACT INJURY; PHORBOL-MYRISTATE ACETATE; AQUAPORIN-4 MESSENGER-RNA; PROTEIN-KINASE-C; ANTAGONIST SR49059; AQP4 EXPRESSION; WATER TRANSPORT; V-2 RECEPTORS; GLIAL-CELLS	The hormone and neuropeptide arginine-vasopressin is designated to the maintenance of osmotic homoeostasis and blood pressure regulation. While experimental data show vasopressin V-1A receptors to regulate aquaporin (AQP)4 water channel dependent brain water movement, the specific role in vasogenic and cytotoxic edema formation remains unclear. The present study was designed to quantify the V-1A receptor mediated regional brain edema formation in two clinically relevant experimental models, brain injury combined with secondary insult and focal ischemia. Male Sprague-Dawley rats were randomly assigned to a continuous infusion of vehicle (1 % DMSO) or the selective non-peptide V-1A antagonist SR49059 (83nM = 1 mg/kg) starting before controlled cortical impact (CCI) injury plus hypoxia and hypotension (HH, 30 min), or middle cerebral artery (MCA) occlusion (2 h + 2 h reperfusion). A global analysis of brain water content by the wet/dry weight method allowed optimizing the SR49059 dosage, and demonstrated the down-regulation of brain AQP4 expression by immunoblotting. Microgravimetrical quantification in 64 one mm(3) samples per animal (n = 6 per group) from bregma +2.7 to -6.3 mm analysis demonstrated brain edema to be reduced at 4 h by SR49059 treatment in the injured and contralateral cortex following CCI + HH (p = 0.007, p < 0.001) and in the infarct area following MCA occlusion (p = 0.013, p = 0.002, p = 0.004). Our findings demonstrate that an early cytotoxic brain edema component following brain injury plus secondary insult or focal ischemia results from a vasopressin V-1A receptor mediated response, and occurs most likely through AQP4 up-regulation. The V-1A antagonist SR49059 offers a new avenue in brain edema treatment and prompts further study into the role of vasopressin following brain injury.	[Kleindienst, Andrea] Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany; [Kleindienst, Andrea; Dunbar, Jana G.; Glisson, Renee; Marmarou, Anthony] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA	Kleindienst, A (corresponding author), Univ Erlangen Nurnberg, Dept Neurosurg, Schwabachanlage 6, D-91054 Erlangen, Germany.	andrea.kleindienst@uk-erlangen.de; glissonre@gmail.com	Kleindienst, Andrea/F-1674-2014	Kleindienst, Andrea/0000-0003-4758-0324	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 12587, NS 19235]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235, R56NS019235, P01NS012587, P50NS012587] Funding Source: NIH RePORTER	This research was supported by grant NS 12587 and grant NS 19235 from the National Institutes of Health. The experimental drug SR49059 was provided by Sanofi-Aventis France, and we thank specifically Dr. Claudine Serradeil Le Gal, Sanofi-Aventis Recherche Exploratoire, and Toulouse, France for providing information about the drug, dosage and safety issues.	Amedee T, 1997, GLIA, V21, P46, DOI 10.1002/(SICI)1098-1136(199709)21:1<46::AID-GLIA5>3.0.CO;2-#; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Ancellin N, 1997, FEBS LETT, V413, P323, DOI 10.1016/S0014-5793(97)00914-9; Badaut J, 2000, J NEUROENDOCRINOL, V12, P960, DOI 10.1046/j.1365-2826.2000.00539.x; Badaut J, 2000, NEUROSCI LETT, V292, P75, DOI 10.1016/S0304-3940(00)01364-1; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; de Vries GJ, 1998, PROG BRAIN RES, V119, P3; Dijkhuizen RM, 1999, J CEREBR BLOOD F MET, V19, P341, DOI 10.1097/00004647-199903000-00012; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fazzina G, 2009, J NEUROTRAUMA; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103; GROEGER U, 1989, ACTA NEUROCHIR, V101, P134, DOI 10.1007/BF01410529; Hawtin SR, 2006, J BIOL CHEM, V281, P14604, DOI 10.1074/jbc.M511610200; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kempski O, 2001, SEMIN NEPHROL, V21, P303, DOI 10.1053/snep.2001.21665; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P303; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P393; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P221, DOI 10.1007/978-3-211-98811-4_41; LANDGRAF R, 1992, PROG BRAIN RES, V91, P29; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; Liu X, 2009, NEUROCRIT CARE; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Lu H, 2003, CHINESE MED J-PEKING, V116, P1063; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1990, ACT NEUR S, V51, P123; Meinild AK, 1998, J BIOL CHEM, V273, P32446, DOI 10.1074/jbc.273.49.32446; Meng SZ, 2004, EUR J NEUROSCI, V19, P2261, DOI 10.1111/j.0953-816X.2004.03315.x; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nakahama K, 1999, GLIA, V25, P240, DOI 10.1002/(SICI)1098-1136(19990201)25:3<240::AID-GLIA4>3.3.CO;2-3; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965; Newman EA, 1995, NEUROGLIA, P717; Nielsen S, 1997, J NEUROSCI, V17, P171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Okuno K, 2008, ACTA NEUROCHIR SUPPL, V102, P431, DOI 10.1007/978-3-211-85578-2_84; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788; Papadopoulos MC, 2008, PROG BRAIN RES, V170, P589, DOI 10.1016/S0079-6123(08)00446-9; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; PEREZPINON MA, 1995, J NEUROPHYSIOL, V74, P565; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Schrier RW, 2007, CURR OPIN INVEST DR, V8, P304; Schrier RW, 2004, NEUROSCIENCE, V129, P897, DOI 10.1016/j.neuroscience.2004.06.043; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Somjen GG, 2002, NEUROSCIENTIST, V8, P254, DOI 10.1177/1073858402008003011; Stroop R, 1998, ACT NEUR S, V71, P303; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Thibonnier M, 1999, HYPERTENSION, V34, P1293, DOI 10.1161/01.HYP.34.6.1293; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Tribollet E, 1999, NEUROENDOCRINOLOGY, V69, P113, DOI 10.1159/000054409; Unterberg AW, 1997, ACT NEUR S, V70, P106; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; Venero JL, 1999, NEUROSCIENCE, V94, P239, DOI 10.1016/S0306-4522(99)00182-7; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; YANG GY, 1994, STROKE, V25, P1658, DOI 10.1161/01.STR.25.8.1658	70	31	34	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2013	155	1					151	164		10.1007/s00701-012-1558-z			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	063QD	WOS:000313013900023	23188468				2021-06-18	
J	Leong, BK; Mazlan, M; Abd Rahim, RB; Ganesan, D				Leong, Be Kim; Mazlan, Mazlina; Abd Rahim, Rameezan Begam; Ganesan, Dharmendra			Concomitant injuries and its influence on functional outcome after traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						Abbreviated Injury Scale; concomitant injury; traumatic brain injury	SEVERE HEAD-INJURY; SECONDARY INSULTS; 1ST YEAR; RECOVERY; MANAGEMENT; FRACTURES; IMPACT; COHORT; WORSE	Purpose: This study aims to describe the presence and severity of extracranial concomitant injuries in traumatic brain injury (TBI) patients and to ascertain their effect on long-term functional outcome. Method: A retrospective cohort study was performed in a single-center recruiting patients with first episode of TBI. The types and severity of extracranial concomitant injuries were documented for patients who fulfilled the inclusion criteria. Injuries with Abbreviated Injury Scale (AIS) grade 3-6 were considered to be high grade. A cross-sectional functional assessment was conducted at 18 months post-injury using Glasgow Outcome Scale. Results: A total of 100 patients were included in the analysis. Extracranial concomitant injuries were seen in 78% of the patients. Three commonest injuries were facial (44%), lower extremity (20%) and upper extremity (12%) injuries. Among the AIS grade >= 3, injury involving the chest was most common (41%). Presence of extracranial concomitant injuries AIS grade >= 3 was significantly associated with disability in TBI patients at 18 months (OR 12.74, 95% CI 2.39-67.95, p = 0.003). Conclusion: Presence of extracranial concomitant injuries was high. In TBI survivors, extracranial concomitant injuries AIS grade >= 3 influenced the long-term functional outcome at 18 months, causing moderate and severe disabilities.	[Leong, Be Kim] Hosp Sultan Ismail, Dept Rehabil Med, Johor Baharu, Malaysia; [Mazlan, Mazlina] Univ Malaya, Fac Med, Dept Rehabil Med, Kuala Lumpur 50603, Malaysia; [Abd Rahim, Rameezan Begam] Prince Court Med Ctr, Kuala Lumpur, Malaysia; [Ganesan, Dharmendra] Univ Malaya, Div Neurosurg, Kuala Lumpur 50603, Malaysia	Mazlan, M (corresponding author), Univ Malaya, Fac Med, Dept Rehabil Med, Kuala Lumpur 50603, Malaysia.	drmazlina@gmail.com	MAZLAN, MAZLINA/Y-9327-2019; GANESAN, DHARMENDRA/B-8437-2010; Mazlan, Mazlina/A-1015-2011	Mazlan, Mazlina/0000-0002-4012-1873	University MalayaUniversiti Malaya [P0027/2009A]	This study was supported in part by postgraduate research fund from University Malaya (Account number: P0027/2009A). The sponsor of the study had no role in the study design, data collection, data analysis, data interpretation or writing the report.	*ASS ADV AUT MED, 1998, ABBR INJ SCAL 1990 R; Baltas I, 1998, J Neurosurg Sci, V42, P85; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Connelly J, 2006, DISABIL REHABIL, V28, P629, DOI 10.1080/09638280500276513; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Grotz MRW, 2004, INJURY, V35, P1077, DOI 10.1016/j.injury.2004.05.025; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Holtslag H, 2006, EUR J TRAUMA, V32, P365, DOI [DOI 10.1007/S00068-006-5112-7, 10.1007/s00068-006-5112-7]; Jagoda AS, 2010, PSYCHIAT CLIN N AM, V33, P797, DOI 10.1016/j.psc.2010.09.004; JENNETT B, 1975, LANCET, V1, P480; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; MacKenzie EJ, 2005, J BONE JOINT SURG AM, V87A, P1801, DOI 10.2106/JBJS.E.00032; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Mendelow AD, 2006, J NEUROTRAUM, V3, P95; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; Okoje V N, 2006, Afr J Med Med Sci, V35, P165; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x	31	31	31	0	6	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2013	35	18					1546	1551		10.3109/09638288.2012.748832			6	Rehabilitation	Rehabilitation	194UJ	WOS:000322657900007	23294408				2021-06-18	
J	Scheff, SW; Ansari, MA; Roberts, KN				Scheff, Stephen W.; Ansari, Mubeen A.; Roberts, Kelly N.			Neuroprotective effect of Pycnogenol (R) following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Bioflavonoids; Head injury; Natural compounds; Neuroinflammation; Oxidative stress; Synaptic proteins; TBI; Traumatic brain injury	AMYLOID-BETA-PEPTIDE; OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; SIGNALING PATHWAY; CAFFEIC ACID; INFLAMMATORY RESPONSE; SUPEROXIDE-DISMUTASE; AKT PHOSPHORYLATION; CORTICAL CONTUSION; SYNAPTIC PROTEINS	Traumatic brain injury (TBI) involves primary and secondary injury cascades that underlie delayed neuronal dysfunction and death. Oxidative stress is one of the most celebrated secondary injury mechanisms. A close relationship exists between levels of oxidative stress and the pathogenesis of TBI. However, other cascades, such as an increase in proinflammatoty cytokines, also play important roles in the overall response to the trauma. Pharmacologic intervention, in order to be successful, requires a multifaceted approach. Naturally occurring flavonoids are unique in possessing not only tremendous free radical scavenging properties but also the ability to modulate cellular homeostasis leading to a reduction in inflammation and cell toxicity. This study evaluated the therapeutic role of Pycnogenol (PYC), a patented combinational bioflavonoid. Young adult Sprague-Dawley rats were subjected to a unilateral moderate cortical contusion and treated post injury with PYC or vehicle. At either 48 or 96 h post trauma, the animals were killed and the cortex and hippocampus analyzed for changes in enzymatic and non-enzymatic oxidative stress markers. In addition, possible changes in both pre- and post-synaptic proteins (synapsin-1, PSD-95, drebrin, synapse associated protein-97) were analyzed. Finally, a separate cohort of animals was used to evaluate two proinflammatory cytokines (IL-6, TNF-alpha). Following the trauma there was a significant increase in oxidative stress in both the injured cortex and the ipsilateral hippocampus. Animals treated with PYC significantly ameliorated levels of protein carbonyls, lipid peroxidation, and protein nitration. The PYC treatment also significantly reduced the loss of key pre- and post-synaptic proteins with some levels in the hippocampus of PYC treated animals not significantly different from sham operated controls. Although levels of the proinflammatory cytokines were significantly elevated in both injury groups, the cohort treated with PYC showed a significant reduction compared to vehicle treated controls. These results are the first to show a neuroprotective effect of PYC following TBI. They also suggest that the diverse effects of bioflavonoids may provide a unique avenue for possible therapeutic intervention following head trauma. (c) 2012 Elsevier Inc. All rights reserved.	[Scheff, Stephen W.; Ansari, Mubeen A.; Roberts, Kelly N.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown, Lexington, KY 40536 USA.	sscheff@email.uky.edu; mansa3@email.uky.edu; 1knrobe2@email.uky.edu			National Institute of Heath Grant [R21NS66117]; Kentucky Spinal Cord and Head Injury Trust [8-15A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS066117] Funding Source: NIH RePORTER	This work was supported by the National Institute of Heath Grant R21NS66117 and Kentucky Spinal Cord and Head Injury Trust 8-15A. Pycnogenol (R) was a very generous gift from Horphag Research Inc., Hoboken, NJ.	Abd El Mohsen MM, 2002, FREE RADICAL BIO MED, V33, P1693, DOI 10.1016/S0891-5849(02)01137-1; Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P1510, DOI 10.1016/j.freeradbiomed.2008.08.025; Ansari MA, 2006, FREE RADICAL BIO MED, V41, P1694, DOI 10.1016/j.freeradbiomed.2006.09.002; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Azevedo MF, 2010, PHYTOTHER RES, V24, pS220, DOI 10.1002/ptr.3118; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BROWN JP, 1980, MUTAT RES, V75, P243, DOI 10.1016/0165-1110(80)90029-9; Carloni S, 2010, AUTOPHAGY, V6, P366, DOI 10.4161/auto.6.3.11261; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Cho KJ, 2001, ANN NY ACAD SCI, V928, P141; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dringen R, 2005, J NEUROSCI RES, V79, P157, DOI 10.1002/jnr.20280; DUARTE J, 1993, GEN PHARMACOL-VASC S, V24, P857, DOI 10.1016/0306-3623(93)90159-U; El Mohsen MA, 2006, BRIT J NUTR, V95, P51, DOI 10.1079/BJN20051596; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gamet-Payrastre L, 1999, GEN PHARMACOL-VASC S, V32, P279, DOI 10.1016/S0306-3623(98)00220-1; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hu LY, 2010, NEUROSCIENCE, V169, P1046, DOI 10.1016/j.neuroscience.2010.05.046; Islekel S, 1999, RES EXP MED, V199, P167, DOI 10.1007/s004330050121; Itoh T, 2011, NEUROMOL MED, V13, P300, DOI 10.1007/s12017-011-8162-x; Jatana M, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-12; Johnson JL, 2011, J MED FOOD, V14, P325, DOI 10.1089/jmf.2010.0310; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kobayashi MS, 2000, FREE RADICAL RES, V32, P115, DOI 10.1080/10715760000300121; Kobuchi H, 1999, METHOD ENZYMOL, V301, P504; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lee HF, 2012, RESP PHYSIOL NEUROBI, V182, P1, DOI 10.1016/j.resp.2012.01.016; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu YH, 2003, CHEM RES TOXICOL, V16, P1589, DOI 10.1021/tx034160a; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; Mandel S, 2006, J NEURAL TRANSM-SUPP, P249; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McIntosh TK, 1996, LAB INVEST, V74, P315; Mercer LD, 2005, BIOCHEM PHARMACOL, V69, P339, DOI 10.1016/j.bcp.2004.09.018; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nardini M, 2000, BBA-GEN SUBJECTS, V1474, P219, DOI 10.1016/S0304-4165(00)00009-X; Neary JT, 2005, IUBMB LIFE, V57, P711, DOI 10.1080/15216540500319143; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Ozturk Erdogan, 2005, Prog Neuropsychopharmacol Biol Psychiatry, V29, P922, DOI 10.1016/j.pnpbp.2005.04.028; Packer L, 1999, FREE RADICAL BIO MED, V27, P704, DOI 10.1016/S0891-5849(99)00090-8; Paganga G, 1999, FREE RADICAL RES, V30, P153, DOI 10.1080/10715769900300161; Parajuli P, 2011, J NEURO-ONCOL, V101, P15, DOI 10.1007/s11060-010-0221-x; Peng QL, 2002, MOL BRAIN RES, V104, P55, DOI 10.1016/S0169-328X(02)00263-2; Robert AM, 2001, PATHOL BIOL, V49, P298, DOI 10.1016/S0369-8114(01)00148-1; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schroeter H, 2001, BIOCHEM J, V358, P547, DOI 10.1042/0264-6021:3580547; Schultke E, 2005, J NEUROTRAUM, V22, P1475, DOI 10.1089/neu.2005.22.1475; SEGER R, 1995, FASEB J, V9, P726; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Sharma V, 2007, BRAIN RES BULL, V73, P55, DOI 10.1016/j.brainresbull.2007.01.016; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Spencer JPE, 2008, BRIT J NUTR, V99, pES60, DOI 10.1017/S0007114508965776; Spencer JPE, 2007, GENES NUTR, V2, P257, DOI 10.1007/s12263-007-0056-z; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Vauzour D, 2007, J NEUROCHEM, V103, P1355, DOI 10.1111/j.1471-4159.2007.04841.x; Vauzour D, 2008, GENES NUTR, V3, P115, DOI 10.1007/s12263-008-0091-4; de la Torre AV, 2012, PHARMACOL RES, V65, P66, DOI 10.1016/j.phrs.2011.08.006; Williams RJ, 2004, FREE RADICAL BIO MED, V36, P838, DOI 10.1016/j.freeradbiomed.2004.01.001; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yan JJ, 2001, BRIT J PHARMACOL, V133, P89, DOI 10.1038/sj.bjp.0704047; Youdim KA, 2001, FREE RADICAL BIO MED, V30, P583, DOI 10.1016/S0891-5849(00)00510-4; Zhang L, 2007, LIFE SCI, V80, P530, DOI 10.1016/j.lfs.2006.09.039; Zhou Y, 2006, ACTA PHARMACOL SIN, V27, P1103, DOI 10.1111/j.1745-7254.2006.00406.x	86	31	32	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2013	239						183	191		10.1016/j.expneurol.2012.09.019			9	Neurosciences	Neurosciences & Neurology	073TH	WOS:000313765000022	23059456	Green Accepted			2021-06-18	
J	Peterson, TC; Anderson, GD; Kantor, ED; Hoane, MR				Peterson, Todd C.; Anderson, Gail D.; Kantor, Eric D.; Hoane, Michael R.			A Comparison of the Effects of Nicotinamide and Progesterone on Functional Recovery of Cognitive Behavior following Cortical Contusion Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						CCI; nicotinamide; progesterone; recovery of function; therapy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NEUROPROTECTION; EXPRESSION; EDEMA	The primary goal of this study was to compare clinically relevant doses of progesterone and nicotinamide within the same injury model. Progesterone has been shown to reduce edema and inflammation and improve functional outcomes following brain injury. Nicotinamide has also been shown to be an effective neuroprotective agent in a variety of neurological injury models. In the current study, nicotinamide was administered beginning 4 h post-cortical contusion injury (CCI) with a loading dose (75 mg/kg, i.p.) combined with continuous infusion (12 mg/h/kg, s.c.) for 72 h post-injury. Progesterone was administered beginning 4 h post-CCI at a dose of 10 or 20 mg/kg, i.p. every 12 h for 72 h. This resulted in the following groups: Injured-nicotinamide treated, Injured-progesterone-10 treated, Injured-progesterone-20 treated, Injured-vehicle treated, and Sham. Functional recovery was assessed with two spatial memory tasks in the Morris water maze (MWM) the acquisition of a reference memory task and a reversal learning task. Neuropathological assessments were conducted in the cortex and hippocampus. It was found that both progesterone (10 mg/kg) and nicotinamide improved reference memory acquisition and reversal learning in the MWM compared with vehicle treatment. The lower dose of progesterone and nicotinamide also reduced tissue loss in the injured cortex and ipsilateral hippocampus compared with vehicle. The beneficial effects of progesterone appear to be dose dependent with the lower 10 mg/kg dose producing significant effects that were not observed at the higher dose. Direct comparison between nicotinamide and low dose progesterone appears to suggest that both are equally effective. The general findings of this study suggest that both nicotinamide and progesterone produce significant improvements in recovery of function following CCI.	[Peterson, Todd C.; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Carbondale, IL 62901 USA; [Anderson, Gail D.; Kantor, Eric D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	National Institutes of Health/National Institute of Child, Health, and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)NIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 HD061944-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061944] Funding Source: NIH RePORTER	The authors thank Jacob Ward and Mahala Logue for their assistance on this project. The research was supported by a grant from the National Institutes of Health/National Institute of Child, Health, and Development (R01 HD061944-01).	Anderson G.D., 2012, J NEUROTRAU IN PRESS; Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Belelli D, 2002, NEUROPHARMACOLOGY, V43, P651, DOI 10.1016/S0028-3908(02)00172-7; Centers for Disease Control, 2010, INJ PREV CONTR TRAUM; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Goffus AM, 2010, OXID MED CELL LONGEV, V3, P145, DOI 10.4161/oxim.3.2.11315; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Haar CV, 2011, BEHAV BRAIN RES, V224, P311, DOI 10.1016/j.bbr.2011.06.009; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Kerr AL, 2010, BEHAV GENET, V40, P76, DOI 10.1007/s10519-009-9296-6; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Noblett KL, 2003, BEHAV NEUROSCI, V117, P785, DOI 10.1037/0735-7044.117.4.785; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Swan AA, 2011, J NEUROTRAUM, V28, P431, DOI 10.1089/neu.2010.1519; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Yang J, 2002, NEUROSCI LETT, V333, P91, DOI 10.1016/S0304-3940(02)01005-4	37	31	32	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2012	29	18					2823	2830		10.1089/neu.2012.2471			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	050ZE	WOS:000312092800012	23016598	Green Published			2021-06-18	
J	Plurad, DS; Bricker, S; Neville, A; Bongard, F; Putnam, B				Plurad, David S.; Bricker, Scott; Neville, Angela; Bongard, Frederic; Putnam, Brant			Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors	AMERICAN JOURNAL OF SURGERY			English	Article						Arginine vasopressin; Transplantation; Organ donation; Hormone replacement therapy; Brain death; Organ procurement; Thyroxine; Traumatic brain injury; Trauma	MANAGEMENT; DONATION; IMPACT; DEFICIENCY; CRITERIA	BACKGROUND: Hormone replacement therapy increases the number and quality of grafts recovered from brain-dead organ donors. Arginine vasopressin (AVP) has also been shown to have beneficial effects. The aim of this study was to determine the effect of AVP on recovery rates. METHODS: The Organ Procurement and Transplantation Network database was used. Donors treated with hormone replacement therapy and vasopressor agents who were successfully procured between January 1, 2009, and June 30, 2011, were studied. AVP-positive and AVP-negative donors were compared. The primary study end point was the rate of high-yield procurement (>= 4 organs). RESULTS: A total of 10,431 donors were included. AVP was infused in 7,873 (75.5%) and was associated with an increased rate of high-yield procurement (50.5% vs 35.6%, P < .001). There was less overall graft refusal due to poor function (38.9% vs 45.6%, P < .001). AVP independently predicted high yield procurement. CONCLUSIONS: The use of AVP with hormone replacement therapy is independently associated with an increased rate of organ recovery. This strategy should be universally adopted in the management of donors progressing to neurologic death. (C) 2012 Elsevier Inc. All rights reserved.	[Plurad, David S.; Bricker, Scott; Neville, Angela; Bongard, Frederic; Putnam, Brant] Harbor UCLA Med Ctr, Div Trauma Acute Care Surg & Surg Crit Care, Torrance, CA 90509 USA	Plurad, DS (corresponding author), Harbor UCLA Med Ctr, Div Trauma Acute Care Surg & Surg Crit Care, Torrance, CA 90509 USA.	dplurad@dhs.lacounty.gov			Health Resources and Services AdministrationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [234-2005-370011C]	This study was based on Organ Procurement and Transplantation Network data of June 30, 2011. This work was supported in part by Health Resources and Services Administration contract 234-2005-370011C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.	Abdelnour T, 2009, J HEART LUNG TRANSPL, V28, P480, DOI 10.1016/j.healun.2009.01.018; Bernat JL, 2006, AM J TRANSPLANT, V6, P281, DOI 10.1111/j.1600-6143.2005.01194.x; Blasco V, 2008, SHOCK, V29, P667, DOI 10.1097/SHK.0b013e31815d0ae7; Cerutti E, 2006, LIVER TRANSPLANT, V12, P1253, DOI 10.1002/lt.20811; Chen JM, 1999, CIRCULATION, V100, P244; Cohn SM, 2011, WORLD J SURG, V35, P430, DOI 10.1007/s00268-010-0875-8; DuBose Joseph, 2008, J Intensive Care Med, V23, P367, DOI 10.1177/0885066608324208; Forni A, 2011, TRANSPL P, V43, P953, DOI 10.1016/j.transproceed.2011.01.117; Holmes CL, 2001, CHEST, V120, P989, DOI 10.1378/chest.120.3.989; HOWLETT TA, 1989, TRANSPLANTATION, V47, P828, DOI 10.1097/00007890-198905000-00016; Kutsogiannis DJ, 2006, CAN J ANAESTH, V53, P820, DOI 10.1007/BF03022800; Landry DW, 1997, CIRCULATION, V95, P1122; Mitchell SLM, 2007, BRIT J ANAESTH, V99, P154, DOI 10.1093/bja/aem204; NOVITZKY D, 1987, TRANSPLANTATION, V43, P852, DOI 10.1097/00007890-198743060-00016; Organ Procurement and Transplantation Network, ORG DON UT US 1999 2; PENNEFATHER SH, 1995, TRANSPLANTATION, V59, P58, DOI 10.1097/00007890-199501150-00011; POWNER DJ, 1990, CRIT CARE MED, V18, P702; RANDELL TT, 1993, TRANSPLANT P, V25, P1552; Rosendale JD, 2003, TRANSPLANTATION, V75, P1336, DOI 10.1097/01.TP.0000062839.58826.6D; Rosendale JD, 2003, TRANSPLANTATION, V75, P482, DOI 10.1097/01.TP.0000045683.85282.93; ROSS SE, 1990, J TRAUMA, V30, P820, DOI 10.1097/00005373-199007000-00009; Russell JA, 2008, NEW ENGL J MED, V358, P877, DOI 10.1056/NEJMoa067373; Saidi RF, 2007, AM J TRANSPLANT, V7, P2769, DOI 10.1111/j.1600-6143.2007.01993.x; Salim A, 2005, J TRAUMA, V58, P991, DOI 10.1097/01.TA.0000168708.78049.32; Salim A, 2007, J TRAUMA, V62, P1411, DOI 10.1097/TA.0b013e3180479876; TANIGUCHI S, 1992, EUR J CARDIO-THORAC, V6, P96, DOI 10.1016/1010-7940(92)90082-9; Van Bakel AB, 2004, TRANSPLANT P, V36, P2573, DOI 10.1016/j.transproceed.2004.10.016; Wood KE, 2004, NEW ENGL J MED, V351, P2730, DOI 10.1056/NEJMra013103	28	31	33	0	6	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	DEC	2012	204	6					856	860		10.1016/j.amjsurg.2012.05.011			5	Surgery	Surgery	060UG	WOS:000312803000008	23116641				2021-06-18	
J	Raible, DJ; Frey, LC; Del Angel, YC; Russek, SJ; Brooks-Kayal, AR				Raible, Daniel J.; Frey, Lauren C.; Del Angel, Yasmin Cruz; Russek, Shelley J.; Brooks-Kayal, Amy R.			GABA(A) Receptor Regulation after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						Egr3 pathway; GABA(A) receptor; JaK/STAT pathway; traumatic brain injury	FLUID PERCUSSION INJURY; POSTTRAUMATIC EPILEPSY; SUBUNIT EXPRESSION; SIGNAL TRANSDUCER; TONIC INHIBITION; DELTA-SUBUNITS; UNITED-STATES; UP-REGULATION; ANIMAL-MODEL; MOUSE MODEL	The gamma-aminobutyric acid (GABA) type A receptor (GABA(A)R) is responsible for most fast synaptic inhibition in the adult brain. The GABA(A)R protein is composed of multiple subunits that determine the distribution, properties, and dynamics of the receptor. Several studies have shown that the Janus kinase/signal transducer and activator of transcription (JaK/STAT) and early growth response 3 (Egr3) signaling pathways can alter GABA(A)R subunit expression after status epilepticus (SE). In this study we investigated changes in these pathways after experimental TBI in the rat using a lateral fluid percussion injury (FPI) model. Our results demonstrated changes in the expression of several GABA(A)R subunit levels after injury, including GABA(A)R alpha 1 and alpha 4 subunits. This change appears to be transcriptional, and there is an associated increase in the phosphorylation of STAT3, and an increase in the expression of Egr3 and inducible cAMP element repressor (ICER) after FPI. These findings suggest that the activation of the JaK/STAT and Egr3 pathways after TBI may regulate injury-related changes in GABA(A)R subunit expression.	[Raible, Daniel J.; Brooks-Kayal, Amy R.] Univ Colorado, Neurosci Program, Aurora, CO USA; [Frey, Lauren C.; Brooks-Kayal, Amy R.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA; [Del Angel, Yasmin Cruz; Brooks-Kayal, Amy R.] Univ Colorado, Sch Med, Div Neurol, Dept Pediat, Aurora, CO USA; [Russek, Shelley J.] Boston Univ, Sch Med, Dept Pharmacol, Lab Translat Epilepsy, Boston, MA 02118 USA; [Brooks-Kayal, Amy R.] Childrens Hosp Colorado, Aurora, CO USA	Brooks-Kayal, AR (corresponding author), Univ Colorado AMC, Dept Pediat, Sch Pharm, 12850 E Montview Blvd C238,RM 3440D, Aurora, CO 80045 USA.	Amy.Brooks-Kayal@childrenscolorado.org		Russek, Shelley/0000-0001-7547-3089	Department of Defense (DoD)United States Department of Defense [W81XWH-11-1-0501]; NIH/NCRR Colorado CTSIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [TL1 RR025778]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR001081] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1RR025778] Funding Source: NIH RePORTER	The funding for this research was provided by Department of Defense (DoD) award number W81XWH-11-1-0501, and by NIH/NCRR Colorado CTSI Grant no. TL1 RR025778. The contents are the authors' sole responsibility and do not necessarily represent official DoD or NIH views.	Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Choi JS, 2003, MOL BRAIN RES, V119, P10, DOI 10.1016/j.molbrainres.2003.08.010; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Gangisetty O, 2010, NEUROSCIENCE, V170, P865, DOI 10.1016/j.neuroscience.2010.07.037; Gibson CJ, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-38; Goodkin HP, 2008, J NEUROSCI, V28, P2527, DOI 10.1523/JNEUROSCI.3426-07.2008; Gupta A, 2012, J NEUROSCI, V32, P2523, DOI 10.1523/JNEUROSCI.4141-11.2012; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Jia F, 2005, J NEUROPHYSIOL, V94, P4491, DOI 10.1152/jn.00421.2005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kralic JE, 2006, J COMP NEUROL, V495, P408, DOI 10.1002/cne.20866; Liang J, 2006, J NEUROSCI, V26, P1749, DOI 10.1523/JNEUROSCI.4702-05.2006; Liang J, 2008, ALCOHOL CLIN EXP RES, V32, P19, DOI 10.1111/j.1530-0277.2007.00564.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lund IV, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1162396; Marcikic M, 1998, INJURY, V29, P613, DOI 10.1016/S0020-1383(98)00146-6; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Nusser Z, 1998, J NEUROSCI, V18, P1693; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Planas AM, 1996, EUR J NEUROSCI, V8, P2612, DOI 10.1111/j.1460-9568.1996.tb01556.x; Raol YH, 2006, J NEUROSCI, V26, P11342, DOI 10.1523/JNEUROSCI.3329-06.2006; Roberts DS, 2006, J BIOL CHEM, V281, P29431, DOI 10.1074/jbc.C600167200; Roberts DS, 2005, P NATL ACAD SCI USA, V102, P11894, DOI 10.1073/pnas.0501434102; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sassoe-Pognetto M, 2000, J COMP NEUROL, V420, P481, DOI 10.1002/(SICI)1096-9861(20000515)420:4<481::AID-CNE6>3.0.CO;2-5; Schneider Gasser EM, 2007, EUR J NEUROSCI, V25, P3287, DOI 10.1111/j.1460-9568.2007.05558.x; Semyanov A, 2004, TRENDS NEUROSCI, V27, P262, DOI 10.1016/j.tins.2004.03.005; Somogyi P, 1996, NEUROPHARMACOLOGY, V35, P1425, DOI 10.1016/S0028-3908(96)00086-X; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sun CS, 2007, J NEUROSCI, V27, P12641, DOI 10.1523/JNEUROSCI.4141-07.2007; Sun CS, 2004, BRAIN RES, V1029, P207, DOI 10.1016/j.brainres.2004.09.056; Sur C, 1999, MOL PHARMACOL, V56, P110; Sur C, 2001, J NEUROSCI, V21, P3409, DOI 10.1523/JNEUROSCI.21-10-03409.2001; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toth Z, 1997, J NEUROSCI, V17, P8106; Wei WZ, 2003, J NEUROSCI, V23, P10650; Zhang G, 2004, NEUROSCIENCE, V125, P299, DOI 10.1016/j.neuroscience.2004.01.040; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018	46	31	33	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	16					2548	2554		10.1089/neu.2012.2483			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	035CS	WOS:000310920900003	22827467	Green Published			2021-06-18	
J	Fernandez, E; Bringas, ML; Salazar, S; Rodriguez, D; Garcia, ME; Torres, M				Fernandez, Elizabeth; Luisa Bringas, Maria; Salazar, Sonia; Rodriguez, Daymi; Eugenia Garcia, Maria; Torres, Maydane			Clinical Impact of RehaCom Software for Cognitive Rehabilitation of Patients with Acquired Brain Injury	MEDICC REVIEW			English	Article						Acute brain injuries; traumatic brain injury; brain injury; vascular; rehabilitation; intellectual disability; neuropsychology; Cuba	IMPAIRMENT; EFFICACY	We describe the clinical impact of the RehaCom computerized cognitive training program instituted in the International Neurological Restoration Center for rehabilitation of brain injury patients. Fifty patients admitted from 2008 through 2010 were trained over 60 sessions. Attention and memory functions were assessed with a pre- and post-treatment design, using the Mini-Mental State Examination, Wechsler Memory Scale and Trail Making Test (Parts A and B). Negative effects were assessed, including mental fatigue, headache and eye irritation. The program's clinical usefulness was confirmed, with 100% of patients showing improved performance in trained functions.	[Fernandez, Elizabeth] Int Neurol Restorat Ctr CIREN, Havana, Cuba; [Luisa Bringas, Maria; Salazar, Sonia; Rodriguez, Daymi; Eugenia Garcia, Maria; Torres, Maydane] CIREN, Havana, Cuba	Fernandez, E (corresponding author), Int Neurol Restorat Ctr CIREN, Havana, Cuba.	efernandez@neuro.ciren.cu		Bringas, Maria L/0000-0003-2507-1959			Odriozola FA, 2009, MED INTENSIVA, V33, P171; Ardila A, 2008, NEUROPSICOLOGIA CLIN; Boosman H, 2012, NEUROPSYCHOL REHABIL, V22, P26, DOI 10.1080/09602011.2011.632907; Bringas ML, 2009, REV NEUROPSICOLOGIA, V9, P53; Buller PI, 2008, CUAD NEUROPSICOL, V2, P10; Carvajal-Castrillon J, 2009, REV CHIL NEUROPSICOL, V4, P52; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; de Norena D, 2010, REV NEUROLOGIA, V51, P733, DOI 10.33588/rn.5112.2009653; de Norena D, 2010, REV NEUROLOGIA, V51, P687, DOI 10.33588/rn.5111.2009652; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Fernandez-Calvo B, 2011, PSICOTHEMA, V23, P44; Fernandez-Guinea S, 2001, REV NEUROLOGIA, V33, P373, DOI 10.33588/rn.3304.2000193; Ginarte Y, 2007, GEROINFO, V2, P1; Helmstaedter C, 2008, EPILEPSY BEHAV, V12, P402, DOI 10.1016/j.yebeh.2007.11.010; Junque C, 1999, REV NEUROLOGIA, V28, P423, DOI 10.33588/rn.2804.98420; O'Neil-Pirozzi TM, 2010, J HEAD TRAUMA REHAB, V25, P43, DOI 10.1097/HTR.0b013e3181bf24b1; Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042; Perez Ortiz L, 2011, REV MED ELECT, V33; Rios-Lago M, 2007, REV NEUROLOGIA, V44, P291, DOI 10.33588/rn.4405.2006208; Schuhfried G, 2003, REHACOM VERSION 5 BA; Sentmanat A, 2003, SISTEMA NEURORREHABI; Tarraga L, 2006, J NEUROL NEUROSUR PS, V77, P1116, DOI 10.1136/jnnp.2005.086074; Wang YJ, 2011, REV MED CHILE, V139, P697, DOI /S0034-98872011000600001; Wilson BA, 2009, NEUROPSYCHOLOGICAL REHABILITATION: THEORY, MODELS, THERAPY AND OUTCOME, P1, DOI 10.1017/CBO9780511581083	24	31	32	0	15	MEDICC-MED EDUC COOPERATION CUBA	DECATUR	1902 CLAIRMONT RD, STE 250, DECATUR, GEORGIA 30033-3406 USA	1555-7960			MEDICC REV	MEDICC Rev.	OCT	2012	14	4					32	35		10.1590/S1555-79602012000400007			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	V33PX	WOS:000209031800007	23154316	Bronze			2021-06-18	
J	Nalbach, SV; Ropper, AE; Dunn, IF; Gormley, WB				Nalbach, Stephen V.; Ropper, Alexander E.; Dunn, Ian F.; Gormley, William B.			Craniectomy-Associated Progressive Extra-Axial Collections with Treated Hydrocephalus (CAPECTH): Redefining a common complication of decompressive craniectomy	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Craniectomy; Cranioplasty; Decompressive hemicraniectomy; Extra-axial collection; External hydrocephalus; Hydrocephalus	MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC HYDROCEPHALUS; EXTERNAL HYDROCEPHALUS; MALIGNANT INFARCTION; HEMICRANIECTOMY; SURGERY; LIFE; MULTICENTER; HYGROMA	Extra-axial fluid collections following decompressive craniectomy have been observed in a variety of patient populations. These collections have traditionally been thought to represent extra-axial signs of hydrocephalus, but they often occur even in settings where hydrocephalus has been optimally treated. This study aims to elucidate the phenomenon of extra-axial fluid collections after decompressive craniectomy in patients with treated hydrocephalus, in order to improve identification, classification, prevention and treatment. We retrospectively reviewed all patients at a single institution undergoing decompressive craniectomy for refractory intracranial pressure elevations from June 2007 through December 2009. We identified 39 patients by reviewing clinical reports and imaging. Any patient who died on or prior to the third post-operative day (POD) was excluded. The analysis focused on patients with extra-axial collections and treated hydrocephalus. Twenty-one of 34 (62%) patients developed extra-axial collections and 18 of these developed collections despite ventricular drainage. Subgroup analysis revealed that seven of seven patients (100%) with subarachnoid hemorrhage, and 11 of 14 (79%) with traumatic brain injury developed collections. Extra-axial collections may develop after decompressive craniectomy despite aggressive treatment of communicating hydrocephalus. In these patients, the term "external hydrocephalus" does not appropriately capture the relevant pathophysiology. Instead, we define a new phenomenon, "Craniectomy-associated Progressive Extra-Axial Collections with Treated Hydrocephalus" (CAPECTH), as progressive collections despite aggressive cerebral spinal fluid (CSF) drainage. Our data indicate that early cranioplasty can help prevent the formation and worsening of this condition, presumably by returning normal CSF dynamics. (C) 2012 Elsevier Ltd. All rights reserved.	[Nalbach, Stephen V.; Ropper, Alexander E.; Dunn, Ian F.; Gormley, William B.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA	Nalbach, SV (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, 15 Francis St, Boston, MA 02115 USA.	svnalbach@partners.org					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper P R, 1976, Surg Neurol, V5, P25; Czosnyka M, 2000, J NEUROL NEUROSUR PS, V68, P246; D'Ambrosio AL, 2005, NEUROSURGERY, V56, P12, DOI 10.1227/01.NEU.0000144820.38439.63; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Huh PW, 2006, J NEUROSURG, V105, P65, DOI 10.3171/jns.2006.105.1.65; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Licata C, 2001, J Neurosurg Sci, V45, P141; Mayer SA, 2007, STROKE, V38, P2410, DOI 10.1161/STROKEAHA.107.494203; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; MORANTZ RA, 1973, J NEUROSURG, V39, P622, DOI 10.3171/jns.1973.39.5.0622; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yoshimoto Y, 1998, J NEUROSURG, V88, P485, DOI 10.3171/jns.1998.88.3.0485; Zanini MA, 2008, J TRAUMA, V64, P705, DOI 10.1097/TA.0b013e3180485cfc	31	31	36	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	SEP	2012	19	9					1222	1227		10.1016/j.jocn.2012.01.016			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	005DO	WOS:000308730900004	22727206				2021-06-18	
J	Chow, JW; Yablon, SA; Stokic, DS				Chow, John W.; Yablon, Stuart A.; Stokic, Dobrivoje S.			Coactivation of ankle muscles during stance phase of gait in patients with lower limb hypertonia after acquired brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						Coactivation; Co-contraction; Stroke; Traumatic brain injury	DISTURBED MOTOR CONTROL; CEREBRAL-PALSY; SPASTIC GAIT; STROKE; COCONTRACTION; CHILDREN; WALKING; JOINT; KINEMATICS; MOVEMENTS	Objective: Examine (1) coactivation between tibialis anterior (TA) and medial gastrocnemius (MG) muscles during stance phase of gait in patients with moderate-to-severe resting hypertonia after stroke or traumatic brain injury (TBI) and (2) the relationship between coactivation and stretch velocity-dependent increase in MG activity. Methods: Gait and surface EMG were recorded from patients with stroke or TBI (11 each) and corresponding healthy controls (n = 11) to determine the magnitude and duration of TA-MG coactivation. The frequency and gain of positive (>0) and significant positive (p < 0.05) EMG-lengthening velocity (EMG-LV) slope in MG were related to coactivation parameters. Results: The magnitude of coactivation was increased on the more-affected (MA) side, whereas the duration was prolonged on the less-affected (LA) side of both stroke and TBI patients. The difference reached significance during the initial and late double support. The magnitude of coactivation positively correlated with the gain of significant positive EMG-LV slope in TBI patients. Conclusions: Increased coactivation between TA and MG during initial and late double support is a unique feature of gait in stroke and TBI patients with muscle hypertonia. Significance: Increased coactivation may represent an adaptation to compensate for impaired stability during step transition after stroke and TBI. (C) 2012 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Chow, John W.; Yablon, Stuart A.; Stokic, Dobrivoje S.] Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, Jackson, MS 39216 USA	Chow, JW (corresponding author), Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, 1350 E Woodrow Wilson Dr, Jackson, MS 39216 USA.	jchow@mmrcrehab.org		Stokic, Dobrivoje/0000-0002-1891-5730	Wilson Research Foundation, Jackson, MS, USA	We are grateful to Mark Hemleben and Terry Horn for their assistance with this study. This work was supported in part by the Wilson Research Foundation, Jackson, MS, USA.	Achache V, 2010, CLIN NEUROPHYSIOL, V121, P930, DOI 10.1016/j.clinph.2009.12.037; Arene N, 2009, TOP STROKE REHABIL, V16, P346, DOI 10.1310/tsr1605-346; BALMASEDA MT, 1988, ARCH PHYS MED REHAB, V69, P1009; BERGER W, 1982, ELECTROEN CLIN NEURO, V53, P538, DOI 10.1016/0013-4694(82)90066-9; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Chow JW, 2010, BRAIN INJURY, V24, P1575, DOI 10.3109/02699052.2010.523053; Chow JW, 2009, NEUR M PLANN; Cram J.R., 1998, INTRO SURFACE ELECTR; Crenna P, 1998, NEUROSCI BIOBEHAV R, V22, P571, DOI 10.1016/S0149-7634(97)00046-8; Damiano DL, 2000, ARCH PHYS MED REHAB, V81, P895, DOI 10.1053/apmr.2000.5579; Den Otter AR, 2007, GAIT POSTURE, V25, P342, DOI 10.1016/j.gaitpost.2006.04.007; Falconer K, 1985, Electromyogr Clin Neurophysiol, V25, P135; Gracies JM, 2005, MUSCLE NERVE, V31, P552, DOI 10.1002/mus.20285; Granata KP, 2000, J BONE JOINT SURG AM, V82A, P174, DOI 10.2106/00004623-200002000-00003; HAWKINS D, 1990, J BIOMECH, V23, P487, DOI 10.1016/0021-9290(90)90304-L; Ishikawa M, 2005, J APPL PHYSIOL, V99, P603, DOI 10.1152/japplphysiol.00189.2005; KADABA MP, 1990, J ORTHOP RES, V8, P383, DOI 10.1002/jor.1100080310; KNUTSSON E, 1979, BRAIN, V102, P405, DOI 10.1093/brain/102.2.405; Lamontagne A, 2000, J ELECTROMYOGR KINES, V10, P407, DOI 10.1016/S1050-6411(00)00028-6; Lamontagne A, 2002, GAIT POSTURE, V15, P244, DOI 10.1016/S0966-6362(01)00190-4; Lamontagne A, 2001, ARCH PHYS MED REHAB, V82, P1696, DOI 10.1053/apmr.2001.26810; Lance J. W., 1980, SPASTICITY DISORDERE, P485; Lin PY, 2006, ARCH PHYS MED REHAB, V87, P562, DOI 10.1016/j.apmr.2005.12.042; Manganotti P, 2007, J REHABIL MED, V39, P115, DOI 10.2340/16501977-0036; MARKS M, 1958, ANN NY ACAD SCI, V74, P59, DOI 10.1111/j.1749-6632.1958.tb39532.x; NIELSEN J, 1994, EXP BRAIN RES, V102, P350; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Pierce SR, 2007, CLIN BIOMECH, V22, P1045, DOI 10.1016/j.clinbiomech.2007.08.003; Shiavi R, 1987, J Rehabil Res Dev, V24, P24; Stokic DS, 2009, NEUR M PLANN; Unnithan V B, 1996, Electromyogr Clin Neurophysiol, V36, P487; van Hedel HJA, 2006, GAIT POSTURE, V24, P35, DOI 10.1016/j.gaitpost.2005.06.015; YANG JF, 1984, ARCH PHYS MED REHAB, V65, P517	33	31	34	1	22	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	AUG	2012	123	8					1599	1605		10.1016/j.clinph.2012.01.006			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	970DJ	WOS:000306108000019	22325644				2021-06-18	
J	Boyko, M; Melamed, I; Gruenbaum, BF; Gruenbaum, SE; Ohayon, S; Leibowitz, A; Brotfain, E; Shapira, Y; Zlotnik, A				Boyko, Matthew; Melamed, Israel; Gruenbaum, Benjamin Fredrick; Gruenbaum, Shaun Evan; Ohayon, Sharon; Leibowitz, Akiva; Brotfain, Evgeny; Shapira, Yoram; Zlotnik, Alexander			The Effect of Blood Glutamate Scavengers Oxaloacetate and Pyruvate on Neurological Outcome in a Rat Model of Subarachnoid Hemorrhage	NEUROTHERAPEUTICS			English	Article						Glutamate; Neurological outcome; Scavengers; Subarachnoid hemorrhage; Oxaloacetate; Pyruvate	TRAUMATIC BRAIN-INJURY; EXCITATORY AMINO-ACIDS; BARRIER PERMEABILITY CHANGES; ACUTE ISCHEMIC-STROKE; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; CLINICAL-TRIALS; CEREBRAL VASOSPASM; EXCESS GLUTAMATE; PLASMA GLUTAMATE	Blood glutamate scavengers have been shown to effectively reduce blood glutamate concentrations and improve neurological outcome after traumatic brain injury and stroke in rats. This study investigates the efficacy of blood glutamate scavengers oxaloacetate and pyruvate in the treatment of subarachnoid hemorrhage (SAH) in rats. Isotonic saline, 250 mg/kg oxaloacetate, or 125 mg/kg pyruvate was injected intravenously in 60 rats, 60 minutes after induction of SAH at a rate of 0.1 ml/100 g/min for 30 minutes. There were 20 additional rats that were used as a sham-operated group. Blood samples were collected at baseline and 90 minutes after SAH. Neurological performance was assessed at 24 h after SAH. In half of the rats, glutamate concentrations in the cerebrospinal fluid were measured 24 h after SAH. For the remaining half, the blood brain barrier permeability in the frontal and parieto-occipital lobes was measured 48 h after SAH. Blood glutamate levels were reduced in rats treated with oxaloacetate or pyruvate at 90 minutes after SAH (p < 0.001). Cerebrospinal fluid glutamate was reduced in rats treated with pyruvate (p < 0.05). Neurological performance was significantly improved in rats treated with oxaloacetate (p < 0.05) or pyruvate (p < 0.01). The breakdown of the blood brain barrier was reduced in the frontal lobe in rats treated with pyruvate (p < 0.05) and in the parieto-occipital lobes in rats treated with either pyruvate (p < 0.01) or oxaloacetate (p < 0.01). This study demonstrates the effectiveness of blood glutamate scavengers oxaloacetate and pyruvate as a therapeutic neuroprotective strategy in a rat model of SAH.	[Boyko, Matthew; Gruenbaum, Benjamin Fredrick; Ohayon, Sharon; Leibowitz, Akiva; Brotfain, Evgeny; Shapira, Yoram; Zlotnik, Alexander] Ben Gurion Univ Negev, Dept Anesthesiol & Crit Care, Soroka Med Ctr, Fac Hlth Sci, IL-84005 Beer Sheva, Israel; [Melamed, Israel] Ben Gurion Univ Negev, Dept Neurosurg, Soroka Med Ctr, Fac Hlth Sci, IL-84005 Beer Sheva, Israel; [Gruenbaum, Shaun Evan] Yale Univ, Dept Anesthesiol, Sch Med, New Haven, CT 06520 USA	Zlotnik, A (corresponding author), Ben Gurion Univ Negev, Dept Anesthesiol & Crit Care, Soroka Med Ctr, Fac Hlth Sci, IL-84005 Beer Sheva, Israel.	zlotnika@bgu.ac.il	Leibowitz, Akiva/F-1397-2012	Boyko, Matthew/0000-0003-3116-1643; Leibowitz, Akiva/0000-0003-4244-1915	European Society of Anesthesiologists	This work was supported by the grant awarded from the European Society of Anesthesiologists in 2010 (to A.Z.). We thank Sarah Boyko and Anastasia Zlotnik for their outstanding help as laboratory assistants. We thank Valeria Frishman, laboratory assistant at the Department of Clinical Biochemistry, Soroka Medical Center, Ben-Gurion University of the Negev, for her help with the biochemical analysis. We thank A. Alir and the staff at the Critical Care Unit, Soroka Medical Center, for their support and helpful discussions.	Abu Fanne R, 2011, AM J PHYSIOL-REG I, V301, pR668, DOI 10.1152/ajpregu.00058.2011; Andreadou E, 2008, IN VIVO, V22, P137; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Barash PG, 2009, CLIN ANESTHESIA; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; BERL S, 1962, J BIOL CHEM, V237, P2562; BERTRAND G, 1992, BRIT J PHARMACOL, V106, P354, DOI 10.1111/j.1476-5381.1992.tb14340.x; Boyko M, 2011, EUR J NEUROSCI, V34, P1432, DOI 10.1111/j.1460-9568.2011.07864.x; BUCHAN AM, 1993, STROKE, V24, pI148; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bunting H, 2010, OPHTHAL RES, V43, P197, DOI 10.1159/000272024; Campos F, 2011, J CEREBR BLOOD F MET, V31, P1378, DOI 10.1038/jcbfm.2011.3; Campos F, 2011, J CEREBR BLOOD F MET, V31, P1387, DOI 10.1038/jcbfm.2011.4; Campos F, 2011, CLIN SCI, V121, P11, DOI 10.1042/CS20100427; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Cross DT, 2003, J NEUROSURG, V99, P810, DOI 10.3171/jns.2003.99.5.0810; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; DOCZI T, 1985, ACTA NEUROCHIR, V77, P110, DOI 10.1007/BF01476215; DOCZI T, 1986, NEUROSURGERY, V18, P733, DOI 10.1227/00006123-198606000-00010; Espey MG, 2002, NEUROLOGY, V58, P1439, DOI 10.1212/WNL.58.9.1439; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feigin VL, 2005, STROKE, V36, P2773, DOI 10.1161/01.STR.0000190838.02954.e8; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; Ferrarese C, 2001, NEUROLOGY, V57, P671, DOI 10.1212/WNL.57.4.671; Germano A, 1998, ACTA NEUROCHIR, V140, P805, DOI 10.1007/s007010050182; Germano A, 2000, ACTA NEUROCHIR, V142, P575, DOI 10.1007/s007010050472; Germano A, 1998, J NEUROSURG, V88, P1075, DOI 10.3171/jns.1998.88.6.1075; GERMANO A, 1992, NEUROSURGERY, V30, P882, DOI 10.1227/00006123-199206000-00011; Germano A, 2007, J NEUROTRAUM, V24, P732, DOI 10.1089/neu.2006.0181; GONOI T, 1994, J BIOL CHEM, V269, P16989; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; GRAF CJ, 1974, STROKE, V5, P557, DOI 10.1161/01.STR.5.4.557; GRAHAM LT, 1966, ANAL BIOCHEM, V15, P487, DOI 10.1016/0003-2697(66)90110-2; Gules I, 2002, AM J PHYSIOL-HEART C, V283, pH2551, DOI 10.1152/ajpheart.00616.2002; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; HARMSEN P, 1992, STROKE, V23, P1410, DOI 10.1161/01.STR.23.10.1410; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Imperatore C, 2000, LIFE SCI, V66, P779, DOI 10.1016/S0024-3205(99)00651-7; INAGAKI N, 1995, FASEB J, V9, P686; JACKOWSKI A, 1990, J CEREBR BLOOD F MET, V10, P835, DOI 10.1038/jcbfm.1990.140; Jeon H, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-103; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; King JT, 1997, NEUROIMAG CLIN N AM, V7, P659; Koura SS, 1998, ACT NEUR S, V71, P244; MARZATICO F, 1988, STROKE, V19, P378, DOI 10.1161/01.STR.19.3.378; Meguro T, 2001, NEUROL RES, V23, P761, DOI 10.1179/016164101101199144; MOLNAR E, 1995, FEBS LETT, V371, P253, DOI 10.1016/0014-5793(95)00890-L; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Phillis JW, 1996, NEUROCHEM INT, V29, P115, DOI 10.1016/0197-0186(95)00154-9; Prunell GF, 2003, NEUROSURGERY, V52, P165, DOI 10.1097/00006123-200301000-00022; Prunell GF, 2004, NEUROSURGERY, V54, P426, DOI 10.1227/01.NEU.0000103670.09687.7A; Sehba FA, 2006, NEUROL RES, V28, P381, DOI 10.1179/016164106X114991; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58; Spranger M, 1996, J NEUROL SCI, V143, P126, DOI 10.1016/S0022-510X(96)00197-9; Stegmayr B, 2004, STROKE, V35, P2059, DOI 10.1161/01.STR.0000138451.07853.b6; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Teichberg VI, 2007, P NATL ACAD SCI USA, V104, P7315, DOI 10.1073/pnas.0702450104; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; VEELKEN JA, 1995, STROKE, V26, P1279, DOI 10.1161/01.STR.26.7.1279; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zlotnik A, 2012, ANESTHESIOLOGY, V116, P73, DOI 10.1097/ALN.0b013e31823d7731; Zlotnik A, 2009, J NEUROSURG ANESTH, V21, P235, DOI 10.1097/ANA.0b013e3181a2bf0b	75	31	31	1	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JUL	2012	9	3					649	657		10.1007/s13311-012-0129-6			9	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	006NV	WOS:000308826800016	22711471	Green Published			2021-06-18	
J	Thompson, HJ; Weir, S; Rivara, FP; Wang, J; Sullivan, SD; Salkever, D; MacKenzie, EJ				Thompson, Hilaire J.; Weir, Sharada; Rivara, Frederick P.; Wang, Jin; Sullivan, Sean D.; Salkever, David; MacKenzie, Ellen J.			Utilization and Costs of Health Care after Geriatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						head injury; health services; informal care outcome	OLDER-ADULTS; OUTCOMES; MORTALITY; SEVERITY; DISORDER; PATIENT; RISK	Despite the growing number of older adults experiencing traumatic brain injury (TBI), little information exists regarding their utilization and cost of health care services. Identifying patterns in the type of care received and determining their costs is an important first step toward understanding the return on investment and potential areas for improvement. We performed a health care utilization and cost analysis using the National Study on the Costs and Outcomes of Trauma (NSCOT) dataset. Subjects were persons 55-84 years of age with TBI treated in 69 U. S. hospitals located in 14 states (n = 414, weighted n = 1038). Health outcomes, health care utilization, and 1-year costs of care following TBI in 2005 U. S. dollars were estimated from hospital bills, patient surveys, medical records, and Medicare claims data. The subjects were further analyzed in three subgroups (55-64, 65-74, and 75-84 years of age). Unadjusted cost models were built, followed by a second set of models adjusting for demographic and pre-injury health status. Those in the oldest category (75-84 years) had significantly higher numbers of re-hospitalizations, home health care visits, and hours per week of unpaid care, and significantly lower numbers of physician and mental health professional visits than younger age groups (age 55-64 and 65-74 years). Significant age-related differences were seen in all health outcomes tested at 12 months post-injury except for incidence of depressive symptoms. One-year total treatment costs did not differ significantly across age categories for brain-injured older adults in either the unadjusted or adjusted models. The unadjusted total mean 1-year cost of care was $77,872 in persons aged 55-64 years, $76,903 in persons aged 65-74 years, and $72,733 in persons aged 75-84 years. There were significant differences in cost drivers among the age groups. In the unadjusted model index hospitalization costs and inpatient rehabilitation costs were significantly lower in the oldest age category, while outpatient care costs and nursing home stays were lower in the younger age categories. In the adjusted model, in addition to these cost drivers, re-hospitalization costs were significantly higher among those 75-84 years of age, and receipt of informal care from friends and family was significantly different, being lowest among those aged 65-74 years, and highest among those aged 75-84 years. Identifying variations in care that these patients are receiving and determining the costs versus benefits is an important next step in understanding potential areas for improvement.	[Thompson, Hilaire J.; Rivara, Frederick P.; Wang, Jin] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Weir, Sharada] Univ Massachusetts, Ctr Hlth Policy & Res, Shrewsbury, MA USA; [Sullivan, Sean D.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA; [Salkever, David] Univ Maryland Baltimore Cty, Dept Publ Policy, Baltimore, MD 21228 USA; [MacKenzie, Ellen J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Thompson, HJ (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Box 357266, Seattle, WA 98195 USA.	hilairet@uw.edu			National Center for Injury Prevention and ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR316840]; National Center for Research Resources, a component of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR025015]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR025015] Funding Source: NIH RePORTER	This work was supported in part by grant number R49/CCR316840 from the National Center for Injury Prevention and Control, and grant number KL2RR025015 from the National Center for Research Resources, a component of the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the granting agencies.	Aitken LM, 2010, J AM GERIATR SOC, V58, P442, DOI 10.1111/j.1532-5415.2010.02728.x; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Blough DK, 2000, HLTH SERV OUTCOMES R, V1, P185, DOI DOI 10.1023/A:1012597123667; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Carter MW, 2011, J AM GERIATR SOC, V59, P406, DOI 10.1111/j.1532-5415.2010.03283.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Eaton WW., 2004, USE PSYCHOL TESTING, V3rd ed, P363; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Jacoby SF, 2006, J NURS SCHOLARSHIP, V38, P133, DOI 10.1111/j.1547-5069.2006.00090.x; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; MacKenzie EJ, 2010, J TRAUMA, V69, P1, DOI 10.1097/TA.0b013e3181e03a21; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; McKevitt EC, 2003, CAN J SURG, V46, P211; Michael YL, 2010, ANN INTERN MED, V153, P815, DOI 10.7326/0003-4819-153-12-201012210-00008; Mullins RJ, 1998, JAMA-J AM MED ASSOC, V279, P1727, DOI 10.1001/jama.279.21.1727; Newell MA, 2009, J TRAUMA, V67, P337, DOI 10.1097/TA.0b013e3181add08b; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; Rochette LM, 2009, J SAFETY RES, V40, P353, DOI 10.1016/j.jsr.2009.08.003; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2010, ANN SURG, V252, P370, DOI 10.1097/SLA.0b013e3181df03d6; Weir S, 2010, EXPERT REV PHARM OUT, V10, P187, DOI [10.1586/erp.10.8, 10.1586/ERP.10.8]; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8	32	31	31	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1864	1871		10.1089/neu.2011.2284			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400390	22435729	Green Published			2021-06-18	
J	Wahab, RA; Choi, M; Liu, YB; Krauthamer, V; Zderic, V; Myers, MR				Wahab, Radia Abdul; Choi, Mina; Liu, Yunbo; Krauthamer, Victor; Zderic, Vesna; Myers, Matthew R.			Mechanical bioeffects of pulsed high intensity focused ultrasound on a simple neural model	MEDICAL PHYSICS			English	Article						nerve; traumatic brain injury; ultrasound bioeffects; HIFU	SQUID GIANT-AXON; PERIPHERAL-NERVES; CONDUCTION; INJURY; BRAIN	Purpose: To study how pressure pulses affect nerves through mechanisms that are neither thermal nor cavitational, and investigate how the effects are related to cumulative radiation-force impulse (CRFI). Applications include traumatic brain injury and acoustic neuromodulation. Methods: A simple neural model consisting of the giant axon of a live earthworm was exposed to trains of pressure pulses produced by an 825 kHz focused ultrasound transducer. The peak negative pressure of the pulses and duty cycle of the pulse train were controlled so that neither cavitation nor significant temperature rise occurred. The amplitude and conduction velocity of action-potentials triggered in the worm were measured as the magnitude of the pulses and number of pulses in the pulse trains were varied. Results: The functionality of the axons decreased when sufficient pulse energy was applied. The level of CRFI at which the observed effects occur is consistent with the lower levels of injury observed in this study relative to blast tubes. The relevant CRFI values are also comparable to CRFI values in other studies showing measureable changes in action-potential amplitudes and velocities. Plotting the measured action-potential amplitudes and conduction velocities from different experiments with widely varying exposure regimens against the single parameter of CRFI yielded values that agreed within 21% in terms of amplitude and 5% in velocity. A predictive model based on the assumption that the temporal rate of decay of action-potential amplitude and velocity is linearly proportional the radiation force experienced by the axon predicted the experimental amplitudes and conduction velocities to within about 20% agreement. Conclusions: The functionality of axons decreased due to noncavitational mechanical effects. The radiation force, possibly by inducing changes in ion-channel permeability, appears to be a possible mechanism for explaining the observed degradation. The CRFI is also a promising parameter for quantifying neural bioeffects during exposure to pressure waves, and for predicting axon functionality. (C) 2012 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4729712]	[Wahab, Radia Abdul; Choi, Mina; Liu, Yunbo; Krauthamer, Victor; Myers, Matthew R.] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA; [Wahab, Radia Abdul; Choi, Mina; Zderic, Vesna] George Washington Univ, Dept Elect & Comp Engn, Washington, DC 20052 USA	Myers, MR (corresponding author), US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA.	matthew.myers@fda.hhs.gov					BULLOCK TH, 1945, J NEUROPHYSIOL, V8, P55; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Colucci V, 2009, ULTRASOUND MED BIOL, V35, P1737, DOI 10.1016/j.ultrasmedbio.2009.05.002; Crisci AR, 2002, ULTRASOUND MED BIOL, V28, P1335, DOI 10.1016/S0301-5629(02)00576-8; Foley JL, 2008, MUSCLE NERVE, V37, P241, DOI 10.1002/mus.20932; Foley JL, 2007, ANN BIOMED ENG, V35, P109, DOI 10.1007/s10439-006-9162-0; Foley JL, 2004, ULTRASOUND MED BIOL, V30, P1199, DOI 10.1016/j.ultrasmedbio.2004.07.004; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gallant PE, 1997, J NEUROTRAUM, V14, P811, DOI 10.1089/neu.1997.14.811; GAVRILOV LR, 1984, ULTRASONICS, V22, P132, DOI 10.1016/0041-624X(84)90008-8; Hancock HA, 2009, ULTRASOUND MED BIOL, V35, P1722, DOI 10.1016/j.ultrasmedbio.2009.04.020; Hariharan P, 2008, J ACOUST SOC AM, V123, P1706, DOI 10.1121/1.2835662; LELE P, 1963, EXP NEUROL, V8, P47, DOI 10.1016/0014-4886(63)90008-6; Maruvada S., 2008, J ACOUST SOC AM, V123; Maruvada S, 2009, AIP CONF PROC, V1113, P286; MIHRAN RT, 1990, ULTRASOUND MED BIOL, V16, P297, DOI 10.1016/0301-5629(90)90008-Z; Miles D., 2008, AM FORCES PRESS 0107; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; NYBORG WL, 1988, PHYS MED BIOL, V33, P785, DOI 10.1088/0031-9155/33/7/002; Oztas O, 1998, ARCH PHYS MED REHAB, V79, P1540, DOI 10.1016/S0003-9993(98)90416-6; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Rosner B., 2000, FUNDAMENTALS BIOSTAT; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; ter Haar G, 2001, PHYS TODAY, V54, P29, DOI 10.1063/1.1445545; Tufail Y, 2010, NEURON, V66, P681, DOI 10.1016/j.neuron.2010.05.008; Tyler WJ, 2011, NEUROSCIENTIST, V17, P25, DOI 10.1177/1073858409348066; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	27	31	33	0	36	AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS	MELVILLE	STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA	0094-2405			MED PHYS	Med. Phys.	JUL	2012	39	7					4274	4283		10.1118/1.4729712			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	980KV	WOS:000306893000025	22830761				2021-06-18	
J	Howells, T; Lewen, A; Skold, MK; Ronne-Engstrom, E; Enblad, P				Howells, Tim; Lewen, Anders; Skold, Mattias K.; Ronne-Engstrom, Elisabeth; Enblad, Per			An evaluation of three measures of intracranial compliance in traumatic brain injury patients	INTENSIVE CARE MEDICINE			English	Article						Intracranial compliance; Traumatic brain injury; Intracranial pressure; Cerebral hemodynamics	INTENSIVE-CARE; DECOMPRESSIVE CRANIECTOMY; SUBARACHNOID HEMORRHAGE; PULSE PRESSURE; VOLUME; HYDROCEPHALUS; MONITOR; COMPENSATION; ANESTHESIA; REACTIVITY	To compare intracranial pressure (ICP) amplitude, ICP slope, and the correlation of ICP amplitude and ICP mean (RAP index) as measures of compliance in a cohort of traumatic brain injury (TBI) patients. Mean values of the three measures were calculated in the 2-h periods before and after surgery (craniectomies and evacuations), and in the 12-h periods preceding and following thiopental treatment, and during periods of thiopental coma. The changes in the metrics were evaluated using the Wilcoxon test. The correlations of 10-day mean values for the three metrics with age, admission Glasgow Motor Score (GMS), and Extended Glasgow Outcome Score (GOSe) were evaluated. Patients under and over 60 years old were also compared using the Student test. The correlation of ICP amplitude with systemic pulse amplitude was analyzed. ICP amplitude was significantly correlated with GMS, and also with age for patients 35 years old and older. The correlations of ICP slope and the RAP index with GMS and with age were not significant. All three metrics indicated significant improvements in compliance following surgery and during thiopental coma. None of the metrics were significantly correlated with outcome, possibly due to confounding effects of treatment factors. The correlation of systemic pulse amplitude with ICP amplitude was low ( = 0.18), only explaining 3 % of the variance. This study provides further validation for all three of these features of the ICP waveform as measures of compliance. ICP amplitude had the best performance in these tests.	[Howells, Tim] Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden; [Howells, Tim; Lewen, Anders; Skold, Mattias K.; Ronne-Engstrom, Elisabeth; Enblad, Per] Uppsala Univ, Dept Neurosci, Neurosurg Sect, Uppsala, Sweden	Howells, T (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden.	timothy.howells@lul.se	SkAld, Mattias/AAJ-8253-2020; Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			Abdullah J, 2005, ACT NEUR S, V95, P311; Asgari S, 2011, NEUROCRIT CARE, V15, P55, DOI 10.1007/s12028-010-9463-x; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Bentsen G, 2008, CRIT CARE MED, V36, P2414, DOI 10.1097/CCM.0b013e318180fe04; Castellani G, 2009, NEUROCRIT CARE, V11, P143, DOI 10.1007/s12028-009-9235-7; Chestnut DE, 2000, J NEUROTRAUM, V17, P573; CONTANT CF, 1995, J NEUROSCI METH, V57, P15, DOI 10.1016/0165-0270(94)00106-Q; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; Czosnyka M, 2001, J NEUROSURG, V94, P482, DOI 10.3171/jns.2001.94.3.0482; Eide PK, 2007, NEUROL RES, V29, P798, DOI 10.1179/016164107X224132; Eide PK, 2010, J NEUROSURG, V112, P616, DOI 10.3171/2009.7.JNS081593; Eide PK, 2011, NEUROSURGERY, V69, P1105, DOI 10.1227/NEU.0b013e318227e0e1; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Engelse WAH, 1979, IEEE COMPUT CARD, V6, P37; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Hoare SW, 2000, MED ENG PHYS, V22, P547, DOI 10.1016/S1350-4533(00)00071-0; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hu X, 2010, IEEE T BIO-MED ENG, V57, P1070, DOI 10.1109/TBME.2009.2037607; Jakob S, 2000, COMPUT METH PROG BIO, V63, P203, DOI 10.1016/S0169-2607(00)00110-3; Kiening KL, 2005, ACT NEUR S, V95, P293; Kiening KL, 2002, ACT NEUR S, V81, P177; Kim DJ, 2009, NEUROSURGERY, V64, P494, DOI 10.1227/01.NEU.0000338434.59141.89; MAKIVIRTA A, 1991, COMPUT METH PROG BIO, V34, P139, DOI 10.1016/0169-2607(91)90039-V; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MILLER JD, 1973, ARCH NEUROL-CHICAGO, V28, P265, DOI 10.1001/archneur.1973.00490220073011; PIERCE EC, 1962, J CLIN INVEST, V41, P1664, DOI 10.1172/JCI104623; Pino Esteban, 2005, AMIA Annu Symp Proc, P604; Piper I, 1999, BRIT J NEUROSURG, V13, P581, DOI 10.1080/02688699943097; PIPER IR, 1990, ACT NEUR S, V51, P387; ROBERTSON CS, 1989, J NEUROSURG, V71, P673, DOI 10.3171/jns.1989.71.5.0673; Salci Kontsantin, 2006, J Clin Monit Comput, V20, P25, DOI 10.1007/s10877-006-2864-x; TEASDALE G, 1974, LANCET, V2, P81; Timofeev I, 2008, ACTA NEUROCHIR SUPPL, V102, P99, DOI 10.1007/978-3-211-85578-2_20; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; WILKINSON HA, 1979, J NEUROSURG, V50, P758, DOI 10.3171/jns.1979.50.6.0758; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yau Y, 2002, ACTA NEUROCHIR SUPPL, V81, P167	37	31	32	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2012	38	6					1061	1068		10.1007/s00134-012-2571-7			8	Critical Care Medicine	General & Internal Medicine	943RO	WOS:000304143100018	22527085				2021-06-18	
J	Terre, R; Mearin, F				Terre, R.; Mearin, F.			Effectiveness of chin-down posture to prevent tracheal aspiration in dysphagia secondary to acquired brain injury. A videofluoroscopy study	NEUROGASTROENTEROLOGY AND MOTILITY			English	Article						aspiration; chin-down posture; stroke; traumatic brain injury; videofluoroscopy	OROPHARYNGEAL DYSPHAGIA; INTERRATER RELIABILITY; ACUTE-PHASE; SWALLOW; STROKE; IMPACT	Background The chin-down posture is generally recommended in patients with neurogenic dysphagia to prevent tracheal aspiration; however, its effectiveness has not been demonstrated. Aim To videofluoroscopically (VDF) assess the effectiveness of chin-down posture to prevent aspiration in patients with neurogenic dysphagia secondary to acquired brain injury. Methods Randomized, alternating, cross-over study (with and without the chin-down posture) in 47 patients with a VDF diagnosis of aspiration [31 stroke, 16 traumatic brain injury (TBI)] and 25 controls without aspiration (14 stroke, 11 TBI). Key Results During the chin-down posture, 55% of patients avoided aspiration (40% preswallow aspiration and 60% aspiration during swallow). The percentage was similar in both etiologies (58% stroke and 50% TBI). Fifty-one percent of patients had silent aspiration; of these, 48% persisted with aspiration while in the chin-down posture. A statistically significant relationship was found between the existence of pharyngeal residue, cricopharyngeal dysfunction, pharyngeal delay time and bolus volume with the persistence of aspiration. The chin-down posture did not change swallow biomechanics in patients without aspiration. Conclusions & Inferences Only half the patients with acquired brain injury avoided aspiration during cervical flexion; 48% of silent aspirators continued to aspire during the maneuver. Several videofluoroscopic parameters were related to inefficiency of the maneuver. Therefore, the indication for chin-down posture should be evaluated by videofluoroscopic examination.	[Terre, R.; Mearin, F.] Autonomous Univ Barcelona, Funct Digest Rehabil Unit, Inst Guttmann, Neurorehabil Hosp,Univ Inst, Badalona 08916, Spain	Terre, R (corresponding author), Autonomous Univ Barcelona, Funct Digest Rehabil Unit, Inst Guttmann, Neurorehabil Hosp,Univ Inst, Cami de Can Ruti S-N, Badalona 08916, Spain.	rterre@guttmann.com					Ashford J, 2009, J REHABIL RES DEV, V46, P195, DOI 10.1682/JRRD.2008.08.0091; Bath P. M, 2000, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000323, 10.1002/14651858.CD000323]; Cook IJ, 1999, GASTROENTEROLOGY, V116, P455, DOI 10.1016/S0016-5085(99)70144-7; Ekberg O, 1988, Dysphagia, V3, P46, DOI 10.1007/BF02406279; Hagen C, 1999, REHABILITATION HEAD; Kendall K, 2008, DYSPHAGIA ASSESSMENT, P233; Lazarus CL, 1989, J HEAD TRAUMA REHAB, V4, P34; Leonard R, 2008, DYSPHAGIA ASSESSMENT, P295; Logemanin JA, 2008, J SPEECH LANG HEAR R, V51, P173, DOI 10.1044/1092-4388(2008/013); Logemann J., 1993, MANUAL VIDEOFLUOROGR, P115; Logemann JA, 2000, J SPEECH LANG HEAR R, V43, P1264, DOI 10.1044/jslhr.4305.1264; Logemann JA, 1998, EVALUATION TREATMENT, P307; Logemann JA, 1998, EVALUATION TREATMENT, P1; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; Morgan A, 2004, BRAIN INJURY, V18, P359, DOI 10.1080/02699050310001617424; Nagaya M, 2004, NAGOYA J MED SCI, V2, P17; Pena-Casanova J., 1991, PROGRAMA INTEGRADO E; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; Scott A, 1998, DYSPHAGIA, V13, P223, DOI 10.1007/PL00009576; SHANAHAN TK, 1993, ARCH PHYS MED REHAB, V74, P736, DOI 10.1016/0003-9993(93)90035-9; Singh S, 2006, POSTGRAD MED J, V82, P383, DOI 10.1136/pgmj.2005.043281; Stoeckli SJ, 2003, DYSPHAGIA, V18, P53, DOI 10.1007/s00455-002-0085-0; Terre R, 2006, NEUROGASTROENT MOTIL, V18, P200, DOI 10.1111/j.1365-2982.2005.00729.x; Terre R, 2009, NEUROGASTROENT MOTIL, V21, P361, DOI 10.1111/j.1365-2982.2008.01208.x; Terre R, 2009, AM J GASTROENTEROL, V104, P923, DOI 10.1038/ajg.2008.160; Terrte R, 2007, BRAIN INJURY, V21, P1411, DOI 10.1080/02699050701785096; WELCH MV, 1993, ARCH PHYS MED REHAB, V74, P178; Wheeler-Hegland K, 2009, J REHABIL RES DEV, V46, P185, DOI 10.1682/JRRD.2008.08.0094	29	31	36	0	14	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1350-1925			NEUROGASTROENT MOTIL	Neurogastroenterol. Motil.	MAY	2012	24	5					414	+		10.1111/j.1365-2982.2011.01869.x			7	Gastroenterology & Hepatology; Clinical Neurology; Neurosciences	Gastroenterology & Hepatology; Neurosciences & Neurology	923IH	WOS:000302612500005	22309385				2021-06-18	
J	Vaccari, JPD; Minkiewicz, J; Wang, XL; Vaccari, JCD; German, R; Marcillo, AE; Dietrich, WD; Keane, RW				de Rivero Vaccari, Juan Pablo; Minkiewicz, Julia; Wang, Xiaoliang; De Rivero Vaccari, Juan Carlos; German, Ramon; Marcillo, Alex E.; Dietrich, W. Dalton; Keane, Robert W.			Astrogliosis involves activation of retinoic acid-inducible gene-like signaling in the innate immune response after spinal cord injury	GLIA			English	Article						innate immunity; neuroinflammation; spinal cord injury; astrocytes	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; REACTIVE ASTROCYTES; I INTERFERON; INFLAMMATION; CULTURE; ROLES; MICE; REGENERATION; PERSPECTIVE	Spinal cord injury (SCI) induces a glial response in which astrocytes become activated and produce inflammatory mediators. The molecular basis for regulation of glial-innate immune responses remains poorly understood. Here, we examined the activation of retinoic acid-inducible gene (RIG)-like receptors (RLRs) and their involvement in regulating inflammation after SCI. We show that astrocytes express two intracellular RLRs: RIG-I and melanoma differentiation-associated gene 5. SCI and stretch injury of cultured astrocytes stimulated RLR signaling as determined by phosphorylation of interferon regulatory factor 3 (IRF3) leading to production of type I interferons (IFNs). RLR signaling stimulation with synthetic ribonucleic acid resulted in RLR activation, phosphorylation of IRF3, and increased expression of glial fibrillary acidic protein (GFAP) and vimentin, two hallmarks of reactive astrocytes. Moreover, mitochondrial E3 ubiquitin protein ligase 1, an RLR inhibitor, decreased production of GFAP and vimentin after RIG-I signaling stimulation. Our findings identify a role for RLR signaling and type I IFN in regulating astrocyte innate immune responses after SCI. (C) 2011 Wiley Periodicals, Inc.	[de Rivero Vaccari, Juan Pablo; German, Ramon; Marcillo, Alex E.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Minkiewicz, Julia; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Wang, Xiaoliang] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [De Rivero Vaccari, Juan Carlos] Louisiana State Univ, Sch Med, New Orleans, LA USA	Vaccari, JPD (corresponding author), Lois Pope LIFE Ctr, Dept Neurol Surg, 1095 NW 14th Terrace,3-25JJ, Miami, FL 33136 USA.	JdeRivero@med.miami.edu	de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	Miami Project to Cure Paralysis; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS059836]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059836] Funding Source: NIH RePORTER	Grant sponsor: The Miami Project to Cure Paralysis; Grant sponsor: NIH grant to R. W. K.; Grant number: NS059836.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Auerbuch V, 2004, J EXP MED, V200, P527, DOI 10.1084/jem.20040976; Barres BA, 2008, NEURON, V60, P430, DOI 10.1016/j.neuron.2008.10.013; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Delhaye S, 2006, P NATL ACAD SCI USA, V103, P7835, DOI 10.1073/pnas.0602460103; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Hamby ME, 2006, GLIA, V54, P566, DOI 10.1002/glia.20411; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Khorooshi R, 2010, J IMMUNOL, V185, P1258, DOI 10.4049/jimmunol.0901753; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Malathi K, 2007, NATURE, V448, P816, DOI 10.1038/nature06042; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Onoguchi K, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001012; Paul S, 2007, BIOCHIMIE, V89, P770, DOI 10.1016/j.biochi.2007.02.009; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Rainer TH, 2006, ANN NY ACAD SCI, V1075, P271, DOI 10.1196/annals.1368.035; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Seo YJ, 2010, ADV APPL MICROBIOL, V73, P83, DOI 10.1016/S0065-2164(10)73004-5; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x; TEDESCHI B, 1986, J CELL BIOL, V102, P2244, DOI 10.1083/jcb.102.6.2244; Teige I, 2003, J IMMUNOL, V170, P4776, DOI 10.4049/jimmunol.170.9.4776; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wilkins C, 2010, CURR OPIN IMMUNOL, V22, P41, DOI 10.1016/j.coi.2009.12.003; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.0.CO;2-8; Wu VW, 1998, J NEUROCHEM, V71, P749; Yoneyama M, 2008, IMMUNITY, V29, P178, DOI 10.1016/j.immuni.2008.07.009; Yoneyama M, 2007, NAT IMMUNOL, V8, P907, DOI 10.1038/ni0907-907; Yoneyama M, 2007, J BIOL CHEM, V282, P15315, DOI 10.1074/jbc.R700007200; Yu N, 2011, EXP DERMATOL, V20, P134, DOI 10.1111/j.1600-0625.2010.01208.x	40	31	31	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAR	2012	60	3					414	421		10.1002/glia.22275			8	Neurosciences	Neurosciences & Neurology	880CE	WOS:000299381200008	22161971	Green Accepted			2021-06-18	
J	Nalder, E; Fleming, J; Foster, M; Cornwell, P; Shields, C; Khan, A				Nalder, Emily; Fleming, Jennifer; Foster, Michele; Cornwell, Petrea; Shields, Cassandra; Khan, Asad			Identifying Factors Associated With Perceived Success in the Transition From Hospital to Home After Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community integration; transition; traumatic brain injury	QUALITY-OF-LIFE; SELF-AWARENESS; ENVIRONMENTAL-FACTORS; OUTCOMES; PARTICIPATION; REINTEGRATION; DEPRESSION; DISCHARGE; VALIDITY; ANXIETY	Objective: To identify the factors associated with perceived success of the transition from hospital to home after traumatic brain injury (TBI). Design: Prospective longitudinal cohort design with data collection at discharge and 1, 3, and 6 months postdischarge. Participants: A total of 127 individuals with TBI discharged to the community and 83 significant others. Main Measures: An analog scale (0-100) of perceived success of the transition from hospital to home rated by individuals and significant others; Sentinel Events Questionnaire; EuroQol Group Quality-of-Life measure visual analog scale; Sydney Psychosocial Reintegration Scale; Mayo-Portland Adaptability Inventory-4; short form of the Depression, Anxiety, Stress Scales; Craig Hospital Inventory of Environmental Factors; and Caregiver Strain Index. Results: Greater perceived success of transition for individuals with a TBI was associated with higher levels of health-related quality of life, level of community integration, and more severe injury. Among survivors, sentinel events such as returning to work and independent community access and changing living situation were associated with greater perceived success; financial strain and difficulty accessing therapy services were associated with less success. Among significant others, lower ratings of transition success were associated with higher significant other stress levels as well as lower levels of community integration and changes in the living situation of the individual with TBI. Conclusion: A combination of sentinel events and personal and environmental factors influences the perceptions of individuals and their families regarding the success of the transition from hospital to home.	[Nalder, Emily; Fleming, Jennifer; Shields, Cassandra; Khan, Asad] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Foster, Michele] Univ Queensland, Sch Social Work & Human Serv, Brisbane, Qld 4072, Australia; [Nalder, Emily; Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; [Fleming, Jennifer] Metro S Hlth Serv Dist, Ctr Functioning & Hlth Res, Brisbane, Qld, Australia; [Cornwell, Petrea] Queensland Hlth, Metro N Hlth Serv Dist, Brisbane, Qld, Australia; [Cornwell, Petrea] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4111, Australia	Nalder, E (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.	e.nalder@uq.edu.au	Khan, Asad/R-8484-2016; Khan, Asad/N-7481-2019; Khan, Asaduzzaman/F-8739-2010; Cornwell, Petrea/AAE-5547-2019	Khan, Asad/0000-0003-4188-2065; Khan, Asad/0000-0003-4188-2065; Khan, Asaduzzaman/0000-0003-4188-2065; 	Australian Research CouncilAustralian Research Council; Department of Communities (Disability Services); Acquired Brain Injury Outreach Service	This project was supported by an Australian Research Council Linkage Grant and partner organizations, Department of Communities (Disability Services), and Acquired Brain Injury Outreach Service. In addition, the authors thank Dr Terrence Haines, Dr Tamara Ownsworth, Professor Linda Worrall, and Dr Melissa Kendall for their contribution.	Austroads, 1998, ASS FITN DRIV AUSTR; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; BRAZIER J, 1993, QUAL LIFE RES, V2, P169, DOI 10.1007/BF00435221; Cornwell P, 2009, BRAIN IMPAIR, V10, P325, DOI 10.1375/brim.10.3.325; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Cott CA, 2007, DISABIL REHABIL, V29, P1566, DOI 10.1080/09638280701618588; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Elder G. H., 1995, EXAMINING LIVES CONT, P101, DOI DOI 10.1037/10176-003; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming J, 2009, DISABIL REHABIL, V31, P1666, DOI 10.1080/09638280902738425; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 2002, J COGNITIVE REHABILI, V20, P28; Gage M, 1997, AM J OCCUP THER, V51, P96, DOI 10.5014/ajot.51.2.96; Heinz W., 2003, SOCIAL DYNAMICS LIFE; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Karlovits T, 1999, BRAIN INJURY, V13, P845; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Malec J. F., 2003, MANUAL MAYO PORTLAND; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mistiaen P, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-47; Nalder E, 2010, RECORDING SENT UNPUB; OTOOLE BI, 1986, AM J EPIDEMIOL, V124, P317, DOI 10.1093/oxfordjournals.aje.a114390; Ownsworth T, 2008, BRAIN INJURY, V22, P858, DOI 10.1080/02699050802446697; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Rittman M, 2004, J REHABIL RES DEV, V41, P259, DOI 10.1682/JRRD.2003.06.0099; Rittman M, 2007, TOP STROKE REHABIL, V14, P21, DOI 10.1310/tsr1402-21; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Schlossberg NK, 2005, COUNSELING ADULTS TR; StataCorp, 2007, STAT STAT SOFTW REL; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Turner B, 2007, BRAIN INJURY, V21, P1119, DOI 10.1080/02699050701651678; Turner B, 2009, BRAIN INJURY, V23, P51, DOI 10.1080/02699050802635257; Turner BJ, 2007, DISABIL REHABIL, V30, P23; Twisk JWR., 2003, APPL LONGITUDINAL DA; Warren L, 1996, J REHABIL RES DEV, V33, P404; Weaver F M, 1998, Home Health Care Serv Q, V17, P27; Whiteneck GG, 2004, ARCH PHYS MED REHAB, V85, P1324, DOI 10.1016/j.apmr.2003.09.027; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; World Health Organization, 2001, INT CLASS FUNCT DIS	48	31	32	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2012	27	2					143	153		10.1097/HTR.0b013e3182168fb1			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	912LI	WOS:000301799100007	21522027				2021-06-18	
J	Franke, LM; Walker, WC; Cifu, DX; Ochs, AL; Lew, HL				Franke, Laura M.; Walker, William C.; Cifu, David X.; Ochs, Alfred L.; Lew, Henry L.			Sensorintegrative dysfunction underlying vestibular disorders after traumatic brain injury: A review	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						Afghanistan; anxiety; balance; blast injuries; brain injuries; central nervous system; Iraq; nonblast injuries; post-traumatic stress disorder; spatial perception; vestibular cortex; vestibular system	BLAST INJURY; POSTCONCUSSIVE SYMPTOMS; POSTURAL CONTROL; HEAD-INJURY; STIMULATION; MOTION; CORTEX; IMPAIRMENT; DIZZINESS; SPACE	Vestibular symptoms are persistent and problematic sequelae of blast exposure. Several lines of evidence suggest that these symptoms often stem from injury to the central nervous system. Current methods of assessing the vestibular system have described vestibular deficits that follow traumatic brain injury and differentiate blunt and blast trauma but have not examined the full range of vestibular functions that depend on the cerebral structures above the midbrain. Damage to the central vestibular circuits can lead to deficits in vital processes of spatial perception and navigation, in addition to dizziness and disequilibrium, and may also affect emotional functioning, particularly noradrenergically modulated states of anxiety. Perceptual functions can be assessed to determine the extent of central nervous system involvement in vestibular symptoms and to provide greater confidence when vestibular dysfunction is to be excluded. The ability to detect central vestibular dysfunction will significantly enhance our response to the dizziness and balance symptoms that are a common source of distress for Veterans.	[Franke, Laura M.; Walker, William C.; Lew, Henry L.] Def & Vet Brain Injury Ctr, Richmond, VA 23249 USA; [Franke, Laura M.; Walker, William C.; Cifu, David X.; Lew, Henry L.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA USA; [Cifu, David X.] Dept Vet Affairs VA, Dept Phys Med & Rehabil, Washington, DC USA; [Ochs, Alfred L.] Hunter Holmes McGuire VA Med Ctr, Neurol Serv, Richmond, VA USA; [Ochs, Alfred L.] Virginia Commonwealth Univ, Dept Biomed Engn, Sch Engn, Richmond, VA USA; [Lew, Henry L.] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA	Franke, LM (corresponding author), Def & Vet Brain Injury Ctr, 1201 Broad Rock Blvd 151, Richmond, VA 23249 USA.	laura.manning3@va.gov	Walker, William C/N-3162-2014	Ochs, Alfred/0000-0003-3932-876X; Cifu, David/0000-0003-1600-9387	Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Henry M. Jackson Foundation; Hunter Holmes McGuire Depaitinent of Veterans Affairs Medical Center	This material is based on work supported in part by the Defense and Veterans Brain Injury Center, the Henry M. Jackson Foundation, and the Hunter Holmes McGuire Depaitinent of Veterans Affairs Medical Center.	Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Aldridge AJ, 2003, J NEURO-OPHTHALMOL, V23, P145, DOI 10.1097/00041327-200306000-00008; Balaban CD, 2001, J ANXIETY DISORD, V15, P53, DOI 10.1016/S0887-6185(00)00042-6; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Barra J, 2010, BRAIN, V133, P3552, DOI 10.1093/brain/awq311; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Bense S, 2001, J NEUROPHYSIOL, V85, P886; Bent LR, 2002, EXP BRAIN RES, V146, P490, DOI 10.1007/s00221-002-1204-8; Brandt T, 1998, BRAIN, V121, P1749, DOI 10.1093/brain/121.9.1749; Brandt T, 1999, ANN NY ACAD SCI, V871, P293, DOI 10.1111/j.1749-6632.1999.tb09193.x; Brandt T, 2005, BRAIN, V128, P2732, DOI 10.1093/brain/awh617; BRANDT T, 1994, ANN NEUROL, V35, P403, DOI 10.1002/ana.410350406; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; DIETERICH M, 1993, NEUROLOGY, V43, P1732, DOI 10.1212/WNL.43.9.1732; Dieterich M, 2008, BRAIN, V131, P2538, DOI 10.1093/brain/awn042; FRIBERG L, 1985, BRAIN, V108, P609, DOI 10.1093/brain/108.3.609; GANNON RP, 1978, ARCH OTOLARYNGOL, V104, P404; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; Gilbertson MW, 2007, BIOL PSYCHIAT, V62, P513, DOI 10.1016/j.biopsych.2006.12.023; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JACOB R, 1993, VESTIBULOOCULAR REFL; Jacob RG, 2009, J NEUROL NEUROSUR PS, V80, P74, DOI 10.1136/jnnp.2007.136432; JACOB RG, 1993, J PSYCHOPATHOL BEHAV, V15, P299, DOI 10.1007/BF00965035; Kapralos B, 2004, 116 AUD ENG SOC CONV; Karnath HO, 2000, P NATL ACAD SCI USA, V97, P13931, DOI 10.1073/pnas.240279997; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Miyai I, 1997, J NEUROL REHABIL, V11, P35; PENFIELD W, 1957, Ann Otol Rhinol Laryngol, V66, P691; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Ramachandran VS, 2007, NEUROCASE, V13, P185, DOI 10.1080/13554790701450446; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; Scherer MR, 2011, OTOL NEUROTOL, V32, P571, DOI 10.1097/MAO.0b013e318210b8fa; Scherer MR, 2011, EXP BRAIN RES, V208, P399, DOI 10.1007/s00221-010-2490-1; SCHWARZ DWF, 1971, SCIENCE, V172, P280, DOI 10.1126/science.172.3980.280; SHUPAK A, 1993, ARCH OTOLARYNGOL, V119, P1362; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Smith Paul F, 2010, Front Neurol, V1, P141, DOI 10.3389/fneur.2010.00141; Stackman RW, 2002, HIPPOCAMPUS, V12, P291, DOI 10.1002/hipo.1112; Suzuki M, 2001, COGNITIVE BRAIN RES, V12, P441, DOI 10.1016/S0926-6410(01)00080-5; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TAKEDA N, 1995, ACTA OTO-LARYNGOL, P110; Taube JS, 1996, BRAIN RES BULL, V40, P477, DOI 10.1016/0361-9230(96)00145-1; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thilo KV, 2003, J NEUROPHYSIOL, V90, P723, DOI 10.1152/jn.00880.2002; TOGLIA JU, 1970, ARCHIV OTOLARYNGOL, V92, P485; Van Campen L E, 1999, J Am Acad Audiol, V10, P467; Vitte E, 1996, EXP BRAIN RES, V112, P523; WAESPE W, 1977, EXP BRAIN RES, V30, P323; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Welgampola MS, 2001, EXP BRAIN RES, V139, P345, DOI 10.1007/s002210100754	58	31	32	0	6	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					985	993		10.1682/JRRD.2011.12.0250			9	Rehabilitation	Rehabilitation	149EZ	WOS:000319303100004	23341274	Bronze			2021-06-18	
J	Gallun, FJ; Lewis, MS; Folmer, RL; Diedesch, AC; Kubli, LR; McDermott, DJ; Walden, TC; Fausti, SA; Lew, HL; Leek, MR				Gallun, Frederick J.; Lewis, M. Samantha; Folmer, Robert L.; Diedesch, Anna C.; Kubli, Lina R.; McDermott, Daniel J.; Walden, Therese C.; Fausti, Stephen A.; Lew, Henry L.; Leek, Marjorie R.			Implications of blast exposure for central auditory function: A review	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						auditory dysfunction; auditory processing disorder; blast; central auditory dysfunction; central auditory processing; central auditory system; hearing loss; rehabilitation; traumatic brain injury; veteran	TRAUMATIC BRAIN-INJURY; HEARING-LOSS; SPEECH IDENTIFICATION; PROCESSING DISORDER; SPATIAL SEPARATION; RECEPTIVE-FIELDS; GLOBAL WAR; CORTEX; REHABILITATION; DYSFUNCTION	Auditory system functions, from peripheral sensitivity to central processing capacities, are all at risk from a blast event. Accurate encoding of auditory patterns in time, frequency, and space are required for a clear understanding of speech and accurate localization of sound sources in environments with background noise, multiple sound sources, and/or reverberation. Further work is needed to refine the battery of clinical tests sensitive to the sorts of central auditory dysfunction observed in individuals with blast exposure. Treatment options include low-gain hearing aids, remote-microphone technology, and auditory-training regimens, but clinical evidence does not yet exist for recommending one or more of these options. As this population ages, the natural aging process and other potential brain injuries (such as stroke and blunt trauma) may combine with blast-related brain changes to produce a population for which the current clinical diagnostic and treatment tools may prove inadequate. It is important to maintain an updated understanding of the scope of the issues present in this population and to continue to identify those solutions that can provide measurable improvements in the lives of Veterans who have been exposed to high-intensity blasts during the course of their military service.	[Gallun, Frederick J.; Lewis, M. Samantha; Folmer, Robert L.; Diedesch, Anna C.; McDermott, Daniel J.; Fausti, Stephen A.; Leek, Marjorie R.] Portland VA Med Ctr, Dept Vet Affairs VA Rehabil Res & Dev Natl Ctr Re, Portland, OR USA; [Gallun, Frederick J.; Lewis, M. Samantha; Folmer, Robert L.; Fausti, Stephen A.; Leek, Marjorie R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Kubli, Lina R.; Walden, Therese C.] WRNMMC, Audiol & Speech Ctr, Bethesda, MD USA; [Lew, Henry L.] DVBIC, Richmond, VA USA	Gallun, FJ (corresponding author), VA RR&D Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	Frederick.Gallun@va.gov	Gallun, Frederick J./G-3792-2012; Folmer, Robert L/E-3105-2010	Gallun, Frederick J./0000-0002-4145-2199; 	VA RR&D Merit Review Award [01807]; VA RR&D Career Development II Awards [C4963-W, C7067-W]; VA RR&D Senior Research Career Scientist Award [C4042-L]; VA RR&D National Center for Rehabilitative Auditory Research; Veterans AffairsUS Department of Veterans Affairs [I01RX000536] Funding Source: NIH RePORTER	This material was based on work supported by VA RR&D Merit Review Award (grant 01807: PIs Leek, Fausti), VA RR&D Career Development II Awards (grant C4963-W: PI Gallun; and grant C7067-W: PI Lewis), VA RR&D Senior Research Career Scientist Award (grant C4042-L: PI Leek), and the VA RR&D National Center for Rehabilitative Auditory Research.	American Academy of Audiology (AAA), 2010, AM AC AUD CLIN PRACT; American Speech-Language-Hearing Association (ASHA), 2005, CENTR AUD PROC DIS W; Bamiou DE, 2006, NEUROLOGY, V67, P614, DOI 10.1212/01.wnl.0000230197.40410.db; Bregman A.S., 1990, AUDITORY SCENE ANAL; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; CHANDLER D, 2006, ASHA LEADER, P8; Chandler D W, 1997, J Am Acad Audiol, V8, P81; Cherney LR, 2010, J HEAD TRAUMA REHAB, V25, P219, DOI 10.1097/HTR.0b013e3181dc82c1; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; Colburn H.S., 1978, HDB PERCEPT, V4, P467; CUSACK R, 2004, ECOLOGICAL PSYCHOACO, P16; Darwin Christopher J., 2008, V29, P215; DEMANY L, 2008, AUDITORY PERCEPTION, P115; *DEP VET AFF OFF P, 2011, TBI COMPR EV SUMM; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dowling W. J., 1986, MUSIC COGNITION; Elhilali M, 2007, J NEUROSCI, V27, P10372, DOI 10.1523/JNEUROSCI.1462-07.2007; Elhilali M, 2008, J ACOUST SOC AM, V124, P3751, DOI 10.1121/1.3001672; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Folmer RL, 2011, INT J PSYCHOPHYSIOL, V82, P4, DOI 10.1016/j.ijpsycho.2011.03.005; Fritz J, 2003, NAT NEUROSCI, V6, P1216, DOI 10.1038/nn1141; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Griffiths TD, 2004, NAT REV NEUROSCI, V5, P887, DOI 10.1038/nrn1538; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Johnston KN, 2009, INT J AUDIOL, V48, P371, DOI 10.1080/14992020802687516; Joris PX, 2004, PHYSIOL REV, V84, P541, DOI 10.1152/physrev.00029.2003; KANDEL ER, 1991, PRINCIPLES NEURAL SC; Katz J., 1998, SSW TEST MANUAL; Kidd G, 2005, J ACOUST SOC AM, V118, P3804, DOI 10.1121/1.2109187; Kidd G, 2005, ACTA ACUST UNITED AC, V91, P526; Kidd Gerald Jr., 2008, V29, P143; Kohler W., 1947, GESTALT PSYCHOL; Kuk F, 2008, J AM ACAD AUDIOL, V19, P465, DOI 10.3766/jaaa.19.6.3; Leaver AM, 2010, J NEUROSCI, V30, P7604, DOI 10.1523/JNEUROSCI.0296-10.2010; Leek MR, 2001, J ACOUST SOC AM, V109, P2944, DOI 10.1121/1.1371761; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lewis MS, 2010, VOLTA REV, V110, P31, DOI 10.17955/tvr.110.1.617; LOUI P, 2010, P 159 M AC SOC AM NO, V9, DOI DOI 10.1121/1.3431713; Loui P, 2008, CURR BIOL, V18, pR331, DOI 10.1016/j.cub.2008.02.045; Marrone N, 2008, J ACOUST SOC AM, V124, P3064, DOI 10.1121/1.2980441; Marrone N, 2008, J ACOUST SOC AM, V124, P1146, DOI 10.1121/1.2945710; Moore B.C.J., 2007, COCHLEAR HEARING LOS; MOORE BCJ, 1992, J ACOUST SOC AM, V91, P2881, DOI 10.1121/1.402925; Musiek FE, 2005, EAR HEARING, V26, P608, DOI 10.1097/01.aud.0000188069.80699.41; MUSIEK FE, 1983, EAR HEARING, V4, P79, DOI 10.1097/00003446-198303000-00002; MUSIEK FE, 1987, AUDIOLOGY, V26, P79; Nelken I, 2003, BIOL CYBERN, V89, P397, DOI 10.1007/s00422-003-0445-3; Noble W, 2006, INT J AUDIOL, V45, P172, DOI 10.1080/14992020500376933; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Oxenham AJ, 2009, J ACOUST SOC AM, V125, P2189, DOI 10.1121/1.3089220; Peru A, 2003, NEUROPSYCHOLOGIA, V41, P634, DOI 10.1016/S0028-3932(02)00203-8; Petkov CI, 2008, NAT NEUROSCI, V11, P367, DOI 10.1038/nn2043; Petkov CI, 2006, PLOS BIOL, V4, P1213, DOI 10.1371/journal.pbio.0040215; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Saunders GH, 2012, J REHABIL RES DEV, V49, P1043, DOI 10.1682/JRRD.2010.08.0157; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scott SK, 2003, TRENDS NEUROSCI, V26, P100, DOI 10.1016/S0166-2236(02)00037-1; Shinn-Cunningham Barbara G, 2008, Trends Amplif, V12, P283, DOI 10.1177/1084713808325306; Smart Jennifer L., 2007, Australian and New Zealand Journal of Audiology, V29, P53, DOI 10.1375/audi.29.1.53; STECKER C, 2012, TRANSLATIONAL PERSPE; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tervaniemi M, 2003, BRAIN RES REV, V43, P231, DOI 10.1016/j.brainresrev.2003.08.004; Turgeon C, 2011, EAR HEARING, V32, P667, DOI 10.1097/AUD.0b013e31821209d6; Wang D., 2006, COMPUTATIONAL AUDITO; Wilson Richard H, 2005, J Am Acad Audiol, V16, P367, DOI 10.3766/jaaa.16.6.5; Winer JA, 2007, HEARING RES, V229, P3, DOI 10.1016/j.heares.2007.01.017; Yost WA, 2009, ATTEN PERCEPT PSYCHO, V71, P1701, DOI 10.3758/APP.71.8.1701; Zatorre RJ, 2007, HEARING RES, V229, P24, DOI 10.1016/j.heares.2007.01.018	76	31	33	0	16	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					1059	1074		10.1682/JRRD.2010.09.0166			16	Rehabilitation	Rehabilitation	149EZ	WOS:000319303100009	23341279	Bronze			2021-06-18	
J	Elliott, JM				Elliott, James M.			Are There Implications for Morphological Changes in Neck Muscles After Whiplash Injury?	SPINE			English	Article						whiplash; spine; MRI; pain; muscle; morphometry	RESONANCE-IMAGING ASSESSMENT; CERVICAL EXTENSOR MUSCLES; TRAUMATIC BRAIN-INJURY; HUMAN SKELETAL-MUSCLE; ACUTE STRESS-RESPONSE; SPINAL-CORD; PSYCHOLOGICAL-FACTORS; FATTY INFILTRATION; ALAR LIGAMENTS; MRI	Study Design. Literature review. Objective. To review the evidence related to the morphological changes (atrophy and fatty degeneration) of neck muscles in whiplash-associated disorders (WAD) and to highlight emerging evidence for the pathophysiological mechanisms behind muscle degeneration and their potential role in the transition from acute to chronic pain after whiplash injury from a motor vehicle crash (MVC). Summary of Background Data. Magnetic resonance imaging (MRI) can be regarded as the gold standard for muscle imaging. There is emerging evidence to highlight in vivo features of neck muscle degeneration in patients with chronic WAD and the temporal development of such acute changes after MVC. However, the precise underlying mechanisms for such changes and their influence on functional recovery after whiplash remain largely unknown. Methods. Literature review of available evidence from both the authors' previous studies and other similar bodies of work. Results. Studies have quantified degenerative changes in the neck muscles of patients with acute and chronic whiplash with structural MRI applications. Conclusion. Current evidence from structural MRI based studies demonstrates the widespread presence of fatty infiltrates in neck muscles of patients with chronic whiplash. Such findings have not shown to feature in patients with chronic insidious onset neck pain, suggesting traumatic factors play a role in their development. Recent studies have revealed that muscle fatty infiltrates manifest soon after whiplash but only in those with higher pain and disability and symptoms of post-traumatic stress disorder. The possibility that such muscle changes are associated with a more severe injury including poor functional recovery remains the focus of current research efforts.	Northwestern Univ, Feinberg Sch Med, Dept Phys Therapy & Human Movement Sci, Chicago, IL 60611 USA	Elliott, JM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Phys Therapy & Human Movement Sci, Chicago, IL 60611 USA.	j-elliott@northwestern.edu			Australian Physiotherapy Research Foundation; Centre for National Research on Disability and Rehabilitation Medicine (CONROD), University of QueenslandUniversity of Queensland; Centre for Research Excellence in Spinal Pain, Injury and Health (CCRE-Spine), University of QueenslandUniversity of Queensland	The Australian Physiotherapy Research Foundation and The Centre for National Research on Disability and Rehabilitation Medicine (CONROD), University of Queensland provided funding for the work. JE received a post-doctoral fellowship from The Centre for Research Excellence in Spinal Pain, Injury and Health (CCRE-Spine), University of Queensland (2008-2010). No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.	Banic B, 2004, PAIN, V107, P7, DOI 10.1016/j.pain.2003.05.001; Blamire AM, 2007, MAGN RESON MED, V58, P880, DOI 10.1002/mrm.21382; Borchgrevink G, 1997, INJURY, V28, P331, DOI 10.1016/S0020-1383(97)00027-2; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; COTE P, 2001, SPINE, V26, P445; Elliott J, 2008, CLIN RADIOL, V63, P681, DOI 10.1016/j.crad.2007.11.011; Elliott JM, 2012, SPINAL CORD, V50, P474, DOI 10.1038/sc.2011.17; Elliott J, 2008, MANUAL THER, V13, P258, DOI 10.1016/j.math.2007.01.012; Elliott J, 2006, SPINE, V31, pE847, DOI 10.1097/01.brs.0000240841.07050.34; Elliott J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021194; Elliott J, 2009, EUR SPINE J, V18, P1371, DOI 10.1007/s00586-009-1130-6; Elliott JM, 2010, SPINE, V35, P948, DOI 10.1097/BRS.0b013e3181bb0e55; Erschbamer M, 2011, EUR J NEUROSCI, V33, P678, DOI 10.1111/j.1460-9568.2010.07562.x; Ferrari R, 1999, CLIN EXP RHEUMATOL, V17, P321; FLECKENSTEIN JL, 1993, RADIOLOGY, V187, P213, DOI 10.1148/radiology.187.1.8451416; Gerber C, 2007, J SHOULDER ELB SURG, V16, P691, DOI 10.1016/j.jse.2007.02.122; Gorgey AS, 2007, SPINAL CORD, V45, P304, DOI 10.1038/sj.sc.3101968; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; Hallgren RC, 2008, CLIN ANAT, V21, P501, DOI 10.1002/ca.20660; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holl N, 2008, SKELETAL RADIOL, V37, P1111, DOI 10.1007/s00256-008-0552-2; Holly LT, 2009, J NEUROSURG-SPINE, V10, P194, DOI 10.3171/2008.12.SPINE08367; INGEMANNHANSEN T, 1977, SCAND J REHABIL MED, V9, P67; Jenkins RR, 2000, AM J CLIN NUTR, V72, p670S, DOI 10.1093/ajcn/72.2.670S; Joslin CC, 2004, J BONE JOINT SURG BR, V86B, P1032, DOI 10.1302/0301-620X.86B7.14633; Kamath S, 2008, SKELETAL RADIOL, V37, P397, DOI 10.1007/s00256-007-0409-0; Kaneoka K, 1999, SPINE, V24, P763, DOI 10.1097/00007632-199904150-00006; Kendi ATK, 2004, NEURORADIOLOGY, V46, P764, DOI 10.1007/s00234-004-1231-1; Kongsted A, 2008, EUR J PAIN, V12, P455, DOI 10.1016/j.ejpain.2007.07.008; Krakenes J, 2002, NEURORADIOLOGY, V44, P617, DOI 10.1007/s00234-002-0799-6; Krakenes J, 2006, SPINE, V31, P2820, DOI 10.1097/01.brs.0000245871.15696.1f; Lee KE, 2009, J PAIN, V10, P436, DOI 10.1016/j.jpain.2008.11.009; Lee KE, 2008, J NEUROTRAUM, V25, P1383, DOI 10.1089/neu.2008.0700; Lovitt S, 2006, CLIN NEUROPHYSIOL, V117, P486, DOI 10.1016/j.clinph.2005.10.010; Manini TM, 2007, AM J CLIN NUTR, V85, P377; Marshall RD, 2002, PSYCHIAT CLIN N AM, V25, P385, DOI 10.1016/S0193-953X(01)00005-3; MARTIN D, 1992, NEURORADIOLOGY, V34, P262, DOI 10.1007/BF00588177; MURPHY WA, 1986, AM J ROENTGENOL, V146, P565, DOI 10.2214/ajr.146.3.565; Myran R, 2008, SPINE, V33, P2012, DOI 10.1097/BRS.0b013e31817bb0bd; Nemeroff CB, 2006, J PSYCHIATR RES, V40, P1, DOI 10.1016/j.jpsychires.2005.07.005; NISHIKAWA H, 1993, INT J EXP PATHOL, V74, P35; Paddon-Jones D, 2006, J CLIN ENDOCR METAB, V91, P4836, DOI 10.1210/jc.2006-0651; Passatore M, 2006, EUR J APPL PHYSIOL, V98, P423, DOI 10.1007/s00421-006-0312-8; Rebbeck T, 2006, INJURY PREV, V12, P93, DOI 10.1136/ip.2005.010421; Ronnen HR, 1996, RADIOLOGY, V201, P93, DOI 10.1148/radiology.201.1.8816527; Scholten-Peeters GGM, 2003, PAIN, V104, P303, DOI 10.1016/S0304-3959(03)00050-2; Sehy JV, 2002, MAGNET RESON MED, V48, P765, DOI 10.1002/mrm.10301; Sjogaard G, 1998, CLIN ORTHOP RELAT R, P21; Sterling M, 2003, PAIN, V104, P509, DOI 10.1016/S0304-3959(03)00078-2; Sterling M, 2006, PAIN, V122, P102, DOI 10.1016/j.pain.2006.01.014; Sullivan MJL, 2009, PAIN, V145, P325, DOI 10.1016/j.pain.2009.06.031; Svensson MY, 1998, ORTHOPADE, V27, P820; Vetti N, 2011, SPINE, V36, pE434, DOI 10.1097/BRS.0b013e3181da21a9; Walton DM, 2009, J ORTHOP SPORT PHYS, V39, P334, DOI 10.2519/jospt.2009.2765; Williamson E, 2008, PAIN, V135, P20, DOI 10.1016/j.pain.2007.04.035; Zaraiskaya T, 2006, J MAGN RESON IMAGING, V24, P402, DOI 10.1002/jmri.20651; Zimmermann M, 2001, EUR J PHARMACOL, V429, P23, DOI 10.1016/S0014-2999(01)01303-6	57	31	33	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	DEC 1	2011	36	25		S			S205	S210		10.1097/BRS.0b013e3182387f57			6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	858PN	WOS:000297813800007	22020614				2021-06-18	
J	Leitgeb, J; Mauritz, W; Brazinova, A; Janciak, I; Majdan, M; Wilbacher, I; Rusnak, M				Leitgeb, Johannes; Mauritz, Walter; Brazinova, Alexandra; Janciak, Ivan; Majdan, Marek; Wilbacher, Ingrid; Rusnak, Martin			Effects of Gender on Outcomes After Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Gender; Outcome	PROGNOSTIC VALUE; HEAD-INJURIES; IMPACT; MANAGEMENT; MORTALITY; SCALE; AGE	Background: It has been reported that female gender may be an independent risk factor for poor outcome after traumatic brain injury (TBI). The goal of this study was to investigate gender differences in outcome after TBI. Methods: Between February 2002 and April 2010, 17 Austrian centers prospectively enrolled 863 patients with moderate and severe TBI into observational studies. Data on crash, treatment, and outcomes were collected. Data sets from patients who had isolated TBI were selected. Six-month outcomes were classified as "favorable" if Glasgow Outcome Scale scores were 5 or 4 and were classified as "unfavorable" if Glasgow Outcome Scale scores were 3 or less. The Rotterdam score was used to classify computed tomography (CT) findings. Univariate statistics (Fisher's exact test, t test, chi(2) test) and logistic regression were used to identify factors associated with hospital mortality and favorable outcome. Results: There were 134 female and 305 male patients. Hospital mortality was 39.6% for females and 32.5% for males (p = 0.16). Rates of unfavorable outcome were 58.7% for females and 53.4% for males (p = 0.09). There were no significant mortality differences between females and males for factors such as age groups, trauma mechanisms, Glasgow Coma Scale scores, lesions on the CT scan, or treatment factors. Logistic regression revealed that gender had no significant influence on mortality of unfavorable outcome. The differences in outcome were due to the higher mean age of females (61.4 vs. 50.4, p < 0.001) and possibly because of small differences in Glasgow Coma Scale scores and in CT scores. Conclusions: Female gender is not an independent risk factor for in-hospital mortality after TBI.	[Leitgeb, Johannes] Med Univ Vienna, Dept Traumatol, A-1090 Vienna, Austria; [Mauritz, Walter; Brazinova, Alexandra; Janciak, Ivan; Majdan, Marek; Wilbacher, Ingrid; Rusnak, Martin] INRO, Vienna, Austria; [Mauritz, Walter] Trauma Hosp Lorenz Boehler, Dept Anesthesiol & Intens Care Med, Vienna, Austria; [Brazinova, Alexandra; Majdan, Marek; Rusnak, Martin] Trnava Univ, Fac Hlth & Social Serv, Dept Publ Hlth, Trnava, Slovakia	Leitgeb, J (corresponding author), Med Univ Vienna, Dept Traumatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	johannes.leitgeb@meduniwien.ac.at	Brazinova, Alexandra/C-4265-2016; Rusnak, Martin/K-9349-2016; Majdan, Marek/K-5017-2012	Brazinova, Alexandra/0000-0003-0625-256X; Rusnak, Martin/0000-0003-3321-1042; Majdan, Marek/0000-0001-8037-742X; Mauritz, Walter/0000-0001-9043-3712	Austrian Worker's Compensation Board (AUVA) [FK 33/2003]; Austrian National Bank [8987]; Ministry of Health; AUVA [FK 11/2008, FK 11/2010]	Supported by the Austrian Worker's Compensation Board (AUVA; FK 33/2003) and by the "Jubilee Fund" of the Austrian National Bank (Project 8987), and for a project funded by the Ministry of Health (Contract October 15, 2008) and the AUVA (FK 11/2008 and FK 11/2010).	Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Farace E, 2000, Neurosurg Focus, V8, pe6; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y	22	31	33	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2011	71	6					1620	1626		10.1097/TA.0b013e318226ea0e			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	869RT	WOS:000298616400032	21808209				2021-06-18	
J	Radolovich, DK; Aries, MJH; Castellani, G; Corona, A; Lavinio, A; Smielewski, P; Pickard, JD; Czosnyka, M				Radolovich, D. K.; Aries, M. J. H.; Castellani, G.; Corona, A.; Lavinio, A.; Smielewski, P.; Pickard, J. D.; Czosnyka, M.			Pulsatile Intracranial Pressure and Cerebral Autoregulation After Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Intracranial pressure amplitude; Flow velocity waveform analysis; Cerebrovascular autoregulation	WAVE-FORM ANALYSIS; HEAD-INJURY; PULSE PRESSURE; HYDROCEPHALUS; REACTIVITY; AMPLITUDE	Strong correlation between mean intracranial pressure (ICP) and its pulse wave amplitude (AMP) has been demonstrated in different clinical scenarios. We investigated the relationship between invasive mean arterial blood pressure (ABP) and AMP to explore its potential role as a descriptor of cerebrovascular pressure reactivity after traumatic brain injury (TBI). We retrospectively analyzed data of patients suffering from TBI with brain monitoring. Transcranial Doppler blood flow velocity, ABP, ICP were recorded digitally. Cerebral perfusion pressure (CPP) and AMP were derived. A new index-pressure-amplitude index (PAx)-was calculated as the Pearson correlation between (averaged over 10 s intervals) ABP and AMP with a 5 min long moving average window. The previously introduced transcranial Doppler-based autoregulation index Mx was evaluated in a similar way, as the moving correlation between blood flow velocity and CPP. The clinical outcome was assessed after 6 months using the Glasgow outcome score. 293 patients were studied. The mean PAx was -0.09 (standard deviation 0.21). This negative value indicates that, on average, an increase in ABP causes a decrease in AMP and vice versa. PAx correlated strong with Mx (R (2) = 0.46, P < 0.0002). PAx also correlated with age (R (2) = 0.18, P < 0.05). PAx was found to have as good predictive outcome value (area under curve 0.71, P < 0.001) as Mx (area under curve 0.69, P < 0.001). We demonstrated significant correlation between the known cerebral autoregulation index Mx and PAx. This new index of cerebrovascular pressure reactivity using ICP pulse wave information showed to have a strong association with outcome in TBI patients.	[Radolovich, D. K.; Aries, M. J. H.; Castellani, G.; Smielewski, P.; Pickard, J. D.; Czosnyka, M.] Univ Cambridge, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England; [Radolovich, D. K.] IRCCS Policlin San Matteo, Dept Intens Care, Pavia, Italy; [Aries, M. J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Castellani, G.] Inst Europeo Oncol, Dept Anaesthesia & Intens Care, Milan, Italy; [Corona, A.] Azienda Osped L Sacco, Dept Intens Care, Milan, Italy; [Lavinio, A.] Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England; [Czosnyka, M.] Warsaw Univ Technol, ISE, Warsaw, Poland	Radolovich, DK (corresponding author), Univ Cambridge, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England.	iperdany@hotmail.com	Corona, Alberto/V-8684-2019; Corona, Alberto/B-3328-2013; Corona, Alberto/G-8914-2018; Lavinio, Andrea/M-1778-2016	Smielewski, Peter/0000-0001-5096-3938	National Institute of Health Research, Biomedical Research Centre, Cambridge University Hospital Foundation Trust - Neurosciences ThemeNational Institute for Health Research (NIHR); Senior Investigator Awards; European Federation of Neurological Societies (EFNS); Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	The project was supported by the National Institute of Health Research, Biomedical Research Centre, Cambridge University Hospital Foundation Trust - Neurosciences Theme (MC, PS) and Senior Investigator Awards (JDP). MJH Aries received a travel grant from the European Federation of Neurological Societies (EFNS) and is supported by the Netherlands Organisation for Health Research and Development. ICM+ is licensed by University of Cambridge, Cambridge Enterprise Ltd.	AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Bentsen G, 2008, CRIT CARE MED, V36, P2414, DOI 10.1097/CCM.0b013e318180fe04; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Carrera E., 2009, J NEUROIMAGING; Carrera E, 2010, J NEUROTRAUM, V27, P317, DOI 10.1089/neu.2009.0951; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Eide PK, 2007, PEDIATR NEUROSURG, V43, P472, DOI 10.1159/000108790; Eide PK, 2006, ACTA NEUROCHIR, V148, P1267, DOI 10.1007/s00701-006-0908-0; Eide PK, 2006, ACTA NEUROCHIR, V148, P1151, DOI 10.1007/s00701-006-0896-0; Eide PK, 2010, ACTA NEUROL SCAND, V122, P262, DOI 10.1111/j.1600-0404.2009.01304.x; GUILLAUME J, 1951, REV NEUROL, V84, P131; Holm S, 2008, MED ENG PHYS, V30, P164, DOI 10.1016/j.medengphy.2007.03.003; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P557; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Madsen Joseph R, 2006, Clin Neurosurg, V53, P48; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; Rosner MJ, 1996, CRIT CARE MED, V24, P1274, DOI 10.1097/00003246-199607000-00040; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002	25	31	31	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	DEC	2011	15	3					379	386		10.1007/s12028-011-9553-4			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	852NT	WOS:000297365400003	21805216				2021-06-18	
J	Krivitzky, LS; Roebuck-Spencer, TM; Roth, RM; Blackstone, K; Johnson, CP; Gioia, G				Krivitzky, Lauren S.; Roebuck-Spencer, Tresa M.; Roth, Robert M.; Blackstone, Kaitlin; Johnson, Chad P.; Gioia, Gerard			Functional Magnetic Resonance Imaging of Working Memory and Response Inhibition in Children with Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Concussion; Brain; Inhibition; Traumatic brain injury; Cerebellum; Prefrontal cortex; Post concussive symptoms	EVENT-RELATED FMRI; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; PREFRONTAL CORTEX; MRI; CONCUSSION; ACTIVATION; TASK; DISORDER; RECOVERY	The current pilot study examined functional magnetic resonance imaging (fMRI) activation in children with mild traumatic brain injury (mTBI) during tasks of working memory and inhibitory control, both of which are vulnerable to impairment following mTBI. Thirteen children with symptomatic mTBI and a group of controls completed a version of the Tasks of Executive Control (TEC) during fMRI scanning. Both groups showed greater prefrontal activation in response to increased working memory load. Activation patterns did not differ between groups on the working memory aspects of the task, but children with mTBI showed greater activation in the posterior cerebellum with the addition of a demand for inhibitory control. Children with mTBI showed greater impairment on symptom report and "real world'' measures of executive functioning, but not on traditional "paper and pencil'' tasks. Likewise, cognitive testing did not correlate significantly with imaging results, whereas increased report of post-concussive symptoms were correlated with increased cerebellar activation. Overall, results provide some evidence for the utility of symptom report as an indicator of recovery and the hypothesis that children with mTBI may experience disrupted neural circuitry during recovery. Limitations of the study included a small sample size, wide age range, and lack of in-scanner accuracy data. (JINS, 2011, 17, 1143-1152)	[Krivitzky, Lauren S.; Blackstone, Kaitlin; Johnson, Chad P.; Gioia, Gerard] George Washington Univ, Sch Med & Hlth Sci, Div Pediat Neuropsychol, Dept Psychiat & Behav Sci,Childrens Natl Med Ctr, Washington, DC 20052 USA; [Roebuck-Spencer, Tresa M.] Univ Oklahoma, Norman, OK 73019 USA; [Roth, Robert M.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Brain Imaging Lab,Dept Psychiat, Hanover, NH 03756 USA	Gioia, G (corresponding author), Childrens Natl Med Ctr, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20852 USA.	ggioia@cnmc.org			Children's Research Institute (CRI) at the Children's National Medical Center; National Rehabilitation Hospital/Medstar Research Institute; GCRC/CTSA at Children's National Medical CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); IDDRC at Children's National Medical Center	This project was supported by an internal RAC grant from the Children's Research Institute (CRI) at the Children's National Medical Center, an internal grant through the National Rehabilitation Hospital/Medstar Research Institute, and through the GCRC/CTSA and IDDRC grants at Children's National Medical Center. We thank Ben Yerys, PhD and Madison Berl, PhD for their assistance with analysis. There are no conflicts of interest.	Aron AR, 2005, BIOL PSYCHIAT, V57, P1285, DOI 10.1016/j.biopsych.2004.10.026; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barkley R. A., 1997, ADHD NATURE SELF CON; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Delis DC, 2001, DELISKAPLAN EXECUTIV; Desmond J.E., 1998, TRENDS COGN SCI, V2, P1364; Evans R.W, 2006, NEUROLOGY TRAUMA, P815; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Gazzaley Adam, 2004, Cognitive Affective & Behavioral Neuroscience, V4, P580, DOI 10.3758/CABN.4.4.580; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia G.A., 2000, BEHAV RATING INVENTO; Giza CC, 2001, J ATHL TRAINING, V36, P228; Habas C, 2009, J NEUROSCI, V29, P8586, DOI 10.1523/JNEUROSCI.1868-09.2009; Isquith P, 2010, TASKS EXECUTIVE CONT; Kelly AMC, 2004, EUR J NEUROSCI, V19, P3105, DOI 10.1111/j.0953-816X.2004.03429.x; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Konishi S, 1999, BRAIN, V122, P981, DOI 10.1093/brain/122.5.981; Korkman M., 1997, NEPSY DEV NEUROPSYCH; Kramer ME, 2008, J INT NEUROPSYCH SOC, V14, P424, DOI 10.1017/S1355617708080545; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Matthews C, 1964, INSTRUCTION MANUAL A; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Miyake A., 1999, MODELS WORKING MEMOR; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; O'Hare ED, 2008, NEUROIMAGE, V42, P1678, DOI 10.1016/j.neuroimage.2008.05.057; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Roth RM, 2007, BIOL PSYCHIAT, V62, P901, DOI 10.1016/j.biopsych.2006.12.007; Roth RM, 2006, FOCUS ON NEUROPSYCHOLOGY RESEARCH, P1; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Smith A., 1982, SYMBOL DIGIT MODALIT; Tamm L, 2004, J AM ACAD CHILD PSY, V43, P1430, DOI 10.1097/01.chi.0000140452.51205.8d; Thomason M.E., 2008, J COGNITIVE NEUROSCI, V21, P1; Tiemeier H, 2010, NEUROIMAGE, V49, P63, DOI 10.1016/j.neuroimage.2009.08.016; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2004, WECHSLER INTELLIGENC; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Woodcock R.W., 2001, WOODCOCKJOHNSON 3 TE; Yeates K. O., 2010, PEDIAT NEUROPSYCHOLO, P112; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	61	31	31	0	29	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2011	17	6					1143	1152		10.1017/S1355617711001226			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	848DF	WOS:000297028500021	22014100				2021-06-18	
J	Long, B; Anderson, V; Jacobs, R; Mackay, M; Leventer, R; Barnes, C; Spencer-Smith, M				Long, Brian; Anderson, Vicki; Jacobs, Rani; Mackay, Mark; Leventer, Richard; Barnes, Chris; Spencer-Smith, Megan			Executive Function Following Child Stroke: The Impact of Lesion Size	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; OF-THE-LITERATURE; PREFRONTAL CORTEX; ISCHEMIC-STROKE; FUTURE-RESEARCH; FRONTAL LOBES; MEMORY; ATTENTION; PERFORMANCE; NETWORKS	Childhood stroke is increasingly recognized as a major cause of childhood morbidity and mortality; however, limited information exists regarding neurobehavioral sequelae. Executive function (EF), important for problem solving, reasoning, social awareness, and adaptive behavior, may be particularly vulnerable to early brain lesions such as stroke, due to its protracted development. This study investigated: (i) the impact of childhood stroke on EF; and (ii) the impact of lesion size on EF outcome. Twenty-eight children diagnosed with stroke at least 12 months prior to assessment were recruited. Neurobehavioral assessment focused on cognitive and behavioral aspects of EF. Lesion volume was determined from standard ratings of brain pathology based on magnetic resonance imaging (MRI) scans. Deficits in cognitive aspects of EF were detected in attentional control, cognitive flexibility and information processing. Difficulties in behavioral aspects of EF were most striking, with problems identified across a wide range of behaviors. Lesion size impacted on EF, with large lesions (greater than 25% of brain volume) proving the most detrimental.	[Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Long, Brian; Jacobs, Rani; Spencer-Smith, Megan] Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au		Mackay, Mark/0000-0002-3787-1112; Spencer-Smith, Megan/0000-0002-1047-0829			Abram HS, 1996, J CHILD NEUROL, V11, P276, DOI 10.1177/088307389601100403; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1997, Pediatr Rehabil, V1, P63; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Aram DM, 1986, DEV NEUROPSYCHOL, V2, P155, DOI 10.1080/87565648609540339; Ballantyne AO, 2008, BRAIN, V131, P2975, DOI 10.1093/brain/awn176; BALLANTYNE AO, 1994, DEV NEUROPSYCHOL, V10, P39, DOI 10.1080/87565649409540565; Bava S, 2007, J CHILD NEUROL, V22, P841, DOI 10.1177/0883073807304700; Beauregard M, 1995, NEUROREPORT, V6, P2521, DOI 10.1097/00001756-199512150-00018; Beebe DW, 2002, J SLEEP RES, V11, P1, DOI 10.1046/j.1365-2869.2002.00289.x; Bertolino A, 1997, CEREB CORTEX, V7, P740, DOI 10.1093/cercor/7.8.740; Block GW, 1999, CHILD NEUROPSYCHOL, V5, P81, DOI 10.1076/chin.5.2.81.3169; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Daniel A, 1993, POWER PRIVILEGE PRES; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DELLAMALVA CL, 1993, NEUROPSYCHOLOGIA, V31, P363; DENNIS M, 1980, BRAIN LANG, V10, P287, DOI 10.1016/0093-934X(80)90058-9; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; deVeber GA, 2000, ANN NEUROL, V48, P514; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Everts R, 2008, CHILD NEUROPSYCHOL, V14, P323, DOI 10.1080/09297040701792383; Gioia G., 2000, BEHAV RATING EXECUTI; Goodman R, 1996, DEV MED CHILD NEUROL, V38, P881, DOI 10.1111/j.1469-8749.1996.tb15045.x; Gordon AL, 2002, J CHILD NEUROL, V17, P429, DOI 10.1177/088307380201700606; Hartel C, 2004, EUR J NEUROL, V11, P431, DOI 10.1111/j.1468-1331.2004.00861.x; Heyder K, 2004, ACTA PSYCHOL, V115, P271, DOI 10.1016/j.actpsy.2003.12.010; Hogan AM, 2000, J CHILD NEUROL, V15, P325, DOI 10.1177/088307380001500509; HUDSPETH WJ, 1992, INT J PSYCHOPHYSIOL, V12, P19, DOI 10.1016/0167-8760(92)90039-E; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; JACOBS R, 2001, CLIN NEUROPSYCHOL, V2, P101; Klingberg T, 1997, CEREB CORTEX, V7, P465, DOI 10.1093/cercor/7.5.465; Knight RT, 1997, J COGNITIVE NEUROSCI, V9, P75, DOI 10.1162/jocn.1997.9.1.75; KOELFEN W, 1993, EUR J PEDIATR, V152, P1030, DOI 10.1007/BF01957231; Kolb B., 2002, PRINCIPLES FRONTAL L, P541; Lansing AE, 2004, J INT NEUROPSYCH SOC, V10, P742, DOI 10.1017/S1355617704105122; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; Leventer RJ, 1999, NEUROLOGY, V53, P715, DOI 10.1212/WNL.53.4.715; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine SC, 2005, BRAIN COGNITION, V59, P114, DOI 10.1016/j.bandc.2005.05.008; Luria A. R, 1973, WORKING BRAIN; Lynch JK, 2002, PEDIATRICS, V109, P116, DOI 10.1542/peds.109.1.116; Manly T., 1999, TEST EVERYDAY ATTENT; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Max JE, 2005, J AM ACAD CHILD PSY, V44, P443, DOI 10.1097/01.chi.0000156661.38576.0f; Max JE, 2004, J INT NEUROPSYCH SOC, V10, P698, DOI 10.1017/S1355617704105092; Max JE, 2002, J AM ACAD CHILD PSY, V41, P555, DOI 10.1097/00004583-200205000-00013; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206; Reilly J, 2004, BRAIN LANG, V88, P229, DOI 10.1016/S0093-934X(03)00101-9; Semel E., 2003, CLIN EVALUATION LANG; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Steinlin M, 2004, EUR J PEDIATR, V163, P245, DOI 10.1007/s00431-003-1357-x; Stiles J, 2005, TRENDS COGN SCI, V9, P136, DOI 10.1016/j.tics.2005.01.002; Stiles J, 2008, NEUROPSYCHOLOGY, V22, P61, DOI 10.1037/0894-4105.22.1.61; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Stuss DT, 1999, NEUROPSYCHOLOGIA, V37, P1005, DOI 10.1016/S0028-3932(98)00158-4; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tabachnick B., 2001, USING MULTIVARIATE S; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Tullberg M, 2004, NEUROLOGY, V63, P246, DOI 10.1212/01.WNL.0000130530.55104.B5; VARGHAKHADEM F, 1992, BRAIN, V115, P315, DOI 10.1093/brain/115.1.315; Wechsler D., 1999, MANUAL WECHSLER ABBR; Wechsler D, 2003, MANUAL WECHSLER SCAL; Westmacott R, 2010, DEV MED CHILD NEUROL, V52, P386, DOI 10.1111/j.1469-8749.2009.03403.x	73	31	33	2	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	NOV-DEC	2011	36	8					971	987		10.1080/87565641.2011.581537			17	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	846VP	WOS:000296931600002	22004019				2021-06-18	
J	Potter, JL; Wade, SL; Walz, NC; Cassedy, A; Stevens, MH; Yeates, KO; Taylor, HG				Potter, Jennifer L.; Wade, Shari L.; Walz, Nicolay C.; Cassedy, Amy; Stevens, M. Hank; Yeates, Keith O.; Taylor, H. Gerry			Parenting Style Is Related to Executive Dysfunction After Brain Injury in Children	REHABILITATION PSYCHOLOGY			English	Article						traumatic; parenting; permissive; authoritarian; preschool	FAMILY ASSESSMENT DEVICE; YOUNG-CHILDREN; BEHAVIOR PROBLEMS; SHORT-TERM; FOLLOW-UP; OUTCOMES; RELIABILITY; VALIDITY; SKILLS; AUTHORITARIAN	Objective: The goal of this study was to examine how parenting style (authoritarian, authoritative, permissive) and family functioning are related to behavioral aspects of executive function following traumatic brain injury (TBI) in young children. Method: Participants included 75 children with TB! and 97 children with orthopedic injuries (OI), ages 3-7 years at injury. Pre-injury parenting behavior and family functioning were assessed shortly after injury, and postinjury executive functions were assessed using the Behavior Rating Inventory of Executive Functioning (BRIEF; Gioia & Isquith, 2004) at 6, 12, and 18 months postinjury. Mixed model analyses, using pre-injury executive functioning (assessed by the BRIEF at baseline) as a covariate, examined the relationship of parenting style and family characteristics to executive functioning in children with moderate and severe TBI compared to OI. Results: Among children with moderate TBI, higher levels of authoritarian parenting were associated with greater executive difficulties at 12 and 18 months following injury. Permissive and authoritative parenting styles were not significantly associated with postinjury executive skills. Finally, fewer family resources predicted more executive deficits across all of the groups, regardless of injury type. Conclusion: These findings provide additional evidence regarding the role of the social and familial environment in emerging behavior problems following childhood TBI.	[Potter, Jennifer L.] Cincinnati Childrens Hosp, Div Behav Med & Clin Psychol, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Stevens, M. Hank] Miami Univ, Dept Bot, Oxford, OH 45056 USA; [Yeates, Keith O.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA	Potter, JL (corresponding author), Cincinnati Childrens Hosp, Div Behav Med & Clin Psychol, Med Ctr, Dept Pediat, MLC 3015,3333 Burnet Ave, Cincinnati, OH 45229 USA.	jennifer.potter@cchmc.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER		Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Arranz EB, 2010, J FAM STUD, V16, P130, DOI 10.5172/jfs.16.2.130; BAUMRIND D, 1966, CHILD DEV, V37, P887, DOI 10.1111/j.1467-8624.1966.tb05416.x; BAUMRIND D, 1971, DEV PSYCHOL, V4, P1, DOI 10.1037/h0030372; Baumrind D., 1967, GENETIC PSYCHOL MONO, V75, P89; Bernier A, 2010, CHILD DEV, V81, P326, DOI 10.1111/j.1467-8624.2009.01397.x; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Calkins SD, 1998, SOC DEV, V7, P350, DOI 10.1111/1467-9507.00072; CAMPOS JJ, 1989, DEV PSYCHOL, V25, P394, DOI 10.1037/0012-1649.25.3.394; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; DeGarmo S., 2004, PREV SCI, V5, P73, DOI DOI 10.1023/B:PREV.0000023078.30191.E0; DeVito C, 2001, DEV PSYCHOPATHOL, V13, P215, DOI 10.1017/S0954579401002024; DORNBUSCH SM, 1987, CHILD DEV, V58, P1244, DOI 10.1111/j.1467-8624.1987.tb01455.x; Eisenberg N, 2005, CHILD DEV, V76, P1055, DOI 10.1111/j.1467-8624.2005.00897.x; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Garth J, 1997, Pediatr Rehabil, V1, P99; GAUVAIN M, 1989, DEV PSYCHOL, V25, P139, DOI 10.1037/0012-1649.25.1.139; GINSBURG GS, 1993, CHILD DEV, V64, P1461, DOI 10.1111/j.1467-8624.1993.tb02964.x; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Hess R. D., 1985, REV CHILD DEV RES, P179; LAMBORN SD, 1991, CHILD DEV, V62, P1049, DOI 10.2307/1131151; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS RH, 1988, SOC SCI MED, V27, P999, DOI 10.1016/0277-9536(88)90291-2; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI 10.2466/pr0.1995.77.3.819; Schroeder VM, 2009, J CHILD FAM STUD, V18, P227, DOI 10.1007/s10826-008-9223-0; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	44	31	32	1	30	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2011	56	4					351	358		10.1037/a0025445			8	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	862AQ	WOS:000298062600008	21928918	Green Accepted			2021-06-18	
J	Boulet, T; Kelso, ML; Othman, SF				Boulet, Thomas; Kelso, Matthew L.; Othman, Shadi F.			Microscopic magnetic resonance elastography of traumatic brain injury model	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury; Microscopic magnetic resonance; elastography; Inverse problem; Rat brain; In vivo mouse	MR ELASTOGRAPHY; VISCOELASTIC PROPERTIES; AXONAL INJURY; EDEMA; TIME; RECONSTRUCTION; IMPACT; SPECTROSCOPY; INVERSION; FIBROSIS	Traumatic brain injury (TB!) is a major cause of death and disability for which there is no cure. One of the issues inhibiting clinical trial success is the lack of targeting specific patient populations due to inconsistencies between clinical diagnostic tools and underlying pathophysiology. The development of reliable, noninvasive markers of TBI severity and injury mechanisms may better identify these populations, thereby improving clinical trial design. Magnetic resonance elastography (MRE), by assessing tissue mechanical properties, can potentially provide such marker. MRE synchronizes mechanical excitations with a phase contrast imaging pulse sequence to noninvasively register shear wave propagation, from which local values of tissue viscoelastic properties can be deduced. The working hypothesis of this study is that TBI involves a compression of brain tissue large enough to bring the material out of its elastic range, sufficiently altering mechanical properties to generate contrast on MRE measurements. To test this hypothesis, we combined microscopic MRE with brain tissue collected from adult male rats subjected to a controlled cortical impact injury. Measurements were made in different regions of interest (somatosensory cortex, hippocampus, and thalamus), and at different time points following the injury (immediate, 24 h, 7 days, 28 days). Values of stiffness in the somatosensory cortex were found to be 23-32% lower in the injured hemisphere than in the healthy one, when no significant difference was observed in the case of sham brains. A preliminary in vivo experiment is also presented, as well as alternatives to improve the faithfulness of stiffness recovery. (C) 2011 Elsevier B.V. All rights reserved.	[Othman, Shadi F.] Univ Nebraska, Dept Biol Syst Engn, Translat & Regenerat Med TREM Imaging Lab, Lincoln, NE 68583 USA; [Boulet, Thomas] Univ Nebraska, Dept Engn Mech, Lincoln, NE 68588 USA; [Kelso, Matthew L.] Univ Nebraska Med Ctr, Dept Pharm Practice, Coll Pharm, Omaha, NE 68198 USA	Othman, SF (corresponding author), Univ Nebraska, Dept Biol Syst Engn, Translat & Regenerat Med TREM Imaging Lab, 249 LW Chase Hall, Lincoln, NE 68583 USA.	thomas.boulet@huskers.unl.edu; mkelso@unmc.edu; sothman2@unl.edu			UNL/UNMC; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO3-EB007299-02]; NIH COBRE Nebraska Center for Nanomedicine [RR021937]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR021937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R03EB007299] Funding Source: NIH RePORTER	The authors wish to thank Mr. Evan Curtis and Mr. Simeng Zhang for their technical assistance. This research was supported in part by UNL/UNMC Engineering for Medicine Research Collaboration Seed Grant, NIH RO3-EB007299-02, and NIH COBRE grant RR021937 (Nebraska Center for Nanomedicine).	Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Basford JR, 2002, ARCH PHYS MED REHAB, V83, P1530, DOI 10.1053/apmr.2002.35472; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Chan RW, 2003, ANN BIOMED ENG, V31, P482, DOI 10.1114/1.1561287; Denic A, 2011, NEUROTHERAPEUTICS, V8, P3, DOI 10.1007/s13311-010-0002-4; Faria SC, 2009, RADIOGRAPHICS, V29, P1615, DOI 10.1148/rg.296095512; Faul M, 2010, HOSP DEATHS 2002 200; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Klatt D, 2007, PHYS MED BIOL, V52, P7281, DOI 10.1088/0031-9155/52/24/006; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kuroiwa T, 2006, ACTA NEUROCHIR SUPPL, V96, P254; Kuroiwa T, 1997, ACT NEUR S, V70, P87; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Manduca A, 2003, MED IMAGE ANAL, V7, P465, DOI 10.1016/S1361-8415(03)00038-0; Mariappan YK, 2009, MAGN RESON MED, V61, P678, DOI 10.1002/mrm.21885; Meral FC, 2009, J ACOUST SOC AM, V126, P3278, DOI 10.1121/1.3242351; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; OHNISHI ST, 1995, CENTRAL NERVOUS SYST, P497; Oliphant TE, 2001, MAGNET RESON MED, V45, P299, DOI 10.1002/1522-2594(200102)45:2<299::AID-MRM1039>3.0.CO;2-O; Othman SF, 2005, MAGN RESON MED, V54, P605, DOI 10.1002/mrm.20584; Othman SF, 2012, NMR BIOMED, V25, P452, DOI 10.1002/nbm.1663; Park E, 2006, PHYS MED BIOL, V51, P3697, DOI 10.1088/0031-9155/51/15/007; Press W.H., 1992, NUMERICAL RECIPES C, VSecond; Romano AJ, 1998, IEEE T ULTRASON FERR, V45, P751, DOI 10.1109/58.677725; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sack I, 2009, NEUROIMAGE, V46, P652, DOI 10.1016/j.neuroimage.2009.02.040; Sadler TR, 2009, APPL IMMUNOHISTO M M, V17, P165, DOI 10.1097/PAI.0b013e3181853001; SCHREGEL K, 2011, P 2011 ANN ISMRM M E; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2002, ACT NEUR S, V81, P209; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Houten EEW, 2001, MAGNET RESON MED, V45, P827, DOI 10.1002/mrm.1111; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Venkatesh SK, 2008, P INT SOC MAGN RES M, P2611; Watase K, 2003, NAT REV GENET, V4, P296, DOI 10.1038/nrg1045; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yin M, 2007, CLIN GASTROENTEROL H, V5, P1207, DOI 10.1016/j.cgh.2007.06.012	45	31	31	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 15	2011	201	2					296	306		10.1016/j.jneumeth.2011.08.019			11	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	834XX	WOS:000295998900003	21871490				2021-06-18	
J	Duncan, CC; Summers, AC; Perla, EJ; Coburn, KL; Mirsky, AF				Duncan, Connie C.; Summers, Angela C.; Perla, Elizabeth J.; Coburn, Kerry L.; Mirsky, Allan. F.			Evaluation of traumatic brain injury: Brain potentials in diagnosis, function, and prognosis	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Traumatic brain injury; TBI; ERP; Coma; Blast injury; P300; Information processing; Cognitive control	EVENT-RELATED POTENTIALS; CLOSED-HEAD-INJURY; LATE POSITIVE COMPLEX; ANTERIOR CINGULATE CORTEX; EVOKED-POTENTIALS; COGNITIVE CONTROL; MISMATCH NEGATIVITY; BLAST INJURY; PROCESSING DEFICITS; MENTAL CHRONOMETRY	The focus of this review is an analysis of the use of event-related brain potential (ERP) abnormalities as indices of functional pathophysiology in survivors of traumatic brain injury (TBI). TBI may be the most prevalent but least understood neurological disorder in both civilian and military populations. In the military, thousands of new brain injuries occur yearly: this lends considerable urgency to the use of highly sensitive ERP tools to illuminate brain changes and to address remediation issues. We review the processes thought to be indexed by the cognitive components of the ERP and outline the rationale for applying ERPs to evaluate deficits after TBI. Studies in which ERPs were used to clarify the nature of cognitive complaints of TBI survivors are reviewed, emphasizing impairment in attention, information processing, and cognitive control. Also highlighted is research on the application of ERPs to predict emergence from coma and eventual outcome. We describe primary blast injury, the leading cause of TBI for active duty military personnel in present day warfare. The review concludes with a description of an ongoing investigation of mild TBI, aimed at using indices of brain structure and function to predict the course of posttraumatic stress disorder. An additional goal of this ongoing investigation is to characterize the structural and functional sequelae of blast injury. (C) 2011 Elsevier B.V. All rights reserved.	[Duncan, Connie C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Duncan, Connie C.; Summers, Angela C.; Perla, Elizabeth J.; Mirsky, Allan. F.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Coburn, Kerry L.] Mercer Univ, Sch Med, Dept Psychiat & Behav Sci, Macon, GA 31207 USA	Duncan, CC (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Psychiat, Bethesda, MD 20814 USA.	cduncan@usuhs.mil			Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; PTSD/TBI Clinical Consortium (DoD) [W81XWH-08-2-0159]	Support for this work and for the Brain Indices study included funding from the Department of Defense in the Center for Neuroscience and Regenerative Medicine and the PTSD/TBI Clinical Consortium Award (DoD Contract #W81XWH-08-2-0159).	Anderson RJ, 2008, MOL INTERV, V8, P204, DOI 10.1124/mi.8.5.2; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Aubry M., 2002, BRIT J SPORT MED, V36, P3, DOI [DOI 10.1136/BJSM.36.1.6, 10.1136/bjsm.36.1.6]; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brain Injury Association of America, 2007, BRAIN INJ AW MONTH M; BrockR.Riggins, 2002, The International Journal of Creativity & Problem Solving, V12, P71; Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Campbell K., 1986, ELECTROENCEPHALOGR S, V38, P486; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; CAMPBELL KB, 1990, ELECTROEN CLIN NEURO, P202; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; Czigler I, 1996, BIOL PSYCHOL, V43, P27, DOI 10.1016/0301-0511(95)05173-2; Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; DAVIS H, 1966, J ACOUST SOC AM, V39, P109, DOI 10.1121/1.1909858; Dawson D.R., 2004, ARCH PHYS MED REHAB, V85, pE8; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; Deacon-Elliott D L, 1987, Electroencephalogr Clin Neurophysiol Suppl, V40, P664; Defense and Veterans Brain Injury Center, 2009, MIL AC CONC EV MACE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dien J, 2004, PSYCHOPHYSIOLOGY, V41, P665, DOI 10.1111/j.1469-8986.2004.00193.x; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Doi R, 2007, AM J PHYS MED REHAB, V86, P641, DOI 10.1097/PHM.0b013e318115aca9; DONCHIN E, 1981, PSYCHOPHYSIOLOGY, V18, P493, DOI 10.1111/j.1469-8986.1981.tb01815.x; Duncan C.C., 2004, COMPREHENSIVE HDB PS, V1, P263; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; DUNCAN CC, 1994, PSYCHOPHYSIOLOGY, V31, P386, DOI 10.1111/j.1469-8986.1994.tb02447.x; Duncan CC, 2003, PSYCHOPHYSIOLOGY, V40, P45, DOI 10.1111/1469-8986.00006; Duncan CC, 2009, CLIN NEUROPHYSIOL, V120, P1883, DOI 10.1016/j.clinph.2009.07.045; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; DUNCANJOHNSON CC, 1981, SCIENCE, V214, P938, DOI 10.1126/science.7302571; DUNCANJOHNSON CC, 1982, BIOL PSYCHOL, V14, P1, DOI 10.1016/0301-0511(82)90016-3; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Ellis C, 2009, NEUROREHABILITATION, V24, P255, DOI 10.3233/NRE-2009-0476; Elting JW, 2008, BRAIN INJURY, V22, P870, DOI 10.1080/02699050802403581; Elting JW, 2005, CLIN NEUROPHYSIOL, V116, P2606, DOI 10.1016/j.clinph.2005.07.014; EVANS RW, 1992, NEUROL CLIN, V10, P815; Falik D., 2009, NEUROL TODAY, V9, P10; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Faul M., 2010, TRAUMATIC BRAIN INJU, P1; Filley CM, 2005, PSYCHIAT CLIN N AM, V28, P685, DOI 10.1016/j.psc.2005.05.008; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Fischer C, 2000, AUDIOL NEURO-OTOL, V5, P192, DOI 10.1159/000013880; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Fischer C, 2005, NEUROPSYCHOL REHABIL, V15, P372, DOI 10.1080/09602010443000434; Fischer C, 2008, CLIN NEUROPHYSIOL, V119, P2224, DOI 10.1016/j.clinph.2008.03.035; Fischer C, 2010, CLIN NEUROPHYSIOL, V121, P1032, DOI 10.1016/j.clinph.2010.02.005; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Ford N.L., 2008, ADF HLTH, V9, P68; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gallagher CN, 2007, CURR OPIN NEUROL, V20, P403, DOI 10.1097/WCO.0b013e32821b987b; Gawryluk JR, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-11; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; GENTILINI M, 1989, MILD HEAD INJURY, P163; Goldstein K., 1942, AFTEREFFECTS BRAIN I; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; Gronwall D, 1989, MILD HEAD INJURY, P153; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Hagen C, 1984, LANGUAGE DISORDERS A, P245; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holland A., 1982, CLIN APH P C, P345; Holroyd CB, 2003, NEUROREPORT, V14, P2481, DOI 10.1097/00001756-200312190-00037; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JARVIE H, 1960, J MENT SCI, V106, P1377; Jennett B, 1981, MANAGEMENT HEAD INJU; JOHNSON R, 1989, PSYCHOPHYSIOLOGY, V26, P651, DOI 10.1111/j.1469-8986.1989.tb03167.x; JOHNSON R, 1989, PSYCHOPHYSIOLOGY, V26, P633, DOI 10.1111/j.1469-8986.1989.tb03165.x; JOHNSON R, 1980, PSYCHOPHYSIOLOGY, V17, P167, DOI 10.1111/j.1469-8986.1980.tb00131.x; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KNIGHT RT, 1995, ADV NEUROL, V66, P21; Knight RT, 1998, REV NEUROSCIENCE, V9, P57; Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Larson M.J., 2007, J INT NEUROPSYCH SOC, V13, P1; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2009, J INT NEUROPSYCH SOC, V15, P927, DOI 10.1017/S1355617709990701; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Larson MJ, 2009, NEUROPSYCHOLOGY, V23, P433, DOI 10.1037/a0015723; LASHLEY KS, 1950, SYM SOC EXP BIOL, V4, P454; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J CLIN NEUROPHYSIOL, V24, P398, DOI 10.1097/WNP.0b013e318150694b; Lew HL, 2007, J CLIN NEUROPHYSIOL, V24, P392, DOI 10.1097/WNP.0b013e31814a56e3; Lew HL, 2006, J HEAD TRAUMA REHAB, V21, P350, DOI 10.1097/00001199-200607000-00006; Lew HL, 2009, AM J PHYS MED REHAB, V88, P1, DOI 10.1097/PHM.0b013e3181911102; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lombardi WJ, 1999, J CLIN EXP NEUROPSYC, V21, P2, DOI 10.1076/jcen.21.1.2.940; Luaute J, 2005, ARCH PHYS MED REHAB, V86, P917, DOI 10.1016/j.apmr.2004.08.011; Luria A.R., 1948, RESTORATION BRAIN FU; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; McDonald CG, 2010, PSYCHOPHYSIOLOGY, V47, P809, DOI 10.1111/j.1469-8986.2010.00986.x; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky AF, 2005, INT J PSYCHOPHYSIOL, V58, P162, DOI 10.1016/j.ijpsycho.2005.06.004; Mirsky Allan F., 2001, VVolume 50, P141; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; Naatanen R, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P169; Naatanen R, 1999, PSYCHOL BULL, V125, P826, DOI 10.1037/0033-2909.125.6.826; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; Naatanen R, 2004, COGNITIVE NEUROSCIEN, P194; Naito Yasuo, 2005, Kobe Journal of Medical Sciences, V51, P95; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; O'Keeffe F.M., 2007, BRAIN RES COGN BRAIN, V22, P101; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Pennardt A., 2010, EMEDICINE; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1017/S0048577200000305; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Pritchard W.S., 1991, ADV PSYCHOPHYSIOLOGY, V4, P43; Reichenbach JR, 2001, NMR BIOMED, V14, P453, DOI 10.1002/nbm.722; Reitan RM, 2000, ARCH CLIN NEUROPSYCH, V15, P433, DOI 10.1016/S0887-6177(99)00038-4; RENAULT B, 1982, SCIENCE, V215, P1413, DOI 10.1126/science.7063853; Reza F, 2006, J CLIN NEUROSCI, V13, P917, DOI 10.1016/j.jocn.2004.11.026; Reza MF, 2007, NEUROPSYCHOL REHABIL, V17, P723, DOI 10.1080/09602010601082441; RITTER W, 1982, SCIENCE, V218, P909, DOI 10.1126/science.7134983; RITTER W, 1979, SCIENCE, V203, P1358, DOI 10.1126/science.424760; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; RUCHKIN DS, 1975, PSYCHOPHYSIOLOGY, V12, P591, DOI 10.1111/j.1469-8986.1975.tb00052.x; Ruchsow M, 2002, NEUROSCI LETT, V325, P203, DOI 10.1016/S0304-3940(02)00288-4; Ruff R.M., 1989, MILD HEAD INJURY, P176; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; Rushby JA, 2005, CLIN NEUROPHYSIOL, V116, P2363, DOI 10.1016/j.clinph.2005.06.008; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; SAMS M, 1985, ELECTROEN CLIN NEURO, V62, P437, DOI 10.1016/0168-5597(85)90054-1; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Sarno S, 2006, FUNCT NEUROL, V21, P21; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; SCHERG M, 1991, ELECTROEN CLIN NEURO, P24; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sivak S, 2008, BRAIN INJURY, V22, P193, DOI 10.1080/02699050801895431; SNYDER E, 1976, BEHAV BIOL, V16, P319, DOI 10.1016/S0091-6773(76)91447-4; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Solbakk AK, 2005, J CLIN EXP NEUROPSYC, V27, P205, DOI 10.1080/13803390490515739; Solbakk AK, 2002, CLIN ELECTROENCEPHAL, V33, P102, DOI 10.1177/155005940203300306; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spencer KM, 2001, PSYCHOPHYSIOLOGY, V38, P343, DOI 10.1111/1469-8986.3820343; Spikman JM, 2004, J INT NEUROPSYCH SOC, V10, P851, DOI 10.1017/S1355617704106061; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; SUTTON S, 1984, ANN NY ACAD SCI, V425, P1, DOI 10.1111/j.1749-6632.1984.tb23520.x; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; van Meel CS, 2005, NEUROPSYCHOLOGIA, V43, P1946, DOI 10.1016/j.neuropsychologia.2005.03.018; Wang JT, 2004, CAN J NEUROL SCI, V31, P438, DOI 10.1017/S0317167100003619; WAYLAND S, 1985, BRAIN COGNITION, V4, P356, DOI 10.1016/0278-2626(85)90027-2; West R, 1999, COGNITIVE BRAIN RES, V8, P157, DOI 10.1016/S0926-6410(99)00017-8; West R, 2000, BRAIN RES, V873, P102, DOI 10.1016/S0006-8993(00)02530-0; West R, 2003, NEUROPSYCHOLOGIA, V41, P1122, DOI 10.1016/S0028-3932(02)00297-X; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207; WICKENS CD, 1984, ANN NY ACAD SCI, V425, P295, DOI 10.1111/j.1749-6632.1984.tb23550.x; WIIG Elizabeth H. Elizabeth W., 1988, NEUROPSYCHOLOGICAL S, P186; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Yang FG, 2010, NEUROPSYCHOLOGIA, V48, P1923, DOI 10.1016/j.neuropsychologia.2010.03.011; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	238	31	33	0	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		24	40		10.1016/j.ijpsycho.2011.02.013			17	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600004	21356253				2021-06-18	
J	Kuo, JR; Lo, CJ; Chang, CP; Lin, KC; Lin, MT; Chio, CC				Kuo, Jinn-Rung; Lo, Chong-Jeh; Chang, Ching-Ping; Lin, Kao-Chang; Lin, Mao-Tsun; Chio, Chung-Ching			Agmatine-Promoted Angiogenesis, Neurogenesis, and Inhibition of Gliosis-Reduced Traumatic Brain Injury in Rats	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Agmatine; Angiogenesis; Neurogenesis; Gliosis	CLONIDINE-DISPLACING SUBSTANCE; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA; SURVIVAL FACTOR; MOUSE MODEL; GDNF; DYSFUNCTION; PRECURSORS; PROTECTION; RECOVERY	Background: The mechanisms of agmatine-induced neuroprotective effects in traumatic brain injury (TBI) remain unclear. This study was to test whether inhibition of gliosis, angiogenesis, and neurogenesis attenuating TBI could be agmatine stimulated. Methods: Anesthetized rats were randomly assigned to sham-operated group, TBI rats treated with saline (1 mL/kg, intraperitoneally), or TBI rats treated with agmatine (50 mg/kg, intraperitoneally). Saline or agmatine was injected 5 minutes after TBI and again once daily for the next 3 postoperative days. Results: Agmatine therapy in rats significantly attenuated TBI-induced motor function deficits (62 degrees vs. 52 degrees maximal angle) and cerebral infarction (88 mm(3) vs. 216 mm(3)), significantly reduced TBI-induced neuronal (9 NeuN-TUNEL double positive cells vs. 60 NeuN-TUNEL double positive cells) and glial (2 GFAP-TUNEL double positive cells vs. 20 GFAP-TUNEL double positive cells) apoptosis (increased TUNEL-positive and caspase-3-positive cells), neuronal loss (82 NeuN-positive cells vs. 60 NeuN-positive cells), gliosis (35 GFAP-positive cells vs. 72 GFAP-positive cells; 60 Iba1-positive cells vs. 90 Iba1-positive cells), and neurotoxicity (30 n-NOS-positive cells vs. 90 n-NOS-positive cells; 35 3-NT-positive cells vs. 90 3-NT-positive cells), and significantly promoted angiogenesis (3 BrdU/endothelial cells vs. 0.5 BrdU/endothelial cells; 50 vascular endothelial growth factor positive cells vs. 20 vascular endothelial growth factor-positive cells) and neurogenesis (27 BrdU/NeuN positive cells vs. 15 BrdU/NeuN positive cells). Conclusions: Resultantly, agmatine therapy may attenuate TBI in rats via promoting angiogenesis, neurogenesis, and inhibition of gliosis.	[Kuo, Jinn-Rung; Lin, Kao-Chang; Chio, Chung-Ching] Chi Mei Med Ctr, Dept Surg, Tainan 710, Taiwan; [Kuo, Jinn-Rung] Natl Cheng Kung Univ, Inst Clin Med, Sch Med, Tainan 70101, Taiwan; [Lo, Chong-Jeh] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Div Trauma & Emergency Surg, Kaohsiung, Taiwan; [Kuo, Jinn-Rung; Chang, Ching-Ping; Lin, Kao-Chang; Lin, Mao-Tsun] So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan; [Lin, Mao-Tsun] Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan; [Lin, Mao-Tsun] Taipei Med Univ, Grad Inst Dis Prevent & Control, Taipei, Taiwan	Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Surg, Tainan 710, Taiwan.	mtlin@ym.edu.tw			Center of Excellence for Clinical Trial and Research in Neuroscience [NSC99-2314-B-384-006-MY2, NSC99-2314-B-384-004-MY3, DOH99-TD-B-111-003]	Supported by grants NSC99-2314-B-384-006-MY2, NSC99-2314-B-384-004-MY3, and DOH99-TD-B-111-003 Center of Excellence for Clinical Trial and Research in Neuroscience.	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; Cai ZW, 1999, NEUROREPORT, V10, P3927, DOI 10.1097/00001756-199912160-00037; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Demady DR, 2001, MOL PHARMACOL, V59, P24; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GILAD GM, 1996, LIFE SCI, V58, P41; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kao CH, 2008, RESUSCITATION, V77, P395, DOI 10.1016/j.resuscitation.2008.01.023; Kim JH, 2004, EXP NEUROL, V189, P122, DOI 10.1016/j.expneurol.2004.05.029; Kitagawa H, 1998, STROKE, V29, P1417, DOI 10.1161/01.STR.29.7.1417; Kuo JR, 2007, RESUSCITATION, V75, P506, DOI 10.1016/j.resuscitation.2007.05.011; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; PILETZ JE, 1995, J PHARMACOL EXP THER, V272, P581; Regunathan S, 2000, J NEUROCHEM, V74, P2201, DOI 10.1046/j.1471-4159.2000.0742201.x; Reis DJ, 2000, TRENDS PHARMACOL SCI, V21, P187, DOI 10.1016/S0165-6147(00)01460-7; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Wang Y, 1997, J NEUROSCI, V17, P4341; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; ZURN AD, 1994, NEUROREPORT, V6, P113, DOI 10.1097/00001756-199412300-00030	34	31	31	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2011	71	4					E87	E93		10.1097/TA.0b013e31820932e2			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	833ZT	WOS:000295925700003	21427621				2021-06-18	
J	Darling, WG; Pizzimenti, MA; Morecraft, RJ				Darling, Warren G.; Pizzimenti, Marc A.; Morecraft, Robert J.			FUNCTIONAL RECOVERY FOLLOWING MOTOR CORTEX LESIONS IN NON-HUMAN PRIMATES: EXPERIMENTAL IMPLICATIONS FOR HUMAN STROKE PATIENTS	JOURNAL OF INTEGRATIVE NEUROSCIENCE			English	Article						Motor cortex; lesion; hand; grasp; manipulation	INDIVIDUATED FINGER MOVEMENTS; MONKEYS MACACA-FASCICULARIS; TRAUMATIC BRAIN-INJURY; ADULT SQUIRREL-MONKEYS; MEDIAL PREMOTOR CORTEX; RHESUS-MONKEY; HAND AREA; SENSORIMOTOR CORTEX; CEREBRAL-CORTEX; SPINAL-CORD	This review discusses selected classical works and contemporary research on recovery of contralesional fine hand motor function following lesions to motor areas of the cerebral cortex in non-human primates. Findings from both the classical literature and contemporary studies show that lesions of cortical motor areas induce paresis initially, but are followed by remarkable recovery of fine hand/digit motor function that depends on lesion size and post-lesion training. Indeed, in recent work where considerable quantification of fine digit function associated with grasping and manipulating small objects has been observed, very favorable recovery is possible with minimal forced use of the contralesional limb. Studies of the mechanisms underlying recovery have shown that following small lesions of the digit areas of primary motor cortex (M1), there is expansion of the digit motor representations into areas of M1 that did not produce digit movements prior to the lesion. However, after larger lesions involving the elbow, wrist and digit areas of M1, no such expansion of the motor representation was observed, suggesting that recovery was due to other cortical or subcortical areas taking over control of hand/digit movements. Recently, we showed that one possible mechanism of recovery after lesion to the arm areas of M1 and lateral premotor cortex is enhancement of corticospinal projections from the medially located supplementary motor area (M2) to spinal cord laminae containing neurons which have lost substantial input from the lateral motor areas and play a critical role in reaching and digit movements. Because human stroke and brain injury patients show variable, and usually poorer, recovery of hand motor function than that of nonhuman primates after motor cortex damage, we conclude with a discussion of implications of this work for further experimentation to improve recovery of hand function in human stroke patients.	[Darling, Warren G.] Univ Iowa, Motor Control Labs, Dept Hlth & Human Physiol, Iowa City, IA 52242 USA; [Pizzimenti, Marc A.] Univ Iowa, Carver Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; [Morecraft, Robert J.] Univ S Dakota, Sanford Sch Med, Div Basic Biomed Sci, Lab Neurol Sci, Vermillion, SD 57069 USA	Darling, WG (corresponding author), Univ Iowa, Motor Control Labs, Dept Hlth & Human Physiol, Iowa City, IA 52242 USA.	warren-darling@uiowa.edu		Pizzimenti, Marc A/0000-0002-1309-6633	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 046367]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS046367, R01NS046367] Funding Source: NIH RePORTER	Supported by National Institutes of Health grant NS 046367. The assistance of staff in the Hardin Library for Health Sciences Rare Book Room at the University of Iowa is gratefully acknowledged.	ARMSTRONG DM, 1985, J PHYSIOL-LONDON, V367, P309, DOI 10.1113/jphysiol.1985.sp015826; BARNARD JW, 1956, J COMP NEUROL, V105, P25, DOI 10.1002/cne.901050103; Bhatt E, 2007, EXP BRAIN RES, V182, P435, DOI 10.1007/s00221-007-1001-5; Black P, 1974, Trans Am Neurol Assoc, V99, P188; Black P, 1971, Trans Am Neurol Assoc, V96, P173; BLACK P, 1975, CIBA ELSEVIER S, V34, P65; BOGOUSSLAVSKY J, 1990, ARCH NEUROL-CHICAGO, V47, P144, DOI 10.1001/archneur.1990.00530020040012; BRINKMAN C, 1984, J NEUROSCI, V4, P918; BRINKMAN C, 1981, NEUROSCI LETT, V27, P267, DOI 10.1016/0304-3940(81)90441-9; BUYS EJ, 1986, J PHYSIOL-LONDON, V381, P529, DOI 10.1113/jphysiol.1986.sp016342; Carmichael ST, 2010, STROKE, V41, pS124, DOI 10.1161/STROKEAHA.110.597146; Carrera E, 2007, CEREBROVASC DIS, V24, P97, DOI 10.1159/000103123; Chamoun RB, 2007, EPILEPSY BEHAV, V11, P384, DOI 10.1016/j.yebeh.2007.05.015; CHEN YC, 1995, EXP BRAIN RES, V102, P461; CHENEY PD, 1985, J NEUROPHYSIOL, V53, P786; Clarke E, 1968, HUMAN BRAIN SPINAL C; Courtine G, 2007, NAT MED, V13, P561, DOI 10.1038/nm1595; D'Arceuil HE, 2006, J MED PRIMATOL, V35, P78, DOI 10.1111/j.1600-0684.2006.00147.x; Darling WG, 2010, EXP BRAIN RES, V202, P529, DOI 10.1007/s00221-010-2157-y; Darling WG, 2009, EXP NEUROL, V220, P90, DOI 10.1016/j.expneurol.2009.07.034; Darling WG, 2006, J NEUROSCI METH, V154, P38, DOI 10.1016/j.jneumeth.2005.11.013; DENNYBROWN D, 1947, RES PUBL ASSOC RES N, V27, P235; DENNYBROWN D, 1950, J NERV MENT DIS, V112, P1; Devanne H, 2006, EUR J NEUROSCI, V23, P2467, DOI 10.1111/j.1460-9568.2006.04760.x; DONOGHUE JP, 1992, EXP BRAIN RES, V89, P1; Dum RP, 1996, J NEUROSCI, V16, P6513; Eisner-Janowicz I, 2008, J NEUROPHYSIOL, V100, P1498, DOI 10.1152/jn.90447.2008; Fang PC, 2010, STROKE, V41, P544, DOI 10.1161/STROKEAHA.109.572073; FERRIER D, 1884, PHILOS T ROY SOC LON, V175, P479; Ferrier D, 1886, FUNCTIONS BRAIN; FETZ EE, 1980, J NEUROPHYSIOL, V44, P751; Feuerstein GZ, 2008, J CEREBR BLOOD F MET, V28, P217, DOI 10.1038/sj.jcbfm.9600516; Finger S., 1994, ORIGINS NEUROSCIENCE; FLOURENS P, 1843, EXAMEN PHRENOLOGIE; Fritsch GT, 1870, ARCH ANAT PHYSL WISS, V37, P300, DOI 10.1016/ j.yebeh.2009.03.001.; Fukuda S, 2003, ILAR J, V44, P96, DOI 10.1093/ilar.44.2.96; Fulton JF, 1934, RES PUBL ASSOC RES N, V13, P157; GLEES P, 1950, J NEUROPHYSIOL, V13, P137; Graham Brown T., 1913, J PHYSL, V46, pxxii; Grunbaum ASF, 1903, P R SOC LONDON, V72, P152, DOI 10.1098/rspl.1903.0033; HALSBAND U, 1985, BEHAV BRAIN RES, V18, P269, DOI 10.1016/0166-4328(85)90035-X; HALSBAND U, 1982, BRAIN RES, V240, P368, DOI 10.1016/0006-8993(82)90239-6; HAMUY TP, 1956, B JOHNS HOPKINS HOSP, V98, P417; HEPPREYMOND MC, 1974, EXP BRAIN RES, V21, P519; Horsley V., 1888, PHILOS T R SOC LON B, V179, P1, DOI DOI 10.1098/RSTB.1888.0001; Jacobsen CF, 1934, RES PUBL ASSOC RES N, V13, P224; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; Kennard MA, 1936, AM J PHYSIOL, V115, P138; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477; Kennard MA, 1942, ARCH NEURO PSYCHIATR, V48, P227, DOI 10.1001/archneurpsyc.1942.02290080073002; KNAPP HD, 1958, SCIENCE, V128, P842, DOI 10.1126/science.128.3328.842; Lang CE, 2004, J NEUROPHYSIOL, V91, P1722, DOI 10.1152/jn.00805.2003; Lashley KS, 1924, ARCH NEURO PSYCHIATR, V12, P249, DOI 10.1001/archneurpsyc.1924.02200030002001; LAWRENCE DG, 1968, BRAIN, V91, P1, DOI 10.1093/brain/91.1.1; LAWRENCE DG, 1976, BRAIN, V99, P235, DOI 10.1093/brain/99.2.235; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Lemon RN, 2005, MUSCLE NERVE, V32, P261, DOI 10.1002/mus.20333; Lemon RN, 1999, EXP BRAIN RES, V128, P6, DOI 10.1007/s002210050811; Leyton ASF, 1917, Q J EXP PHYSIOL, V11, P135, DOI 10.1113/expphysiol.1917.sp000240; Lindenberg R, 2010, NEUROLOGY, V74, P280, DOI 10.1212/WNL.0b013e3181ccc6d9; LIU CN, 1964, J COMP NEUROL, V123, P257, DOI 10.1002/cne.901230209; Liu Y, 1999, EXP BRAIN RES, V128, P149, DOI 10.1007/s002210050830; Maier MA, 2002, CEREB CORTEX, V12, P281, DOI 10.1093/cercor/12.3.281; McNeal DW, 2010, J COMP NEUROL, V518, P586, DOI 10.1002/cne.22218; Mikuni N, 2005, EPILEPSY BEHAV, V7, P559, DOI 10.1016/j.yebeh.2005.07.016; Morecraft RJ, 2002, BRAIN, V125, P176, DOI 10.1093/brain/awf011; Morecraft RJ, 1998, BRAIN RES BULL, V45, P209, DOI 10.1016/S0361-9230(97)00344-4; Morecraft RJ, 2009, CINGULATE NEUROBIOLO, P113; Morecraft RJ, 2007, J COMP NEUROL, V500, P134, DOI 10.1002/cne.21165; Mott FW, 1908, P R SOC LOND B-CONTA, V80, P136, DOI 10.1098/rspb.1908.0013; Murata Y, 2008, J NEUROPHYSIOL, V99, P773, DOI 10.1152/jn.01001.2007; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nagamoto-Combs K, 2010, J NEUROTRAUM, V27, P565, DOI 10.1089/neu.2009.0966; Nudo RJ, 1999, REV NEUROL, V155, P713; Nudo RJ, 1999, CURR OPIN NEUROBIOL, V9, P740, DOI 10.1016/S0959-4388(99)00027-6; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144; Nudo RJ, 1996, J NEUROSCI, V16, P785; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Ogden R, 1917, PSYCHOBIOLOGY, V1, P33, DOI [10.1037/h0074814, DOI 10.1037/H0074814]; Page SJ, 2003, AM J PHYS MED REHAB, V82, P76, DOI 10.1097/00002060-200301000-00014; PASSINGHAM R, 1978, BRAIN RES, V145, P410, DOI 10.1016/0006-8993(78)90878-8; PASSINGHAM RE, 1985, BEHAV BRAIN RES, V18, P175, DOI 10.1016/0166-4328(85)90073-7; PASSINGHAM RE, 1983, BRAIN, V106, P675, DOI 10.1093/brain/106.3.675; PASSINGHAM RE, 1986, BEHAV NEUROSCI, V100, P695, DOI 10.1037/0735-7044.100.5.695; PENFIELD W, 1951, AMA ARCH NEUROL PSY, V66, P289, DOI 10.1001/archneurpsyc.1951.02320090038004; Pizzimenti MA, 2007, J NEUROPHYSIOL, V98, P1015, DOI 10.1152/jn.00354.2007; Plautz EJ, 2003, NEUROL RES, V25, P801, DOI 10.1179/016164103771953880; Plow EB, 2009, STROKE, V40, P1926, DOI 10.1161/STROKEAHA.108.540823; Qiu MG, 2011, NEUROREHAB NEURAL RE, V25, P275, DOI 10.1177/1545968310389183; Roitberg B, 2003, NEUROL RES, V25, P68, DOI 10.1179/016164103101200950; ROSTOMILY RC, 1991, J NEUROSURG, V75, P62, DOI 10.3171/jns.1991.75.1.0062; ROTHMANN M, 1907, ARCH ANAT PHYSL P, P217; Rouiller EM, 1998, EUR J NEUROSCI, V10, P729, DOI 10.1046/j.1460-9568.1998.00075.x; SATO KC, 1989, J NEUROPHYSIOL, V62, P959; Schieber MH, 2009, ADV EXP MED BIOL, V629, P559, DOI 10.1007/978-0-387-77064-2_30; SCHIEBER MH, 1993, SCIENCE, V261, P489, DOI 10.1126/science.8332915; Schieber MH, 1998, J NEUROSCI, V18, P9038; Schneider C, 2001, NEUROSCI LETT, V310, P183, DOI 10.1016/S0304-3940(01)02105-X; SLOPER JJ, 1983, BRAIN, V106, P707, DOI 10.1093/brain/106.3.707; Stinear CM, 2007, BRAIN, V130, P170, DOI 10.1093/brain/awl333; Tatu L, 1998, NEUROLOGY, V50, P1699, DOI 10.1212/WNL.50.6.1699; TAUB E, 1966, SCIENCE, V151, P593, DOI 10.1126/science.151.3710.593; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Taub E, 1999, J REHABIL RES DEV, V36, P237; TAUB E, 2011, CURRENT ATHEROSCLERO, V3, P279; THALER D, 1995, EXP BRAIN RES, V102, P445; TRAVIS AM, 1955, BRAIN, V78, P155, DOI 10.1093/brain/78.2.155; TRAVIS AM, 1955, BRAIN, V78, P174, DOI 10.1093/brain/78.2.174; VANDERZWAN A, 1992, J NEUROSURG, V77, P927, DOI 10.3171/jns.1992.77.6.0927; Vilensky JA, 2002, INT J PRIMATOL, V23, P1319, DOI 10.1023/A:1021135122571; West GA, 2009, J CEREBR BLOOD F MET, V29, P1175, DOI 10.1038/jcbfm.2009.43; Wiesendanger M, 2011, J HIST NEUROSCI, V20, P42, DOI 10.1080/09647041003775446; WOLF SL, 2006, JAMA-J AM MED ASSOC, V296, P20095; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238	114	31	31	0	11	IMR PRESS	WAN CHAI	RM 19C, LOCKHART CTR, 301-307 LOCKHART RD, WAN CHAI, 00000, HONG KONG	0219-6352	1757-448X		J INTEGR NEUROSCI	J. Integr. Neurosci.	SEP	2011	10	3					353	384		10.1142/S0219635211002737			32	Neurosciences	Neurosciences & Neurology	826BY	WOS:000295327600006	21960307	Green Accepted			2021-06-18	
J	Mao, L; Wang, HD; Wang, XL; Liao, H; Zhao, XZ				Mao, Lei; Wang, Handong; Wang, Xiaoliang; Liao, Hong; Zhao, Xianzhong			Transcription Factor Nrf2 Protects the Spinal Cord from Inflammation Produced by Spinal Cord Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						sulforaphane; Nrf2; spinal cord injury; inflammation; neuroprotection	TRAUMATIC BRAIN-INJURY; SMOKE-INDUCED EMPHYSEMA; KAPPA-B ACTIVATION; NRF2-DEFICIENT MICE; INTRACEREBRAL HEMORRHAGE; ENHANCES SUSCEPTIBILITY; FUNCTIONAL RECOVERY; SULFORAPHANE; EXPRESSION; DAMAGE	Background. Inflammation plays an important role in the pathogenesis of secondary damage after spinal cord injury (SCI). Previous studies have suggested that nuclear factor-erythroid 2-related factor 2 (Nrf2), a pleiotropic transcription factor, may play a key role in modulating inflammation in a variety of experimental models. This study evaluated the neuroprotective role of Nrf2 in the inflammatory response after SCI in mice. Materials and Methods. Nrf2-deficient (Nrf2(-/-)) and wild-type (Nrf2(+/+)) mice spinal cord compression injury was induced by the application of vascular clips (force of 10 g) to the dura. Sulforaphane (SFN) was used to activate Nrf2 after SCI. Inflammatory cytokines, NF-kappa B activity, histologic injury score, dying neurons count in grey matter, water content of impaired spinal cord, and Basso open-field motor score (BMS) were assessed to determine the extent of SCI-mediated damage. Results. The results showed that SFN activated Nrf2 in impaired spinal cord tissue, improved hindlimb locomotor function assessed by BMS, reduced inflammatory damage, histologic injury, dying neurons count, and spinal cord edema caused by SCI. Nrf2(-/-) mice demonstrated more severe neurologic deficit and spinal cord edema after SCI and did not benefit from the protective effect of SFN. Conclusions. Taken together, our results suggest that Nrf2 may represent a strategic target for SCI therapies. (C) 2011 Elsevier Inc. All rights reserved.	[Mao, Lei; Wang, Handong; Wang, Xiaoliang] Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, Nanjing 210002, Jiangsu, Peoples R China; [Liao, Hong] China Pharmaceut Univ, Natl Ctr Drug Screening, Nanjing 210009, Jiangsu, Peoples R China; [Zhao, Xianzhong] Nantong Univ, Dept Plast & Burn Surg, Affiliated Nantong Hosp 3, Nantong, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hdwang_nj@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070974]; Jiangsu Provincial Key Subject [X4200722]; Jinling Hospital of Nanjing, China [2009Q016]	This work was supported by grants from the National Natural Science Foundation of China (no. 81070974), the Jiangsu Provincial Key Subject (X4200722), and Jinling Hospital of Nanjing, China (2009Q016). The authors thank Dr. Gengbao Feng and Dr. Jianya Xu for technical assistance.	Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bauchet L., 2009, Annals of Physical and Rehabilitation Medicine, V52, P330, DOI 10.1016/j.annrmp.2008.10.004; Bethea JR, 2000, PROG BRAIN RES, V128, P33; Bethea JR, 1998, J NEUROSCI, V18, P3251; Boldin C, 2006, SPINE, V31, P554, DOI 10.1097/01.brs.0000201274.59427.a4; Brandenburg LO, 2010, INFLAMM RES, V59, P443, DOI 10.1007/s00011-009-0116-5; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Brown DA, 2007, J COMP NEUROL, V502, P236, DOI 10.1002/cne.21307; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Choo AM, 2008, EXP NEUROL, V212, P490, DOI 10.1016/j.expneurol.2008.04.038; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Esposito E, 2008, J PINEAL RES, V45, P149, DOI 10.1111/j.1600-079X.2008.00569.x; Genovese T, 2007, NEUROSCI LETT, V423, P41, DOI 10.1016/j.neulet.2007.05.058; Genovese T, 2007, J PINEAL RES, V43, P140, DOI 10.1111/j.1600-079X.2007.00454.x; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Hurlbert RJ, 2006, SPINE, V31, pS16, DOI 10.1097/01.brs.0000218264.37914.2c; Iizuka T, 2005, GENES CELLS, V10, P1113, DOI 10.1111/j.1365-2443.2005.00905.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5; Kelly VP, 2000, CANCER RES, V60, P957; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kim GM, 2001, J NEUROSCI, V21, P6617; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Li WG, 2008, BIOCHEM PHARMACOL, V76, P1485, DOI 10.1016/j.bcp.2008.07.017; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; Mao L, 2010, ANN CLIN LAB SCI, V40, P354; Mao L, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/238321; Marques SA, 2009, J NEUROSCI METH, V177, P183, DOI 10.1016/j.jneumeth.2008.10.015; Mautes AEM, 2000, PHYS THER, V80, P673, DOI 10.1093/ptj/80.7.673; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494; Pomeshchik Y, 2009, J NEUROTRAUM, V26, pA41; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Rice T, 2007, J NEUROPATH EXP NEUR, V66, P184, DOI 10.1097/01.jnen.0000248552.07338.7f; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P422, DOI 10.1196/annals.1344.037; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Surh YJ, 2008, GENES NUTR, V2, P313, DOI 10.1007/s12263-007-0063-0; Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506; Zhou ML, 2007, J SURG RES, V137, P103, DOI 10.1016/j.jss.2006.06.023	63	31	32	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	SEP	2011	170	1					E105	E115		10.1016/j.jss.2011.05.049			11	Surgery	Surgery	804BD	WOS:000293627800014	21764072				2021-06-18	
J	Tang, JF; Chen, PL; Tang, EJ; May, TA; Stiver, SI				Tang, Julin F.; Chen, Po-Liang; Tang, Eric J.; May, Todd A.; Stiver, Shirley I.			Dexmedetomidine Controls Agitation and Facilitates Reliable, Serial Neurological Examinations in a Non-Intubated Patient with Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Hypercarbia; Hypoxemia; Agitation; Alcohol withdrawal; Dexmedetomidine; Traumatic brain injury	ETHANOL WITHDRAWAL SYMPTOMS; CEREBRAL-BLOOD-FLOW; ALCOHOL-WITHDRAWAL; INTRACRANIAL-PRESSURE; PRACTICE GUIDELINE; METABOLIC-RATE; MANAGEMENT; DELIRIUM; SEDATION; HUMANS	Introduction We report the effective use of dexmedetomidine in the treatment of a patient with a history of chronic alcohol abuse and an acute traumatic brain injury who developed agitation that was unresolved if from traumatic brain injury, or alcohol withdrawal or the combination of both. Treatment with benzodiazepines failed; lorazepam therapy obscured our ability to do reliable neurological testing to follow his brain injury and nearly resulted in intubation of the patient secondary to respiratory suppression. Upon admission to hospital, the patient was first treated with intermittent, prophylactic doses of lorazepam for potential alcohol withdrawal based upon our institution's standard of care. His neurological examinations including a motor score of 6 (obeying commands) on his Glasgow Coma Scale testing, laboratory studies, and repeat CT head imaging remained stable. For lack of published literature in diagnosing symptoms of patients with a history of both alcohol withdrawal and traumatic brain injury, a diagnosis of agitation secondary to presumed alcohol withdrawal was made when the patient developed acute onset of tachycardia, confusion, and extreme anxiety with tremor and attempts to climb out of bed requiring him to be restrained. Additional lorazepam doses were administered following a hospital-approved protocol for titration of benzodiazepine therapy for alcohol withdrawal. The patient's mental status and respiratory function deteriorated with the frequent lorazepam dosing needed to control his agitation. Dexmedetomidine IV infusion at a rate of 0.5 mcg/kg/h was then administered and was titrated ultimately to 1.5 mcg/kg/h. After 8 days of therapy with dexmedetomidine, the patient was transferred from the ICU to a step-down unit with an intact neurological examination and no evidence of alcohol withdrawal. Airway intubation was avoided during the patient's entire hospitalization. This case report highlights the intricate balance between the side effects of benzodiazepine sedation for treatment of agitation and the difficulties of monitoring the neurological status of non-intubated patients with traumatic brain injury Conclusion Given the large numbers of alcohol-dependent patients who suffer a traumatic brain injury and subsequently develop agitation and alcohol withdrawal in hospital, dexmedetomidine offers a novel strategy to facilitate sedation without neurological or respiratory depression. As this case report demonstrates, dexmedetomidine is an emerging treatment option for agitation in patients who require reliable, serial neurological testing to monitor the course of their traumatic brain injury.	[Tang, Julin F.; Chen, Po-Liang; Tang, Eric J.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Anesthesia & Crit Care Med, San Francisco, CA 94110 USA; [May, Todd A.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, San Francisco, CA 94110 USA; [Stiver, Shirley I.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurol Surg, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA	Tang, JF (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Anesthesia & Crit Care Med, 1001 Potrero Ave, San Francisco, CA 94110 USA.	tangj@anesthesia.ucsf.edu					Al-Sanouri I, 2005, SOUTH MED J, V98, P372, DOI 10.1097/01.SMJ.0000154769.33508.20; Aryan HE, 2006, BRAIN INJURY, V20, P791, DOI 10.1080/02699050600789447; Bekker A, 2005, NEUROSURGERY, V57, P1, DOI 10.1227/01.NEU.0000163476.42034.A1; BELLEVILLE JP, 1992, ANESTHESIOLOGY, V77, P1125, DOI 10.1097/00000542-199212000-00013; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cosar M, 2009, SURG NEUROL, V71, P54, DOI 10.1016/j.surneu.2007.08.020; Coursin D B, 2001, Curr Opin Crit Care, V7, P221, DOI 10.1097/00075198-200108000-00002; Darrouj J, 2008, ANN PHARMACOTHER, V42, P1703, DOI 10.1345/aph.1K678; DeCarolis DD, 2007, PHARMACOTHERAPY, V27, P510, DOI 10.1592/phco.27.4.510; Devlin JW, 2008, CURR OPIN CRIT CARE, V14, P403, DOI 10.1097/MCC.0b013e32830280b3; Drummond JC, 2008, ANESTHESIOLOGY, V108, P225, DOI 10.1097/01.anes.0000299576.00302.4c; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Hecksel KA, 2008, MAYO CLIN PROC, V83, P274, DOI 10.4065/83.3.274; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; KARLSSON BR, 1990, ANESTH ANALG, V71, P125; Lonergan E, 2009, COCHRANE DATABASE SY; Ma DQ, 2004, EUR J PHARMACOL, V502, P87, DOI 10.1016/j.ejphar.2004.08.044; Maccioli GA, 2003, ANESTHESIOLOGY, V98, P575, DOI 10.1097/00000542-200302000-00041; Mayo-Smith MF, 2004, ARCH INTERN MED, V164, P1405, DOI 10.1001/archinte.164.13.1405; MayoSmith MF, 1997, JAMA-J AM MED ASSOC, V278, P144, DOI 10.1001/jama.278.2.144; Meagher DJ, 2001, BMJ-BRIT MED J, V322, P144, DOI 10.1136/bmj.322.7279.144; Nakano T, 2009, J ANESTH, V23, P378, DOI 10.1007/s00540-009-0777-9; Pletcher MJ, 2005, JT COMM J QUAL PATIE, V31, P148, DOI 10.1016/S1553-7250(05)31020-8; Riihioja P, 1999, ALCOHOL CLIN EXP RES, V23, P432, DOI 10.1097/00000374-199903000-00008; Riihioja P, 1997, ALCOHOL, V14, P537, DOI 10.1016/S0741-8329(97)00044-X; Riihioja P, 1997, ALCOHOL CLIN EXP RES, V21, P804, DOI 10.1111/j.1530-0277.1997.tb03843.x; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Rovasalo A, 2006, GEN HOSP PSYCHIAT, V28, P362, DOI 10.1016/j.genhosppsych.2006.03.002; Werner C, 1995, ANAESTHESIST, V44, pS566; Yost DA, 1996, AM FAM PHYSICIAN, V54, P657; ZORNOW MH, 1992, ANESTH ANALG, V75, P232	31	31	35	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2011	15	1					175	181		10.1007/s12028-009-9315-8			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	789XI	WOS:000292552100029	20198514				2021-06-18	
J	Bouvier, D; Castellani, C; Fournier, M; Dauphin, JB; Ughetto, S; Breton, M; Labbe, A; Weinberg, AM; Sapin, V				Bouvier, Damien; Castellani, Christoph; Fournier, Mathilde; Dauphin, Jean-Benoit; Ughetto, Sylvie; Breton, Mathias; Labbe, Andre; Weinberg, Annelie-Martina; Sapin, Vincent			Reference ranges for serum S100B protein during the first three years of life	CLINICAL BIOCHEMISTRY			English	Article						S100B; Children; Reference ranges	TRAUMATIC BRAIN-INJURY; DELIVERY; CHILDREN; BLOOD; SEX	Objective: Clinical and diagnostic management of traumatic brain injuries is problematic in young children. To facilitate this management, we describe blood reference ranges for the well established biomarker S100B in children younger than 3 years. Design and methods: Serum S100B concentrations were determined by electro-chemiluminescence immunoassay in a population of 186 healthy children aged 0-3 years. Results: Four age groups emerged, i.e. 0-3, 4-9, 10-24 and 25-36 months. We also found an interesting inverse correlation with head circumference. Conclusion: This study provides useful serum S100B values from the largest cohort of healthy children aged 0-3 years old. (C) 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.	[Bouvier, Damien; Fournier, Mathilde; Sapin, Vincent] Clermont Ferrand Teaching Hosp, Dept Biochem, Clermont Ferrand, France; [Castellani, Christoph; Weinberg, Annelie-Martina] Graz Med Univ, Dept Paediat & Adolescent Surg, Graz, Austria; [Dauphin, Jean-Benoit; Labbe, Andre] Clermont Ferrand Teaching Hosp, Dept Paediat Emergency, Clermont Ferrand, France; [Ughetto, Sylvie; Breton, Mathias] Clermont Ferrand Teaching Hosp, Dept Med Informat, Clermont Ferrand, France	Sapin, V (corresponding author), CHU Gabriel Montpied, Lab Biochim Med, Ctr Biol, Rue Montalembert, F-63000 Clermont Ferrand, France.	vsapin@chu-clermontferrand.fr		Bouvier, Damien/0000-0002-2707-4320			Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; Amer-Wahlin I, 2001, CLIN CHIM ACTA, V304, P57, DOI 10.1016/S0009-8981(00)00408-3; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Castellani C, 2008, CLIN CHEM LAB MED, V46, P1296, DOI 10.1515/CCLM.2008.262; CHEN C, 2007, P 30 ANN SAS US GROU; Filippidis AS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.8.FOCUS10185; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Klig JE, 2010, CURR OPIN PEDIATR, V22, P257, DOI 10.1097/MOP.0b013e328339736e; Remontet L, 1999, ARCH PEDIATRIE, V6, P520, DOI 10.1016/S0929-693X(99)80558-2; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Schulpis KH, 2006, SCAND J CLIN LAB INV, V66, P733, DOI 10.1080/00365510600977737; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	12	31	34	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120			CLIN BIOCHEM	Clin. Biochem.	JUL	2011	44	10-11					927	929		10.1016/j.clinbiochem.2011.05.004			3	Medical Laboratory Technology	Medical Laboratory Technology	783IN	WOS:000292074800033	21601568				2021-06-18	
J	Cap, AP; Spinella, PC				Cap, Andrew Peter; Spinella, Philip C.			Severity of Head Injury Is Associated With Increased Risk of Coagulopathy in Combat Casualties	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Coagulopathy; Combat; Trauma; Mortality	TRAUMATIC BRAIN-INJURY; FIBRINOGEN CONCENTRATE; THROMBOELASTOMETRY; HYPOPERFUSION; MANAGEMENT	Background: Traumatic brain injury (TBI) is believed to cause more profound trauma-induced coagulopathy than other injuries of comparable severity. This has not been reported in a large series of combat casualties in which penetrating injuries predominate. Methods: Among US combat casualties severely injured in Iraq and Afghanistan who received transfused blood products, isolated TBI patients (head Abbreviated Injury Score [AIS] >= 3 and all other AIS <2) were compared with non-TBI patients (head AIS <= 2 and any other AIS >= 3) to determine the degree to which TBI is associated with coagulopathy as measured by International Normalized Ratio (INR) and to describe characteristics of this population. Stepwise multiple regression analysis was also performed on all US casualties who received transfused blood products to analyze independent predictors of coagulopathy. Results: We compared 117 patients with isolated TBI and 1,492 patients with non-TBI injuries. Admission INR was significantly higher in TBI patients. There were no differences in age, admission base deficit, systolic or diastolic blood pressure, or hemoglobin. On stepwise multiple regression, base deficit, Glasgow Coma Scale, and head AIS score were independently associated with increased coagulopathy as measured by INR. Conclusion: Patients with severe combat-related trauma and isolated TBI had worse coagulopathy than non-TBI patients. Base deficit, Glasgow Coma Scale, and severity of head injury, as reflected by head AIS, are independently associated with increased coagulopathy as measured by INR.	[Cap, Andrew Peter; Spinella, Philip C.] USA, Inst Surg Res, Ft Sam Houston, TX 78234 USA	Cap, AP (corresponding author), USA, Inst Surg Res, Bldg 3611, Ft Sam Houston, TX 78234 USA.	Andre.P.Cap@us.army.mil			US ArmyUnited States Department of Defense	Supported by the US Army.	Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4; Dunbar NM, 2009, TRANSFUSION, V49, P2652, DOI 10.1111/j.1537-2995.2009.02335.x; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Jeger V, 2010, EMERG MED J, V27, P551, DOI 10.1136/emj.2009.075994; Johansson PI, 2010, TRANSFUS APHER SCI, V43, P401, DOI 10.1016/j.transci.2010.09.002; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kitchen DP, 2010, SEMIN THROMB HEMOST, V36, P757, DOI 10.1055/s-0030-1265292; LUSTENBERGER T, 2010, INJURY          0512; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Nylund Cade M, 2009, Pediatr Crit Care Med, V10, pe22, DOI 10.1097/PCC.0b013e31819bb939; Park MS, 2009, J TRAUMA, V67, P266, DOI 10.1097/TA.0b013e3181ae6f1c; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; Schochl H, 2010, ANAESTHESIA, V65, P199, DOI 10.1111/j.1365-2044.2009.06188.x; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Schreiber M, 2009, J TRAUMA, V67, P275; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0	21	31	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2011	71			1			S78	S81		10.1097/TA.0b013e3182218cd8			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	790RW	WOS:000292607900013	21795882				2021-06-18	
J	Ecker, RD; Mulligan, LP; Dirks, M; Bell, RS; Severson, MA; Howard, RS; Armonda, RA				Ecker, Robert D.; Mulligan, Lisa P.; Dirks, Michael; Bell, Randy S.; Severson, Meryl A.; Howard, Robin S.; Armonda, Rocco A.			Outcomes of 33 patients from the wars in Iraq and Afghanistan undergoing bilateral or bicompartmental craniectomy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						craniectomy; penetrating head injury; traumatic brain injury	MIDDLE CEREBRAL-ARTERY; DECOMPRESSIVE SURGERY; MALIGNANT INFARCTION; HEMICRANIECTOMY; EDEMA	Object. There are no published long-term data for patients with penetrating head injury treated with bilateral supratentorial craniectomy, or supra- and infratentorial craniectomy. The authors report their experience with 33 patients treated with bilateral or bicompartmental craniectomy from the ongoing conflicts in Iraq and Afghanistan. Methods. An exploratory analysis of Glasgow Outcome Scale (GOS) scores at 6 months in 33 patients was performed. Follow-up lasting a median of more than 2 years was performed in 30 (91%) of these patients. The association of GOS score with categorical variables was explored using the Wilcoxon rank-sum test or Kruskal-Wallis analysis of variance. The Spearman correlation coefficient was used for ordinal/continuous data. To provide a clinically meaningful format to present GOS scores with categorical variables, patients with GOS scores of 1-3 were categorized as having a poor outcome and those with scores of 4 and 5 as having a good outcome. This analysis does not include the patients who died in theater or in Germany who underwent bilateral decompressive craniectomy because those figures have not been released due to security concerns. Results. All patients were men with a median age of 24 years (range 19-46 years) and a median initial Glasgow Coma Scale (GCS) score of 5 (range 3-14). At 6 months, 9 characteristics were statistically significant: focus of the initial injury, systemic infection, initial GCS score, initial GCS score excluding patients with a GCS score of 3, GCS score on arrival to the US. GCS score on dismissal from the medical center, Injury Severity Score, and patients with cerebrovascular injury. Six factors were significant at long-term follow-up: focus of initial injury, systemic infection, initial GCS score excluding patients with a GCS score of 3, GCS score on arrival to the US, and GCS score on dismissal from the medical center. At long-term follow-up, 7 (23%) of 30 patients had died, 5 (17%) of 30 had a GOS score of 2 or 3, and 18 (60%) of 30 had a GOS score of 4 or 5. Conclusions. In this selected group of patients who underwent bilateral or bicompartmental craniectomy, 60% are independent at long-term follow-up. Patients with bifrontal injury fared best. Systemic infection and cerebrovascular injury corresponded with a worse outcome. (DOI: 10.3171/2011.2.JNS101490)	[Ecker, Robert D.] Maine Med Partners Neurosurg & Spine, Scarborough, ME 04074 USA; [Mulligan, Lisa P.; Bell, Randy S.; Severson, Meryl A.; Armonda, Rocco A.] Natl Naval Med Ctr, Dept Neurosurg, Bethesda, MD USA; [Dirks, Michael] Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA; [Howard, Robin S.] Walter Reed Army Med Ctr, Dept Clin Invest, Washington, DC 20307 USA	Ecker, RD (corresponding author), Maine Med Partners Neurosurg & Spine, 49 Spring St, Scarborough, ME 04074 USA.	robertecker@me.com					Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bell RS, 2010, NEUROSURGERY, V66, P66, DOI 10.1227/01.NEU.0000361285.50218.A8; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RANSOHOFF J, 1971, J NEUROL NEUROSUR PS, V34, P106, DOI 10.1136/jnnp.34.1.106-a; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Vahedi K, 2009, CURR TREAT OPTION N, V11, P113, DOI 10.1007/s11940-009-0014-8; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429	10	31	33	1	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2011	115	1					124	129		10.3171/2011.2.JNS101490			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	782JO	WOS:000292004700026	21438659				2021-06-18	
J	Nardone, R; Bergmann, J; Kunz, A; Caleri, F; Seidl, M; Tezzon, F; Gerstenbrand, F; Trinka, E; Golaszewski, S				Nardone, Raffaele; Bergmann, Juergen; Kunz, Alexander; Caleri, Francesca; Seidl, Martin; Tezzon, Frediano; Gerstenbrand, Franz; Trinka, Eugen; Golaszewski, Stefan			Cortical Excitability Changes in Patients with Sleep-Wake Disturbances after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						excessive daytime sleepiness; hypocretin; sleep-wake disturbances; transcranial magnetic stimulation; traumatic brain injury	EXCESSIVE DAYTIME SLEEPINESS; HUMAN MOTOR CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; HUMAN NARCOLEPSY; SPINAL-CORD; HEAD-INJURY; NEURONS; MODAFINIL; INHIBITION; DEFICIENCY	Although chronic sleepiness is common after head trauma, the cause remains unclear. Transcranial magnetic stimulation (TMS) represents a useful complementary approach in the study of sleep pathophysiology. We aimed to determine in this study whether post-traumatic sleep-wake disturbances (SWD) are associated with changes in excitability of the cerebral cortex. TMS was performed 3 months after mild to moderate traumatic brain injury (TBI) in 11 patients with subjective excessive daytime sleepiness (EDS; defined by the Epworth Sleepiness Scale >= 10), 12 patients with objective EDS (as defined by mean sleep latency <5 on multiple sleep latency tests), 11 patients with fatigue (defined by daytime tiredness without signs of subjective or objective EDS), 10 patients with post-traumatic hypersomnia "sensu strictu," and 14 control subjects. Measures of cortical excitability included central motor conduction time, resting motor threshold (RMT), short-latency intracortical inhibition (SICI), and intracortical facilitation to paired-TMS. RMT was higher and SICI was more pronounced in the patients with objective EDS than in the control subjects. In the other patients all TMS parameters did not differ significantly from the controls. Similarly to that reported in patients with narcolepsy, the cortical hypoexcitability may reflect the deficiency of the excitatory hypocretin/orexin-neurotransmitter system. These observations may provide new insights into the causes of chronic sleepiness in patients with TBI. A better understanding of the pathophysiology of post-traumatic SWD may also lead to better therapeutic strategies in these patients.	[Nardone, Raffaele; Kunz, Alexander; Seidl, Martin; Trinka, Eugen; Golaszewski, Stefan] Paracelsus Med Univ, Christian Doppler Clin, Dept Neurol, Salzburg, Austria; [Bergmann, Juergen; Kunz, Alexander; Seidl, Martin; Trinka, Eugen; Golaszewski, Stefan] Christian Doppler Clin, Inst Neurosci, Salzburg, Austria; [Bergmann, Juergen] Paris Lodron Univ, Dept Psychol, Salzburg, Austria; [Bergmann, Juergen] Paris Lodron Univ, Ctr Neurocognit Res, Salzburg, Austria; [Gerstenbrand, Franz] Karl Landsteiner Inst Neurorehabil & Space Neurol, Vienna, Austria; [Nardone, Raffaele; Caleri, Francesca; Tezzon, Frediano] Franz Tappeiner Hosp, Dept Neurol, Merano, Italy	Nardone, R (corresponding author), F Tappeiner Hosp Meran O, Dept Neurol, Via Rossini 5, I-39012 Meran O, BZ, Italy.	raffaele.nardone@asbmeran-o.it		Nardone, Raffaele/0000-0001-5243-6760; Trinka, Eugen/0000-0002-5950-2692; Kunz, Alexander/0000-0002-8455-8436			Adamantidis AR, 2007, NATURE, V450, P420, DOI 10.1038/nature06310; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; BASTUJI H, 1988, PROG NEURO-PSYCHOPH, V12, P695, DOI 10.1016/0278-5846(88)90014-0; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; BROUGHTON R, 1986, SLEEP, V9, P205, DOI 10.1093/sleep/9.1.205; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Civardi C, 2009, SLEEP MED REV, V13, P35, DOI 10.1016/j.smrv.2008.04.001; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Contreras D, 1996, J PHYSIOL-LONDON, V494, P251, DOI 10.1113/jphysiol.1996.sp021488; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Di Lazzaro V, 2000, CLIN NEUROPHYSIOL, V111, P794, DOI 10.1016/S1388-2457(99)00314-4; DOUGLASS AB, 1994, SLEEP, V17, P160, DOI 10.1093/sleep/17.2.160; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gerashchenko D, 2003, EXP NEUROL, V184, P1010, DOI 10.1016/S0014-4886(03)00388-1; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Hassani OK, 2009, P NATL ACAD SCI USA, V106, P2418, DOI 10.1073/pnas.0811400106; Huang ZL, 2001, P NATL ACAD SCI USA, V98, P9965, DOI 10.1073/pnas.181330998; HUBLIN C, 1994, J SLEEP RES, V3, P52, DOI 10.1111/j.1365-2869.1994.tb00104.x; Jang IS, 2001, J PHYSIOL-LONDON, V534, P791, DOI 10.1111/j.1469-7793.2001.00791.x; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; LLINAS R, 1964, J NEUROPHYSIOL, V27, P1117; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mitler MM, 1998, ANN NEUROL, V43, P88; Nardone R, 2010, SLEEP MED, V11, P870, DOI 10.1016/j.sleep.2010.05.007; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; Oliviero A, 2005, J NEUROL, V252, P56, DOI 10.1007/s00415-005-0598-1; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; RECHTSSCHAFFEN A, 1968, MANUAL STANDARDIZED; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Scammell T., 2007, SLEEP DISORDERS NEUR, P117; SCAMMELL TE, 2007, NARCOLEPSY HYPERSOMN, P547; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Timofeev I, 2001, P NATL ACAD SCI USA, V98, P1924, DOI 10.1073/pnas.041430398; Timofeev I, 1996, J PHYSIOL-LONDON, V494, P265, DOI 10.1113/jphysiol.1996.sp021489; VINCENT SR, 1983, SCIENCE, V220, P1309; YOO EY, 2010, SLEEP MED, V11, P862; Ziemann U, 1998, NEUROLOGY, V51, P1320, DOI 10.1212/WNL.51.5.1320; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	49	31	32	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2011	28	7					1165	1171		10.1089/neu.2010.1748			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	794BL	WOS:000292869600005	21446790				2021-06-18	
J	Vilalta, A; Sahuquillo, J; Merino, MA; Poca, MA; Garnacho, A; Martinez-Valverde, T; Dronavalli, M				Vilalta, Anna; Sahuquillo, Juan; Merino, Maria-Angels; Poca, Maria-Antonia; Garnacho, Angel; Martinez-Valverde, Tamara; Dronavalli, Mithilesh			Normobaric Hyperoxia in Traumatic Brain Injury: Does Brain Metabolic State Influence the Response to Hyperoxic Challenge?	JOURNAL OF NEUROTRAUMA			English	Article						anaerobic metabolism; brain tissue oxygen pressure; cerebral metabolism; hyperoxia; MD; mitochondrial dysfunction; NH; TBI	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; POSITRON-EMISSION-TOMOGRAPHY; INTRACRANIAL-PRESSURE; MITOCHONDRIAL DYSFUNCTION; OXYGENATION STRATEGY; ARTERIAL HYPEROXIA; TISSUE-OXYGENATION; INSPIRED OXYGEN; BLOOD-FLOW	This study sought to investigate whether normobaric hyperoxia (NH) improves brain oxygenation and brain metabolism in the early phase of severe and moderate traumatic brain injury (TBI) and whether this effect occurs uniformly in all TBI patients. Thirty patients (9 women and 21 men) with a median initial Glasgow Coma Score (GCS) of 6 (range, 3-12) were monitored using a brain microdialysis (MD) catheter with a brain tissue oxygen sensor (PtiO(2)) placed in the least-injured hemisphere. The inspired oxygen fraction was increased to 100% for 2 h. Patients were divided into two groups: Group 1: patients with baseline brain lactate <= 3mmol/L and Group 2: patients with baseline brain lactate >3mmol/L, and therefore increased anaerobic metabolism in the brain. In Group 1, no significant changes in brain metabolic parameters were found after hyperoxic challenge, whereas a significant increase in glucose and a decrease in the lactate-pyruvate ratio (LPR) were found in Group 2. In this latter group of patients, brain glucose increased on average by 17.9% (95% CI, +9.2% to +26.6%, p<0.001) and LPR decreased by 11.6% (95% CI, -16.2% to -6.9%, p<0.001). The results of our study show that moderate and severe TBI may induce metabolic alterations in the brain, even in macroscopically normal brain tissue. We observed that NH increased PaO2 and PtiO(2) and significantly decreased LPR in patients in whom baseline brain lactate levels were increased, suggesting that NH improved the brain redox state. In patients with normal baseline brain lactate levels, we did not find any significant changes in the metabolic variables after NH. This suggests that the baseline metabolic state should be taken into account when applying NH to patients with TBI. This maneuver may only be effective in a specific group of patients.	[Sahuquillo, Juan] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurotraumatol & Neurosurg Res Unit, Dept Neurosurg, Barcelona 08035, Spain; [Vilalta, Anna; Merino, Maria-Angels; Poca, Maria-Antonia; Martinez-Valverde, Tamara] Univ Autonoma Barcelona, Neurotraumatol & Neurosurg Res Unit UNINN, Barcelona 08035, Spain; [Garnacho, Angel] Univ Autonoma Barcelona, Neurotraumatol Intens Care Unit, Barcelona 08035, Spain; [Dronavalli, Mithilesh] Univ Melbourne, Clin Sch Fac, Melbourne, Vic, Australia	Sahuquillo, J (corresponding author), Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurotraumatol & Neurosurg Res Unit, Dept Neurosurg, Paseo Vall Hebron 119-129, Barcelona 08035, Spain.	sahuquillo@neurotrauma.net	Garnacho, Angel/A-9309-2013; Dronavalli, Mithilesh/B-6290-2017; Dronavalli, Mithilesh/C-6495-2011; Poca, Maria A./B-8475-2008; Sahuquillo, Juan/B-3577-2008	Dronavalli, Mithilesh/0000-0002-5084-5023; Poca, Maria A./0000-0002-3831-0536; Sahuquillo, Juan/0000-0003-0713-5875; Vilalta, Anna/0000-0002-2183-072X	Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [PI080480]; European Regional Development Fund (ERDF)European Commission; Institut Fundacio de Recerca; Hospital Vall d'Hebron; Marie Curie Intra-European FellowshipEuropean Commission	This study was supported by Instituto de Salud Carlos III, grant number PI080480 co-financed by the European Regional Development Fund (ERDF) to Dr. J. Sahuquillo. Dr. A. Vilalta was the recipient of a pre-doctoral grant from the Institut Fundacio de Recerca, Hospital Vall d'Hebron, and is currently the recipient of a Marie Curie Intra-European Fellowship grant. We thank Sabrina Voss for editorial assistance.	Alves OL, 2004, CURR PHARM DESIGN, V10, P2163, DOI 10.2174/1381612043384187; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1991, J NEUROSURG, V74, pA364; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CARLSSON A, 2008, APPL NOTES CASE REPO; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Forgue J, 2001, J EXP BIOL, V204, P933; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; JAIN KK, 2009, TXB HYPERBARIC MED, P47; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Massabuau JC, 2003, MECH AGEING DEV, V124, P857, DOI 10.1016/S0047-6374(03)00147-7; Massabuau JC, 2001, RESP PHYSIOL, V128, P249, DOI 10.1016/S0034-5687(01)00305-X; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Nelson DW, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-21; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Patel D, 2003, J INDIAN ACAD CLIN M, V4, P234; Poca MA, 2002, J NEUROTRAUM, V19, P439, DOI 10.1089/08977150252932398; Poca MA, 2006, J NEUROTRAUM, V23, P1510, DOI 10.1089/neu.2006.23.1510; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Rieger A, 1997, NEUROSURGERY, V41, P462, DOI 10.1097/00006123-199708000-00027; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sahuquillo J, 1994, INTRACRANIAL PRESSUR, P48; SIGGAARDANDERSEN O, 1995, CRIT CARE MED, V23, P1284, DOI 10.1097/00003246-199507000-00020; SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P137; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	45	31	33	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2011	28	7					1139	1148		10.1089/neu.2010.1720			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	794BL	WOS:000292869600002	21534719	Green Published			2021-06-18	
J	Zhao, TT; Li, YQ; Tang, LS; Li, YH; Fan, F; Jiang, B				Zhao, Tantai; Li, Yunqin; Tang, Luosheng; Li, Yuehua; Fan, Fang; Jiang, Bing			Protective effects of human umbilical cord blood stem cell intravitreal transplantation against optic nerve injury in rats	GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						Human umbilical cord blood stem cells (hUCBSCs); Traumatic optic neuropathy (TON); Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF); Neural regeneration	RETINAL GANGLION-CELLS; NEUROTROPHIC FACTOR; BONE-MARROW; NEUROPATHY; THERAPY; DIFFERENTIATION; SURVIVAL; MODEL; STATE	The majority of studies addressing traumatic optic neuropathy (TON) have focused on drugs, proteins, cytokines, and various surgical techniques. A recent study reported that transplantation of human umbilical cord blood stem cells (hUCBSCs) achieved therapeutic effects on TON, but the exact effects on optic nerve injury are still unknown, and the mechanisms underlying nerve protection remain poorly understood. A total of 135 healthy Sprague-Dawley adult rats were randomly assigned to three groups: sham-surgery, model and transplantation, with 45 rats in each group. TON was induced in the model and transplantation groups via optic nerve crush injury. The crush injury was not performed in the sham-surgery group. Seven days after the injury, 10(6) hUCBSCs were injected into the rat vitreous cavity of transplantation group, and an equal volume of physiological saline was administered to the model and sham-surgery groups. Pathological observation of rat retina tissues was performed by hematoxylin-eosin (H&E) staining at days 3, 7, 14, 21 and 28 post-surgery. The number of retinal ganglion cells (RGCs) and mRNA expression levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) were assessed by the Fluorogold (FG) retrograde labeling and reverse transcriptase-polymerase chain reaction (RT-PCR) methods, respectively. The number of labeled RGCs and the expression of BDNF and GDNF mRNA obviously increased, and pathological injury was significantly ameliorated in the transplantation group compared to the model group (P < 0.05). Via intravitreal transplantation, the hUCBSCs resulted in a significant increase in the survival of the RGCs, and improved pathological changes in the rat retina, following TON. The protective mechanism is correlated with the continuous secretion of BDNF and GDNF in vivo of retina in optic nerve injury rats by the transplanted hUCBSCs.	[Zhao, Tantai; Tang, Luosheng; Li, Yuehua; Fan, Fang; Jiang, Bing] Cent S Univ, Dept Ophthalmol, Xiang Ya Hosp 2, Changsha 410011, Hunan, Peoples R China; [Li, Yunqin] Second Peoples Hosp Yunnan Prov, Dept Ophthalmol, Kunming 650021, Yunnan Province, Peoples R China	Tang, LS (corresponding author), Cent S Univ, Dept Ophthalmol, Xiang Ya Hosp 2, 139 Renmin Rd, Changsha 410011, Hunan, Peoples R China.	welovetls57@126.com		fan, fang/0000-0002-0958-9996			BACIGALUPO A, 1988, BONE MARROW TRANSPL, V3, P531; Bjugstad KB, 2005, CELL TRANSPLANT, V14, P183, DOI 10.3727/000000005783983098; Bojanic Ines, 2006, Acta Med Croatica, V60, P215; Canque B, 2000, BLOOD, V96, P3748, DOI 10.1182/blood.V96.12.3748.h8003748_3748_3756; Dasari VR, 2007, J NEUROTRAUM, V24, P391, DOI 10.1089/neu.2006.0142; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Garbuzova-Davis S, 2006, PROG BRAIN RES, V157, P207, DOI 10.1016/S0079-6123(06)57014-1; Haas S, 2005, CURR OPIN NEUROL, V18, P59, DOI 10.1097/00019052-200502000-00012; HAO QL, 1995, BLOOD, V86, P3745, DOI 10.1182/blood.V86.10.3745.bloodjournal86103745; Kao CH, 2008, SHOCK, V29, P49, DOI 10.1097/shk.0b013c31805cddce; KNUDTZON S, 1974, BLOOD, V43, P357, DOI 10.1182/blood.V43.3.357.357; Lagreze W, 2009, KLIN MONATSBL AUGENH, V226, P875, DOI 10.1055/s-0028-1109728; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Lee AG, 2000, OPHTHALMOLOGY, V107, P814, DOI 10.1016/S0161-6420(99)00164-5; Li H, 2008, J LARYNGOL OTOL, V122, P1325, DOI 10.1017/S0022215108002296; Martin KRG, 2003, INVEST OPHTH VIS SCI, V44, P4357, DOI 10.1167/iovs.02-1332; Mattson M P, 2001, Expert Rev Neurother, V1, P267, DOI 10.1586/14737175.1.2.267; Newcomb JD, 2007, CELL TRANSPLANT, V16, P151; Osborne NN, 2004, EYE, V18, P1075, DOI 10.1038/sj.eye.6701588; Parrilla-Reverter G, 2009, EXP EYE RES, V89, P32, DOI 10.1016/j.exer.2009.02.015; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Selhorst JB, 2009, SEMIN NEUROL, V29, P29, DOI 10.1055/s-0028-1124020; Sieskiewicz Andrzej, 2008, Klin Oczna, V110, P155; Slater BJ, 2008, INVEST OPHTH VIS SCI, V49, P3671, DOI 10.1167/iovs.07-0504; Steinsapir K D, 1999, Curr Opin Ophthalmol, V10, P340, DOI 10.1097/00055735-199910000-00011; Van Adel BA, 2003, HUM GENE THER, V14, P103, DOI 10.1089/104303403321070801; Wilhelm H, 2004, KLIN MONATSBL AUGENH, V221, P702, DOI 10.1055/s-2004-813268; Wittekind D, 2003, BIOTECH HISTOCHEM, V78, P261, DOI 10.1080/10520290310001633725; Wu N, 2008, J INT MED RES, V36, P883, DOI 10.1177/147323000803600503; Zapala Jan, 2005, Klin Oczna, V107, P263; Zuo Ke-Jun, 2009, Zhonghua Yi Xue Za Zhi, V89, P389	31	31	36	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0721-832X	1435-702X		GRAEF ARCH CLIN EXP	Graefes Arch. Clin. Exp. Ophthalmol.	JUL	2011	249	7					1021	1028		10.1007/s00417-011-1635-7			8	Ophthalmology	Ophthalmology	784NG	WOS:000292163400009	21360302				2021-06-18	
J	Yilmaz, N; Karaali, K; Ozdem, S; Turkay, M; Unal, A; Dora, B				Yilmaz, Nurgul; Karaali, Kamil; Ozdem, Sebahat; Turkay, Mehtap; Unal, Ali; Dora, Babur			Elevated S100B and Neuron Specific Enolase Levels in Patients with Migraine-without Aura: Evidence for Neurodegeneration?	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Blood-brain barrier; Brain damage; Migraine; Neuron specific enolase; NSE; S100B	TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; MESSENGER-RNA; ALZHEIMERS-DISEASE; TRANSGENIC MICE; CARDIAC-SURGERY; NEUROBIOCHEMICAL MARKERS; S100-BETA PROTEIN; AMYLOID PLAQUES; S-100B PROTEIN	Although migraine has mainly been considered as a benign disease, there is cumulative evidence of silent changes in the brain, brainstem, or cerebellum and subtle subclinical cerebellar dysfunction. In this study, in order to investigate a possible neuronal and/or glial damage at the cellular level in migraine, we measured and compared serum levels of S100B which is a protein marker of glial damage or activation, and neuron specific enolase (NSE) which is a marker of neuronal damage, in migraine patients and control subjects. Serum levels of S100B and NSE were measured in blood samples from 41 patients with migraine-without aura taken during a migraine attack (ictal) and in the attack-free period between migraine attacks (interictal) and 35 age- and sex-matched controls. Patients with migraine-without aura had significantly higher ictal serum levels of S100B and NSE (P < 0.05, for both) than control subjects; whereas in the interictal phase, there was a significant increment only in S100B levels (P < 0.05) compared to controls. On the other hand, serum levels of S100B and NSE in ictal and interictal blood samples did not differ significantly. The findings of increased ictal serum S100B and NSE levels together with increased interictal levels of S100B suggested that migraine might be associated with glial and/or neuronal damage in the brain and a prolonged disruption of blood-brain barrier. Increased interictal serum levels of S100B might point out to an insidious and slow damaging process in migraine patients.	[Yilmaz, Nurgul; Unal, Ali; Dora, Babur] Akdeniz Univ, Fac Med, Dept Neurol, TR-07070 Antalya, Turkey; [Karaali, Kamil] Akdeniz Univ, Fac Med, Dept Radiol, TR-07070 Antalya, Turkey; [Ozdem, Sebahat] Akdeniz Univ, Fac Med, Dept Med Biochem, TR-07070 Antalya, Turkey; [Turkay, Mehtap] Akdeniz Univ, Fac Med, Dept Med Educ, TR-07070 Antalya, Turkey	Dora, B (corresponding author), Akdeniz Univ, Fac Med, Dept Neurol, TR-07070 Antalya, Turkey.	bdora@akdeniz.edu.tr	OZDEM, SEBAHAT/C-1412-2016; Turkay, Mehtap/I-9476-2017; Dora, Babur/C-1053-2016; Karaali, Kamil/C-6926-2016	Turkay, Mehtap/0000-0003-4956-4395; Karaali, Kamil/0000-0002-2716-4422	Akdeniz UniversityAkdeniz University	This study was funded by the Akdeniz University Scientific Research Project Unit and was conducted at the Akdeniz University Hospital.	Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Capuano A, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-43; Cooper E. H., 1994, International Journal of Biological Markers, V9, P205; Craft JM, 2005, GLIA, V51, P209, DOI 10.1002/glia.20194; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Ertan T, 2000, INT PSYCHOGERIATR, V12, P163, DOI 10.1017/S1041610200006293; Etminan M, 2005, BMJ-BRIT MED J, V330, P63, DOI 10.1136/bmj.38302.504063.8F; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; Fulle S, 2000, EXP PHYSIOL, V85, P243; Gerlach R, 2006, NEUROSCIENCE, V141, P1697, DOI 10.1016/j.neuroscience.2006.05.008; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Green AJE, 1997, NEUROSCI LETT, V235, P5, DOI 10.1016/S0304-3940(97)00701-5; Griffin WST, 1998, NEUROBIOL AGING, V19, P401, DOI 10.1016/S0197-4580(98)00074-8; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Harno H, 2003, NEUROLOGY, V61, P1748, DOI 10.1212/01.WNL.0000098882.82690.65; Herrmann M, 2000, STROKE, V31, P645, DOI 10.1161/01.STR.31.3.645; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KATO K, 1990, J NEUROCHEM, V54, P1269, DOI 10.1111/j.1471-4159.1990.tb01958.x; Kruit MC, 2004, JAMA-J AM MED ASSOC, V291, P427, DOI 10.1001/jama.291.4.427; Lam AGM, 2001, NEUROBIOL AGING, V22, P765, DOI 10.1016/S0197-4580(01)00233-0; Li YK, 2000, J NEUROCHEM, V74, P143; Li YK, 1998, J NEUROCHEM, V71, P1421; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Marks A, 1996, MOL BRAIN RES, V36, P343, DOI 10.1016/0169-328X(95)00293-2; Mrak RE, 1996, J NEUROPATH EXP NEUR, V55, P273, DOI 10.1097/00005072-199603000-00002; Nygaard O, 1998, SCAND J CLIN LAB INV, V58, P183; Papandreou O, 2005, HEADACHE, V45, P1313, DOI 10.1111/j.1526-4610.2005.00263.x; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Reuter U, 2001, BRAIN, V124, P2490, DOI 10.1093/brain/124.12.2490; Rocca MA, 2006, STROKE, V37, P1765, DOI 10.1161/01.STR.0000226589.00599.4d; ROYDS JA, 1981, J NEUROL NEUROSUR PS, V44, P1129, DOI 10.1136/jnnp.44.12.1129; Sandor PS, 2001, ANN NEUROL, V49, P668, DOI 10.1002/ana.1019; Sarchielli P, 2006, HEADACHE, V46, P200, DOI 10.1111/j.1526-4610.2006.00337.x; Schmidt-Wilcke T, 2008, CEPHALALGIA, V28, P1, DOI 10.1111/j.1468-2982.2007.01428.x; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; Sheng JG, 2000, J NEUROCHEM, V74, P295, DOI 10.1046/j.1471-4159.2000.0740295.x; SINGH VK, 1994, MOL NEUROBIOL, V9, P73, DOI 10.1007/BF02816106; Swartz RH, 2004, ARCH NEUROL-CHICAGO, V61, P1366, DOI 10.1001/archneur.61.9.1366; Teepker M, 2009, HEADACHE, V49, P245, DOI 10.1111/j.1526-4610.2008.01228.x; Welch KMA, 2001, HEADACHE, V41, P629, DOI 10.1046/j.1526-4610.2001.041007629.x; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; YAO JB, 1995, BRAIN RES, V702, P32, DOI 10.1016/0006-8993(95)00991-7; Yilmaz IA, 2010, PAIN MED, V11, P492, DOI 10.1111/j.1526-4637.2009.00791.x	57	31	34	0	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	MAY	2011	31	4					579	585		10.1007/s10571-011-9651-z			7	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	755AC	WOS:000289898000010	21293918				2021-06-18	
J	Davis, DP; Koprowicz, KM; Newgard, CD; Daya, M; Bulger, EM; Stiell, I; Nichol, G; Stephens, S; Dreyer, J; Minei, J; Kerby, JD				Davis, Daniel P.; Koprowicz, Kent M.; Newgard, Craig D.; Daya, Mohamud; Bulger, Eileen M.; Stiell, Ian; Nichol, Graham; Stephens, Shannon; Dreyer, Jonathan; Minei, Joseph; Kerby, Jeffrey D.		ROC Investigators	THE RELATIONSHIP BETWEEN OUT-OF-HOSPITAL AIRWAY MANAGEMENT AND OUTCOME AMONG TRAUMA PATIENTS WITH GLASGOW COMA SCALE SCORES OF 8 OR LESS	PREHOSPITAL EMERGENCY CARE			English	Article						prehospital intubation; traumatic brain injury; airway management; paramedic; outcomes; major trauma victim; ventilation; mortality; Glasgow Coma Scale score	RAPID-SEQUENCE INTUBATION; INDUCED LUNG INJURY; ENDOTRACHEAL INTUBATION; MECHANICAL VENTILATION; BRAIN-INJURY; HYPERVENTILATION; IMPACT; CYTOKINES; SURVIVAL; MODEL	Background. Airway management remains a fundamental component of optimal care of the severely injured patient, with endotracheal intubation representing the definitive strategy for airway control. However, multiple studies document an association between out-of-hospital intubation and increased mortality for severe traumatic brain injury. Objectives. To explore the relationship between out-of-hospital intubation attempts and outcome among trauma patients with Glasgow Coma Scale (GCS) scores <= 8 across sites participating in the Resuscitation Outcomes Consortium (ROC). Methods. The ROC Epistry-Trauma, an epidemiologic database of prehospital encounters with critically injured trauma victims, was used to identify emergency medical services (EMS)-treated patients with GCS scores <= 8. Multiple logistic regression was used to explore the association between intubation attempts and vital status at discharge, adjusting for the following covariates: age, gender, GCS score, hypotension, mechanism of injury, and ROC site. Sites were then stratified by frequency of intubation attempts and chi-square test for trend was used to associate the frequency of intubation attempts with outcome. Results. A total of 1,555 patients were included in this analysis; intubation was attempted in 758 of these. Patients in whom intubation was attempted had higher mortality (adjusted odds ratio [OR] 2.91, 95% confidence interval [CI] 2.13-3.98, p < 0.01). However, sites with higher rates of attempted intubation had lower mortality across all trauma victims with GCS scores <= 8 (OR 1.40, 95% CI 1.15-1.72, p < 0.01). Conclusions. Patients in whom intubation is attempted have higher adjusted mortality. However, sites with a higher rate of attempted intubation have lower adjusted mortality across the entire cohort of trauma patients with GCS scores <= 8.	[Davis, Daniel P.] UCSD Ctr Resuscitat Sci, Dept Emergency Med, San Diego, CA USA; [Bulger, Eileen M.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Koprowicz, Kent M.] Axio Res Corp, Seattle, WA USA; [Newgard, Craig D.; Daya, Mohamud] Oregon Hlth & Sci Univ, Ctr Policy & Res Emergency Med, Dept Emergency Med, Portland, OR 97201 USA; [Stiell, Ian] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Nichol, Graham] Univ Washington, Clin Trials Ctr, Seattle, WA 98195 USA; [Stephens, Shannon; Kerby, Jeffrey D.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Dreyer, Jonathan] Univ Western Ontario, Div Emergency Med, London, ON, Canada; [Minei, Joseph] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dallas, TX 75390 USA	Davis, DP (corresponding author), Univ Calif San Diego, 200 W Arbor Dr, San Diego, CA 92103 USA.	davismd@cox.net	Daya, Mohamud R/A-9322-2012; Nichol, Graham/Z-4996-2019	Stiell, Ian/0000-0002-2583-6408; Stephens, Shannon/0000-0001-5898-5170	National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077885, HL077877, HL077873]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); U.S. Army Medical Research & Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Canadian Institutes of Health Research (CIHR)-Institute of Circulatory and Respiratory Health, Defence Research and Development CanadaCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; American Heart AssociationAmerican Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077873, U01HL077863, U01HL077866, U01HL077908, U01HL077867, U01HL077871, U01HL077885, U01HL077872, U01HL077881] Funding Source: NIH RePORTER	The Resuscitation Outcomes Consortium (ROC) was supported by a series of cooperative agreements to 10 regional clinical centers and one data coordinating center (5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077885, HL077877, HL077873) from the National Heart, Lung and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, U.S. Army Medical Research & Material Command, The Canadian Institutes of Health Research (CIHR)-Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, the Heart and Stroke Foundation of Canada, and the American Heart Association.	Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Bao Yinghui, 2000, Chin J Traumatol, V3, P210; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Bozeman WP, 2005, J TRAUMA, V58, P278, DOI 10.1097/01.TA.0000152536.71932.85; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chiu EHH, 2006, ARCH NEUROL-CHICAGO, V63, P741, DOI 10.1001/archneur.63.5.741; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; Cudnik MT, 2010, J EMERG MED, V38, P175, DOI 10.1016/j.jemermed.2008.01.022; Davis DP, 2008, CAN MED ASSOC J, V178, P1171, DOI 10.1503/cmaj.080234; Davis DP, 2007, PREHOSP EMERG CARE, V11, P369, DOI 10.1080/10903120701537147; Davis DP, 2006, PREHOSP EMERG CARE, V10, P356, DOI 10.1080/10903120600725751; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; DAVIS DP, 2005, PREHOSP EMERG CARE; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Klinger G, 2005, ARCH DIS CHILD-FETAL, V90, pF49, DOI 10.1136/adc.2003.048785; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; McDonald C C, 1998, Prehosp Emerg Care, V2, P29, DOI 10.1080/10903129808958836; McSwain NE, 2004, J TRAUMA, V57, P8; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Newgard CD, 2008, RESUSCITATION, V78, P170, DOI 10.1016/j.resuscitation.2008.01.029; Pepe PE, 2003, J TRAUMA, V54, P1048, DOI 10.1097/01.TA.0000064280.05372.7C; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Slutsky A S, 2000, Respir Res, V1, P73, DOI 10.1186/rr15; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/00003246-200208000-00003; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; Wang H E, 2001, Prehosp Emerg Care, V5, P10, DOI 10.1080/10903120190940254; Wang H E, 2001, Prehosp Emerg Care, V5, P134, DOI 10.1080/10903120190939995; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Wilson MR, 2003, J APPL PHYSIOL, V95, P1385, DOI 10.1152/japplphysiol.00213.2003; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Zhang HB, 2002, ANESTHESIOLOGY, V97, P1426, DOI 10.1097/00000542-200212000-00014	45	31	31	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	APR-JUN	2011	15	2					184	192		10.3109/10903127.2010.545473			9	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	729FG	WOS:000287933400006	21309705	Green Accepted			2021-06-18	
J	Hudak, A; Warner, M; de la Plata, CM; Moore, C; Harper, C; Diaz-Arrastia, R				Hudak, Anne; Warner, Matthew; de la Plata, Carlos Marquez; Moore, Carol; Harper, Caryn; Diaz-Arrastia, Ramon			Brain morphometry changes and depressive symptoms after traumatic brain injury	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						MRI; BDI-II; Cerebral atrophy	II PSYCHIATRIC-DISORDERS; SURFACE-BASED ANALYSIS; GLASGOW OUTCOME SCALE; MAJOR DEPRESSION; MOOD DISORDERS; HEAD-INJURY; AXIS-I; MILD; OUTPATIENTS; IMPAIRMENT	Traumatic brain injury (TBI) is associated with an increased risk of depressive symptoms. Recent imaging studies on spontaneous depression have implicated several brain structures: however, few studies have done the same for post-TBI depression. We report on a pilot observational study correlating atrophy of brain regions of interest in subjects after TBI with depressive symptoms measured by the Beck Depression Inventory-II. Regional brain volumes were calculated on both acute and 6-month MRI using an automated segmentation algorithm (FreeSurfer). Percent volume changes in brain regions were correlated with BDI-II scores using Spearman's rank order correlation coefficient. Correction for multiple comparisons was performed using the false discovery rate (FDR). Three regions of interest (left rostral anterior cingulate and bilateral orbitofrontal cortex) were found to be significantly correlated with depressive symptoms (FDR 0.05). With FDR 0.1, six regions were significantly correlated. The use of volumetric analysis of brain regions of interest to study post-TBI depression is worthy of further study. Regions associated with depressive symptoms in this pilot study were similar to those implicated in study of spontaneous depression. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Hudak, Anne] Univ Texas SW Med Ctr Dallas, Dept Phys Med & Rehabil, Dallas, TX 75390 USA; [Warner, Matthew; Moore, Carol; Harper, Caryn; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [de la Plata, Carlos Marquez] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75235 USA	Hudak, A (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Phys Med & Rehabil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Anne.Hudak@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	Mike Winters Fund; Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23 NS060827, R01 HD48179, U01 HD 42652]; NIH, Department of EducationUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS060827] Funding Source: NIH RePORTER	This publication was supported by the Mike Winters Fund (Anne Hudak), Doris Duke Charitable Foundation Clinical Research Fellowship (Matthew Warner), NIH K23 NS060827 (Carlos Marquez de la Plata), and NIH R01 HD48179, U01 HD 42652, Department of Education H133 A020526 (Ramon Diaz-Arrastia).	Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Beck AT., 1996, BECK DEPRESSION INVE, V2; Benton AL, 1983, MULTILINGUAL APHASIA; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Deb S, 1999, AM J PSYCHIAT, V156, P374; Delis DC, 2000, CALIFORNIA VERBAL LE; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Douglas KM, 2009, AUST NZ J PSYCHIAT, V43, P1105, DOI 10.3109/00048670903279887; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Kirkness Catherine J, 2002, J Neurosci Nurs, V34, P134; Koolschijn PCMP, 2009, HUM BRAIN MAPP, V30, P3719, DOI 10.1002/hbm.20801; Koponen S, 2006, PSYCHIAT RES-NEUROIM, V146, P263, DOI 10.1016/j.pscychresns.2005.05.015; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kronenberg G, 2009, J PSYCHIATR RES, V43, P1112, DOI 10.1016/j.jpsychires.2009.03.007; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Mak AKY, 2009, PROG NEURO-PSYCHOPH, V33, P1184, DOI 10.1016/j.pnpbp.2009.06.025; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; NIMH, 2009, NIH PUBL, V09-4702; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Reitan R. M., 1992, TRAIL MAKING TEST MA; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; SAS, 2008, SAS WIND VERS 9 2; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seminowicz DA, 2004, NEUROIMAGE, V22, P409, DOI 10.1016/j.neuroimage.2004.01.015; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Theberge Jean, 2008, Top Magn Reson Imaging, V19, P111, DOI 10.1097/RMR.0b013e3181808140; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yucel K, 2008, NEUROPSYCHOPHARMACOL, V33, P3157, DOI 10.1038/npp.2008.40	56	31	31	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	MAR 31	2011	191	3					160	165		10.1016/j.pscychresns.2010.10.003			6	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	739OW	WOS:000288728500002	21310594	Green Accepted			2021-06-18	
J	Johnson, U; Nilsson, P; Ronne-Engstrom, E; Howells, T; Enblad, P				Johnson, Ulf; Nilsson, Pelle; Ronne-Engstrom, Elisabeth; Howells, Tim; Enblad, Per			Favorable Outcome in Traumatic Brain Injury Patients With Impaired Cerebral Pressure Autoregulation When Treated at Low Cerebral Perfusion Pressure Levels	NEUROSURGERY			English	Article						Cerebral perfusion pressure; Cerebrovascular pressure autoregulation; Head injury; Outcome	SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL HYPERTENSION; REACTIVITY; CRANIECTOMY; MANAGEMENT; DYNAMICS; PROTOCOL; THERAPY; INSULTS	BACKGROUND: Cerebral pressure autoregulation (CPA) is defined as the ability of the brain vasculature to maintain a constant blood flow over a range of different systemic blood pressures by means of contraction and dilatation. OBJECTIVE: To study CPA in relation to physiological parameters, treatment, and outcome in a series of traumatic brain injury patients. METHODS: In this prospective observational study, 44 male and 14 female patients (age, 15-72 years; mean, 38.7 years; Glasgow Coma Scale score, 4-13; median, 7) were analyzed. Patients were divided into groups on the basis of status of CPA (more pressure active vs more pressure passive) and level of cerebral perfusion pressure (CPP; low vs high CPP). The proportions of favorable outcome in the groups were assessed. Differences in physiological variables in the different groups were analyzed. RESULTS: Patients with more impaired CPA treated at CPP levels below median had a significantly higher proportion of favorable outcome compared with patients with more impaired CPA treated at CPP levels above median. No significant difference in outcome was seen between patients with more intact CPA when divided by level of CPP. In patients with more impaired CPA, CPP < 50 mm Hg and CPP < 60 mm Hg were associated with favorable outcome, whereas CPP > 70 mm Hg and CPP > 80 mm Hg were associated with unfavorable outcome. In patients with more intact CPA, no difference in physiological variables was seen between patients with favorable and unfavorable outcomes. CONCLUSION: Our results support that in traumatic brain injury patients with impaired CPA, CPP should not be elevated.	[Johnson, Ulf; Nilsson, Pelle; Ronne-Engstrom, Elisabeth; Howells, Tim; Enblad, Per] Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden	Johnson, U (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden.	ulf.johnson@neuro.uu.se		Johnson, Ulf/0000-0002-3879-6476	Swedish Research CouncilSwedish Research CouncilEuropean Commission	This work was supported by a Swedish Research Council grant. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Balestreri M, 2005, ACT NEUR S, V95, P25; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chieregato A, 2007, INTENS CARE MED, V33, P856, DOI 10.1007/s00134-007-0604-4; Chieregato A, 2007, NEUROSURGERY, V60, P115, DOI 10.1227/01.NEU.0000249194.76527.28; Consonni F, 2009, NEUROCRIT CARE, V10, P232, DOI 10.1007/s12028-008-9151-2; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; CZOSNYKA M, 1992, ACTA NEUROCHIR, V115, P90, DOI 10.1007/BF01406364; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Huang SJ, 2007, J CLIN NEUROSCI, V14, P449, DOI 10.1016/j.jocn.2005.12.012; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Takahashi R, 2000, TOHOKU J EXP MED, V190, P129, DOI 10.1620/tjem.190.129; Thorat JD, 2008, J CLIN NEUROSCI, V15, P143, DOI 10.1016/j.jocn.2006.08.014; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; TODA N, 1976, BRIT J PHARMACOL, V58, P121, DOI 10.1111/j.1476-5381.1976.tb07700.x; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	32	31	34	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAR	2011	68	3					714	721		10.1227/NEU.0b013e3182077313			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	719WN	WOS:000287242300043	21311298				2021-06-18	
J	Rao, V; Bergey, A; Hill, H; Efron, D; McCann, U				Rao, Vani; Bergey, Alyssa; Hill, Hugh; Efron, David; McCann, Una			Sleep Disturbance After Mild Traumatic Brain Injury: Indicator of Injury?	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							SPECTRAL-ANALYSIS	Mild traumatic brain injury (mTBI) is a complex entity with no known objective diagnostic markers. To test the hypothesis that sleep disturbances in the acute mTBI period can serve as an indicator of brain injury, the authors compared sleep polysomnograms (PSG) and sleep EEG power spectra (PS) data in seven mTBI subjects with seven age- and race-matched healthy-control subjects. The two groups differed significantly on PS measures, suggesting that mTBI can result in a disruption of sleep microarchitecture and, in theory, could be of use as a marker for brain injury. These pilot findings need to be replicated on larger samples. (The Journal of Neuropsychiatry and Clinical Neurosciences 2011; 23: 201-205)	[Rao, Vani] Johns Hopkins Univ, Johns Hopkins Sch Med, Dept Psychiat, Div Neuropsychiat & Geriatr Psychiat, Baltimore, MD 21224 USA; Johns Hopkins Sch Med, Dept Emergency Med, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Psychiat, Anxiety Disorders Program, Baltimore, MD USA	Rao, V (corresponding author), Johns Hopkins Univ, Johns Hopkins Sch Med, Dept Psychiat, Div Neuropsychiat & Geriatr Psychiat, 5300 Alpha Commons Dr,4th Floor,444, Baltimore, MD 21224 USA.	vrao@jhmi.edu			NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 066894, DA16563]; NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002719]; PfizerPfizer; MerckMerck & Company; Elan; Eli LillyEli Lilly; Forest; Jazz PharmaceuticalsJazz Pharmaceuticals; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA016563] Funding Source: NIH RePORTER	This work was supported by K23 MH 066894 from the NIMH (Rao) DA16563 (McCann); and NCRR grant M01RR002719 (Ford). Dr. Rao has a grant from Forest to conduct a clinical trial in post-TBI depression and a grant from Pfizer to conduct a clinical trial in post-stroke anxiety. Dr. McCann served as a speaker for Jazz Pharmaceuticals in 2008 and received $ 14,000 for speaking engagements. She also served as an expert legal witness in an ongoing legal case and has received $ 18,000 for her services. Ms. Bergey is a research assistant on many studies supported by pharmaceutical companies (Merck, Forest, Elan, Pfizer, Eli Lilly).	FEINBERG I, 1979, PSYCHOPHYSIOLOGY, V16, P283, DOI 10.1111/j.1469-8986.1979.tb02991.x; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Iber C, 2007, AASM MANUAL SCORING; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; MURILLORODRI G, 2009, TARGETS, V8, P245; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Pace-Schott EF, 2002, NAT REV NEUROSCI, V3, P591, DOI 10.1038/nrn895; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Valente M, 2002, CLIN NEUROPHYSIOL, V113, P1798, DOI 10.1016/S1388-2457(02)00218-3; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Zhang L, 2008, CHEST, V133, P427, DOI 10.1378/chest.07-1190	11	31	32	0	4	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2011	23	2					201	205		10.1176/jnp.23.2.jnp201			5	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	777VF	WOS:000291652500138	21677251				2021-06-18	
J	Mostany, R; Portera-Cailliau, C				Mostany, Ricardo; Portera-Cailliau, Carlos			Absence of Large-Scale Dendritic Plasticity of Layer 5 Pyramidal Neurons in Peri-Infarct Cortex	JOURNAL OF NEUROSCIENCE			English	Article							ADULT-RATS; LONG-TERM; STROKE; RECOVERY; INJURY; GROWTH; BRAIN; ACTIVATION; HEMISPHERE; INFARCTION	When stroke or traumatic brain injury lead to cortical damage, how do surviving neurons rewire the brain to restore lost functionalities? Several Golgi studies have argued for de novo growth and branching of dendrites of pyramidal neurons in the spared hemisphere, but the results could not always be replicated. Functional brain imaging studies in humans and rodents suggest that significant neuronal plasticity occurs in areas surrounding the cortical lesion, but whether dendritic rearrangements occur there has been less well studied, especially after stroke. We used in vivo two-photon microscopy in adult mice expressing green fluorescent protein to monitor longitudinally the length and branch complexity of entire apical dendritic arbors from layer 5 pyramidal neurons distributed over a large peri-infarct cortex region after middle cerebral artery occlusion. We find no evidence of growth of dendrites or addition of new branches to their arbors over a period of 3 months after stroke. Instead, we observed a two-step pruning process: an initial decrease in dendritic length, followed by a loss of dendritic branches. Importantly, the shortening of branch tips reflected a general shrinkage in the dendritic apical tree, suggesting that mechanical forces attributable to the involution of the infarct contributed to the changes in dendritic length. These results help resolve a long-standing debate regarding the role of large-scale dendritic plasticity of pyramidal neurons in functional recovery after cortical injury.	[Mostany, Ricardo; Portera-Cailliau, Carlos] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Reed Neurol Res Ctr, Los Angeles, CA 90095 USA; [Mostany, Ricardo; Portera-Cailliau, Carlos] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Reed Neurol Res Ctr, Los Angeles, CA 90095 USA	Mostany, R (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Reed Neurol Res Ctr, Room A-145,710 Westwood Plaza, Los Angeles, CA 90095 USA.	mostany@ucla.edu; cpcailliau@mednet.ucla.edu	Mostany, Ricardo/A-7040-2011; Mostany, Ricardo/B-3624-2008	Mostany, Ricardo/0000-0002-5379-0080	Larry L. Hillblom Foundation; The March of Dimes FoundationMarch of Dimes	This work was supported by grants from the Larry L. Hillblom Foundation and The March of Dimes Foundation. We thank Abinav Baweja for technical assistance and Dr. S. Thomas Carmichael for guidance at early stages of this project.	Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Brown CE, 2010, J CEREBR BLOOD F MET, V30, P783, DOI 10.1038/jcbfm.2009.241; Brown CE, 2009, J NEUROSCI, V29, P1719, DOI 10.1523/JNEUROSCI.4249-08.2009; Carmichael ST, 2008, STROKE, V39, P1380, DOI 10.1161/STROKEAHA.107.499962; Chow DK, 2009, NAT NEUROSCI, V12, P116, DOI 10.1038/nn.2255; Dijkhuizen RM, 2001, P NATL ACAD SCI USA, V98, P12766, DOI 10.1073/pnas.231235598; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Forgie ML, 1996, BRAIN RES, V710, P249, DOI 10.1016/0006-8993(95)01348-2; Gibb RL, 2010, BEHAV BRAIN RES, V214, P102, DOI 10.1016/j.bbr.2010.04.008; Gonzalez CLR, 2003, EUR J NEUROSCI, V18, P1950, DOI 10.1046/j.1460-9568.2003.02928.x; Holtmaat A, 2009, NAT PROTOC, V4, P1128, DOI 10.1038/nprot.2009.89; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Lee WCA, 2006, PLOS BIOL, V4, P271, DOI 10.1371/journal.pbio.0040029; Marshall RS, 2000, STROKE, V31, P656, DOI 10.1161/01.STR.31.3.656; Mostany R, 2008, J VIS EXP; Mostany R, 2010, J NEUROSCI, V30, P14116, DOI 10.1523/JNEUROSCI.3908-10.2010; Pologruto TA, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-13; Prusky G, 1996, BRAIN RES, V714, P1, DOI 10.1016/0006-8993(95)01347-4; Rowntree S, 1997, EUR J NEUROSCI, V9, P2432, DOI 10.1111/j.1460-9568.1997.tb01660.x; Takatsuru Y, 2009, J NEUROSCI, V29, P10081, DOI 10.1523/JNEUROSCI.1638-09.2009; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	24	31	31	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 2	2011	31	5					1734	1738		10.1523/JNEUROSCI.4386-10.2011			5	Neurosciences	Neurosciences & Neurology	715WE	WOS:000286922100021	21289182	Green Published, Bronze			2021-06-18	
J	Kim, WR; Chun, SK; Kim, TW; Kim, H; Ono, K; Takebayashi, H; Ikenaka, K; Oppenheim, RW; Sun, W				Kim, Woon Ryoung; Chun, Sung Kun; Kim, Tae Woo; Kim, Hyun; Ono, Katsuhiko; Takebayashi, Hirohide; Ikenaka, Kazuhiro; Oppenheim, Ronald W.; Sun, Woong			Evidence for the spontaneous production but massive programmed cell death of new neurons in the subcallosal zone of the postnatal mouse brain	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						adult neurogenesis; Bax; brain injury; programmed cell death; subcallosal zone; subventricular zone	NEURAL STEM-CELLS; IN-VIVO ANALYSIS; ADULT NEUROGENESIS; OLFACTORY-BULB; SUBVENTRICULAR ZONE; NEUROTROPHIC FACTOR; GENERATED NEURONS; CEREBRAL-ISCHEMIA; DNA-SYNTHESIS; C-JUN	In the last 10 years, many studies have reported that neural stem/progenitor cells spontaneously produce new neurons in a subset of adult brain regions, including the hippocampus, olfactory bulb (OB), cerebral cortex, substantia nigra, hypothalamus, white matter and amygdala in several mammalian species. Although adult neurogenesis in the hippocampus and OB has been clearly documented, its occurrence in other brain regions is controversial. In the present study, we identified a marked accumulation of new neurons in the subcallosal zone (SCZ) of Bax-knockout mice in which programmed cell death (PCD) of adult-generated hippocampal and OB neurons has been shown to be completely prevented. By contrast, in the SCZ of wild-type (WT) mice, only a few immature (but no mature) newly generated neurons were observed, suggesting that virtually all postnatally generated immature neurons in the SCZ were eliminated by Bax-dependent PCD. Treatment of 2-month-old WT mice with a caspase inhibitor, or with the neurotrophic factor brain-derived neurotrophic factor, promoted the survival of adult-generated neurons, suggesting that it is the absence of sufficient neurotrophic signaling in WT SCZ that triggers the Bax-dependent, apoptotic PCD of newly generated SCZ neurons. Furthermore, following focal traumatic brain injury to the posterior brain, SCZ neurogenesis in WT mice was increased, and a subset of these newly generated neurons migrated toward the injury site. These data indicate that the adult SCZ maintains a neurogenic potential that could contribute to recovery in the brain in response to the injury-induced upregulation of neurotrophic signaling.	[Kim, Woon Ryoung; Chun, Sung Kun; Kim, Tae Woo; Kim, Hyun; Sun, Woong] Korea Univ, Coll Med, Dept Anat, BK21 Program, Seoul 136705, South Korea; [Ono, Katsuhiko] Kyoto Prefectural Univ Med, Dept Biol, Kita Ku, Kyoto, Japan; [Ono, Katsuhiko; Ikenaka, Kazuhiro] Natl Inst Physiol Sci, Div Neurobiol & Bioinformat, Aichi, Japan; [Takebayashi, Hirohide] Kumamoto Univ, Grad Sch Med Sci, Dept Morphol Neural Sci, Kumamoto, Japan; [Oppenheim, Ronald W.] Wake Forest Univ, Dept Neurobiol & Anat, Winston Salem, NC 27109 USA; [Oppenheim, Ronald W.] Wake Forest Univ, Program Neurosci, Winston Salem, NC 27109 USA	Sun, W (corresponding author), Korea Univ, Coll Med, Dept Anat, BK21 Program, 126-1 Anam Dong, Seoul 136705, South Korea.	woongsun@korea.ac.kr	Takebayashi, Hirohide/AAO-1693-2020; Chun, Sungkun/R-1614-2016	Chun, Sungkun/0000-0001-9837-2299	Korean Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of Korea [2010K000803, M10641280003-06N4128-00310, 2009K001284]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS20402, NS048982]; Korea Research FoundationKorea Research Foundation [KRF-2007-355-H00002]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048982, R01NS020402] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22500295, 23123524] Funding Source: KAKEN	This work is supported by Korean Ministry of Education, Science and Technology Grants 2010K000803 (W.S.), M10641280003-06N4128-00310 (W.S.) and 2009K001284 (H.K.), and NIH grants NS20402 and NS048982 (R.W.O.). This work is also partly supported by the Korea Research Foundation Grant KRF-2007-355-H00002 (S.K.C.).	Aguirre A, 2004, J NEUROSCI, V24, P10530, DOI 10.1523/JNEUROSCI.3572-04.2004; Bernier PJ, 2002, P NATL ACAD SCI USA, V99, P11464, DOI 10.1073/pnas.172403999; Burns KA, 2007, CEREB CORTEX, V17, P2585, DOI 10.1093/cercor/bhl164; Buss RR, 2006, ANNU REV NEUROSCI, V29, P1, DOI 10.1146/annurev.neuro.29.051605.112800; Chang MY, 2007, MOL CELL BIOL, V27, P4293, DOI 10.1128/MCB.00031-07; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Dong HX, 2003, J NEUROSCI, V23, P8682; Dupret D, 2007, PLOS BIOL, V5, P1683, DOI 10.1371/journal.pbio.0050214; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Gage FH, 2008, ADULT NEUROGENESIS; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gould E, 2007, NAT REV NEUROSCI, V8, P481, DOI 10.1038/nrn2147; Hack MA, 2005, NAT NEUROSCI, V8, P865, DOI 10.1038/nn1479; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kanhema T, 2006, J NEUROCHEM, V99, P1328, DOI 10.1111/j.1471-4159.2006.04158.x; Katoh-Semba R, 2002, FASEB J, V16, P1328, DOI 10.1096/fj.02-0143fje; Kim EJ, 2007, J NEUROSCI, V27, P12764, DOI 10.1523/JNEUROSCI.3178-07.2007; Kim WR, 2007, J NEUROSCI, V27, P14392, DOI 10.1523/JNEUROSCI.3903-07.2007; Kim WR, 2009, EUR J NEUROSCI, V29, P1408, DOI 10.1111/j.1460-9568.2009.06693.x; Kohwi M, 2005, J NEUROSCI, V25, P6997, DOI 10.1523/JNEUROSCI.1435-05.2005; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Kuan CY, 2004, J NEUROSCI, V24, P10763, DOI 10.1523/JNEUROSCI.3883-04.2004; Ligon KL, 2006, P NATL ACAD SCI USA, V103, P7853, DOI 10.1073/pnas.0511001103; Luzzati F, 2006, J NEUROSCI, V26, P609, DOI 10.1523/JNEUROSCI.4371-05.2006; Magavi SS, 2000, NATURE, V405, P951; Masahira N, 2006, DEV BIOL, V293, P358, DOI 10.1016/j.ydbio.2006.02.029; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Merkle FT, 2007, SCIENCE, V317, P381, DOI 10.1126/science.1144914; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nguyen-Ba-Charvet KT, 2004, J NEUROSCI, V24, P1497, DOI 10.1523/JNEUROSCI.4729-03.2004; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Ono K, 2008, DEV BIOL, V320, P456, DOI 10.1016/j.ydbio.2008.06.001; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; Rietze R, 2000, J COMP NEUROL, V424, P397; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Sairanen M, 2005, J NEUROSCI, V25, P1089, DOI 10.1523/JNEUROSCI.3741-04.2005; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; Seri B, 2006, CEREB CORTEX, V16, pI103, DOI 10.1093/cercor/bhk027; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Sun W, 2005, J NEUROSCI, V25, P5595, DOI 10.1523/JNEUROSCI.4970-04.2005; Sun W, 2004, J NEUROSCI, V24, P11205, DOI 10.1523/JNEUROSCI.1436-04.2004; Sun W, 2003, J NEUROSCI, V23, P7298, DOI 10.1523/jneurosci.23-19-07298.2003; Takebayashi H, 2002, CURR BIOL, V12, P1157, DOI 10.1016/S0960-9822(02)00926-0; Takemura NU, 2005, NEUROSCIENCE, V134, P121, DOI 10.1016/j.neuroscience.2005.04.033; Tatsumi K, 2005, NEUROCHEM INT, V46, P381, DOI 10.1016/j.neuint.2004.12.007; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; Vessal M, 2010, J NEUROSCI, V30, P8613, DOI 10.1523/JNEUROSCI.5272-09.2010; Waclaw RR, 2006, NEURON, V49, P503, DOI 10.1016/j.neuron.2006.01.018; Winseck AK, 2006, EUR J NEUROSCI, V24, P2105, DOI 10.1111/j.1460-9568.2006.05107.x; Zhao M, 2003, P NATL ACAD SCI USA, V100, P7925, DOI 10.1073/pnas.1131955100	54	31	34	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2011	33	4					599	611		10.1111/j.1460-9568.2010.07557.x			13	Neurosciences	Neurosciences & Neurology	720WA	WOS:000287312200003	21219476				2021-06-18	
J	Castel, AD; Lee, SS; Humphreys, KL; Moore, AN				Castel, Alan D.; Lee, Steve S.; Humphreys, Kathryn L.; Moore, Amy N.			Memory Capacity, Selective Control, and Value-Directed Remembering in Children With and Without Attention-Deficit/Hyperactivity Disorder (ADHD)	NEUROPSYCHOLOGY			English	Article						ADHD; memory; cognitive control; metamemory; encoding strategies	DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; EXECUTIVE FUNCTION; IV; INHIBITION; PERFORMANCE; VALIDITY; GENDER; RECALL	Objective: The ability to select what is important to remember, to attend to this information, and to recall high-value items leads to the efficient use of memory. The present study examined how children with and without attention-deficit/hyperactivity disorder (ADHD) performed on an incentive-based selectivity task in which to-be-remembered items were worth different point values. Method: Participants were 6-9 year old children with ADHD (n = 57) and without ADHD (n = 59). Using a selectivity task, participants studied words paired with point values and were asked to maximize their score, which was the overall value of the items they recalled. This task allows for measures of memory capacity and the ability to selectively remember high-value items. Results: Although there were no significant between-groups differences in the number of words recalled (memory capacity), children with ADHD were less selective than children in the control group in terms of the value of the items they recalled (control of memory). All children recalled more high-value items than low-value items and showed some learning with task experience, but children with ADHD Combined type did not efficiently maximize memory performance (as measured by a selectivity index) relative to children with ADHD Inattentive type and healthy controls, who did not differ significantly from one another. Conclusions: Children with ADHD Combined type exhibit impairments in the strategic and efficient encoding and recall of high-value items. The findings have implications for theories of memory dysfunction in childhood ADHD and the key role of metacognition, cognitive control, and value-directed remembering when considering the strategic use of memory.	[Castel, Alan D.; Lee, Steve S.; Humphreys, Kathryn L.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Moore, Amy N.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA	Castel, AD (corresponding author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA.	castel@ucla.edu			UCLA; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R03AA020186] Funding Source: NIH RePORTER	We thank David McCabe for assistance with the exploratory factor analysis and useful discussions regarding the data. We also thank the families for participation in the study and the research staff for their help with data collection and management. Portions of this research were supported through a UCLA Faculty Career Development Award to Alan D. Castel.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ariel R, 2009, J EXP PSYCHOL GEN, V138, P432, DOI 10.1037/a0015928; BADDELEY A, 1992, Q J EXP PSYCHOL-A, V44, P1, DOI 10.1080/14640749208401281; Baddeley A, 2007, WORKING MEMORY THOUG; Balota DA, 2007, BEHAV RES METHODS, V39, P445, DOI 10.3758/BF03193014; BARKLEY RA, 1990, J AM ACAD CHILD PSY, V29, P546, DOI 10.1097/00004583-199007000-00007; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Barkley RA, 2002, J ABNORM PSYCHOL, V111, P279, DOI 10.1037//0021-843X.111.2.279; Bedard AC, 2002, DEV NEUROPSYCHOL, V21, P93, DOI 10.1207/S15326942DN2101_5; Burgess C, 1997, LANG COGNITIVE PROC, V12, P177, DOI 10.1080/016909697386844; Castel AD, 2002, MEM COGNITION, V30, P1078, DOI 10.3758/BF03194325; Castel AD, 2007, PSYCHOL LEARN MOTIV, V48, P225, DOI 10.1016/S0079-7421(07)48006-9; Castel AD, 2007, MEM COGNITION, V35, P689, DOI 10.3758/BF03193307; Castel AD, 2009, NEUROPSYCHOLOGY, V23, P297, DOI 10.1037/a0014888; Conners C. K., 1997, J ATTEN DISORD, V1, P217, DOI DOI 10.1177/108705479700100403; Cowan N, 2001, BEHAV BRAIN SCI, V24, P87, DOI 10.1017/S0140525X01003922; CRAIK FIM, 1987, J EXP PSYCHOL LEARN, V13, P474, DOI 10.1037/0278-7393.13.3.474; DOUGLAS VI, 1988, J CHILD PSYCHOL PSYC, V29, P453, DOI 10.1111/j.1469-7610.1988.tb00737.x; Engelhardt PE, 2008, J ABNORM PSYCHOL, V117, P591, DOI 10.1037/a0012593; Geary DC, 2007, CHILD DEV, V78, P1343, DOI 10.1111/j.1467-8624.2007.01069.x; Geurts HM, 2005, ARCH CLIN NEUROPSYCH, V20, P457, DOI 10.1016/j.acn.2004.11.001; Halperin JM, 2008, J CHILD PSYCHOL PSYC, V49, P958, DOI 10.1111/j.1469-7610.2008.01926.x; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hanten G, 2007, DEV NEUROPSYCHOL, V32, P585, DOI 10.1080/87565640701361112; Hasher L., 2001, PERSPECTIVES HUMAN M, P286; Hinshaw SP, 2002, J CONSULT CLIN PSYCH, V70, P1086, DOI 10.1037//0022-006X.70.5.1086; Houghton S, 1999, J CHILD NEUROL, V14, P801, DOI 10.1177/088307389901401206; JONES TC, 1995, EUR J COGN PSYCHOL, V7, P65, DOI 10.1080/09541449508520158; Kane MJ, 2003, J EXP PSYCHOL GEN, V132, P47, DOI 10.1037/0096-3445.132.1.47; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Klorman R, 1999, J AM ACAD CHILD PSY, V38, P1148, DOI 10.1097/00004583-199909000-00020; Kohls G, 2009, DEVELOPMENTAL SCI, V12, P614, DOI 10.1111/j.1467-7687.2009.00816.x; Koriat A, 1996, PSYCHOL REV, V103, P490, DOI 10.1037/0033-295X.103.3.490; LAHEY BB, 1994, AM J PSYCHIAT, V151, P1673; Lahey BB, 2004, AM J PSYCHIAT, V161, P2014, DOI 10.1176/appi.ajp.161.11.2014; Lee SS, 2008, J ABNORM CHILD PSYCH, V36, P373, DOI 10.1007/s10802-007-9184-6; Lowe PA, 2003, ARCH CLIN NEUROPSYCH, V18, P865, DOI 10.1016/S0887-6177(02)00162-2; Lynn R, 2008, INTELLIGENCE, V36, P226, DOI 10.1016/j.intell.2007.06.002; Mahone EM, 2009, J AM ACAD CHILD PSY, V48, P749, DOI 10.1097/CHI.0b013e3181a565f1; Martinussen R, 2005, J AM ACAD CHILD PSY, V44, P377, DOI 10.1097/01.chi.0000153228.72591.73; Milich R, 2001, CLIN PSYCHOL-SCI PR, V8, P463, DOI 10.1093/clipsy/8.4.463; Nigg JT, 2002, J AM ACAD CHILD PSY, V41, P59, DOI 10.1097/00004583-200201000-00012; Oie M, 1999, NEUROPSYCHOLOGIA, V37, P1351, DOI 10.1016/S0028-3932(99)00043-3; ONeill ME, 1996, J PEDIATR PSYCHOL, V21, P73, DOI 10.1093/jpepsy/21.1.73; Owens EB, 2009, J CLIN CHILD ADOLESC, V38, P132, DOI 10.1080/15374410802575313; Sattler J. M., 2004, ASSESSMENT CHILDREN; Shaffer D, 2000, J AM ACAD CHILD PSY, V39, P28, DOI 10.1097/00004583-200001000-00014; Watkins M. J., 1999, SELECTIVITY ME UNPUB; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2002, WECHSLER INDIVIDUAL; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Zelazo PD, 2004, ACTA PSYCHOL, V115, P167, DOI 10.1016/j.actpsy.2003.12.005	54	31	32	1	25	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2011	25	1					15	24		10.1037/a0020298			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	711AQ	WOS:000286558500002	20873928	Green Accepted			2021-06-18	
J	Eonta, SE; Carr, W; McArdle, JJ; Kain, JM; Tate, C; Wesensten, NJ; Norris, JN; Balkin, TJ; Kamimori, GH				Eonta, Stephanie E.; Carr, Walter; McArdle, Joseph J.; Kain, Jason M.; Tate, Charmaine; Wesensten, Nancy J.; Norris, Jacob N.; Balkin, Thomas J.; Kamimori, Gary H.			Automated Neuropsychological Assessment Metrics: Repeated Assessment with Two Military Samples	AVIATION SPACE AND ENVIRONMENTAL MEDICINE			English	Article						neuropsychological assessment; computer-based testing; practice effects; repeated measures	WORKING-MEMORY; PERFORMANCE; TESTS	EONTA SE, CARR W, MCARDLE JJ, KAIN JM, TATE C, WESENSTEN NJ, No Rats JN, BALKIN TJ, KAMIMORI GH. Automated Neuropsychological Assessment Metrics: repeated assessment with two military samples. Aviat Space Environ Med 2011; 82:34-9. Introduction: U.S. military troops deploying to war zones are currently administered the Automated Neuropsychological Assessment Metrics (ANAM4) Traumatic Brain Injury (TBI) Battery to establish individual neurocognitive performance baselines. In part, the utility of the ANAM4 TBI Battery baseline measurement depends on test-retest reliability of this instrument. The purpose of this report was to evaluate performance following multiple administrations of the ANAM4 TBI Battery: does performance in a repeated measures paradigm constitute a stable, interpretable indication of baseline neurocognitive ability? Methods: The data presented here are from the ANAM4 TBI Battery administered four times to a group of U.S. Marines in Study 1 and eight times to a group of New Zealand Defence Force personnel in Study 2. Results: The results show practice effect in five of six performance sub-tests in both Study 1 and Study 2. Discussion: Results are consistent with expectations that multiple test sessions are required to reach stable performance on some computerized tasks. These results have implications for taking ANAM4 TBI Battery practice effects into account in test administration and in data interpretation.	[Eonta, Stephanie E.] USN, Med Res Ctr, Silver Spring, MD 20910 USA; Walter Reed Army Inst Res, Silver Spring, MD USA; USN, Hlth Res Ctr, Silver Spring, MD 20910 USA; New Zealand Def Force, Auckland, New Zealand	Eonta, SE (corresponding author), USN, Med Res Ctr, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	stephanie.eonta@med.navy.mil			 [602702E.0000.000A0811]	This work was supported and funded by work unit number 602702E.0000.000A0811. The study protocols were approved by the Naval Medical Research Center Institutional Review Board in compliance with all applicable Federal regulations governing the protection of human subjects.	Baddeley A, 2001, J EXP PSYCHOL GEN, V130, P641, DOI 10.1037//0096-3445.130.4.641; Baddeley AD, 2001, AM PSYCHOL, V56, P851, DOI 10.1037/0003-066X.56.11.851; Basso MR, 2002, CLIN NEUROPSYCHOL, V16, P57, DOI 10.1076/clin.16.1.57.8329; Basso MR, 1999, CLIN NEUROPSYCHOL, V13, P283, DOI 10.1076/clin.13.3.283.1743; Beglinger LJ, 2005, ARCH CLIN NEUROPSYCH, V20, P517, DOI 10.1016/j.acn.2004.12.003; BENDETTO J, 1995, EPRLTR9502 MANK STAT; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; *C SHOP, 2007, ANAM4 TBI US MAN; *C SHOP, 2007, AUT NEUR ASS METR; CARR W, 2010, J NEUROTRAUMA S, V27, pA29; CERASO J, 1967, SCI AM, V217, P117, DOI 10.1038/scientificamerican1067-117; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Duff K, 2001, ARCH CLIN NEUROPSYCH, V16, P461; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Friedl KE, 2007, ARCH CLIN NEUROPSYCH, V22, pS7, DOI 10.1016/j.acn.2006.10.002; Goldstone RL, 1998, ANNU REV PSYCHOL, V49, P585, DOI 10.1146/annurev.psych.49.1.585; Lowe M, 2007, ARCH CLIN NEUROPSYCH, V22, pS89, DOI 10.1016/j.acn.2006.10.010; MCCAFFREY RJ, 1993, ARCH CLIN NEUROPSYCH, V8, P519; MCCAFFREY RJ, 1992, NEUROPSYCHOL REV, V3, P235, DOI 10.1007/BF01109049; MCCAFFREY RJ, 1992, CLIN NEUROPSYCHOL, V6, P32, DOI DOI 10.1080/13854049208404115; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Roebuck-Spencer T, 2007, ARCH CLIN NEUROPSYCH, V22, pS79, DOI 10.1016/j.acn.2006.10.011; Schranz S, 2009, WIEN KLIN WOCHENSCHR, V121, P405, DOI 10.1007/s00508-009-1193-8; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; WATSON FL, 1994, HUM PSYCHOPHARM CLIN, V9, P51, DOI 10.1002/hup.470090107; WICKENS DD, 1972, CODING PROCESSES HUM	28	31	31	3	13	AEROSPACE MEDICAL ASSOC	ALEXANDRIA	320 S HENRY ST, ALEXANDRIA, VA 22314-3579 USA	0095-6562	1943-4448		AVIAT SPACE ENVIR MD	Aviat. Space Environ. Med.	JAN	2011	82	1					34	39		10.3357/ASEM.2799.2011			6	Public, Environmental & Occupational Health; Medicine, General & Internal; Sport Sciences	Public, Environmental & Occupational Health; General & Internal Medicine; Sport Sciences	702OH	WOS:000285903500007	21235103				2021-06-18	
J	Potvin, MJ; Rouleau, I; Senechal, G; Giguere, JF				Potvin, Marie-Julie; Rouleau, Isabelle; Senechal, Genevieve; Giguere, Jean-Francois			Prospective memory rehabilitation based on visual imagery techniques	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Prospective memory; Cognitive rehabilitation; Prospective remembering; Visual imagery; Mnemonic strategy	TRAUMATIC BRAIN-INJURY; MILD ALZHEIMERS-DISEASE; EVERYDAY MEMORY; ADULTS; QUESTIONNAIRE; INDIVIDUALS; RELIABILITY; PERFORMANCE; INTENTIONS; RETRIEVAL	Despite the frequency of prospective memory (PM) problems in the traumatic brain injury (TBI) population, there are only a few rehabilitation programmes that have been specifically designed to address this issue, other than those using external compensatory strategies. In the present study, a PM rehabilitation programme based on visual imagery techniques expected to strengthen the cue-action association was developed. Ten moderate to severe chronic TBI patients learned to create a mental image representing the association between a prospective cue and an intended action within progressively more complex and naturalistic PM tasks. We hypothesised that compared to TBI patients (n = 20) who received a short session of education (control condition), TBI patients in the rehabilitation group would exhibit a greater improvement on the event-based than on the time-based condition of a PM ecological task. Results revealed however that this programme was similarly beneficial for both conditions. TBI patients in the rehabilitation group and their relatives also reported less everyday PM failures following the programme, which suggests generalisation. The PM improvement appears to be specific since results on cognitive control tasks remained similar. Therefore, visual imagery techniques appear to improve PM functioning by strengthening the memory trace of the intentions and inducing an automatic recall of the intentions.	[Rouleau, Isabelle] Univ Quebec, Dept Psychol, Inst Cognit Sci, Montreal, PQ H3C 3P8, Canada; [Potvin, Marie-Julie; Giguere, Jean-Francois] Hop Sacre Coeur Montreal, Neurotraumatol Program, Montreal, PQ, Canada	Rouleau, I (corresponding author), Univ Quebec, Dept Psychol, Inst Cognit Sci, CP 8888,Succursale Ctr Ville, Montreal, PQ H3C 3P8, Canada.	rouleau.isabelle@uqam.ca		Potvin, Marie-Julie/0000-0001-5503-8063	NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); FRSQFonds de la Recherche en Sante du Quebec	This research was supported by NSERC and FRSQ scholarships (M.-J. Potvin), as well as an FRSQ clinical research grant (I. Rouleau). We would like to thank Jean Begin, PhD, for suggestions for the statistical analysis, Daniel Lamoureux, PhD, for help with the recruitment of patients, as well as Simon Charbonneau, PhD, for useful comments.	Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck A.T., 1993; Benton A., 1994, MULTILINGUAL APHASIA; Brandt J., 2001, BRIEF VISUOSPATIAL M; Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; Cavallini E, 2003, ARCH GERONTOL GERIAT, V37, P241, DOI 10.1016/S0167-4943(03)00063-3; Chasteen AL, 2001, PSYCHOL SCI, V12, P457, DOI 10.1111/1467-9280.00385; Chervinsky AB, 1998, ARCH CLIN NEUROPSYCH, V13, P433, DOI 10.1016/S0887-6177(97)00016-4; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Coyette F., 2003, EVALUATION PRISE CHA, P333; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dunn L. M., 1993, ECHELLE VOCABULAIRE; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Hannon R, 1999, ARCH CLIN NEUROPSYCH, V14, P798, DOI 10.1016/S0887-6177(99)80344-8; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kinsella GJ, 2007, NEUROPSYCHOL REHABIL, V17, P688, DOI 10.1080/09602010600892824; Kixmiller JS, 2002, BRAIN COGNITION, V49, P237, DOI 10.1006/brcg.2001.1476; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Kliegel M., 2008, PROSPECTIVE MEMORY C, P283; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Levine B, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P80; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mackinnon A, 1999, INT J METHODS PSYCHI, V8, P27, DOI [10.1002/mpr.54., DOI 10.1002/MPR.54]; Madjan A., 1996, J CLIN EXP NEUROPSYC, V18, P416; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McDaniel M. A., 2007, PROSPECTIVE MEMORY O; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; MCDANIEL MA, 1992, ADV LEARNING BEHAVIO, V7, P87; MCKITRICK LA, 1992, J GERONTOL, V47, pP337, DOI 10.1093/geronj/47.5.P337; Mesulam M., 1985, CONT NEUROLOGY SERIE, V26; PAIVIO A, 1983, CAN J PSYCHOL, V37, P461, DOI 10.1037/h0080749; Potvin M.-J., 2002, COMM AFF PRES 25 C A; Potvin M.-J., 2004, J INT NEUROPSYCH SOC, V10, P38; Potvin MJ, 2011, BRAIN INJURY, V25, P192, DOI 10.3109/02699052.2010.541896; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rey A., 1958, LEXAMEN CLINIQUE PSY; Rude SS, 1999, COGNITION EMOTION, V13, P267, DOI 10.1080/026999399379276; Salinsky MC, 2001, J INT NEUROPSYCH SOC, V7, P597, DOI 10.1017/S1355617701755075; Schmidt IW, 2001, EDUC GERONTOL, V27, P455, DOI 10.1080/036012701316894162; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199604000-00007; Sullivan K, 2005, ARCH CLIN NEUROPSYCH, V20, P745, DOI 10.1016/j.acn.2005.04.006; Thone-Otto A.I., 2008, PROSPECTIVE MEMORY C, P321; van den Broek MD, 2000, BRAIN INJURY, V14, P455; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; Waugh N., 1999, THESIS GRIFFITH U BR; Wechsler D, 1997, WAIS 3 ADM SCORING M; WESCHLER D, 1991, WECHSLER INTELLIGENC; Wilson Barbara A., 2009, MEMORY REHABILITATIO	61	31	31	0	26	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	6					899	924		10.1080/09602011.2011.630882			26	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	885OT	WOS:000299789200008	22150454				2021-06-18	
J	Gillett, GR; Honeybul, S; Ho, KM; Lind, CRP				Gillett, G. R.; Honeybul, S.; Ho, K. M.; Lind, C. R. P.			Neurotrauma and the RUB: where tragedy meets ethics and science	JOURNAL OF MEDICAL ETHICS			English	Article							TRAUMATIC BRAIN-INJURY; EARLY DECOMPRESSIVE CRANIECTOMY; CEREBRAL-ARTERY INFARCTION; GLASGOW COMA SCALE; SEVERE HEAD-INJURY; SURGICAL DECOMPRESSION; RANDOMIZED-TRIAL; HEMICRANIECTOMY; MULTICENTER; VALIDATION	Decompressive craniectomy is a technically straightforward procedure whereby a large section of the cranium is temporarily removed in cases where the intracranial pressure is dangerously high. While its use has been described for a number of conditions, it is increasingly used in the context of severe head injury. As the use of the procedure increases, a significant number of patients may survive a severe head injury who otherwise would have died. Unfortunately some of these patients will be left severely disabled; a condition likened to the RUB, an acronym for the Risk of Unacceptable Badness. Until recently it has been difficult to predict this outcome, however an accurate prediction model has been developed and this has been applied to a large cohort of patients in Western Australia. It is possible to compare the predicted outcome with the observed outcome at 18 months within this cohort. By using predicted and observed outcome data this paper considers the ethical implications in three cases of differing severity of head injury in view of the fact that it is possible to calculate the RUB for each case.	[Gillett, G. R.] Univ Otago, Sch Med, Otago Bioeth Ctr, Dunedin, New Zealand; [Gillett, G. R.] Univ Otago, Dunedin Hosp, Dunedin, New Zealand; [Honeybul, S.; Lind, C. R. P.] Sir Charles Gairdner Hosp, Dept Neurosurg, Nedlands, WA, Australia; [Honeybul, S.; Lind, C. R. P.] Royal Perth Hosp, Perth, WA, Australia; [Ho, K. M.] Univ Western Australia, Dept Intens Care Med, Nedlands, WA 6009, Australia; [Ho, K. M.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia; [Lind, C. R. P.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Nedlands, WA 6009, Australia	Gillett, GR (corresponding author), Univ Otago, Sch Med, Otago Bioeth Ctr, 201 Great King St,POB 913, Dunedin, New Zealand.	gillett@stonebow.otago.ac.nz	Lind, Christopher/K-3629-2012; Ho, Kwok M./E-3546-2010	Lind, Christopher/0000-0001-9991-1725; Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Gillett G, 2001, NEW ZEAL MED J, V114, P188; GILLETT G, 2004, BIOETHICS CLIN; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Gupta R, 2004, STROKE, V35, P539, DOI 10.1161/01.STR.0000109772.64650.18; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jennett B, 1986, Health Serv J, V96, P6; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Meier U, 2005, ACT NEUR S, V95, P55; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Potts MB, 2008, ACTA NEUROCHIR SUPPL, V102, P109, DOI 10.1007/978-3-211-85578-2_22; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235	25	31	33	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-6800	1473-4257		J MED ETHICS	J. Med. Ethics	DEC	2010	36	12					727	730		10.1136/jme.2010.037424			4	Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical	Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences	692XU	WOS:000285190000002	20852302				2021-06-18	
J	Petronilho, F; Feier, G; de Souza, B; Gughelmi, C; Constantino, LS; Walz, R; Quevedo, J; Dal-Pizzol, F				Petronilho, Fabricia; Feier, Gustavo; de Souza, Bruna; Gughelmi, Cecilia; Constantino, Larissa S.; Walz, Roger; Quevedo, Joao; Dal-Pizzol, Felipe			Oxidative Stress in Brain According to Traumatic Brain Injury Intensity	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; lipid peroxidation; protein carbonyls	NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; N-ACETYLCYSTEINE; HEAD-INJURY; PATHOPHYSIOLOGY; HIPPOCAMPUS; GLUTAMATE; STROKE; CORTEX; DAMAGE	Background The mechanisms of brain damage and neuroplasticity following traumatic brain injury (TB!) are complex and not completely understood Thus, we investigated markers of oxidative stress in the central nervous system after mild and severe TBI in rats Material and Methods Adult male wistar rats (five animals per group) submitted to mild (mTBI group) or severe TBI (sTBI Group) were sacrificed 30min, 3, 6, or 12 h after the injury to quantify markers of oxidative damage in different brain regions Levels of thiobarbituric acid reactive species and protein carbonyl in the cortex, hippocampus, striatum, and cerebellum of mTBI and sTBI groups were compared with the control group Results After mTBI, levels of protein oxidation were increased in all analyzed structures in several different times after injury The increase in TBARS levels was not so consistent in mTBI In contrast, sTBI did not induce a sustainable increase in oxidative damage markers in all analyzed structures Conclusions Oxidative damage seemed to be inversely proportional to severity of traumatic brain injury (C) 2010 Elsevier Inc All rights reserved	[Feier, Gustavo; Gughelmi, Cecilia; Quevedo, Joao] Univ Extremo Catarinense, Unidade Acad Ciencias Saude, Programa Pos Grad Ciencias Saude, Lab Neurociencias, BR-88806000 Criciuma, SC, Brazil; [Petronilho, Fabricia; de Souza, Bruna; Constantino, Larissa S.; Dal-Pizzol, Felipe] Univ Extremo Catarinense, Unidade Acad Ciencias Saude, Programa Pos Grad Ciencias Saude, Lab Fisiopatol Expt, BR-88806000 Criciuma, SC, Brazil; [Walz, Roger] Univ Fed Santa Catarina, Nucleo Pesquisas Neurol Expt & Clin NUPNEC, Florianopolis, SC, Brazil; [Walz, Roger] Hosp Governador Celso Ramos, Ctr Cirurgia Epilepsia Santa Catarina CEPESC, Florianopolis, SC, Brazil	Dal-Pizzol, F (corresponding author), Univ Extremo Catarinense, Lab Fisiopatol, BR-88806000 Criciuma, SC, Brazil.		de Quevedo, Joao Luciano/E-5491-2013; Constantino, Larissa/I-7062-2015; de Quevedo, Joao Luciano/N-1407-2019; Walz, Roger/K-9096-2013; Petronilho, Fabricia/D-8822-2013; Dal-Pizzol, Felipe/F-2756-2015	de Quevedo, Joao Luciano/0000-0003-3114-6611; de Quevedo, Joao Luciano/0000-0003-3114-6611; Walz, Roger/0000-0002-9875-6687; Dal-Pizzol, Felipe/0000-0003-3003-8977; Constantino, Larissa/0000-0002-5400-6331	CNPq/MCT BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); UNESC Brazil	The authors acknowledge support for this research by grants from CNPq/MCT Brazil and UNESC Brazil	Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feier G, 2006, NEUROCHEM RES, V31, P665, DOI 10.1007/s11064-006-9064-4; Fortunato JJ, 2006, NEUROCHEM RES, V31, P671, DOI 10.1007/s11064-006-9065-3; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Harukuni I, 2006, NEUROL CLIN, V24, P1, DOI 10.1016/j.ncl.2005.10.004; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jornada LK, 2007, NEUROCHEM RES, V32, P389, DOI 10.1007/s11064-006-9214-8; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; SHERKI YG, 2002, PHARMACOL REV, V54, P271; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tuzgen S, 2003, NEUROL RES, V25, P31, DOI 10.1179/016164103101201085; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Weng GZ, 1999, SCIENCE, V284, P92, DOI 10.1126/science.284.5411.92; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yi JH, 2006, J NEUROTRAUM, V23, P86, DOI 10.1089/neu.2006.23.86; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x	39	31	32	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	DEC	2010	164	2					316	320		10.1016/j.jss.2009.04.031			5	Surgery	Surgery	690AO	WOS:000284972600022	19691993				2021-06-18	
J	Podell, K; Gifford, K; Bougakov, D; Goldberg, E				Podell, Kenneth; Gifford, Katherine; Bougakov, Dmitri; Goldberg, Elkhonon			Neuropsychological Assessment in Traumatic Brain Injury	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Executive control; Neuropsychological testing	CLOSED-HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; FRONTAL LOBES; PSYCHIATRIC CONDITIONS; ECOLOGICAL VALIDITY; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; COGNITIVE BIAS; CHRONIC PAIN; TEST-SCORES	Traumatic brain injury (TBI) is a neurological injury that can affect the cognitive emotional, psychological, and physical functioning of an individual The clinical neuropsychologist working with TBI patients must take a holistic approach when assessing and treating the patient and consider the patient in total, including premorbid and post-incident factors, to formulate a comprehensive and accurate picture of the patient This approach will guide the clinician regarding multiple types of treatment the patient may require	[Podell, Kenneth; Gifford, Katherine] Henry Ford Hlth Syst, Div Neuropsychol, Detroit, MI 48322 USA; [Podell, Kenneth] Wayne State Univ, Dept Psychiat, Detroit, MI USA; [Bougakov, Dmitri] CUNY, New York, NY 10021 USA; [Goldberg, Elkhonon] New York Univ, Sch Med, Dept Neurol, New York, NY 10016 USA	Podell, K (corresponding author), Henry Ford Hlth Syst, Div Neuropsychol, 1 Ford Pl 1E, Detroit, MI 48322 USA.						Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; Barth JT, 2003, ARCH CLIN NEUROPSYCH, V18, P551, DOI 10.1016/S0887-6177(02)00146-4; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CARROLL S, 1995, COSTS EXCESS MED CLA; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; Danckwerts A, 2003, NEUROPSYCHOL REV, V13, P221, DOI 10.1023/B:NERV.0000009485.76839.b7; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2001, DELISKAPLAN EXECUTIV; DEUTSCH G, 1987, J CEREBR BLOOD F MET, V7, P29, DOI 10.1038/jcbfm.1987.5; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; DYER FN, 1973, J EXP PSYCHOL, V98, P438, DOI 10.1037/h0034353; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; ERIKSEN CW, 1979, PERCEPT PSYCHOPHYS, V25, P249, DOI 10.3758/BF03198804; Fuster JM, 2008, PREFRONTAL CORTEX, 4TH EDITION, P1; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GAULTIERI R, 1991, BRAIN INJURY, V5, P219; GOLDBERG E, 1994, J COGNITIVE NEUROSCI, V6, P276, DOI 10.1162/jocn.1994.6.3.276; GOLDBERG E, 1992, NEUROPSY NEUROPSY BE, V5, P231; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Goldberg E., 2000, EXECUTIVE CONTROL BA; Goldberg E., 1987, FRONTAL LOBES REVISI, P159; Goldberg EM, 2000, PROC SPIE, V3913, P93, DOI 10.1117/12.382021; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; GONZALEZ R, 2009, NEUROPSYCHOLOGICAL A, P455; GOODGLASS H, 1986, NEUROPSYCHOLOGICAL A, P121; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein M. F., 2008, TXB CLIN NEUROPSYCHO, P905; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; Greiffenstein MF, 2003, CLIN NEUROPSYCHOL, V17, P561, DOI 10.1076/clin.17.4.561.27937; Greiffenstein MF, 2002, PSYCHOL ASSESSMENT, V14, P202, DOI 10.1037//1040-3590.14.2.202; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Halstead NC, 1943, ARCH NEURO PSYCHIATR, V49, P489; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Harris I, 2005, JAMA-J AM MED ASSOC, V293, P1644, DOI 10.1001/jama.293.13.1644; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HEATON RK, 2000, HDB NEUROPSYCHOLOGY; Hongwanishkul D, 2005, DEV NEUROPSYCHOL, V28, P617, DOI 10.1207/s15326942dn2802_4; Hoofien D, 2001, BRAIN INJURY, V15, P189; INCAGNOLI T, 1986, NEUROPSYCHOLOGICAL T; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; JENSEN AR, 1966, ACTA PSYCHOL, V25, P36, DOI 10.1016/0001-6918(66)90004-7; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; KANE R L, 1991, Neuropsychology Review, V2, P281, DOI 10.1007/BF01108849; Kaplan E, 1983, HOLISTIC DEV PSYCHOL, P143; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kerr A, 2004, BRAIN COGNITION, V55, P148, DOI 10.1016/s0278-2626(03)00275-6; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Lange RT, 2008, CLIN NEUROPSYCHOL, V22, P209, DOI 10.1080/13854040701290062; Langenecker SA, 2009, NEUROPSYCHOLOGICAL A, P523; Larrabee GJ, 2000, J CLIN EXP NEUROPSYC, V22, P702, DOI 10.1076/1380-3395(200010)22:5;1-9;FT702; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; LARUE A, 1992, AGING NEUROPSYCHOLOG; Lees-Haley PR, 2003, PSYCHOL REP, V93, P561, DOI 10.2466/PR0.93.6.561-584; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Luria A. R., 1966, HIGHER CORTICAL FUNC; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MILNER B, 1982, PHILOS T R SOC B, V298, P211, DOI 10.1098/rstb.1982.0083; MITTENBERG W, 2002, J FORENSIC NEUROPSYC, V3, P227, DOI DOI 10.1300/J151V03N01_03; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; PARSONS OA, 1986, CLIN APPLICATIONS NE, P155; Pobereskin LH, 2005, J NEUROL NEUROSUR PS, V76, P1146, DOI 10.1136/jnnp.2004.049189; PODELL K, 1995, J NEUROPSYCH CLIN N, V7, P491; PODELL K, 1999, INT NEUR SOC 27 ANN; PODELL K, 1999, 10 ANN ROTM RES I C; Reitan RM., 1985, HALSTEAD REITAN NEUR; ROGERS R, 1990, PROF PSYCHOL-RES PR, V21, P182; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; Rourke S.B., 2009, NEUROPSYCHOLOGICAL A, P398; Russell E. W., 1984, CLIN NEUROPSYCHOLOGY, P50; Ryu WHA, 2010, INT J REHABIL RES, V33, P84, DOI 10.1097/MRR.0b013e32832e6b4b; SCHEAR JM, 1984, CLIN NEUROPSYCHOLOGY, P199; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sjogren P, 2000, J PAIN SYMPTOM MANAG, V19, P100, DOI 10.1016/S0885-3924(99)00143-8; SPIKMAN JM, 1995, J CLIN EXP NEUROPSYC, V17, P29, DOI 10.1080/13803399508406578; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; TARTER RE, 1986, CLIN APPL NEUROPSYCH, P135; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; WOOD RL, 1990, TRAUMATIC BRAIN INJU, P121; Zelazo P. D., 2007, HDB EMOTION REGULATI, P135; ZILLMER E. A., 2008, PRINCIPLES NEUROPSYC	117	31	33	1	23	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	DEC	2010	33	4					855	+		10.1016/j.psc.2010.08.003			24	Psychiatry	Psychiatry	694TA	WOS:000285320700008	21093682				2021-06-18	
J	Schwetye, KE; Cirrito, JR; Esparza, TJ; Mac Donald, CL; Holtzman, DM; Brody, DL				Schwetye, Katherine E.; Cirrito, John R.; Esparza, Thomas J.; Mac Donald, Christine L.; Holtzman, David M.; Brody, David L.			Traumatic brain injury reduces soluble extracellular amyloid-beta in mice: A methodologically novel combined microdialysis-controlled cortical impact study	NEUROBIOLOGY OF DISEASE			English	Article						Amyloid-beta; Traumatic brain injury; Microdialysis; EEG; Alzheimer's disease; Dementia; Mouse	PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; HEAD-INJURY; IN-VIVO; TRANSGENIC MICE; AXONAL INJURY; INTERSTITIAL FLUID; INTRACEREBRAL MICRODIALYSIS; INDUCED INCREASES; MOUSE MODEL	Acute amyloid-beta; peptide (A beta) deposition has been observed in young traumatic brain injury (TB!) patients, leading to the hypothesis that elevated extracellular A beta levels could underlie the increased risk of dementia following TBI. However, a recent microdialysis-based study in human brain injury patients found that extracellular A beta dynamics correlate with changes in neurological status. Because neurological status is generally diminished following injury, this correlation suggested the alternative hypothesis that soluble extracellular A beta levels may instead be reduced after TBI relative to baseline. We have developed a methodologically novel mouse model that combines experimental controlled cortical impact TBI with intracerebral microdialysis. In this model, we found that A beta levels in microdialysates were immediately decreased by 25-50% in the ipsilateral hippocampus following TBI. This result was found in PDAPP. Tg2576, and Tg2576-ApoE2 transgenic mice producing human A beta plus wild-type animals. Changes were not due to altered probe function, edema, changes in APP levels, or A beta deposition. Similar decreases in A beta were observed in phosphate buffered saline-soluble tissue extracts. Hippocampal electroencephalographic activity was also decreased up to 40% following TBI, and correlated with reduced microdialysate A beta; levels. These results support the alternative hypothesis that post-injury extracellular soluble A beta levels are acutely decreased relative to baseline. Reduced neuronal activity may contribute, though the underlying mechanisms have not been definitively determined. Further work will be needed to assess the dynamics of insoluble and oligomeric A beta after TBI. (C) 2010 Elsevier Inc. All rights reserved.	Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS049237, AG13956]; Burroughs Wellcome Career Award in the Biomedical SciencesBurroughs Wellcome Fund; Thrasher Research Fund; Cure Alzheimer's Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37AG013956, R01AG013956] Funding Source: NIH RePORTER	This work was supported by grants from the NIH NS049237 (DLB), AG13956 (DMH), a Burroughs Wellcome Career Award in the Biomedical Sciences (DLB), Thrasher Research Fund (DLB), and Cure Alzheimer's Fund (DMH). We are grateful to Eli Lilly and Co. for providing antibodies and the founders of our PDAPP mouse colony. The authors have no conflicts of interest to disclose.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Cirrito JR, 2008, NEURON, V58, P42, DOI 10.1016/j.neuron.2008.02.003; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Elvang AB, 2009, J NEUROCHEM, V110, P1377, DOI 10.1111/j.1471-4159.2009.06215.x; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Franklin KBJ, 2001, MOUSE BRAIN STEREOTA; Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; JACOBSON I C, 1985, J NEUROSCI METH, V15, P263; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kang JE, 2007, P NATL ACAD SCI USA, V104, P10673, DOI 10.1073/pnas.0700148104; KANG JE, 2009, AMYLOID BETA DYNAMIC; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Lazarov O, 2002, J NEUROSCI, V22, P9785; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PALMER AM, 1993, J NEUROCHEM, V61, pS284; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Sastre M, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-25; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X	60	31	32	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	DEC	2010	40	3					555	564		10.1016/j.nbd.2010.06.018			10	Neurosciences	Neurosciences & Neurology	675NH	WOS:000283836900005	20682338	Green Accepted			2021-06-18	
J	Kalappa, BI; Gusev, AG; Uteshev, VV				Kalappa, Bopanna I.; Gusev, Alexander G.; Uteshev, Victor V.			Activation of Functional alpha 7-Containing nAChRs in Hippocampal CA1 Pyramidal Neurons by Physiological Levels of Choline in the Presence of PNU-120596	PLOS ONE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN-INJURY; SYNAPTIC PLASTICITY; COGNITIVE IMPROVEMENT; ALPHA-7 RECEPTORS; RAT HIPPOCAMPUS; SPATIAL MEMORY; ACH RECEPTORS; INTERNEURONS	Background: The level of expression of functional alpha 7-containing nicotinic acetylcholine receptors (nAChRs) in hippocampal CA1 pyramidal neurons is believed to be very low compared to hippocampal CA1 interneurons, and for many years this expression was largely overlooked. However, high densities of expression of functional alpha 7-containing nAChRs in CA1 pyramidal neurons may not be necessary for triggering important cellular and network functions, especially if activation of alpha 7-containing nAChRs occurs in the presence of positive allosteric modulators such as PNU-120596. Methodology/Principal Findings: An approach previously developed for alpha 7-containing nAChRs expressed in tuberomammillary neurons was applied to investigate functional CA1 pyramidal alpha 7-containing nAChRs using rat coronal hippocampal slices and patch-clamp electrophysiology. The majority (similar to 71%) of tested CA1 pyramidal neurons expressed low densities of functional alpha 7-containing nAChRs as evidenced by small whole-cell responses to choline, a selective endogenous agonist of alpha 7 nAChRs. These responses were potentiated by PNU-120596, a novel positive allosteric modulator of alpha 7 nAChRs. The density of functional alpha 7-containing nAChRs expressed in CA1 pyramidal neurons (and thus, the normalized net effect of activation, i.e., response net charge per unit of membrane capacitance per unit of time) was estimated to be similar to 5% of the density observed in CA1 interneurons. The results of this study demonstrate that despite low levels of expression of functional pyramidal alpha 7-containing nAChRs, physiological levels of choline (similar to 10 mM) are sufficient to activate these receptors and transiently depolarize and even excite CA1 pyramidal neurons in the presence of PNU-120596. The observed effects are possible because in the presence of 10 mM choline and 1-5 mM PNU-120596, a single opening of an individual pyramidal alpha 7-containing nAChR ion channel appears to transiently depolarize (similar to 4 mV) the entire pyramidal neuron and occasionally trigger action potentials. Conclusions: 1) The majority of hippocampal CA1 pyramidal neurons express functional alpha 7-containing nAChRs. In the absence of PNU-120596, a positive allosteric modulator of alpha 7 nAChRs, a lack of responsiveness of some hippocampal CA1 pyramidal neurons to focal application of 0.5-1 mM choline does not imply a lack of expression of functional alpha 7-containing nAChRs in these neurons. Rather, it may indicate a lack of detection of alpha 7-containing nAChR-mediated currents by patch-clamp electrophysiology. 2) PNU-120596 can serve as a powerful tool for detection and enhancement of responsiveness of low densities of functional alpha 7-containing nAChRs such as those present in hippocampal CA1 pyramidal neurons. 3) In the presence of PNU-120596, physiological concentrations of choline activate functional CA1 pyramidal alpha 7-containing nAChRs and produce step-like currents that cause repetitive step-like depolarizations, occasionally triggering bursts of action potentials in CA1 pyramidal neurons. Therefore, the results of this study suggest that in the presence of PNU-120596 and possibly other positive allosteric modulators, endogenous choline may persistently activate CA1 pyramidal alpha 7-containing nAChRs, enhance the excitability of CA1 pyramidal neurons and thus act as a potent therapeutic agent with potential neuroprotective and cognition-enhancing properties.	[Kalappa, Bopanna I.; Gusev, Alexander G.; Uteshev, Victor V.] So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA	Kalappa, BI (corresponding author), So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA.	vuteshev@siumed.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA021216, DK082625]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK082625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R21DA021216] Funding Source: NIH RePORTER	This study was supported by the NIH grants DA021216 (http://www.nida.nih.gov/) and DK082625 (http://www2.niddk.nih.gov/) to VU. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams CE, 2002, DEV BRAIN RES, V139, P175, DOI 10.1016/S0165-3806(02)00547-3; AKAIKE A, 1994, BRAIN RES, V644, P181, DOI 10.1016/0006-8993(94)91678-0; Akaike A, 2010, J MOL NEUROSCI, V40, P211, DOI 10.1007/s12031-009-9236-1; Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; Albuquerque EX, 1997, J PHARMACOL EXP THER, V280, P1117; ALKONDON M, 1994, J PHARMACOL EXP THER, V271, P494; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; ARENDASH GW, 1995, PHARMACOL BIOCHEM BE, V52, P517, DOI 10.1016/0091-3057(95)00119-H; BARRON SC, 2009, MOL PHARM; Bertrand N, 1996, NEUROCHEM INT, V28, P293, DOI 10.1016/0197-0186(95)00086-0; Bobinski M, 1998, BRAIN RES, V805, P267, DOI 10.1016/S0006-8993(98)00759-8; Buccafusco J, 2004, MOL INTERV, V4, P285, DOI 10.1124/mi.4.5.8; Buccafusco JJ, 2007, BIOCHEM PHARMACOL, V74, P1202, DOI 10.1016/j.bcp.2007.07.010; Buccafusco JJ, 2005, TRENDS PHARMACOL SCI, V26, P352, DOI 10.1016/j.tips.2005.05.007; Buccafusco JJ, 2004, J ALZHEIMERS DIS, V6, pS85; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157; Disterhoft JF, 2007, AGING CELL, V6, P327, DOI 10.1111/j.1474-9726.2007.00297.x; Disterhoft JF, 2006, TRENDS NEUROSCI, V29, P587, DOI 10.1016/j.tins.2006.08.005; Egea J, 2007, NEUROSCIENCE, V145, P866, DOI 10.1016/j.neuroscience.2006.12.036; Faghih Ramin, 2007, Recent Pat CNS Drug Discov, V2, P99; Frazier CJ, 1998, J NEUROSCI, V18, P8228; Frazier CJ, 1998, J NEUROSCI, V18, P1187; Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745; Gronlien JH, 2007, MOL PHARMACOL, V72, P715, DOI 10.1124/mol.107.035410; Grybko M, 2010, J MOL NEUROSCI, V40, P114, DOI 10.1007/s12031-009-9266-8; GUSEV AG, 2009, J PHARM EXP THER; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Hurst RS, 2005, J NEUROSCI, V25, P4396, DOI 10.1523/JNEUROSCI.5269-04.2005; Ji D, 2001, NEURON, V31, P131, DOI 10.1016/S0896-6273(01)00332-4; Ji DY, 2000, J NEUROPHYSIOL, V83, P2682; Jiang Z, 2010, J NEUROSCI, V30, P2582, DOI 10.1523/JNEUROSCI.3971-09.2010; Jones S, 1997, J PHYSIOL-LONDON, V504, P603, DOI 10.1111/j.1469-7793.1997.603bd.x; JOPE RS, 1991, NEUROCHEM RES, V16, P1219, DOI 10.1007/BF00966699; Kaczorowski CC, 2009, LEARN MEMORY, V16, P362, DOI 10.1101/lm.1365609; Kandel ER, 2009, J NEUROSCI, V29, P12748, DOI 10.1523/JNEUROSCI.3958-09.2009; Kem WR, 2000, BEHAV BRAIN RES, V113, P169, DOI 10.1016/S0166-4328(00)00211-4; Kihara T, 1997, ANN NEUROL, V42, P159, DOI 10.1002/ana.410420205; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kitagawa H, 2003, NEUROPSYCHOPHARMACOL, V28, P542, DOI 10.1038/sj.npp.1300028; Leiser SC, 2009, PHARMACOL THERAPEUT, V122, P302, DOI 10.1016/j.pharmthera.2009.03.009; Li YX, 1999, BRAIN RES, V830, P218, DOI 10.1016/S0006-8993(99)01372-4; LOPEZHERNANDEZ GY, 2009, NEUROPHARMACOLOGY; McQuiston AR, 1999, J NEUROSCI, V19, P2887; Meyer EM, 1997, BRAIN RES, V768, P49, DOI 10.1016/S0006-8993(97)00536-2; Meyer EM, 1998, J PHARMACOL EXP THER, V287, P918; Mielke JG, 2009, NEUROSCI RES, V65, P296, DOI 10.1016/j.neures.2009.08.003; Mike A, 2000, BRAIN RES, V882, P155, DOI 10.1016/S0006-8993(00)02863-8; Olincy A, 2007, BIOCHEM PHARMACOL, V74, P1192, DOI 10.1016/j.bcp.2007.07.015; Papke RL, 2002, BRIT J PHARMACOL, V137, P49, DOI 10.1038/sj.bjp.0704833; Parikh V, 2006, J NEUROCHEM, V97, P488, DOI 10.1111/j.1471-4159.2006.03766.x; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Ren K, 2007, NEUROSCIENCE, V145, P314, DOI 10.1016/j.neuroscience.2006.11.023; Roncarati R, 2008, ASSAY DRUG DEV TECHN, V6, P181, DOI 10.1089/adt.2007.120; Ross RG, 2010, J CHILD PSYCHOL PSYC, V51, P535, DOI 10.1111/j.1469-7610.2009.02187.x; Sarter M, 2005, NAT REV NEUROSCI, V6, P48, DOI 10.1038/nrn1588; SCREMIN OU, 1991, STROKE, V22, P643, DOI 10.1161/01.STR.22.5.643; Shimohama S, 1998, BRAIN RES, V779, P359, DOI 10.1016/S0006-8993(97)00194-7; Shimohama S, 2001, BIOL PSYCHIAT, V49, P233, DOI 10.1016/S0006-3223(00)01100-8; Shimohama S, 2009, BIOL PHARM BULL, V32, P332, DOI 10.1248/bpb.32.332; Son JH, 2008, J COMP NEUROL, V511, P286, DOI 10.1002/cne.21828; Thomsen MS, 2010, CURR PHARM DESIGN, V16, P323, DOI 10.2174/138161210790170094; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Uteshev VV, 2010, ACTA BIOCH BIOPH SIN, V42, P8, DOI 10.1093/abbs/gmp101; Uteshev VV, 2003, J NEUROPHYSIOL, V89, P1797, DOI 10.1152/jn.00943.2002; Uteshev VV, 2002, BRAIN RES, V948, P33, DOI 10.1016/S0006-8993(02)02946-3; Verbois SL, 2003, NEUROPHARMACOLOGY, V44, P224, DOI 10.1016/S0028-3908(02)00366-0; Young GT, 2008, P NATL ACAD SCI USA, V105, P14686, DOI 10.1073/pnas.0804372105; Zapata A, 1998, J NEUROSCI, V18, P3597	71	31	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2010	5	11							e13964	10.1371/journal.pone.0013964			15	Multidisciplinary Sciences	Science & Technology - Other Topics	679FT	WOS:000284147700014	21103043	DOAJ Gold, Green Published			2021-06-18	
J	Alban, RF; Berry, C; Ley, E; Mirocha, J; Margulies, DR; Tillou, A; Salim, A				Alban, Rodrigo F.; Berry, Cherisse; Ley, Eric; Mirocha, James; Margulies, Daniel R.; Tillou, Areti; Salim, Ali			Does Health Care Insurance Affect Outcomes after Traumatic Brain Injury? Analysis of the National Trauma Databank	AMERICAN SURGEON			English	Article							RACIAL DISPARITIES; MORTALITY; PREDICTION; CANCER; RACE	Increasing evidence indicates insurance status plays a role in the outcome of trauma patients; however its role on outcomes after traumatic brain injury (TB!) remains unclear. A retrospective review was queried within the National Trauma Data Bank. Moderate to severe TBI insured patients were compared with their uninsured counterparts with respect to demographics, Injury Severity Score, Glasgow Coma Scale score, and outcome. Multivariate logistic regression analysis was used to determine independent risk factors for mortality. Of 52,344 moderate to severe TBI patients, 41,711 (79.7%) were insured. Compared with the uninsured, insured TBI patients were older (46.1 +/- 22.4 vs 37.3 +/- 16.3 years, P < 0.0001), more severely injured (ISS >= 16: 78.4% vs 74.4%, P < 0.0001), had longer intensive care unit length of stay (6.0 +/- 9.4 vs 5.1 +/- 7.6, P < 0.0001) and had higher mortality (9.3% vs 8.0%, P < 0.0001). However, when controlling for confounding variables, the presence of insurance had a significant protective effect on mortality (adjusted odds ratio 0.89; 95% confidence interval: 0.82-0.97, P = 0.007). This effect was most noticeable in patients with head abbreviated injury score = 5 (adjusted odds ratio 0.7; 95% confidence interval: 0.6-0.8, P < 0.0001), indicating insured severe TBI patients have improved outcomes compared with their uninsured counterparts. There is no clear explanation for this finding however the role of insurance in outcomes after trauma remains a topic for further investigation.	[Alban, Rodrigo F.; Berry, Cherisse; Ley, Eric; Mirocha, James; Margulies, Daniel R.; Tillou, Areti; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	all.salim@cshs.org	Berry, Cherisse/AAO-5701-2020				Alliance for Health Reform, 2006, RAC ETHN DISP HLTH C; Berry J, 2010, CANCER-AM CANCER SOC, V116, P713, DOI 10.1002/cncr.24757; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; DENAVASWALT C, 2007, CURRENT POPULATION R; Farjah F, 2009, ARCH SURG-CHICAGO, V144, P14, DOI 10.1001/archsurg.2008.519; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Lu N, 2004, J HEALTH CARE POOR U, V15, P618, DOI 10.1353/hpu.2004.0053; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Rosen H, 2009, ARCH SURG-CHICAGO, V144, P1006, DOI 10.1001/archsurg.2009.195; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; Salim A, 2010, J TRAUMA, V68, P211, DOI 10.1097/TA.0b013e3181a0e659; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Sorani MD, 2009, J TRAUMA, V67, P75, DOI 10.1097/TA.0b013e31818234e8; Tasaki O, 2009, J TRAUMA, V66, P304, DOI 10.1097/TA.0b013e31815d9d3f; U.S. Census Bureau, 2011, INC POV HLTH INS COV; United States Agency for Healthcare Research Quality, NAT HEALTHC DISP REP; Yoo HY, 2004, LIVER TRANSPLANT, V10, P235, DOI 10.1002/lt.20069	18	31	31	0	2	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	OCT	2010	76	10					1108	1111					4	Surgery	Surgery	663AO	WOS:000282855600019	21105621				2021-06-18	
J	Kahraman, S; Dutton, RP; Hu, P; Stansbury, L; Xiao, Y; Stein, DM; Scalea, TM				Kahraman, Sibel; Dutton, Richard P.; Hu, Peter; Stansbury, Lynn; Xiao, Yan; Stein, Deborah M.; Scalea, Thomas M.			Heart Rate and Pulse Pressure Variability are Associated With Intractable Intracranial Hypertension After Severe Traumatic Brain Injury	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						TBI; time-frequency analysis; cerebral pressure monitoring	SPECTRAL-ANALYSIS; BLOOD-PRESSURE; NOCICEPTION; MORTALITY; MECHANISM; DEATH	Calculation of integer heart rate variability (HRVi) permits monitoring over extended periods. We asked whether continuous monitoring of HRVi or integer pulse pressure (PP) variability (PPVi) could predict intracranial hypertension, defined as ICP > 20 mm Hg, cerebral hypoperfusion, defined as CPP < 60 mm Hg, mortality or functional outcome after severe traumatic brain injury. Dense integer data collected during continuous intensive care unit monitoring for periods of 1 to 11 days on 25 patients admitted to our Level I trauma center with Glasgow Coma Scale < 9 provided 1,715,000 data points over a mean 106 +/- 62 hours. PP, HRVi, and PPVi increased in response to increasing ICP when CPP > 60 mm Hg (P < 0.001), but HRVi and PPVi decreased when CPP < 60 mm Hg and P < 50 mm Hg, even with ICP < 20 mm Hg (P < 0.001). ICP up to 40 mm Hg still evoked an increase in HRVi and PPVi (P < 0.001), but both were suppressed with CPP < 50 mm Hg and ICP > 40 mm Hg (actual or impending brain death). Mean HRVi and PPVi predicted in-hospital mortality (sensitivity, 67%; specificity, 91% to 100%). Combining HRVi and PPVi as an "autonomic index" (AI) best predicted long-term functional outcome [Area Under the Curve: 0.84 +/- 0.08 for AI < 0.5]. Our data show that HRVi and PPVi can be monitored and calculated automatically and can provide useful prognostic information in patients with severe traumatic brain injury, particularly when combined into a single index.	[Kahraman, Sibel; Dutton, Richard P.; Hu, Peter; Stansbury, Lynn; Xiao, Yan; Stein, Deborah M.; Scalea, Thomas M.] Univ Maryland, Shock Trauma Anesthesia Res Organized Res Ctr, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA	Stansbury, L (corresponding author), Univ Maryland, Shock Trauma Anesthesia Res Organized Res Ctr, R Adams Cowley Shock Trauma Ctr, 220 Warren Ave, Baltimore, MD 21201 USA.	lynn.stansbury@gmail.com	Xiao, Yan/A-7506-2009	Xiao, Yan/0000-0003-2805-0619; Stein, Deborah/0000-0003-3683-3963	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22592026] Funding Source: KAKEN		Ayres-de-Campos D, 2005, EUR J OBSTET GYN R B, V118, P52, DOI 10.1016/j.ejogrb.2004.04.013; Baillard C, 2002, CRIT CARE MED, V30, P306, DOI 10.1097/00003246-200202000-00007; BIGGER JT, 1992, CIRCULATION, V85, P164, DOI 10.1161/01.CIR.85.1.164; Biswas AK, 2004, J NEUROSURG ANESTH, V16, P62, DOI 10.1097/00008506-200401000-00011; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; Camm AJ, 1996, EUR HEART J, V17, P354; CARTER MC, 1993, BRIT J OBSTET GYNAEC, V100, P21, DOI 10.1111/j.1471-0528.1993.tb10631.x; Conci F, 2001, J NEUROL NEUROSUR PS, V71, P621, DOI 10.1136/jnnp.71.5.621; Cushing H, 1901, B JOHNS HOPKINS HOSP, V12, P290; Cushing H, 1902, AM J MED SCI, V124, P375, DOI 10.1097/00000441-190209000-00001; Freitas J, 1996, CLIN AUTON RES, V6, P141, DOI 10.1007/BF02281900; Goldstein B, 1998, CRIT CARE MED, V26, P352, DOI 10.1097/00003246-199802000-00040; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; Haji-Michael PG, 2000, CRIT CARE MED, V28, P2578, DOI 10.1097/00003246-200007000-00066; HON EH, 1963, AM J OBSTET GYNECOL, V87, P814; Jeanne M, 2009, AUTON NEUROSCI-BASIC, V147, P91, DOI 10.1016/j.autneu.2009.01.005; KAHRAMAN S, J TRAUMA IN PRESS; KJEIGER RE, 1987, AM J CARDIOL, V59, P256; Larma JD, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.06.053; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; MALIK M, 1989, EUR HEART J, V10, P1060, DOI 10.1093/oxfordjournals.eurheartj.a059428; Morris JA, 2006, J TRAUMA, V60, P1165, DOI 10.1097/01.ta.0000220384.04978.3b; Mowery NT, 2008, J TRAUMA, V65, P621, DOI 10.1097/TA.0b013e3181837980; Norris PR, 2005, J SURG RES, V129, P122, DOI 10.1016/j.jss.2005.04.024; PAUL RH, 1975, AM J OBSTET GYNECOL, V123, P206, DOI 10.1016/0002-9378(75)90528-1; Rantanen M, 2006, BRIT J ANAESTH, V96, P367, DOI 10.1093/bja/ael005; SCHIFRIN BS, 1972, J AMER MED ASSOC, V222, P196, DOI 10.1001/jama.222.2.196; Schifrin BS, 2004, BEST PRACT RES CL OB, V18, P437, DOI 10.1016/j.bpobgyn.2004.03.001; SCHMIDT EA, 2004, CLIN PHYSIOL FUNCT I, V24, P304; Toweill Daniel L, 2003, Pediatr Crit Care Med, V4, P308, DOI 10.1097/01.PCC.0000074260.93430.6A; Unoki T, 2009, AM J CRIT CARE, V18, P42, DOI 10.4037/ajcc2009509; VALLBONA C, 1965, AM J CARDIOL, V16, P379, DOI 10.1016/0002-9149(65)90729-0; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	34	31	35	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2010	22	4					296	302		10.1097/ANA.0b013e3181e25fc3			7	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	650ER	WOS:000281832500002	20622688				2021-06-18	
J	Zhang, Q; Hu, WZ; Meng, B; Tang, TS				Zhang, Qin; Hu, Wenzhi; Meng, Bin; Tang, Tiansi			PPAR gamma agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats	NEUROLOGICAL RESEARCH			English	Article						Spinal cord injury; rosiglitazone; inflammation; apoptosis	ACTIVATED-RECEPTOR-GAMMA; TRANSIENT FOCAL ISCHEMIA; HEAT-SHOCK PROTEINS; INFLAMMATION; EXPRESSION; MODEL; HEAT-SHOCK-PROTEIN-70; PIOGLITAZONE; DYSFUNCTION; PROTECTION	Spinal cord injury (SCI) results in the loss of function below the lesion. Secondary injury following the primary impact includes a number of biochemical and cellular alterations leading to tissue necrosis and cell death. Peroxisome proliferator-activated receptor-gamma (PPAR gamma) is a ligand-activated transcription factor of nuclear hormone receptor superfamily. Thiazolidinedione rosiglitazone is a potent agonist of PPAR gamma which is shown to induce neuroprotection in animal models of focal ischemia and traumatic brain injury. SCI is induced by the application of vascular clips (force of 24 g) to the dura via a four-level T-5-T-8 laminectomy. To gain a better insight into the mechanism of action of the anti-inflammatory effects of rosiglitazone, the following end points of the inflammatory process were evaluated: (1) spinal cord inflammation and tissue injury (histological score); (2) neutrophil infiltration (myeloperoxidase activity); (3) apoptosis (terminal deoxynucleotidyl transferase-mediated UTP end labeling staining and electron microscopy); (4) proinflammatory cytokines TNF-alpha and IL-beta; (5) PPAR gamma, HSP70 and HSP27 expressions. To elucidate whether the protective effects of rosiglitazone were mediated via the estrogen receptors, we investigated the effect of a PPAR gamma antagonist, GW9662, on the protective effects of rosiglitazone. GW9662 significantly antagonized the effect of the rosiglitazone and abolished the protective effect against SCI. Taken together, our results clearly demonstrate that administration of rosiglitazone after SCI reduces the development of inflammation and tissue injury associated with spinal cord trauma.	[Zhang, Qin; Meng, Bin; Tang, Tiansi] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Peoples R China; [Hu, Wenzhi] Nanjing Med Univ, Affiliated Hosp 2, Nanjing 210000, Peoples R China	Tang, TS (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Shizi St 96, Suzhou 215006, Peoples R China.	tiansitang19762@126.com					Bale TL, 2002, J NEUROSCI, V22, P193, DOI 10.1523/JNEUROSCI.22-01-00193.2002; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Chen Yu, 2007, Inflammation & Allergy Drug Targets, V6, P91; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Dehmer T, 2004, J NEUROCHEM, V88, P494, DOI 10.1046/j.1471-4159.2003.02210.x; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Genovese T, 2008, SHOCK, V30, P142, DOI 10.1097/SHK.0b013e31815dd381; Guay J, 1997, J CELL SCI, V110, P357; Guzman-Lenis MS, 2008, NEUROSCIENCE, V155, P104, DOI 10.1016/j.neuroscience.2008.04.078; Hihi AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/s00018-002-8467-x; Imura T, 1999, J NEUROSCI, V19, P9768; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jones TB, 2005, CURR PHARM DESIGN, V11, P1223, DOI 10.2174/1381612053507468; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kiaei M, 2005, EXP NEUROL, V191, P331, DOI 10.1016/j.expneurol.2004.10.007; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Liu XZ, 1997, J NEUROSCI, V17, P5395; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; McTigue DM, 2008, PPAR RES, V2008, DOI 10.1155/2008/517162; McTigue DM, 2000, PROG BRAIN RES, V128, P3; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Robinson MB, 2005, J NEUROSCI, V25, P9735, DOI 10.1523/JNEUROSCI.1912-05.2005; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Sundararajan S, 2005, NEUROSCIENCE, V130, P685, DOI 10.1016/j.neuroscience.2004.10.021; Tachibana T, 2002, NEUROSCI LETT, V327, P133, DOI 10.1016/S0304-3940(02)00375-0; Tolman Keith G, 2003, Clin Liver Dis, V7, P369, DOI 10.1016/S1089-3261(03)00020-5; Toumpoulis IK, 2003, J THORAC CARDIOV SUR, V125, P1030, DOI 10.1067/mtc.2003.174; Tureyen K, 2007, J NEUROCHEM, V101, P41, DOI 10.1111/j.1471-4159.2006.04376.x; Victor NA, 2006, EUR J NEUROSCI, V24, P1653, DOI 10.1111/j.1460-9568.2006.05037.x; Watson GS, 2005, AM J GERIAT PSYCHIAT, V13, P950, DOI 10.1176/appi.ajgp.13.11.950; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhao XR, 2006, J CEREBR BLOOD F MET, V26, P811, DOI 10.1038/sj.jcbfm.9600233	37	31	35	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	OCT	2010	32	8					852	859		10.1179/016164110X12556180206112			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	647NU	WOS:000281626000012	20350367				2021-06-18	
J	Yoshioka, N; Hisanaga, SI; Kawano, H				Yoshioka, Nozomu; Hisanaga, Shin-Ichi; Kawano, Hitoshi			Suppression of Fibrotic Scar Formation Promotes Axonal Regeneration Without Disturbing Blood-Brain Barrier Repair and Withdrawal of Leukocytes After Traumatic Brain Injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						reactive astrocyte; meningeal fibroblast; leukocyte infiltration; 2,2 '-dipyridyl; nigrostriatal dopaminergic pathway; immunohistochemistry	SPINAL-CORD-INJURY; NIGROSTRIATAL DOPAMINERGIC AXONS; OLFACTORY ENSHEATHING CELLS; NONNEURAL ENDOTHELIAL-CELLS; REACTIVE ASTROCYTES; FUNCTIONAL RECOVERY; GLIAL SCAR; RAT-BRAIN; NEURONAL DEGENERATION; CEREBRAL HEMISPHERE	The fibrotic scar containing type IV collagen (Col IV) formed in a lesion site is considered as an obstacle to axonal regeneration, because intracerebral injection of 2,2'-dipyridyl (DPY), an inhibitor of Col IV triple-helix formation, suppresses fibrotic scar formation in the lesion site and promotes axonal regeneration. To determine the role of the fibrotic scar on the healing process of injured central nervous system (CNS), the restoration of blood-brain barrier (BBB) and withdrawal of inflammatory leukocytes were examined in mice subjected to unilateral transection of the nigrostriatal dopaminergic pathway and intracerebral DPY injection. At 5 days after injury, destruction of BBB represented by leakage of Evans blue (EB) and widespread infiltration of CD45-immunoreactive leukocytes was observed around the lesion site, whereas reactive astrocytes increased surrounding the BBB-destroyed area. By 2 weeks after injury, the region of EB leakage and the diffusion of leukocytes were restricted to the inside of the fibrotic scar, and reactive astrocytes gathered around the fibrotic scar. In the DPY-treated lesion site, formation of the fibrotic scar was suppressed (84% decrease in Col IV-deposited area), reactive astrocytes occupied the lesion center, and areas of both EB leakage and leukocyte infiltration decreased by 86%. DPY treatment increased the number of regenerated dopaminergic axons by 2.53-fold. These results indicate that suppression of fibrotic scar formation does not disturb the healing process in damaged CNS, and suggest that this strategy is a reliable tool to promote axonal regeneration after traumatic injury in the CNS. J. Comp. Neurol. 518:3867-3881, 2010. (C) 2010 Wiley-Liss, Inc.	[Yoshioka, Nozomu; Kawano, Hitoshi] Tokyo Metropolitan Inst Neurosci, Dept Dev Morphol, Tokyo 1838526, Japan; [Yoshioka, Nozomu; Hisanaga, Shin-Ichi] Tokyo Metropolitan Univ, Dept Biol Sci, Tokyo 1920397, Japan	Kawano, H (corresponding author), 2-6 Musashidai, Tokyo 1838526, Japan.	kawano-ht@igakuken.or.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20500318]	Grant sponsor: The Ministry of Education, Science, Sports and Culture of Japan; Grant number: 20500318.	ABNET K, 1991, DEV BRAIN RES, V59, P187, DOI 10.1016/0165-3806(91)90099-5; Benton RL, 2008, J COMP NEUROL, V507, P1031, DOI 10.1002/cne.21570; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brazda N, 2009, PROG BRAIN RES, V175, P269, DOI 10.1016/S0079-6123(09)17518-0; Bundesen LQ, 2003, J NEUROSCI, V23, P7789; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Camand E, 2004, EUR J NEUROSCI, V20, P1161, DOI 10.1111/j.1460-9568.2004.03558.x; De Winter F, 2002, EXP NEUROL, V175, P61, DOI 10.1006/exnr.2002.7884; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Hayashi Y, 1997, GLIA, V19, P13, DOI 10.1002/(SICI)1098-1136(199701)19:1<13::AID-GLIA2>3.0.CO;2-B; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; IKEDA H, 1992, HEPATOLOGY, V15, P282, DOI 10.1002/hep.1840150218; Kawano H, 2005, J NEUROSCI RES, V80, P191, DOI 10.1002/jnr.20441; Klapka N, 2005, EUR J NEUROSCI, V22, P3047, DOI 10.1111/j.1460-9568.2005.04495.x; Kuchler-Bopp S, 1999, NEUROREPORT, V10, P1347, DOI 10.1097/00001756-199904260-00035; Li HP, 2007, J NEUROSCI RES, V85, P536, DOI 10.1002/jnr.21141; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; McAuliffe JJ, 2008, BRAIN RES, V1190, P175, DOI 10.1016/j.brainres.2007.11.038; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; MOGI M, 1984, ANAL BIOCHEM, V138, P125, DOI 10.1016/0003-2697(84)90779-6; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; PERSSON L, 1976, ACTA NEUROPATHOL, V34, P125, DOI 10.1007/BF00684663; Rakos G, 2007, ACTA NEUROBIOL EXP, V67, P149; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; ROSENSTEIN JM, 1994, J COMP NEUROL, V350, P229, DOI 10.1002/cne.903500207; Shearer MC, 2001, CELL TISSUE RES, V305, P267, DOI 10.1007/s004410100384; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Soares HD, 1995, J NEUROSCI, V15, P8223; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Teng X, 2008, J NEUROSCI RES, V86, P3140, DOI 10.1002/jnr.21767; Uemura K, 1996, J BIOL CHEM, V271, P4581; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	47	31	33	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	SEP 15	2010	518	18					3867	3881		10.1002/cne.22431			15	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	634RD	WOS:000280600400013	20653039				2021-06-18	
J	Brown, T; Williams, B; Boyle, M; Molloy, A; McKenna, L; Molloy, L; Lewis, B				Brown, Ted; Williams, Brett; Boyle, Malcolm; Molloy, Andrew; McKenna, Lisa; Molloy, Liz; Lewis, Belinda			Levels of Empathy in Undergraduate Occupational Therapy Students	OCCUPATIONAL THERAPY INTERNATIONAL			English	Article						empathy; occupational therapy; students; education; Jefferson Scale of Physician Empathy; Medical Condition Regard Scale	PHYSICIAN EMPATHY; MEDICAL-STUDENTS; JEFFERSON SCALE; SPECIALTY; GENDER; DRUG	Empathy is an important attribute for occupational therapists in establishing rapport and in better understanding their clients. However, empathy can be compromised by high workloads, personal stressors and pressures to demonstrate efficacy. Occupational therapists also work with patients from a variety of diagnostic groups. The objective of this study was to determine the extent of empathy and attitudes towards clients amongst undergraduate occupational therapy students at one Australian University. A cross-sectional study was undertaken using a written survey of the Jefferson Scale of Physician Empathy (JSPE) and the Medical Condition Regard Scale. Overall, a strong level of empathy was reported amongst students. Four medical conditions that occupational therapists work with (stroke, cerebral palsy, traumatic brain injury and depression) were held in high regard. Substance abuse, however, was held in comparatively low regard. Overall, the year of study appeared to have no significant impact on the students' empathy. Despite having a lower reported empathy level than found in health professions from other studies using the JSPE, occupational therapy students were found to have a good level of empathy. Of concern, however, was the bias reported against the medical condition of substance abuse, highlighting that the there may be a need to reinforce that patients from this diagnostic group are equally deserving of quality care irrespective of their clinical condition. Recommendations for future research include completing a longitudinal study of occupational therapy students' empathy levels and investigating the empathy levels of occupational therapists working with different client groups. Limitations of the study include the convenience sampling of occupational therapy students enrolled at one university which limits the generalizability of the results to groups of participants with similar characteristics. Copyright (C) 2010 John Wiley & Sons, Ltd.	[Brown, Ted; Molloy, Andrew] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Primary Hlth Care, Dept Occupat Therapy, Frankston, Vic 3199, Australia; [Williams, Brett; Boyle, Malcolm] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Primary Hlth Care, Dept Community Emergency Hlth & Paramed Practice, Frankston, Vic 3199, Australia; [McKenna, Lisa] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Nursing & Midwifery, Frankston, Vic 3199, Australia; [Molloy, Liz] Monash Univ, Fac Med Nursing & Hlth Sci, Notting Hill, Vic, Australia; [Lewis, Belinda] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Primary Hlth Care, Dept Hlth Sci, Frankston, Vic 3199, Australia	Brown, T (corresponding author), Monash Univ, Fac Med Nursing & Hlth Sci, Sch Primary Hlth Care, Dept Occupat Therapy Program, Peninsula Campus,POB 527, Frankston, Vic 3199, Australia.	ted.brown@med.monash.edu.au	Williams, Brett/AAJ-2685-2020; McKenna, Lisa/K-2603-2013; Williams, Brett/F-6776-2014; Boyle, Malcolm/A-4301-2008	Williams, Brett/0000-0001-6307-1779; McKenna, Lisa/0000-0002-0437-6449; Williams, Brett/0000-0001-6307-1779; Boyle, Malcolm/0000-0003-4186-1280; Molloy, Elizabeth/0000-0001-9457-9348; Brown, Ted/0000-0001-9403-5877	Monash University Faculty of Medicine, Nursing and Health Sciences Learning and Teaching PerformanceMonash University	The Monash University Faculty of Medicine, Nursing and Health Sciences Learning and Teaching Performance Fund - Projects Grant Scheme provided the funding for this project to be completed. The Monash University health science students who took the time to complete the questionnaires are thanked for their input and insights.	Chen D, 2007, J GEN INTERN MED, V22, P1434, DOI 10.1007/s11606-007-0298-x; CHRISTIANSEN CH, 1977, AM J OCCUP THER, V31, P19; Christison GW, 2002, ACAD MED, V77, P257, DOI 10.1097/00001888-200203000-00017; Fields SK, 2004, EVAL HEALTH PROF, V27, P80, DOI 10.1177/0163278703261206; Gray JM, 1998, AM J OCCUP THER, V52, P354, DOI 10.5014/ajot.52.5.354; GREENE D, 1998, PHYS OCCUPATIONAL TH, V15, P39; Hemmerdinger Joanne M, 2007, BMC Med Educ, V7, P24, DOI 10.1186/1472-6920-7-24; Henry-Tillman R, 2002, AM J SURG, V183, P659, DOI 10.1016/S0002-9610(02)00867-X; Hojat M, 2002, AM J PSYCHIAT, V159, P1563, DOI 10.1176/appi.ajp.159.9.1563; Hojat M, 2005, J SOC PSYCHOL, V145, P663, DOI 10.3200/SOCP.145.6.663-672; Hojat M, 2005, PERS INDIV DIFFER, V39, P1205, DOI 10.1016/j.paid.2005.04.007; Hojat M, 2002, ACAD MED, V77, pS58, DOI 10.1097/00001888-200210001-00019; Hojat M, 2002, MED EDUC, V36, P522, DOI 10.1046/j.1365-2923.2002.01234.x; Hojat M, 2001, EDUC PSYCHOL MEAS, V61, P349, DOI 10.1177/00131640121971158; Hojat M., 2003, SEMIN INTEGR MED, V1, P25, DOI DOI 10.1016/S1543-1150(03)00002-4; Hojat M, 2007, EMPATHY PATIENT CARE; Hojat Mohammadreza, 2003, Nurse Pract, V28, P45, DOI 10.1097/00006205-200304000-00010; Jamieson Margaret, 2006, Can J Occup Ther, V73, P76; LEVASSEUR J, 1993, EMPATHY PRACTICE MED, P76; Lyons M, 1996, DISABIL REHABIL, V18, P197, DOI 10.3109/09638289609166300; Newton BW, 2008, ACAD MED, V83, P244, DOI 10.1097/ACM.0b013e3181637837; Norman R, 2001, J NURS EDUC, V40, P371; PELOQUIN SM, 1995, AM J OCCUP THER, V49, P24, DOI 10.5014/ajot.49.1.24; Reynolds WJ, 2000, J ADV NURS, V31, P226, DOI 10.1046/j.1365-2648.2000.01242.x; Sherman Jeffrey J, 2005, J Dent Educ, V69, P338; Skinner N, 2007, J APPL SOC PSYCHOL, V37, P163, DOI 10.1111/j.0021-9029.2007.00154.x; Spiro Howard M., 1993, EMPATHY PRACTICE MED; Wilkes M, 2002, MED EDUC, V36, P528, DOI 10.1046/j.1365-2923.2002.01230.x; Yerxa EJ, 2009, AM J OCCUP THER, V63, P490, DOI 10.5014/ajot.63.4.490	29	31	31	0	18	WILEY-HINDAWI	LONDON	ADAM HOUSE, 3RD FL, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND	0966-7903	1557-0703		OCCUP THER INT	Occup. Ther. Int.	SEP	2010	17	3					135	141		10.1002/oti.297			7	Rehabilitation	Rehabilitation	748YH	WOS:000289428700004	20623554				2021-06-18	
J	Hanell, A; Clausen, F; Bjork, M; Jansson, K; Philipson, O; Nilsson, LNG; Hillered, L; Weinreb, PH; Lee, D; McIntosh, TK; Gimbel, DA; Strittmatter, SM; Marklund, N				Hanell, Anders; Clausen, Fredrik; Bjork, Maria; Jansson, Kristine; Philipson, Ola; Nilsson, Lars N. G.; Hillered, Lars; Weinreb, Paul H.; Lee, Daniel; McIntosh, Tracy K.; Gimbel, David A.; Strittmatter, Stephen M.; Marklund, Niklas			Genetic Deletion and Pharmacological Inhibition of Nogo-66 Receptor Impairs Cognitive Outcome after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						cognition; mossy fiber sprouting; NgR(-/-) mice; Nogo-66 receptor; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; AMYLOID PRECURSOR PROTEIN; AXONAL REGENERATION; TRANSGENIC MICE; POSTTRAUMATIC EPILEPSY; FUNCTIONAL RECOVERY; DOWN-REGULATION; BINDS NOGO-66	Functional recovery is markedly restricted following traumatic brain injury (TBI), partly due to myelin-associated inhibitors including Nogo-A, myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMgp), that all bind to the Nogo-66 receptor-1 (NgR1). In previous studies, pharmacological neutralization of both Nogo-A and MAG improved outcome following TBI in the rat, and neutralization of NgR1 improved outcome following spinal cord injury and stroke in rodent models. However, the behavioral and histological effects of NgR1 inhibition have not previously been evaluated in TBI. We hypothesized that NgR1 negatively influences behavioral recovery following TBI, and evaluated NgR1(-/-) mice (NgR1(-/-) study) and, in a separate study, soluble NgR1 infused intracerebroventricularly immediately post-injury to neutralize NgR1 (sNgR1 study) following TBI in mice using a controlled cortical impact (CCI) injury model. In both studies, motor function, TBI-induced loss of tissue, and hippocampal beta-amyloid immunohistochemistry were not altered up to 5 weeks post-injury. Surprisingly, cognitive function (as evaluated with the Morris water maze at 4 weeks post-injury) was significantly impaired both in NgR1(-/-) mice and in mice treated with soluble NgR1. In the sNgR1 study, we evaluated hippocampal mossy fiber sprouting using the Timm stain and found it to be increased at 5 weeks following TBI. Neutralization of NgR1 significantly increased mossy fiber sprouting in sham-injured animals, but not in brain-injured animals. Our data suggest a complex role for myelin-associated inhibitors in the behavioral recovery process following TBI, and urge caution when inhibiting NgR1 in the early post-injury period.	[Hanell, Anders; Clausen, Fredrik; Bjork, Maria; Jansson, Kristine; Hillered, Lars; Marklund, Niklas] Uppsala Univ, Dept Neurosurg, Uppsala, Sweden; [Philipson, Ola; Nilsson, Lars N. G.] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden; [Weinreb, Paul H.; Lee, Daniel] Biogen Idec Inc, Cambridge, MA USA; [McIntosh, Tracy K.; Marklund, Niklas] Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; [Gimbel, David A.; Strittmatter, Stephen M.] Yale Univ, Sch Med, Dept Neurol, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06510 USA	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, Ing 85,3 Tr, SE-75185 Uppsala, Sweden.	niklas.marklund@neuro.uu.se	Strittmatter, Stephen/F-5739-2011; Hanell, Anders/E-4776-2011	Strittmatter, Stephen/0000-0001-8188-3092; Hanell, Anders/0000-0001-9369-3886; Hillered, Lars/0000-0002-2808-9292; Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626; Weinreb, Paul/0000-0002-0802-0052; nilsson, lars/0000-0002-8362-1042	Upplandsstiftelsen; Swedish Brain Foundation; Uppsala University; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Jeanssons Foundation; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS RO1-40978, NIH NS RO1-56485, NIH NS RO1-42304, NIH NS P50-08803]; Veterans AdministrationUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, R01NS039962, R37NS033020, R01NS056485, R01NS042304, P50NS008803] Funding Source: NIH RePORTER	Supported by Upplandsstiftelsen and the Swedish Brain Foundation (to N.M.), Uppsala University (to N.M. and L. H.), Swedish Research Council (to N.M. and L. H.), Jeanssons Foundation (to N.M.), National Institutes of Health (NIH) NS RO1-40978 (to T. K. M.), NIH NS RO1-56485 (to S. M. S.), NIH NS RO1-42304 (to S. M. S.), a Merit Review Grant from the Veterans Administration (to T. K. M.), and NIH NS P50-08803 (to T. K. M.).	Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Buchli AD, 2005, ANN MED, V37, P556, DOI 10.1080/07853890500407520; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Fournier AE, 2002, J NEUROSCI, V22, P8876; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Harrington AW, 2008, J BIOL CHEM, V283, P24690, DOI 10.1074/jbc.M802188200; Harvey PA, 2009, J NEUROSCI, V29, P6285, DOI 10.1523/JNEUROSCI.5885-08.2009; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Josephson A, 2003, CELL TISSUE RES, V311, P333, DOI 10.1007/s00441-002-0695-8; Karlen A, 2009, P NATL ACAD SCI USA, V106, P20476, DOI 10.1073/pnas.0905390106; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Li SX, 2003, J NEUROSCI, V23, P4219; Li SX, 2005, MOL CELL NEUROSCI, V29, P26, DOI 10.1016/j.mcn.2004.12.008; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lord A, 2006, NEUROBIOL AGING, V27, P67, DOI 10.1016/j.neurobiolaging.2004.12.007; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Mingorance A, 2004, MOL CELL NEUROSCI, V26, P34, DOI 10.1016/j.mcn.2004.01.001; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Park JH, 2006, J NEUROSCI, V26, P13279, DOI 10.1523/JNEUROSCI.4504-06.2006; Park JH, 2006, J NEUROSCI, V26, P1386, DOI 10.1523/JNEUROSCI.3291-05.2006; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Philipson O, 2009, FEBS LETT, V583, P3021, DOI 10.1016/j.febslet.2009.08.009; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wang XX, 2006, ANN NEUROL, V60, P540, DOI 10.1002/ana.20953; Woodlee MT, 2005, EXP NEUROL, V191, P310, DOI 10.1016/j.expneurol.2004.09.005; Xie F, 2008, EXP NEUROL, V209, P302, DOI 10.1016/j.expneurol.2007.07.005; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102; 1996, NATL RES COUNCIL GUI, P1	59	31	31	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1297	1309		10.1089/neu.2009.1255			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100014	20486800	Green Published			2021-06-18	
J	Mrakovcic-Sutic, I; Tokmadzic, VS; Laskarin, G; Mahmutefendic, H; Lucin, P; Zupan, Z; Sustic, A				Mrakovcic-Sutic, I.; Tokmadzic, V. Sotosek; Laskarin, G.; Mahmutefendic, H.; Lucin, P.; Zupan, Z.; Sustic, A.			Early Changes in Frequency of Peripheral Blood Lymphocyte Subpopulations in Severe Traumatic Brain-Injured Patients	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Article							NERVOUS-SYSTEM; INFECTIONS; IMMUNOSUPPRESSION; IMMUNODEPRESSION	Infections are leading causes of increased morbidity and mortality of severe traumatic brain-injured (STBI) patients. The mechanism underlying the susceptibility to the infections is still unexplained. The purpose of the study was to investigate changes in frequency of leucocytes subpopulations in peripheral blood of patients with STBI during the course of intensive care treatment. Twenty patients with STBI were included in the study. Healthy age- and sex- volunteers served as control. Peripheral blood samples were taken from these patients at day 1, 4 and 7, and peripheral blood mononuclear cells (PBMC) were isolated. The percentage of T, B lymphocyte, NK and NKT cells as well as monocytes was analysed by simultaneous detection of surface antigens using fluorochrome-conjugated monoclonal antibodies. The two major subsets of T lymphocytes (CD3+CD56-CD4+ and CD3+CD56-CD8+) and NK cells (CD3-CD56+dim and CD3-CD56+bright) were also analysed by flow cytometry. Extracranial infections were presented in 55% patients with STBI. At day 4, the percentage of T lymphocytes with cytotoxic phenotype significantly diminished and their numbers restored at day 7. The frequency of NKT cells showed the identical time-dependent pattern, whereas the percentage of NK cells diminished on day 4 but did not restore after 7 days. The frequency of B lymphocytes did not change significantly during the time investigated, whereas the percentage of monocytes increased immediately after the injury and gradually diminished. The decrease in cells with cytotoxic phenotype might explain high incidence of susceptibility to infection of patients with STBI.	[Tokmadzic, V. Sotosek; Zupan, Z.; Sustic, A.] Univ Rijeka, Fac Med, Dept Anaesthesiol Reanimatol & Intens Care, Rijeka 51000, Croatia; [Mrakovcic-Sutic, I.; Laskarin, G.; Mahmutefendic, H.; Lucin, P.] Univ Rijeka, Fac Med, Dept Physiol & Immunol, Rijeka 51000, Croatia	Tokmadzic, VS (corresponding author), Univ Rijeka, Fac Med, Dept Anaesthesiol Reanimatol & Intens Care, B Branchetta 20-1, Rijeka 51000, Croatia.	vsotosek@medri.hr	Mrakovcic-Sutic, Ines/S-6688-2018; Laskarin, Gordana/O-6972-2018; Mahmutefendic Lucin, Hana/Q-8500-2018; Lucin, Pero/R-8341-2018; Zupan, Zeljko/AAO-1749-2021; Sotosek Tokmadzic, Vlatka/O-2359-2018; Zupan, Zeljko/S-2786-2018	Mrakovcic-Sutic, Ines/0000-0003-0679-2849; Laskarin, Gordana/0000-0002-6134-155X; Mahmutefendic Lucin, Hana/0000-0001-8462-4686; Lucin, Pero/0000-0001-8776-8634; Zupan, Zeljko/0000-0003-4576-7961; Sotosek Tokmadzic, Vlatka/0000-0003-2645-5364; Zupan, Zeljko/0000-0003-4576-7961	Croatian Ministry of Science, Education and SportsMinistry of Science, Education and Sports, Republic of Croatia [062-0000000-0220]	This investigation was supported by the grant from the Croatian Ministry of Science, Education and Sports (project no. 062-0000000-0220).	Angele MK, 2005, LANGENBECK ARCH SURG, V390, P333, DOI 10.1007/s00423-005-0557-4; Angele MK, 2002, CRIT CARE, V6, P298, DOI 10.1186/cc1514; Babcock GF, 2003, CYTOM PART B-CLIN CY, V53B, P48, DOI 10.1002/cyto.b.10038; Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Klehmet J, 2009, NEUROSCIENCE, V158, P1184, DOI 10.1016/j.neuroscience.2008.07.044; Lunemann A, 2008, J IMMUNOL, V181, P6170, DOI 10.4049/jimmunol.181.9.6170; McMahon CW, 2002, J IMMUNOL, V169, P1444, DOI 10.4049/jimmunol.169.3.1444; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; MILLER C H, 1991, Neurological Research, V13, P117; Molina PE, 2005, SHOCK, V24, P3, DOI 10.1097/01.shk.0000167112.18871.5c; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; REICHERT T, 1991, CLIN IMMUNOL IMMUNOP, V60, P190, DOI 10.1016/0090-1229(91)90063-G; Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa; Sanders RD, 2009, CRIT CARE CLIN, V25, P551, DOI 10.1016/j.ccc.2009.05.001; Schwacha MG, 2002, INT J MOL MED, V10, P239; Smrcka M, 2005, Bratisl Lek Listy, V106, P144; Tang ME, 2009, MT SINAI J MED, V76, P119, DOI 10.1002/msj.20106; WOLACH B, 1993, BRAIN INJURY, V7, P401, DOI 10.3109/02699059309029683; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706	22	31	33	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	JUL	2010	72	1					57	65		10.1111/j.1365-3083.2010.02407.x			9	Immunology	Immunology	608FT	WOS:000278569300009	20591077	Bronze			2021-06-18	
J	Goodrich-Hunsaker, NJ; Hopkins, RO				Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.			Spatial Memory Deficits in a Virtual Radial Arm Maze in Amnesic Participants With Hippocampal Damage	BEHAVIORAL NEUROSCIENCE			English	Article						amnesia; hippocampus; radial arm maze; spatial memory	TRAUMATIC BRAIN INJURY; SHORT-TERM-MEMORY; HUMAN NAVIGATION; CAUDATE-NUCLEUS; WATER-MAZE; PERFORMANCE; FMRI; ROUTE; ACTIVATION; HUMANS	Extensive research with laboratory animals indicates that the hippocampus is crucial for the formation and use of spatial memory. Hippocampal lesions in rodents impair spatial memory on radial arm maze tasks. It is unknown whether amnesic patients with hippocampal damage would exhibit similar impairments on a virtual version of a radial arm maze. To evaluate the importance of the hippocampus in spatial learning and memory, we tested amnesic participants with hippocampal damage in a virtual radial arm maze environment. The virtual radial arm maze required participants to learn and remember 4 rewarded arms of 8 total arms. Spatial learning and memory were assessed using the participants' ability to use salient distal cues in the virtual room to remember the 4 rewarded arms. Amnesic participants' latencies were longer and distance traveled was greater to the rewarded arms compared with nonamnesic participants. Amnesic participants made more errors than nonamnesic participants by either entering nonrewarded arms or by revisiting previously entered arms. These data are analogous to previous animal research. Overall, the human hippocampus is necessary for spatial memory and navigation in a virtual radial arm maze task.	[Goodrich-Hunsaker, Naomi J.] Brigham Young Univ, Dept Physiol & Dev Biol, Sacramento, CA USA; [Goodrich-Hunsaker, Naomi J.] Brigham Young Univ, Ctr Neurosci, Sacramento, CA USA; [Goodrich-Hunsaker, Naomi J.] Univ Calif Davis, Med Ctr, NeuroTherapeut Res Inst, Sacramento, CA 95817 USA; [Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Murray, UT USA; [Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Murray, UT USA; [Hopkins, Ramona O.] Intermt Med Ctr, Dept Med, Div Pulm & Crit Care, Murray, UT USA	Goodrich-Hunsaker, NJ (corresponding author), MIND Inst, 2825 50th St,Room 1362, Sacramento, CA 95817 USA.	naomihunsaker@me.com					Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Astur R, 2005, APPL PSYCHOPHYS BIOF, V30, P307, DOI 10.1007/s10484-005-6385-z; Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Baddeley AD, 2001, AM PSYCHOL, V56, P851, DOI 10.1037/0003-066X.56.11.851; BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; Barrash J, 2000, NEUROPSYCHOLOGIA, V38, P820, DOI 10.1016/S0028-3932(99)00131-1; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bohbot VD, 2004, NEUROPSYCHOLOGY, V18, P418, DOI 10.1037/0894-4105.18.3.418; Buffalo EA, 1998, BEHAV NEUROSCI, V112, P3, DOI 10.1037/0735-7044.112.1.3; CAVE CB, 1992, HIPPOCAMPUS, V2, P151, DOI 10.1002/hipo.450020207; Cornwell BR, 2008, J NEUROSCI, V28, P5983, DOI 10.1523/JNEUROSCI.5001-07.2008; Etchamendy N, 2007, HIPPOCAMPUS, V17, P595, DOI 10.1002/hipo.20303; Goodrich-Hunsaker NJ, 2009, CHEM SENSES, V34, P513, DOI 10.1093/chemse/bjp026; GOODRICHHUNSAKE.NJ, 2009, HIPPOCAMPUS, DOI DOI 10.1002/HIPO.20651; Gron G, 2000, NAT NEUROSCI, V3, P404; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; Hartley T, 2003, NEURON, V37, P877, DOI 10.1016/S0896-6273(03)00095-3; Holdstock JS, 1995, NEUROPSYCHOLOGIA, V33, P1583, DOI 10.1016/0028-3932(95)00145-X; Hopkins RO, 2004, NEUROPSYCHOLOGIA, V42, P524, DOI 10.1016/j.neuropsychologia.2003.09.005; Iaria G, 2003, J NEUROSCI, V23, P5945; Jarrard L E, 1991, Hippocampus, V1, P236, DOI 10.1002/hipo.450010304; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Jonides J, 2008, ANNU REV PSYCHOL, V59, P193, DOI 10.1146/annurev.psych.59.103006.093615; Kandel E. R., 1995, ESSENTIALS NEURAL SC; Kesner RP, 2006, BIOL PSYCHOL, V73, P3, DOI 10.1016/j.biopsycho.2006.01.004; Kesner RP, 2010, NEUROPSYCHOLOGIA, V48, P2290, DOI 10.1016/j.neuropsychologia.2009.10.027; Kumaran D, 2005, J NEUROSCI, V25, P7254, DOI 10.1523/JNEUROSCI.1103-05.2005; Lauritzen M, 2001, J CEREBR BLOOD F MET, V21, P1367, DOI 10.1097/00004647-200112000-00001; Lee I, 2003, J NEUROSCI, V23, P1517; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1997, J NEUROSCI, V17, P7103; Mellet E, 2000, NEUROIMAGE, V12, P588, DOI 10.1006/nimg.2000.0648; Meyers J., 1995, REY COMPLEX FIGURE T; MILNER B, 1966, AMNESIA, P109; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; OKAICHI H, 1990, PSYCHOBIOLOGY, V18, P416; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Parslow DM, 2004, NEUROPSYCHOLOGY, V18, P450, DOI 10.1037/0894-4105.18.3.450; Rosenbaum RS, 2004, HIPPOCAMPUS, V14, P826, DOI 10.1002/hipo.10218; ROSS ED, 1980, ARCH NEUROL-CHICAGO, V37, P193, DOI 10.1001/archneur.1980.00500530031001; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shrager Y, 2007, P NATL ACAD SCI USA, V104, P2961, DOI 10.1073/pnas.0611233104; Spiers HJ, 2007, NEUROSCIENCE, V149, P7, DOI 10.1016/j.neuroscience.2007.06.056; Spiers HJ, 2006, NEUROPSYCHOLOGIA, V44, P1674, DOI 10.1016/j.neuropsychologia.2006.03.028; Squire LR, 1997, PHILOS T R SOC B, V352, P1663, DOI 10.1098/rstb.1997.0148; Voermans NC, 2004, NEURON, V43, P427, DOI 10.1016/j.neuron.2004.07.009; Wais PE, 2006, NEURON, V49, P459, DOI 10.1016/j.neuron.2005.12.020; WALKER JA, 1979, PHYSIOL BEHAV, V23, P11, DOI 10.1016/0031-9384(79)90114-8; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1997, WMS 3 WECHSLER MEMOR	52	31	31	1	11	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0735-7044			BEHAV NEUROSCI	Behav. Neurosci.	JUN	2010	124	3					405	413		10.1037/a0019193			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	606YV	WOS:000278466000012	20528085				2021-06-18	
J	Grof, TM; Bledsoe, KA				Grof, Tina M.; Bledsoe, Kathleen A.			Evaluating the Use of Dexmedetomidine in Neurocritical Care Patients	NEUROCRITICAL CARE			English	Article						Dexmedetomidine; Analgesics; Sedatives; Intensive care unit; Adverse events	TRAUMATIC BRAIN-INJURY; SEDATION; AGITATION; UNIT; ADULT	Dexmedetomidine is a highly selective alpha(2)-adrenoreceptor agonist that produces dose-dependent sedation, anxiolysis, and analgesia without respiratory depression. Dexmedetomidine has been used in critically ill medical, surgical, and pediatric patients, as an adjunct to sedation and/or for treating drug or alcohol withdrawal. Information regarding the dosing and utilization of dexmedetomidine has been derived primarily from studies in critically ill patients in the medical intensive care unit. There has been no study designed specifically to evaluate dexmedetomidine for these therapeutic uses in the neurocritical care population. The primary and secondary objectives were to evaluate the starting dose of dexmedetomidine for neurocritical care patients and to assess the effect on hemodynamic parameters, respectively. This was a prospective, observational study conducted from October 2007 to March 2008. Patients were included if they were admitted to the Neuro-Intensive Care Unit and received dexmedetomidine infusion. Six patients met the criteria for the study. The mean initial dexmedetomidine infusion rate and mean maximum infusion rate were 0.67 +/- A 0.2 and 1.3 +/- A 0.5 mcg/kg/h, respectively. The mean duration of dexmedetomidine infusion was 66 +/- A 10 h. Two patients (33%) experienced a significant change in mean heart rate and systolic blood pressure after starting dexmedetomidine infusion. Neurocritically ill patients may require high doses of dexmedetomidine to achieve desired levels of sedation. The high rates and long duration of dexmedetomidine infusion had a statistically, but not clinically, significant impact on hemodynamic parameters.	[Grof, Tina M.; Bledsoe, Kathleen A.] Univ Virginia Hlth Syst, Charlottesville, VA USA	Grof, TM (corresponding author), Univ Virginia Hlth Syst, Charlottesville, VA USA.	tg9m@virginia.edu	Viani, Rafael/V-1196-2018				Bekker A, 2005, NEUROSURGERY, V57, P1, DOI 10.1227/01.NEU.0000163476.42034.A1; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kim E, 2002, NEUROREHABILITATION, V17, P297; Levy M, 2005, NEUROREHABILITATION, V20, P279; MacLaren R, 2007, PHARMACOTHERAPY, V27, P351, DOI 10.1592/phco.27.3.351; Prielipp RC, 2002, ANESTH ANALG, V95, P1052, DOI 10.1097/00000539-200210000-00048; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2004, INTENS CARE MED, V30, P2188, DOI 10.1007/s00134-004-2417-z; Venn RM, 2003, INTENS CARE MED, V29, P201, DOI 10.1007/s00134-002-1579-9; 2004, PRECEDEX DEXMEDETOMI	11	31	33	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	JUN	2010	12	3					356	361		10.1007/s12028-008-9156-x			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	590RJ	WOS:000277244700008	20217277				2021-06-18	
J	Sroufe, NS; Fuller, DS; West, BT; Singal, BM; Warschausky, SA; Maio, RF				Sroufe, Nicole S.; Fuller, Douglas S.; West, Brady T.; Singal, Bonita M.; Warschausky, Seth A.; Maio, Ronald F.			Postconcussive Symptoms and Neurocognitive Function After Mild Traumatic Brain Injury in Children	PEDIATRICS			English	Article						traumatic brain injury; postconcussive symptoms; prospective study; longitudinal study	POST-CONCUSSIVE SYNDROME; HEAD-INJURY; UNITED-STATES; EPIDEMIOLOGY; PERFORMANCE; SEVERITY	OBJECTIVES: We describe children's postconcussive symptoms (PCSs), neurocognitive function, and recovery during 4 to 5 weeks after mild traumatic brain injury (MTBI) and compare performance and recovery with those of injured control group participants without MTBIs. METHODS: A prospective, longitudinal, observational study was performed with a convenience sample from a tertiary care, pediatric emergency department. Participants were children 10 to 17 years of age who were treated in the emergency department and discharged. The MTBI group included patients with blunt head trauma, Glasgow Coma Scale scores of 13 to 15, loss of consciousness for <= 30 minutes, posttraumatic amnesia of <= 24 hours, altered mental status, or focal neurologic deficits, and no intracranial abnormalities. The control group included patients with injuries excluding the head. The Post-Concussion Symptom Questionnaire and domain-specific neurocognitive tests were completed at baseline and at 1 and 4 to 5 weeks after injury. RESULTS: Twenty-eight MTBI group participants and 45 control group participants were compared. There were no significant differences in demographic features. Control group participants reported some PCSs; however, MTBI group participants reported significantly more PCSs at all times. Among MTBI group participants, PCSs persisted for 5 weeks after injury, decreasing significantly between 1 and 4 to 5 weeks. Patterns of recovery on the Trail-Making Test Part B differed significantly between groups; performance on other neurocognitive measures did not differ. CONCLUSIONS: In children 10 to 17 years of age, self-reported PCSs were not exclusive to patients with MTBIs. However, PCSs and recovery patterns for the Trail-Making Test Part B differed significantly between the groups. Pediatrics 2010; 125: e1331-e1339	[Sroufe, Nicole S.; Maio, Ronald F.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Warschausky, Seth A.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Sroufe, Nicole S.; Maio, Ronald F.] Univ Michigan, Injury Res Ctr, Ann Arbor, MI 48109 USA; [Fuller, Douglas S.; West, Brady T.] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA; [Singal, Bonita M.] St Joseph Mercy Hosp, Dept Clin Res, Ann Arbor, MI 48104 USA; [Maio, Ronald F.] Univ Michigan, Off Vice President Res Univ, Ann Arbor, MI 48109 USA	Sroufe, NS (corresponding author), 1500 E Med Ctr Dr,Room TC B1 380, Ann Arbor, MI 48109 USA.	nicolel@med.umich.edu			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE00284-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000284] Funding Source: NIH RePORTER	This work was funded by the Centers for Disease Control and Prevention (grant R49CE00284-01).	ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BIJUR PE, 1990, PEDIATRICS, V86, P337; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Diggle P., 2002, ANAL LONGITUDINAL DA; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Halstead WC, 1985, HALSTEAD REITAN NEUR; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Molenberghs G., 2005, MODELS DISCRETE LONG; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; PARKER RS, 1994, SEMIN NEUROL, V14, P67, DOI 10.1055/s-2008-1041061; Pinkston JB, 2000, BRAIN COGNITION, V44, P74; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Rutter M, 1996, J DEV BEHAV PEDIATR, V17, P183; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schmidt M., 1996, REY AUDITORY VERBAL; Schootman M, 2000, BRAIN INJURY, V14, P373; Smith A., 2002, SYMBOL DIGIT MODALIT; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; THOMSON JB, 2000, NEUROPSYCHOLOGICAL M, P233; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; TWISK JWR, 2003, APPL LONGITUDINAL DA, P280; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	49	31	31	0	11	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2010	125	6					E1331	E1339		10.1542/peds.2008-2364			9	Pediatrics	Pediatrics	604GX	WOS:000278268600036	20478946				2021-06-18	
J	Gibson, CJ; Meyer, RC; Hamm, RJ				Gibson, Cynthia J.; Meyer, Rebecca C.; Hamm, Robert J.			Traumatic brain injury and the effects of diazepam, diltiazem, and MK-801 on GABA-A receptor subunit expression in rat hippocampus	JOURNAL OF BIOMEDICAL SCIENCE			English	Article							CALCIUM-CHANNEL BLOCKER; FLUID-PERCUSSION INJURY; EXCITATORY AMINO-ACIDS; TEMPORAL-LOBE EPILEPSY; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; HUMAN NT-2 NEURONS; CORTICAL-NEURONS; DIFFERENTIAL EXPRESSION; SIGNAL-TRANSDUCTION	Background: Excitatory amino acid release and subsequent biochemical cascades following traumatic brain injury (TBI) have been well documented, especially glutamate-related excitotoxicity. The effects of TBI on the essential functions of inhibitory GABA-A receptors, however, are poorly understood. Methods: We used Western blot procedures to test whether in vivo TBI in rat altered the protein expression of hippocampal GABA-A receptor subunits alpha 1, alpha 2, alpha 3, alpha 5, beta 3, and gamma 2 at 3 h, 6 h, 24 h, and 7 days post-injuy. We then used pre-injury injections of MK-801 to block calcium influx through the NMDA receptor, diltiazem to block L-type voltage-gated calcium influx, or diazepam to enhance chloride conductance, and re-examined the protein expressions of alpha 1, alpha 2, alpha 3, and gamma 2, all of which were altered by TBI in the first study and all of which are important constituents in benzodiazepine-sensitive GABA-A receptors. Results: Western blot analysis revealed no injury-induced alterations in protein expression for GABA-A receptor alpha 2 or alpha 5 subunits at any time point post-injury. Significant time-dependent changes in alpha 1, alpha 3, alpha 3, and gamma 2 protein expression. The pattern of alterations to GABA-A subunits was nearly identical after diltiazem and diazepam treatment, and MK-801 normalized expression of all subunits 24 hours post-TBI. Conclusions: These studies are the first to demonstrate that GABA-A receptor subunit expression is altered by TBI in vivo, and these alterations may be driven by calcium-mediated cascades in hippocampal neurons. Changes in GABA-A receptors in the hippocampus after TBI may have far-reaching consequences considering their essential importance in maintaining inhibitory balance and their extensive impact on neuronal function.	[Gibson, Cynthia J.] Washington Coll, Dept Psychol, Chestertown, MD 21620 USA; [Meyer, Rebecca C.] Emory Univ, Neurosci Program, Atlanta, GA 30322 USA; [Hamm, Robert J.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA	Gibson, CJ (corresponding author), Washington Coll, Dept Psychol, Chestertown, MD 21620 USA.	cgibson2@washcoll.edu			NIH, National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20 RR016469]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016469] Funding Source: NIH RePORTER	This publication was made possible by NIH grant number P20 RR016469 from the INBRE Program of the National Center for Research Resources.	BADING H, 1995, NEUROSCIENCE, V64, P653, DOI 10.1016/0306-4522(94)00462-E; Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; Brooks-Kayal AR, 2001, J NEUROCHEM, V77, P1266, DOI 10.1046/j.1471-4159.2001.00329.x; Chandra D, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-30; CHOI DW, 1987, J NEUROSCI, V7, P369; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Das P, 2004, NEUROSCIENCE, V124, P195, DOI 10.1016/j.neuroscience.2003.12.005; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Golarai G, 2001, J NEUROSCI, V21, P8523; Hamm RJ, 1993, BRAIN RES COGN BRAIN, V1, P223, DOI [10.1016/0926-6410(93)90006-Q, DOI 10.1016/0926-6410(93)90006-Q]; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Houlihan LM, 2000, NEUROPHARMACOLOGY, V39, P2533, DOI 10.1016/S0028-3908(00)00116-7; Huopaniemi L, 2004, J NEUROCHEM, V88, P1059, DOI 10.1046/j.1471-4159.2003.02216.x; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kim HS, 2000, BRAIN RES, V880, P28, DOI 10.1016/S0006-8993(00)02687-1; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Lavoie AM, 1997, BIOPHYS J, V73, P2518, DOI 10.1016/S0006-3495(97)78280-8; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Lyons HR, 2001, J NEUROCHEM, V78, P1114, DOI 10.1046/j.1471-4159.2001.00501.x; Marowsky A, 2004, EUR J NEUROSCI, V20, P1281, DOI 10.1111/j.1460-9568.2004.03574.x; MATLIB MA, 1983, LIFE SCI, V32, P2837, DOI 10.1016/0024-3205(83)90319-3; Matthews DB, 2000, J NEUROCHEM, V74, P1522, DOI 10.1046/j.1471-4159.2000.0741522.x; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Mohler H, 2006, CELL TISSUE RES, V326, P505, DOI 10.1007/s00441-006-0284-3; MOHLER H, 1996, ION CHANNELS, V4; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; OBATA K, 1978, BRAIN RES, V144, P179, DOI 10.1016/0006-8993(78)90447-X; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; Olsen RW, 2009, NEUROPHARMACOLOGY, V56, P141, DOI 10.1016/j.neuropharm.2008.07.045; Paquet-Durand F, 2004, BRAIN RES, V1011, P33, DOI 10.1016/j.brainres.2004.02.060; Paquet-Durand F, 2006, BRAIN RES, V1124, P45, DOI 10.1016/j.brainres.2006.09.077; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; Poulter MO, 1999, J NEUROSCI, V19, P4654; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Rudolph U, 2006, CURR OPIN PHARMACOL, V6, P18, DOI 10.1016/j.coph.2005.10.003; Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579; Sarnowska A, 2009, NEUROCHEM INT, V55, P164, DOI 10.1016/j.neuint.2009.01.024; SCANLON JM, CELL CALCIUM, V28, P317; SCHURR A, 1995, BRAIN RES, V684, P233, DOI 10.1016/0006-8993(95)00466-4; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)01118-8; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; SKEEN GA, 1994, J PHARMACOL EXP THER, V271, P30; Sotiriou E, 2005, J NEUROSCI RES, V82, P690, DOI 10.1002/jnr.20670; Sperk G, 1998, EPILEPSY RES, V32, P129, DOI 10.1016/S0920-1211(98)00046-1; Stein V, 2003, NEURON, V37, P375, DOI 10.1016/S0896-6273(03)00056-4; STELZER A, 1994, NEUROSCIENCE, V62, P813, DOI 10.1016/0306-4522(94)90479-0; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; Thompson CL, 2000, J NEUROCHEM, V74, P920, DOI 10.1046/j.1471-4159.2000.0740920.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vaknin UA, 2006, J CELL BIOCHEM, V97, P1094, DOI 10.1002/jcb.20708; Vallazza-Deschamps G, 2005, DOC OPHTHALMOL, V110, P25, DOI 10.1007/s10633-005-7341-1; Wang L, 2009, NEUROPHARMACOLOGY, V56, P198, DOI 10.1016/j.neuropharm.2008.07.004; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Whiting PJ, 2003, DRUG DISCOV TODAY, V8, P445, DOI 10.1016/S1359-6446(03)02703-X; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x	72	31	34	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1021-7770			J BIOMED SCI	J. Biomed. Sci.	MAY 18	2010	17								38	10.1186/1423-0127-17-38			11	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	616MW	WOS:000279214500001	20482789	DOAJ Gold, Green Published			2021-06-18	
J	Bourdages, M; Bigras, JL; Farrell, CA; Hutchison, JS; Lacroix, J				Bourdages, Macha; Bigras, Jean-Luc; Farrell, Catherine A.; Hutchison, James S.; Lacroix, Jacques		Canadian Critical Care Trials Grp	Cardiac arrhythmias associated with severe traumatic brain injury and hypothermia therapy	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						clinical trial; critical care medicine; hypothermia therapy; arrhythmias; traumatic brain injury; pediatrics	PEDIATRIC HEAD-INJURY; CHILDREN; CATECHOLAMINES; ADULTS; TRIAL	Objective: Severe head trauma and/or severe hypothermia (<= 32 degrees C) can cause cardiac arrhythmias. Effect of moderate hypothermia (32-33 degrees C) on cardiac arrhythmias in children after severe traumatic brain injury is not well characterized. The objective is to determine the effect of moderate and short-term (24 hrs) hypothermia therapy on the incidence and severity of cardiac arrhythmias in children with severe traumatic brain injury compared with normothermic control subject using a 24-hr Holter recording. Design: Prospective ancillary study of a multicenter randomized, controlled clinical trial. Setting: A Canadian university-affiliated pediatric intensive care unit in a level III trauma center. Patients: Patients <18 yrs with severe traumatic brain injury. Interventions: Holter recording during moderate hypothermia (HYPO group; esophageal temperature 32-33 degrees C) or normothermia (NORMO group; 36.5-37.5 degrees C) induced for 24 hrs started within 8 hrs after a severe traumatic brain injury. Measurements and Main Results: Sixteen patients who had a median age of 12.7 yrs (range, 7.2-17.0 yrs) were enrolled. The time from the injury to the start of the cooling process was 7.3 hrs (range, 6.6-7.8 hrs). The temperature when Holter recording began was 32.9 degrees C (range, 31.6-34.4 degrees C) in the HYPO group. Overall, 44% of all patients (seven of 16 patients) had arrhythmias (two of nine in the NORMO group and five of seven in the HYPO group, p = .13). The most frequent arrhythmias were isolated premature atrial contractions. Hypothermic patients had lower heart rates than normothermic patients (p = .01), but none had a severe bradycardia. In the NORMO group, one patient had accelerated junctional rhythm associated with hypotension. In the HYPO group, one patient had nonsustained monomorphic ventricular tachycardia. Conclusions: Arrhythmias are frequent in severe pediatric traumatic brain injury. Further studies are needed to characterize the epidemiology and clinical impact of arrhythmias associated with severe pediatric head trauma and moderate hypothermia. (Pediatr Crit Care Med 2010;11:408-414)	[Bourdages, Macha] Univ Laval, CHUQ, Div Pediat Intens Care Med, Ctr Mere Enfant,Dept Pediat, Quebec City, PQ, Canada; [Bigras, Jean-Luc] Univ Montreal, CHU St Justine, Div Pediat Cardiol, Dept Pediat, Montreal, PQ, Canada; [Farrell, Catherine A.; Lacroix, Jacques] Univ Montreal, CHU St Justine, Div Pediat Intens Care Med, Dept Pediat, Montreal, PQ, Canada; [Hutchison, James S.] Hosp Sick Children, Dept Crit Care Med, Dept Pediat, Toronto, ON M5G 1X8, Canada	Bourdages, M (corresponding author), Univ Laval, CHUQ, Div Pediat Intens Care Med, Ctr Mere Enfant,Dept Pediat, Quebec City, PQ, Canada.	macha.bourdages@mail.chuq.qc.ca			Fonds de la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec [004095-104]; Canadian Institutes of Health Research/Canadian Neurotrauma Research ProgramCanadian Institutes of Health Research (CIHR) [MCT50398]; Ontario Neurotrauma Foundation [ONBO-00009, ONRO-41]; Rick Hansen Institute; Hospital for Sick Children Foundation [XG 99-057]; Physicians Services Incorporated [98-62]; Children's Hospital of Eastern Ontario Research Institute [98/16S[E]]	Supported by a grant from the Fonds de la Recherche en Sante du Quebec (grant 004095-104). The HyP-HIT study was funded by the Canadian Institutes of Health Research/Canadian Neurotrauma Research Program (MCT50398), the Ontario Neurotrauma Foundation (ONBO-00009 and ONRO-41), the Rick Hansen Institute, the Hospital for Sick Children Foundation (XG 99-057), the Physicians Services Incorporated (98-62), and the Children's Hospital of Eastern Ontario Research Institute (98/16S[E]).	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Attari M, 2004, PEDIATR CLIN N AM, V51, P1355, DOI 10.1016/j.pcl.2004.04.007; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Dash M, 2003, J NEUROSURG ANESTH, V15, P270, DOI 10.1097/00008506-200307000-00017; DICKINSON DF, 1984, BRIT HEART J, V51, P179; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Fish FA, 2001, HEART DIS INFANTS CH, P482; GADKARY CS, 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001048; GARSON A, 1993, AM J CARDIOL, V72, pB14, DOI 10.1016/0002-9149(93)90034-A; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Grosse-Wortmann L, 2006, PEDIATR CARDIOL, V27, P286, DOI 10.1007/s00246-005-1248-1; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Lam WH, 1999, PAEDIATR ANAESTH, V9, P377; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MCLEOD AA, 1982, BRIT HEART J, V47, P221; MOSS AJ, 1993, AM J CARDIOL, V72, pB23, DOI 10.1016/0002-9149(93)90036-C; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; NADAS AS, 1951, AM HEART J, V42, P888, DOI 10.1016/0002-8703(51)90061-0; NAGASHIMA M, 1987, PEDIATR CARDIOL, V8, P103, DOI 10.1007/BF02079464; Naidech AM, 2005, CIRCULATION, V112, P2851, DOI 10.1161/CIRCULATIONAHA.105.533620; Natale JE, 2007, PEDIATR CRIT CARE ME, V8, P1, DOI 10.1097/01.pcc.0000256620.55512.5f; Oppenheimer S, 2006, CLIN AUTON RES, V16, P6, DOI 10.1007/s10286-006-0276-0; Oppenheimer SM, 1996, CLIN AUTON RES, V6, P131, DOI 10.1007/BF02281899; Oppenheimer SM, 1998, J NEUROL NEUROSUR PS, V64, P289, DOI 10.1136/jnnp.64.3.289; OSBORN JJ, 1953, AM J PHYSIOL, V175, P389; Ozdemir D, 2005, PEDIATR EMERG CARE, V21, P658, DOI 10.1097/01.pec.0000181427.25342.e0; Taylor AA, 1998, SCI PRACTICE PEDIAT, P415; Wittebole X, 2005, J ELECTROCARDIOL, V38, P77, DOI 10.1016/j.jelectrocard.2004.09.004; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875	35	31	33	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2010	11	3					408	414		10.1097/PCC.0b013e3181c51dea			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	593WO	WOS:000277493200015	20464781				2021-06-18	
J	Mossberg, KA; Amonette, WE; Masel, BE				Mossberg, Kurt A.; Amonette, William E.; Masel, Brent E.			Endurance Training and Cardiorespiratory Conditioning After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						disability; fitness; head injury; oxygen consumption; rehabilitation	PHYSICAL-ACTIVITY; AEROBIC EXERCISE; HEAD-INJURY; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; AMERICAN-COLLEGE; CHRONIC STROKE; PUBLIC-HEALTH; OLDER-ADULTS; FITNESS	Objective: To examine the importance of cardiorespiratory conditioning after traumatic brain injury (TBI) and provide recommendations for patients recovering from TBI. Method: Review of literature assessing the effectiveness of endurance training programs. Main outcomes and results: A sedentary lifestyle and lack of endurance are common characteristics of individuals with TBI who have a reduction in peak aerobic capacity of 25% to 30% compared with healthy sedentary persons. Increased physical activity and exercise training improves cardiorespiratory fitness in many populations with physical and cognitive impairments. Therefore, increasing the endurance and cardiorespiratory fitness of persons with TBI would seem to have important health implications. However, review of the TBI literature reveals that there have been few well-designed, well-controlled studies of physiologic and psychological adaptations of fitness training. Also lacking are long-term follow-up studies of persons with TBI. Conclusions: Assessing endurance capacity and cardiorespiratory fitness early in the TBI rehabilitation process merits consideration as a standard of care by professional rehabilitation societies. Also, providing effective, safe, and accessible training modalities would seem to be an important consideration for persons with TBI, given the mobility impairments many possess. Long-term follow-up studies are needed to assess the effectiveness of cardiorespiratory training programs on overall morbidity and mortality.	[Mossberg, Kurt A.; Amonette, William E.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA	Mossberg, KA (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossberg@utmb.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD046570, T32 HD007539]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007539, R01HD046570] Funding Source: NIH RePORTER	This work was partially supported by the National Institutes of Health R01 HD046570 to Dr Mossberg and T32 HD007539 to Mr Amonette. The authors thank Paula Skinkis for editorial assistance.	Abbott RD, 2004, JAMA-J AM MED ASSOC, V292, P1447, DOI 10.1001/jama.292.12.1447; ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Acosta AMD, 2001, J PHYSIOL BIOCHEM, V57, P313, DOI 10.1007/BF03179825; Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Bell K, 2007, BRAIN INJURY MED, P605; Bhambhani Y, 2005, ARCH PHYS MED REHAB, V86, P268, DOI 10.1016/j.apmr.2004.04.022; Bhambhani Y, 2003, ARCH PHYS MED REHAB, V84, P1629, DOI 10.1053/S0003-9993(03)00343-5; Booth F, 2000, Exerc Sport Sci Rev, V28, P145; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bussmann JBJ, 1998, CLIN REHABIL, V12, P455, DOI 10.1191/026921598674267844; BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Chakravarthy M. V., 2003, EXERCISE; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Colcombe SJ, 2003, J GERONTOL A-BIOL, V58, P176; Colditz GA, 1999, MED SCI SPORT EXER, V31, pS663, DOI 10.1097/00005768-199911001-00026; Cooper KH, 1968, JAMA-J AM MED ASSOC, V203, P135; Cooper RA, 1999, J REHABIL RES DEV, V36, P142; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; COWELL LL, 1986, MED SCI SPORT EXER, V18, P501; Crouter SE, 2006, J APPL PHYSIOL, V100, P1324, DOI 10.1152/japplphysiol.00818.2005; CURTIS KA, 1986, ARCH PHYS MED REHAB, V67, P862; de Vries WR, 2000, PSYCHOSOM MED, V62, P866, DOI 10.1097/00006842-200011000-00017; Dimeo FC, 1999, CANCER, V85, P2273, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2273::AID-CNCR24>3.3.CO;2-2; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; Gonzalez-Alonso J, 2004, J PHYSIOL-LONDON, V557, P331, DOI 10.1113/jphysiol.2004.060574; Goodwin RD, 2003, PREV MED, V36, P698, DOI 10.1016/S0091-7435(03)00042-2; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Gordon WA, 2008, J HEAD TRAUMA REHAB, V23, P2, DOI 10.1097/01.HTR.0000308715.03462.dd; Grealy M A, 2000, Pediatr Rehabil, V4, P41; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Greenleaf J E, 1982, Exerc Sport Sci Rev, V10, P84; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Harrison TR, 1944, J AMER MED ASSOC, V125, P1075, DOI 10.1001/jama.1944.02850340001001; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Haskell WL, 2007, CIRCULATION, V116, P1081, DOI 10.1161/CIRCULATIONAHA.107.185649; Hassmen P, 2000, PREV MED, V30, P17, DOI 10.1006/pmed.1999.0597; Heath G W, 1997, Exerc Sport Sci Rev, V25, P195; HERMANSE.L, 1969, J APPL PHYSIOL, V26, P31; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; Institute of Medicine, 2009, GULF WAR HLTH LONG T, V7; Ivey FM, 2008, J CARDIOPULM REHABIL, V28, P2, DOI 10.1097/01.HCR.0000311501.57022.a8; Jacobs PL, 2004, SPORTS MED, V34, P727, DOI 10.2165/00007256-200434110-00003; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32; Kiraly MA, 2005, INT J PSYCHIAT MED, V35, P75, DOI 10.2190/HX7L-4B40-PQNY-2A4P; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Macko RF, 2005, STROKE, V36, P2206, DOI 10.1161/01.STR.0000181076.91805.89; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; MAZZEO RS, 1991, MED SCI SPORT EXER, V23, P839, DOI 10.1249/00005768-199107000-00012; McArdle WD, 2001, EXERCISE PHYSL ENERG; McTiernan A, 2004, CANCER INVEST, V22, P68, DOI 10.1081/CNV-120027581; *MERR WEBST, FAT; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2003, AM J PHYS MED REHAB, V82, P385, DOI 10.1097/01.PHM.0000052589.96202.BE; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; Mossberg KA, 2008, J CLIN ENDOCR METAB, V93, P2581, DOI 10.1210/jc.2008-0368; Mossberg KA, 2008, PHYS THER, V88, P77, DOI 10.2522/ptj.20070022; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Mostert S, 2002, MULT SCLER J, V8, P161, DOI 10.1191/1352458502ms779oa; NOREAU L, 1992, PARAPLEGIA, V30, P563, DOI 10.1038/sc.1992.116; NORTON KI, 1995, EUR J APPL PHYSIOL O, V70, P115, DOI 10.1007/BF00361538; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Petajan JH, 1996, ANN NEUROL, V39, P432, DOI 10.1002/ana.410390405; PITETTI KH, 1993, SPORTS MED, V16, P23, DOI 10.2165/00007256-199316010-00004; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; SANTIAGO MC, 1993, ARCH PHYS MED REHAB, V74, P1192; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SEGAL SS, 2006, ACSMS ADV EXERCISE P, P343; SHAPIRO CM, 1984, EUR J APPL PHYSIOL O, V53, P1, DOI 10.1007/BF00964680; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Stuart M, 2008, J REHABIL RES DEV, V45, P329, DOI 10.1682/JRRD.2007.02.0027; SULLIVAN K, 2007, BRAIN INJURY MED, P929; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Thompson WR., 2010, ACSMS GUIDELINES EXE; Vitale AE, 1997, BRAIN INJURY, V11, P67, DOI 10.1080/026990597123827; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; WINDER WW, 1979, J APPL PHYSIOL, V46, P766; Winsley RJ, 2005, INT J SPORTS MED, V26, P768, DOI 10.1055/s-2004-830560; Yamada K, 2003, J PHARMACOL SCI, V91, P267; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	95	31	31	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2010	25	3					173	183		10.1097/HTR.0b013e3181dc98ff			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	606KG	WOS:000278423300004	20473091	Green Accepted			2021-06-18	
J	Weightman, MM; Bolgla, R; McCulloch, KL; Peterson, MD				Weightman, Margaret M.; Bolgla, Robyn; McCulloch, Karen L.; Peterson, Michelle D.			Physical Therapy Recommendations for Service Members With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; military personnel; physical therapy; practice guidelines	HIGH-LEVEL MOBILITY; HEAD-INJURY; INTERRATER RELIABILITY; CONCURRENT VALIDITY; RETEST RELIABILITY; BALANCE DISORDERS; ASSESSMENT-TOOL; CONCUSSION; MANAGEMENT; EXERCISE	Mild traumatic brain injuries (MTBIs) are of increasing concern in both the military and civilian populations as the potential long-term effects and costs of such injuries are being further recognized. Injuries from conflicts in Afghanistan and Iraq have increased public awareness and concern for TBI. The Proponency Office for Rehabilitation and Reintegration, Office of the Surgeon General, US Army tasked a team of physical and occupational therapists to assemble evidence-informed guidelines for assessment and intervention specific to MTBI. Given the paucity of specific guidelines for physical therapy related to MTBI, we focused on literature that dealt with the specific problem area or complaint of the Service member following MTBI. Recommendations, characterized as practice standards or practice options based on strength of evidence, are provided relative to patient/client education, activity intolerance, vestibular dysfunction, high-level balance dysfunction, posttraumatic headache, temporomandibular disorder, attention and dual-task performance deficits, and participation in exercise. While highlighting the need for additional research, this work can be considered a starting point and impetus for the development of evidence-based practice in physical therapy for our deserving Service members.	[Weightman, Margaret M.] Abbott NW Hosp, Sister Kenny Res Ctr, Minneapolis, MN 55407 USA; [Weightman, Margaret M.] Proponency Off Rehabil & Reintegrat, Falls Church, VA USA; Dept Vet Affairs Miami & Broward Cty OPC, Sunrise, FL USA; [Bolgla, Robyn] USAH Army Prof Management Command, Forest Pk, GA USA; [McCulloch, Karen L.] Univ N Carolina, Div Phys Therapy, Chapel Hill, NC 27515 USA; [Peterson, Michelle D.] Minneapolis VA Med Ctr, Polytrauma Rehabil Ctr, Minneapolis, MN USA	Weightman, MM (corresponding author), Abbott NW Hosp, Sister Kenny Res Ctr, 800 E 28th St & Chicago, Minneapolis, MN 55407 USA.	margaret.weightman@allina.com			US Army Center for Health Promotion and Preventative Medicine (USACHPPM)	This project was supported in part by Margaret M. Weightman's appointment to the Internship/Research Participation Program for the US Army Center for Health Promotion and Preventative Medicine (USACHPPM) administered by the Oak Ridge Institute for Science and Education through an agreement with the US Department of Energy and the USACHPPM.	Bell KR, 1999, J HEAD TRAUMA REHAB, V14, P34, DOI 10.1097/00001199-199902000-00006; Bhattacharyya N, 2008, OTOLARYNG HEAD NECK, V139, pS47, DOI 10.1016/j.otohns.2008.08.022; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Biondi DM, 2005, HEADACHE, V45, P738, DOI 10.1111/j.1526-4610.2005.05141.x; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casscells SW, 2007, TRAUMATIC BRAIN INJU; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; *DEF VET BRAIN INJ, 2006, DVBIC WORK GROUP AC; *DEF VET BRAIN INJ, 2008, CLIN GUID EV MAN CON; Dehail P, 2007, J REHABIL MED, V39, P531, DOI 10.2340/16501977-0096; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dworkin SF, 2002, J OROFAC PAIN, V16, P259; Evans JJ, 2009, J INT NEUROPSYCH SOC, V15, P112, DOI 10.1017/S1355617708090152; Goldberg Michael B., 1996, Journal of Orofacial Pain, V10, P126; Gordon CR, 2004, ARCH NEUROL-CHICAGO, V61, P1590, DOI 10.1001/archneur.61.10.1590; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gottshall Kim R, 2005, Int Tinnitus J, V11, P81; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1249/mss.0b013e3180616b27; HERDMAN SJ, 2007, VESTIBULAR REHABILIT, V3; Hillier SL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub2; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horak FB, 2009, PHYS THER, V89, P484, DOI 10.2522/ptj.20080071; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; INVERSON GL, 2007, BRAIN INJURY MED PRI, V1, P373; IVERSON GL, 2007, BRAIN INJURY MED PRI, P338; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; JACOBSON GP, 1995, HEADACHE, V35, P534, DOI 10.1111/j.1526-4610.1995.hed3509534.x; JACOBSON GP, 1994, NEUROLOGY, V44, P837, DOI 10.1212/WNL.44.5.837; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; MacDermid JC, 2009, J ORTHOP SPORT PHYS, V39, P400, DOI 10.2519/jospt.2009.2930; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; MCCULLOCH K, 2007, J NEUROL PHYS THER, V31, P104; McCulloch KL, 2009, J GERIATR PHYS THER, V32, P2, DOI 10.1519/00139143-200932010-00002; McNeely ML, 2006, PHYS THER, V86, P710, DOI 10.1093/ptj/86.5.710; Medlicott MS, 2006, PHYS THER, V86, P955, DOI 10.1093/ptj/86.7.955; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Ohrbach R, 2008, J OROFAC PAIN, V22, P219; Ohrbach R, 2008, COMMUNITY DENT ORAL, V36, P228, DOI 10.1111/j.1600-0528.2007.00397.x; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 2008, CURR PAIN HEADACHE R, V12, P67, DOI 10.1007/s11916-008-0013-6; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Pehling J, 2002, J OROFAC PAIN, V16, P296; Pho C, 2004, J ORTHOP SPORT PHYS, V34, P521; Pho C, 2004, J ORTHOP SPORT PHYS, V34, P511; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Radomski MV, 2009, AM J OCCUP THER, V63, P646, DOI 10.5014/ajot.63.5.646; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schmid A, 2007, STROKE, V38, P2096, DOI 10.1161/STROKEAHA.106.475921; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scrivani SJ, 2008, NEW ENGL J MED, V359, P2693, DOI 10.1056/NEJMra0802472; SHEPARD NT, 2007, BRAIN INJURY MED PRI, V1, P491; Silsupadol P, 2006, PHYS THER, V86, P269, DOI 10.1093/ptj/86.2.269; Springer Barbara A, 2007, J Geriatr Phys Ther, V30, P8; Stratford P., 1995, PHYSIOTHER CAN, V47, P258, DOI DOI 10.3138/PTC.47.4.258; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *TRAUM BRAIN INJ T, 2007, REP ARM SURG GEN TRA; Truelove E, 2006, J AM DENT ASSOC, V137, P1099, DOI 10.14219/jada.archive.2006.0348; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; van Loo M, 2003, CLIN REHABIL, V17, P775, DOI 10.1191/0269215503cr677oa; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whitney SL, 2005, PHYS THER, V85, P1034, DOI 10.1093/ptj/85.10.1034; Whitney SL, 2005, OTOL NEUROTOL, V26, P1027, DOI 10.1097/01.mao.0000185066.04834.4e; Whitney SL, 2000, LARYNGOSCOPE, V110, P1528, DOI 10.1097/00005537-200009000-00022; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Williams GP, 2006, PHYS THER, V86, P395, DOI 10.1093/ptj/86.3.395; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Wrisley DM, 2002, OTOL NEUROTOL, V23, P483, DOI 10.1097/00129492-200207000-00016	94	31	31	1	38	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2010	25	3					206	218		10.1097/HTR.0b013e3181dc82d3			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	606KG	WOS:000278423300007	20473094				2021-06-18	
J	Zollman, FS; Cyborski, C; Duraski, SA				Zollman, Felise S.; Cyborski, Cherina; Duraski, Sylvia A.			Actigraphy for assessment of sleep in traumatic brain injury: Case series, review of the literature and proposed criteria for use	BRAIN INJURY			English	Article						Actigraphy; insomnia; sleep; traumatic brain injury; TBI	INSOMNIA; DISORDERS	Primary objective: To demonstrate that actigraphy is an appropriate means of measuring sleep in patients with TBI and to define parameters for its use in this population. Research design: Case series and review of the literature. Methods and procedures: Subjects participating in one of two externally funded studies addressing the role of acupuncture in treating insomnia in TBI underwent actigraphy for the purpose of quantifying sleep time. Cases selected for presentation illustrate challenges in use of this modality in this population. Main outcomes and results: Caution should be exercised in interpreting actigraphy data in patients with TBI and (1) motor impairment or (2) cognitive and behavioural impairments which include agitation and impulsivity. Conclusions: Guidelines for use of actigraphy in patients with TBI are proposed: (1) Patients should be at Rancho Los Amigos cognitive level of III or above; (2) Patients with paresis, significant spasticity or contractures of one or more limbs should have the device placed on the least affected limb; and (3) For patients with tetraparesis, the device may not be an appropriate instrument for measurement of sleep; if it is to be used, consideration should be given to placing it on the head, rather than limbs or torso.	[Zollman, Felise S.] Northwestern Univ, Feinberg Sch Med, Rehabil Inst Chicago, Dept Phys Med & Rehabil, Chicago, IL 60611 USA	Zollman, FS (corresponding author), Northwestern Univ, Feinberg Sch Med, Rehabil Inst Chicago, Dept Phys Med & Rehabil, 345 E Super St, Chicago, IL 60611 USA.	fzollman@ric.org	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604	NIDRR [H133A080045]; CDMRPUnited States Department of Defense [W81XWH-08-1-0752]	The authors wish to thank Laura Wasek, MPH for her assistance in preparation of this manuscript. Supported by grants from NIDRR (#H133A080045) and CDMRP (US Army Medical Research and Material Command #W81XWH-08-1-0752).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Krahn L E, 1997, Ann Clin Psychiatry, V9, P203; Laakso ML, 2004, SLEEP MED, V5, P541, DOI 10.1016/j.sleep.2004.05.002; Lockley SW, 1999, J SLEEP RES, V8, P175, DOI 10.1046/j.1365-2869.1999.00155.x; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Morgenthaler T, 2007, SLEEP, V30, P519, DOI 10.1093/sleep/30.4.519; Muller U, 2006, BRAIN INJURY, V20, P157, DOI 10.1080/02699050500443467; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; SADEH A, 1995, SLEEP, V18, P288, DOI 10.1093/sleep/18.4.288; Spivak E, 2007, SPINAL CORD, V45, P765, DOI 10.1038/sj.sc.3102040; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; THAXTON L, 2007, BRAIN INJURY MED PRI, P557	21	31	32	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2010	24	5					748	754		10.3109/02699051003692167			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	592PJ	WOS:000277391300007	20334470				2021-06-18	
J	Nagamoto-Combs, K; Morecraft, RJ; Darling, WG; Combs, CK				Nagamoto-Combs, Kumi; Morecraft, Robert J.; Darling, Warren G.; Combs, Colin K.			Long-Term Gliosis and Molecular Changes in the Cervical Spinal Cord of the Rhesus Monkey after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						injury; microglia; motor recovery; spinal cord; synapse	GLUTAMATE TRANSPORTER GLT-1; PROTEIN-KINASE PATHWAYS; CORTICAL IMPACT INJURY; NOGO RECEPTOR; ARM REPRESENTATION; CEREBRAL-ISCHEMIA; IMMUNE-RESPONSE; CELL-DEATH; EXPRESSION; RECOVERY	Recovery of fine motor skills after traumatic brain injury (TBI) is variable, with some patients showing progressive improvements over time while others show poor recovery. We therefore studied possible cellular mechanisms accompanying the recovery process in a non-human primate model system, in which the lateral frontal motor cortex areas controlling the preferred upper limb were unilaterally lesioned, and the animals eventually regained fine hand motor function. Immunohistochemical staining of the cervical spinal cord, the site of compensatory sprouting and degeneration of corticospinal axons, showed profound increases in immunoreactivities for major histocompatibility complex class II molecule (MHC-II) and extracellular signal-regulated kinases (ERK1/2) up to 12 months post lesion, particularly within the lateral corticospinal tract (LCST). Double immunostaining demonstrated that phosphorylated ERK1/2 colocalized within the MCH-II+ microglia, suggesting a trophic role of long-term microglia activation after TBI at the site of compensatory sprouting. Active sprouting was observed in the LCST as well as in the spinal gray matter of the lesioned animals, as illustrated by increases in growth associated protein 43. Upregulation of Nogo receptor and glutamate transporter expression was also observed in this region after TBI, suggesting possible mechanisms for controlling aberrant sprouting and/or synaptic formation en route and interstitial glutamate concentration changes at the site of axon degeneration, respectively. Taken together, these changes in the non-human primate spinal cord support a long-term trophic/tropic role for reactive microglia, in particular, during functional and structural recovery after TBI.	[Combs, Colin K.] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA; [Nagamoto-Combs, Kumi] Univ N Dakota, Sch Med & Hlth Sci, Dept Anat & Cell Biol, Grand Forks, ND 58202 USA; [Morecraft, Robert J.] Univ S Dakota, Sch Med, Div Basic Biomed Sci, Vermillion, SD 57069 USA; [Darling, Warren G.] Univ Iowa, Dept Integrat Physiol, Iowa City, IA USA	Combs, CK (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, 504 Hamline St,Neurosci Bldg, Grand Forks, ND 58202 USA.	ccombs@medicine.nodak.edu	Nagamoto-Combs, Kumi/AAN-6697-2021		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS046367, 5P20RR017699-08]; South Dakota Spinal Cord and Traumatic Brain Injury Research Council; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR017699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS046367, R01NS046367] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health grants, NS046367 and 5P20RR017699-08, and The South Dakota Spinal Cord and Traumatic Brain Injury Research Council.	Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; Agrawal SK, 1997, J NEUROSCI, V17, P1055; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Batchelor PE, 2000, EUR J NEUROSCI, V12, P3462, DOI 10.1046/j.1460-9568.2000.00239.x; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 2008, BRAIN RES, V1209, P49, DOI 10.1016/j.brainres.2008.02.098; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Beschorner R, 2007, HISTOL HISTOPATHOL, V22, P515, DOI 10.14670/HH-22.515; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Butefisch CM, 2006, NEUROL SCI, V27, pS18, DOI 10.1007/s10072-006-0540-z; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; Carmichael ST, 2003, NEUROSCIENTIST, V9, P64, DOI 10.1177/1073858402239592; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Conti AC, 1998, J NEUROSCI, V18, P5663; Courtine G, 2007, NAT MED, V13, P561, DOI 10.1038/nm1595; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Darling WG, 2009, EXP NEUROL, V220, P90, DOI 10.1016/j.expneurol.2009.07.034; Darling WG, 2006, J NEUROSCI METH, V154, P38, DOI 10.1016/j.jneumeth.2005.11.013; David S, 2008, TRENDS NEUROSCI, V31, P221, DOI 10.1016/j.tins.2008.02.002; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FELTEN DL, 1987, IMMUNOL REV, V100, P225, DOI 10.1111/j.1600-065X.1987.tb00534.x; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fry EJ, 2007, NEURON, V53, P649, DOI 10.1016/j.neuron.2007.02.009; Fukuda S, 2003, ILAR J, V44, P96, DOI 10.1093/ilar.44.2.96; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hamo L, 2007, GLIA, V55, P1169, DOI 10.1002/glia.20538; HODGE CW, 2008, NEW ENGL J MED, V358, P453; Jara JH, 2007, J NEUROCHEM, V100, P1407, DOI 10.1111/j.1471-4159.2006.04330.x; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Koura SS, 1998, ACT NEUR S, V71, P244; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lemon RN, 2005, MUSCLE NERVE, V32, P261, DOI 10.1002/mus.20333; Li SX, 2003, J NEUROSCI, V23, P4219; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; Lotze M, 2006, NEUROREHAB NEURAL RE, V20, P14, DOI 10.1177/1545968305282919; Mark V W, 2006, Eura Medicophys, V42, P269; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; Matute C, 2007, J ANAT, V210, P693, DOI 10.1111/j.1469-7580.2007.00733.x; McNeal DW, 2010, J COMP NEUROL, V518, P586, DOI 10.1002/cne.22218; Morecraft RJ, 2004, J COMP NEUROL, V469, P37, DOI 10.1002/cne.10980; Morecraft RJ, 2001, BRAIN, V124, P176, DOI 10.1093/brain/124.1.176; Morecraft RJ, 2002, BRAIN, V125, P176, DOI 10.1093/brain/awf011; MORECRAFT RJ, 1992, J COMP NEUROL, V323, P341, DOI 10.1002/cne.903230304; Morecraft RJ, 2007, J COMP NEUROL, V504, P149, DOI 10.1002/cne.21438; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nudo RJ, 1999, CURR OPIN NEUROBIOL, V9, P740, DOI 10.1016/S0959-4388(99)00027-6; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Otani N, 2007, J CLIN NEUROSCI, V14, P42, DOI 10.1016/j.jocn.2005.11.044; Ouardouz M, 2009, ANN NEUROL, V65, P160, DOI 10.1002/ana.21539; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Persson M, 2005, GLIA, V51, P111, DOI 10.1002/glia.20191; Pizzimenti MA, 2007, J NEUROPHYSIOL, V98, P1015, DOI 10.1152/jn.00354.2007; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Redwine JM, 2001, AM J PATHOL, V159, P1219, DOI 10.1016/S0002-9440(10)62507-2; RINK A, 1995, AM J PATHOL, V147, P1575; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Satoh JI, 2005, J NEUROPATH EXP NEUR, V64, P129, DOI 10.1093/jnen/64.2.129; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Stagi M, 2005, J NEUROSCI, V25, P352, DOI 10.1523/JNEUROSCI.3887-04.2005; Stoll M, 2006, NEUROPATH APPL NEURO, V32, P650, DOI 10.1111/j.1365-2990.2006.00774.x; Straub RH, 1998, IMMUNOL TODAY, V19, P409, DOI 10.1016/S0167-5699(98)01297-3; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; Yaguchi M, 2008, J NEUROSCI RES, V86, P1972, DOI 10.1002/jnr.21658; Yamamoto T, 1999, ACT NEUR S, V75, P17	87	31	32	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					565	585		10.1089/neu.2009.0966			21	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100010	20030560	Green Published			2021-06-18	
J	Petroni, G; Quaglino, M; Lujan, S; Kovalevski, L; Rondina, C; Videtta, W; Carney, N; Temkin, N; Chesnut, R				Petroni, Gustavo; Quaglino, Marta; Lujan, Silvia; Kovalevski, Leandro; Rondina, Carlos; Videtta, Walter; Carney, Nancy; Temkin, Nancy; Chesnut, Randall			Early Prognosis of Severe Traumatic Brain Injury in an Urban Argentinian Trauma Center	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic Brain Injury; Prognosis; Argentina	SEVERE HEAD-INJURY	Background: Previous studies indicate that age, Glasgow Coma Scale score (GCS), arterial hypotension, computed tomography (CT) findings, and pupillary reactivity are strong predictors of outcome for patients with severe traumatic brain injury (TBI). However, the predictive validity of these variables has never been rigorously tested in patients from the developing world. The objective of this study was to evaluate the prognostic value of these variables in a resource-limited setting and to test their predictive power by using them to create an outcome model. Methods: The study was conducted at Hospital Emergencias "Dr. Clemente Alvarez" in Rosario, Argentina. All patients with severe TBI meeting criteria between August 2000 and February 2003 were included. Outcome at 6 months postinjury was measured by mortality and by the Extended Glasgow Outcome Scale score. Two logistic regression models were created for predicting mortality and outcome. Results: Outcome measures were acquired for 100% of the sample (N = 148). There was 58% mortality; 30% had moderate to good recovery, and 12% were severely disabled. The model accurately predicted 83.9% of mortality, and 81.1% of outcome. Because of variation in timing of CT scans, the models were recalculated without the CT variable. The accuracy of prediction was 79.7% and 79% for mortality and Extended Glasgow Outcome Scale, respectively. Conclusions: This study provides rigorous, prospective data that (1) validates the generalizability of the five World Health Organization/Organization Mondiale de la Sante TBI prognostic predictors outside of the developed world, and (2) provides outcome benchmarks for mortality and morbidity from severe TBI in developing countries.	[Petroni, Gustavo; Lujan, Silvia; Rondina, Carlos] Hosp Emergencias Dr Clemente Alvarez, Intens Care Unit, Rosario, Santa Fe, Argentina; [Quaglino, Marta; Kovalevski, Leandro] Univ Nacl Rosario, Sch Econ & Stat, RA-2000 Rosario, Santa Fe, Argentina; [Videtta, Walter] Hosp Nacl Prof Dr Alejandro Posadas, Intens Care Unit, Buenos Aires, DF, Argentina; [Temkin, Nancy; Chesnut, Randall] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Carney, Nancy] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA	Petroni, G (corresponding author), 1734 10 Floor,Apt 2, RA-2000 Rosario, Santa Fe, Argentina.	gustavopetroni@gmail.com		Chesnut, Randall/0000-0001-6377-3666	U. S. Department of EducationUS Department of Education; National Institute on Disability and Rehabilitation Research [H133G 000154]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5 D43 TW007566]; National Institute of Neurological Disorders and Stroke and Fogarty International Center of the NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)NIH Fogarty International Center (FIC) [1 R01 NS058302]; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW007566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058302] Funding Source: NIH RePORTER	Supported by U. S. Department of Education, National Institute on Disability and Rehabilitation Research grant H133G 000154, Fogarty International Center of the National Institutes of Health (NIH) grant 5 D43 TW007566, and National Institute of Neurological Disorders and Stroke and Fogarty International Center of the NIH grant 1 R01 NS058302.	*BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P559; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; Edwards P, 2005, LANCET, V365, P1957; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guyatt G. H., 2006, CLIN EPIDEMIOLOGY DO, P323; Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; Ratanalert S, 2002, BRIT J NEUROSURG, V16, P487, DOI 10.1080/0268869021000030311; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1974, LANCET, V2, P81; TIEN R, 2000, HEAD INJURY, P457; WILBERGER JE, 2000, HEAD INJURY, P27; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	23	31	36	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2010	68	3					564	570		10.1097/TA.0b013e3181ce1eed			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	567ZY	WOS:000275491200014	20220417				2021-06-18	
J	Elkin, BS; Shaik, MA; Morrison, B				Elkin, Benjamin S.; Shaik, Mohammed A.; Morrison, Barclay, III			Fixed negative charge and the Donnan effect: a description of the driving forces associated with brain tissue swelling and oedema	PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES			English	Article						oedema; brain injury; Donnan effect	ARTICULAR-CARTILAGE; CEREBRAL CONTUSION; RAT-BRAIN; INTRACRANIAL HYPERTENSION; MECHANICAL-PROPERTIES; CHONDROITIN SULFATE; VOLUME REGULATION; OSMOTIC-PRESSURE; CELLULAR EDEMA; INJURY	Cerebral oedema or brain tissue swelling is a significant complication following traumatic brain injury or stroke that can increase the intracranial pressure (ICP) and impair blood flow. Here, we have identified a potential driver of oedema: the negatively charged molecules fixed within cells. This fixed charge density (FCD), once exposed, could increase ICP through the Donnan effect. We have shown that metabolic processes and membrane integrity are required for concealing this FCD as slices of rat cortex swelled immediately (within 30 min) following dissection if treated with 2 deoxyglucose + cyanide (2DG+CN) or Triton X-100. Slices given ample oxygen and glucose, however, did not swell significantly. We also found that dead brain tissue swells and shrinks in response to changes in ionic strength of the bathing medium, which suggests that the Donnan effect is capable of pressurizing and swelling brain tissue. As predicted, a non-ionic osmolyte, 1,2 propanediol, elicited no volume change at 2000 x 10(-3) osmoles l(-1) (Osm). Swelling data were well described by triphasic mixture theory with the calculated reference state FCD similar to that measured with a 1,9 dimethylmethylene blue assay. Taken together, these data suggest that intracellular fixed charges may contribute to the driving forces responsible for brain swelling.	[Elkin, Benjamin S.; Shaik, Mohammed A.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864	Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	The authors would like to thank Gerard A. Ateshian for help with constitutive modelling and useful discussions, Vikrum A. Thimmappa for help with tissue-slice imaging and Michael B. Albro for useful discussions. This work was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) postgraduate scholarship (BSE).	Albro MB, 2007, J BIOMECH ENG-T ASME, V129, P503, DOI 10.1115/1.2746371; ALVARADO MV, 1984, J NEUROSCI RES, V11, P13, DOI 10.1002/jnr.490110103; Amorini AM, 2003, ACT NEUR S, V86, P261; AQUINO DA, 1984, J CELL BIOL, V99, P1130, DOI 10.1083/jcb.99.3.1130; ARNAUD FG, 1990, CRYOBIOLOGY, V27, P107, DOI 10.1016/0011-2240(90)90002-L; Asher RA, 2000, J NEUROSCI, V20, P2427; Ateshian GA, 2009, J BIOMECH, V42, P781, DOI 10.1016/j.jbiomech.2009.01.015; Azeloglu EU, 2008, AM J PHYSIOL-HEART C, V294, pH1197, DOI 10.1152/ajpheart.01027.2007; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Bhardwaj A, 2007, CURR NEUROL NEUROSCI, V7, P513, DOI 10.1007/s11910-007-0079-2; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chahine NO, 2005, BIOPHYS J, V89, P1543, DOI 10.1529/biophysj.104.057315; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Costa C, 2007, J CHEM NEUROANAT, V33, P111, DOI 10.1016/j.jchemneu.2007.01.006; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FISHMAN RA, 1977, J NEUROCHEM, V28, P1061, DOI 10.1111/j.1471-4159.1977.tb10669.x; Goodacre S, 2008, EMERG MED J, V25, P556, DOI 10.1136/emj.2007.055723; Goodman JA, 2005, MAGN RESON MED, V53, P1040, DOI 10.1002/mrm.20444; Hatashita S, 1990, Adv Neurol, V52, P85; Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007; Hrabetova S, 2002, J CEREBR BLOOD F MET, V22, P80, DOI 10.1097/00004647-200201000-00010; Hutchinson Peter, 2007, Neurosurg Focus, V22, pE14; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; JENKINS HG, 1988, J NEUROCHEM, V51, P1634, DOI 10.1111/j.1471-4159.1988.tb01134.x; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kawamata T, 2006, ACTA NEUROCHIR SUPPL, V96, P3; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Koppe G, 1997, CELL TISSUE RES, V288, P33, DOI 10.1007/s004410050790; Kurbel S, 2008, J THEOR BIOL, V252, P769, DOI 10.1016/j.jtbi.2008.02.022; Kuroiwa Toshihiko, 2007, Neurosurg Focus, V22, pE11, DOI 10.3171/foc.2007.22.5.12; LAI WM, 1991, J BIOMECH ENG-T ASME, V113, P245, DOI 10.1115/1.2894880; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Lu XL, 2007, J BIOMECH, V40, P2434, DOI 10.1016/j.jbiomech.2006.11.015; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Maeda T, 2003, ACT NEUR S, V86, P329; Marchi N, 2009, EPILEPSIA, V50, P664, DOI 10.1111/j.1528-1167.2008.01989.x; MARGOLIS RK, 1979, P NATL ACAD SCI USA, V76, P1711, DOI 10.1073/pnas.76.4.1711; MARGOLIS RK, 1976, BRAIN RES, V112, P363, DOI 10.1016/0006-8993(76)90290-0; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mongin Alexander A, 2007, Pathophysiology, V14, P183, DOI 10.1016/j.pathophys.2007.09.009; MOW VC, 1980, J BIOMECH ENG-T ASME, V102, P73, DOI 10.1115/1.3138202; Neprasova H, 2007, PFLUG ARCH EUR J PHY, V453, P839, DOI 10.1007/s00424-006-0151-9; Nguyen MK, 2006, J APPL PHYSIOL, V100, P1293, DOI 10.1152/japplphysiol.01274.2005; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Osada T, 2006, CLIN HEMORHEOL MICRO, V34, P223; OVERBEEK JTG, 1956, PROG BIOPHYS MOL BIO, V6, P58; Papadopoulos MC, 2004, FASEB J, V18, P425, DOI 10.1096/fj.04-2834fje; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raslan A., 2007, NEUROSURG FOCUS, V22, P1; SAMES K, 1992, ARCH GERONTOL GERIAT, V14, P75, DOI 10.1016/0167-4943(92)90008-R; Sherman LS, 2008, TRENDS NEUROSCI, V31, P44, DOI 10.1016/j.tins.2007.11.001; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Sun DD, 2004, J BIOMECH ENG-T ASME, V126, P6, DOI 10.1115/1.1644562; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; TOMITA M, 1979, EXP NEUROL, V65, P66, DOI 10.1016/0014-4886(79)90248-6; TOMITA M, 1988, BRAIN RES, V474, P165, DOI 10.1016/0006-8993(88)90679-8; TOMITA M, 1992, AM J PHYSIOL, V262, pH603; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van Pul C, 2005, MAGNET RESON MED, V53, P348, DOI 10.1002/mrm.20353; Vorisek I, 2002, MAGNET RESON MED, V48, P994, DOI 10.1002/mrm.10305; Wang Q, 2008, PHYS MED BIOL, V53, P2537, DOI 10.1088/0031-9155/53/10/006; Wang Q, 2007, J BIOMECH ENG-T ASME, V129, P413, DOI 10.1115/1.2720919; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; YATES AJ, 1975, AM J PATHOL, V79, P555; Young W, 1986, Cent Nerv Syst Trauma, V3, P215; YOUNG W, 1987, STROKE, V18, P751, DOI 10.1161/01.STR.18.4.751	81	31	31	0	10	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	1364-503X	1471-2962		PHILOS T R SOC A	Philos. Trans. R. Soc. A-Math. Phys. Eng. Sci.	FEB 13	2010	368	1912					585	603		10.1098/rsta.2009.0223			19	Multidisciplinary Sciences	Science & Technology - Other Topics	539DJ	WOS:000273233400004	20047940	Green Published			2021-06-18	
J	Bahrami, S; Pelinka, L; Khadem, A; Maitzen, S; Hawa, G; van Griensven, M; Redl, H				Bahrami, Soheyl; Pelinka, Linda; Khadem, Anna; Maitzen, Sonja; Hawa, Gerhard; van Griensven, Martijn; Redl, Heinz			Circulating NT-proCNP predicts sepsis in multiple-traumatized patients without traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						diagnosis; SIRS; traumatic brain injury; polytrauma; MOF; C-type natriuretic peptide	INFLAMMATORY RESPONSE SYNDROME; NATRIURETIC PEPTIDE; CNP; RECEPTORS; PROCALCITONIN; PITUITARY; FAILURE; ATRIAL; CELLS; FORMS	Objectives: C-type natriuretic peptide (CNP), a member of the natriuretic peptide family, is produced in vascular endothelium. We assessed the accuracy of natriuretic (NT)-proCNP, the N-terminal fragment of the C-type natriuretic peptide precursor, in predicting development of sepsis in multiple-traumatized patients with/without traumatic brain injury verified by computed tomography. Design: Retrospective clinical study. Setting: Level II trauma center. Patients: Three patient groups were stratified according to computed tomography results: isolated traumatic brain injury (n = 20), multiple-traumatized with traumatic brain injury (n = 26) and multiple-traumatized without traumatic brain injury (n = 26). During 13 days after multiple trauma, 37 (51%) patients developed sepsis. Measurements and Main Results: Circulating plasma NT-proCNP levels were measured daily (days 0-13) in all patients. Without any retrospective stratification of trauma patients, plasma NT-proNCP levels did not differ in septic (n = 37) and nonseptic (n = 35) patients (p = .505). Between days 2 and 6 posttrauma, there was a significant (p = .002) increase of circulating NT-proCNP in multi pie-traumatized patients without traumatic brain injury who developed sepsis (n = 19) compared with nonseptic multiple-traumatized patients without traumatic brain injury. Conversely, in septic patients either with traumatic brain injury alone or with multiple trauma and traumatic brain injury, the NT-proCNP showed a trend toward lower levels than in nonseptic patients. Prediction of sepsis (receiver-operating characteristic test) from days 2 to 6 after multiple trauma by NT-proCNP in patients without traumatic brain injury was accurate with an area under the curve of 0.84 +/- 0.03. The optimal cutoff value of 2.3 pmol/L produced sensitivity of 84% to 96% and specificity of 61% to 91% from day 2 to 6 after trauma. Conclusions: Our data showed that the levels of circulating NT-proCNP between multiple-traumatized patients without traumatic brain injury who do and do not develop sepsis are distinctly different. Plasma NT-proCNP concentration can potentially serve as an accurate predictor of sepsis in this cohort of patients. (Crit Care Med 2010; 38:161-166)	[Bahrami, Soheyl; Pelinka, Linda; Khadem, Anna; van Griensven, Martijn; Redl, Heinz] Res Ctr AUVA, Ludwig Boltzmann Inst Expt & Clin Traumatol, Vienna, Austria; [Maitzen, Sonja; Hawa, Gerhard] Biomed Med Prod GmbH & CoKG, Vienna, Austria	Bahrami, S (corresponding author), Res Ctr AUVA, Ludwig Boltzmann Inst Expt & Clin Traumatol, Vienna, Austria.	Soheyl.Bahrami@trauma.lbg.ac.at	van Griensven, Martijn/F-5808-2012; Redl, Heinz/AAD-8157-2019	van Griensven, Martijn/0000-0001-5104-9881; Bahrami, Soheyl/0000-0002-4563-6251			BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bossink AWJ, 1998, CHEST, V113, P1533, DOI 10.1378/chest.113.6.1533; Charles CJ, 1996, AM J PHYSIOL-REG I, V271, pR373; Chauhan SD, 2003, P NATL ACAD SCI USA, V100, P1426, DOI 10.1073/pnas.0336365100; Daggubati S, 1997, CARDIOVASC RES, V36, P246, DOI 10.1016/S0008-6363(97)00164-8; Del Ry S, 2005, EUR J HEART FAIL, V7, P1145, DOI 10.1016/j.ejheart.2004.12.009; DREWETT JG, 1995, J BIOL CHEM, V270, P4668, DOI 10.1074/jbc.270.9.4668; ERTEL W, 1994, EUR J PEDIATR SURG, V4, P243, DOI 10.1055/s-2008-1066112; Garcha RS, 2006, J RENIN-ANGIO-ALDO S, V7, P87, DOI 10.3317/jraas.2006.014; Giamarellos-Bourboulis EJ, 2002, INTENS CARE MED, V28, P1351, DOI 10.1007/s00134-002-1398-z; HAGIWARA H, 1994, J BIOCHEM-TOKYO, V116, P606, DOI 10.1093/oxfordjournals.jbchem.a124567; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; HAMA N, 1994, BIOCHEM BIOPH RES CO, V198, P1177, DOI 10.1006/bbrc.1994.1166; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harbarth S, 2001, AM J RESP CRIT CARE, V164, P396, DOI 10.1164/ajrccm.164.3.2009052; Hobbs A, 2004, CIRCULATION, V110, P1231, DOI 10.1161/01.CIR.0000141802.29945.34; Igaki T, 1998, HYPERTENS RES-CLIN E, V21, P7, DOI 10.1291/hypres.21.7; Jaszberenyi M, 1998, NEUROREPORT, V9, P2601, DOI 10.1097/00001756-199808030-00032; Kubo A, 2001, EXP HEMATOL, V29, P609, DOI 10.1016/S0301-472X(01)00625-7; Kuo JY, 2007, SCAND CARDIOVASC J, V41, P155, DOI 10.1080/14017430701302482; Marty B, 2001, J VOLCANOL GEOTH RES, V108, P1, DOI 10.1016/S0377-0273(00)00275-4; MCARDLE CA, 1994, ENDOCRINOLOGY, V135, P2794, DOI 10.1210/en.135.6.2794; MINAMINO N, 1991, BIOCHEM BIOPH RES CO, V179, P535, DOI 10.1016/0006-291X(91)91404-Z; Nishimura M, 1998, J HYPERTENS, V16, P1175; Potter LR, 2006, ENDOCR REV, V27, P47, DOI 10.1210/er.2005-0014; Prickett TCR, 2007, AM J PHYSIOL-ENDOC M, V292, pE1395, DOI 10.1152/ajpendo.00469.2006; Schachner T, 2004, EUR J CARDIO-THORAC, V25, P585, DOI 10.1016/j.ejcts.2003.07.013; Schulz S, 2005, PEPTIDES, V26, P1024, DOI 10.1016/j.peptides.2004.08.027; Scotland RS, 2005, P NATL ACAD SCI USA, V102, P14452, DOI 10.1073/pnas.0504961102; SHINOMIYA M, 1994, BIOCHEM BIOPH RES CO, V205, P1051, DOI 10.1006/bbrc.1994.2772; STINGO AJ, 1992, AM J PHYSIOL, V263, pH1318; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; Takida S, 1999, HYPERTENSION, V33, P124, DOI 10.1161/01.HYP.33.1.124; TOGASHI K, 1992, CLIN CHEM, V38, P2136; TOTSUNE K, 1994, PEPTIDES, V15, P37, DOI 10.1016/0196-9781(94)90167-8; Wright SP, 2004, HYPERTENSION, V43, P94, DOI 10.1161/01.HYP.0000105623.04382.C0; Wu CL, 2003, J BIOL CHEM, V278, P25847, DOI 10.1074/jbc.M301223200	37	31	32	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2010	38	1					161	166		10.1097/CCM.0b013e3181b78a06			6	Critical Care Medicine	General & Internal Medicine	539AE	WOS:000273224800024	19730251				2021-06-18	
J	Di Gennaro, JL; Mack, CD; Malakouti, A; Zimmerman, JJ; Armstead, W; Vavilala, MS				Di Gennaro, Jane L.; Mack, Christopher D.; Malakouti, Amin; Zimmerman, Jerry J.; Armstead, William; Vavilala, Monica S.			Use and Effect of Vasopressors after Pediatric Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Hypotension; Head injury; Children; Vasopressor	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURIES; INTRACRANIAL-PRESSURE; CORTICAL PERFUSION; BLOOD-PRESSURE; NOREPINEPHRINE; DOPAMINE; RESUSCITATION; THRESHOLDS; PREDICTORS	Background: Vasopressors are commonly used to increase mean arterial blood pressure (MAP) and cerebral perfusion pressure (CPP) after traumatic brain injury (TBI), but there are few data comparing vasopressor effectiveness after pediatric TBI. Objective: To determine which vasopressor is most effective at increasing MAP and CPP in children with moderate-to-severe TBI. Methods: After institutional review board approval, we performed a retrospective cohort study of children 0-17 years old admitted to a level 1 trauma center (Harborview Medical Center, Seattle, Wash., USA) between 2002 and 2007 with moderate-to-severe TBI who received a vasopressor to increase blood pressure. Baseline demographic and physiologic characteristics and hourly physiologic monitoring for 3 h after having started a vasopressor were abstracted. We evaluated differences in MAP and CPP at 3 h after initiation of therapy between phenylephrine, dopamine and norepinephrine among patients who did not require a second vasopressor during this time. Multivariate linear regression was used to adjust for age, gender, injury severity score and baseline MAP or CPP and to cluster by subject. Results: Eighty-two patients contributed data to the entire dataset. The most common initial medication was phenylephrine for 47 (57%). Patients receiving phenylephrine and norepinephrine tended to be older than those receiving dopamine and epinephrine. Thirteen (16%) of the patients received a second vasopressor during the first 3 h of treatment and were thus not included in the regression analyses; these patients received more fluid resuscitation and exhibited higher in-hospital mortality (77 vs. 32%; p = 0.004) compared to patients receiving a single vasopressor. The norepinephrine group exhibited a 5 mm Hg higher MAP (95% CI: -4 to 13; p = 0.31) and a 12 mm Hg higher CPP (95% CI: -2 to 26; p = 0.10) than the phenylephrine group, and a 5 mm Hg higher MAP (95% CI: -4 to 15; p = 0.27) and a 10 mm Hg higher CPP (95% CI: -5 to 25; p = 0.18) than the dopamine group. However, in post hoc analysis, after adjusting for time to start of vasopressor, hypertonic saline and pentobarbital, the effect on MAP was lost, but the CPP was 8 mm Hg higher (95% CI: -10 to 25; p = 0.39) than in the phenylephrine group, and 5 mm Hg higher (95% CI: -14 to 24; p = 0.59) than in the dopamine group. Conclusions: Vasopressor use varied by age. While there was no statistically significant difference in MAP or CPP between vasopressor groups, norepinephrine was associated with a clinically relevant higher CPP and lower intracranial pressure at 3 h after start of vasopressor therapy compared to the other vasopressors examined. Copyright (C) 2010 S. Karger AG, Basel	[Di Gennaro, Jane L.; Zimmerman, Jerry J.; Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Malakouti, Amin; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Mack, Christopher D.; Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Armstead, William] Univ Penn, Dept Anesthesiol, Philadelphia, PA 19104 USA	Vavilala, MS (corresponding author), Harborview Med Ctr, Dept Anesthesiol & Pediat, 325 9th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu			Lyford Family Endowment for Intensive Care; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23]	We gratefully acknowledge Sandra Burkhart, and the financial support from the Lyford Family Endowment for Intensive Care (J.L.D.G.) and the NIH (K23; M.S.V.) for this project.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Antunes VR, 2006, J PHYSIOL-LONDON, V576, P569, DOI 10.1113/jphysiol.2006.115766; Batista MB, 2009, CRIT CARE MED, V37, P2968, DOI 10.1097/CCM.0b013e3181b02e3b; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Costa EFD, 2009, SHOCK, V32, P190, DOI 10.1097/SHK.0b013e31819c3841; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; DUDKIEWICZ M, 2008, CRIT CARE MED, V36, P1; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; Farquhar WB, 2005, J APPL PHYSIOL, V99, P1545, DOI 10.1152/japplphysiol.00262.2005; Giusti-Paiva A, 2007, SHOCK, V27, P416, DOI 10.1097/01.shk.0000239759.05583.fd; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Kroppenstedt SN, 2002, ACT NEUR S, V81, P225; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; LEE C, 2009, HARRIET LANE HDB MAN, P697; Myburgh JA, 1998, ACT NEUR S, V71, P19; Ract C, 2001, INTENS CARE MED, V27, P101, DOI 10.1007/s001340000754; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; 10 LEADING CAUSES DE	35	31	31	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					420	430		10.1159/000322083			11	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900010	21124016	Green Published, Bronze			2021-06-18	
J	Diedler, J; Sykora, M; Hahn, P; Heerlein, K; Scholzke, MN; Kellert, L; Bosel, J; Poli, S; Steiner, T				Diedler, Jennifer; Sykora, Marek; Hahn, Philipp; Heerlein, Kristin; Schoelzke, Marion N.; Kellert, Lars; Boesel, Julian; Poli, Sven; Steiner, Thorsten			Low hemoglobin is associated with poor functional outcome after non-traumatic, supratentorial intracerebral hemorrhage	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL-BLOOD-FLOW; CRITICALLY-ILL; ANEMIC HYPOXIA; TRANSFUSION; HEMODILUTION; METABOLISM; OXYGENATION; ISCHEMIA	Introduction: The impact of anemia on functional outcome and mortality in patients suffering from non-traumatic intracerebral hemorrhage (ICH) has not been investigated. Here, we assessed the relationship between hemoglobin (HB) levels and clinical outcome after ICH. Methods: One hundred and ninety six patients suffering from supratentorial, non-traumatic ICH were extracted from our local stroke database (June 2004 to June 2006). Clinical and radiologic computed tomography data, HB levels on admission, mean HB values and nadir during hospital stay were recorded. Outcome was assessed at discharge and 3 months using the modified Rankin score (mRS). Results: Forty six (23.5%) patients achieved a favorable functional outcome (mRS <= 3) and 150 (76.5%) had poor outcome (mRS 4 - 6) at discharge. Patients with poor functional outcome had a lower mean HB (12.3 versus 13.7 g/dl, P < 0.001) and nadir HB (11.5 versus 13.0 g/dl, P < 0.001). Ten patients (5.1%) received red blood cell (RBC) transfusions. In a multivariate logistic regression model, the mean HB was an independent predictor for poor functional outcome at three months (odds ratio (OR) 0.73, 95% confidence interval (CI) 0.58-0.92, P = 0.007), along with National Institute of Health Stroke Scale (NIHSS) at admission (OR 1.17, 95% CI 1.11 - 1.24, P < 0.001), and age (OR 1.08, 95% CI 1.04 - 1.12, P < 0.001). Conclusions: We report an association between low HB and poor outcome in patients with non-traumatic, supratentorial ICH. While a causal relationship could not be proven, previous experimental studies and studies in brain injured patients provide evidence for detrimental effects of anemia on brain metabolism. However, the potential risk of anemia must be balanced against the risk of harm from red blood cell infusion.	[Diedler, Jennifer; Sykora, Marek; Hahn, Philipp; Heerlein, Kristin; Schoelzke, Marion N.; Kellert, Lars; Boesel, Julian; Poli, Sven; Steiner, Thorsten] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; [Sykora, Marek] Comenius Univ, Dept Neurol, Bratislava 81369, Slovakia	Diedler, J (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	jennifer.diedler@med.uni-heidelberg.de	Steiner, Thorsten/A-7391-2014; Steiner, Thorsten/L-2868-2018	Steiner, Thorsten/0000-0002-5080-8222			Beutler E, 2006, BLOOD, V107, P1747, DOI 10.1182/blood-2005-07-3046; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Gujjar AR, 1998, NEUROLOGY, V51, P447, DOI 10.1212/WNL.51.2.447; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Huan WY, 2009, J CLIN NEUROSCI, V16, P645, DOI 10.1016/j.jocn.2008.08.014; Kim-Han JS, 2006, STROKE, V37, P2457, DOI 10.1161/01.STR.0000240674.99945.4e; Kramer AH, 2008, CRIT CARE MED, V36, P2070, DOI 10.1097/CCM.0b013e31817c1095; Kramer AH, 2009, NEUROCRIT CARE, V10, P157, DOI 10.1007/s12028-008-9171-y; Kumar MA, 2009, CRIT CARE MED, V37, P1442, DOI 10.1097/CCM.0b013e31819ced3a; Kuwata N, 1995, NEUROSURG REV, V18, P237, DOI 10.1007/BF00383874; Lee EJ, 1999, J NEUROL SCI, V164, P117, DOI 10.1016/S0022-510X(99)00068-4; Lee EJ, 2001, J NEUROL SCI, V190, P3, DOI 10.1016/S0022-510X(01)00567-6; Miller CM, 2007, NEUROCRIT CARE, V6, P22, DOI 10.1385/NCC:6:1:22; Naidech AM, 2007, CRIT CARE MED, V35, P2383, DOI 10.1097/01.CCM.0000284516.17580.2C; Nybo M, 2007, EUR J NEUROL, V14, P477, DOI 10.1111/j.1468-1331.2006.01591.x; Powers WJ, 2001, NEUROLOGY, V57, P18, DOI 10.1212/WNL.57.1.18; Reasoner DK, 1996, ANESTH ANALG, V82, P61, DOI 10.1097/00000539-199601000-00011; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Steiner T, 2006, NEUROSURGERY, V59, P767, DOI 10.1227/01.NEU.0000232837.34992.32; TODD MM, 1994, J NEUROTRAUM, V11, P149, DOI 10.1089/neu.1994.11.149; Tomiyama Y, 1999, AM J PHYSIOL-HEART C, V276, pH1190; Tseng MY, 2008, BRIT J NEUROSURG, V22, P257, DOI 10.1080/02688690701832100; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; van Bommel J, 2002, ANESTHESIOLOGY, V97, P660, DOI 10.1097/00000542-200209000-00021; Vespa PM, 2006, CURR OPIN CRIT CARE, V12, P119, DOI 10.1097/01.ccx.0000216577.57180.bd; Vespa PM, 2009, STROKE, V40, P1547, DOI 10.1161/STROKEAHA.108.542803; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; WADE JPH, 1987, STROKE, V18, P68, DOI 10.1161/01.STR.18.1.68; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Zazulia AR, 2009, STROKE, V40, P1638, DOI 10.1161/STROKEAHA.108.536037; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	36	31	32	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2010	14	2							R63	10.1186/cc8961			8	Critical Care Medicine	General & Internal Medicine	611LO	WOS:000278816800038	20398266	DOAJ Gold, Green Published			2021-06-18	
J	Livingston, SC; Saliba, EN; Goodkin, HP; Barth, JT; Hertel, JN; Ingersoll, CD				Livingston, Scott C.; Saliba, Ethan N.; Goodkin, Howard P.; Barth, Jeffrey T.; Hertel, Jay N.; Ingersoll, Christopher D.			A preliminary investigation of motor evoked potential abnormalities following sport-related concussion	BRAIN INJURY			English	Article						Concussion; mild traumatic brain injury; motor evoked potential; transcranial magnetic stimulation	TRANSCRANIAL MAGNETIC STIMULATION; CENTRAL SOMATOSENSORY CONDUCTION; INDUCED AXONAL INJURY; BRAIN-INJURY; SPINAL-CORD; HEAD-INJURY; LONG-TERM; PROPAGATION; CORTEX; MILD	Background: Assessment of concussion is primarily based on self-reported symptoms, neurological examination and neuropsychological testing. The neurophysiologic sequelae and the integrity of the corticomotor pathways could be obtained by evaluating motor evoked potentials (MEPs). Objectives: To compare MEPs obtained through transcranial magnetic stimulation (TMS) in acutely concussed and non-concussed collegiate athletes. Methods: Eighteen collegiate athletes (12 males, six females, aged 20.4 +/- 1.3 years) including nine subjects with acute concussion (<= 24 hours) matched to nine control subjects. TMS was applied over the motor cortex and MEP responses were recorded from the contralateral upper extremity. MEP thresholds (%), latencies (milliseconds per metre) and amplitudes were assessed. Central motor conduction time (CMCT) was calculated from MEP, M response and F wave latencies. Testing was performed on days 1, 3, 5 and 10 post-concussion. Results: Ulnar MEP amplitudes were significantly different between post-concussion days 3 and 5 (F-3,F-48 = 3.13, p = 0.041) with smaller amplitudes recorded on day 3 (0.28 +/- 0.10 ms m(-1)). Median MEP latencies were significantly longer (F-3,F-48 = 4.53, p = 0.023) 10 days post-concussion (27.1 +/- 1.4 ms m(-1)) compared to day 1 (25.7 +/- 1.5 ms m(-1)). No significant differences for motor thresholds or CMCTs were observed (p > 0.05). Conclusion: MEP abnormalities among acutely concussed collegiate athletes provide direct electrophysiologic evidence for the immediate effects of concussion.	[Livingston, Scott C.] Univ Kentucky, Dept Rehabil Sci, Div Phys Therapy, Lexington, KY 40536 USA; [Saliba, Ethan N.] Univ Virginia, Dept Athlet Sports Med, Charlottesville, VA USA; [Goodkin, Howard P.] Univ Virginia, Dept Neurol, Charlottesville, VA USA; [Barth, Jeffrey T.] Univ Virginia, Dept Psychiat Med, Charlottesville, VA USA; [Hertel, Jay N.] Univ Virginia, Dept Human Sci, Charlottesville, VA USA; [Ingersoll, Christopher D.] Cent Michigan Univ, Coll Hlth Sci, Mt Pleasant, MI 48859 USA	Livingston, SC (corresponding author), Univ Kentucky, Dept Rehabil Sci, Div Phys Therapy, 900 S Limestone, Lexington, KY 40536 USA.	scott.livingston@uky.edu	Ingersoll, Christopher/H-6474-2015	Ingersoll, Christopher/0000-0001-9157-6846; Goodkin, Howard/0000-0003-0528-4949	National Operating Committee on the Standards of Athletic Equipment [13-06]; National Athletic Trainers' Association Research and Education Foundation [305DGP002]	This project was funded by the National Operating Committee on the Standards of Athletic Equipment (grant 13-06) and the National Athletic Trainers' Association Research and Education Foundation (grant 305DGP002).	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, J ATHL TRAINING, V36, P236; BARKER AT, 1985, LANCET, V1, P1106; BRASILNETO JP, 1992, ELECTROEN CLIN NEURO, V85, P9, DOI 10.1016/0168-5597(92)90095-S; Broglio SP, 2009, SPORTS HEALTH, V1, P361, DOI 10.1177/1941738109343158; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; *COMMT INSTR LTD, 2001, MMS3000 T6V4 OWN MAN; Conforto AB, 2004, CLIN NEUROPHYSIOL, V115, P812, DOI 10.1016/j.clinph.2003.11.010; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; DUPIUS F, 2000, CLIN NEUROSCIENCE NE, V11, P4087; Facco E., 1993, Neurophysiologie Clinique, V23, P237, DOI 10.1016/S0987-7053(05)80233-3; FACCO E, 1991, ELECTROEN CLIN NEURO, V80, P469, DOI 10.1016/0168-5597(91)90128-K; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GANDEVIA SC, 1987, BRAIN, V110, P1117, DOI 10.1093/brain/110.5.1117; GHEZZI A, 1991, ACTA NEUROL SCAND, V84, P503, DOI 10.1111/j.1600-0404.1991.tb05003.x; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; Harris-Love ML, 2006, ARCH PHYS MED REHAB, V87, pS84, DOI 10.1016/j.apmr.2006.08.330; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hugon M., 1973, NEW DEVELOPMENTS ELE, P277; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; Kaneko K, 1996, ELECTROMYOGR MOTOR C, V101, P478, DOI 10.1016/S0921-884X(96)96021-X; Kimura J., 1989, ELECTRODIAGNOSIS DIS, V2nd ed.; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lefebvre R, 2004, J MANIP PHYSIOL THER, V27, P97, DOI 10.1016/j.jmpt.2003.12.004; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; LIVINGSTON S, J CLIN MONI IN PRESS; Livingston SC, 2008, INT J NEUROSCI, V118, P239, DOI 10.1080/00207450701668020; MERTON PA, 1982, LANCET, V2, P597; Mills KR, 1997, MUSCLE NERVE, V20, P570, DOI 10.1002/(SICI)1097-4598(199705)20:5<570::AID-MUS5>3.3.CO;2-F; MILLS KR, 1992, ELECTROEN CLIN NEURO, V85, P17, DOI 10.1016/0168-5597(92)90096-T; Mills KR, 1999, MAGNETIC STIMULATION; Miranda PC, 1997, ELECTROMYOGR MOTOR C, V105, P116, DOI 10.1016/S0924-980X(97)95720-9; MISULIS KE, 2001, SPEHLMANNS EVOKED PO, P25; MURRAY NMF, 1999, ELECTRODIAGNOSIS CLI, P549; Palmieri RM, 2004, J ATHL TRAINING, V39, P268; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POWELL JW, 1994, P MILD BRAIN INJ SPO; Pridmore S, 1998, J ECT, V14, P25; Rossini PM, 2007, NEUROLOGY, V68, P484, DOI 10.1212/01.wnl.0000250268.13789.b2; ROSSINI PM, 1987, BRAIN RES, V415, P211, DOI 10.1016/0006-8993(87)90203-4; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; ROSSINI PM, 1991, BRAIN RES, V567, P111, DOI 10.1016/0006-8993(91)91442-4; ROSSINI PM, 1985, ELECTROEN CLIN NEURO, V61, P272, DOI 10.1016/0013-4694(85)91094-6; ROSSINI PM, 1985, ELECTROEN CLIN NEURO, V60, P320, DOI 10.1016/0013-4694(85)90006-9; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; Rutkove SB, 2001, MUSCLE NERVE, V24, P867, DOI 10.1002/mus.1084; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher RW, 2001, CLIN NEUROPHYSIOL, V112, P1729, DOI 10.1016/S1388-2457(01)00609-5; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; TOLEIKIS JR, 1991, ELECTROEN CLIN NEURO, V81, P443, DOI 10.1016/0168-5597(91)90053-Z; Tredget John, 2005, Nurs Stand, V19, P49; UOZUMI T, 1991, ELECTROEN CLIN NEURO, V81, P251, DOI 10.1016/0168-5597(91)90010-U; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; Weber M, 2002, MUSCLE NERVE, V25, P160; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; 2006, JALINOUS RGUIDE MAGN	68	31	31	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	6					904	913		10.3109/02699051003789245			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	620MT	WOS:000279504700013	20433286				2021-06-18	
J	Naim, MY; Friess, S; Smith, C; Ralston, J; Ryall, K; Helfaer, MA; Margulies, SS				Naim, Maryam Y.; Friess, Stuart; Smith, Colin; Ralston, Jill; Ryall, Karen; Helfaer, Mark A.; Margulies, Susan S.			Folic Acid Enhances Early Functional Recovery in a Piglet Model of Pediatric Head Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Neuroprotection; Folic acid; Traumatic brain injury; Neurobehavioral assessment; Pediatric brain injury; Axonal injury; Swine	TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; SPATIAL MEMORY; AXONAL INJURY; SWINE MODEL; FOLATE; RESUSCITATION; EXPRESSION; NEWBORN; STRESS	For stroke and spinal cord injury, folic acid supplementation has been shown to enhance neurodevelopment and to provide neuroprotection. We hypothesized that folic acid would reduce brain injury and improve neurological outcome in a neonatal piglet model of traumatic brain injury (TBI), using 4 experimental groups of 3- to 5-day-old female piglets. Two groups were intubated, anesthetized and had moderate brain injury induced by rapid axial head rotation without impact. One group of injured (Inj) animals received folic acid (Fol; 80 mu g/kg) by intraperitoneal (IP) injection 15 min following injury, and then daily for 6 days (Inj + Fol; n = 7). The second group of injured animals received an IP injection of saline (Sal) at the same time points (Inj + Sal; n = 8). Two uninjured (Uninj) control groups (Uninj + Fol, n = 8; Uninj + Sal, n = 7) were intubated, anesthetized and received folic acid (80 mu g/kg) or saline by IP injection at the same time points as the injured animals following a sham procedure. Animals underwent neurobehavioral and cognitive testing on days 1 and 4 following injury to assess behavior, memory, learning and problem solving. Serum folic acid and homocysteine levels were collected prior to injury and again before euthanasia. The piglets were euthanized 6 days following injury, and their brains were perfusion fixed for histological analysis. Folic acid levels were significantly higher in both Fol groups on day 6. Homocysteine levels were not affected by treatment. On day 1 following injury, the Inj + Fol group showed significantly more exploratory interest, and better motor function, learning and problem solving compared to the Inj + Sal group. Inj + Fol animals had a significantly lower cognitive composite dysfunction score compared to all other groups on day 1. These functional improvements were not seen on day 4 following injury. Axonal injury measured by beta-amyloid precursor protein staining 6 days after injury was not affected by treatment. These results suggest that folic acid may enhance early functional recovery in this piglet model of pediatric head injury. This is the first study to describe the application of complex functional testing to assess an intervention outcome in a swine model of TBI. Copyright (C) 2011 S. Karger AG, Basel	[Ralston, Jill; Ryall, Karen; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Naim, Maryam Y.; Friess, Stuart; Helfaer, Mark A.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Smith, Colin] Western Gen Hosp, Dept Neuropathol, Edinburgh EH4 2XU, Midlothian, Scotland	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulies@seas.upenn.edu		Smith, Colin/0000-0002-4507-5132	Thrasheresearch Foundation; Children's Hospital of Philadelphia; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS39679]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER	We are grateful to Ashley Young for her technical help in behavioral testing. This study was supported by the Thrasheresearch Foundation New Investigator award (M.Y.N.), the Endowed Chair in Critical Care Medicine from the Children's Hospital of Philadelphia (M.A.H.) and National Institutes of Health grant R01 NS39679 (S.S.M.).	Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Broom DM, 2009, ANIM BEHAV, V78, P1037, DOI 10.1016/j.anbehav.2009.07.027; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Endres M, 2005, STROKE, V36, P321, DOI 10.1161/01.STR.0000153008.60517.ab; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Glass TF, 2001, J NEUROTRAUM, V18, P57, DOI 10.1089/089771501750055776; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Ho PI, 2003, NEUROBIOL DIS, V14, P32, DOI 10.1016/S0969-9961(03)00070-6; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Iskandar BJ, 2004, ANN NEUROL, V56, P221, DOI 10.1002/ana.20174; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lin YP, 2004, NEUROREPORT, V15, P2241, DOI 10.1097/00001756-200410050-00020; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Luna SPL, 2007, AM J VET RES, V68, P258, DOI 10.2460/ajvr.68.3.258; Martin H, 2007, PEDIATRICS, V119, P1152, DOI 10.1542/peds.2006-2706; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Povlishock JT, 1996, ACT NEUR S, V66, P81; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Reynolds EH, 2002, J NEUROL NEUROSUR PS, V72, P567, DOI 10.1136/jnnp.72.5.567; Reynolds EH, 2002, BMJ-BRIT MED J, V324, P1512, DOI 10.1136/bmj.324.7352.1512; Rochat P, 2002, CHILD DEV, V73, P35, DOI 10.1111/1467-8624.00390; Rosenthal G, 2008, J NEUROSURG, V108, P575, DOI 10.3171/JNS/2008/108/3/0575; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SMITHELLS RW, 1976, ARCH DIS CHILD, V51, P944, DOI 10.1136/adc.51.12.944; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; TEASDALE G, 1974, LANCET, V2, P81; Van Guelpen B, 2005, STROKE, V36, P1426, DOI 10.1161/01.STR.0000169934.96354.3a; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wu DF, 1999, PHARMACEUT RES, V16, P415, DOI 10.1023/A:1018829920158; YEE WM, 1993, EXP BRAIN RES, V94, P193; Zhang J, 2008, EXP NEUROL, V210, P645, DOI 10.1016/j.expneurol.2007.12.019	40	31	32	1	11	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					466	479		10.1159/000322448			14	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900015	21212637	Green Published, Bronze			2021-06-18	
J	Vodovotz, Y				Vodovotz, Yoram			Translational systems biology of inflammation and healing	WOUND REPAIR AND REGENERATION			English	Article							IN-SILICO; COMPLEXITY; INJURY; MODELS; SELF	Personalized medicine is a major goal for the future of healthcare, and we suggest that computational simulations are necessary in order to achieve it. Inflammatory diseases, both acute and chronic, represent an area in which personalized medicine is especially needed, given the high level of individual variability that characterizes these diseases. We have created such simulations, and have used them to gain basic insights into the inflammatory response under baseline, gene-knockout, and drug-treated experimental animals; for in silico experiments and clinical trials in sepsis, trauma, and wound healing; and to create patient-specific simulations in polytrauma, traumatic brain injury, and vocal fold inflammation. Since they include both circulating and tissue-level inflammatory mediators, these simulations transcend typical cytokine networks by associating inflammatory processes with tissue/organ damage via tissue damage/dysfunction. We suggest that computational simulations are the cornerstone of Translational Systems Biology approaches for inflammatory diseases.	Univ Pittsburgh, Dept Surg, Ctr Inflammat & Regenerat Modeling, McGowan Inst Regenerat Med, Pittsburgh, PA 15213 USA	Vodovotz, Y (corresponding author), Univ Pittsburgh, Dept Surg, Ctr Inflammat & Regenerat Modeling, McGowan Inst Regenerat Med, W944 Starzl Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.	vodovotzy@upmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-GM-67240, P50-GM-53789, R33-HL-089082, R01-HL080926, R01-AI080799, R01-HL-76157]; National Institute on Disability and Rehabilitation Research [H133E070024]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL080926, R33HL089082, R01HL076157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI080799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P50GM053789, R01GM067240] Funding Source: NIH RePORTER	This work was supported in part by the National Institutes of Health grants R01-GM-67240, P50-GM-53789, R33-HL-089082, R01-HL080926, R01-AI080799, and R01-HL-76157; National Institute on Disability and Rehabilitation Research grant H133E070024; as well as grants from the Commonwealth of Pennsylvania, the Pittsburgh Lifesciences Greenhouse, and the Pittsburgh Tissue Engineering Initiative. Disclosure: Dr. Vodovotz is a co-founder and stakeholder in Immunetrics, Inc., which is commercializing aspects of the computational modeling work described herein.	Boulton AJ, 1999, WOUND REPAIR REGEN, V7, P7, DOI 10.1046/j.1524-475X.1999.00007.x; Buchman TG, 2002, NATURE, V420, P246, DOI 10.1038/nature01260; Callaghan T, 2006, J STAT PHYS, V122, P909, DOI 10.1007/s10955-006-9022-1; Chow CC, 2005, SHOCK, V24, P74, DOI 10.1097/01.shk.0000168526.97716.f3; Clermont G, 2004, CRIT CARE MED, V32, P2061, DOI 10.1097/01.CCM.0000142394.28791.C3; Cobbold CA, 2000, J THEOR BIOL, V204, P257, DOI 10.1006/jtbi.2000.2012; Creange A, 1997, EUR CYTOKINE NETW, V8, P145; Doyle J, 2007, NATURE, V446, P860, DOI 10.1038/446860a; Ideker T, 2001, ANNU REV GENOM HUM G, V2, P343, DOI 10.1146/annurev.genom.2.1.343; Kaczorowski DJ, 2008, J LEUKOCYTE BIOL, V83, P546, DOI 10.1189/jlb.0607374; Kitano H, 2002, NATURE, V420, P206, DOI 10.1038/nature01254; Kumar R, 2008, SHOCK, V29, P104, DOI 10.1097/SHK.0b013e318067da56; Lagoa CE, 2006, SHOCK, V26, P592, DOI 10.1097/01.shk.0000232272.03602.0a; MacArthur BD, 2004, BIOCHEM BIOPH RES CO, V313, P825, DOI 10.1016/j.bbrc.2003.11.171; Marshall JC, 2004, CRIT CARE MED, V32, P2157, DOI 10.1097/01.CCM.0000142935.34916.B5; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Mesarovic M. D., 2004, Systems Biology, V1, P19, DOI 10.1049/sb:20045010; MORAIN WD, 1990, CLIN PLAST SURG, V17, P493; Pedersen BK, 1998, CAN J PHYSIOL PHARM, V76, P505, DOI 10.1139/cjpp-76-5-505; Prince JM, 2006, MOL MED, V12, P88, DOI 10.2119/2006-00012.Prince; SHERRATT JA, 1990, P ROY SOC B-BIOL SCI, V241, P29, DOI 10.1098/rspb.1990.0061; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Vodovotz Y, 2007, J CRIT CARE, V22, P77, DOI 10.1016/j.jcrc.2006.12.001; Vodovotz Y, 2006, SHOCK, V26, P235, DOI 10.1097/01.shk.0000225413.13866.fo; Vodovotz Y, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000014; Wagner GP, 2007, NAT REV GENET, V8, P921, DOI 10.1038/nrg2267; Walker DC, 2004, BIOSYSTEMS, V76, P89, DOI 10.1016/j.biosystems.2004.05.025; Waugh HV, 2007, WOUND REPAIR REGEN, V15, P556, DOI 10.1111/j.1524-475X.2007.00270.x	29	31	32	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1067-1927	1524-475X		WOUND REPAIR REGEN	Wound Repair Regen.	JAN-FEB	2010	18	1					3	7		10.1111/j.1524-475X.2009.00566.x			5	Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery	Cell Biology; Dermatology; Research & Experimental Medicine; Surgery	542FQ	WOS:000273478800002	20082674	Green Accepted, Bronze			2021-06-18	
J	Shakur, H; Andrews, P; Asser, T; Balica, L; Boeriu, C; Quintero, JDC; Dewan, Y; Druwe, P; Fletcher, O; Frost, C; Hartzenberg, B; Mantilla, JM; Murillo-Cabezas, F; Pachl, J; Ravi, RR; Ratsep, I; Sampaio, C; Singh, M; Svoboda, P; Roberts, I				Shakur, Haleema; Andrews, Peter; Asser, Toomas; Balica, Laura; Boeriu, Cristian; Ciro Quintero, Juan Diego; Dewan, Yashbir; Druwe, Patrick; Fletcher, Olivia; Frost, Chris; Hartzenberg, Bennie; Mejia Mantilla, Jorge; Murillo-Cabezas, Francisco; Pachl, Jan; Ravi, Ramalingam R.; Raetsep, Indrek; Sampaio, Cristina; Singh, Manmohan; Svoboda, Petr; Roberts, Ian			The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury	TRIALS			English	Article							FOCAL CEREBRAL-ISCHEMIA; LF 16-0687 MS; EDEMA FORMATION; TISSUE-DAMAGE	Background: Cerebral oedema is associated with significant neurological damage in patients with traumatic brain injury. Bradykinin is an inflammatory mediator that may contribute to cerebral oedema by increasing the permeability of the blood-brain barrier. We evaluated the safety and effectiveness of the non-peptide bradykinin B2 receptor antagonist Anatibant in the treatment of patients with traumatic brain injury. During the course of the trial, funding was withdrawn by the sponsor. Methods: Adults with traumatic brain injury and a Glasgow Coma Scale score of 12 or less, who had a CT scan showing an intracranial abnormality consistent with trauma, and were within eight hours of their injury were randomly allocated to low, medium or high dose Anatibant or to placebo. Outcomes were Serious Adverse Events (SAE), mortality 15 days following injury and in-hospital morbidity assessed by the Glasgow Coma Scale (GCS), the Disability Rating Scale (DRS) and a modified version of the Oxford Handicap Scale (HIREOS). Results: 228 patients out of a planned sample size of 400 patients were randomised. The risk of experiencing one or more SAEs was 26.4% (43/163) in the combined Anatibant treated group, compared to 19.3% (11/57) in the placebo group (relative risk = 1.37; 95% CI 0.76 to 2.46). All cause mortality in the Anatibant treated group was 19% and in the placebo group 15.8% (relative risk 1.20, 95% CI 0.61 to 2.36). The mean GCS at discharge was 12.48 in the Anatibant treated group and 13.0 in the placebo group. Mean DRS was 11.18 Anatibant versus 9.73 placebo, and mean HIREOS was 3.94 Anatibant versus 3.54 placebo. The differences between the mean levels for GCS, DRS and HIREOS in the Anatibant and placebo groups, when adjusted for baseline GCS, showed a non-significant trend for worse outcomes in all three measures. Conclusion: This trial did not reach the planned sample size of 400 patients and consequently, the study power to detect an increase in the risk of serious adverse events was reduced. This trial provides no reliable evidence of benefit or harm and a larger trial would be needed to establish safety and effectiveness.	[Shakur, Haleema; Fletcher, Olivia; Frost, Chris; Roberts, Ian] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; [Andrews, Peter] Univ Edinburgh, Dept Anaesthesia Crit Care & Pain Med, Edinburgh EH16 4SA, Midlothian, Scotland; [Asser, Toomas] Univ Tartu, Dept Neurol & Neurosurg, EE-51014 Tartu, Estonia; [Balica, Laura] Spitalul Clin Urgenta Bacuresti, Emergency Dept, Bucharest 014461, Romania; [Boeriu, Cristian] Spitalul Clin Judetean Mures, Mobile Emergency Serv, Targu Mures 540103, Romania; [Ciro Quintero, Juan Diego] Clin Amer, Dept Crit Care, Medellin, Colombia; [Ciro Quintero, Juan Diego] Inst Neurol Antioquia, Neurol Clin, Medellin, Colombia; [Dewan, Yashbir] Christian Med Coll & Hosp, Dept Neurosurg, Ludhiana 141008, Punjab, India; [Druwe, Patrick] Sint Vincentiushosp, Dept Accid & Emergency Intens Care, B-2018 Antwerp, Belgium; [Hartzenberg, Bennie] Tygerberg Acad Hosp, Dept Neurosurg, ZA-7505 Tygerberg, South Africa; [Mejia Mantilla, Jorge] Fdn Clin Valle del Lili, Dept Anaesthesia & Intens Care, Cali, Valle Del Cauca, Colombia; [Murillo-Cabezas, Francisco] Hosp Univ Virgen del Rocio, Dept Emergency & Intens Care, Seville 41013, Spain; [Pachl, Jan] Hosp Kralovske Vinohrady, Dept Anaesthesiol, Prague 10034 10, Czech Republic; [Pachl, Jan] Hosp Kralovske Vinohrady, CCM, Prague 10034 10, Czech Republic; [Ravi, Ramalingam R.] Med Trust Hosp, Kochi 682016, Kerala, India; [Raetsep, Indrek] N Estonian Reg Hosp, Dept Postoperat Intens Care, EE-13419 Tallinn, Estonia; [Sampaio, Cristina] Fac Med Lisbon, Lab Farmacol Clin & Tereapeut, P-1629049 Lisbon, Portugal; [Singh, Manmohan] All India Inst Med Sci, Dept Neurosurg, Ctr Neurosci, New Delhi 110029, India; [Svoboda, Petr] Res Inst Special Surg & Trauma, Brno 66250, Moravia, Czech Republic	Shakur, H (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, Keppel St, London WC1E 7HT, England.	haleema.shakur@lshtm.ac.uk; p.andrews@ed.ac.uk; Toomas.Asser@kliinikum.ee; l_balica@yahoo.com; cboeriu@smurd.ro; jdcq0911@gmail.com; ydewan@yahoo.com; Patrick.druwe@pandora.be; olivia.fletcher@lshtm.ac.uk; chris.frost@lshtm.ac.uk; hbh@sun.ac.za; jorge.mejia.m@etb.net.co; francisco.murillo.sspa@juntadeandalucia.es; ianpachl@seznam.cz; indcrash2@gmail.com; Indrek.Ratsep@regionaalhaigla.ee; crissampaio@mail.telepac.pt; manmohan1972@gmail.com; p.svoboda@unbr.cz; ian.roberts@lshtm.ac.uk	Asser, Toomas/G-8446-2015; IBIS, NEUROCRITICOS/C-1805-2016; Murillo-Cabezas, Francisco/AAO-3348-2021	Shakur-Still, Haleema/0000-0002-6511-109X; Frost, Chris/0000-0003-0098-9915			[Anonymous], 1996, ICH HARMONISED TRIPA; Cook D, 2008, CAN MED ASSOC J, V178, P1181, DOI 10.1503/cmaj.071366; *INV BROCH, 2006, XY2405 BRAD B2 REC A; Kaplanski J, 2002, J NEUROTRAUM, V19, P953, DOI 10.1089/089771502320317104; Ker K, 2009, CNS NEUROSCI THER, V15, P52, DOI 10.1111/j.1755-5949.2008.00069.x; KER K, 2008, COCHRANE DATABASE SY; Li DZ, 2003, BRIT J PHARMACOL, V139, P1539, DOI 10.1038/sj.bjp.0705385; MAAS AI, 2005, HEAD INJURY, P406; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2005, J NEUROTRAUM, V22, P1444, DOI 10.1089/neu.2005.22.1444; Marmarou A, 2001, J NEUROSURG, V94, P349; Schilling L, 1997, KIDNEY INT, pS69; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; Vincent JL, 2005, CRIT CARE MED, V33, P2266, DOI 10.1097/01.CCM.0000181729.46010.83; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; Zausinger S, 2003, ACT NEUR S, V86, P205; Zausinger S, 2002, BRAIN RES, V950, P268, DOI 10.1016/S0006-8993(02)03053-6	17	31	33	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-6215			TRIALS	Trials	DEC 3	2009	10								109	10.1186/1745-6215-10-109			10	Medicine, Research & Experimental	Research & Experimental Medicine	532KM	WOS:000272746800001	19958521	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Senft, C; Schuster, T; Forster, MT; Seifert, V; Gerlach, R				Senft, Christian; Schuster, Thomas; Forster, Marie-Therese; Seifert, Volker; Gerlach, Ruediger			Management and outcome of patients with acute traumatic subdural hematomas and pre-injury oral anticoagulation therapy	NEUROLOGICAL RESEARCH			English	Article						Acute subdural hematoma; surgical treatment; traumatic brain injury; oral anticoagulation; outcome	PROTHROMBIN COMPLEX CONCENTRATE; ACTIVATED FACTOR-VII; INTRACRANIAL HEMORRHAGE; PREINJURY WARFARIN; ELDERLY-PATIENTS; BRAIN-INJURY; HEAD-INJURY; COMATOSE PATIENTS; VITAMIN-K; REVERSAL	Background: Acute subdural hematomas (aSDHs) are found in up to one-third of patients with severe traumatic brain injury and are associated with an unfavorable outcome in the majority of cases. Mortality ranges between 40 and 60%, but was reported to be even higher in patients undergoing oral anticoagulation therapy (OAT) at the time of injury. The objective of this study is to specifically report on the peri-operative management and outcome of patients with aSDH and pre-injury OAT. Material and Methods: From June 2002 to June 2006, all patients with OAT who underwent surgical treatment of aSDH were retrospectively analysed. Results of pre-operative blood tests, the peri-operative and surgical management and the clinical courses were assessed. Patient outcome is reported according to the Glasgow Outcome Scale (GOS) at 6 months. Results: Eleven (10.3%) out of 107 patients with aSDH were on OAT. Patients with OAT were significantly older than patients without OAT (72.4 +/- 9.3 versus 59.9 +/- 17.5 years; p<0.05, Mann-Whitney U-test). Intensity of head trauma was moderate in four and severe in seven patients with a median pre-operative Glasgow Coma Scale (GCS) of 8. Median pre-treatment prothrombin time and international normalized ratio were 23% (range: 10-65%) and 3.3 (range: 1.5-10.6), respectively. Replacement therapy consisted of administration of prothrombin complex concentrates, vitamin K and FFP (fresh frozen plasma). In four patients, antithrombin was additionally given to prevent disseminated intravascular coagulation. Surgical treatment consisted of craniotomy (n = 10) or craniectomy (n = 1) and hematoma evacuation with intracranial pressure probe placement. Low molecular weight heparin was administered as pharmacological prophylaxis of thrombembolic events in an increasing dose post-operatively. At 6 months, six out of 11 patients survived with a median GOS of 4. All-cause mortality was 45.5%. A pre-operative GCS of <= 8 was not associated with an increased risk of mortality (p>0.5, Fisher's exact test). No relevant rebleedings or thrombembolic complications were observed. The mortality rate of patients who did not undergo OAT was 50%. Conclusion: A large number of patients with aSDH are on pre-injury OAT. Specific replacement therapy facilitates successful clot evacuation without bleeding complications. The overall outcome of these patients does not seem to differ from historical cohorts with aSDH without OAT, but a large prospective multicenter study is warranted to answer that question. [Neurol Res 2009; 31: 1012-1018]	[Senft, Christian; Schuster, Thomas; Forster, Marie-Therese; Seifert, Volker; Gerlach, Ruediger] Goethe Univ Frankfurt, Dept Neurosurg, D-60528 Frankfurt, Germany	Senft, C (corresponding author), Goethe Univ Frankfurt, Dept Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	c.senft@med.uni-frankfurt.de	Senft, Christian/F-4252-2010; Forster, Marie-Therese/AAY-5616-2020	Senft, Christian/0000-0003-1288-6913; 			Aguilar MI, 2007, MAYO CLIN PROC, V82, P82, DOI 10.1016/s0025-6196(11)60970-1; Akopov SE, 2005, CEREBROVASC DIS, V19, P337, DOI 10.1159/000085027; BOSTROM S, 1986, ACTA NEUROCHIR, V80, P83, DOI 10.1007/BF01812279; Browd SR, 2004, NEUROSURG FOCUS, V17, pE1, DOI DOI 10.3171/F0C.2004.17.4.1; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Cartmill M, 2000, BRIT J NEUROSURG, V14, P458; Chen CS, 2000, EUR PHYS J-APPL PHYS, V11, P3, DOI 10.1051/epjap:2000139; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Depreitere B, 2003, ACTA NEUROCHIR, V145, P541, DOI 10.1007/s00701-003-0020-7; Dunn AS, 2007, J THROMB HAEMOST, V5, P2211, DOI 10.1111/j.1538-7836.2007.02729.x; Epstein NE, 2005, SURG NEUROL, V64, P295, DOI 10.1016/j.surneu.2005.04.039; Fang MC, 2007, AM J MED, V120, P700, DOI 10.1016/j.amjmed.2006.07.034; FELL DA, 1975, J NEUROSURG, V42, P37, DOI 10.3171/jns.1975.42.1.0037; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Garcia DA, 2008, J THROMB THROMBOLYS, V25, P116, DOI 10.1007/s11239-007-0124-7; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gerlach R, 2003, NEUROSURGERY, V53, P1028, DOI 10.1227/01.NEU.0000088565.15719.22; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; HEIN L, 2006, ANTIKOAGULANTIEN THR; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Iantosca MR, 2000, NEUROSURG CLIN N AM, V11, P447, DOI 10.1016/S1042-3680(18)30107-4; Iorio A, 2000, ARCH INTERN MED, V160, P2327, DOI 10.1001/archinte.160.15.2327; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2006, J TRAUMA, V61, P318, DOI 10.1097/01.ta.0000223944.25922.91; JENNETT B, 1975, LANCET, V1, P480; Karadimov D, 2003, J NEUROSURG ANESTH, V15, P330, DOI 10.1097/00008506-200310000-00008; Karni A, 2001, AM SURGEON, V67, P1098; Kawamata T, 1995, SURG NEUROL, V44, P438, DOI 10.1016/0090-3019(95)00249-9; Khan ZH, 2007, J ANESTH, V21, P258, DOI 10.1007/s00540-006-0481-y; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Leissinger CA, 2008, AM J HEMATOL, V83, P137, DOI 10.1002/ajh.21046; Levine MN, 2004, CHEST, V126, p287S, DOI 10.1378/chest.126.3_suppl.287S; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Lorenz R, 2007, BLOOD COAGUL FIBRIN, V18, P565, DOI 10.1097/MBC.0b013e3282010d7a; Machulda MM, 2000, NEUROSURG CLIN N AM, V11, P473, DOI 10.1016/S1042-3680(18)30110-4; Makris M, 1997, THROMB HAEMOSTASIS, V77, P477; Marion DW, 2006, NEUROSURGERY, V58, P655; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; O'Connell KA, 2006, JAMA-J AM MED ASSOC, V295, P293, DOI 10.1001/jama.295.3.293; O'Donnell M, 2003, CAN J SURG, V46, P129; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pautas E, 2006, DRUG AGING, V23, P13, DOI 10.2165/00002512-200623010-00002; Pieracci FM, 2007, J TRAUMA, V63, P519, DOI 10.1097/TA.0b013e31812e519b; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Preston FE, 2002, BRIT J HAEMATOL, V116, P619, DOI 10.1046/j.0007-1048.2001.03295.x; Raabe A, 2001, ACTA NEUROCHIR, V143, P1, DOI 10.1007/s007010170131; Saba Hussain I, 2006, Clin Adv Hematol Oncol, V4, P919; Schulman S, 2003, NEW ENGL J MED, V349, P675, DOI 10.1056/NEJMcp025373; Schulman S, 2007, TRANSFUS MED REV, V21, P37, DOI 10.1016/j.tmrv.2006.08.002; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Servadei F, 2000, NEUROSURGERY, V46, P70; SILVA RL, 2007, REV PORT CARDIOL, V26, P769; Taborski U, 1999, SEMIN THROMB HEMOST, V25, P43, DOI 10.1055/s-2007-996423; TEASDALE G, 1974, LANCET, V2, P81; Veshchev Igor, 2002, Med Sci Monit, V8, pCS98; Wilberger JE, 2000, NEUROSURG CLIN N AM, V11, P435, DOI 10.1016/S1042-3680(18)30105-0; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Woods K, 2007, J THROMB THROMBOLYS, V24, P93, DOI 10.1007/s11239-007-0022-z; Yasaka M, 2005, THROMB RES, V115, P455, DOI 10.1016/j.thromres.2004.09.002	63	31	31	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	DEC	2009	31	10					1012	1018		10.1179/174313209X409034			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	530XR	WOS:000272626800002	19570326				2021-06-18	
J	Axell, MZ; Zlateva, S; Curtis, M				Axell, Mathilda Zetterstrom; Zlateva, Suzana; Curtis, Maurice			A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Human embryonic stem cells; Neural progenitors; Derivation; Differentiation; Proliferation; Propagation; Gelatine; Laminin	IN-VITRO; DIRECTED DIFFERENTIATION; NEURONAL DIFFERENTIATION; HUMAN BLASTOCYSTS; POU-DOMAIN; PRECURSORS; LINEAGES; CULTURE; LINES; PROTEIN	Neuronal loss is a common feature of many neurological disorders, including stroke, Parkinson's disease, Alzheimer's disease and traumatic brain injury. Human embryonic stem cell (hESC)-derived neural progenitors (NPs) may provide new ways of treatment for several diseases and injuries in the brain, as well as enhance our understanding of early human development. Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs. In this rapid and simple protocol, NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor. After the first passage, adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers, such as Nestin, Sox1, Sox2, Sox3, Internexin, Musashi-1, NCAM, and Pax6. This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation, and the progenitors have the capacity to differentiate in vitro into all three neural lineages (neurons, astrocytes and oligodendrocytes). This method allows rapid, cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development. (C) 2009 Elsevier B.V. All rights reserved.	[Axell, Mathilda Zetterstrom] Gothenburg Univ, Ctr Brain Repair & Regenerat, CBR,Dept Neurosci & Physiol, Inst Neurosci & Physiol, SE-40530 Gothenburg, Sweden; [Curtis, Maurice] Univ Auckland, Fac Med & Hlth Sci, Dept Anat Radiol, Auckland 1, New Zealand	Axell, MZ (corresponding author), Gothenburg Univ, Ctr Brain Repair & Regenerat, CBR,Dept Neurosci & Physiol, Inst Neurosci & Physiol, Medicinaregatan 11,Box 432, SE-40530 Gothenburg, Sweden.	mathilda.zetterstrom@neuro.gu.se		Curtis, Maurice/0000-0003-4496-0233	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission	We would like to thank Cellartis AB, for financial support and for the supply of human embryonic stem cell lines, and the Swedish Medical Research Council for financial support. Eva Kilmare and Michelle Anderson for intellectual contributions. jenny Lindqvist and Jonas Faijerson for technical assistance with immunocytochemistry. Charlotta Lindwall and Jonas Faijerson for critical analysis of the manuscript. Prof. Peter S. Eriksson who had significant input into this project but who passed away before the study was completed.	Alessandri G, 2004, LANCET, V364, P1872, DOI 10.1016/S0140-6736(04)17443-6; Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Barberi T, 2007, NAT MED, V13, P642, DOI 10.1038/nm1533; Benzing C, 2006, NEUROREPORT, V17, P1675, DOI 10.1097/01.wnr.0000236861.01210.72; Carpenter MK, 2001, EXP NEUROL, V172, P383, DOI 10.1006/exnr.2001.7832; Davidson KC, 2007, MOL CELL NEUROSCI, V36, P408, DOI 10.1016/j.mcn.2007.07.013; Erceg S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002122; Gerrard L, 2005, STEM CELLS, V23, P1234, DOI 10.1634/stemcells.2005-0110; Heins N, 2004, STEM CELLS, V22, P367, DOI 10.1634/stemcells.22-3-367; Hong S, 2008, J NEUROCHEM, V104, P316, DOI 10.1111/j.1471-4159.2007.04952.x; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; JIANG X, 2008, STEM CELLS DEV, V18; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kania G, 2005, STEM CELLS, V23, P791, DOI 10.1634/stemcells.2004-0232; Koch P, 2009, P NATL ACAD SCI USA, V106, P3225, DOI 10.1073/pnas.0808387106; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; Li Y, 2005, BIOTECHNOL BIOENG, V91, P688, DOI 10.1002/bit.20536; Ma W, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-90; Minguell JJ, 2005, STEM CELLS DEV, V14, P408, DOI 10.1089/scd.2005.14.408; Peh GSL, 2009, STEM CELLS DEV, V18, P269, DOI 10.1089/scd.2008.0124; Pevny LH, 1998, DEVELOPMENT, V125, P1967; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rathjen J, 2002, DEVELOPMENT, V129, P2649; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399; Ronn LCB, 1998, EXP GERONTOL, V33, P853, DOI 10.1016/S0531-5565(98)00040-0; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Rutishauser U., 1992, DEVELOPMENT S, V116, P99; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Schuldiner M, 2001, BRAIN RES, V913, P201, DOI 10.1016/S0006-8993(01)02776-7; Schulz TC, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-27; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Shin S, 2005, STEM CELLS DEV, V14, P266, DOI 10.1089/scd.2005.14.266; Sjogren-Jansson E, 2005, DEV DYNAM, V233, P1304, DOI 10.1002/dvdy.20459; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tsai RYL, 2000, J NEUROSCI, V20, P3725; Wang TW, 2006, J COMP NEUROL, V497, P88, DOI 10.1002/cne.20984; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wilson PG, 2006, STEM CELL REV, V2, P67, DOI 10.1007/s12015-006-0011-1; Witusik M, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-56; Wood HB, 1999, MECH DEVELOP, V86, P197, DOI 10.1016/S0925-4773(99)00116-1; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhou JM, 2008, CELL BIOL INT, V32, P80, DOI 10.1016/j.cellbi.2007.08.015	49	31	33	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	NOV 15	2009	184	2					275	284		10.1016/j.jneumeth.2009.08.015			10	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	521IN	WOS:000271914400011	19715727				2021-06-18	
J	Adamo, MA; Drazin, D; Smith, C; Waldman, JB				Adamo, Matthew A.; Drazin, Doniel; Smith, Caitlin; Waldman, John B.			Comparison of accidental and nonaccidental traumatic brain injuries in infants and toddlers: demographics, neurosurgical interventions, and outcomes	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						decompressive craniectomy; head trauma; traumatic brain injury; infant; toddler; outcome; complications	SHAKEN BABY SYNDROME; HEAD-INJURY; YOUNG-CHILDREN; SHAKING	Object Nonaccidental trauma has become a leading cause of death in infants and toddlers Compared with children suffering from accidental trauma. many children with nonaccidental trauma present with injuries requiring neurosurgical management and operative interventions Methods. A retrospective review was performed concerning the clinical and radiological findings, need for neurosurgical intervention. and outcomes in infants and toddlers with head injuries who presented to Albany Medical Center between 1999 and 2007 The Fisher exact probability test and OR,, were computed for Glasgow Coma Scale (GCS) scores, hyperdense versus hypodense subdural collections. and discharge and follow-Lip King's Outcome Scale for Childhood Head Injury (KOSCHI) scores Results There were 219 patients, among whom 164 had sustained accidental trauma. and 54 had sustained nonaccidental trauma (NAT) The patient,,, with accidental traumatic injuries were more likely to present with GCS scores of 13-15 (OR 6 95), and the patients with NATs with of GCS scores 9-12 (OR 6.83) and 3-8 (OR 2 99). Skull fractures were present in 57.2% of accidentally Injured patients at presentation, and 15% had subdural collections Skull fractures were present in 30% of nonaccidentally injured patients. and subdural collections in 52% Patients with evidence of hypodense subdual collections were significantly more likely to be in the NAT group (OR 20.56). Patients with NAT injuries were also much more likely to require neurosurgical operative intervention. Patients with accidental trauma were more likely to have a KOSCHI score of 5 at discharge and follow-Lip (ORs 6 48 and 4.58). while patient,; with NAT had KOSCHI scores of 3a, 3b. 4a, and 4b at discharge (ORs 6 48, 5 47. 2 44. and 3.62. respectively), and 3b and 4a at follow-up. Conclusions. Infant and toddler victim,, of NAT have significantly Worse injuries and outcomes than those whose trauma was accidental. In the authors' experience, however. With aggressive intervention. many of these patients can make significant neurological improvements at subsequent follow-up visits. (DOI: 10.3171/2009.6.PEDS0939)	[Adamo, Matthew A.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Drazin, Doniel] Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA; [Smith, Caitlin; Waldman, John B.] Albany Med Ctr, Div Neurosurg, Albany, NY USA	Adamo, MA (corresponding author), Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Dept Neurosurg, 3705 5th Ave,3rd Floor,Purple Bldg, Pittsburgh, PA 15213 USA.						Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr RG, 2008, AM J PREV MED, V34, pS106, DOI 10.1016/j.amepre.2008.01.021; CAFFEY J, 1974, PEDIATRICS, V54, P396; Case ME, 2008, BRAIN PATHOL, V18, P583, DOI 10.1111/j.1750-3639.2008.00203.x; Cory CZ, 2003, MED SCI LAW, V43, P317, DOI 10.1258/rsmmsl.43.4.317; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; Jayawant S, 2007, ARCH DIS CHILD, V92, P343, DOI 10.1136/adc.2005.084988; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Karandikar S., 2004, CHILD ABUSE REV, V13, P178, DOI DOI 10.1002/CAR.850; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kesler H, 2008, J NEUROSURG-PEDIATR, V1, P351, DOI 10.3171/PED/2008/1/5/351; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; Miyake H, 2002, CHILD NERV SYST, V18, P500, DOI 10.1007/s00381-002-0596-x; Newton AW, 2005, CURR OPIN PEDIATR, V17, P246, DOI 10.1097/01.mop.0000158730.56669.b1; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Squier W, 2008, DEV MED CHILD NEUROL, V50, P10, DOI 10.1111/j.1469-8749.2007.02004.x; U.S. Census Bureau, 2000, AM FACT FIND; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Zouros A, 2004, J NEUROSURG, V100, P512, DOI 10.3171/ped.2004.100.5.0512	26	31	31	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	NOV	2009	4	5					414	419		10.3171/2009.6.PEDS0939			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	512JO	WOS:000271244400004	19877772				2021-06-18	
J	Koltowska-Haggstrom, M; Mattsson, AF; Shalet, SM				Koltowska-Haggstrom, Maria; Mattsson, Anders F.; Shalet, Stephen M.			Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							GROWTH-HORMONE DEFICIENCY; INTERNATIONAL-METABOLIC-DATABASE; BASE-LINE CHARACTERISTICS; HEALTH-CARE CONSUMPTION; TRAUMATIC BRAIN-INJURY; REPLACEMENT THERAPY; HYPOPITUITARY ADULTS; QOL-AGHDA; REPORTED OUTCOMES; CHILDHOOD-ONSET	Quality of life (QoL) has emerged as an important construct that has found numerous applications across healthcare-related fields, ranging from research and clinical evaluation of treatment effects to pharmacoeconomic evaluations and global healthcare policy. Impairment of QoL is one of the key clinical characteristics in adult GHD and has been extensively Studied in the Pfizer International Metabolic Database (KIMS). We provide summarized evidence on GH treatment effects for both clinical and health economic applications based on the KIMS data. The primary focus is on those aspects of QoL research that cannot be investigated in the traditional clinical trial setting, such as specific patient subgroups, cross-country comparisons and long-term follow-up. First, the impact of age, gender, disease onset, primary aetiology, extent of hypopituitarism, previous radiotherapy and obesity on QoL before and during long-term GH replacement is discussed. Secondly, the studies on QoL in relation to country-specific normative values are reviewed. Finally, health economic data derived from KIMS including both burden of disease and utility assessment are evaluated. We conclude that the wide spectrum of analyses performed on the KIMS data allows for practical application of the results not only to research and clinical practice but also to health policy and global medical decision making.	[Koltowska-Haggstrom, Maria; Mattsson, Anders F.] Pfizer Hlth AB, Endocrine Care, KIMS Med Outcomes, SE-19091 Sollentuna, Sweden; [Shalet, Stephen M.] Christie Hosp NHS Trust, Dept Endocrinol, Manchester M20 4BX, Lancs, England	Koltowska-Haggstrom, M (corresponding author), Pfizer Hlth AB, Endocrine Care, KIMS Med Outcomes, SE-19091 Sollentuna, Sweden.	maria.koltowska-haggstrom@pfizer.com			Pfizer Inc.Pfizer	Maria Koltowska-Hiiggstrbin and Anders FMattsson are permanently employed by Plizer Health AB. Stephen M Shalet received speaker fees from Plizer and Eli Lilly. KIMS (R) is Supported by Pfizer Inc. This paper forms part of a European journal of Endocrinology supplement, supported by Pfizer Inc.	Abrams P, 2008, EUR J ENDOCRINOL, V159, P825, DOI 10.1530/EJE-08-0448; Abs R, 2005, GROWTH HORM IGF RES, V15, P349, DOI 10.1016/j.ghir.2005.06.018; Abs R, 1999, CLIN ENDOCRINOL, V50, P703, DOI 10.1046/j.1365-2265.1999.00695.x; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P47, DOI 10.1016/j.ghir.2004.11.004; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; Badia X, 1998, CLIN ENDOCRINOL, V49, P765, DOI 10.1046/j.1365-2265.1998.00634.x; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; Bengtsson BA, 1999, J CLIN ENDOCR METAB, V84, P3929, DOI 10.1210/jc.84.11.3929; BESHYAH SA, 1995, CLIN ENDOCRINOL, V42, P73, DOI 10.1111/j.1365-2265.1995.tb02601.x; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; Black N, 1999, HORM RES, V51, P44, DOI 10.1159/000053135; Blum WF, 2003, J CLIN ENDOCR METAB, V88, P4158, DOI 10.1210/jc.2002-021792; Bulow B, 2002, CLIN ENDOCRINOL, V56, P183, DOI 10.1046/j.0300-0664.2001.01461.x; BURMAN P, 1995, J CLIN ENDOCR METAB, V80, P3585, DOI 10.1210/jc.80.12.3585; Carroll PV, 1997, EUR J ENDOCRINOL, V137, P146, DOI 10.1530/eje.0.1370146; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; Chihara K, 2006, GROWTH HORM IGF RES, V16, P132, DOI 10.1016/j.ghir.2006.03.012; Coast J, 2004, BRIT MED J, V329, P1233, DOI 10.1136/bmj.329.7476.1233; Cuneo RC, 1998, J CLIN ENDOCR METAB, V83, P107, DOI 10.1210/jc.83.1.107; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; Dixon S, 2003, J OUTCOMES RES, V7, P1; Dupuy HJ., 1984, ASSESSMENT QUALITY L, P170; Ehrnborg C, 2000, PHARMACOECONOMICS, V17, P621, DOI 10.2165/00019053-200017060-00008; *EUROQOL GROUP, 1990, HLTH POLICY, V16, P19; Feldt-Rasmussen U, 2002, EUR J ENDOCRINOL, V146, P67, DOI 10.1530/eje.0.1460067; Gutierrez LP, 2008, PHARMACOEPIDEM DR S, V17, P90, DOI 10.1002/pds.1510; Hakkaart-van Roijen L, 1998, PHARMACOECONOMICS, V14, P395, DOI 10.2165/00019053-199814040-00006; Hernberg-Stahl E, 2001, J CLIN ENDOCR METAB, V86, P5277, DOI 10.1210/jc.86.11.5277; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; HOLMES SJ, 1995, ENDOCRINOL METAB, V2, P63; Hoybye C, 2007, EUR J ENDOCRINOL, V157, P589, DOI 10.1530/EJE-07-0364; HUNT SM, 1981, SOC SCI MED-MED SOC, V15, P221, DOI 10.1016/0271-7123(81)90005-5; HUNT SM, 1992, HEALTH POLICY, V22, P307, DOI 10.1016/0168-8510(92)90004-U; HUNT SM, 1993, ACTA ENDOCRINOL-COP, V128, P37; HURNY C, 1992, EUR J CANCER, V28A, P118, DOI 10.1016/0959-8049(92)90399-M; INGLEHART R, 1986, RES QUALITY LIFE; Kahn MG, 1999, HORM RES, V51, P50, DOI 10.1159/000053136; Kelestimur F, 2005, EUR J ENDOCRINOL, V152, P581, DOI 10.1530/eje.1.01881; Kendall-Taylor P, 2005, EUR J ENDOCRINOL, V152, P557, DOI 10.1530/eje.1.01877; Koltowska-Haggstrom M, 2005, HORM RES, V64, P46, DOI 10.1159/000087444; Koltowska-Haggstrom M, 2008, CLIN ENDOCRINOL, V68, P122, DOI 10.1111/j.1365-2265.2007.03010.x; Koltowska-Haggstrom M, 2007, VALUE HEALTH, V10, P73, DOI 10.1111/j.1524-4733.2006.00146.x; Koltowska-Haggstrom M, 2006, EUR J ENDOCRINOL, V155, P109, DOI 10.1530/eje.1.02176; Kreitschmann-Andermahr I, 2008, GROWTH HORM IGF RES, V18, P472, DOI 10.1016/j.ghir.2008.08.007; Maiter D, 2006, EUR J ENDOCRINOL, V155, P253, DOI 10.1530/eje.1.02209; Mard G, 1994, ENDOCRINOLOGY MET SA, VI, P43; MCGAULEY GA, 1990, HORM RES, V33, P52, DOI 10.1159/000181584; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; MCKENNA SP, 1992, BR J MED EC, V4, P41; Monson JP, 2000, CLIN ENDOCRINOL, V53, P281, DOI 10.1046/j.1365-2265.2000.01104.x; Monson JP, 2003, HORM RES, V60, P112, DOI 10.1159/000071235; Moock J, 2009, EUR J ENDOCRINOL, V160, P17, DOI 10.1530/EJE-08-0738; O'Connor R, 2004, MEASURING QUALITY LI, P1; RANKE MB, 2000, GH REPLACEMENT ADULT, P1; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; Rosilio M, 2004, J CLIN ENDOCR METAB, V89, P1684, DOI 10.1210/jc.2003-030134; Saller B, 2006, EUR J ENDOCRINOL, V154, P843, DOI 10.1530/eje.1.02149; Sanmarti A, 1999, EUR J ENDOCRINOL, V141, P481, DOI 10.1530/eje.0.1410481; Sathiavageeswaran M, 2007, EUR J ENDOCRINOL, V156, P439, DOI 10.1530/eje.1.02346; Siyambalapitiya S, 2009, CLIN ENDOCRINOL, V70, P907, DOI 10.1111/j.1365-2265.2008.03435.x; Svensson J, 2004, GROWTH HORM IGF RES, V14, P207, DOI 10.1016/j.ghir.2003.12.001; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; TORRANCE GW, 1976, MANAGE SCI, V22, P990, DOI 10.1287/mnsc.22.9.990; Van den Wyngaert T, 2005, EJC SUPPL, V3, P363; Verhelst J, 1997, CLIN ENDOCRINOL, V47, P485, DOI 10.1046/j.1365-2265.1997.3041112.x; Verhelst J, 2005, J CLIN ENDOCR METAB, V90, P4636, DOI 10.1210/jc.2005-0185; Wallymahmed ME, 1997, CLIN ENDOCRINOL, V47, P439, DOI 10.1046/j.1365-2265.1997.2801076.x; Wilton P, 2009, EUR J ENDOCRINOL, V161, pS1, DOI 10.1530/EJE-09-0841; Wiren L, 1998, CLIN ENDOCRINOL, V48, P613, DOI 10.1046/j.1365-2265.1998.00462.x; Wiren L, 2000, CLIN ENDOCRINOL, V52, P143, DOI 10.1046/j.1365-2265.2000.00899.x; Woodhouse LJ, 2006, ENDOCR REV, V27, P287, DOI 10.1210/er.2004-0022	74	31	33	0	3	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	NOV	2009	161			1	SI		S51	S64		10.1530/EJE-09-0266			14	Endocrinology & Metabolism	Endocrinology & Metabolism	534ZC	WOS:000272935100008	19684056	Bronze			2021-06-18	
J	Morochovic, R; Racz, O; Kitka, M; Pingorova, S; Cibur, P; Tomkova, D; Lenartova, R				Morochovic, R.; Racz, O.; Kitka, M.; Pingorova, S.; Cibur, P.; Tomkova, D.; Lenartova, R.			Serum S100B protein in early management of patients after mild traumatic brain injury	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						cranial computed tomography; mild traumatic brain injury; S100B	MINOR HEAD-INJURY; NEURON-SPECIFIC ENOLASE; COMPUTED-TOMOGRAPHY; MULTIPLE TRAUMA; S-100B; DAMAGE; ALCOHOL; MARKER; MULTICENTER; EMERGENCY	Background and purpose: Neuronal protein S100B assays are available now with a perspective of being an early screening tool for serious intracranial injury. The aim of the study was to correlate early S100B measurements and initial CCT findings in the patients sustaining mild traumatic brain injury (MTBI). Methods: The prospective study included patients of all ages with a history of MTBI. CCT scans and venous blood sampling for S100B analysis were performed within 6 h after injury. Levels of S100B above 0.1 ng/ml (S100B+) and any CCT detectable trauma-relevant intracranial lesions were considered positive (CCT+). Results: A series of 102 patients were involved in the study. CCT+ scans were present in eighteen (17.6%) and CCT- scans in 84 (82.4%) patients. There were 74 (72.5%) patients in S100B+ and 28 (27.5%) in S100B- group. Sensitivity of S100B assay attained 83.3% with a negative predictive value of 89.3%. Three patients from CCT+ group had negative plasma level of S100B. Two of them required surgical treatment. Discussion: S100B serum protein marker seems to be an unrealiable screening tool for determination of an intracranial injury risk group due to low sensitivity and negative predictive value seen from samples taken greater than 3 h after an MTBI.	[Morochovic, R.; Kitka, M.; Pingorova, S.; Cibur, P.] Safarik Univ, Dept Trauma Surg, Sch Med, Kosice 04190, Slovakia; [Racz, O.] Safarik Univ, Dept Pathophysiol, Sch Med, Kosice 04190, Slovakia; [Tomkova, D.] Fac Hosp L Pasteur, Dept Radiol, Rastislavova, Slovakia; [Lenartova, R.] Safarik Univ, Inst Med Chem Biochem & Clin Biochem, Sch Med, Kosice 04190, Slovakia	Morochovic, R (corresponding author), Safarik Univ, Dept Trauma Surg, Sch Med, Rastislavova 43, Kosice 04190, Slovakia.	rado17@post.sk		Racz, Oliver/0000-0002-4006-3394	Ministry of Education of the Slovak Republic (ME SR); Slovak Academy of Sciences (SAS) [1/4260/07]	This work was supported by the scientific grant agency of The Ministry of Education of the Slovak Republic (ME SR) and of The Slovak Academy of Sciences (SAS) No. 1/4260/07. We kindly thank Dr Dana Potocekova, and Dr Jozefina Petrovicova, PhD from The Institute of Medical Informatics, School of Medicine, University of P.J.Safarik, Kosice for statistical assistance and Carroll Christie for revising the manuscript.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2004, UNFALLCHIRURG, V107, P197, DOI 10.1007/s00113-004-0730-1; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Castellani C, 2008, CLIN CHEM LAB MED, V46, P1296, DOI 10.1515/CCLM.2008.262; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Enochsson L, 2005, EUR J NEUROL, V12, P445, DOI 10.1111/j.1468-1331.2005.00996.x; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Morochovic R, 2008, Rozhl Chir, V87, P279; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Mussack T, 2003, EUR J MED RES, V8, P457; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Mussack T, 2006, CLIN CHEM LAB MED, V44, P1140, DOI 10.1515/CCLM.2006.190; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	33	31	33	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	OCT	2009	16	10					1112	1117		10.1111/j.1468-1331.2009.02653.x			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	494HU	WOS:000269803300011	19469828				2021-06-18	
J	Lo, TYM; Jones, PA; Minns, RA				Lo, Tsz-Yan M.; Jones, Patricia A.; Minns, Robert A.			Pediatric Brain Trauma Outcome Prediction Using Paired Serum Levels of Inflammatory Mediators and Brain-Specific Proteins	JOURNAL OF NEUROTRAUMA			English	Article						adhesion molecules; brain-specific proteins; interleukins; outcome prediction; pediatric traumatic brain injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; GLASGOW COMA SCALE; CEREBROSPINAL-FLUID; YOUNG-CHILDREN; BIOMARKER CONCENTRATIONS; MULTIPLEX ASSESSMENT; INTERLEUKIN-6; SEVERITY; DAMAGE	Many potential brain trauma biomarkers have been reported, but no previous study has described outcome prediction using combinations of biomarker levels. We aimed to investigate the outcome predictive values of multiple biomarkers from different mediator families and to determine whether combinations of two serum biomarkers may achieve higher outcome predictive values than individual biomarker levels. A prospective observational study was conducted involving 28 children requiring intensive care management following brain trauma. Day 1 post-injury serum concentrations of eight different biomarkers-S100b protein (S100b), neuron-specific enolase (NSE), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), soluble intracellular adhesion molecule (SICAM), L-selectin, and endothelin-were quantified using enzyme-linked immunosorbent assay (ELISA). Global outcome was assessed at 6 months post-injury using the Glasgow Outcome Score (GOS). Receiver operator characteristic curve (ROC) analysis and its multivariate extension, Multivariate ROC (MultiROC), were used to assess the outcome predictive values of the individual and the paired biomarkers. None of the eight biomarkers assessed individually achieved an area under the ROC curve (AUC) of more than 0.95 for predicting unfavorable outcome, but five of the 20 biomarker pairs assessed had this high degree of outcome predictability. Two combinations using S100b as the "screening marker'' and either L-selectin or IL-6 as the "varying marker'' achieved an AUC of 0.98, and their specificity and sensitivity for unfavorable outcome prediction were 96% and 100%, respectively. Prognostic pairs combining serum levels of two biomarkers (inflammatory mediators and brain-specific proteins) offer better outcome predictive values for unfavorable outcome after childhood brain trauma than may be achieved using individual marker levels.	[Lo, Tsz-Yan M.; Jones, Patricia A.; Minns, Robert A.] Univ Edinburgh, Edinburgh, Midlothian, Scotland	Lo, TYM (corresponding author), 218 Queens Quay W,Suite 2504, Toronto, ON M5J 2Y6, Canada.	mils.lo@doctors.org.uk					Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Ergun R, 1998, NEUROL RES, V20, P418; FACCO E, 1986, CHILD NERV SYST, V2, P67; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Ponsky TA, 2005, J TRAUMA, V59, P1292, DOI 10.1097/01.ta.0000197439.19171.25; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SHULTZ EK, 1995, CLIN CHEM, V41, P1248; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Suominen P, 1998, INJURY, V29, P425; Takahashi H, 1989, Neurol Med Chir (Tokyo), V29, P192, DOI 10.2176/nmc.29.192; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WALKER PJ, 1987, AUST NZ J SURG, V57, P715, DOI 10.1111/j.1445-2197.1987.tb01249.x; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yang Yunmei, 2002, Chin J Traumatol, V5, P259	53	31	37	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1479	1487		10.1089/neu.2008.0753			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200005	19275469				2021-06-18	
J	Lenhardt, R; Orhan-Sungur, M; Komatsu, R; Govinda, R; Kasuya, Y; Sessler, DI; Wadhwa, A				Lenhardt, Rainer; Orhan-Sungur, Mukadder; Komatsu, Ryu; Govinda, Raghavendra; Kasuya, Yusuke; Sessler, Daniel I.; Wadhwa, Anupama			Suppression of Shivering during Hypothermia Using a Novel Drug Combination in Healthy Volunteers	ANESTHESIOLOGY			English	Article							COMPUTER-CONTROLLED INFUSION; TRAUMATIC BRAIN-INJURY; ADULT HUMAN VOLUNTEERS; DEXMEDETOMIDINE HYDROCHLORIDE; ISOFLURANE ANESTHESIA; SWEATING THRESHOLD; ADDITIVELY REDUCE; SHORT-TERM; VASOCONSTRICTION; MEPERIDINE	Background: Hypothermia may be beneficial in stroke victims; however, it provokes vigorous shivering. Buspirone and dexmedetomidine each linearly reduce the shivering threshold with minimal sedation and no respiratory depression. This study tested the hypotheses that the combination of buspirone and dexmedetomidine would (1) synergistically reduce the shivering threshold, (2) synergistically reduce die gain and maximum intensity of shivering, and (3) produce sufficient inhibition to permit cooling to 34 degrees C without excessive hypotension or sedation. Methods: Eight healthy men were randomly assigned on 4 days to (1) no drug, (2) buspirone (60 mg orally), (3) dexmedetomidine (intravenous infusion to target plasma concentration of 0.6 ng/ml), or (4) combination of buspirone and dexmedetomidine at same doses. lactated Ringer's solution (approximately 3 degrees C) was infused intravenously to decrease tympanic membrane temperature by 1.5 degrees C/h. Shivering threshold was defined as an increase in oxygen consumption greater than 20%. Sedation was evaluated using the Observer's Assessment of Sedation/Alertness scale. Results: Mean arterial pressure and heart rate were slightly lower on dexmedetomidine and combination days. Likewise, the level of sedation was statistically different on these 2 days but clinically unimportant. Buspirone reduced the shivering threshold from 36.6 degrees C +/- 0.4 degrees C to 35.9 degrees C +/- 0.4 degrees C, dexmedetomidine reduced it to 34.7 degrees C +/- 0.5 degrees C, and the combination to 34.1 +/- 0.4 degrees C. The interaction effect of 0.04 degrees C was not significant. The gain of shivering and maximum shivering intensity were similar on each day. Conclusions: The combination of buspirone and dexmedetomidine additively reduced the shivering threshold. Thus, supplementing dexmedetomidine with buspirone blocks shivering and causes only minimal sedation.	Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA; Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA	Lenhardt, R (corresponding author), Univ Hosp, Dept Anesthesiol, 530 S Jackson St, Louisville, KY 40202 USA.	lenhardt@louisville.edu	wadhwa, Anupama/AAO-2571-2020; Sessler, Daniel/D-3504-2011; Sungur, Mukadder Orhan/A-6574-2017	wadhwa, Anupama/0000-0002-4655-0169; Sessler, Daniel/0000-0001-9932-3077; Sungur, Mukadder Orhan/0000-0002-0770-8904	Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, Kentucky; Department of Outcomes Research, The Cleveland Clinic, Cleveland, Ohio; National Institutes of Health, Bethesda, MarylandUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [061655]; Joseph Drown Foundation, Los Angeles, California; Gheen's Foundation, Louisville, Kentucky; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM061655] Funding Source: NIH RePORTER	Received from the Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, Kentucky, and the Department of Outcomes Research, The Cleveland Clinic, Cleveland, Ohio. Submitted for publication July 9, 2008. Accepted for publication December 17, 2008. Dr. Orhan-Sungur's current position: Attending Physician, Department of Anesthesia, Istanbul University, Istanbul, Turkey; Dr. Komatsu's current position: Clinical Instructor, Department of Anesthesiology, Tokyo Women's Medical University, Tokyo, Japan. Funded by GM 061655 from the National Institutes of Health, Bethesda, Maryland (to Dr. Sessler), the Joseph Drown Foundation, Los Angeles, California, and the Gheen's Foundation, Louisville, Kentucky. Mallinckrodt Anesthesiology Products, Inc., St. Louis, Missouri, donated the thermocouples we used.	ARMSTRONG PJ, 1986, ANESTH ANALG, V65, P536; BARNARD MS, 1973, S AFR MED J, V47, P469; Campbell K, 2008, BRAIN RES, V1230, P258, DOI 10.1016/j.brainres.2008.06.110; Chenzbraun A, 1995, J Am Soc Echocardiogr, V8, P1, DOI 10.1016/S0894-7317(05)80351-7; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; DYCK JB, 1993, ANESTHESIOLOGY, V78, P813, DOI 10.1097/00000542-199305000-00002; DYCK JB, 1993, ANESTHESIOLOGY, V78, P821, DOI 10.1097/00000542-199305000-00003; Hemmen TM, 2007, STROKE, V38, P794, DOI 10.1161/01.STR.0000247920.15708.fa; Hoehn T, 2008, RESUSCITATION, V78, P7, DOI 10.1016/j.resuscitation.2008.04.027; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jacobs S, 2007, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003311.PUB2; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; Kimberger O, 2007, CRIT CARE, V11, DOI 10.1186/cc5709; Kollmar R, 2007, STROKE, V38, P1585, DOI 10.1161/STROKEAHA.106.475897; KURZ A, 1995, ANESTHESIOLOGY, V83, P293, DOI 10.1097/00000542-199508000-00009; Lamberg TS, 1998, CLIN PHARMACOL THER, V63, P640, DOI 10.1016/S0009-9236(98)90087-X; Lee SH, 2008, J NEUROL SCI, V275, P18, DOI 10.1016/j.jns.2008.05.024; LESLIE K, 1994, ANESTHESIOLOGY, V81, P353, DOI 10.1097/00000542-199408000-00013; Leslie K, 1996, ANESTHESIOLOGY, V84, P52, DOI 10.1097/00000542-199601000-00006; LOPEZ M, 1994, ANESTHESIOLOGY, V80, P780, DOI 10.1097/00000542-199404000-00009; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P1169, DOI 10.1097/00000542-199505000-00012; MERILAINEN PT, 1987, INT J CLIN MONIT COM, V4, P167, DOI 10.1007/BF02915904; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; SESSLER DI, 1991, ANESTHESIOLOGY, V75, P985, DOI 10.1097/00000542-199112000-00010; SESSLER DI, 1992, ANESTHESIOLOGY, V76, P670, DOI 10.1097/00000542-199205000-00002; SHAFER SL, 1992, J PHARMACOKINET BIOP, V20, P147, DOI 10.1007/BF01070999; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Slinker BK, 1998, J MOL CELL CARDIOL, V30, P723, DOI 10.1006/jmcc.1998.0655; Sterz Fritz, 2006, Acute Card Care, V8, P25, DOI 10.1080/14628840600621371; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017; TALLARIDA RJ, 1989, LIFE SCI, V45, P947, DOI 10.1016/0024-3205(89)90148-3; Tayefeh F, 1998, PFLUG ARCH EUR J PHY, V435, P402, DOI 10.1007/s004240050530; TISSOT S, 1995, INTENS CARE MED, V21, P149, DOI 10.1007/BF01726538; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; WEYLAND A, 1994, ANAESTHESIST, V43, P658; Wilson TE, 2007, J APPL PHYSIOL, V103, P1257, DOI 10.1152/japplphysiol.00401.2007; Xiong JY, 1996, ANESTHESIOLOGY, V85, P240, DOI 10.1097/00000542-199608000-00003; ZEISBERGER E, 1996, HDB PHYSL 4, P579	40	31	34	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUL	2009	111	1					110	115		10.1097/ALN.0b013e3181a979a3			6	Anesthesiology	Anesthesiology	462IY	WOS:000267346200019	19512867	Bronze			2021-06-18	
J	Stiver, SI; Gean, AD; Manley, GT				Stiver, Shirley I.; Gean, Alisa D.; Manley, Geoffrey T.			Survival with good outcome after cerebral herniation and Duret hemorrhage caused by traumatic brain injury Case report	JOURNAL OF NEUROSURGERY			English	Article						intracranial hypertension; outcome; traumatic brain injury; traumatic brainstem hemorrhage	PONTINE HEMORRHAGE; STEM HEMORRHAGE; HEAD-INJURY; CT; DISTORTION; SECONDARY; RECOVERY; LESIONS; DAMAGE	ZBrainstem hemorrhage can occur as a primary or secondary event in traumatic brain injury (TBI). Secondary brainstem hemorrhage that evolves from raised intracranial pressure and transtentorial herniation is referred to as Duret hemorrhage. Duret hemorrhage following TBI has been considered an irreversible and terminal event. The authors report on the case of a young adult patient with TBI who presented with a low Glasgow Coma Scale score and advanced signs of cerebral herniation. She underwent an urgent decompressive hemicraniectomy for evacuation of an acute epidural hematoma and developed a Duret hemorrhage postoperatively. In accordance with the family's wishes, aggressive TBI monitoring and treatment in the intensive care unit was continued even though the anticipated outcome was poor. After a lengthy hospital course, the patient improved dramatically and was discharged ambulatory, with good cognitive functioning and a Glasgow Outcome Scale score of 4. Duret hemorrhage secondary to raised intracranial pressure is not always a terminal event, and by itself should not trigger a decision to withdraw care. Aggressive intracranial monitoring and treatment of a Duret hemorrhage arising secondary to cerebral herniation may enable a good recovery in selected patients after severe TBI. (DOI: 10.3171/2008.8.JNS08314)	[Stiver, Shirley I.; Gean, Alisa D.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94110 USA; [Gean, Alisa D.] Univ Calif San Francisco, Sch Med, Dept Radiol, San Francisco, CA 94110 USA; [Stiver, Shirley I.; Gean, Alisa D.; Manley, Geoffrey T.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA	Stiver, SI (corresponding author), Univ Calif San Francisco, Dept Neurosurg, 1001 Potrero Ave,Room 101, San Francisco, CA 94110 USA.	sstiver@neurosurg.ucsf.edu					ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Andeweg J, 1999, NEURORADIOLOGY, V41, P233, DOI 10.1007/s002340050739; BRENDLER SJ, 1970, BRAIN, V93, P381, DOI 10.1093/brain/93.2.381; CAPLAN LR, 1977, ANN NEUROL, V1, P587, DOI 10.1002/ana.410010613; Dziewas R, 2003, CEREBROVASC DIS, V16, P224, DOI 10.1159/000071120; FREEDMAN H, 1952, J NEUROSURG, V9, P52, DOI 10.3171/jns.1952.9.1.0052; FREYTAG E, 1963, ARCH PATHOL, V75, P402; Fujimoto Y, 2000, NEUROL MED-CHIR, V40, P508, DOI 10.2176/nmc.40.508; Gean A, 1994, IMAGING HEAD TRAUMA; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; HOWELL DA, 1961, ARCH NEUROL-CHICAGO, V4, P572, DOI 10.1001/archneur.1961.00450110102010; Kamijo Y, 2005, AM J EMERG MED, V23, P908, DOI 10.1016/j.ajem.2005.07.014; KLINTWOR.GK, 1965, AM J PATHOL, V47, P525; Lindenberg R, 1964, Clin Neurosurg, V12, P129; Marupaka SK, 2008, EMERG MED AUSTRALAS, V20, P180, DOI 10.1111/j.1742-6723.2008.01072.x; MEYER CA, 1991, RADIOLOGY, V179, P813, DOI 10.1148/radiology.179.3.2027997; Parizel PM, 2002, INTENS CARE MED, V28, P85, DOI 10.1007/s00134-001-1160-y; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Rabinstein AA, 2004, CEREBROVASC DIS, V17, P66, DOI 10.1159/000073900; THOMPSON RK, 1988, NEUROSURGERY, V22, P629, DOI 10.1227/00006123-198804000-00002; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; TSAI FY, 1980, AM J ROENTGENOL, V134, P717, DOI 10.2214/ajr.134.4.717; WEINSTEI.JD, 1968, J NEUROSURG, V28, P513, DOI 10.3171/jns.1968.28.6.0513; ZUCCARELLO M, 1983, ACTA NEUROCHIR, V67, P103, DOI 10.1007/BF01401670	27	31	34	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUN	2009	110	6					1242	1246		10.3171/2008.8.JNS08314			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	451HH	WOS:000266460800020	19012479				2021-06-18	
J	Ahmed, N; Bialowas, C; Kuo, YH; Zawodniak, L				Ahmed, Nasim; Bialowas, Christie; Kuo, Yen-Hong; Zawodniak, Leonard			Impact of Preinjury Anticoagulation in Patients with Traumatic Brain Injury	SOUTHERN MEDICAL JOURNAL			English	Article						aspirin; clopidogrel bisulfate; head injury; heparin; warfarin	HEAD-INJURY; INTRACRANIAL HEMORRHAGE; ELDERLY-PATIENTS; WARFARIN USE; ASPIRIN; RISK; CLOPIDOGREL; MORTALITY; INCREASE; AGE	'Introduction: This study was undertaken to examine the impact of various anticoagulation agents in head injury patients. Methods: The medical records and trauma registry were used to analyze the data. All adult trauma patients using aspirin, clopidogrel bisulfate (Plavix (R)), warfarin (Coumadin (R)), or heparin and admitted to the hospital with computed tomography (CT) scan evidence of brain injuries were included in the study. Patients were classified into three groups based on medication used. Results: From July 2004 through December 2006, 29 patients admitted to the trauma center were found to be on anticoagulation or antiplatelet agents. The control group consisted of 63 patients with CT evidence of head injury not on antiplatelet or anticoagulant medications. There were no significant differences among the groups regarding age, gender, Glasgow Coma Scale, Injury Severity Score, mortality (P = 0.65), ventilator days (P = 0.69), intensive care unit (ICU) days (P = 0.65), total hospital days (P = 0.41) or discharge disposition (P = 0.65). Conclusion: Prehead injury anticoagulation did not have any significant impact on outcomes.	[Ahmed, Nasim] Jersey Shore Univ, Dept Surg, Div Trauma & Surg Crit Care, Med Ctr, Neptune, NJ 07754 USA; Monmouth Med Ctr, Long Branch, NJ USA	Ahmed, N (corresponding author), Jersey Shore Univ, Dept Surg, Div Trauma & Surg Crit Care, Med Ctr, 1945 State Route 33, Neptune, NJ 07754 USA.	nahmed@meridianhealth.com					Ajani UA, 2006, AM J PREV MED, V30, P74, DOI 10.1016/j.amepre.2005.08.042; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Parris R, 2007, EMERG MED J, V24, P435, DOI 10.1136/emj.2007.049528; Serebruany VL, 2003, AM HEART J, V146, P713, DOI 10.1016/S0002-8703(03)00260-6; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Wahl WL, 2001, J TRAUMA, V51, P1151; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	12	31	31	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0038-4348			SOUTH MED J	South.Med.J.	MAY	2009	102	5					476	480		10.1097/SMJ.0b013e31819f97a3			5	Medicine, General & Internal	General & Internal Medicine	445KI	WOS:000266049300013	19373146				2021-06-18	
J	Robinson, RG; Jorge, RE; Clarence-Smith, K; Starkstein, S				Robinson, Robert G.; Jorge, Ricardo E.; Clarence-Smith, Kathleen; Starkstein, Sergio			Double-Blind Treatment of Apathy in Patients with Poststroke Depression Using Nefiracetam	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; MOOD DISORDERS; STROKE; AMANTADINE; VALIDITY; RATS; RELIABILITY; DYSFUNCTION; MECHANISMS	Nefiracetam is a novel pyrrolidone-type nootropic compound shown in preliminary trials to increase blood flow and improve patient outlook and energy following stroke. Of 137 stroke patients with major depression, 70 also met published diagnostic criteria for apathy (51.1%) and were randomly assigned either to placebo or 600 mg or 900 mg of nefiracetam per day, and received at least 4 weeks of treatment. Using the group with at least 4 weeks of treatment as the intention-to-treat sample with last observation carried forward, repeated measures analysis of variance of Apathy Scale scores demonstrated a significant time-by-treatment interaction. Patients taking 900 mg nefiracetam had a significantly greater change in Apathy Scale scores compared to 600 mg of nefiracetam or placebo. Future studies should assess whether apathy without depression may respond to this novel treatment.	[Robinson, Robert G.; Jorge, Ricardo E.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA; [Clarence-Smith, Kathleen] Prestwick Sci Capital, Washington, DC USA; [Starkstein, Sergio] Univ Western Australia, Dept Psychiat, Perth, WA 6009, Australia	Robinson, RG (corresponding author), Univ Iowa, Dept Psychiat, Carver Coll Med, 200 Hawkins Dr, Iowa City, IA 52242 USA.	robert-robinson@uiowa.edu	Robinson, Robert/AAF-6191-2021				American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ando T, 2005, EUR J PHARMACOL, V507, P49, DOI 10.1016/j.ejphar.2004.11.033; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Beck AT., 1987, DEPRESSION INVENTORY; Cummings Jeffrey L, 2005, Am J Geriatr Pharmacother, V3, P137, DOI 10.1016/S1543-5946(05)80020-0; Forer S., 1987, FUNCTIONAL INDEPENDE; Freo U, 2002, J NEURAL TRANSM, V109, P857, DOI 10.1007/s007020200070; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HOUSE A, 1990, BRAIN, V113, P1113, DOI 10.1093/brain/113.4.1113; Jin JJ, 2002, PHARMACOLOGY, V64, P119, DOI 10.1159/000056160; Kalivas PW, 2005, NEURON, V45, P647, DOI 10.1016/j.neuron.2005.02.005; Kitano Y, 2005, EPILEPSIA, V46, P1561, DOI 10.1111/j.1528-1167.2005.00261.x; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; KRAUS MF, 1995, INT J PSYCHIAT MED, V25, P39, DOI 10.2190/BXRM-3M58-WBC5-A7EL; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; Levy R, 2006, CEREB CORTEX, V16, P916, DOI 10.1093/cercor/bhj043; Marin RA, 2005, TXB TRAUMATIC BRAIN, P337; MARIN RS, 1993, J AFFECT DISORDERS, V28, P117, DOI 10.1016/0165-0327(93)90040-Q; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Moriguchi S, 2003, J PHARMACOL EXP THER, V307, P160, DOI 10.1124/jpet.103.050823; Moriguchi S, 2007, MOL PHARMACOL, V71, P580, DOI 10.1124/mol.106.027607; Narahashi T, 2004, BIOL PHARM BULL, V27, P1701, DOI 10.1248/bpb.27.1701; Newburn G, 2005, BRAIN INJURY, V19, P149, DOI 10.1080/02699050410001719989; Nishizaki T, 1998, MOL PHARMACOL, V53, P1; Okada K, 1997, STROKE, V28, P2437, DOI 10.1161/01.STR.28.12.2437; OTOMO E, 1994, RINSHO IYAKU, V10, P1871; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; ROBINSON RG, 1983, STROKE, V14, P736, DOI 10.1161/01.STR.14.5.736; Robinson RG, 2008, JAMA-J AM MED ASSOC, V299, P2391, DOI 10.1001/jama.299.20.2391; Sartorius N, 1974, MEASUREMENT CLASSIFI; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Starkstein SE, 2001, AM J PSYCHIAT, V158, P872, DOI 10.1176/appi.ajp.158.6.872; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Tsuchiya Y, 2003, EUR J PHARMACOL, V475, P119, DOI 10.1016/S0014-2999(03)02123-X; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; Watanabe A, 2003, J NEUROPSYCH CLIN N, V15, P442, DOI 10.1176/appi.neuropsych.15.4.442; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Yamagata S, 2004, STROKE, V35, P1935, DOI 10.1161/01.STR.0000135017.51144.c9; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014; Zhao XL, 2001, ANN NY ACAD SCI, V939, P179	45	31	32	0	6	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	MAY	2009	21	2					144	151					8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	472SL	WOS:000268152300005	19622685				2021-06-18	
J	Yan, W; Wang, HD; Feng, XM; Ding, YS; Jin, W; Tang, K				Yan, Wei; Wang, Han-Dong; Feng, Xiao-Mei; Ding, Ya-Suo; Jin, Wei; Tang, Ke			The Expression of NF-E2-Related Factor 2 in the Rat Brain After Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						NF-E2-related factor 2; Traumatic brain injury; Expression; Brain	RESPONSIVE ELEMENT; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; HEME OXYGENASE-1; IN-VIVO; NRF2; INDUCTION; PROTECTS; NEUROPROTECTION; PATHWAY	Background: Secondary brain damage plays a critical role in the outcome of patients with traumatic brain injury (TBI). The mechanisms underlying secondary brain damage are complex. A target that can interrupt multiple mechanisms underlying secondary brain damage may represent a promising new therapeutic approach for TBI. NF-E2-related factor 2 (Nrf2) is the key regulator in reducing oxidative stress, inflammatory damage, and the accumulation of toxic metabolites, which are all involved in secondary brain damage after TBI. Therefore, Nrf2 might represent a new direction for the treatment of TBI. However, the expression pattern of Nrf2 after TBI has not yet been studied. Methods: This study involved the detection of Nrf2 mRNA levels by reverse-transcriptase polymerase chain reaction, and its nuclear protein levels by Western blot from 3 hour to 72 hour after TBI. Nrf2 distribution in the brain after TBI was also investigated by immunohistochemistry. Results: After TBI, the nuclear Nrf2 protein level is significantly increased, whereas its mRNA level remains unchanged. Increased Nrf2 immunostaining was detected not only in the vulnerable regions but also in the brain barrier system. Conclusion: Nrf2 might play a protective role in the brain after TBI, possibly by reducing oxidative stress and brain edema.	[Wang, Han-Dong] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; Nanjing Univ, Sch Med, Jinling Hosp, Dept Anesthesiol, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.	njwanghd@gmail.com		Yan, Wei/0000-0002-1123-0835			Campagne MV, 2000, J NEUROSCI, V20, P5200, DOI 10.1523/JNEUROSCI.20-14-05200.2000; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chen J, 2005, CURR NEUROVASC RES, V2, P189, DOI 10.2174/1567202054368344; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Ramsey CP, 2007, J NEUROPATH EXP NEUR, V66, P75, DOI 10.1097/nen.0b013e31802d6da9; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; STEARDO L, 1987, SCIENCE, V235, P470, DOI 10.1126/science.2879355; Tanito M, 2007, FREE RADICAL BIO MED, V42, P1838, DOI 10.1016/j.freeradbiomed.2007.03.018; Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; TREVISANI GT, 1994, J TRAUMA, V37, P452, DOI 10.1097/00005373-199409000-00021; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	26	31	33	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2009	66	5					1431	1435		10.1097/TA.0b013e318180f5c7			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	445AJ	WOS:000266021700031	19430250				2021-06-18	
J	Rochkind, S; El-Ani, D; Nevo, Z; Shahar, A				Rochkind, Shimon; El-Ani, Dalia; Nevo, Zvi; Shahar, Abraham			Increase of Neuronal Sprouting and Migration Using 780 nm Laser Phototherapy as Procedure for Cell Therapy	LASERS IN SURGERY AND MEDICINE			English	Article						axonal sprouting; cross-linked hyaluronic acid with laminin gel; embryonic nerve cells; low power laser irradiation; microcarriers	HE-NE-LASER; TRAUMATIC PARAPLEGIA; IRRADIATION ALTERS; NERVE; GROWTH; REGENERATION; RECOVERY	Background and Objectives: The present study focuses on the effect. of 780 nm laser irradiation on the growth of embryonic rat brain cultures embedded in NVR-Gel (crosslinked hyaluronic acid with adhesive molecule laminin and several growth factors). Dissociated neuronal cells were first grown in suspension attached to cylindrical microcarriers (MCs). The formed floating cell-MC aggregates were subsequently transferred into stationary cultures in gel and then laser treated. The response of neuronal growth following laser irradiation was investigated. Materials and Methods: Whole brains were dissected from 16 days Sprague-Dawley rat embryos. Cells were mechanically dissociated, using narrow pipettes, and seeded on positively charged cylindrical MCs. After 414 days in suspension, the formed floating cell-MC aggregates were seeded as stationary cultures in NVR-Gel. Single cell-MC aggregates were either irradiated with near-infrared 780 nm laser beam for 1, 4, or 7 minutes, or cultured without irradiation. Laser powers were 10, 30, 50, 110, 160, 200, and 250 mW. Results: 781) nm laser irradiation accelerated fiber sprouting and neuronal cell migration from the aggregates. Furthermore, unlike control cultures, the irradiated cultures (mainly after I minute irradiation of 50 mW) were already established after a short time of cultivation. They contained a much higher number of large size neurons (P<0.01), which formed dense branched interconnected networks of thick neuronal fibers. Conclusions:780 nm laser phototherapy of embryonic rat brain cultures embedded in hyaluronic acid-laminin gel and attached to positively charged cylindrical MCs, stimulated migration and fiber sprouting of neuronal cells aggregates, developed large size neurons with dense branched interconnected network of neuronal fibers and, therefore, can tie considered as potential procedure for cell therapy of neuronal injury or disease. Lasers Surg. Med. 41:277-281, 2009. (C) 2009 Wiley-Liss, Inc.	[Rochkind, Shimon] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Peripheral Nerve Reconstruct, IL-64239 Tel Aviv, Israel; [El-Ani, Dalia; Nevo, Zvi; Shahar, Abraham] NVR Labs, IL-74031 Ness Ziona, Israel	Rochkind, S (corresponding author), Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Peripheral Nerve Reconstruct, Weizman St, IL-64239 Tel Aviv, Israel.	rochkind@zahav.net.il	Rochkind, Shimon/AAO-6447-2020	Shahar, Abraham/0000-0003-4894-2593			ANDERS JJ, 1993, LASER SURG MED, V13, P72, DOI 10.1002/lsm.1900130113; Byrnes KR, 2005, LASER SURG MED, V37, P161, DOI 10.1002/lsm.20202; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; CAMU W, 1992, J NEUROSCI METH, V44, P59, DOI 10.1016/0165-0270(92)90114-S; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Ehrlicher A, 2002, P NATL ACAD SCI USA, V99, P16024, DOI 10.1073/pnas.252631899; Gigo-Benato D, 2004, LASER MED SCI, V19, P57, DOI 10.1007/s10103-004-0300-3; JONES TA, 1994, J NEUROSCI, V14, P2140; ROCHKIND S, 1987, LASER SURG MED, V7, P441, DOI 10.1002/lsm.1900070512; Rochkind S, 2006, EUR SPINE J, V15, P234, DOI 10.1007/s00586-005-0981-8; ROCHKIND S, 1988, ACTA NEUROCHIR, V94, P74, DOI 10.1007/BF01406620; Rochkind S, 2002, NEUROL RES, V24, P355, DOI 10.1179/016164102101200131; ROCHKIND S, 1990, SPINE, V15, P6, DOI 10.1097/00007632-199001000-00003; ROCHKIND S, 1987, NEUROSURGERY, V20, P843, DOI 10.1227/00006123-198706000-00004; ROCHKIND S, 1992, Neurological Research, V14, P2; ROCHKIND S, 1978, MORPHOG REGEN, V83, P48; SHAHAR A, 1990, METHODS NEUROSCI, V2, P195; Shin DH, 2003, NEUROSCI LETT, V344, P71, DOI 10.1016/S0304-3940(03)00354-9; Snyder SK, 2002, LASER SURG MED, V31, P216, DOI 10.1002/lsm.10098; Solecki DJ, 2004, NAT NEUROSCI, V7, P1195, DOI 10.1038/nn1332; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; VANBREUGEL HHFI, 1993, J NEUROCYTOL, V22, P185, DOI 10.1007/BF01246357; Wollman Y, 1996, NEUROL RES, V18, P467; Wollman Y, 1998, NEUROL RES, V20, P470	24	31	36	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0196-8092	1096-9101		LASER SURG MED	Lasers Surg. Med.	APR	2009	41	4					277	281		10.1002/lsm.20757			5	Dermatology; Surgery	Dermatology; Surgery	436HS	WOS:000265404000005	19347939				2021-06-18	
J	Horn, S; Gregory, P; Guskiewicz, KM				Horn, Scott; Gregory, Patricia; Guskiewicz, Kevin M.			Self-Reported Anabolic-Androgenic Steroids Use and Musculoskeletal Injuries	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Anabolic Agents; Football; Ligaments; Musculoskeletal System	PROFESSIONAL FOOTBALL; RUPTURE; TENDON; CONCUSSION; EPIDEMIOLOGY; PATTERNS; STRENGTH; EXERCISE; TRICEPS; PLAYERS	Objective: The relationship between musculoskeletal injuries and anabolic-androgenic steroids is not well understood. The purpose of our study was to investigate the association between self-reported anabolic-androgenic steroids use and the prevalence of musculoskeletal injuries in a unique group of retired professional football players. Design: A general health questionnaire was completed by 2552 retired professional football players. Survey data were collected between May 2001 and April 2003. Results of self-reported musculoskeletal injuries were compared with the use of anabolic-androgenic steroids using frequency distributions and X-2 analyses. Results: Of the retired players, 9.1% reported using anabolic-androgenic steroids during their professional career. A total of 16.3% of all offensive line and 14.8% of all defensive line players reported using anabolic-androgenic steroids. Self-reported anabolic-androgenic steroids use was significantly associated (P < 0.05) with the following self-reported, medically diagnosed, joint and cartilaginous injuries in comparison with the nonanabolic-androgenic steroids users: disc herniations, knee ligamentous/meniscal injury, elbow injuries, neck stinger/burner, spine injury, and foot/toe/ankle injuries. There was no association between anabolic-androgenic steroids use and reported muscle/tendon injuries. Conclusions: Our findings demonstrate that an association may exist between anabolic-androgenic steroids use and the prevalence of reported musculoskeletal injury sustained during a professional football career, particularly ligamentous/joint-related injuries. There may also be an associated predisposition to selected types of injuries in anabolic-androgenic steroids users.	[Horn, Scott; Gregory, Patricia] Univ N Carolina, Dept Phys Med & Rehabil, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA	Horn, S (corresponding author), 20 Porters Glen Pl, Durham, NC 27713 USA.			Guskiewicz, Kevin/0000-0002-8682-2130			Albright JP, 2004, AM J SPORT MED, V32, P1394, DOI 10.1177/0363546504264159; BACH BR, 1987, AM J SPORT MED, V15, P285, DOI 10.1177/036354658701500319; Brophy RH, 2007, MED SCI SPORT EXER, V39, P22, DOI 10.1249/01.mss.0000241637.52231.18; BROWER KJ, 1991, BRIT J ADDICT, V86, P759; Centers for Disease Control and Prevention, 2007, BEH RISK FACT SURV S; Cohen SB, 2007, AM J SPORT MED, V35, P442, DOI 10.1177/0363546506295082; Courson S., 1991, FALSE GLORY; DAVID HG, 1995, J BONE JOINT SURG BR, V77B, P159; Evans NA, 1998, INJURY, V29, P769, DOI 10.1016/S0020-1383(98)00183-1; FAIR JD, 1999, MUSCLETOWN USA BOB H; FRIEDL KE, 1991, J STEROID BIOCHEM, V40, P607, DOI 10.1016/0960-0760(91)90283-B; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hartgens F, 2004, SPORTS MED, V34, P513, DOI 10.2165/00007256-200434080-00003; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI 10.1001/archpsyc.62.10.1097; HERRICK RT, 1987, AM J SPORT MED, V15, P514, DOI 10.1177/036354658701500517; HERVEY GR, 1981, CLIN SCI, V60, P457, DOI 10.1042/cs0600457; HILL JA, 1983, AM J SPORT MED, V11, P269, DOI 10.1177/036354658301100417; Hoffman JR, 2006, J SPORT SCI MED, V5, P182; JOHNSON W, 1985, STEROIDS PROBLEM HUG; KRAMHOFT M, 1986, J HAND SURG-BRIT EUR, V11B, P87, DOI 10.1016/0266-7681(86)90022-7; LASETER JT, 1991, MED SCI SPORT EXER, V23, P1; LIOW RYL, 1995, BRIT J SPORT MED, V29, P77, DOI 10.1136/bjsm.29.2.77; LOUGHTON SJ, 1977, J SPORT MED PHYS FIT, V17, P285; McDuff DR, 2005, CLIN SPORT MED, V24, P885, DOI 10.1016/j.csm.2005.06.004; MICHELSEN CB, 1982, J TRAUMA, V22, P410, DOI 10.1097/00005373-198205000-00011; MICHNA H, 1987, INT ORTHOP, V11, P157; MILES JW, 1992, J BONE JOINT SURG AM, V74A, P411, DOI 10.2106/00004623-199274030-00013; Millman RB, 2003, AM J ADDICTION, V12, pS48, DOI 10.1080/10550490390210100; *NAT I DRUG AB, 2006, MON FUT STUD TRENDS; *NCAA, 2001, NCAA STUD SUBST AB H; *NCAA, 2006, NCAA DRUG TEST 2004; Nicholas SJ, 2007, AM J SPORT MED, V35, P1674, DOI 10.1177/0363546507302219; O'SHEA J P, 1971, Nutrition Reports International, V4, P363; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; SPSS, 2007, SPSS WIND REL 16 0; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; VISURI T, 1994, MED SCI SPORT EXER, V26, P941; WOOD TO, 1988, AM J SPORT MED, V16, P153, DOI 10.1177/036354658801600211; Young J, 2007, BRIT J SPORT MED, V41, P335, DOI 10.1136/bjsm.2006.030585	40	31	34	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR	2009	88	3					192	200		10.1097/PHM.0b013e318198b622			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	430XX	WOS:000265027000003	19847128				2021-06-18	
J	Anderson, MI; Simpson, GK; Morey, PJ; Mok, MMC; Gosling, TJ; Gillett, LE				Anderson, Malcolm I.; Simpson, Grahame K.; Morey, Peter J.; Mok, Magdalena M. C.; Gosling, Tamera J.; Gillett, Lauren E.			Differential pathways of psychological distress in spouses vs. parents of people with severe traumatic brain injury (TBI): Multi-group analysis	BRAIN INJURY			English	Article						Family; neurobehavioral; psychological; stress; traumatic brain injury	CAREGIVER BURDEN; LIFE SATISFACTION; FAMILY CAREGIVERS; PREDICTORS; RELATIVES; STRESS; MODEL; REHABILITATION; INDIVIDUALS; INDICATORS	Primary objective: A contemporary model of psychological stress based on an amalgamation of Conservation of Resources theory and the McMaster Model of Family Functioning was devised to compare the effects of neurobehavioural impairments on family functioning and psychological distress in spouses and parents caring for relatives with TBI. Method: Participants were 64 spouses and 58 parents. They completed the Neurobehavioral Problem Checklist, Family Assessment Device and the Brief Symptom Inventory. Structural equation modelling (SEM) was used to test the model for the combined (spouses and parents) sample. Multi-group analysis was then employed for examining differences in structural weights for spouses and parents. Main results: SEM supported the model for the combined sample. Multi-group analysis showed for spouses cognitive and behavioural impairments significantly disrupted family functioning, which in turn increased psychological distress. In contrast, cognitive and behavioural impairments did not significantly disrupt family functioning in parents. For parents, however, cognitive impairments increased psychological distress. Furthermore, parents who reported disrupted family functioning also experienced higher levels of psychological distress. The effect of cognitive impairments was statistically more influential on the level of distress in parents when compared to spouses. Conclusions: Understanding these differences can assist in better targeting family support interventions.	[Anderson, Malcolm I.; Gosling, Tamera J.] Avondale Coll, Fac Nursing & Hlth, Wahroonga, NSW 2076, Australia; [Simpson, Grahame K.; Gillett, Lauren E.] Liverpool Hlth Serv, Brain Injury Unit, Liverpool, NSW, Australia; [Morey, Peter J.] Avondale Coll, Fac Business & Informat Technol, Cooranbong, NSW, Australia; [Mok, Magdalena M. C.] Hong Kong Inst Educ, Ctr Assessment Res & Dev, Hong Kong, Hong Kong, Peoples R China	Anderson, MI (corresponding author), Avondale Coll, Fac Nursing & Hlth, Sydney Campus,185 Fox Valley Rd, Wahroonga, NSW 2076, Australia.	malcolm.anderson@avondale.edu.au	Mok, Magdalena M. C./G-1713-2017; Simpson, Grahame K/W-1074-2019	Mok, Magdalena M. C./0000-0002-6503-8152; Simpson, Grahame K/0000-0001-8156-9060; Anderson, Malcolm/0000-0003-2963-7497			AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; Anderson M. I., 2006, STRESS ITS IMPACT SO, P23; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; ARBUCKLE JL, 2006, AMOS 7 COMPUTER SOFT; Bentler P.M, 1980, PSYCHOL BULL, V107, P238; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; BISHOP DS, 1988, J HEAD TRAUMA REHAB, V3, P6; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; CAMPLAIR PS, 1989, THESIS VIRGINIA COMM; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Derogatis L, 1993, BRIEF SYMPTOM INVENT; Ding L, 1995, STRUCT EQU MODELING, V2, P119, DOI 10.1080/10705519509540000; Elliott G.R., 1982, STRESS HUMAN HLTH; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EPSTEIN NB, 1978, J MARRIAGE FAM COUNS, V4, P19, DOI 10.1111/j.1752-0606.1978.tb00537.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Flanagan DAJ, 1998, BRIT J CLIN PSYCHOL, V37, P431, DOI 10.1111/j.2044-8260.1998.tb01400.x; Frosch S, 1997, BRAIN INJURY, V11, P891; Gan C, 2002, BRAIN INJURY, V16, P311, DOI 10.1080/02699050110104426; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Ho R., 2006, HDB UNIVARIATE MULTI; Hobfoll S.E., 1992, J FAM PSYCHOL, V6, P99, DOI [10.1037/0893-3200.6.2.99, DOI 10.1037/0893-3200.6.2.99]; HOBFOLL SE, 1989, AM PSYCHOL, V44, P513, DOI 10.1037/0003-066X.44.3.513; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoyle R. H., 1995, STRUCTURAL EQUATION; Joreskog KG., 1993, LISREL 8 USERS REFER; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kosciulek JF, 1997, BRAIN INJURY, V11, P821, DOI 10.1080/026990597123034; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Laroi F, 2003, BRAIN INJURY, V17, P175, DOI 10.1080/0269905021000010140; Lazarus R. S., 1987, EUR J PERSONALITY, V1, P141, DOI 10.1002/per.2410010304; LEATHAM J, 1996, BRAIN INJURY, V10, P543; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MacCallum RC, 1997, MULTIVAR BEHAV RES, V32, P193, DOI 10.1207/s15327906mbr3202_5; Man DWK, 2002, BRAIN INJURY, V16, P1025, DOI 10.1080/0269905021000010087; Man DWK, 1998, BRAIN INJURY, V12, P245, DOI 10.1080/026990598122728; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Panting A., 1972, REHABILITATION, V38, P33; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; RICE VH, 2000, HDB STRESS COPING IM; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2007, NEUROREHABILITATION, V22, P9; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Stebbins P, 2001, REHABIL PSYCHOL, V46, P178, DOI 10.1037/0090-5550.46.2.178; TATE R, BRAIN INJURY OUTCOME; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; ZEIGLER EA, 1990, COGNITIVE REHABILITA, V8, P14	71	31	31	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	12					931	943		10.3109/02699050903302336			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	529YL	WOS:000272555200001	19831490				2021-06-18	
J	Ettenhofer, ML; Abeles, N				Ettenhofer, Mark L.; Abeles, Norman			The significance of mild traumatic brain injury to cognition and self-reported symptoms in long-term recovery from injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Mild head injury; Neurocognition; Postconcussive symptoms; Postconcussion syndrome	HEAD-INJURY; POSTCONCUSSION SYNDROME; DIAGNOSTIC-CRITERIA; DISABILITY; DEPRESSION; AWARENESS; ANXIETY; UTILITY; ADULTS	The aim of this study was to evaluate neurocognition and self-reported symptoms in long-term recovery from mild traumatic brain injury (mild TBI). Participants' time since injury ranged from 3 to 72 (M = 36.75) months. Relative to orthopedic injury controls (n = 63), mild TBI participants (n = 63) did not demonstrate cognitive impairment in any domains examined, or differences in self-report of postconcussive or psychiatric symptoms. However, postconcussive and psychiatric symptoms were strongly related (r = .50, p .05). Results provide additional evidence that neurological injury in single-incident mild TBI is of little clinical significance to long-term cognitive and symptom outcome.	[Ettenhofer, Mark L.] Univ Calif Los Angeles, Semel Inst, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Abeles, Norman] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA	Ettenhofer, ML (corresponding author), Univ Calif Los Angeles, Semel Inst, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,C8-746, Los Angeles, CA 90095 USA.	MEttenhofer@mednet.ucla.edu	Ettenhofer, Mark L./J-7171-2019	Ettenhofer, Mark L./0000-0001-9381-7578			Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Bigler ED, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P63; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Derogatis L., 1982, BRIEF SYMPTOM INVENT; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; FEE CRA, 1987, ARCH EMERG MED, V4, P159; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Heaton R., 1993, WISCONSIN CARD SORTI; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jeyakumar SLE, 2004, EDUC PSYCHOL MEAS, V64, P71, DOI 10.1177/0013164403258407; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P327; Lees-Haley PR, 2003, ARCH CLIN NEUROPSYCH, V18, P585; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Marschark M, 2000, J HEAD TRAUMA REHAB, V15, P1227, DOI 10.1097/00001199-200012000-00004; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilcox RR, 1998, BRIT J MATH STAT PSY, V51, P123, DOI 10.1111/j.2044-8317.1998.tb00670.x; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	58	31	31	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	3					363	372	PII 794907397	10.1080/13803390802175270			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	423QF	WOS:000264510100010	18618356				2021-06-18	
J	Hux, K; Schneider, T; Bennett, K				Hux, Karen; Schneider, Trish; Bennett, Keri			Screening for traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; screening; assessment; prevalence; identification	BATTERED WOMEN; DAMAGE; TBI	Primary objective: The researchers implemented a traumatic brain injury (TBI) screening procedure in settings likely to have relatively frequent contacts with survivors to better document TBI occurrence among populations at high-risk for under-identification. Methods and procedures: Professionals from four service agencies administered a TBI screening protocol to all incoming clients over a 6-month period. Main outcomes and results: Of the 1999 protocols collected, 531 (26.56%) were positive for a possible history of TBI of sufficient severity to impact quality of life. Memory challenges were the most common chronic complaint among individuals with positive screen results, with struggles with headaches, depression, concentration and anxiety also commonly reported. Conclusions: Large numbers of people seeking vocational rehabilitation, domestic abuse, homeless shelter or mental health services may experience persistent challenges stemming from unidentified TBIs. Identifying these individuals and the source of their challenges is important when developing intervention and supportive services. Using a TBI screening tool is one means of facilitating this identification process.	[Hux, Karen; Schneider, Trish] Univ Nebraska, Barkley Mem Ctr Special Educ & Commun Disorders, Lincoln, NE 68583 USA; [Bennett, Keri] Dept Vocat Rehabil, Lincoln, NE USA	Hux, K (corresponding author), Univ Nebraska, Barkley Mem Ctr 318N, Lincoln, NE 68583 USA.	khux1@unl.edu	Hux, Karen/AAQ-2078-2020		US Department of Health and Human Resources, Health Resources and Services Administration (HRSA)United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [H21MC06758]	Support for this research came in part from the TBI Partnership Implementation Grant #H21MC06758 from the US Department of Health and Human Resources, Health Resources and Services Administration (HRSA). The opinions expressed in this manuscript are those of the authors and do not necessarily reflect those of the Department of Education.	Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BRICKER DD, 1986, SPECIAL ED RES TREND, P28; BURTON TM, 2008, WALL ST J, pA1; Colantonio A, 2007, BRAIN INJURY, V21, P1353, DOI 10.1080/02699050701785054; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Gilchrist G, 2005, EUR J PUBLIC HEALTH, V15, P587, DOI 10.1093/eurpub/cki036; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; GUERRERO J, 2000, BRAIN INJURY, V14, P8; Hallahan D., 2003, EXCEPTIONAL LEARNERS; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Kaiser AP, 2000, BEHAV DISORDERS, V26, P26; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; *MICH DEP COMM HLT, ADDR MICH PUBL SERV; Monahan K, 1999, HEALTH SOC WORK, V24, P269, DOI 10.1093/hsw/24.4.269; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Picard M, 1991, HELPS TBI SCREENING; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; *US CENS BUR, 2008, STAT COUNTR QUICK FA; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009	26	31	31	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	1					8	14	PII 906994626	10.1080/02699050802590353			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	399FY	WOS:000262787000004	19096967				2021-06-18	
J	Monson, KL; Barbaro, NM; Manley, GT				Monson, Kenneth L.; Barbaro, Nicholas M.; Manley, Geoffrey T.			Biaxial Response of Passive Human Cerebral Arteries	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Cerebral artery properties; Mechanical testing; Traumatic brain injury; Head injury; Cerebrovascular disease	BLOOD-VESSELS; WALL; STRESSES; BEHAVIOR	The cerebral circulation is fundamental to the health and maintenance of brain tissue, but injury and disease may result in dysfunction of the vessels. Characterization of cerebral vessel mechanical response is an important step toward a more complete understanding of injury mechanisms and disease development in these vessels, paving the way for improved prevention and treatment. We recently reported a large series of uniaxial tests on fresh human cerebral vessels, but the multi-axial behavior of these vessels has not been previously described. Twelve arteries were obtained from the surface of the temporal lobe of patients undergoing surgery and were subjected to various combinations of axial stretch and pressure around typical physiological conditions before being stretched to failure. Axial and circumferential responses were compared, and measured data were fit to a four-parameter, Fung-type hyperelastic constitutive model. Artery behavior was nonlinear and anisotropic, with considerably greater resistance to deformation in the axial direction than around the circumference. Results from axial failure tests of pressurized vessels resulted in a small shift in stress-stretch response compared to previously reported data from unpressurized specimens. These results further define the biaxial response of the cerebral arteries and provide data required for more rigorous study of head injury mechanisms and development of cerebrovascular disease.	[Monson, Kenneth L.] Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA; [Monson, Kenneth L.; Barbaro, Nicholas M.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA	Monson, KL (corresponding author), Univ Utah, Dept Mech Engn, 50 S Cent Campus Dr,MEB 2132, Salt Lake City, UT 84112 USA.	ken.monson@mech.utah.edu	Monson, Ken/L-4702-2019	Monson, Ken/0000-0002-8461-6034	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE000460]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1K25HD 048643-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K25HD048643] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000460] Funding Source: NIH RePORTER	Funding for this study was provided by the Centers for Disease Control and Prevention (R49 CE000460) and the National Institutes of Health (1K25HD 048643-01A1). The authors would like to express their appreciation to the fellows and residents of the UCSF Neurosurgery Department, in particular Karl Sillay, M. D., and Paul House, M. D., who assisted in the surgical acquisition of tissue. We also greatly appreciate the help of Tyler Siebert and Aaron Rutman in tissue acquisition and transport.	ALCOLADO R, 1988, NEUROPATH APPL NEURO, V14, P1, DOI 10.1111/j.1365-2990.1988.tb00862.x; BUSBY DE, 1965, CAN J PHYSIOL PHARM, V43, P185, DOI 10.1139/y65-018; Chalupnik J. D., 1971, MAT PROPERTIES CEREB; CHUONG CJ, 1986, J BIOMECH ENG-T ASME, V108, P189, DOI 10.1115/1.3138600; Finkelstein E., 2006, INCIDENCE EC BURDEN, P187; FINLAY HM, 1995, J VASC RES, V32, P301, DOI 10.1159/000159104; Gleason RL, 2007, J BIOMECH, V40, P766, DOI 10.1016/j.jbiomech.2006.03.018; Graham DI, 1996, NEUROTRAUMA, P43; HAYASHI K, 1980, J BIOMECH, V13, P175, DOI 10.1016/0021-9290(80)90191-8; Holzapfel GA, 2000, J ELASTICITY, V61, P1, DOI 10.1023/A:1010835316564; Humphrey J. D., 2002, CARDIOVASCULAR SOLID, P757; HUMPHREY JD, 1986, MECH RES COMMUN, V13, P277, DOI 10.1016/0093-6413(86)90069-8; JANZ RF, 1989, BIOPHYS J, V55, P173, DOI 10.1016/S0006-3495(89)82789-4; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Monson KL, 2005, J BIOMECH, V38, P737, DOI 10.1016/j.jbiomech.2004.05.004; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; SAE, 1995, SAE HDB, P384; SCHULZE B, 2003, J BIOMED ENG, V125, P395, DOI DOI 10.1115/1.1574331; VAISHNAV RN, 1973, CIRC RES, V32, P577, DOI 10.1161/01.RES.32.5.577; WEIZSACKER HW, 1988, J BIOMECH, V21, P477, DOI 10.1016/0021-9290(88)90240-0	21	31	31	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	DEC	2008	36	12					2028	2041		10.1007/s10439-008-9578-9			14	Engineering, Biomedical	Engineering	372YC	WOS:000260937200009	18855141	Green Accepted			2021-06-18	
J	VanLandingham, JW; Cekic, M; Cutler, SM; Hoffman, SW; Washington, ER; Johnson, SJ; Miller, D; Stein, DG				VanLandingham, Jacob W.; Cekic, Milos; Cutler, Sarah M.; Hoffman, Stuart W.; Washington, Ebony R.; Johnson, Sarah J.; Miller, Darren; Stein, Donald G.			Progesterone and its metabolite allopregnanolone differentially regulate hemostatic proteins after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						allopregnanolone; coagulation; hemostasis; progesterone; traumatic brain injury	TISSUE-PLASMINOGEN ACTIVATOR; CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; PROCOAGULANT ACTIVITY; CATAMENIAL EPILEPSY; NEUROPROTECTION; RATS; THROMBIN; RECEPTOR; COAGULOPATHY	Our laboratory has shown in numerous experiments that the neurosteroids progesterone (PROG) and allopregnanolone ( ALLO) improve molecular and functional outcomes after traumatic brain injury (TBI). As coagulopathy is an important contributor to the secondary destruction of nervous tissue, we hypothesized that PROG and ALLO administration may also have a beneficial effect on coagulation protein expression after TBI. Adult male Sprague-Dawley rats were given bilateral contusions of the medial frontal cortex followed by treatments with PROG ( 16 mg/kg), ALLO ( 8 mg/kg), or vehicle (22.5% hydroxypropyl-beta-cyclodextrin). Controls received no injury or injections. Progesterone generally maintained procoagulant (thrombin, fibrinogen, and coagulation factor XIII), whereas ALLO increased anticoagulant protein expression (tissue-type plasminogen activator, tPA). In addition, PROG significantly increased the ratio of tPA bound to neuroserpin, a serine protease inhibitor that can reduce the activity of tPA. Our findings suggest that in a model of TBI, where blood loss may exacerbate injury, it may be preferable to treat patients with PROG, whereas it might be more appropriate to use ALLO as a treatment for thrombotic stroke, where a reduction in coagulation would be more beneficial.	[Stein, Donald G.] Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Sch Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Sch Med, Suite 5100,1365B Clifton Rd NE, Atlanta, GA 30322 USA.	donald.stein@emory.edu	Cekic, Milos/AAR-8250-2020; Stein, Donald/AAJ-5139-2020		NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RO1N540825, 1RO1N538664]; Department of Emergency Medicine at Emory University; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008169] Funding Source: NIH RePORTER	The funding for this study was provided by the NINDS Grants 1RO1N540825 and 1RO1N538664 and the Department of Emergency Medicine at Emory University.	Bulens F, 1997, J BIOL CHEM, V272, P663; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Frye CA, 2005, PHARMACOL BIOCHEM BE, V81, P907, DOI 10.1016/j.pbb.2005.06.016; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Herkert O, 2001, CIRCULATION, V104, P2826, DOI 10.1161/hc4801.099737; Herzog AG, 2008, SEIZURE-EUR J EPILEP, V17, P151, DOI 10.1016/j.seizure.2007.11.014; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Kato S, 2005, J CLIN ENDOCR METAB, V90, P1181, DOI 10.1210/jc.2004-0857; Langmade SJ, 2006, P NATL ACAD SCI USA, V103, P13807, DOI 10.1073/pnas.0606218103; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Melchor JP, 2005, THROMB HAEMOSTASIS, V93, P655, DOI 10.1160/TH04-12-0838; Miranda E, 2006, CELL MOL LIFE SCI, V63, P709, DOI 10.1007/s00018-005-5077-4; Monsonego A, 1998, FASEB J, V12, P1163; MOSESSON MW, 1992, NOUV REV FR HEMATOL, V34, P11; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Reddy DS, 2004, METHOD FIND EXP CLIN, V26, P547, DOI 10.1358/mf.2004.26.7.863737; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Savitz SI, 2005, STROKE, V36, P1447, DOI 10.1161/01.STR.0000170647.42126.a8; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Schindler AE, 2003, MATURITAS, V46, pS31, DOI 10.1016/j.maturitas.2003.09.016; Schreiber MA, 2005, CURR OPIN CRIT CARE, V11, P590, DOI 10.1097/01.ccx.0000186374.49320.ab; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sheehan JJ, 2005, GLIA, V50, P340, DOI 10.1002/glia.20150; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; WILLIAMS JE, 1981, BIOCHEM J, V197, P661, DOI 10.1042/bj1970661; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Yepes M, 2004, THROMB HAEMOSTASIS, V91, P457, DOI 10.1160/TH03-12-0766	40	31	36	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2008	28	11					1786	1794		10.1038/jcbfm.2008.73			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	366IB	WOS:000260472900003	18628783	Bronze			2021-06-18	
J	Mowery, NT; Norris, PR; Riordan, W; Jenkins, JM; Williams, AE; Morris, JA				Mowery, Nathan Teague; Norris, Patrick R.; Riordan, William; Jenkins, Judith M.; Williams, Anna E.; Morris, John A., Jr.			Cardiac uncoupling and heart rate variability are associated with intracranial hypertension and mortality: A study of 145 trauma patients with continuous monitoring	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		heart rate variability (HRV); cardiac uncoupling; closed head injury; intracranial pressure; traumatic brain injury	SYSTEMS; DEATH	Background: A noninvasive tool reflecting intracranial hypertension (ICH) should prompt early invasive monitoring and reduce secondary injury after traumatic brain injury. We hypothesized that integer heart rate variability (HRV) may be associated with rises in intracranial pressure (ICP); changes in HRV may precede changes in ICP; and both increases in ICP and cardiac uncoupling (low HRV) predict mortality. Methods: Of 14,330 consecutive trauma admissions, 291 of these patients had an injury requiring intracranial monitoring. Of these patients 145 had simultaneous HRV and ICP monitoring with a Camino monitor. ICP and heart rate (HR) data were matched and divided into 5-minute intervals (N = 117,956, representing 24.4 million HR and ICP data points). In each interval, the median ICP, and SD of HR (HRSD5) were calculated. Cardiac uncoupling was defined as an interval with HRSD5 between 0.3 bpm and 0.6 bpm. Cardiac uncoupling was compared between ICP categories using the Wilcoxon Rank-Sum test, and logistic regression was used to assess the continuous relationship between ICP and risk of uncoupling. Results: Cardiac uncoupling increases as ICP increases (p < 0.001). Uncoupling nearly doubles when comparing acceptable ICP (<20mm Hg, 11% uncoupled) to ICH (31-50 mm Hg, 18% uncoupled), with uncoupling = 13% in the intermediate group (ICP 21-30 mm Hg). This trend continues at the level of malignant ICH (>50 mm Hg, 22% uncoupled). Conclusion: Cardiac uncoupling increases as ICP increases. Both cardiac uncoupling and ICH predict mortality. Cardiac uncoupling may precede ICH but is not yet an indication for invasive monitoring.	[Mowery, Nathan Teague; Norris, Patrick R.; Riordan, William; Jenkins, Judith M.; Williams, Anna E.; Morris, John A., Jr.] Vanderbilt Univ, Med Ctr, Div Trauma & Surg Crit Care, Nashville, TN USA	Morris, JA (corresponding author), 404 Med Arts Bldg,1211 21st Ave S, Nashville, TN 37212 USA.	john.morris@vanderbilt.edu	Pockley, Alan G/I-4704-2015; Doucet, Jay/Y-7951-2019; Doucet, Jay J/O-3005-2018	Pockley, Alan G/0000-0001-9593-6431; Doucet, Jay/0000-0001-9617-001X; Doucet, Jay J/0000-0001-9617-001X			ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; *BRAIN TRAUM FDN, 2000, MAN PROGN SEV TRAUM; Bunten DC, 1998, CLIN AUTON RES, V8, P329, DOI 10.1007/BF02309623; Grogan EL, 2005, J TRAUMA, V58, P7, DOI 10.1097/01.TA.0000151179.74839.98; Grogan EL, 2004, ANN SURG, V240, P547, DOI 10.1097/01.sla.0000137143.65540.9c; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Morris JA, 2007, J AM COLL SURGEONS, V204, P885, DOI 10.1016/j.jamcollsurg.2007.01.019; Morris JA, 2006, J TRAUMA, V60, P1165, DOI 10.1097/01.ta.0000220384.04978.3b; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Norris PR, 2005, J SURG RES, V129, P122, DOI 10.1016/j.jss.2005.04.024; Norris PR, 2001, J AM MED INFORM ASSN, P498; Norris PR, 1997, J AM MED INFORM ASSN, P794; Riordan WP, 2006, CRIT CARE MED, V34, pA10, DOI 10.1097/00003246-200612002-00040; Seely AJE, 2004, CRIT CARE, V8, pR367, DOI 10.1186/cc2948; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	16	31	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2008	65	3					621	626		10.1097/TA.0b013e3181837980			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	350BC	WOS:000259326400023	18784576				2021-06-18	
J	Cao, C; Tutwiler, RL; Slobounov, S				Cao, Cheng; Tutwiler, Richard Laurence; Slobounov, Semyon			Automatic classification of athletes with residual functional deficits following concussion by means of EEG signal using support vector machine	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						electroencephalography (EEG); feature selection; mild traumatic brain injury (MTBI); support vector machine (SVM)	MILD HEAD-INJURY; FEATURE-SELECTION; POSTURAL RESPONSES; MUTUAL INFORMATION; QUANTITATIVE EEG; BRAIN-INJURY; RECOVERY; MOVEMENT; SPECT	There is a growing body of knowledge indicating long-lasting residual electroencephalography (EEG) abnormalities in concussed athletes that may persist up to 10-year postinjury. Most often, these abnormalities are initially overlooked using traditional concussion assessment tools. Accordingly, premature return to sport participation may lead to recurrent episodes of concussion, increasing the risk of recurrent concussions with more severe consequences. Sixty-one athletes at high risk for concussion (i.e., collegiate rugby and football players) were recruited and underwent EEG baseline assessment. Thirty of these athletes suffered from concussion and were retested at day 30 postinjury. A number of task-related EEG recordings were conducted. A novel classification algorithm, the support vector machine (SVM), was applied as a classifier to identify residual functional abnormalities in athletes suffering from concussion using a multichannel EEG data set. The total accuracy of the classifier using the 10 features was 77.1%. The classifier has a high sensitivity of 96.7% (linear SVM), 80.0% (nonlinear SVM), and a relatively lower but acceptable selectivity of 69.1% (linear SVM) and 75.0% (nonlinear SVM). The major findings of this report are as follows: 1) discriminative features were observed at theta, alpha, and beta frequency bands, 2) the minimal redundancy relevance method was identified as being superior to the univariate t-test method in selecting features for the model calculation, 3) the EEG features selected for the classification model are linked to temporal and occipital areas, and 4) postural parameters influence EEG data set and can be used as discriminative features for the classification model. Overall, this report provides sufficient evidence that 10 EEG features selected for final analysis and SVM may be potentially used in clinical practice for automatic classification of athletes with residual brain functional abnormalities following a concussion episode.	[Cao, Cheng; Tutwiler, Richard Laurence; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, State Coll, PA 16802 USA; [Cao, Cheng; Tutwiler, Richard Laurence] Penn State Univ, Dept Elect Engn, State Coll, PA 16802 USA	Cao, C (corresponding author), Penn State Univ, Dept Kinesiol, State Coll, PA 16802 USA.	cxc687@psu.edu; rlt1@psu.edu; sins18@psu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	The work of S. Slobounov was supported by the National Institutes of Health under Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury."	Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Acir N, 2005, IEEE T BIO-MED ENG, V52, P30, DOI 10.1109/TBME.2004.839630; BANKMAN IN, 1992, IEEE T BIO-MED ENG, V39, P1305, DOI 10.1109/10.184707; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Ding C, 2003, PROCEEDINGS OF THE 2003 IEEE BIOINFORMATICS CONFERENCE, P523, DOI 10.1109/CSB.2003.1227396; Dong B, 2005, ENERG BUILDINGS, V37, P545, DOI 10.1016/j.enbuild.2004.09.009; Duda R.O, 2002, PATTERN CLASSIFICATI, V2nd; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; GEETS W, 1985, ELECTROEN CLIN NEURO, V14, P333; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iannarilli FJ, 2003, IEEE T PATTERN ANAL, V25, P779, DOI 10.1109/TPAMI.2003.1201827; Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kohavi R, 1997, ARTIF INTELL, V97, P273, DOI 10.1016/S0004-3702(97)00043-X; Kwak N, 2002, IEEE T PATTERN ANAL, V24, P1667, DOI 10.1109/TPAMI.2002.1114861; Lal TN, 2004, IEEE T BIO-MED ENG, V51, P1003, DOI 10.1109/TBME.2004.827827; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Lotte F, 2007, J NEURAL ENG, V4, pR1, DOI 10.1088/1741-2560/4/2/R01; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; MORENO L, 1995, IEEE T BIO-MED ENG, V42, P428, DOI 10.1109/10.376139; Noble WS, 2004, KERNEL METHODS COMPU, V14, P71; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OZDAMAR O, 1991, COMPUTER BASED MED S, V12, P272; Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shimada T, 2000, IEEE T BIO-MED ENG, V47, P369, DOI 10.1109/10.827301; Slobounov S, 2006, BIOL PSYCHOL, V72, P188, DOI 10.1016/j.biopsycho.2005.10.005; Slobounov S, 2006, MOTOR CONTROL, V10, P69, DOI 10.1123/mcj.10.1.69; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P1125, DOI 10.1016/S1388-2457(02)00123-2; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Vapnik V, 2000, STAT LEARNING THEORY; Wang L., 2005, SUPPORT VECTOR MACHI; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; XIAO Y, 2007, EURASIP J BIOINFORMA	54	31	34	2	14	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	AUG	2008	16	4					327	335		10.1109/TNSRE.2008.918422			9	Engineering, Biomedical; Rehabilitation	Engineering; Rehabilitation	339IR	WOS:000258571800002	18701381				2021-06-18	
J	Goverover, Y; Chiaravalloti, N; DeLuca, J				Goverover, Yael; Chiaravalloti, Nancy; DeLuca, John			Self-generation to improve learning and memory of functional activities in persons with multiple sclerosis: Meal preparation and managing finances	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						activities of daily living; learning; memory; multiple sclerosis; rehabilitation	TRAUMATIC BRAIN-INJURY; COGNITIVE DYSFUNCTION; SEMANTIC MEMORY; CONTEXT MEMORY; ALZHEIMER-TYPE; DEMENTIA; WORDS; ACQUISITION; INFORMATION; IMPAIRMENT	Objective: To examine the utility of using a self-generation strategy to improve learning and performance of everyday functional tasks in persons with multiple sclerosis (MS). Design: Mixed-design with both a within- and between-subject factor. Setting: Nonprofit rehabilitation research institution. Participants: Participants (n=20) with MS and healthy controls (n=18). Interventions: Participants completed 2 meal preparation and 2 financial management tasks. One task in each area was presented in the provided condition, in which all instructions were provided to and read by the participants, and the other task was presented in the generated condition, in which participants were asked to generate (fill in the blank) the necessary items needed to perform each step of the task. Main Outcome Measures: Correct recall of task items and step sequence immediately and 1 week after initial learning and correct performance of task items and step sequence 30 minutes after initial learning. The maximum possible score in each of the recall tests was 24. Results: Although the MS and healthy groups did not differ in overall items recalled, in both groups tasks learned in the generated condition enhanced memory performance significantly for the tasks used when compared with similar tasks learned in the provided condition. Conclusions: Self-generation during learning can significantly improve subsequent recall of information and performance of activities of daily living for persons with MS. Implications of these findings for cognitive rehabilitation in MS are discussed.	[DeLuca, John] Kessler Med Rehabil Res & Educ Ctr, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; [Chiaravalloti, Nancy; DeLuca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Goverover, Yael] NYU, Dept Occupat Therapy, Steinhardt Sch Culture Educ & Human Dev, New York, NY USA	DeLuca, J (corresponding author), Kessler Med Rehabil Res & Educ Ctr, Neuropsychol & Neurosci Lab, 300 Execut Dr,Ste 010, W Orange, NJ 07052 USA.	jdeluca@kmrrec.org					Arnett PA, 1997, NEUROPSYCHOLOGY, V11, P535, DOI 10.1037/0894-4105.11.4.535; Barrett AM, 2000, NEUROLOGY, V54, P1258, DOI 10.1212/WNL.54.6.1258; Basso MR, 2006, J INT NEUROPSYCH SOC, V12, P640, DOI 10.1017/S1355617706060759; BEATTY WW, 1988, ARCH NEUROL-CHICAGO, V45, P611, DOI 10.1001/archneur.1988.00520300029013; Beatty WW, 1995, J NEUROL REHABIL, V9, P167; BEGG I, 1989, J EXP PSYCHOL LEARN, V15, P977, DOI 10.1037/0278-7393.15.5.977; BLOCH MW, 1989, AM J OCCUP THER, V43, P25, DOI 10.5014/ajot.43.1.25; Bobholz JA, 2003, CURR OPIN NEUROL, V16, P283, DOI 10.1097/00019052-200306000-00006; BOWER GH, 1979, J RES PERS, V13, P420, DOI 10.1016/0092-6566(79)90005-9; BUYER LS, 1989, AM J PSYCHOL, V102, P353, DOI 10.2307/1423055; Camp SJ, 1999, BRAIN, V122, P1341, DOI 10.1093/brain/122.7.1341; Chialva D, 2005, J HIGH ENERGY PHYS; Chiaravalloti ND, 2002, ARCH PHYS MED REHAB, V83, P1070, DOI 10.1053/apmr.2002.33729; CRAIK FIM, 1975, J EXP PSYCHOL GEN, V104, P268, DOI 10.1037/0096-3445.104.3.268; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; CRUTCHER RJ, 1989, J EXP PSYCHOL LEARN, V15, P669, DOI 10.1037/0278-7393.15.4.669; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 2000, DELISKAPLAN EXECUTIV; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; Demaree HA, 2000, J CLIN EXP NEUROPSYC, V22, P865, DOI 10.1076/jcen.22.6.865.961; DICK MB, 1989, BRAIN COGNITION, V9, P88, DOI 10.1016/0278-2626(89)90046-8; FISHER AG, 2001, ASSESSMENT MOTOR PRO; FRANKLIN GM, 1988, NEUROLOGY, V38, P1826, DOI 10.1212/WNL.38.12.1826; GARDINER JM, 1984, MEM COGNITION, V12, P443, DOI 10.3758/BF03198305; Gaudino EA, 2001, NEUROPSY NEUROPSY BE, V14, P32; Goverover Y, 2007, MULT SCLER, V13, P636, DOI 10.1177/1352458506072984; Hsieh S, 1999, PERCEPT MOTOR SKILL, V89, P355, DOI 10.2466/PMS.89.6.355-367; JOHNSON MK, 1981, AM J PSYCHOL, V94, P37, DOI 10.2307/1422342; Jurica PJ, 1999, MEM COGNITION, V27, P648, DOI 10.3758/BF03211558; Kaplan E., 1983, BOSTON NAMING TEST; KESSLER HR, 1992, INT J NEUROSCI, V62, P17, DOI 10.3109/00207459108999754; Kinjo H, 2000, AM J PSYCHOL, V113, P95, DOI 10.2307/1423462; Lengenfelder J, 2007, REHABIL PSYCHOL, V52, P290, DOI 10.1037/0090-5550.52.3.290; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Ma HI, 1999, AM J OCCUP THER, V53, P138, DOI 10.5014/ajot.53.2.138; Marsh EJ, 2001, MEM COGNITION, V29, P798, DOI 10.3758/BF03196409; MARTENIUK RG, 1987, CAN J PSYCHOL, V41, P365, DOI 10.1037/h0084157; MITCHELL DB, 1986, J GERONTOL, V41, P79, DOI 10.1093/geronj/41.1.79; Mulligan NW, 2006, J EXP PSYCHOL LEARN, V32, P836, DOI 10.1037/0278-7393.32.4.836; Multhaup KS, 1997, NEUROPSYCHOLOGY, V11, P382, DOI 10.1037/0894-4105.11.3.382; Nyenhuis DL, 1998, J PERS ASSESS, V70, P386, DOI 10.1207/s15327752jpa7002_14; O'Brien A, 2007, NEUROPSYCHOL REHABIL, V17, P273, DOI 10.1080/09602010600751160; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; POZZILLI C, 1991, CORTEX, V27, P441, DOI 10.1016/S0010-9452(13)80039-1; Rao S.M., 1993, NEUROPSYCHOLOGY, V7, P364, DOI [10.1037/0894-4105.7.3.364, DOI 10.1037/0894-4105.7.3.364]; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Schulz D, 2006, J NEUROL, V253, P1002, DOI 10.1007/s00415-006-0145-8; SLAMECKA NJ, 1983, J VERB LEARN VERB BE, V22, P153, DOI 10.1016/S0022-5371(83)90112-3; SLAMECKA NJ, 1978, J EXP PSYCHOL-HUM L, V4, P592, DOI 10.1037/0278-7393.4.6.592; Smith A, 1982, SYMBOL DIGITS MODALI; Smith KJ, 1996, J AM ACAD DERMATOL, V34, P63, DOI 10.1016/S0190-9622(96)90835-X; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; *SPSS INC, 1997, SPSS BAS APPL GUID; SWIRSKYSACCHETTI T, 1992, NEUROLOGY, V42, P1291, DOI 10.1212/WNL.42.7.1291; Thornton AE, 1997, NEUROPSYCHOLOGY, V11, P357, DOI 10.1037/0894-4105.11.3.357; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Westmacott R, 2003, MEM COGNITION, V31, P761, DOI 10.3758/BF03196114; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	60	31	32	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2008	89	8					1514	1521		10.1016/j.apmr.2007.11.059			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	336UP	WOS:000258390400013	18586224				2021-06-18	
J	Hansen, TS; Engberg, AW; Larsen, K				Hansen, Trine S.; Engberg, Aase W.; Larsen, Klaus			Functional oral intake and time to reach unrestricted dieting for patients with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; deglutition disorders; rehabilitation	FORMAL SWALLOWING EVALUATION; IMPROVES DYSPHAGIA OUTCOMES; HEAD-INJURY; DISORDERS; CONSCIOUSNESS; PREDICTORS; THERAPY; STROKE; ADULTS; SCALE	Objectives: To investigate the status of functional oral intake for patients with severe traumatic brain injury (TBI) and time to return to unrestricted dieting; and to investigate whether severity of brain injury is a predictor for unrestricted dieting. Design: Observational retrospective cohort study. Setting: Subacute rehabilitation department, university hospital. Participants: Patients age 16 to 65 years (N=173) with severe TBI (posttraumatic amnesia from 7d to >6mo) admitted over a 5-year period. Patients are transferred to the brain injury unit as soon as they ventilate spontaneously. Intervention: Facial oral tract therapy. Main Outcome Measure: Unrestricted dieting assessed by the Functional Oral Intake Scale (FOIS). Results: We found that 93% of all patients had problems with functional oral intake at admission. Within 126 days of rehabilitation, 64% recovered to unrestricted dieting before discharge. The chance of returning to total oral diet depends on the severity of the brain injury and can be predicted by Glasgow Coma Scale (GCS; measured the day after cessation of sedation; Wald chi(2)=42.78, P<.01), Rancho Los Amigos Scale (RLAS) level (Wald chi(2)=11.84, P=.01), FIM instrument (Wald chi(2)=44.40, P<.01), and FOIS score at admission (Wald chi(2)=82.93, P<.01). Conclusions: Impairment in functional oral intake was found to be very common for patients with severe TBI admitted to a subacute rehabilitation department. For those who recovered during hospital rehabilitation, return to unrestricted dieting happened within 126 days of rehabilitation. The chance of returning to unrestricted dieting depends on the severity of the brain injury and can be predicted by GCS score, RLAS level, FIM score, and functional oral intake at admission. These results are important when planning rehabilitation, giving information to patients and relatives, and designing efficacy studies of facial oral tract therapy, which are highly recommended.	[Hansen, Trine S.; Engberg, Aase W.] Univ Copenhagen, Dept Neurorehabil, Hvidovre Hosp, Brain Injury Unit, DK-2650 Hvidovre, Denmark; [Hansen, Trine S.] Univ Copenhagen, Dept Occupat Therapy, Hvidovre Hosp, DK-2650 Hvidovre, Denmark; [Larsen, Klaus] Univ Copenhagen, Clin Res Unit, Hvidovre Hosp, DK-2650 Hvidovre, Denmark	Hansen, TS (corresponding author), Univ Copenhagen, Dept Neurorehabil, Hvidovre Hosp, Brain Injury Unit, 354 Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.	trine.schow@gmail.com					AFFOLTER F, 1980, PERCEPTUAL PROCESSES; AVERYSMITH W, 1994, AM J OCCUP THER, V48, P235, DOI 10.5014/ajot.48.3.235; Brady SL, 2006, BRAIN INJURY, V20, P1329, DOI 10.1080/02699050601111435; Carnaby G, 2006, LANCET NEUROL, V5, P31, DOI 10.1016/S1474-4422(05)70252-0; Cherney LR, 1996, SEMIN NEUROL, V16, P349, DOI 10.1055/s-2008-1040993; Cherney LR, 1989, J HEAD TRAUMA REHAB, V4, P42; Coombes K, 1996, WEGE ANFANG FRUHREHA, P137; COOMBES K, 2001, 1991 2001 JUBILAUMSS; Crary MA, 2005, ARCH PHYS MED REHAB, V86, P1516, DOI 10.1016/j.apmr.2004.11.049; DAVIES PM, 1994, STARTING EARLY REHAB; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Halper AS, 1999, J HEAD TRAUMA REHAB, V14, P486, DOI 10.1097/00001199-199910000-00009; Hind JA, 2001, ARCH PHYS MED REHAB, V82, P1661, DOI 10.1053/apmr.2001.28006; HOLLAND A, 1984, LANGUAGE DISORDERS A; JENNETT B, 1976, LANCET, V1, P1031; Jurkovich GJ, 1999, J TRAUMA, V46, P821; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Morgan A, 2003, J HEAD TRAUMA REHAB, V18, P239, DOI 10.1097/00001199-200305000-00002; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; SECHREST L, 1972, J CROSS CULT PSYCHOL, V3, P41, DOI 10.1177/002202217200300103; Ward EC, 2007, J HEAD TRAUMA REHAB, V22, P184, DOI 10.1097/01.HTR.0000271119.96780.f5; Welter F L, 1998, Rehabilitation (Stuttg), V37, P58; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992	27	31	37	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2008	89	8					1556	1562		10.1016/j.apmr.2007.11.063			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	336UP	WOS:000258390400019	18674990				2021-06-18	
J	Engel, DC; Mies, G; Terpolilli, NA; Trabold, R; Loch, A; De Zeeuw, CI; Weber, JT; Maas, AIR; Plesnila, N				Engel, Doortje C.; Mies, Guenter; Terpolilli, Nicole A.; Trabold, Raimund; Loch, Alexander; De Zeeuw, Chris I.; Weber, John T.; Maas, Andrew I. R.; Plesnila, Nikolaus			Changes of cerebral blood flow during the secondary expansion of a cortical contusion assessed by C-14-iodoantipyrine autoradiography in mice using a non-invasive protocol	JOURNAL OF NEUROTRAUMA			English	Article						autoradiography; brain contusion; brain edema; cerebral blood flow; controlled cortical impact; mice; secondary brain damage; traumatic brain injury	TRAUMATIC BRAIN-INJURY; IMPACT INJURY; HEAD-INJURY; OXYGEN-CONSUMPTION; NEURONAL DEATH; RATS; ISCHEMIA; EDEMA; PERFUSION; MOUSE	Although changes of cerebral blood flow (CBF) in and around traumatic contusions are well documented, the role of CBF for the delayed death of neuronal cells in the traumatic penumbra ultimately resulting in secondary contusion expansion remains unclear. The aim of the current study was therefore to investigate the relationship between changes of CBF and progressive peri-contusional cell death following traumatic brain injury (TBI). CBF and contusion size were measured in C57Bl6 mice under continuous on-line monitoring of ETpCO2 before, and at 15 min and 24 h following controlled cortical impact by C-14-iodoantipyrine autoradiography (IAP-AR; n = 5-6 per group) and by Nissl staining, respectively. Contused and ischemic (CBF < 10%) tissue volumes were calculated and compared over time. Cortical CBF in not injured mice varied between 69 and 93 mL/100mg/min depending on the anatomical location. Fifteen minutes after trauma, CBF decreased in the whole brain by similar to 50% (39 +/- 18 mL/100mg/min; p < 0.05), except in contused tissue where it fell by more than 90% (3 +/- 2 mL/100mg/min; p < 0.001). Within 24 h after TBI, CBF recovered to normal values in all brain areas except the contusion where it remained reduced by more than 90% (p < 0.001). Contusion volume expanded from 24.9 to 35.5 mm3 (p < 0.01) from 15 min to 24 h after trauma (+43%), whereas the area of severe ischemia (CBF < 10%) showed only a minimal (+13%) and not significant increase (22.3 to 25.1 mm(3)). The current data therefore suggest that the delayed secondary expansion of a cortical contusion following traumatic brain injury may not be caused by a reduction of CBF alone.	[Engel, Doortje C.; Terpolilli, Nicole A.; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich, Med Ctr, Dept Neurosurg, Munich, Germany; [Engel, Doortje C.; Terpolilli, Nicole A.; Loch, Alexander; Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Surg Res, Munich, Germany; [Engel, Doortje C.; De Zeeuw, Chris I.; Weber, John T.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands; [Maas, Andrew I. R.] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; [Mies, Guenter] Max Planck Inst Neurol Res, Cologne, Germany	Plesnila, N (corresponding author), Royal Coll Surgeons Ireland, 123 St Stevens Green, Dublin 2, Ireland.	nikolausplesnila@rcsi.ie	Terpolilli, Nicole/AAG-3598-2021; Plesnila, Nikolaus/T-7522-2019; Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264			ALEXANDER MJ, 1994, ACTA NEUROCHIR, P479; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Holmstrom A, 2005, ACTA ANAESTH SCAND, V49, P16, DOI 10.1111/j.1399-6576.2004.00576.x; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JAY TM, 1988, J CEREBR BLOOD F MET, V8, P121, DOI 10.1038/jcbfm.1988.16; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; Katayama Y, 1998, ACT NEUR S, V71, P289; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MADSEN FF, 1990, ACTA NEUROCHIR, V105, P150, DOI 10.1007/BF01670000; Maeda K, 2000, J CEREBR BLOOD F MET, V20, P10, DOI 10.1097/00004647-200001000-00003; Maeda T, 1997, ACT NEUR S, V70, P102; MARTINS AN, 1978, STROKE, V9, P509, DOI 10.1161/01.STR.9.5.509; MARTINS AN, 1977, J NEUROSURG, V47, P346, DOI 10.3171/jns.1977.47.3.0346; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Pollay M, 1980, Adv Exp Med Biol, V131, P321; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SCHWARZMAIER S, 2007, J NEUROTRAUM, V23, P769; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; SUTTON RL, 1994, ACTA NEUROCHIR, P446; TANAKA H, 1994, ACTA NEUROCHIR, P524; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Tornheim P A, 1990, Adv Neurol, V52, P377; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Wellons JC, 2000, BRAIN RES, V868, P14, DOI 10.1016/S0006-8993(00)02216-2; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	62	31	32	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					739	753		10.1089/neu.2007.0480			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000003	18627253				2021-06-18	
J	Falo, MC; Reeves, TM; Phillips, LL				Falo, M. Cristina; Reeves, Thomas M.; Phillips, Linda L.			Agrin expression during synaptogenesis induced by traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						extracellular matrix; neuroplasticity; traumatic brain injury	HEPARAN-SULFATE PROTEOGLYCAN; CULTURED HIPPOCAMPAL-NEURONS; ADULT-RAT BRAIN; EXTRACELLULAR-MATRIX; SYNAPTIC PLASTICITY; ACETYLCHOLINE-RECEPTORS; ORGANIZING PROTEIN; NERVOUS-SYSTEM; DEFICIENT MICE; MESSENGER-RNA	Interaction between extracellular matrix proteins and regulatory proteinases can mediate synaptic integrity. Previously, we documented that matrix metalloproteinase 3 (MMP-3) expression and activity increase following traumatic brain injury (TBI). We now report protein and mRNA analysis of agrin, a MMP- 3 substrate, over the time course of trauma-induced synaptogenesis. Agrin expression during the successful synaptic reorganization of unilateral entorhinal cortical lesion (UEC) was compared with expression when normal synaptogenesis fails (combined fluid percussion TBI and bilateral entorhinal lesion [BEC]). We observed that agrin protein was increased in both models at 2 and 7 days postinjury, and immuohistochemical (IHC) co-localization suggested reactive astrocytes contribute to that increase. Agrin formed defined boundaries for sprouting axons along deafferented dendrites in the UEC, but failed to do so after combined insult. Similarly, Western blot analysis revealed greater increase in UEC agrin protein relative to the combined TBI + BEC model. Both models showed increased agrin transcription at 7 days postinjury and mRNA normalization by 15 days. Attenuation of synaptic pathology with the NMDA antagonist MK-801 reduced 7-day UEC agrin transcript to a level not different from unlesioned controls. By contrast, MK-801 in the combined insult failed to significantly change 7-day agrin transcript, mRNA levels remaining elevated over uninjured sham cases. Together, these results suggest that agrin plays an important role in the sprouting phase of reactive synaptogenesis, and that both its expression and distribution are correlated with extent of successful recovery after TBI. Further, when pathogenic conditions which induce synaptic plasticity are reduced, increase in agrin mRNA is attenuated.	[Falo, M. Cristina; Reeves, Thomas M.; Phillips, Linda L.] Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Phillips, LL (corresponding author), Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	llphilli@vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS044372, R56NS044372] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-44372, R01 NS044372, P30 NS-047463] Funding Source: Medline		Bergstrom RA, 2007, NEUROSCIENCE, V149, P527, DOI 10.1016/j.neuroscience.2007.08.017; Bose CM, 2000, J NEUROSCI, V20, P9086; BRINES ML, 1993, BRAIN RES, V631, P1, DOI 10.1016/0006-8993(93)91179-V; BRODKEY JA, 1995, J NEUROSURG, V82, P106, DOI 10.3171/jns.1995.82.1.0106; Burgess RW, 2000, J CELL BIOL, V151, P41, DOI 10.1083/jcb.151.1.41; Cohen-Cory S, 2002, SCIENCE, V298, P770, DOI 10.1126/science.1075510; Cotman SL, 1999, EXP CELL RES, V249, P54, DOI 10.1006/excr.1999.4463; Deller T, 2001, RESTOR NEUROL NEUROS, V19, P159; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eyupoglu IY, 2003, FASEB J, V17, P1110, DOI 10.1096/fj.02-0825fje; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Ferreira A, 1999, J CELL SCI, V112, P4729; Frotscher M, 2006, CELL TISSUE RES, V326, P361, DOI 10.1007/s00441-006-0269-2; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; Halfter W, 1997, J COMP NEUROL, V383, P1; Hilgenberg LGW, 2006, CELL, V125, P359, DOI 10.1016/j.cell.2006.01.052; Hilgenberg LGW, 2002, MOL CELL NEUROSCI, V19, P97, DOI 10.1006/mcne.2001.1056; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kim MJ, 2003, J NEUROBIOL, V55, P261, DOI 10.1002/neu.10213; Koulen P, 1999, EUR J NEUROSCI, V11, P4188, DOI 10.1046/j.1460-9568.1999.00848.x; Kroger S, 2002, NEWS PHYSIOL SCI, V17, P207, DOI 10.1152/01390.2002; Kroger S, 1996, EUR J NEUROSCI, V8, P500, DOI 10.1111/j.1460-9568.1996.tb01234.x; Lesuisse C, 2000, MOL BRAIN RES, V81, P92, DOI 10.1016/S0169-328X(00)00161-3; Li Z, 1999, J NEUROBIOL, V39, P547, DOI 10.1002/(SICI)1097-4695(19990615)39:4<547::AID-NEU8>3.0.CO;2-C; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; Mantych KB, 2001, J NEUROSCI, V21, P6802; McCroskery S, 2006, MOL CELL NEUROSCI, V33, P15, DOI 10.1016/j.mcn.2006.06.004; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; OCONNOR LT, 1995, MOL BRAIN RES, V33, P277, DOI 10.1016/0169-328X(95)00147-K; OCONNOR LT, 1994, J NEUROSCI, V14, P1141; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Povlishock John T., 1995, P504; Reif R, 2007, FASEB J, V21, P3468, DOI 10.1096/fj.07-8800com; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Serpinskaya AS, 1999, DEV BIOL, V205, P65, DOI 10.1006/dbio.1998.9112; Smith MA, 2002, NEUROREPORT, V13, P1485, DOI 10.1097/00001756-200208270-00001; Sole S, 2004, J NEUROPATH EXP NEUR, V63, P338, DOI 10.1093/jnen/63.4.338; STEWARD O, 1988, J COMP NEUROL, V267, P203, DOI 10.1002/cne.902670205; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; SZKLARCZYK A, 2002, J NEUROSCI, V267, P203; THOMAS WS, 1993, DEV BIOL, V158, P523, DOI 10.1006/dbio.1993.1210; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tournell CE, 2006, NEUROSCIENCE, V141, P1327, DOI 10.1016/j.neuroscience.2006.05.004; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; Yang JF, 2001, J NEUROSCI, V21, P9572, DOI 10.1523/JNEUROSCI.21-24-09572.2001; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618	55	31	31	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					769	783		10.1089/neu.2008.0511			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000005	18627255	Green Published			2021-06-18	
J	Fearing, MA; Bigler, ED; Wilde, EA; Johnson, JL; Hunter, JV; Li, XQ; Hanten, G; Levin, HS				Fearing, Michael A.; Bigler, Erin D.; Wilde, Elisabeth A.; Johnson, Jamie L.; Hunter, Jill V.; Li, Xiaoqi; Hanten, Gerri; Levin, Harvey S.			Morphometric MRI findings in the thalamus and brainstem in children after moderate to severe traumatic brain injury	JOURNAL OF CHILD NEUROLOGY			English	Article; Proceedings Paper	34th Annual Meeting of the International-Neuropsychological-Society	FEB 01-04, 2006	Boston, MA	Int Neuropsychol Soc		brainstem; morphometry; thalamus; traumatic brain injury	CLOSED-HEAD INJURY; MAGNETIC-RESONANCE; AXONAL INJURY; CELL-DEATH; DAMAGE; ADOLESCENTS; ATROPHY; MEMORY; ABNORMALITIES; TOMOGRAPHY	Generalized whole brain volume loss is well documented in moderate to severe traumatic brain injury. Whether this atrophy occurs in the thalamus and brainstem has not been systematically studied in children, Magnetic resonance imaging (MRI) quantitative analysis was used to investigate brain volume loss in the thalamus and brainstem in 16 traumatic brain injury subjects (age range 9-16 years) compared with 16 age and demographically matched controls. Based on Multiple analysis of covariance, controlling for age and head size, reduced volume in the thalamus and the midbrain region of the brainstem were found. General linear model analyses revealed a relation between processing speed on a working memory task and mid-brain and brain stein volumes. Reduced volume in thalamic and brainstem structures were associated with traumatic brain injury. Reduction in midbrain and thalamic Volume is probably a reflection of the secondary effects of diffuse axonal injury and reduction in cortical volume from brain injury.	[Wilde, Elisabeth A.; Hunter, Jill V.; Hanten, Gerri; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; [Fearing, Michael A.] Hebrew SeniorLife, Inst Aging Res, Aging Brain Ctr, Boston, MA USA; [Fearing, Michael A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA; [Bigler, Erin D.; Johnson, Jamie L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Radiol & Psychiat, Salt Lake City, UT USA; [Hunter, Jill V.] Texas Childrens Hosp, Dept Diagnost Imaging, Houston, TX 77030 USA	Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ewilde@bcm.tmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19HD035476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19 HD035476] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS021889] Funding Source: Medline		AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Constantinidis Christos, 2004, Cognitive Affective & Behavioral Neuroscience, V4, P444, DOI 10.3758/CABN.4.4.444; Garcia-Cabezas MA, 2007, NEUROIMAGE, V34, P965, DOI 10.1016/j.neuroimage.2006.07.032; Gerring J, 2000, BRAIN INJURY, V14, P205; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hebb MO, 2007, J NEUROTRAUM, V24, P579, DOI 10.1089/neu.2006.0146; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Louis ED, 1996, ARCH NEUROL-CHICAGO, V53, P450, DOI 10.1001/archneur.1996.00550050080027; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Meyer-Lindenberg A, 2005, NAT NEUROSCI, V8, P594, DOI 10.1038/nn1438; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morgane PJ, 2005, PROG NEUROBIOL, V75, P143, DOI 10.1016/j.pneurobio.2005.01.001; Nakamizo A, 2002, J CLIN NEUROSCI, V9, P685, DOI 10.1054/jocn.2002.1146; Natale JE, 2002, NEUROSCIENCE, V112, P665, DOI 10.1016/S0306-4522(02)00098-2; OADES RD, 1987, BRAIN RES REV, V12, P117, DOI 10.1016/0165-0173(87)90011-7; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Patrick PD, 2007, BRAIN INJURY, V21, P63, DOI 10.1080/02699050601111401; Pol HEH, 2000, NEUROREPORT, V11, P3039, DOI 10.1097/00001756-200009110-00042; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Rosen GD, 2006, NEUROSCIENCE, V141, P875, DOI 10.1016/j.neuroscience.2006.04.035; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Seidler RD, 2004, NEUROIMAGE, V22, P1775, DOI 10.1016/j.neuroimage.2004.05.003; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; Wedekind C, 2005, BRAIN INJURY, V19, P681, DOI 10.1080/02699050400025182; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Woischneck D, 2003, CHILD NERV SYST, V19, P174, DOI 10.1007/s00381-002-0703-z; WOOD DMG, 1995, BRAIN RES BULL, V38, P545, DOI 10.1016/0361-9230(95)02026-0	46	31	32	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	JUL	2008	23	7					729	737		10.1177/0883073808314159			9	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	330GP	WOS:000257929000003	18658073				2021-06-18	
J	Calvert, S; Miller, HE; Curran, A; Hameed, B; McCarter, R; Edwards, RJ; Hunt, L; Sharples, PM				Calvert, Sophie; Miller, Helen E.; Curran, Andrew; Hameed, Biju; McCarter, Renee; Edwards, Richard J.; Hunt, Linda; Sharples, Peta Mary			The King's Outcome Scale for Childhood Head Injury and injury severity and outcome measures in children with traumatic brain injury	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							QUALITY-OF-LIFE; ADOLESCENTS; COMA	The aim of this study was to relate discharge King's Outcome Scale for Childhood Head Injury (KOSCHI) category to injury severity and detailed outcome measures obtained in the first year post-traumatic brain injury (TBI). We used a prospective cohort study. Eighty-one children with TBI were studied: 29 had severe, 15 moderate, and 37 mild TBI. The male:female ratio was 1.8:1. The mean age was 11 years 10 months (SD 3.6, range 5-16y). Discharge KOSCHI categories were good (n=34), moderate (n=39), severe (n=6), and unclassifiable (n=2). KOSCHI category correlated strongly with admission Glasgow Coma Score, length of hospital stay, and post-traumatic amnesia. It also correlated significantly with Verbal IQ and Performance IQ (Wechsler); measures of attention; health status (Health Utilities Index [HUI]); health-related quality of life (Pediatric Quality of Life Inventory [PedsQL]); depressive symptoms (Birleson Depression Scale) assessed within 3 months postTBI; and with Verbal IQ, selective attention (map mission), and HUI and PedsQL domains assessed at least 6 months post-TBI discharge. KOSCHI did not correlate with behaviour or executive function. We conclude that the KOSCHI scored at hospital discharge correlates with severity of injury and some cognitive, health status, and HRQL outcomes early after TBI. It is not helpful at predicting later difficulties, or behavioural and emotional problems.	[Miller, Helen E.] Frenchay Hosp, Acad Ctr, Bristol BS16 1LE, Avon, England; [Hunt, Linda; Sharples, Peta Mary] Bristol Royal Hosp Children, Inst Child Life & Hlth, Bristol, Avon, England	Miller, HE (corresponding author), Frenchay Hosp, Acad Ctr, Room 1, Bristol BS16 1LE, Avon, England.	Helen.Miller@north-bristol.swest.nhs.uk		Hameed, Biju/0000-0002-8783-6163; Edwards, Richard/0000-0001-8415-2180	Department of HealthEuropean Commission Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BIRLESON P, 1987, J CHILD PSYCHOL PSYC, V28, P43, DOI 10.1111/j.1469-7610.1987.tb00651.x; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; CROUCHMAN MR, 1998, INJURY YOUNG, P263; Curran A., 2003, ARCH DIS CHILD S, V88, pA24; CURRAN AL, 2005, BRAIN INJ S1, V19, P22; Fasoli SE, 2004, NEUROREHAB NEURAL RE, V18, P88, DOI 10.1177/0888439004267434; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LINDSAY JT, 1998, J NEUROTRAUM, V15, P573; MANLEY T, 1999, TEACH TEST EVERYDAY; MAROSSZEKEY NEV, 1998, PTA PROTOCOL GUIDELI; MILLER HE, 2004, ARCH DIS CHILD S, V89, pA56; SAS Institute Inc, SAS STAT SOFTW VERS; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sharples PM, 1998, INJURY YOUNG, V263-299; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; TEASDALE G, 1974, LANCET, V2, P81; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Wechsler D., 1991, WECHSLER INTELLIGENC; Yule W, 1997, CHILD PSYCHOL PORTFO	30	31	32	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUN	2008	50	6					426	431		10.1111/j.1469-8749.2008.02061.x			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	302AC	WOS:000255937200010	18422680	Bronze			2021-06-18	
J	Gilmer, LK; Roberts, KN; Scheff, SW				Gilmer, Lesley K.; Roberts, Kelly N.; Scheff, Stephen W.			Efficacy of progesterone following a moderate unilateral cortical contusion injury	JOURNAL OF NEUROTRAUMA			English	Article						cortical contusion injury; edema; neuroprotection; progesterone; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; BINDING-PROTEIN 25-DX; SPINAL-CORD; CELL-DEATH; MALE-RATS; MITOCHONDRIAL DYSFUNCTION; INFLAMMATORY RESPONSE; NEUROTROPHIC FACTOR; FACTOR EXPRESSION	Traumatic brain injury (TBI) results in an accumulation of edema and loss of brain tissue. Progesterone (PROG) has been reported to reduce edema and cortical tissue loss in a bilateral prefrontal cortex injury. This study tests the hypothesis that PROG is neuroprotective following a unilateral parietal cortical contusion injury (CCI). Adult male Sprague- Dawley rats were subjected to a moderate unilateral TBI using the CCI model. Rats were given 8 mg/kg PROG 15 min post- injury with four subsequent injections (6 h, and days 1, 2, and 3). Edema was determined 3 days post- injury, while cortical tissue sparing was also evaluated at 7 days post- injury. Animals were injured and given one of four treatments: (I) vehicle; (II) low dose: 8 mg/kg PROG; (III) high dose: 16 mg/kg PROG; (IV) tapered: 8 mg/kg PROG. Animals were given an initial injection within 15 min, followed by five injections (6 h, and days 1, 2, 3, and 4). Group IV received two additional injections (4 mg/kg on day 5; 2 mg/kg on day 6). PROG failed to alter both cortical edema and tissue sparing at any dose. Failure to modify two major sequelae associated with TBI brings into question the clinical usefulness of PROG as an effective treatment for all types of brain injury.	[Gilmer, Lesley K.; Roberts, Kelly N.; Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Scheff, Stephen W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown Bldg, Lexington, KY 40536 USA.	sscheff@email.uky.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 21981] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER		Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Fee DB, 2007, BRAIN RES, V1137, P146, DOI 10.1016/j.brainres.2006.12.024; Fukui S, 2003, ACT NEUR S, V86, P301; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MOUTON PR, 2002, PRICIPLES PRACTICES; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	60	31	33	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					593	602		10.1089/neu.2007.0477			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900003	18476780	Green Published			2021-06-18	
J	Brewer-Smyth, K; Burgess, AW				Brewer-Smyth, Kathleen; Burgess, Ann W.			Childhood sexual abuse by a family member, salivary cortisol, and homicidal behavior of female prison inmates	NURSING RESEARCH			English	Article						brain injuries; child abuse; homicide; murder; sexual abuse of child; traumatic brain injury	DEVELOPMENTAL TRAUMATOLOGY; MENTAL-ILLNESS; PHYSICAL ABUSE; STRESS; WOMEN; BRAIN; MALTREATMENT; ADULTS; OUTPATIENTS; AGGRESSION	Background., Little is understood about neuropathophysiology and neuroendocrinology associated with childhood sexual abuse by a family member in females who commit homicide. Objectives: To determine if females sexually abused by a family member as a child also experienced more childhood physical abuse, had more neurological histories including traumatic brain injuries (TBIs), displayed more homicidal behaviors, and had abnormal diurnal variation in the stress hormone cortisol compared with females not sexually abused by a family member. Methods: A cross-sectional study was conducted with 137 female inmates, including 9 murderers and 12 noncriminal females, with logistic regression statistical analysis comparing females who have (n = 60) and have not (n = 89) been sexually abused by a family member, as determined by Muenzenmaier's Childhood Abuse Scale. Results: Final multivariate logistic regression model controlling for higher numbers of incarcerated adult family members (odds ratio [OR] = 1.63, p =.01) revealed that female victims of childhood sexual abuse by a family member experienced more childhood physical abuse (OR = 1.09, p = .05), experienced more TBIs (OR = 1.49, p =.01), and displayed increased violent behaviors including homicide (OR = 1.67, p =.05) compared with those not sexually abused by a family member. In univariate analysis, females sexually abused by a family member also experienced more sexual abuse by a non-family member (OR = 1.21, p = .036), more hospital visits for abuse injuries (OR = 1.27, p = .03), and more recent abuse (OR =.95, p = .008). Childhood sexual abuse by a family member was related significantly to decreased diurnal cortisol variation (OR = .087, p = .044) when controlling for number of years since last abuse, number of incarcerated adult family members, body mass index, depression, and TBIs. lo- Discussion: Risks associated with sexual abuse by a family member should be considered for individuals and policies to prevent potential homicide by those who experienced it. Further study is needed.	[Brewer-Smyth, Kathleen] Univ Delaware, Sch Nursing, Coll Hlth Sci, Newark, DE 19716 USA; [Burgess, Ann W.] Boston Coll, Chestnut Hill, MA 02167 USA	Brewer-Smyth, K (corresponding author), Univ Delaware, Sch Nursing, Coll Hlth Sci, 313 McDowell Hall, Newark, DE 19716 USA.	kbsmyth@udel.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016472] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [2 P20 RR016472-04] Funding Source: Medline		Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Beck A. T., 1996, BECK DEPRESSION INVE; Bremner JD, 2003, CHILD ADOL PSYCH CL, V12, P271, DOI 10.1016/S1056-4993(02)00098-6; Brewer-Smyth K, 2004, BIOL PSYCHIAT, V55, P21, DOI 10.1016/S0006-3223(03)00705-4; Brewer-Smyth Kathleen, 2007, J Neurosci Nurs, V39, P361; BREWERSMYTH K, 2001, DISS ABSTR INT, V62, P776; BREWERSMYTH K, IN PRESS ADV NURSING; Browne A, 1999, INT J LAW PSYCHIAT, V22, P301, DOI 10.1016/S0160-2527(99)00011-4; BUYDENSBRANCHEY L, 1992, PSYCHONEUROENDOCRINO, V17, P45, DOI 10.1016/0306-4530(92)90075-I; Carpenter LL, 2007, BIOL PSYCHIAT, V62, P1080, DOI 10.1016/j.biopsych.2007.05.002; *CDCP, BMI BOD MASS IND; De Bellis MD, 1999, BIOL PSYCHIAT, V45, P1259, DOI 10.1016/S0006-3223(99)00044-X; De Bellis MD, 1999, BIOL PSYCHIAT, V45, P1271, DOI 10.1016/S0006-3223(99)00045-1; De Bellis MD, 2001, DEV PSYCHOPATHOL, V13, P539, DOI 10.1017/S0954579401003078; Epel E, 2001, PSYCHONEUROENDOCRINO, V26, P37, DOI 10.1016/S0306-4530(00)00035-4; FRODI A, 1984, CHILD ABUSE NEGLECT, V8, P459, DOI 10.1016/0145-2134(84)90027-9; Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592; Heim Christine, 2002, Semin Clin Neuropsychiatry, V7, P147, DOI 10.1053/scnp.2002.33127; Hennekens CH, 1987, EPIDEMIOLOGY MED; Joyce PR, 2007, AUST NZ J PSYCHIAT, V41, P62, DOI 10.1080/00048670601050473; Kaufman D, 2007, DIABETES, V56, P1382, DOI 10.2337/db06-1409; Kaufman J, 1998, BIOL PSYCHIAT, V44, P973, DOI 10.1016/S0006-3223(98)00203-0; Kaufman J, 2001, DEV PSYCHOPATHOL, V13, P451, DOI 10.1017/S0954579401003030; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; Leeb RT, 2007, J ADOLESCENT HEALTH, V40, P551, DOI 10.1016/j.jadohealth.2007.01.006; Mamun AA, 2007, OBESITY, V15, P2103, DOI 10.1038/oby.2007.250; Manco M, 2007, DIABETES CARE, V30, P1494, DOI 10.2337/dc06-1353; McBurnett K, 2000, ARCH GEN PSYCHIAT, V57, P38, DOI 10.1001/archpsyc.57.1.38; Meyer IH, 1996, CHILD ABUSE NEGLECT, V20, P213, DOI 10.1016/S0145-2134(95)00137-9; MUENZENMAIER K, 1993, HOSP COMMUNITY PSYCH, V44, P666; Pajer K, 2001, ARCH GEN PSYCHIAT, V58, P297, DOI 10.1001/archpsyc.58.3.297; Rinne T, 2000, BIOL PSYCHIAT, V47, P548, DOI 10.1016/S0006-3223(99)00181-X; Schwartz EB, 1998, CHILD DEV, V69, P1503, DOI 10.1111/j.1467-8624.1998.tb06173.x; Steer RA, 1997, PSYCHOL REP, V80, P443, DOI 10.2466/pr0.1997.80.2.443; Steiger H, 2001, ARCH GEN PSYCHIAT, V58, P837, DOI 10.1001/archpsyc.58.9.837; Tarullo AR, 2006, HORM BEHAV, V50, P632, DOI 10.1016/j.yhbeh.2006.06.010; Van Voorhees Elizabeth, 2004, Trauma Violence Abuse, V5, P333, DOI 10.1177/1524838004269486; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; ZIMRIN H, 1986, CHILD ABUSE NEGLECT, V10, P339, DOI 10.1016/0145-2134(86)90009-8	39	31	31	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0029-6562	1538-9847		NURS RES	Nurs. Res.	MAY-JUN	2008	57	3					166	174		10.1097/01.NNR.0000319501.97864.d5			9	Nursing	Nursing	302YB	WOS:000256004900007	18496102				2021-06-18	
J	Ling, GSF; Marshall, SA				Ling, Geoffrey S. F.; Marshall, Scott A.			Management of traumatic brain injury in the intensive care unit	NEUROLOGIC CLINICS			English	Article							CLOSED-HEAD INJURY; DECOMPRESSIVE CRANIECTOMY; US ARMY; EXPERIENCE; COMBAT; HYPOTHERMIA; PREVENTION; MODERATE; TRENDS; DEATH	Traumatic brain injury is a common and complex clinical entity that deserves better and continued research on interventions and initial treatment postinjury. Current medical management of traumatic brain injury is articulated on minimizing secondary injury by optimizing cerebral perfusion and oxygenation and preventing or treating nonneurologic morbidity. There are major medical research efforts examining the underlying mechanisms of secondary brain injury, which provides hope for effective therapies in the future. Presently, a number of promising therapeutic modalities are undergoing clinical trials, and as new pharmacologic and medical approaches are introduced, there will be increasing opportunity to treat these patients and improve their neurologic outcomes.	[Ling, Geoffrey S. F.; Marshall, Scott A.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 21042 USA; [Ling, Geoffrey S. F.; Marshall, Scott A.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA	Ling, GSF (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, 4301 Jones Bridge Rd, Bethesda, MD 21042 USA.	gling@usuhs.mil					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; BELLAMY RF, 1992, WORLD J SURG, V16, P888, DOI 10.1007/BF02066987; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bledsoe GH, 2005, SOUTH MED J, V98, P436, DOI 10.1097/01.SMJ.0000154309.83339.C0; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Casey KF, 1994, J HEAD TRAUMA REHAB, V9, P82; Chesnut Randall M., 1993, P203; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; Chung CY, 2006, PEDIATR NEUROL, V34, P379, DOI 10.1016/j.pediatrneurol.2005.10.012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; GEOCADIN R, 2004, TRAUMATIC BRAIN INJU, P73; GIACINO J, 1994, J HEAD TRAUMA REHAB, V273, P1778; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; JAGGER J, 1992, J NEUROTRAUM, V9, pS313; Jia XF, 2008, RESUSCITATION, V76, P431, DOI 10.1016/j.resuscitation.2007.08.014; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kelly JP, 1997, NEUROLOGY, V48, P581; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LING G, 2007, TXB MED, P2646; Ling G, 2007, J TRAUMA, V62, pS102, DOI 10.1097/TA.0b013e318065b442; LING GS, 1997, NEUROCRITICAL CARE C, P973; Lu J, 2005, ACT NEUR S, V95, P281; Marion D W, 1995, New Horiz, V3, P439; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Morgan T. H., 1894, J MORPHOL, V9, P1, DOI [DOI 10.1002/JMOR.1050090102, 10.1002/jmor.1050090102]; *MRC CRASH TRIAL C, 2008, BRIT MED J, P425; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Munch E, 2000, NEUROSURGERY, V47, P315; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; PALTER M, 1994, J HEAD TRAUMA REHAB, V9, P20; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Patel TH, 2004, J TRAUMA, V57, P201, DOI 10.1097/01.TA.0000133638.30269.38; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; POVLISHOCK JT, 2007, J NEUROTRAUM, V24, P7; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Rosenfeld JV, 2007, J NEUROSURG, V106, P195, DOI 10.3171/jns.2007.106.1.195; Rustemeyer J, 2007, BRIT J ORAL MAX SURG, V45, P556, DOI 10.1016/j.bjoms.2007.01.003; SALAZAR AM, 1990, CHALLENGES NEUROLOGY; SALAZAR AM, 1990, CURRENT THERAPIES NE, P202; Sariego Jack, 2006, Disaster Manag Response, V4, P114, DOI 10.1016/j.dmr.2006.09.001; Schlifka B, 2007, J TRAUMA, V62, pS103, DOI 10.1097/TA.0b013e318065b4e5; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; Temkin N R, 1995, New Horiz, V3, P518; *US DEP DEF, MAN TECHN PROGR; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Warden DL, 2005, NEW ENGL J MED, V353, P633; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Wedmore I, 2006, J TRAUMA, V60, P655, DOI 10.1097/01.ta.0000199392.91772.44; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048; ZOROYA G, KEY IRAQ WOUND BRAIN; Zwahlen RA, 2007, J CRANIO MAXILL SURG, V35, P142, DOI 10.1016/j.jcms.2007.01.006; 2001, J TRAUMA, V5, pS3	68	31	34	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	MAY	2008	26	2					409	+		10.1016/j.ncl.2008.02.001			19	Clinical Neurology; Neurosciences	Neurosciences & Neurology	320CG	WOS:000257210700005	18514820				2021-06-18	
J	Samant, UB; Mack, CD; Koepsell, T; Rivara, FP; Vavilala, MS				Samant, Uma B.; Mack, Christopher D.; Koepsell, Thomas; Rivara, Frederick P.; Vavilala, Monica S.			Time of hypotension and discharge outcome in children with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						hypotension; pediatric trauma; traumatic brain injury	BLOOD-PRESSURE; SURVIVAL	We performed a retrospective study at a level I pediatric trauma center of patients admitted between 1998 and 2005 to determine the time after severe pediatric traumatic brain injury (TBI) that hypotension (systolic blood pressure [SBP] of <5(th) percentile) is most strongly associated with poor outcome. One hundred forty-six patients of <18 years of age with TBI, head Abbreviated Injury Score (AIS) of >= 3, and PICU admission Glasgow Coma Scale (GCS) score of <9 formed the analytic sample. Available SBP readings through the first 72 h after severe TBI were collected. SBP of <5(th) percentile was defined as hypotension. Discharge Glasgow Outcome Scale (GOS) score of <4 defined poor outcome. Of 146, 59 (40%) patients had discharge GOS of <4 and 12% died. The adjusted risk of poor outcome associated with hypotension stabilized by 8 h (adjusted risk ratio [RR] 1.7; 95% confidence interval [CI] 1.1-2.6) after injury. The risk of poor outcome peaked with hypotension occurring within the first 6 h after injury (RR 2.0, 95% CI 1.3-3.3). Poor discharge GOS was predicted by hypotension occurring during the first 6 h after injury. SBP data beyond the first 6 h did not improve our ability to predict poor discharge GOS. The first 6 h after severe pediatric TBI may represent a critical time period for either predicting or improving outcome.	[Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; [Koepsell, Thomas] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Rivara, Frederick P.; Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Mack, Christopher D.; Koepsell, Thomas; Rivara, Frederick P.; Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Samant, Uma B.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9Th Ave, Seattle, WA 98104 USA.	Vavilala@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD044632-05] Funding Source: Medline		*AAAM, 2002, 2000 NASS INJ COD MA; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Blood NIH, 2004, PEDIATRICS, V114, P555; Chiaretti A, 2002, CHILD NERV SYST, V18, P54, DOI 10.1007/s00381-001-0533-4; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; JENNETT B, 1975, LANCET, V1, P480; Jones PA, 2005, ACT NEUR S, V95, P29; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Langlois JA, 2001, TRAUMATIC BRAIN INJU; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; REINSCH CH, 1967, NUMER MATH, V10, P177, DOI 10.1007/BF02162161; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Royston J. Patrick, 2005, STATA J, V5, P1; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	22	31	31	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2008	25	5					495	502		10.1089/neu.2007.0491			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	303PY	WOS:000256054100006	18419252				2021-06-18	
J	Shelton, SB; Pettigrew, DB; Hermann, AD; Zhou, W; Sullivan, PM; Crutcher, KA; Strauss, KI				Shelton, Shirley B.; Pettigrew, David B.; Hermann, Alison D.; Zhou, Weidong; Sullivan, Patrick M.; Crutcher, Keith A.; Strauss, Kenneth I.			A simple, efficient tool for assessment of mice after unilateral cortex injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						apolipoprotein E; targeted-replacernent; beam walk; foot fault; water maze	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; SENSORIMOTOR DYSFUNCTION; MOUSE STRAINS; HEAD TRAUMA; DEFICITS; SHIRPA; MODEL; RAT; PHENOTYPE	A refined battery of neurological tests, SNAP (Simple Neuroassessment of Asymmetric Impairment), was developed and validated to efficiently assess neurological deficits induced in a mouse model of traumatic brain injury. Four to 7-month old mice were subjected to unilateral controlled cortical impact or sham injury (craniectomy only). Several behavioral tests (SNAP, beam walk, foot fault, and water maze) were used to assess functional deficits. SNAP was unique among these in that it required no expensive equipment and was performed in less than 5 min per mouse. SNAP demonstrated a high level of sensitivity and specificity as determined by receiver-operator characteristics curve analysis. Interrater reliability was good, as determined by Cohen's Kappa method and by comparing the sensitivity and specificity across various raters. SNAP detected deficits in proprioception, visual fields, and motor strength in brain-injured mice at 3 days, and was sensitive enough to detect magnitude and recovery of injury. The contribution of individual battery components changed as a function of time after injury, however, each was important to the overall SNAP score. SNAP provided a sensitive, reliable, time-efficient and cost-effective means of assessing neurological deficits in mice after unilateral brain injury. (c) 2007 Elsevier B.V. All rights reserved.	[Shelton, Shirley B.; Pettigrew, David B.; Hermann, Alison D.; Zhou, Weidong; Crutcher, Keith A.; Strauss, Kenneth I.] Univ Cincinnati, Div Res, Dept Neurosurg, Cincinnati, OH 45267 USA; [Sullivan, Patrick M.] Duke Univ, Durham VA Med Ctr, Div Geriatr, Dept Med, Durham, NC 27705 USA	Shelton, SB (corresponding author), Univ Cincinnati, Div Res, Dept Neurosurg, 231 Albert Sabin Way,Med Sci Bldg, Cincinnati, OH 45267 USA.	sheitosb@uc.edu; pettigdb@email.uc.edu; alison.hermann@downstate.edu; zhouwd@email.uc.edu; p.sullivan@duke.edu; crutchka@email.uc.edu; kstrauss@uc.edu	Crutcher, Keith/B-5435-2019; Shelton, Shirley/A-8358-2008	Crutcher, Keith/0000-0002-9176-5759; 	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K01RR020360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054890, R01NS038654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG020249] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K01 RR020360, K01 RR020360-03, K01 RR020360-01A1, K01 RR020360-02] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG20249, R01 AG020249] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS054890, R01 NS054890-01A2, R01 NS38654, R01 NS038654] Funding Source: Medline		Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CRAWLEY JN, 2000, WHATS WRONG MY MOUSE, P65; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Glantz S.A., 1992, PRIMER BIOSTATISTICS; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Lalonde R, 2005, BEHAV BRAIN RES, V157, P91, DOI 10.1016/j.bbr.2004.06.020; Landini G., 2006, CORRECT BACKGROUND I; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Maier NRF, 1935, J COMP NEUROL, V61, P395, DOI 10.1002/cne.900610209; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Motulsky H., 2003, Prism 4 statistics guide-statistical analyses for laboratory and clinical researchers, P122; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Rogers DC, 1999, BEHAV BRAIN RES, V105, P207, DOI 10.1016/S0166-4328(99)00072-8; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Rosner B., 1995, FUNDAMENTALS BIOSTAT, V4th ed; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	31	31	31	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 15	2008	168	2					431	442		10.1016/j.jneumeth.2007.11.003			12	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	271YK	WOS:000253824400016	18164073	Green Accepted			2021-06-18	
J	Kobeissy, FH; Jeung, JA; Warren, MW; Geier, JE; Gold, MS				Kobeissy, Firas H.; Jeung, Jennifer A.; Warren, Matthew W.; Geier, Jacqueline E.; Gold, Mark S.			Changes in leptin, ghrelin, growth hormone and neuropeptide-Y after an acute model of MDMA and methamphetamine exposure in rats	ADDICTION BIOLOGY			English	Article						ghrelin; growth hormone; leptin; MDMA; methamphetamine; neuropeptide-Y	TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; APPETITE SUPPRESSION; INDUCED NEUROTOXICITY; ARCUATE NUCLEUS; GENE-EXPRESSION; MESSENGER-RNA; SERUM LEPTIN; ECSTASY	Club drug abuse is a growing problem in the United States. Beyond addiction and toxicity are endocrine effects which are not well characterized. Specifically, the changes in appetite following exposure to drugs of abuse are an interesting but poorly understood phenomenon. Serum hormones such as leptin, ghrelin, growth hormone (GH), and neuropeptide-Y (NP-Y) are known to affect appetite, but have not been studied extensively with drugs of abuse. In this work, we examine the effects of club drugs 3,4-methylenedioxymethamphetamine (MDMA) (ecstasy) and methamphetamine (METH) (doses of 5, 20 and 40 mg/kg) on serum concentrations of these hormones in adult male Sprague-Dawley rats 6, 12, 24 and 48 hours after drug administration. In a dose-dependent manner, MDMA was shown to cause transient significant decreases in serum leptin and GH followed by a base line recovery after 24 hours. Conversely, serum ghrelin increased and normalized after 24 hours. Interestingly, serum NP-Y showed a steady decrease in both treatment of MDMA and METH at different time points and dosages. In humans, abuse of these drugs reduces eating. As evident from these data, acute administration of METH and MDMA had significant effects on different serum hormone levels involved in appetite regulation. Future studies should be performed to see how chronic, low dose drug administration would affect hormone levels and try to answer questions about the physiological mechanisms involved in the anorexic paradigm observed in drug use.	[Kobeissy, Firas H.; Jeung, Jennifer A.; Warren, Matthew W.; Geier, Jacqueline E.; Gold, Mark S.] Univ Florida, Coll Med, Gainesville, FL 32610 USA; [Kobeissy, Firas H.; Gold, Mark S.] Univ Florida, Dept Psychiat, Div Addict Med, Gainesville, FL 32611 USA; [Gold, Mark S.] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA	Kobeissy, FH (corresponding author), Univ Florida, Coll Med, PO Box 100215, Gainesville, FL 32610 USA.	firasko@ufl.edu; msgold@ufl.edu	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T35HL007489] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T 35 HL07489] Funding Source: Medline		BATTAGLIA G, 1987, J PHARMACOL EXP THER, V242, P911; Baucum AJ, 2004, J NEUROSCI, V24, P3436, DOI 10.1523/JNEUROSCI.0387-04.2004; Baumann MH, 2007, PSYCHOPHARMACOLOGY, V189, P407, DOI 10.1007/s00213-006-0322-6; Chan YY, 1996, ENDOCRINOLOGY, V137, P1319, DOI 10.1210/en.137.4.1319; Cho AK, 2001, SYNAPSE, V39, P161, DOI 10.1002/1098-2396(200102)39:2<161::AID-SYN7>3.0.CO;2-E; CRANE C, 2007, J HISTOCHEM CYTOCHEM; Crowley WR, 2005, NEUROSCIENCE, V132, P167, DOI 10.1016/j.neuroscience.2004.11.037; Curzon G, 1997, TRENDS PHARMACOL SCI, V18, P21, DOI 10.1016/S0165-6147(96)01003-6; Daberkow DP, 2005, PHARMACOL BIOCHEM BE, V81, P198, DOI 10.1016/j.pbb.2005.03.010; DAFTERS RI, 1995, PHYSIOL BEHAV, V58, P877, DOI 10.1016/0031-9384(95)00136-7; Davidson C, 2005, NEUROCHEM INT, V46, P189, DOI 10.1016/j.neuint.2004.11.004; Davidson C, 2001, BRAIN RES REV, V36, P1, DOI 10.1016/S0165-0173(01)00054-6; Deng XL, 1999, J NEUROSCI, V19, P10107; DeSouza I, 1997, PHARMACOL TOXICOL, V80, P207; DUBE MG, 1992, BRAIN RES BULL, V29, P865, DOI 10.1016/0361-9230(92)90157-S; Egecioglu E, 2006, AM J PHYSIOL-ENDOC M, V290, pE317, DOI 10.1152/ajpendo.00181.2005; Faria R, 2006, ANN NY ACAD SCI, V1074, P643, DOI 10.1196/annals.1369.062; Federici M, 2007, BIOL PSYCHIAT, V62, P680, DOI 10.1016/j.biopsych.2006.11.019; Gayle DA, 2006, LIFE SCI, V79, P1531, DOI 10.1016/j.lfs.2006.04.015; Gerra G, 2002, BEHAV BRAIN RES, V134, P403, DOI 10.1016/S0166-4328(02)00052-9; Ginawi OT, 2005, REGUL TOXICOL PHARM, V41, P122, DOI 10.1016/j.yrtph.2004.10.005; Ginawi OT, 2005, PHARMACOL RES, V51, P255, DOI 10.1016/j.phrs.2004.09.002; GUY J, 1988, PEPTIDES, V9, P567, DOI 10.1016/0196-9781(88)90165-9; Halford J C, 2000, Prog Drug Res, V54, P25; Hegadoren KM, 1999, NEUROSCI BIOBEHAV R, V23, P539, DOI 10.1016/S0149-7634(98)00046-3; HERNANDEZ L, 1988, PHYSIOL BEHAV, V44, P599, DOI 10.1016/0031-9384(88)90324-1; Hosoda Hiroshi, 2002, Mol Interv, V2, P494, DOI 10.1124/mi.2.8.494; Hsieh YS, 2006, TOXICOL APPL PHARM, V212, P99, DOI 10.1016/j.taap.2005.07.006; Islam SKN, 2002, BRIT J NUTR, V88, P507, DOI 10.1079/BJN2002702; Jaehne EJ, 2005, PHARMACOL BIOCHEM BE, V81, P485, DOI 10.1016/j.pbb.2005.04.005; JONAS JM, 1986, LANCET, V1, P390; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kalra SP, 2004, J ADDICT DIS, V23, P5, DOI 10.1300/J069v23n03_02; Kleiner KD, 2004, J ADDICT DIS, V23, P105, DOI 10.1300/J069v23n03_08; Malpass A, 1999, PHARMACOL BIOCHEM BE, V64, P29, DOI 10.1016/S0091-3057(99)00116-1; Mas M, 1999, J PHARMACOL EXP THER, V290, P136; Morley KC, 2001, EUR J PHARMACOL, V433, P91, DOI 10.1016/S0014-2999(01)01512-6; Nogueiras R, 2004, DIABETES, V53, P2552, DOI 10.2337/diabetes.53.10.2552; PAUL SM, 1982, SCIENCE, V218, P487, DOI 10.1126/science.7123250; PELLETIER G, 1991, NEUROSCI LETT, V127, P96, DOI 10.1016/0304-3940(91)90903-7; SALISBURY JJ, 1985, BEHAV NEUROSCI, V99, P1153, DOI 10.1037/0735-7044.99.6.1153; SAMANIN R, 1993, PHARMACOL TOXICOL, V73, P63, DOI 10.1111/j.1600-0773.1993.tb01537.x; Sanchez J, 2004, PFLUG ARCH EUR J PHY, V448, P500, DOI 10.1007/s00424-004-1283-4; Santolaria F, 2003, ALCOHOL ALCOHOLISM, V38, P60, DOI 10.1093/alcalc/agg015; Staszewski RD, 2006, J NEUROCHEM, V96, P1267, DOI 10.1111/j.1471-4159.2005.03618.x; Stephenson CP, 1999, NEUROSCIENCE, V92, P1011, DOI 10.1016/S0306-4522(99)00049-4; Thiriet N, 2005, J NEUROSCI, V25, P5273, DOI 10.1523/JNEUROSCI.4893-04.2005; Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6; Wang XY, 2005, J PHARMACOL EXP THER, V314, P1002, DOI 10.1124/jpet.105.088476; Warren MW, 2007, INT J NEUROPSYCHOPH, V10, P479, DOI 10.1017/S1461145706007061; Warren MW, 2006, J ADDICT DIS, V25, P115, DOI 10.1300/J069v25n04_11; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; Yu J, 2004, BRAIN RES, V1007, P124, DOI 10.1016/j.brainres.2004.01.077	53	31	31	2	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1355-6215	1369-1600		ADDICT BIOL	Addict. Biol.	MAR	2008	13	1					15	25		10.1111/j.1369-1600.2007.00083.x			11	Biochemistry & Molecular Biology; Substance Abuse	Biochemistry & Molecular Biology; Substance Abuse	259GN	WOS:000252927900002	17910739				2021-06-18	
J	Rossiter, K; Gray, J; Kontos, P; Keightley, M; Colantonio, A; Gilbert, J				Rossiter, Kate; Gray, Julia; Kontos, Pia; Keightley, Michelle; Colantonio, Angela; Gilbert, Julie			From page to stage - Dramaturgy and the art of interdisciplinary translation	JOURNAL OF HEALTH PSYCHOLOGY			English	Article						dramaturgy; health research; interdisciplinary collaboration; theatre; traumatic brain injury		In recent years, interdisciplinary collaboration between artists and social scientists has received sustained interest from many members of the academic community. However, cross-disciplinary work is often more difficult than presumed. Epistemological and methodological differences between disciplines create barriers that may impede collaborative projects. This article explores some of the unique tensions and challenges that arose from the creation of 'After the Crash', a research-based theatre production about traumatic brain injury. Through the narrative lens of the project's dramaturg, we explore moments of interdisciplinary tension, and the possibility for the role of the dramaturg to build bridges between disparate methods of knowledge generation and translation.	[Rossiter, Kate] Univ Toronto, Dept Publ Hlth, Toronto, ON M5T 3M7, Canada; [Gray, Julia] York Univ, N York, ON M3J 1P3, Canada; [Kontos, Pia; Colantonio, Angela] Toronto Rehabil Inst, Toronto, ON, Canada; [Kontos, Pia; Keightley, Michelle; Gilbert, Julie] Univ Toronto, Toronto, ON M5S 1A1, Canada	Rossiter, K (corresponding author), Univ Toronto, Dept Publ Hlth, 6th Floor,Hlth Sci Bldg,155 Coll St, Toronto, ON M5T 3M7, Canada.	kate.rossiter@utoronto.ca		Kontos, Pia/0000-0002-8893-2544			Cardullo Bert, 1995, WHAT IS DRAMATURGY, P3; COLANTONIO A, 2006, WORLD FED OCC THER C; Cole A.L., 2008, HDB ARTS QUALITATIVE; Copelin D., 1995, WHAT IS DRAMATURGY, P17; Denzin N. K., 1997, INTERPRETIVE ETHNOGR; Gray Ross, 2000, Health Expect, V3, P137, DOI 10.1046/j.1369-6513.2000.00071.x; Gray Ross, 2003, QUALITATIVE RES, V3, P284; HEARN A, 1996, OUTSIDE LINES ISSUES; Katz Leon, 1995, WHAT IS DRAMATURGY, P13; Kontos P.C., 2006, QUAL RES, V6, DOI [10.1177/1468794106065005, DOI 10.1177/1468794106065005]; Martin Carol, 1993, DRAMA REV, V37, P45; MCCALL H, 2000, HDB QUALITATIVE RES, P112; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Palmer C., 2001, WORK BOUNDARIES SCI; Rowe J.W., 2003, EXPANDING BOUNDARIES, P3; RUDAKOFF JB, 2002, LINES PROCESS DRAMAT, pR3; Saldana J, 2003, QUAL INQ, V9, P218, DOI 10.1177/1077800402250932; Schechner Richard, 1993, DRAMA REV, V37, P63; Smith A. D., 1993, FIRES MIRROR; SMITH AD, 2000, TALK ME LISTENING LI; SMITH AD, 1994, TWILIGHT LOS ANGELES; Stehr Nico, 2000, PRACTISING INTERDISC	22	31	31	3	13	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1359-1053			J HEALTH PSYCHOL	J. Health Psychol.	MAR	2008	13	2					277	286		10.1177/1359105307086707			10	Psychology, Clinical	Psychology	291BL	WOS:000255167200012	18375632				2021-06-18	
J	Theys, C; van Wieringen, A; De Nil, LF				Theys, Catherine; van Wieringen, Astrid; De Nil, Luc F.			A clinician survey of speech and non-speech characteristics of neurogenic stuttering	JOURNAL OF FLUENCY DISORDERS			English	Article						stuttering; acquired stuttering; neurogenic stuttering; neurological disease; survey	ONSET	This study presents survey data on 58 Dutch-speaking patients with neurogenic stuttering following various neurological injuries. Stroke was the most prevalent cause of stuttering in our patients, followed by traumatic brain injury, neurodegenerative diseases, and other causes. Speech and non-speech characteristics were analyzed separately for these four etiology groups. Results suggested possible group differences, including site of lesion and influence of speech conditions on stuttering. Other characteristics, such as within-word localization of disfluencies and presence of secondary behaviors were comparable across the etiology groups. The implications of our results for the diagnosis of neurogenic stuttering will be discussed. Educational objectives: After reading this article, the reader will be able to: (1) provide a concise overview of the main literature on neurogenic stuttering; (2) discuss the speech and non-speech characteristics of neurogenic stuttering; (3) provide an overview of current clinical practices for intervention with neurogenic stuttering patients and their perceived outcome. (C) 2007 Elsevier Inc. All rights reserved.	[Theys, Catherine; van Wieringen, Astrid; De Nil, Luc F.] Katholieke Univ Leuven, Dept Neurosci, ExpORL, B-3000 Louvain, Belgium; [De Nil, Luc F.] Univ Toronto, Dept Speech Language Pathol, Toronto, ON M5G 1V7, Canada; [De Nil, Luc F.] Toronto Western Res Inst, Toronto, ON, Canada; [De Nil, Luc F.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada	Theys, C (corresponding author), Katholieke Univ Leuven, Dept Neurosci, ExpORL, Herestr 49 B 721, B-3000 Louvain, Belgium.	Catherine.Theys@med.kuleuven.be	van Wieringen, Astrid/AAG-4112-2020	van Wieringen, Astrid/0000-0002-6320-7936			AMBROSE NG, 1993, J SPEECH HEAR RES, V36, P701, DOI 10.1044/jshr.3604.701; BYRNE A, 1993, INT J EAT DISORDER, V14, P511, DOI 10.1002/1098-108X(199312)14:4<511::AID-EAT2260140416>3.0.CO;2-L; CANTER GJ, 1971, BRIT J DISORD COMMUN, V6, P139; Caplan L, 1972, J S Afr Speech Hear Assoc, V19, P52; De Nil L., 2007, STUTTERING RELATED D, P326; DENIL LF, IN PRESS CLIN MANAGE; Foerch C, 2005, LANCET, V366, P392, DOI 10.1016/S0140-6736(05)67024-9; HELM NA, 1978, NEUROLOGY, V28, P1159, DOI 10.1212/WNL.28.11.1159; Helm-Estabrooks N., 1993, STUTTERING RELATED D, P205; Helm-Estabrooks N, 1999, STUTTERING RELATED D, P255; HELMESTABROOKS N, 1986, ATYPICAL STUTTERER P, P193; Jokel R, 2007, J MED SPEECH-LANG PA, V15, P243; KOLLER WC, 1983, ARCH NEUROL-CHICAGO, V40, P175, DOI 10.1001/archneur.1983.04050030069014; Lebrun Y, 1997, NEUROPS COG, V12, P105; Leder SB, 1996, J COMMUN DISORD, V29, P471, DOI 10.1016/0021-9924(95)00055-0; LUDLOW CL, 1987, ANN NEUROL, V22, P60, DOI 10.1002/ana.410220114; MARKET KE, 1990, J FLUENCY DISORD, V15, P21, DOI 10.1016/0094-730X(90)90029-R; MCCLEAN MD, 1985, J FLUENCY DISORD, V10, P241, DOI 10.1016/0094-730X(85)90023-3; MEGHJI C, 1994, J FAM PRACTICE, V39, P326; Movsessian P, 2005, MED HYPOTHESES, V64, P290, DOI 10.1016/j.mehy.2004.07.026; Mowrer DE, 2001, J FLUENCY DISORD, V26, P269, DOI 10.1016/S0094-730X(01)00107-3; Naess Halvor, 2006, J Stroke Cerebrovasc Dis, V15, P241, DOI 10.1016/j.jstrokecerebrovasdis.2006.06.003; Natke U, 2004, J FLUENCY DISORD, V29, P109, DOI 10.1016/j.jfludis.2003.11.002; Perino M, 2000, HEADACHE, V40, P170, DOI 10.1046/j.1526-4610.2000.00025.x; Ringo C. C., 1995, J MED SPEECH-LANG PA, V3, P111; Rowley D. T., 2003, P 6 OXF DYSFL C, P59; Sahin HA, 2005, BEHAV NEUROL, V16, P37, DOI 10.1155/2005/941926; SHTREMEL A Kh, 1963, Zh Nevropatol Psikhiatr Im S S Korsakova, V63, P828; Stewart T, 1996, EUR J DISORDER COMM, V31, P1; Tsao JW, 2004, AM J MED, V116, P211, DOI 10.1016/j.amjmed.2003.07.020; Van Borsel J, 2003, BRAIN LANG, V85, P185, DOI 10.1016/S0093-934X(03)00061-0; Van Borsel J, 2001, J COMMUN DISORD, V34, P385, DOI 10.1016/S0021-9924(01)00057-0; Yeoh HK, 2006, CHILD NERV SYST, V22, P310, DOI 10.1007/s00381-005-1154-0	33	31	32	2	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0094-730X	1873-801X		J FLUENCY DISORD	J. Fluency Disord.	MAR	2008	33	1					1	23		10.1016/j.jfludis.2007.09.001			23	Audiology & Speech-Language Pathology; Education, Special; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Education & Educational Research; Linguistics; Rehabilitation	273OA	WOS:000253939300001	18280866				2021-06-18	
J	Carter, BG; Butt, W; Taylor, A				Carter, B. G.; Butt, W.; Taylor, A.			ICP and CPP: excellent predictors of long term outcome in severely brain injured children	CHILDS NERVOUS SYSTEM			English	Article						intracranial pressure (ICP); cerebral perfusion pressure (CPP); outcome; predictive value of tests; traumatic brain injury; non-traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; TARGETED THERAPY; CHILDHOOD; SURVIVAL; CARE; LESIONS; AGE	Objective To determine the predictive powers of intracranial pressure (ICP) and cerebral perfusion pressure (CPP) amongst severely brain injured children. Materials and methods ICP and CPP were recorded from thirty-five severely brain injured children who were prospectively recruited after admission to paediatric intensive care. Twenty-five suffered traumatic brain injury (TBI) and ten suffered non-TBI. Peak ICP and minimum CPP recorded for each patient during their admission were related to 5 year Glasgow Outcome Scale outcome. Receiver operator characteristic curves determined that the optimum threshold for unfavourable outcome prediction was >= 40 mmHg for ICP and <= 49 mmHg for CPP. At these thresholds the sensitivity/specificity pairs for the prediction of unfavourable outcome were 33.3/100% and 55.6/100% for ICP and CPP, respectively, amongst patients suffering TBI and were 46.2/100% and 66.2/100% for ICP and CPP, respectively, amongst all patients. Conclusion ICP and CPP are accurate predictors of unfavourable outcome.	[Carter, B. G.; Butt, W.; Taylor, A.] Royal Childrens Hosp, Paediat Intens Care Unit, Parkville, Vic 3052, Australia; [Butt, W.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia	Carter, BG (corresponding author), Royal Childrens Hosp, Paediat Intens Care Unit, Flemington Rd, Parkville, Vic 3052, Australia.	icu.tech@rch.org.au					ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Altman D. G., 1999, PRACTICAL STAT MED R; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Biggerstaff BJ, 2000, STAT MED, V19, P649, DOI 10.1002/(SICI)1097-0258(20000315)19:5&lt;649::AID-SIM371&gt;3.0.CO;2-H; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; CHAMBERS IR, 2003, BR NEUROSURG, V17, P478; CHO DY, 1985, PEDIATR NEUROSURG, V23, P192; Ciurea AV, 2005, ACT NEUR S, V93, P209; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; GOITEIN KJ, 1983, J PEDIATR-US, V103, P40, DOI 10.1016/S0022-3476(83)80772-0; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; HANLEY JA, 1989, CRIT REV DIAGN IMAG, V29, P307; JENNETT B, 1975, LANCET, V1, P480; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; Kieslich M, 2001, DISABIL REHABIL, V23, P665; LEROUX PD, 1991, CHILD NERV SYST, V7, P34, DOI 10.1007/BF00263831; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Odetola FO, 2005, INTENS CARE MED, V31, P92, DOI 10.1007/s00134-004-2501-4; Papo I, 1982, J Neurosurg Sci, V26, P193; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; PFENNINGER J, 1984, Z KINDERCHIR, V39, P223; POPLE IK, 1985, PEDIATR NEUROSURG, V23, P64; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; REBAUD P, 1988, INTENS CARE MED, V14, P522, DOI 10.1007/BF00263524; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Ward J D, 1987, Brain Inj, V1, P21, DOI 10.3109/02699058709034440; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; ZWEIG MH, 1993, CLIN CHEM, V39, P561; 2002, PROTOCOL MANAGEMENT; 2003, PEDIAT CRIT CARE M S, V4, pS31; 2003, PEDIAT CRIT CARE M S, V4, pS65; 2003, PEDIAT CRIT CARE M S, V4, pS19; 2003, PEDIAT CRIT CARE M S, V4, pS25	47	31	32	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	FEB	2008	24	2					245	251		10.1007/s00381-007-0461-z			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	244MW	WOS:000251871000016	17712566				2021-06-18	
J	Collins, CL; Fields, SK; Comstock, RD				Collins, C. L.; Fields, S. K.; Comstock, R. D.			When the rules of the game are broken: what proportion of high school sports-related injuries are related to illegal activity?	INJURY PREVENTION			English	Article							RUGBY UNION FOOTBALL; UNITED-STATES; PROFESSIONAL FOOTBALL; ONE SEASON; WORLD CUP; PLAYERS; EPIDEMIOLOGY; SOCCER; INCIDENTS; FREQUENCY	Objectives: To compare sport and gender differences in injury rates and proportions of injuries related to illegal activity and to describe the epidemiology of injuries related to illegal activity. Design: Descriptive epidemiology study. Setting: 100 US high schools. Subjects: Athletes participating in nine sports: boys' football, soccer, basketball, wrestling, and baseball plus girls' soccer, volleyball, basketball, and softball. Main outcome measures: Illegal activity-related injuries were analyzed using data from the 2005-06 and 2006-07 National High School Sports-Related Injury Surveillance Study. Results: Nationally, an estimated 98 066 injuries were directly related to an action that was ruled illegal activity by a referee/official or disciplinary committee, giving an injury rate of 0.24 injuries per 1000 athletic competition-exposures. Boys' and girls' soccer had the highest rates of injuries related to illegal activity, and girls' volleyball, girls' softball, and boys' baseball had the lowest. Overall, 6.4% of all high school sports-related injuries were related to illegal activity, with the highest proportion in girls' basketball (14.0%), girls' soccer (11.9%), and boys' soccer (11.4%). A greater proportion of injuries related to illegal activity were to the head/face (32.3%) and were concussions (25.4%) than injuries not related to illegal activity (13.8% (injury proportion ratio 2.35; 95% CI 1.82 to 3.04; p<0.001) and 10.9% (injury proportion ratio 2.35; 95% CI 1.71 to 3.22; p<0.001), respectively). Conclusions: Illegal activity is an overlooked risk factor for sports-related injury. Reducing illegal activity through enhanced enforcement of sports' rules and targeted education about the dangers of illegal activity for players, coaches, and referees/officials may reduce sports-related injuries.	[Collins, C. L.; Comstock, R. D.] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Fields, S. K.] Ohio State Univ, Coll Educ & Human Ecol, Sch Phys Activ & Educ Serv, Columbus, OH 43210 USA; [Comstock, R. D.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Comstock, R. D.] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA	Collins, CL (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	christy.collins@nationwidechildrens.org			NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674] Funding Source: NIH RePORTER; NCIPC CDC HHS [R49/CE000674-01] Funding Source: Medline		Allen W. D., 2002, Journal of Sports Economics, V3, P39, DOI 10.1177/1527002502003001004; Andersen TE, 2004, AM J SPORT MED, V32, p62S, DOI 10.1177/0363546503261412; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; *CDCP, NAT CTR PREV CONTR F; Chalmers DJ, 2004, J SCI MED SPORT, V7, P74, DOI 10.1016/S1440-2440(04)80046-X; Chomiak J, 2000, AM J SPORT MED, V28, pS58; COLLINS CL, IN PRESS ARCH PEDIAT; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Comstock RD, 2005, J SCI MED SPORT, V8, P101, DOI 10.1016/S1440-2440(05)80030-1; Cromwell F, 2000, BRIT J SPORT MED, V34, P104, DOI 10.1136/bjsm.34.2.104; DAVIES JE, 1978, BRIT MED J, V2, P1759, DOI 10.1136/bmj.2.6154.1759; Fauno P, 2006, INT J SPORTS MED, V27, P75, DOI 10.1055/s-2005-837485; Fields SK, 2007, TRAUMA VIOLENCE ABUS, V8, P359, DOI 10.1177/1524838007307293; FINKE RC, 1998, J ORTHOP SPORT PHYS, V10, P54; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Giza E, 2003, AM J SPORT MED, V31, P550, DOI 10.1177/03635465030310041201; Hawkins RD, 1998, BRIT J SPORT MED, V32, P326, DOI 10.1136/bjsm.32.4.326; Hawkins RD, 1996, BRIT J SPORT MED, V30, P165, DOI 10.1136/bjsm.30.2.165; INGLIS GS, 1981, NEW ZEAL MED J, V94, P349; Jakoet I, 1998, S AFR MED J, V88, P45; Junge A, 2000, AM J SPORT MED, V28, pS47; Junge A, 2004, AM J SPORT MED, V32, p80S, DOI 10.1177/0363546503261245; Junge A, 2004, AM J SPORT MED, V32, p23S, DOI 10.1177/0363546503261246; LEWIS ER, 1996, SPORTS EXERC INJURY, V2, P186; *NAT COLL ATHL ASS, NCAA INJ SURV SYST; Peterson L, 2000, AM J SPORT MED, V28, pS51; ROY SP, 1974, S AFR MED J, V48, P2321; SCHER AT, 1991, S AFR MED J, V79, P614; Schwebel DC, 2006, J SAFETY RES, V37, P507, DOI 10.1016/j.jsr.2006.08.002; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; SMITHERS M, 1985, MED J AUSTRALIA, V142, P457, DOI 10.5694/j.1326-5377.1985.tb113452.x; *US CENS BUR, REG US; WATSON AWS, 1984, AM J SPORT MED, V12, P65, DOI 10.1177/036354658401200110; Watson AWS, 1996, AM J SPORT MED, V24, P323, DOI 10.1177/036354659602400313; Watson AWS, 1996, IRISH J MED SCI, V165, P12, DOI 10.1007/BF02942792; WATTERS DAK, 1984, ARCH EMERG MED, V1, P105; Yard EE, 2006, PEDIATRICS, V118, pE1342, DOI 10.1542/peds.2006-0834	39	31	31	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	FEB	2008	14	1					34	38		10.1136/ip.2007.017277			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	258LB	WOS:000252868300009	18245313				2021-06-18	
J	Gutierrez-Gonzalez, R; Boto, GR; Rivero-Garvia, M; Perez-Zamarron, A; Gomez, G				Gutierrez-Gonzalez, Raquel; Boto, Gregorio R.; Rivero-Garvia, Monica; Perez-Zamarron, Alvaro; Gomez, Gustavo			Penetrating brain injury by drill bit	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						head injury; non-missile; penetrating brain injury; self-inflicted	TRANSCRANIAL STAB WOUNDS; CRANIOCEREBRAL INJURIES; POWER DRILL; NAIL-GUN; ANGIOGRAPHY	Non-missile low velocity penetrating brain injuries are unusual among civilian population. They show specific characteristics different from missile wounds. In this paper we describe a rare case of self-inflicted penetrating head trauma by electric drill. We document neuroimaging studies and review the management concerning this pathology. To our knowledge, this is the first case of intracranial retained drill bit with such radiological findings reported in the literature. An 80-year-old male with no previous psychiatric disorder presented at our hospital after suffering an accident while working with an electric drill. Physical examination revealed right lower extremity plegia and three penetrating scalp wounds to the left parasagittal region. Skull Xray and computed tomography demonstrated an intracranial metallic foreign body located in the left parietal lobe and an intraparenchymal hematoma with no mass effect close to the foreign body. The patient was taken to the operating room to remove the drill bit fragment. Antibiotic and antiseizure prophylaxis were administered. Postoperative computed tomography confirmed no residual metallic fragments and functional recovery was excellent. After psychiatric assessment, suicide attempt was confirmed and antidepressive therapy was then started. On follow-up, no complication was documented. It is essential to exclude penetrating brain trauma whenever a scalp wound is noticed in order to provide proper treatment and prevention care. The permanent neurological deficit in low velocity injuries is related to the degree and location of the primary injury. It also depends on an early diagnosis and treatment and the absence of delayed complications. (C) 2007 Elsevier B.V. All rights reserved.	[Gutierrez-Gonzalez, Raquel; Boto, Gregorio R.; Rivero-Garvia, Monica; Gomez, Gustavo] Hosp Clin San Carlos, Dept Neurosurg, Madrid 28040, Spain; [Perez-Zamarron, Alvaro] Hosp Univ La Paz, Dept Neurosurg, Madrid 28046, Spain	Gutierrez-Gonzalez, R (corresponding author), Hosp Clin San Carlos, Dept Neurosurg, Prof Martin Lagos S-N, Madrid 28040, Spain.	rgutierrezgonzalez@yahoo.es	IBIS, NEUROCIENCIA APLICAD/C-2516-2016; Rivero-Garvia, Monica MRG/F-1567-2015	Rivero-Garvia, Monica MRG/0000-0001-5125-6151			[Anonymous], 2001, J TRAUMA S2, V51, pS41; [Anonymous], 2001, J TRAUMA S2, V51, pS34; Carey ME, 2004, YOUMANS NEUROLOGICAL, V4, P5223; Chibbaro S, 2006, ACTA NEUROCHIR, V148, P937, DOI 10.1007/s00701-006-0794-5; COSTANTINIDES F, 1982, AM J FOREN MED PATH, V3, P241, DOI 10.1097/00000433-198209000-00009; CZASTKA H, 1997, NEUROL NEUROCHIR POL, V11, P395; DUTREVOU MD, 1992, NEUROSURGERY, V31, P905, DOI 10.1227/00006123-199211000-00012; Gonul E, 1997, NEUROSURG REV, V20, P177, DOI 10.1007/BF01105561; Karabatsou K, 2005, AM J FOREN MED PATH, V26, P174, DOI 10.1097/01.paf.0000163823.55149.60; KELLY AJ, 1992, SURG NEUROL, V38, P471, DOI 10.1016/0090-3019(92)90118-7; KHALIL N, 1991, SURG NEUROL, V35, P294, DOI 10.1016/0090-3019(91)90008-W; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; Litvack ZN, 2006, J NEUROSURG, V104, P828, DOI 10.3171/jns.2006.104.5.828; Nathoo N, 2000, NEUROSURGERY, V47, P1117, DOI 10.1097/00006123-200011000-00018; Navarro Celma J A, 1989, Acta Med Leg Soc (Liege), V39, P247; RISH BL, 1980, J NEUROSURG, V53, P772, DOI 10.3171/jns.1980.53.6.0772; Schmeling Andreas, 2003, Archiv fuer Kriminologie, V211, P65; Zazpe I, 2006, NEUROCIRUGIA, V17, P544; 2001, J TRAUMA S2, V51, pS26; 2001, J TRAUMA S2, V51, pS7; 2001, J TRAUMA S2, V51, pS44	22	31	33	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467			CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	FEB	2008	110	2					207	210		10.1016/j.clineuro.2007.09.014			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	266CE	WOS:000253408100019	17983703				2021-06-18	
J	Haagsma, JA; van Beeck, EF; Polinder, S; Hoeymans, N; Mulder, S; Bonsel, GJ				Haagsma, J. A.; van Beeck, E. F.; Polinder, S.; Hoeymans, N.; Mulder, S.; Bonsel, G. J.			Novel empirical disability weights to assess the burden of non-fatal injury	INJURY PREVENTION			English	Article							HEALTH; DISEASE; COMPARABILITY; RELIABILITY; POPULATION; SCALE; DALYS	Background: Disability weights are necessary to estimate the disability component (years lived with disability, YLDs) of disability-adjusted life years. The original global burden of disease approach to deriving disability weights ignores temporary consequences of injury. Objectives: To develop and apply novel empirical disability weights to improve estimates of the non-fatal burden of injury. Methods: A set of 45 disability weights was derived for both permanent and temporary consequences of injury, using the annual profile approach. A population panel (n=143) provided the values. The novel set of disability weights was then linked to epidemiological surveillance data on the incidence of injury in The Netherlands to calculate YLD resulting from permanent and temporary consequences of injury. Results: The empirical disability weights for injury consequences varied from minor (corneal abrasion, 0.004) to very severe (quadriplegia, 0.719) health loss. Increasing disability weights by level of severity were found, as illustrated by concussion (0.02), versus moderate brain injury (0.193), versus severe brain injury (0.540). Application of these new disability weights showed a 36% increase in YLD as the result of unintentional injury. Conclusions: YLD calculations based on global burden of disease disability weights underestimate the size of the injury problem by ignoring temporary health consequences. Application of novel empirical disability weights, derived using the annual profile approach, may improve calculations on the burden of non-fatal injury.	[Haagsma, J. A.; Hoeymans, N.] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; [Haagsma, J. A.; Bonsel, G. J.] Univ Amsterdam, Acad Med Ctr, Dept Social Med, NL-1105 AZ Amsterdam, Netherlands; [Haagsma, J. A.; Bonsel, G. J.] Erasmus Univ, Erasmus Med Ctr, Inst Hlth Policy & Management, Rotterdam, Netherlands; [van Beeck, E. F.; Polinder, S.] Erasmus Univ, Erasmus Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Mulder, S.] Consumer Safety Inst, Amsterdam, Netherlands	Haagsma, JA (corresponding author), Natl Inst Publ Hlth & Environm, POB 1, NL-3720 BA Bilthoven, Netherlands.	juanita.haagsma@rivm.nl					Anand S, 1997, J HEALTH ECON, V16, P685, DOI 10.1016/S0167-6296(97)00005-2; Arnesen T, 2004, HEALTH POLICY, V70, P137, DOI 10.1016/j.healthpol.2003.08.004; Badia X, 1999, QUAL LIFE RES, V8, P303, DOI 10.1023/A:1008952423122; BONSEL GJ, 2003, ZIEKTELASTBEPALING 2; Brazier J, 1999, J Health Serv Res Policy, V4, P174; Cubo E, 2005, MOVEMENT DISORD, V20, P1481, DOI 10.1002/mds.20622; Drummond MF., 1997, METHODS EC EVALUATIO, V2nd; Essink-Bot ML, 2002, SUMMARY MEASURES OF POPULATION HEALTH: CONCEPTS, ETHICS, MEASUREMENT AND APPLICATIONS, P449; Essink-Bot ML, 2002, B WORLD HEALTH ORGAN, V80, P644; Field M., 1998, SUMMARIZING POPULATI; Gold MR, 2002, ANNU REV PUBL HEALTH, V23, P115, DOI 10.1146/annurev.publhealth.23.100901.140513; Jankovic S, 2007, EUR J PUBLIC HEALTH, V17, P80, DOI 10.1093/eurpub/ckl072; JANSSEN MF, 2008, IN PRESS VALUE HTLH; Krabbe PFM, 1999, J CLIN EPIDEMIOL, V52, P293, DOI 10.1016/S0895-4356(98)00163-2; Krabbe PFM, 1997, SOC SCI MED, V45, P1641, DOI 10.1016/S0277-9536(97)00099-3; Lin MR, 2006, PHYS THER, V86, P337, DOI 10.1093/ptj/86.3.337; Lyons R A, 2006, Int J Inj Contr Saf Promot, V13, P63, DOI 10.1080/17457300500258682; MATHERS CD, 1999, 17 AIHW PHE; McClure RJ, 1996, ACCIDENT ANAL PREV, V28, P443, DOI 10.1016/0001-4575(96)00012-7; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Murray CJL, 1997, J HEALTH ECON, V16, P703, DOI 10.1016/S0167-6296(97)00004-0; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P481; Murray CJL, 1996, GLOBAL BURDEN DIS CO; NORMAN R, REVISED BURDEN DIS E; Polinder S, 2005, PEDIATRICS, V116, pE810, DOI 10.1542/peds.2005-1035; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; Schwarzinger M, 2003, POPUL HEALTH METR, V1, P1, DOI DOI 10.1186/1478-7954-1-9; Sim F, 2002, PUBLIC HEALTH, V116, P251, DOI 10.1038/sj.ph.1900883; Stouthard MEA, 2000, EUR J PUBLIC HEALTH, V10, P24, DOI 10.1093/eurpub/10.1.24; Torrance G W, 1972, Health Serv Res, V7, P118; Ustun TB, 1999, LANCET, V354, P111, DOI 10.1016/S0140-6736(98)07507-2; VOS T, 2002, SUMMARY MEASURES POP; Westert GP, 2005, EUR J PUBLIC HEALTH, V15, P59, DOI 10.1093/eurpub/cki116; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	35	31	32	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	FEB	2008	14	1					5	10		10.1136/ip.2007.017178			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	258LB	WOS:000252868300004	18245308				2021-06-18	
J	Lumpkins, K; Bochicchio, GV; Zagol, B; Ulloa, K; Simard, JM; Schaub, S; Meyer, W; Scalea, T				Lumpkins, Kimberly; Bochicchio, Grant V.; Zagol, Bradley; Ulloa, Kristian; Simard, J. Marc; Schaub, Stacey; Meyer, Walter; Scalea, Thomas			Plasma levels of the beta chemokine regulated upon activation, normal T cell expressed, and secreted (RANTES) correlate with severe brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	37th Annual Meeting of the Western-Trauma-Association	FEB 25-MAR 02, 2007	Steamboat Springs, CO	Western Trauma Assoc		RANTES; traumatic brain injury; cytokine	INFLAMMATION; INDUCTION	Background: The expression of the beta chemokine RANTES (regulated upon activation, normal T cell expressed, and secreted) has previously been shown to be elevated after traumatic brain injury (TBI) in animal models, but it was unknown whether the plasma level of RANTES was predictive of TBI in critically injured trauma patients. Methods: A prospective study was conducted on 108 critically ill trauma patients. Patients were stratified by radiologic diagnosis of TBI. Severe TBI was classified as the presence of diffuse axonal injury, midline shift, or herniation based on admission head computed tomography findings. Serum levels were evaluated at admission and hospital day 7. RANTES was measured using Luminex multiplex assays. Results: Fifty-four patients with and without TBI were compared. Severe TBI was diagnosed in 23 of the 54 TBI patients (43%) and mild/moderate TBI was found in 31 (57%) patients. The mean age of the study population was 43 +/- 20 years with a mean Injury Severity Score of 29 +/- 14. There was no significant difference between groups in age, sex, and Injury Severity Score. At admission, RANTES was significantly higher in patients with severe brain injury than in non-TBI patients (mean 1,339 pg/mL vs. 708 pg/mL, p=0.046), and there was a trend toward significance when comparing patients with severe versus mild/moderate brain injury (mean 1,339 pg/mL vs. 752 pg/mL, p=0.069). There was no statistically significant difference on day 7. Conclusions: RANTES was a significant early marker of severe TBI in critically injured trauma patients, consistent with animal models. Future research on the role of RANTES in the pathogenesis of human TBI is warranted.	[Lumpkins, Kimberly; Bochicchio, Grant V.; Zagol, Bradley; Ulloa, Kristian; Simard, J. Marc; Meyer, Walter; Scalea, Thomas] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Clin Outcomes Res, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA	Bochicchio, GV (corresponding author), 22 S Greene St,Rm T3R85B, Baltimore, MD 21201 USA.	gbochicchio@umm.edu		Lumpkins, Kimberly/0000-0002-5236-9411			Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fitch MT, 1999, J NEUROSCI, V19, P8182; Frank S, 2000, BIOCHEM J, V347, P265, DOI 10.1042/0264-6021:3470265; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Lee HP, 2005, J NEUROIMMUNOL, V158, P26, DOI 10.1016/j.jneuroim.2004.08.010; Omari KM, 2004, J NEUROIMMUNOL, V146, P203, DOI 10.1016/j.jneuroim.2003.10.032; Sarto BY, 2004, ANN TROP MED PARASIT, V98, P297, DOI 10.1179/000349804225003271; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Song A, 2000, IMMUNOL REV, V177, P236, DOI 10.1034/j.1600-065X.2000.17610.x	12	31	32	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2008	64	2					358	361		10.1097/TA.0b013e318160df9b			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	264KV	WOS:000253287100021	18301198				2021-06-18	
J	Bendel, S; Koivisto, T; Ruokonen, E; Rinne, J; Romppanen, J; Vauhkonen, I; Kiviniemi, V; Uusaro, A				Bendel, Stepani; Koivisto, Timo; Ruokonen, Esko; Rinne, Jaakko; Romppanen, Jarkko; Vauhkonen, Ilkka; Kiviniemi, Vesa; Uusaro, Ari			Pituitary-adrenal function in patients with acute subarachnoid haemorrhage: a prospective cohort study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; CRITICALLY-ILL PATIENTS; SEPTIC SHOCK; NEUROENDOCRINE DYSFUNCTION; PLASMA-CORTISOL; ACUTE-PHASE; HIGH-RISK; INSUFFICIENCY; HYPOPITUITARISM; HYDROCORTISONE	Introduction Subarachnoid haemorrhage (SAH) may damage the hypothalamo-pituitary-adrenal gland (HPA) axis and disturb cortisol metabolism. There are no available data that relates to the response of the HPA axis in the acute phase of SAH. We aimed to characterise the behavior of serum adrenocorticotropic hormone (ACTH), total cortisol, stimulated total cortisol and free cortisol concentrations in acute aneurysmal SAH. Methods A prospective cohort study was conducted of patients with acute aneurysmal SAH (n = 30) admitted to a tertiary university hospital. Patients admitted for elective aneurysmal surgery (n = 16) served as the control group. An ACTH stimulation test was performed twice during the first week and at three months. The main outcome measure was description of the ACTH-cortisol response by calculating serum free cortisol and measuring total cortisol and ACTH concentrations. A mixed models method was used for testing between the groups, allowing heterogeneity between the groups. Results Patients with SAH had higher initial serum total cortisol (mean +/- SD; 793 +/- 312 nmol/L) and free cortisol concentrations (83 +/- 55 nmol/L) than control patients (535 +/ - 193 nmol/L, p = 0.001 and 33 +/- 18 nmol/ L, p < 0.001, respectively). Thereafter, there were no differences in this respect. Serum free and total cortisol concentrations correlated but were unaffected by the severity of SAH. ACTH concentrations were comparable between SAH and control groups. Patients with Hunt-Hess grades IV to V had higher ACTH concentrations at day one (10.7 +/- 7.1 pmol/l/L) and day five (8.2 +/- 7.7 pmol/L) than patients with grade I-III (day one: 3.8 +/- 2.0 pmol/L, p = 0.002; day five: 4.7 +/- 1.8 pmol/L, p = 0.04). Conclusions Calculation of serum free cortisol concentration was not helpful in identifying patients with potential hypocortisolism. SAH severity did not affect cortisol concentrations, possibly indicating relative pituitary-adrenal insufficiency in patients with more severe bleeding. Trial registration ClinicalTrials. gov Identifier NCT00614887.	[Bendel, Stepani; Ruokonen, Esko; Uusaro, Ari] Kuopio Univ Hosp, Dept Intens Care, Kuopio 70211, Finland; [Kiviniemi, Vesa] Univ Kuopio, IT Ctr, FIN-70211 Kuopio, Finland; [Koivisto, Timo; Rinne, Jaakko] Kuopio Univ Hosp, Dept Neurosurg, Kuopio 70211, Finland; [Romppanen, Jarkko] Kuopio Univ Hosp, Eastern Finland Lab Ctr, Kuopio 70211, Finland; [Vauhkonen, Ilkka] Kuopio Univ Hosp, Dept Med, Kuopio 70211, Finland	Bendel, S (corresponding author), Kuopio Univ Hosp, Dept Intens Care, Puijonlaaksontie 2, Kuopio 70211, Finland.	Stepani.Bendel@kuh.fi					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; ARON DC, 2007, BASIC CLIN ENDOCRINO, P346; Bernard F, 2006, BRIT J ANAESTH, V96, P72, DOI 10.1093/bja/aei277; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cohen J, 2006, INTENS CARE MED, V32, P1901, DOI 10.1007/s00134-006-0389-x; COOLENS JL, 1987, J STEROID BIOCHEM, V26, P197, DOI 10.1016/0022-4731(87)90071-9; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; Dimopoulou I, 2005, INTENS CARE MED, V31, P1020, DOI 10.1007/s00134-005-2689-y; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; Dimopoulou I, 2004, INTENS CARE MED, V30, P1216, DOI 10.1007/s00134-004-2297-2; Dorin RI, 2003, ANN INTERN MED, V139, P194, DOI 10.7326/0003-4819-139-3-200308050-00009; Espiner EA, 2002, CLIN ENDOCRINOL, V56, P629, DOI 10.1046/j.1365-2265.2002.01285.x; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; Ho JT, 2006, J CLIN ENDOCR METAB, V91, P105, DOI 10.1210/jc.2005-0265; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, J CLIN ENDOCR METAB, V92, P1326, DOI 10.1210/jc.2006-1791; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Kreitschmann-Andermahr I, 2003, J NEUROL NEUROSUR PS, V74, P1133, DOI 10.1136/jnnp.74.8.1133; Marik PE, 2003, CRIT CARE MED, V31, P141, DOI 10.1097/00003246-200301000-00022; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Tanriverdi F, 2007, CLIN ENDOCRINOL, V67, P931, DOI 10.1111/j.1365-2265.2007.02989.x	30	31	31	2	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X			CRIT CARE	Crit. Care		2008	12	5							R126	10.1186/cc7084			10	Critical Care Medicine	General & Internal Medicine	381UJ	WOS:000261561100014	18851750	DOAJ Gold, Green Published			2021-06-18	
J	Gentry, T				Gentry, Tony			PDAs as cognitive aids for people with multiple sclerosis	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						assistive technology; cognition; multiple sclerosis; occupational therapy; personal digital assistant (PDA)	TRAUMATIC BRAIN-INJURY; ELECTRONIC MEMORY AID; MENTAL-RETARDATION; NEUROPSYCHOLOGICAL REHABILITATION; EVERYDAY MEMORY; PAGING SYSTEM; HEAD-INJURY; INDIVIDUALS; COMPUTER; OUTCOMES	OBJECTIVE. Cognitive impairment is a common symptom for people with multiple sclerosis (MS). This study evaluated the effects of an occupational therapy training protocol using personal digital assistants (PDAs) as assistive technology for people with cognitive impairment related to MS. METHODS. Twenty participants were trained to use PDAs by an occupational therapist. Assessments of functional performance were taken at the start of an 8-week pretreatment period, at the beginning and end of training, and 8 weeks after the conclusion of training. RESULTS. Participants demonstrated the ability to learn how to use basic PDA functions and retain learning for at least 8 weeks. Functional performance increased significantly with PDA use, and this gain was maintained at 8-week follow-up. CONCLUSION. This study provides evidence of an association between an intervention providing training in the use of a PDA and improvements in the everyday function of people with cognitive impairment related to MS.	Virginia Commonwealth Univ, Dept Occupat Therapy, Richmond, VA 23298 USA	Gentry, T (corresponding author), Virginia Commonwealth Univ, Dept Occupat Therapy, Med Coll Virginia Campus, Richmond, VA 23298 USA.	logentry@vcu.edu					BOSCH J, 1995, RELIABILITY VALIDITY; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Davies DK, 2004, J DEV PHYS DISABIL, V16, P95, DOI 10.1023/B:JODD.0000010041.13710.33; Davies DK, 2003, EDUC TRAIN MENT RET, V38, P106; Davies DK, 2002, EDUC TRAIN MENT RET, V37, P209; Davies DK, 2002, MENT RETARD, V40, P358, DOI 10.1352/0047-6765(2002)040<0358:EITMSO>2.0.CO;2; Dedding C, 2004, CLIN REHABIL, V18, P660, DOI 10.1191/0269215504cr746oa; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; Gorman P, 2003, NEUROREHABILITATION, V18, P57; Hall KM, 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; HARRIS J, 1984, CLIN MANAGEMENT MEMO, P46; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; KERNER M, 1985, COGNITIVE REHABILITA, V3, P26; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; LaRocca NG, 2000, MULTIPLE SCLEROSIS: DIAGNOSIS, MEDICAL MANAGEMENT, AND REHABILITATION, P405; Law M., 2004, CANADIAN OCCUPATIONA; Law MJS, 1998, CLIENT CTR OCCUPATIO; Levinson R, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199704000-00010; LYNCH W, 1992, J HEAD TRAUMA REHAB, V7, P36; Mihailidis A, 2004, NEUROPSYCHOL REHABIL, V14, P135, DOI 10.1080/09602010343000156; Polgar J. M., 2002, SEATING MOBILITY, V11, P114; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Rogers EM., 2003, DIFFUSION INNOVATION, V5th ed; SBORDONE RJ, 1986, PSYCHOTHERAPY PRIVAT, V4, P51; SEGAL ME, 1995, AM J PHYS MED REHAB, V74, P276, DOI 10.1097/00002060-199507000-00004; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sterns AA, 2005, GERONTOLOGIST, V45, P828, DOI 10.1093/geront/45.6.828; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WHITENECK G, 1998, GUIDE USE CHART CRAI; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1992, GUIDE CHART CRAIG AS; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 2003, NEUROREHABILITATION, V18, P3; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wood R L, 1987, Int Disabil Stud, V9, P149; World Health Organization, 1980, INT CLASSIFICATION I; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161	46	31	31	1	11	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	JAN-FEB	2008	62	1					18	27		10.5014/ajot.62.1.18			10	Rehabilitation	Rehabilitation	251BM	WOS:000252345600003	18254427				2021-06-18	
J	Mezzich, AC; Tarter, RE; Feske, U; Kirisci, L; McNamee, RL; Day, BS				Mezzich, Ada C.; Tarter, Ralph E.; Feske, Ulrike; Kirisci, Levent; McNamee, Rebecca L.; Day, Bang-Shiuh			Assessment of risk for substance use disorder consequent to consumption of illegal drugs: Psychometric validation of the neurobehavior disinhibition trait	PSYCHOLOGY OF ADDICTIVE BEHAVIORS			English	Article						addiction; behavior; etiology; frontal lobes; substance abuse	DEPRESSIVE SYMPTOMS; YOUNG ADULTHOOD; FAMILY-HISTORY; FRONTAL-LOBE; COGNITIVE DISTORTIONS; AGGRESSIVE-BEHAVIOR; ANTISOCIAL-BEHAVIOR; ADOLESCENT FEMALES; USE INVOLVEMENT; EYE-MOVEMENTS	Previous research has shown that the trait neurobehavior disinhibition (ND), which consists of affect, behavior, and cognitive indicators of self-regulation, is a significant predictor of substance use disorder (SUD) between childhood and young adulthood. The authors evaluated the psychometric properties of the ND trait in 278 boys evaluated at ages 10-12 and 16 years. ND score significantly predicted SUD and outcomes that commonly manifest in tandem with SUD by age 19, such as violence, arrests, committing crime while intoxicated, and concussion injury. In addition to predictive validity, the ND trait was found to have good construct, discriminative, and concurrent validity, as well as good test-retest and internal reliability. The ND trait may be useful for detecting youths at high risk for developing SUD and related outcomes.	Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, CEDAR, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA	Mezzich, AC (corresponding author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, CEDAR, 707 Salk Hall, Pittsburgh, PA 15261 USA.	adacm@pitt.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50 CA05605] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA020130, R01 DA05952, K02 DA017822, K01 DA14568] Funding Source: Medline; NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01 DE13844] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE013844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K02DA017822, R01DA005952, R01DA020130, K25DA014568] Funding Source: NIH RePORTER		*AM PSYCH ASS, 2007, APA DICT PSYCH; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Bauer LO, 2001, BIOL PSYCHIAT, V50, P600, DOI 10.1016/S0006-3223(01)01066-6; Blackson TC, 1999, DRUG ALCOHOL DEPEN, V56, P115, DOI 10.1016/S0376-8716(99)00030-7; Brunelle C, 2005, ALCOHOL CLIN EXP RES, V29, p153A; Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041; Chen LS, 1999, J CHILD ADOLES SUBST, V8, P37, DOI 10.1300/J029v08n04_03; Clark DB, 2002, J CONSULT CLIN PSYCH, V70, P1207, DOI 10.1037//0022-006X.70.6.1207; Clark DB, 1996, CHILD ADOL PSYCH CL, V5, P45, DOI 10.1016/S1056-4993(18)30384-5; Clark DB, 1999, J CLIN CHILD PSYCHOL, V28, P333, DOI 10.1207/S15374424jccp280305; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COLE PM, 1993, J CLIN CHILD PSYCHOL, V22, P154, DOI 10.1207/s15374424jccp2202_3; Costa FM, 1999, J STUD ALCOHOL, V60, P480, DOI 10.15288/jsa.1999.60.480; *CTR ED DRUG AB RE, 1990, CEDAR FOLL QUEST; Curran GM, 2000, J DRUG ISSUES, V30, P375, DOI 10.1177/002204260003000208; Doricchi F, 1997, EXP BRAIN RES, V116, P50, DOI 10.1007/PL00005744; Eddy WF, 2004, HANDBOOK OF COMPUTATIONAL STATISTICS: CONCEPTS AND METHODS, P1001; FINN PR, 1992, ALCOHOL CLIN EXP RES, V16, P585, DOI 10.1111/j.1530-0277.1992.tb01421.x; Giancola PR, 1996, J STUD ALCOHOL, V57, P352, DOI 10.15288/jsa.1996.57.352; Giancola PR, 1999, PSYCHOL ADDICT BEHAV, V13, P22, DOI 10.1037/0893-164X.13.1.22; Giancola PR, 1998, J ABNORM PSYCHOL, V107, P629, DOI 10.1037/0021-843X.107.4.629; Giancola PR, 2004, J ABNORM PSYCHOL, V113, P541, DOI 10.1037/0021-843X.113.4.541; Giancola PR, 2003, J CHILD PSYCHOL PSYC, V44, P857, DOI 10.1111/1469-7610.00170; Giancola PR, 2000, J STUD ALCOHOL, V61, P809, DOI 10.15288/jsa.2000.61.809; Giancola PR, 2001, EXP CLIN PSYCHOPHARM, V9, P215, DOI 10.1037//1064-1297.9.2.215; Giancola PR, 1999, PSYCHOL SCI, V10, P203, DOI 10.1111/1467-9280.00135; Giancola PR, 2000, AGGRESSIVE BEHAV, V26, P359; GORENSTEIN EE, 1980, PSYCHOL REV, V87, P301, DOI 10.1037/0033-295X.87.3.301; GUITTON D, 1985, EXP BRAIN RES, V58, P455; Habeych ME, 2005, PSYCHOL ADDICT BEHAV, V19, P123, DOI 10.1037/0893-164X.19.2.123; HENRY B, 1993, J ABNORM CHILD PSYCH, V21, P469, DOI 10.1007/BF00916314; Hicks BM, 2004, ARCH GEN PSYCHIAT, V61, P922, DOI 10.1001/archpsyc.61.9.922; Iacono WG, 2000, INT J PSYCHOPHYSIOL, V38, P81, DOI 10.1016/S0167-8760(00)00132-X; Kirisci L, 2006, ADDICT BEHAV, V31, P686, DOI 10.1016/j.addbeh.2005.05.049; Kirisci L, 2004, DRUG ALCOHOL DEPEN, V76, P125, DOI 10.1016/j.drugalcdep.2004.04.015; KIRISCI L, IN PRESS J ADDICTIVE; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; Loehlin J. C., 2004, LATENT VARIABLE MODE; Luna B, 2001, NEUROIMAGE, V13, P786, DOI 10.1006/nimg.2000.0743; Luria A. R., 1966, HIGHER CORTICAL FUNC; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Measelle JR, 2006, PSYCHOL ADDICT BEHAV, V20, P225, DOI 10.1037/0893-164X.20.3.225; Mezzich AC, 2001, J CHILD ADOLES SUBST, V10, P35, DOI 10.1300/J029v10n04_04; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Muri RM, 1998, J NEUROL NEUROSUR PS, V65, P374, DOI 10.1136/jnnp.65.3.374; ODRISCOLL GA, 1995, P NATL ACAD SCI USA, V92, P925, DOI 10.1073/pnas.92.3.925; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; PARSONS OA, 1972, J ABNORM PSYCHOL, V80, P308, DOI 10.1037/h0033740; Pelham W, 1987, DBD RATING SCALE PAR; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Reckase M.D., 1979, J EDUC STAT, V4, P207, DOI 10.3102/10769986004003207; SCHNEIDER W, 1987, PSYCHOL LEARN MOTIV, V21, P53; Schweinsburg AD, 2004, ANN NY ACAD SCI, V1021, P391, DOI 10.1196/annals.1308.050; SILVERMAN IW, 1992, J ABNORM CHILD PSYCH, V20, P415, DOI 10.1007/BF00918985; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2; SPITZER R, 1987, MANUAL STRUCTURED CL; STEIGER JH, 1990, MULTIVAR BEHAV RES, V25, P173, DOI 10.1207/s15327906mbr2502_4; Stice E, 1998, J ABNORM PSYCHOL, V107, P616, DOI 10.1037/0021-843X.107.4.616; Sweeney JA, 1996, J NEUROPHYSIOL, V75, P454; Tarter R, 1999, DEV PSYCHOPATHOL, V11, P657, DOI 10.1017/S0954579499002266; Tarter RE, 2004, DRUG ALCOHOL DEPEN, V73, P121, DOI 10.1016/j.drugalcdep.2003.07.004; Tarter RE, 2003, AM J PSYCHIAT, V160, P1078, DOI 10.1176/appi.ajp.160.6.1078; TARTER RE, 1985, J STUD ALCOHOL, V46, P329, DOI 10.15288/jsa.1985.46.329; TARTER RE, 1995, DRUG ALCOHOL DEPEN, V39, P253, DOI 10.1016/0376-8716(95)01175-6; Vanyukov MM, 2003, NEUROSCI BIOBEHAV R, V27, P507, DOI 10.1016/j.neubiorev.2003.08.002; WECHSLER D, 1972, WECHSLER ADULT INTEL; Wills TA, 2006, PSYCHOL ADDICT BEHAV, V20, P265, DOI 10.1037/0893-164X.20.3.265; WINDLE M, 1992, J YOUTH ADOLESCENCE, V21, P1, DOI 10.1007/BF01536980; Windle M., 1992, PSYCHOL ASSESSMENT, V4, P228, DOI [DOI 10.1037/1040-3590.4.2.228, 10.1037/1040-3590.4.2.228]; Windle M., 1986, J ADOLESC RES, V1, P213, DOI [DOI 10.1177/074355488612007, 10.1177/074355488612007]	71	31	31	0	14	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0893-164X	1939-1501		PSYCHOL ADDICT BEHAV	Psychol. Addict. Behav.	DEC	2007	21	4					508	515		10.1037/0893-164X.21.4.508			8	Substance Abuse; Psychology, Multidisciplinary	Substance Abuse; Psychology	237EJ	WOS:000251356100009	18072833				2021-06-18	
J	Heitger, MH; Jones, RD; Frampton, CM; Ardagh, MW; Anderson, TJ				Heitger, Marcus H.; Jones, Richard D.; Frampton, Chris M.; Ardagh, Michael W.; Anderson, Tim J.			Recovery in the first year after mild head injury: Divergence of symptom status and self-perceived quality of life	JOURNAL OF REHABILITATION MEDICINE			English	Article						head injury; recovery; IQ; rehabilitation; health status	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYMPTOMS; FOLLOW-UP; POSTCONCUSSION SYNDROME; PREDICTIVE-VALUE; ADULTS; QUESTIONNAIRE; POPULATION; DISABILITY; COMPLAINTS	Objective: To examine self-perceived health status during the first year following mild closed head injury. Methods: At 1 week, and at 3, 6 and 12 months post-injury, 37 patients with mild closed head injury completed written versions of the Rivermead Post-Concussion Symptoms Questionnaire (RPSQ), the Rivermead Head-Injury Followup Questionnaire (RHIFQ) and the SF-36 Health Survey. Thirty-seven controls provided baselines for the SF-36 and the RPSQ. Results: The 3 questionnaires conveyed differing impressions of recovery. On the RPSQ, the patients exhibited ongoing symptomatic complaints and higher scores compared with controls. The RHIFQ conveyed a better recovery in terms of everyday function. The SF-36 showed the best recovery, with the mild closed head injury group achieving normal scores at 3, 6 and 12 months. Regression analyses indicated an influence of IQ, but not of age, education, or clinical measures of injury severity, on long-term health status. Conclusion: Recovery after mild closed head injury can involve a dichotomy of persistent post-concussional symptoms but relatively normal functionality and quality of life. In addition to indicating an influence of IQ on perception of recovery in mild closed head injury, our findings demonstrate that the nature of self-report questionnaires considerably influences the picture of recovery. This emphasizes the importance of methods unaffected by IQ and self-evaluative accuracy in the assessment of mild closed head injury.	Van Veer Inst Parkinsons & Brain Res, Christchurch, New Zealand; Univ Otago, Dept Med, Christchurch, New Zealand; Christchurch Hosp, Dept Neurol, Christchurch, New Zealand	Heitger, MH (corresponding author), Van Veer Inst Parkinsons & Brain Res, POB 2682, Christchurch, New Zealand.	marcus.heitger@chmeds.ac.nz		Jones, Richard/0000-0003-2287-3358			Anderson T, 2006, PRACT NEUROL, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; EVANS RW, 1992, NEUROL CLIN, V10, P815; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895-4356(98)00081-X	40	31	31	0	7	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	OCT	2007	39	8					612	621		10.2340/16501977-0100			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	225UK	WOS:000250543400005	17896052	DOAJ Gold			2021-06-18	
J	Lew, HL; Gray, M; Poole, JH				Lew, Henry L.; Gray, Max; Poole, John H.			Temporal stability of auditory event-related potentials in healthy individuals and patients with traumatic brain injury	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						brain injury; event-related potentials; reliability	TEST-RETEST RELIABILITY; SOMATOSENSORY-EVOKED POTENTIALS; MISMATCH NEGATIVITY; ODDBALL TASK; P300; RESPONSES; SCHIZOPHRENIA; RECOGNITION; VARIABILITY; ALCOHOLICS	Historically, cognitive event-related potentials (ERPs) have received limited acceptance for clinical use due to lack of evidence for their reliability. However, recent advances in computer technology and artifact rejection methods have greatly enhanced the fidelity of ERP measurements. The present study examined the test-retest reliability of ERP measurement by using current data processing methods. We assessed the temporal stability of the most commonly used ERP paradigm, auditory pure-tone "odd ball" detection, and compared it with other commonly used clinical measures reported in the literature. Auditory ERPs were collected in 19 healthy subjects and 7 patients with traumatic brain injury at two time points, 2 days to 2 months apart. Test-retest reliability was calculated for four ERP components: N1, MMN (mismatch negativity), P3, and N4. In healthy subjects, temporal stabilities of these four commonly studied ERP components' amplitude measurements were moderate to high, with intraclass correlations ranging from 0.6 to 0.8. In contrast, in patients with traumatic brain injury, ERPs were stable only for the NI component (intraclass correlation = 0.7).	VA Palo Alto Hlth Care Syst, Palo Alto, CA USA	Lew, HL (corresponding author), PM&R, 3801 Miranda Ave,MS-117B, Palo Alto, CA 94304 USA.	henrylew@stanford.edu					Barnes VA, 2004, BLOOD PRESS MONIT, V9, P173, DOI 10.1097/00126097-200408000-00001; Comas A, 1998, Aten Primaria, V22, P142; Debener S, 2002, INT J PSYCHOPHYSIOL, V46, P77, DOI 10.1016/S0167-8760(02)00072-7; Duzel E, 2001, P NATL ACAD SCI USA, V98, P8101, DOI 10.1073/pnas.131205798; Fallgatter AJ, 2001, J NEURAL TRANSM, V108, P679, DOI 10.1007/s007020170045; Ford JM, 2004, ARCH GEN PSYCHIAT, V61, P119, DOI 10.1001/archpsyc.61.2.119; Fowler B, 1997, BIOL PSYCHOL, V46, P113, DOI 10.1016/S0301-0511(97)05253-8; Giaquinto S, 2004, FUNCT NEUROL, V19, P219; GLENN S, 1994, BIOL PSYCHIAT, V36, P443, DOI 10.1016/0006-3223(94)90639-4; Hummel T, 2002, PULM PHARMACOL THER, V15, P321, DOI 10.1006/pupt.2002.0356; Kiehl KA, 1999, BIOL PSYCHIAT, V45, P1498, DOI 10.1016/S0006-3223(98)00193-0; KILENY PR, 1987, EAR HEARING, V8, P110, DOI 10.1097/00003446-198704000-00008; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; LEW HL, 2004, PHYS MED REHABILITAT, V15, pR13; Mathalon DH, 2000, BIOL PSYCHIAT, V47, P434, DOI 10.1016/S0006-3223(99)00277-2; Naatanen R, 2003, INT J PSYCHOPHYSIOL, V48, P179, DOI 10.1016/S0167-8760(03)00053-9; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; Nieuwenhuis S, 2004, PSYCHOPHYSIOLOGY, V41, P157, DOI 10.1046/j.1469-8986.2003.00128.x; Nuwer MR, 1998, ELECTROEN CLIN NEURO, V106, P142, DOI 10.1016/S0013-4694(97)00117-X; OADES RD, 1995, INT J NEUROSCI, V81, P265, DOI 10.3109/00207459509004891; PEKKONEN E, 1995, EVOKED POTENTIAL, V96, P546, DOI 10.1016/0013-4694(95)00148-R; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1017/S0048577200000305; Polich J, 1997, INT J PSYCHOPHYSIOL, V25, P169, DOI 10.1016/S0167-8760(96)00742-8; Raikkonen K, 2003, NEUROREPORT, V14, P2121, DOI 10.1097/01.wnr.0000095493.09138.31; Ramchandani VA, 1999, ALCOHOL CLIN EXP RES, V23, P1320, DOI 10.1097/00000374-199908000-00005; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SINHA R, 1992, BIOL PSYCHIAT, V32, P992; Spikman JM, 2004, J INT NEUROPSYCH SOC, V10, P851, DOI 10.1017/S1355617704106061; Swerdlow NR, 2005, BIOL PSYCHOL, V69, P133, DOI 10.1016/j.biopsycho.2004.07.002; Thesen T, 2002, PSYCHOPHYSIOLOGY, V39, P733, DOI 10.1111/1469-8986.3960733; Walhovd KB, 2002, INT J PSYCHOPHYSIOL, V46, P29, DOI 10.1016/S0167-8760(02)00039-9; Wambacq I, 2004, EPILEPSY BEHAV, V5, P503, DOI 10.1016/j.yebeh.2004.03.012; Williams LM, 2005, INT J NEUROSCI, V115, P1605, DOI 10.1080/00207450590958475; WOODS DL, 1986, ELECTROEN CLIN NEURO, V65, P447, DOI 10.1016/0168-5597(86)90024-9	38	31	34	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258			J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	OCT	2007	24	5					392	397		10.1097/WNP.0b013e31814a56e3			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	221FS	WOS:000250213400004	17912063				2021-06-18	
J	Onate, JA; Beck, BC; Van Lunen, BL				Onate, James A.; Beck, Brian C.; Van Lunen, Bonnie L.			On-field testing environment and balance error scoring system performance during preseason screening of healthy collegiate baseball players	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; attention; environment; postural control	MILD HEAD-INJURY; POSTURAL STABILITY; STANDARDIZED ASSESSMENT; CONSTRUCT-VALIDITY; FOOTBALL PLAYERS; CONCUSSION; ATTENTION; SYMPTOMS; SPORTS; MANAGEMENT	Context: To determine if testing environment affects Balance Error Scoring System (BESS) scores in healthy collegiate baseball players. Design: Experimental, randomized, repeated-measures design with a sample of convenience. Setting: Uncontrolled sideline and controlled locker room baseball environments. Patients or Other Participants: A total of 21 healthy collegiate baseball players (age = 20.1 +/- 1.4 years, height = 185.1 +/- 6.8 cm, mass = 86.3 +/- 9.5 kg) with no history of head injury within the last 12 months, no lower extremity injuries reported within the past 2 months that caused them to miss 1 or more days of practice or game time, and no history of otitis media, Parkinson disease, or Meniere disease. Main Outcome Measure(s): Participants performed the BESS test in 2 environments, controlled locker room and uncontrolled sideline, in 2 testing sessions 1 week apart during the baseball preseason. The BESS scores were evaluated for each of the 6 conditions and total score across the testing sessions. Separate, paired-samples t tests with Bonferroni adjustment (P <.008) were used to examine differences between testing environments for each BESS subcategory and total score. Cohen d tests were calculated to evaluate effect sizes and relative change. Results: Significant group mean differences were found between testing environments for single-leg foam stance (P =.001), with higher scores reported for the uncontrolled sideline environment (7.33 +/- 2.11 errors) compared with the controlled clinical environment (5.19 +/- 2.16 errors). Medium to large effect sizes (0.53 to 1.03) were also found for single-leg foam, tandem foam, and total BESS scores, with relative increases (worse scores) of 30% to 44% in the sideline environment compared with the clinical environment. Conclusions: The BESS performance was impaired when participants were tested in a sideline environment compared with a clinical environment. Baseline testing for postural control using the BESS should be conducted in the setting or environment in which testing after injury will most likely be conducted.	[Onate, James A.; Beck, Brian C.; Van Lunen, Bonnie L.] Old Dominion Univ, Dept Exercise Sci Phys Educ & Recreat, Norfolk, VA 23529 USA	Onate, JA (corresponding author), Old Dominion Univ, Dept Exercise Sci Phys Educ & Recreat, 111 Spong Hall, Norfolk, VA 23529 USA.	jonate@odu.edu	Onate, James/E-3790-2011				Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Huxhold O, 2006, BRAIN RES BULL, V69, P294, DOI 10.1016/j.brainresbull.2006.01.002; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Landers M, 2005, PHYSIOTHERAPY, V91, P152, DOI 10.1016/j.physio.2004.11.010; McCollum G, 1996, J THEOR BIOL, V180, P257, DOI 10.1006/jtbi.1996.0101; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Onate JA, 2000, J ATHL TRAINING, V35, P155; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Rankin JK, 2000, J GERONTOL A-BIOL, V55, pM112, DOI 10.1093/gerona/55.3.M112; Redfern MS, 2001, GAIT POSTURE, V14, P211, DOI 10.1016/S0966-6362(01)00144-8; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Susco TM, 2004, J ATHL TRAINING, V39, P241; THALHEIMER W, 2007, CALCULATE EFFECT SIZ; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Weeks DL, 2003, GERONTOLOGY, V49, P225, DOI 10.1159/000070402; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Woollacott M, 2002, GAIT POSTURE, V16, P1, DOI 10.1016/S0966-6362(01)00156-4	35	31	32	1	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2007	42	4					446	451					6	Sport Sciences	Sport Sciences	251AQ	WOS:000252343100002	18174931				2021-06-18	
J	Wang, HE; Abo, BN; Lave, JR; Yeally, DM				Wang, Henry E.; Abo, Benjamin N.; Lave, Judith R.; Yeally, Donald M.			How would minimum experience standards affect the distribution of out-of-hospital endotracheal intubations?	ANNALS OF EMERGENCY MEDICINE			English	Article							RAPID-SEQUENCE INTUBATION; PERCUTANEOUS-CORONARY-INTERVENTION; TRAUMATIC BRAIN-INJURY; MYOCARDIAL-INFARCTION; CARE; HYPERVENTILATION; PERSONNEL; HYPOXIA	Study objective: Out-of-hospital endotracheal intubation is a complex intervention. One strategy for improving the quality of a complex intervention is to limit the procedure to practitioners or agencies that meet minimum procedure experience standards. The system-level influence of such limits is unknown. We seek to determine how minimum endotracheal intubation experience standards influence the number and distribution of out-of-hospital endotracheal intubations. Methods: We used 2003 Pennsylvania statewide emergency medical services (EMS) data. We included enclotracheal intubations that could be attributed to a valid rescuer, EMS agency, and minor civil division. We calculated the total number of enclotracheal intubations performed across the state. We calculated the absolute and relative changes in total, cardiac arrest, nonarrest, pediatric, and trauma enclotracheal intubation when the procedure was limited to on-scene rescuers meeting minimum enclotracheal intubation experience standards, ranging from zero to 20 annual enclotracheal intubations. We evaluated the same relationships when the procedure was limited to EMS agencies meeting minimum endotracheal intubation experience standards, ranging from zero to 200 annual enclotracheal intubations. We evaluated these relationships with line plots and geographic information system maps. Results: During the study period there were 11,771 enclotracheal intubations (7,854 cardiac arrest, 3,917 non-arrest, 1,325 trauma and 561 pediatric enclotracheal intubations). Limiting enclotracheal intubations to rescuers with at least 3, 5, 10, and 15 endotracheal intubations per year would result in relative endotracheal intubation reductions of 12%, 32%, 79%, and 93%, respectively. Limiting enclotracheal intubations to EMS agencies with at least 20, 30, 50, 100, and 150 endotracheal intubations per year would result in relative endotracheal intubation reductions of 15%, 27%, 41%, 65%, and 73%, respectively. Cardiac arrest endotracheal intubations would exhibit the largest absolute reduction. Conclusion: Minimum endotracheal intubation experience standards would result in absolute and relative reductions in total and subgroup endotracheal intubations. These findings provide vital perspectives about the system-wide organization of out-of-hospital airway management.	Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA	Wang, HE (corresponding author), Univ Pittsburgh, Sch Med, Dept Emergency Med, 230 Mckee Pl,Suite 400, Pittsburgh, PA 15213 USA.	wanghe@upmc.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS013628] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08-HS013628] Funding Source: Medline		Adams R, 2002, STROKE, V33, P326; Association for the Advancement of Automotive Medicine, 1998, ABBR INJ SCAL 1990; Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Burton John H, 2003, Prehosp Emerg Care, V7, P352, DOI 10.1080/10903120390936554; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DELEO BC, 1977, HEART LUNG, V6, P851; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; *EM CARD CAR COMM, 2005, CIRCULATION S4, V112, P51; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; GUSS DA, 1984, AM J EMERG MED, V2, P399, DOI 10.1016/0735-6757(84)90041-X; Hagberg C, 2006, ANESTH ANALG, V102, P621, DOI 10.1213/01.ane.0000189101.26403.06; Hulley SB, 2001, DESIGNING CLIN RES E; JACOBS LM, 1983, JAMA-J AM MED ASSOC, V250, P2175, DOI 10.1001/jama.250.16.2175; Johnston BD, 2006, ACAD EMERG MED, V13, P1051, DOI 10.1197/j.aem.2006.06.031; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Luft HS, 1990, HOSP VOLUME PHYS VOL; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Nallamothu BK, 2005, CIRCULATION, V111, P761, DOI 10.1161/01.CIR.0000155258.44268.F8; Nallamothu BK, 2006, CIRCULATION, V113, P222, DOI 10.1161/CIRCULATIONAHA.105.578195; National Highway Traffic Safety Administration, EM MED TECHN PAR NAT; Ornato JP, 1997, RESUSCITATION, V34, P3; Pepe Paul E, 2004, Crit Care Med, V32, pS414, DOI 10.1097/01.CCM.0000134264.88332.37; STEWART RD, 1984, CHEST, V85, P341, DOI 10.1378/chest.85.3.341; *US CENS BUR, GEOGR CHANG CENS 200; Wang HE, 2006, ACAD EMERG MED, V13, P372, DOI 10.1197/j.aem.2005.11.001; Wang HE, 2006, HEALTH AFFAIR, V25, P501, DOI 10.1377/hlthaff.25.2.501; Wang HE, 2005, CRIT CARE MED, V33, P1718, DOI 10.1097/01.CCM.0000171208.07895.2A; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2003, RESUSCITATION, V58, P49, DOI 10.1016/S0300-9572(03)00058-3; Wang Henry E, 2005, Prehosp Emerg Care, V9, P156	34	31	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	SEP	2007	50	3					246	252		10.1016/j.annemergmed.2007.04.023			7	Emergency Medicine	Emergency Medicine	206YN	WOS:000249218900006	17597255				2021-06-18	
J	Suh, SW; Aoyama, K; Alano, CC; Anderson, CM; Hamby, AM; Swanson, RA				Suh, Sang Won; Aoyama, Koji; Alano, Conrad C.; Anderson, Christopher M.; Hamby, Aaron M.; Swanson, Raymond A.			Zinc inhibits astrocyte glutamate uptake by activation of poly(ADP-ribose) polymerase-1	MOLECULAR MEDICINE			English	Article; Proceedings Paper	6th Zinc Signals Conference	2006	Oliveto, ITALY				FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CELL-DEATH; NEURONAL DEATH; NITRIC-OXIDE; DNA-DAMAGE; INTRACELLULAR ZINC; ADP-RIBOSYLATION; CORTICAL-NEURONS; NERVOUS-SYSTEM	Several processes by which astrocytes protect neurons during ischemia are now well established. However, less is known about how neurons themselves may influence these processes. Neurons release zinc (Zn2+)from presynaptic terminals during ischemia, seizure, head trauma, and hypoglycemia, and modulate postsynaptic neuronal function. Peak extracellular zinc may reach concentrations as high as 400 mu M. Excessive levels of free, ionic zinc can initiate DNA damage and the subsequent activation of poly(ADP-ribose) polymerase I (PARP-1), which in turn lead to NAD(+) and ATP depletion when DNA damage is extensive. In this study, cultured cortical astrocytes were used to explore the effects of zinc on astrocyte glutamate uptake, an energy-dependent process that is critical for neuron survival, Astrocytes incubated with 100 or 400 mu M of zinc for 30 min showed significant decreases in ATP levels and glutamate uptake capacity. These changes were prevented by the PARP inhibitors benzamide or DPQ (3,4-dihydro-5-(4-(1-piperidinyl)butoxyl)-1 (2H-isoquinolinone) or PARP-1 gene deletion (PARP-1 KO). These findings suggest that release of Zn2+ from neurons during brain insults could induce PARP-1 activation in astrocytes, leading to impaired glutamate uptake and exacerbation of neuronal injury.	Vet Adm Med Ctr, Dept Neurol 127, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA	Suh, SW (corresponding author), Vet Adm Med Ctr, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA.	song.suh@ucsf.edu	Anderson, Chris/J-7081-2014	Anderson, Christopher/0000-0003-0678-3002	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041421] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS41421, R01 NS041421] Funding Source: Medline		Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Anderson CM, 2000, GLIA, V32, P1; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BURZIO LO, 1979, J BIOL CHEM, V254, P3029; Calderone A, 2004, J NEUROSCI, V24, P9903, DOI 10.1523/JNEUROSCI.1713-04.2004; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; Frederickson CJ, 2006, EXP NEUROL, V198, P285, DOI 10.1016/j.expneurol.2005.08.030; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; Frederickson CJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1659, DOI 10.1177/002215540205001210; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; GAAL JC, 1985, BIOCHEM J, V230, P1; GABRIELSSON B, 1986, BRAIN RES, V384, P218, DOI 10.1016/0006-8993(86)91157-1; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lee H. L., 2000, International Journal of Manufacturing Technology and Management, V1, P79, DOI 10.1504/IJMTM.2000.001329; Noh KM, 2000, J NEUROSCI, V20; OBRENOVITCH TP, 1995, BRAIN METAB REV, V7, P297; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Rao VLR, 2001, NEUROCHEM RES, V26, P497; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sheline CT, 2003, EUR J NEUROSCI, V18, P1402, DOI 10.1046/j.1460-9568.2003.02865.x; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Spiridon M, 1998, J PHYSIOL-LONDON, V506, P363, DOI 10.1111/j.1469-7793.1998.363bw.x; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2001, NEUROREPORT, V12, P1523, DOI 10.1097/00001756-200105250-00044; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; SWANSON RA, 1992, NEUROSCI LETT, V147, P143, DOI 10.1016/0304-3940(92)90580-Z; SWANSON RA, 1992, GLIA, V6, P198, DOI 10.1002/glia.440060307; SWANSON RA, 1995, J CEREBR BLOOD F MET, V15, P417, DOI 10.1038/jcbfm.1995.52; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189; WAHL F, 1994, J NEUROCHEM, V63, P1003; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; YOKOYAMA M, 1986, NEUROSCI LETT, V71, P351, DOI 10.1016/0304-3940(86)90646-4; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	50	31	32	0	2	FEINSTEIN INST MED RES	MANHASSET	350 COMMUNITY DR, MANHASSET, NY 11030 USA	1076-1551			MOL MED	Mol. Med.	JUL-AUG	2007	13	7-8					344	349		10.2119/2007-00043.Suh			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	204NF	WOS:000249050300004	17728843	DOAJ Gold, Green Published			2021-06-18	
J	Tiesman, H; Young, T; Torner, JC; McMahon, M; Peek-Asa, C; Fiedler, J				Tiesman, Hope; Young, Tracy; Torner, James C.; McMahon, Mark; Peek-Asa, Corinne; Fiedler, John			Effects of a rural trauma system on traumatic brain injuries	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	133rd Annual Meeting of the American-Public-Health-Association	DEC 10-14, 2005	Philadelphia, PA	Amer Public Hlth Assoc		brain injuries; emergency medical services; rural hospitals	CARE; TRANSPORT; CHALLENGE; PATIENT	The response of trauma systems in rural areas is uncertain since distances between injury scenes and trauma care are considerable. Timely arrival at definitive care is critical for persons with traumatic brain injury (TBI) since secondary damage can occur during the hours following injury. We evaluated how the implementation of a trauma system in a predominately rural state affected the triage of TBI patients and their risk for mortality. The Iowa System Trauma Registry Dataset was analyzed, and included patients evaluated before trauma system implementation, 1997-1998, and after implementation, 2002-2003. Patients were identified using ICD9-CM codes or AIS codes, and included 710 pre-system patients and 886 post-system patients. Multivariate logistic regression assessed the effect of the trauma system on survival while controlling for confounders. Following implementation of the trauma system, patients treated in Level I or II facilities were older (p = 0.019), more often had multiple injuries (p = 0.0002), and had more severe TBI (p = 0.008). After controlling for confounders, transferred patients and those directly admitted were less likely to die in 72 h in the post-system than the pre-system (odds ratio [OR] = 0.56, 95% confidence interval (CI) = 0.36, 0.88; OR = 0.50, 95% CI = 0.32, 0.79). Implementation of the Iowa trauma system seems to have led to more appropriate triage and transport for TBI patients, and this likely contributed to reduced in-hospital mortality.	Univ Iowa, Injury Prevent Res Ctr, Iowa City, IA USA; Iowa Dept Publ Hlth, Des Moines, IA 50319 USA	Tiesman, H (corresponding author), NIOSH, Div Safety Res, 1095 Willowdale Rd,MS 1811, Morgantown, WV 26505 USA.	fto9@cdc.gov					*AAAM, 1990, ABBR INJ SCAL 1990 R; *ACS, 1999, COMM TRAUM RES OPT C; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CALES RH, 1986, SYSTEM TRAUMA REGIST; CERTO TF, 1983, J TRAUMA, V23, P559, DOI 10.1097/00005373-198307000-00003; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLAY MN, 2001, MED CARE, V39, P643; *DIG INN INC, 2001, COLLECTOR SOFTW 1987; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; GROSSMAN DC, 1995, J TRAUMA, V38, P14, DOI 10.1097/00005373-199501000-00006; Hosmer D, 1989, APPL LOGISTIC REGRES; KEARNEY PA, 1991, ANN EMERG MED, V20, P882, DOI 10.1016/S0196-0644(05)81431-3; Lewis RJ, 2004, JAMA-J AM MED ASSOC, V291, P1382, DOI 10.1001/jama.291.11.1382; MARION DW, 1999, TRAUMATIC BRAIN INJU; Mullins RJ, 2002, J TRAUMA, V52, P1019, DOI 10.1097/00005373-200206000-00002; Mullins RJ, 1999, J TRAUMA, V47, pS59, DOI 10.1097/00005373-199909001-00013; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1910; Nathens AB, 2004, LANCET, V363, P1794, DOI 10.1016/S0140-6736(04)16307-1; PAYNE SR, 1989, J TRAUMA, V29, P424, DOI 10.1097/00005373-198904000-00002; Rogers FB, 1999, J TRAUMA, V46, P328, DOI 10.1097/00005373-199902000-00022; Rogers FB, 1999, J TRAUMA, V47, P802, DOI 10.1097/00005373-199910000-00038; Sollid S, 2003, J NEUROTRAUM, V20, P309, DOI 10.1089/089771503321532897; WALLER JA, 1988, J TRAUMA, V28, P1632, DOI 10.1097/00005373-198812000-00003; Wright KD, 1996, INJURY, V27, P719, DOI 10.1016/S0020-1383(96)00119-2; Young T, 2003, J EMERG MED, V24, P189, DOI 10.1016/S0736-4679(02)00724-2	26	31	32	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1189	1197		10.1089/neu.2006.0196			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200010	17610358				2021-06-18	
J	Kauppinen, TM				Kauppinen, Tiina M.			Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease	NEUROCHEMISTRY INTERNATIONAL			English	Article; Proceedings Paper	Symposium on Excitotoxicity in Neurologic Disease held at the 37th Annual Meeting of the American-Society-for-Neurochemistry	MAR 11-15, 2006	Portland, OR	Amer Soc Neurochem		PARP-1; neuronal death; inflammation; DNA repair; neuroprotection	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; ADP-RIBOSE POLYMERASE; APOPTOSIS-INDUCING FACTOR; CELL-DEATH; DNA-DAMAGE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; POLYADP-RIBOSYLATION; CEREBRAL-ISCHEMIA	Poly(ADP-ribose)polymerase-1 (PARP-1) is a nuclear protein activated by DNA damage. PARP-1 activation is associated in DNA repair, cell death and inflammation. Since oxidative stress induced robust DNA damage and wide spread inflammatory responses are common pathologies of various CNS diseases, the interest toward PARP-1 as a therapeutic target has peaked. This review introduces mechanism of PARP-1 activation, the role of PARP-1 in cell physiology and pathology, and discusses the potential of PARP-1 inhibition as a therapy in acute and chronic CNS diseases. (C) 2006 Elsevier Ltd. All rights reserved.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Kauppinen, TM (corresponding author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.	Tiina.Kauppinen@ucsf.edu	Kauppinen, Tiina/I-1009-2019	Kauppinen, Tiina/0000-0001-7219-9862			Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Andreone TL, 2003, J IMMUNOL, V170, P2113, DOI 10.4049/jimmunol.170.4.2113; Besson VC, 2005, BRAIN RES, V1041, P149, DOI 10.1016/j.brainres.2005.01.096; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chiarugi A, 2002, BRIT J PHARMACOL, V137, P761, DOI 10.1038/sj.bjp.0704934; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Cho IJ, 2005, FREE RADICAL BIO MED, V39, P1523, DOI 10.1016/j.freeradbiomed.2005.07.017; Cohen-Armon M, 2004, SCIENCE, V304, P1820, DOI 10.1126/science.1096775; Czapski GA, 2004, NEUROSCI LETT, V356, P45, DOI 10.1016/j.neulet.2003.11.022; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Feng YZ, 2002, CRIT CARE MED, V30, P2420, DOI 10.1097/00003246-200211000-00003; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Halliwell B, 1989, FREE RADICALS BIOL M; Hasko G, 2002, MOL MED, V8, P283, DOI 10.1007/BF03402154; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Huang JY, 2006, NUCLEIC ACIDS RES, V34, P2398, DOI 10.1093/nar/gkl241; Iwashita A, 2004, J PHARMACOL EXP THER, V310, P425, DOI 10.1124/jpet.104.066944; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kaplan J, 2005, SHOCK, V23, P233, DOI 10.1097/01.shk.0000151026.30624.ef; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Kauppinen TM, 2005, J NEUROSCI RES, V81, P190, DOI 10.1002/jnr.20525; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Koistinaho J, 2004, E SCHERING RES FDN W, V47, P101; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Love S, 1999, BRAIN, V122, P247, DOI 10.1093/brain/122.2.247; Love S, 2000, NEUROPATH APPL NEURO, V26, P55, DOI 10.1046/j.1365-2990.2000.00218.x; Mandir AS, 2000, J NEUROSCI, V20, P8005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Martin-Oliva D, 2006, CANCER RES, V66, P5744, DOI 10.1158/0008-5472.CAN-05-3050; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; Nakajima H, 2004, J BIOL CHEM, V279, P42774, DOI 10.1074/jbc.M407923200; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; OKA J, 1984, J BIOL CHEM, V259, P986; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Suh SW, 2003, J NEUROSCI, V23, P10681; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Visochek L, 2005, J NEUROSCI, V25, P7420, DOI 10.1523/JNEUROSCI.0333-05.2005; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; Whalen MJ, 2000, ACT NEUR S, V76, P61; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang J, 2000, BIOCHEM BIOPH RES CO, V278, P590, DOI 10.1006/bbrc.2000.3816; ZHANG JJH, 2002, POLYMERASE INHIBITIO	67	31	36	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JUN	2007	50	7-8			SI		954	958		10.1016/j.neuint.2006.11.010			5	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	195UH	WOS:000248436900009	17222947				2021-06-18	
J	Becerra, GD; Tatko, LM; Pak, ES; Murashov, AK; Hoane, MR				Becerra, G. D.; Tatko, L. M.; Pak, E. S.; Murashov, A. K.; Hoane, M. R.			Transplantation of GABAergic neurons but not astrocytes induces recovery of sensorimotor function in the traumatically injured brain	BEHAVIOURAL BRAIN RESEARCH			English	Article						GABA; traumatic brain injury; recovery of function; embryonic stem cells; rat; astrocytes	EMBRYONIC STEM-CELLS; NEUROTROPHIC FACTOR; MOUSE MODEL; COGNITIVE FUNCTION; RAT; DEFICITS; SURVIVE; LESIONS; CORTEX; DIFFERENTIATION	Embryonic stem (ES) cells have been investigated in many animal models of injury and disease. However, few studies have examined the ability of pre-differentiated ES cells to improve functional outcome following traumatic brain injury (TBI). The purpose of the present study was to compare the effect of murine ES cells that were pre-differentiated into GABAergic neurons or astrocytes on functional recovery following TBI. Neural and astrocyte induction was achieved by co-culturing ES cells on a bone marrow stromal fibroblast (M2-10B4) feeder layer and incubating them with various mitogenic factors. Rats were initially prepared with a unilateral controlled cortical contusion injury of the sensorimotor cortex or sham procedure. Rats were transplanted 7 days following injury with similar to 100 K GABAergic neurons, astrocytes, fibroblasts, or media. Animals were assessed on a battery of sensorimotor tasks following transplantation. The stromal fibroblast cells (M2-10B4), as a control cell line, did not differ significantly from media infusions. Transplantation of GABAergic neurons facilitated complete and total recovery on the vibrissae-forelimb placing test as opposed to all other groups, which failed to show any recovery. It was also found that GABAergic neurons reduced the magnitude of the initial impairment on the limb use test. Histological analysis revealed infiltration of host brain with transplanted neurons and astrocytes. The results of the present study suggest that transplantation of pre-differentiated GABAergic neurons significantly induces recovery of sensorimotor function; whereas, astrocytes do not. (c) 2007 Elsevier B.V. All rights reserved.	So Illinois Univ, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, So Illinois Regenerat Med Inst,Dept Psychol, Carbondale, IL 62901 USA; E Carolina Univ, Dept Physiol, Brody Sch Med, Greenville, NC 27858 USA	Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, So Illinois Regenerat Med Inst,Dept Psychol, MC 6502, Carbondale, IL 62901 USA.	GDB0205@ECU.EDU; PAKE@ecu.edu; murashoval@ecu.edu; mhoane@siu.edu	Murashov, Alexander K/F-2241-2011; Murashov, Alexander/ABB-2151-2020	Murashov, Alexander K/0000-0002-8912-5891; Murashov, Alexander/0000-0002-8912-5891; Hoane, Michael/0000-0001-7779-2657	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15 NS045647-01, R15 NS045647] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER		Akerud P, 2001, J NEUROSCI, V21, P8108; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Baldelli P, 2005, J NEUROSCI, V25, P3358, DOI 10.1523/JNEUROSCI.4227-04.2005; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Chiba S, 2004, J NEUROL SCI, V219, P107, DOI 10.1016/j.jns.2004.01.006; Frahm C, 2004, NEUROSCIENCE, V127, P341, DOI 10.1016/j.neuroscience.2004.05.027; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Hendricks WA, 2006, MOL MED, V12, P34, DOI 10.2119/2006-00014.Hendricks; Hill CE, 2004, EXP NEUROL, V190, P289, DOI 10.1016/j.expneurol.2004.05.043; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hu De-zhi, 2005, Chin J Traumatol, V8, P23; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Kozlowski DA, 1997, BRAIN RES, V763, P159, DOI 10.1016/S0006-8993(97)00377-6; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Mehta A, 2005, EXP NEUROL, V193, P110, DOI 10.1016/j.expneurol.2005.01.001; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Muramatsu D, 2005, EXP NEUROL, V194, P1, DOI 10.1016/j.expneurol.2005.01.025; Murashov AK, 2004, FASEB J, V18, P252, DOI 10.1096/fj.04-2251fje; Murashov AK, 2005, BIOCHEM BIOPH RES CO, V332, P653, DOI 10.1016/j.bbrc.2005.04.167; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Suzuki F, 2005, EPILEPSIA, V46, P193, DOI 10.1111/j.0013-9580.2005.35504.x; Woodlee M.T., 2005, BEHAV LAB RAT HDB TE, P129	27	31	31	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	APR 16	2007	179	1					118	125		10.1016/j.bbr.2007.01.024			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	161RM	WOS:000246033300014	17324477	Green Accepted			2021-06-18	
J	Park, E; Liu, E; Shek, M; Park, A; Baker, AJ				Park, Eugene; Liu, Elaine; Shek, Melissa; Park, Andrea; Baker, Andrew J.			Heavy neurofilament accumulation and alpha-spectrin degradation accompany cerebellar white matter functional deficits following forebrain fluid percussion injury	EXPERIMENTAL NEUROLOGY			English	Article						calpain; cerebellum; DAI; electrophysiology; FPI; neurofilament; alpha-spectrin; TAI; TBI	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; PURKINJE-CELL VULNERABILITY; ACUTE SUBDURAL-HEMATOMA; AXOLEMMAL PERMEABILITY; MEDIATED PROTEOLYSIS; CALPAIN ACTIVATION; CORPUS-CALLOSUM; UNITED-STATES; SPINAL-CORD	Evidence for diffuse traumatic axonal injury (TAI) in clinical cases and animal models of traumatic brain injury (TBI) indicate that pathophysiological mechanisms extend to regions remote from the injury epicenter. The potential for indirect cerebellar trauma contributing to TBI pathophysiology is of significance since impairment of motor function and coordination is a common consequence of TBI but is also a domain associated with cerebellar function. The relationship between cerebellar white matter structure and function following traumatic head injury has not been examined. Using the fluid percussion injury (FPI) device applied unilaterally in the forebrain, evoked compound action potential (CAP) recordings from cerebellar white matter of Sprague-Dawley rats indicated a spatial and temporal pattern of electrophysiological deficits throughout the cerebellar vermis. The posterior and middle lobules of the cerebellum exhibited significant declines in evoked CAP amplitude compared to sham controls (p = 0.004, p = 0.005, respectively). Duration of the CAP decay also increased, suggesting that functional white matter deficits were a combination of axonal loss and compromised axonal integrity. Functional white matter deficits persisted at 14 days post-injury in the posterior and middle regions of the cerebellum. Evidence of heavy chain neurofilament (NF200) degradation was observed at 1 day post-injury by Western blot. Immunohistochemistry labeling for NF200 indicated the presence of highly immunoreactive NF200 axonal swellings consistent with morphological features of TAL alpha-Spectrin degradation was also observed between 1 and 14 days post-injury. This study demonstrates the electrophysiological consequences of cerebellar white matter injury and a temporal profile of NF200 and spectrin degradation following forebrain FPI. (c) 2006 Elsevier Inc. All rights reserved.	St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	Baker, AJ (corresponding author), Cara Phelan Ctr Trauma Res, 7086 Bond Wing,30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 2000, J NEUROSCI, V20, P2825; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Gusmao SNS, 2003, ARQ NEURO-PSIQUIAT, V61, P746, DOI 10.1590/S0004-282X2003000500008; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; Ivry R B, 1992, Curr Opin Neurobiol, V2, P212, DOI 10.1016/0959-4388(92)90015-D; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; KRAUSS JK, 1995, NEUROL RES, V17, P409, DOI 10.1080/01616412.1995.11740353; LEINER HC, 1989, BEHAV NEUROSCI, V103, P998, DOI 10.1037/0735-7044.103.5.998; LEINER HC, 1986, BEHAV NEUROSCI, V100, P443, DOI 10.1037/0735-7044.100.4.443; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Menon E. B., 1993, Singapore Medical Journal, V34, P45; Middleton FA, 1998, TRENDS NEUROSCI, V21, P367, DOI 10.1016/S0166-2236(98)01330-7; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morton SM, 2004, NEUROSCIENTIST, V10, P247, DOI 10.1177/1073858404263517; Moruzzi, 1958, PHYSL PATHOLOGY CERE; MYSIW W J, 1990, Brain Injury, V4, P247, DOI 10.3109/02699059009026174; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; PETERSEN SE, 1993, ANNU REV NEUROSCI, V16, P509, DOI 10.1146/annurev.ne.16.030193.002453; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Petrosini L, 1998, PROG NEUROBIOL, V56, P191, DOI 10.1016/S0301-0082(98)00036-7; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; Stys PK, 2002, NEUROSCI LETT, V328, P150, DOI 10.1016/S0304-3940(02)00469-X; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TOMASCH J, 1969, BRAIN RES, V13, P476, DOI 10.1016/0006-8993(69)90261-3; Wang MS, 2000, J NEUROPATH EXP NEUR, V59, P599, DOI 10.1093/jnen/59.7.599; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182	72	31	32	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2007	204	1					49	57		10.1016/j.expneurol.2006.09.012			9	Neurosciences	Neurosciences & Neurology	148PC	WOS:000245086100006	17070521				2021-06-18	
J	Stulemeijer, M; Andriessen, TMJC; Brauer, JMP; Vos, PE; Van Der Werf, S				Stulemeijer, Maja; Andriessen, Teuntje M. J. C.; Brauer, Jolanda M. P.; Vos, Pieter E.; Van Der Werf, Sieberen			Cognitive performance after Mild Traumatic Brain Injury: The impact of poor effort on test results and its relation to distress, personality and litigation	BRAIN INJURY			English	Article						cognition; outcome; mild brain injury; neuropsychological; effort tests	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; CLOSED-HEAD INJURY; SOCIAL INHIBITION; MEMORY TEST; COMPENSATION; IMPAIRMENT; DEFICITS; FATIGUE; DISTURBANCE; PREDICTORS	Primary objective: To compare consecutive Mild Traumatic Brain Injury ( MTBI) patients with and without adequate effort on cognitive performance, litigation status, fatigue, distress and personality. Research design: ( Neuro) psychological assessment was done 6 months post- injury in 110 patients from a cohort of 618 consecutive MTBI patients aged 18 - 60, who attended the emergency department of our level I trauma centre. Effort was tested with the Amsterdam Short Term Memory test. Main outcome and results: Thirty patients ( 27%) failed the effort test. Poor effort was associated with significantly poorer scores on seven out of eleven measures, covering all tested domains. Poor effort was associated with lower educational level and changes in work status, but not litigation. Furthermore, poor effort was related to high levels of distress, Type- D personality and fatigue. Conclusions: Even in a sample of non- referred MTBI patients, poor effort was common and was strongly associated with inferior test performance. These findings imply that effort testing should be part of all cognitive assessments, also outside mediolegal settings. Behavioural factors like distress and personality should be considered as potential threats to the validity of neuropsychological testing after MTBI.	Radboud Univ Nijmegen, Nijemegen Med Ctr, Dept Med Psychol, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Nijemegen Med Ctr, Dept Neurol, Nijmegen, Netherlands	Stulemeijer, M (corresponding author), Radboud Univ Nijmegen, Nijemegen Med Ctr, Dept Med Psychol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	M.Stulemeijer@neuro.umcn.nl	Vos, Pieter/A-6043-2012				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Beck AT, 1997, BEHAV RES THER, V35, P785, DOI 10.1016/S0005-7967(97)00025-9; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Bolan B, 2002, J CLIN EXP NEUROPSYC, V24, P154, DOI 10.1076/jcen.24.2.154.1000; BREHM JW, 1983, J EXP SOC PSYCHOL, V19, P21, DOI 10.1016/0022-1031(83)90003-3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; DEGORATIS LR, 1994, SCL90; Delis DC, 1987, CALIFORNIA VERBAL LE; Denollet J, 2006, EUR HEART J, V27, P171, DOI 10.1093/eurheartj/ehi616; Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Efklides A., 2006, METACOGN LEARN, V1, P33, DOI [10.1007/s11409-006-6581-0, DOI 10.1007/S11409-006-6581-0]; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Kahneman D., 1973, ATTENTION EFFORT; Keller M, 2000, J NEUROL NEUROSUR PS, V68, P761, DOI 10.1136/jnnp.68.6.761; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lindem K, 2003, J PSYCHOPATHOL BEHAV, V25, P129, DOI 10.1023/A:1023399100404; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; MULDER JL, 1996, HANDLEIDING VERBALE; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; REVELLE W, 1993, NONCOGNITIVE DETERMI, P346; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Rose CL, 2002, EUR J PERSONALITY, V16, P185, DOI 10.1002/per.451; Ross SR, 2006, J CLIN EXP NEUROPSYC, V28, P111, DOI 10.1080/13803390590929270; Sanderman R, 1995, METEN PERSOONLIJKHEI; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Schmand B, 1998, J NEUROL NEUROSUR PS, V64, P339, DOI 10.1136/jnnp.64.3.339; Schmand B, 1991, Tijdschr Gerontol Geriatr, V22, P15; Schmand B, 1999, AMSTERDAM SHORT TERM; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; van Hout MSE, 2003, NEUROTOXICOLOGY, V24, P547, DOI 10.1016/S0161-813X(03)00054-8; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vercoulen JHMM, 1998, J CLIN EXP NEUROPSYC, V20, P144, DOI 10.1076/jcen.20.2.144.1160; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wechsler D, 1997, WAIS 3 ADM SCORING M; ZIMMERMANN P, 1996, MANUAL TESTBATTERY A	52	31	32	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	3					309	318		10.1080/02699050701209980			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IW	WOS:000246518400006	17453759				2021-06-18	
J	Tanriverdi, F; Ulutabanca, H; Unluhizarci, K; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Ulutabanca, Halil; Unluhizarci, Kursad; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			Pituitary functions in the acute phase of traumatic brain injury: Are they related to severity of the injury or mortality?	BRAIN INJURY			English	Article						traumatic brain injury; Glasgow Coma Scale; mild brain injury; pituitary; hypopituitarism	CLOSED-HEAD INJURY; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; STIMULATION TEST; GH DEFICIENCY; HIGH-RISK; HYPOPITUITARISM; REHABILITATION; ABNORMALITIES; PREVALENCE	Primary objective: There are only limited data regarding pituitary functions in the acute phase of traumatic brain injury ( TBI) and previous studies have been conducted in only small cohorts of subjects. Therefore we have investigated the pituitary functions in the early acute phase, within 24 hours of trauma, in 104 patients with TBI. Additionally, the relationships between basal pituitary hormones, severity of the trauma and mortality due to trauma were also investigated. Methods and procedures: One hundred and four TBI patients were included in the study consecutively. All patients underwent basal hormonal evaluation within the first 24 hours of admission. Twenty of 104 patients died during the acute phase. Main outcomes: Prolactin levels were negatively correlated with the Glasgow coma scale ( GCS), cortisol levels were positively correlated with the GCS and cortisol levels were positively correlated with ACTH levels. Additionally there was a significant positive correlation between the total testosterone levels and the GCS in males. Logistic regression analysis revealed that mortality after TBI was unrelated to basal pituitary hormone levels. However age and GCS were significantly related to the mortality. The percentages of pituitary hormone deficiencies were as follows: 3.8% had TSH deficiency, 40.0% had gonadotrophin deficiency, 8.8% had ACTH deficiency and 20.0% had GH deficiency. Conclusions: Present data clearly demonstrate that pituitary function is disturbed in TBI and the most frequently deficient pituitary hormones were gonadotrophins in the early acute phase of TBI. Basal hormone levels including cortisol, prolactin and total testosterone were related to the severity of the trauma. However there was no relation between basal hormones and mortality due to TBI. Age and GCS were significantly related to mortality.	Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; Univ Santiago de Compostela, Sch Med, Dept Med, Santiago De Compostela, Spain; Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Santiago De Compostela, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DANIEL PM, 1959, LANCET, V2, P927; Della Corte F, 1998, CRIT CARE MED, V26, P1419; Dimopoulou I, 2004, INTENS CARE MED, V30, P1216, DOI 10.1007/s00134-004-2297-2; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Pentelenyi T, 1992, Acta Neurochir Suppl (Wien), V55, P21; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; ZIEGLER MG, 1990, CRIT CARE MED, V18, P253, DOI 10.1097/00003246-199003000-00001	33	31	35	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	4					433	439		10.1080/02699050701311083			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IY	WOS:000246518600009	17487641				2021-06-18	
J	Thompson, HJ; Marklund, N; LeBold, DG; Morales, DM; Keck, CA; Vinson, M; Royo, NC; Grundy, R; McIntosh, TK				Thompson, Hilaire J.; Marklund, Niklas; LeBold, David G.; Morales, Diego M.; Keck, Carrie A.; Vinson, Mary; Royo, Nicolas C.; Grundy, Robert; McIntosh, Tracy K.			Tissue sparing and functional recovery following experimental traumatic brain injury is provided by treatment with an anti-myelin-associated glycoprotein antibody	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						adhesive/sticky paper test; head injury; hemispheric tissue loss; myelin-associated glycoprotein; osmotic minipumps; rat	CORTICAL LESION; NOGO RECEPTOR; COGNITIVE IMPAIRMENT; NEURITE OUTGROWTH; AXONAL INJURY; OPTIC-NERVE; HEAD-INJURY; ADULT RATS; MAG; INHIBITOR	Axonal injury is a hallmark of traumatic brain injury (TBI) and is associated with a poor clinical outcome. Following central nervous system injury, axons regenerate poorly, in part due to the presence of molecules associated with myelin that inhibit axonal outgrowth, including myelin-associated glycoprotein (MAG). The involvement of MAG in neurobehavioral deficits and tissue loss following experimental TBI remains unexplored and was evaluated in the current study using an MAG-specific monoclonal antibody (mAb). Anesthetized rats (n = 102) were subjected to either lateral fluid percussion brain injury (n = 59) or sham injury (n = 43). In surviving animals, beginning at 1 h post-injury, 8.64 mu g anti-MAG mAb (n = 33 injured, n = 21 sham) or control IgG (n = 26 injured, n = 22 sham) was infused intracerebroventricularly for 72 h. One group of these rats (n = 14 sham, n = 11 injured) was killed at 72 h post-injury for verification of drug diffusion and MAG immunohistochemistry. All other animals were evaluated up to 8 weeks post-injury using tests for neurologic motor, sensory and cognitive function. Hemispheric tissue loss was also evaluated at 8 weeks post-injury. At 72 h post-injury, increased immunoreactivity for MAG was seen in the ipsilateral cortex, thalamus and hippocampus of brain-injured animals, and anti-MAG mAb was detectable in the hippocampus, fimbria and ventricles. Brain-injured animals receiving anti-MAG mAb showed significantly improved recovery of sensorimotor function at 6 and 8 weeks (P < 0.01) post-injury when compared with brain-injured IgG-treated animals. Additionally, at 8 weeks post-injury, the anti-MAG mAb-treated brain-injured animals demonstrated significantly improved cognitive function and reduced hemispheric tissue loss (P < 0.05) when compared with their brain-injured controls. These results indicate that MAG may contribute to the pathophysiology of experimental TBI and treatment strategies that target MAG may be suitable for further evaluation.	Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Univ Washington, Seattle, WA 98195 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Uppsala Hosp, Dept Neurosurg, Uppsala, Sweden; GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, Harlow, Essex, England	Thompson, HJ (corresponding author), Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA.	hilairet@u.washington.edu		Morales, Diego/0000-0001-6672-9046; Marklund, Niklas/0000-0002-9797-5626	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K12RR023265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, T32NS043126, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR007106] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K12 RR023265, K12 RR023265-02, K12RR023265] Funding Source: Medline; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [L30 DC008284-01, L30 DC008284] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040978-04, P50 NS008803-320013, T32 NS043126, T32 NS043126-01A1, T32-NS043126] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32-NR07106, T32 NR007106, T32 NR007106-07] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P50-08803, R01-40978] Funding Source: Medline		Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; BARTSCH U, 1989, J COMP NEUROL, V284, P451, DOI 10.1002/cne.902840310; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Blokland A, 1999, EUR J NEUROSCI, V11, P223, DOI 10.1046/j.1460-9568.1999.00431.x; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CARONI P, 1988, PROG BRAIN RES, V78, P363; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; Cirulli F, 2004, HIPPOCAMPUS, V14, P802, DOI 10.1002/hipo.10220; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Emerick AJ, 2003, J NEUROSCI, V23, P4826; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; FRUTTIGER M, 1995, EUR J NEUROSCI, V7, P511, DOI 10.1111/j.1460-9568.1995.tb00347.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; *INT BRAIN INJ ASS, 2005, BRAIN INJ FACTS; Irving EA, 2005, J CEREBR BLOOD F MET, V25, P98, DOI 10.1038/sj.jcbfm.9600011; Kottis V, 2002, J NEUROCHEM, V82, P1566, DOI 10.1046/j.1471-4159.2002.01146.x; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Lee DHS, 2003, NAT REV DRUG DISCOV, V2, P872, DOI 10.1038/nrd1228; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Li SX, 2003, J NEUROSCI, V23, P4219; Maas AIR, 2002, NEUROL RES, V24, P19, DOI 10.1179/016164102101199495; Marcus J, 2002, J CELL BIOL, V156, P567, DOI 10.1083/jcb.200111047; Marklund N, 2005, J NEUROTRAUM, V22, P1229; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MARKLUND N, 2004, SOC NEUR ABSTR; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKerracher L, 2002, NEURON, V36, P345, DOI 10.1016/S0896-6273(02)01018-8; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Paivalainen S, 2003, J NEUROCHEM, V84, P533, DOI 10.1046/j.1471-4159.2003.01539.x; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; PAXINOS G, 1994, RAT BRAIN STEREOTAXI; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock JT, 1999, ACT NEUR S, V73, P15; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; QUARLES RH, 1973, BRAIN RES, V58, P506, DOI 10.1016/0006-8993(73)90022-X; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Schaumburg Jochen, 2000, Silva Gabreta, V4, P29; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Silver MA, 2001, J COMP NEUROL, V436, P391, DOI 10.1002/cne.1075; Soares HD, 1995, J NEUROSCI, V15, P8223; Tang S, 1997, MOL CELL NEUROSCI, V9, P333, DOI 10.1006/mcne.1997.0633; Tang S, 2001, MOL CELL NEUROSCI, V18, P259, DOI 10.1006/mcne.2001.1020; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; TRAPP BD, 1989, J NEUROCYTOL, V18, P47, DOI 10.1007/BF01188423; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Vinson M, 2003, MOL CELL NEUROSCI, V22, P344, DOI 10.1016/S1044-7431(02)00031-3; Vinson M, 2001, J BIOL CHEM, V276, P20280, DOI 10.1074/jbc.M100345200; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Weiss MD, 2000, J NEUROSCI RES, V62, P772, DOI 10.1002/1097-4547(20001215)62:6<772::AID-JNR3>3.3.CO;2-O; Wong EV, 2003, J NEUROSCI, V23, P3112; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	71	31	32	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	DEC	2006	24	11					3063	3072		10.1111/j.1460-9568.2006.05197.x			10	Neurosciences	Neurosciences & Neurology	124IO	WOS:000243361700010	17156367	Green Accepted			2021-06-18	
J	Finehout, EJ; Franck, Z; Relkin, N; Lee, KH				Finehout, Erin J.; Franck, Zsofia; Relkin, Norman; Lee, Kelvin H.			Proteomic analysis of cerebrospinal fluid changes related to postmortem interval	CLINICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; POTENTIAL BIOMARKERS; ALZHEIMERS-DISEASE; EARLY-DIAGNOSIS; ISCHEMIC BRAIN; ACUTE STROKE; PROTEIN; MARKERS; IDENTIFICATION; MICRODIALYSIS	Background: The study of proteins with altered production in postmortem cerebrospinal fluid (CSF) compared with antemortem CSF may improve the understanding of biochemical changes that occur immediately after death. Methods: Two CSF samples (1 antemortem and 1 postmortem) were collected from 7 patients and analyzed by 2-dimensional gel electrophoresis. An analysis was also performed to identify proteins that showed a correlation between concentration change and postmortem interval. Tandem mass spectrometry was used to identify the proteins. Results: Fifty-four protein spots were identified that showed a consistent and significant change in concentration in the postmortem CSF of all 7 patients (> 3.5-fold, P < 0.01). The proteins in these spots derive from a variety of functional groups, including cytoskeletal proteins, enzymes involved in glycolysis, and proteins that prevent oxidative stress. Fourteen protein spots were found to have an increase in production that correlated with postmortem interval. Conclusions: Changes in protein production of postmortem vs antemortem CSF were studied. The proteins observed to change production in the postmortem CSF include several proteins previously observed as potential stroke biomarkers. (c) 2006 American Association for Clinical Chemistry.	Cornell Univ, Sch Chem & Biomol Engn, Ithaca, NY USA; Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY USA	Lee, KH (corresponding author), 120 Olin Hall, Ithaca, NY 14853 USA.	KHL9@cornell.edu	Lee, Kelvin H/A-4673-2010; Crozier, Laura/C-2170-2011	Lee, Kelvin H/0000-0003-0908-2981; 	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH059926] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH59926] Funding Source: Medline		Allard L, 2005, CLIN CHEM, V51, P2043, DOI 10.1373/clinchem.2005.053942; CAPOCCHI G, 1987, ITAL J NEUROL SCI, V8, P567, DOI 10.1007/BF02333663; Carrette O, 2003, PROTEOMICS, V3, P1486, DOI 10.1002/pmic.200300470; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; DAVSON H, 1987, PHYSL PATHOPHYSIOLOG, P1013; DONNAN GA, 1983, STROKE, V14, P266, DOI 10.1161/01.STR.14.2.266; Finehout EJ, 2004, ELECTROPHORESIS, V25, P2564, DOI 10.1002/elps.200406012; Finehout EJ, 2003, ELECTROPHORESIS, V24, P3508, DOI 10.1002/elps.200305615; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; GLANTZ SA, 1987, PRIMER BIOSTATISTICS, P230; Hatzimanikatis V, 1999, BIOTECHNOL PROGR, V15, P312, DOI 10.1021/bp990004b; HAY E, 1984, J NEUROL NEUROSUR PS, V47, P724, DOI 10.1136/jnnp.47.7.724; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; KARKELA JT, 1993, J FORENSIC SCI, V38, P603; Lescuyer P, 2004, PROTEOMICS, V4, P2234, DOI 10.1002/pmic.200300822; Long DJ, 2000, CHEM-BIOL INTERACT, V129, P99, DOI 10.1016/S0009-2797(00)00200-3; Marrif H, 1999, J NEUROSCI RES, V57, P255; PAULSON GW, 1971, CONFIN NEUROL, V33, P149; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Puchades M, 2003, MOL BRAIN RES, V118, P140, DOI 10.1016/j.molbrainres.2003.08.005; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; Sommer JB, 2002, EUR NEUROL, V47, P224, DOI 10.1159/000057904; VAAGENES P, 1986, ARCH NEUROL-CHICAGO, V43, P357, DOI 10.1001/archneur.1986.00520040043017; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; WEISNER B, 1978, J NEUROL SCI, V37, P205, DOI 10.1016/0022-510X(78)90204-6; WERMUTH B, 1986, BIOCHEM PHARMACOL, V35, P1277, DOI 10.1016/0006-2952(86)90271-6; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zimmermann-Ivol CG, 2004, MOL CELL PROTEOMICS, V3, P66, DOI 10.1074/mcp.M300066-MCP200	29	31	32	0	2	AMER ASSOC CLINICAL CHEMISTRY	WASHINGTON	2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA	0009-9147	1530-8561		CLIN CHEM	Clin. Chem.	OCT	2006	52	10					1906	1913		10.1373/clinchem.2006.070508			8	Medical Laboratory Technology	Medical Laboratory Technology	089CP	WOS:000240858000011	16887899	Bronze			2021-06-18	
J	Cazalis, F; Feydy, A; Valabregue, R; Pelegrini-Issac, M; Pierot, L; Azouvi, P				Cazalis, Fabienne; Feydy, Antoine; Valabregue, Romain; Pelegrini-Issac, Melanie; Pierot, Laurent; Azouvi, Philippe			fMRI study of problem-solving after severe traumatic brain injury	BRAIN INJURY			English	Article						Tower of London; anterior cingulate cortex; left dorsolateral pre-frontal cortex	CLOSED-HEAD INJURY; WORKING-MEMORY; PLANNING TASK; ACTIVATION; TOWER; MILD; PET; FLEXIBILITY; PERFORMANCE; ATTENTION	Objective: To assess the cerebral correlates of the dysexecutive syndrome after diffuse severe traumatic brain injury (TBI). Methods: Ten patients with sub-acute/chronic severe TBI without detectable focal cortical contusion and 11 matched healthy subjects were included in a parametric fMRI study using a planning task, the Tower of London. Results: Brain activation in the left Dorsolateral Pre-frontal Cortex (DLPFC) and the Anterior Cingulate Cortex (ACC) was closely related to performance. Patients with TBI who performed the task efficiently showed, like healthy controls who obtained a similar pattern of performance, a large activation in the left DLPFC and a small activation in the ACC. In contrast, poor performance was associated with a reduced activation in these both regions. Conclusion: Problem-solving deficits after severe diffuse TBI could be related to an impaired activation of the DLPFC and of the ACC.	Univ Calif Los Angeles, Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90025 USA; INSERM, U 483, Paris, France; Beaujon Hosp, Dept Neuroradiol, Clichy, France; Maison Blanche Hosp, Dept Radiol, Reims, France; R Poincare Hosp, Rehabil Dept, Garches, France	Cazalis, F (corresponding author), Univ Calif Los Angeles, Sch Med, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,Rm 58-217, Los Angeles, CA 90025 USA.	fabfab@ucla.edu	FEYDY, ANTOINE/P-5289-2016	valabregue, romain/0000-0002-1814-9570; Pelegrini-Issac, Melanie/0000-0003-3260-5795			Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; Braun M, 2000, ANN FR ANESTH, V19, P296; Cazalis F, 2003, EUR J NEUROSCI, V17, P2219, DOI 10.1046/j.1460-9568.2003.02633.x; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; Dagher A, 1999, BRAIN, V122, P1973, DOI 10.1093/brain/122.10.1973; Dreher JC, 2003, CEREB CORTEX, V13, P329, DOI 10.1093/cercor/13.4.329; Elliott R, 1997, PSYCHOL MED, V27, P931, DOI 10.1017/S0033291797005187; Fan J, 2003, P NATL ACAD SCI USA, V100, P7406, DOI 10.1073/pnas.0732088100; Feydy A, 2002, STROKE, V33, P1610, DOI 10.1161/01.STR.0000017100.68294.52; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gron G, 2003, NEUROBIOL AGING, V24, P453, DOI 10.1016/S0197-4580(02)00128-8; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; JENKINS A, 1986, LANCET, V2, P445; Lazeron RHC, 2000, AM J NEURORADIOL, V21, P1407; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; MARIKO O, 2003, NEUROIMAGE, V18, P789; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MORRIS RG, 1993, NEUROPSYCHOLOGIA, V31, P1367, DOI 10.1016/0028-3932(93)90104-8; Netter F, 1997, ATLAS HUMAN ANATOMY; Ono M, 1990, ATLAS CEREBRAL SULCI; Owen AM, 1998, BRAIN, V121, P949, DOI 10.1093/brain/121.5.949; Owen AM, 1996, EUR J NEUROSCI, V8, P353, DOI 10.1111/j.1460-9568.1996.tb01219.x; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Prigatano GP, 2004, BRAIN INJURY, V18, P661, DOI 10.1080/02699050310001646170; Rowe JB, 2001, NEUROPSYCHOLOGIA, V39, P315, DOI 10.1016/S0028-3932(00)00109-3; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Talairach J., 1988, COPLANAR STEREOTAXIC; TRUWIT CL, 1994, HIGH RESOLUTION ATLA; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y	41	31	32	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2006	20	10					1019	1028		10.1080/02699050600664384			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	093FA	WOS:000241152100003	17060134				2021-06-18	
J	Holmberg, E; Nordstrom, T; Gross, M; Kluge, B; Zhang, SX; Doolen, S				Holmberg, Eric; Nordstrom, Tuija; Gross, Mica; Kluge, Bridget; Zhang, Shu-Xin; Doolen, Suzanne			Simvastatin promotes neurite outgrowth in the presence of inhibitory molecules found in central nervous system injury	JOURNAL OF NEUROTRAUMA			English	Article						HMG-CoA reductase inhibitor; isoprenoids; myelin stripe assay; regenerative failure; Rho GTPase; spinal cord injury; traumatic brain injury	MYELIN-ASSOCIATED GLYCOPROTEIN; SPINAL-CORD; NOGO RECEPTOR; AXON REGENERATION; RHO; IDENTIFICATION; GROWTH; TOLERABILITY; MEMBRANES; INTERACTS	Statins (3-hydroxy-3-methylglutaryl-CoA [HMG-CoA] reductase inhibitors) inhibit the rate-limiting step in the mevalonate pathway, conversion of HMG-CoA to mevalonate, by competitive inhibition with the enzyme HMG-CoA reductase. Statins not only lower cholesterol levels, but are also thought to exert neuroprotective and neurogenic effects that may be beneficial in treating brain and spinal cord injuries. Data presented here illustrate that simvastatin enables neurite outgrowth in the presence of growth-inhibitory molecules commonly found at central nervous system (CNS) injury sites. To assess the effect of simvastatin on neurite outgrowth in the presence of inhibitory molecules present at CNS injury sites, rat embryonic cortex explants or postnatal spinal cord explants were grown on membrane filters prepared with alternating stripes of laminin and myelin/laminin. Immunostaining indicated that myelin stripes contain myelin-associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (OMgp), and Nogo, but do not contain chondroitin sulfate proteoglycan (CSPG). When control explants were grown in the presence of alternating stripes, neurite outgrowth preferentially extended in regions containing laminin only. In contrast, neurite outgrowth from explants grown in the presence of simvastatin was significantly less selective for laminin regions and was able to extend into regions containing myelin (p < 0.01). Simvastatin-induced effects were reversed by addition of mevalonate. Isoprenyl transferase inhibitors GGTI-286 and FTI-277, inhibitors of biochemical steps subsequent to HMG-CoA conversion to mevalonate, mimicked simvastatin-induced effects. These data suggest that simvastatin counteracts myelin-associated neurite outgrowth inhibition signals via mevalonate pathway inhibition, and may be beneficial in promoting axon regeneration in brain and spinal cord injury.	SCS, Res Ctr, Ft Collins, CO 80526 USA; Univ Alaska Anchorage, Dept Chem, Anchorage, AK USA	Doolen, S (corresponding author), SCS, Res Ctr, 2401 Res Blvd,Ste 206, Ft Collins, CO 80526 USA.	sdoolen@scs.cbeyond.com					Agarwal B, 2002, CARCINOGENESIS, V23, P521, DOI 10.1093/carcin/23.3.521; Andrews TC, 2001, AM J MED, V111, P185, DOI 10.1016/S0002-9343(01)00799-9; Bonetti PO, 2003, EUR HEART J, V24, P225, DOI 10.1016/S0195-668X(02)00419-0; Bottorff M, 2000, ARCH INTERN MED, V160, P2273, DOI 10.1001/archinte.160.15.2273; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chen ZJ, 2002, MOL CELL NEUROSCI, V20, P125, DOI 10.1006/mcne.2002.1102; Davidson MH, 1997, AM J CARDIOL, V79, P38, DOI 10.1016/S0002-9149(96)00742-4; Davidson MH, 2001, DRUGS, V61, P197, DOI 10.2165/00003495-200161020-00005; DeBellard ME, 1996, MOL CELL NEUROSCI, V7, P89, DOI 10.1006/mcne.1996.0007; Dergham P, 2002, J NEUROSCI, V22, P6570; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Erschbamer MK, 2005, J COMP NEUROL, V484, P224, DOI 10.1002/cne.20471; Farmer JA, 2000, DRUG SAFETY, V23, P197, DOI 10.2165/00002018-200023030-00003; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; HORI Y, 1991, ONCOGENE, V6, P515; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Illingworth DR, 2001, ADV PROTEIN CHEM, V56, P77; Jain A, 2004, J NEUROSCI RES, V77, P299, DOI 10.1002/jnr.20161; Jin Z, 1997, J NEUROSCI, V17, P6256; Kottis V, 2002, J NEUROCHEM, V82, P1566, DOI 10.1046/j.1471-4159.2002.01146.x; Laufs Ulrich, 2003, Curr Atheroscler Rep, V5, P372, DOI 10.1007/s11883-003-0008-z; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Madura T, 2004, EMBO REP, V5, P412, DOI 10.1038/sj.embor.7400117; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Meske V, 2003, EUR J NEUROSCI, V17, P93, DOI 10.1046/j.1460-9568.2003.02433.x; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Schweigreiter R, 2004, MOL CELL NEUROSCI, V27, P163, DOI 10.1016/j.mcn.2004.06.004; Song J, 2005, INVEST OPHTH VIS SCI, V46, P2424, DOI 10.1167/iovs.04-0776; WALTER J, 1987, DEVELOPMENT, V101, P685; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wherlock M, 2002, J CELL SCI, V115, P239; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975	41	31	32	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2006	23	9					1366	1378		10.1089/neu.2006.23.1366			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	085LP	WOS:000240605900008	16958588				2021-06-18	
J	McGraw-Hunter, M; Faw, GD; Davis, PK				McGraw-Hunter, M.; Faw, G. D.; Davis, P. K.			The use of video self-modelling and feedback to teach cooking skills to individuals with traumatic brain injury: A pilot study	BRAIN INJURY			English	Article						modelling; video self-modelling; cooking; activities of daily living	CHILDREN; AUTISM; REHABILITATION; SETTINGS	Objective: To evaluate the effectiveness of video self-modelling plus prompting and feedback to teach a cooking skill to people with traumatic brain injury (TBI) and to examine skill generalization to a novel food item. Research design: Multiple probe across participants. Methods and procedures: Four individuals with TBI received instruction in cooking. They watched videotapes of themselves cooking and practiced that skill while receiving prompts and feedback. Treatment effects were evaluated by comparing performance before, during and after training and at a 2 and 4 week follow-up. Additionally, cooking performance on a novel food item was examined. Main outcomes and results: Three of the four individuals achieved criterion performance within four training sessions. Those individuals also substantially maintained their skills 2 and 4 weeks following training and generalized their skills to a novel food item. Conclusions: Video self-modelling plus prompting and feedback appears to be an effective treatment for teaching simple cooking skills to individuals with TBI. Further research should examine whether the video alone is sufficient for skill acquisition and evaluate the effectiveness of video self-modelling to teach other skills.	So Illinois Univ, Inst Rehabil, Carbondale, IL 62901 USA; Ctr Comprehens Serv, Carbondale, IL USA	Davis, PK (corresponding author), So Illinois Univ, Inst Rehabil, Carbondale, IL 62901 USA.	pdavis@siu.edu					ANDREW STV, 1993, J MENTAL HLTH COUNSE, V15, P206; Bandura A., 1977, SOCIAL LEARNING THEO; BARRY NJ, 1977, AM J MENT DEF, V82, P33; Boman IL, 2004, BRAIN INJURY, V18, P985, DOI 10.1080/02699050410001672396; Charlop-Christy MH, 2003, J POSIT BEHAV INTERV, V5, P12, DOI 10.1177/10983007030050010101; CUVO AJ, 1990, HDB APPL BEHAV ANAL, P39; D'Ateno P, 2003, J POSIT BEHAV INTERV, V5, P5, DOI 10.1177/10983007030050010801; Fabiano RJ, 1998, J REHABIL, V64, P9; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; GLANG A, 1992, J HEAD TRAUMA REHAB, V7, P93; Goldenberg G, 2001, NEUROPSYCHOL REHABIL, V11, P147, DOI 10.1080/09602010042000204; HARING TG, 1987, J APPL BEHAV ANAL, V20, P89, DOI 10.1901/jaba.1987.20-89; Hepting NH, 1996, TOP EARLY CHILD SPEC, V16, P407, DOI 10.1177/027112149601600308; Hitchcock CH, 2003, REM SPEC EDUC, V24, P36, DOI 10.1177/074193250302400104; Landa-Gonzalez BELKIS, 2001, Occup Ther Int, V8, P49, DOI 10.1002/oti.131; Lasater MW., 1995, EDUC TREAT CHILD, V18, P389; MEHARG SS, 1990, ADV BEHAV RES THER, V12, P85, DOI 10.1016/0146-6402(90)90008-E; MERCER C, 1975, J LEARNING DISABILIT, V8, P45; Norman J. M., 2001, Journal of Special Education Technology, V16, P5; RICHARDS SB, 1999, SINGLE SUBJECT RES A; Sherer M, 2001, BEHAV MODIF, V25, P140, DOI 10.1177/0145445501251008; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; Zhou J, 1996, J HEAD TRAUMA REHAB, V11, P51, DOI 10.1097/00001199-199602000-00007	23	31	32	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2006	20	10					1061	1068		10.1080/02699050600912163			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	093FA	WOS:000241152100008	17060139				2021-06-18	
J	Lundgren-Nilsson, A; Tennant, A; Grimby, G; Sunnerhagen, KS				Lundgren-Nilsson, A.; Tennant, A.; Grimby, G.; Sunnerhagen, K. S.			Cross-diagnostic validity in a generic instrument: an example from the Functional Independence Measure in Scandinavia	HEALTH AND QUALITY OF LIFE OUTCOMES			English	Article							RASCH MODEL; DISABILITY; REHABILITATION; ADAPTATION; INDEX; FIM	Background: To analyse the cross-diagnostic validity of the Functional Independence Measure (FIM(TM)) motor items in patients with spinal cord injury, stroke and traumatic brain injury and the comparability of summed scores between these diagnoses. Methods: Data from 471 patients on FIM T motor items at admission ( stroke 157, spinal cord injury 157 and traumatic brain injury 157), age range 11 - 90 years and 70 % male in nine rehabilitation facilities in Scandinavia, were fitted to the Rasch model. A detailed analysis of scoring functions of the seven categories of the FIM T motor items was made prior to testing fit to the model. Categories were re-scored where necessary. Fit to the model was assessed initially within diagnosis and then in the pooled data. Analysis of Differential Item Functioning (DIF) was undertaken in the pooled data for the FIM T motor scale. Comparability of sum scores between diagnoses was tested by Test Equating. Results: The present seven category scoring system for the FIM T motor items was found to be invalid, necessitating extensive rescoring. Despite rescoring, the item-trait interaction fit statistic was significant and two individual items showed misfit to the model, Eating and Bladder management. DIF was also found for Spinal Cord Injury, compared with the other two diagnoses. After adjustment, it was possible to make appropriate comparisons of sum scores between the three diagnoses. Conclusion: The seven-category response function is a problem for the FIM T instrument, and a reduction of responses might increase the validity of the instrument. Likewise, the removal of items that do not fit the underlying trait would improve the validity of the scale in these groups. Cross-diagnostic DIF is also a problem but for clinical use sum scores on group data in a generic instrument such as the FIM T can be compared with appropriate adjustments. Thus, when planning interventions ( group or individual), developing rehabilitation programs or comparing patient achievements in individual items, cross-diagnostic DIF must be taken into account.	Gothenburg Univ, Sahlgrenska Acad, Inst Neurosci & Physiol Rehabil Med, S-41345 Gothenburg, Sweden; Univ Leeds, Acad Unit Musculoskeletal Dis, Dept Rehabil Med, Leeds LS2 9NZ, W Yorkshire, England	Lundgren-Nilsson, A (corresponding author), Gothenburg Univ, Sahlgrenska Acad, Inst Neurosci & Physiol Rehabil Med, Guldhedsgatan 19, S-41345 Gothenburg, Sweden.	asa.lundgren-nilsson@rehab.gu.se; alantennant@compuserve.com; gunnar.grimby@rehab.gu.se; ks.sunnerhagen@neuro.gu.se	Grimby, Gunnar/AAB-3178-2019; Sunnerhagen, Katharina Stibrant/AAE-2405-2020	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400			Andrich D., 2003, RUMM2020; Andrich David, 2003, J Appl Meas, V4, P205; Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Bode Rita K, 2003, J Appl Meas, V4, P124; Bode RK, 2003, ARCH PHYS MED REHAB, V84, pS52, DOI 10.1053/apmr.2003.50247; BOND TG, 2001, APPL RASCH MODEL FUN, pR24; Catz A, 1997, SPINAL CORD, V35, P850, DOI 10.1038/sj.sc.3100504; Claesson L, 2001, J REHABIL MED, V33, P137; Cohen ME, 2000, ARCH PHYS MED REHAB, V81, pS21, DOI 10.1053/apmr.2000.20620; Dallmeijer AJ, 2005, J REHABIL MED, V37, P346, DOI 10.1080/16501970510038284; Deutsch A, 1996, CRIT REV PHYS REHABI, V8, P267; Dorans NJ, 1993, DIFFERENTIAL ITEM FU, P36; Elhan AH, 2005, J REHABIL MED, V37, P306, DOI 10.1080/16501970510037573; Fisher WP., 1992, RASCH MEASUREMENT T, V6, P238; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Grimby G, 1996, ARCH PHYS MED REHAB, V77, P1109, DOI 10.1016/S0003-9993(96)90131-8; Haigh R, 2001, J REHABIL MED, V33, P273; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEINEMANN AW, 2001, REDUSING STEP DISORD; KEITH RA, 1984, ARCH PHYS MED REHAB, V65, P74; Kucukdeveci AA, 2001, CLIN REHABIL, V15, P311, DOI 10.1191/026921501676877265; Lai J. S., 2002, RASCH MEAS T, V15, P850; LAWTON G, 2006, CROSS CULTURAL VALID; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Lundgren-Nilsson A, 2005, J REHABIL MED, V37, P23, DOI 10.1080/16501970410032696; Luo Guanzhong, 2005, J Appl Meas, V6, P128; MARINO RJ, 1993, PARAPLEGIA, V31, P225, DOI 10.1038/sc.1993.41; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; Nilsson AL, 2005, ACTA NEUROL SCAND, V111, P264, DOI 10.1111/j.1600-0404.2005.00404.x; Orlando M, 2002, PSYCHOL ASSESSMENT, V14, P50, DOI 10.1037//1040-3590.14.1.50; PALLANT JFT, 2006, BRIT J CLIN PSYCHOL; RASCH G, 1980, PROBABILISTIC MODELS, pR23; Smith R M, 2000, J Appl Meas, V1, P199; STREINER DL, 1995, OXFORD MED PUBLICATI, pR8; Tennant A, 2004, MED CARE, V42, P37, DOI 10.1097/01.mlr.0000103529.63132.77; van Buuren S, 2003, EUR J PUBLIC HEALTH, V13, P15, DOI 10.1093/eurpub/13.suppl_1.15; VANALPHEN A, 1994, J ADV NURS, V20, P196; Wright B. D, 2003, RAS MEAS T, V17, P905; Wright BD, 1997, SCAND J REHABIL MED, V29, P267; WRIGHT BD, 1982, RATING SCALE ANAL, pR11	41	31	32	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1477-7525		HEALTH QUAL LIFE OUT	Health Qual. Life Outcomes	AUG 23	2006	4								55	10.1186/1477-7525-4-55			8	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	091NF	WOS:000241034900001	16928268	DOAJ Gold, Green Published			2021-06-18	
J	Soustiel, JF; Mahamid, E; Chistyakov, A; Shik, V; Benenson, R; Zaaroor, M				Soustiel, J. F.; Mahamid, E.; Chistyakov, A.; Shik, V.; Benenson, R.; Zaaroor, M.			Comparison of moderate hyperventilation and mannitol for control of intracranial pressure control in patients with severe traumatic brain injury - a study of cerebral blood flow and metabolism	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; cerebral blood flow; cerebral metabolism; intracranial pressure; hyperventilation	SEVERE HEAD-INJURY; INTERNAL CAROTID-ARTERY; RANDOMIZED-TRIAL; PRACTICAL SCALE; HYPERTENSION; DYSFUNCTION; LACTATE; GLUCOSE; HUMANS; COMA	Objective. To compare the respective effects of established measures used for management of traumatic brain injury (TBI) patients on cerebral blood flow (CBF) and cerebral metabolic rates of oxygen (CMRO2), glucose (CMRGlc) and lactate (CMRLct). Methods. Thirty-six patients suffering from severe traumatic brain injury (TBI) were prospectively evaluated. In all patients baseline assessments were compared with that following moderate hyperventilation (reducing PaCO2 from 36 +/- 4 to 32 +/- 4mmHg) and with that produced by administration of 0.5gr/kg mannitol 20% intravenously. Intracranial and cerebral perfusion pressure (ICP, CPP), CBF and arterial jugular differences in oxygen, glucose and lactate contents were measured for calculation of CMRO2, CMRGlc and CMRLct. Results. Following hyperventilation, CBF was significantly reduced (P < 0.0001). CBF remained most often above the ischemic range although values less than 30ml center dot 100gr(-1)center dot min(-1) were found in 27.8% of patients. CBF reduction was associated with concurrent decrease in CMRO2, anaerobic hyperglycolysis and subsequent lactate production. In contrast, mannitol resulted in significant albeit moderate improvement of cerebral perfusion. However, administration of mannitol had no ostensible effect either on oxidative or glucose metabolism and lactate balance remained mostly unaffected. Conclusions. Moderate hyperventilation may exacerbate pre-existing impairment of cerebral blood flow and metabolism in TBI patients and should be therefore carefully used under appropriate monitoring. Our findings rather support the use of mannitol for ICP control.	Rambam Med Ctr, Dept Neurosurg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Acute Brain Injury Res Lab, Haifa, Israel	Soustiel, JF (corresponding author), Rambam Med Ctr, Dept Neurosurg, POB 9602, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il					ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Clausen T, 2004, BRAIN RES, V1019, P113, DOI 10.1016/j.brainres.2004.05.099; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2001, NEUROSURGERY, V49, P864; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; Kirkpatrick PJ, 1996, NEUROSURGERY, V39, P714, DOI 10.1097/00006123-199610000-00013; LUNDBERG N, 1959, Acta Psychiatr Scand Suppl, V34, P1; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Rothoerl RD, 2005, NEUROL RES, V27, P209, DOI 10.1179/016164105X35567; Rothoerl RD, 2003, ACTA NEUROCHIR, V145, P943, DOI 10.1007/s00701-003-0108-0; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Soustiel JF, 2003, STROKE, V34, P1876, DOI 10.1161/01.STR.0000080942.32331.39; Soustiel JF, 2002, J ULTRAS MED, V21, P1405, DOI 10.7863/jum.2002.21.12.1405; TEASDALE G, 1974, LANCET, V2, P81; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamaki T, 1996, J NUCL MED, V37, P1166; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; ZWEINENBERGLEE M, 2004, YOUMANS NEUROLOGICAL, P5039	35	31	33	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	AUG	2006	148	8					845	851		10.1007/s00701-006-0792-7			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	066RL	WOS:000239247700007	16763735				2021-06-18	
J	Ricci-Vitiani, L; Casalbore, P; Petrucci, G; Lauretti, L; Montano, N; Larocca, LM; Falchetti, ML; Lombardi, DG; Gerevini, VD; Cenciarelli, C; D'Alessandris, QG; Fernandez, E; De Maria, R; Maira, G; Peschle, C; Parati, E; Pallini, R				Ricci-Vitiani, Lucia; Casalbore, Patrizia; Petrucci, Giovanna; Lauretti, Liverana; Montano, Nicola; Larocca, Luigi Maria; Falchetti, Maria Laura; Lombardi, Dario Giuseppe; Di Giorgio Gerevini, Valeria; Cenciarelli, Carlo; D'Alessandris, Quintino Giorgio; Fernandez, Eduardo; De Maria, Ruggero; Maira, Giulio; Peschle, Cesare; Parati, Eugenio; Pallini, Roberto			Influence of local environment on the differentiation of neural stem cells engrafted onto the injured spinal cord	NEUROLOGICAL RESEARCH			English	Article; Proceedings Paper	Congress on Advances in Biology and Treatment of Malignant Brain Gliomas and Stem Cells and Neurosciences	SEP 23-24, 2005	Rome, ITALY			neural stem cells; spinal cord injury; inflammatory cytokines; astrocytic differentiation	FIBROBLAST-GROWTH-FACTOR; PRECURSOR CELLS; MOUSE-BRAIN; TNF-ALPHA; CYTOKINES; RAT; STIMULATION; ACTIVATION; EXPRESSION; LINEAGE	Objectives: In vitro, neural stem cells (NSCs) proliferate as undifferentiated spheroids and differentiate into neurons, astrocytes and oligodendrocytes. These features make NSCs suitable for spinal cord (SC) reconstruction. However, in vivo experiments have demonstrated that in the injured SC transplanted NSCs either remain undifferentiated or differentiate into the astrocytic phenotype. The microenvironment of the injured SC is believed to play a crucial role in driving the differentiation of the engrafted NSCs. Here, we tested the hypothesis that inflammatory cytokines (ICs) may be involved in the restricted differentiation of NSCs after grafting onto the injured SC. Methods: As the first step, we used immunohistochemistry to analyse the expression of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta and interferon (IFN)-gamma in the normal SC of mice and following traumatic injury. Then, we investigated whether a combination of TNF-alpha, IL-1 beta and IFN-gamma may affect the phenotype of murine NSCs in vitro. Results: We found that TNF-alpha, IL-1 beta and IFN-gamma, which are absent in the normal SC, are all expressed in the injured SC and the expression of these cytokines follows a timely tuned fashion with IFN-gamma being detectable as long as 4 weeks after injury. In culture, exposure of proliferating NSCs to a combination of TNF-alpha, IL-1 beta and IFN-gamma was per se sufficient to induce the astrocytic differentiation of these cells even in the absence of serum. Conclusions: In the traumatically injured SC, differentiation of engrafted NSCs is restricted towards the astrocytic lineage because of the inflammatory environment. ICs are likely to play a major role in differentiation of NSCs in the in vivo conditions.	Univ Sacred Heart, Sch Med, Dept Neurosurg, I-00168 Rome, Italy; Univ Sacred Heart, Sch Med, Inst Human Pathol, I-00168 Rome, Italy; Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; CNR, Inst Neurobiol & Mol Med, Rome, Italy; Ist Nazl Neurol Carlo Besta, Neurobiol Lab, Dept Neurobiol & Neurorestorat Therapies, Milan, Italy; Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy	Pallini, R (corresponding author), Univ Sacred Heart, Sch Med, Dept Neurosurg, Largo A Gemelli 8, I-00168 Rome, Italy.	pallini@rm.unicatt.it	Parati, Eugenio Agostino/AAN-5893-2021; CENCIARELLI, CARLO/AAC-1603-2019; Ricci Vitiani, Lucia/J-8320-2016; D'Alessandris, Quintino Giorgio/J-8827-2018; Montano, Nicola/M-4565-2016; falchetti, maria laura/AAA-5586-2019; Larocca, Luigi M/A-1577-2008; Larocca, Luigi Maria/M-9590-2019; Parati, Eugenio A/G-8765-2011; Pallini, Roberto/AAA-3760-2019; De Maria, Ruggero/S-6385-2019; PALLINI, Roberto/AAA-3747-2019	Parati, Eugenio Agostino/0000-0001-5020-6523; CENCIARELLI, CARLO/0000-0001-7480-4608; Ricci Vitiani, Lucia/0000-0001-7336-5615; D'Alessandris, Quintino Giorgio/0000-0002-2953-9291; Montano, Nicola/0000-0002-4965-1950; Larocca, Luigi M/0000-0003-1739-4758; Larocca, Luigi Maria/0000-0003-1739-4758; De Maria, Ruggero/0000-0003-2255-0583; PALLINI, Roberto/0000-0002-4611-8827; PETRUCCI, Giovanna/0000-0002-9280-3673			BALASINGAM V, 1994, J NEUROSCI, V14, P846; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; FERNANDEZ E, 1985, ACTA NEUROCHIR, V76, P145, DOI 10.1007/BF01418478; Gritti A, 1999, J NEUROSCI, V19, P3287; Gritti A, 1996, J NEUROSCI, V16, P1091; Han SSW, 2002, EXP NEUROL, V177, P360, DOI 10.1006/exnr.2002.7995; Janabi N, 1998, GLIA, V23, P304; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Kojima A, 2000, J NEUROPATH EXP NEUR, V59, P687, DOI 10.1093/jnen/59.8.687; Krathwohl MD, 2004, STEM CELLS, V22, P109, DOI 10.1634/stemcells.22-1-109; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; Pagano SF, 2000, STEM CELLS, V18, P295, DOI 10.1634/stemcells.18-4-295; Pallini R, 2005, NEUROSURGERY, V57, P1014, DOI 10.1227/01.NEU.0000180058.58372.4c; Reier P J, 1988, Adv Neurol, V47, P87; Tuna M, 2001, J NEUROSURG, V95, P64, DOI 10.3171/spi.2001.95.1.0064; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009	22	31	43	0	4	MANEY PUBLISHING	LEEDS	HUDSON RD, LEEDS LS9 7DL, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	JUL	2006	28	5					488	492		10.1179/016164106X115134			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	058HT	WOS:000238656800004	16808877				2021-06-18	
J	Shutter, L; Tong, KA; Lee, A; Holshouser, BA				Shutter, Lori; Tong, Karen A.; Lee, Ann; Holshouser, Barbara A.			Prognostic role of proton magnetic resonance spectroscopy in acute traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						diffuse axonal injury; proton magnetic resonance spectroscopy; traumatic brain injury	SEVERE HEAD-INJURY; OUTCOME PREDICTION; IN-VIVO; MR SPECTROSCOPY; AXONAL INJURY; METABOLISM; CHILDREN; RECOVERY; TREE	Proton magnetic resonance spectroscopy (MRS) is being used to evaluate individuals after acute traumatic brain injury. These studies have shown that changes in certain brain metabolites are associated with poor neurologic outcomes. The majority of MRS studies have been obtained relatively late after injury, but there have been a few reports of use early after injury to assist with outcome prediction. Altered brain metabolites may be sensitive indicators of injury and thus provide additional prognostic information when spectroscopy is done early after injury. This technology may provide a noninvasive means to evaluate early excitotoxic injury; and show changes associated with both neuronal injury and membrane disruption secondary to diffuse axonal injury. This article will review the technology of MRS, discuss its role in patient assessment after traumatic brain injury, and present a summary of our published and ongoing research.	Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45267 USA; Loma Linda Univ, Med Ctr, Dept Radiol, Loma Linda, CA USA; DPF Orthoped, Rehabil Serv, Kansas City, MO USA	Shutter, L (corresponding author), Univ Cincinnati, Med Ctr, Dept Neurosurg, POB 670515, Cincinnati, OH 45267 USA.	shuttel@healthall.com	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			*AM ASS NEUR SURG, 2000, GUID MAN SEV HEAD IN; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; HOLSHOUSER BA, 2002, JOINT S NAT INT NEUR; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEE A, 2004, COMP PREDICATIVE ACC; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; SHUTTER L, 2002, JOINT S NAT INT NEUR; Signoretti S, 2002, ACT NEUR S, V81, P373; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109	30	31	31	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2006	21	4					334	349		10.1097/00001199-200607000-00005			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	064SJ	WOS:000239109100005	16915009				2021-06-18	
J	Rutterford, NA; Wood, RLL				Rutterford, Neil A.; Wood, Rodger L. L.			Evaluating a theory of stress and adjustment when predicting long-term psychosocial outcome after brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						psychosocial factors; brain injuries; outcome studies; personality; stress; adjustment	CLOSED-HEAD-INJURY; FOLLOW-UP; PERSONALITY-TRAITS; IMPAIRED AWARENESS; SELF-AWARENESS; LIFE; INTEGRATION; DISABILITY; DEPRESSION; SCALE	Kendall and Terry (1996) include many psychosocial predictors in their theoretical model that explains individual differences in psychosocial adjustment (Lazarus & Folkman, 1984). The model depicts appraisal and coping variables as mediating relationships between situation factors, environmental and personal resources, and multidimensional outcome. The aim of this Study was to explore these theoretical relationships at very late stages of recovery from traumatic brain injury. A total of 131 participants who were more than 10 years post-injury (mean = 15.31 years) completed several psychosocial measures relating to outcome dimensions comprising employment. community integration, life satisfaction, quality of life (QoL), and emotion. There was no evidence that appraisal and coping variables mediated relationships between psychosocial and any of the outcome variables. However. when appraisal and coping variables were combined with psychosocial variables as direct predictors of outcome, every outcome except employment status was reliably predicted, accounting for between 31 and 46% of the variance. Personality significantly influenced all predicted outcomes. Self-efficacy contributed to the prediction of all outcomes except QoL. Data did not support for the theory of stress and adjustment as a framework for explaining the nature of predictive relationships between psychosocial variables and very long-term, multidimensional outcome after brain injury.	Univ Coll Swansea, Sch Human Sci, Dept Psychol, Swansea SA2 8PP, W Glam, Wales	Wood, RLL (corresponding author), Univ Coll Swansea, Sch Human Sci, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk					BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BARTLETT MS, 1954, J ROY STAT SOC B, V16, P296; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Eysenck H. J., 1991, MANUAL EYSENCK PERSO; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Holosko M, 1989, CANADIAN J REHABILIT, V2, P145; Hoofien D, 2001, BRAIN INJURY, V15, P189; KAISER HF, 1970, PSYCHOMETRIKA, V35, P401, DOI 10.1007/BF02291817; KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Lazarus R.S., 1984, STRESS APPRAISAL COP; LAZARUS RS, 1993, PSYCHOSOM MED, V55, P234, DOI 10.1097/00006842-199305000-00002; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Little RJA, 1987, STAT ANAL MISSING DA; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; Miller MA, 1997, J PSYCHOSOM RES, V43, P279, DOI 10.1016/S0022-3999(97)00118-9; MILNE D, 1992, ASSESSMENT MENTAL HL; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Moore AD, 1994, CAN J REHABIL, V4, P122; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PIRGATANO GP, 1991, AWARENESS DEFICIT BR; POWER MJ, 1988, BRIT J CLIN PSYCHOL, V27, P349, DOI 10.1111/j.2044-8260.1988.tb00799.x; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Schretlen DJ, 2000, REHABIL PSYCHOL, V45, P260, DOI 10.1037/0090-5550.45.3.260; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Tabachnick B., 2001, USING MULTIVARIATE S; Tate RL, 2003, NEUROPSYCHOL REHABIL, V13, P43, DOI 10.1080/09602010244000372; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	46	31	31	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2006	12	3					359	367		10.1017/S1355617706060450			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	046PP	WOS:000237823800006	16903128				2021-06-18	
J	Su, W; Hui, T; Shaw, K				Su, Wendy; Hui, Thomas; Shaw, Kenneth			All-terrain vehicle injury patterns: are current regulations effective?	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	37th Annual Meeting of the Canadian-Association-of-Paediatric-Surgeons	SEP 22-25, 2005	Quebec City, CANADA	Canadian Assoc Paediat Surg		all-terrain vehicles; helmet use; injury prevention	CHILDREN; PREVENTION; TRAUMA; IMPACT; HELMET; ATV	Purpose: All-terrain vehicle (ATV)-related injuries continued to increase in recent years. We aimed to analyze the ATV injury patterns at our institution to help structure public awareness campaign and encourage governmental regulation, with the ultimate goal of injury prevention. Methods: A retrospective review of all ATV-related admissions at a pediatric trauma center was performed. Results: From 2001 to 2004, 50 ATV-related injuries requiting hospital admission were identified. The annual incidence had increased 2.5-fold from 2001 (8 admissions) to 2004 (20 admissions). The ages ranged from 3 to 17 years (median, 13 years), with equal sex distribution. Fifty-four percent of admissions were traumatic brain injuries, 28% had orthopedic injuries, 14% with facial fractures, and 4% with abdominal injuries. Average length of stay was 6 days (range, 1-47 days); 5 of the 7 intensive care unit admissions occurred in 2004. Eighty-four percent of patients did not wear helmet (97% among those from northern communities). Conclusions: Both the incidence and severity of ATV-related injuries are increasing in a regional pediatric trauma center. There is a lack of regulation enforcement and public awareness of the danger of ATV use in children. Efforts to ensure helmet use and limit operator age are urgently needed to reduce childhood ATV-related injuries. (c) 2006 Elsevier Inc. All rights reserved.	Montreal Childrens Hosp, Dept Surg, Montreal, PQ H3H 1P3, Canada	Shaw, K (corresponding author), Montreal Childrens Hosp, Dept Surg, Montreal, PQ H3H 1P3, Canada.	wendysu2@hotmail.com; kenneth.shaw@muhc.mcgill.ca					Aitken ME, 2004, INJURY PREV, V10, P303, DOI 10.1136/ip.2003.004176; American Academy of Pediatrics Committee on Accident and Poison Prevention, 1987, PEDIATRICS, V79, P306; Bercher D L, 2001, J Ark Med Soc, V97, P351; Bhutta ST, 2004, PEDIATR RADIOL, V34, P130, DOI 10.1007/s00247-003-1085-4; Bull MJ, 2000, PEDIATRICS, V105, P1352, DOI 10.1542/peds.105.6.1352; *CAN PAED SOC ACC, 1987, CMAJ, V136, P119; *CONS PROD SAF COM, 1998, TERR VEH EXP INJ DEA; Helmkamp J C, 2000, W V Med J, V96, P361; Helmkamp James C, 2003, W V Med J, V99, P224; Injury Prevention Committee, 2004, PAED CHILD HLTH, V9, P337; Keenan HT, 2004, PEDIATRICS, V113, pE330, DOI 10.1542/peds.113.4.e330; Killingsworth JB, 2005, PEDIATRICS, V115, pE316, DOI 10.1542/peds.2004-1585; LEVENSON M, 2001, TERR VEH 2001 INJ EX; Lister DG, 1998, J PEDIATR SURG, V33, P1081, DOI 10.1016/S0022-3468(98)90535-8; Lynch JM, 1998, J PEDIATR SURG, V33, P329, DOI 10.1016/S0022-3468(98)90456-0; Mangus RS, 2004, INJURY PREV, V10, P56, DOI 10.1136/ip.2003.002626; Moroney P, 2003, INJURY, V34, P203, DOI 10.1016/S0020-1383(02)00317-0; Murphy N, 2004, J TRAUMA, V56, P1185, DOI 10.1097/01.TA.0000123038.94864.E2; NAGELBERG A, AM AC ORTH SURG POS; Ross RT, 1999, AM SURGEON, V65, P870; Russell A, 1998, PEDIATR EMERG CARE, V14, P31, DOI 10.1097/00006565-199802000-00009; Upperman JS, 2003, J PEDIATR SURG, V38, P1284, DOI 10.1016/S0022-3468(03)00383-X; KAWASAKI KFX50 INFOR	23	31	31	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	MAY	2006	41	5					931	934		10.1016/j.jpedsurg.2006.01.011			4	Pediatrics; Surgery	Pediatrics; Surgery	054PI	WOS:000238390700012	16677886				2021-06-18	
J	Pinto, FCG; Capone-Neto, A; Prist, R; Silva, MRE; Poli-de-Figueiredo, LF				Pinto, FCG; Capone-Neto, A; Prist, R; Silva, MRE; Poli-de-Figueiredo, LF			Volume replacement with lactated ringer's or 3% hypertonic saline solution during combined experimental hemorrhagic shock and traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Japanese-Association-for-Acute-Medicine	SEP 29-OCT 02, 2004	Maui, HI	Amer Assoc Surg Trauma, Japanese Assoc Acute Med		hemorrhagic shock; traumatic brain injury; hypertonic saline solution; lactated Ringer's solution	HEAD-INJURY; INTRACRANIAL-PRESSURE; RESUSCITATION; FLUID; MODEL; DEXTRAN-40; WATER	Background. The devastating effects of hypotension on head-trauma-related mortality are well known. This study evaluates the systemic and cerebral hemodynamic responses to volume replacement with 3% hypertonic saline (HSS) or lactated Ringer's solution (LR), during the acute phase of hemorrhagic shock (HS) associated with traumatic brain injury (TBI). Methods: Fifteen dogs were assigned to one of three groups (n = 5, each) according to the volume replacement protocol, infused after TBI (brain fluid percussion, 4 atm) and epidural balloon to an intracranial pressure (ICP) higher than 20 mm Hg and HS, induced by blood removal to a mean arterial pressure (MAP) of 40 rum Hg in 5 minutes: Group HS+TBI+HSS (8 mL/kg of 3% HSS), HS+TBI+LR (16 mL/kg LR), and Group HS+TBI (controls, no fluids). We simulated treatment during prehospital and early hospital admission. Groups HS+ TBI and HS+TBI+LR received shed blood infusion to a target hematocrit of 30%. Measurements included shed blood volume, fluid volume infused to restore MAP, MAP, cardiac output, cerebral perfusion pressure, cerebral and systemic lactate, and oxygen extraction ratios. Results: Fluid replacement with HSS 3% or LR promoted major hemodynamic benefits over control animals without luids. Cerebral perfusion pressure was higher than controls and similar between treated groups; however, HSS 3% infusion was associated with lower ICP during the "early hospital phase" and a higher serum sodium and osmolarity. Conclusion: In the event of severe head trauma and hemorrhagic shock, the use of HSS 3% and larger volumes of LR promote similar systemic and cerebral hemodynamic benefits. However, a lower ICP was observed after HSS 3% than after LR.	Univ Sao Paulo, Div Appl Physiol, Inst Heart, Sch Med,InCor, BR-05403000 Sao Paulo, Brazil	Pinto, FCG (corresponding author), Univ Sao Paulo, Div Appl Physiol, Inst Heart, Sch Med,InCor, Av Eneas Carvalho Aguiar 44, BR-05403000 Sao Paulo, Brazil.	acapuano@terra.com.br	Pinto, Fernando Gomes/F-6094-2012	PINTO, FERNANDO/0000-0003-2384-2190; Namias, Nicholas/0000-0001-7021-2250			*AM COLL SURG, 1996, ADV TRAUM LIF SUPP I; Anderson JT, 1997, J TRAUMA, V42, P592, DOI 10.1097/00005373-199704000-00003; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; Bhardwaj, 1999, Curr Treat Options Neurol, V1, P179, DOI 10.1007/s11940-999-0002-z; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; DeWitt DS, 1996, CRIT CARE MED, V24, P109, DOI 10.1097/00003246-199601000-00019; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; ELIASTAM M, 1984, ANN EMERG MED, V13, P874, DOI 10.1016/S0196-0644(84)80464-3; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GUNNAR W, 1989, BRAZ J MED BIOL RES, V22, P287; GUNNAR W, 1988, SURGERY, V103, P398; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; Harukuni Izumi, 2002, J Anesth, V16, P229, DOI 10.1007/s005400200030; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; KIRKEBY OJ, 1995, J NEUROSURG, V83, P1067, DOI 10.3171/jns.1995.83.6.1067; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Rocha-e-Silva Mauricio, 2005, Clinics, V60, P159, DOI 10.1590/S1807-59322005000200013; ROPPER A, 1993, NEUROLOGICAL NEUROSU; Schell RM, 1996, J NEUROSURG ANESTH, V8, P178, DOI 10.1097/00008506-199604000-00022; SHACKFORD SR, 1988, SURGERY, V104, P553; Sheikh AA, 1996, CRIT CARE MED, V24, P1226, DOI 10.1097/00003246-199607000-00027; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; VELANOVICH V, 1989, SURGERY, V105, P65; VELASCO IT, 1980, AM J PHYSIOL, V239, P664; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021; 2002, J NEUROTRAUMA, V19, P149	36	31	41	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2006	60	4					758	763		10.1097/01.ta.0000214581.89316.73			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	033RY	WOS:000236868100014	16612295				2021-06-18	
J	Esper, DH; Coplin, WM; Carhuapoma, JR				Esper, Dema Halasa; Coplin, William M.; Carhuapoma, J. Ricardo			Energy expenditure in patients with nontraumatic intracranial hemorrhage	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article; Proceedings Paper	2nd Annual Nutrition Week Conference	JAN 20, 2003	SAN ANTONIO, TX				SPONTANEOUS INTRACEREBRAL HEMORRHAGE; INDIRECT CALORIMETRY; ACUTE STROKE; INJURY	Background: Patients with intracerebral (ICH), intraventricular (IVH) and subarachnoid hemorrhage (SAH) have increased morbidity and mortality compared with other forms of stroke. We postulate that the systemic inflammatory state triggered by these forms of nontraumatic intracranial hemorrhage (IH) translates into higher nutrition requirements than traditionally assumed. In order to test this hypothesis,, we performed a retrospective study comparing the resting energy expenditure (REE) of 14 mechanically ventilated IH patients with the REE of 6 severe traumatic brain injury (sTBI) patients (a disease known to induce an increased metabolic state). Methods: Using nonparametric analysis, we compared 2 contemporary cohorts of patients-IH and sTBI-who required mechanical ventilation and who underwent indirect calorimetry (IC) within 7 days after the ictus. Results: Fourteen patients with nontraumatic IH (IVH, 2; SAH, 9; SAH/ICH, 1; ICI/SAH/IVH, 2) who underwent IC within 7 days from injury were identified; median age: 59 (28-84) years, median admission Glasgow Coma Scale (GCS): 6 (4-9), and median APACHE 11: 19.5 (15-28). A control cohort of 6 patients with sTBI was identified; median age: 57.5 (18-80) years, admission GCS: 6.5 (4-8), and APACHE 11: 16 (11-31). Sedation was used in 11/14 patients with IH and in 5/6 severe TBI patients. No patient was pharmacologically paralyzed. Median REE was 1810 (1124-2806) and 2238 (1860-2780) kcal/d for the IH and for the sTBI patient cohorts, respectively. Using Wilcoxon signed ranks test, the 2 patient groups were found comparable in regard to baseline clinical variables and disease severity (APACHE II). We did not identify a statistically significant difference in the REE between these 2 cohorts of patients (p =.25). Conclusions: Patients with severe TBI and patients with IH have similar increments in metabolic rate during the initial phase (1 week from onset) of their disease. This information needs to be confirmed in a larger cohort of patients. If reproduced, our results suggest that nontraumatic IH patients are at high risk of inadequate nutrition if their metabolic rate is estimated after conventional nutrition practice.	Detroit Receiving Hosp & Univ Hlth Ctr, Dept Nutr, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA	Carhuapoma, JR (corresponding author), Johns Hopkins Univ Hosp, Div Neurosci Crit Care, 600 N Wolfe St,Meyer 8-140, Baltimore, MD 21287 USA.	jcarhua1@jhmi.edu	Carhuapoma, Juan/AAC-5279-2019; Carhuapoma, Juan/X-9195-2018	Carhuapoma, Juan/0000-0002-5868-7701; 			Blackburn G L, 1977, JPEN J Parenter Enteral Nutr, V1, P11, DOI 10.1177/014860717700100111; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Chalela JA, 2004, NEUROCRIT CARE, V1, P331, DOI 10.1385/NCC:1:3:331; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; Davalos A, 1996, STROKE, V27, P1028, DOI 10.1161/01.STR.27.6.1028; DAVERAT P, 1991, STROKE, V22, P1, DOI 10.1161/01.STR.22.1.1; Frankenfield DC, 1998, J AM DIET ASSOC, V98, P439, DOI 10.1016/S0002-8223(98)00100-X; Kasuya H, 1998, NEUROSURGERY, V42, P1268, DOI 10.1097/00006123-199806000-00038; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; McClave SA, 2003, JPEN-PARENTER ENTER, V27, P16, DOI 10.1177/014860710302700116; McClave SA, 2001, J CLIN GASTROENTEROL, V33, P14, DOI 10.1097/00004836-200107000-00005; McClave SA, 1998, JPEN-PARENTER ENTER, V22, P375, DOI 10.1177/0148607198022006375; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Rhoney DH, 2002, NEUROL RES, V24, P613, DOI 10.1179/016164102101200456; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; Silva Y, 2005, STROKE, V36, P86, DOI 10.1161/01.STR.0000149615.51204.0b; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363	22	31	33	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0148-6071	1941-2444		JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	MAR-APR	2006	30	2					71	75		10.1177/014860710603000271			5	Nutrition & Dietetics	Nutrition & Dietetics	195WT	WOS:000248443700001	16517949				2021-06-18	
J	Yang, Y; Xie, YY; Chai, H; Fan, M; Liu, SH; Liu, H; Bruce, I; Wu, WT				Yang, Y; Xie, YY; Chai, H; Fan, M; Liu, SH; Liu, H; Bruce, I; Wu, WT			Microarray analysis of gene expression patterns in adult spinal motoneurons after different types of axonal injuries	BRAIN RESEARCH			English	Article						motoneuron; axotomy; avulsion; regeneration; gene expression; CDNA microarray	NITRIC-OXIDE SYNTHASE; SCIATIC-NERVE CRUSH; ROOT AVULSION; CORD-INJURY; NEUROTROPHIC FACTOR; C-JUN; TRAUMATIC INJURY; TRANSGENIC MICE; MOTOR-NEURONS; BRAIN-INJURY	Three experimental models of axonal injuries in adult rat spinal motoneurons were established to investigate changes of gene expression in response to such injuries. We took advantage of cDNA microarray analysis to determine the differential expression of genes in injured motoneurons following distal axotomy or root avulsion in the absence or presence of BDNF. The major finding was that, in response to proximal axonal injury (avulsion), expression of genes that are known to facilitate neuronal survival and axonal regeneration (e.g., IGFRII, PI3K, IGFBP-6, GSTs, GalR2) were down-regulated; but following treatment with BDNF they were up-regulated. In addition, the expression of genes known to be involved in apoptosis and DNA damage (e.g., ANX5, TS, ALR) were down-regulated in BDNF-treated animals with avulsion. Furthermore, many functional families of genes previously shown to play roles in the pathophysiology of axonal injury, including SNAP-2SA, SV2B, Ras-related ras3a/4b, ERK1/2, 14-3-3 proteins, proteasome proteins, oncogenes, GAP-43, and NMDAR1, were altered after either distal axotomy or avulsion injury. Some of the changes in gene expression, including Lim-2, FRAG1, GlaR2, GSTs, ALR, TS, ANX3/5, and nhe1/2, are first reported here in injured motoneurons. The differential expression of genes identified by the expression arrays was confirmed by gene-specific RT-PCR for eight genes (GAP-43, IGFR II, Lim-2, MIF, NDAP1, TS, PCC3, and FRAGI) and by in situ hybridization for Lim-2. These results suggest that abnormal regulation of particular biochemical pathways may induce motoneuron death after ventral root avulsion in adult animals. This study presents an approach for selecting specific genes and their products that may be involved in motoneuron degeneration following axonal injuries. (c) 2005 Elsevier B.V. All rights reserved.	Univ Hong Kong, Fac Med, Dept Anat, Hong Kong, Peoples R China; Beijing Inst Basic Med Sci, Dept Neurobiol, Beijing 100850, Peoples R China; Univ Hong Kong, Fac Med, Dept Physiol, Hong Kong, Peoples R China	Wu, WT (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, 21 Sassoon Rd, Hong Kong, Peoples R China.	wtwu@hkucc.hku.hk	Bruce, Iain C/K-8912-2017; Chai, Hong/H-5438-2011	Bruce, Iain C/0000-0002-5710-3970; Yang, Yanqi/0000-0002-3582-1277			Aimone JB, 2004, EXP NEUROL, V189, P204, DOI 10.1016/j.expneurol.2004.05.042; Cao Xiaojian, 2002, Chin J Traumatol, V5, P228; Cao Xiaojian, 2002, Chin J Traumatol, V5, P131; Chai H, 1999, NEUROSCI LETT, V274, P147, DOI 10.1016/S0304-3940(99)00671-0; Counts SE, 2002, J NEUROCHEM, V83, P442, DOI 10.1046/j.1471-4159.2002.01148.x; Di Giovanni S, 2004, FASEB J, V18, P153, DOI 10.1096/fj.04-2694fje; Dolcet X, 1999, J NEUROCHEM, V73, P521, DOI 10.1046/j.1471-4159.1999.0730521.x; Donovan SL, 2002, J NEUROSCI, V22, P3543; Enge M, 2003, NEUROCHEM RES, V28, P271, DOI 10.1023/A:1022421001288; Erdmann KS, 1998, BIOCHEM BIOPH RES CO, V249, P891, DOI 10.1006/bbrc.1998.9219; FAWCETT JW, 1992, TRENDS NEUROSCI, V15, P5, DOI 10.1016/0166-2236(92)90338-9; Ford P, 2002, J MEMBRANE BIOL, V190, P117, DOI 10.1007/s00232-002-1030-8; Forsberg-Nilsson K, 2003, GLIA, V41, P276, DOI 10.1002/glia.10191; Fujimoto Shin, 1997, Hokkaido Journal of Medical Science, V72, P409; Gagliardini V, 2000, MOL CELL NEUROSCI, V16, P27, DOI 10.1006/mcne.2000.0850; Gu YM, 1997, DEV NEUROSCI-BASEL, V19, P255, DOI 10.1159/000111214; Harding DI, 1999, EUR J NEUROSCI, V11, P2237, DOI 10.1046/j.1460-9568.1999.00640.x; Hashimoto M, 2005, ACTA NEUROPATHOL, V109, P165, DOI 10.1007/s00401-004-0926-z; Hayashi T, 1998, J NEUROCHEM, V71, P356; HOKOH Y, 2001, FREE RADICAL RES, V33, P739; Hu J, 2002, EUR J NEUROSCI, V16, P1409, DOI 10.1046/j.1460-9568.2002.02218.x; Islamov RR, 2003, BRAIN RES, V966, P65, DOI 10.1016/S0006-8993(02)04191-4; Jacobsson G, 1996, MOL BRAIN RES, V37, P49, DOI 10.1016/0169-328X(95)00272-T; JOHNSON JA, 1993, J NEUROSCI, V13, P2013; Ju WK, 2002, NEUROREPORT, V13, P861, DOI 10.1097/00001756-200205070-00025; Kania A, 2000, CELL, V102, P161, DOI 10.1016/S0092-8674(00)00022-2; Kishino A, 2003, BRAIN RES, V964, P56, DOI 10.1016/S0006-8993(02)04066-0; Krasnova IN, 2002, FASEB J, V16, P1379, DOI 10.1096/fj.01-0796com; Kurihara S, 2000, ENDOCR J, V47, P739, DOI 10.1507/endocrj.47.739; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; Lin Wan-Min, 2003, Shengli Xuebao, V55, P79; LINDA H, 1992, EXP BRAIN RES, V91, P284; Mahoney SA, 2003, J NEUROSCI, V23, P416; Martin LJ, 1999, J NEUROBIOL, V40, P185, DOI 10.1002/(SICI)1097-4695(199908)40:2<185::AID-NEU5>3.0.CO;2-#; Martin LJ, 2002, J NEUROBIOL, V50, P181, DOI 10.1002/neu.10026; Mason MRJ, 2000, EXP NEUROL, V165, P143, DOI 10.1006/exnr.2000.7445; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Namikawa K, 1998, MOL BRAIN RES, V55, P315, DOI 10.1016/S0169-328X(98)00012-6; Nishio Y, 1999, BBA-MOL BASIS DIS, V1453, P74, DOI 10.1016/S0925-4439(98)00086-6; Novikova L, 1997, EUR J NEUROSCI, V9, P2774, DOI 10.1111/j.1460-9568.1997.tb01706.x; Oliveira ALR, 2000, NEUROSCI LETT, V293, P131, DOI 10.1016/S0304-3940(00)01506-8; Resnick DK, 2004, NEUROREPORT, V15, P837, DOI 10.1097/00001756-200404090-00020; Rogove AD, 1998, CURR BIOL, V8, P19, DOI 10.1016/S0960-9822(98)70016-8; Roldan V, 2002, REV ESP CARDIOL, V55, P1230, DOI 10.1016/S0300-8932(02)76794-8; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Tachibana T, 2002, NEUROSCI LETT, V327, P133, DOI 10.1016/S0304-3940(02)00375-0; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Wang ZH, 1998, J NEURO-ONCOL, V36, P219, DOI 10.1023/A:1005883128175; Wehrle R, 2001, EUR J NEUROSCI, V13, P857, DOI 10.1046/j.1460-9568.2001.01452.x; WELLS MR, 1994, EXP BRAIN RES, V101, P53; WU W, 1994, NEUROSCIENCE, V61, P719, DOI 10.1016/0306-4522(94)90394-8; Wu WT, 1996, EXP NEUROL, V141, P190, DOI 10.1006/exnr.1996.0153; Wu WT, 2003, J NEUROTRAUM, V20, P603, DOI 10.1089/089771503767168528; WU WT, 1994, NEUROSCI LETT, V179, P157, DOI 10.1016/0304-3940(94)90958-X; Xin W, 2003, AM J PATHOL, V162, P255, DOI 10.1016/S0002-9440(10)63816-3; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Zhao SR, 1998, NEUROSURGERY, V42, P1357, DOI 10.1097/00006123-199806000-00099; Zhao YU, 1999, SCIENCE, V284, P1155, DOI 10.1126/science.284.5417.1155	62	31	34	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 23	2006	1075						1	12		10.1016/j.brainres.2005.12.060			12	Neurosciences	Neurosciences & Neurology	029LS	WOS:000236564700001	16460709				2021-06-18	
J	Bernard, F; Outtrim, J; Menon, DK; Matta, BF				Bernard, F; Outtrim, J; Menon, DK; Matta, BF			Incidence of adrenal insufficiency after severe traumatic brain injury varies according to definition used: clinical implications	BRITISH JOURNAL OF ANAESTHESIA			English	Article						brain; hypothalamus; head; injury; hormones; corticosteroids; sympathetic nervous system; sympathoadrenal responses	SEPTIC SHOCK; PITUITARY DYSFUNCTION; CRITICALLY-ILL; HEAD TRAUMA; STIMULATION; RESPONSES; CARE	Background. Adrenal insufficiency impacts on the haemodynamic management of patients in intensive care. Very little is known about the incidence of adrenal insufficiency in the first 10 days after traumatic brain injury. Methods. We retrospectively reviewed the charts of 113 traumatic brain injury patients within 10 days of their injury. They all had a high-dose corticotropin stimulation test performed because of haemodynamic instability. Blood cortisol concentrations were measured at baseline, 30 and 60 min after the administration of high-dose corticotropin. The incidence of adrenal insufficiency was determined according to various definitions used in the literature. Results. The baseline cortisol concentration was < 414 nmol litre(-1) (15 mu g dl(-1)) in 78% of patients and < 690 nmol litre(-1) (25 mu g dl(-1)) in all patients. The cortisol concentration did not rise above 500 nmol litre(-1) (18 mu g dl(-1)) at 30 and 60 min in 49 and 22% of patients, respectively. The cortisol concentration did not rise by 250 nmol litre(-1) (9 mu g dl(-1)) at 30 and 60 min in 48 and 25% of patients respectively. Primary adrenal insufficiency defined by an abnormal baseline cortisol concentration and an abnormal response to the high-dose corticotropin stimulation test was present in 13-28% of patients according to the cut-off values used. Conclusions. The incidence of adrenal insufficiency varies from 25 to 100% in the first 10 days after traumatic brain injury. The range of incidences reported illustrates the need for standardization of the definition of adrenal insufficiency. This has a direct impact on treatment. Sampling at 60 min after the high-dose corticotropin stimulation test seems to correlate better with the maximum secreting capacity of the adrenal glands.	Univ Montreal, Hop Sacre Coeur, Dept Crit Care Med & Gen Internal Med, Montreal, PQ H3C 3J7, Canada; Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Cambridge CB2 2QQ, England	Bernard, F (corresponding author), Univ Montreal, Hop Sacre Coeur, Dept Crit Care Med & Gen Internal Med, Montreal, PQ H3C 3J7, Canada.	bernard.francis@gmail.com			Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Annane D, 2003, SHOCK, V20, P197, DOI 10.1097/01.shk.0000079423.72656.2f; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Briegel J, 1996, INTENS CARE MED, V22, P894; Burchard K, 2001, J TRAUMA, V51, P800, DOI 10.1097/00005373-200110000-00033; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; Dimopoulou I, 2004, INTENS CARE MED, V30, P1216, DOI 10.1007/s00134-004-2297-2; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Dimopoulou I, 2003, CRIT CARE MED, V31, P1113, DOI 10.1097/01.CCM.0000059644.54819.67; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P541, DOI 10.1097/00001199-200311000-00008; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; Grundy PL, 2001, BRAIN RES, V892, P386, DOI 10.1016/S0006-8993(00)03258-3; HUME DM, 1959, ANN SURG, V150, P697, DOI 10.1097/00000658-195910000-00013; Lamberts SWJ, 1997, NEW ENGL J MED, V337, P1285, DOI 10.1056/NEJM199710303371807; Marik PE, 2004, CRIT CARE MED, V32, P596, DOI 10.1097/01.CCM.0000110729.73061.4B; Marik PE, 2003, CRIT CARE MED, V31, P141, DOI 10.1097/00003246-200301000-00022; Marik PE, 2002, CHEST, V122, P1784, DOI 10.1378/chest.122.5.1784; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Murakawa T, 1998, Masui, V47, P1350; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; VANHEMELRIJCK J, 1995, ANESTH ANALG, V80, P573, DOI 10.1097/00000539-199503000-00025; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011	27	31	35	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JAN	2006	96	1					72	76		10.1093/bja/aei277			5	Anesthesiology	Anesthesiology	000AM	WOS:000234433300013	16311283	Bronze			2021-06-18	
J	Boran, BO; Boran, P; Barut, N; Akgun, C; Celikoglu, E; Bozbuga, M				Boran, Burak O.; Boran, Perran; Barut, Nehir; Akgun, Cem; Celikoglu, Erhan; Bozbuga, Mustafa			Evaluation of mild head injury in a pediatric population	PEDIATRIC NEUROSURGERY			English	Article						head injury, mild; linear skull fracture	TRAUMATIC BRAIN-INJURY; COMA SCALE SCORE; COMPUTED-TOMOGRAPHY; GUIDELINES; MANAGEMENT; EMERGENCY; ADMISSION; CRITERIA	Approximately 5 million children present to emergency departments, seeking care for head injuries, each year, and 80% of these children are classified as cases of mild head injury. Due to the huge number of patients and low frequency of intracranial lesions in this group, obtaining a computed tomography scan for each and every patient is a significant economic problem. This study was conducted to identify the clinical parameters and the radiographic findings that may be associated with intracranial lesions in children with mild head injury. 421 patients, with a Glasgow Coma Scale score of 15 and without any focal neurological deficit, were studied. Intracranial lesion was noted in 37 cases (8.8%). Sensitivity of a plain radiogram was 43.2%, and specificity was 93%. An intracranial pathology was demonstrated in 28.9% of the patients with a linear skull fracture. The only clinical parameters associated with an increase in the frequency of detection of intracranial lesions were posttraumatic seizures and loss of consciousness. Age, sex, headache, vomiting and scalp lacerations were not associated with a higher frequency. Even when patients with a history of loss of consciousness or posttraumatic seizure were subtracted from the study group, intracranial lesions were noted in 4.1% of the cases, and in 1.8% neurosurgical intervention was required. Computed tomography is the gold standard in the evaluation of pediatric patients with mild head trauma, and every child who has experienced a head injury should undergo a cranial computed tomography evaluation, even if he or she appears in perfect health. Copyright (c) 2006 S. Karger AG, Basel.	Dr Lutfi Kirdar Kartal Res & Training Hosp, Neurosurg Clin 2, TR-34720 Istanbul, Turkey; Dr Lutfi Kirdar Kartal Res & Training Hosp, Clin Pediat 2, Istanbul, Turkey	Boran, BO (corresponding author), Dr Lutfi Kirdar Kartal Res & Training Hosp, Neurosurg Clin 2, Ortac Apt 13-12, TR-34720 Istanbul, Turkey.	burakoboran@hotmail.com	Boran, Perran/AAS-4469-2020	Boran, Perran/0000-0002-9885-7656			Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Duhaime AC, 1999, PRINCIPLES AND PRACTICE OF PEDIATRIC NEUROSURGERY, P799; DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Holmes JF, 1997, ACAD EMERG MED, V4, P788, DOI 10.1111/j.1553-2712.1997.tb03786.x; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Hsiang JNK, 1997, J NEUROSURG, V72, P189; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kamerling SN, 2003, PEDIATR EMERG CARE, V19, P431, DOI 10.1097/01.pec.0000092590.40174.1f; KAUFMAN BA, 1996, PEDIATR NEUROSURG, V25, P204; Lapierre F, 1998, NEUROCHIRURGIE, V44, P55; Luerssen TG, 1999, PRINCIPLES AND PRACTICE OF PEDIATRIC NEUROSURGERY, P813; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Murgio A, 2001, CHILD NERV SYST, V17, P257, DOI 10.1007/s003810000403; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; Nagurney JT, 1998, ACAD EMERG MED, V5, P678, DOI 10.1111/j.1553-2712.1998.tb02485.x; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SERVADEI F, 2004, YOUMANS NEUROLOGICAL, P5065; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5	26	31	31	0	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.		2006	42	4					203	207		10.1159/000092355			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	120CH	WOS:000243060700001	16714859				2021-06-18	
J	Harvey, L; de Jong, I; Goehl, G; Marwedel, S				Harvey, Lisa; de Jong, Inge; Goehl, Gerlinde; Marwedel, Samantha			Twelve weeks of nightly stretch does not reduce thumb web-space contractures in people with a neurological condition: a randomised controlled trial	AUSTRALIAN JOURNAL OF PHYSIOTHERAPY			English	Article						contracture; rehabilitation; thumb; hand deformities; splints; physiotherapy	ELBOW FLEXION CONTRACTURES; SPINAL-CORD-INJURY; MUSCLE CONTRACTURE; ANKLE MOBILITY; SHOULDER PAIN; REFLEX; IMMOBILIZATION; PREVENTION; NONREFLEX; STIFFNESS	Question: What is the effectiveness of 12 weeks of nightly stretch in reducing thumb web-space contracture in people with neurological conditions? Design: Assessor-blinded, randomised controlled trial. Participants: Forty-four (one dropout) community-dwelling patients with a neurological condition (14 stroke, 7 traumatic brain injury, 23 spinal cord injury) who had uni- or bilateral thumb web-space contractures (60 thumbs). Intervention: The experimental thumbs were splinted into a stretched, abducted position each night for 12 weeks. The control thumbs were not splinted. Outcome measures: Thumb web-space was measured as the carpometacarpal angle during the application of a 0.9 Nm abduction torque before and after intervention. Results: The mean increase in thumb web-space after 12 weeks was 1 deg (95% Cl, -1 to 2). Conclusion: Intensive stretch administered regularly over three months does not reduce thumb web-space contractures in neurological conditions.	Royal Rehabil Ctr Sydney, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Univ Sydney, Sydney, NSW 2006, Australia	Harvey, L (corresponding author), Royal Rehabil Ctr Sydney, Rehabil Studies Unit, Ryde, NSW 1680, Australia.	lhar9299@mail.usyd.edu.au		Harvey, Lisa A/0000-0002-4365-0236			Ada L, 2005, ARCH PHYS MED REHAB, V86, P230, DOI 10.1016/j.apmr.2004.02.031; AKESON WH, 1977, CLIN ORTHOP RELAT R, V122, P359; AMIEL D, 1985, CLIN ORTHOP RELAT R, V196, P306; Ben M, 2005, AUST J PHYSIOTHER, V51, P251, DOI 10.1016/S0004-9514(05)70006-4; Bryden AM, 2004, ARCH PHYS MED REHAB, V85, P1880, DOI 10.1016/j.apmr.2004.01.042; CHERRY DB, 1981, PHYS THER, V61, P1601, DOI 10.1093/ptj/61.11.1601; CONINE TA, 1990, ARCH PHYS MED REHAB, V71, P310; COOPER JE, 1993, ARCH PHYS MED REHAB, V74, P805, DOI 10.1016/0003-9993(93)90005-U; Dalyan M, 1998, SPINAL CORD, V36, P405, DOI 10.1038/sj.sc.3100620; Dietz V, 2000, SPINAL CORD, V38, P389, DOI 10.1038/sj.sc.3101030; EVANS EB, 1960, J BONE JOINT SURG AM, V42, P737, DOI 10.2106/00004623-196042050-00001; Grover J, 1996, J BONE JOINT SURG AM, V78A, P1397, DOI 10.2106/00004623-199609000-00016; Harvey LA, 2000, ARCH PHYS MED REHAB, V81, P1340, DOI 10.1053/apmr.2000.9168; Harvey LA, 2003, AUST J PHYSIOTHER, V49, P176, DOI 10.1016/S0004-9514(14)60237-3; Harvey L, 2006, J HAND THER, V19, P403, DOI 10.1197/j.jht.2006.07.026; Harvey Lisa, 2002, Physiother Res Int, V7, P1, DOI 10.1002/pri.236; HERMAN R, 1970, BRAIN, V93, P273, DOI 10.1093/brain/93.2.273; Johnson GR, 2002, EUR J NEUROL, V9, P10, DOI 10.1046/j.1468-1331.2002.0090s1010.x; Kendall FP, 1983, MUSCLES TESTING FUNC, V3rd; KENT H, 1990, Physiotherapy Canada, V42, P189; Lamontagne A, 1998, PHYS THER, V78, P964, DOI 10.1093/ptj/78.9.964; Lannin NA, 2003, ARCH PHYS MED REHAB, V84, P297, DOI 10.1053/apmr.2003.50031; Looney SW, 2003, STAT MED, V22, P1601, DOI 10.1002/sim.1514; MACKAYLYONS M, 1989, PHYS THER, V69, P292, DOI 10.1093/ptj/69.4.292; MCDONALD C, 1989, PHYS MED REHABILITAT, V9, P187; McDonald MF, 2005, J BIOMECH, V38, P2344, DOI 10.1016/j.jbiomech.2004.10.024; ODwyer NJ, 1996, CURR OPIN NEUROL, V9, P451, DOI 10.1097/00019052-199612000-00010; Pocock SJ, 1983, CLIN TRIALS PRACTICA; SCOTT JA, 1981, PARAPLEGIA, V19, P313, DOI 10.1038/sc.1981.59; Scott O M, 1981, Physiotherapy, V67, P177; SILFVERSKIOLD J, 1991, CLIN ORTHOP RELAT R, P141; SINKJAER T, 1994, BRAIN, V117, P355, DOI 10.1093/brain/117.2.355; SINKJAER T, 1993, MUSCLE NERVE, V16, P69, DOI 10.1002/mus.880160112; TABARY JC, 1972, J PHYSIOL-LONDON, V224, P231, DOI 10.1113/jphysiol.1972.sp009891; TARDIEU C, 1981, MECH MUSCLE ADAPTATI, P99; Turton AJ, 2005, CLIN REHABIL, V19, P600, DOI 10.1191/0269215505cr891oa; WARING WP, 1991, PARAPLEGIA, V29, P37, DOI 10.1038/sc.1991.5; WILLIAMS PE, 1988, ANN RHEUM DIS, V47, P1014, DOI 10.1136/ard.47.12.1014; YARKONY GM, 1985, PARAPLEGIA, V23, P265, DOI 10.1038/sc.1985.43	39	31	31	0	6	AUSTRALIAN PHYSIOTHERAPY ASSOC	ST KILDA	LEVEL 3, 201  FITZROY ST, ST KILDA, 3182, AUSTRALIA	0004-9514			AUST J PHYSIOTHER	Aust. J. Physiother.		2006	52	4					251	258		10.1016/S0004-9514(06)70004-6			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	144GD	WOS:000244783600004	17132119				2021-06-18	
J	Hyam, JA; Welch, CA; Harrison, DA; Menon, DK				Hyam, Jonathan A.; Welch, Catherine A.; Harrison, David A.; Menon, David K.			Case mix, outcomes and comparison of risk prediction models for admissions to adult, general and specialist critical care units for head injury: a secondary analysis of the ICNARC Case Mix Programme Database	CRITICAL CARE			English	Article							GLASGOW COMA SCALE; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE; MORTALITY PREDICTION; APACHE-III; PROGNOSIS; REGRESSION; SCORE; MANAGEMENT; SEVERITY	Introduction This report describes the case mix and outcome ( mortality, intensive care unit (ICU) and hospital length of stay) for admissions to ICU for head injury and evaluates the predictive ability of five risk adjustment models. Methods A secondary analysis was conducted of data from the Intensive Care National Audit and Research Centre (ICNARC) Case Mix Programme, a high quality clinical database, of 374,594 admissions to 171 adult critical care units across England, Wales and Northern Ireland from 1995 to 2005. The discrimination and calibration of five risk prediction models, SAPS II, MPM II, APACHE II and III and the ICNARC model plus raw Glasgow Coma Score (GCS) were compared. Results There were 11,021 admissions following traumatic brain injury identified (3% of all database admissions). Mortality in ICU was 23.5% and in-hospital was 33.5%. Median ICU and hospital lengths of stay were 3.2 and 24 days, respectively, for survivors and 1.6 and 3 days, respectively, for non-survivors. The ICNARC model, SAPS II and MPM II discriminated best between survivors and non-survivors and were better calibrated than raw GCS, APACHE II and III in 5,393 patients eligible for all models. Conclusion Traumatic brain injury requiring intensive care has a high mortality rate. Non-survivors have a short length of ICU and hospital stay. APACHE II and III have poorer calibration and discrimination than SAPS II, MPM II and the ICNARC model in traumatic brain injury; however, no model had perfect calibration.	Intens Care Natl Audit & Res Ctr, London WC1H 9HR, England; Charing Cross Hosp, Dept Neurosurg, London, England; Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England	Welch, CA (corresponding author), Intens Care Natl Audit & Res Ctr, Tavistock House,Tavistock Sq, London WC1H 9HR, England.	cathy.welch@icnarc.org	Harrison, David A/O-4355-2018	Harrison, David A/0000-0002-9002-9098; Welch, Catherine/0000-0002-6687-964X			Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Bennett-Guerrero E, 2003, BRIT J SURG, V90, P1593, DOI 10.1002/bjs.4347; BION J, 1995, BMJ-BRIT MED J, V310, P682, DOI 10.1136/bmj.310.6981.682; Brier GW, 1950, MONTHLY WEATHER REV, V75, P1, DOI DOI 10.1175/1520-0493(1950)078<0001:V0FEIT>2.0.C0;2; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; *DEP HLTH, 2006, NHS REF COSTS 2005; EDNA TH, 1983, ACTA NEUROCHIR, V69, P15, DOI 10.1007/BF02055848; GROCOTT MPW, 2000, CLIN INTENSIVE CARE, V11, P263; Gupta D, 2004, CRIT CARE, V8, pR112, DOI 10.1186/cc2835; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrison DA, 2006, CRIT CARE MED, V34, P1378, DOI 10.1097/01.CCM.0000216702.94014.75; Harrison DA, 2004, CRIT CARE, V8, pR99, DOI 10.1186/cc2834; HARRISON DA, 2006, INTENSIVE CARE ME S1, V32, pS204; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1976, LANCET, V1, P1031; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Lane PL, 2000, CAN J SURG, V43, P442; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; LE GJ, 1993, JAMA-J AM MED ASSOC, V270, P2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Metcalfe MA, 1997, LANCET, V350, P7, DOI 10.1016/S0140-6736(96)10018-0; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; O'Jile JR, 2004, APPL NEUROPSYCHOL, V11, P107, DOI 10.1207/s15324826an1102_7; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; ROWAN K, 1992, THESIS U OXFORD; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P161; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Watkins LD, 2000, SURGERY, V18, P219; Wildman MJ, 2005, CRIT CARE, V9, DOI 10.1186/cc3719; Young JD, 2001, BRIT J ANAESTH, V87, P543, DOI 10.1093/bja/87.4.543	45	31	31	0	3	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1466-609X			CRIT CARE	Crit. Care		2006	10			2					S2	10.1186/cc5066			11	Critical Care Medicine	General & Internal Medicine	185OA	WOS:000247719100002	17352796	DOAJ Gold, Green Published			2021-06-18	
J	Brunelle, JP; Goulet, C; Arguin, H				Brunelle, JP; Goulet, C; Arguin, H			Promoting respect for the rules and injury prevention in ice hockey: evaluation of the Fair-Play program	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article							CONCUSSIONS; PENALTIES; CHECKING; CHILDREN; CANADA; YOUTH; SPORT	Objective: To reduce the number of transgressions to the rule, the occurrence of violent acts and to prevent injuries, Hockey Quebec adopted the Fair-Play Program (FPP). The objective of the present study was to evaluate the effectiveness of the FPP. Methods: 52 Bantam (14-15 years) teams participated in this cohort study. In total, 49 games (13 with the FPP, 36 without FPP) were systematically assessed for transgressions to the rule. Body checking was allowed in all games. Transgressions to the rule data were obtained using a real time observation system in a natural setting, while injury data were collected through a self-administered questionnaire. Data were analysed using generalised linear models with generalised estimating equations accounting for potential team effect. Results: The number of penalties per game was significantly lower (p < 0.01) for games played with the FPP. Overall, no difference was noted in the number of transgressions observed during games played with or without the FPP. Players in leagues where the FPP was used held their opponents more frequently (p < 0.0001). On the other hand, players in leagues without the FPP shoved and hit more (p = 0.05). No difference was noted in the injury rate for games played with or without the FPP. Conclusions: This study showed that the FPP is one of the tools available to help those in the hockey world promote fair play values. Moreover, this project clearly showed the importance of program evaluation and the value of direct observation in a natural setting.	Univ Sherbrooke, Fac Educ Phys & Sport, Sherbrooke, PQ J1K 2R1, Canada		claude.goulet@mels.gouv.qc.ca					AVANZINI G, 1994, REV SCI TECHNIQUES A, V15, P7; BERNARD D, 1993, ASTM STP, V1212, P44; Chalmers DJ, 2002, INJ PREV S4, V8, P22; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; Gilbert WD, 2000, AM SOC TEST MATER, V1341, P291, DOI 10.1520/STP15246S; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; *HOCK CAN, BACKGR CHECK; Hutchings CB, 2003, ACCIDENT ANAL PREV, V35, P3, DOI 10.1016/S0001-4575(01)00081-1; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MacKay M, 2004, J SCI MED SPORT, V7, P58, DOI 10.1016/S1440-2440(04)80045-8; Marchie A, 2003, CAN MED ASSOC J, V169, P124; MARCOTTE G, 1993, ASTM STP, V1212, P100; McCullagh P., 1989, GEN LINEAR MODELS; MCMAHON KA, 1993, MED J AUSTRALIA, V159, P301, DOI 10.5694/j.1326-5377.1993.tb137864.x; Molsa J, 2003, AM J SPORT MED, V31, P751; PFISTER R, 1989, ETUDES PSYCHOTHERAPE, V20, P209; REGNIER G, 1989, ASTM STP, V1050, P84; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Tator CH, 2000, CAN MED ASSOC J, V162, P787; Trudel P, 2000, AM SOC TEST MATER, V1341, P274, DOI 10.1520/STP15245S; Trudel P, 2000, AM SOC TEST MATER, V1341, P237, DOI 10.1520/STP15242S; TRUDEL P, 1993, ASTM STP, V1212, P95; Watson RC, 1996, CLIN J SPORT MED, V6, P108, DOI 10.1097/00042752-199604000-00008; 1999, SAS SYSTEM WINDOWS P	25	31	31	0	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	SEP	2005	8	3					294	304		10.1016/S1440-2440(05)80040-4			11	Sport Sciences	Sport Sciences	974VB	WOS:000232618400006	16248470				2021-06-18	
J	Martinez-Lucas, P; Moreno-Cuesta, J; Garcia-Olmo, DC; Sanchez-Sanchez, F; Escribano-Martinez, J; del Pozo, AC; Lizan-Garcia, M; Garcia-Olmo, D				Martinez-Lucas, P; Moreno-Cuesta, J; Garcia-Olmo, DC; Sanchez-Sanchez, F; Escribano-Martinez, J; del Pozo, AC; Lizan-Garcia, M; Garcia-Olmo, D			Relationship between the Arg72Pro Polymorphism of p53 and outcome for patients with traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						single nucleotide polymorphism; brain injury; Glasgow Outcome Scale; p53	TUMOR-SUPPRESSOR GENE; POLYMORPHIC VARIANTS; HEAD-INJURY; APACHE-II; APOPTOSIS; CODON-72; EXPRESSION; SUSCEPTIBILITY; MORTALITY; ISCHEMIA	Objective: To determine the relationship between the Arg72Pro polymorphism of p53 and the outcome after traumatic brain injury (TBI) in humans. Design and setting: A prospective study was carried out in a ten-bed surgical intensive care unit (SICU) of a university hospital. Patients: The study included 90 caucasian patients who had experienced a severe TBI within the previous 24 h. The exclusion criterion was a previous deficit in the central nervous system. Measurements and results: The main recorded outcomes were values on the Glasgow Outcome Scale (GOS) at discharge from the SICU (GOS-0) and 6 months later (GOS-6). A blood sample was taken from each patient and all samples were analyzed by an allele-specific polymerase chain reaction for detection of Arg72Pro polymorphism of p53. These polymorphisms were tested for their association with values of GOS-0 and GOS-6. A two-tailed value of p < 0.05 was considered statistically significant. The frequency of the argine/argine (Arg/Arg) genotype was greater among the patients who had a bad outcome at GOS-0 (69 vs 31% in the bad-outcome group; p=0.029). A multiple logistic regression analysis showed that patients with the Arg/Arg variation had a 2.9-fold greater risk of having a bad outcome at discharge from the SICU (95% confidence interval, 1.05-8.31; p=0.039 ). There was no similar relationship with respect to GOS-6. Conclusion: The Arg/Arg genotype of the Arg72Pro polymorphism in p53 is associated with increased likelihood of a bad outcome at discharge from the SICU.	Gen Univ Hosp, Dept Anaesthesia, Albacete 02006, Spain; Gen Univ Hosp, Expt Res Unit, Albacete 02006, Spain; Univ Castilla La Mancha, Fac Med, Dept Genet, Albacete 02006, Spain; Gen Univ Hosp, Dept Epidemiol, Albacete 02006, Spain; Autonomous Univ Madrid, Dept Surg, E-28049 Madrid, Spain	Moreno-Cuesta, J (corresponding author), Gen Univ Hosp, Dept Anaesthesia, C Hermanos Falco 37, Albacete 02006, Spain.	jmocuest@med-ab.uclm.es	Garcia-Olmo, Dolores C./L-5733-2014; Escribano, Julio/D-9742-2015	Garcia-Olmo, Dolores C./0000-0001-9071-547X; Garcia Olmo, Damian/0000-0002-9369-2338; Escribano, Julio/0000-0002-8919-8134			ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; Bonafe M, 2004, CELL DEATH DIFFER, V11, P962, DOI 10.1038/sj.cdd.4401415; BROWN PJ, 1989, J TRAUMA, V29, P746; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Chopp M, 1999, BRAIN RES, V828, P197, DOI 10.1016/S0006-8993(99)01354-2; CLARK CG, 2000, TROPICAL MED SCI PRA, V2, P1; Clark RSB, 1999, FASEB J, V13, P813; COOKE RS, 1995, INJURY, V26, P399, DOI 10.1016/0020-1383(95)00064-G; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fisher DE, 2001, APOPTOSIS, V6, P7, DOI 10.1023/A:1009659708549; Granja F, 2004, CANCER LETT, V210, P151, DOI 10.1016/j.canlet.2004.01.016; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HARTLEY C, 1995, BRIT J NEUROSURG, V9, P179, DOI 10.1080/02688699550041520; Hughes PE, 1996, NEUROSCIENCE, V74, P1143, DOI 10.1016/S0306-4522(96)00174-1; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Lai Y. C., 1998, Annals Academy of Medicine Singapore, V27, P326; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; MARTINEZLUCAS P, 2004, INTENS CARE MED S, V30, pS138; Mira JP, 1999, JAMA-J AM MED ASSOC, V282, P561, DOI 10.1001/jama.282.6.561; Morrison RS, 1996, J NEUROSCI, V16, P1337; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Peters DL, 2003, CRIT CARE MED, V31, P1691, DOI 10.1097/01.CCM.0000065190.24116.A4; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Schneider-Stock R, 2004, AM J PATHOL, V164, P1233, DOI 10.1016/S0002-9440(10)63211-7; Silberstein Morry, 2002, Neurosurg Focus, V13, pecp2, DOI 10.3171/foc.2002.13.1.6; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Storey A, 1998, NATURE, V393, P229; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Woischneck D, 1998, ACT NEUR S, V71, P138	39	31	35	1	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2005	31	9					1168	1173		10.1007/s00134-005-2715-0			6	Critical Care Medicine	General & Internal Medicine	965KK	WOS:000231949200006	16007417				2021-06-18	
J	Gotts, JE; Chesselet, MF				Gotts, JE; Chesselet, MF			Mechanisms of subventricular zone expansion after focal cortical ischemic injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						neurogenesis; stereology; rostral migratory stream; cell migration; cell death; cell proliferation	NEURAL STEM-CELLS; MICROTUBULE-ASSOCIATED PROTEIN; TRAUMATIC BRAIN-INJURY; OLFACTORY-BULB; CEREBRAL-CORTEX; ADULT-RATS; SUBEPENDYMAL LAYER; PROGENITOR CELLS; NEURONAL MIGRATION; GENE-EXPRESSION	The rodent subventricular zone (SVZ) contains neural precursor cells that divide and then die in place or migrate to the olfactory bulb through the rostral migratory stream (RMS) to become new neurons. Despite the normally tight control in cell numbers in this region in adults, previous work from our laboratory and others has shown that SVZ cell number increases after a variety of brain injuries. The relative contribution of changes in rostral migration, cell proliferation, and cell death to increased cell number is poorly understood. We examined these parameters after focal cortical ischemic lesions distal from the SVZ in adult rats. Stereological analysis revealed that cell numbers remain constant in the SVZ and RMS until 5 days postinjury but then rapidly expanded by 150,000 cells by day 7 in each region. Rostral migration of SVZ cells was unaffected by the injury. Both cell death and proliferation increased in the SVZ as early as day 5. However, these two mechanisms became uncoupled when cell number increased, indicating that a distant brain injury expands the SVZ by disrupting the balance between cell death and proliferation in this adult neurogenic zone. (c) 2005 Wiley-Liss, Inc.	Univ Calif Los Angeles, Dept Neurol, Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurobiol, Geffen Sch Med, Los Angeles, CA 90095 USA	Chesselet, MF (corresponding author), Univ Calif Los Angeles, Dept Neurol, Geffen Sch Med, 710 Westwood Plaza,RNRC B114, Los Angeles, CA 90095 USA.	mchessel@ucla.edu			NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH012798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039276] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31-MH12798] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39276] Funding Source: Medline		Alonso G, 1999, J COMP NEUROL, V405, P508, DOI 10.1002/(SICI)1096-9861(19990322)405:4<508::AID-CNE5>3.0.CO;2-5; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Belvindrah R, 2002, J NEUROSCI, V22, P3594; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Doetsch F, 2002, J NEUROSCI, V22, P2255, DOI 10.1523/JNEUROSCI.22-06-02255.2002; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Goings GE, 2002, NEUROSCI LETT, V329, P161, DOI 10.1016/S0304-3940(02)00611-0; Gotts JE, 2005, J NEUROSCI RES, V80, P160, DOI 10.1002/jnr.20434; GOTTS JE, 2005, IN PRESS EXP NEUROL; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; Iwai M, 2003, J CEREBR BLOOD F MET, V23, P331, DOI 10.1097/01.WCB.0000050060.57184.E7; Jankovski A, 1998, EUR J NEUROSCI, V10, P3853, DOI 10.1046/j.1460-9568.1998.00397.x; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kirschenbaum B, 1999, J NEUROSCI, V19, P2171; Lee A, 2003, ANN NEUROL, V53, P668, DOI 10.1002/ana.10579; Levison SW, 2000, DEV NEUROSCI-BASEL, V22, P106, DOI 10.1159/000017432; Levison SW, 2001, DEV NEUROSCI-BASEL, V23, P234, DOI 10.1159/000046149; LEWIS PD, 1974, BRAIN RES, V76, P520, DOI 10.1016/0006-8993(74)90827-0; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Magavi SS, 2000, NATURE, V405, P951; Mandairon N, 2003, NEUROSCIENCE, V119, P507, DOI 10.1016/S0306-4522(03)00172-6; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; Morshead CM, 2000, J NEUROBIOL, V42, P338, DOI 10.1002/(SICI)1097-4695(20000215)42:3<338::AID-NEU5>3.0.CO;2-K; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Nait-Oumesmar B, 1999, EUR J NEUROSCI, V11, P4357, DOI 10.1046/j.1460-9568.1999.00873.x; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Picard-Riera N, 2002, P NATL ACAD SCI USA, V99, P13211, DOI 10.1073/pnas.192314199; SALIN P, 1992, P NATL ACAD SCI USA, V89, P9954, DOI 10.1073/pnas.89.20.9954; Szele FG, 1996, J COMP NEUROL, V368, P439, DOI 10.1002/(SICI)1096-9861(19960506)368:3<439::AID-CNE9>3.0.CO;2-6; SZELE FG, 1995, J NEUROSCI, V15, P4429; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Tonchev AB, 2003, MOL CELL NEUROSCI, V23, P292, DOI 10.1016/S1044-7431(03)00058-7; Weinstein DE, 1996, BRAIN RES, V743, P11, DOI 10.1016/S0006-8993(96)00979-1; WILLIS P, 1976, NEUROPATH APPL NEURO, V2, P377, DOI 10.1111/j.1365-2990.1976.tb00511.x; Yoshiya K, 2003, J NEUROTRAUM, V20, P1147, DOI 10.1089/089771503770802844; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	43	31	31	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	JUL 25	2005	488	2					201	214		10.1002/cne.20609			14	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	936FP	WOS:000229841200006	15924343				2021-06-18	
J	Constantinidou, F; Thomas, RD; Scharp, VL; Laske, KM; Hammerly, MD; Guitonde, S				Constantinidou, F; Thomas, RD; Scharp, VL; Laske, KM; Hammerly, MD; Guitonde, S			Effects of categorization training in patients with TBI during postacute rehabilitation - Preliminary findings	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; categorization; cognitive rehabilitation; effectiveness; efficacy; outcomes	BRAIN-INJURY; SYSTEMS; MEMORY; MODALITY; SCALE	Background: Previous research suggests that traumatic brain injury (TBI) interferes with the ability to extract and use attributes to describe objects. This study explored the effects of a systematic Categorization Program (CP) in participants with TBI and noninjured controls. Participants: Ten persons with moderate to severe TBI who received comprehensive postacute rehabilitation services and 13 matched-noninjured controls participated in the study. Intervention: All participants received CP training for 3 to 5 hours per week for 10 to 12 weeks that consisted of 8 levels and targeted concept formation, object categorization, and decision-making abilities. Main outcome measures: The Mayo-Portland Adaptability Inventory-3 (MPAI-3) and the Community Integration Questionnaire (CIQ). Two Categorization Tests (administered pretraining and posuraining) and 3 Probe Tasks (administered at specified intervals during training) assessed skills relating to categorization. Results: Both groups showed significant improvement in categorization performance after the CP training on the 2 Categorization Tests related to the CP They also were able to generalize and apply categorization and sorting skills in new situations (as measured by the Probe Tasks). Participants with TBI had improved functional outcome performance measured by the MPAI-3 and the CIQ. Conclusions: The systematic and hierarchical structure of the CP is beneficial to participants with TBI during postacute rehabilitation. This study contributes to the growing body of evidence supporting cognitive rehabilitation after moderate to severe TBI. Key words: brain injury, categorization, cognitive rehabilitation, effectiveness, efficacy, outcomes.	Miami Univ, Dept Speech Pathol & Audiol, Oxford, OH 45056 USA; Miami Univ, Dept Psychol, Oxford, OH 45056 USA	Constantinidou, F (corresponding author), Miami Univ, Dept Speech Pathol & Audiol, Oxford, OH 45056 USA.	constaf@muohio.edu		Constantinidou, Fofi/0000-0002-7928-8363	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R15HD044554A01A1] Funding Source: Medline		ADAMOVICH VV, 1985, COGNITIVE REHABILITA; *AM PSYCHI ASS, 1994, DSM 4 DIAGN STAT MAN; Ashby FG, 1998, PSYCHOL REV, V105, P442, DOI 10.1037/0033-295X.105.3.442; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bracy O. L., 1986, COGN REHABIL, V4, P11; Caramazza A, 1998, J COGNITIVE NEUROSCI, V10, P1, DOI 10.1162/089892998563752; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; COLTHEART M, 2001, DB COGNITIVE NEUROPS, P3; Constantinidou F, 2004, BRAIN LANG, V89, P216, DOI 10.1016/S0093-934X(03)00399-7; Constantinidou F, 1999, J MED SPEECH-LANG PA, V7, P283; CONSTANTINIDOU F, 2001, CATEGORIZATION PROGR; Constantinidou F., 2004, TRAUMATIC BRAIN INJU, P337; Erickson MA, 1998, J EXP PSYCHOL GEN, V127, P107, DOI 10.1037/0096-3445.127.2.107; FARAH MJ, 1991, J EXP PSYCHOL GEN, V120, P339, DOI 10.1037/0096-3445.120.4.339; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENTILINI M, 1989, MILD HEAD INJURY, P163; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; HAGEN C, 1957, REHABILITATION HEAD; Humphreys GW, 1999, PSYCHOL RES-PSYCH FO, V62, P118, DOI 10.1007/s004260050046; HUMPHREYS GW, 1994, COGNITIVE NEUROPSYCH, V11, P393, DOI 10.1080/02643299408251980; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KNOWLTON BJ, 1993, SCIENCE, V262, P1747, DOI 10.1126/science.8259522; Kolb B., 1999, COGNITIVE NEUROREHAB, P9; Lamberts K, 2002, BRAIN DAM B, P291; LEVIN HS, 1992, SCAND J REHABIL MED, P14; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Luria A. R., 1963, RESTORATION FUNCTION; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; MALEC JF, 1996, NEUROLOGY TRAUMA, P231; NOSOFSKY RM, 1986, J EXP PSYCHOL GEN, V115, P39, DOI 10.1037/0096-3445.115.1.39; SPIKMAN JM, 1995, J CLIN EXP NEUROPSYC, V17, P29, DOI 10.1080/13803399508406578; Task Force on Promotion and Dissemination of Psychological Procedures, 1995, CLIN PSYCHOL, V48, P13; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Zeno S. M, 1995, ED WORD FREQUENCY GU; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002; ISHIHARA TEST COLOR	40	31	31	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2005	20	2					143	157		10.1097/00001199-200503000-00003			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	910VV	WOS:000227961200003	15803038				2021-06-18	
J	Leon-Carrion, J; Dominguez-Morales, MR; Martin, JMBY				Leon-Carrion, J; Dominguez-Morales, MR; Martin, JMBY			Driving with cognitive deficits: neurorehabilitation and legal measures are needed for driving again after severe traumatic brain injury	BRAIN INJURY			English	Article						driving; acquired brain injury; neurorehabilitation; neuropsychology	HEAD-INJURY; FITNESS; RECOMMENDATIONS; DRIVERS; ISSUES; DAMAGE	Primary objective: This article presents a retrospective study on a group of survivors of severe traumatic brain injury with the purpose of discerning whether post- traumatic cognitive deficits prevent them from safely resuming driving and to see if holistic neurorehabilitation improves the rate of patients fit for returning to driving. Methods and procedures: We studied 17 patients who had suffered severe traumatic brain injury ( TBI) as measured by Glasgow Coma Scale scores. All subjects underwent a holistic, intensive and multidisciplinary neurorehabilitation program during a mean period of 10.53 months in the Centro de Rehabilitacion de Dano Cerebral ( CRECER(R)) - Center for Brain Injury Rehabilitation - in Seville, Spain. Patients were divided into two different groups: drivers ( patients who drove despite strong and repeated recommendations from the Center to desist from doing so when they began the rehabilitation program) and non- drivers ( patients not driving at the time they began the rehabilitation program although they had a pre- injury driver's license). The FIM+FAM- Revised Scale [ 1] was administered both before commencing treatment and upon termination. Results and conclusion: ( 1) Patients showing physical functionality above 80% returned to driving, regardless of their cognitive and/ or emotional deficits, and against doctor recommendations. ( 2) Severe TBI survivors that have not been certified as fit to drive are at increased risk for driving incidents other than collisions and traffic accidents. This is illustrated by significant incidents involving some of the subjects in our study that were due to disorientation, confusion and confrontations with people or situations. ( 3) We found that neurorehabilitation is worthwhile; after integral and multidisciplinary neurorehabilitation more than 70% of survivors of severe TBI can return to driving with regular safety. ( 4) We also suggest that laws be introduced to keep not- clinically- apt patients from driving.	Univ Seville, Fac Psicol, Dept Expt Psychol, Seville 41008, Spain; Ctr Brain Injury Rehabil, CRECER, Seville, Spain	Leon-Carrion, J (corresponding author), Univ Seville, Fac Psicol, Dept Expt Psychol, Campus Ramon y Cajal,C Camilo Jose Cela S-N, Seville 41008, Spain.	leoncarrion@us.es	Leon Carrion, Jose/D-5638-2012				Benton A. L., 1994, CONTRIBUTIONS NEUROP; BENTON AL, 1973, REV PSYCHOL APPL, V23, P1; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Christensen AL, 1974, LURIAS NEUROPSYCHOLO; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; DOMINGUEZMORALE.MR, 2001, REV ESPANOLA NEUROPS, V3, P77; Fisk GD, 1998, BRAIN INJURY, V12, P683; FORMISANO R, 2001, EUROPA MEDICOPHYSICA, V37, P257; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; HANDLER BS, 1995, J REHABIL, V61, P43; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hooper, 1983, HOOPER VISUAL ORG TE; Hopewell CA, 2002, J HEAD TRAUMA REHAB, V17, P48, DOI 10.1097/00001199-200202000-00007; JIMENEZ FL, 1999, REV ESPANOLA NEUROPS, V1, P105; KlOve H, 1963, MED CLIN N AM; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Leon-Carrion J, 1998, NEUROREHABILITATION, V11, P129, DOI 10.1016/S1053-8135(98)00017-1; Leon-Carrion J., 1999, REV ESPANOLA NEUROPS, V1, P49; LEONCARRION J, 1999, FIM FAM REVISITED SC; LEONCARRION J, 1999, NEUROPSYCHOLOGICAL T; LEONCARRION J, 2001, REV ESPANOLA NEUROPS, V33, P58; Lundqvist A, 2001, BRAIN INJURY, V15, P981, DOI 10.1080/02699050110065637; Lundqvist A, 2001, NEUROPSYCHOL REHABIL, V11, P171, DOI 10.1080/09602010042000240; Mosberg A, 2000, Tidsskr Nor Laegeforen, V120, P3392; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; PERINO C, 1997, GIORNALE ITALIANO RI, V1, P53; PIDIKITI RD, 1991, ARCH PHYS MED REHAB, V72, P109; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Radford KA, 2004, BRAIN INJURY, V18, P775, DOI 10.1080/02699050310001657394; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STROKX LC, 1986, J CLIN EXPT NEUROPSY, V8, P421; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	40	31	32	0	8	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2005	19	3					213	219		10.1080/02699050400017205			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	906WJ	WOS:000227675000007	15832895				2021-06-18	
J	Prasad, MR; Kramer, LA; Ewing-Cobbs, L				Prasad, MR; Kramer, LA; Ewing-Cobbs, L			Cognitive and neuroimaging findings in physically abused preschoolers	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							TRAUMATIC BRAIN-INJURY; CHILDREN; CHILDHOOD	Aims: To characterise the cognitive, motor, and language skills of toddlers and preschoolers who had been physically abused and to obtain concurrent MRIs of the brain. Methods: A between groups design was used to compare a sample of 19 children, aged 14-77 months, who had been hospitalised for physical abuse with no evidence of neurological injury to a comparison group of 19 children matched for age and socioeconomic status. Children underwent cognitive, language, and motor testing within three months of their discharge from the hospital. Caregivers of the injured children were interviewed and were asked to complete questionnaires to characterise the child's developmental level and behaviour just prior to the hospitalisation. Results: Children who had been physically abused scored significantly lower than the comparison group on measures of cognitive functioning, motor skills, and language skills. The groups did not differ in child behaviour ratings completed by the caregivers. MRI of the brain was performed for 15 children in the physical abuse group; two were found to have significant cerebral atrophy. Conclusions: Children who have been physically abused are at high risk for delays in cognitive, motor, and language development. Standard of care for these children should include developmental testing as well as neuroimaging of the brain to detect occult brain injury.	Univ Texas, Hlth Sci Ctr Houston, Dept Pediat, Div Dev Pediat, Houston, TX 77025 USA; Univ Texas, Hlth Sci Ctr Houston, Dept Radiol, Houston, TX 77025 USA	Prasad, MR (corresponding author), Univ Texas, Hlth Sci Ctr Houston, Dept Pediat, Div Dev Pediat, 7000 Fannin,Suite 2401, Houston, TX 77025 USA.	mary.r.prasad@uth.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 29462-07] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER		Abidin RR., 1995, PARENTING STRESS IND; Bayley N., 2006, BAYLEY SCALES INFANT; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; ECKENRODE J, 1993, DEV PSYCHOL, V29, P53, DOI 10.1037/0012-1649.29.1.53; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; HEDRICK DL, 1995, SEQUENCED INVENTORY; HOFFMANPLOTKIN D, 1984, CHILD DEV, V55, P794, DOI 10.1111/j.1467-8624.1984.tb03816.x; HOLLINGSHED A, 1975, 4 FACTOR INDEX SOCIA; Keshavan MS, 2002, LIFE SCI, V70, P1909, DOI 10.1016/S0024-3205(02)01492-3; LEVENTHAL JM, 1993, AM J DIS CHILD, V147, P87, DOI 10.1001/archpedi.1993.02160250089028; McCarthy D., 1972, MCCARTHY SCALES CHIL; PEREZ CM, 1994, CHILD ABUSE NEGLECT, V18, P617, DOI 10.1016/0145-2134(94)90012-4; ROGOSCH FA, 1995, DEV PSYCHOPATHOL, V7, P591, DOI 10.1017/S0954579400006738; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Semel E. M., 1995, CLIN EVALUATION LANG; Sparrow S., 1984, VINELAND ADAPTIVE BE; THORNDIKE RL, 1986, STANFORDBINET INTELL; VONDRA JI, 1990, CHILD ABUSE NEGLECT, V14, P525, DOI 10.1016/0145-2134(90)90101-X; WISSOW LS, 1995, NEW ENGL J MED, V332, P1425, DOI 10.1056/NEJM199505253322107	20	31	34	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	JAN	2005	90	1					82	85		10.1136/adc.2003.045583			4	Pediatrics	Pediatrics	881KH	WOS:000225865900021	15613522	Green Published, Bronze			2021-06-18	
J	Chuah, YML; Maybery, MT; Fox, AM				Chuah, YML; Maybery, MT; Fox, AM			The long-term effects of mild head injury on short-term memory for visual form, spatial location, and their conjunction in well-functioning university students	BRAIN AND COGNITION			English	Article						mild head injury; short-term memory; visual span; spatial span; visuospatial span; nonverbal memory	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; PARKINSONS-DISEASE; OBJECT; PERFORMANCE; SYMPTOMS; TASK	Research has suggested the presence of subtle long-term cognitive changes in otherwise well-functioning individuals who have previously sustained a mild head injury (MHI). This paper investigated the long-term effects of MHI on visual, spatial, and visual-spatial short-term memory in well-functioning university students. Sixteen students who reported having sustained a MHI were compared to 16 controls on tests of short-term memory (STM) for abstract polygons in haphazardly arranged locations. The three tests differed only in the requirements for recall (shapes for the visual task, locations for the spatial task, and the shapes in their respective locations for the visual-spatial task). MHI participants were selectively impaired on spatial memory, suggesting that tasks of spatial STM may be more sensitive, compared to tasks of visual STM, to the subtle long-term cognitive changes that may be present after a MHI. (C) 2004 Elsevier Inc. All rights reserved.	Univ Western Australia, Sch Psychol, Crawley, WA 6009, Australia	Chuah, YML (corresponding author), Univ Western Australia, Sch Psychol, 35 Stirling Highway, Crawley, WA 6009, Australia.	pcmcyml@nus.edu.sg	Fox, Allison M/H-9218-2014; Maybery, Murray/H-5390-2014	Fox, Allison M/0000-0001-5189-6271; Maybery, Murray/0000-0002-3760-1382			BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Chalfonte BL, 1996, MEM COGNITION, V24, P403, DOI 10.3758/BF03200930; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FOX GA, 1991, ADV APPL RES, P165; FRENCHAM KA, IN PRESS J CLIN EXPT; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; HULME C, 1991, J MEM LANG, V30, P685, DOI 10.1016/0749-596X(91)90032-F; JASTAK S, 1984, WRAT R WIDE RANGE AC; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin HS, 1989, MILD HEAD INJURY; Luciana M, 1997, J COGNITIVE NEUROSCI, V9, P330, DOI 10.1162/jocn.1997.9.3.330; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; National Health and Medical Research Centre (NHMRC), 2001, AUSTR ALC GUID HLTH; Owen AM, 1996, P NATL ACAD SCI USA, V93, P9212, DOI 10.1073/pnas.93.17.9212; Postle BR, 1997, NEUROPSYCHOLOGIA, V35, P1413, DOI 10.1016/S0028-3932(97)00054-7; Postle BR, 1997, NEUROPSYCHOLOGY, V11, P171, DOI 10.1037/0894-4105.11.2.171; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; SMITH EE, 1995, J COGNITIVE NEUROSCI, V7, P337, DOI 10.1162/jocn.1995.7.3.337; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; TRESCH MC, 1993, NEUROPSYCHOLOGIA, V31, P211, DOI 10.1016/0028-3932(93)90085-E; Wilson JTL, 1989, NEUROPSYCHOLOGY, V3, P255, DOI 10.1037//0894-4105.3.4.255	35	31	31	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	DEC	2004	56	3					304	312		10.1016/j.bandc.2004.08.002			9	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	872LT	WOS:000225209400004	15522768				2021-06-18	
J	Charles, PD				Charles, PD			Botulinum neurotoxin serotype A: A clinical update on non-cosmetic uses	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article						botulinum toxin A; dosage; drugs; Food and Drug Administration (US); skeletal muscle relaxants; toxicity	TOXIN TYPE-A; CHRONIC ANAL-FISSURE; DETRUSOR-SPHINCTER DYSSYNERGIA; PLACEBO-CONTROLLED TRIAL; TRAUMATIC BRAIN-INJURY; DOUBLE-BLIND; CERVICAL DYSTONIA; CEREBRAL-PALSY; SPASMODIC TORTICOLLIS; ESOPHAGEAL ACHALASIA	Purpose. Clinical experience with botulinum toxin type A for non-cosmetic uses that are approved by the Food and Drug Administration (FDA) and various other non-cosmetic uses that are not approved by FDA, including some applications that are widely known and others that currently are emerging, is discussed. Summary. FDA-approved indications for botulinum toxin type A (Botox) include the temporary treatment of cervical dystonia (a neuromuscular disorder involving the head and neck), the oculomotor disorders strabismus (improperly aligned eyes) and blepharospasm (involuntary contraction of the eye muscles), and severe primary axillary hyperhidrosis (excessive sweating). Other uses of botulinum toxin type A that are widely known but not approved by FDA include spastic disorders associated with injury or disease of the central nervous system including trauma, stroke, multiple sclerosis, or cerebral palsy and focal dystonias affecting the limbs, face, jaw, or vocal cords. Treatment and prevention of chronic headache and chronic musculoskeletal pain are emerging uses for botulinum toxin type A. Conclusion. Many of the conditions for which botulinum toxin type A has been explored are common and difficult to treat. Temporary improvement in symptoms is associated with botulinum toxin type A injection, and repeat treatment often is required. The drug is well tolerated and has a wide margin of safety.	Vanderbilt Univ, Movement Disorders Clin, Nashville, TN 37240 USA	Charles, PD (corresponding author), Vanderbilt Univ, Movement Disorders Clin, Nashville, TN 37240 USA.	david.charles@vanderbilt.edu					*ALL INC, 2004, BOT PACK INS; *AM ASS OPHTH STRA, ADULT STRAB GEN INF; *AM HEART ASS, HEART DIS STROK STAT; Annese V, 2000, GUT, V46, P597, DOI 10.1136/gut.46.5.597; ARTHURS B, 1987, CAN J OPHTHALMOL, V22, P24; Barwood S, 2000, DEV MED CHILD NEUROL, V42, P116, DOI 10.1017/S0012162200000220; *BEN ESS BLEPH RES, BEBRF BLEPH PAG; *BETH ISR MED CTR, PAIN MED; Binder WJ, 2000, OTOLARYNG HEAD NECK, V123, P669, DOI 10.1067/mhn.2000.110960; Blitzer A, 1998, LARYNGOSCOPE, V108, P1435, DOI 10.1097/00005537-199810000-00003; Blumenfeld AM, 2003, HEADACHE, V43, P884, DOI 10.1046/j.1526-4610.2003.03167.x; Bothwell JE, 2002, PEDIATR NEUROL, V27, P18, DOI 10.1016/S0887-8994(02)00381-8; Brans JWM, 1998, NEUROLOGY, V50, P1461, DOI 10.1212/WNL.50.5.1461; Brashear A, 2003, ARCH PHYS MED REHAB, V84, P103, DOI 10.1053/apmr.2003.50070; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; Brashear A, 1999, NEUROLOGY, V53, P1439, DOI 10.1212/WNL.53.7.1439; Brin M F, 1997, Muscle Nerve Suppl, V6, pS208; Brin MF, 1999, NEUROLOGY, V53, P1431, DOI 10.1212/WNL.53.7.1431; Brisinda G, 1999, NEW ENGL J MED, V341, P65, DOI 10.1056/NEJM199907083410201; Chang L B, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P1; Dionne RA, 1997, ORAL SURG ORAL MED O, V83, P134, DOI 10.1016/S1079-2104(97)90104-9; Dogu O, 2004, CLIN NEUROL NEUROSUR, V106, P93, DOI 10.1016/j.clineuro.2003.10.012; *DYST MED RES FDN, DYST DEF; *EL PHARM INC, 2000, MYOBL PACK INS; Fehlings D, 2000, J PEDIATR-US, V137, P331, DOI 10.1067/mpd.2000.108393; Fock J, 2004, BRAIN INJURY, V18, P57, DOI 10.1080/0269905031000149498; Foster L, 2001, NEUROLOGY, V56, P1290, DOI 10.1212/WNL.56.10.1290; Freund B, 1998, Oral Health, V88, P32; Freund BJ, 2000, HEADACHE, V40, P231, DOI 10.1046/j.1526-4610.2000.00033.x; Goldman A, 2000, AESTHET PLAST SURG, V24, P280, DOI 10.1007/s002660010046; Goldstein EM, 2001, J CHILD NEUROL, V16, P16, DOI 10.1177/088307380101600104; Gracies JM, 1997, MUSCLE NERVE, pS92; GRACIES JM, 1997, MUSCLE NERVE       S, V6, pS61; GREENE P, 1990, NEUROLOGY, V40, P1213, DOI 10.1212/WNL.40.8.1213; Hockstein NG, 2004, AM FAM PHYSICIAN, V69, P2628; Hu XH, 1999, ARCH INTERN MED, V159, P813, DOI 10.1001/archinte.159.8.813; *INT HYP SOC, UND HYP; Jankovic J, 1997, MUSCLE NERVE, pS129; Kessler KR, 1999, J NEUROL, V246, P265, DOI 10.1007/s004150050345; KOMAN LA, 1994, J PEDIATR ORTHOPED, V14, P299, DOI 10.1097/01241398-199405000-00005; Koman LA, 2000, J PEDIATR ORTHOPED, V20, P108, DOI 10.1097/00004694-200001000-00022; LANG AM, 2000, AM J PAIN MANAGE, V18, P108; Lew MF, 2000, NEUROLOGY, V55, pS29; Lew MF, 1997, NEUROLOGY, V49, P701, DOI 10.1212/WNL.49.3.701; Lindsey I, 2004, BRIT J SURG, V91, P270, DOI 10.1002/bjs.4531; LOVE SC, 1920, EUR J NEUROL S5, V8, P50; Lu Chin-Song, 1995, Journal of the Formosan Medical Association, V94, P189; *MARCH DIM BIRTH D, CER PALS; Mentes BB, 2003, DIS COLON RECTUM, V46, P232, DOI 10.1097/01.DCR.0000044712.58674.09; Muehldorfer SM, 1999, ENDOSCOPY, V31, P517, DOI 10.1055/s-1999-56; *NAL HEAD FDN, NHF HEAD FACTS; *NAT I NEUR DIS ST, NINDS CER PALS INF P; *NAT I NEUR DIS ST, NINDS SPAST INF PAG; *NAT LIB MED, MEDL PLUS ACH; *NAT LIBR MED, MEDL PLUS STRAB; *NAT MULT SCLER SO, WHO GETS MS; *NAT MULT SCLER SO, CONTR SPAST MS; *NAT ORG RAR DIS I, FREYS SYNDR; Naumann M, 1997, ANN NEUROL, V42, P973; Naumann M, 2004, CURR MED RES OPIN, V20, P981, DOI 10.1185/030079904125003962; Naumann M, 2001, BRIT MED J, V323, P596, DOI 10.1136/bmj.323.7313.596; ODERGREN T, 1994, SCAND J REHABIL MED, V26, P191; Ondo WG, 2004, CEPHALALGIA, V24, P60, DOI 10.1111/j.1468-2982.2004.00641.x; Pal PK, 2000, NEUROLOGY, V54, P244, DOI 10.1212/WNL.54.1.244; POLO KB, 1994, MOVEMENT DISORD, V9, P233, DOI 10.1002/mds.870090221; Porta M, 2000, PAIN, V85, P101, DOI 10.1016/S0304-3959(99)00264-X; Reynard JM, 2003, SPINAL CORD, V41, P1, DOI 10.1038/sj.sc.3101378; Royal MA, 2001, NEUROLOGY, V56, pA350; Satkunam WE, 2003, CAN MED ASSOC J, V169, P1173; Schurch B, 1996, J UROLOGY, V155, P1023, DOI 10.1016/S0022-5347(01)66376-6; Sedano MJ, 2000, EUR NEUROL, V43, P137, DOI 10.1159/000008152; Sharma R R, 1992, J Postgrad Med, V38, P37; Silberstein S, 2000, HEADACHE, V40, P445, DOI 10.1046/j.1526-4610.2000.00066.x; Smuts JA, 1999, EUR J NEUROL, V6, pS99, DOI 10.1111/j.1468-1331.1999.tb00044.x; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; Sutherland DH, 1999, GAIT POSTURE, V10, P1, DOI 10.1016/S0966-6362(99)00012-0; Tejedor J, 2001, INVEST OPHTH VIS SCI, V42, P2542; Tejedor J, 1999, BRIT J OPHTHALMOL, V83, P783, DOI 10.1136/bjo.83.7.783; TSUI JKC, 1987, CAN J NEUROL SCI, V14, P533, DOI 10.1017/S0317167100038063; Utzig MJ, 2003, AM J GASTROENTEROL, V98, P968, DOI 10.1016/S0002-9270(03)00141-2; von Lindern JJ, 2000, CANCER-AM CANCER SOC, V89, P1659, DOI 10.1002/1097-0142(20001015)89:8<1659::AID-CNCR2>3.0.CO;2-M; Wissel J, 1999, NEUROPEDIATRICS, V30, P120, DOI 10.1055/s-2007-973475; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939; Yazici Y, 1999, Clin Cornerstone, V2, P1, DOI 10.1016/S1098-3597(99)90010-8; YOSHIMURA DM, 1992, NEUROLOGY, V42, P627, DOI 10.1212/WNL.42.3.627	85	31	33	0	11	AMER SOC HEALTH-SYSTEM PHARMACISTS	BETHESDA	7272 WISCONSIN AVE, BETHESDA, MD 20814 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	NOV 15	2004	61	22		6			S11	S23		10.1093/ajhp/61.suppl_6.S11			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	874UC	WOS:000225374300003	15598005				2021-06-18	
J	Dumont, C; Gervais, M; Fougeyrollas, P; Bertrand, R				Dumont, C; Gervais, M; Fougeyrollas, P; Bertrand, R			Toward an explanatory model of social participation for adults with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						determination; fatigue; self-efficacy; social participation; traumatic brain injury	COMMUNITY INTEGRATION; COGNITIVE REHABILITATION; LIFE SATISFACTION; DISABILITY; RESILIENCY; EFFICACY; OUTCOMES; RETURN; WORK; CONSEQUENCES	To identify resiliency factors that could improve social participation for adults with traumatic brain injury. Design: Cross-sectional single measurement, correlational and exploratory study, including quantitative and qualitative data. Participants: Fifty-three community-dwelling people with sequelae of traumatic brain injury, individually interviewed, which included filling out questionnaires and answering open-ended questions. Main Measures: Social participation, self-efficacy, and positive mental states. Results: Dynamism, self-efficacy, and will account for 51% of the variance in social participation and are the main resiliency factors. Fatigue is one of the sequelae that pose the greatest challenge to self-efficacy and limit social participation. Conclusion: Resiliency factors constitute a target for research and intervention for this population.	Univ Laval, Fac Med, Dept Readaptat, Quebec City, PQ G1K 7P4, Canada; Univ Laval, CRIRES, Quebec City, PQ G1K 7P4, Canada	Dumont, C (corresponding author), Univ Laval, Fac Med, Dept Readaptat, Pavillon Ferdinand Vandry, Quebec City, PQ G1K 7P4, Canada.	Claire.Dumont@rea.ulaval.ca					AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; BANDURA A, 2001, IN PRESS GUIDE CONST; Bandura A., 1986, SOCIAL FDN THOUGHT A; Bent N, 2001, CLIN REHABIL, V15, P552, DOI 10.1191/026921501680425270; Bond T.G., 2001, APPL RASCH MODEL FUN; Bowen A, 1999, NEUROREHABILITATION, V13, P147; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Christensen AL, 1998, J HEAD TRAUMA REHAB, V13, P79, DOI 10.1097/00001199-199810000-00009; Christiansen CH, 1999, AM J OCCUP THER, V53, P547, DOI 10.5014/ajot.53.6.547; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CONDELUCI A, 1995, INTERDEPENDENCE ROUT; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; CRISP R, 1992, J REHABIL, V58, P27; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DeHope E, 1999, NEUROREHABILITATION, V13, P3; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; DUMONT C, 2001, CAN J OCCUP THER, V68, P239; Dumont Claire, 2003, J Appl Meas, V4, P309; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming J, 1999, BRAIN INJURY, V13, P417; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Fougeyrollas P., 1999, QUEBEC CLASSIFICATIO; FRASER D, 1999, QSRNUD IST VIVO REFE; Fraser MW, 1999, SOC WORK RES, V23, P131, DOI 10.1093/swr/23.3.131; Gillham JE, 1999, BEHAV RES THER, V37, pS163, DOI 10.1016/S0005-7967(99)00055-8; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; GUTMAN SA, 2000, OCCUPATIONAL THERAPY, V15, P1; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HELFRICH C, 1994, AM J OCCUP THER, V48, P311, DOI 10.5014/ajot.48.4.311; HINDS P, 1992, QUALITATIVE HLTH RES, V2, P61, DOI DOI 10.1177/104973239200200105; HOWELL DC, 1997, METHODES STAT SCI HU; Huberman A.M., 1991, ANAL DONNEES QUALITA; Jerusalem M., 1997, SELF EFFICACY CHANGI, P177; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; KIELHOFNER G, 1996, MODEL HUMAN OCCUPATI; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; KREFTING L, 1991, AM J OCCUP THER, V45, P214, DOI 10.5014/ajot.45.3.214; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levy AJ, 2000, FAM SOC-J CONTEMP H, V81, P402, DOI 10.1606/1044-3894.1083; LINACRE JM, 1999, WINSTEPS BIGSTEPS RA; LUBRUSCO AA, 1994, BRAIN INJURY, V8, P65; Markstrom CA, 2000, J ADOLESCENCE, V23, P693, DOI 10.1006/jado.2000.0353; Marshall C., 1995, DESIGNING QUALITATIV; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; Meyerson MD, 2001, CLEFT PALATE-CRAN J, V38, P231, DOI 10.1597/1545-1569(2001)038<0231:RASIAW>2.0.CO;2; Moon DG, 2000, J DRUG EDUC, V30, P373, DOI 10.2190/4AEC-BV03-5KDE-FUMW; Noreau L, 2000, DISABIL REHABIL, V22, P170; NOREAU L, 1996, CANADIAN J REHABILIT, V10, P81; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; PAJARES F, 2003, OVERVIEW SOCIAL COGN; Paradiso S, 1999, J NEUROL NEUROSUR PS, V67, P664, DOI 10.1136/jnnp.67.5.664; PEPIN M, 1999, TEST PERSONALITE PER; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Resnick M D, 2000, Adolesc Med, V11, P157; Richards L., 1999, USING NVIVO QUALITAT; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Schootman M, 1999, BRAIN INJURY, V13, P995; SCHWARZER R, 1994, PSYCHOL HEALTH, V9, P161, DOI 10.1080/08870449408407475; Schwarzer R.E., 1992, SELF EFFICACY THOUGH; SHERER M, 1982, PSYCHOL REP, V51, P663, DOI 10.2466/pr0.1982.51.2.663; SHERER M, 1983, PSYCHOL REP, V53, P899, DOI 10.2466/pr0.1983.53.3.899; Sherman SE, 2000, J GEN INTERN MED, V15, P2; SMITH RM, 1997, PHYS MED REHABIL STA, P261; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WARR P, 1978, BRIT J PSYCHOL, V69, P111, DOI 10.1111/j.2044-8295.1978.tb01638.x; WEISS DM, 1999, J COGN REHABIL, V17, P6; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; WILLER B, 1994, BRAIN INJURY, V8, P647, DOI 10.3109/02699059409151017; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089; WOODRUFF SL, 1993, PSYCHOL REP, V72, P423, DOI 10.2466/pr0.1993.72.2.423; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Ylvisaker M., 2003, BRAIN IMPAIR, V4, P1, DOI [10.1375/brim.4.1.1.27031, DOI 10.1375/brim.4.1.1.27031]	80	31	32	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2004	19	6					431	444		10.1097/00001199-200411000-00002			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	873LZ	WOS:000225283100002	15602307				2021-06-18	
J	Fyffe, CE; Kahng, S; Fittro, E; Russell, D				Fyffe, CE; Kahng, S; Fittro, E; Russell, D			Functional analysis and treatment of inappropriate sexual behavior	JOURNAL OF APPLIED BEHAVIOR ANALYSIS			English	Article						functional analysis; inappropriate sexual behavior; traumatic brain injury	DEVELOPMENTAL-DISABILITIES; SELF-INJURY	The results of a functional analysis showed that inappropriate sexual behaviors exhibited by a 9-year-old boy who had been diagnosed with traumatic brain injury were maintained by positive reinforcement in the form of social attention. An intervention consisting of functional communication training and extinction resulted in reduced levels of inappropriate sexual behaviors.	Kennedy Krieger Inst, Dept Behav Psychol, Baltimore, MD 21205 USA; Univ Maryland Baltimore Cty, Baltimore, MD 21228 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA	Kahng, S (corresponding author), Kennedy Krieger Inst, Dept Behav Psychol, 707 N Broadway, Baltimore, MD 21205 USA.	Kahng@kennedykrieger.org	Kahng, SungWoo/L-3099-2019; Kahng, SungWoo/A-9994-2009	Kahng, SungWoo/0000-0002-6031-5026; 			IWATA BA, 1994, J APPL BEHAV ANAL, V27, P197, DOI 10.1901/jaba.1994.27-197; Kahng S, 2002, AM J MENT RETARD, V107, P212, DOI 10.1352/0895-8017(2002)107<0212:BTOSIT>2.0.CO;2; LeBlanc LA, 2000, BEHAV INTERVENT, V15, P135, DOI 10.1002/(SICI)1099-078X(200004/06)15:2<135::AID-BIN51>3.0.CO;2-3; MACE FC, 1991, RES DEV DISABIL, V12, P155, DOI 10.1016/0891-4222(91)90004-C; PROVINALE R, 1980, MENT RETARD, V18, P27; Roane HS, 2004, J APPL BEHAV ANAL, V37, P213, DOI 10.1901/jaba.2004.37-213	6	31	32	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8855	1938-3703		J APPL BEHAV ANAL	J. Appl. Behav. Anal.	FAL	2004	37	3					401	404		10.1901/jaba.2004.37-401			4	Psychology, Clinical	Psychology	860BD	WOS:000224311300013	15529897	Bronze, Green Published			2021-06-18	
J	Jha, S; Patel, R				Jha, S; Patel, R			Kluver-Bucy syndrome - An experience with six cases	NEUROLOGY INDIA			English	Article						Kluyer-Bucy syndrome; herpes; anoxia-ischemic encephalopathy; neurocysticercosis; traumatic brain injury; tuberculous meningitis	ENCEPHALITIS	The Kluver-Bucy syndrome (KBS) is a neurobehavioral syndrome and can be seen in association with a variety of neurological disorders. Case records of 6 patients with KBS seen during a period of 5 years in a university hospital were reviewed. During the study period 6 patients with KBS, aged between 4 and 14 years, were seen. Hyperorality, hypersexuality, and abnormal behavior were the most common manifestations. Of the 6 patients, 5 had recurrent unprovoked seizures. The associated neurological disorders included anoxia-ischemic encephalopthy (2), herpes simplex encephalitis (1), neurocysticercosis (NCC) (1), traumatic brain injury with gliosis (1 case) and tuberculous meningitis (1 case). Prognosis was poor in all the patients except in the patient with NCC.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurol, Lucknow 226014, Uttar Pradesh, India	Jha, S (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurol, Raebareli Rd, Lucknow 226014, Uttar Pradesh, India.	sjha@sgpgi.ac.in					Biswas A, 1998, J Assoc Physicians India, V46, P318; Duggal H. S., 2000, Indian Journal of Pediatrics, V67, P74; GREENWOOD R, 1983, J NEUROL NEUROSUR PS, V46, P809, DOI 10.1136/jnnp.46.9.809; HART RP, 1986, SOUTHERN MED J, V79, P1376, DOI 10.1097/00007611-198611000-00014; Hayman LA, 1998, J NEUROPSYCH CLIN N, V10, P354, DOI 10.1176/jnp.10.3.354; HOOSHMAND H, 1974, JAMA-J AM MED ASSOC, V229, P1782, DOI 10.1001/jama.229.13.1782; JOHN AA, 1993, J NEUROL NEUROSUR PS, V56, P311; Kluver H, 1937, AM J PHYSL, V119, P352; MARLOWE W B, 1975, Cortex, V11, P53; MISRA UK, 1994, NEUROL INDIA, V42, P29; Muller A, 1999, NEUROPSY NEUROPSY BE, V12, P136; Olson DA, 2003, SOUTH MED J, V96, P323, DOI 10.1097/01.SMJ.0000061505.81880.96; POECK K, 1985, HDB CLIN NEUROLOGY, V1, P257; Pradhan S, 1998, CLIN NEUROL NEUROSUR, V100, P254, DOI 10.1016/S0303-8467(98)00055-9; SHRABERG D, 1978, J NERV MENT DIS, V166, P130, DOI 10.1097/00005053-197802000-00008; TERZIAN H, 1955, NEUROLOGY, V5, P373, DOI 10.1212/WNL.5.6.373	16	31	32	0	3	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	SEP	2004	52	3					369	371					3	Neurosciences	Neurosciences & Neurology	865QE	WOS:000224716800015	15472430				2021-06-18	
J	Akman, MN; Cetin, N; Bayramoglu, M; Isiklar, I; Kilinc, S				Akman, MN; Cetin, N; Bayramoglu, M; Isiklar, I; Kilinc, S			Value of the D-dimer test in diagnosing deep vein thrombosis in rehabilitation inpatients	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation	NOV 20-24, 2002	ORLANDO, FL	Amer Acad Phys Med & Rehabil		fibrin degradation products; rehabilitation; venous thrombosis	SPINAL-CORD-INJURY; VENOUS THROMBOSIS; BRAIN-INJURY; EXCLUSION; ASSAYS; ADMISSION	Objective: To assess the utility of the D-dimer test-a widely available, less costly, and less time-consuming test than others used to diagnose or exclude deep vein thrombosis (DVT) and pulmonary embolism. Design: Blind comparison. Setting: An inpatient rehabilitation facility in Turkey. Participants: Sixty-eight consecutive inpatients being rehabilitated after stroke, spinal cord injury, hip arthroplasty, or traumatic brain injury. Interventions: A latex D-dimer assay was performed on each patient at admission and then weekly throughout the hospital stay. Color Doppler ultrasonography of the lower limbs was also done for each patient at admission and was repeated when indicated by clinical signs and symptoms of DVT or by elevated D-dimer levels. Main Outcome Measures: Patients' clinical findings, D-dimer test results, and ultrasonography results were recorded. Sensitivity, specificity, and positive and negative predictive values were calculated for the D-dimer test, each clinical finding, and combinations of D-dimer results and clinical findings in relation to DVT diagnosis. Results: The sensitivity and negative predictive value of the D-dimer test were high, at 95.2% and 96.2%, respectively. The specificity and positive predictive value were low, at 55.3% and 48.7%, respectively. No single clinical finding was reliably diagnostic for DVT. Conclusions: The D-dimer assay is a reliable method for ruling out DVT. In the rehabilitation setting, it can be used as a routine screening test or to assess cases of suspected DVT. D-dimer testing may reduce the need for sophisticated, time-consuming, and expensive diagnostic workup of rehabilitation inpatients, a group that is at increased risk for DVT.	Baskent Univ, Fac Med, Dept Phys Med & Rehabil, TR-06490 Ankara, Turkey; Baskent Univ, Fac Med, Dept Radiol, TR-06490 Ankara, Turkey; Baskent Univ, Phys Med & Rehabil Ctr, TR-06490 Ankara, Turkey	Akman, MN (corresponding author), Baskent Univ, Fac Med, Dept Phys Med & Rehabil, 5 Sokak 48,Bahcelievler, TR-06490 Ankara, Turkey.	nafiza@baskent-ank.edu.tr	Cetin, Nuri/AAK-4129-2021; AYAS, SEHRI/AAJ-7520-2021; Bayramoglu, Meral/W-8293-2018	Cetin, Nuri/0000-0002-9950-8917; AYAS, SEHRI/0000-0002-5078-6529; 			[Anonymous], 1993, Thromb Haemost, V70, P909; Barloon TJ, 1997, AM FAM PHYSICIAN, V56, P791; Birdwell B, 1999, Curr Opin Hematol, V6, P275, DOI 10.1097/00062752-199909000-00001; Burn PR, 1997, CLIN RADIOL, V52, P625, DOI 10.1016/S0009-9260(97)80257-7; Cappeliez O, 1996, Rev Med Brux, V17, P127; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; Elias A, 1996, THROMB HAEMOSTASIS, V76, P518; Garrison SJ, 1993, REHABILITATION MED P, P801; Janssen MCH, 1998, SEMIN THROMB HEMOST, V24, P393, DOI 10.1055/s-2007-996028; Janssen MCH, 1997, THROMB HAEMOSTASIS, V77, P262; Kozman H, 1997, SOUTHERN MED J, V90, P907, DOI 10.1097/00007611-199709000-00009; Lensing AWA, 1999, LANCET, V353, P479, DOI 10.1016/S0140-6736(98)04298-6; MERLI GJ, 1993, ARCH PHYS MED REHAB, V74, P1199; Meythaler JM, 2003, ARCH PHYS MED REHAB, V84, P285, DOI 10.1053/apmr.2003.50116; Michiels JJ, 1998, SEMIN THROMB HEMOST, V24, P401, DOI 10.1055/s-2007-996029; Powell M, 1999, ARCH PHYS MED REHAB, V80, P1044, DOI 10.1016/S0003-9993(99)90058-8; Rossi R, 1998, Minerva Cardioangiol, V46, P507; Roussi J, 1999, SPINAL CORD, V37, P548, DOI 10.1038/sj.sc.3100891; Zhang GJ, 1996, SURG TODAY, V26, P683, DOI 10.1007/BF00312084	19	31	33	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2004	85	7					1091	1094		10.1016/j.apmr.2003.10.023			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	835XU	WOS:000222519600008	15241755				2021-06-18	
J	Rosenfeld, JV				Rosenfeld, JV			Damage control neurosurgery	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						damage control; neurosurgery; traumatic brain injury; rural surgery; military surgery	ACUTE SUBDURAL HEMATOMAS; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; NEW-SOUTH-WALES; EXTRADURAL HEMORRHAGE; LEBANESE CONFLICT; COMATOSE PATIENTS; MANAGEMENT; EXPERIENCE; CRANIOTOMY	Damage control neurosurgery (DCNS) is abbreviated urgent neurosurgery performed on the injured patient which helps to prevent secondary brain injury, assists in stabilising the patient and improves survival and outcome. It may be urgent surgery done by the neurosurgeon in a trauma centre, but it has particular application in the remote, rural or military environment where the surgery can be performed by a generalist. This surgery should always be done in collaboration with the trauma team caring for the overall needs of the patient. The Definitive Surgery Trauma Course (DSTC) is an ideal educational vehicle to disseminate the principles of DCNS. (C) 2004 Elsevier Ltd. All rights reserved.	Monash Univ, Alfred Hosp, Dept Neurosurg & Surg, Prahran, Vic 3181, Australia	Rosenfeld, JV (corresponding author), Monash Univ, Alfred Hosp, Dept Neurosurg & Surg, Commercial Rd, Prahran, Vic 3181, Australia.	j.rosenfeld@alfred.org.au	Rosenfeld, Jeffrey V/B-7249-2011				Alam HB, 2003, J TRAUMA, V54, P1077, DOI 10.1097/01.TA.0000068258.99048.70; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; Connolly E, 2002, FUNDAMENTALS OPERATI; Coutts A, 1998, BRIT MED J, V317, P1687, DOI 10.1136/bmj.317.7174.1687; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Cruz J, 2001, NEUROSURGERY, V49, P864; DAN NG, 1986, AUST NZ J SURG, V56, P535, DOI 10.1111/j.1445-2197.1986.tb07096.x; DUFOUR D, 1990, SURG VICTIMS WAR; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Harding JN, 1996, ANAESTH INTENS CARE, V24, P500, DOI 10.1177/0310057X9602400417; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; McDermott FT, 2004, J TRAUMA, V56, P137, DOI 10.1097/01.TA.0000056163.58047.74; Moore EE, 1998, WORLD J SURG, V22, P1184, DOI 10.1007/s002689900542; Newcombe R, 1999, J CLIN NEUROSCI, V6, P85, DOI 10.1016/S0967-5868(99)90619-7; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Rosenfeld JV, 2002, J CLIN NEUROSCI, V9, P9, DOI 10.1054/jocn.2001.0949; ROSENFELD JV, 2001, NEUROSURGERY TROPICS; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; ROTONDO MF, 1997, SURG CLIN N AM, V77, P12; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SIMPSON DA, 1988, INJURY, V19, P307, DOI 10.1016/0020-1383(88)90100-3; STENING WA, 1986, AUST NZ J SURG, V56, P549, DOI 10.1111/j.1445-2197.1986.tb07098.x; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; Woodman T, 1996, NEUROTRAUMA, P519	30	31	41	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	JUL	2004	35	7					655	660		10.1016/j.injury.2004.03.006			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	834WL	WOS:000222441500004	15203305				2021-06-18	
J	Ibarra, A; Hauben, E; Butovsky, O; Schwartz, M				Ibarra, A; Hauben, E; Butovsky, O; Schwartz, M			The therapeutic window after spinal cord injury can accommodate T cell-based vaccination and methylprednisolone in rats	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						inflammation; neurodegeneration; neuroprotection; paraplegia; protective autoimmunity	PROTECTIVE AUTOIMMUNITY; NEURONAL SURVIVAL; SELF-ANTIGEN; OPTIC-NERVE; RECOVERY; SYSTEM; PROSPECTS; GANGLION; TRAUMA; BRAIN	Immune system activity has traditionally been considered harmful for recovery after spinal cord injury (SCI). Recent evidence suggests, however, that immune activity - and specifically autoimmune activity - is evoked by the insult, is beneficial if properly regulated and is amenable to boosting. Thus, for example, vaccination with an altered peptide ligand derived from myelin basic protein reduces the progressive degeneration of neurons that escaped the initial insult, thereby promoting recovery after SCI. As the steroid drug methylprednisolone (MP) is currently the only treatment available for patients with SCI, our purpose in the present study was to examine the mutual compatibility of the two treatments within the post-traumatic therapeutic window. We show, using rats of two different strains, that if MP is injected concomitantly with the therapeutic vaccination, the beneficial effect of the vaccination is diminished. However, if MP is given immediately after the insult and the vaccination 48 h later, MP does not detract from the beneficial effect of the vaccination. These results demonstrate that the therapeutic window after SCI can accommodate immediate administration of MP plus a delayed therapeutic vaccination.	IMSS, Camina Res Ctr, Med Res Unit Neurol Dis, Dept Neuroimmunol, Mexico City, DF, Mexico; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Ibarra, A (corresponding author), IMSS, Camina Res Ctr, Med Res Unit Neurol Dis, Dept Neuroimmunol, Mexico City, DF, Mexico.	iantonio65@yahoo.com	Hauben, Ehud/R-8692-2019	Ibarra, Antonio/0000-0003-2489-4689; Hauben, Ehud/0000-0002-6062-411X			BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Butovsky Oleg, 2001, FASEB Journal, V15, P1065; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Diaz-Ruiz A, 2000, NEUROREPORT, V11, P1765, DOI 10.1097/00001756-200006050-00033; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001; Goodman A.G., 1990, PHARM BASIS THERAPEU; Haghighi SS, 2000, SPINAL CORD, V38, P733, DOI 10.1038/sj.sc.3101074; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI12837; Hauben E, 2002, EUR J NEUROSCI, V16, P1731, DOI 10.1046/j.1460-9568.2002.02241.x; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; Karlik S J, 1996, Mult Scler, V1, P228; Kipnis J, 2002, P NATL ACAD SCI USA, V99, P15620, DOI 10.1073/pnas.232565399; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; KOYANAGI I, 1993, NEUROSURGERY, V33, P285, DOI 10.1227/00006123-199308000-00016; Koyanagi I., 1993, NEUROSURGERY, V33, P292, DOI DOI 10.1097/00006123-199308000-00016; KWO S, 1989, Journal of Neurotrauma, V6, P13, DOI 10.1089/neu.1989.6.13; Mizrahi T, 2002, J IMMUNOL, V169, P5971, DOI 10.4049/jimmunol.169.10.5971; Moalem G, 1999, FASEB J, V13, P1207; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Qian T, 2000, MED HYPOTHESES, V55, P452, DOI 10.1054/mehy.2000.1165; Schori H, 2002, J IMMUNOL, V169, P2861, DOI 10.4049/jimmunol.169.6.2861; Schori H, 2001, J NEUROIMMUNOL, V119, P199, DOI 10.1016/S0165-5728(01)00358-7; Schori H, 2001, P NATL ACAD SCI USA, V98, P3398, DOI 10.1073/pnas.041609498; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Schwartz M, 2002, TRENDS IMMUNOL, V23, P530, DOI 10.1016/S1471-4906(02)02322-0; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Schwartz M, 2001, PROG NEUROBIOL, V65, P489, DOI 10.1016/S0301-0082(01)00009-0; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; SMOLEN AJ, 1983, J NEUROCYTOL, V12, P739, DOI 10.1007/BF01258148; STEINER I, 1991, ISRAEL J MED SCI, V27, P365; Steinsapir KD, 2000, RESTOR NEUROL NEUROS, V17, P157; Sun YN, 1999, J PHARMACOL EXP THER, V288, P720; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Yoon DH, 1999, YONSEI MED J, V40, P313, DOI 10.3349/ymj.1999.40.4.313; Young W, 1996, SCIENCE, V273, P451, DOI 10.1126/science.273.5274.451	44	31	32	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUN	2004	19	11					2984	2990		10.1111/j.0953-816X.2004.03402.x			7	Neurosciences	Neurosciences & Neurology	825WP	WOS:000221789800008	15182305				2021-06-18	
J	Tolentino, PJ; Waghray, A; Wang, KKW; Hayes, RL				Tolentino, PJ; Waghray, A; Wang, KKW; Hayes, RL			Increased expression of tissue-type transglutaminase following middle cerebral artery occlusion in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						brain injury; cross-linking; ischemia; transglutaminase	GTP-BINDING PROTEIN; ALZHEIMERS-DISEASE; RETINOIC ACID; CROSS-LINKING; CELL-DEATH; DIFFERENTIAL EXPRESSION; BRAIN-INJURY; SPINAL-CORD; APOPTOSIS; CALCIUM	Tissue-type transglutaminase (TG-2) has been implicated in neurodegenerative diseases. In this study, induction of TG-2 was studied in rats following transient middle cerebral artery occlusion. Alterations in 2,3,5-triphenylterazolium chloride staining revealed maximum infarction 3 days after injury. Measurement of mRNA transcript levels by real-time PCR analysis showed both forms of TG-2 mRNA peaking on day 5 after injury in ipsilateral cortex, with greater induction of the full-length TG-2 (TG-L) transcript than the truncated form of the TG-2 (TG-S) transcript. However, in the ipsilateral hippocampus, peak induction of both forms of TG-2 mRNA peaked 1 day after injury and to a lesser extent than observed in the ipsilateral cortex. Western blot analysis demonstrated that TG-L protein expression progressively increased from 1 to 7 days after ischemia, with greater expression in cortex than hippocampus (525+/-10% vs. 196+/-8% of control, respectively). However, expression of TG-S was not detected. These results demonstrate that increased TG-2 mRNA and protein expression occurs in a delayed fashion following ischemic injury. The temporal profile of TG-2 induction after ischemia was similar to that observed after traumatic brain injury (previously described), suggesting a similar role of TG-2 in both pathological conditions.	Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Dept Psychiat, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32610 USA	Hayes, RL (corresponding author), Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, 100 S Newell Dr,Box 100244, Gainesville, FL 32610 USA.	hayes@ufbi.ufl.edu		Wang, Kevin/0000-0002-9343-6473			ANDO M, 1993, BRAIN RES, V604, P64, DOI 10.1016/0006-8993(93)90352-N; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Blass JP, 2003, NEW ENGL J MED, V348, P1277, DOI 10.1056/NEJMe030017; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Buki A, 2000, J NEUROSCI, V20, P2825; Casadio R, 1999, EUR J BIOCHEM, V262, P672, DOI 10.1046/j.1432-1327.1999.00437.x; Chu D, 2002, NEUROCHEM RES, V27, P97, DOI 10.1023/A:1014858707218; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; Elkind MS, 1998, SEMIN NEUROL, V18, P429, DOI 10.1055/s-2008-1040896; Facchiano F, 2001, EXP CELL RES, V271, P118, DOI 10.1006/excr.2001.5356; Ferrari N, 1998, MOL CELL BIOL, V18, P6482, DOI 10.1128/MCB.18.11.6482; Festoff BW, 2002, J NEUROCHEM, V81, P708, DOI 10.1046/j.1471-4159.2002.00850.x; Fujita K, 1995, NEUROCHEM RES, V20, P1195, DOI 10.1007/BF00995383; GILAD GM, 1985, J NEUROCHEM, V44, P1385, DOI 10.1111/j.1471-4159.1985.tb08774.x; Gill LS, 1998, BRAIN RES, V788, P95, DOI 10.1016/S0006-8993(97)01526-6; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; GREENBERG CS, 1991, FASEB J, V5, P3071; Hayes RL, 2001, HEAD TRAUMA, P219; He Z, 2000, J NEUROL SCI, V182, P16, DOI 10.1016/S0022-510X(00)00434-2; IKURA K, 1994, BIOSCI BIOTECH BIOCH, V58, P1540, DOI 10.1271/bbb.58.1540; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lai TS, 2001, BIOCHEMISTRY-US, V40, P4904, DOI 10.1021/bi002321t; Lefebvre O, 1999, CELL DEATH DIFFER, V6, P433, DOI 10.1038/sj.cdd.4400510; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; MADDOX AM, 1988, EXP CELL BIOL, V56, P49; Mattson MP, 2000, BRAIN PATHOL, V10, P300, DOI 10.1111/j.1750-3639.2000.tb00264.x; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Norlund MA, 1999, BRAIN RES, V851, P154, DOI 10.1016/S0006-8993(99)02179-4; Pennypacker KR, 1999, BRAIN RES BULL, V48, P539, DOI 10.1016/S0361-9230(99)00031-3; Piredda L, 1999, FASEB J, V13, P355; Pluta R, 2000, ANN NY ACAD SCI, V903, P324, DOI 10.1111/j.1749-6632.2000.tb06383.x; SUEDHOFF T, 1990, CANCER RES, V50, P7830; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	44	31	33	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2004	89	5					1301	1307		10.1111/j.1471-4159.2004.02436.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	821CK	WOS:000221437200024	15147523				2021-06-18	
J	Ariza, M; Junque, C; Mataro, M; Poca, MA; Bargallo, N; Olondo, M; Sahuquillo, J				Ariza, M; Junque, C; Mataro, M; Poca, MA; Bargallo, N; Olondo, M; Sahuquillo, J			Neuropsychological correlates of basal ganglia and medial temporal lobe NAA/Cho reductions in traumatic brain injury	ARCHIVES OF NEUROLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; MR SPECTROSCOPY; AXONAL INJURY; HYPOXIA	Background: Proton magnetic resonance spectroscopy can assess neurochemical sequelae in traumatic brain injury. Metabolic abnormalities are present in the acute or subacute period in patients with traumatic brain injury and correlate with outcome on clinical scales. Objective: To investigate the use of proton magnetic resonance spectroscopy in detecting possible gray subcortical neurochemical impairments and their relationship with neuropsychological performance. Design: Group comparisons and correlations of brain metabolites with clinical and neuropsychological variables. Patients and Methods: Metabolite concentrations were acquired from voxels localized to the basal ganglia and medial temporal region in 20 patients with long-term moderate and severe traumatic brain injury and 20 matched control subjects. Both groups under-went neuropsychological assessment. Results: N-acetylaspartate-choline-containing compounds ratios were decreased in patients in the basal ganglia (t=-3.28, P=.002) and medial temporal region (t=-3.52, P=.001). The basal ganglia ratio correlated to measures of speed, motor scanning, and attention. Conclusion: Patients with long-term TBI present a regional correlation pattern that may help identify the neurological basis of cognitive sequelae in traumatic brain injury.	Vall Hebron Univ Hosp, Dept Neurosurg, Barcelona, Spain; Hosp Clin Barcelona, Dept Radiol, Ctr Diagnost Imatge, Barcelona, Spain; Univ Barcelona, Dept Psiquiat & Psicobiol Clin, Inst Invest Biomed August Pi & Sunyer, E-08036 Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, Dept Psiquiat & Psicobiol Clin, Inst Invest Biomed August Pi & Sunyer, C Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Junque, Carme/B-4400-2011; Ariza, Mar/F-2754-2019; Sahuquillo, Juan/B-3577-2008; Mataro, Maria/B-4524-2011; Poca, Maria A./B-8475-2008; Bargallo, Nuria/G-6854-2016	Junque, Carme/0000-0002-6381-3063; Sahuquillo, Juan/0000-0003-0713-5875; Mataro, Maria/0000-0002-9946-2656; Poca, Maria A./0000-0002-3831-0536; Bargallo, Nuria/0000-0001-6284-5402; Ariza, Mar/0000-0003-1020-6945			Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; CALABRESI P, 1995, BRAIN, V118, P1027, DOI 10.1093/brain/118.4.1027; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; LUYTEN PR, 1986, RADIOLOGY, V161, P795, DOI 10.1148/radiology.161.3.3786735; Nakano K, 2000, J NEUROL, V247, P1; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Sinson G, 2001, AM J NEURORADIOL, V22, P143	13	31	32	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	APR	2004	61	4					541	544		10.1001/archneur.61.4.541			4	Clinical Neurology	Neurosciences & Neurology	810RX	WOS:000220722500012	15096403	Bronze			2021-06-18	
J	Yildirim, E; Kaptanoglu, E; Ozisik, K; Beskonakli, E; Okutan, O; Sargon, MF; Kilinc, K; Sakinci, U				Yildirim, E; Kaptanoglu, E; Ozisik, K; Beskonakli, E; Okutan, O; Sargon, MF; Kilinc, K; Sakinci, U			Ultrastructural changes in pneumocyte type II cells following traumatic brain injury in rats	EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY			English	Article; Proceedings Paper	17th Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery/11th Annual Meeting of the European-Society-of-Thoracic-Surgeons	OCT 12-15, 2003	VIENNA, AUSTRIA	European Assoc Cardio Thorac Surg, European Soc Thorac Surg		brain; trauma; animal model; electron microscopy; lung; pneumocyte type II cells	NEUROGENIC PULMONARY-EDEMA; SPINAL-CORD-INJURY; LUNG; METHYLPREDNISOLONE	Objective: We aimed to demonstrate the time-dependent ultrastructural changes in pneumocyte type II cells following brain injury, and to propose an electron microscopic scoring model for the damage. Methods: Forty Wistar-Albino female rats weighing 170-200 g were used. The rats were allocated into five groups. The first group was the control and the second was the craniotomy without trauma. The others were trauma groups. Weight-drop method was used for achieving head trauma. Samples were obtained from the right and left pulmonary lobes at 2-, 8-, and 24-h intervals after transcardiac perfusion. An electron microscopic scoring model was used to reveal the changes. Results: There were no ultrastructural pathological findings pointing to lung injury in any rat of the control groups. There was intense intracellular oedema in type II pneumocyte and interstitial oedema in the adjacent tissue in trauma groups. Oedema in mitochondria and dilatation in both smooth endoplasmic reticulum and Golgi apparatus was more evident in the 8- and 24-h trauma groups. The chromatin dispersion was disintegrated in the nucleus in all trauma groups. Scores of all trauma groups were significantly different from the controls (P < 0.05). All trauma groups were different from each other at significant levels (P < 0.05 for each trauma groups). Conclusions: The data suggested that ultrastructural damage is obvious at 2 h and deteriorates with time. The electron microscopic scoring model worked well in depicting the traumatic changes, which were supported by lipid peroxidation. Further experiments are needed to determine the exact outcome after brain death model. (C) 2004 Elsevier B.V. All rights reserved.	Ankara Numune Educ & Res Hosp, Dept Thorac Surg, Ankara, Turkey; Ankara Numune Educ & Res Hosp, Dept Neurosurg, Ankara, Turkey; Hacettepe Univ, Fac Med, Dept Anat, TR-06100 Ankara, Turkey; Hacettepe Univ, Fac Med, Dept Biochem, TR-06100 Ankara, Turkey	Yildirim, E (corresponding author), Asagiovecler Mh,79-Sk,8-3 Dikmen,Cankaya, Ankara, Turkey.	erseyda@yahoo.com	YILDIRIM, Erkan/AAO-6961-2020	Sargon, Mustafa Fevzi/0000-0001-6360-6008			Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; CORMAN J, 1991, ANN CHIR, V45, P791; COTTRELL TS, 1967, CIRC RES, V21, P783, DOI 10.1161/01.RES.21.6.783; DETTBARN CL, 1989, HEART LUNG, V18, P583; EDMONDS HL, 1986, NEUROSURGERY, V19, P36, DOI 10.1227/00006123-198607000-00005; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hall SRR, 2002, ANESTH ANALG, V94, P948; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kaptanoglu E, 2002, J NEUROSURG ANESTH, V14, P114, DOI 10.1097/00008506-200204000-00005; MARON MB, 1989, J APPL PHYSIOL, V67, P305; MIHARA M, 1981, YAKUGAKU ZASSHI, V101, P221, DOI 10.1248/yakushi1947.101.3_221; Novick RJ, 1996, ANN THORAC SURG, V62, P302, DOI 10.1016/0003-4975(96)00333-5; Pyeron A M, 2001, J Neurosci Nurs, V33, P203; Schwarz S, 1997, NERVENARZT, V68, P956, DOI 10.1007/s001150050222; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SINGBARTL G, 1989, ANAESTHESIST, V38, P360; Smith WS, 1997, CHEST, V111, P1326, DOI 10.1378/chest.111.5.1326; WANG NS, 1971, AM J PATHOL, V62, P237; West JB, 2000, J APPL PHYSIOL, V89, P2483	21	31	32	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1010-7940	1873-734X		EUR J CARDIO-THORAC	Eur. J. Cardio-Thorac. Surg.	APR	2004	25	4					523	529		10.1016/j.ejcts.2003.12.021			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	811IL	WOS:000220765500010	15037266	Green Published, Bronze			2021-06-18	
J	Jin, C; Schachar, R				Jin, C; Schachar, R			Methylphenidate treatment of attention-deficit/hyperactivity disorder secondary to traumatic brain injury: A critical appraisal of treatment studies	CNS SPECTRUMS			English	Article								Objective: Are stimulants effective in treating attention-deficit/hyperactivity disorder secondary to traumatic brain injury (ADHD/TBI)? The authors reviewed and examined the current knowledge on efficacy of stimulant treatment ADHD/TBI. Method: A systematic review of the literature using a quality assessment scale to assess the quality of randomized clinical trials was undertaken. We identified all studies in which stimulants had been administered to individuals with ADHD/TBI. Information was extracted on study characteristics, interventions, and outcomes. A meta,analysis was not performed because of the limited number of studies with strict research design and the heterogeneity of outcome measures. Seven studies involving 118 subjects, 41 of whom were children and adolescents, were identified. Results: Of the seven identified studies, one was a chart review, one used a single-blind, placebo-controlled crossover design, and five were double-blind, placebo-controlled crossovers. These studies used >50 subjective and objective tests to measure behavioral and cognitive outcomes. Methylphenidate (MPH) effects on behavior (hyperactivity, impulsivity) were evident but were not as robust as those typically observed with MPH in primary ADHD. The effect of MPH on cognition was less apparent. More favorable outcome was associated with initiation of treatment soon after head injury, although this factor was not systematically studied, and trials with relativly long durations. Studies with negative MPH response reported neither improvement in behavioral nor cognitive symptoms. Conclusion: There is only modest evidence to support the efficacy of MPH in the treatment of ADHD/TBI. While MPH might still be a promising treatment for ADHD/TBI, there is need for rigorous treatment outcome research among representative samples of ADHD/TBI individuals. CNS Spectr. 2004;9(3):217-226	Univ Toronto, Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; N Shore Univ Hosp, Dept Psychiat, Div Child & Adolescent Psychiat, Manhasset, NY 11030 USA; NYU, Sch Med, Dept Psychiat, New York, NY USA	Schachar, R (corresponding author), Univ Toronto, Hosp Sick Children, Dept Psychiat, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	atm@sickkids.on.ca		Schachar, Russell/0000-0002-2015-4395			Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; [Anonymous], 1999, JAMA-J AM MED ASSOC, V10, P974; Biederman J, 1996, ARCH GEN PSYCHIAT, V53, P437; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Coull JT, 1998, PROG NEUROBIOL, V55, P343, DOI 10.1016/S0301-0082(98)00011-2; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FRANCES A, 1985, HOSP COMMUNITY PSYCH, V36, P711; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GUALTIERI CT, 1988, BRAIN INJURY, V4, P273; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAAS JF, 1985, ARCH PHYS MED REHAB, V66, P472; Handen BL, 1999, J AM ACAD CHILD PSY, V38, P805, DOI 10.1097/00004583-199907000-00009; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jadad AR, 1999, CAN J PSYCHIAT, V44, P1025, DOI 10.1177/070674379904401009; Justice AC, 1998, JAMA-J AM MED ASSOC, V280, P240, DOI 10.1001/jama.280.3.240; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kube DA, 2002, CLIN PEDIATR, V41, P461, DOI 10.1177/000992280204100702; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LPPER S, 1976, J NERV MENT DIS, V5, P366; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; MAHALICK DM, 1996, TRAUMA, V38, P39; Max JE, 1998, BRAIN INJURY, V12, P31; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Mehta MA, 2000, J NEUROSCI, V20; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Parmelee D X, 1987, Brain Inj, V1, P41, DOI 10.3109/02699058709034443; PARY R, 2002, ANN CLIN PSYCHIAT, V2, P105; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; SALAZAR AM, 2000, JAMA-J AM MED ASSOC, V23, P3075; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Seeman P, 1998, MOL PSYCHIATR, V3, P386, DOI 10.1038/sj.mp.4000421; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; STERN JM, 1978, SCAND J REHABIL MED, V10, P7; TANNOCK R, 1995, J AM ACAD CHILD PSY, V34, P886, DOI 10.1097/00004583-199507000-00012; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; Weinberg R M, 1987, Brain Inj, V1, P57, DOI 10.3109/02699058709034445; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Worzniak M, 1997, J FAM PRACTICE, V44, P495; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86; Wroblewski Bruno, 1993, Brain Injury, V7, P353, DOI 10.3109/02699059309034962	52	31	31	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1092-8529	2165-6509		CNS SPECTRUMS	CNS Spectr.	MAR	2004	9	3					217	226		10.1017/S1092852900009019			10	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	895VB	WOS:000226890800008	14999162				2021-06-18	
J	Cassidy, JD; Carroll, L; Cote, P; Holm, L; Nygren, A				Cassidy, JD; Carroll, L; Cote, P; Holm, L; Nygren, A			Mild traumatic brain injury after traffic collisions: A population-based inception cohort study	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; epidemiology; prognosis; compensation	WHIPLASH INJURY; PAIN INTENSITY; HEAD-INJURY; BACK-PAIN; COMPENSATION; OUTCOMES; WORKERS; CARE; NECK	Objective: To study the incidence and claim closure of traffic-related mild traumatic brain injury and the effect of insurance factors. Design: Population-based, cohort study of mild traumatic brain injury caused by traffic collisions in Saskatchewan, Canada, between July 1, 1994 and December 31, 1995. On January 1, 1995 the insurance law changed from tort to no fault. Subjects: 657 adults, 18 years or older, who hit their head and indicated loss of consciousness or uncertain loss of consciousness and were not hospitalized for more than 2 days. Methods: Subjects entered the cohort on the injury date and exited on the day the insurance claim closed, or on November 1, 1997, when remaining open claims were censored. All 657 subjects answered a baseline questionnaire, and 479 who did not reopen their claim were included in the follow-up. The relationship between claim closure and health was studied in 225 (47%) of these claimants. Results: The 6-month incidence dropped from 36/100,000 to 27/100,000 after the insurance change. The median time-to-claim closure dropped from 408 days to 233 days. Prolonged claim closure was associated with both injury and insurance-related factors. Claim closure occurred faster when claimants' health improved. Conclusions: Mild traumatic brain injury incidence and claim closure is affected by both health and insurance-related factors.	Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden; Univ Toronto, Inst Work & Hlth, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	Cassidy, JD (corresponding author), Univ Hlth Network, Toronto Western Hosp, Div Outcomes & Populat Hlth, Res Inst, 399 Bathurst St,MP 10-328A, Toronto, ON M5T 2S8, Canada.	dcassidy@uhnres.utoronto.ca	Cote, Pierre/AAG-5358-2021	Cote, Pierre/0000-0002-6986-6676; Carroll, Linda/0000-0003-0876-2336			ABENHAIM L, 1987, J OCCUP ENVIRON MED, V29, P670; Allison P.D., 1995, SURVIVAL ANAL USING; Beaton DE, 2001, ARTHRIT RHEUM-ARTHR, V45, P270, DOI 10.1002/1529-0131(200106)45:3<270::AID-ART260>3.3.CO;2-K; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cassidy JD, 2000, NEW ENGL J MED, V342, P1179, DOI 10.1056/NEJM200004203421606; Cote P, 2001, J CLIN EPIDEMIOL, V54, P275, DOI 10.1016/S0895-4356(00)00319-X; GREENLAND S, 1998, MODERN EPIDEMIOLOGY, P253; Hadler NM, 1996, SPINE, V21, P2397, DOI 10.1097/00007632-199610150-00021; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Kessels RPC, 2000, J INT NEUROPSYCH SOC, V6, P271, DOI 10.1017/S1355617700633027; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LANSKY D, 1992, MED CARE, V30, pMS57, DOI 10.1097/00005650-199205001-00006; LOESER JD, 1995, MED CARE RES REV, V52, P34, DOI 10.1177/107755879505200104; MARGOLIS RB, 1986, PAIN, V24, P57, DOI 10.1016/0304-3959(86)90026-6; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Mercado AC, 2000, HEALTH PSYCHOL, V19, P333, DOI 10.1037/0278-6133.19.4.333; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Phillips R C, 1992, J Heart Valve Dis, V1, P42; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Radanov BP, 1996, SPINE, V21, P392, DOI 10.1097/00007632-199602010-00029; Ruff RM, 1999, BRAIN INJURY, V13, P943; *SAS I, 1996, SAS COMP PROGR VERS; *SASK GOV INS, 1996, SASK TRAFF ACC FACTS; *SASK HLTH, 1995, HLTH INS REG COV POP; Sinclair SJ, 1997, SPINE, V22, P2919, DOI 10.1097/00007632-199712150-00015; *SPSS, 1999, SPSS COMP PROGRAM VE; Ware JE., 1993, SF 36 HLTH SURVEY MA; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298	34	31	31	0	3	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			15	21		10.1080/16501960410023688			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	800QR	WOS:000220043300005	15083868	DOAJ Gold			2021-06-18	
J	Hlatky, R; Contant, CF; Diaz-Marchan, P; Valadka, AB; Robertson, CS				Hlatky, R; Contant, CF; Diaz-Marchan, P; Valadka, AB; Robertson, CS			Significance off a reduced cerebral blood flow during the first 12 hours after traumatic brain injury	NEUROCRITICAL CARE			English	Article						cerebral blood flow; brain injury; xenon-enhanced computed tomography; ischemia; intracranial hypertension	ARTERIOVENOUS OXYGEN DIFFERENCE; CORTICAL IMPACT INJURY; HEAD-INJURY; COMATOSE PATIENTS; NORMAL VALUES; CIRCULATION; METABOLISM; ISCHEMIA	Background: It is controversial whether a low cerebral blood flow (CBF) simply reflects the severity of injury or whether ischemia contributes to the brain's injury. It is also not clear whether posttraumatic cerebral hypoperfusion results from intracranial hypertension or from pathologic changes of the cerebral vasculature. The answers to these questions have important implications for whether and how to treat a low CBF. Methods: We performed a retrospective analysis of 77 patients with severe traumatic brain injury who had measurement of CBF within 12 hours of injury. CBF was measured using xenon-enhanced computed tomography (XeCT). Global CBF, physiological parameters at the time of XeCT, and outcome measures were analyzed. Results; Average global CBF for the 77 patients was 36 +/- 16 mL/100 g/minutes. Nine patients had an average global CBF <18 (average 12 +/- 5). The remaining 68 patients had a global CBF of 39 +/- 15. The initial ICP was >20 mmHg in 90% and >30 mmHg in 80% of patients in the group with CBF <18, compared to 33% and 16%, respectively, in the patients with CBF >= 18. Mortality was 90% at 6 months postinjury in patients with CBF <18. Mortality in the patients with CBF >18 was 19% at 6 months after injury. Conclusion: In patients with CBF <18 mL/100 g/minutes, intracranial hypertension plays a major causative role in the reduction in CBE Treatment would most likely be directed at controlling intracranial pressure, but the early, severe intracranial hypertension also probably indicates a severe brain injury. For levels of CBF between 18 and 40 mL/100 g/minutes, the presence of regional hypoperfusion was a more important factor in reducing the average CBF.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Charles Univ Prague, Univ Hosp, Dept Neurosurg, Hradec Kralove, Czech Republic; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 FAnnin,Suite 944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS38660] Funding Source: Medline		ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; Feldman Z, 1997, CRIT CARE CLIN, V13, P51, DOI 10.1016/S0749-0704(05)70296-7; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; OVERGAARD J, 1983, J NEUROSURG, V59, P439, DOI 10.3171/jns.1983.59.3.0439; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; YONAS H, 1991, J CEREBR BLOOD F MET, V11, P716, DOI 10.1038/jcbfm.1991.128	19	31	32	1	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2004	1	1					69	83		10.1385/NCC:1:1:69			15	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	945FL	WOS:000230488300008	16174900				2021-06-18	
J	Figg, RE; Burry, TS; Vander Kolk, WE				Figg, RE; Burry, TS; Vander Kolk, WE			Clinical efficacy of serial computed tomographic scanning in severe closed head injury patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	16th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 15-18, 2003	FT MYERS, FLORIDA	Eastern Assoc Surg Trauma		head computed tomographic scan; intracranial pressure monitor; intensive care unit; closed head injury	PROGRESSIVE BRAIN INJURY; TRANSPORT; TRAUMA; MANAGEMENT; CHILDREN	Background. The purpose of this study was to determine whether serial computed tomographic (CT) scans of the head serve to prompt operative intervention. After the initial and 24- to 48-hour repeat scans, if no operative intervention has been performed, further serial scans are ordered on a planned basis or on the basis of changes in clinical status. Methods. This study is a retrospective review from January 1996 to December 2000. Results of the initial, follow-up, and serial CT scans were recorded for the 51 patients who met the inclusion/exclusion criteria. Results. One hundred seventeen (53.4%) serial CT scans were ordered. No urgent operative interventions were performed on the basis of the serial CT scans. Three scans (2.56%) led to nonurgent neurosurgical intervention. Conclusion. In severe head-injured patients who are nonneurosurgical candidates on the basis of initial and repeat CT scans, serial head CT scans have little clinical efficacy and do not lead to urgent operative intervention.	MSU, MERC Dept Surg, Spectrum Hlth Trauma Serv, Grand Rapids, MI USA	Figg, RE (corresponding author), 1688 Edith Ave,NE, Grand Rapids, MI 49505 USA.						Aldrich EF CL, 2001, SABISTON TXB SURG, P1529; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER P, 1993, NEUROSURG CLIN N AM, V3, P659; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Evans A, 1995, Am J Crit Care, V4, P106; Gruen JP, 1996, SURG CLIN N AM, V76, P905, DOI 10.1016/S0039-6109(05)70487-4; KANTER RK, 1992, PEDIATRICS, V90, P893; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; SMITH I, 1990, CRIT CARE MED, V18, P278, DOI 10.1097/00003246-199003000-00006; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597, DOI [10.1089/neu.2000.17.597, DOI 10.1089/NEU.2000.17.597]; VALADKA AB, 2000, TRAUMA, P377; ZWIENENBERG M, 2002, ACS SURG PRINCIPLES, P355; 1997, ADV TRAUMA LIFE SUPP	20	31	32	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1061	1064		10.1097/01.TA.0000096712.90133.5C			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	758TL	WOS:000187666200010	14676651				2021-06-18	
J	Cantin, B; Kwok, BWK; Chan, MCY; Valantine, HA; Oyer, PE; Robbins, RC; Hunt, SA				Cantin, B; Kwok, BWK; Chan, MCY; Valantine, HA; Oyer, PE; Robbins, RC; Hunt, SA			The impact of brain death on survival after heart transplantation: Time is of the essence	TRANSPLANTATION			English	Article							LUNG-TRANSPLANTATION; ACUTE REJECTION; DONORS; ACTIVATION; ORGANS	Background. It has been suggested that the modality of brain death and time from brain death until harvest impact survival and rejection after heart transplantation. Methods. Donor files from 475 adult heart-transplant recipients were examined. From these files, a total management time (time from incident leading to brain death until aortic cross clamp) was determined, and the cause of brain death was noted. Recipient characteristics, details of postoperative course, as well as survival were obtained from the Stanford University Medical Center Heart Transplantation Database. Results. Two hundred and thirty (48.4%) donors sustained traumatic injuries, 112 (23.6%) suffered a subarachnoid hemorrhage, and 102 (21.4%) died of a gunshot wound to the head. The modality of brain death did not influence medium and long-term survival. A management time longer than 72 hours was associated with poorer outcome of the heart-transplant recipients. There were significantly more treated rejection episodes in recipients whose donor sustained traumatic injuries. Conclusion. Modality of brain death does not impact survival but appears to influence rejection. Increased management time is associated with adverse survival trends in heart-transplant recipients.	Quebec Heart Inst, Quebec City, PQ, Canada; Natl Heart Ctr, Singapore, Singapore; Royal Alexandra Hosp Children, Edmonton, AB, Canada; Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA	Cantin, B (corresponding author), Hop Laval, 2725 Chemoin Ste Foy, St Foy, PQ G1V 4G5, Canada.						AYANWU AC, 2003, J HEART LUNG TRANSPL, V22, P281; Baroldi G, 1997, J HEART LUNG TRANSPL, V16, P994; Billingham M E, 1990, J Heart Transplant, V9, P587; Ciccone AM, 2002, J THORAC CARDIOV SUR, V123, P429, DOI 10.1067/mtc.2002.120732; COOPER DKC, 1989, ANN ROY COLL SURG, V71, P261; de Groot-Kruseman HA, 2001, J HEART LUNG TRANSPL, V20, P503, DOI 10.1016/S1053-2498(00)00325-9; Hosenpud JD, 2001, J HEART LUNG TRANSPL, V20, P805, DOI 10.1016/S1053-2498(01)00323-0; Mehra Mandeep R., 1999, Journal of Heart and Lung Transplantation, V18, P49; Plenz G, 2002, J AM COLL CARDIOL, V39, P1508, DOI 10.1016/S0735-1097(02)01791-6; Pratschke J, 1999, TRANSPLANTATION, V67, P343, DOI 10.1097/00007890-199902150-00001; Pratschke J, 2001, J AM SOC NEPHROL, V12, P2474, DOI 10.1681/ASN.V12112474; Pratschke J, 2000, ANN SURG, V232, P263, DOI 10.1097/00000658-200008000-00017; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Scott Robert L., 1999, Journal of Heart and Lung Transplantation, V18, P39; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; Tsai FC, 2002, J HEART LUNG TRANSPL, V21, P623, DOI 10.1016/S1053-2498(01)00425-9; WICOMB WN, 1986, J SURG RES, V40, P276, DOI 10.1016/0022-4804(86)90161-7; Wilhelm MJ, 2000, J HEART LUNG TRANSPL, V19, P414, DOI 10.1016/S1053-2498(00)00073-5; Wilhelm MJ, 2000, CIRCULATION, V102, P2426, DOI 10.1161/01.CIR.102.19.2426	21	31	33	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0041-1337			TRANSPLANTATION	Transplantation	NOV 15	2003	76	9					1275	1279		10.1097/01.TP.0000093445.50624.5A			5	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	744VG	WOS:000186653100001	14627902				2021-06-18	
J	Murphy, GM; Kremer, C; Rodrigues, H; Schatzberg, AF				Murphy, GM; Kremer, C; Rodrigues, H; Schatzberg, AF		Mirtazapine versus Paroxetine Stud	The apolipoprotein E epsilon 4 allele and antidepressant efficacy in cognitively intact elderly depressed patients	BIOLOGICAL PSYCHIATRY			English	Article						pharmacogenetics; antidepressant; apolipoprotein E; major depression; aging	E-DEFICIENT MICE; INCREASED NEURONAL DAMAGE; GLOBAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; DWELLING OLDER-ADULTS; LATE-LIFE DEPRESSION; MINI-MENTAL-STATE; TRANSGENIC MICE; DOUBLE-BLIND; E GENOTYPE	Background: Patients vary in response to antidepressant medications. Apolipoprotein E (APOE) genotype affects vulnerability to stress and risk for cognitive impairment. We sought to determine if the APOE epsilon4 allele influences response in geriatric depression to mirtazapine and paroxetine, two frequently prescribed antidepressants. We hypothesized that epsilon4 carriers would show impaired antidepressant response. Methods: The study was a double-blind, randomized, 8-week trial with a 16-week extension phase involving 246 cognitively intact patients aged 65 years or older with major depression. Patients were treated with mirtazapine 15-45 mg (n = 124) or paroxetine 20-40 mg (n = 122). The outcome measures were the Hamilton Depression Rating Scale, the Geriatric Depression Scale, and the Clinical Global Impression Scale. APOE genotype was determined by restriction isotyping. Results: Patients carrying the epsilon4 allele showed a rapid onset of mirtazapine action, whereas paroxetine-treated patients with the epsilon4 allele were slow to respond. This difference could not be attributed to dosage, compliance, severity of adverse events, ethnicity, baseline depression or cognition, gender, or age. Conclusions: The APOE epsilon4 allele may affect antidepressant treatment outcome, but the effect depends on the medication. Further studies should determine if this result applies to other samples and medications. (C) 2003 Society of Biological Psychiatry.	Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Neurosci Res Labs, Stanford, CA 94305 USA; Organon Pharmaceut Inc, W Orange, NJ USA	Schatzberg, AF (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Neurosci Res Labs, 401 Quarry Rd,Room 300, Stanford, CA 94305 USA.						ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Benkert O, 2000, J CLIN PSYCHIAT, V61, P656, DOI 10.4088/JCP.v61n0911; Bondi MW, 1995, NEUROLOGY, V45, P2203, DOI 10.1212/WNL.45.12.2203; Brown ES, 1999, NEUROPSYCHOPHARMACOL, V21, P474, DOI 10.1016/S0893-133X(99)00054-8; Caselli RJ, 2001, J NEUROL SCI, V189, P93, DOI 10.1016/S0022-510X(01)00577-9; Chapman S, 1998, J NEUROCHEM, V70, P708; Chapman S, 2000, NEUROSCIENCE, V97, P419, DOI 10.1016/S0306-4522(00)00087-7; Class CA, 1997, AM J GERIAT PSYCHIAT, V5, P339, DOI 10.1097/00019442-199700540-00009; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; deBoer T, 1996, J PHARMACOL EXP THER, V277, P852; deBoer T, 1996, J CLIN PSYCHIAT, V57, P19; DECHANT KL, 1991, DRUGS, V41, P225, DOI 10.2165/00003495-199141020-00007; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forsell Y, 1997, BIOL PSYCHIAT, V42, P898, DOI 10.1016/S0006-3223(96)00468-4; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gordon I, 1996, NEUROSCI LETT, V206, P212, DOI 10.1016/S0304-3940(96)12470-8; Guy W., 1976, DHEW PUBLICATION; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Leinonen E, 1999, INT CLIN PSYCHOPHARM, V14, P329, DOI 10.1097/00004850-199911000-00002; Leonard BE, 2000, J CLIN PSYCHIAT, V61, P12; LOUIS EJ, 1987, BIOMETRICS, V43, P805, DOI 10.2307/2531534; Mauricio M, 2000, AM J GERIAT PSYCHIAT, V8, P196, DOI 10.1176/appi.ajgp.8.3.196; Mulsant BH, 1999, J CLIN PSYCHIAT, V60, P16; Murphy GM, 1997, AM J PSYCHIAT, V154, P603; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; O'Hara R, 1998, J AM GERIATR SOC, V46, P1493, DOI 10.1111/j.1532-5415.1998.tb01532.x; Owens MJ, 2000, BIOL PSYCHIAT, V47, P842, DOI 10.1016/S0006-3223(99)00314-5; Peskind ER, 2001, NEUROLOGY, V56, P1094, DOI 10.1212/WNL.56.8.1094; Puolivali J, 2000, NEUROSCIENCE, V95, P353; Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728; Schatzberg AF, 2002, AM J GERIAT PSYCHIAT, V10, P541, DOI 10.1176/appi.ajgp.10.5.541; Schmand B, 1998, SOC PSYCH PSYCH EPID, V33, P21; Schule C, 2002, PSYCHOPHARMACOLOGY, V163, P95, DOI 10.1007/s00213-002-1148-5; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Small GW, 1999, AM J PSYCHIAT, V156, P1035; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stahl SM, 1998, J CLIN PSYCHIAT, V59, P5; Stahl SM, 2001, J CLIN PSYCHIAT, V62, P17; Walters G, 1999, J CLIN PSYCHIAT, V60, P21; Wheatley DP, 1998, J CLIN PSYCHIAT, V59, P306, DOI 10.4088/JCP.v59n0606; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	49	31	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	OCT 1	2003	54	7					665	673		10.1016/S0006-3223(03)00174-4			9	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	724RL	WOS:000185500500001	14512205				2021-06-18	
J	Warriner, EM; Rourke, BP; Velikonja, D; Metham, L				Warriner, EM; Rourke, BP; Velikonja, D; Metham, L			Subtypes of emotional and behavioural sequelae in patients with traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; CODE-TYPE CONGRUENCE; PSYCHIATRIC-DISORDERS; MMPI PROFILES; FOLLOW-UP; AXIS-I; REHABILITATION; ADJUSTMENT; SYMPTOMS	This study examined patterns of emotional and behavioural sequelae in 300 individuals who sustained a traumatic brain injury (TBI). Participants were obtained through the Adult Acquired Brain Injury Program at Chedoke Hospital in Hamilton, Ontario, based on the following inclusionary criteria: (1) single incident of TBI; (2) no history of additional neurological diseases; (3) time postinjury less than or equal to8.5 years; (4) WAIS-R FSIQ >85 and/or estimated reading skills above grade 5 level; and (5) valid Minnesota Multiphasic Personality Inventory (MMPI) profiles (i.e., F < 90, L < 66, and K < 66). MMPI profiles of these individuals, in randomly split samples of 150 per group, were subjected to a three-step cluster analytic approach. A six-cluster solution was adequately replicated across samples and across clustering techniques. The identified subtypes included profiles indicative of: (1) no concerns or normal functioning; (2) mild somatic and pain concerns; (3) mild internalizing difficulties; (4) marked disinhibition and extemalizing behavioural difficulties; (5) marked internalizing difficulties; and (6) marked somatic, internalizing, and externalizing behavioural disturbances. Members of the Externalized subtype were significantly younger in age than those in the other five subtypes, and more likely to be single than those in the Internalized subtype. Individuals in the Internalized subtype tended to be married, have longer times postaccident, and lower WAIS-R Verbal Intelligence Quotients than those comprising the Normal subtype.	Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; Yale Univ, Dept Child Psychiat, New Haven, CT USA; Yale Univ, Ctr Child Study, New Haven, CT USA; Chedoke Hosp, Adult Acquired Brain Injury Program, Hamilton, ON, Canada; McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada	Warriner, EM (corresponding author), 25 Brae Crest Dr, Stoney Creek, ON L8G 3A5, Canada.	emwarriner@hotmail.com					ALDENDERFER MS, 1984, CLUSTER ANAL SERIES; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ben-Yishay Y, 2000, REHABIL PSYCHOL, V45, P112, DOI 10.1037/0090-5550.45.2.112; BORNSTEIN RA, 1988, NEUROSURGERY, V23, P622, DOI 10.1227/00006123-198811000-00013; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Burke J M, 1989, Brain Inj, V3, P35, DOI 10.3109/02699058909008071; Butcher, 1989, MINNESOTA MULTIPHASI; BUTLER K, 1995, CHILD NEUROPSYCHOL, V3, P98; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DULLUM CM, 1988, J NERV MENT DIS, V176, P332; Emilien G, 1996, ACTA NEUROL BELG, V96, P89; Franulic A, 2000, BRAIN INJURY, V14, P431; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GRAHAM JR, 1991, J PERS ASSESS, V57, P205, DOI 10.1207/s15327752jpa5702_2; GRAHAM JR, 1977, MMPI PRACTICAL GUIDE; Graham JR., 2000, MMPI 2 ASSESSING PER; Greene RL, 1980, MMPI INTERPRETIVE MA; Gualtari CT, 1991, BRAIN INJURY, V5, P219; GURNS S, 1994, BRAIN INJURY, V8, P413, DOI 10.3109/02699059409150993; Hair Jr J.F., 1998, MULTIVAR DATA ANAL, P147; Hathaway Starke, 1967, MINNESOTA MULTIPHASI; HAYMANABELLO SE, IN PRESS J INT NEURO; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; *HLTH CAN, INJ STAT 1996 1997 C; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MACK JL, 1979, MMPI CLIN RES TRENDS, P53; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; Mamelak M, 2000, NEUROPSY NEUROPSY BE, V13, P125; MILLER HB, 1995, J CLIN EXP NEUROPSYC, V17, P58, DOI 10.1080/13803399508406581; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prigatano G. P., 1987, NEUROPSYCHOL REHABIL, P355; SAND P, 1972, REHABIL PSYCHOL, V19, P146; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; Taylor C.A., 1998, SEMINARS CLIN NEUROP, V3, P224; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wechsler D., 1981, WAIS R MANUAL WECHSL; WIRT RD, 1984, MULTIDIMENSIONAL DES; WOOTEN AJ, 1983, J CLIN PSYCHOL, V39, P392, DOI 10.1002/1097-4679(198305)39:3<392::AID-JCLP2270390313>3.0.CO;2-H	50	31	31	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2003	25	7					904	917		10.1076/jcen.25.7.904.16494			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	739WM	WOS:000186369800002	13680439				2021-06-18	
J	Dunn, L; Henry, J; Beard, D				Dunn, L; Henry, J; Beard, D			Social deprivation and adult head injury: a national study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							BRAIN-INJURY; DISABILITY; MORTALITY; EPIDEMIOLOGY; SEVERITY; SURVIVAL; SCOTLAND; DISEASE	Objectives: To establish the association between measures of social deprivation, mechanisms of injury, patterns of care, and outcome following closed head injury. Methods: All Scottish adult A&E attendees with closed head injury (AIS Head greater than or equal to 3) between July 1996 and December 2000 were studied. Results: Trauma was more common in individuals from more deprived areas. Within the trauma population head injury was relatively more common in patients from deprived areas; these individuals were more likely to sustain an isolated head injury as a result of an assault. Admission GCS was higher and normal physiology ( as assessed by the RTS) was more common in individuals from more deprived areas. Recorded co-morbidity was similar between the two groups with the exception of a history of alcohol or substance abuse which was more common among patients from more deprived areas. Similar proportions of patients from more deprived and less deprived areas were transferred to the Regional Neurosurgical Centre. For patients who were transferred directly from A&E, time to neurosurgical theatre was similar for both groups. Length of hospital and ITU stay was less in patients from more deprived areas. After adjusting for known predictors of outcome using logistic regression analysis, there was no significant difference in mortality between patients from more deprived and less deprived areas. Conclusions: Residing in a more deprived area is not associated with increased mortality from head injury among adults in Scotland. It is associated with different patterns of injury and a different process of care following presentation to hospital.	Univ Glasgow, Dept Neurosurg, Glasgow G12 8QQ, Lanark, Scotland; Royal Infirm, STAG, Edinburgh EH3 9YW, Midlothian, Scotland	Dunn, L (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland.	ltd1x@udcf.gla.ac.uk					Beard D, 2000, Health Bull (Edinb), V58, P118; CARSTAIRS V, 1992, DEPRIVATION HLTH SCO; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; KRAUS JF, 1993, HEAD INJURY; McEntegart A, 1997, ANN RHEUM DIS, V56, P410, DOI 10.1136/ard.56.7.410; McKinney PA, 1999, EUR J CANCER, V35, P1816, DOI 10.1016/S0959-8049(99)00173-2; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; MCLOONE P, 1994, CARSTAIRS SCORES SCO; *MED AAFA, 1985, ABBR INJ SCAL 1985 R; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; Morrison A, 1999, BRIT MED J, V318, P567, DOI 10.1136/bmj.318.7183.567; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; ROCKETT IRH, 1987, AM J PUBLIC HEALTH, V77, P1345, DOI 10.2105/AJPH.77.10.1345; SCHRIJVERS CTM, 1995, BRIT J CANCER, V72, P738, DOI 10.1038/bjc.1995.403; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; Stark AD, 2002, BRIT MED J, V324, P457, DOI 10.1136/bmj.324.7335.457; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Williamson LM, 2002, J EPIDEMIOL COMMUN H, V56, P285, DOI 10.1136/jech.56.4.285; YATES DW, 1992, BRIT MED J, V305, P737, DOI 10.1136/bmj.305.6856.737	25	31	31	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2003	74	8					1060	1064		10.1136/jnnp.74.8.1060			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	703MJ	WOS:000184283100013	12876234	Green Published, Bronze			2021-06-18	
J	Holtzer, R; Wegesin, DJ; Albert, SM; Marder, K; Bell, K; Albert, M; Brandt, J; Stern, Y				Holtzer, R; Wegesin, DJ; Albert, SM; Marder, K; Bell, K; Albert, M; Brandt, J; Stern, Y			The rate of cognitive decline and risk of reaching clinical milestones in Alzheimer disease	ARCHIVES OF NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL TESTS; PATIENT DEPENDENCE; DEMENTIA; PREDICTION; OUTCOMES	Background: Previous studies revealed that cognitive test scores were related to functional outcome in Alzheimer disease (AD). However, the relationship between the rate of cognitive decline at the initial disease phase and the risk of reaching clinical milestones in subsequent years has not yet been examined. Objective: To examine whether the rate of cognitive decline predicts the risk of reaching functional milestones in patients with probable AD. Design: A 5-year prospective study was conducted at 3 sites. Setting: Outpatient research and treatment centers. Participants: Patients diagnosed with probable AD (N = 236, mean age, 73 years; 59% women; mean years of education, 13). Main Outcome Measures: Modified Mini-Mental State Examination (mMMSE) scores were used to assess the rate of cognitive decline over time. Total dependence score and 2 clinical milestones: (1) the need to be dressed, groomed, and washed and (2) receiving a level of care equivalent to a placement in a health-related facility, were derived from the Dependence Scale. Results: General estimating equation analyses revealed that the rate of cognitive decline during the entire follow-up period was positively related to an increase in total dependence scores. Cox analyses showed that a fast rate of decline during the first year was related to an increase in the risk of reaching clinical milestones in subsequent years. Analyses controlled for age, sex, education, and baseline mMMSE scores. Conclusion: A fast rate of cognitive decline was associated with increasing risk of reaching clinical milestones in AD.	Columbia Univ Coll Phys & Surg, Segievsky Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Harvard Univ, Massachusetts Gen Hosp, Med Ctr, Dept Psychiat, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Med Ctr, Dept Neurol, Boston, MA 02129 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Stern, Y (corresponding author), Columbia Univ Coll Phys & Surg, Segievsky Ctr, 630 W 168th St,19th Floor,P&S Box 16, New York, NY 10032 USA.	ys11@columbia.edu		Brandt, Jason/0000-0001-7381-6244; Albert, Steven/0000-0001-6786-9956; Stern, Yaakov/0000-0001-7542-3241; Holtzer, Roee/0000-0001-6639-0724	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR 00645] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 07370] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000645] Funding Source: NIH RePORTER		American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; BarbergerGateau P, 1997, DISABIL REHABIL, V19, P175, DOI 10.3109/09638289709166525; BENYISHA.Y, 1970, J CONSULT CLIN PSYCH, V34, P436, DOI 10.1037/h0029366; Brickman AM, 2002, ARCH NEUROL-CHICAGO, V59, P1304, DOI 10.1001/archneur.59.8.1304; DRACHMAN DA, 1990, ARCH NEUROL-CHICAGO, V47, P851, DOI 10.1001/archneur.1990.00530080033007; Feyereisen P, 1999, NEUROPSYCHOL REHABIL, V9, P169, DOI 10.1080/713755598; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; GALASKO D, 1995, NEUROLOGY, V45, P1451, DOI 10.1212/WNL.45.8.1451; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GURLAND B, 1978, DEPENDENCY ELDERLY N; Hartman D. E., 1998, ECOLOGICAL VALIDITY, P113; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; JACOBS D, 1994, NEUROLOGY, V44, P1215, DOI 10.1212/WNL.44.7.1215; Kaplan E., 1983, BOSTON NAMING TEST; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORITZ DJ, 1995, AM J EPIDEMIOL, V141, P41, DOI 10.1093/oxfordjournals.aje.a117344; Njegovan V, 2001, J GERONTOL A-BIOL, V56, pM638, DOI 10.1093/gerona/56.10.M638; REED BR, 1989, GERONTOLOGIST, V29, P804, DOI 10.1093/geront/29.6.804; RICHARDS M, 1993, ALZ DIS ASSOC DIS, V7, P22, DOI 10.1097/00002093-199307010-00003; SCHERR PA, 1988, AM J EPIDEMIOL, V128, P1084; Searight HR, 1989, NEUROPSYCHOLOGY, V3, P135; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; STERN Y, 1987, Neurology, V37, P179; STERN Y, 1990, NEUROLOGY, V40, P8, DOI 10.1212/WNL.40.1.8; STERN Y, 1994, J GERONTOL, V49, pM216, DOI 10.1093/geronj/49.5.M216; Stern Y, 1996, J GERONTOL A-BIOL, V51, pM179, DOI 10.1093/gerona/51A.4.M179; STERN Y, 1993, ALZ DIS ASSOC DIS, V7, P3, DOI 10.1097/00002093-199307010-00002; VITALIANO PP, 1984, J GERONTOL, V39, P58, DOI 10.1093/geronj/39.1.58; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wedding D., 1983, CLIN NEUROPSYCHOLOGY, V5, P49; Wild Katherine V., 1995, Clinical Gerontologist, V15, P3, DOI 10.1300/J018v15n03_02; WRIOGHT RE, 2000, READING UNDERSTANDIN, P263	33	31	33	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	AUG	2003	60	8					1137	1142		10.1001/archneur.60.8.1137			6	Clinical Neurology	Neurosciences & Neurology	710RE	WOS:000184692600017	12925372	Bronze			2021-06-18	
J	McIntosh, AS; Janda, D				McIntosh, AS; Janda, D			Evaluation of cricket helmet performance and comparison with baseball and ice hockey helmets	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INJURIES; CONCUSSIONS; IMPACT	Background: Protective helmets in sport are important for reducing the risk of head and facial injury. In cricket and other sports with projectiles, national test standards control the minimum helmet performance. However, there are few field data showing if helmets are effective in reducing head injury. Objectives: (a) To examine the performance of cricket helmets in laboratory tests; (b) to examine performance with regard to test standards, game hazards, and helmet construction; (c) to compare and contrast these findings with baseball and ice hockey helmets. Methods: Impact tests were conducted on a selection of helmet models: five cricket, two baseball, and two ice hockey. Ball to helmet impacts at speeds of 19, 27, 36, and 45 m/s were produced using an air cannon and a Hybrid III dummy headform and neck unit. Free fall drop tests with a rigid headform on to a selection of anvils (flat rigid, flat deformable, and hemispherical rigid) were conducted. Resultant headform acceleration was measured and compared between tests. Results: At the lower speed impacts, all helmets produced a good reduction in headform acceleration, and thus injury risk. At the higher speed impacts, the effectiveness was less. For example, the mean maximum headform accelerations for all cricket helmets at each speed were: 67, 160, 316, and 438 for 19, 27, 36, and 45 m/s ball speeds respectively. Drop tests on to a hemispherical anvil produced the highest accelerations. The variation in performance increased as the magnitude of the impact energy increased, in both types of testing. Conclusions: The test method used for baseball helmets in which the projectile is fired at the helmet may be superior to helmet drop tests. Cricket helmet performance is satisfactory for low speed impacts, but not for impacts at higher, more realistic, speeds. Baseball and ice hockey helmets offer slightly better relative and absolute performance at the 27 m/s ball and puck impacts.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Inst Prevent Sports Med, Ann Arbor, MI USA	McIntosh, AS (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.						*AM SOC TEST MAT, 1999, 1045B99 ASTM F; *AUSTR NZ STAND, 1997, 20631996 ASNZS; *AUSTR NZ STAND, 1997, 449911997 ASNZS; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; British Standard, 1998, 79281998 BS; *CAN STAND, 1990, CANCSAZ2621M90; *CAN STAND ASS, 2001, D1132M89R2001 CANCSA; Cheng TL, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.3.e32; Finch C, 1998, BRIT J SPORT MED, V32, P220, DOI 10.1136/bjsm.32.3.220; Finch CF, 1999, SPORTS MED, V28, P263, DOI 10.2165/00007256-199928040-00004; Glazier PS, 2000, J SPORT SCI, V18, P1013; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; HAY G, 1993, BIOMECHANICS SPORTS, P198; HIRSCH AE, 1970, P 14 STAPP CAR CRASH, P144; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; *INT STAND ORG, 1996, 10256 ISO; McIntosh A, 1995, P 39 STAPP CAR CRASH; National Operating Committee on Standards for Athletic Equipment Baseball Helmet Task Force, 1991, STAND METH IMP TEST; NEWMAN J, 1980, P 24 STAPP CAR CRASH, P701; NUSHOLTZ GS, 1984, P 28 STAPP CAR CRASH, P41; Pasternack JS, 1996, PEDIATRICS, V98, P445; Portus MR, 2000, J SPORT SCI, V18, P999, DOI 10.1080/026404100446801; Powell JW, 2001, J ATHL TRAINING, V36, P307; Stretch RA, 2000, J SPORT SCI, V18, P959, DOI 10.1080/026404100446766; Stretch RA, 2000, J SPORT SCI, V18, P931, DOI 10.1080/026404100446766	25	31	31	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	AUG 1	2003	37	4					325	330		10.1136/bjsm.37.4.325			6	Sport Sciences	Sport Sciences	706VB	WOS:000184474800014	12893718	Bronze, Green Published			2021-06-18	
J	Steiner, LA; Johnston, AJ; Chatfield, DA; Czosnyka, M; Coleman, MR; Coles, JP; Gupta, AK; Pickard, JD; Menon, DK				Steiner, LA; Johnston, AJ; Chatfield, DA; Czosnyka, M; Coleman, MR; Coles, JP; Gupta, AK; Pickard, JD; Menon, DK			The effects of large-dose propofol on cerebrovascular pressure autoregulation in head-injured patients	ANESTHESIA AND ANALGESIA			English	Article							CEREBRAL BLOOD-FLOW; TRANSIENT HYPEREMIC RESPONSE; CARBON-DIOXIDE REACTIVITY; TRAUMATIC BRAIN INJURY; HYPERVENTILATION; CIRCULATION; SUPPRESSION; RELEVANCE; INFUSION; VELOCITY	In healthy individuals, cerebrovascular pressure autoregulation is preserved or even improved when propofol is infused. We examined the effect of an increase in propofol plasma concentration on pressure autoregulation in 10 head-injured patients. Using target-controlled infusions, the static rate of autoregulation was determined at a moderate (2.3 +/- 0.4 mug/mL) and a large (4.3 +/- 0.04 mug/mL) plasma target concentration of propofol. Using norepinephrine to control cerebral perfusion pressure, transcranial Doppler measurements from the middle cerebral artery were made at a cerebral perfusion pressure of 70 and 85 mm Hg at each propofol concentration. Middle cerebral artery flow velocities at the large propofol concentration were significantly lower than at the moderate concentration, without any concurrent increase in arterio-jugular difference in oxygen content, a finding compatible with maintained flow-metabolism coupling. Despite this, static rate of autoregulation decreased significantly from 54% +/- 36% to 28% +/- 35% (P = 0.029). Our data suggest that after head injury, the cerebrovascular effects of propofol are different from those observed in healthy individuals. We propose that large doses of propofol should be used cautiously in head-injured patients, because there is the potential to increase the injured brain's vulnerability to secondary insults.	Addenbrookes Hosp, Acad Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England	Steiner, LA (corresponding author), Addenbrookes Hosp, Acad Neurosurg, Box 167, Cambridge CB2 2QQ, England.		Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011		Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Brauer P, 1998, J NEUROSURG ANESTH, V10, P80, DOI 10.1097/00008506-199804000-00003; CHILLON JM, 2002, CEREBRAL BLOOD FLOW, P395; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Ederberg S, 1998, ANESTH ANALG, V86, P1201, DOI 10.1097/00000539-199806000-00011; Harrison JM, 1999, BRIT J ANAESTH, V83, P839, DOI 10.1093/bja/83.6.839; Kazama T, 1999, ANESTHESIOLOGY, V90, P1517, DOI 10.1097/00000542-199906000-00004; Kinoshita H, 1998, BRIT J ANAESTH, V81, P766, DOI 10.1093/bja/81.5.766; LAM AM, 1995, ANESTHESIOLOGY, V82, P1536, DOI 10.1097/00000542-199506000-00035; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STEINER LA, 2002, J NEUROTRAUM, V19, P1301; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; Tibble RK, 2001, ANESTH ANALG, V93, P171	25	31	31	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2003	97	2					572	576		10.1213/01.ANE.0000070234.17226.B0			5	Anesthesiology	Anesthesiology	704RW	WOS:000184354600047	12873955				2021-06-18	
J	Altura, BM; Gebrewold, A; Zhang, AM; Altura, BT				Altura, BM; Gebrewold, A; Zhang, AM; Altura, BT			Low extracellular magnesium ions induce lipid peroxidation and activation of nuclear factor-kappa B in canine cerebral vascular smooth muscle: possible relation to traumatic brain injury and strokes	NEUROSCIENCE LETTERS			English	Article						Mg2+ deficits; vascular smooth muscle; nuclear transcription factor kappa B; I kappa B; reactive oxygen species; lipid peroxidation; stroke; traumatic brain injury	P-31-NMR IN-VIVO; ALCOHOL; CALCIUM; PLASMA; MG2+; RATS	The present study was designed to test the hypothesis that administration of low extracellular levels of magnesium ions ([Mg2+](o)) to primary cultured cerebral vascular smooth muscle cells will cause lipid peroxidation, degradation Of IbetaB-alpha, and activation of nuclear transcription factor kappa B (NF-kappaB) in cultured cerebral vascular smooth muscle cells. Low [Mg2+](o) (0, 0.15, 0.3 and 0.48 mM) resulted in concentration-dependent rises in malondialdehyde (MDA) in as little as 3 h after exposure to low [Mg2+](o), rising to levels 3-12 X normal after 18-24 h; the lower the [Mg2+](o), the higher the MDA level. Using electrophoretic mobility shift assays and specific antibodies, low [Mg2+](o) caused two DNA-binding proteins (p50, p65) to rise in nuclear extracts in a concentration-dependent manner. High [Mg2+](o) (i.e. 4.8 mM) downregulated p50 and p65. Using a rabbit antibody, IkappaB phosphorylation (and degradation) was stimulated by low [Mg2+](o) (in a concentration-dependent manner) and inhibited by a low concentration of the NF-kappaB inhibitor, pyrrolidine dithiocarbamate. These new biochemical and molecular data indicate that low [Mg2+](o), in concentrations found in the blood of patients, after traumatic brain injury (TBI) and diverse types of strokes, can elicit rapid lipid peroxidation and activation of NF-kappaB in cerebral vascular smooth muscle cells. The present results, when viewed in light of other recently published data, suggest that low [Mg2+](o)-induced lipid peroxidation and activation of NF-kappaB play important roles in TBI and diverse types of strokes. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.	SUNY Downstate Med Ctr, Dept Physiol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Ctr Cardiovasc & Muscle Res, Brooklyn, NY 11203 USA	Altura, BM (corresponding author), SUNY Hlth Sci Ctr, Box 31,450 Clarkson Ave, Brooklyn, NY 11203 USA.				NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA-08674] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA008674] Funding Source: NIH RePORTER		Altura BM, 1998, ALCOHOL, V15, P181, DOI 10.1016/S0741-8329(97)00107-9; Altura BM, 1997, BBA-MOL CELL RES, V1358, P1, DOI 10.1016/S0167-4889(97)00077-3; ALTURA BM, 1994, ALCOHOL CLIN EXP RES, V18, P1057, DOI 10.1111/j.1530-0277.1994.tb00082.x; ALTURA BM, 1995, ALCOHOL, V12, P131, DOI 10.1016/0741-8329(94)00072-7; ALTURA BM, 1997, MAGNESIUM CURRENT ST, P385; ALTURA BM, 1995, SCI AM SCI MED, V2, P28; Altura BT, 1997, NEUROSCI LETT, V230, P37, DOI 10.1016/S0304-3940(97)00471-0; ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; BAICHWAL VR, 1997, PHARM NEWS, V4, P17; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.physiol.53.1.259; GUTTERIDGE JMC, 1978, ANAL BIOCHEM, V91, P250, DOI 10.1016/0003-2697(78)90838-2; Kinoshita Y, 2001, J NEUROTRAUM, V18, P435, DOI 10.1089/089771501750171038; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; Morrill GA, 1997, FEBS LETT, V408, P191, DOI 10.1016/S0014-5793(97)00420-1; Regan RF, 1998, J NEUROCHEM, V70, P77; Siegel G.J., 1999, BASIC NEUROCHEMISTRY; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; Yang ZW, 2000, PFLUG ARCH EUR J PHY, V439, P240, DOI 10.1007/s004240050935	23	31	37	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAY 8	2003	341	3					189	192		10.1016/S0304-3940(03)00134-4			4	Neurosciences	Neurosciences & Neurology	669HW	WOS:000182346700005	12697280				2021-06-18	
J	Bentzer, P; Venturoli, D; Carlsson, O; Grande, PO				Bentzer, P; Venturoli, D; Carlsson, O; Grande, PO			Low-dose prostacyclin improves cortical perfusion following experimental brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						blood flow; edema; endothelium; microvascular; permeability; surface area	CEREBRAL BLOOD-FLOW; HEAD-INJURY; HEMORRHAGIC HYPOTENSION; CAPILLARY PERFUSION; SKELETAL-MUSCLE; PERMEABILITY; ISCHEMIA; ILOPROST; EDEMA; TRANSPORT	It was recently shown that prostacyclin at a low dose reduces cortical cell death following brain trauma in the rat. Conceivably, prostacyclin with its vasodilatory, anti-aggregatory, anti-adhesive and permeability-reducing properties improved a compromised perfusion caused by post-traumatic vasoconstriction, microthrombosis and increased microvascular permeability. The objective of the present study was therefore to investigate the hemodynamic effects of low-dose prostacyclin in the traumatized rat cortex. Following a fluid percussion brain injury or a sham procedure, animals were treated with a continuous intravenous infusion of prostacyclin of 1 or 2 ng (.) kg(-1 .) min(-1), or vehicle. Blood flow ([C-14]-iodoantipyrine), the permeability-surface area product (PS) for [Cr-51]-EDTA, and brain water content were measured after 3 or 48 h of treatment. Blood flow values in the injured cortex were transiently reduced to 0.42 +/- 0.2 mL (.) min(-1) in the vehicle group 3 h following trauma from a corresponding value of about 1.6 mL (.) min(-1) in the sham group, with recovery of blood flow after 48 h. Prostacyclin treatment caused a dose-dependent increase in blood flow which reached statistical significance 48 h following trauma. Brain water content and PS increased in the injured cortex post trauma and the higher dose of prostacyclin increased these parameters further at 48 h compared to the vehicle group (p < 0.05). The latter effects of prostacyclin cannot be attributed to an increase in permeability, as prostacyclin did not influence PS or brain water content following sham trauma. In fact prostacyclin has been shown to have permeability-decreasing properties. We conclude that prostacyclin improves cortical perfusion following brain trauma. The simultaneous aggravation of brain edema can be explained by an increased surface area, perhaps in combination with increased capillary hydrostatic pressure.	Lund Univ, Dept Physiol Sci, SE-22184 Lund, Sweden; Lund Univ, Dept Anesthesia & Intens Care, SE-22184 Lund, Sweden; Univ Lund Hosp, S-22185 Lund, Sweden	Bentzer, P (corresponding author), Lund Univ, Dept Physiol Sci, BMC F11, SE-22184 Lund, Sweden.	peter.bentzer@mphy.lu.se					Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Bentzer P, 1999, J VASC RES, V36, P516, DOI 10.1159/000025695; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BLASBERG RG, 1983, J CEREBR BLOOD F MET, V3, P8, DOI 10.1038/jcbfm.1983.2; BLEBEA J, 1990, J VASC SURG, V12, P657, DOI 10.1067/mva.1990.25129; CRUMRINE RC, 1991, J CEREBR BLOOD F MET, V11, P272, DOI 10.1038/jcbfm.1991.59; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ERLANSSON M, 1991, PROSTAGLANDINS, V41, P157, DOI 10.1016/0090-6980(91)90028-E; FENSTERMACHER JD, 1981, PHARMACOL THERAPEUT, V14, P217, DOI 10.1016/0163-7258(81)90062-0; FENSTERMACHER JD, 1984, EDEMA, P383; FUKUYAMA H, 1993, NEUROL RES, V15, P169; GOROG P, 1986, HAEMOSTASIS, V16, P337; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; Heinert G, 1999, ACTA PHYSIOL SCAND, V166, P183; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HIGGS EA, 1978, PROSTAGLANDINS, V16, P17, DOI 10.1016/0090-6980(78)90197-1; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Jiang XW, 1998, AM J RESP CRIT CARE, V158, P1669, DOI 10.1164/ajrccm.158.5.9609082; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kuschinsky W, 1996, PFLUG ARCH EUR J PHY, V432, pR42; LO WD, 1987, STROKE, V18, P150, DOI 10.1161/01.STR.18.1.150; Maeda T, 1997, ACT NEUR S, V70, P102; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MCCALDEN TA, 1984, LIFE SCI, V34, P1801, DOI 10.1016/0024-3205(84)90672-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MULLER B, 1987, PROSTA LEUKOTR MED, V29, P187, DOI 10.1016/0262-1746(87)90008-4; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; ORFEO T, 1994, J TRAUMA, V37, P347, DOI 10.1097/00005373-199409000-00003; PLUTA R, 1994, ACTA NEUROCHIR, P303; Raczka E, 1999, BRIT J PHARMACOL, V126, P1325, DOI 10.1038/sj.bjp.0702426; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SARNA GS, 1977, BRAIN RES, V138, P550, DOI 10.1016/0006-8993(77)90692-8; SAWA Y, 1988, CIRCULATION, V78, P191; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHIMA K, 1995, ACTA NEUROCHIR, V137, P89, DOI 10.1007/BF02188788; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1984, J CEREBR BLOOD F MET, V4, P107, DOI 10.1038/jcbfm.1984.14; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Taoka Y, 1997, J NEUROSURG, V86, P1007, DOI 10.3171/jns.1997.86.6.1007; TERAWAKI T, 1998, EUR J PHARMACOL, V152, P63; VILLRINGER A, 1994, CIRC RES, V75, P55, DOI 10.1161/01.RES.75.1.55; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2; WU NZ, 1992, MICROVASC RES, V44, P334, DOI 10.1016/0026-2862(92)90092-4; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	56	31	32	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2003	20	5					447	461		10.1089/089771503765355522			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682MY	WOS:000183096900005	12803977				2021-06-18	
J	Reichard, RR; White, CL; Hladik, CL; Dolinak, D				Reichard, RR; White, CL; Hladik, CL; Dolinak, D			Beta-amyloid precursor protein staining of nonaccidental central nervous system injury in pediatric autopsies	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid precursor protein; brain; diffuse axonal injury; immunohistochemistry; pediatric	DIFFUSE AXONAL INJURY; INFLICTED HEAD-INJURY; SHAKEN-BABY SYNDROME; BRAIN TRAUMA; NEUROPATHOLOGY; INFANTS; DAMAGE; DIAGNOSIS	Immunohistochemical staining for beta-amyloid precursor protein (betaAPP) is a well-established marker of traumatic axonal injury in adults. Recent studies have used similar techniques to evaluate nonaccidental central nervous system injury (NAI) in infants and young children. In this prospective study, we report the results of betaAPP immunohistochemistry on the brain and spinal cord in 28 pediatric cases of NAI. betaAPP-immunoreactive axons were present in 27/28 cases. Vascular axonal injury (VAI) due to brain swelling and secondary vascular compromise was the most common pattern of betaAPP immunoreactivity and was detected in 22 of 28 cases. Traumatic axonal injury was detected in 19/28 cases, although only eight of these cases showed brainstem staining, thus fulfilling the criteria for the diagnosis of diffuse traumatic axonal injury (dTAI). TAI and VAI were both present in 16/28 cases. Isolated TAI and VAI occurred in three and five cases, respectively. All children with isolated VAI were <18 months of age. An additional finding highlighted by PAPP immunostaining was a penumbra of axonal injury adjacent to focal lesions, such as lacerations. We conclude that betaAPP immunohistochemistry aids in documenting trauma in nonaccidental central nervous system injury in infants and young children and that VAI is a common finding.	SW Inst Forens Sci, Dallas, TX USA; Univ Texas, SW Med Sch, Dept Pathol, Immunohistochem Labs, Dallas, TX 75230 USA; Univ Texas, SW Med Sch, Dept Pathol, Neuropathol Lab, Dallas, TX 75230 USA	Reichard, RR (corresponding author), 922 Varian Way, Palo Alto, CA 94304 USA.		White, Charles L/AAJ-1858-2021	White, Charles L/0000-0002-3870-2804			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Dolinak D, 2000, NEUROPATH APPL NEURO, V26, P448, DOI 10.1046/j.1365-2990.2000.00273.x; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, V1, P197; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; Reichard RR, 2003, J NEUROPATH EXP NEUR, V62, P237, DOI 10.1093/jnen/62.3.237; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185	20	31	31	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2003	20	4					347	355		10.1089/089771503765172309			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	673YY	WOS:000182609900004	12866814				2021-06-18	
J	Waller, PF; Hill, EM; Maio, RF; Blow, FC				Waller, PF; Hill, EM; Maio, RF; Blow, FC			Alcohol effects on motor vehicle crash injury	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						ethanol; wounds and injury; accidents; traffic; alcohol-related disorders; public health	TRAUMATIC BRAIN INJURY; HEMORRHAGIC-SHOCK; ETHANOL POTENTIATION; SEVERITY SCORE; INTOXICATION; EMERGENCY; SYSTEM; ABUSE; MORTALITY; DRUGS	Context: Although alcohol is frequently present in injured patients, whether it exacerbates injury and whether tolerance to alcohol changes such a relationship is less clear. Most clinical studies do not consider other important predictors of injury, making interpretation of their findings problematic. Objective: To examine alcohol's role in injuries, taking into account other important factors, and to examine the effect of tolerance, if any. Design: Prospective cohort study. Setting: University hospital and community hospital emergency departments and morgue. Patients: 1362 Motor Vehicle Crash patients age greater than or equal to18, treated and released, admitted, and deceased. Main Outcome Measures: Excess injury measured by Injury Severity Scale (ISS) 90, Weighted Revised Trauma Score (WRTS), and G-Score. Results: Using regression analysis, the best predictors of injury severity were vehicle crush (TAD), safety belt use, and their interaction, and age. Alcohol use further predicted injury. Using the final regression model, the effect of alcohol was to increase ISS90, on average, by about 30% (from a predicted ISS90 of 5.1 to 6.8, all else being equal). The adjusted odds ratio for serious injury (ISS90>15), was 1.59 for a patient with a positive blood alcohol concentration (alc+) compared to a alc-patient. This potentiating effect is seen even for patients with low levels of alcohol (<22mmol/liter; <0.100 BAC) but is not linear with increasing alcohol level. Tolerance to alcohol did not affect the potentiation of injury by alcohol. Conclusion: When other relevant variables are considered, alcohol increases injury, but the effects of. alcohol level and alcohol tolerance are less clear. These findings have important implications for injury prevention, treatment, and research.	Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; Univ Detroit Mercy, Dept Psychol, Detroit, MI 48221 USA; Univ Michigan, Dept Emergency Med, Injury Res Ctr, Ann Arbor, MI 48109 USA	Maio, RF (corresponding author), 300 N Ingalls Bldg,Room 2D06,Box 0437, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA009110] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA09110] Funding Source: Medline		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDERSEN JA, 1990, J TRAUMA, V30, P415, DOI 10.1097/00005373-199030040-00007; Anderson T E, 1986, Cent Nerv Syst Trauma, V3, P183; [Anonymous], 1990, ABBR INJ SCAL AIS 19; ANTTI-POIKA I, 1986, Injury, V17, P359, DOI 10.1016/0020-1383(86)90163-4; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BRODNER RA, 1981, J TRAUMA, V21, P124, DOI 10.1097/00005373-198102000-00005; CHAMPION HR, 1990, J TRAUMA, V30, P539, DOI 10.1097/00005373-199005000-00003; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHEN B, 1995, J TRAUMA, V38, P228, DOI 10.1097/00005373-199502000-00014; CHERPITEL CJ, 1995, ANN EMERG MED, V26, P158, DOI 10.1016/S0196-0644(95)70146-X; CHERPITEL CJS, 1988, BRIT J ADDICT, V83, P1299; CHERPITEL CJS, 1988, ALCOHOL CLIN EXP RES, V12, P105, DOI 10.1111/j.1530-0277.1988.tb00141.x; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; CREWS FT, 1993, NIAAA RES MONOGRAPH, V22, P355; DeCrescito V, 1974, Surg Forum, V25, P438; DESIDERIO MA, 1988, J TRAUMA, V28, P765, DOI 10.1097/00005373-198806000-00007; DILUZIO NR, 1969, EXP MOL PATHOL, V11, P38, DOI 10.1016/0014-4800(69)90069-0; DISCHINGER PC, 1988, P AM ASS AUTOMOTIVE, V32, P299; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FELL JC, 1990, ALCOHOL DRUGS DRIVIN, V9, P97; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; GARRISON HG, 1984, ANN EMERG MED, V13, P26, DOI 10.1016/S0196-0644(84)80379-0; GETTLER DT, 1963, ANN SURG, V158, P151, DOI 10.1097/00000658-196308000-00001; Grant R J, 1998, Prehosp Emerg Care, V2, P23, DOI 10.1080/10903129808958835; Hopkins K. D., 1996, STAT METHODS ED PSYC; House EG, 1982, P AM ASS AUT MED ARL, P349; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; JACOBSON B, 1983, J TRAFFIC MED, V11, P28; JAMES JJ, 1984, MIL MED, V149, P369; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LIEDTKE AJ, 1975, AM J CARDIOL, V35, P243, DOI 10.1016/0002-9149(75)90008-9; MACKENZIE EJ, 1989, J TRAUMA, V29, P757, DOI 10.1097/00005373-198906000-00011; Maio RF, 1997, ACAD EMERG MED, V4, P256, DOI 10.1111/j.1553-2712.1997.tb03545.x; MAIO RF, 1992, ACCIDENT ANAL PREV, V24, P631, DOI 10.1016/0001-4575(92)90015-B; MALT SH, 1971, J TRAUM, V11, P76, DOI 10.1097/00005373-197101000-00007; MCCALL D, 1989, BIOCHEM PHARMACOL, V38, P2593, DOI 10.1016/0006-2952(89)90543-1; MOSS LK, 1959, SURG FORUM, V10, P390; *NAT HIGHW TRAFF S, 2000, TRAFF SAF FACTS 1999; *NAT SAF COUNC, 1984, VEH DAM SCAL TRAFF A; NICHOLAS GG, 1980, J TRAUMA, V20, P58, DOI 10.1097/00005373-198020010-00009; Nicholl J, 1997, BRIT MED J, V315, P1349, DOI 10.1136/bmj.315.7119.1349; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; Nordmann R, 1996, ANN GASTROENT HEPATO, V32, P128; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; PERSSON LI, 1978, ACTA NEUROL SCAND, V57, P405; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Ridella S A, 1986, Cent Nerv Syst Trauma, V3, P195; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; Robins L, 1989, NIMH DIAGNOSTIC INTE; SELIGMAN ML, 1977, LIPIDS, V12, P945, DOI 10.1007/BF02533316; SIGGINS GR, 1996, PHARM TOXIC, P175; SODERSTROM CA, 1984, ALCOHOL CLIN EXP RES, V8, P269, DOI 10.1111/j.1530-0277.1984.tb05509.x; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; SODERSTROM CA, 1987, 31 P AM ASS AUT MED, P79; STEWART JR, 1988, 32 ANN P ASS ADV AUT, P319; THAL ER, 1985, ARCH SURG-CHICAGO, V120, P708; WALLER J, 1987, 31 P AM ASS AUT MED, P95; WALLER JA, 1995, J TRAUMA, V38, P325, DOI 10.1097/00005373-199503000-00002; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; Waller PF, 1997, ACCIDENT ANAL PREV, V29, P817, DOI 10.1016/S0001-4575(97)00051-1; WALLER PF, 1989, 33 ANN P ASS ADV AUT, P1; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WARREN RA, 1981, 25TH ANN P AM ASS AU, P133; WEBB WR, 1966, ANN SURG, V163, P811, DOI 10.1097/00000658-196606000-00001; ZINK BJ, 1988, ANN EMERG MED, V17, P15, DOI 10.1016/S0196-0644(88)80496-7; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7; ZINK BJ, 1988, CIRC SHOCK, V24, P19; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	74	31	34	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0145-6008			ALCOHOL CLIN EXP RES	Alcoholism (NY)	APR	2003	27	4					695	703		10.1097/01.ALC.0000062758.18918.7C			9	Substance Abuse	Substance Abuse	669CT	WOS:000182334900015	12711933				2021-06-18	
J	Wang, ND; Stevens, MH; Doty, DB; Hammond, EH				Wang, ND; Stevens, MH; Doty, DB; Hammond, EH			Blunt chest trauma: An experimental model for heart and lung contusion	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						blunt chest trauma; cardiac contusion; pulmonary contusion	CARDIAC TRAUMA; MYOCARDIAL CONTUSION; INJURY	Background: Blunt chest trauma is an important clinical problem leading to injury of the heart and lungs that may be fatal. Experimental models in large animals have been developed previously. This study was aimed at developing a small-animal (rat) model for the purpose of evaluating blunt chest trauma. Methods: Blunt trauma was delivered to the left side of the chest in rats by a captive bolt handgun. The gun was modified so that the amount of energy delivered to the chest wall could be adjusted. The injury energy varied from 1.7 to 6.8 J. Thirty-eight experiments in adult rats were performed. Electrocardiographic monitoring was performed continuously to determine cardiac rhythm. Gross and histologic examination of lungs and heart was performed at the time of death resulting from injury or euthanasia up to 13 days after injury. Results: Some form of cardiac arrhythmia accompanied blunt chest trauma in every case. Serious ventricular arrhythmia (tachycardia or fibrillation) was nearly always fatal (15 of 16 cases), but gross or histologic evidence of cardiac injury was present in only 31% of fatal cases. Lung injury (often bilateral) as shown by atelectasis and hemorrhage into the parenchyma or airway was found in 93% of the experiments when medium range energy force was applied. Conclusion: This study has established a useful model for the study of blunt chest trauma in a small animal (rat). Blunt chest trauma is associated with cardiac arrhythmia, which may be fatal. Injury to the heart may not correlate with serious cardiac arrhythmia resulting in death, lending credence to the concept of cardiac concussion or commotio cordis. Lung contusion is always more obvious than morphologic injury to the heart.	Latter Day St Hosp, Dept Surg, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Dept Pathol, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Trauma Serv, Salt Lake City, UT 84143 USA	Doty, DB (corresponding author), 324 10th Ave, Salt Lake City, UT 84130 USA.						Allen GS, 1996, AM SURGEON, V62, P895; BIFFL WL, 1994, AM J SURG, V169, P523; BRATHWAITE CEM, 1990, ANN SURG, V212, P701, DOI 10.1097/00000658-199012000-00008; Crown LA, 1997, AM FAM PHYSICIAN, V55, P2467; DOTY DB, 1974, ANN SURG, V180, P452, DOI 10.1097/00000658-197410000-00010; FEGHALI NT, 1995, CHEST, V108, P1673, DOI 10.1378/chest.108.6.1673; FILDES JJ, 1995, AM SURGEON, V61, P832; GUEST TM, 1995, JAMA-J AM MED ASSOC, V273, P1945, DOI 10.1001/jama.273.24.1945; Maenza RL, 1996, AM J EMERG MED, V14, P237, DOI 10.1016/S0735-6757(96)90165-5; Michalodimitrakis EN, 1997, AM J FOREN MED PATH, V18, P282, DOI 10.1097/00000433-199709000-00010; MOSELEY RV, 1970, J TRAUM, V10, P673, DOI 10.1097/00005373-197008000-00008; PARMLEY LF, 1958, CIRCULATION, V18, P371, DOI 10.1161/01.CIR.18.3.371; RuDusky BM, 1997, ANGIOLOGY, V48, P929, DOI 10.1177/000331979704801012; SHORR RM, 1987, ANN SURG, V206, P200, DOI 10.1097/00000658-198708000-00013	14	31	38	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2003	54	4					744	748		10.1097/01.TA.0000052362.40754.F2			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	675AT	WOS:000182671400024	12707538				2021-06-18	
J	Verbois, SL; Scheff, SW; Pauly, JR				Verbois, SL; Scheff, SW; Pauly, JR			Chronic nicotine treatment attenuates alpha 7 nicotinic receptor deficits following traumatic brain injury	NEUROPHARMACOLOGY			English	Article						alpha 7; bungarotoxin; cholinergic; traumatic brain injury; nicotinic receptors; nicotine	CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; ACETYLCHOLINE-RECEPTORS; HEAD-INJURY; RAT-BRAIN; SUBTYPES; BINDING; DYSFUNCTION; FOREBRAIN; MEMORY	Traumatic brain injury (TBI) often causes a persistent and debilitating impairment of cognitive function. Although the neurochemical basis for TBI-induced cognitive dysfunction is not well characterized, some studies suggest prominent involvement of the CNS cholinergic system. Previous studies from our laboratories have shown that alpha7* nicotinic cholinergic receptors (nAChrs) are especially vulnerable to the pathophysiological effects of TBI. Hippocampal and cortical alpha-[I-125]-bungarotoxin (BTX) expression of a7* nAChrs is significantly decreased in many brain regions following TBI and this reduction persists for at least 3 weeks following injury. In the present study we evaluated whether chronic nicotine infusion Could attenuate TBI-induced deficits in alpha7* nAChr expression. Male Sprague-Dawley rats were sham-operated, or subjected to mild or moderate Unilateral cortical contusion injury. Immediately following brain injury. osmotic mini-pumps that delivered chronic saline or nicotine (0.125 or 0.25 mg/kg/h) were implanted. The animals were euthanatized and the brains prepared for nAChr quantitative autoradiography, 7 days following surgery. Brain injury caused significant decreases in BTX binding in several regions of the hippocampus, TBI-induced deficits in alpha7* nAChr density were reversed in four of the six hippocampal brain regions evaluated following chronic nicotine administration. If TBI-induced deficits in a7* nAChr expression play a role in post-injury cognitive impairment, pharmacological treatments which restore nAChr binding to control levels may be therapeutically useful. (C) 2003 Elsevier Science Ltd. All rights reserved.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Pauly, JR (corresponding author), Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828, R01NS042196] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42196, NS39828] Funding Source: Medline		Alkondon M, 2000, NEUROPHARMACOLOGY, V39, P2726, DOI 10.1016/S0028-3908(00)00156-8; Amenta F, 2001, MECH AGEING DEV, V122, P2025, DOI 10.1016/S0047-6374(01)00310-4; Attaway CM, 1999, PHYSIOL BEHAV, V67, P421, DOI 10.1016/S0031-9384(99)00081-5; Blokland A, 1995, BRAIN RES REV, V21, P285, DOI 10.1016/0165-0173(95)00016-X; Buisson B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; Burnashev N, 1998, CELL CALCIUM, V24, P325, DOI 10.1016/S0143-4160(98)90056-2; CORTES R, 1984, J NEURAL TRANSM, V60, P169, DOI 10.1007/BF01249092; Dani JA, 2001, BIOL PSYCHIAT, V49, P166, DOI 10.1016/S0006-3223(00)01011-8; Decker MW, 1997, J PHARMACOL EXP THER, V283, P247; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DUNNETT SB, 1993, PROG BRAIN RES, V98, P413; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jenkins LW, 1999, BRAIN RES, V817, P132, DOI 10.1016/S0006-8993(98)01237-2; Ke L, 1998, J PHARMACOL EXP THER, V286, P825; Lavine N, 1997, J COMP NEUROL, V380, P175, DOI 10.1002/(SICI)1096-9861(19970407)380:2<175::AID-CNE3>3.0.CO;2-0; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; Lukas RJ, 1999, PHARMACOL REV, V51, P397; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MARKS MJ, 1992, J NEUROSCI, V12, P2765; Molinari EJ, 1998, EUR J PHARMACOL, V347, P131, DOI 10.1016/S0014-2999(98)00084-3; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nordberg A, 2001, BIOL PSYCHIAT, V49, P200, DOI 10.1016/S0006-3223(00)01125-2; O'Neill AB, 1998, NEUROBIOL LEARN MEM, V69, P46, DOI 10.1006/nlme.1997.3803; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olale F, 1997, J PHARMACOL EXP THER, V283, P675; PAULY JR, 1991, J PHARMACOL EXP THER, V258, P1127; Pauly JR, 1996, J PHARMACOL EXP THER, V278, P361; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Peng X, 1997, MOL PHARMACOL, V51, P776; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; Perry EK, 2001, ALCOHOL, V24, P63, DOI 10.1016/S0741-8329(01)00130-6; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rezvani AH, 2001, BIOL PSYCHIAT, V49, P258, DOI 10.1016/S0006-3223(00)01094-5; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sarter M, 2001, BRAIN RES REV, V35, P146, DOI 10.1016/S0165-0173(01)00044-3; Sarter M, 2000, NEUROSCIENCE, V95, P933; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sparks JA, 1999, PSYCHOPHARMACOLOGY, V141, P145, DOI 10.1007/s002130050818; Tsuneki H, 2000, EUR J NEUROSCI, V12, P2475, DOI 10.1046/j.1460-9568.2000.00138.x; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238	43	31	32	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908			NEUROPHARMACOLOGY	Neuropharmacology	FEB	2003	44	2					224	233		10.1016/S0028-3908(02)00366-0			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	647DL	WOS:000181077100009	12623221				2021-06-18	
S	Alves, OL; Doyle, AJ; Clausen, T; Gilman, C; Bullock, R		Slikker, W; Andrews, RJ; Trembly, B		Alves, OL; Doyle, AJ; Clausen, T; Gilman, C; Bullock, R			Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis	NEUROPROTECTIVE AGENTS	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	6th International Conference on Neuroprotective Agents	SEP 15-19, 2002	HILTON HEAD ISL, SOUTH CAROLINA			neuroprotection; severe TBI; topiramate; clinical trials; microdialysis	TRAUMATIC BRAIN INJURY; HEAD-INJURY; ISCHEMIA; BARRIER; ACID	Despite recent advances in our understanding of human traumatic brain injury (TBI) pathophysiology, we still need effective neuroprotective agents. The lack of rigorous drug pharmacokinetic studies in the "living" brain is an important cause of neuroprotection trials failure in human TBI research. In the past, several drugs have been labeled as inefficient, and even withdrawn from expensive trials, without knowing their actual penetration in the traumatized human brain. The injured brain is characterized by an increased diffusion distance, due to edema, and reduced blood flow that modulates drug transport across the blood-brain barrier (BBB). In the study reported in this paper, we used cerebral microdialysis to provide a safe and efficient tool for continuous in vivo evaluation of bioavailability and pharmacologic efficacy of topiramate, a glutamate release inhibitor. Topiramate crossed the BBB in neuroprotective concentrations, and showed a lowering effect on glutamate levels, thereby modifying the natural history of glutamate release after TBI. The use of cerebral microdialysis in phase II drug studies will allow the detection of the appropriate therapeutic window and dosage for the neuroprotective agent. This strategy represents a clear improvement compared to traditional clinical trial design, and will reduce the trial costs.	Ctr Hosp Vila Nova Gaia, Serv Neurocirurgia, Oporto, Portugal; Univ Porto, Fac Med, P-4100 Oporto, Portugal; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Alves, OL (corresponding author), Ctr Hosp Vila Nova Gaia, Serv Neurocirurgia, Oporto, Portugal.						Beaumont A, 2002, ACT NEUR S, V81, P217; Begley DJ, 1996, J PHARM PHARMACOL, V48, P136, DOI 10.1111/j.2042-7158.1996.tb07112.x; BENEVISTE H, 1989, J NEUROCHEM, V52, P1667; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1995, NEUROCHEMICAL BRAIN, P65; Elmquist WF, 1997, PHARMACEUT RES, V14, P267, DOI 10.1023/A:1012081501464; Goodman JC, 1996, ACT NEUR S, V67, P37; Hamani C, 1997, NEUROL RES, V19, P281, DOI 10.1080/01616412.1997.11740814; Kanda T, 1996, LIFE SCI, V59, P1607, DOI 10.1016/0024-3205(96)00492-4; Lee SR, 2000, NEUROSCI LETT, V281, P183, DOI 10.1016/S0304-3940(00)00847-8; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Yang Y, 1998, BRAIN RES, V804, P169, DOI 10.1016/S0006-8993(98)00410-7	16	31	31	0	2	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-468-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2003	993						25	34		10.1111/j.1749-6632.2003.tb07508.x			10	Multidisciplinary Sciences; Neurosciences	Science & Technology - Other Topics; Neurosciences & Neurology	BX10T	WOS:000184303000003	12853292				2021-06-18	
J	Coelho, C; Flewellyn, L				Coelho, C; Flewellyn, L			Longitudinal assessment of coherence in an adult with fluent aphasia: A follow-up study	APHASIOLOGY			English	Article							DISCOURSE	Background: It has been suggested that individuals with fluent aphasia demonstrate microlinguistic impairments and relatively preserved macrolinguistic abilities (Glosser & Deser, 1990). However, results of a previous study in which measures of sentence production, intersentential cohesion, and story grammar were assessed longitudinally over a period of 12 months did not support this contention (Coelho, Liles, Duffy, Clarkson, & Elia, 1994). In that investigation, as the individual with fluent aphasia recovered severity of aphasia decreased and microlinguistic abilities improved, but macrolinguistic skills remained quite limited. Aims: The present study sought to clarify the discrepancy between these two studies by re-analysing the narrative samples collected by Coelho et al. for adequacy of coherence in order for similar macrolinguistic measures to be compared across studies. Methods & Procedures: Two types of story narratives were elicited from a 55-year-old male with mild-moderate anomic aphasia on a monthly basis over a 12-month period. Story narratives were analysed for local and global coherence, and coherence ratings were compared to the mean performance of three matched non-brain-injured participants. Outcomes & Results: Neither local or global coherence improved appreciably over the 12-month period and both remained moderately impaired, inspite of gains noted in microlinguistic abilities. The individual with fluent aphasia also consistently demonstrated greater difficulties with global than local coherence. Conclusions: This pattern of impaired macrolinguistic abilities, is consistent with that of individuals with Alzheimer's disease and closed head injuries, and suggests that difficulty with discourse organisation may result from focal as well as diffuse brain pathology. These findings suggest the importance of expanding assessment procedures for individuals with aphasia, particularly mild aphasia, to include macrolinguistic dimensions of discourse organisation such as the analysis of coherence and story grammar-and further, that such macrolinguistic abilities need to addressed specifically in language therapy.	Univ Connecticut, Dept Commun Sci, Storrs, CT 06269 USA; Hosp Special Care, New Britain, CT USA	Coelho, C (corresponding author), Univ Connecticut, Dept Commun Sci, Unit 1085, Storrs, CT 06269 USA.	coelho@uconn.edu					COELHO CA, 1994, CLIN APHASIOL, V22, P145; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; GLOSSER G, 1993, NARRATIVE DISCOURSE; Goodglass H., 1983, ASSESSMENT APHASIA R; HOLLINGSHEAD A, 1972, UNPUB 4 FACTOR INDEX; HUNT K, 1970, MONOGRAPHS SOC RES C, V134; PORCH BE, 1984, PORCH INDEX COMMUNIC; Ulatowska H.K., 1990, DISCOURSE ABILITY BR, P180, DOI [10.1007/978-1-4612-3262-9_8, DOI 10.1007/978-1-4612-3262-9_8]; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Winter P., 1976, BEAR FLY	10	31	33	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology		2003	17	2					173	182		10.1080/729255216			10	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	641UK	WOS:000180765100006					2021-06-18	
J	Soukiasian, HJ; Hui, T; Avital, I; Eby, J; Thompson, R; Kleisli, T; Margulies, DR; Cunneen, S				Soukiasian, HJ; Hui, T; Avital, I; Eby, J; Thompson, R; Kleisli, T; Margulies, DR; Cunneen, S			Decompressive craniectomy in trauma patients with severe brain injury	AMERICAN SURGEON			English	Article; Proceedings Paper	Annual Meeting of the Southern-California-Chapter of the American-College-of-Surgeons	JAN 18-20, 2002	SANTA BARBARA, CA	Amer Coll Surg, SO Calif Chapter			CEREBRAL EDEMA; HEAD-INJURY; MANAGEMENT	Decompressive craniectomy in the treatment of severe traumatic brain injury (TBI) is controversial. We conducted a retrospective review of prospectively collected data on all patients requiring surgery for TBI from 1995 through 2001 at Cedars-Sinai Medical Center. Patients were separated into two groups: Group A, craniectomy, and Group B, craniotomy. We had 120 patients; 24 (20%) had craniectomy and 96 (80%) had craniotomy. There were no significant differences in demographics or Injury Severity Scores. The craniectomy group had significantly more TBI as evidenced by more frequently collapsed basilar cisterns on CT scan (P = 0.0001). There was no significant difference in actuarial survival between the groups: 52.8 per cent in the craniectomy group and 79.2 per cent in the craniotomy group (P = 0.08). Calculated mortality for craniectomy was 37.5 percent versus 18.8 per cent for craniotomy (P = NS). We found four preoperative findings to be significant predictors of mortality: 1) Glasgow Coma Scale score, 2) Injury Severity Score, 3) Simplified Acute Physiology Score, and 4) Acute Physiology and Chronic Health Evaluation II. The type of surgery was not found to be a significant predictor of death even when adjusted for severity of injury. Craniectomy may be helpful for patients with TBI associated with preoperative CT scan evidence of basilar cistern collapse. This is evidenced by similar survival rates between the two groups despite clinical evidence of greater TBI among craniectomy patients.	Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA	Soukiasian, HJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, 8700 Beverly Blvd,Suite 8215, Los Angeles, CA 90048 USA.						CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; GAAB M, 1979, CHILD BRAIN, V5, P484; GAAB MR, 1990, ACT NEUR S, V51, P326; GERL A, 1980, Zentralblatt fuer Neurochirurgie, V41, P125; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hieu PD, 1996, CHILD NERV SYST, V12, P270; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Munch E, 2000, NEUROSURGERY, V47, P315; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Ogawa M, 1974, Med J Osaka Univ, V25, P73; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; RINALDI A, 1990, ACT NEUR S, V51, P394; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; WHITFIELD P, 1995, STROKE, V26, P1125; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; YAMAURA A, 1979, Neurologia Medico-Chirurgica, V19, P717, DOI 10.2176/nmc.19.717	24	31	33	0	1	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	DEC	2002	68	12					1066	1071					6	Surgery	Surgery	629WE	WOS:000180074100008	12516810				2021-06-18	
J	Gray, WP; May, K; Sundstrom, LE				Gray, WP; May, K; Sundstrom, LE			Seizure induced dentate neurogenesis does not diminish with age in rats	NEUROSCIENCE LETTERS			English	Article						seizures; neurogenesis; age; dentate gyrus	ADULT-RAT; GRANULE CELLS; GYRUS; HIPPOCAMPUS; PROLIFERATION; NEURONS; REORGANIZATION; APOPTOSIS	Neurogenesis in the mammalian dentate gyrus occurs throughout I if e, is believed to be important for the laying down of episodic memory and diminishes significantly with increasing age. Pathological insults such as seizures, hypoxia and traumatic brain injury increase dentate neurogenesis compared to age matched controls. Using unilateral intracerebroventricular kainate we show that although baseline neurogenesis is significantly lower in 3 month old rats compared to 1 month old rats, kainate increases neurogenesis to reach similar levels in both age groups. Additionally, this effect is bilateral after a unilateral intracerebroventricular kainate injection. We conclude that the potential for dentate neurogenesis is maintained despite diminishing baseline levels with increasing age and that injury signals override the age related suppression of neurogenesis. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Southampton, Sch Biomed Sci, Div Clin Neurosci, Southampton SO16 7PX, Hants, England	Gray, WP (corresponding author), Univ Southampton, Sch Biomed Sci, Div Clin Neurosci, Bassett Crescent E, Southampton SO16 7PX, Hants, England.			Gray, William/0000-0001-7595-8887			ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Cameron H, 1996, J COMP NEUROL, V369, P56, DOI 10.1002/(SICI)1096-9861(19960520)369:1<56::AID-CNE4>3.0.CO;2-J; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CAMERON HA, 1995, J NEUROSCI, V15, P4687; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LEWIS PD, 1978, NEUROPATH APPL NEURO, V4, P191, DOI 10.1111/j.1365-2990.1978.tb00536.x; Long JM, 1998, NEUROBIOL AGING, V19, P497, DOI 10.1016/S0197-4580(98)00088-8; Nacher J, 2001, EUR J NEUROSCI, V13, P512, DOI 10.1046/j.0953-816x.2000.01424.x; Parent JM, 1997, J NEUROSCI, V17, P3727; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Seki T, 1995, NEUROREPORT, V6, P2479, DOI 10.1097/00001756-199512150-00010; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; SUNDSTROM LE, 1993, BRAIN RES, V609, P321, DOI 10.1016/0006-8993(93)90890-Y; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a	20	31	32	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	SEP 27	2002	330	3					235	238	PII S0304-3940(02)00810-8	10.1016/S0304-3940(02)00810-8			4	Neurosciences	Neurosciences & Neurology	611HP	WOS:000179010800006	12270636				2021-06-18	
J	Hackbarth, RM; Rzeszutko, KM; Sturm, G; Donders, J; Kuldanek, AS; Sanfilippo, DJ				Hackbarth, RM; Rzeszutko, KM; Sturm, G; Donders, J; Kuldanek, AS; Sanfilippo, DJ			Survival and functional outcome in pediatric traumatic brain injury: A retrospective review and analysis of predictive factors	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	30th International Educational and Scientific Symposium of the Society-for-Critical-Care-Medicine	FEB 11-14, 2001	SAN FRANCISCO, CALIFORNIA	Soc Crit Care Med		wounds; injuries; brain injuries; cerebral perfusion pressure; survival; outcome assessment; child; intracranial pressure; critical care; mortality; rehabilitation	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; BLOOD-FLOW; CHILDREN; HYPERVENTILATION; RESISTANCE; MANAGEMENT; SEVERITY; INDEXES	Objective. The aim of this study was to evaluate the relationship of patient care variables to survival and functional outcome in the pediatric population with traumatic brain injury. Design: Retrospective chart review. Setting: A 16-bed pediatric critical care unit in an academic community children's hospital. Patients. A total of 320 consecutive pediatric patients with traumatic brain injuries admitted to our pediatric critical care unit between 1992 and 1996. Interventions: Patients were managed using our standard traumatic brain injury protocol. Measurements and Main Results. A total of 230 patient variables encompassing demographic data, prehospital, emergency department, and pediatric critical care unit care were recorded. A total of 79 patients were severely injured, with admitting Glasgow Coma Scale scores of less than or equal to10. There were 18 deaths. Only two patients survived without cognition. Ninety-five of 302 survivors required inpatient rehabilitation. Of these, 73 were old enough to be compared using FIM(TM) scores. At the time of discharge from rehabilitation, 52 patients (71%) were functioning independently, 20 (27%) were moderately dependent, and one patient was completely dependent. Analysis of variables with respect to survival revealed that an inability to maintain a cerebral perfusion pressure of greater than or equal to50 mm Hg on the first pediatric critical care unit day (p = .0002) and the presence of bradycardia in the emergency department (p = .0139) were the strongest factors associated with mortality. By using the regression equation generated from this model, we could correctly identify survivors and nonsurvivors with a predictive value of 94%. Conclusions. The ability to maintain a cerebral perfusion pressure of greater than or equal to50 mm Hg was the single most important predictor of traumatic brain injury survival in this study. This suggests that monitoring and optimizing cerebral perfusion pressure is critical to the management of these patients. The relationship between cognitive outcome and therapeutic interventions used to optimize cerebral perfusion pressure is unclear and requires further evaluation in a large prospective study.	DeVos Childrens Hosp, Div Pediat Crit Care, Grand Rapids, MI 49503 USA; Michigan State Univ, Cook Res Inst, Grand Rapids, MI USA; Michigan State Univ, Mary Free Bed Rehabil Hosp, Grand Rapids, MI USA; Michigan State Univ, Coll Human Med, Grand Rapids, MI USA	Hackbarth, RM (corresponding author), DeVos Childrens Hosp, Div Pediat Crit Care, Spectrum Hlth Downtown,100 Michigan NE, Grand Rapids, MI 49503 USA.						Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; BRUCE DA, 1979, CHILD BRAIN, V5, P174; Chesnut RM, 1997, CRIT CARE MED, V25, P1275, DOI 10.1097/00003246-199708000-00011; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Guyer B, 1999, PEDIATRICS, V104, P1229, DOI 10.1542/peds.104.6.1229; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MAYER T, 1981, JAMA-J AM MED ASSOC, V245, P719; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Miller JI, 1998, ACT NEUR S, V71, P82; Miller TR, 1996, AM J PUBLIC HEALTH, V86, P89, DOI 10.2105/AJPH.86.1.89; Rivara FP, 1999, PEDIATRICS, V103, P883; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; *SUNY, 1991, GUID US UN DAT SET M; *UB FDN ACT, 1993, GUID UN DAT SET MAN	20	31	32	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JUL	2002	30	7					1630	1635		10.1097/00003246-200207000-00038			6	Critical Care Medicine	General & Internal Medicine	573PY	WOS:000176841100038	12130990				2021-06-18	
J	Montgomery, V; Oliver, R; Reisner, A; Fallat, ME				Montgomery, V; Oliver, R; Reisner, A; Fallat, ME			The effect of severe traumatic brain injury on the family	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; trauma; children; family	PEDIATRIC TRAUMA; HEAD-INJURY; CHILDREN; COHORT; RECOVERY	Background: The effects of traumatic brain injury on family dynamics and finances have not been extensively studied. We designed a 30-item survey to determine the effects of the injury on the child, parent(s), and siblings, and whether parents were retrospectively content with the decisions related to aggressiveness of care. Methods: A questionnaire written on a sixth-grade reading level was mailed to 46 families of children who survived a traumatic brain injury resulting in an initial Glasgow Coma Scale score less than or equal to 7. This is a descriptive study without statistical analysis. Human Studies Committee review and informed consent were obtained. Results: Thirty-two of 46 (69.6%) surveys were completed by mail or telephone. Mean patient age at time of injury was 8.7 years, mean time since injury was 3 years, and mean Glasgow Coma Scale score was 3.7. Approximately one third of children have disabilities related to education, socialization, and/or self-care skills; require multiple health care visits each month; and require prescription medications. Over one third of families were impacted in a moderate to profoundly negative way; 30% of families reported a deterioration in finances or loss of job; and 16% reported a worsening of adult relationships. In 13 of 32 cases, modification of current housing or new housing was required to facilitate home care. Siblings were adversely affected in approximately 16 of 28 families, exhibiting behavioral problems, increased fear, and withdrawal from the injured child. Only 1 of 32 families stated that they would have considered less aggressive treatment, even if it led to the child's death. Conclusion: Traumatic brain injury of a child had a negative impact on family dynamics and/or sibling behavior in more than one third of families. Despite this, most families would not limit or withdraw care if they could reconsider decisions regarding treatment. This information can be used to counsel families.	Childrens Hlth Care Atlanta, Dept Neurosurg, Atlanta, GA USA; Kosair Childrens Hosp, Off Pastoral Care, Louisville, KY USA; Univ Louisville, Div Pediat Surg, Dept Surg, Louisville, KY 40292 USA; Univ Louisville, Dept Pediat, Louisville, KY 40292 USA	Fallat, ME (corresponding author), 233 E Gray St,Suite 708, Louisville, KY 40202 USA.						BARRY P, 1992, Brain Injury, V6, P229, DOI 10.3109/02699059209029664; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; HU XH, 1993, CAN MED ASSOC J, V149, P421; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; OATES W, 1981, YOUR PARTICULAR GRIE; Osberg JS, 1996, PEDIATRICS, V98, P890; RESNICK C, 1993, SOC WORK HEALTH CARE, V18, P49, DOI 10.1300/J010v18n02_03; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; WESSON DE, 1992, J TRAUMA, V33, P252, DOI 10.1097/00005373-199208000-00015	21	31	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2002	52	6					1121	1124		10.1097/00005373-200206000-00016			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	562KJ	WOS:000176195700023	12045640				2021-06-18	
J	Letts, M; Davidson, D; Lapner, P				Letts, M; Davidson, D; Lapner, P			Multiple trauma in children: predicting outcome and long-term results	CANADIAN JOURNAL OF SURGERY			English	Article							PEDIATRIC TRAUMA; INJURY SEVERITY; MAJOR TRAUMA; SCORE; EXPERIENCE; SURVIVAL	Objective: To analyze the management of pediatric trauma and the efficacy of the Pediatric Trauma Score (PTS) in classifying injury severity and predicting prognosis. Design: A retrospective case series. Setting: The Children's Hospital of Eastern Ontario, a major pediatric trauma centre. Patients: One hundred and forty-nine traumatized children with 2 or more injuries to I body system or a single injury to 2 or more body systems. Interventions: Use of the PTS and Glasgow Coma Scale score in trauma management. Main outcome measures: Types of injuries sustained, complications, missed injuries, psychosocial effects and residual deficiencies. Results: The average PTS was 8.5 (range from -3 to 11). T c total number of injuries sustained was 494, most commonly closed head injury (86). Forty-two percent of children with an average trauma score of 8.5 were treated surgically. There were 13 missed injuries, and complications were encountered in 57 children, the most common being secondary to fractures. Forty-eight (32%) children had residual long-term deficiency, most commonly neurologic deficiency secondary, to head injury. Conclusions: Fractures should be stabilized early to decrease long-term complications. A deficiency of the PTS is the weighting of open fractures of minor bone. For example, metacarpal fracture is given the same weight as an open fracture of the femur, Neuropsychologic difficulties secondary to trauma are a major sequela of trauma in children.	Univ Ottawa, Childrens Hosp Eastern Ontario, Div Orthopaed, Ottawa, ON, Canada	Letts, M (corresponding author), Childrens Hosp Eastern Ontario, Dept Surg, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.						APRAHAMIAN C, 1990, ARCH SURG-CHICAGO, V125, P1128; BORN CT, 1989, J TRAUMA, V29, P1643, DOI 10.1097/00005373-198912000-00010; BREAUX CW, 1990, J TRAUMA, V30, P37, DOI 10.1097/00005373-199001000-00006; BUCKLEY SL, 1994, J PEDIATR ORTHOPED, V14, P449, DOI 10.1097/01241398-199407000-00005; CHAN BSH, 1989, J TRAUMA, V29, P1540, DOI 10.1097/00005373-198911000-00014; CHAN RNW, 1980, J TRAUMA, V20, P684, DOI 10.1097/00005373-198008000-00009; COLOMBANI PM, 1985, J PEDIATR SURG, V20, P8, DOI 10.1016/S0022-3468(85)80382-1; CRAMER KE, 1995, CLIN ORTHOP RELAT R, P125; EICHELBERGER MR, 1989, ANN EMERG MED, V18, P1053, DOI 10.1016/S0196-0644(89)80930-8; ENDERSON BL, 1990, J TRAUMA, V30, P666, DOI 10.1097/00005373-199006000-00002; Furnival RA, 1996, PEDIATRICS, V98, P56; GORDON JA, 1986, S AFR MED J, V70, P415; GULY HR, 1984, INJURY, V15, P403, DOI 10.1016/0020-1383(84)90207-9; HARRISON S, 1989, MAN, V24, P1, DOI 10.2307/2802544; HOLMES MJ, 1984, J TRAUMA, V24, P253, DOI 10.1097/00005373-198403000-00012; HU XH, 1994, J TRAUMA, V37, P209, DOI 10.1097/00005373-199408000-00010; Hulka F, 1997, J TRAUMA, V42, P514, DOI 10.1097/00005373-199703000-00020; JUBELIRER RA, 1990, J TRAUMA, V30, P1544, DOI 10.1097/00005373-199012000-00019; KAUFMANN CR, 1990, JAMA-J AM MED ASSOC, V263, P69, DOI 10.1001/jama.263.1.69; KLASEN HJ, 1996, UPDATE INTENSIVE CAR, P11; LAVERY RF, 1992, PEDIATR EMERG CARE, V8, P9, DOI 10.1097/00006565-199202000-00004; Loder R T, 1987, J Orthop Trauma, V1, P48; MARCUS RE, 1983, J BONE JOINT SURG AM, V65, P1290, DOI 10.2106/00004623-198365090-00010; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; McLaren C A, 1983, J R Coll Surg Edinb, V28, P399; NAKAYAMA DK, 1991, J TRAUMA, V31, P1521, DOI 10.1097/00005373-199111000-00010; NAYDUCH DA, 1991, J TRAUMA, V31, P452, DOI 10.1097/00005373-199104000-00003; Orliaguet GA, 1998, ANESTH ANALG, V87, P537, DOI 10.1097/00000539-199809000-00006; PAAR O, 1992, EUR J PEDIATR SURG, V2, P345, DOI 10.1055/s-2008-1063475; RAMENOFSKY ML, 1988, J TRAUMA, V28, P1038, DOI 10.1097/00005373-198807000-00021; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; Tepas JJ, 1997, J TRAUMA, V43, P258, DOI 10.1097/00005373-199708000-00009; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; Wan GJ, 1996, J TRAUMA, V40, P412, DOI 10.1097/00005373-199603000-00015; WESSON DE, 1992, J TRAUMA, V33, P252, DOI 10.1097/00005373-199208000-00015	36	31	32	0	3	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0008-428X	1488-2310		CAN J SURG	Can. J. Surg.	APR	2002	45	2					126	131					6	Surgery	Surgery	535XK	WOS:000174671500014	11939656				2021-06-18	
J	Grasso, G; Passalacqua, M; Sfacteria, A; Conti, A; Morabito, A; Mazzullo, G; De Vico, G; Buemi, M; Macri, B; Tomasello, F				Grasso, G; Passalacqua, M; Sfacteria, A; Conti, A; Morabito, A; Mazzullo, G; De Vico, G; Buemi, M; Macri, B; Tomasello, F			Does administration of recombinant human erythropoietin attenuate the increase of S-100 protein observed in cerebrospinal fluid after experimental subarachnoid hemorrhage?	JOURNAL OF NEUROSURGERY			English	Article						erythropoietin; S-100 protein; subarachnoid hemorrhage; rabbit	MINOR HEAD-INJURY; TRAUMATIC BRAIN-DAMAGE; IN-VIVO EVIDENCE; ACUTE VASOCONSTRICTION; SERUM MARKER; ACUTE STROKE; RECEPTOR; CELLS; RATS; INFARCTION	Object. Results of recent studies indicate that erythropoietin (EPO) produces a neuroprotective effect on experimental subarachnoid hemorrhage (SAH). It has been reported that S-100 protein levels increase in cerebrospinal fluid (CSF) after SAH, providing a highly prognostic indication of unfavorable outcome. This study was conducted to validate further the findings of S-100 protein as an index of brain damage and to assess whether treatment with recombinant human EPO (rhEPO) would limit the increase of S-100 protein level in CSF following experimental SAH. Methods. Thirty-two rabbits were each assigned to one of four groups: Group 1, control; Group 2, SAH; Group 3, SAH plus placebo; and Group 4, SAH plus rhEPO (each group consisted of eight rabbits). The rhEPO and placebo were administered to the rabbits after SAH had been induced, and S-100 protein levels in the CSF of these animals were measured at 24, 48, and 72 hours after the experimental procedure. In each group of animals levels of S-100 protein were compared with the mortality rate, neurological outcome, and neuronal ischemic damage. High S-100 protein levels were found in rabbits in Groups 2 and 3, which exhibited poor neurological status and harbored a high number of damaged cortical neurons. Favorable neurological outcome and significant reductions in total numbers of damaged neurons were observed in animals in Group 4 in which there were significantly lower S-100 protein concentrations compared with animals in Groups 2 and 3 (p < 0.001). Conclusions. The results of this study support the concept that determination of the S-100 protein level in CSF has prognostic value after SAH. The findings also confirm that rhEPO acts as a neuroprotective agent during experimental SAH.	Univ Messina, Policlin Univ, Dept Neurosurg, I-98122 Messina, Italy; Univ Messina, Dept Vet Pathol, I-98122 Messina, Italy; Univ Messina, Dept Internal Med, I-98122 Messina, Italy	Grasso, G (corresponding author), Univ Messina, Policlin Univ, Dept Neurosurg, Via Consolare Valeria 1, I-98122 Messina, Italy.		Morabito, Antonino/AAB-3265-2019; De Vico, Gionata/N-7268-2016; grasso, giovanni/K-3774-2018; Sfacteria, Alessandra/AAK-1839-2020; Conti, Alfredo/H-3022-2019	De Vico, Gionata/0000-0001-5953-4160; grasso, giovanni/0000-0001-5362-0092; Conti, Alfredo/0000-0002-9408-2662; Morabito, Antonino/0000-0002-5323-3620			Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Alafaci C, 2000, EUR J PHARMACOL, V406, P219, DOI 10.1016/S0014-2999(00)00691-9; ALLCOCK JM, 1965, J NEUROSURG, V22, P21, DOI 10.3171/jns.1965.22.1.0021; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; BUEMI M, 1993, NEPHRON, V65, P440, DOI 10.1159/000187526; Buemi M, 2000, EUR J PHARMACOL, V392, P31, DOI 10.1016/S0014-2999(00)00081-9; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; ENDO S, 1988, STROKE, V19, P1420, DOI 10.1161/01.STR.19.11.1420; GARCIA JH, 1978, ACTA NEUROPATHOL, V43, P85; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Grasso G, 2001, J Neurosurg Sci, V45, P7; HAIMOTO H, 1987, LAB INVEST, V57, P489; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; ISOBE T, 1977, BIOCHIM BIOPHYS ACTA, V494, P222, DOI 10.1016/0005-2795(77)90150-7; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; JELKMANN W, 1992, PHYSIOL REV, V72, P449; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MCQUEEN JD, 1967, ARCH NEUROL-CHICAGO, V16, P501, DOI 10.1001/archneur.1967.00470230053007; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Morishita E, 1996, BLOOD, V88, P465, DOI 10.1182/blood.V88.2.465.bloodjournal882465; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sehba FA, 1999, STROKE, V30, P1955, DOI 10.1161/01.STR.30.9.1955; STEFANSSON K, 1982, NATURE, V295, P63, DOI 10.1038/295063a0; TAKAYASU M, 1985, J NEUROSURG, V63, P417, DOI 10.3171/jns.1985.63.3.0417; UMANSKY F, 1983, J NEUROSURG, V58, P210, DOI 10.3171/jns.1983.58.2.0210; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x; Yoon WH, 1997, RES COMMUN MOL PATH, V96, P227; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640	43	31	34	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2002	96	3					565	570		10.3171/jns.2002.96.3.0565			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	525ZN	WOS:000174104100015	11883842				2021-06-18	
J	Farmer, JE; Kanne, SM; Haut, JS; Williams, J; Johnstone, B; Kirk, K				Farmer, JE; Kanne, SM; Haut, JS; Williams, J; Johnstone, B; Kirk, K			Memory functioning following traumatic brain injury in children with premorbid learning problems	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	Annual Meeting of the International-Neuropsychological-Society	FEB 14-17, 1996	CHICAGO, IL	Int Neuropsychol Soc, US PHS, Natl Inst Aging, Alzheimers Dis Cooperat Study			WIDE-RANGE ASSESSMENT; HEAD-INJURY; RECOVERY	This study examines the memory functioning of 25 children who sustained a traumatic brain injury (TBI) and who had prior learning problems, 48 children with TBI who did not have prior learning problems, and 23 noninjured controls. The children with TBI and prior learning problems displayed significantly worse memory abilities than both the control participants and the children with TBI and no prior learning problems They differed significantly from these 2 groups on measures of general memory, verbal memory, sound-symbol learning, and attention. The results suggest that children with premorbid learning problems who sustain TBI have less cognitive reserve and a lower threshold for the expression of cognitive impairments in areas that reflect preexisting learning and language problems, compared to children without premorbid learning problems.	Univ Missouri, Sch Med, Columbia, MO USA; W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA; Univ Arkansas, Med Ctr, Fayetteville, AR 72701 USA	Johnstone, B (corresponding author), DCO4646,1 Hosp Dr, Columbia, MO 65212 USA.	farmerje@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			ADAMS W, 1991, 11 ANN M NAT AC NEUR; AYLWARD GP, 1995, J PSYCHOEDUC ASSESS, V13, P132, DOI 10.1177/073428299501300203; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BEGALI V, 1992, HEAD INJURY CHILDREN; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; Burton DB, 1999, CHILD NEUROPSYCHOL, V5, P34, DOI 10.1076/chin.5.1.34.7077; CALLAHAN TS, 1993, 101 ANN M AM PSYCH A; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Donders J, 1997, Pediatr Rehabil, V1, P179; Donders J, 2000, J HEAD TRAUMA REHAB, V15, P792, DOI 10.1097/00001199-200004000-00004; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEAGANS L, 1993, CURRENT TOPICS HUMAN, V3, P121; Fletcher JM, 1995, HDB PEDIAT PSYCHOL, P362; Kramer JH, 1997, NEUROPSYCHOLOGY, V11, P577, DOI 10.1037/0894-4105.11.4.577; Kramer JH, 2000, ARCH CLIN NEUROPSYCH, V15, P83, DOI 10.1016/S0887-6177(99)00022-0; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; MCBRIDECHANG C, 1995, EDUC PSYCHOL, V30, P109, DOI 10.1207/s15326985ep3003_2; *NAT PED TRAUM REG, 2000, PHAS 3; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Prior M., 1996, UNDERSTANDING SPECIF; Sattler JM, 1988, ASSESSMENT CHILDREN; SAVAGE RC, 1994, ED DIMENSIONS ACQUIR; Sheslow D., 1990, MANUAL WIDE RANGE AS; SWANSON HL, 1998, LEARNING LEARNING DI, P107; TEPAS JJ, 1989, J PEDIATR SURG, V24, P81; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1989, WECHSLER PRESCHOOL P; Wechsler D., 1991, MANUAL WECHSLER INTE; WILLOWS DM, 1998, LEARNING LEARNING DI, P203; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	36	31	31	0	3	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2002	22	2					455	469		10.1207/S15326942DN2202_2			15	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	635ER	WOS:000180385900002	12537333				2021-06-18	
J	Segers, P; Van Schil, P; Jorens, P; Van Den Brande, F				Segers, P; Van Schil, P; Jorens, P; Van Den Brande, F			Thoracic trauma : an analysis of 187 patients	ACTA CHIRURGICA BELGICA			English	Article						thoracic injuries; trauma severity indices; motorcycles; traffic accidents	CHEST TRAUMA; RUPTURE; INJURIES	A retrospective analysis of 187 cases of thoracic trauma seen between January 1, 1994 and June 30, 1999 is presented. The majority of the patients were male (male-female ratio 2.9 :1) and the average age at admission was 41.1 years. Blunt trauma, especially motor vehicle accidents (72.2%) and falls (17.1%), were the most frequent causes of chest injury (95.8%). We used the injury severity score (ISS) to assess the severity of trauma. The average ISS for the total group was 27.8 (ranges : 4-75). In only 17.6% of the patients an isolated thoracic trauma was present. Rib fractures (n = 133), pulmonary contusion (n = 110), pneumothorax (n = 78) and haemothorax (n = 65) were the most frequent lesions. Most patients (97.9%) were admitted to the intensive care department. A minority of the patients required thoracotomy (n = 19, 10.2%). Main indications for thoracotomy were pulmonary laceration (n = 5), aortic rupture (n = 3) and rupture of the diaphragm (n = 3). For the majority of cases, observation and/or tube thoracostomy (52.4%) and/or mechanical ventilation (61.0%) were sufficient. Pneumonia and adult respiratory distress syndrome were the most common complications (38.0 and 7.0% respectively). The overall mortality rate was 16.6%. Main causes of death were intracranial hypertension, sepsis combined with multiple organ failure, and hypovolaemic shock. For patients who did not survive the average ISS was 40.3. In a survival analysis the ISS was found to be the most significant determining survival (p < 0.0001), followed by neurotrauma (p = 0.05). Mortality after thoracic trauma remains relatively high, especially in case of associated neurotrauma. The ISS is a valuable score for assessing the severity of trauma and predicting outcome.	Univ Antwerp Hosp, Dept Thorac & Vasc Surg, B-2650 Edegem, Belgium	Van Schil, P (corresponding author), Univ Antwerp Hosp, Dept Thorac & Vasc Surg, Wilrijkstr 10, B-2650 Edegem, Belgium.	paul.van.schil@uza.be	Van Schil, Paul/AAC-8139-2019	Van Schil, Paul/0000-0002-1962-8821			BESSON A, 1989, COLOR ATLAS CHEST TR; CHAMPION HR, 1983, WORLD J SURG, V7, P4, DOI 10.1007/BF01655906; ENDERSON BL, 1990, J TRAUMA, V30, P666, DOI 10.1097/00005373-199006000-00002; FECZKO JD, 1992, J TRAUMA, V33, P846, DOI 10.1097/00005373-199212000-00009; GALAN G, 1992, EUR J CARDIO-THORAC, V6, P284, DOI 10.1016/1010-7940(92)90143-L; Galli R, 1998, ANN THORAC SURG, V65, P461, DOI 10.1016/S0003-4975(97)01302-7; Glinz W, 1981, CHEST TRAUMA DIAGNOS; Goverde P, 1996, ACTA CHIR BELG, V96, P233; KOTWICA Z, 1990, ACTA NEUROCHIR, V103, P109, DOI 10.1007/BF01407515; KSHETTRY VR, 1994, CLIN CHEST MED, V15, P137; LANGLAZDUNSKI L, 1999, CURR OPIN CRIT CARE, V5, P488; MATTOX KL, 1989, SURG CLIN N AM, V69, P77; MATTOX KL, 1989, SURG CLIN N AM, V69, P31; MATTOX KL, 1989, SURG CLIN N AM, V69, P59; MATTOX KL, 1989, SURG CLIN N AM, V69, P15; Pate JW, 1999, WORLD J SURG, V23, P59, DOI 10.1007/s002689900565; Rousseau H, 1999, CIRCULATION, V99, P498, DOI 10.1161/01.CIR.99.4.498; SHORR RM, 1987, ANN SURG, V206, P200, DOI 10.1097/00000658-198708000-00013; SYMBAS PN, 1992, ANN THORAC SURG, V54, P177, DOI 10.1016/0003-4975(92)91177-B; Tatou E, 2000, ANN THORAC SURG, V69, P70, DOI 10.1016/S0003-4975(99)01054-1; Trupka A, 1998, UNFALLCHIRURG, V101, P244, DOI 10.1007/s001130050265; Vasquez JC, 1997, INJURY, V28, P45, DOI 10.1016/S0020-1383(96)00133-7	22	31	32	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0001-5458			ACTA CHIR BELG	Acta Chir. Belg.	NOV-DEC	2001	101	6					277	282					6	Surgery	Surgery	512WK	WOS:000173346400006	11868503				2021-06-18	
J	Zec, RF; Zellers, D; Belman, J; Miller, J; Matthews, J; Ferneau-Belman, D; Robbs, R				Zec, RF; Zellers, D; Belman, J; Miller, J; Matthews, J; Ferneau-Belman, D; Robbs, R			Long-term consequences of severe closed head injury on episodic memory	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; DEGENERATIVE CHANGES; MILD HEAD; CHILDREN; DAMAGE; RISK; PREVALENCE; STRATEGIES; MORPHOLOGY	This is the first systematic investigation of the very long-term effects of severe closed head injury (CFH) on objective measures of memory, and the first to employ both a normal control group and an 'other injury' control group consisting of spinal cord injury (SCI) patients. The CM group displayed significantly poorer performance on every memory measure, and the effect sizes were large. This impairment in episodic memory is neither due to pre-injury nor post-injury differences between CHI and normal control subjects because the same differences were found when the CHI group was compared to a group of SCI patients. The findings demonstrate severe impairment in learning and retention many years after sustaining a severe CHI, which is likely in part due to the bilateral hippocampal damage shown in neuropathological studies. This lifelong memory impairment needs to be addressed by community service programs.	So Illinois Univ, Sch Med, Ctr Alzheimer Dis & Related Disorders, Springfield, IL 62794 USA; So Illinois Univ, Sch Med, Dept Neurol, Springfield, IL 62794 USA; So Illinois Univ, Sch Med, Dept Psychiat, Springfield, IL 62794 USA; Univ Illinois, Dept Psychol, Springfield, IL USA; Illinois Sch Profess Psychol, Chicago, IL USA	Zec, RF (corresponding author), So Illinois Univ, Sch Med, Ctr Alzheimer Dis & Related Disorders, Springfield, IL 62794 USA.	rzec@siumed.edu					ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BENNETTLEVY JM, 1984, ACTA NEUROL SCAND, V70, P285; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; BIGLER ED, 1987, J LEARN DISABIL, V20, P458, DOI 10.1177/002221948702000804; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BIJUR PE, 1990, PEDIATRICS, V86, P337; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CONKEY RC, 1938, ARCH PSYCHOL, V33, P232; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CULLUM CM, 1985, INT J NEUROSCI, V28, P279, DOI 10.3109/00207458508985395; DENCKER SJ, 1960, ARCH GEN PSYCHIAT, V2, P569; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DUHAIME AC, 1990, BRAIN RES, V512, P169, DOI 10.1016/0006-8993(90)91188-M; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HEATON SR, 1981, HDB CLIN NEUROPSYCHO; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HIRST W, 1988, BRAIN COGNITION, V8, P379, DOI 10.1016/0278-2626(88)90060-7; HYMAN BT, 1993, NEUROPSYCHOLOGY ALZH, P138; JENNETT WB, 1969, SPECIAL PUBLICATION, V4; Kesler SR, 2000, BRAIN INJURY, V14, P851; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1991, INTRACRANIAL PRESSUR, V8; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MARION DW, 1999, TRAUMATIC BRAIN INJU; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rey A, 1964, EXAMEN CLIN PSYCHOL; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SMITH E, 1974, J NEUROL NEUROSUR PS, V37, P719, DOI 10.1136/jnnp.37.6.719; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; WECHSLER D, 1987, MANUAL WECHSLER MEM; WILSON B, 1992, J NEUROL NEUROSUR PS, V55, P177, DOI 10.1136/jnnp.55.3.177; Zec R. F., 1993, NEUROPSYCHOLOGY ALZH, P3; ZEC RF, 1992, HDB HEAD TRAUMA ACUT, P219; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	66	31	31	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2001	23	5					671	691		10.1076/jcen.23.5.671.1247			21	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	480RN	WOS:000171476200011	11778644				2021-06-18	
J	Kay, GG; Quig, ME				Kay, GG; Quig, ME			Impact of sedating antihistamines on safety and productivity	ALLERGY AND ASTHMA PROCEEDINGS			English	Article; Proceedings Paper	Southwest Allergy Forum (SWAF)/Eastern Allergy Conference (EAC)	JAN   10, 2001	ACAPULCO, MEXICO				PSYCHOMOTOR PERFORMANCE; LORATADINE; CHLORPHENIRAMINE; DIPHENHYDRAMINE; CETIRIZINE; COGNITION; MOOD	The use of sedating antihistamines by allergy sufferers remains common, and physicians continue to prescribe these older anti-histamines with great frequency. Precautionary statements Warning of possible drowsiness and the need for caution when driving or operating machinery, which are required for sedating antihistamines, don't appear to be having much impact. Sedating antihistamines are frequently found to be a causal factor in fatal traffic accidents and are the leading medication found on autopsy of pilots who have crashed their aircraft. Patients taking sedating antihistamines frequently don't feel sleepy, yet they have difficulty staying awake and their brain functioning is impaired. The impact on safety is found in the increased risk of traumatic work-related injuries, driving accidents, and aviation fatalities. The cognitive and psychomotor deficits translate into losses in worker productivity and student learning.	Georgetown Univ, Sch Med, Dept Neurol, Washington, DC 20057 USA	Kay, GG (corresponding author), WNI, 4910 Massachusetts Ave,NW 100, Washington, DC 20016 USA.						*AM AC ALL ASTHM I, 2000, ALL REP; Cockburn IM, 1999, J OCCUP ENVIRON MED, V41, P948, DOI 10.1097/00043764-199911000-00005; Gilmore TM, 1996, AM J IND MED, V30, P234; Hindmarch I, 1999, CLIN EXP ALLERGY, V29, P133, DOI 10.1046/j.1365-2222.1999.0290s3133.x; Kay GG, 1997, AM J MANAG CARE, V3, P1843; Kay GG, 1999, CLIN EXP ALLERGY, V29, P147, DOI 10.1046/j.1365-2222.1999.0290s3147.x; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; Nicholson AN, 1998, AVIAT SPACE ENVIR MD, V69, P166; Salmun LM, 2000, CLIN THER, V22, P573, DOI 10.1016/S0149-2918(00)80045-4; Soper JW, 2000, AVIAT SPACE ENVIR MD, V71, P1206; STARMER G, 1985, ACCIDENT ANAL PREV, V17, P311, DOI 10.1016/0001-4575(85)90032-6; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Weiler JM, 2000, ANN INTERN MED, V132, P354, DOI 10.7326/0003-4819-132-5-200003070-00004; 1998, IMS NATL DIS THERAPE	14	31	31	0	7	OCEAN SIDE PUBLICATIONS INC	PROVIDENCE	95 PITMAN ST, PROVIDENCE, RI 02906 USA	1088-5412			ALLERGY ASTHMA PROC	Allergy Asthma Proc.	SEP-OCT	2001	22	5					281	283					3	Allergy	Allergy	491NL	WOS:000172114700003	11715216				2021-06-18	
J	Garnett, MR; Blamire, AM; Corkill, RG; Rajagopalan, B; Young, JD; Cadoux-Hudson, TAD; Styles, P				Garnett, MR; Blamire, AM; Corkill, RG; Rajagopalan, B; Young, JD; Cadoux-Hudson, TAD; Styles, P			Abnormal cerebral blood volume in regions of contused and normal appearing brain following traumatic brain injury using perfusion magnetic resonance imaging	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood volume; magnetic resonance imaging; outcome; perfusion; traumatic brain injury	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; HYPERACUTE STROKE; CONTRAST; ISCHEMIA; ARTERY; FLOW; MILD; MRI	Following traumatic brain injury, there may be secondary alterations in cerebrovascular parameters leading to ischemia and further cellular damage. To assess possible subacute hemodynamic disturbances following traumatic brain injury, we used conventional and perfusion magnetic resonance imaging (MRI) in 18 patients, on average 10 days following injury. Six of the 18 patients had focal contusions or edema visible on conventional MRI. These six patients had a significantly reduced normalized regional cerebral blood volume (rCBV) in the regions of focal pathology compared to equivalent areas in control subjects (patients 0.47 +/- 0.20 [means +/- SD], controls 1.02 +/- 0.11, p < 0.001). In addition, four of these six patients had an increased rCBV (outside control range) in the region of normal appearing brain immediately surrounding the contusion. These six patients were more significantly injured and had a worse clinical outcome compared to the remaining patients (p = 0.004, p = 0.03, respectively). There were five patients who had a region of reduced rCBV (outside control range) in a quadrant of normal appearing white matter, away from any visible abnormality, who were not more significantly injured than the remaining patients but went on to have a significantly poorer clinical outcome (p = 0.27, p = 0.01, respectively). Traumatic brain injury is a heterogeneous insult causing a variety of pathology, not all of which is visible using conventional imaging methods. The current study has shown that regions of both normal appearing and contused brain may have an abnormal rCBV and that alterations in rCBV may play a role in determining the clinical outcome of patients.	John Radcliffe Hosp, MRC, Biochem & Clin Magnet Resonance Unit, Dept Biochem, Oxford OX3 9DU, England; Oxford Radcliffe Hosp, Dept Neurosurg, Oxford, England; Oxford Radcliffe Hosp, Dept Neurol, Oxford, England; Oxford Radcliffe Hosp, Dept Anaesthet, Oxford, England	Garnett, MR (corresponding author), John Radcliffe Hosp, MRC, Biochem & Clin Magnet Resonance Unit, Dept Biochem, Headley Way, Oxford OX3 9DU, England.	mg@bioch.ox.ac.uk	Young, John D/M-9756-2016	Blamire, Andrew/0000-0002-8749-1257			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Beaulieu C, 1999, ANN NEUROL, V46, P568, DOI 10.1002/1531-8249(199910)46:4<568::AID-ANA4>3.0.CO;2-R; BELLIVEAU JW, 1990, MAGNET RESON MED, V14, P538, DOI 10.1002/mrm.1910140311; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BOUMA GJ, 1993, ACTA NEUROCHIR, P34; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P555, DOI 10.1002/mrm.1910340412; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; JENNETT B, 1975, LANCET, V1, P480; Kastrup A, 1999, J NEUROL SCI, V166, P91, DOI 10.1016/S0022-510X(99)00121-5; Kempski O, 1997, J TRAUMA, V42, pS38, DOI 10.1097/00005373-199705001-00007; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Pierce AR, 1997, J CEREBR BLOOD F MET, V17, P183, DOI 10.1097/00004647-199702000-00008; ROBERTS TPL, 1993, J CEREBR BLOOD F MET, V13, P940, DOI 10.1038/jcbfm.1993.117; Rordorf G, 1998, STROKE, V29, P939, DOI 10.1161/01.STR.29.5.939; ROSEN BR, 1990, MAGNET RESON MED, V14, P249, DOI 10.1002/mrm.1910140211; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Sorensen AG, 1999, RADIOLOGY, V210, P519, DOI 10.1148/radiology.210.2.r99fe06519; Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784; TEASDALE G, 1974, LANCET, V2, P81; VILLRINGER A, 1988, MAGNET RESON MED, V6, P164, DOI 10.1002/mrm.1910060205; WADDINGTON W, 1998, P 6 ANN SCI M ISMRM, P2069; Warach S, 1996, J CEREBR BLOOD F MET, V16, P53, DOI 10.1097/00004647-199601000-00006; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; YOSHINO E, 1985, J NEUROSURG, V63, P830, DOI 10.3171/jns.1985.63.6.0830	36	31	33	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2001	18	6					585	593		10.1089/089771501750291828			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	445ZQ	WOS:000169488800002	11437081				2021-06-18	
J	Tsushima, WT; Tsushima, VG				Tsushima, WT; Tsushima, VG			Comparison of the Fake Bad Scale and other MMPI-2 validity scales with personal injury litigants	ASSESSMENT			English	Article						MMPI-2; Fake Bad Scale; validity scales; personal injury; litigation; malingering	CLOSED-HEAD INJURY; FORENSIC ASSESSMENT; F(P) SCALE	Five MMPI-2 validity scales were evaluated with 120 personal injury litigation patients (LP) and 208 clinical patients (CP) along with 43 normal participants (NP). The validity measures included the Fake Bad Scale (FBS), Infrequency scale (F), Back Infrequency scale (Fb), Infrequency-Psychopathology scale (F-[p]), and the Dissimulation scale-2 (Ds(2)). Results showed that only the FBS significantly differentiated the LP and CP, whereas the LP and CP scored significantly higher than the NP on FBS, F, Fb, and Ds(2). The content of the FBS, with several items from the Hypochondriasis (Hs) and Hysteria (Hy) Scales, appears to enhance the FBS' ability to detect the somatic overreporting often observed with personal injury claimants. The authors suggest that the FBS may be a useful index of symptom magnification when employed within a comprehensive assessment of malingering in personal injury plaintiffs.	Straub Clin & Hosp, Dept Psychiat & Psychol, Honolulu, HI 96813 USA; Goodsill Anderson Quinn & Stifel, Honolulu, HI USA	Tsushima, WT (corresponding author), Straub Clin & Hosp, Dept Psychiat & Psychol, 888 S King St, Honolulu, HI 96813 USA.						Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Arbisi PA, 1998, PSYCHOL ASSESSMENT, V10, P221, DOI 10.1037/1040-3590.10.3.221; Arbisi PA, 1997, PSYCHOL ASSESSMENT, V9, P102, DOI 10.1037/1040-3590.9.2.102; BAGBY RM, 1995, PSYCHOL ASSESSMENT, V7, P84; Berry DTR, 1995, PSYCHOL ASSESSMENT, V7, P517; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Butcher JN, 1995, PSYCHOL ASSESSMENT, V7, P320, DOI 10.1037/1040-3590.7.3.320; Butcher JN, 1989, MANUAL ADM SCORING M; GOUGH HG, 1954, J CONSULT PSYCHOL, V18, P287; GRAHAM JR, 1991, J PERS ASSESS, V57, P264, DOI 10.1207/s15327752jpa5702_6; GREENE RL, 1997, CLIN ASSESSMENT MALI, P169; Hathaway SR, 1943, MANUAL MINNESOTA MUL; Hoffman R. G., 1999, J FORENSIC NEUROPSYC, V1, P3, DOI DOI 10.1300/J151V01N02_02; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; POPE KS, 2000, MMPI MMPI2 MMPIA COU; ROGERS R, 1994, LAW HUMAN BEHAV, V18, P543, DOI 10.1007/BF01499173; Rogers R., 1995, ASSESSMENT, V2, P81; Rogers R., 1997, CLIN ASSESSMENT MALI, V2nd; Rothke SE, 2000, PSYCHOL ASSESSMENT, V12, P335, DOI 10.1037/1040-3590.12.3.335; Sivec, 1994, Assessment, V1, P69, DOI 10.1177/1073191194001001010; Wetter M. W., 1992, PSYCHOL ASSESSMENT, V4, P369, DOI 10.1037/1040-3590.4.3.369; Williams CW, 1999, PROF PSYCHOL-RES PR, V30, P361, DOI 10.1037/0735-7028.30.4.361; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177; Ziskin J, 1988, COPING PSYCHIAT PSYC, P481	27	31	31	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911			ASSESSMENT	Assessment	JUN	2001	8	2					205	212		10.1177/107319110100800208			8	Psychology, Clinical	Psychology	537LB	WOS:000174759100008	11428699				2021-06-18	
J	Brodhun, M; Fritz, H; Walter, B; Antonow-Schlorke, I; Reinhart, K; Zwiener, U; Bauer, R; Patt, S				Brodhun, M; Fritz, H; Walter, B; Antonow-Schlorke, I; Reinhart, K; Zwiener, U; Bauer, R; Patt, S			Immunomorphological sequelae of severe brain injury induced by fluid-percussion in juvenile pigs - effects of mild hypothermia	ACTA NEUROPATHOLOGICA			English	Article						trauma; fluid percussion brain injury; pig hypothermia; immunohistochemistry	MICROTUBULE-ASSOCIATED PROTEIN-2; DIFFUSE AXONAL INJURY; CEREBRAL BLOOD-FLOW; HEAD-INJURY; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; SYSTEMIC HYPOTHERMIA; RAT-BRAIN; BETA-APP	Severe traumatic brain injury (TBI) often leads to a bad outcome with considerable neurological deficits. Secondary brain injuries due to a rise of intracranial pressure (ICP) and global hypoxia-ischemia are critical and may be reduced in extent by mild hypothermia. A porcine animal model was used to study the effect of severe TBI, induced by fluid percussion (FP; 3.5 +/-0.3 atm) in combination with a secondary insult, i.e., temporary blood loss with hypovolemic hypotension. Six-week-old juvenile pigs were subjected to this kind of severe TBI; one group was then submitted to moderate hypothermia at 32 degreesC for 6 h, starting 1 h after brain injury. Animals were killed after 24 h. TBI and hypothermia-associated alterations in the brains were investigated by immunohistochemistry with antibodies against microtubule-associated protein 2 (MAP-2) and beta -amyloid precursor protein (beta APP). In addition, DNA fragmentation was investigated by the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) method. Seven of the 13 normothermic TBI animals developed a secondary increase in ICP (TBI-NT-ICP) after an interval of several hours. None of the animals in the hypothermic trauma (TBI-HT) group exhibited a secondary ICP increase, indicating a protective effect of the treatment. TBI-HT animals showed significantly higher levels of MAP-2 immunoreactivity, lower levels of beta APP immunoreactivity and less DNA fragmentation than the TBI-NT-ICP animals. Differences between the TBI-HT group and normothermic animals without an ICP increase (TBI-NT) were less marked. A considerable decrease in MAP-2 outside the site of TBI-FP administration was seen only in the TBI-NT-ICP animals. MAP-2 immunohistochemistry was thus a reliable marker of diffuse brain damage. Axonal injury was present in all TBI groups, indicating its special significance in neurotrauma. Thus, severe TBI caused by FP, combined with temporary blood loss, consistently produced traumatic axonal injury and focal brain damage. Mild hypothermia was able to prevent a secondary increase in ICP and its sequelae of diffuse hypoxic-ischemic brain injury. However, hypothermia did not afford protection from traumatic axonal injury.	Univ Jena, Inst Pathol Neuropathol, D-07740 Jena, Germany; Univ Jena, Clin Anesthesiol & Intens Care, D-07740 Jena, Germany; Univ Jena, Inst Pathophysiol, D-07740 Jena, Germany	Patt, S (corresponding author), Univ Jena, Inst Pathol Neuropathol, Bachstr 18, D-07740 Jena, Germany.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Arani R B, 1998, J Biopharm Stat, V8, P585, DOI 10.1080/10543409808835262; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Bernard S, 1996, ANAESTH INTENS CARE, V24, P382, DOI 10.1177/0310057X9602400315; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CRUTCHFIELD JS, 1990, J NEUROSURG, V72, P482, DOI 10.3171/jns.1990.72.3.0482; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentleman SM, 1999, NEUROPATH APPL NEURO, V25, P41; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P198; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Laptook AR, 1997, PEDIATR RES, V42, P17, DOI 10.1203/00006450-199707000-00004; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Patt S, 1999, EXP TOXICOL PATHOL, V51, P119, DOI 10.1016/S0940-2993(99)80084-0; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Suehiro E, 1999, J NEUROTRAUM, V16, P285, DOI 10.1089/neu.1999.16.285; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SUNDBARG G, 1987, J NEUROSURG, V67, P841, DOI 10.3171/jns.1987.67.6.0841; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TOMINAGA T, 1993, BRAIN RES, V608, P21, DOI 10.1016/0006-8993(93)90768-I; WALTER B, 1997, PFLUGERS ARCH S, V433, pR63; Wladis A, 1998, J TRAUMA, V45, P527, DOI 10.1097/00005373-199809000-00019; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610; Yoshikawa T., 1968, ATLAS BRAINS DOMESTI; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046	68	31	31	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAY	2001	101	5					424	434					11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	446UU	WOS:000169533200002	11484813				2021-06-18	
J	Bondarenko, A; Chesler, M				Bondarenko, A; Chesler, M			Calcium dependence of rapid astrocyte death induced by transient hypoxia, acidosis, and extracellular ion shifts	GLIA			English	Article						ischemia; BCECF; BAPTA-AM; Na+-Ca2(+) exchange; benzamil; KB-R7943	PERMEABILITY TRANSITION; NA+/CA2+ EXCHANGE; NA+ HOMEOSTASIS; RAT; ISCHEMIA; NEURONS; SODIUM; VULNERABILITY; INHIBITION; CULTURES	Exposure to hypoxic, acidic, ion-shifted Ringer (HAIR) for 15-40 min has been shown to cause rapid astrocyte death upon reperfusion with normal media. The ion shifts of the HAIR solution included a rise in extracellular K+ (e.g., [K+](o)) and a fall in [Na+](o), [Cl-](o), and [Ca2+](o), characteristic of ischemic-traumatic brain insults. We investigated the ionic basis of the HAIR-induced injury. After HAIR exposure, reperfusion in 0 Ca2+/EGTA media completely protected astrocytes. Preincubation of cells in BAPTA-AM ester was also protective, indicating that the injury was triggered by Ca2+ influx during reperfusion. Neither nimodipine, CNQX, APV, nor TTX reduced injury. Astrocyte death could be blocked by 100 muM Ni2+ or 100 muM benzamil, suggesting involvement of Na+-Ca2+ exchange. KB-R7943, which preferentially inhibits reverse Na+-Ca2+ exchange, also protected astrocytes. Elevation of [K+](o) was not necessary for astrocyte death. However, when [Na+](o) was maintained at 151 mM throughout the HAIR protocol, cell death was markedly reduced. We postulate that [Na+](o) shifts aid reversal of Na+-Ca2+ exchange by favoring cytosolic Na+ loading. Possible means of astrocytic Na+ accumulation are discussed. GLIA 34:143-149, 2001. (C) 2001 Wiley-Liss, Inc.	NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Dept Neurosurg, New York, NY 10016 USA	Chesler, M (corresponding author), NYU, Sch Med, Dept Physiol & Neurosci, 550 1st Ave, New York, NY 10016 USA.	mitch.chesler@med.nyu.edu	Bondarenko, Alexander I/B-3080-2013	Chesler, Mitchell/0000-0002-3189-8234	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034906] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34906] Funding Source: Medline		Agrawal SK, 1996, J NEUROSCI, V16, P545; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BEVENSEE M, 2000, SOC NEUR ABS, V26, P2061; BEVENSEE MO, 1995, J NEUROSCI METH, V58, P61, DOI 10.1016/0165-0270(94)00159-E; Bondarenko A, 2001, GLIA, V34, P134, DOI 10.1002/glia.1048; BONDARENKO A, 2000, SOC NEUR ABS, V26, P1893; Breder J, 2000, NEUROPHARMACOLOGY, V39, P1779, DOI 10.1016/S0028-3908(00)00027-7; Chidekel AS, 1997, EXP NEUROL, V146, P403, DOI 10.1006/exnr.1997.6544; Dubinsky JM, 1999, BIOCHEM SOC SYMP, V66, P75, DOI 10.1042/bss0660075; Duffy S, 1996, J NEUROSCI, V16, P71; DUGAN LL, 1995, J NEUROSCI, V15, P4545; GOLDMAN WF, 1994, J NEUROSCI, V14, P5834; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; Hoyt KR, 1998, MOL PHARMACOL, V53, P742; Iwamoto T, 1998, AM J PHYSIOL-CELL PH, V275, pC423; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; Kristal BS, 1997, J NEUROCHEM, V69, P524; MACVICAR BA, 1991, GLIA, V4, P448, DOI 10.1002/glia.440040504; Matsuda T, 1996, EUR J NEUROSCI, V8, P951, DOI 10.1111/j.1460-9568.1996.tb01582.x; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Phillis JW, 1999, BRAIN RES, V839, P199, DOI 10.1016/S0006-8993(99)01705-9; PITTS BJR, 1979, J BIOL CHEM, V254, P6232; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; Rose CR, 1997, J PHYSIOL-LONDON, V499, P573, DOI 10.1113/jphysiol.1997.sp021951; Rose CR, 1998, J NEUROSCI, V18, P3554; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; SHELDON C, 2000, SOC NEUR ABS, V26, P763; STYS PK, 1992, J NEUROSCI, V12, P430; TAKUMA K, 1994, GLIA, V12, P336, DOI 10.1002/glia.440120410; Vornov JJ, 1996, J NEUROCHEM, V67, P2379; YAO H, 2000, SOC NEUR ABS, V26, P1671; Ying WH, 1999, J NEUROCHEM, V73, P1549, DOI 10.1046/j.1471-4159.1999.0731549.x	34	31	33	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR 15	2001	34	2					143	149		10.1002/glia.1049			7	Neurosciences	Neurosciences & Neurology	429NH	WOS:000168523500008	11307163				2021-06-18	
J	Arciniegas, DB; Topkoff, JL; Rojas, DC; Sheeder, J; Teale, P; Young, DA; Sandberg, E; Reite, ML; Adler, LE				Arciniegas, DB; Topkoff, JL; Rojas, DC; Sheeder, J; Teale, P; Young, DA; Sandberg, E; Reite, ML; Adler, LE			Reduced hippocampal volume in association with P50 nonsuppression following traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							HEAD-INJURY; NICOTINIC RECEPTORS; EVOKED RELEASE; WHITE-MATTER; SCHIZOPHRENICS; ACETYLCHOLINE; RATS; NORMALIZATION; CONSCIOUSNESS; DYSFUNCTION	Traumatic brain injury (TBI) may produce persistently impaired auditory gating. This cholinergic-dependent, hippocampally mediated preattentive cognitive function that facilitates filtering of auditory stimuli may be indexed by the P50 evoked waveform to paired auditory stimuli. Abnormal P50 suppression post TBI is believed to result from injury to the hippocampus and/or its afferent cholinergic projections. This hypothesis was tested by comparing hippocampal and total brain volumes on MRI between ten P50-nonsuppressing TBI patients and ten normal control subjects matched for age, gender, and education. TBI subjects had highly significant bilateral hippocampal volume reductions, even when covaried for reductions in total brain volume. Degree of volume loss was not correlated with initial TBI severity. Findings support the hypothesis that hippocampal injury underlies P50 nonsuppression post TBI and suggest that such structural abnormalities may be observed even in "mildly" injured persons.	Vet Affairs Med Ctr, Res Serv, Denver, CO USA; Vet Affairs Med Ctr, Serv Radiol, Denver, CO USA; Vet Affairs Med Ctr, Psychiat Serv, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Radiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA	Arciniegas, DB (corresponding author), Campus Box C268-68,4200 E 9th Ave, Denver, CO 80262 USA.		Arciniegas, David/A-3792-2009; Rojas, Don/F-4296-2012; Sheeder, Jeanelle/D-4960-2013; Rojas, Don/AAX-6678-2020	Sheeder, Jeanelle/0000-0002-4463-3569; Rojas, Don/0000-0001-6560-9616			Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320; ADLER LE, 1992, BIOL PSYCHIAT, V32, P607, DOI 10.1016/0006-3223(92)90073-9; ADLER LE, 1993, AM J PSYCHIAT, V150, P1856; Adler LE, 1999, BIOL PSYCHIAT, V46, P8, DOI 10.1016/S0006-3223(99)00085-2; ADLER LE, 1994, NEUROPSYCHOPHARMACOL, V10, P249, DOI 10.1038/npp.1994.28; ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Cassidy John W., 1994, P43; CAVE CB, 1992, HIPPOCAMPUS, V2, P151, DOI 10.1002/hipo.450020207; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DLER LE, 1991, AM PSYCH ASS 144 ANN; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; Filley C., 1995, NEUROBEHAVIORAL ANAT; Filley CM, 1998, NEUROLOGY, V50, P1535, DOI 10.1212/WNL.50.6.1535; FREEDMAN R, 1993, J NEUROSCI, V13, P1965; FREEDMAN R, 1994, HARVARD REV PSYCHIAT, V2, P179, DOI 10.3109/10673229409017136; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Halliday A, 1999, TRAUMATIC BRAIN INJU, P29; Jackson GD, 1996, MRI NEUROANATOMY NEW; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; JENNETT B, 1975, LANCET, V1, P480; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P947, DOI 10.1080/01688639308402610; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCALLISTER TW, 1994, NEUROPSYCHIATRY TRAU, P35; Mesulam M-M, 1985, PRINCIPLES BEHAV NEU, P125; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Mu QW, 1999, AM J NEURORADIOL, V20, P207; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Naatanen R., 1986, ADAPTATION STRESS TA, P91; Naatanen R., 1992, ATTENTION BRAIN FUNC; Nagamoto HT, 1996, BIOL PSYCHIAT, V40, P181, DOI 10.1016/0006-3223(95)00371-1; NAGAMOTO HT, 1989, BIOL PSYCHIAT, V25, P549, DOI 10.1016/0006-3223(89)90215-1; Neppe VM, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P149; NIEWENHUYS R, 1988, HUMAN CENTRAL NERVOU; REITE M, 1994, COGNITIVE BRAIN RES, V2, P13, DOI 10.1016/0926-6410(94)90016-7; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Silver JM., 1994, NEUROPSYCHIATRY TRAU; STRUB RL, 1988, NEUROBEHAVIORAL DISR; TEASDALE G, 1974, LANCET, V2, P81; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; WALDO MC, 1994, SCHIZOPHR RES, V12, P93, DOI 10.1016/0920-9964(94)90067-1; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514	55	31	33	0	3	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2001	13	2					213	221		10.1176/appi.neuropsych.13.2.213			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	432JE	WOS:000168687800007	11449028				2021-06-18	
J	Leon-Carrion, J; de Serdio-Arias, ML; Murillo-Cabezas, F; Roldan, JMD; Dominguez-Morales, R; Martin, JMBY; Sanchez, MAM				Leon-Carrion, J; de Serdio-Arias, ML; Murillo-Cabezas, F; Roldan, JMD; Dominguez-Morales, R; Martin, JMBY; Sanchez, MAM			Neurobehavioural and cognitive profile of traumatic brain injury patients at risk for depression and suicide	BRAIN INJURY			English	Article								The possibility that patients who have suffered a traumatic brain injury will commit suicide is high, and in many cases clinicians tend to underestimate this possibility. In this study, 39 consecutive patients are studied through a Rorschach technique more than 1.5 years after their hospital discharge. The data show that 48.6% of the patients fulfil the criteria that classifies them as depressive, and, of these, 65% are at clinical risk to commit suicide (33.3% of the total of TBI patients); 25.6% have not met the criteria of depression or suicidal tendencies, and another 25.6% show very low suicide tendency scores. Only 15.6% of the total patients presented only depression without risk of suicide. The neurobehavioural and cognitive profile of the TBI suicide-prone patient shows an emotional person with cognitive difficulties in how they interpret reality, the person tries to understand what is happening around them, but is unable to cope. They show concrete thoughts, although they have difficulties solving problems and have few intellectual resources to cope with their surroundings. They do not know how to distance themselves from the emotional aspects of situations.	Univ Seville, Dept Expt Psychol, Human Neuropsychol Lab, Avda San Francisco Javier S-N, Seville 41005, Spain; Univ Hosp Traumatol, Seville, Spain; Ctr Brain Injury Rehabil CRECER, Seville, Spain	Leon-Carrion, J (corresponding author), Univ Seville, Dept Expt Psychol, Human Neuropsychol Lab, Avda San Francisco Javier S-N, Seville 41005, Spain.	jleon@cica.es	Dominguez-Roldan, Jose-Maria/M-1728-2016; Murillo-Cabezas, Francisco/AAO-3348-2021; IBIS, NEUROCRITICOS/C-1805-2016; Leon Carrion, Jose/D-5638-2012	Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478; 			ACHTE KA, 1971, ACTA PSYCHIAT SCAND, P1; EXNER JE, 1986, RORSCHACH COMPREHENS, V1; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GAULTIERI C, 1991, BRAIN INJURY, V5, P219; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; HUTCHINSON G, 1991, W INDIAN MED J, V40, P69; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Leon-Carrion J, 1997, NEUROPSYCHOL REHABIL, P415; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MITTERAUER B, 1989, Versicherungsmedizin, V41, P181; Montgomery S A, 1992, Drugs, V43 Suppl 2, P24; ROBERTS AH, 1997, SEVERE ACCIDENTAL HE; Robinson Robert G., 1994, P219; SECHTER D, 1991, Encephale, V17, P361; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128	15	31	32	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2001	15	2					175	181		10.1080/026990501458407			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	398BG	WOS:000166733800009	11260767				2021-06-18	
J	Tauskela, JS; Comas, T; Hewitt, K; Monette, R; Paris, J; Hogan, M; Morley, P				Tauskela, JS; Comas, T; Hewitt, K; Monette, R; Paris, J; Hogan, M; Morley, P			Cross-tolerance to otherwise lethal N-methyl-D-aspartate and oxygen-glucose deprivation in preconditioned cortical cultures	NEUROSCIENCE			English	Article						ischemia; calpain; PSD-95; MAP-2; calcium; Fluo-4	CEREBELLAR GRANULE CELLS; HIPPOCAMPAL CA1 NEURONS; TRAUMATIC BRAIN INJURY; NMDA RECEPTOR; ISCHEMIC TOLERANCE; CALPAIN-I; GERBIL HIPPOCAMPUS; CEREBRAL-ISCHEMIA; GENE-EXPRESSION; GLOBAL-ISCHEMIA	In vitro ischemic preconditioning induced by subjecting rat cortical cultures to nonlethal oxygen-glucose deprivation protects against a subsequent exposure to otherwise lethal oxygen-glucose deprivation. We provide evidence that attenuation of the postsynaptic,N-methyl-D-aspartate (NMDA) receptor- and Ca2+-dependent neurotoxicity underlies oxygen-glucose deprivation tolerance. It is demonstrated that extended tolerance to otherwise lethal NMDA or oxygen-glucose deprivation can be induced by either of their sublethal forms of preconditioning. These four pathways are linked. since NMDA receptor blockade during preconditioning by oxygen-glucose deprivation eliminates tolerance. These results suggest that NMDA tolerance, induced by nonlethal activation of these receptors during oxygen-glucose deprivation preconditioning, underlies oxygen-glucose deprivation tolerance. Several neurotoxic downstream Ca2+-dependent signaling events specifically linked to NMDA receptor activation are attenuated during otherwise lethal oxygen-glucose deprivation in preconditioned cultures. Specifically, calpain activation, as well as degradation of microtubule-associated protein-2 and postsynaptic density-95. are attenuated 2 h following otherwise lethal NMDA treatment alone or oxygen-glucose deprivation in preconditioned cultures. Formation of microtubule-associated protein-2-labeled dendritic varicosities is also attenuated in preconditioned cultures within 1 h of lethal oxygen-glucose deprivation or NMDA application. Intracellular Ca2+ levels, measured using the high- or low-affinity dyes Fluo-4 (K-d congruent to 345 nM) or Fluo-4FF (K-d congruent to 9.7 muM) respectively, are markedly attenuated during lethal oxygen-glucose deprivation in preconditioned cultures. Collectively. the results suggest the attenuation of the postsynaptic NMDA-mediated component of otherwise lethal oxygen-glucose deprivation through the suppression of Ca2+-dependent neurotoxic signaling, a mechanism that is initially induced by transient nonlethal activation of this receptor during ischemic preconditioning. Crown Copyright (C) 2001 Published by Elsevier Science Ltd on behalf of IBRO, All rights reserved.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Ottawa, Dept Mol Genet, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada	Tauskela, JS (corresponding author), Natl Res Council Canada, Inst Biol Sci, Montreal Rd Campus,Bldg M-54, Ottawa, ON K1A 0R6, Canada.		Hogan, Matthew/AAP-4735-2020	Hogan, Matthew/0000-0003-4660-8743			Adamchik Y, 2000, NEUROSCIENCE, V99, P731, DOI 10.1016/S0306-4522(00)00229-3; Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; BLACK MA, 1995, J NEUROCHEM, V65, P2170; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; Bond A, 1999, EUR J PHARMACOL, V380, P91, DOI 10.1016/S0014-2999(99)00523-3; BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259; Bruer U, 1997, FEBS LETT, V414, P117, DOI 10.1016/S0014-5793(97)00954-X; CHUANG DM, 1992, MOL PHARMACOL, V42, P210; DAMSCHRODERWILLIAMS P, 1995, J NEUROCHEM, V65, P1069; Dickie BGM, 1996, NEUROSCIENCE, V72, P731, DOI 10.1016/0306-4522(95)00611-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farwell W, 1998, NEUROCHEM RES, V23, P539, DOI 10.1023/A:1022486619201; Gage AT, 1996, BRAIN RES, V719, P172, DOI 10.1016/0006-8993(96)00092-3; Gidday JM, 1999, J CEREBR BLOOD F MET, V19, P331, DOI 10.1097/00004647-199903000-00011; GOLDBERG MP, 1990, STROKE, V21, P75; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Grabb MC, 1999, J NEUROSCI, V19, P1657; Hewitt KE, 1998, J NEUROSCI RES, V54, P223, DOI 10.1002/(SICI)1097-4547(19981015)54:2<223::AID-JNR10>3.0.CO;2-5; HIMORI N, 1991, NEUROPHARMACOLOGY, V30, P1179, DOI 10.1016/0028-3908(91)90163-6; Johns L, 2000, BIOCHEM BIOPH RES CO, V276, P134, DOI 10.1006/bbrc.2000.3443; Jonas W, 2001, NEUROREPORT, V12, P335, DOI 10.1097/00001756-200102120-00031; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KATO H, 1992, NEUROSCI LETT, V139, P118, DOI 10.1016/0304-3940(92)90871-4; Kawai K, 1998, J CEREBR BLOOD F MET, V18, P288, DOI 10.1097/00004647-199803000-00007; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; Laferriere NB, 1999, NEUROL RES, V21, P524, DOI 10.1080/01616412.1999.11740969; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Lipsky RH, 2001, J NEUROCHEM, V78, P254, DOI 10.1046/j.1471-4159.2001.00386.x; Lu XY, 2000, NEUROSCI LETT, V286, P149, DOI 10.1016/S0304-3940(00)01101-0; MARINI AM, 1993, ANN NY ACAD SCI, V679, P253, DOI 10.1111/j.1749-6632.1993.tb18305.x; Marini AM, 1998, J BIOL CHEM, V273, P29394, DOI 10.1074/jbc.273.45.29394; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; Nath R, 1998, J NEUROCHEM, V71, P186; Ohta S, 1996, J CEREBR BLOOD F MET, V16, P915, DOI 10.1097/00004647-199609000-00015; OSTER Y, 1993, NEUROSCI LETT, V163, P85, DOI 10.1016/0304-3940(93)90235-D; Perez-Pinzon MA, 1999, NEUROREPORT, V10, P2951, DOI 10.1097/00001756-199909290-00014; Plamondon H, 1999, J CEREBR BLOOD F MET, V19, P1296, DOI 10.1097/00004647-199912000-00002; Pringle AK, 1999, BRAIN RES, V845, P152, DOI 10.1016/S0006-8993(99)01916-2; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Sattler R, 2000, J NEUROSCI, V20, P22, DOI 10.1523/JNEUROSCI.20-01-00022.2000; SCHURR A, 1986, BRAIN RES, V374, P244, DOI 10.1016/0006-8993(86)90418-X; Schurr A, 2001, NEUROSCI LETT, V307, P151, DOI 10.1016/S0304-3940(01)01937-1; Shamloo M, 1999, J CEREBR BLOOD F MET, V19, P173; Shimazaki K, 1998, NEUROREPORT, V9, P1875, DOI 10.1097/00001756-199806010-00038; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Stagliano NE, 1999, J CEREBR BLOOD F MET, V19, P757, DOI 10.1097/00004647-199907000-00005; Takagi N, 2000, J NEUROCHEM, V74, P169, DOI 10.1046/j.1471-4159.2000.0740169.x; Tauskela JS, 1999, BRAIN RES, V827, P143, DOI 10.1016/S0006-8993(99)01322-0; Tokunaga H, 1998, BRAIN RES, V784, P316, DOI 10.1016/S0006-8993(97)01237-7; Tremblay R, 2000, J NEUROSCI, V20, P7183; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; XU GP, 2001, J CEREB BLOOD FLO S1, V21, pS238; Ying HS, 1997, J NEUROSCI, V17, P9536	60	31	32	1	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2001	107	4					571	584		10.1016/S0306-4522(01)00381-5			14	Neurosciences	Neurosciences & Neurology	501AV	WOS:000172661600004	11720781				2021-06-18	
J	Mautes, AEM; Bergeron, M; Sharp, FR; Panter, SS; Weinzierl, M; Guenther, K; Noble, LJ				Mautes, AEM; Bergeron, M; Sharp, FR; Panter, SS; Weinzierl, M; Guenther, K; Noble, LJ			Sustained induction of heme oxygenase-1 in the traumatized spinal cord	EXPERIMENTAL NEUROLOGY			English	Article						heat shock proteins; HSP32; HSP70; heme oxygenase-1; spinal cord hemisection; microglia/macrophages; astrocytes; inflammation	HEAT-SHOCK-PROTEIN; TRANSIENT FOREBRAIN ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; FACTOR-KAPPA-B; RAT-BRAIN; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; INSITU HYBRIDIZATION; OXIDATIVE STRESS; CELL-DEATH	Oxidative stress contributes to secondary injury after spinal cord trauma. Among the consequences of oxidative stress is the induction of heme oxygenase-1 (HO-1), an inducible isozyme that metabolizes heme to iron, biliverdin, and carbon monoxide. Here we examine the induction of HO-1 in the hemisected spinal cord, a model that results in reproducible degeneration in the ipsilateral white matter. HO-1 was induced in microglia and macrophages from 24 h to at least 42 days after injury. Within the first week after injury, HO-1 was induced in both the gray and the white matter. Thereafter, HO-1 expression was limited to degenerating fiber tracts. HSP70, a heat shock protein induced mainly by the presence of denatured proteins, was consistently colocalized with HO-1 in the microglia and macrophages. This study to demonstrates long-term induction of HO-1 and HSP70 in microglia and macrophages after traumatic injury and an association between induction of HO-1 and Wallerian degeneration. White matter degeneration is characterized by phagocytosis of cellular debris and remodeling of surviving tissue. This results in the metabolism, synthesis, and turnover of heme and heme proteins. Thus, sustained induction of HO-1 and HSP70 in microglia and macrophages suggests that tissue degeneration is an ongoing process, lasting 6 weeks and perhaps even longer. (C) 2000 Academic Press.	Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; San Francisco State Univ, Grad Program Phys Therapy, San Francisco, CA 94132 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Dept Vet Affairs Med Ctr, San Francisco, CA USA; Univ Saarland, Sch Med, Neurosurg Res Lab, D-66421 Homburg, Germany; Rhein Westfal TH Aachen, Dept Neurosurg, D-52074 Aachen, Germany	Mautes, AEM (corresponding author), Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL053040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023324] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL53040] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS23324] Funding Source: Medline		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; ALAM J, 1992, J BIOL CHEM, V267, P21894; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; APPLEGATE LA, 1991, CANCER RES, V51, P974; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Bauer I, 1998, HEPATOLOGY, V27, P829, DOI 10.1002/hep.510270327; Bergeron M, 1998, DEV BRAIN RES, V105, P181, DOI 10.1016/S0165-3806(97)00169-7; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CANTONI L, 1991, BIOCHEM J, V279, P891, DOI 10.1042/bj2790891; CONNOR JR, 1994, J NEUROSCI RES, V37, P461, DOI 10.1002/jnr.490370405; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DINARELLO CA, 1992, BACTERIAL ENDOTOXIC, P105; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; DWYER BE, 1995, NEUROREPORT, V6, P973, DOI 10.1097/00001756-199505090-00006; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; Ewing JF, 1997, BRAIN RES PROTOC, V1, P165, DOI 10.1016/S1385-299X(96)00027-X; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Foster J, 1996, BRAIN RES, V724, P73, DOI 10.1016/0006-8993(96)00266-1; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Harrub JB, 1998, NEUROCHEM RES, V23, P703, DOI 10.1023/A:1022499107910; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; LAVROVSKY Y, 1993, BIOCHEM BIOPH RES CO, V196, P336, DOI 10.1006/bbrc.1993.2253; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PJ, 1996, AM J RESP CELL MOL, V14, P556, DOI 10.1165/ajrcmb.14.6.8652184; Liu XZ, 1997, J NEUROSCI, V17, P5395; LONGO FM, 1993, J NEUROSCI RES, V36, P325, DOI 10.1002/jnr.490360310; MAINES MD, 1988, FASEB J, V2, P2557; MAINES MD, 1986, J BIOL CHEM, V261, P411; MANZERRA P, 1994, SOC NEUR ABSTR, V20; MASING TE, 1989, NEUROCHEM RES, V14, P725, DOI 10.1007/BF00964949; MASSA SM, 1995, J NEUROSCI RES, V40, P807, DOI 10.1002/jnr.490400612; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MITANI K, 1992, BLOOD, V79, P1255; MULLER RM, 1987, J BIOL CHEM, V262, P6795; Nesathurai S, 1998, J TRAUMA, V45, P1088, DOI 10.1097/00005373-199812000-00021; Nimura T, 1996, MOL BRAIN RES, V37, P201, DOI 10.1016/0169-328X(95)00315-J; OKINAGA S, 1993, EUR J BIOCHEM, V212, P167, DOI 10.1111/j.1432-1033.1993.tb17647.x; Panizzon KL, 1996, NEUROREPORT, V7, P662, DOI 10.1097/00001756-199601310-00067; PASCHEN W, 1994, NEUROSCI LETT, V180, P5, DOI 10.1016/0304-3940(94)90900-8; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Povlishock J T, 1992, Hum Cell, V5, P345; PREMKUMAR DRD, 1995, J NEUROCHEM, V65, P1399; Richmon JD, 1998, BRAIN RES, V780, P108, DOI 10.1016/S0006-8993(97)01314-0; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Sakurai M, 1997, J THORAC CARDIOV SUR, V113, P159, DOI 10.1016/S0022-5223(97)70411-2; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHWARTZMAN AN, 1997, BIOCHEM PHARMACOL, V53, P1069; SHARMA HS, 1995, NEUROSCI RES, V21, P241, DOI 10.1016/0168-0102(94)00855-A; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; SMITH MA, 1995, MOL CHEM NEUROPATHOL, V24, P227, DOI 10.1007/BF02962147; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Takeda A, 1996, NEUROSCI LETT, V205, P169, DOI 10.1016/0304-3940(96)12405-8; Takizawa S, 1998, J CEREBR BLOOD F MET, V18, P559, DOI 10.1097/00004647-199805000-00011; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87	74	31	33	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2000	166	2					254	265		10.1006/exnr.2000.7520			12	Neurosciences	Neurosciences & Neurology	380PB	WOS:000165709300006	11085891				2021-06-18	
J	Thornton, K				Thornton, K			Improvement/rehabilitation of memory functioning with neurotherapy/QEEG biofeedback	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						auditory memory rehabilitation; EEG biofeedback; memory improvement; neurotherapy; QEEG biofeedback	CLOSED-HEAD-INJURY; REHABILITATION; REMEDIATION; PERFORMANCE; STRATEGIES; COMPLAINT; DISORDERS; PROGRAM	This article presents a new approach to the remediation of memory deficits by studying the electrophysiological functioning involved in memory and applying biofeedback techniques. A Quantitative EEG (QEEG) activation database was obtained with 59 right-handed subjects during two auditory memory tasks (prose passages and word lists). Memory performance was correlated with the QEEG variables. Clinical cases were administered the same QEEG activation study to determine their deviations from the values that predicted success for the reference group. EEG biofeedback interventions were designed to increase the value (to normal levels) of the specific electrophysiological variable that was related to successful memory function and deviant hi the subject. Case examples are presented that indicate the successful use of this intervention style in normal subjects and in subjects with brain injury; improvement cannot be fully explained by spontaneous recovery; given the time postinjury. Five cases (two normal, two subjects with brain injury, and one subject who had stereotactic surgery of the hippocampus for seizure control) are presented. Improvements ranged from 68% to 181% in the group of patients with brain injury, as a result of the interventions.	Ctr Hlth Psychol, S Plainfield, NJ 07080 USA	Thornton, K (corresponding author), Ctr Hlth Psychol, S Plainfield, NJ 07080 USA.			thornton, kirtley/0000-0002-3303-4747			Benedict R. H., 1992, J HEAD TRAUMA REHAB, V7, P83; BENEDICT RHB, 1989, CLIN PSYCHOL REV, V9, P605; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; BEST DL, 1992, APPL COGNITIVE PSYCH, V6, P405, DOI 10.1002/acp.2350060505; Campbell D.T, 1963, EXPT QUASIEXPERIMENT; CROSSON B, 1984, J CLIN NEUROPSYCHOL, V6, P287, DOI 10.1080/01688638408401219; FRANZEN M D, 1991, Neuropsychology Review, V2, P29, DOI 10.1007/BF01108846; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; Grafman J, 1984, BEHAV ASSESSMENT TRE, P151; HARDT JV, 1978, SCIENCE, V201, P79, DOI 10.1126/science.663641; Linden Michael, 1996, BIOFEEDBACK SELF REG, V21; LUBAR JO, 1984, BIOFEEDBACK SELF-REG, V9, P1, DOI 10.1007/BF00998842; MALEC J, 1983, ARCH PHYS MED REHAB, V64, P436; MATEER CA, 1990, COGNITIVE REHABILITA, P68; MATEER CA, 1988, NEUROPSYCHOLOGICAL S, P204; MATEER CA, 1992, REHABILITATION POSTC, P143; McKinlay W W, 1992, Brain Inj, V6, P107, DOI 10.3109/02699059209029649; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; OTHMER S, 1992, HANDOUT EEG SPECTRUM; PENICK EC, 1990, J CHEM DEPEND TREAT, V3, P1; PENISTON EG, 1991, MED PSYCHOTHERAPY, V4, P1; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Roland P. E., 1993, BRAIN ACTIVATION; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; STEINGASS HP, 1994, NEUROPSYCHOL REHABIL, V4, P49, DOI 10.1080/09602019408401455; Sterman MB, 2000, CLIN ELECTROENCEPHAL, V31, P45, DOI 10.1177/155005940003100111; TANSEY MA, 1991, AUST J PSYCHOL, V43, P147, DOI 10.1080/00049539108260139; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; Thompson L, 1998, APPL PSYCHOPHYS BIOF, V23, P243, DOI 10.1023/A:1022213731956; THORNTON K, 2000, J NEUROTHER, V4; VANDAM G, 1986, AM J PSYCHOL, V99, P103, DOI 10.2307/1422307; WILSON M, 1991, ARCH VIROL         S, V2, P117; ZARIT SH, 1981, EDUC GERONTOL, V6, P11, DOI 10.1080/0380127810060102	35	31	32	0	4	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2000	15	6					1285	1296		10.1097/00001199-200012000-00008			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	378ZX	WOS:000165617400008	11056409				2021-06-18	
J	Kennedy, MRT; Yorkston, KM				Kennedy, MRT; Yorkston, KM			Accuracy of metamemory after traumatic brain injury: Predictions during verbal learning	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						brain injury memory; metamemory; unawareness; executive function	CLOSED-HEAD-INJURY; BRAIN INJURY; IMPAIRED AWARENESS; AMNESIC PATIENTS; MEMORY; JUDGMENTS; JOL; DEFICITS; ADULTS; SCALE	The primary intent of this study was to investigate the metamemory monitoring abilities of adult survivors of at least moderate traumatic brain injury (TBI) during a verbal-learning activity Eighteen survivors and 18 non-injured control participants made judgment-of-learning (JOL) predictions of their recall ability immediately after studying 3 lists of noun-pairs or after a slight delay. A secondary intent of this study was to determine if verbal retrieval attempts would enhance predictive accuracy. One half of participants made retrieval attempts during the second and third list-learning task, and the other half made retrieval attempts during the third list-learning task only. Measures of the correlation between JOL predictions and recall accuracy revealed that survivors were as accurate as controls when making delayed predictions and were less accurate when making immediate predictions. This occurred regardless of retrieval attempts. Absolute measures that compared mean JOL ratings to overall recall revealed that the survivor group was well-calibrated when making delayed JOL predictions but overestimated when making immediate JOL predictions. The non-injured control group underestimated when making both types of predictions. However, within-group variability was high. These findings are compared to those from studies that investigated metamemory beliefs in which survivors' ratings were compared to family-member ratings. Clinical implications for basing executive decisions about compensatory strategies on delayed and immediate predictions of Future recall are discussed. Additionally, a rationale is provided for the use of both relative and absolute measures of predictive accuracy in metamemory studies involving neurological clinical populations.	Univ Minnesota, Dept Commun Disorders, Minneapolis, MN 55455 USA; Univ Washington, Seattle, WA 98195 USA	Kennedy, MRT (corresponding author), Univ Minnesota, Dept Commun Disorders, 115 Shevlin Hall,164 Pillsbury Dr SE, Minneapolis, MN 55455 USA.	kenne047@tc.umn.edu					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; AMMONS RB, 1979, PSYCHOL REP, V45, P943, DOI 10.2466/pr0.1979.45.3.943; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; CHIANG I, 1999, P RES EXP UND PROGR, P79; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1993, NEUROPSYCHOLOGY, V7, P193, DOI DOI 10.1037/0894-4105.7.2.193; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DUNLOSKY J, 1992, MEM COGNITION, V20, P374, DOI 10.3758/BF03210921; DUNLOSKY J, 1994, J MEM LANG, V33, P545, DOI 10.1006/jmla.1994.1026; Dunlosky J, 1997, J MEM LANG, V36, P34, DOI 10.1006/jmla.1996.2476; DUNLOSKY J, 1997, J GERONTOL B-PSYCHOL, V52, P178; FLAVELL JH, 1979, AM PSYCHOL, V34, P906, DOI 10.1037/0003-066X.34.10.906; Fleming JM, 1996, BRAIN INJURY, V10, P1; GASQUOINE P G, 1991, Brain Injury, V5, P169, DOI 10.3109/02699059109008087; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JANOWSKY JS, 1989, PSYCHOBIOLOGY, V17, P3; Kelemen WL, 1997, J EXP PSYCHOL LEARN, V23, P1394, DOI 10.1037/0278-7393.23.6.1394; KENNEDY MR, 1995, AM J SPEECH-LANG PAT, V4, P159; Kertesz A., 1982, W APHASIA BATTERY; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; LOVELACE EA, 1984, J EXP PSYCHOL LEARN, V10, P756, DOI 10.1037/0278-7393.10.4.756; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MCGLYNN SM, 1991, J COGNITIVE NEUROSCI, V3, P183, DOI 10.1162/jocn.1991.3.2.183; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; METCALF J, 1994, METACOGNITION; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Nelson T. O., 1992, METACOGNITION CORE R; NELSON TO, 1991, PSYCHOL SCI, V2, P267, DOI 10.1111/j.1467-9280.1991.tb00147.x; NELSON TO, 1994, PSYCHOL SCI, V5, P207, DOI 10.1111/j.1467-9280.1994.tb00502.x; NELSON TO, 1984, PSYCHOL BULL, V95, P109, DOI 10.1037/0033-2909.95.1.109; NELSON TO, 1992, PSYCHOL SCI, V3, P317, DOI 10.1111/j.1467-9280.1992.tb00681.x; PAIVIO A, 1968, J EXP PSYCHOL, V76, P1, DOI 10.1037/h0025327; PARKER SA, 1976, ACTA NEUROCHIR, V34, P71, DOI 10.1007/BF01405864; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; REITAN RM, 1985, HALSTAD REITAN NEURO; ROTH DL, 1985, J CLIN PSYCHOL, V41, P521, DOI 10.1002/1097-4679(198507)41:4<521::AID-JCLP2270410412>3.0.CO;2-N; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SCHACTER DL, 1991, AWARENESS DEFICIT BR, P127; SHIMAMURA AP, 1986, J EXP PSYCHOL LEARN, V12, P452, DOI 10.1037/0278-7393.12.3.452; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; TEASDALE G, 1974, LANCET, V2, P81; Trosset M W, 1996, J Int Neuropsychol Soc, V2, P315; Wechsler D., 1987, WECHSLER MEMORY SCAL; YATES FJ, 1990, JUDGMENT DECISION MA; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005	56	31	33	0	3	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA	1092-4388			J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	OCT	2000	43	5					1072	1086		10.1044/jslhr.4305.1072			15	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	365ZC	WOS:000089979500002	11063231				2021-06-18	
J	Eker, C; Schalen, W; Asgeirsson, B; Grande, PO; Ranstam, J; Nordstrom, CH				Eker, C; Schalen, W; Asgeirsson, B; Grande, PO; Ranstam, J; Nordstrom, CH			Reduced mortality after severe head injury will increase the demands for rehabilitation sevices	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-LESIONS; INTRACRANIAL HYPERTENSION; SOCIAL-ADJUSTMENT; SELF-REPORT; PSYCHIATRIC-ILLNESS; VOLUME REGULATION; THERAPY; DIHYDROERGOTAMINE; RECOVERY; CIRCULATION	Primary objective: In 1989, a new therapy to reduce intracranial pressure in severely head-injured patients was introduced in Lund. The new treatment reduced mortality significantly. The present study describes the quality of life for the survivor; Methods and procedures: The study includes 53 patients treated during 1989-1994, according to a new treatment protocol for increased intracranial pressure ('Lund concept' group). During 1982-1986, 38 patients were managed according to a protocol including high dose thiopentone ('Thiopentone' group). The two groups are compared regarding neurophysical and psychiatric symptoms as well as aspects regarding the patient's role, performance, interpersonal relationship, frictions, feelings and satisfaction in work, areas of social and leisure activities, and extended family. Results: Mortality was reduced from 47% to 8%, but the number of patients with a persistent vegetative state and/or remaining severe disability did not increase. However, the number of patients with persisting emotional and intellectual deficits increased significantly. Conclusion: The new treatment regime has dramatically increased the number of survivors after severe head trauma. Although most patients have a favourable outcome, there are more patients with remaining sequelae and disabilities, and the demand for qualified rehabilitation has increased.	Univ Lund Hosp, Dept Clin Neurosci, S-22185 Lund, Sweden	Eker, C (corresponding author), Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden.	carl-henrik.nordstrom@neurokir.lu.se	Ranstam, Jonas/A-4386-2009	Ranstam, Jonas/0000-0002-8287-7273			ASBERG M, 1978, ACTA PSYCHIAT SCAND, V271, P1; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P922, DOI 10.1111/j.1399-6576.1995.tb04199.x; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DODWELL D, 1988, J NEUROL NEUROSUR PS, V51, P833, DOI 10.1136/jnnp.51.6.833; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; GLASS RM, 1978, ARCH GEN PSYCHIAT, V35, P1189; GOLDBERG DP, 1976, BRIT J PSYCHIAT, V129, P61, DOI 10.1192/bjp.129.1.61; GOLDSMITH E, 1972, ECOLOGIST, V2, P2; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; HANSSON L, 1994, SOC PSYCH PSYCH EPID, V29, P83; HESBACHER PT, 1980, J CLIN PSYCHIAT, V41, P6; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MELLANDER S, 1970, CLIN SCI, V39, P183, DOI 10.1042/cs0390183; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P916, DOI 10.1111/j.1399-6576.1995.tb04198.x; Nilsson F, 1997, ACTA ANAESTH SCAND, V41, P1257, DOI 10.1111/j.1399-6576.1997.tb04641.x; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SCHALEN W, 1992, ACTA NEUROCHIR, V117, P153, DOI 10.1007/BF01400613; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEISSMAN MM, 1978, J NERV MENT DIS, V166, P317, DOI 10.1097/00005053-197805000-00002; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140; WINOKUR A, 1984, BRIT J PSYCHIAT, V144, P395, DOI 10.1192/bjp.144.4.395	45	31	31	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2000	14	7					605	619					15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	335AV	WOS:000088220600002	10914643				2021-06-18	
J	Serradji, N; Bensaid, O; Martin, M; Kan, E; Dereuddre-Bosquet, N; Redeuilh, C; Huet, J; Heymans, F; Lamouri, A; Clayette, P; Dong, CZ; Dormont, D; Godfroid, JJ				Serradji, N; Bensaid, O; Martin, M; Kan, E; Dereuddre-Bosquet, N; Redeuilh, C; Huet, J; Heymans, F; Lamouri, A; Clayette, P; Dong, CZ; Dormont, D; Godfroid, JJ			Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; BIOLOGICAL-ACTIVITY; HUMAN MONOCYTES; TNF-ALPHA; RECEPTOR; DESIGN; RP-55778; EXPRESSION	Excessive levels of PAF and cells of macrophage lineage appear to play an important role in neuronal cell injury, inflammatory syndrome, and HIV replication in CNS resulting in AIDS dementia complex (ADC). The beneficial effects of PAF receptor antagonists are evident and give rise to expected therapeutic strategies for neurotrauma. Piperazine derivatives bearing a "cache-oreilles" (ear-muff) electronic distribution are able to inhibit in vitro PAF effects and, thus, could be used in pathologies where this mediator is involved. Therefore, their potential anti-HIV activity was investigated, and we find that (i) these PAF antagonists are effectively active in HIV-infected monocyte-derived macrophages (MDM) but there is no correlation between both anti-HIV and anti-PAF activities; (ii) the presence of a carbamate function (compounds 1a-d) is favorable to the antiviral activity; (iii) the lipophilicity of the substituent on the piperazinic cycle seems to be less important for the anti-PAF activity than for the antiviral one. Our leading compound, PMS 601 (compound la), presents a dual activity with IC50 of 8 and 11 mu M for anti-PAF and anti-HIV activity, respectively, without cytotoxic events at 1000 mu M in MDM. Although its mode of action is not clearly defined, these data suggest that PMS 601, which displays no effect on acellular reverse transcriptase or protease tests, deserves further investigation in the treatment of HIV-1-associated dementia.	Univ Paris 07, Lab Pharmacochim Mol, Unite Rech Pharmacochim Mol & Syst Membranaires, F-75251 Paris 05, France; CEA, Serv Neurovirol, DSV DRM, CRSSA, F-92265 Fontenay Aux Roses, France; SPI BIO, F-91741 Massy, France	Godfroid, JJ (corresponding author), Univ Paris 07, Lab Pharmacochim Mol, Unite Rech Pharmacochim Mol & Syst Membranaires, Case 7066,2 Pl Jussieu, F-75251 Paris 05, France.		Serradji, Nawal/AAJ-9599-2020				BATT JP, 1991, J LIPID MEDIATOR, V4, P343; BINISTI C, 1996, J LIPID MEDIAT CELL, V15, P125; Bouras A, 1999, J MED CHEM, V42, P957, DOI 10.1021/jm9803976; CAZENAVE JP, 1979, LAB INVEST, V41, P275; Dagenais P, 1997, J LEUKOCYTE BIOL, V61, P106; DEREUDDREBOSQUE.N, 1997, AIDS RES HUM RETROV, V13, P9961; DIVE G, 1989, J LIPID MEDIATOR, V1, P201; Enting RH, 1998, AIDS, V12, P1941, DOI 10.1097/00002030-199815000-00005; FIDGOR CG, 1983, CELL BIOPHYS, V5, P105; FLOCH A, 1989, J LIPID MEDIATOR, V1, P349; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; HANSCH C, 1973, J MED CHEM, V16, P1207, DOI 10.1021/jm00269a003; Heymans F, 1997, J LIPID MEDIAT CELL, V15, P161, DOI 10.1016/S0929-7855(96)00550-0; HOWARD AD, 1995, CELL IMMUNOL, V164, P105, DOI 10.1006/cimm.1995.1148; Johnson CD, 1999, DIGEST SURG, V16, P93, DOI 10.1159/000018699; KARBER G, 1931, ARCH EXP PATHOL PH, V162, P956; Kolson DL, 1998, ADV VIRUS RES, V50, P1, DOI 10.1016/S0065-3527(08)60804-0; LAMOTTEBRASSEUR J, 1991, LIPIDS, V26, P1167, DOI 10.1007/BF02536524; LAMOURI A, 1993, J MED CHEM, V36, P990, DOI 10.1021/jm00060a006; LENAOUR R, 1994, J GEN VIROL, V75, P1379, DOI 10.1099/0022-1317-75-6-1379; LeTexier L, 1996, J LIPID MEDIAT CELL, V13, P207; MARTIN M, UNPUB ANTIMICROB AGE; Perry SW, 1998, J BIOL CHEM, V273, P17660, DOI 10.1074/jbc.273.28.17660; REKKER RF, 1979, EUR J MED CHEM, V14, P479; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; ROLAPLESZCZYNSKI M, 1990, J LIPID MEDIATOR, V2, pS77; Schifitto G, 1999, NEUROLOGY, V53, P391, DOI 10.1212/WNL.53.2.391; SEDIVY P, 1985, PROSTAGLANDINS, V30, P688, DOI 10.1016/0090-6980(85)90032-2; Tavet F, 1997, J LIPID MEDIAT CELL, V15, P145, DOI 10.1016/S0929-7855(96)00551-2; Walh L. M., 1989, P NATL ACAD SCI USA, V86, P621; WEISSMAN D, 1993, P NATL ACAD SCI USA, V90, P2537, DOI 10.1073/pnas.90.6.2537	32	31	35	0	4	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623			J MED CHEM	J. Med. Chem.	JUN 1	2000	43	11					2149	2154		10.1021/jm9911276			6	Chemistry, Medicinal	Pharmacology & Pharmacy	320XG	WOS:000087425700008	10841793				2021-06-18	
J	Ramos, CT; Koplewitz, BZ; Babyn, PS; Manson, D; Ein, SH				Ramos, CT; Koplewitz, BZ; Babyn, PS; Manson, D; Ein, SH			What have we learned about traumatic diaphragmatic hernias in children?	JOURNAL OF PEDIATRIC SURGERY			English	Article						traumatic diaphragmatic rupture; diaphragmatic hernia	BLUNT TRAUMA; RUPTURE; DIAGNOSIS	Background/Purpose: Diaphragmatic injuries have been reported to be a predictor of serious associated injuries in trauma and a marker of severity. The aim of this retrospective study was to identify pitfalls in the diagnosis and treatment of these injuries in children. Methods: Data were collected from all patients admitted to the trauma service with traumatic diaphragmatic hernias for the period of January 1977 to August 1998. The authors evaluated 15 cases of traumatic diaphragmatic rupture (6 girls and 9 boys). Results: Mean age was 7.5 years (range, 3 weeks to 15 years). Thirteen patients suffered from blunt trauma, and 2 patients suffered from penetrating trauma. The rig ht a nd left hemidiaphragms were injured equally (7 patients each), with 1 additional patient suffering from bilateral injuries. All but 1 patient had laparotomies for trauma (n = 14). The diagnosis was made preoperatively in 8 patients (53%) with just a chest radiograph. Computed tomography (CT) scan, magnetic resonance imaging (MRI), and oral contrast studies were used as ancillary tests to diagnose traumatic diaphragmatic rupture, There were 3 missed injuries. Associated injuries included liver lacerations (47%), pelvic fractures (47%), major vessels tear (40%), bowel perforations (33%), long bone fractures (20%), renal lacerations (20%), splenic lacerations (13%), and closed head injuries (13%). The mean hospital stay was 20 days (range, 7 to 60 days). Complications were observed most commonly in those patients with multiple injuries and included postoperative ileus (40%), pneumonia (30%), pancreatitis (20%), wound infection (20%), intestinal obstruction (20%), cholestasis (10%), and renal failure (6%). Five deaths (33%) were caused by hemorrhagic shock, respiratory failure, coagulopathy, and refractory acidosis. Conclusions: Traumatic diaphragmatic hernias usually are associated with serious injuries in children. It is important to combine a high index of suspicion with radiological diagnostic tests in patients at risk. Palpation and/or visualization of both diaphragms at laparotomy is extremely important in detecting these injuries when they are not suspected preoperatively. Copyright (C) 2000 by W.B. Saunders Company.	Hosp Sick Children, Div Gen Surg, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada	Ein, SH (corresponding author), Hosp Sick Children, Div Gen Surg, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Ramos, Carmen/0000-0002-1130-1576			ADEYEMI SD, 1981, CAN J SURG, V24, P355; Aoki AA, 1998, AM J ROENTGENOL, V171, P386, DOI 10.2214/ajr.171.2.9694457; BARON B, 1994, EMER RADIOL, V5, P231; BOULANGER BR, 1992, J TRAUMA, V32, P89, DOI 10.1097/00005373-199201000-00019; BRANDT ML, 1992, J TRAUMA, V32, P298, DOI 10.1097/00005373-199203000-00006; Degiannis E, 1996, BRIT J SURG, V83, P88, DOI 10.1002/bjs.1800830128; Israel RS, 1996, AM J ROENTGENOL, V167, P637, DOI 10.2214/ajr.167.3.8751669; KAULESARSUKUL DMK, 1991, INJURY, V22, P303; KOEHLER RH, 1994, J TRAUMA, V36, P424, DOI 10.1097/00005373-199403000-00031; LEE WC, 1994, EUR J SURG, V160, P479; MADDEN MR, 1994, J TRAUMA, V3, P417; MADDOX PR, 1991, INJURY, V22, P299, DOI 10.1016/0020-1383(91)90010-C; MEYERS BF, 1993, ANN SURG, V218, P783, DOI 10.1097/00000658-199312000-00013; Mueller CF, 1994, EMERG RADIOL, V1, P118; NINAN G, 1993, BRIT MED J, V306, P643, DOI 10.1136/bmj.306.6878.643; SEBAYEL MI, 1989, INJURY, V20, P94, DOI 10.1016/0020-1383(89)90149-6; SERPELL JW, 1994, J TRAUMA, V36, P421, DOI 10.1097/00005373-199403000-00030; Shackleton KL, 1998, RADIOGRAPHICS, V18, P49, DOI 10.1148/radiographics.18.1.9460108; SHARMA OP, 1989, J TRAUMA, V29, P678, DOI 10.1097/00005373-198905000-00024; SOLA JE, 1994, J TRAUMA, V36, P417, DOI 10.1097/00005373-199403000-00029; VANVUGT AB, 1989, J TRAUMA, V29, P683, DOI 10.1097/00005373-198905000-00025	21	31	37	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	APR	2000	35	4					601	604		10.1053/jpsu.2000.0350601			4	Pediatrics; Surgery	Pediatrics; Surgery	299MW	WOS:000086203200015	10770391				2021-06-18	
J	Donaldson, JW; Edwards-Brown, M; Luerssen, TG				Donaldson, JW; Edwards-Brown, M; Luerssen, TG			Arachnoid cyst rupture with concurrent subdural hygroma	PEDIATRIC NEUROSURGERY			English	Article						arachnoid cyst; subdural hygroma; head injury	FOSSA; SPACE; CT	Arachnoid cysts (ACs) are relatively common intracranial mass lesions, which occur most often in the middle cranial fossa, While these lesions can present as a mass lesion, many are asymptomatic, Rarely, posttraumatic or spontaneous rupture of ACs can result in intracystic hemorrhage, subdural hematoma or subdural hygroma, We have encountered two cases of ruptured arachnoid cysts that resulted in subdural hygromas. Both patients harbored middle cranial fossa cysts and suffered mild closed head injuries. The presentation, radiographic findings and surgical management of these patients as well as the association between ACs and subdural hygromas are described, Copyright (C) 2000 S.Karger AG, Basel.	Indiana Univ, Sch Med, Sect Neurol Surg, Dept Surg,Dept Radiol, Indianapolis, IN 46202 USA	Donaldson, JW (corresponding author), Indiana Univ, Sch Med, Sect Neurol Surg, Dept Surg,Dept Radiol, Emerson 139,545 Barnhill Dr, Indianapolis, IN 46202 USA.						Albuquerque FC, 1997, NEUROSURGERY, V41, P951, DOI 10.1097/00006123-199710000-00036; BECKER T, 1991, NEURORADIOLOGY, V33, P341, DOI 10.1007/BF00587820; Choong CT, 1998, BRAIN DEV-JPN, V20, P319, DOI 10.1016/S0387-7604(98)00039-4; CHOUX M, 1978, CHILD BRAIN, V4, P15; CULLIS PA, 1983, J NEUROL NEUROSUR PS, V46, P454, DOI 10.1136/jnnp.46.5.454; EUSTACE S, 1992, J COMPUT ASSIST TOMO, V16, P995, DOI 10.1097/00004728-199211000-00034; GALASSI E, 1980, SURG NEUROL, V14, P211; KULALI A, 1989, Neurosurgical Review, V12, P508, DOI 10.1007/BF01790696; OSBORN AG, 1994, DIAGNOSTIC NEURORADI, P639; RAKIER A, 1995, J NEUROSURG, V83, P1085, DOI 10.3171/jns.1995.83.6.1085; Sener RN, 1997, COMPUT MED IMAG GRAP, V21, P341; YAMANOUCHI Y, 1986, CHILD NERV SYST, V2, P40, DOI 10.1007/BF00274033	12	31	34	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	MAR	2000	32	3					137	139		10.1159/000028918			3	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	327ZK	WOS:000087824200006	10867560				2021-06-18	
J	Masumura, M; Hata, R; Uramoto, H; Murayama, N; Ohno, T; Sawada, T				Masumura, M; Hata, R; Uramoto, H; Murayama, N; Ohno, T; Sawada, T			Altered expression of amyloid precursor proteins after traumatic brain injury in rats: In situ hybridization and immunohistochemical study	JOURNAL OF NEUROTRAUMA			English	Article						amyloid precursor protein; Alzheimer's disease; amyloid-beta protein; immunohistochemistry; in situ hybridization; traumatic brain injury	PROTEASE INHIBITOR DOMAIN; TRANSIENT FOCAL ISCHEMIA; BETA-APP METABOLISM; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; MESSENGER-RNA; CEREBRAL-ISCHEMIA; AXONAL DAMAGE; DIFFERENTIAL EXPRESSION; SELECTIVE INDUCTION	The expression of alternatively spliced mRNAs for amyloid precursor protein (APP) isoforms and their translation products were examined in the rat cerebral cortex 1, 3, 6, and 12 h and 1, 3, and 7 days (12 = 4-5 in each group) after fluid-percussion brain injury. In situ hybridization studies demonstrated that the expression of APP695 mRNA decreased in and around the damaged area of the cerebral cortex exposed to fluid-percussion injury 1 h after the insult. On the other hand, APP751/770 mRNAs were increased in the regions surrounding the damaged cortical areas 1 day after the injury. An increase of immunoreactive APP was detected in the regions around the damaged cortical areas 3 h after traumatic injury and maintained for the following 3 days. The APP immunoreactivity in the damaged cortices declined to the level of sham-operated animals by post-experimental day 7, Using an anti-amyloid beta (A beta) protein (17-24) antibody, no deposits of immunoreactive A beta (17-24) were observed in any of the samples examined in these experiments. These results suggest that the induction of Kunitz-type protease inhibitor (KPI) domain-containing APP mRNAs and the increased accumulation of APP are involved in the physiological and neuropathological responses of brains under various neurodegenerative conditions, including head trauma.	Natl Cardiovasc Ctr, BF Res Inst, Suita, Osaka 5650873, Japan; Suntory Inst Biomed Res, Osaka, Japan	Masumura, M (corresponding author), Natl Cardiovasc Ctr, BF Res Inst, 7-1,5 Chome, Suita, Osaka 5650873, Japan.						ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ALLSOP D, 1990, AM J PATHOL, V136, P255; Apelt J, 1997, INT J DEV NEUROSCI, V15, P95, DOI 10.1016/S0736-5748(96)00073-1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRUGG B, 1995, P NATL ACAD SCI USA, V92, P3032, DOI 10.1073/pnas.92.7.3032; DENMAN R, 1991, ARCH BIOCHEM BIOPHYS, V288, P29, DOI 10.1016/0003-9861(91)90161-B; deSilva HAR, 1997, MOL BRAIN RES, V47, P147; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 1996, ACT NEUR S, V66, P96; HEURTEAUX C, 1993, P NATL ACAD SCI USA, V90, P9431, DOI 10.1073/pnas.90.20.9431; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; HOLTZMAN DM, 1992, EMBO J, V11, P619, DOI 10.1002/j.1460-2075.1992.tb05094.x; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; Kim HS, 1998, NEUROREPORT, V9, P533; Koistinaho J, 1996, NEUROREPORT, V7, P2727, DOI 10.1097/00001756-199611040-00064; Komori N, 1997, MOL BRAIN RES, V49, P103, DOI 10.1016/S0169-328X(97)00133-2; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; Masumura M, 1996, NEUROSCI LETT, V213, P119, DOI 10.1016/0304-3940(96)12841-X; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; Neve RL, 1996, MOL BRAIN RES, V39, P185, DOI 10.1016/0169-328X(96)00007-1; OConnell AW, 1997, NEUROCHEM INT, V30, P313, DOI 10.1016/S0197-0186(96)00052-6; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; OYAMA F, 1991, J NEUROPATH EXP NEUR, V50, P560, DOI 10.1097/00005072-199109000-00004; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; Pierce JES, 1996, J NEUROSCI, V16, P1083; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHEA TB, 1995, BRAIN RES REV, V20, P171, DOI 10.1016/0165-0173(94)00010-M; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SISODIA SS, 1994, AMYLOID PROTEIN PREC, P121; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; SOLA C, 1993, NEUROSCIENCE, V53, P267, DOI 10.1016/0306-4522(93)90304-X; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; TANAKA S, 1989, BIOCHEM BIOPH RES CO, V165, P1406, DOI 10.1016/0006-291X(89)92760-5; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; TOMIMOTO H, 1994, J CEREBR BLOOD F MET, V14, P565, DOI 10.1038/jcbfm.1994.70; TOPPER R, 1995, ACTA NEUROPATHOL, V89, P23; WAKITA H, 1992, NEUROSCI LETT, V146, P135, DOI 10.1016/0304-3940(92)90061-B; WALLACE W, 1993, P NATL ACAD SCI USA, V90, P8712, DOI 10.1073/pnas.90.18.8712; Wallace WC, 1997, MOL BRAIN RES, V52, P201, DOI 10.1016/S0169-328X(97)00258-1; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yokota M, 1996, J CEREBR BLOOD F MET, V16, P1219, DOI 10.1097/00004647-199611000-00016; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510	65	31	33	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2000	17	2					123	134		10.1089/neu.2000.17.123			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	286MB	WOS:000085448800002	10709870				2021-06-18	
J	Buchner, K; Meixensberger, J; Dings, J; Roosen, K				Buchner, K; Meixensberger, J; Dings, J; Roosen, K			Near-infrared spectroscopy - not useful to monitor cerebral oxygenation after severe brain injury	ZENTRALBLATT FUR NEUROCHIRURGIE			English	Article						neuromonitoring; brain tissue partial pressure; head injury; subarachnoid hemorrhage	CLOSED-HEAD INJURY; PRESSURE; OXIMETRY	Since its development more than twenty years ago, non-invasive near-infrared-spectroscopy (NIRS) has been widely used to monitor cerebral oxygenation. Despite of its growing number of users, the diagnostic value of near-infrared spectroscopy still remains unclear, especially in case of acute brain injury and long-term neuromonitoring, necessary during intensive care therapy. To evaluate quality and sensitivity of NIRS measurements compared to invasive ICP-, CPP- and regional brain tissue - pO(2) (p(ti)O-2) monitoring, 31 patients, suffering from severe brain injury due to subarachnoid hemorrhage or severe head injury, were studied. NIRS measurements were only possible in 80% (using the INVOS oximeter) and in 46% (using the CRITIKON monitor), while good data quality was obtained in 100% from ICP, CPP and p(ti)O-2. Major reasons for the failure of NIRS measurements were: (1) a wet chamber between sensor and skin, (2) galea hematoma or (3) subdural air after craniotomy. Different tests were performed to compare the sensitivity of regular oxygen saturation (NIRS) with the sensitivity of invasively determined p(ti)O-2. Only induced hyperoxia (FiO(2)=1.0) revealed a significant correlation between both parameters (r=0.67, p<0.01). Lower or no correlation was found after changing p(a)CO(2) and administration of mannitol. The high failure rate and the limited sensitivity does not make the clinical use of near-infrared spectroscopy suitable as a part of neuromonitoring after acute brain injury at the present time.	Univ Wurzburg, Dept Neurosurg, D-97080 Wurzburg, Germany		meix@nch.uni-wuerzburg.de					Adelson PD, 1998, ACT NEUR S, V71, P250; CLARK LC, 1956, T AM SOC ART INT ORG, V2, P41; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; DUJOVNY M, 1994, NEUROSURGERY, V34, P935; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; Holzschuh M, 1997, NEUROL RES, V19, P246, DOI 10.1080/01616412.1997.11740807; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; KIRKPATRICK PJ, 1995, J NEUROSURG, V82, P756, DOI 10.3171/jns.1995.82.5.0756; Kirkpatrick PJ, 1997, PHILOS T ROY SOC B, V352, P701, DOI 10.1098/rstb.1997.0052; Kuebler WM, 1998, J CEREBR BLOOD F MET, V18, P445, DOI 10.1097/00004647-199804000-00013; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; McKeating EG, 1997, ANAESTHESIA, V52, P136, DOI 10.1111/j.1365-2044.1997.18-az015.x; Meixensberger J, 1998, ACT NEUR S, V71, P260; ROSENTHAL A, 1994, ZENTRALBL NEUROCHI S, V31; Schwarz G, 1996, J NEUROSURG ANESTH, V8, P189, DOI 10.1097/00008506-199607000-00001; Ter Minassian A, 1999, ANESTHESIOLOGY, V91, P985; UNTERBERG A, 1995, NEUROCHEMICAL MONITO, P204; Urlesberger B, 1997, TRANSCRANIAL CEREBRAL OXIMETRY, P76; WILLIAMS IM, 1994, ANAESTHESIA, V49, P76, DOI 10.1111/j.1365-2044.1994.tb03325.x	20	31	35	0	3	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0044-4251			ZBL NEUROCHIR	Zent.bl. Neurochir.		2000	61	2					69	73		10.1055/s-2000-8262			5	Neurosciences; Surgery	Neurosciences & Neurology; Surgery	346YD	WOS:000088897900001	10986754				2021-06-18	
J	Chang, RCC; Hudson, PM; Wilson, BC; Liu, B; Abel, H; Hong, JS				Chang, RCC; Hudson, PM; Wilson, BC; Liu, B; Abel, H; Hong, JS			High concentrations of extracellular potassium enhance bacterial endotoxin lipopolysaccharide-induced neurotoxicity in glia-neuron mixed cultures	NEUROSCIENCE			English	Article						glia; potassium; microglia; nitric oxide; tumor necrosis factor-alpha; cerebral inflammation	NITRIC-OXIDE SYNTHASE; TNF-ALPHA; MICROGLIAL ACTIVATION; SPREADING DEPRESSION; GENE-EXPRESSION; CELL-CULTURES; BRAIN; RAT; CHANNELS; INVOLVEMENT	A sudden increase in extracellular potassium ions (K+) often occurs in cerebral ischemia and after brain trauma. This increase of extracellular K+ constitutes the basis for spreading depression across the cerebral cortex, resulting in the expansion of neuronal death after ischemic and traumatic brain injuries. Besides spreading depression, it has become clear that cerebral inflammation also is a key factor contributing to secondary brain injury in acute neurological disorders. Experiments to validate the relationship between elevated levels of extracellular K+ and inflammation have not been studied. This study aims to elucidate the roles of high concentrations of extracellular K+ in bacterial endotoxin lipopolysaccharide-induced production of inflammatory factors. Increased concentration of KCl in the medium (20 mM) significantly enhanced neurotoxicity by lipopolysaccharide in glia-neuron mixed cultures. To delineate the underlying mechanisms of increased neurotoxicity, the effects of high extracellular K+ were examined by using mixed glial cultures. KCl at 20 mM significantly enhanced nitrite, an index for nitric oxide, production by about twofold, and was pronounced from 24 to 48 h, depending on the concentration of KCl. Besides nitric oxide production of tumor necrosis factor-alpha was also enhanced. The augmentative effects of high KCl on the production of inflammatory factors were probably due to the further activation of microglia, since high KCl also enhanced the production of tumor necrosis factor-alpha in microglia-enriched cultures. The increased production of nitrite by high K+ was eliminated through use of a K+-blocker. Taken together, the results show that increases of extracellular K+ concentrations in spreading depression augment lipopolysaccharide-elicited neurotoxicity, because production of inflammatory factors such as nitric oxide and tumor necrosis factor-alpha are potentiated. Since spreading depression and cerebral inflammation are important in acute neurological disorders, the present results suggest a biochemical mechanism: elevated extracellular K+ concentrations augment glial inflammatory responses, and thus the neurotoxicity. Published by Elsevier Science Ltd.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27713 USA	Hong, JS (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, POB 12233 MFDF1-01, Res Triangle Pk, NC 27713 USA.	hong3@niehs.nih.gov	Chang, Raymond Chuen-Chung/C-1107-2009; liu, Bin/A-7695-2009; Hong, Jau-shyong/F-1920-2019	Chang, Raymond Chuen-Chung/0000-0001-8538-7993; Hong, Jau-shyong/0000-0002-3056-8401; Cope, Heidi/0000-0003-0586-9277			Abiru Y, 1998, BRAIN RES, V809, P115, DOI 10.1016/S0006-8993(98)00849-X; Andreeva N, 1996, EXP NEUROL, V137, P255, DOI 10.1006/exnr.1996.0024; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bronstein DM, 1995, BRAIN RES, V704, P112, DOI 10.1016/0006-8993(95)01189-7; BUSCH E, 1995, NMR BIOMED, V8, P59, DOI 10.1002/nbm.1940080203; Chang RCC, 2000, BRAIN RES, V853, P236, DOI 10.1016/S0006-8993(99)02255-6; Chen W., 1998, Society for Neuroscience Abstracts, V24, P1615; CHUNG IY, 1992, J IMMUNOL, V149, P3894; CHUNG IY, 1991, J EXP MED, V173, P801, DOI 10.1084/jem.173.4.801; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; COLTON CA, 1994, AM J PHYSIOL, V266, pC1650; DAS KP, 1995, J NEUROIMMUNOL, V62, P9, DOI 10.1016/0165-5728(95)00083-E; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/0304-3940(96)13116-5; Eder C, 1998, J NEUROSCI, V18, P7127; Eder C, 1998, AM J PHYSIOL-CELL PH, V275, pC327; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fiebich BL, 1998, J NEUROIMMUNOL, V92, P170, DOI 10.1016/S0165-5728(98)00201-X; Galea E, 1996, J NEUROIMMUNOL, V64, P19, DOI 10.1016/0165-5728(95)00143-3; Ginis I, 1999, AM J PHYSIOL-CELL PH, V276, pC1171; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; Illes P, 1996, NEUROCHEM INT, V29, P13; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; Koistinaho J, 1999, STROKE, V30, P114, DOI 10.1161/01.STR.30.1.114; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Rostworowski M, 1997, J NEUROSCI, V17, P3664; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sun D, 1998, J NEUROIMMUNOL, V89, P122, DOI 10.1016/S0165-5728(98)00124-6; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; Taniwaki Y, 1996, NEUROSCI LETT, V217, P29; UCHIYAMATSUYUKI Y, 1995, EUR J PHARM-ENVIRON, V293, P245, DOI 10.1016/S0922-4106(05)80050-1; WOOD PL, 1995, NEUROL RES, V17, P242, DOI 10.1080/01616412.1995.11740321	35	31	31	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2000	97	4					757	764		10.1016/S0306-4522(00)00059-2			8	Neurosciences	Neurosciences & Neurology	324VH	WOS:000087641700016	10842021				2021-06-18	
J	Ippolito, E; Formisano, R; Caterini, R; Farsetti, P; Penta, F				Ippolito, E; Formisano, R; Caterini, R; Farsetti, P; Penta, F			Operative treatment of heterotopic hip ossification in patients with coma after brain injury	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article								In 13 joints of 12 patients who sustained traumatic brain injury, heterotopic ossifications of the hip were surgically excised at an average of 15 months after the patients' recovery from coma. All of the patients were referred by neurologists of the postcoma unit who deemed surgery necessary to speed up the rehabilitation program of the patients, Before surgery, three patients were able to ambulate, whereas nine were not ambulatory, Eight hips were ankylosed, whereas five had a severe painful limitation of joint motion, All of the patients were checked at regular intervals after the operation, and the final followup averaged 38 months. In an attempt to prevent postoperative recurrence of ossification, 100 mg of indomethacin was administered daily after surgery for 6 weeks, At followup, 10 patients could ambulate and two were able to sit in a wheelchair. patients with poor neuromuscular control tended to lose part of their postoperative range of motion, and heterotopic periarticular ossification recurred in two of them (three hips), No correlation was found between recurrence and the time that elapsed from head injury to the operation, but old ossifications continued to show osteogenic activity at the histologic level.	Univ Roma Tor Vergata, Dept Orthoped Surg, Rome, Italy; IRCCS Santa Lucia, Postcoma Neurorehabil Unit, Rome, Italy	Ippolito, E (corresponding author), Via Cattaro 28, I-00198 Rome, Italy.						Charnley G, 1996, INJURY, V27, P125, DOI 10.1016/0020-1383(95)00180-8; GACON G, 1978, REV CHIR ORTHOP, V64, P375; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P59; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Knelles D, 1997, J BONE JOINT SURG BR, V79B, P596, DOI 10.1302/0301-620X.79B4.6829; MOED BR, 1994, J ORTHOP TRAUMA, V8, P34, DOI 10.1097/00005131-199402000-00008; Moore KD, 1998, J BONE JOINT SURG BR, V80B, P259, DOI 10.1302/0301-620X.80B2.8157; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; RANDELLI G, 1992, J BONE JOINT SURG AM, V74A, P1344, DOI 10.2106/00004623-199274090-00007; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; SCHMIDT SA, 1988, J BONE JOINT SURG AM, V70A, P834, DOI 10.2106/00004623-198870060-00005; STOVER SL, 1991, CLIN ORTHOP RELAT R, P71	13	31	32	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	AUG	1999		365					130	138		10.1097/00003086-199908000-00018			9	Orthopedics; Surgery	Orthopedics; Surgery	225PR	WOS:000081970400018	10627697				2021-06-18	
J	Kasher, A; Batori, G; Soroker, N; Graves, D; Zaidel, E				Kasher, A; Batori, G; Soroker, N; Graves, D; Zaidel, E			Effects of right- and left-hemisphere damage on understanding conversational implicatures	BRAIN AND LANGUAGE			English	Article							CLOSED HEAD-INJURY; DEFICITS; ABILITY	Processing of implicatures was examined in 27 right-brain-damaged (RBD) and 31 left-brain-damaged (LBD) stroke patients with focal lesions using a new implicatures battery (IB) as part of an exploration of the neural basis and modularity of natural language pragmatics. Following Grice, we sampled implicatures of Quantity, Quality, Relation, and Manner. Verbal implicatures consisted of two-sentence conversational vignettes which are literally problematic. Nonverbal implicatures consisted mostly of famous paintings that are literally problematic (e.g., Magritte's "Le Domain d'Arnheim"). The patient has to identify and solve the problem. To compare with performance on the IB, patients also received a Hebrew adaptation of Gardner and Brownell's Right Hemisphere Communication Battery, a new test of basic speech acts (verbal and nonverbal assertions, questions, requests, and commands), a Hebrew version of the Western Aphasia Battery, and standardized neuropsychological tests. Both LED and RED patients were significantly impaired in implicature processing relative to age-matched normal controls. In general, both patient groups showed weak correlations of implicatures with extents of lesions in left perisylvian language area or its right-hemisphere (RH) homolog. However, performance of LED and RED patients on the IB revealed different patterns of correlations with other pragmatic, language, and nonlanguage tests. In LED patients, there was a greater association between performance on verbal and nonverbal implicatures and between performance on implicatures and basic speech acts than in RED patients. Given the different modes in which right-and left-hemisphere (LK) damage affect the processing of conversational implicatures, it remains to be discovered how the two hemispheres interact to process natural language pragmatics in the normal brain in real time, (C) 1999 Academic Press.	Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; Tel Aviv Univ, Dept Philosophy, Ramat Aviv, Israel; Tel Aviv Univ, Dept Psychol, Ramat Aviv, Israel; Tel Aviv Univ, Loewenstein Rehabil Hosp, Ramat Aviv, Israel; Acad Coll Tel Aviv Jaffa, Tel Aviv, Israel	Zaidel, E (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.		Soroker, Nachum/V-7094-2019	Soroker, Nachum/0000-0003-4909-5576	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020187] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20187] Funding Source: Medline		AHLSEN E, 1993, J PRAGMATICS, V19, P57, DOI 10.1016/0378-2166(93)90070-6; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Brownell H, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P309; BROWNELL HH, 1986, BRAIN LANG, V27, P310, DOI 10.1016/0093-934X(86)90022-2; Fodor J. A., 1983, MODULARITY MIND; GARDNER H, 1986, RIGHT HEMISPHERE COM; Grice H.P, 1989, STUDIES WAYS WORDS; GRICE HP, 1975, SPEECH ACTS, P41; KASHER A, 1991, J PRAGMATICS, V16, P381, DOI 10.1016/0378-2166(91)90132-H; KASHER A, 1984, J PRAGMATICS, V8, P539, DOI 10.1016/0378-2166(84)90041-9; Kasher A., 1982, PHILOSOPHICA GENT, V29, P25; Kasher A., 1998, PRAGMATICS CRITICAL; Kasher A., 1976, LANGUAGE FOCUS FDN M, P197, DOI DOI 10.1007/978-94-010-1876-0_12; Kasher A., 1991, CHOMSKYAN TURN, P122; Kertesz A., 1979, APHASIA ASS DISORDER; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; RAVEN JC, 1965, COLOURED PROGR MATRI; SPENCE SJ, 1990, J CLIN EXPT NEUROPSY, V12, P42; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TALAIRACH J, 1988, COPLANOR STEREOTAXIC; Tompkins C.A., 1995, RIGHT HEMISPHERE COM; VANDERVEKEN D, 1990, MEANING SPEECH ACTS, V1, P103; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilson B., 1987, BEHAV INATTENTION TE; Wilson D., 1995, RELEVANCE COMMUNICAT; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; ZAIDEL E, UNPUB EFFECTS RIGHT; ZAIDEL E, UNPUB HEMISPHERIC CO; ZAIDEL E, 1988, ACAD APH ABSTR, V26, P69	32	31	37	0	9	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JUL	1999	68	3					566	590		10.1006/brln.1999.2129			25	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	226TE	WOS:000082037100012	10441195				2021-06-18	
J	Morita-Fujimura, Y; Fujimura, M; Kawase, M; Murakami, K; Kim, GW; Chan, PH				Morita-Fujimura, Y; Fujimura, M; Kawase, M; Murakami, K; Kim, GW; Chan, PH			Inhibition of interleukin-1 beta converting enzyme family proteases (caspases) reduces cold injury-induced brain trauma and DNA fragmentation in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cold injury; caspase inhibitor; neuronal apoptosis; vasogenic edema	CUZN-SUPEROXIDE-DISMUTASE; FOCAL CEREBRAL-ISCHEMIA; CYTOCHROME-C; TRANSGENIC MICE; CELL-DEATH; ICE/CED-3 PROTEASE; EDEMA FORMATION; NEURONAL DEATH; APOPTOSIS; DAMAGE	The authors examined the effect of z-VAD.FMK, an inhibitor that blocks caspase family proteases, on cold injury-induced brain trauma, in which apoptosis as well as necrosis is assumed to play a role. A vehicle alone or with zVAD.FMK was administered into the cerebral ventricles of mice 15 minutes before and 24 and 48 hours after cold injury. At 24 hours after cold injury, infarction volumes in the zVAD.FMK-treated animals were significantly smaller than infarction volumes in the vehicle-treated animals, and were further decreased at 72 hours (0.92 +/- 1.80 mm(3), z-VAD.FMK treated animals: 7.46 +/- 3.53 mm(3), vehicle-treated animals: mean +/- SD, n = 7 to 8). The amount of DNA fragmentation was significantly decreased in the z-VAD.FMK-treated animals compared with the vehicle-treated animals, as shown by terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end labeling staining and DNA gel electrophoresis. By Western blot analysis, both the proform and activated form of interleukin-1 beta converting enzyme (caspase 1) were detected in the control brain, and the activated form showed moderate reduction after sold injury-induced brain trauma. These results indicate that caspase inhibitors could reduce cold injury-induced brain trauma by preventing neuronal cell death by DNA damage. The caspase family pretenses appear to contribute to the mechanisms of cell death in cold injury-induced brain trauma and to provide therapeutic targets for traumatic brain injury.	Stanford Univ, Neurosurg Labs, Sch Med, Dept Neurosurg, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Neurol Sci, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Neurosci, Palo Alto, CA 94304 USA	Chan, PH (corresponding author), Stanford Univ, Neurosurg Labs, Sch Med, Dept Neurosurg, 701B Welch Rd,148, Palo Alto, CA 94304 USA.		fujimura, yuiko/M-7393-2013; Morita-fujimura, Yuiko/N-4804-2014		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36147, NS25372, NS14543] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, R01NS036147, P50NS014543, R01NS025372] Funding Source: NIH RePORTER		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Cain K, 1996, BIOCHEM J, V314, P27, DOI 10.1042/bj3140027; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; D'Mello SR, 1998, J NEUROCHEM, V70, P1809; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo T, 1997, J NEUROSCI, V17, P4180; Liu PK, 1996, J NEUROSCI, V16, P6795; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Murakami K, 1997, NEUROSCIENCE, V81, P231, DOI 10.1016/S0306-4522(97)00197-8; Murakami K, 1997, ACT NEUR S, V70, P234; Namura S, 1998, J NEUROSCI, V18, P3659; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thornberry NA, 1997, BRIT MED BULL, V53, P478; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; TOMINAGA T, 1992, NEUROSCI LETT, V139, P265, DOI 10.1016/0304-3940(92)90568-R; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	34	31	36	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	1999	19	6					634	642		10.1097/00004647-199906000-00006			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	277TB	WOS:000084948700006	10366193	Bronze			2021-06-18	
J	Aloni, R; Katz, S				Aloni, R; Katz, S			A review of the effect of traumatic brain injury on the human sexual response	BRAIN INJURY			English	Article							HEAD-INJURY; RELATIVES; DAMAGE; FAMILY	A human sexual response format was used to describe possible sexual dysfunctions after TBI. Additional material was also included to qualify the information drawn from the above format. A number of possible conclusions were drawn, indicating that the causes and effects of sexual functioning after TBI are very confusing and that the literature does not clarify this confusion. One cannot accurately differentiate between primary and secondary sexual problems and, therefore, cannot evaluate the contribution of each problem to the presented sexual dysfunction.	Bar Ilan Univ, Dept Psychol, Ramat Gan, Israel; Beit Loewenstein Hosp, Raanana, Israel	Katz, S (corresponding author), Bar Ilan Univ, Dept Psychol, Ramat Gan, Israel.						ALTMAN R, 1961, ANN INTERN MED, V55, P1; Berrol S, 1981, SEXUALITY PHYSICAL D, P203; BIENENFELD D, 1989, J CLIN PSYCHIAT, V50, P68; Blackerby WF, 1994, HDI PROFESSIONAL SER, V10; Blackerby WF, 1990, J HEAD TRAUMA REHAB, V5, P73; BLAZYK S, 1983, SOCIAL WORK HLTH CAR, V8, P4; BLUMER D, 1970, AM J PSYCHIAT, V126, P8; BOLLER F, 1982, SEXUAL DYSFUNCTION N; BROOKS N, 1985, J HEAT TRAUMA REHABI, V2, P13; BURKE WH, 1988, HDI PROFESSIONAL SER, V9; BURTON LA, 1988, J NEUROLOGICAL REHAB, V2, P4; CHUSID JG, 1982, CORRELATIVE NEUROANA; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; COX W, 1980, MED ASPECTS HUMAN SE, V14, P103; CRENSHAW LT, 1985, MED ASPECTS HUMAN SE, V19, P115; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DAVIDSON JM, 1982, CLIN ENDOCRINOLOGY M, V11, P3; DAVIS D, 1990, J HEAD TRAUMA REHAB, V5, P38; DUCHARME S, 1986, J HEAD TRAUMA REHAB, V5, P38; EDWARDS OM, 1986, MEDICINE, V65, P4; GARDEN F, 1991, SEX DISABIL, V9, P1; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; GLEN MB, 1988, J HEAD TRAUMA REHAB, V3, P86; GRIFFITH E, 1990, REHABILITATION ADULT, P205; Griffith ER, 1993, SEXUALITY PERSON TRA; HORN J, 1990, J HEAD TRAUMA REHAB, V5, P1; JOSEPH AB, 1995, J HEAD TRAUMA REHAB, V10, P2; Kaplan HS, 1974, NEW SEX THERAPY; KAPLAN HS, 1983, EVALUATION SEXUAL DI; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KLINGBEIL GE, 1985, ARCH PHYSICAL MED RE, V65, P88; KREUTZER SJ, 1989, BRAIN INJURY, V3, P177; LEHNE GK, 1986, SEX DISABIL, V7, P3; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Lundberg PO, 1992, ANN REV SEX RES, V3, P121; MASTERS HW, 1970, HUMAN SEXUAL INADEQU; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLAUGHLIN AM, 1985, COGNITIVE REHABILITA, V11, P4; MEDLER MT, 1993, SEX DISABIL, V11, P57; MESULAM MM, 1988, PRINCIPLES BEHAV NEU; MILLER BL, 1986, J NEUROL NEUROSUR PS, V49, P867, DOI 10.1136/jnnp.49.8.867; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P8; SABHESAN S, 1989, ARCH SEXUAL BEHAV, V18, P4; SOLOMON R, 1991, BRAIN INJURY, V5, P253; SOROKER N, 1996, BRAIN FUNCTION STRUC; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; STRAUSS D, 1991, SEX DISABIL, V9, P34; VALENTICH M, 1986, SEX DISABIL, V7, P1; ZASLER ND, 1995, PHYSICAL MED REHABIL, V9, P330; ZASLER ND, 1990, J HEAD TRAUMA REHAB, V5, P14, DOI DOI 10.1097/00001199-199005020-00004; Zasler ND, 1991, SEX DISABIL, V9, P11; ZASLER ND, 1998, SEXUALITY UPDATE, V1, P1; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163	57	31	32	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1999	13	4					269	280		10.1080/026990599121647			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	186RH	WOS:000079742400006	10230528				2021-06-18	
J	Perry, J				Perry, J			The use of gait analysis for surgical recommendations in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						dynamic electromyography; gait analysis; kinematics; kinetics; traumatic brain injury	FOOT DEFORMITY; CEREBRAL-PALSY; ADULT	Traumatic brain injury causes unpredictable errors in the patient's gait by introducing varying mixtures of spasticity, contractures, primitive flexion and extension synergies, and impaired selective control. Surgical release or transfer of the offending muscles can improve the patient's ability to walk if functional errors have been accurately identified. While clinical testing is inadequate, Instrumented motion analysis and dynamic electromyography can supply an accurate definition of the abnormalities in muscle action and provide guidelines fur distinguishing local from referred motion errors. Examples of the diagnostic differences related to the equinovarus foot and the common types of knee dysfunction are presented.	Univ So Calif, Rancho Los Amigos Med Ctr, Pathokinesiol Serv, Downey, CA 90242 USA; Univ So Calif, Los Angeles, CA USA	Perry, J (corresponding author), Univ So Calif, Rancho Los Amigos Med Ctr, Pathokinesiol Serv, Downey, CA 90242 USA.						AKESON WAYNE H., 1964, J SURG RES, V4, P523, DOI 10.1016/S0022-4804(64)80024-X; BEASLEY W C, 1961, Arch Phys Med Rehabil, V42, P398; BODINEFOWLER SC, 1992, ORTHOPAEDIC REHABILI; BOTTE MJ, 1988, CLIN ORTHOP RELAT R, P7; DE LUCA CJ, 1988, ELECTROEN CLIN NEURO, V69, P568, DOI 10.1016/0013-4694(88)90169-1; FORERO N, 1989, J PEDIATR ORTHOPED, V9, P391; GRONLEY JK, 1984, PHYS THER, V64, P1831, DOI 10.1093/ptj/64.12.1831; JORDAN C, 1988, CLIN ORTHOP RELAT R, P102; Keenan M A, 1988, Orthop Rev, V17, P1185; Kerrigan DC, 1996, ARCH PHYS MED REHAB, V77, P645, DOI 10.1016/S0003-9993(96)90002-7; KOH TJ, 1992, J ORTHOPAED RES, V10, P701, DOI 10.1002/jor.1100100512; Lance J., 1980, SPASTICITY DISORDERE; LAWRENCE SJ, 1994, FOOT ANKLE INT, V15, P340, DOI 10.1177/107110079401500610; LEJUNE T, 1996, ARCH PHYS MED REHAB, V77, P827; PERRY J, 1993, CLIN ORTHOP RELAT R, P10; PERRY J, 1975, J BONE JOINT SURG AM, V57, P961, DOI 10.2106/00004623-197557070-00014; Perry J, 1992, GAIT ANAL NORMAL PAT; PINZUR MS, 1996, J HEAD TRAUMA REHAB, V1, P68; SUTHERLAND DH, 1990, J PEDIATR ORTHOPED, V10, P433; SUTHERLAND DH, 1978, DEV MED CHILD NEUROL, V20, P807; Sutherland DH., 1988, DEV MATURE WALKING; Vogt J C, 1998, J Foot Ankle Surg, V37, P2; WATERS RL, 1979, J BONE JOINT SURG AM, V61, P927, DOI 10.2106/00004623-197961060-00022; WINTERS TF, 1987, J BONE JOINT SURG AM, V69A, P437; WOO SLY, 1975, ARTHRITIS RHEUM, V18, P257, DOI 10.1002/art.1780180311; YOUNG RR, 1987, CLIN ORTHOP RELAT R, P50; YOUNG S, 1990, FOOT ANKLE, V10, P317, DOI 10.1177/107110079001000606	27	31	32	0	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1999	14	2					116	135		10.1097/00001199-199904000-00003			20	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	187DN	WOS:000079771800003	10191371				2021-06-18	
J	Park, HK; Fernandez, I; Dujovny, M; Diaz, FG				Park, HK; Fernandez, I; Dujovny, M; Diaz, FG			Experimental animal models of traumatic brain injury: medical and biomechanical mechanism	CRITICAL REVIEWS IN NEUROSURGERY			English	Article						head injury; experimental animal model; diffuse axonal injury; biomechanics; cerebral ischemia; cerebral blood flow; brain retractor	CEREBRAL BLOOD-FLOW; RAT	The numerous traumatic brain injury models were designed to study the nature of the human brain injury. The properties of six experimental injury models were reviewed in this article. Weight-drop models with or without skull protection were compared in terms of experimental setup, possible error source, and biomechanical prospect. The modified percussion models with or without rigid cortical impact were contrasted with regard to reliability, histopathological production, and deformation. The focal contusion model by mechanical suction force represented isolated cortical injury without compression brain injury. As a class of traumatic brain injury, brain retraction damage was reviewed in this article.	Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA							ANDREWS R J, 1992, Neurological Research, V14, P12; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mathew P, 1996, J NEUROSURG, V85, P860, DOI 10.3171/jns.1996.85.5.0860; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613	6	31	31	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0939-0146			CRIT REV NEUROSURG	Crit. Rev. Neurosurg.	JAN	1999	9	1					44	52		10.1007/s003290050108			9	Neurosciences; Surgery	Neurosciences & Neurology; Surgery	162WM	WOS:000078370100007	9933368				2021-06-18	
J	Fukuda, T; Hasue, M; Ito, H				Fukuda, T; Hasue, M; Ito, H			Does traumatic subarachnoid hemorrhage caused by diffuse brain injury cause delayed ischemic brain damage? Comparison with subarachnoid hemorrhage caused by ruptured intracranial aneurysms	NEUROSURGERY			English	Article						delayed ischemic brain damage; diffuse brain injury; head trauma; neurological deterioration; subarachnoid hemorrhage; vasospasm	CEREBRAL BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASOUND; HEAD-INJURY; COMPUTED TOMOGRAPHY; VASOSPASM; TIME	OBJECTIVE: To examine whether traumatic subarachnoid hemorrhage (TSAH) caused by severe diffuse brain injury leads to delayed ischemic brain damage and secondary deterioration of outcome, as does aneurysmal subarachnoid hemorrhage (ASAH). METHODS: We examined 99 patients with diffuse brain injury with TSAH and 114 patients with ASAH. Computed tomographic (CT) findings, cerebral blood flow, and neurological outcomes were assessed during the acute and subacute phases and were compared between the two groups. RESULTS: The distribution of subarachnoid hemorrhage on the CT scans differed between the two groups. Unlike ASAH, TSAH was not limited to cisterns surrounding the circle of Willis but extended to supratentorial regions and interhemispheric fissures. Computed tomography-detected subarachnoid hemorrhage disappeared very early with TSAH and gradually with ASAH. In the ASAH group, mean cerebral blood flow decreased to 75% of normal during the acute phase and decreased a further 10% during the subacute phase. In the TSAH group, mean cerebral blood flow decreased to 85% of normal during the acute phase and increased slightly during the subacute phase. Neurological deterioration and in-hospital death peaked on Day 0 in association with TSAH and showed twin peaks in association with ASAH. The incidence of low-density areas on the CT scans was significantly higher with ASAH than with TSAH. All low-density areas on the CT scans of patients with ASAH corresponded to vascular territories, but low-density areas on the CT scans of patients with TSAH were rarely associated with vascular territories and contained deep-seated or gliding contusion types. CONCLUSION: The findings suggest that the incidence of vasospasm is low in association with TSAH and that the cause is different compared with ASAH. There is no evidence that the presence of TSAH in cases of diffuse brain injury leads to delayed ischemic brain damage and secondary deterioration of outcome.	Tokyo Med Coll, Hachioji Med Ctr, Dept Neurosurg, Hachioji, Tokyo 193, Japan	Fukuda, T (corresponding author), Tokyo Med Coll, Hachioji Med Ctr, Dept Neurosurg, 1163 Tate Machi, Hachioji, Tokyo 193, Japan.						ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P485; Asano T, 1980, CEREBRAL ARTERIAL SP, P190; CHAN KH, 1992, NEUROSURGERY, V30, P697; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FINDLAY JM, 1991, J NEUROSURG, V75, P181, DOI 10.3171/jns.1991.75.2.0181; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fukuda T, 1996, NEUROL SURG TOKYO, V24, P723; FUKUDA T, 1993, DEVEL NEUR, V8, P71; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; HOEDTRASMUSSEN K, 1966, CIRC RES, V18, P237; Hunt W E, 1974, Clin Neurosurg, V21, P79; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KANNO I, 1979, J COMPUT ASSIST TOMO, V3, P71, DOI 10.1097/00004728-197902000-00012; KASSELL NF, 1983, NEUROSURGERY, V13, P479, DOI 10.1227/00006123-198311000-00001; KNUCKEY NW, 1985, J NEUROSURG, V62, P850, DOI 10.3171/jns.1985.62.6.0850; KUHL DE, 1982, J NUCL MED, V23, P196; KWAK R, 1979, SURG NEUROL, V11, P257; LILIEQUIST B, 1978, ACTA NEUROL SCAND, V57, P165; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MEYER CHA, 1982, BMJ-BRIT MED J, V285, P1149, DOI 10.1136/bmj.285.6349.1149; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PETRUK KC, 1988, J NEUROSURG, V68, P505, DOI 10.3171/jns.1988.68.4.0505; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Sundt T M Jr, 1977, Clin Neurosurg, V24, P228; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; WILKINS RH, 1975, HDB CLIN NEUROLOGY 1, V23, P163; YONAS H, 1989, NEUROSURGERY, V24, P368, DOI 10.1227/00006123-198903000-00010; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	30	31	31	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	1998	43	5					1040	1048		10.1097/00006123-199811000-00022			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	130ER	WOS:000076507400020	9802847				2021-06-18	
J	Dombovy, ML; Drew-Cates, J; Serdans, R				Dombovy, ML; Drew-Cates, J; Serdans, R			Recovery and rehabilitation following subarachnoid haemorrhage: part II long-term follow-up	BRAIN INJURY			English	Article							ANEURYSM-SURGERY; HEMORRHAGE; MANAGEMENT; IMPAIRMENT; MORBIDITY; MORTALITY; DEFICITS; SAH	Background and purpose: Subarachnoid haemorrhage (SAH) accounts for 5-10% of all strokes, strikes at a mean age of 50 years and results in a pattern of deficits similar to that of traumatic brain injury. This study is an extension of a previous study which described outcome at discharge from inpatient rehabilitation. The purpose of this Follow-up study was to describe long-term functional, cognitive and psychosocial outcome in a cohort of SAH survivors who received inpatient rehabilitation Methods: Subjects were interviewed by telephone. Functional status was assessed using the Functional independence Measure (FIM) and cognitive status with the Telephone Interview for Cognitive Status (TICS). Social Function was determined via a brief questionnaire. Results: Thirty two out of 80 subjects who received inpatient rehabilitation participated in the study. The 32 did not differ from the original group of 80 on any demographic or clinical criteria. The mean time from onset of SAH to follow-up was 28 months. Total FIM scores improved significantly between discharge and follow up (p < 0.0001) and most subjects functioned at a physically independent level. However, almost 40% scored in the cognitively impaired range on the TICS. Between 40% and 50% required help with common household activities, and none returned to full-time work. Functional and cognitive outcome was not related to any demographic or clinical characteristics at SAH onset. Conclusion: The majority of SAH survivors who received inpatient rehabilitation attain physical independence, but many continue to have cognitive impairments which result in social and vocational disabilities.	Unity Hlth Syst, Dept Phys Med & Rehabil, Rochester, NY 14611 USA	Dombovy, ML (corresponding author), Unity Hlth Syst, Dept Phys Med & Rehabil, 89 Genesee St, Rochester, NY 14611 USA.						ADAMS HP, 1985, NEUROLOGY, V35, P1263, DOI 10.1212/WNL.35.9.1263; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111, DOI DOI 10.1159/000264678; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Dombovy ML, 1998, BRAIN INJURY, V12, P443, DOI 10.1080/026990598122412; FOGELHOLM R, 1993, STROKE, V24, P1649, DOI 10.1161/01.STR.24.11.1649; GILSBACH JM, 1989, ACTA NEUROCHIR, V96, P1, DOI 10.1007/BF01403488; Granger C. V., 1986, UNIFORM DATA SYSTEM; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; HUTTER BO, 1995, BRIT J NEUROSURG, V9, P465, DOI 10.1080/02688699550041106; INAGAWA T, 1988, STROKE, V19, P170, DOI 10.1161/01.STR.19.2.170; JENNETT B, 1975, LANCET, P480; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Le Roux P, 1993, CLIN NEUROSURG, P325; LJUNGGREN B, 1985, J NEUROSURG, V62, P673, DOI 10.3171/jns.1985.62.5.0673; Ogden J. A., 1990, NEUROPSY NEUROPSY BE, V3, P260; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; Ogden JA, 1997, NEUROSURGERY, V41, P25, DOI 10.1097/00006123-199707000-00008; PHILLIPS LH, 1980, NEUROLOGY, V30, P1034, DOI 10.1212/WNL.30.10.1034; PLASSMAN BL, 1994, NEUROPSYCHIATRY NEUR, V7, P35; *RES FDN STAT U NE, 1990, UN DAT SET MED REH I; ROPPER AH, 1984, J NEUROSURG, V60, P909, DOI 10.3171/jns.1984.60.5.0909; SONESSON B, 1987, NEUROSURGERY, V21, P279, DOI 10.1227/00006123-198709000-00001; TIDSWELL P, 1995, NEUROLOGY, V45, P875; VIKKI J, 1977, NEUROLOGY, V27, P592	26	31	32	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1998	12	10					887	894					8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	121FR	WOS:000076003100007	9783086				2021-06-18	
J	Hicks, RR; Zhang, L; Dhillon, HS; Prasad, MR; Seroogy, KB				Hicks, RR; Zhang, L; Dhillon, HS; Prasad, MR; Seroogy, KB			Expression of trkB mRNA is altered in rat hippocampus after experimental brain trauma	MOLECULAR BRAIN RESEARCH			English	Article						traumatic brain injury; lateral fluid percussion; neurotrophin receptors; in situ hybridization; neuronal plasticity	PROTEIN-TYROSINE KINASE; NERVE GROWTH-FACTOR; MESSENGER-RNA; NEUROTROPHIN RECEPTORS; FULL-LENGTH; INJURY; NEURONS; NT-3; BDNF; FOREBRAIN	Recent investigations have shown that expression of mRNAs for the neurotrophins brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) is differentially altered in the hippocampus following traumatic brain injury. In the present study, modulation of neurotrophin receptor expression was examined in the hippocampus in a rat model of traumatic brain injury using in situ hybridization. Messenger RNA for trkB, the high-affinity receptor for BDNF and neurotrophin-4 (NT-4), was increased between 3 and 6 h bilaterally in the dentate gyrus following a lateral fluid-percussion brain injury of moderate severity (2.0-2.1 atm). No time-dependent alterations were observed for trkB mRNA in hippocampal subfields CA1 and CA3. Levels of mRNA for trkC, the high-affinity receptor for NT-3, did not change in any region of the hippocampus. These data demonstrate that lateral fluid-percussion injury modulates expression of trkB mRNA in the hippocampus and support a role for BDNF/trkB signalling mechanisms in secondary events associated with traumatic brain injury. (C) 1998 Elsevier Science B.V. All rights reserved.	Univ Kentucky, Dept Clin Sci, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Surg, Lexington, KY 40536 USA	Hicks, RR (corresponding author), Univ Kentucky, Dept Clin Sci, Lexington, KY 40536 USA.	rrhick00@pop.uky.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34264, NS35164] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034264, R01NS035164] Funding Source: NIH RePORTER		Albers KM, 1996, J CELL BIOL, V134, P487, DOI 10.1083/jcb.134.2.487; Alcantara S, 1997, J NEUROSCI, V17, P3623; ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON JE, 1994, DEV BRAIN RES, V77, P177, DOI 10.1016/0165-3806(94)90194-5; Frank L, 1996, EUR J NEUROSCI, V8, P1220, DOI 10.1111/j.1460-9568.1996.tb01290.x; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; Goodness TP, 1997, EUR J NEUROSCI, V9, P1574, DOI 10.1111/j.1460-9568.1997.tb01515.x; Hagg T, 1998, EXP NEUROL, V149, P183, DOI 10.1006/exnr.1997.6684; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON J, 1994, CURR BIOL, V4, P662, DOI 10.1016/S0960-9822(00)00149-4; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; Lindsay RM, 1996, PHILOS T ROY SOC B, V351, P365, DOI 10.1098/rstb.1996.0030; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; MUDO G, 1993, NEUROSCIENCE, V57, P901, DOI 10.1016/0306-4522(93)90036-F; Numan S, 1997, EUR J NEUROSCI, V9, P489, DOI 10.1111/j.1460-9568.1997.tb01626.x; Seroogy K., 1997, NEUROCHEMISTRY PRACT, P121; Singh TD, 1997, NEUROCHEM RES, V22, P791, DOI 10.1023/A:1022075508176; Snider WD, 1996, MOL CELL NEUROSCI, V7, P433, DOI 10.1006/mcne.1996.0031; VALENZUELA DM, 1993, ALTERNATIVE FORMS RA, P963; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	35	31	31	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	AUG 31	1998	59	2					264	268		10.1016/S0169-328X(98)00158-2			5	Neurosciences	Neurosciences & Neurology	123LF	WOS:000076126100014	9729420				2021-06-18	
J	Wallace, CA; Bogner, J; Corrigan, JD; Clinchot, D; Mysiw, WJ; Fugate, LP				Wallace, CA; Bogner, J; Corrigan, JD; Clinchot, D; Mysiw, WJ; Fugate, LP			Primary caregivers of persons with brain injury: life change 1 year after injury	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; FAMILY NEEDS; RELATIVES; PATIENT; STRESS; IMPACT	The impact of a traumatic brain injury on the family of the injured person is just beginning to be explored. In the current study, 61 primary caregivers were contacted at 1 year following injury. They completed the Relative and Friend Support Index, Social Support Index, Trauma Complaints List and the Life Change Question. The majority of caregivers indicated at least mild negative life change following the brain injury. Greater social support was correlated with less life change and greater injury severity was correlated with negative life change. Neither of these relationships was found to be significant at the 0.05 level. A significant positive correlation was found between caregivers' perception of deficits and the degree of negative life change. Perceived deficits accounted for the greatest amount of variance in life change followed by relative and friend support when all variables were entered into a stepwise regression. Further analyses indicated that the most significant factor of the Trauma Complaints List in predicting life change may be problems with cognition, which accounted for a significant amount of the variance in life change. Implications for counselling and further research regarding caregivers of persons with brain injury are discussed.	Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Bogner, J (corresponding author), Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.		Corrigan, John D./E-2921-2011; Mysiw, Walter/E-3724-2011	Clinchot, Daniel/0000-0002-2810-7227			Acorn S., 1993, CANADIAN J REHABILIT, V7, P149; ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; FLORIAN V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; GLECKMAN AD, 1995, BRAIN INJURY, V9, P385, DOI 10.3109/02699059509005778; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; HINKELDEY N, 1989, BRAIN INJURY, V4, P115; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lauer-Listhaus B, 1991, COUNSELING PSYCHOL Q, V4, P351, DOI 10.1080/09515079108254443; LEAF LE, 1993, BRAIN INJURY, V7, P543, DOI 10.3109/02699059309008182; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McCubbin H., 1982, FAMILY ASSESSMENT RE, P295; MCCUBBIN H, 1981, FAMILY ASSESSMENT IN, P203; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER L, 1993, AM J FAM THER, V21, P111, DOI 10.1080/01926189308250910; MINTZ MC, 1995, BRAIN INJURY, V9, P173, DOI 10.3109/02699059509008190; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1984, CLOSED HEAD INJURY P, P108; PANTING A, 1972, ARCH PHYSICAL MED RE, V73, P771; *SAS I INC, 1985, SAS US GUID BAS VERS; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21	34	31	33	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1998	12	6					483	493		10.1080/02699052.1998.11910751			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZU400	WOS:000074193300004	28925743				2021-06-18	
J	Cresswell, TR; Smith, RB				Cresswell, TR; Smith, RB			Bilateral anterior shoulder dislocations in bench pressing: an unusual cause	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						shoulder dislocation; anterior glenohumeral dislocation; weight training; bench pressing	FRACTURE-DISLOCATION	A case of bilateral anterior glenohumeral dislocation in a young weight trainer is presented. The patient, an insurance clerk, had been using a free weight bar in the bench press position and had become tired when the weight on the bar forced his arms into hyperextension in the mid-abducted position. The humeral shaft gradually pivoted on the bench and the humeral heads were slowly dislocated anteriorly by the weight of the bar. Simple closed reduction under sedation was performed and there were no complications. After six weeks in bilateral broad arm slings, with pendulum exercises from two weeks, the patient began to mobilise his arms and he achieved a full range of movements. This unusual mechanism of injury has not previously been reported and we recommend that bench pressing should be performed with a weight that can be "locked" to prevent crushing of the user. Furthermore, the bench should be narrow enough to allow the shoulders to overhang, allowing greater extension in the abducted position without the arm pivoting on the edge of the bench.	Royal Preston Hosp, Dept Orthopaed & Trauma, Preston PR2 9HT, Lancs, England	Cresswell, TR (corresponding author), Childrens Hosp, Dept Orthopaed & Trauma, Western Bank, Sheffield S10 2TH, S Yorkshire, England.						BRADY WJ, 1995, J EMERGENCY MED, V15, P37; BROWN RJ, 1984, INJURY, V15, P267, DOI 10.1016/0020-1383(84)90012-3; CAREWMCCOLL M, 1980, BRIT J CLIN PRACT, V34, P251; Jones M, 1987, Br J Sports Med, V21, P139; Lal M, 1992, Indian J Med Sci, V46, P209; LITCHFIELD JC, 1988, POSTGRAD MED J, V64, P450, DOI 10.1136/pgmj.64.752.450; MAFFULLI N, 1990, INJURY, V21, P254, DOI 10.1016/0020-1383(90)90020-U; MARKEL DC, 1994, ORTHOPEDICS, V17, P945; Martens C, 1995, Acta Orthop Belg, V61, P249; MARTY B, 1994, UNFALLCHIRURG, V97, P382; MATHIS RD, 1980, J EMERGENCY MED, V1, P41; MEHTA MP, 1989, ANN EMERG MED, V18, P589, DOI 10.1016/S0196-0644(89)80850-9; Mesa M, 1996, Acta Orthop Belg, V62, P116; PAGE AE, 1995, J ORTHOP TRAUMA, V9, P526, DOI 10.1097/00005131-199509060-00012; THOMAS T, 1995, CLIN RHEUMATOL, V14, P467, DOI 10.1007/BF02207684	15	31	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	MAR	1998	32	1					71	72		10.1136/bjsm.32.1.71			2	Sport Sciences	Sport Sciences	ZE503	WOS:000072799400025	9562170	Green Published, Bronze			2021-06-18	
J	Zhao, XR; Posmantur, R; Kampfl, A; Liu, SJ; Wang, KKW; Newcomb, JK; Pike, BR; Clifton, GL; Hayes, RL				Zhao, XR; Posmantur, R; Kampfl, A; Liu, SJ; Wang, KKW; Newcomb, JK; Pike, BR; Clifton, GL; Hayes, RL			Subcellular localization and duration of mu-calpain and m-calpain activity after traumatic brain injury in the rat: A casein zymography study	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article							LEVELS DECREASE; ACTIVATION; CALCIUM; FORMS; ACCUMULATION; PROTEINASES; AUTOLYSIS; CELLS	Casein zymographic assays were performed to identify changes in mu-calpain and m-calpain activity in naive, sham-injured, and injured rat cortex at 15 minutes, 3 hours, 6 hours, and 24 hours after unilateral cortical impact brain injury. Cortical samples ipsilateral and contralateral to the site of injury were separated into cytosolic and total membrane fractions. Marked increases in mu-calpain activity in cytosolic fractions in the ipsilateral cortex occurred as early as 15 minutes, became maximal at 6 hours, and decreased at 24 hours to levels observed at 15 minutes after injury. A similar temporal profile of cytosolic mu-calpain activity in the contralateral cortex was observed, although the increases in the contralateral cortex were substantially lower than those in the ipsilateral cortex. Differences were also noted between cytosolic and total membrane fractions. The detection of a shift in mu-calpain activity to the total membrane fraction first occurred at 3 hours after traumatic brain injury and became maximal at 24 hours after traumatic brain injury. This shift in mu-calpain activity between the two fractions could be due to the redistribution of mu-calpain from the cytosol to the membrane, m-Calpain activity was detected only in cytosolic fractions. m-Calpain activity in cytosolic fractions did not differ significantly between ipsilateral and contralateral cortices, and increased in both cortices from 15 minutes to 6 hours after injury. Relative magnitudes of In-calpain versus mu-calpain activity in cytosolic fractions differed, at different time points after injury. These studies suggest that traumatic brain injury can activate both calpain isoforms and that calpain activity is not restricted to sites of focal contusion and cell death at the site of impact injury but may represent a more global response to injury.	Univ Texas, Houston Hlth Sci Ctr, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Houston, TX 77030 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Lab Neurobiochem, Dept Neurosci Therapeut, Ann Arbor, MI USA; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria	Hayes, RL (corresponding author), Univ Texas, Houston Hlth Sci Ctr, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, 6431 Fannin,Suite 7-154, Houston, TX 77030 USA.			Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 21458] Funding Source: Medline		Chakrabarti AK, 1996, J NEUROSCI RES, V44, P374; CONG JY, 1989, J BIOL CHEM, V264, P10096; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EDMUNDS T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P197, DOI 10.1016/0167-4838(91)90059-9; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KAWASHIMA S, 1988, BIOCHIM BIOPHYS ACTA, V965, P130, DOI 10.1016/0304-4165(88)90048-7; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NILSSON P, 1993, J CEREB BLOOD FLOW M, V13, P185; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; OSTWALD K, 1993, BRAIN RES, V630, P289, DOI 10.1016/0006-8993(93)90668-D; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POSMANTUR RM, 1995, J NEUROTRAUM, V12, P972; RASER KJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P211, DOI 10.1006/abbi.1995.1284; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAATMAN KE, 1996, J NEUROPATH EXP NEUR, V55, P852; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814; SHAPIRA Y, 1989, Neurological Research, V11, P169; SIMAN R, 1983, J NEUROCHEM, V41, P950, DOI 10.1111/j.1471-4159.1983.tb09039.x; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; VITTO A, 1986, J NEUROCHEM, V47, P1039; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291; ZHANG W, 1996, J BIOL CHEM, V33, P25239	38	31	34	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	1998	18	2					161	167		10.1097/00004647-199802000-00006			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	YV905	WOS:000071876100006	9469158	Bronze			2021-06-18	
J	Lannoo, E; Colardyn, F; Vandekerckhove, T; De Deyne, C; De Soete, G; Jannes, C				Lannoo, E; Colardyn, F; Vandekerckhove, T; De Deyne, C; De Soete, G; Jannes, C			Subjective complaints versus neuropsychological test performance after moderate to severe head injury	ACTA NEUROCHIRURGICA			English	Article						closed head injury; neuropsychological test performance; subjective complaints	PSYCHOSOCIAL RECOVERY; EVERYDAY MEMORY; BRAIN INJURY; BASE RATES; SYMPTOMS; DEFICITS; DISORDER	Neuropsychological test performance and subjective complaints of 85 patients with moderate to severe head injury were investigated at 6 months postinjury. The neuropsychological test battery included 10 measures of attention, memory, mental flexibility, reaction time, visuoconstruction and verbal fluency. Subjective complaints were assessed using a self-report questionnaire subdivided into four subscales (somatic, cognitive, emotional and behavioural). Ratings were obtained for the pre-injury and current status. Thirty-three trauma patients with injuries to other parts of the body than the head were used as controls. For the head injured, relatives also completed the questionnaire. Head injured patients performed significantly below trauma control patients on nearly all test measures. Head injured patients and their relatives reported a significant increase in subjective complaints since the injury on all four subscales, with no differences between patients' and relatives' reports. These changes were also reported by the trauma controls, but they report fewer changes in somatic and cognitive functioning. Exploratory canonical correlation analyses revealed no correlations between any of the four scales of the questionnaire and the test measures, nor for the head injured, the trauma controls, or the relatives, indicating no relevant relationship between subjective complaints and neuropsychological test performance.	State Univ Ghent, Dept Neuropsychol, B-9000 Ghent, Belgium; State Univ Ghent, Dept Intens Care, B-9000 Ghent, Belgium; State Univ Ghent, Dept Neurosurg, B-9000 Ghent, Belgium; State Univ Ghent, Dept Data Anal, B-9000 Ghent, Belgium; State Univ Ghent, Dept Psychiat, B-9000 Ghent, Belgium	Lannoo, E (corresponding author), State Univ Ghent Hosp, Rehabil Ctr K7, De Pintelaan 185, B-9000 Ghent, Belgium.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BROWN FH, 1991, J CLIN PSYCHOL, V47, P772, DOI 10.1002/1097-4679(199111)47:6<772::AID-JCLP2270470607>3.0.CO;2-P; COUCH JR, 1995, J NEUROL REHABIL, V9, P83; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Dodrill CB, 1997, CLIN NEUROPSYCHOL, V11, P1, DOI 10.1080/13854049708407025; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GASQUOINE PG, 1992, NEUROPSYCHOLOGY, V9, P606; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kinsella G, 1989, Int Disabil Stud, V11, P9; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LONG CJ, 1991, J HEAD INJURY, V2, P18; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Reitan RM, 1997, NEUROPSYCHOL REV, V7, P3, DOI 10.1007/BF02876970; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; Schmand B., 1992, NLV NEDERLANDSE LEES; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spreen O., 1991, COMPENDIUM NEUROPSYC; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; TRUELLE JL, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P69; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VERMEULEN J, 1993, EPILEPSY RES, V15, P157, DOI 10.1016/0920-1211(93)90096-P; VINGERHOETS G, 1995, J PSYCHOSOM RES, V39, P843, DOI 10.1016/0022-3999(95)00021-3; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	40	31	31	0	3	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1998	140	3					245	253		10.1007/s007010050091			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZM414	WOS:000073537600016	9638261				2021-06-18	
J	Lopez-Pison, J; Arana, T; Baldellou, A; Rebage, V; Garcia-Jimenez, MC; Pena-Segura, JL				Lopez-Pison, J; Arana, T; Baldellou, A; Rebage, V; Garcia-Jimenez, MC; Pena-Segura, JL			A study of the demand for neuropaediatric attention in a general hospital. III. Diagnosis	REVISTA DE NEUROLOGIA			Spanish	Article						diagnosis; healthcare administration; hospital; neuropaediatrics	OPEN-HEART-SURGERY; TUBEROUS-SCLEROSIS; SPINA-BIFIDA; NEUROFIBROMATOSIS TYPE-1; NEUROCUTANEOUS SYNDROMES; BRAIN-TUMORS; CHILDREN; CHILDHOOD; MRI; RADIOTHERAPY	Introduction and objectives. In order to determine the requirements for neuropaediatric attention in the Hospital Miguel Servet of Zaragoza, we studied the diagnoses of the 2,046 children evaluated during the 5 year period-May 1990 to May 1995-, when a neuropaediatrician was appointed to the hospital (which previously did not have such a specialist). Results. The most frequent problems were non-epileptic paroxystic disorders, epilepsies and febrile crises. The following is a list in descending order, of diseases affecting these children: Prenatal encephalopathies, disorders of development and behaviour, head injury (TCE), peripheral nervous system and cranial nerve disorders (which were neither traumatic nor secondary to space-occupying lesions), headaches, perinatal encephalopathies, infections and para-infectious diseases of the nervous system, cardiovascular problems, hydrocephalus, metabolic disorders, hypovision and eye disorders, neuromuscular disorders, tumours, dyskinesias, medulla problems and neurocutaneous syndromes. Conclusions. The frequency and diversity of the neurological pathology seen in childhood and the continual advances in knowledge and the related sciences are more than a single professional person can be expected to cope with. Experts are required in areas such as electroencephalography and epilepsy, neonatal neurology, the neurological aspects of intensive care, neuropsychology, neuro-oncology, neurometabolic disorders, neurogenetics and neuromuscular disorders. Neuropaediatricians are required to control illnesses with great personal, family and social impact, such as thge neurocutaneous syndromes and myelomeningocoele. Neuropaediatric services working in close inter-disciplinary collaboration with other specialists are necessary.	Hosp Miguel Servet, Secc Neuropediat, E-50009 Zaragoza, Spain; Hosp Gen Univ Guadalajara, Secc Metabolopatias, Guadalajara, Spain; Hosp Gen Univ Guadalajara, Secc Neonatal, Guadalajara, Spain; Hosp Gen Univ Guadalajara, Serv Pediat, Guadalajara, Spain; CS Miraflores, Zaragoza, Spain				PENA SEGURA, JOSE LUIS/0000-0002-9336-780X; Lopez Pison, Francisco Javier/0000-0002-1876-1495			Aicardi J, 1992, DIS NERVOUS SYSTEM C; Aicardi J., 1986, EPILEPSY CHILDREN; ALELISSA Y, 1992, DEV MED CHILD NEUROL, V34, P1085; ALEXANDER M, 1993, DEV MED CHILD NEUROL, V35, P753; ALRAJEH S, 1991, DEV MED CHILD NEUROL, V33, P1048; ANDERSON VE, 1993, TXB EPILEPSY, P47; AVIZONIS VN, 1992, NEUROPEDIATRICS, V23, P228, DOI 10.1055/s-2008-1071348; AYSUN S, 1994, PEDIATR NEUROL, V10, P40, DOI 10.1016/0887-8994(94)90065-5; AZIMULLAH PC, 1991, CHILD NERV SYST, V7, P63; BELL WE, 1978, MAJOR PROBLEMS CLIN, V8; BERG BO, 1991, BRAIN DEV-JPN, V13, P9, DOI 10.1016/S0387-7604(12)80290-7; BEYER RA, 1986, NEUROLOGY, V36, P1173, DOI 10.1212/WNL.36.9.1173; BRAAKMAN R, 1994, NEUROLOGIA CRITICA, P221; BRAFFMAN BH, 1992, RADIOLOGY, V183, P227, DOI 10.1148/radiology.183.1.1549677; BRENINGSTALL GN, 1992, PEDIATR NEUROL, V8, P267, DOI 10.1016/0887-8994(92)90363-4; CAMFIELD P, 1994, DEV MED CHILD NEUROL, V36, P887; CASSIDY SB, 1983, JAMA-J AM MED ASSOC, V249, P1302, DOI 10.1001/jama.249.10.1302; CHAPMAN CA, 1995, J CHILD NEUROL, V10, P209, DOI 10.1177/088307389501000308; CHIOFALO N, 1986, PRINCIPLES PEDIAT NE, P217; Cohen M E, 1985, Pediatr Neurol, V1, P77, DOI 10.1016/0887-8994(85)90040-2; COHEN ME, 1993, J CHILD NEUROL, V8, P287, DOI 10.1177/088307389300800401; CZARTORYSKA B, 1994, PEDIATR NEUROL, V11, P295, DOI 10.1016/0887-8994(94)90004-3; DELGADOESCUETA AV, 1994, REV NEUROL, V114, P92; DIMARIO FJ, 1992, PEDIATR NEUROL, V8, P303, DOI 10.1016/0887-8994(92)90371-5; DUFFNER PK, 1991, PEDIATR NEUROL, V7, P237, DOI 10.1016/0887-8994(91)90038-M; ELSTER AD, 1992, AM J NEURORADIOL, V13, P1078; FEJERMAN N, 1986, CONVULSIONES INFANCI; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; GARCIAPEREZ A, 1993, DEV MED CHILD NEUROL, V35, P139; GREENWALD MJ, 1992, DERMATOL CLIN, V10, P623; HUNT GM, 1995, DEV MED CHILD NEUROL, V37, P19; Ilveskoski I, 1996, NEUROPEDIATRICS, V27, P124, DOI 10.1055/s-2007-973762; ITO M, 1991, PEDIATR NEUROL, V7, P436, DOI 10.1016/0887-8994(91)90027-I; JENNET B, 1986, CHILDREN NEUROLOGICA, P176; KAISER G, 1986, PRINCIPLES PEDIAT NE, P263; KORF BR, 1992, PEDIATRICS, V90, P924; KUENZLE C, 1994, NEUROPEDIATRICS, V25, P295, DOI 10.1055/s-2008-1073043; LANSKA MJ, 1991, PEDIATR NEUROL, V7, P333, DOI 10.1016/0887-8994(91)90062-P; LopezPison J, 1997, REV NEUROLOGIA, V25, P1535; MCENERY G, 1992, DEV MED CHILD NEUROL, V34, P342; MCMURDO SK, 1987, AM J NEURORADIOL, V8, P77; MILLER G, 1994, J CHILD NEUROL, V9, P390, DOI 10.1177/088307389400900411; Miller G, 1996, J CHILD NEUROL, V11, P49, DOI 10.1177/088307389601100112; National Institutes of Health Consensus Development Conference Statement on Neurofibromatosis, 1987, ARCH NEUROL-CHICAGO, V45, P575; Nordin V, 1996, DEV MED CHILD NEUROL, V38, P297; NORTH K, 1993, J CHILD NEUROL, V8, P395, DOI 10.1177/088307389300800421; OZAND PT, 1992, J CHILD NEUROL, V7, pS4, DOI 10.1177/08830738920070010211; PACKER RJ, 1985, PEDIATRICS, V76, P194; PAMPOLS T, 1995, CROMOSOMA GEN ANOMAL, P173; PAMPOLS T, 1995, CROMOSOMA GEN ANOMAL, P445; PONT MS, 1992, AM J ROENTGENOL, V158, P1193, DOI 10.2214/ajr.158.6.1590106; RIVA D, 1991, NEUROPEDIATRICS, V22, P36, DOI 10.1055/s-2008-1071413; ROACH ES, 1992, J CHILD NEUROL, V7, P221, DOI 10.1177/088307389200700219; TRUHAN AP, 1993, ARCH DERMATOL, V129, P219, DOI 10.1001/archderm.129.2.219; UVEBRANT P, 1992, NEUROPEDIATRICS, V23, P209, DOI 10.1055/s-2008-1071343; VANDENBERG BJ, 1969, PEDIATR RES, V3, P298, DOI 10.1203/00006450-196907000-00005; VANHALL MHJA, 1992, NEUROPEDIATRICS, V23, P276, DOI 10.1055/s-2008-1071358; WANG AM, 1983, AM J NEURORADIOL, V4, P466; WELLESLEY D, 1991, DEV MED CHILD NEUROL, V33, P963; WILLIAMS BA, 1992, J CHILD NEUROL, V7, P291, DOI 10.1177/088307389200700309; WONG VCN, 1994, PEDIATR NEUROL, V11, P301, DOI 10.1016/0887-8994(94)90006-X	61	31	33	0	4	REVISTA DE NEUROLOGIA	BARCELONA	C/O CESAR VIGUERA, EDITOR, APDO 94121, 08080 BARCELONA, SPAIN	0210-0010	1576-6578		REV NEUROLOGIA	Rev. Neurologia	DEC	1997	25	148					1896	1905					10	Clinical Neurology	Neurosciences & Neurology	YW287	WOS:000071917200014	9580291				2021-06-18	
J	Buffington, ALH; Malec, JF				Buffington, ALH; Malec, JF			The vocational rehabilitation continuum: Maximizing outcomes through bridging the gap from hospital to community-based services	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							BRAIN INJURY REHABILITATION	Objective: To describe and examine the effects of a specialized brain injury vocational service delivery model on vocational outcome for individuals with traumatic or other acquired brain injury. Design: A prospective case series was used. Setting: Inpatient and outpatient rehabilitation departments at a large midwest regional trauma center. Participants: Eighty adults with traumatic or other acquired brain injury were residents of the state of Minnesota, did not have a primary psychiatric or substance abuse diagnosis, and did not live in a residential I:are facility. Main Outcome Measures: Vocational Outcome Scale (VOS), Client Satisfaction Survey, and data on participant's level of independent living, job type and setting, rate of pay, and number of hours worked per week. Results: Through emphasizing early vocational intervention, closely integrating this with medical rehabilitative treatment, and providing a smooth transition from medical to community-based services, 40% of project participants were placed in a job within the first 3 months of project participation; about 70% were placed within 12 months of project participation. Those placed have an average rate of pay of $7.70 per hour and a 90-day job retention rate of 100%. Conclusions: Results indicate that this system of specialized brain injury vocational service delivery is effective.		Buffington, ALH (corresponding author), MAYO MED CTR,200 1ST ST SW,ROCHESTER,MN 55905, USA.						BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; COOK J, 1990, REHABILITATION ADULT, P493; COURTNEY C, 1992, 84235 CFDA MINN DEP; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Fawber HL, 1987, J HEAD TRAUMA REHAB, V2, P27; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; Lezak M. D., 1989, ASSESSMENT BEHAV CON, P113; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; *MAYO F, 1995, UND BRAIN INJ GUID E; PARENTE R, 1991, J HEAD TRAUMA REHAB, V6, P35; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; ROESSLER RT, 1992, J REHABIL, P17; WEHMAN P, 1993, STAFF DEV CLIN INTER, P129; WEHMAN P, 1993, COMMUNITY BASED EMPL	21	31	31	0	7	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1997	12	5					1	13		10.1097/00001199-199710000-00002			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YA515	WOS:A1997YA51500002					2021-06-18	
J	McKee, MD; Schemitsch, EH; Vincent, LO; Sullivan, I; Yoo, D				McKee, MD; Schemitsch, EH; Vincent, LO; Sullivan, I; Yoo, D			The effect of a femoral fracture on concomitant closed head injury in patients with multiple injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the Canadian-Orthopedic-Association	MAY 26-28, 1996	QUEBEC CITY, CANADA	Canadian Orthoped Assoc		head injury; femoral fracture; multiple injuries; early reamed intramedullary nailing	FAT-EMBOLISM; SHAFT FRACTURES	Objective: We sought to determine the effect of a femoral shaft fracture, and its treatment by early intramedullary nailing, on the neurologic outcome of patients with multiple injuries with a concomitant head injury. Design: Retrospective, case-control design using a prospectively gathered trauma data base. Materials and Methods: We identified 46 patients with multiple injuries (mean Injury Severity Score [ISS] = 33.2) with closed head injuries (mean Glasgow Coma Scale [GCS] score = 7.8) and femur fractures, and matched as controls 99 patients with multiple injuries with head injuries but without femur fractures for age, sex, mechanism of injury, ISS (mean ISS = 34.0), and GCS (mean GCS score = 8.0). Follow-up parameters examined included early mortality, length of hospital or intensive-care unit stay, neuropsychological testing, and level of neurologic disability. Results: There were no significant differences in the demographics or injury parameters between the study and control groups. There were no significant differences between the two groups in terms of early mortality (study group, 28%; control group, 27%; p = not significant), length of hospital/intensive-care unit stay (study group, 17.5/6.9 days; control group, 18.0/6.3 days; p = not significant), level of neurologic disability, or results of cognitive testing. Conclusion: Our study suggests that a femoral fracture in a patient with a concomitant head injury does not increase mortality or neurologic disability, and supports the continued early intramedullary nailing of femoral fractures for these patients.	ST MICHAELS HOSP, DIV ORTHOPAED SURG, TORONTO, ON M5B 1W8, CANADA; ST MICHAELS HOSP, HEAD INJURY TEAM, TORONTO, ON M5B 1W8, CANADA; UNIV TORONTO, TORONTO, ON, CANADA			Schemitsch, Emil/G-5706-2017	Schemitsch, Emil/0000-0002-6435-9069			*ASS ADV AUT MED, 1990, ABBR INJ SCAL; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BELLAMY R, 1974, J TRAUMA, V14, P1021, DOI 10.1097/00005373-197412000-00004; FRY K, 1976, J TRAUMA, V16, P371, DOI 10.1097/00005373-197605000-00008; GARLAND DE, 1978, CLIN ORTHOP RELAT R, P111; GARLAND DE, 1980, CLIN ORTHOP RELAT R, V150, P198; GARLAND DE, 1982, CLIN ORTHOP RELAT R, V166, P219; GLENN JN, 1973, J TRAUMA, V13, P958, DOI 10.1097/00005373-197311000-00004; KARZMARK P, 1992, BRAIN INJURY, V63, P213; KOTWICA Z, 1990, ACTA NEUROCHIR, V102, P19, DOI 10.1007/BF01402180; LEVY D, 1990, CLIN ORTHOP RELAT R, V261, P281; MALISANO LP, 1994, J ORTHOP TRAUMA, V8, P1, DOI 10.1097/00005131-199402000-00001; MANNING JB, 1983, J TRAUMA, V23, P322, DOI 10.1097/00005373-198304000-00009; MEEK RN, 1972, J TRAUM, V12, P432, DOI 10.1097/00005373-197205000-00015; PELL ACH, 1993, J BONE JOINT SURG BR, V75, P921; PELTIER LF, 1988, CLIN ORTHOP RELAT R, V232, P263; RAYMOND C, 1983, J BONE J SURG, V146, P107; RISKA EB, 1982, J TRAUMA, V22, P891, DOI 10.1097/00005373-198211000-00001; TALUCCI RC, 1983, AM J SURG, V146, P107, DOI 10.1016/0002-9610(83)90269-6; Turchin DC, 1995, T ORTHOP RES SOC, V20, P252	20	31	31	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1997	42	6					1041	1045		10.1097/00005373-199706000-00009			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	XH700	WOS:A1997XH70000014	9210538				2021-06-18	
J	Baxter, PJ; Gresham, A				Baxter, PJ; Gresham, A			Deaths and injuries in the eruption of Galeras Volcano, Colombia, 14 January 1993	JOURNAL OF VOLCANOLOGY AND GEOTHERMAL RESEARCH			English	Article						deaths; pathology; eruption; Galeras volcano		Six volcanologists and three tourists were killed in the crater of Galeras Volcano, Colombia, when it erupted without warning. The scientists were attending the United Nations International Decade for Natural Disaster Reduction Workshop which had been convened to improve monitoring, research and disaster mitigation at Galeras, at the time the most active and one of the most hazardous volcanoes in South America. Information on the events surrounding the eruption was obtained by sending a questionnaire to twelve scientists who had been inside the caldera at the time of the eruption or who had assisted in the search and rescue operation. The autopsy reports on the five corpses, and the few pieces of equipment and clothing retrieved from the crater area, were also studied. The main causes of death and injury were the forces at the eruptive vent and the bombardment by hot rocks ejected in the first 15 min of the emption, ranging from blocks over 1 m in size to pea-sized lapilli which fell last. Some conclusions can be drawn for the future safety of volcanologists working in craters at high altitude. Hard hats would protect against concussion from blows to the head during escape from the danger area, and a Lightweight, heat-resistant and water-repellent coverall would limit the skin bums and the risk of clothing being ignited from contact with incandescent, falling ejecta. The coverall could also be life saving by protecting immobilised casualties from hypothermia due to the rain and wind whilst waiting to be rescued, especially as the volcanic activity, cloud cover or nightfall could curtail rescue efforts. Work in hazardous craters should be strictly limited to essential tasks and periods of good visibility, and a climbing team should leave the area at least four hours before nightfall in case rescue is needed. Tourists must be warned against visiting active crater areas.		Baxter, PJ (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.						CHESTER DK, 1985, MOUNT ETNA MAKING VO; FINK J, 1995, NATURE, V373, P660, DOI 10.1038/373660a0; Munoz F.A., 1993, EOS T AM GEOPHYS UN, V74, P281, DOI [10.1029/93EO00391, DOI 10.1029/93EO00391]; *SMITHS I, 1995, GLOB VOLC NETW, V20, P11; Stix J, 1997, J VOLCANOL GEOTH RES, V77, P285, DOI 10.1016/S0377-0273(96)00100-X; TILLING RI, 1993, NATURE, V364, P277, DOI 10.1038/364277a0; TNO, 1992, METH DET POSS DAM PE; WILSON L, 1980, J VOLCANOL GEOTH RES, V8, P297, DOI 10.1016/0377-0273(80)90110-9	8	31	32	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0377-0273			J VOLCANOL GEOTH RES	J. Volcanol. Geotherm. Res.	MAY	1997	77	1-4					325	338		10.1016/S0377-0273(96)00103-5			14	Geosciences, Multidisciplinary	Geology	XC670	WOS:A1997XC67000021					2021-06-18	
J	Koelfen, W; Freund, M; Dinter, D; Schmidt, B; Koenig, S; Schultze, C				Koelfen, W; Freund, M; Dinter, D; Schmidt, B; Koenig, S; Schultze, C			Long-term follow up of children with head injuries classified as ''good recovery'' using the Glasgow Outcome Scale: Neurological, neuropsychological and magnetic resonance imaging results	EUROPEAN JOURNAL OF PEDIATRICS			English	Article						head trauma; Glasgow Outcome Scale; neuropsychological tests; magnetic resonance imaging; long-term follow up	TRAUMATIC BRAIN INJURY; FEATURES; COHORT; MOTOR; COMA	The primary issues addressed in this study were: (1) determination of the significance of the classification ''good outcome'' utilizing the Glasgow Outcome Scale (GOS) in children at least 1 year after brain injury; (2) detection of residual lesions of brain parenchyma in these children upon follow up MRI scans; and (3) detection of relationships between neuropsychological test performance and MRI results. Selection criteria included children 6-15 years of age at the time of testing who received an initial CT scan at the time of their head injury and who had been injured at least 12 months prior to the follow up test. Only children who did not demonstrate neurological disability at the time of follow up examination were selected. The children showed a status of ''good outcome'' as defined by the GOS. Neurological examination, neuropsychological tests and an MRI were done. The test results of 59 patients were compared to those of a matched control group. Children, after receiving head injuries, showed significantly poorer results with respect to cognitive, motor and fine motor skills. Of all MRI-scans 66% revealed pathological findings. Cortical lesions were detected on MRI in 14% of cases; subcortical injuries were detected in 12% and, deep white matter lesions in 31%. Furthermore, corpus callosum damage was observed in 26% of cases. Pathological MRI findings were also observed in children with mild head injuries. All of the children with normal MRI findings showed abilities comparable to those of children in the control group. Patients with cortical lesions exhibited only motor deficits, whereas motor and cognitive deficits were seen in patients with deep white matter lesions. Children with multiple lesions demonstrated test results in all variables 1 to 2 standard deviations below those of the control group. Conclusions Children suffering a brain injury who 1 year later are classified within the ''good outcome'' group according to the Glasgow Outcome Scale often have significant morphological and functional brain deficits.	FAC CLIN MED, DEPT RADIOL, MANNHEIM, GERMANY	Koelfen, W (corresponding author), UNIV MANNHEIM, KINDERKLIN, SCHWERPUNKT NEUROPADIATR, POSTFACH 1000 23, THEODOR KUTZER UFER, D-68167 MANNHEIM, GERMANY.						AULD KL, 1995, PEDIATR NEUROL, V12, P323, DOI 10.1016/0887-8994(95)00062-K; Cattell R. B., 1960, CULTURE FAIR INTELLI; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRIMM H, 1978, HEIDELBERGER SPRACHE; HADLEY DM, 1988, CLIN RADIOL, V39, P131; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JENNETT B, 1975, LANCET, V1, P480; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; Kiphard EJ, 1974, KORPERKOORDINATIONST; KORNMANN R, 1977, TESTBATTERIE ENTWICK; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; Kubinger K.D., 1985, ADAPTIVES INTELLIGEN; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P15; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1993, CURR OPIN NEUROL, V6, P841, DOI 10.1097/00019052-199312000-00003; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MOHANTY A, 1995, PEDIATR NEUROSURG, V23, P57, DOI 10.1159/000120936; PAMPUS I, 1995, TRAUMATISCHE HIMSCHA, P171; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; SCHMIDTKE A, 1980, RAVEN MATRIZEN TEST; SHAPIRO K, 1993, HEAD INJURY, P427; TEWES U, 1983, HAMBURG WECHSLER INT; VOLLMER DG, 1993, HEAD INJURY, P553; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WILSON J T L, 1992, Brain Injury, V6, P391, DOI 10.3109/02699059209008135; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	37	31	31	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-6199	1432-1076		EUR J PEDIATR	Eur. J. Pediatr.	MAR	1997	156	3					230	235		10.1007/s004310050590			6	Pediatrics	Pediatrics	WL980	WOS:A1997WL98000015	9083767				2021-06-18	
J	Bullard, DE; Nashold, BS				Bullard, DE; Nashold, BS			The caudalis DREZ for facial pain	STEREOTACTIC AND FUNCTIONAL NEUROSURGERY			English	Article; Proceedings Paper	XIIth Meeting of the World Society for Stereotactic and Functional Neurosurgery	JUL 01-04, 1997	LYON, FRANCE	World Soc Stereotact & Funct Neurosurg		facial pain; DREZ; Caudalis nucleus	ENTRY ZONE LESIONS	During a 3-year period, 25 caudalis dorsal root entry zone (DREZ) operations were done for severe, facial pain. Intraoperative brainstem recordings were done before and after DREZ in all patients. Primary diagnosis included refractory trigeminal neuralgia, atypical headaches or facial pain, posttraumatic closed head injuries, postsurgical anesthesia dolorosa, multiple sclerosis, brainstem infarction, postherpetic neuralgia and cancer-related pain. At the time of discharge, good to excellent pain relief was present in 24/25 patients and fair relief in 1. At 1 month, 19/25 (76%) patients had good to excellent results and at 3 months following surgery, 17/25 (68%) continued to have good to excellent pain relief. One year following surgery, 18 patients could be evaluated, 12/18 (67%) still considered their relief as good to excellent, 2 fair and 4 poor. Transient postoperative ataxia was present in 15/25 patients (60%), but was largely resolved at 1 months. In 3/18 (17%) patients, a degree of ataxia was still present at 1 year although in none was it disabling. Two patients had transient diplopia, and 3 had increased corneal anesthesia with 1 later developing a keratitis. No surgical or postsurgical mortality was noted. This procedure has proven to be a satisfactory treatment for many patients with debilitating facial pain syndromes with acceptable morbidity.	Raleigh Neurosurg Clin, Raleigh, NC 27609 USA	Bullard, DE (corresponding author), Raleigh Neurosurg Clin, 3700 Barrett Dr, Raleigh, NC 27609 USA.						ANDERSON LS, 1971, J NEUROSURG, V35, P444, DOI 10.3171/jns.1971.35.4.0444; Bernard E J Jr, 1987, Br J Neurosurg, V1, P81, DOI 10.3109/02688698709034343; Crue B L, 1967, Bull Los Angeles Neurol Soc, V32, P86; Gorecki JP, 1995, STEREOT FUNCT NEUROS, V65, P111, DOI 10.1159/000098679; HITCHCOCK E, 1970, Annals of Clinical Research, V2, P131; HITCHCOCK ER, 1972, J NEUROSURG, V37, P412, DOI 10.3171/jns.1972.37.4.0412; KERR RWL, 1961, P MAYO CLIN, V36, P254; KING RB, 1970, TRIGEMINAL NEURALGIA, P78; KUNC Z, 1966, PAIN, P351; LOESER JD, 1968, J NEUROSURG, V29, P48, DOI 10.3171/jns.1968.29.1.0048; McKenzie KG, 1955, CLIN NEUROSURG, V2, P50; NASHOLD BS, 1994, J NEUROSURG, V80, P1116, DOI 10.3171/jns.1994.80.6.1116; NASHOLD BS, 1966, DREZ OPERATION, P159; SCHVARCZ JR, 1978, APPL NEUROPHYSIOL, V41, P99; SCHVAREZ JR, 1977, ADV PAIN RES THER, V3, P331; SHARPE R, 1966, DREZ OPERATION, P27; SINDOU M, 1976, PROGR NEUROLOGICAL S, V7, P201; SJOQVIST O., 1938, ACTA PSYCHIAT KBH, V17, P1; SPIEGELMANN R, 1991, STEREOT FUNCT NEUROS, V56, P166, DOI 10.1159/000099403; THOMAS DGT, 1994, J NEUROL NEUROSUR PS, V57, P737, DOI 10.1136/jnnp.57.6.737	20	31	31	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1011-6125			STEREOT FUNCT NEUROS	Stereotact. Funct. Neurosurg.		1997	68	1-4					168	174		10.1159/000099918			7	Neurosciences; Neuroimaging; Surgery	Neurosciences & Neurology; Surgery	ZZ207	WOS:000074706300025	9711711				2021-06-18	
J	Levinson, DM; Reeves, DL				Levinson, DM; Reeves, DL			Monitoring recovery from traumatic brain injury using automated neuropsychological assessment metrics (ANAM V1.0)	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							PERFORMANCE	Twenty-two students in the Coastline Community College Traumatic Head Injury Program completed two sessions of neuropsychological testing spaced 2-3 months apart, using ANAM V1.0. Eight (GP1) were marginally injured, seven (GP2) mildly, and seven (GP3) moderately. Comparisons of first-session accuracy scores with normative data revealed that GP1 was impaired on one test, while GPs 2 and 3 were impaired on 3 and 4 rests, respectively. Second-session accuracy scores were normal for GPs 1 and 2 on all tests, and impaired on one for GP3. Comparisons of first-session efficiency scores with normative data indicated that GP1 was significantly impaired on 2 tests, while GPs 2 and 3 were impaired on all 6. Second-session efficiency scores, were normal for GP1 on 5 tests; GPs 2 and 3 also improved but remained impaired on all 6 tests. Based on efficiency, 91% of the individuals were correctly classified. (C) 1997 National Academy of Neuropsychology.	NAVAL MED CTR, SAN DIEGO, CA USA; NATL COGNIT RECOVERY FDN, SAN DIEGO, CA USA	Levinson, DM (corresponding author), NATL COGNIT RECOVERY FDN, RES OFF, 13202 ETON PL, SANTA ANA, CA 92705 USA.						BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; BLEIBERG J, 1989, PHYSICAL MED REHABIL, V3, P95; BLEIBERG J, 1992, ARCH PHYSICAL MED RE, V73, P1994; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; LEANDOWSKI AG, 1994, 14 ANN FRONT S AM CO; LEVINSON DM, 1994, NCRFTR9401; LEVINSON DM, 1996, NCRFTR9602; LEVINSON DM, 1990, 98 AM PSYCH ASS ANN; REEVES D, 1996, NCRFTR9601; REEVES D, 1992, ANAM DOCUMENTATION, V1; Reeves D, NCRFTR9501; Reeves D, 1993, AUTOMATED NEUROPSYCH; SHINGLEDECKER CA, 1984, AFAMRLTR84; STANNY RR, 1994, UNPUB EFFECTS SUSTAI; STERNBERG S, 1969, AM SCI, V57, P421; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; Tabachnick B.G., 1989, USING MULTIVARIATE S; THORNE D, 1990, THROUGHPUT SIMPLE PE; THORNE DR, 1985, NEUROBEH TOXICOL TER, V7, P415	19	31	31	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1997	12	2					155	166		10.1016/S0887-6177(96)00026-1			12	Psychology, Clinical; Psychology	Psychology	WV548	WOS:A1997WV54800007	14588427	Bronze			2021-06-18	
J	Viano, DC; Gargan, MF				Viano, DC; Gargan, MF			Headrest position during normal driving: Implication to neck injury risk in rear crashes	ACCIDENT ANALYSIS AND PREVENTION			English	Article						whiplash; neck injury; car crash injury; seat design	RESTRAINTS; ACCIDENTS	The gap and relative height of headrest behind drivers were determined for 1915 vehicles approaching an intersection on a two lane road. Vehicle type and headrest adjustment were also evaluated using film of normal driving taken by the Insurance Institute for Highway Safety. Only 10% of drivers had headrests in the most favorable position to prevent neck extension during a rearend crash. 73% of cars had adjustable headrests, but only a quarter were placed in the up position. 83% of the adjustable headrests could have been raised to better protect the driver. Hyge sled tests were run to determine biomechanical responses for the various conditions observed in normal driving. This included three headrest heights and three gaps behind the head. Neck extension from the Hybrid III dummy was normalized to the response for a high, close headrest, and injury risk was assumed to be proportional to neck extension. The current driving situation has a relative injury risk of 3.4 in rearend crashes, compared to 1.0 for the favorable condition. If all adjustable headrests were placed in the up position, the relative risk would be lowered to 2.4, a 28.3% reduction in whiplash injury risk. Public education and vehicle design should address the importance of proper headrest placement for driving safety. Copyright (C) 1996 Elsevier Science Ltd.		Viano, DC (corresponding author), GM CORP,CTR RES & DEV,WARREN,MI 48090, USA.						BERTON RJ, 1968, 680080 SAE WARR; CAMERON MH, 1979, CR5 DEP TRANSP FED O; CAMERON MH, 1980, CR12 DEP TRANSP FED; CICCONE MA, 1988, HUM FACTORS, V30, P359, DOI 10.1177/001872088803000309; GALASKO CSB, 1993, INJURY, V24, P155, DOI 10.1016/0020-1383(93)90279-F; GARRETT JW, 1972, 720034 SAE WARR; HILDINGSSON C, 1990, ACTA ORTHOP SCAND, V61, P357, DOI 10.3109/17453679008993536; KAHANE CJ, 1982, 806108 US DOTNHTSA; LUBIN S, 1993, CAN FAM PHYSICIAN, V39, P1284; MAAG U, 1993, 37 AAAM P; MILLER TR, 1993, J TRAUMA, V34, P270, DOI 10.1097/00005373-199302000-00017; MORRIS F, 1989, ARCH EMERG MED, V6, P17; *NAT SAF COUNC, 1990, ACC FACTS, P59; NYGREN A, 1984, AKTA OTOLARYNGOLOG S, V395; NYGREN A, 1985, 10 INT C EXP SAF VEH, P85; OLNEY DB, 1986, INJURY, V17, P365, DOI 10.1016/0020-1383(86)90070-7; OLSSON L, 1990, P 1990 INT IRCOBI C, P269; ONEILL B, 1972, AM J PUBLIC HEALTH N, V62, P399, DOI 10.2105/AJPH.62.3.399; ONO K, 1993, IRCOBI C BIOM IMP SE, P201; PARKIN S, 1993, 37 AAAM C P; SEVERY DM, 1968, 680774 SAE WARR; SEVERY DM, 1967, 11 STAPP CAR CRASH C, P337; SHEE TR, 1994, J BIOMECHANICAL ENG, V116, P37; Society of Auto Engineers, 1986, J885 SAE; VIANO DC, 1988, 32ND P STAPP CAR CRA, P1; 1993, RECOVERY MAGAZINE	26	31	32	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	NOV	1996	28	6					665	674		10.1016/S0001-4575(96)00011-5			10	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	WB035	WOS:A1996WB03500001	9006635				2021-06-18	
J	Farmer, JE; Clippard, DS; LuehrWiemann, Y; Wright, E; Owings, S				Farmer, JE; Clippard, DS; LuehrWiemann, Y; Wright, E; Owings, S			Assessing children with traumatic brain injury during rehabilitation: Promoting school and community reentry	JOURNAL OF LEARNING DISABILITIES			English	Article							CLOSED-HEAD-INJURY; YOUNG-CHILDREN; SEVERITY; ADOLESCENTS; COHORT; PERFORMANCE; PREDICTORS; CHILDHOOD; RECOVERY; SCALE	Children with traumatic brain injuries (TBI) require a comprehensive, multidisciplinary evaluation during rehabilitation to promote recovery and to facilitate a smooth transition to home and school. This article summarizes the common consequences-of TBI and reviews a process-oriented approach to assessing children with moderate to severe TBI during rehabilitation. An emphasis is placed on early and regular communication among rehabilitation specialists, family members, and educators. Such collaboration permits clear identification of functional abilities and increases the child's potential for a positive long-term outcome.	ST JOHNS MERCY MED CTR, PROFESS REHABIL CTR, ST LOUIS, MO 63141 USA	Farmer, JE (corresponding author), UNIV MISSOURI, SCH MED, DEPT PHYS MED & REHABIL, COLUMBIA, MO 65211 USA.						Abidin R.R, 1983, Parenting Stress Index; ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; ASHER IA, 1989, ANNOTATED INDEX OCCU; BAKER RS, 1991, SURV OPHTHALMOL, V35, P245, DOI 10.1016/0039-6257(91)90046-I; Beery K. E., 1982, DEV TEST VISUAL MOTO; BEGALI V, 1992, HEAD INJURY CHILDREN; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; BRAUN SL, 1991, OCCUPATIONAL THERAPY, V2, P46; Bruininks R. H., 1978, BRUININKS OSERETSKY; Burke C.L., 1987, READING MISCUE INVEN; CARNEY J, 1990, Pediatrician, V17, P222; COBBS LW, 1986, J HEAD TRAUMA REHAB, V1, P57; Colarusso R. P., 1972, MOTOR FREE VISUAL PE; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; CROWLEY JA, 1991, J PEDIATR PSYCHOL, V16, P611, DOI 10.1093/jpepsy/16.5.611; DEATON AV, 1994, ED DIMENSIONS ACQUIR, P239; DEFINA A, 1991, PORTFOLIO ASSESSMENT; Delis DC, 1989, CALIFORNIA VERBAL LE; DENNEY DR, 1973, DEV PSYCHOL, V9, P275, DOI 10.1037/h0035092; DENNIS M, 1992, TOP LANG DISORD, V13, P66, DOI 10.1097/00011363-199211000-00008; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DEPAEPE JL, 1994, ED DIMENSIONS ACQUIR, P345; DEPOMPEI R, 1994, ED DIMENSIONS ACQUIR, P489; DEPOMPEI R, 1993, STAFF DEV CLIN INTER, P229; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FOLIO R, 1983, PEABODY DEV SCALES; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127; HAGEN C, 1981, RANCHO LOS AMIGOS LE; Haley S.M., 1992, PEDIAT EVALUATION DI; HALEY SM, 1991, PHYS MED REH CLIN N, V2, P689; HANSON SL, 1992, PHYSICAL MED REHABIL, V6, P483; Heaton R. K, 1981, WISCONSIN CARD SORTI; IVERSON GL, 1994, ANN M INT NEUR SOC C; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JAFFE KM, 1986, J HEAD TRAUMA REHAB, V1, P30; JANUS PL, 1994, ED DIMENSIONS ACQUIR, P345; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; JORGENSON C, 1981, WORD TEST; Kaufman A., 1985, KAUFMAN TEST ED ACHI; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kovich K., 1988, HEAD INJURY GUIDE FU; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lash M, 1993, NeuroRehabilitation, V3, P13, DOI 10.3233/NRE-1993-3304; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Lehr E, 1990, PSYCHOL MANAGEMENT T; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MCCUBBIN HI, 1985, FAMILY INVENTORIES I; MCKEE WT, 1990, HDB SCH PSYCHOL, P821; Miller L. J., 1982, MILLER ASSESSMENT PR; MILNER M, 1990, Pediatrician, V17, P287; MOOS RH, 1976, FAM PROCESS, V15, P357, DOI 10.1111/j.1545-5300.1976.00357.x; MURPHYBERMAN V, 1987, PERCEPT MOTOR SKILL, V64, P1139, DOI 10.2466/pms.1987.64.3c.1139; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PIEPER E, 1983, POINTER, V27, P40; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; PRATT PN, 1989, OCCUPATIONAL THERAPY; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Reitan R.M., 1992, NEUROPSYCHOLOGICAL E; RESCHLY D, 1992, CONTROVERSIAL ISSUES, P127; Reynolds C.R., 1994, TEST MEMORY LEARNING; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, ARCH PHYSICAL MED RE, V75, P269; Russell N, 1993, LANG SPEECH HEAR SER, V24, P67; SAVAGE RC, 1994, ED DIMENSIONS ACQUIR; Semel E., 1987, CLIN EVALUATION LANG; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Sparrow S., 1984, VINELAND ADAPTIVE BE; STORY TB, 1991, COGNITIVE REHABILITA, P251; TEASDALE G, 1974, LANCET, V2, P81; Trombly CA, 1989, OCCUPATIONAL THERAPY; *VIRG DEP ED, 1992, GUID ED SERV STUD TR; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167; Wechsler D., 1991, WECHSLER INTELLIGENC; WIIG EH, 1988, TEST LANGUAGE COMPET; WOODCOCK RW, 1989, WOODCOCKJOHNSON PSYC; WORTHEN BR, 1993, PHI DELTA KAPPAN, V74, P444; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; YLVISAKER M, 1990, REHABILITATION ADULT, P558; Ylvisaker M., 1994, ED DIMENSIONS ACQUIR, P69; 1991, FED REGISTER, V56, P41266	98	31	31	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0022-2194	1538-4780		J LEARN DISABIL-US	J. Learn. Disabil.	SEP	1996	29	5					532	548		10.1177/002221949602900508			17	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	VJ057	WOS:A1996VJ05700008	8870523				2021-06-18	
J	Borrelli, J; Koval, KJ; Helfet, DL				Borrelli, J; Koval, KJ; Helfet, DL			The crescent fracture: A posterior fracture dislocation of the sacroiliac joint	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						crescent fracture; fracture-dislocation; sacroiliac joint	PELVIC FRACTURE	Between October 1987 and August 1992, 22 patients with crescent fractures, a posterior fracture-dislocation of the sacroiliac joint, were admitted, treated, and available for review at Tampa General Hospital and The Hospital for Special Surgery. The purpose of the study was twofold: (a) to evaluate the incidence, severity, and pattern of associated injuries, and (b) to determine the efficacy of a treatment protocol using a posterior extrapelvic approach and extraarticular internal fixation. The study population was composed of 13 females and nine males; the average age was 25 years (range 10-52). Despite the fracture pattern resulting in a rotationally unstable hemi-pelvis, all patients were hemodynamically stable at the time of presentation. Fourteen patients (64%) had other associated injuries, including five (23%) with closed head injury. In all cases a posterior extrapelvic approach was used with an anatomic reduction of the fractured iliac wing and the sacroiliac joint dislocation. Stable extraarticular internal fixation was obtained using intertable lag screws and outer-table neutralization plates. All the fractures were clinically and radiographically healed within 8-10 weeks postoperatively, and there were no acute wound, neurologic, or vascular complications. One patient developed osteomyelitis of the iliac crest 6 months postoperatively.	HOSP SPECIAL SURG, DEPT ORTHOPAED TRAUMA, NEW YORK, NY 10021 USA; ORTHOPAED HOSP JOINT DIS, NEW YORK, NY USA; HOSP JOINT DIS & MED CTR, INST ORTHOPAED, NEW YORK, NY 10003 USA							BUCHOLZ RW, 1981, J BONE JOINT SURG AM, V63, P400, DOI 10.2106/00004623-198163030-00013; BURGESS AR, 1990, J TRAUMA, V30, P848, DOI 10.1097/00005373-199007000-00015; DABEZIES SA, 1989, CLIN ORTHOP RELAT R, V246, P165; DALAL SA, 1989, J TRAUMA, V29, P981, DOI 10.1097/00005373-198907000-00012; Ebraheim N A, 1987, J Orthop Trauma, V1, P197, DOI 10.1097/00005131-198701030-00001; GOKCEN EC, 1994, J TRAUMA, V36, P789, DOI 10.1097/00005373-199406000-00007; Helfet DL, 1990, TECH ORTHOP, V4, P67; HOLDSWORTH FW, 1948, J BONE JOINT SURG BR, V30, P461; KELLAM JF, 1987, ORTHOP CLIN N AM, V18, P25; KELLAM JF, 1992, SKET TRAUMA, V2, P848; Lange R, 1990, J ORTHOP TRAUMA, V4, P220; MEARS DC, 1988, AAOS INSTRUCT COURSE, P143; Muller M, 1991, MANUAL INTERNAL FIXA, VThird; PATTEE GA, 1986, J BONE JOINT SURG AM, V68A, P769, DOI 10.2106/00004623-198668050-00022; PENNAL GF, 1980, CLIN ORTHOP RELAT R, P124; PENNAL GF, 1980, CLIN ORTHOP RELAT R, V151, P12; POHLEMANN T, 1994, CLIN ORTHOP RELAT R, V305, P69; RAND JA, 1985, J BONE JOINT SURG AM, V67A, P157, DOI 10.2106/00004623-198567010-00021; SHAW JA, 1985, CLIN ORTHOP RELAT R, P240; SIMPSON LA, 1987, J TRAUMA, V27, P1332, DOI 10.1097/00005373-198712000-00003; TILE M, 1980, ORTHOP CLIN N AM, V11, P423; TILE M, 1984, FRACTURES PELVIS ACE, P1; TITLE M, 1982, RATIONALE OPERATIVE, P133; WILD JJ, 1982, J BONE JOINT SURG AM, V64, P1010, DOI 10.2106/00004623-198264070-00007	24	31	37	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma		1996	10	3					165	170		10.1097/00005131-199604000-00004			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	UE052	WOS:A1996UE05200004	8667108				2021-06-18	
J	Francisco, GE; Ivanhoe, CB				Francisco, GE; Ivanhoe, CB			Successful treatment of post-traumatic narcolepsy with methylphenidate - A case report	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						narcolepsy; traumatic brain injury; methylphenidate	SLEEPINESS	Narcolepsy is a rare sequela of brain injury. We report the case of a 27-yr-old male with post-traumatic narcolepsy who was successfully treated with methylphenidate. This patient sustained moderate brain injury from a motorcycle accident. Subsequently, he manifested the classic tetrad of narcolepsy: cataplexy, excessive daytime sleepiness, sleep paralysis, and hypnogogic hallucinations. There was no premorbid seizure or sleep disorder. There was no family history of sleep disorders. Polysomnography and Multiple Sleep Latency Test confirmed the diagnosis of narcolepsy. Sleep latency (time to sleep onset), rapid eye movement sleep latency (time from sleep onset to rapid eye movement sleep onset), and mean multiple sleep latency were all pathologically shortened (2.5, 66, and 1.2 min, respectively). Twenty-four hour electroencephalographic monitoring and magnetic resonance imaging of the brain were normal, as were serum chemistries. Treatment with caffeine was unsuccessful. He was then started on methylphenidate, 10 mg twice daily, which was increased to 30 mg twice daily over a 4-mo period. Cataplexy and excessive daytime sleepiness started to improve 1 mo after adjustments in methylphenidate dosing. Six months after the initiation of methylphenidate therapy, the patient is completely asymptomatic.	BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030; INST REHABIL & RES,BRAIN INJURY PROGRAM,HOUSTON,TX							BILLIARD M, 1986, SLEEP, V9, P149, DOI 10.1093/sleep/9.1.149; BOUNDELLE M, 1976, ADV SLEEP RES, V3, P313; CARSKADON MA, 1982, SLEEP, V5, pS67, DOI 10.1093/sleep/5.S2.S67; GOOD JL, 1989, J NEUROSURG, V71, P765, DOI 10.3171/jns.1989.71.5.0765; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; GUILLEMINAULT C, 1994, PRINCIPLES PRACTICE, P549; GUILLEMINAULT C, 1994, PRINCIPLES PRACTICE, P562; KALES A, 1979, ARCH NEUROL-CHICAGO, V36, P650, DOI 10.1001/archneur.1979.00500460084015; MACCARIO M, 1987, MIL MED, V152, P370; MITLER MM, 1990, J CLIN NEUROPHYSIOL, V7, P93, DOI 10.1097/00004691-199001000-00008; MITLER MM, 1991, SLEEP, V14, P218, DOI 10.1093/sleep/14.3.218; PARKES JD, 1993, SLEEP, V16, P201, DOI 10.1093/sleep/16.3.201; WING YK, 1994, POSTGRAD MED J, V70, P34, DOI 10.1136/pgmj.70.819.34; YOSS RE, 1959, NEUROLOGY, V9, P171, DOI 10.1212/WNL.9.3.171; 1986, SLEEP, V9, P519	15	31	31	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JAN-FEB	1996	75	1					63	65		10.1097/00002060-199601000-00016			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	TY971	WOS:A1996TY97100012	8645441				2021-06-18	
J	CHAPMAN, SB; LEVIN, HS; MATEJKA, J; HARWARD, H; KUFERA, JA				CHAPMAN, SB; LEVIN, HS; MATEJKA, J; HARWARD, H; KUFERA, JA			DISCOURSE ABILITY IN CHILDREN WITH BRAIN INJURY - CORRELATIONS WITH PSYCHOSOCIAL, LINGUISTIC, AND COGNITIVE-FACTORS	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED HEAD-INJURY; ADOLESCENTS; VALIDATION; SEQUELAE	Discourse deficits have recently been documented in children with closed head injury (CHI). The relationships among discourse and other variables such as psychosocial and cognitive abilities are not well understood. This investigation represents an exploratory study to elucidate potential relationships across linguistic, cognitive, and psychosocial variables in children after CHI, ranging from mild to severe, at 3 and 12 months postinjury. The most clinically salient finding was a significant relationship between narrative discourse measures and perceived communicative competence on a well-validated psychosocial measure at 1 year after injury. Additional results suggest that receptive vocabulary and certain cognitive functions (ie, planning and semantic organization), as well as injury severity, may also be related to discourse abilities. Although the findings should be interpreted with caution, the relationships across these variables warrant further validation in pediatric populations with CHI because of the functional relevance of discourse abilities to social and academic settings.	UNIV MARYLAND,MED SYST,DIV NEUROL SURG,BALTIMORE,MD	CHAPMAN, SB (corresponding author), UNIV TEXAS,CALLIER CTR COMMUN DISORDERS,1966 INWOOD RD,DALLAS,TX 75235, USA.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Applebee A., 1978, CHILDS CONCEPT STORY; BISHOP DVM, 1987, J SPEECH HEAR DISORD, V52, P156, DOI 10.1044/jshd.5202.156; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P72; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, IN PRESS BRAIN LANG; CHAPMAN SB, IN PRESS CONSEQUENCE; CHAPMAN SB, 1994, APR ANN C TEX SPEECH; CHAPMAN SB, 1995, HDB NEUROLOGICAL SPE; CHAPMAN SB, 1994, NOV AM SPEECH LANG H; CULHANESHELBURN.K, 1992, FEB INT NEUR SOC M S; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; DENNIS M, 1994, BRAIN LANG, V46, P129, DOI 10.1006/brln.1994.1008; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dunn L., 1981, PEABODY PICTURE VOCA; FEAGANS L, 1986, J EDUC PSYCHOL, V78, P358, DOI 10.1037/0022-0663.78.5.358; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Frederiksen C. H., 1990, DISCOURSE ABILITY BR; GROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754; Holland A, 1980, COMMUNICATIVE ABILIT; Hunt K. W., 1965, 3 NAT COUNC TEACH EN; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Labov William., 1972, LANGUAGE INNER CITY; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; MROSS EF, 1990, DISCOURSE ABILITY BR; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; ULATOWSKA HK, 1991, HDB GERIATRIC COMMUN; ULATOWSKA HK, 1990, DISCOURSE ABILITY BR; Van Dijk T. A., 1985, HDB DISCOURSE ANAL; WESTBY C, 1989, READING DISABILITIES; WESTBY C, 1984, LANGUAGE LEARNING DI; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447	41	31	31	1	7	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1995	10	5					36	54		10.1097/00001199-199510000-00006			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RY617	WOS:A1995RY61700006					2021-06-18	
J	GERBER, DJ; SCHRAA, JC				GERBER, DJ; SCHRAA, JC			MILD TRAUMATIC BRAIN INJURY - SEARCHING FOR THE SYNDROME	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							MINOR HEAD-INJURY; SYMPTOMS	A prospective study compared 22 consecutively admitted patients with mild traumatic brain injury (MTBT) to matched orthopedically injured (OI) and uninjured control subjects on measures of injury severity, symptoms, and disability immediately after injury and at 6 months after injury. The results showed that the method for evaluating symptoms (ie, volunteered versus elicited) has a significant effect on symptom frequency and ability of symptoms to differentiate the MTBI group from the other groups. In comparison to OI and control subjects, a small but significant percentage of,MTBI subjects volunteered somatic and cognitive symptoms at 6 months after injury, suggesting that these symptoms are core components of the postconcussion disorder. Pain and emotional distress also seem to contribute to the disorder but appear to represent the general effects of trauma rather than the specific effects of MTBI. The presence of pain has a significant effect on recovery from trauma, including MTBI. A significant percentage of MTBI and OI subjects perceive that they have not recovered by 6 months after injury; however, there appears to be a specific perception of vocational disability after MTBI that is primarily characterized by cognitive symptoms and is not accounted for by a more general effect of trauma.		GERBER, DJ (corresponding author), CRAIG HOSP,DEPT PSYCHOL,ENGLEWOOD,CO 80110, USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BENTON AL, 1989, MILD HEAD INJURY; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; LEVIN H, 1987, NEUROBEHAVIORAL OUTC; LIDVALL HF, 1970, ACTA NEUROL SCAN S56, V50; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R. M., 1989, MILD HEAD INJURY; RUTHERFORD WH, 1989, MILD HEAD INJURY; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61	21	31	31	0	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1995	10	4					28	40		10.1097/00001199-199508000-00004			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RN010	WOS:A1995RN01000004					2021-06-18	
J	MILLIS, SR; KLER, S				MILLIS, SR; KLER, S			LIMITATIONS OF THE REY 15-ITEM TEST IN THE DETECTION OF MALINGERING	CLINICAL NEUROPSYCHOLOGIST			English	Article								The capacity of Rey's (1964) Fifteen-Item Test (FIT) to detect feigned memory impairment in a group of clinical malingerers was investigated. Seven malingerers were identified by significantly below chance performance on a forced-choice memory measure, the Recognition Memory Test, and were given the FIT. A reference group of 7 patients with acute moderate and severe traumatic brain injuries was also given the FIT. The brain-injured subjects recalled significantly more items on the FIT than the malingering subjects. Using a cutoff score of 7, the FIT was able to detect only 57% of the malingerers but did not misclassify any brain-injured subjects. Although possessing good specificity, the FIT appears to lack adequate sensitivity to detect feigned impairment when used as a single measure. The FIT may be sensitive primarily to blatant deceptive strategies.	REHABIL INST MICHIGAN,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DETROIT,MI 48202							GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; LEVIN H, 1975, J NERV MENT DIS, V167, P675; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; Rey A, 1964, EXAMEN CLIN PSYCHOL; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; TEASDALE G, 1974, LANCET, V2, P81; Warrington EK., 1984, RECOGNITION MEMORY T	9	31	31	0	5	SWETS ZEITLINGER BV	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JUL	1995	9	3					241	244		10.1080/13854049508400486			4	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	RJ646	WOS:A1995RJ64600006					2021-06-18	
J	NAWASHIRO, H; SHIMA, K; CHIGASAKI, H				NAWASHIRO, H; SHIMA, K; CHIGASAKI, H			IMMEDIATE CEREBROVASCULAR RESPONSES TO CLOSED-HEAD INJURY IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article						CLOSED HEAD INJURY; CEREBRAL BLOOD FLOW; BLOOD-BRAIN BARRIER; AUTOREGULATION; CEREBRAL PLASMA VOLUME; INTRACRANIAL PRESSURE	CEREBRAL BLOOD-FLOW; CONCUSSIVE BRAIN INJURY; AUTOREGULATION; METABOLISM; CAPILLARY; POTASSIUM; RELEASE	Changes in cerebrovascular dynamics were investigated immediately after closed head injury in the rat using a newly developed closed head injury model developed by Marmarou et al. Intracranial pressure (ICP) and mean arterial blood pressure (MABP) were monitored before and after trauma. Regional cerebral blood flow (rCBF), regional cerebral plasma volume (rCPV), and blood-brain barrier (BBB) permeability were measured autoradiographically with iodo[C-14]antipyrine [C-14]sucrose, and [alpha-C-14]aminoisobutyric acid, respectively. rCBF responses to induced hypertension after trauma were measured by laser-Doppler flowmetry to investigate the status of autoregulation. Before injury, baseline ICP values ranged from 6 to 10 mm Ng in all animals. Immediately after trauma, ICP increased synchronously with MABP to >100 mm Hg and then rapidly returned to baseline values. MABP increased rapidly by 20% after trauma and returned to baseline values within 30 sec. At 30 sec after injury, a significant increase in rCBF was observed in five subcortical regions (p < 0.05), and a significant increase in rCPV was observed in the frontal cortex, parietal cortex, thalamus, and hypothalamus (p < 0.05). At 10 min after injury, BBB permeability (the transfer constant for [alpha(14)C]aminoisobutyric acid) was <0.1 mL/kg/min for all regions except those with a relatively permeable BBB, for example, median eminence, choroidal plexus, pineal body, and pituitary gland. Induced hypertension resulted in a prolonged increase in rCBF after trauma. Thus, in this closed head injury model, which is not associated with marked hypertension or prolonged BBB disruption, widespread increases in rCBF and impaired cerebral autoregulation were apparent immediately after injury.		NAWASHIRO, H (corresponding author), NATL DEF MED COLL,DEPT NEUROSURG,3-2 NAMIKI,TOKOROZAWA,SAITAMA 359,JAPAN.						ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; BLASBERG RG, 1983, J CEREBR BLOOD F MET, V3, P8, DOI 10.1038/jcbfm.1983.2; BRUSSEL T, 1991, ANESTH ANALG, V73, P758; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; EKLOF B, 1971, ACTA PHYSIOL SCAND, V82, P172, DOI 10.1111/j.1748-1716.1971.tb04956.x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KLEIN B, 1986, AM J PHYSIOL, V251, pH1333; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; NILSSON B, 1975, CEREBRAL CIRCULATION; Ohno K, 1978, AM J PHYSIOL, V235, P299; PAULSON OB, 1987, SCIENCE, V237, P896, DOI 10.1126/science.3616619; Reivich M, 1972, Prog Brain Res, V35, P191; SAKURADA O, 1978, AM J PHYSIOL, V234, P59; SHIMA K, 1991, ADV EXPT NEUROTRAUMA, V3, P84; SHIMA K, 1990, ADV EXPT NEUROTRAUMA, V2, P53; SMITH D R, 1969, Journal of Neurosurgery, V30, P664, DOI 10.3171/jns.1969.30.6.0664; TAKAHASHI H, 1981, J NEUROSURG, V55, P705; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	22	31	31	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1995	12	2					189	197		10.1089/neu.1995.12.189			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	QZ508	WOS:A1995QZ50800005	7629865				2021-06-18	
J	Mathiesen, T; Kakarieka, A; Edner, G				Mathiesen, T; Kakarieka, A; Edner, G			Traumatic intracerebral lesions without extracerebral haematoma in 218 patients	ACTA NEUROCHIRURGICA			English	Article						brain injury; brain contusion; intracerebral haematoma; compound fracture; diffuse axial injury	DIFFUSE AXONAL INJURY; SEVERE HEAD-INJURY; CONTUSIONS; COMA	218 of the 852 patients in the HIT-2 study of head injury had intracerebral lesions only. They were analysed to get more information on the optimal treatment of these severely injured patients. The initial CT scans were reviewed to exclude patients with extra cerebral lesions, and to make a radiological diagnosis of contusion, contusion under a depressed fracture, diffuse axonal injury, or intracerebral haematoma. Deterioration after admission to hospital was seen in 71% of patients. Patients with contusions, and contusions from depressed fractures in particular showed a worse outcome than expected, while patients with diffuse injury had a tendency to improve rather than to deteriorate. Patients with intracerebral haematoma seemed to improve if the mass was evacuated. Nimodipine had an impact only in patients with contusions. Our findings mandate surgical evacuation of contusions and intracerebral haematomas in patients with lesions larger than 20 ml who also have radiological signs of a mass effect. Regardless of an apparently good clinical state in the early phase, intracerebral lesions larger than 50 ml seemed to benefit from surgery as compared to nonsurgical treatment. The findings indicated that a further refinement of diagnostic criteria may enable individually tailored head injury treatment to interfere with most important pathogenic mechanisms. More accurate-diagnoses will improve head injury treatment and outcome, and are a prerequisite for making successful pharmaceutical trials of head injury in the future.	BAYER RES CTR,WUPPERTAL,GERMANY	Mathiesen, T (corresponding author), KAROLINSKA HOSP,DEPT NEUROSURG,S-10401 STOCKHOLM,SWEDEN.			Mathiesen, Tiit/0000-0001-9463-1919			ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; COWAN DH, 1980, SEMIN HEMATOL, V17, P137; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1990, NEUROLOGICAL SURGERY, P1953; GRCEVIC N, 1982, RAD JUGOSL AKAD ZNAN, V402, P265; JENNET B, 1981, MANAGEMENT HEAD INJU, P71; KATAYAMA Y, 1990, ACTA NEUROCHIR WIE S, V60, P308; KWAK R, 1983, STROKE, V14, P493, DOI 10.1161/01.STR.14.4.493; MATHIESEN T, 1993, NEUROSURGERY 93, pF24; MCLAURIN RL, 1964, J NEUROSURG, P296; Miller J D, 1988, Brain Inj, V2, P83, DOI 10.3109/02699058809150934; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; The European Study Group on Nimodipine in Severe Head Injury, 1994, J NEUROSURG, V80, P797; TODD NV, 1990, NEUROCHIR WIEN S, V51, P296	20	31	33	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1995	137	3-4					155	163		10.1007/BF02187188			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TL370	WOS:A1995TL37000012	8789656				2021-06-18	
J	ALFANO, DP; PANIAK, CE; FINLAYSON, MAJ				ALFANO, DP; PANIAK, CE; FINLAYSON, MAJ			THE MMPI AND CLOSED HEAD-INJURY - A NEUROCORRECTIVE APPROACH	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article								This study examined neurologic content bias in the MMPIs of 102 patients with closed head injury (CHI). Twenty-four items that were significantly endorsed in a pathological direction were identified. Principal components analysis of these items produced two conceptually coherent factors that together accounted for 33% of the total variance. The first factor was comprised of items primarily tapping complaints of cognitive and sensory-motor dysfunction. The second factor was comprised of items primarily tapping complaints of an emotional or somatic nature. A neurocorrective approach that took into account the contribution of the first factor items to MMPI profile configuration revealed significant alterations in mean group clinical scale elevations, and high-point and two-point code type in individual cases. The results of this study are discussed in terms of the important practical implications for neuropsychological clinicians providing assessment and intervention for patients with CHI using the MMPI.	CHEDOKE MCMASTER HOSP,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA; GLENROSE REHABIL HOSP,EDMONTON,ALBERTA,CANADA	ALFANO, DP (corresponding author), UNIV REGINA,DEPT PSYCHOL,REGINA S4S 0A2,SASKATCHEWAN,CANADA.						Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Alfano Dennis P, 1992, Clin Neuropsychol, V6, P134, DOI 10.1080/13854049208401850; ALFANO DP, 1991, NEUROPSYCHOLOGY, V5, P35; BALDWIN MV, 1952, J NERV MENT DIS, V115, P299; BLISHEN BR, 1976, CAN REV SOC ANTHROP, V13, P71, DOI 10.1111/j.1755-618X.1976.tb00759.x; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BORNSTEIN RA, 1990, NEUROPSY NEUROPSY BE, V3, P200; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10; Dahlstrom W. G., 1972, MMPI HDB CLIN INTERP, V1; FARR SP, 1988, MMPI USE SPECIFIC PO, P214; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GOLDEN CJ, 1984, RES METHODS CLIN PSY, P233; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; GREENE RL, 1988, MMPI USE SPECIFIC PO, P1; Greene RL, 1980, MMPI INTERPRETIVE MA; Halstead WC, 1947, BRAIN INTELLIGENCE; KENDALL PC, 1978, J CONSULT CLIN PSYCH, V46, P370, DOI 10.1037/0022-006X.46.2.370; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LUBIN B, 1985, AM PSYCHOL, V40, P857, DOI 10.1037/0003-066X.40.7.857; MACK JL, 1979, MMPI CLIN RES TRENDS, P53; MEYERINK LH, 1988, J CLIN PSYCHOL, V44, P764, DOI 10.1002/1097-4679(198809)44:5<764::AID-JCLP2270440517>3.0.CO;2-Y; SCHMIDT MM, 1990, J CLIN EXP NEUROPSYC, V12, P415; Tabachnick BG, 1983, USING MULTIVARIATE S; TAYLOR GP, 1970, J CONSULT CLIN PSYCH, V35, P183, DOI 10.1037/h0030127	24	31	31	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	APR	1993	6	2					111	116					6	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	KV540	WOS:A1993KV54000006					2021-06-18	
J	SCHWEITZER, JB; PARK, MR; EINHAUS, SL; ROBERTSON, JT				SCHWEITZER, JB; PARK, MR; EINHAUS, SL; ROBERTSON, JT			UBIQUITIN MARKS THE REACTIVE SWELLINGS OF DIFFUSE AXONAL INJURY	ACTA NEUROPATHOLOGICA			English	Article						UBIQUITIN; NEUROFILAMENT; DIFFUSE AXONAL INJURY; IMMUNOHISTOCHEMISTRY; HEAD TRAUMA	NONMISSILE HEAD-INJURY; BRAIN INJURY; PROTEIN; CAT	Ubiquitin is a protein that targets proteins for non-lysosomal degradation. It has been found to be present in a number of inclusions characteristic of neurodegenerative diseases. Using the fluid percussion model of closed head injury in the cat, a well-established model of diffuse axonal injury (DAI), we now report that the reactive axonal swellings and the retraction balls produced in this model stain positively with antiubiquitin immunohistochemistry. Furthermore., the affected axons become ubiquitin positive quickly (within the first 6 h after injury). Anti-ubquitin immunohistochemistry compares well with the recently reported ability of antibodies to low molecular weight neurofilament proteins to demonstrate reactive axonal change in DAI, and it could provide additional clues to the pathogenesis of axonal transection.	UNIV TENNESSEE CTR HLTH SCI,DEPT PATHOL,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT ANAT & NEUROBIOL,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT NEUROSURG,MEMPHIS,TN 38163	SCHWEITZER, JB (corresponding author), UNIV TENNESSEE CTR HLTH SCI,BRAIN INJURY RES CTR,800 MADISON AVE,RM 568 BMH-M,MEMPHIS,TN 38163, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS01230] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001230] Funding Source: NIH RePORTER		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; COCHRAN E, 1991, AM J PATHOL, V139, P485; DICKSON DW, 1990, LAB INVEST, V63, P87; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HILTON DL, 1993, IN PRESS J NEUROTRAU; MANETTO V, 1988, P NATL ACAD SCI USA, V85, P4501, DOI 10.1073/pnas.85.12.4501; MARTIN JE, 1990, BRAIN, V113, P1553, DOI 10.1093/brain/113.5.1553; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	16	31	31	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	APR	1993	85	5					503	507					5	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	KX439	WOS:A1993KX43900009	8388148				2021-06-18	
J	KATZ, RT; DELUCA, J				KATZ, RT; DELUCA, J			SEQUELAE OF MINOR TRAUMATIC BRAIN INJURY	AMERICAN FAMILY PHYSICIAN			English	Article								Minor traumatic brain injury is the most common type of traumatic encephalopathy, with approximately 290,000 to 325,000 new cases occurring each year. Recent research has suggested that both anatomic factors (acceleration-deceleration injury, contusions) and neurotransmitter factors (cholinergic systems) may contribute to the pathologic sequelae. Symptoms may be broadly categorized as physical, behavioral/affective, cognitive and integrative. Patients with mild brain injury may demonstrate significant attention and information-processing impairments in the absence of apparent neurologic problems. Most symptoms abate within the first few months, but a sizable subgroup of patients remain symptomatic up to one year or more. Evidence suggests that patients whose symptoms persist are not simply "neurotic." Rehabilitation efforts should focus on proper evaluation, reassurance, education, support and monitoring of progress.		KATZ, RT (corresponding author), SSM REHABIL INST,ST LOUIS,MO, USA.							0	31	34	0	2	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797	0002-838X			AM FAM PHYSICIAN	Am. Fam. Physician	NOV	1992	46	5					1491	1498					8	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	JY229	WOS:A1992JY22900013	1442467				2021-06-18	
J	TEASDALE, G; TEASDALE, E; HADLEY, D				TEASDALE, G; TEASDALE, E; HADLEY, D			COMPUTED TOMOGRAPHIC AND MAGNETIC-RESONANCE-IMAGING CLASSIFICATION OF HEAD-INJURY	JOURNAL OF NEUROTRAUMA			English	Article							DIFFUSE AXONAL INJURY; INTRACRANIAL-PRESSURE; CT SCAN; INTRAVENTRICULAR HEMORRHAGE; TRAUMATIC COMA; BRAIN EDEMA; MANAGEMENT; HEMATOMA; CHILDREN; LESIONS	Neuroimaging with CT and MRI is a basis for decision making in individual head-injured patients and also provides a classification of patients according to severity of damage, patterns of injury, pathophysiologic mechanisms and prognosis. Such classifications can be based on the intracranial lesions identified: subdural, extradural, and intracerebral hematomas, contusions, and shearing lesions, or indirect indications of raised intracranial pressure and brain swelling: shift, obliteration of the third ventricle and basal cisterns, and signs of ischemia. The appropriate classification for early diagnosis and acute decision making may differ from the assessment of severity of damage, prognosis and late sequelae. Parallel systems of classification, suitable for these purposes, are proposed.	UNIV GLASGOW, SO GEN HOSP, INST NEUROL SCI, DEPT NEURORADIOL, GLASGOW G51 4TF, SCOTLAND	TEASDALE, G (corresponding author), UNIV GLASGOW, SO GEN HOSP, INST NEUROL SCI, DEPT NEUROSURG, GLASGOW G51 4TF, SCOTLAND.						Adams J H, 1981, Acta Neuropathol Suppl, V7, P26; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; AMBROSE J, 1976, LANCET, V1, P847; ARTRU F, 1989, ICP, V7, P603; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BULLOCH R, 1990, IN PRESS VINKEN BRUY, V24; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; CORDOBES F, 1983, J NEUROSURG, V58, P217, DOI 10.3171/jns.1983.58.2.0217; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FRENCH BN, 1977, SURG NEUROL, V7, P171; FUJITSU K, 1988, NEUROSURGERY, V23, P423, DOI 10.1227/00006123-198810000-00003; GALBRAITH S, 1976, BRIT MED J, V2, P1371, DOI 10.1136/bmj.2.6048.1371; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentleman D, 1989, Br J Neurosurg, V3, P367, DOI 10.3109/02688698909002817; GRANT R, 1987, MAGN RESON IMAGING, V5, P465, DOI 10.1016/0730-725X(87)90380-8; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; Gudeman S. K., 1989, TXB HEAD INJURY, P138; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; HADLEY DM, 1988, CLIN RADIOL, V39, P131; ITO U, 1986, ACTA NEUROCHIR, V79, P120, DOI 10.1007/BF01407455; JENKINS A, 1986, LANCET, V2, P445; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KISHORE PRS, 1981, AM J NEURORADIOL, V2, P307; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; KONAYASHI S, 1983, SURG NEUROL, V20, P25; LANG D, UNPUB J NEUROSURGERY; LANG D, UNPUB MRI NEUROPATHO; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; LIPPER MH, 1985, AM J NEURORADIOL, V6, P7; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MARSHALL L, 1989, ICP, V7, P552; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; MIZUTANI T, 1990, SURG NEUROL, V33, P178, DOI 10.1016/0090-3019(90)90181-N; MURPHY A, 1983, INTRACRANIAL PRESSUR, V5, P562; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; QUENCER RM, 1990, NEURORADIOLOGY, V32, P371, DOI 10.1007/BF00588471; RABOW L, 1989, ACTA NEUROCHIR, V100, P155, DOI 10.1007/BF01403604; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; SADHU VK, 1979, RADIOLOGY, V133, P507, DOI 10.1148/133.2.507; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; Servadei F, 1988, Brain Inj, V2, P87, DOI 10.3109/02699058809150935; SNOEK J, 1979, J NEUROL NEUROSUR PS, V42, P215, DOI 10.1136/jnnp.42.3.215; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; TABADDOR K, 1982, SURG NEUROL, V18, P212, DOI 10.1016/0090-3019(82)90395-0; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; TEASDALE G, UNPUB MR IMAGING OUT; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; TURAZZI S, 1987, ACTA NEUROCHIR, V85, P87, DOI 10.1007/BF01456103; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WILSON JTL, UNPUB INTERCORRELATI; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	70	31	32	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S249	S257					9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600023	1588613				2021-06-18	
J	WEHMAN, PH; REVELL, WG; KREGEL, J; KREUTZER, JS; CALLAHAN, M; BANKS, PD				WEHMAN, PH; REVELL, WG; KREGEL, J; KREUTZER, JS; CALLAHAN, M; BANKS, PD			SUPPORTED EMPLOYMENT - AN ALTERNATIVE MODEL FOR VOCATIONAL-REHABILITATION OF PERSONS WITH SEVERE NEUROLOGIC, PSYCHIATRIC, OR PHYSICAL-DISABILITY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						EMPLOYMENT; REHABILITATION; VOCATIONAL		Participation in paid work in competitive industry through placement in supported employment is compared and analyzed for 278 severely disabled persons. Differential outcomes are described for persons with chronic mental illness, cerebral palsy, traumatic brain injury, and dual diagnoses of chronic mental illness and mental retardation. Results indicated that supported employment appears to be an effective means of assisting these historically unemployable individuals to acquire and retain work. Cross-disability group differences were found in areas such as hourly wages, type of employment, services provided by employment specialists, and job retention. The results represent a baseline from which to evaluate future efforts at competitive work placement for persons with severe disabilities, using the supported-employment model.		WEHMAN, PH (corresponding author), VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DEPT REHABIL MED,VCU BOX 2011,RICHMOND,VA 23284, USA.						KIERNAN WE, 1988, MENT RETARD, V26, P279; KREGEL J, 1989, J ASSOC PERS SEVERE, V14, P293; KREGEL J, 1989, SUPPORTED EMPLOYMENT; KREGEL J, 1989, J APPL BEHAV ANAL, V22, P395; RUSCH F, 1986, COMPETITIVE EMPLOYME; SCHLOSS P, 1987, EXCEPT CHILDREN, V57, P272; SHAFER MS, 1988, VOCATION REHABILITAT, P55; WEHMAN P, 1989, ARCH PHYS MED REHAB, V70, P109; WEHMAN P, 1988, VOCATIONAL REHABILIT; WEHMAN P, 1989, EMERGING TRENDS SUPP; WEHMAN P, 1990, HELPING PERSONS SEVE; WEHMAN P, 1989, SUPPORTED EMPLOYMENT; WEHMAN P, 1990, VOCATIONAL REHABILIT; 1987, DATA MANAGEMENT SYST	14	31	31	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1991	72	2					101	105					5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	EX239	WOS:A1991EX23900002	1991008				2021-06-18	
J	DENNIS, M; SPIEGLER, BJ; HOFFMAN, HJ; HENDRICK, EB; HUMPHREYS, RP; BECKER, LE				DENNIS, M; SPIEGLER, BJ; HOFFMAN, HJ; HENDRICK, EB; HUMPHREYS, RP; BECKER, LE			BRAIN-TUMORS IN CHILDREN AND ADOLESCENTS .1. EFFECTS ON WORKING, ASSOCIATIVE AND SERIAL-ORDER MEMORY OF IQ, AGE AT TUMOR ONSET AND AGE OF TUMOR	NEUROPSYCHOLOGIA			English	Article							CRANIOPHARYNGIOMA; CHILDHOOD; MEDULLOBLASTOMA; LESIONS	Memory impairment was demonstrated in a sample of 46 children and adolescents with brain tumors. The overall distribution of memory scores was skewed positively; over half of the total number of test measures were in the lowest quarter of the score distribution; and more than three-quarters of the individual subjects had at least one memory score in the impaired range. Verbal intelligence accounted for less than one-quarter of the variance in memory scores. The type of memory impairment was analyzed in relation to various demographic and medical variables: age at onset of tumor symptoms, age or duration of tumor, sex, pre-tumor developmental disturbances, pre-tumor closed head injury, post-tumor anticonvulsant treatment and post-tumor epileptic seizures. The working memory task, in which each in a succession of heard words is stored in temporary memory long enough to be compared to or contrasted with incoming words, was unaffected by these variables, as was memory for semantically-based word-picture associations. Memory for the serial order of pictures that corresponded to heard words varied inversely with the age at tumor onset such that the later the onset, the lower the memory test performance.	TORONTO GEN HOSP,TORONTO M5G 1L7,ONTARIO,CANADA	DENNIS, M (corresponding author), HOSP SICK CHILDREN,DEPT PSYCHOL,DUNDAS SUITE,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.						AMACHER AL, 1976, CHILD BRAIN, V2, P81; Baddeley A. D., 1987, WORKING MEMORY; BAMFORD FN, 1976, CANCER, V37, P1149, DOI 10.1002/1097-0142(197602)37:2+<1149::AID-CNCR2820370825>3.0.CO;2-C; BROWN ER, 1987, J CLIN EXP NEUROPSYC, V9, P57; CARRERA R, 1983, BRAIN TUMORS YOUNG, P3; CHIN HW, 1984, CANCER-AM CANCER SOC, V53, P1952, DOI 10.1002/1097-0142(19840501)53:9<1952::AID-CNCR2820530925>3.0.CO;2-X; CLOPPER RR, 1977, PSYCHONEUROENDOCRINO, V2, P365, DOI 10.1016/0306-4530(77)90006-3; COHEN ME, 1985, NEUROL CLIN, V3, P147, DOI 10.1016/S0733-8619(18)31060-0; Cohen Michael E., 1982, MAJOR TOPICS PEDIATR, P241; DEATON AV, 1987, J CLIN EXP NEUROPSYC, V9, P25; DENNIS M, 1988, NEUROPSYCHOLOGIA, V26, P53, DOI 10.1016/0028-3932(88)90030-9; DUFFNER PK, 1983, CANCER, V51, P233, DOI 10.1002/1097-0142(19830115)51:2<233::AID-CNCR2820510211>3.0.CO;2-8; ELLENBERG L, 1987, NEUROSURGERY, V21, P638, DOI 10.1227/00006123-198711000-00006; GOLDMAN R, 1974, GOLDMANFRISTOEWOODCO; GOMEZ MR, 1985, PRACT PEDIAT, V9, P1; GRANT DB, 1982, CHILD BRAIN, V9, P201; GROSS PL, 1987, J CLIN EXP NEUROPSYC, V9, P27; HIRSCH JF, 1979, ACTA NEUROCHIR, V48, P1, DOI 10.1007/BF01406016; HOFFMAN HJ, 1985, CAN J NEUROL SCI, V12, P348, DOI 10.1017/S0317167100035514; HOFFMAN HJ, 1977, J NEUROSURG, V47, P218, DOI 10.3171/jns.1977.47.2.0218; JUDD BW, 1988, J CLIN EXP NEUROPSYC, V10, P45; KUN LE, 1983, J NEUROSURG, V58, P1, DOI 10.3171/jns.1983.58.1.0001; MURDOCK BB, 1982, HDB RES METHODS HUMA; SIEGEL LS, 1988, CAN J PSYCHOL, V42, P201, DOI 10.1037/h0084184; Wechsler, 1949, WECHSLER INTELLIGENC; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 2008, WECHSLER ADULT INTEL; WINSTON KR, 1979, NEUROSURGERY, V4, P386, DOI 10.1227/00006123-197905000-00003; WOODCOCK RW, 1976, GOLDMANFRISTOEWOODCO; YATES AJ, 1979, CHILD BRAIN, V5, P31; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7	32	31	31	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		1991	29	9					813	827		10.1016/0028-3932(91)90049-E			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	GK875	WOS:A1991GK87500001	1944880				2021-06-18	
J	ODER, W; GOLDENBERG, G; PODREKA, I; DEECKE, L				ODER, W; GOLDENBERG, G; PODREKA, I; DEECKE, L			HM-PAO-SPECT IN PERSISTENT VEGETATIVE STATE AFTER HEAD-INJURY - PROGNOSTIC INDICATOR OF THE LIKELIHOOD OF RECOVERY	INTENSIVE CARE MEDICINE			English	Article						REGIONAL CEREBRAL BLOOD FLOW; TC-99M HEXAMETHYL-PROPYLENAMINEOXIME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; PERSISTENT VEGETATIVE STATE; APALLIC SYNDROME; HEAD INJURY; PROGNOSIS	CEREBRAL BLOOD-FLOW; PERFUSION; LESIONS; TRAUMA; MR; CT	Management of patients presenting with traumatic persistent vegetative state (PVS) calls for extensive resources. The ability to predict whether or not a patient is likely to recover is a critical issue. In 12 patients with PVS admitted consecutively for early rehabilitation after head injury, pattern of brain activity was measured by Tc-99m-hexamethyl-propylenamineoxime (Tc-99m-HM-PAO) brain SPECT (single photon emission computer tomography). All patients were re-investigated after a mean observation period of 3 years. A global reduction of cortical blood flow was a reliable predictor of poor long-term outcome, but the demonstration of only focal deficits did not reliably indicate a favourable outcome. Brain SPECT may help to improve outcome prediction in patients with traumatic PVS.		ODER, W (corresponding author), UNIV VIENNA,NEUROL CLIN,LAZARETTGASSE 14,A-1090 VIENNA,AUSTRIA.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1977, BRAIN, V100, P498; BERROL S, 1986, ARCH PHYS MED REHAB, V67, P283; BINIEK R, 1989, INTENS CARE MED, V15, P212, DOI 10.1007/BF01058577; BRICOLO A, 1976, HDB CLINICAL NEUROLO, V24, P699; DEUTSCH G, 1983, ANN NEUROL, V13, P38, DOI 10.1002/ana.410130109; DEUTSCH G, 1987, J CEREBR BLOOD F MET, V7, P29, DOI 10.1038/jcbfm.1987.5; DEVOLDER AG, 1990, ARCH NEUROL-CHICAGO, V47, P197, DOI 10.1001/archneur.1990.00530020103022; GENARELLI TA, 1982, J NEUROSURG, V56, P26; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Gerstenbrand F., 1967, TRAUMATISCHE APALLIS; HAGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876; HANS P, 1989, J NEUROSURG, V71, P54, DOI 10.3171/jns.1989.71.1.0054; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; HEISS WD, 1972, J NEUROL SCI, V16, P373, DOI 10.1016/0022-510X(72)90045-7; HORMANN M, 1982, TRAUMATISCHE MITTELH, P241; INGVAR DH, 1972, ARCH PSYCHIAT NERVEN, V215, P219, DOI 10.1007/BF01042864; INGVAR DH, 1979, ACTA NEUROL SCAND, V60, P12, DOI 10.1111/j.1600-0404.1979.tb02947.x; INGVAR DH, 1973, ACTA NEUROL SCAND, V49, P233; JAGGI JL, 1990, J NEUROSURG, V72, P1763; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1979, Acta Neurochir Suppl (Wien), V28, P149; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; MEYERS CA, 1983, J NEUROL NEUROSUR PS, V46, P1092, DOI 10.1136/jnnp.46.12.1092; Miller JD, 1986, ADV NEUROTRAUMATOLOG, V1, P230; NEIRINCKX RD, 1987, J NUCL MED, V28, P191; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; PAGNI CA, 1977, ACTA NEUROCHIR, V36, P37, DOI 10.1007/BF01405985; Plum F., 1983, DIAGNOSIS STUPOR COM; PODREKA I, 1987, J NUCL MED, V28, P1657; Sato M, 1989, Neurol Med Chir (Tokyo), V29, P389, DOI 10.2176/nmc.29.389; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1984, CLOSED HEAD INJURY P, P4; ULE G, 1961, ARCH PSYCHIAT NERVEN, V202, P1525; VALPALTHI M, 1971, BRIT MED J, V3, P404; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZIMMERMAN RA, 1986, AM J NEURORADIOL, V7, P757	44	31	31	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0342-4642			INTENS CARE MED	Intensive Care Med.		1991	17	3					149	153		10.1007/BF01704718			5	Critical Care Medicine	General & Internal Medicine	FN420	WOS:A1991FN42000004	2071761				2021-06-18	
J	TOMPKINS, CA; HOLLAND, AL; RATCLIFF, G; COSTELLO, A; LEAHY, LF; COWELL, V				TOMPKINS, CA; HOLLAND, AL; RATCLIFF, G; COSTELLO, A; LEAHY, LF; COWELL, V			PREDICTING COGNITIVE RECOVERY FROM CLOSED HEAD-INJURY IN CHILDREN AND ADOLESCENTS	BRAIN AND COGNITION			English	Article									UNIV MASSACHUSETTS,DEPT PSYCHIAT,WORCESTER,MA 01605; UNIV PITTSBURGH,DEPT OTORHINOLARYNGOL,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; HARMARVILLE REHAB CTR,PITTSBURGH,PA	TOMPKINS, CA (corresponding author), UNIV PITTSBURGH,DEPT COMMUN,1101 CATHEDRAL LEARNING,PITTSBURGH,PA 15260, USA.						[Anonymous], 1944, ARMY INDIVIDUAL TEST; ATTIAS D, 1982, ISRAEL J MED SCI, V18, P917; Beery K. E., 1982, DEV TEST VISUAL MOTO; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; COWELL VS, 1986, M AM SPEECH LANGUAGE; DELIS D, 1983, CALIFORNIA VERBAL LE; DENCKLA M B, 1974, Cortex, V10, P186; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; DERENZI E, 1978, CORTEX, V14, P279; Dunn L., 1981, PEABODY PICTURE VOCA; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; FRATTALI CM, 1985, M AM SPEECH LANGUAGE; GARDNER M, 1979, EXPRESSIVE ONE WORD; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; GRATZ RR, 1979, J TRAUMA, V19, P551, DOI 10.1097/00005373-197908000-00001; Hollingshead A. B., 1958, SOCIAL CLASS MENTAL; JACOBSON MS, 1986, PEDIATRICS, V77, P236; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R, 1968, PERCEPT MOTOR SKILL, V25, P717; LEAHY LF, 1985, M AM SPEECH LANGUAGE; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MILLER J, 1972, MILLERYODER TEST GRA; PRATHER EM, 1980, SCREENING TEST ADOLE; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2; Wechsler D., 1974, MANUAL WECHSLER INTE; YORKSTON KM, 1977, CLIN APHASIOLOGY C P, P175; 1986, LANCET, P1361	33	31	31	0	3	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0278-2626			BRAIN COGNITION	Brain Cogn.	MAY	1990	13	1					86	97		10.1016/0278-2626(90)90042-M			12	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	DE048	WOS:A1990DE04800007	2346641				2021-06-18	
J	MORGAN, MK; BESSER, M; JOHNSTON, I; CHASELING, R				MORGAN, MK; BESSER, M; JOHNSTON, I; CHASELING, R			INTRACRANIAL CAROTID-ARTERY INJURY IN CLOSED HEAD TRAUMA	JOURNAL OF NEUROSURGERY			English	Article									ROYAL ALEXANDRA HOSP CHILDREN,DEPT NEUROSURG,CAMPERDOWN,NSW 2050,AUSTRALIA				Morgan, Michael/0000-0002-9841-9461			AARABI B, 1978, SURG NEUROL, V10, P233; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; DAVIS JM, 1983, NEURORADIOLOGY, V25, P55, DOI 10.1007/BF00333294; DHARKER SR, 1978, SURG NEUROL, V9, P77; DRATZ HM, 1947, J NEUROPATH EXP NEUR, V6, P286, DOI 10.1097/00005072-194707000-00009; Erikson S, 1943, ACTA RADIOL, V24, P392, DOI 10.3109/00016924309137646; GORE I, 1971, PATHOLOGY, V1, P748; HIGAZI I, 1963, J NEUROSURG, V20, P354, DOI 10.3171/jns.1963.20.4.0354; HOCKADAY TDR, 1959, J NEUROL NEUROSUR PS, V22, P229, DOI 10.1136/jnnp.22.3.229; JOHNSON AC, 1977, SURG NEUROL, V7, P49; MASTAGLIA FL, 1969, J NEUROL NEUROSUR PS, V32, P383, DOI 10.1136/jnnp.32.5.383; MILLER JDR, 1967, RADIOLOGY, V89, P95, DOI 10.1148/89.1.95; POZZATI E, 1982, J NEUROSURG, V57, P418, DOI 10.3171/jns.1982.57.3.0418; RECOULESARCHE D, 1976, NEUROCHIRURGIE, V22, P293; REDDY SVR, 1981, J NEUROSURG, V55, P813, DOI 10.3171/jns.1981.55.5.0813; RITCHIE G, 1961, Wis Med J, V60, P556; ROSEGAY H, 1956, NEUROLOGY, V6, P143, DOI 10.1212/WNL.6.2.143; SEDZIMIR CB, 1955, J NEUROL NEUROSUR PS, V18, P293, DOI 10.1136/jnnp.18.4.293; SULLIVAN HG, 1973, RADIOLOGY, V109, P91; THOMSON JLG, 1963, BRIT J RADIOL, V36, P840, DOI 10.1259/0007-1285-36-431-840; TORKILDSEN A, 1951, J NEUROSURG, V8, P269, DOI 10.3171/jns.1951.8.3.0269; VIGOUROUX R, 1962, NEURO-CHIR, V8, P115; WEST TET, 1976, BRIT MED J, V1, P818, DOI 10.1136/bmj.1.6013.818; YAMADA S, 1967, J TRAUM, V7, P333, DOI 10.1097/00005373-196705000-00001; YASHON D, 1964, J NEUROL NEUROSUR PS, V27, P547, DOI 10.1136/jnnp.27.6.547; YONAS H, 1980, NEUROSURGERY, V7, P499, DOI 10.1227/00006123-198011000-00016; ZILKHA A, 1970, RADIOLOGY, V97, P543, DOI 10.1148/97.3.543	28	31	31	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	1987	66	2					192	197		10.3171/jns.1987.66.2.0192			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	F8334	WOS:A1987F833400006	3806201				2021-06-18	
J	SMITH, A				SMITH, A			DURATION OF IMPAIRED CONSCIOUSNESS AS AN INDEX OF SEVERITY IN CLOSED HEAD-INJURIES - A REVIEW	DISEASES OF THE NERVOUS SYSTEM			English	Article																AKERLUND E, 1959, Acta Chir Scand, V117, P275; Anderson C, 1942, LANCET, V2, P1; BAY E, 1953, NEUROL PSYCHIAT, V21, P151; BIRKMAYER W, 1952, ACTA NEUROVEG, V4, P453, DOI 10.1007/BF01236396; COBB S, 1943, TRANS AM NEUROL ASSO, P113; DAILEY CA, 1956, J CLIN PSYCHOL, V12, P349, DOI 10.1002/1097-4679(195610)12:4<349::AID-JCLP2270120410>3.0.CO;2-L; DENCKER SJ, 1958, ACTA PSYCHIAT N S123, V33; DENCKER SJ, 1958, ACTA PSYCHIAT N S122, V33, P119; Denny-Brown D., 1942, NEW ENGL J MED, V227, P771; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DENNYBROWN D, 1942, NEW ENGL J MED, V227, P813; ECHLIN FA, 1956, HITM; GURDJIAN ES, 1958, HEAD INJURIES; HARRER G, 1950, DEUTSCH MED RESCH, V4, P148; HEWSON LR, 1949, J NERV MENT DIS, V109, P246, DOI 10.1097/00005053-194903000-00007; HEWSON LR, 1949, J NERV MENT DIS, V109, P158, DOI 10.1097/00005053-194902000-00006; JACKSON JH, 1931, SC, V1; JEFFERSON G, 1942, GLASGOW MED J, V20, P77; LECHNER H, 1954, Confin Neurol, V14, P219; Leigh AD, 1943, LANCET, V1, P38; LYNN JG, 1945, A RES NERV MENT DIS, V24, P296; MERRITT HH, 1955, TEXTBOOK NEUROLOGY; METTLER FA, 1945, A RES NERV MENT DIS, V24, P1; MILLER H, 1949, NEWCASTLE MED J, V24, P12; Moore BE, 1944, NEW ENGL J MED, V230, P445, DOI 10.1056/NEJM194404132301501; PENFIELD W, 1945, ARNMD, V24, P296; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; PIA HW, 1956, ARCH LIN CHIR, V281, P652; PILCHER C, 1942, WAR MED, V9, P114; PROBST H, 1949, Z Kinderpsychiatr, V15, P186; REISNER H, 1951, Z NERVENHELK, V3, P475; Reynell WR, 1944, J MENT SCI, V90, P710; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; RUSSELL W R, 1948, Edinb Med J, V55, P92; Russell W Ritchie, 1934, Edinb Med J, V41, P129; RUSSELL WR, 1949, J NEUROL NEUROSUR PS, V12, P52, DOI 10.1136/jnnp.12.1.52; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Symonds CP, 1943, LANCET, V1, P7; Symonds CP, 1935, LANCET, V1, P486; Symonds CP, 1936, LANCET, V1, P854; Symonds CP, 1928, BRIT MED J, V1928, P829, DOI 10.1136/bmj.2.3540.829; Taylor J., 1931, SELECTED WRITINGS JO, V1; TONNIS W, 1949, LINISCHE WOCHENSCHRI, V27, P390; TOOTH G, 1947, J NEUROL NEUROSUR PS, V10, P1, DOI 10.1136/jnnp.10.1.1; USBECK N, 1953, ARTZL WSCH, V8, P152; VORIS HC, 1950, AM J SURG, V80, P707, DOI 10.1016/0002-9610(50)90595-2	47	31	31	0	0	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0012-3714			DIS NERV SYST	Dis. Nerv. Syst.		1961	22	2					69	+					1	Psychiatry	Psychiatry	10490	WOS:A19611049000009					2021-06-18	
J	GROAT, R; SIMMONS, JQ				GROAT, R; SIMMONS, JQ			LOSS OF NERVE CELLS IN EXPERIMENTAL CEREBRAL CONCUSSION	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article																BECKER RF, 1945, FED PROC, V4, P6; BECKER RF, 1946, FED PROC, V5, P7; Denny-Brown D, 1943, ANN INTERN MED, V19, P427, DOI 10.7326/0003-4819-19-3-427; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DOW RS, 1945, J NEUROPHYSIOL, V8, P161; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; Groat RA, 1944, AM J PHYSIOL, V141, P0117; GROAT RA, UNPUB; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; KOENIG H, 1945, STAIN TECHNOL, V20, P13, DOI 10.3109/10520294509107124; Pitts RF, 1939, AM J PHYSIOL, V127, P654; RHINES R, 1946, AM J PHYSIOL, V146, P344; SPIEGEL EA, 1947, RES PUBL ASS RES NER, V26, P84; WARD JW, 1948, SCIENCE, V107, P349, DOI 10.1126/science.107.2779.349; WARD JW, 1948, J NEUROPHYSIOL, V11, P59; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210; WINDLE WF, 1946, J NEUROSURG, V3, P157, DOI 10.3171/jns.1946.3.2.0157; WINDLE WF, 1944, T AM NEUROL ASSOC, P117	21	31	31	0	1	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.		1950	9	2					150	163		10.1097/00005072-195004000-00003			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	UZ248	WOS:A1950UZ24800003	15415758				2021-06-18	
J	Miller, GG				Miller, GG			Cerebral concussion	ARCHIVES OF SURGERY			English	Article																ADAMS F, GENUINE HIPPOCRATES, V1, P254; ALQUIE, 1865, GAZ MED PARIS, P314; ALQUIE, 1865, GAZ MED PARIS, P254; ALQUIE, 1865, GAZ MED PARIS, P382; ALQUIE, 1865, GAZ MED PARIS, P463; ALQUIE, 1865, GAZ MED PARIS, P396; ALQUIE, 1865, GAZ MED PARIS, P226; ARCHIBALD E, 1908, AM PRACT SURF, V5, P147; ARCHIBLAD E, 1908, AM PRACT SURG, V5, P150; BAYLISS WM, 1920, PRINCIPLES GEN PHYSL, P427; BECK B, 1879, VIRCHOWS ARCH PATH A, V75, P207; BICKELES, 1899, MUNCHEN MED WCHNSCHR, V46, P79; BOIREL, 1677, TRAITE PLAIES TETE; BOYN, 1818, THESIS PARIS; BRESLAUERSCHUEC, 1921, BRUNS BEITR KLIN CHI, V121, P590; BRYNANT R, 1888, LANCET, V2, P405; Cannon WB, 1901, AM J PHYSIOL, V6, P91; Cushing H, 1903, AM J MED SCI, V125, P1017, DOI 10.1097/00000441-190306000-00006; Cushing H, 1901, B JOHNS HOPKINS HOSP, V12, P290; Cushing H, 1902, AM J MED SCI, V124, P375, DOI 10.1097/00000441-190209000-00001; CUSHING H, 1908, SURG HEAD SURG, V3, P182; DEUCHER, DTSCH Z CHIR, V35, P145; DURET, 1874, ARCH PHYSL, P320; FANO, 1894, REV CHIR, V141, P278; FELIZET, 1894, REV CHIR, V14, P280; FERRARI, 1901, SPEZIELLE PATHOLOGIE, P320; FISCHER H, 1871, VOLKMANN SAMML KLIN, V27, P219; FRIEDLANDER C, 1879, VIRCHOWS ARCH PATH A, V75, P24; HILL L, 1896, CEREBRAL CIRCULATION; HUTCHINSON J, 1892, BRAIN, V15, P154; KOCH W, 1874, ARCH KLIN CHIR, V17, P190; KOCHER T, 1901, SPEZIELLE PATHOLOGIE, V267; KRAMER SP, 1894, ANN SURG, V23, P163; KUSSMAUL, 1896, CEREBRAL CIRCULATION; LEGROS C, 1870, DIAGNOSIS VISCERAL L, V1; LITTRE, 1705, ACAD ROY SC PARIS, P54; MILES A, 1892, BRAIN, V15, P153; MILES A, 1892, BRAIN, V15, P157; MILES A, 1892, BRAIN, V15, P154; MOURIER, 1834, THESIS PARIS; PARE A, 1840, OCUVRES COMPLETES AM, V2, P23; PETIT JL, TRAITE MALADIES CHIR, V1, P1774; PIROGOFF, 1864, GRUND ZUGE ALLGEMEIN, P77; POLIS A, 1894, REV CHIR, V14, P275; POLIS A, 1894, REV CHIR PARIS, V14, P274; Polis A, 1894, REV CHIR, V14, P273; RAHM H, 1920, ZENTRALBL CHIR, V47, P146; SABATIER, MED OPERAT, V2, P400; SAVORY WS, 1869, ST BARTH HOSP REP, V5, P72; Scagliosi G., 1898, VIRCHOWS ARCH, V152, P487; SCHMAUS H, 1899, MUNCHEN MED WCHNSCHR, V46, P75; SCHMAUS H, 1899, MUNCHEN MED WCHNSCHR, V37, P485; STROMEYER, 1894, REV CHIR, V14, P281; TILMAN, 1899, ARCH KLIN CHIR, V59, P239; TILMANN, 1899, ARCH KLIN CHIR, V59, P236; TRENDELENBURG F, 1910, DTSCH MED WCHNSCHR, V36, P1; TROTTER W, 1923, SYSTEM SURG, V3, P468; VONBERGMANN, 1880, DTSCH CHIRURGIE, P296; VONBERGMANN, 1880, DTSCH CHIR, V30, P341; WITKOWSKIL, 1877, VIRCHOWS ARCH PATH A, V69, P498	60	31	31	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	APR	1927	14	4					891	916		10.1001/archsurg.1927.01130160100005			26	Surgery	Surgery	V06PK	WOS:000200445600005					2021-06-18	
J	McCrea, M; Broglio, S; McAllister, T; Zhou, WX; Zhao, S; Katz, B; Kudela, M; Harezlak, J; Nelson, L; Meier, T; Marshall, SW; Guskiewicz, KM; Hoy, AM; Hazzard, JB; Kelly, LA; Ortega, JD; Port, N; Putukian, M; Langford, TD; Tierney, R; Pasquina, P; Campbell, DE; Jackson, J; McGinty, G; O'Donnell, P; Cameron, K; Houston, M; Svoboda, S; Giza, C; Goldman, J; DiFiori, J; Benjamin, HJ; Buckley, T; Kaminski, TW; Clugston, JR; Schmidt, JD; Feigenbaum, LA; Eckner, JT; Mihalik, JP; Miles, JD; Anderson, S; Arbogast, K; Master, CL; Collins, M; Kontos, AP; Bazarian, JJ; Chrisman, SPD; Brooks, MA; Duma, S; Rowson, S; Miles, CM; Dykhuizen, BH; Lintner, L				McCrea, Michael; Broglio, Steven; McAllister, Thomas; Zhou, Wenxian; Zhao, Shi; Katz, Barry; Kudela, Maria; Harezlak, Jaroslaw; Nelson, Lindsay; Meier, Timothy; Marshall, Stephen William; Guskiewicz, Kevin M.; Hoy, April Marie (Reed); Hazzard, Joseph B., Jr.; Kelly, Louise A.; Ortega, Justus D.; Port, Nicholas; Putukian, Margot; Langford, T. Dianne; Tierney, Ryan; Pasquina, Paul; Campbell, Darren E.; Jackson, Jonathan; McGinty, Gerald; O'Donnell, Patrick; Cameron, Kenneth; Houston, Megan; Svoboda, Steven; Giza, Christopher; Goldman, Joshua; DiFiori, Jon; Benjamin, Holly J.; Buckley, Thomas; Kaminski, Thomas W.; Clugston, James R.; Schmidt, Julianne D.; Feigenbaum, Luis A.; Eckner, James T.; Mihalik, Jason P.; Miles, Jessica Dysart; Anderson, Scott; Arbogast, Kristy; Master, Christina L.; Collins, Micky; Kontos, Anthony P.; Bazarian, Jeffrey J.; Chrisman, Sara P. D.; Brooks, M. Alison; Duma, Stefan; Rowson, Steven; Miles, Christopher M.; Dykhuizen, Brian H.; Lintner, Laura		CARE Consortium Investigators	Return to play and risk of repeat concussion in collegiate football players: comparative analysis from the NCAA Concussion Study (1999-2001) and CARE Consortium (2014-2017)	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; FREE WAITING PERIOD; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; MANAGEMENT; ZURICH	Objective We compared data from the National Collegiate Athletic Association (NCAA) Concussion Study (1999-2001) and the NCAA-Department of Defense Concussion Assessment, Research and Education (CARE) Consortium (2014-2017) to examine how clinical management, return to play (RTP) and risk of repeat concussion in collegiate football players have changed over the past 15 years. Methods We analysed data on reported duration of symptoms, symptom-free waiting period (SFWP), RTP and occurrence of within-season repeat concussion in collegiate football players with diagnosed concussion from the NCAA Study (n=184) and CARE (n=701). Results CARE athletes had significantly longer symptom duration (CARE median=5.92 days, IQR=3.02-9.98 days; NCAA median=2.00 days, IQR=1.00-4.00 days), SFWP (CARE median=6.00 days, IQR=3.49-9.00 days; NCAA median=0.98 days, IQR=0.00-4.00 days) and RTP (CARE median=12.23 days, IQR=8.04-18.92 days; NCAA median=3.00 days, IQR=1.00-8.00 days) than NCAA Study athletes (all p<0.0001). In CARE, there was only one case of repeat concussion within 10 days of initial injury (3.7% of within-season repeat concussions), whereas 92% of repeat concussions occurred within 10 days in the NCAA Study (p<0.001). The average interval between first and repeat concussion in CARE was 56.41 days, compared with 5.59 days in the NCAA Study (M difference=50.82 days; 95% CI 38.37 to 63.27; p<0.0001). Conclusion Our findings indicate that concussion in collegiate football is managed more conservatively than 15 years ago. These changes in clinical management appear to have reduced the risk of repetitive concussion during the critical period of cerebral vulnerability after sport-related concussion (SRC). These data support international guidelines recommending additional time for brain recovery before athletes RTP after SRC.	[McCrea, Michael] Med Coll Wisconsin, Neurosurg, Milwaukee, WI 53226 USA; [Broglio, Steven] Univ Michigan, Kinesiol, Ann Arbor, MI 48109 USA; [McAllister, Thomas] Indiana Univ Sch Med, Psychiat, Indianapolis, IN 46202 USA; [Zhou, Wenxian; Zhao, Shi; Katz, Barry] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA; [Kudela, Maria] Takeda Pharmaceut, Osaka, Japan; [Harezlak, Jaroslaw] Indiana Univ Syst, Sch Publ Hlth Bloomington, Dept Epidemiol & Biostat, Bloomington, IN USA; [Nelson, Lindsay] Med Coll Wisconsin, Neurosurg & Neurol, Milwaukee, WI 53226 USA; [Meier, Timothy] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Meier, Timothy] Med Coll Wisconsin, Dept Cell Biol, Milwaukee, WI 53226 USA; [Marshall, Stephen William] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27515 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Sports Med Res Lab, Chapel Hill, NC 27515 USA; [Hoy, April Marie (Reed)] Azusa Pacific Univ, Azusa, CA 91702 USA; [Hazzard, Joseph B., Jr.] Bloomsburg Univ, Bloomsburg, PA USA; [Kelly, Louise A.] Calif Lutheran Univ, Thousand Oaks, CA USA; [Ortega, Justus D.] Humboldt State Univ, Arcata, CA 95521 USA; [Port, Nicholas] Indiana Univ, Bloomington, IN 47405 USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Langford, T. Dianne; Tierney, Ryan] Temple Univ, Philadelphia, PA 19122 USA; [Pasquina, Paul] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Campbell, Darren E.; Jackson, Jonathan; McGinty, Gerald] US Air Force Acad, Colorado Springs, CO 80840 USA; [O'Donnell, Patrick] US Coast Guard Acad, New London, CT USA; [Cameron, Kenneth; Houston, Megan; Svoboda, Steven] US Mil Acad, West Point, NY 10996 USA; [Giza, Christopher; Goldman, Joshua; DiFiori, Jon] Univ Calif Los Angeles, Los Angeles, CA USA; [Benjamin, Holly J.] Univ Chicago, Chicago, IL 60637 USA; [Buckley, Thomas; Kaminski, Thomas W.] Univ Delaware, Newark, DE 19716 USA; [Clugston, James R.] Univ Florida, Gainesville, FL 32611 USA; [Schmidt, Julianne D.] Univ Georgia, Athens, GA 30602 USA; [Feigenbaum, Luis A.] Univ Miami, Coral Gables, FL 33124 USA; [Eckner, James T.] Univ Michigan, Ann Arbor, MI 48109 USA; [Mihalik, Jason P.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Miles, Jessica Dysart] Univ North Georgia, Dahlonega, GA USA; [Anderson, Scott] Univ Oklahoma, Norman, OK 73019 USA; [Arbogast, Kristy; Master, Christina L.] Univ Penn, Philadelphia, PA 19104 USA; [Collins, Micky; Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; [Bazarian, Jeffrey J.] Univ Rochester, Rochester, NY 14627 USA; [Chrisman, Sara P. D.] Univ Washington, Seattle, WA 98195 USA; [Brooks, M. Alison] Univ Wisconsin, Madison, WI 53706 USA; [Duma, Stefan; Rowson, Steven] Virginia Tech, Blacksburg, VA USA; [Miles, Christopher M.] Wake Forest Univ, Winston Salem, NC 27101 USA; [Dykhuizen, Brian H.] Wilmington Coll, Wilmington, OH USA; [Lintner, Laura] Winston Salem State Univ, Winston Salem, NC USA	McCrea, M (corresponding author), Med Coll Wisconsin, Neurosurg, Milwaukee, WI 53226 USA.	mmccrea@mcw.edu	Rowson, Steven/B-1270-2012; Buckley, Thomas A/B-7525-2016; Harezlak, Jaroslaw/P-8557-2014	Rowson, Steven/0000-0002-3227-0596; Buckley, Thomas A/0000-0002-0515-0150; Harezlak, Jaroslaw/0000-0002-3070-7686; Clugston, James/0000-0002-2103-1039; Cameron, Kenneth/0000-0002-6276-4482	Grand Alliance Concussion Assessment, Research and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Department of Defense (DOD)United States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research and Education (CARE) Consortium, funded, in part by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DOD). The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award No W81XWH-14-2-0151.	Broglio SP, 2017, SPORTS MED, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Lancaster MA, 2016, HUM BRAIN MAPP, V37, P3821, DOI 10.1002/hbm.23278; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2017, BR J SPORTS MED, V26; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; NCAA Sports Science Institute, CONC ED RES; NCAA Sports Science Institute, CONC SAF PROT MAN; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pfaller AY, 2016, AM J SPORT MED, V44, P2941, DOI 10.1177/0363546516651821; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Sarmiento K, 2014, J SAFETY RES, V50, P143, DOI 10.1016/j.jsr.2014.05.003; Svan Buuren, 2011, J STAT SOFTWARE, V45; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Yang J, 2017, AM J PUBLIC HLTH, V107, pe1	35	30	30	3	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2020	54	2					102	109		10.1136/bjsports-2019-100579			8	Sport Sciences	Sport Sciences	KD4WR	WOS:000507867100010	31036562	Bronze			2021-06-18	
J	Navratilova, E; Rau, J; Oyarzo, J; Tien, J; Mackenzie, K; Stratton, J; Remeniuk, B; Schwedt, T; Anderson, T; Dodick, D; Porreca, F				Navratilova, Edita; Rau, Jill; Oyarzo, Janice; Tien, Jason; Mackenzie, Kimberly; Stratton, Jennifer; Remeniuk, Bethany; Schwedt, Todd; Anderson, Trent; Dodick, David; Porreca, Frank			CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice	CEPHALALGIA			English	Article						Post-traumatic headache (PTH); acute post-traumatic headache (APTH); persistent post-traumatic headache (PPTH); mild traumatic brain injury (mTBI); concussion; CGRP; CGRP monoclonal antibody; cutaneous allodynia	GENE-RELATED PEPTIDE; EXTRACEREBRAL CIRCULATION; CALCITONIN RECEPTOR; MIGRAINE HEADACHE; DOUBLE-BLIND; RISK-FACTORS; MAST-CELLS; ALLODYNIA; MODEL; PAIN	Background Acute and persistent post-traumatic headache are often debilitating consequences of traumatic brain injury. Underlying physiological mechanisms of post-traumatic headache and its persistence remain unknown, and there are currently no approved therapies for these conditions. Post-traumatic headache often presents with a migraine-like phenotype. As calcitonin-gene related peptide promotes migraine headache, we explored the efficacy and timing of intervention with an anti- calcitonin-gene related peptide monoclonal antibody in novel preclinical models of acute post-traumatic headache and persistent post-traumatic headache following a mild traumatic brain injury event in mice. Methods Male, C57Bl/6 J mice received a sham procedure or mild traumatic brain injury resulting from a weight drop that allowed free head rotation while under minimal anesthesia. Periorbital and hindpaw tactile stimulation were used to assess mild traumatic brain injury-induced cutaneous allodynia. Two weeks after the injury, mice were challenged with stress, a common aggravator of migraine and post-traumatic headache, by exposure to bright lights (i.e. bright light stress) and cutaneous allodynia was measured hourly for 5 hours. A murine anti- calcitonin-gene related peptide monoclonal antibody was administered after mild traumatic brain injury at different time points to allow evaluation of the consequences of either early and sustained calcitonin-gene related peptide sequestration or late administration only prior to bright light stress. Results Mice with mild traumatic brain injury, but not a sham procedure, exhibited both periorbital and hindpaw cutaneous allodynia that resolved by post-injury day 13. Following resolution of injury-induced cutaneous allodynia, exposure to bright light stress re-instated periorbital and hindpaw cutaneous allodynia in injured, but not sham mice. Repeated administration of anti-calcitonin-gene related peptide monoclonal antibody at 2 hours, 7 and 14 days post mild traumatic brain injury significantly attenuated the expression of cutaneous allodynia when evaluated over the 14-day post injury time course and also prevented bright light stress-induced cutaneous allodynia in injured mice. Administration of anti-calcitonin-gene related peptide monoclonal antibody only at 2 hours and 7 days after mild traumatic brain injury blocked injury-induced cutaneous allodynia and partially prevented bright light stress-induced cutaneous allodynia. A single administration of anti-calcitonin-gene related peptide monoclonal antibody after the resolution of the peak injury-induced cutaneous allodynia, but prior to bright light stress challenge, did not prevent bright light stress-induced cutaneous allodynia. Conclusions We used a clinically relevant mild traumatic brain injury event in mice along with a provocative stimulus as novel models of acute post-traumatic headache and persistent post-traumatic headache. Following mild traumatic brain injury, mice demonstrated transient periorbital and hindpaw cutaneous allodynia suggestive of post-traumatic headache-related pain and establishment of central sensitization. Following resolution of injury-induced cutaneous allodynia, exposure to bright light stress re-established cutaneous allodynia, suggestive of persistent post-traumatic headache-related pain. Continuous early sequestration of calcitonin-gene related peptide prevented both acute post-traumatic headache and persistent post-traumatic headache. In contrast, delayed anti-calcitonin-gene related peptide monoclonal antibody treatment following establishment of central sensitization was ineffective in preventing persistent post-traumatic headache. These observations suggest that mechanisms involving calcitonin-gene related peptide underlie the expression of acute post-traumatic headache, and drive the development of central sensitization, increasing vulnerability to headache triggers and promoting persistent post-traumatic headache. Early and continuous calcitonin-gene related peptide blockade following mild traumatic brain injury may represent a viable treatment option for post-traumatic headache and for the prevention of post-traumatic headache persistence.	[Navratilova, Edita; Remeniuk, Bethany; Porreca, Frank] Univ Arizona, Arizona Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ USA; [Rau, Jill; Oyarzo, Janice; Schwedt, Todd; Dodick, David; Porreca, Frank] Mayo Clin, Scottsdale, AZ USA; [Tien, Jason; Mackenzie, Kimberly; Stratton, Jennifer] Teva Biol, Redwood City, CA USA; [Anderson, Trent] Univ Arizona, Coll Med, Dept Basic Med Sci, Phoenix, AZ USA	Porreca, F (corresponding author), Univ Arizona, Dept Pharmacol, Tucson, AZ 85724 USA.	frankp@medadmin.arizona.edu		Tien, Jason/0000-0003-3853-0827; Remeniuk, Bethany/0000-0003-1961-5163	TEVA	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by an unrestricted grant from TEVA to FP.	Ashkenazi A, 2007, CEPHALALGIA, V27, P111, DOI 10.1111/j.1468-2982.2006.01255.x; Benemei S, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0811-5; Bharadwaj VN, 2018, NANOMED-NANOTECHNOL, V14, P2155, DOI 10.1016/j.nano.2018.06.004; Bigal ME, 2008, NEUROLOGY, V70, P1525, DOI 10.1212/01.wnl.0000310645.31020.b1; Bower RL, 2016, AM J PHYSIOL-REG I, V310, pR788, DOI 10.1152/ajpregu.00539.2015; Bree D, 2019, PAIN, V160, P1050, DOI 10.1097/j.pain.0000000000001481; Bree D, 2018, CEPHALALGIA, V38, P246, DOI 10.1177/0333102416681571; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N; Burstein R, 2001, PAIN, V89, P107, DOI 10.1016/S0304-3959(00)00478-4; Burstein R, 2010, ANN NEUROL, V68, P81, DOI 10.1002/ana.21994; Cady RK, 2009, HEADACHE, V49, P1258, DOI 10.1111/j.1526-4610.2009.01523.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention (CDC), 2010, FACTS CONC BRAIN INJ; Cernuda-Morollon E, 2013, NEUROLOGY, V81, P1191, DOI 10.1212/WNL.0b013e3182a6cb72; Daiutolo BV, 2016, J NEUROTRAUM, V33, P748, DOI 10.1089/neu.2015.4087; De Felice M, 2010, ANN NEUROL, V67, P325, DOI 10.1002/ana.21897; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Defrin R, 2014, J MAN MANIP THER, V22, P36, DOI 10.1179/2042618613Y.0000000053; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; Dodick DW, 2019, CEPHALALGIA, V39, P1075, DOI 10.1177/0333102419858355; Dodick DW, 2019, CEPHALALGIA, V39, P873, DOI 10.1177/0333102418825346; Dodick DW, 2019, CEPHALALGIA, V39, P445, DOI 10.1177/0333102418821662; Dodick DW, 2018, JAMA-J AM MED ASSOC, V319, P1999, DOI 10.1001/jama.2018.4853; Dodick DW, 2018, CEPHALALGIA, V38, P1026, DOI 10.1177/0333102418759786; Edvinsson L, 2017, HEADACHE, V57, P47, DOI 10.1111/head.13081; Eftekhari S, 2010, NEUROSCIENCE, V169, P683, DOI 10.1016/j.neuroscience.2010.05.016; Eftekhari S, 2016, J COMP NEUROL, V524, P90, DOI 10.1002/cne.23828; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Ferrari MD, 2001, LANCET, V358, P1668, DOI 10.1016/S0140-6736(01)06711-3; Giani L, 2019, NEUROL SCI, V40, pS129, DOI 10.1007/s10072-019-03786-7; Goadsby PJ, 2019, NEW ENGL J MED, V381, P132, DOI 10.1056/NEJMoa1813440; GOADSBY PJ, 1988, ANN NEUROL, V23, P193, DOI 10.1002/ana.410230214; GOADSBY PJ, 1990, ANN NEUROL, V28, P183, DOI 10.1002/ana.410280213; Goddeyne C, 2015, J NEUROPHYSIOL, V113, P3268, DOI 10.1152/jn.00970.2014; Hansen JM, 2010, CEPHALALGIA, V30, P1179, DOI 10.1177/0333102410368444; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Holland PR, 2018, NEUROTHERAPEUTICS, V15, P304, DOI 10.1007/s13311-018-0617-4; Holtkamp MD, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0572-x; Iyengar S, 2017, PAIN, V158, P543, DOI 10.1097/j.pain.0000000000000831; Juhasz G, 2005, CEPHALALGIA, V25, P179, DOI 10.1111/j.1468-2982.2005.00836.x; Kandasamy R, 2015, HANDB EXP PHARMACOL, V227, P15, DOI 10.1007/978-3-662-46450-2_2; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kopruszinski CM, 2017, CEPHALALGIA, V37, P560, DOI 10.1177/0333102416650702; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lennerz JK, 2008, J COMP NEUROL, V507, P1277, DOI 10.1002/cne.21607; Levy D, 2016, CEPHALALGIA, V36, P915, DOI 10.1177/0333102415617412; Lucas S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0520-1; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Manning BM, 2016, ACS CHEM BIOL, V11, P3077, DOI 10.1021/acschembio.6b00616; Marcus R, 2014, CEPHALALGIA, V34, P114, DOI 10.1177/0333102413500727; Markus TE, 2016, J CHILD NEUROL, V31, P1213, DOI 10.1177/0883073816650036; Martelletti P, 2019, EXPERT OPIN PHARMACO, V20, P209, DOI 10.1080/14656566.2018.1549223; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Moye LS, 2019, CEPHALALGIA, V39, P77, DOI 10.1177/0333102418777507; Mustafa G, 2016, NEUROPHARMACOLOGY, V107, P27, DOI 10.1016/j.neuropharm.2016.03.016; Mychasiuk R, 2014, JOVE-J VIS EXP, V94, P1; Nation KM, 2018, PAIN, V159, P919, DOI 10.1097/j.pain.0000000000001167; Nordhaug LH, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0838-2; Price TJ, 2015, PROG MOL BIOL TRANSL, V131, P409, DOI 10.1016/bs.pmbts.2014.11.010; Ramachandran R, 2018, SEMIN IMMUNOPATHOL, V40, P301, DOI 10.1007/s00281-018-0676-y; Silverberg ND, 2019, J NEUROTRAUM, V36, P1544, DOI 10.1089/neu.2018.6025; Skandsen T, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-018-0495-0; Skljarevski V, 2018, CEPHALALGIA, V38, P1442, DOI 10.1177/0333102418779543; Stemper BD, 2016, ANN BIOMED ENG, V44, P3252, DOI 10.1007/s10439-016-1647-x; Stemper BD, 2015, ANN BIOMED ENG, V43, P1071, DOI 10.1007/s10439-014-1171-9; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tepper SJ, 2019, NEUROL SCI, V40, pS99, DOI 10.1007/s10072-019-03769-8; Tepper SJ, 2018, HEADACHE, V58, P238, DOI 10.1111/head.13379; Theoharides TC, 2005, BRAIN RES REV, V49, P65, DOI 10.1016/j.brainresrev.2004.11.006; Voss T, 2016, CEPHALALGIA, V36, P887, DOI 10.1177/0333102416653233; Walker WC, 2013, CEPHALALGIA, V33, P998, DOI 10.1177/0333102413482197; Wang XJ, 2010, HEADACHE, V50, P579, DOI 10.1111/j.1526-4610.2010.01632.x; Warfvinge K, 2019, CEPHALALGIA, V39, P342, DOI 10.1177/0333102417728873; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; Yilmaz T, 2017, EMERG MED J, V34, P800, DOI 10.1136/emermed-2015-205429	83	30	30	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	DEC	2019	39	14					1762	1775	0333102419877662	10.1177/0333102419877662		SEP 2019	14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	JT6CT	WOS:000491780000001	31550910				2021-06-18	
J	Critchfield, E; Soble, JR; Marceaux, JC; Bain, KM; Chase Bailey, K; Webber, TA; Alex Alverson, W; Messerly, J; Gonzalez, DA; O'Rourke, JJF				Critchfield, Edan; Soble, Jason R.; Marceaux, Janice C.; Bain, Kathleen M.; Chase Bailey, K.; Webber, Troy A.; Alex Alverson, W.; Messerly, Johanna; Gonzalez, David Andres; O'Rourke, Justin J. F.			Cognitive impairment does not cause invalid performance: analyzing performance patterns among cognitively unimpaired, impaired, and noncredible participants across six performance validity tests	CLINICAL NEUROPSYCHOLOGIST			English	Article						Performance validity; neuropsychological evaluation; service-connection; cognitive impairment; veterans	MEMORY MALINGERING TOMM; TRAUMATIC BRAIN-INJURY; RELIABLE DIGIT SPAN; FALSE DISCOVERY RATE; VERBAL-LEARNING TEST; CLASSIFICATION ACCURACY; RECOGNITION TRIAL; SCREENING MEASURE; RATES; SPECIFICITY	Objective: Performance validity tests (PVTs) are essential in neuropsychological evaluations; however, it has been questioned how PVTs function in the context of cognitive impairment, and whether cognitive impairment alone is sufficient to cause PVT failure. Further, there is concern that some clinicians will disregard failed PVTs due to their perception that failures represent false-positive errors secondary to cognitive impairment. This study examined patterns associated with cognitively impaired versus noncredible performance across a battery of PVTs and neuropsychological tests. Additionally, the impact of VA service-connection and disability-seeking status on test validity was investigated. Method: A mixed-clinical sample of 103 veterans were administered six PVTs and neuropsychological tests. Performance was compared across three groups: valid-cognitively unimpaired, valid-cognitively impaired, and noncredible. Results: Significant PVT score differences and failure rates emerged across the three groups, with nonsignificant to small differences between valid-unimpaired and valid-impaired groups, and large differences between impaired and noncredible groups. In contrast, there were nonsignificant to small differences on neuropsychological tests between the valid-impaired and noncredible groups, indicating that impaired participants performed significantly better on PVTs despite comparable neurocognitive test scores. Service-connection rating itself was not associated with PVT failure, but an active disability claim to increase and/or establish service connection was associated with worse PVT performance. Conclusion: This study supports the use of multiple PVTs during evaluations of patients with varied cognitive abilities. Results indicated increased risk of PVT failure in patients who were seeking initiation/increase in service-connected payments, and shows that cognitive impairment does not cause PVT failure.	[Critchfield, Edan; Soble, Jason R.; Marceaux, Janice C.; Bain, Kathleen M.; Webber, Troy A.; Alex Alverson, W.; Messerly, Johanna; O'Rourke, Justin J. F.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA; [Soble, Jason R.] Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL USA; [Soble, Jason R.] Univ Illinois, Coll Med, Dept Neurol, Chicago, IL USA; [Marceaux, Janice C.; Gonzalez, David Andres] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA; [Chase Bailey, K.] UT Southwestern Med Ctr, Div Psychol, Dallas, TX USA	Critchfield, E (corresponding author), South Texas Vet Hlth Care Syst 116B, Psychol Serv, 7400 Merton Minter, San Antonio, TX 78229 USA.	Edan.Critchfield@va.gov		Bailey, Kenneth/0000-0002-5389-5229			American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Armistead-Jehle P, 2018, ARCH CLIN NEUROPSYCH, V33, P120, DOI 10.1093/arclin/acx031; Bailey KC, 2018, CLIN NEUROPSYCHOL, V32, P119, DOI 10.1080/13854046.2017.1333151; Bain K. M., 2017, ASSESSMENT; Barhon LI, 2015, APPL NEUROPSYCH-ADUL, V22, P114, DOI 10.1080/23279095.2013.863775; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Boone, 2007, ASSESSMENT FEIGNED C; Boone K. B., 2002, DOT COUNTING TEST MA; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Glickman ME, 2014, J CLIN EPIDEMIOL, V67, P850, DOI 10.1016/j.jclinepi.2014.03.012; Graver C.J., 2012, MIL MED, V177, P7; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; Green P., 1996, WORD MEMORY TEST USE; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Hampson NE, 2014, APPL NEUROPSYCH-ADUL, V21, P183, DOI 10.1080/09084282.2013.787425; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry M, 2010, J CLIN EXP NEUROPSYC, V32, P19, DOI 10.1080/13803390902791653; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Howe L, 2009, CLIN NEUROPSYCHOL, V23, P329, DOI 10.1080/13854040801945060; Kiewel NA, 2012, CLIN NEUROPSYCHOL, V26, P965, DOI 10.1080/13854046.2012.694478; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Loring DW, 2016, ARCH CLIN NEUROPSYCH, V31, P313, DOI 10.1093/arclin/acw014; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nutter-Upham KE, 2008, ARCH CLIN NEUROPSYCH, V23, P229, DOI 10.1016/j.acn.2008.01.005; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Pearson, 2009, ADV CLIN SOL WAIS 4; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rohling M., 2007, ASSESSMENT FEIGNED C, P453; Sawyer RJ, 2017, CLIN NEUROPSYCHOL, V31, P207, DOI 10.1080/13854046.2016.1245787; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Schutte C., 2013, MILD TRAUMATIC BRAIN, P159; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Suhr J. A., 2007, ASSESSMENT MALINGERE; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1996, TEST MEMORY MALINGER; Walter J, 2014, CLIN NEUROPSYCHOL, V28, P1197, DOI 10.1080/13854046.2014.960454; Webber T. A., 2017, CLIN NEUROPSYCHOL, V32, P1; Wechsler D, 2008, WAIS 4 ADM SCORING M; Wechsler D., 2009, WECHSLER MEMORY SCAL; Willis PF, 2011, MIL MED, V176, P1426, DOI 10.7205/MILMED-D-11-00168; Wolfson D., 1993, HALSTEAD REITAN NEUR; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083	70	30	30	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG 18	2019	33	6					1083	1101		10.1080/13854046.2018.1508615			19	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	IF6TJ	WOS:000473212700005	30475095				2021-06-18	
J	Sarmiento, K; Thomas, KE; Daugherty, J; Waltzman, D; Haarbauer-Krupa, JK; Peterson, AB; Haileyesus, T; Breiding, MJ				Sarmiento, Kelly; Thomas, Karen E.; Daugherty, Jill; Waltzman, Dana; Haarbauer-Krupa, Juliet K.; Peterson, Alexis B.; Haileyesus, Tadesse; Breiding, Matthew J.			Emergency Department Visits for Sports- and Recreation-Related Traumatic Brain Injuries Among Children - United States, 2010-2016	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article									[Sarmiento, Kelly; Daugherty, Jill; Waltzman, Dana; Haarbauer-Krupa, Juliet K.; Peterson, Alexis B.; Breiding, Matthew J.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA; [Thomas, Karen E.; Haileyesus, Tadesse] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA	Sarmiento, K (corresponding author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.	KSarmiento@cdc.gov					Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Haarbauer-Krupa J, 2018, J PEDIATR-US, V197, P241, DOI 10.1016/j.jpeds.2018.01.075; Lumba-Brown A, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.2853; Schroeder T., 2001, NEISS SAMPLE DESIGN; Waltzman D, 2019, J SAFETY RES, V68, P157, DOI 10.1016/j.jsr.2018.11.005	9	30	30	0	2	CENTERS  DISEASE CONTROL & PREVENTION	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	MAR 15	2019	68	10					237	242		10.15585/mmwr.mm6810a2			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	HO7WI	WOS:000461160300002	30870404	Green Published, Bronze			2021-06-18	
J	Kerr, N; Lee, SW; Perez-Barcena, J; Crespi, C; Ibanez, J; Bullock, MR; Dietrich, WD; Keane, RW; Vaccari, JPD				Kerr, Nadine; Lee, Stephanie W.; Perez-Barcena, Jon; Crespi, Catalina; Ibanez, Javier; Bullock, M. Ross; Dietrich, W. Dalton; Keane, Robert W.; Vaccari, Juan Pablo de Rivero			Inflammasome proteins as biomarkers of traumatic brain injury	PLOS ONE			English	Article							NLRP3 INFLAMMASOME; CEREBROSPINAL-FLUID; ACTIVATION; HYPOTHERMIA; INHIBITION; MICROGLIA	Background The inflammasome plays an important role in the inflammatory innate immune response after central nervous system (CNS) injury. Inhibition of the inflammasome after traumatic brain injury (TBI) results in improved outcomes by lowering the levels of caspase-1 and interleukin (IL)-1b. We have previously shown that inflammasome proteins are elevated in the cerebrospinal fluid (CSF) of patients with TBI and that higher levels of these proteins were consistent with poorer outcomes after TBI when compared to patients that presented these inflammasome proteins at lower levels. Methods and findings Here we extend our work by analyzing serum from 21 TBI patients and CSF from 18 TBI patients compared to 120 serum samples and 30 CSF samples from no-TBI donor controls for the expression of caspase-1, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), interleukin(IL)-1b and IL-18. Analysis was carried out using the Ella Simple Plex system (Protein Simple) to determine the sensitivity and specificity of inflammasome proteins as biomarkers of TBI. Receiver operator characteristic (ROC) curves, confidence intervals and likelihood ratios for each biomarker was determined. ROC curves, confidence intervals, sensitivity and specificity for each biomarker examined revealed that caspase-1 (0.93 area under the curve (AUC)) and ASC (0.90 AUC) in serum and ASC (1.0 AUC) and IL-18 (0.84 AUC) in CSF are promising biomarkers of TBI pathology. Importantly, higher protein levels (above 547.6 pg/ml) of ASC (0.91 AUC) were consistent with poorer outcomes after TBI as determined by the Glasgow Outcome Scale-Extended (GOSE). Conclusion These findings indicate that inflammasome proteins are excellent diagnostic and predictive biomarkers of TBI.	[Kerr, Nadine; Lee, Stephanie W.; Bullock, M. Ross; Dietrich, W. Dalton; Keane, Robert W.; Vaccari, Juan Pablo de Rivero] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg,Neurosci Program, Miami, FL 33136 USA; [Kerr, Nadine; Lee, Stephanie W.; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Perez-Barcena, Jon] Son Espases Hosp, Intens Care Dept, Palma De Mallorca, Spain; [Crespi, Catalina] Son Espases Hosp, Fundacio Inst Invest Sanitaria Illes Balears IdIS, Palma De Mallorca, Spain; [Ibanez, Javier] Son Espases Hosp, Dept Neurol Surg, Palma De Mallorca, Spain; [Bullock, M. Ross; Dietrich, W. Dalton; Vaccari, Juan Pablo de Rivero] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA	Vaccari, JPD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg,Neurosci Program, Miami, FL 33136 USA.; Vaccari, JPD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA.	JdeRivero@med.miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020; Crespi, Catalina/A-5543-2013	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; Crespi, Catalina/0000-0003-0781-9708; Ibanez, Javier/0000-0003-3735-8332	STTR grant from the NINDS/NIH [4R42NS086274-012]; Fondo de Investigacion SanitariaInstituto de Salud Carlos III [FIS PI16/00737]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R42NS086274, R01NS042133, R01NS089443] Funding Source: NIH RePORTER	This work was supported by a STTR grant (4R42NS086274-012) from the NINDS/NIH to RWK: https://www.nih.gov/; and by a public grant from Fondo de Investigacion Sanitaria (FIS PI16/00737) to JPB: https://portalfis.isciii.es/es/Paginas/inicio.aspx.No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by a STTR grant (4R42NS086274-012) from the NINDS/NIH to RWK and WDD and by a public grant from Fondo de Investigacion Sanitaria (FIS PI16/00737) to JPB.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Brand FJ, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-016-0137-0; Cai X, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a023580; Freeman L, 2017, J EXP MED, V214, P1351, DOI 10.1084/jem.20150237; Ge XT, 2018, BRAIN RES, V1697, P10, DOI 10.1016/j.brainres.2018.06.008; Geng FY, 2016, NEUROIMMUNOMODULAT, V23, P122, DOI 10.1159/000445689; Goldmann T, 2013, CELL RES, V23, P595, DOI 10.1038/cr.2013.24; Heneka MT, 2018, NAT REV NEUROSCI, V19, P610, DOI 10.1038/s41583-018-0055-7; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; IRRERA N, 2017, FRONT PHARMACOL, V8; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Keane RW, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00135; Kerr N, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00309; Kerr NA, 2018, J NEUROTRAUM, V35, P2067, DOI 10.1089/neu.2017.5430; Lagerstedt L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200394; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Mondello S, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-85; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Schnaars Mareike, 2013, Methods Mol Biol, V1040, P1, DOI 10.1007/978-1-62703-523-1_1; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Syed SA, 2018, NEURON, V99, P914, DOI 10.1016/j.neuron.2018.08.001; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2016, TRANSL RES, V167, P35, DOI 10.1016/j.trsl.2015.05.003; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Xu X, 2018, NEUROBIOL DIS, V117, P15, DOI 10.1016/j.nbd.2018.05.016; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Yokobori S, 2013, J NEUROSURG, V118, P370, DOI 10.3171/2012.10.JNS12725; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zou P, 2018, MOL MED REP, V17, P3212, DOI 10.3892/mmr.2017.8241	40	30	30	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2018	13	12							e0210128	10.1371/journal.pone.0210128			16	Multidisciplinary Sciences	Science & Technology - Other Topics	HG0IO	WOS:000454627200146	30596792	DOAJ Gold, Green Published			2021-06-18	
J	Krukowski, K; Chou, A; Feng, X; Tiret, B; Paladini, MS; Riparip, LK; Chaumeil, MM; Lemere, C; Rosi, S				Krukowski, Karen; Chou, Austin; Feng, Xi; Tiret, Brice; Paladini, Maria-Serena; Riparip, Lara-Kirstie; Chaumeil, Myriam M.; Lemere, Cynthia; Rosi, Susanna			Traumatic Brain Injury in Aged Mice Induces Chronic Microglia Activation, Synapse Loss, and Complement-Dependent Memory Deficits	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						traumatic brain injury; complement; C1q; microglia; synapse	COGNITIVE FUNCTION; CNS; DYSFUNCTION; INHIBITION; DRIVES; IMPACT	Traumatic brain injury (TBI) is of particular concern for the aging community since there is both increased incidence of TBI and decreased functional recovery in this population. In addition, TBI is the strongest environmental risk factor for development of Alzheimer's disease and other dementia-related neurodegenerative disorders. Critical changes that affect cognition take place over time following the initial insult. Our previous work identified immune system activation as a key contributor to cognitive deficits observed in aged animals. Using a focal contusion model in the current study, we demonstrate a brain lesion and cavitation formation, as well as prolonged blood-brain barrier breakdown. These changes were associated with a prolonged inflammatory response, characterized by increased microglial cell number and phagocytic activity 30 days post injury, corresponding to significant memory deficits. We next aimed to identify the injury-induced cellular and molecular changes that lead to chronic cognitive deficits in aged animals, and measured increases in complement initiation components C1q, C3, and CR3, which are known to regulate microglial-synapse interactions. Specifically, we found significant accumulation of C1q on synapses within the hippocampus, which was paralleled by synapse loss 30 days post injury. We used genetic and pharmacological approaches to determine the mechanistic role of complement initiation on cognitive loss in aging animals after TBI. Notably, both genetic and pharmacological blockade of the complement pathway prevented memory deficits in aged injured animals. Thus, therapeutically targeting early components of the complement cascade represents a significant avenue for possible clinical intervention following TBI in the aging population.	[Krukowski, Karen; Chou, Austin; Feng, Xi; Tiret, Brice; Paladini, Maria-Serena; Riparip, Lara-Kirstie; Chaumeil, Myriam M.; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA; [Krukowski, Karen; Chou, Austin; Feng, Xi; Paladini, Maria-Serena; Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Tiret, Brice; Chaumeil, Myriam M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Surbeck Lab Adv Imaging, San Francisco, CA 94143 USA; [Lemere, Cynthia] Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, 75 Francis St, Boston, MA 02115 USA; [Lemere, Cynthia] Harvard Med Sch, Boston, MA 02115 USA; [Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Rosi, Susanna] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Rosi, Susanna] Univ Calif San Francisco, Kavli Inst Fundamental Neurosci, San Francisco, CA 94143 USA	Rosi, S (corresponding author), Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Kavli Inst Fundamental Neurosci, San Francisco, CA 94143 USA.	karen.krukowski@ucsf.edu; austinc06@gmail.com; xi.feng@ucsf.edu; brice.tiret@ucsf.edu; paladini.mariaserena@gmail.com; lriparip@gmail.com; myriam.chaumeil@ucsf.edu; clemere@bwh.harvard.edu; susanna.rosi@ucsf.edu	Feng, Xi/N-7160-2016	Feng, Xi/0000-0002-6920-1519; Chaumeil, Myriam/0000-0002-2110-4613; Chou, Austin/0000-0003-4328-5811; PALADINI, MARIA SERENA/0000-0001-7320-6622	NIH NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG056770, R21NS096718, AG042016, AG044713, R01AG060057]; NRSA post-doctoral fellowship from the NIA [F32AG054126]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AI027763]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA213441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG056770] Funding Source: NIH RePORTER	This work was supported by NIH NIA grants R01AG056770 (SR), R21NS096718 (SR, MC), AG042016 (SR), AG044713 (CL), and R01AG060057 (CL). K.K. is supported by an NRSA post-doctoral fellowship from the NIA F32AG054126. The San Francisco General Hospital Flow Core Facility was supported by the National Institutes of Health (P30 AI027763).	Alawieh A, 2018, J NEUROSCI, V38, P2519, DOI 10.1523/JNEUROSCI.2197-17.2018; Chou A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061616; Chou A, 2017, P NATL ACAD SCI USA, V114, pE6420, DOI 10.1073/pnas.1707661114; Feng X, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0671-y; Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004; Guglielmetti C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17758-4; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008; Krukowski K, 2018, BRAIN BEHAV IMMUN, V74, P106, DOI 10.1016/j.bbi.2018.08.008; Krukowski K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26039-7; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lee Jea-Young, 2019, Methods Mol Biol, V2045, P299, DOI 10.1007/7651_2018_121; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Norris GT, 2018, J EXP MED, V215, P1789, DOI 10.1084/jem.20172244; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Patel NA, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1240-3; Prieto GA, 2015, P NATL ACAD SCI USA, V112, pE5078, DOI 10.1073/pnas.1514486112; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Shi QQ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf6295; Shi QQ, 2015, J NEUROSCI, V35, P13029, DOI 10.1523/JNEUROSCI.1698-15.2015; Snigdha S, 2016, J NEUROSCI, V36, P3611, DOI 10.1523/JNEUROSCI.2693-15.2016; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stephan AH, 2013, J NEUROSCI, V33, P13460, DOI 10.1523/JNEUROSCI.1333-13.2013; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Vasek MJ, 2016, NATURE, V534, P538, DOI 10.1038/nature18283	39	30	30	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1422-0067		INT J MOL SCI	Int. J. Mol. Sci.	DEC	2018	19	12							3753	10.3390/ijms19123753			17	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	HG9JM	WOS:000455323500055	30486287	DOAJ Gold, Green Published			2021-06-18	
J	Treangen, TJ; Wagner, J; Burns, MP; Villapol, S				Treangen, Todd J.; Wagner, Justin; Burns, Mark P.; Villapol, Sonia			Traumatic Brain Injury in Mice Induces Acute Bacterial Dysbiosis Within the Fecal Microbiome	FRONTIERS IN IMMUNOLOGY			English	Article						microbiome; gut-brain axis; Lactobacillus; brain damage; gut microbes; traumatic brain injury; bacterial dysbiosis; controlled cortical impact injury	LACTOBACILLUS-HELVETICUS R0052; BIFIDOBACTERIUM-LONGUM R0175; GUT-MICROBIOTA; INFLAMMATION; STRESS; AXIS	The secondary injury cascade that is activated following traumatic brain injury (TBI) induces responses from multiple physiological systems, including the immune system. These responses are not limited to the area of brain injury; they can also alter peripheral organs such as the intestinal tract. Gut microbiota play a role in the regulation of immune cell populations and microglia activation, and microbiome dysbiosis is implicated in immune dysregulation and behavioral abnormalities. However, changes to the gut microbiome induced after acute TBI remains largely unexplored. In this study, we have investigated the impact of TBI on bacterial dysbiosis. To test the hypothesis that TBI results in changes in microbiome composition, we performed controlled cortical impact (CCI) or sham injury in male 9-weeks old C57BL/6J mice. Fresh stool pellets were collected at baseline and at 24 h post-CCI. 16S rRNA based microbiome analysis was performed to identify differential abundance in bacteria at the genus and species level. In all baseline vs. 24 h post-CCI samples, we evaluated species-level differential abundances via clustered and annotated operational taxonomic units (OTU). At a high-level view, we observed significant changes in two genera after TBI, Marvinbryantia, and Clostridiales. At the species-level, we found significant decreases in three species (Lactobacillus gasseri, Ruminococcus flavefaciens, and Eubacterium ventriosum), and significant increases in two additional species (Eubacterium sulci, and Marvinbryantia formatexigens). These results pinpoint critical changes in the genus-level and species-level microbiome composition in injured mice compared to baseline; highlighting a previously unreported acute dysbiosis in the microbiome after TBI.	[Treangen, Todd J.] Rice Univ, Dept Comp Sci, Houston, TX USA; [Wagner, Justin] Univ Maryland, Ctr Bioinformat & Computat Biol, College Pk, MD 20742 USA; [Burns, Mark P.] Georgetown Univ, Dept Neurosci, Washington, DC USA; [Villapol, Sonia] Houston Methodist Res Inst, Ctr Neuroregenerat, Houston, TX 77030 USA	Villapol, S (corresponding author), Houston Methodist Res Inst, Ctr Neuroregenerat, Houston, TX 77030 USA.	svillapol@houstonmethodist.org		Burns, Mark P/0000-0003-4750-2000; Villapol, Sonia/0000-0002-6174-4113	National Institute for Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS106640]; Houston Methodist Research Institute; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS106640] Funding Source: NIH RePORTER	This work was supported by an R21NS106640 (SV) grant from the National Institute for Neurological Disorders and Stroke (NINDS), and funds from the Houston Methodist Research Institute.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Ariza Ana Carolina, 2012, Front Endocrinol (Lausanne), V3, P22, DOI 10.3389/fendo.2012.00022; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Benakis C, 2016, NAT MED, V22, P516, DOI 10.1038/nm.4068; Bienenstock J, 2015, NUTR REV, V73, P28, DOI 10.1093/nutrit/nuv019; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Dewan MC, 2019, J NEUROSURG, V130, P1080, DOI 10.3171/2017.10.JNS17352; Druart C, 2014, LIPIDS, V49, P397, DOI 10.1007/s11745-014-3881-z; Ghodsi M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-271; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Kang S, 2010, INFLAMM BOWEL DIS, V16, P2034, DOI 10.1002/ibd.21319; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kasai C, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0330-2; Kelly JR, 2016, J PSYCHIATR RES, V82, P109, DOI 10.1016/j.jpsychires.2016.07.019; Kigerl KA, 2016, J EXP MED, V213, P2603, DOI 10.1084/jem.20151345; Koren O, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002863; Lepage P, 2013, GUT, V62, P146, DOI 10.1136/gutjnl-2011-301805; Li H, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13260; Luczynski P, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw020; Ma EL, 2017, BRAIN BEHAV IMMUN, V66, P56, DOI 10.1016/j.bbi.2017.06.018; Manrique P, 2016, P NATL ACAD SCI USA, V113, P10400, DOI 10.1073/pnas.1601060113; Marin IA, 2017, SCI REP-UK, V7, DOI 10.1038/srep43859; Messaoudi M, 2011, GUT MICROBES, V2, P256, DOI 10.4161/gmic.2.4.16108; Messaoudi M, 2011, BRIT J NUTR, V105, P755, DOI 10.1017/S0007114510004319; Morgan XC, 2013, TRENDS GENET, V29, P51, DOI 10.1016/j.tig.2012.09.005; Nicholson SE, 2019, SHOCK, V52, P240, DOI 10.1097/SHK.0000000000001211; Olsen AB, 2013, NEUROGASTROENT MOTIL, V25, DOI 10.1111/nmo.12121; Ondov BD, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-385; Park JA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14726-w; Paulson JN, 2013, NAT METHODS, V10, P1200, DOI [10.1038/nmeth.2658, 10.1038/NMETH.2658]; Pigrau M, 2016, NEUROGASTROENT MOTIL, V28, P463, DOI 10.1111/nmo.12717; Rey FE, 2010, J BIOL CHEM, V285, P22082, DOI 10.1074/jbc.M110.117713; Robertson RC, 2017, BRAIN BEHAV IMMUN, V59, P21, DOI 10.1016/j.bbi.2016.07.145; Rowin J, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13443; Singh V, 2016, J NEUROSCI, V36, P7428, DOI 10.1523/JNEUROSCI.1114-16.2016; Sirisinha S, 2016, ASIAN PAC J ALLERGY, V34, P249, DOI 10.12932/AP0803; Sundman MH, 2017, BRAIN BEHAV IMMUN, V66, P31, DOI 10.1016/j.bbi.2017.05.009; Tan M, 2011, CRIT CARE, V15, DOI 10.1186/cc10579; Villapol S, 2007, J NEUROSCI RES, V85, P3545, DOI 10.1002/jnr.21450; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Wagner J, 2018, NUCLEIC ACIDS RES, V46, P2777, DOI 10.1093/nar/gky136; Zakostelska Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027961	43	30	33	2	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 27	2018	9								2757	10.3389/fimmu.2018.02757			7	Immunology	Immunology	HB9XZ	WOS:000451449400001	30546361	DOAJ Gold, Green Published			2021-06-18	
J	Mustafi, SM; Harezlak, J; Koch, KM; Nencka, AS; Meier, TB; West, JD; Giza, CC; DiFiori, JP; Guskiewicz, KM; Mihalik, JP; LaConte, SM; Duma, SM; Broglio, SP; Saykin, AJ; McCrea, M; McAllister, TW; Wu, YC				Mustafi, Sourajit Mitra; Harezlak, Jaroslaw; Koch, Kevin M.; Nencka, Andrew S.; Meier, Timothy B.; West, John D.; Giza, Christopher C.; DiFiori, John P.; Guskiewicz, Kevin M.; Mihalik, Jason P.; LaConte, Stephen M.; Duma, Stefan M.; Broglio, Steven P.; Saykin, Andrew J.; McCrea, Michael; McAllister, Thomas W.; Wu, Yu-Chien			Acute White-Matter Abnormalities in Sports-Related Concussion: A Diffusion Tensor Imaging Study from the NCAA-DoD CARE Consortium	JOURNAL OF NEUROTRAUMA			English	Article						acute; CARE; diffusion tensor imaging; sports-related concussion; tract-based spatial statistics; white matters	TRAUMATIC BRAIN-INJURY; AXONAL INJURY; WATER DIFFUSION; SPINAL-CORD; MRI; DYSMYELINATION; EPIDEMIOLOGY; DEGENERATION; DEPENDENCE; NETWORKS	Sports-related concussion (SRC) is an important public health issue. Although standardized assessment tools are useful in the clinical management of acute concussion, the underlying pathophysiology of SRC and the time course of physiological recovery after injury remain unclear. In this study, we used diffusion tensor imaging (DTI) to detect white matter alterations in football players within 48h after SRC. As part of the NCAA-DoD CARE Consortium study of SRC, 30 American football players diagnosed with acute concussion and 28 matched controls received clinical assessments and underwent advanced magnetic resonance imaging scans. To avoid selection bias and partial volume effects, whole-brain skeletonized white matter was examined by tract-based spatial statistics to investigate between-group differences in DTI metrics and their associations with clinical outcome measures. Mean diffusivity was significantly higher in brain white matter of concussed athletes, particularly in frontal and subfrontal long white matter tracts. In the concussed group, axial diffusivity was significantly correlated with the Brief Symptom Inventory and there was a similar trend with the symptom severity score of the Sport Concussion Assessment Tool. In addition, concussed athletes with higher fractional anisotropy performed better on the cognitive component of the Standardized Assessment of Concussion. Overall, the results of this study are consistent with the hypothesis that SRC is associated with changes in white matter tracts shortly after injury, and these differences are correlated clinically with acute symptoms and functional impairments.	[Mustafi, Sourajit Mitra; West, John D.; Saykin, Andrew J.; Wu, Yu-Chien] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, 355 West 16th St,Suite 4100, Indianapolis, IN 46202 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychol, Indianapolis, IN 46202 USA; [Harezlak, Jaroslaw] Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Bloomington, IN USA; [Koch, Kevin M.; Nencka, Andrew S.] Med Coll Wisconsin, Dept Radiol, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Meier, Timothy B.; McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp UCLA Los Angeles, Dept Neurosurg,Div Pediat Neurol, Los Angeles, CA 90095 USA; [DiFiori, John P.] Univ Calif Los Angeles, Dept Family Med, Div Sports Med, Los Angeles, CA USA; [DiFiori, John P.] Univ Calif Los Angeles, Dept Orthoped, Div Sports Med, Los Angeles, CA USA; [Guskiewicz, Kevin M.; Mihalik, Jason P.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA; [LaConte, Stephen M.] Wake Forest & Virginia Tech Univ, Virginia Tech, Carilion Res Inst, Sch Biomed Engn & Sci, Roanoke, VA USA; [Duma, Stefan M.] Wake Forest & Virginia Tech Univ, Sch Biomed Engn & Sci, Blacksburg, VA USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA	Wu, YC (corresponding author), Indiana Univ Sch Med, Dept Radiol & Imaging Sci, 355 West 16th St,Suite 4100, Indianapolis, IN 46202 USA.	yucwu@iupui.edu	Koch, Kevin/AAD-6403-2021; Harezlak, Jaroslaw/P-8557-2014	Harezlak, Jaroslaw/0000-0002-3070-7686	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Department of Defense (DOD)United States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS075791, R01 AG053993, P30 AG010133, R01 AG019771]; ICTSI NIH/NCRR [UL1TR001108]; U.S. Army Medical Research Acquisition Activity (Chandler Street, Fort Detrick, MD); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG053993, P30AG010133, R01AG019771] Funding Source: NIH RePORTER	This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded, in part, by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DOD). The U.S. Army Medical Research Acquisition Activity (820 Chandler Street, Fort Detrick, MD 21702-5014) is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award NO W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (DHP funds). Other funding supports include National Institutes of Health grant R21 NS075791 (to Y.C.W. and T.W.M.), R01 AG053993 (to Y.C.W.), P30 AG010133 and R01 AG019771 (to A.J.S.), and a Project Development Team within the ICTSI NIH/NCRR Grant Number UL1TR001108 (to Y.C.W.).	Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; Andersson JLR, 2016, NEUROIMAGE, V125, P1063, DOI 10.1016/j.neuroimage.2015.10.019; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2005, NEUROIMAGE, V27, P48, DOI 10.1016/j.neuroimage.2005.03.042; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cabeen RP, 2017, NEUROIMAGE, V146, P100, DOI 10.1016/j.neuroimage.2016.11.020; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Derogatis L. R., 1993, BSI BRIEF SYMPTOM IN; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Field AS, 2004, J MAGN RESON IMAGING, V20, P555, DOI 10.1002/jmri.20169; Fieremans E, 2011, NEUROIMAGE, V58, P177, DOI 10.1016/j.neuroimage.2011.06.006; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Goni J, 2014, P NATL ACAD SCI USA, V111, P833, DOI 10.1073/pnas.1315529111; Goni J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058070; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones D.K, 2011, DIFFUSION MRI THEORY, p[1, xvi]; Jones DK, 2008, CORTEX, V44, P936, DOI 10.1016/j.cortex.2008.05.002; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Kinoshita M, 2010, J NEURO-ONCOL, V96, P409, DOI 10.1007/s11060-009-9979-0; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koschutzki D, 2008, GENE REGUL SYST BIO, V2, P193; Lancaster MA, 2016, HUM BRAIN MAPP, V37, P3821, DOI 10.1002/hbm.23278; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2009, IEEE ENG MED BIO, P1113, DOI 10.1109/IEMBS.2009.5334457; Lee JE, 2007, NEUROSCI LETT, V424, P127, DOI 10.1016/j.neulet.2007.07.042; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Manjon JV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073021; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1996, STANDARDIZED ASSESSM; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Meier TB, 2016, HUM BRAIN MAPP, V37, P833, DOI 10.1002/hbm.23072; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Nencka AS, 2018, BRAIN IMAGING BEHAV, V12, P1121, DOI 10.1007/s11682-017-9775-y; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Pan J, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15607; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Rocca MA, 2016, MULT SCLER J, V22, P620, DOI 10.1177/1352458515596600; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Simon CM, 2009, J NEUROTRAUM, V26, P563, DOI 10.1089/neu.2008.0523; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Sporns O, 2016, ANNU REV PSYCHOL, V67, P613, DOI 10.1146/annurev-psych-122414-033634; Suri AK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142288; Thomas AW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178360; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Tournier JD, 2008, NEUROIMAGE, V42, P617, DOI 10.1016/j.neuroimage.2008.05.002; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Tustison NJ, 2014, NEUROIMAGE, V99, P166, DOI 10.1016/j.neuroimage.2014.05.044; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wechsler D., 1987, MANUAL WECHSLER ADUL; Westlye LT, 2010, CEREB CORTEX, V20, P2055, DOI 10.1093/cercor/bhp280; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wu Y.C., 2006, MED PHYS, P150; Wu YC, 2011, NEUROIMAGE, V58, P829, DOI 10.1016/j.neuroimage.2011.06.067; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	88	30	31	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2018	35	22					2653	2664		10.1089/neu.2017.5158			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GZ0MO	WOS:000449057900005	29065805	Green Published			2021-06-18	
J	Khoshnam, SE; Sarkaki, A; Rashno, M; Farbood, Y				Khoshnam, Seyed Esmaeil; Sarkaki, Alireza; Rashno, Masome; Farbood, Yaghoob			Memory deficits and hippocampal inflammation in cerebral hypoperfusion and reperfusion in male rats: Neuroprotective role of vanillic acid	LIFE SCIENCES			English	Article						Vanillic acid; Ischemic stroke; Spatial memory; Hippocampus; IL-6; TNF-alpha; IL-10; Rat	TRANSIENT FOREBRAIN ISCHEMIA; CAROTID-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; POTASSIUM CONDUCTANCE; THERAPEUTIC TARGETS; VASCULAR DEMENTIA; OXIDATIVE STRESS; NEURONAL DAMAGE; SPATIAL MEMORY; GALLIC ACID	Ischemic stroke is one of the leading causes of neurological deterioration and mortality worldwide. Neuroprotective strategies are being investigated to minimize cognitive deficits after ischemic events. Here we investigated the neuroprotective potential of vanillic acid (VA) in an animal model of transient bilateral common carotid artery occlusion and reperfusion (BCCAO/R). Adult male Wistar rats (250-300 g) were randomly divided in 4 groups and submitted to either cerebral hypoperfusion-reperfusion or a sham surgery after two-weeks of pretreatment with VA and/or normal saline. To induce the animal model of hypoperfusion, bilateral common carotid arteries were occluded (2VO model) for 30 min, followed by 72 h of reperfusion. Subsequently, their cognitive performance was evaluated in a Morris water maze (MWM) test, and also hippocampi were removed for ELISA assays and TUNEL staining test. The results showed that 2VO significantly reduced the spatial memory performance in MWM. As well as, BCCAO/R increased the level of IL-6, TNF-alpha and TUNEL positive cells, and also decreased the contents of IL-10 in the hippocampus of vehicle- pretreated groups as compared to the sham-operated groups. Furthermore, 14 consecutive days pretreatment with VA significantly restored the spatial memory, decreased the levels of IL-6, TNF-alpha and TUNEL positive cells and also increased the IL-10 levels in the hippocampi of the BCCAO/R rats. VA alone did not show any change neither in the status of various cytokines nor behavioral and TUNEL staining tests over sham values. Our data confirm that VA could potentially serve as a novel, promising, and accessible neuroprotective agent against cerebrovascular insufficiency states and vascular dementia.	[Khoshnam, Seyed Esmaeil; Sarkaki, Alireza; Rashno, Masome; Farbood, Yaghoob] Ahvaz Jundishapur Univ Med Sci, Dept Physiol, Fac Med, Physiol Res Ctr, Ahwaz, Iran	Farbood, Y (corresponding author), Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Physiol, Physiol Res Ctr, Ahwaz, Iran.	farbood_y@yahoo.com	Khoshnam, Seyed Esmaeil/M-8868-2017; Rashno, Masome/AAW-6382-2020; Farbood, Yaghoob/M-3076-2017	Khoshnam, Seyed Esmaeil/0000-0002-3834-4242; Rashno, Masome/0000-0002-1290-3499; Farbood, Yaghoob/0000-0002-6390-0079; rashno, mohammad/0000-0001-5473-1384	Ahvaz Jundishapur University of Medical Sciences [APRC-95-17]	This paper was extracted as a part of Seyed Esmaeil Khoshnam's Ph.D. thesis. The study was financially supported by research affairs of Ahvaz Jundishapur University of Medical Sciences (Grant No. APRC-95-17). Authors have no conflict of interest.	Aboutaleb N, 2014, INT J PEPT RES THER, V20, P127, DOI 10.1007/s10989-013-9374-8; Arisi GM, 2014, EPILEPSY BEHAV, V38, P43, DOI 10.1016/j.yebeh.2014.01.017; Bielewicz J., 2009, WIADOMOSCI LEKARSKIE, V63, P213; Block F, 1999, PROG NEUROBIOL, V58, P279, DOI 10.1016/S0301-0082(98)00085-9; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Calixto-Campos C, 2015, J NAT PROD, V78, P1799, DOI 10.1021/acs.jnatprod.5b00246; Chen S, 2014, PHARMACOL BIOCHEM BE, V122, P7, DOI 10.1016/j.pbb.2014.03.004; Collino M, 2006, EUR J PHARMACOL, V530, P70, DOI 10.1016/j.ejphar.2005.11.049; Delaquis P, 2005, J FOOD PROTECT, V68, P1472, DOI 10.4315/0362-028X-68.7.1472; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Dhananjaya BL, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1315, DOI 10.1134/S0006297909120037; Doll DN, 2014, AGING DIS, V5, P294, DOI 10.14336/AD.2014.0500294; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; Erdemli G, 1998, J NEUROPHYSIOL, V80, P2378; Farbood Y, 2015, LIFE SCI, V124, P120, DOI 10.1016/j.lfs.2015.01.013; Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003; Ghaderinezhad F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02931-6; Gheibi S, 2014, J MOL NEUROSCI, V54, P264, DOI 10.1007/s12031-014-0284-9; HANSEN AJ, 1982, ACTA PHYSIOL SCAND, V115, P301, DOI 10.1111/j.1748-1716.1982.tb07082.x; Hori E, 2002, COGNITIVE BRAIN RES, V13, P1, DOI 10.1016/S0926-6410(01)00083-0; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Itoh T, 1999, MECH AGEING DEV, V111, P155, DOI 10.1016/S0047-6374(99)00062-7; Jia H, 2012, NEUROL SCI, V33, P1063, DOI 10.1007/s10072-011-0898-4; Jordan J, 2008, CURR PHARM DESIGN, V14, P3549, DOI 10.2174/138161208786848766; Kam A, 2012, CURR MED CHEM, V19, P1830, DOI 10.2174/092986712800099794; Khorsandi L, 2016, BALK MED J, V33, P252, DOI 10.5152/balkanmedj.2016.150017; Khoshnam S. E., 2017, NEUROL SCI, P1; Khoshnam SE, 2018, METAB BRAIN DIS, P1; Khoshnam SE, 2017, BIOMED PHARMACOTHER, V96, P667, DOI 10.1016/j.biopha.2017.10.052; Khoshnam SE, 2017, J NEUROPATH EXP NEUR, V76, P548, DOI 10.1093/jnen/nlx036; Khoshnam SE, 2017, J STROKE, V19, P166, DOI 10.5853/jos.2016.01368; Kim MC, 2011, IMMUNOPHARM IMMUNOT, V33, P525, DOI 10.3109/08923973.2010.547500; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Korani MS, 2014, EUR J PHARMACOL, V733, P62, DOI 10.1016/j.ejphar.2014.03.044; Mattila P, 2002, J AGR FOOD CHEM, V50, P3660, DOI 10.1021/jf020028p; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Niimura M, 2006, J CEREBR BLOOD F MET, V26, P1354, DOI 10.1038/sj.jcbfm.9600287; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Peers C, 2009, ANN NY ACAD SCI, V1177, P169, DOI 10.1111/j.1749-6632.2009.05026.x; Prince PSM, 2011, EUR J PHARMACOL, V668, P233, DOI 10.1016/j.ejphar.2011.06.053; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Sarkaki A, 2015, CAN J PHYSIOL PHARM, V93, P687, DOI 10.1139/cjpp-2014-0546; Sarti C, 2002, J NEUROL SCI, V203, P263, DOI 10.1016/S0022-510X(02)00302-7; Sarti C, 2002, BEHAV BRAIN RES, V136, P13, DOI 10.1016/S0166-4328(02)00090-6; Singh JCH, 2015, PHARM BIOL, V53, P630, DOI 10.3109/13880209.2014.935866; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; Tai A, 2012, BIOSCI BIOTECH BIOCH, V76, P314, DOI 10.1271/bbb.110700; Taoufik E, 2008, CURR PHARM DESIGN, V14, P3565, DOI 10.2174/138161208786848748; Vakili A, 2011, BRAIN RES, V1377, P119, DOI 10.1016/j.brainres.2011.01.001; Varma R. S., 1993, Indian Journal of Experimental Biology, V31, P819; Vila N, 2003, STROKE, V34, P671, DOI 10.1161/01.STR.0000057976.53301.69; Wang LM, 2000, EUR J PHARMACOL, V398, P65, DOI 10.1016/S0014-2999(00)00291-0; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Xia WL, 2010, CLIN EXP PHARMACOL P, V37, P253, DOI 10.1111/j.1440-1681.2009.05279.x; Xu X, 2012, NEUROSCIENCE, V206, P136, DOI 10.1016/j.neuroscience.2011.12.050; Yasuda Y, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-70; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Zhang HB, 2013, NEURAL REGEN RES, V8, P916, DOI 10.3969/j.issn.1673-5374.2013.10.006; Zhang X, 2010, EXP NEUROL, V223, P299, DOI 10.1016/j.expneurol.2009.07.033; Zhu X.-f., 2010, MED RECAPITULATE, V18	63	30	31	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	OCT 15	2018	211						126	132		10.1016/j.lfs.2018.08.065			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	GV4KO	WOS:000446068200014	30195619				2021-06-18	
J	Andelic, N; Howe, EI; Hellstrom, T; Sanchez, MF; Lu, J; Lovstad, M; Roe, C				Andelic, Nada; Howe, Emilie, I; Hellstrom, Torgeir; Sanchez, Maria Fernandez; Lu, Juan; Lovstad, Marianne; Roe, Cecilie			Disability and quality of life 20 years after traumatic brain injury	BRAIN AND BEHAVIOR			English	Article						functional outcomes; long-term follow-up; quality of life; traumatic brain injury	SF-36 HEALTH SURVEY; MODERATE; PREDICTORS; OUTCOMES; ADULTS	Objectives: The study describes functional outcomes and health-related quality of life (HRQL) in patients with traumatic brain injury (TBI) 20 years postinjury. Materials and Methods: Forty-four survivors who acquired moderate and severe TBI during 1995-1996 were followed 10 and 20 years postinjury. Outcomes were Glasgow Outcome Scale Extended (GOSE), Community Integration Questionnaire (CIQ), and SF-36 questionnaire (SF-36). Multiple regressions were performed to examine the relationship between follow-up measurements, controlling for baseline demographics and injury severity. Results: There were no significant differences in baseline age and civil status between moderate and severe TBI, but patients with severe injury had significantly lower employment rates (p = 0.05). Mean age at 20-years follow-up was 50.8 (SD 11.4) years, and 73% were males. Most patients showed good recovery (52%) or moderate disability (43%). Disability levels remained stable between and within severity groups from 10 to 20 years. Community integration including social integration improved from 10 to 20 years (p = 0.01 and p = 0.005, respectively). HRQL remained stable, except for subscales Bodily Pain and Role Emotional (p = 0.02 and p = 0.06). Depression at 10 years and females were associated with poorer mental health, while productive activity at 10 years indicated better physical and mental health at 20 years postinjury, respectively. Conclusions: Functional limitations persist even decades after moderate and severe TBI, with poorer prognosis for females and persons who were depressed at the 10-year follow-up. Development and evaluation of targeted long-term follow-up programs and access to rehabilitation services for these groups should be highlighted. Improved community integration despite stable functional limitations draws attention to long-term adaptation to adversity and illness.	[Andelic, Nada; Howe, Emilie, I; Hellstrom, Torgeir; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Andelic, Nada; Lu, Juan] Univ Oslo, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, Oslo, Norway; [Howe, Emilie, I; Roe, Cecilie] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Sanchez, Maria Fernandez] Univ Salamanca, Fac Psychol, Inst Community Integrat INICO, Salamanca, Spain; [Lu, Juan] Virginia Commonwealth Univ, Dept Family Med & Populat Hlth, Div Epidemiol, Richmond, VA USA; [Lovstad, Marianne] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway; [Lovstad, Marianne] Univ Oslo, Dept Psychol, Oslo, Norway	Howe, EI (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway.	emilie.howe@medisin.uio.no	Fernandez, Maria/H-2632-2018	Fernandez, Maria/0000-0002-3398-6086; Lu, Juan/0000-0002-5389-7603; Andelic, Nada/0000-0002-3719-4406			Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2016, J NEUROTRAUM, V33, P95, DOI 10.1089/neu.2014.3844; Beck A T, 1974, Mod Probl Pharmacopsychiatry, V7, P151; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Dahm J, 2015, INJURY, V46, P142, DOI 10.1016/j.injury.2014.07.012; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Forslund MV, 2017, BRAIN INJURY, V31, P329, DOI 10.1080/02699052.2016.1255778; Gray M, 2018, ARCH PHYS MED REHAB, V99, pS33, DOI 10.1016/j.apmr.2017.08.465; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jourdan C, 2016, ANN PHYS REHABIL MED, V59, P100, DOI 10.1016/j.rehab.2015.10.009; Lexell J, 2016, BRAIN INJURY, V30, P969, DOI 10.3109/02699052.2016.1148196; Loge JH, 1998, SCAND J SOC MED, V26, P250; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Sandhaug M, 2015, BRAIN INJURY, V29, P915, DOI 10.3109/02699052.2015.1022880; Schulz-Heik RJ, 2016, BRAIN INJURY, V30, P271, DOI 10.3109/02699052.2015.1113567; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Soberg HL, 2015, J TRAUMA ACUTE CARE, V78, P628, DOI 10.1097/TA.0000000000000541; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TEASDALE G, 1974, LANCET, V2, P81; Tuominen R, 2012, BRAIN INJURY, V26, P1697, DOI 10.3109/02699052.2012.722256; WARE JE, 1994, INT J MENT HEALTH, V23, P49, DOI 10.1080/00207411.1994.11449283; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540	37	30	30	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	JUL	2018	8	7								10.1002/brb3.1018			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	GM8PT	WOS:000438495400012	29888869	DOAJ Gold, Green Published			2021-06-18	
J	Lawrence, DW; Richards, D; Comper, P; Hutchison, MG				Lawrence, David Wyndham; Richards, Doug; Comper, Paul; Hutchison, Michael G.			Earlier time to aerobic exercise is associated with faster recovery following acute sport concussion	PLOS ONE			English	Article							PROPENSITY SCORE METHODS; REST; SYMPTOMS; METAANALYSIS; OUTCOMES; CHILDREN; ADULTS	Objective To determine whether earlier time to initiation of aerobic exercise following acute concussion is associated with time to full return to (1) sport and (2) school or work. Methods A retrospective stratified propensity score survival analysis of acute (<= 14 days) concussion was used to determine whether time (days) to initiation of aerobic exercise post-concussion was associated with, both, time (days) to full return to (1) sport and (2) school or work. Results A total of 253 acute concussions [median (IQR) age, 17.0 (15.0-20.0) years; 148 (58.5%) males] were included in this study. Multivariate Cox regression models identified that earlier time to aerobic exercise was associated with faster return to sport and school/work adjusting for other covariates, including quintile propensity strata. For each successive day in delay to initiation of aerobic exercise, individuals had a less favourable recovery trajectory. Initiating aerobic exercise at 3 and 7 days following injury was associated with a respective 36.5% (HR, 0.63; 95% CI, 0.53-0.76) and 73.2% (HR, 0.27; 95% CI, 0.16-0.45) reduced probability of faster full return to sport compared to within 1 day; and a respective 45.9% (HR, 0.54; 95% CI, 0.44-0.66) and 83.1% (HR, 0.17; 95% CI, 0.10-0.30) reduced probability of faster full return to school/work. Additionally, concussion history, symptom severity, LOC deleteriously influenced concussion recovery. Conclusion Earlier initiation of aerobic exercise was associated with faster full return to sport and school or work. This study provides greater insight into the benefits and safety of aerobic exercise within the first week of the injury.	[Lawrence, David Wyndham; Richards, Doug; Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Lawrence, David Wyndham; Comper, Paul] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada; [Lawrence, David Wyndham] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada	Lawrence, DW (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada.; Lawrence, DW (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada.; Lawrence, DW (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.	dw.lawrence@mail.utoronto.ca					Austin PC, 2006, STAT MED, V25, P2084, DOI 10.1002/sim.2328; Austin PC, 2014, STAT MED, V33, P1242, DOI 10.1002/sim.5984; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bidonde J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012700; Buckley TA, 2016, J HEAD TRAUMA REHAB, V31, P233, DOI 10.1097/HTR.0000000000000165; Chieffi S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00188; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Dobney DM, 2017, BRAIN INJURY, V31, P1753, DOI 10.1080/02699052.2017.1346294; EDMONDS M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003200.PUB2; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Hsu CL, 2018, BRIT J SPORT MED, V52, P184, DOI 10.1136/bjsports-2016-096846; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Krogh J, 2011, J CLIN PSYCHIAT, V72, P529, DOI 10.4088/JCP.08r04913blu; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Lal A, 2018, AM J SPORT MED, V46, P743, DOI 10.1177/0363546517706137; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, 5 INT C CONC SPORT H; McDonnell MN, 2011, ARCH PHYS MED REHAB, V92, P1044, DOI 10.1016/j.apmr.2011.01.021; Moor HM, 2015, INT J SPORTS PHYS TH, V10, P225; Pang MYC, 2013, CEREBROVASC DIS, V35, P7, DOI 10.1159/000346075; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Winters-Stone KM, 2014, BRIT J SPORT MED, V48, P987, DOI 10.1136/bjsports-2012-091732; Wipfli BM, 2008, J SPORT EXERCISE PSY, V30, P392, DOI 10.1123/jsep.30.4.392	34	30	31	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2018	13	4							e0196062	10.1371/journal.pone.0196062			12	Multidisciplinary Sciences	Science & Technology - Other Topics	GD1VU	WOS:000430290200076	29668716	DOAJ Gold, Green Published			2021-06-18	
J	Sun, LQ; Liu, AH; Zhang, JB; Ji, WJ; Li, YX; Yang, XJ; Wu, ZX; Guo, J				Sun, Liqian; Liu, Aihua; Zhang, Jingbo; Ji, Wenjun; Li, Youxiang; Yang, Xinjian; Wu, Zhongxue; Guo, Jian			miR-23b improves cognitive impairments in traumatic brain injury by targeting ATG12-mediated neuronal autophagy	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Cognitive impairments; miR-23b; ATG12; Autophagy	DOWN-REGULATION; CELL-DEATH; ACTIVATION; EXPRESSION; MODEL	Dysregulated microRNAs (miRNAs) have been reported to involve in the pathophysiological process of traumatic brain injury (TBI), and modulate autophagy-related genes (ATGs) expression. Our previous studies showed that neuronal autophagy was activated in the injury hippocampus post-TBI and associated with neurological and cognitive impairments. The present study was designed to investigate the possible role of miR-23b in TBI-induced cognitive impairments. We found the overexpression of miR-23b conferred a better neuronprotective effects after TBI by decreasing lesion volume, alleviating brain edema, inhibiting neuron apoptosis and attenuating long-term neurological deficits, and most interestingly, improving cognitive impairments. To further explore the molecular underlying this neuronprotection, we evaluated autophagic activity and ATG12 expression in the injury hippocampus CA1 region. The results identified that miR-23b directly targeted to the 3'UTR region of ATG12 mRNA to suppress the activation of neuronal autophagy by a dual-luciferase reporter system. Notably, overexpression of ATG12 abrogated the neuronprotective effects of miR-23b on TBI-induced neurological and cognitive impairments. Taken together, these date revealed inhibition of ATG12-mediated autophagic activity by miR-23b overexpression might be involve in cognitive improvement after TBI, indicating that miR-23b might be a potential therapeutic target for TBI. (C) 2016 Published by Elsevier B.V.	[Sun, Liqian; Liu, Aihua; Zhang, Jingbo; Ji, Wenjun; Li, Youxiang; Yang, Xinjian; Wu, Zhongxue] Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing 100050, Peoples R China; [Sun, Liqian; Liu, Aihua; Zhang, Jingbo; Ji, Wenjun; Li, Youxiang; Yang, Xinjian; Wu, Zhongxue] Capital Med Univ, Beijing Tiantan Hosp, Beijing 100050, Peoples R China; [Guo, Jian] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Neurosurg, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China	Guo, J (corresponding author), Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Neurosurg, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.	slg20000@126.com		Yang, Xinjian/0000-0001-7306-0125	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171078]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2015M580117]; Beijing Postdoctoral Research FoundationChina Postdoctoral Science Foundation [2015ZZ-49, 2016ZZ-38]	This work was supported by a grant from the National Natural Science Foundation of China (81171078), the China Postdoctoral Science Foundation (2015M580117), the Project supported by Beijing Postdoctoral Research Foundation (2015ZZ-49 and 2016ZZ-38).	Ayyadurai S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087614; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Comincini S, 2013, CANCER BIOL THER, V14, P574, DOI 10.4161/cbt.24597; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Haar C. V., 2012, BEHAV BRAIN RES, V240, P153; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200; Hu Z., 2012, PLOS ONE, V7, P1495; Jiang JD, 2013, ONCOL REP, V30, P2105, DOI 10.3892/or.2013.2712; Kawasaki H, 2003, NATURE, V423, P838, DOI 10.1038/nature01730; Kimura Hitomi, 2004, Nucleic Acids Symp Ser (Oxf), P213; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li S. F., 2016, WORLD J GASTROENTERO, V22; Li W., 2016, FEBS LETT; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Liu L., 2014, ADV DIFFER EQU, V217, P9, DOI DOI 10.1371/J0URNAL.P0NE.0103948; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meissner Lilja, 2015, J NEUROTRAUMA; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Pan BZ, 2015, ONCOTARGET, V6, P32805, DOI 10.18632/oncotarget.5352; Reimunde P, 2011, BRAIN INJURY, V25, P65, DOI 10.3109/02699052.2010.536196; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Sun KT, 2015, BONE, V73, P145, DOI 10.1016/j.bone.2014.11.026; Sun LQ, 2015, MOL MED REP, V11, P4419, DOI 10.3892/mmr.2015.3264; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Sun LQ, 2015, BEHAV BRAIN RES, V291, P315, DOI 10.1016/j.bbr.2015.05.049; Sun LQ, 2014, NEUROL SCI, V35, P677, DOI 10.1007/s10072-013-1575-6; Suzuki NN, 2005, AUTOPHAGY, V1, P119, DOI 10.4161/auto.1.2.1859; Taheri S., 2016, J NEUROTRAUMA; Tanriverdi F, 2015, ENDOCR REV, V36, P305, DOI 10.1210/er.2014-1065; Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhao HP, 2013, STROKE, V44, P1706, DOI 10.1161/STROKEAHA.111.000504	39	30	34	1	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 15	2018	340				SI		126	136		10.1016/j.bbr.2016.09.020			11	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FU9JY	WOS:000424173400015	27630106				2021-06-18	
J	Theadom, A; Starkey, N; Barker-Collo, S; Jones, K; Ameratunga, S; Feigin, V				Theadom, Alice; Starkey, Nicola; Barker-Collo, Suzanne; Jones, Kelly; Ameratunga, Shanthi; Feigin, Valery		BIONIC4you Res Grp	Population-based cohort study of the impacts of mild traumatic brain injury in adults four years post-injury	PLOS ONE			English	Article							POST-CONCUSSION SYMPTOMS; HEAD-INJURY; HOSPITAL ANXIETY; NEW-ZEALAND; PARTICIPATION; MODERATE; QUESTIONNAIRE; PREDICTORS; DEPRESSION; VALIDITY	There is increasing evidence that some people can experience persistent symptoms for up to a year following mild TBI. However, few longitudinal studies of mild TBI exist and the longer-term impact remains unclear. The purpose of this study is to determine if there are long-term effects of mild traumatic brain injury (TBI) four-years later. Adults (aged >= 16 years) identified as part of a TBI incidence study who experienced a mild-TBI four-years ago (N = 232) were compared to age-sex matched controls (N = 232). Sociodemographic variables, prior TBI and symptoms were assessed at the time of injury. Four years post-injury participants completed the Rivermead Post-Concussion Symptom Questionnaire, Hospital Anxiety and Depression Scale, Pittsburgh Sleep Quality Index and the Participation Assessment with Recombined Tools. Analysis of covariance was used to compare differences between TBI cases four years post-injury and controls, controlling for prior TBI and depression. A multiple regression model was used to identify the predictors of increased symptoms and reduced participation. The mild-TBI sample experienced significantly increased self-reported cognitive symptoms (F = 19.90, p = < 0.01) four years post-injury than controls. There were no differences between the groups for somatic (F = 0.02, p = 0.89) or emotional symptoms (F = 0.31, p = 0.58). Additionally, the mild-TBI group reported significantly poorer community participation across all three domains: productivity (F = 199.07, p = < 0.00), social relations (F = 13.93, p = < 0.00) and getting out and about (F = 364.69, p = < 0.00) compared to controls. A regression model accounting for 41% of the variance in cognitive symptoms in TBI cases revealed a history of TBI, receiving acute medical attention and baseline cognitive symptoms, sleep quality, anxiety and depression were predictive of outcome. The results indicate that whilst somatic and emotional symptoms resolve over time, cognitive symptoms can become persistent and that mild TBI can impact longer-term community participation. Early intervention is needed to reduce the longer-term impact of cognitive symptoms and facilitate participation.	[Theadom, Alice; Jones, Kelly; Feigin, Valery] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Starkey, Nicola] Univ Waikato, Dept Psychol, Knighton Rd, Waikato, New Zealand; [Barker-Collo, Suzanne] Univ Auckland, Dept Psychol, Auckland, New Zealand; [Ameratunga, Shanthi] Univ Auckland, Sch Populat Hlth, Auckland, New Zealand	Theadom, A (corresponding author), Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand.	alice.theadom@aut.ac.nz	Jones, Kelly/I-5199-2019; Starkey, Nicola/AAJ-3795-2020; Feigin, Valery/AAF-2313-2019	Starkey, Nicola/0000-0002-4370-8186; Theadom, Alice/0000-0003-0351-6216; Feigin, Valery L./0000-0002-6372-1740	Health Research Council of New ZealandHealth Research Council of New Zealand [13/408]	This work was supported by Health Research Council of New Zealand 13/408 to VF.	Barker-Collo S, 2015, BRAIN INJURY, V29, P1604, DOI 10.3109/02699052.2015.1075143; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Gilworth G, 2008, J REHABIL MED, V40, P334, DOI 10.2340/16501977-0169; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Hopkins WG., 2002, NEW VIEW STAT; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/316575; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirsch NL, 2010, ARCH PHYS MED REHAB, V91, P35, DOI 10.1016/j.apmr.2009.09.019; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Matuseviciene G, 2016, J REHABIL MED, V48, P19, DOI 10.2340/16501977-2025; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sveen U, 2016, DISABIL REHABIL, V38, P2296, DOI 10.3109/09638288.2015.1129445; Te Ao B, 2014, NEUROLOGY, V83, P1645, DOI 10.1212/WNL.0000000000000933; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Theadom A, 2017, ARCH PHYS MED REHAB, V98, P1560, DOI 10.1016/j.apmr.2017.01.010; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	37	30	31	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2018	13	1							e0191655	10.1371/journal.pone.0191655			13	Multidisciplinary Sciences	Science & Technology - Other Topics	FU2GT	WOS:000423668400052	29385179	DOAJ Gold, Green Published			2021-06-18	
J	Gao, C; Qian, Y; Huang, JH; Wang, D; Su, WQ; Wang, P; Guo, LY; Quan, W; An, S; Zhang, JN; Jiang, RC				Gao, Chuang; Qian, Yu; Huang, Jinhao; Wang, Dong; Su, Wanqiang; Wang, Peng; Guo, Linyue; Quan, Wei; An, Shuo; Zhang, Jianning; Jiang, Rongcai			A Three-Day Consecutive Fingolimod Administration Improves Neurological Functions and Modulates Multiple Immune Responses of CCI Mice	MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury (TBI); Fingolimod; Immuno-inflammatory response; Regulatory T cell (Treg); Macrophage/microglia subtype; Cytokine array	TRAUMATIC BRAIN-INJURY; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; CENTRAL-NERVOUS-SYSTEM; REGULATORY T-CELLS; MACROPHAGE SUBSETS; WHITE-MATTER; FTY720; RECRUITMENT; NEUROTOXICITY; DEGENERATION	Excessive inflammation after traumatic brain injury (TBI) is a major cause of secondary TBI. Though several inflammatory biomarkers have been postulated as the risk factors of TBI, there has not been any comprehensive description of them. Fingolimod, a new kind of immunomodulatory agent which can diminish various kinds of inflammatory responses, has shown additional therapeutic effects in the treatment of intracranial cerebral hematoma (ICH), ischemia, spinal cord injury (SCI), and many other CNS disorders. However, its therapeutic application has not been confirmed in TBI. Thus, we hypothesized that a 3-day consecutive fingolimod administration could broadly modulate the inflammatory reactions and improve the outcomes of TBI. The TBI models of C57/BL6 mice were established with the controlled cortical impact injury (CCI) system. A 3-day consecutive fingolimod therapy (given at 1, 24, and 48 h post injury) was performed at a dose of 1 mg/kg. The flow cytometry, immunoflourence, cytokine array, and ELISA were all applied to evaluate the immune cells and inflammatory markers in the injured brains. Immunohistochemical staining with anti-APP antibody was performed to assess the axonal damage. The neurological functions of these TBI models were assessed by mNSS/Rota-rod and Morris water maze (MWM). The brain water content and integrity of the blood-brain barrier (BBB) were also observed. On the 3rd day after TBI, the accumulation of inflammatory cytokines and chemokines reached the peak and administration of fingolimod reduced as many as 20 kinds of cytokines and chemokines. Fingolimod decreased infiltrated T lymphocytes and NK cells but increased the percentage of regulatory T (Treg) cells, and the concentration of IL-10 on the 3rd day after TBI. Fingolimod also notably attenuated the general activated microglia but augmented the M2/M1 ratio accompanied by decreased axonal damage. The neurological functions were improved after the fingolimod treatment accompanied with alleviation of the brain edema and BBB damage. This study suggests that the 3-day consecutive fingolimod administration extensively modulates multiple immuno-inflammatory responses and improves the neurological deficits after TBI, and therefore, it may be a new approach to the treatment of secondary TBI.	[Gao, Chuang; Qian, Yu; Huang, Jinhao; Wang, Dong; Su, Wanqiang; Wang, Peng; Guo, Linyue; Quan, Wei; An, Shuo; Zhang, Jianning; Jiang, Rongcai] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Gao, Chuang; Qian, Yu; Huang, Jinhao; Wang, Dong; Su, Wanqiang; Wang, Peng; Guo, Linyue; Quan, Wei; An, Shuo; Zhang, Jianning; Jiang, Rongcai] Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin, Peoples R China	Jiang, RC (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.; Jiang, RC (corresponding author), Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin, Peoples R China.	jiang116216@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271359, 81330059, 81671380]; Ontario-China Research and Innovation Fund (OCRIF) [2011DFG33430]; Tianjin Research Program of Application Foundation and Advanced Technology [14ZCZDSY00179]	We are grateful to Guoqiang Chang, Guili Yang, Weiyun Cui, Lei Zhou, and Li Liu from the Tianjin Neurological Institute for their assistance with the experiments and data analyses. This work was supported by the National Natural Science Foundation of China (grant81271359, 81330059, and 81671380), the Ontario-China Research and Innovation Fund (OCRIF, 2011DFG33430), and the Tianjin Research Program of Application Foundation and Advanced Technology (grant 14ZCZDSY00179).	[Anonymous], 2012, J NEUROINFLAMM, V7, P9; Bai XF, 2004, J EXP MED, V200, P447, DOI 10.1084/jem.20040131; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Brunkhorst R, 2014, FRONT CELL NEUROSCI, V8, DOI [10.3389/frice1.2014.00283, 10.3389/fncel.2014.00283]; Budde K, 2003, AM J TRANSPLANT, V38, P683; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Fu Y, 2014, JAMA NEUROL, V71, P1092, DOI 10.1001/jamaneurol.2014.1065; Gerbatin RD, 2017, MOL NEUROBIOL, V54, P7585, DOI 10.1007/s12035-016-0238-z; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hawryluk GWJ, 2016, NEUROSURG CLIN N AM, V27, P375, DOI 10.1016/j.nec.2016.05.002; Helmy A, 2016, J CEREBR BLOOD F MET, V36, P1434, DOI 10.1177/0271678X15620204; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Lee KD, 2009, J NEUROTRAUM, V26, P2335, DOI 10.1089/neu.2008.0840; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li MY, 2015, CHINESE MED J-PEKING, V128, P2019, DOI 10.4103/0366-6999.161351; Li PY, 2013, ANN NEUROL, V74, P458, DOI 10.1002/ana.23815; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Mencl S, 2014, J NEUROIMMUNOL, V274, P125, DOI 10.1016/j.jneuroim.2014.07.010; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Noda H, 2013, J NEUROIMMUNOL, V256, P13, DOI 10.1016/j.jneuroim.2012.12.005; Rolland WB, 2013, EXP NEUROL, V241, P45, DOI 10.1016/j.expneurol.2012.12.009; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Slowik A, 2015, BRIT J PHARMACOL, V172, P80, DOI 10.1111/bph.12938; Soares HD, 1995, J NEUROSCI, V15, P8223; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Taams LS, 2005, HUM IMMUNOL, V66, P222, DOI 10.1016/j.humimm.2004.12.006; Tang ZW, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-26; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walsh JT, 2015, J CLIN INVEST, V125, P699, DOI [10.1172/JCI176210, 10.1172/JCI76210]; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wei Y, 2011, ANN NEUROL, V69, P119, DOI 10.1002/ana.22186; Zhang L, 2016, CELL MOL NEUROBIOL, V36, P131, DOI 10.1007/s10571-015-0227-1; Zhang Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-79; Zhang Z, 2008, NEUROPATH APPL NEURO, V34, P330, DOI 10.1111/j.1365-2990.2007.00893.x; Zhang ZY, 2007, J CELL MOL MED, V11, P307, DOI 10.1111/j.1582-4934.2007.00019.x	51	30	31	2	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	DEC	2017	54	10					8348	8360		10.1007/s12035-016-0318-0			13	Neurosciences	Neurosciences & Neurology	FM8MF	WOS:000415341900064					2021-06-18	
J	Hsieh, TH; Lee, HHC; Hameed, MQ; Pascual-Leone, A; Hensch, TK; Rotenberg, A				Hsieh, Tsung-Hsun; Lee, Henry Hing Cheong; Hameed, Mustafa Qadir; Pascual-Leone, Alvaro; Hensch, Takao K.; Rotenberg, Alexander			Trajectory of Parvalbumin Cell Impairment and Loss of Cortical Inhibition in Traumatic Brain Injury	CEREBRAL CORTEX			English	Article						intracortical inhibition; Otx2; oxidative stress; perineuronal nets; transcranial magnetic stimulation	TRANSCRANIAL MAGNETIC STIMULATION; FLUID PERCUSSION INJURY; OXIDATIVE STRESS; PERINEURONAL NETS; POSTTRAUMATIC EPILEPTOGENESIS; EXTRACELLULAR-MATRIX; OTX2 HOMEOPROTEIN; GABAERGIC NEURONS; N-ACETYLCYSTEINE; MOOD DISORDERS	Many neuropsychiatric symptoms that follow traumatic brain injury (TBI), including mood disorders, sleep disturbance, chronic pain, and posttraumatic epilepsy (PTE) are attributable to compromised cortical inhibition. However, the temporal trajectory of cortical inhibition loss and its underlying mechanisms are not known. Using paired-pulse transcranial magnetic stimulation (ppTMS) and immunohistochemistry, we tracked functional and cellular changes of cortical inhibitory network elements after fluid-percussion injury (FPI) in rats. ppTMS revealed a progressive loss of cortical inhibition as early as 2 weeks after FPI. This profile paralleled the increasing levels of cortical oxidative stress, which was accompanied by a gradual loss of parvalbumin (PV) immunoreactivity in perilesional cortex. Preceding the PV loss, we identified a degradation of the perineuronal net (PNN)-a specialized extracellular structure enwrapping cortical PV-positive (PV+) inhibitory interneurons which binds the PV+ cell maintenance factor, Otx2. The trajectory of these impairments underlies the reduced inhibitory tone, which can contribute to posttraumatic neurological conditions, such as PTE. Taken together, our results highlight the use of ppTMS as a biomarker to track the course of cortical inhibitory dysfunction post-TBI. Moreover, the neuroprotective role of PNNs on PV+ cell function suggests antioxidant treatment or Otx2 enhancement as a promising prophylaxis for post-TBI symptoms.	[Hsieh, Tsung-Hsun; Hameed, Mustafa Qadir; Rotenberg, Alexander] Harvard Med Sch, Boston Childrens Hosp, Div Epilepsy & Clin Neurophysiol, Neuromodulat Program,Dept Neurol, Boston, MA 02115 USA; [Hsieh, Tsung-Hsun] Chang Gung Univ, Dept Phys Therapy, Coll Med, Taoyuan 33302, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Grad Inst Rehabil Sci, Coll Med, Taoyuan 33302, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Mem Hosp, Neurosci Res Ctr, Linkou Med Ctr, Taoyuan 33305, Taiwan; [Lee, Henry Hing Cheong; Hameed, Mustafa Qadir; Hensch, Takao K.; Rotenberg, Alexander] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Hameed, Mustafa Qadir] Harvard Med Sch, Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Pascual-Leone, Alvaro; Rotenberg, Alexander] Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Hensch, Takao K.] Harvard Univ, Dept Mol & Cellular Biol, Ctr Brain Sci, Cambridge, MA 02138 USA	Hensch, TK; Rotenberg, A (corresponding author), Boston Childrens Hosp, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA.	takao.hensch@childrens.harvard.edu; alexander.rotenberg@childrens.harvard.edu	Lee, Henry HC/S-6014-2016; Pascual-Leone, Alvaro/AAC-5101-2019; Hensch, Takao/L-4182-2019; Hsieh, Tung-Hsun/AAZ-5010-2020	Lee, Henry HC/0000-0003-4975-7330; Pascual-Leone, Alvaro/0000-0001-8975-0382; Hsieh, Tung-Hsun/0000-0002-1794-7941	Boston Children's Hospital Translational Research Program; NIH National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS088583]; Assimon Family Fund; Ministry of Science and Technology of TaiwanMinistry of Science and Technology, Taiwan [MOST 103-2320-B-182-033-MY2, MOST 105-2314-B-182-016]; Chang Gung Memorial HospitalChang Gung Memorial Hospital [CMRPD1F0501]; Croucher Foundation (Hong Kong); Georgetown University Center for Brain Plasticity and Recovery; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD090255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088583] Funding Source: NIH RePORTER	Boston Children's Hospital Translational Research Program (A.R. and T.K.H.), NIH National Institute of Neurological Disorders and Stroke (NINDS) R01 NS088583 (A.R. and T.K.H.), the Assimon Family Fund (A.R.), the Ministry of Science and Technology of Taiwan (MOST 103-2320-B-182-033-MY2, MOST 105-2314-B-182-016) and Chang Gung Memorial Hospital (CMRPD1F0501) to T.H.H.. H.H.C.L. was further supported by a postdoctoral fellowship from the Croucher Foundation (Hong Kong) and funding from the Georgetown University Center for Brain Plasticity and Recovery (to T.K.H.).	Andary MT, 1997, CLIN J PAIN, V13, P244, DOI 10.1097/00002508-199709000-00010; Andre V, 2001, HIPPOCAMPUS, V11, P452, DOI 10.1002/hipo.1060.abs; Ascoli GA, 2008, NAT REV NEUROSCI, V9, P557, DOI 10.1038/nrn2402; Avramescu S, 2009, J NEUROTRAUM, V26, P799, DOI 10.1089/neu.2008.0739; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Badawy RAB, 2014, EPILEPSY RES, V108, P153, DOI 10.1016/j.eplepsyres.2013.11.014; BARKER AT, 1984, LANCET, V1, P994; Bashir S, 2012, RESTOR NEUROL NEUROS, V30, P277, DOI 10.3233/RNN-2012-110207; Benali A, 2011, J NEUROSCI, V31, P1193, DOI 10.1523/JNEUROSCI.1379-10.2011; Berezin V, 2014, PROG BRAIN RES, V214, P353, DOI 10.1016/B978-0-444-63486-3.00015-3; Beurdeley M, 2012, J NEUROSCI, V32, P9429, DOI 10.1523/JNEUROSCI.0394-12.2012; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Cabungcal JH, 2013, P NATL ACAD SCI USA, V110, P9130, DOI 10.1073/pnas.1300454110; Cabungcal JH, 2013, BIOL PSYCHIAT, V73, P574, DOI 10.1016/j.biopsych.2012.09.020; Cantu D, 2015, CEREB CORTEX, V25, P2306, DOI 10.1093/cercor/bhu041; Carulli D, 2007, J COMP NEUROL, V501, P83, DOI 10.1002/cne.21231; Carulli D, 2010, BRAIN, V133, P2331, DOI 10.1093/brain/awq145; Cepeda S, 2016, J NEUROTRAUM, V33, P1034, DOI 10.1089/neu.2015.4153; Chen TW, 2013, NATURE, V499, P295, DOI 10.1038/nature12354; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Eggers SDZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132075; Fawcett JW, 2015, PROG BRAIN RES, V218, P213, DOI 10.1016/bs.pbr.2015.02.001; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Fraser DD, 2009, CRIT CARE MED, V37, P787, DOI 10.1097/CCM.0b013e318194be10; Gherardini L, 2015, CEREB CORTEX, V25, P202, DOI 10.1093/cercor/bht217; Golarai G, 2001, J NEUROSCI, V21, P8523; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Hameed MQ, 2014, NEUROREPORT, V25, P532, DOI 10.1097/WNR.0000000000000132; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Hou LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076087; Hsieh TH, 2012, J NEUROPHYSIOL, V107, P966, DOI 10.1152/jn.00690.2011; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Huusko N, 2014, NEUROSCIENCE, V267, P30, DOI 10.1016/j.neuroscience.2014.02.026; Imbrosci B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111105; Immonen R, 2013, J NEUROTRAUM, V30, P1305, DOI 10.1089/neu.2012.2815; JENSEN FE, 2009, EPILIPSIA, V50, P1, DOI DOI 10.1111/J.1528-1167.2009.02293.X; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; Joshi RL, 2011, FEBS LETT, V585, P1573, DOI 10.1016/j.febslet.2011.05.006; Kelsom C, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-19; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Kwok JCF, 2011, DEV NEUROBIOL, V71, P1073, DOI 10.1002/dneu.20974; Laitinen T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00128, 10.3389/fnins.2015.00128]; Lefebvre G, 2015, BRAIN INJURY, V29, P1032, DOI 10.3109/02699052.2015.1028447; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Lucke-Wold BP, 2015, SEIZURE-EUR J EPILEP, V33, P13, DOI 10.1016/j.seizure.2015.10.002; Major BP, 2015, CLIN EXP PHARMACOL P, V42, P394, DOI 10.1111/1440-1681.12363; Makino Y, 2004, J NEUROTRAUM, V21, P585, DOI 10.1089/089771504774129919; McIntosh TK, 1996, LAB INVEST, V74, P315; MITTMANN T, 1994, NEUROSCIENCE, V60, P891, DOI 10.1016/0306-4522(94)90270-4; Mix A, 2010, EUR J NEUROSCI, V32, P1575, DOI 10.1111/j.1460-9568.2010.07425.x; Morawski M, 2014, PROG BRAIN RES, V214, P207, DOI 10.1016/B978-0-444-63486-3.00010-4; Morishita H, 2015, BIOL PSYCHIAT, V78, P396, DOI 10.1016/j.biopsych.2014.12.026; Muller PA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091065; Nagel S, 2005, BRAIN RES, V1056, P43, DOI 10.1016/j.brainres.2005.07.036; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Orlando C, 2015, BRAIN STRUCT FUNCT, V220, P1077, DOI 10.1007/s00429-013-0701-9; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Petronilho F, 2010, J SURG RES, V164, P316, DOI 10.1016/j.jss.2009.04.031; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Prince DA, 1998, EPILEPSY RES, V32, P83, DOI 10.1016/S0920-1211(98)00042-4; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Rakhade SN, 2009, NAT REV NEUROL, V5, P380, DOI 10.1038/nrneurol.2009.80; Rankin-Gee EK, 2015, EPILEPSIA, V56, P1124, DOI 10.1111/epi.13026; Rao V, 2014, BRAIN INJURY, V28, P20, DOI 10.3109/02699052.2013.847210; Ratzliff AD, 2000, HIPPOCAMPUS, V10, P162; Ren LK, 2015, NEUROLOGY, V84, P602, DOI 10.1212/WNL.0000000000001234; Rodgers KM, 2012, J NEUROTRAUM, V29, P1886, DOI 10.1089/neu.2011.2273; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Rotenberg A, 2010, BRAIN TOPOGR, V22, P257, DOI 10.1007/s10548-009-0116-3; Rowe RK, 2014, SLEEP, V37, P743, DOI 10.5665/sleep.3582; Rudy B, 2011, DEV NEUROBIOL, V71, P45, DOI 10.1002/dneu.20853; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sawyer K, 2015, ARCH PHYS MED REHAB, V96, P2000, DOI 10.1016/j.apmr.2015.07.006; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; Sebe JY, 2011, DEV NEUROBIOL, V71, P107, DOI 10.1002/dneu.20813; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Skopin MD, 2015, J NEUROTRAUM, V32, P289, DOI 10.1089/neu.2014.3664; Soleman S, 2013, NEUROSCIENCE, V253, P194, DOI 10.1016/j.neuroscience.2013.08.050; Spatazza J, 2013, CELL REP, V3, P1815, DOI 10.1016/j.celrep.2013.05.014; Sugiyama S, 2009, DEV GROWTH DIFFER, V51, P369, DOI 10.1111/j.1440-169X.2009.01093.x; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Sundman M, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00334; Szaflarski JP, 2010, EPILEPSY BEHAV, V18, P404, DOI 10.1016/j.yebeh.2010.05.009; Theadom A, 2015, SLEEP MED, V16, P926, DOI 10.1016/j.sleep.2015.04.013; Torbic H, 2013, AM J HEALTH-SYST PH, V70, P759, DOI 10.2146/ajhp120203; Vahabzadeh-Hagh AM, 2012, NEUROMODULATION, V15, P296, DOI 10.1111/j.1525-1403.2012.00482.x; Vahabzadeh-Hagh AM, 2011, J NEUROPHYSIOL, V105, P615, DOI 10.1152/jn.00660.2010; Valk-Kleibeuker L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087414; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028	100	30	30	1	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	DEC	2017	27	12					5509	5524		10.1093/cercor/bhw318			16	Neurosciences	Neurosciences & Neurology	FN8MV	WOS:000416280200007	27909008	Green Published, Bronze			2021-06-18	
J	Wang, J; Ma, MW; Dhandapani, KM; Brann, DW				Wang, Jing; Ma, Merry W.; Dhandapani, Krishnan M.; Brann, Darrell W.			Regulatory role of NADPH oxidase 2 in the polarization dynamics and neurotoxicity of microglia/macrophages after traumatic brain injury	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						NADPH oxidase; NOX2; Microglia; Traumatic brain injury; Inflammation; Oxidative stress; NF-kappa B	NF-KAPPA-B; NEURAL STEM-CELLS; NLRP3 INFLAMMASOME; GANGLIOSIDE GD3; ACTIVATION; EXPRESSION; NEURODEGENERATION; NEURONS; CLONING; DAMAGE	Traumatic brain injury (TBI) is a leading cause of death and disability. Secondary injuries that develop after the initial trauma contribute to long-lasting neurophysiological deficits. Polarization of microglia/macrophages toward a pro-inflammatory (M1) phenotype may increase the progression of secondary injury following TBI; however, the regulatory and functional mechanisms underlying these changes remain poorly defined. In the present study, we showed elevated expression of NADPH oxidase 2 (NOX2) and activation of nuclear factorkappa B (NF-kappa B) predominantly in microglia/macrophages at 4-and 7-days after controlled cortical impact in mice. Delayed inhibition of NOX2, beginning one day after TBI, reduced reactive oxygen species production of myeloid cells and protected neurons from oxidative damage. Moreover, delayed NOX inhibition or global genetic NOX2 knockout suppressed the M1 "pro-inflammatory" profile of microglia/macrophages and simultaneously increased the M2 "anti-inflammatory" profile in the injured brain. These changes were associated with marked down-regulation of the classical NF-kappa B pathway in microglia/macrophages and reduced production of pro-inflammatory cytokines, tumor necrosis factor-alpha and interleukin-1 beta, after TBI. Finally, we demonstrated that wildtype microglia/macrophages isolated from the ipsilateral cortex at 7 days post-TBI were neurotoxic to co-cultured primary neurons, whereas this neurotoxicity was largely attenuated in microglia/macrophages from NOX2-KO mice. Taken together, our study shows a direct link between NOX2 and the NF-kappa B pathway in microglia/ macrophages after TBI, and it provides a novel mechanism by which NOX2 activation leads to the enhanced inflammatory response and neuronal damage after brain injury. Our data also supports the therapeutic potential of targeting NOX2, which may provide efficacy with an extended therapeutic window after TBI.	[Wang, Jing; Ma, Merry W.; Dhandapani, Krishnan M.; Brann, Darrell W.] Charlie Norwood Med Ctr, One Freedom Way, Augusta, GA 30904 USA; [Wang, Jing; Ma, Merry W.; Brann, Darrell W.] Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, 1120 15th St,CA 4004, Augusta, GA 30912 USA; [Dhandapani, Krishnan M.] Augusta Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA USA	Brann, DW (corresponding author), Augusta Univ, Dept Neurosci & Regenerat Med, 1120 15th St,CA-4004, Augusta, GA 30912 USA.	dbrann@augusta.edu		Dhandapani, Krishnan/0000-0001-7044-1117	VA Merit Review Award from the United States Department of Veteran's Affairs, Biomedical Laboratory Research and Development ServiceUS Department of Veterans Affairs [5l101BX001117]	This research was supported by a VA Merit Review Award (5l101BX001117) from the United States Department of Veteran's Affairs, Biomedical Laboratory Research and Development Service.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Braun M, 2017, J IMMUNOL, V198, P3615, DOI 10.4049/jimmunol.1601948; Brewer GJ, 1996, NEUROREPORT, V7, P1509, DOI 10.1097/00001756-199606170-00014; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Correa Fernando G, 2013, Methods Mol Biol, V1041, P215, DOI 10.1007/978-1-62703-520-0_20; Dasuri K, 2013, FREE RADICAL BIO MED, V62, P170, DOI 10.1016/j.freeradbiomed.2012.09.016; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Frakes AE, 2014, NEURON, V81, P1009, DOI 10.1016/j.neuron.2014.01.013; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Gupta SC, 2010, CANCER METAST REV, V29, P405, DOI 10.1007/s10555-010-9235-2; Hu X, 2015, J MAT PHY, V56, P1; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kaltschmidt B, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001271; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lukiw WJ, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt150; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Ma MW, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0150-7; Maraldi T, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/271602; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Sheng WS, 2013, NEUROCHEM RES, V38, P2148, DOI 10.1007/s11064-013-1123-z; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Taetzsch T, 2015, GLIA, V63, P423, DOI 10.1002/glia.22762; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wallisch J. S., 2017, NEUROCRIT CARE; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang J, 2014, J NEUROSCI, V34, P13790, DOI 10.1523/JNEUROSCI.2275-14.2014; Wang J, 2013, P NATL ACAD SCI USA, V110, P19137, DOI 10.1073/pnas.1307224110; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; You WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060290; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	48	30	32	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	DEC	2017	113						119	131		10.1016/j.freeradbiomed.2017.09.017			13	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	FN2FP	WOS:000415806800011	28942245				2021-06-18	
J	Ghuman, H; Gerwig, M; Nicholls, FJ; Liu, JR; Donnelly, J; Badylak, SF; Modo, M				Ghuman, Harmanvir; Gerwig, Madeline; Nicholls, Francesca J.; Liu, Jessie R.; Donnelly, Julia; Badylak, Stephen F.; Modo, Michel			Long-term retention of ECM hydrogel after implantation into a sub-acute stroke cavity reduces lesion volume	ACTA BIOMATERIALIA			English	Article						Extracellular matrix; Magnetic resonance imaging; Stroke; Hydrogel; Behavior; Tissue repair; Biodegradation; Biomaterial; Implantation; Cell invasion	FOCAL CEREBRAL-ISCHEMIA; URINARY-BLADDER MATRIX; IN-VIVO DEGRADATION; EXTRACELLULAR-MATRIX; STEM-CELLS; TISSUE REGENERATION; BIOLOGIC SCAFFOLDS; INDUCTIVE SCAFFOLD; LOCAL-DELIVERY; HOST RESPONSE	Salvaging or functional replacement of damaged tissue caused by stroke in the brain remains a major therapeutic challenge. In situ gelation and retention of a hydrogel bioscaffold composed of 8 mg/mL extracellular matrix (ECM) can induce a robust invasion of cells within 24 h and potentially promote a structural remodeling to replace lost tissue. Herein, we demonstrate a long-term retention of ECM hydro gel within the lesion cavity. A decrease of approximately 32% of ECM volume is observed over 12 weeks. Lesion volume, as measured by magnetic resonance imaging and histology, was reduced by 28%, but a battery of behavioral tests (bilateral asymmetry test; footfault; rotameter) did not reveal a therapeutic or detrimental effect of the hydrogel. Glial scarring and peri-infarct astrocytosis were equivalent between untreated and treated animals, potentially indicating that permeation into host tissue is required to exert therapeutic effects. These results reveal a marked difference of biodegradation of ECM hydrogel in the stroke-damaged brain compared to peripheral soft tissue repair. Further exploration of these structure function relationships is required to achieve a structural remodeling of the implanted hydrogel, as seen in peripheral tissues, to replace lost tissue and promote behavioral recovery. Statement of Significance In situ gelation of ECM is essential for its retention within a tissue cavity. The brain is a unique environment with restricted access that necessitates image-guided delivery through a thin needle to access tissue cavities caused by stroke, as well as other conditions, such as traumatic brain injury or glioma resection. Knowledge about a brain tissue response to implanted hydrogels remains limited, especially in terms of long-term effects and potential impact on behavioral function. We here address the long-term retention of hydrogel within the brain environment, its impact on behavioral function, as well as its ability to reduce further tissue deformation caused by stroke. This study highlights considerable differences in the brain's long-term response to an ECM hydrogel compared to peripheral soft tissue. It underlines the importance of understanding the effect of the structural presence of a hydrogel within a cavity upon host brain tissue and behavioral function. As demonstrated herein, ECM hydrogel can fill a cavity long-term to reduce further progression of the cavity, while potentially serving as a reservoir for local drug or cell delivery. (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Ghuman, Harmanvir; Nicholls, Francesca J.; Badylak, Stephen F.; Modo, Michel] Univ Pittsburgh, McGowan Inst Regenerat Med, 3025 East Carson St, Pittsburgh, PA 15203 USA; [Ghuman, Harmanvir; Liu, Jessie R.; Badylak, Stephen F.; Modo, Michel] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA; [Gerwig, Madeline] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA; [Nicholls, Francesca J.; Modo, Michel] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA; [Donnelly, Julia] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; [Badylak, Stephen F.] Univ Pittsburgh, Dept Surg, 497 Scaife Hall, Pittsburgh, PA USA	Modo, M (corresponding author), Univ Pittsburgh, McGowan Inst Regenerat Med, 3025 East Carson St, Pittsburgh, PA 15203 USA.	modomm@upmc.edu	Nicholls, Francesca/F-2369-2013	Nicholls, Francesca/0000-0001-5639-1790; Modo, Michel/0000-0003-4436-735X; Liu, Jessie/0000-0001-9316-7624; Ghuman, Harmanvir/0000-0002-9123-7796	C.R. Bard; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082226]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082226] Funding Source: NIH RePORTER	The study was funded by C.R. Bard and NINDS (R01NS082226). C.R. Bard has biologic products for non-CNS applications and supported the investigation of this ECM hydrogel for treatment of stroke. C.R. Bard has no proprietary interest in the UBM technology per se, nor does C.R. Bard have any products directed at the CNS.	Aamodt JM, 2016, BIOMATERIALS, V86, P68, DOI 10.1016/j.biomaterials.2016.02.003; Ahearne M, 2014, INTERFACE FOCUS, V4, DOI 10.1098/rsfs.2013.0038; Ashioti M, 2007, BRAIN RES, V1145, P177, DOI 10.1016/j.brainres.2007.01.111; Aurand ER, 2012, J FUNCT BIOMATER, V3, P839, DOI 10.3390/jfb3040839; Aurand ER, 2012, NEUROSCI RES, V72, P199, DOI 10.1016/j.neures.2011.12.005; Badylak SF, 2006, CELL TRANSPLANT, V15, pS29, DOI 10.3727/000000006783982368; Banerjee A, 2009, BIOMATERIALS, V30, P4695, DOI 10.1016/j.biomaterials.2009.05.050; Bechmann I, 2005, NEUROMOL MED, V7, P217, DOI 10.1385/NMM:7:3:217; Bette S, 2016, J NEUROSURG, V21, P1; Bible E, 2012, BIOMATERIALS, V33, P2858, DOI 10.1016/j.biomaterials.2011.12.033; Bible E, 2009, NAT PROTOC, V4, P1440, DOI 10.1038/nprot.2009.156; Bissell M J, 1987, Prog Clin Biol Res, V249, P251; Blakney AK, 2012, J BIOMED MATER RES A, V100A, P1375, DOI 10.1002/jbm.a.34104; Boisserand LSB, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6810562; BRETELER MMB, 1994, STROKE, V25, P1109, DOI 10.1161/01.STR.25.6.1109; Brown BN, 2014, TRANSL RES, V163, P268, DOI 10.1016/j.trsl.2013.11.003; Brown BN, 2012, ACTA BIOMATER, V8, P978, DOI 10.1016/j.actbio.2011.11.031; Carey LE, 2014, BIOMATERIALS, V35, P8297, DOI 10.1016/j.biomaterials.2014.06.015; Chan BP, 2008, EUR SPINE J, V17, pS467, DOI 10.1007/s00586-008-0745-3; CIANO PS, 1986, LAB INVEST, V54, P62; Cook DJ, 2017, J CEREBR BLOOD F MET, V37, P1030, DOI 10.1177/0271678X16649964; Crapo PM, 2014, TISSUE ENG PT A, V20, P313, DOI [10.1089/ten.tea.2013.0186, 10.1089/ten.TEA.2013.0186]; Crapo PM, 2012, BIOMATERIALS, V33, P3539, DOI 10.1016/j.biomaterials.2012.01.044; Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057; Dearth CL, 2016, ACTA BIOMATER, V31, P50, DOI 10.1016/j.actbio.2015.11.043; Fallon A, 2012, J SURG RES, V175, pE25, DOI 10.1016/j.jss.2011.11.001; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Forbes SJ, 2014, NAT MED, V20, P857, DOI 10.1038/nm.3653; Freytes DO, 2008, BIOMATERIALS, V29, P1630, DOI 10.1016/j.biomaterials.2007.12.014; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Ghuman H, 2016, BIOMATERIALS, V91, P166, DOI 10.1016/j.biomaterials.2016.03.014; Gilbert TW, 2007, BIOMATERIALS, V28, P147, DOI 10.1016/j.biomaterials.2006.08.022; Goldsmith W, 2001, CRIT REV BIOMED ENG, V29, P441, DOI 10.1615/CritRevBiomedEng.v29.i56.10; Huleihel L, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600502; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Jeon SB, 2016, J STROKE, V18, P328, DOI 10.5853/jos.2016.00262; Jin T, 2017, BIOMATERIALS, V113, P176, DOI 10.1016/j.biomaterials.2016.10.043; Kajbafzadeh AM, 2007, J SURG RES, V139, P189, DOI 10.1016/j.jss.2006.11.003; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; Lee Bruce, 2005, NeuroRx, V2, P372; Lien SM, 2009, ACTA BIOMATER, V5, P670, DOI 10.1016/j.actbio.2008.09.020; Loh QL, 2013, TISSUE ENG PART B-RE, V19, P485, DOI [10.1089/ten.teb.2012.0437, 10.1089/ten.TEB.2012.0437]; Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386; Marcal H, 2012, REGEN MED, V7, P159, DOI [10.2217/RME.12.6, 10.2217/rme.12.6]; Marcoli M, 2015, REV NEUROSCIENCE, V26, P489, DOI 10.1515/revneuro-2015-0007; Massensini AR, 2015, ACTA BIOMATER, V27, P116, DOI 10.1016/j.actbio.2015.08.040; Medberry CJ, 2013, BIOMATERIALS, V34, P1033, DOI 10.1016/j.biomaterials.2012.10.062; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; Modo M, 2009, NEUROIMAGE, V47, pT133, DOI 10.1016/j.neuroimage.2008.06.017; Modo Michel, 2009, J Exp Stroke Transl Med, V2, P52; Moreau F, 2012, STROKE, V43, P1837, DOI 10.1161/STROKEAHA.111.647859; Pashos NC, 2017, CELLS TISSUES ORGANS, V203, P183, DOI 10.1159/000455070; Qiu WS, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-112; Record RD, 2001, BIOMATERIALS, V22, P2653, DOI 10.1016/S0142-9612(01)00007-2; Rossetti T., 2015, CELL TRANSPLANT; Slivka PF, 2014, BIOMATER SCI-UK, V2, P1521, DOI 10.1039/c4bm00189c; Smith EJ, 2012, STEM CELLS, V30, P785, DOI 10.1002/stem.1024; Soon HW, 2015, MAGN RESON IMAGING, V33, P110, DOI 10.1016/j.mri.2014.09.001; Sreejit P, 2013, STEM CELL REV REP, V9, P158, DOI 10.1007/s12015-013-9427-6; Stille M, 2013, J NEUROSCI METH, V219, P27, DOI 10.1016/j.jneumeth.2013.06.003; Swinehart IT, 2016, DEV DYNAM, V245, P351, DOI 10.1002/dvdy.24379; Tao J, 2017, J BIOMAT SCI-POLYM E, V28, P107, DOI 10.1080/09205063.2016.1250344; Taylor Z, 2004, J BIOMECH, V37, P1263, DOI 10.1016/j.jbiomech.2003.11.027; Tuladhar A, 2015, J CONTROL RELEASE, V215, P1, DOI 10.1016/j.jconrel.2015.07.023; Valentin JE, 2009, TISSUE ENG PT A, V15, P1687, DOI 10.1089/ten.tea.2008.0419; Vespa P, 2016, STROKE, V47, P2749, DOI 10.1161/STROKEAHA.116.013837; Wang JY, 2013, CNS NEUROL DISORD-DR, V12, P413, DOI 10.2174/1871527311312030014; Wang YF, 2013, J CONTROL RELEASE, V172, P1, DOI 10.1016/j.jconrel.2013.07.032; Wolf K, 2013, J CELL BIOL, V201, P1069, DOI 10.1083/jcb.201210152; Wolf MT, 2012, BIOMATERIALS, V33, P7028, DOI 10.1016/j.biomaterials.2012.06.051; Wu Y., 2016, CELL TRANSPLANT; Zhang L, 2013, TISSUE ENG PT A, V19, P1909, DOI [10.1089/ten.tea.2012.0622, 10.1089/ten.TEA.2012.0622]; Zhu JM, 2011, EXPERT REV MED DEVIC, V8, P607, DOI [10.1586/erd.11.27, 10.1586/ERD.11.27]	74	30	30	2	36	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	NOV	2017	63						50	63		10.1016/j.actbio.2017.09.011			14	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	FM0AG	WOS:000414620600004	28917705	Green Accepted			2021-06-18	
J	Caeyenberghs, K; Verhelst, H; Clemente, A; Wilson, PH				Caeyenberghs, Karen; Verhelst, Helena; Clemente, Adam; Wilson, Peter H.			Mapping the functional connectome in traumatic brain injury: What can graph metrics tell us?	NEUROIMAGE			English	Article						Traumatic brain injury; Connectome; Functional MRI; Graph theory; Network	SMALL-WORLD; MODULAR ORGANIZATION; COGNITIVE CONTROL; CONTROL NETWORKS; CORPUS-CALLOSUM; AXONAL INJURY; HEAD-INJURY; CONNECTIVITY; MILD; REORGANIZATION	Objective: Traumatic brain injury (TBI) is associated with cognitive and motor deficits, and poses a significant personal, societal, and economic burden. One mechanism by which TBI is thought to affect cognition and behavior is through changes in functional connectivity. Graph theory is a powerful framework for quantifying topological features of neuroimaging-derived functional networks. The objective of this paper is to review studies examining functional connectivity in TBI with an emphasis on graph theoretical analysis that is proving to be valuable in uncovering network abnormalities in this condition. Methods: We review studies that have examined TBI-related alterations in different properties of the functional brain network, including global integration, segregation, centrality and resilience. We focus on functional data using task-related fMRI or resting-state fMRI in patients with TBI of different severity and recovery phase, and consider how graph metrics may inform rehabilitation and enhance efficacy. Moreover, we outline some methodological challenges associated with the examination of functional connectivity in patients with brain injury, including the sample size, parcellation scheme used, node definition and subgroup analyses. Results: The findings suggest that TBI is associated with hyperconnectivity and a suboptimal global integration, characterized by increased connectivity degree and strength and reduced efficiency of functional networks. This altered functional connectivity, also evident in other clinical populations, is attributable to diffuse white matter pathology and reductions in gray and white matter volume. These functional alterations are implicated in postconcussional symptoms, posttraumatic stress and neurocognitive dysfunction after TBI. Finally, the effects of focal lesions have been found to depend critically on topological position and their role in the network. Conclusion: Graph theory is a unique and powerful tool for exploring functional connectivity in brain-injured patients. One limitation is that its results do not provide specific measures about the biophysical mechanism underlying TBI. Continued work in this field will hopefully see graph metrics used as biomarkers to provide more accurate diagnosis and help guide treatment at the individual patient level.	[Caeyenberghs, Karen; Clemente, Adam; Wilson, Peter H.] Australian Catholic Univ, Fac Hlth Sci, Sch Psychol, 115 Victoria Pde, Melbourne, Vic 3065, Australia; [Verhelst, Helena] Univ Ghent, Fac Psychol & Educ Sci, Dept Expt Psychol, Ghent, Belgium	Caeyenberghs, K (corresponding author), Australian Catholic Univ, Fac Hlth Sci, Sch Psychol, 115 Victoria Pde, Melbourne, Vic 3065, Australia.	Karen.Caeyenberghs@acu.edu.au	Wilson, Peter H./E-2881-2018	Wilson, Peter H./0000-0003-3747-0287; Verhelst, Helena/0000-0002-6861-0249; Clemente, Adam/0000-0002-4742-7015; Caeyenberghs, Karen/0000-0001-7009-6843			Abdelnour F, 2014, NEUROIMAGE, V90, P335, DOI 10.1016/j.neuroimage.2013.12.039; Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Aerts H., 2016, BRAIN; Ahn YY, 2010, NATURE, V466, P761, DOI 10.1038/nature09182; Alstott J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000408; Arnemann KL, 2015, NEUROLOGY, V84, P1568, DOI 10.1212/WNL.0000000000001476; Balanc B, 2016, J NEUROSCI RES, V94, P39, DOI 10.1002/jnr.23676; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Bosma I, 2008, J NEURO-ONCOL, V88, P77, DOI 10.1007/s11060-008-9535-3; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2009, BRAIN, V132, P684, DOI 10.1093/brain/awn344; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cristofori Irene, 2015, Handb Clin Neurol, V128, P579, DOI 10.1016/B978-0-444-63521-1.00037-6; Currie S, 2016, POSTGRAD MED J, V92, P41, DOI 10.1136/postgradmedj-2014-133211; Davis SW, 2009, NEUROIMAGE, V46, P530, DOI 10.1016/j.neuroimage.2009.01.068; Delvaux V, 2003, CLIN NEUROPHYSIOL, V114, P1217, DOI 10.1016/S1388-2457(03)00070-1; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Drijkoningen D, 2015, HUM BRAIN MAPP, V36, P4897, DOI 10.1002/hbm.22958; Eguiluz VM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.018102; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Fornito A, 2015, NAT REV NEUROSCI, V16, P159, DOI 10.1038/nrn3901; Fornito A, 2013, NEUROIMAGE, V80, P426, DOI 10.1016/j.neuroimage.2013.04.087; Friedman J, 2008, BIOSTATISTICS, V9, P432, DOI 10.1093/biostatistics/kxm045; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gooijers J., 2016, BRAIN; Gratton C, 2012, J COGNITIVE NEUROSCI, V24, P1275, DOI 10.1162/jocn_a_00222; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Griffa A, 2013, NEUROIMAGE, V80, P515, DOI 10.1016/j.neuroimage.2013.04.056; Guye M, 2010, MAGN RESON MATER PHY, V23, P409, DOI 10.1007/s10334-010-0205-z; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; Han K, 2016, J INT NEUROPSYCH SOC, V22, P263, DOI 10.1017/S1355617715001393; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hannawi Y, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0642-9; Harris NG, 2016, EXP NEUROL, V277, P124, DOI 10.1016/j.expneurol.2015.12.020; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Heitger MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062133; Hillary F.G., 2014, PLOS ONE, V9; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Holme P, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.056108; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Iraji A, 2016, NEUROIMAGE-CLIN, V12, P100, DOI 10.1016/j.nicl.2016.06.012; Iraji A, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/4072402; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kaiser M, 2006, PLOS COMPUT BIOL, V2, P805, DOI 10.1371/journal.pcbi.0020095; Killgore WDS, 2016, NEUROSCI LETT, V612, P238, DOI 10.1016/j.neulet.2015.12.033; Kou ZF, 2014, NEURAL REGEN RES, V9, P693, DOI 10.4103/1673-5374.131568; Kuceyeski A, 2016, NEUROIMAGE-CLIN, V11, P635, DOI 10.1016/j.nicl.2016.04.006; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P155, DOI 10.1097/HTR.0b013e3181dc82e7; Medaglia JD, 2012, HUM BRAIN MAPP, V33, P979, DOI 10.1002/hbm.21264; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Nair DG, 2007, NEUROIMAGE, V34, P253, DOI 10.1016/j.neuroimage.2006.09.010; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Nomura EM, 2010, P NATL ACAD SCI USA, V107, P12017, DOI 10.1073/pnas.1002431107; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Papo D., 2014, PHILOS T R SOC LON B, V369; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rincon S, 2016, HAND CLINIC, V135, P447, DOI 10.1016/B978-0-444-53485-9.00022-2; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Rudie JD, 2013, NEUROIMAGE-CLIN, V2, P79, DOI 10.1016/j.nicl.2012.11.006; Scott G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0445-y; Serbruyns L, 2015, BRAIN STRUCT FUNCT, V220, P273, DOI 10.1007/s00429-013-0654-z; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sinopoli KJ, 2014, J NEUROTRAUM, V31, P1843, DOI 10.1089/neu.2014.3326; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; Soto-Ares G, 2001, NEUROPEDIATRICS, V32, P153, DOI 10.1055/s-2001-16615; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Spielberg JM, 2015, BIOL PSYCHIAT, V78, P210, DOI 10.1016/j.biopsych.2015.02.013; Sporns O, 2014, NAT NEUROSCI, V17, P652, DOI 10.1038/nn.3690; Stam CJ, 2014, NAT REV NEUROSCI, V15, P683, DOI 10.1038/nrn3801; Thomas C, 2013, NEUROIMAGE, V73, P225, DOI 10.1016/j.neuroimage.2012.03.069; Turner GR, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00009; van den Heuvel MP, 2008, NEUROIMAGE, V43, P528, DOI 10.1016/j.neuroimage.2008.08.010; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; van Ruitenbeek P., 2016, BRAIN STRUCT FUNCT, V221; Vargas ER, 2016, MED BIOL ENG COMPUT, V54, P235, DOI 10.1007/s11517-015-1396-2; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wang JH, 2009, HUM BRAIN MAPP, V30, P1511, DOI 10.1002/hbm.20623; Wang L, 2009, HUM BRAIN MAPP, V30, P638, DOI 10.1002/hbm.20530; Warren DE, 2014, P NATL ACAD SCI USA, V111, P14247, DOI 10.1073/pnas.1322173111; Zhao XH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033540; Zhu DJ, 2014, HUM BRAIN MAPP, V35, P2911, DOI 10.1002/hbm.22373	103	30	30	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	OCT 15	2017	160				SI		113	123		10.1016/j.neuroimage.2016.12.003			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	FL5DV	WOS:000414252800010	27919750				2021-06-18	
J	Salman, SD; Leman, Z; Sultan, MTH; Ishak, MR; Cardona, F				Salman, Suhad D.; Leman, Z.; Sultan, M. T. H.; Ishak, M. R.; Cardona, F.			Effect of kenaf fibers on trauma penetration depth and ballistic impact resistance for laminated composites	TEXTILE RESEARCH JOURNAL			English	Article						ballistic; trauma; aramid; kenaf; helmets	PERFORMANCE; PERFORATION; BEHAVIOR; ARMOR; THICKNESS; POLYMER; HELMET	Combat helmets have been utilized to provide protection against a variety of ballistic threats, by reducing traumatic head injuries and fatalities. Nevertheless, head protection from injury is critical to function and for survivability. Soldiers and civilians incur Traumatic Brain Injury (TBI) most commonly from exposure to homemade bombs or improvised explosive devices. Although the Personal Armor System for Ground Troops (PASGT) helmet is expensive, environmental issues are some technical advantages that encourage using natural/synthetic hybrid laminated composites. The effects of different configuration patterns of kenaf fibers on the Backface Signature and energy absorbed by a military helmet (PASGT) were investigated. The ballistic behaviors of the 19 layers of aramid composite and plain woven kenaf composite were compared to hybrid laminated composites. The ballistic impact tests were performed using a 9 mm full metal jacket bullet and fragment simulating projectiles at various impact velocities, using a powder gun on fabricated square panels and helmets. The results showed the positive effect of hybridization in terms of energy absorbed (i.e. penetration), Backface Signature and damage mechanisms for ballistic impact and NIJ (National Institute of Justice) tests. Hybridization of plain woven kenaf/Kevlar laminated composites will open new avenues to reduce the dependency on the ballistic resistance component (Kevlar) in the helmet shell.	[Salman, Suhad D.; Leman, Z.] Univ Putra Malaysia, Dept Mech & Mfg Engn, Serdang, Selangor, Malaysia; [Salman, Suhad D.] Univ Mustansiriyah, Mat Engn Dept, Baghdad, Iraq; [Sultan, M. T. H.; Ishak, M. R.; Cardona, F.] Univ Putra Malaysia, AMRC, Serdang, Selangor, Malaysia; [Ishak, M. R.] Univ Putra Malaysia, Lab Biocomposites Technol, Inst Trop Forestry & Forest Prod INTROP, Serdang, Selangor, Malaysia	Salman, SD (corresponding author), Univ Putra Malaysia, Dept Mech & Mfg Engn, Fac Engn, Serdang 43400, Selangor, Malaysia.	suhaddawood2007@yahoo.com	Salman, Suhad Dawood/C-9059-2016; Leman, Zulkiflle/AAE-5267-2020; Sultan, M.T.H./H-2338-2019	Salman, Suhad Dawood/0000-0001-6091-8145; Leman, Zulkiflle/0000-0002-3273-6675; 	UPM [GP-IPS/2014/9438714]; UPM under GP-IPB [9415402]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by UPM under GP-IPS/2014/9438714 and UPM under GP-IPB grant, 9415402.	Ahmad MR, 2008, MATER DESIGN, V29, P1353, DOI 10.1016/j.matdes.2007.06.007; Ali A, 2011, POLYM-PLAST TECHNOL, V50, P622, DOI 10.1080/03602559.2010.551381; [Anonymous], MLH44099A DEP DEF TE; [Anonymous], 1985, 010801 NIJ US DEP JU; [Anonymous], MILSTD662F DEP DEF T; [Anonymous], 1981, 010601 NIJ US DEP JU; Boccaccini AR, 2005, COMPOS SCI TECHNOL, V65, P325, DOI 10.1016/j.compscitech.2004.08.002; Carey ME, 2000, NEUROSURGERY, V47, P678, DOI 10.1097/00006123-200009000-00031; Cheeseman BA, 2003, COMPOS STRUCT, V61, P161, DOI 10.1016/S0263-8223(03)00029-1; Findik F, 2003, COMPOS STRUCT, V61, P187, DOI 10.1016/S0263-8223(03)00065-5; Findik F, 2002, SCI ENG COMPOS MATER, V10, P287; Freitas CJ, 2014, INT J MED SCI, V11, P409, DOI 10.7150/ijms.8079; GANESH BABU M., 2006, LAT AM J SOLIDS STRU, V3, P21; Gellert EP, 2000, INT J IMPACT ENG, V24, P445, DOI 10.1016/S0734-743X(99)00175-X; Greenhalgh ES, 2013, COMPOS PART A-APPL S, V44, P51, DOI 10.1016/j.compositesa.2012.08.012; Lee BL, 2001, J COMPOS MATER, V35, P1605, DOI 10.1106/YRBH-JGT9-U6PT-L555; Muhi RJ, 2009, COMPOS PART B-ENG, V40, P798, DOI 10.1016/j.compositesb.2009.08.002; Pandya KS, 2015, INT J DAMAGE MECH, V24, P471, DOI 10.1177/1056789514531440; Park JL, 2013, TEXT RES J, V83, P471, DOI 10.1177/0040517512444337; Radif ZS, 2011, PERTANIKA J SCI TECH, V19, P339; Rahner CP, 2012, THESIS; Randjbaran E, 2014, SCI WORLD J, DOI 10.1155/2014/413753; Rashid AHA, 2011, ADV MATER RES-SWITZ, V277, P36, DOI [10.4028/www.scientific.net/AMR.277.36, 10.4028/www.scientific.net/AMR.277J6]; Risby MS, 2008, DEFENCE SCI J, V58, P248, DOI 10.14429/dsj.58.1645; Sabet AR, 2009, POLYM COMPOSITE, V30, P1497, DOI 10.1002/pc.20720; Salman SD., 2015, MANUF SCI TECHNOL, V3, P119; Salman SD, 2015, INT J POLYM SCI, V2015, DOI 10.1155/2015/894565; Salman SD, 2015, BIORESOURCES, V10, P8580; Sayer M, 2010, J APPL POLYM SCI, V118, P580, DOI 10.1002/app.32437; Sultan MTH, 2012, ADV MATER RES-SWITZ, V399-401, P2318, DOI 10.4028/www.scientific.net/AMR.399-401.2318; Tan VBC, 2005, INT J IMPACT ENG, V31, P793, DOI 10.1016/j.ijimpeng.2004.04.003; Tarim N, 2002, COMPOS STRUCT, V56, P13, DOI 10.1016/S0263-8223(01)00177-5; Tham CY, 2008, INT J IMPACT ENG, V35, P304, DOI 10.1016/j.ijimpeng.2007.03.008; *US DEP JUST, 2000, 010104 NIJ US DEP JU; Walsh S.M., 2005, DEV HYBRID THERMOPLA; Wambua P, 2007, COMPOS STRUCT, V77, P232, DOI 10.1016/j.compstruct.2005.07.006; Yetkin SH, 2013, POLYM-PLAST TECHNOL, V52, P433, DOI 10.1080/03602559.2012.748802; Zhang DT, 2014, MATER DESIGN, V54, P315, DOI 10.1016/j.matdes.2013.08.074	38	30	30	2	16	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0040-5175	1746-7748		TEXT RES J	Text. Res. J.	OCT	2017	87	17					2051	2065		10.1177/0040517516663155			15	Materials Science, Textiles	Materials Science	FL7LL	WOS:000414429100001					2021-06-18	
J	Brabazon, F; Wilson, CM; Jaiswal, S; Reed, J; Frey, WH; Byrnes, KR				Brabazon, Fiona; Wilson, Colin M.; Jaiswal, Shalini; Reed, John; Frey, William H., II; Byrnes, Kimberly R.			Intranasal insulin treatment of an experimental model of moderate traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Glucose uptake; intranasal insulin; microglia; positron emission tomography; traumatic brain injury	MORRIS WATER MAZE; CONTROLLED CORTICAL IMPACT; MEMORY DYSFUNCTION; GLUCOSE-UPTAKE; COMBINED MICRODIALYSIS; MICROGLIAL ACTIVATION; EMISSION-TOMOGRAPHY; SPINAL-CORD; (18)FDG PET; RAT-BRAIN	Traumatic brain injury (TBI) results in learning and memory dysfunction. Cognitive deficits result from cellular and metabolic dysfunction after injury, including decreased cerebral glucose uptake and inflammation. This study assessed the ability of intranasal insulin to increase cerebral glucose uptake after injury, reduce lesion volume, improve memory and learning function and reduce inflammation. Adult male rats received a controlled cortical impact (CCI) injury followed by intranasal insulin or saline treatment daily for 14 days. PET imaging of [F-18]-FDG uptake was performed at baseline and at 48 h and 10 days post-injury and MRI on days three and nine post injury. Motor function was tested with the beam walking test. Memory function was assessed with Morris water maze. Intranasal insulin after CCI significantly improved several outcomes compared to saline. Insulin-treated animals performed better on beam walk and demonstrated significantly improved memory. A significant increase in [F-18]-FDG uptake was observed in the hippocampus. Intranasal insulin also resulted in a significant decrease in hippocampus lesion volume and significantly less microglial immunolabeling in the hippocampus. These data show that intranasal insulin improves memory, increases cerebral glucose uptake and decreases neuroinflammation and hippocampal lesion volume, and may therefore be a viable therapy for TBI.	[Brabazon, Fiona; Reed, John; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Neurosci Program, Bethesda, MD 20814 USA; [Wilson, Colin M.; Jaiswal, Shalini] Uniformed Serv Univ Hlth Sci, Dept Radiol, Bethesda, MD 20814 USA; [Wilson, Colin M.; Jaiswal, Shalini; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Frey, William H., II] Hlth Partners Neurosci Res, St Paul, MN USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Byrnes, KR (corresponding author), Dept Anat Physiol & Genet, Room C2115,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	kimberly.byrnes@usuhs.edu		Brabazon, Fiona/0000-0003-1642-808X	Cosmos Club Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS073667-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073667] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Cosmos Club Foundation and NIH grant number 1R01NS073667-01A1.	Apostolatos A, 2012, J BIOL CHEM, V287, P9299, DOI 10.1074/jbc.M111.313080; Benedict C, 2004, PSYCHONEUROENDOCRINO, V29, P1326, DOI 10.1016/j.psyneuen.2004.04.003; Berg J.M., 2002, BIOCHEMISTRY; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Cashion MF, 1996, HORM BEHAV, V30, P280, DOI 10.1006/hbeh.1996.0034; Chen YX, 2014, EXP NEUROL, V261, P610, DOI 10.1016/j.expneurol.2014.06.004; Chio CC, 2015, CURR MED CHEM, V22, P759, DOI 10.2174/0929867321666141106124657; Chiu SL, 2008, NEURON, V58, P708, DOI 10.1016/j.neuron.2008.04.014; Cooney SJ, 2014, FREE RADICAL RES, V48, P929, DOI 10.3109/10715762.2014.927578; Craft S, 2012, ARCH NEUROL-CHICAGO, V69, P29, DOI 10.1001/archneurol.2011.233; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dhuria SV, J PHARM SCI, V99, P1654; Dineley KT, 2014, NEUROBIOL DIS, V72, P92, DOI 10.1016/j.nbd.2014.09.001; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Duarte Ana I, 2012, J Aging Res, V2012, P384017, DOI 10.1155/2012/384017; Fridman EA, 2014, P NATL ACAD SCI USA, V111, P6473, DOI 10.1073/pnas.1320969111; Gallagher M, 2015, BEHAV NEUROSCI, V129, P540, DOI 10.1037/bne0000080; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Janus C, 2004, LEARN MEMORY, V11, P337, DOI 10.1101/lm.70104; Jauch-Chara K, 2012, DIABETES, V61, P2261, DOI 10.2337/db12-0025; LEMAY DR, 1988, STROKE, V19, P1411, DOI 10.1161/01.STR.19.11.1411; Li J, 2012, J NEUROTRAUM, V29, P2635, DOI 10.1089/neu.2012.2411; Li L, 2009, NEUROSCIENCE, V164, P497, DOI 10.1016/j.neuroscience.2009.08.011; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lochhead JJ, 2015, J CEREBR BLOOD F MET, V35, P371, DOI 10.1038/jcbfm.2014.215; Maimaiti S, 2016, J GERONTOL A-BIOL, V71, P30, DOI 10.1093/gerona/glu314; Marin-Teva JL, 2011, NEURON GLIA BIOL, V7, P25, DOI 10.1017/S1740925X12000014; MARKS JL, 1990, ENDOCRINOLOGY, V127, P3234, DOI 10.1210/endo-127-6-3234; Mergenthaler P, 2013, TRENDS NEUROSCI, V36, P587, DOI 10.1016/j.tins.2013.07.001; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629; Plum L, 2005, TRENDS ENDOCRIN MET, V16, P59, DOI 10.1016/j.tem.2005.01.008; Rassovsky Y, 2015, J CLIN EXP NEUROPSYC, V37, P354, DOI 10.1080/13803395.2015.1015498; Redish AD, 1998, NEURAL COMPUT, V10, P73, DOI 10.1162/089976698300017908; Reger MA, 2008, J ALZHEIMERS DIS, V13, P323, DOI 10.3233/jad-2008-13309; Renner DB, 2012, J PHARM PHARMACOL, V64, P1709, DOI 10.1111/j.2042-7158.2012.01555.x; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schulingkamp RJ, 2000, NEUROSCI BIOBEHAV R, V24, P855, DOI 10.1016/S0149-7634(00)00040-3; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Selwyn RG, 2016, J NEUROTRAUM, V33, P1479, DOI 10.1089/neu.2015.4129; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Song JP, 2015, TRANSL STROKE RES, V6, P290, DOI 10.1007/s12975-015-0396-8; Spielman LJ, 2015, CURR ALZHEIMER RES, V12, P684, DOI 10.2174/1567205012666150710104428; Sun MY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11445; Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029; Uemura E, 2006, EXP NEUROL, V198, P48, DOI 10.1016/j.expneurol.2005.10.035; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhao WQ, 2001, MOL CELL ENDOCRINOL, V177, P125, DOI 10.1016/S0303-7207(01)00455-5	54	30	30	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2017	37	9					3203	3218		10.1177/0271678X16685106			16	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	FF2EV	WOS:000408711600012	28058996	Green Published, Bronze			2021-06-18	
J	De Vos, A; Bjerke, M; Brouns, R; De Roeck, N; Jacobs, D; Van den Abbeele, L; Guldolf, K; Zetterberg, H; Blennow, K; Engelborghs, S; Vanmechelen, E				De Vos, Ann; Bjerke, Maria; Brouns, Raf; De Roeck, Naomi; Jacobs, Dirk; Van den Abbeele, Lien; Guldolf, Kaat; Zetterberg, Henrik; Blennow, Kaj; Engelborghs, Sebastiaan; Vanmechelen, Eugeen			Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke	BMC NEUROLOGY			English	Article						AIS; Neurogranin; Tau; Plasma; CSF; Elisa; Simoa; NIHSS; mRS; Biomarker	ALZHEIMERS-DISEASE; NEUROBIOCHEMICAL MARKERS; PROTEIN NEUROGRANIN; COGNITIVE DECLINE; BRAIN-DAMAGE; CORRELATE; BIOMARKER; SEVERITY	Background: While neurogranin has no value as plasma biomarker for Alzheimer's disease, it may be a potential blood biomarker for traumatic brain injury. This evokes the question whether there are changes in neurogranin levels in blood in other conditions of brain injury, such as acute ischemic stroke (AIS). Methods: We therefore explored neurogranin in paired cerebrospinal fluid (CSF)/plasma samples of AIS patients (n = 50) from a well-described prospective study. In parallel, we investigated another neuronal protein, i.e. tau, which has already been suggested as potential AIS biomarker in CSF and blood. ELISA as well as Single Molecule Array (Simoa) technology were used for the biochemical analyses. Statistical analyses included Shapiro-Wilk testing, Mann-Whitney analyses and Pearson's correlation analysis. Results: In contrast to tau, of which high levels in both CSF and plasma were related to stroke characteristics like severity and long-term outcome, plasma neurogranin levels were only correlated with infarct volume. Likewise, CSF neurogranin levels were significantly higher in patients with an infarct volume > 5 mL than in patients with smaller infarct volumes. Finally, neurogranin and tau were significantly correlated in CSF, whereas a weaker relationship was observed in plasma. Conclusions: These findings indicate that although plasma and CSF neurogranin may reflect the volume of acute cerebral ischemia, this synaptic protein is less likely to be a potential AIS biomarker. Levels of tau correlated with severity and outcome of stroke in both plasma and CSF, in the present study as well as previous reports, confirming the potential of tau as an AIS biomarker.	[De Vos, Ann; Jacobs, Dirk; Van den Abbeele, Lien; Vanmechelen, Eugeen] ADx NeuroSci NV, Technol Pk 4, B-9052 Ghent, Belgium; [Bjerke, Maria; De Roeck, Naomi; Guldolf, Kaat; Engelborghs, Sebastiaan] Univ Antwerp, Inst Born Bunge, Reference Ctr Biol Markers Dementia BIODEM, Antwerp, Belgium; [Brouns, Raf] Hosp ZorSaam, Dept Neurol, Terneuzen, Netherlands; [Guldolf, Kaat; Engelborghs, Sebastiaan] Hosp Network Antwerp ZNA Middelheim & Hoge Beuken, Dept Neurol, Antwerp, Belgium; [Guldolf, Kaat; Engelborghs, Sebastiaan] Hosp Network Antwerp ZNA Middelheim & Hoge Beuken, Memory Clin, Antwerp, Belgium; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, London, England	Vanmechelen, E (corresponding author), ADx NeuroSci NV, Technol Pk 4, B-9052 Ghent, Belgium.	Eugeen.vanmechelen@adxneurosciences.com	Vanmechelen, Eugeen/AAA-8005-2019; Brouns, Raf/E-1044-2013	Brouns, Raf/0000-0001-6540-5699; De Vos, Ann/0000-0002-8200-5336; Vanmechelen, Eugeen/0000-0002-9466-5366	Agency for Innovation by Science and Technology (VLAIO) [140,105]; University of Antwerp Research Fund; Alzheimer Research Foundation (SAO-FRA); Institute Born-Bunge (IBB); Belgian Science Policy Office Interuniversity Attraction Poles (IAP) program (BELSPO); Flemish Government initiated Methusalem excellence grant (EWI); Flanders Impulse Program on Networks for Dementia Research (VIND); Research Foundation Flanders (FWO)FWO; VINNOVAVinnova; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Brain Foundation; Torsten Soderberg Foundation at the Royal Swedish Academy of Sciences	This work was funded in part by the Agency for Innovation by Science and Technology (VLAIO, www.vlaio.be, grant nr 140,105); University of Antwerp Research Fund; the Alzheimer Research Foundation (SAO-FRA, http://alzh.org); the Institute Born-Bunge (IBB,www.bornbunge.be); the Belgian Science Policy Office Interuniversity Attraction Poles (IAP) program (BELSPO, www.belspo.be); the Flemish Government initiated Methusalem excellence grant (EWI, www.ewi-vlaanderen.be); the Flanders Impulse Program on Networks for Dementia Research (VIND); the Research Foundation Flanders (FWO,www.fwo.be); VINNOVA; the Swedish Research Council (www.vr.se/inenglish); the Swedish Brain Foundation (www.hjarnfonden.se) and Torsten Soderberg Foundation at the Royal Swedish Academy of Sciences. The funding sources had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Albers GW, 2002, NEW ENGL J MED, V347, P1713, DOI 10.1056/NEJMsb020987; Bielewicz J, 2011, J MOL NEUROSCI, V43, P241, DOI 10.1007/s12031-010-9403-4; Bitsch A, 2002, EUR NEUROL, V47, P45, DOI 10.1159/000047946; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brouns R, 2008, CLIN CHIM ACTA, V397, P27, DOI 10.1016/j.cca.2008.07.016; Brouns R, 2011, EUR NEUROL, V65, P23, DOI 10.1159/000321965; Brouns R, 2010, CLIN CHEM, V56, P451, DOI 10.1373/clinchem.2009.134122; Brouns R, 2009, NEUROCHEM RES, V34, P1642, DOI 10.1007/s11064-009-9954-3; Dage JL, 2016, ALZHEIMERS DEMENT, V12, P1226, DOI 10.1016/j.jalz.2016.06.001; De Vos A, 2016, J ALZHEIMERS DIS, V53, P1523, DOI 10.3233/JAD-160227; De Vos A, 2015, ALZHEIMERS DEMENT, V11, P1461, DOI 10.1016/j.jalz.2015.05.012; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Duncan PW, 2000, STROKE, V31, P1429, DOI 10.1161/01.STR.31.6.1429; Hesse C, 2001, NEUROSCI LETT, V297, P187, DOI 10.1016/S0304-3940(00)01697-9; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Hjalmarsson C, 2014, J CENT NERV SYST DIS, V6, P51, DOI 10.4137/JCNSD.S13821; Janelidze S, 2016, ANN CLIN TRANSL NEUR, V3, P12, DOI 10.1002/acn3.266; Kaerst L, 2013, J NEUROL, V260, P2722, DOI 10.1007/s00415-013-7047-3; Kehoe K, 2015, NEUROCHEM RES, V40, P81, DOI 10.1007/s11064-014-1468-y; Kester MI, 2015, JAMA NEUROL, V72, P1275, DOI 10.1001/jamaneurol.2015.1867; Kvartsberg H, 2015, ALZHEIMERS DEMENT, V11, P1180, DOI 10.1016/j.jalz.2014.10.009; Kvartsberg H, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0124-3; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; Portelius E, 2015, BRAIN, V138, DOI 10.1093/brain/awv267; Reddy PH, 2005, J ALZHEIMERS DIS, V7, P103, DOI 10.3233/jad-2005-7203; STRAND T, 1984, STROKE, V15, P138, DOI 10.1161/01.STR.15.1.138; Sulter G, 1999, STROKE, V30, P1538, DOI 10.1161/01.STR.30.8.1538; Tarawneh R, 2016, JAMA NEUROL, V73, P561, DOI 10.1001/jamaneurol.2016.0086; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Thorsell A, 2010, BRAIN RES, V1362, P13, DOI 10.1016/j.brainres.2010.09.073; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Willemse JL, 2008, J THROMB HAEMOST, V6, P200; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006; Yang J, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0468-0; Yang J, 2015, CLIN BIOCHEM, V48, P843, DOI 10.1016/j.clinbiochem.2015.05.015	37	30	30	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	AUG 30	2017	17								170	10.1186/s12883-017-0945-8			8	Clinical Neurology	Neurosciences & Neurology	FF2JY	WOS:000408724900001	28854881	DOAJ Gold, Green Published			2021-06-18	
J	von Leden, RE; Khayrullina, G; Moritz, KE; Byrnes, KR				von Leden, Ramona E.; Khayrullina, Guzal; Moritz, Kasey E.; Byrnes, Kimberly R.			Age exacerbates microglial activation, oxidative stress, inflammatory and NOX2 gene expression, and delays functional recovery in a middle-aged rodent model of spinal cord injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Spinal cord injury; Aging; NOX2; Microglia; Inflammation	TRAUMATIC BRAIN-INJURY; THERAPEUTIC TARGETS; LOCOMOTOR RECOVERY; NADPH OXIDASE; RATS; MACROPHAGES; MICE; CNS; HYPERALGESIA; MECHANISMS	Background: Spinal cord injury (SCI) among people over age 40 has been steadily increasing since the 1980s and is associated with worsened outcome than injuries in young people. Age-related increases in reactive oxygen species (ROS) are suggested to lead to chronic inflammation. The NADPH oxidase 2 (NOX2) enzyme is expressed by microglia and is a primary source of ROS. This study aimed to determine the effect of age on inflammation, oxidative damage, NOX2 gene expression, and functional performance with and without SCI in young adult (3 months) and middle-aged (12 months) male rats. Methods: Young adult and middle-aged rats were assessed in two groups-naive and moderate contusion SCI. Functional recovery was determined by weekly assessment with the Basso, Beattie, and Breshnahan general motor score (analyzed two-way ANOVA) and footprint analysis (analyzed by Chi-square analysis). Tissue was analyzed for markers of oxidative damage (8-OHdG, Oxyblot, and 3-NT), microglial-related inflammation (Iba1), NOX2 component (p47(PHOX), p22(PHOX), and gp91(PHOX)), and inflammatory (CD86, CD206, TNF alpha, and NF kappa B) gene expression (all analyzed by unpaired Student's t test). Results: In both naive and injured aged rats, compared to young rats, tissue analysis revealed significant increases in 8-OHdG and Iba1, as well as inflammatory and NOX2 component gene expression. Further, injured aged rats showed greater lesion volume rostral and caudal to the injury epicenter. Finally, injured aged rats showed significantly reduced Basso-Beattie-Bresnahan (BBB) scores and stride length after SCI. Conclusions: These results show that middle-aged rats demonstrate increased microglial activation, oxidative stress, and inflammatory gene expression, which may be related to elevated NOX2 expression, and contribute to worsened functional outcome following injury. These findings are essential to elucidating the mechanisms of age-related differences in response to SCI and developing age-appropriate therapeutics.	[von Leden, Ramona E.; Khayrullina, Guzal; Moritz, Kasey E.; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Neurosci Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [von Leden, Ramona E.; Khayrullina, Guzal; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA	von Leden, RE (corresponding author), Uniformed Serv Univ Hlth Sci, Neurosci Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; von Leden, RE (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Ramona.von-leden.ctr@usush.edu			NINDS/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS073667-01A1, 1F31NS090737-01A1]; Uniformed Services University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS090737, R01NS073667] Funding Source: NIH RePORTER	This work was funded by the NINDS/NIH (Grant number 1R01NS073667-01A1) and a pilot grant from the Uniformed Services University. R. von Leden was supported by the NINDS/NIH (Grant number 1F31NS090737-01A1).	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Batchelor PE, 2008, J NEUROTRAUM, V25, P1217, DOI 10.1089/neu.2007.0308; Beare JE, 2009, J NEUROTRAUM, V26, P2045, DOI 10.1089/neu.2009.0914; Blakeman KH, 2003, NEUROSCIENCE, V117, P221, DOI 10.1016/S0306-4522(02)00779-0; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Cooney SJ, 2014, FREE RADICAL RES, V48, P929, DOI 10.3109/10715762.2014.927578; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Fouad K, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00085; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Groah SL, 2012, AM J PHYS MED REHAB, V91, P80, DOI 10.1097/PHM.0b013e31821f70bc; Gwak YS, 2004, J NEUROTRAUM, V21, P983, DOI 10.1089/0897715041650999; Gwak YS, 2004, NEUROSCI LETT, V362, P232, DOI 10.1016/j.neulet.2004.03.019; HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S; Hooshmand MJ, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-15; Hygge-Blakeman K, 2004, BRAIN RES, V1025, P152, DOI 10.1016/j.brainres.2004.07.078; Jain NB, 2015, JAMA-J AM MED ASSOC, V313, P2236, DOI 10.1001/jama.2015.6250; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Khayrullina G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0391-8; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kregel KC, 2007, AM J PHYSIOL-REG I, V292, pR18, DOI 10.1152/ajpregu.00327.2006; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Loy DN, 2002, EXP NEUROL, V177, P575, DOI 10.1006/exnr.2002.7959; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Moritz KE, 2014, RESTOR NEUROL NEUROS, V32, P701, DOI 10.3233/RNN-140414; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; NSCISC, 2016, FACTS FIG GLANC, P2016; Ritzel RM, 2015, NEUROBIOL AGING, V36, P2153, DOI 10.1016/j.neurobiolaging.2015.02.016; Ronsyn MW, 2008, SPINAL CORD, V46, P532, DOI 10.1038/sc.2008.13; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Zhang B, 2014, EXP NEUROL, V258, P112, DOI 10.1016/j.expneurol.2014.04.007; Zhang B, 2016, NEUROBIOL AGING, V47, P157, DOI 10.1016/j.neurobiolaging.2016.07.029; Zhang B, 2015, EXP NEUROL, V273, P83, DOI 10.1016/j.expneurol.2015.08.001	43	30	30	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 18	2017	14								161	10.1186/s12974-017-0933-3			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	FE0YI	WOS:000407945200001	28821269	DOAJ Gold, Green Published			2021-06-18	
J	Bhagya, VR; Srikumar, BN; Veena, J; Rao, BSS				Bhagya, Venkanna Rao; Srikumar, Bettadapura N.; Veena, Jayagopalan; Rao, Byrathnahalli S. Shankaranarayana			Short-term exposure to enriched environment rescues chronic stress-induced impaired hippocampal synaptic plasticity, anxiety, and memory deficits	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						chronic stress; environmental enrichment; hippocampus; synaptic plasticity; working memory	TRAUMATIC BRAIN-INJURY; CA3 DENDRITIC ATROPHY; RESTRAINT STRESS; COGNITIVE FUNCTION; DENTATE GYRUS; SPATIAL MEMORY; PSYCHOSOCIAL STRESS; NEUROTROPHIC FACTOR; PREFRONTAL CORTEX; RATS	Exposure to prolonged stress results in structural and functional alterations in the hippocampus including reduced long-term potentiation (LTP), neurogenesis, spatial learning and working memory impairments, and enhanced anxiety-like behavior. On the other hand, enriched environment (EE) has beneficial effects on hippocampal structure and function, such as improved memory, increased hippocampal neurogenesis, and progressive synaptic plasticity. It is unclear whether exposure to short-term EE for 10 days can overcome restraint stress-induced cognitive deficits and impaired hippocampal plasticity. Consequently, the present study explored the beneficial effects of short-term EE on chronic stress-induced impaired LTP, working memory, and anxiety-like behavior. Male Wistar rats were subjected to chronic restraint stress (6hr/day) over a period of 21 days, and then they were exposed to EE (6hr/day) for 10 days. Restraint stress reduced hippocampal CA1-LTP, increased anxiety-like symptoms in elevated plus maze, and impaired working memory in T-maze task. Remarkably, EE facilitated hippocampal LTP, improved working memory performance, and completely overcame the effect of chronic stress on anxiety behavior. In conclusion, exposure to EE can bring out positive effects on synaptic plasticity in the hippocampus and thereby elicit its beneficial effects on cognitive functions. (c) 2016 Wiley Periodicals, Inc.	[Bhagya, Venkanna Rao; Srikumar, Bettadapura N.; Veena, Jayagopalan; Rao, Byrathnahalli S. Shankaranarayana] NIMHANS, Dept Neurophysiol, Hosur Rd,PB 2900, Bengaluru 560029, India	Bhagya, VR (corresponding author), NIMHANS, Dept Neurophysiol, Hosur Rd,PB 2900, Bengaluru 560029, India.	bhagyapkumar@gmail.com	Rao, Bhagya Venkanna/AAY-7370-2020	Rao, Bhagya Venkanna/0000-0003-0664-0335; Shankaranarayana Rao, BS/0000-0002-8323-8211			Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; Anuradha H, 2008, J NEURAL TRANSM, V115, P35, DOI 10.1007/s00702-007-0821-6; Artola A, 2006, EUR J NEUROSCI, V23, P261, DOI 10.1111/j.1460-9568.2005.04552.x; Ashokan A, 2016, PSYCHONEUROENDOCRINO, V69, P189, DOI 10.1016/j.psyneuen.2016.04.009; Beauquis J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013993; Benaroya-Milshtein N, 2004, EUR J NEUROSCI, V20, P1341, DOI 10.1111/j.1460-9568.2004.03587.x; Bhagya V, 2016, INDIAN J PHARMACOL, V48, P687, DOI 10.4103/0253-7613.194853; Bhagya V, 2015, J NEUROSCI RES, V93, P104, DOI 10.1002/jnr.23473; Bhagya V, 2011, PSYCHOPHARMACOLOGY, V214, P477, DOI 10.1007/s00213-010-2054-x; Bindu B, 2007, NEUROSCIENCE, V144, P412, DOI 10.1016/j.neuroscience.2006.09.057; Buchhold B, 2007, RESTOR NEUROL NEUROS, V25, P467; Burrows EL, 2015, NEUROPSYCHOPHARMACOL, V40, P1947, DOI 10.1038/npp.2015.44; Buschler A, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00085; Chapillon P, 1999, BEHAV GENET, V29, P41, DOI 10.1023/A:1021437905913; Chiba S, 2012, PROG NEURO-PSYCHOPH, V39, P112, DOI 10.1016/j.pnpbp.2012.05.018; Conrad CD, 1999, BEHAV NEUROSCI, V113, P902, DOI 10.1037/0735-7044.113.5.902; Cordner ZA, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.127; Cui MH, 2006, NEUROSCI LETT, V404, P208, DOI 10.1016/j.neulet.2006.05.048; Czeh B, 2002, BIOL PSYCHIAT, V52, P1057, DOI 10.1016/S0006-3223(02)01457-9; Diamond DM, 2004, EUR NEUROPSYCHOPHARM, V14, pS491, DOI 10.1016/j.euroneuro.2004.09.003; Duffy SN, 2001, LEARN MEMORY, V8, P26, DOI 10.1101/lm.36301; Fares RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053888; Fox C, 2006, BEHAV BRAIN RES, V175, P1, DOI 10.1016/j.bbr.2006.08.016; Furuie H, 2013, BEHAV PHARMACOL, V24, P678, DOI 10.1097/FBP.0000000000000003; Garcia R, 1997, NEUROSCI LETT, V233, P41, DOI 10.1016/S0304-3940(97)00621-6; Gerges NZ, 2004, HIPPOCAMPUS, V14, P402, DOI 10.1002/hipo.10193; Gerges NZ, 2001, BRAIN RES, V922, P250, DOI 10.1016/S0006-8993(01)03181-X; Gould E, 1997, J NEUROSCI, V17, P2492; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Han B, 2016, J ALZHEIMERS DIS, V53, P1539, DOI 10.3233/JAD-160189; Hellemans KGC, 2004, DEV BRAIN RES, V150, P103, DOI 10.1016/j.devbrainres.2004.03.003; Henn FA, 2005, NEUROSCI BIOBEHAV R, V29, P799, DOI 10.1016/j.neubiorev.2005.03.019; Huang FL, 2006, J NEUROSCI, V26, P6230, DOI 10.1523/JNEUROSCI.1182-06.2006; Irvine GI, 2006, HIPPOCAMPUS, V16, P149, DOI 10.1002/hipo.20142; Joels M, 2004, STRESS, V7, P221, DOI 10.1080/10253890500070005; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; Kempermann G, 2000, Prog Brain Res, V127, P35; Kleen JK, 2006, BEHAV NEUROSCI, V120, P842, DOI 10.1037/0735-7044.120.4.842; Krugers HJ, 2006, EUR J NEUROSCI, V23, P3051, DOI 10.1111/j.1460-9568.2006.04842.x; Liu LX, 2016, BEHAV BRAIN RES, V305, P148, DOI 10.1016/j.bbr.2016.03.005; Mahati K, 2016, NEUROBIOL LEARN MEM, V134, P379, DOI 10.1016/j.nlm.2016.08.017; Malchow B, 2015, SCHIZOPHRENIA BULL, V41, P847, DOI 10.1093/schbul/sbv020; McEwen BS, 2000, BRAIN RES, V886, P172, DOI 10.1016/S0006-8993(00)02950-4; McKittrick CR, 2000, SYNAPSE, V36, P85, DOI 10.1002/(SICI)1098-2396(200005)36:2<85::AID-SYN1>3.3.CO;2-P; McLaughlin KJ, 2007, BRAIN RES, V1161, P56, DOI 10.1016/j.brainres.2007.05.042; Mora F, 2007, BRAIN RES REV, V55, P78, DOI 10.1016/j.brainresrev.2007.03.011; Morley-Fletcher S, 2003, EUR J NEUROSCI, V18, P3367, DOI 10.1111/j.1460-9568.2003.03070.x; Nithianantharajah J, 2004, NEUROBIOL LEARN MEM, V81, P200, DOI 10.1016/j.nlm.2004.02.002; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Nowakowska E, 2014, PHARMACOL REP, V66, P404, DOI 10.1016/j.pharep.2013.12.008; Pang TYC, 2013, NEUROPHARMACOLOGY, V64, P515, DOI 10.1016/j.neuropharm.2012.06.029; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pham K, 2003, EUR J NEUROSCI, V17, P879, DOI 10.1046/j.1460-9568.2003.02513.x; Pham TM, 1999, NEUROSCIENCE, V94, P279, DOI 10.1016/S0306-4522(99)00316-4; Piazza F, 2014, METAB BRAIN DIS, V29, P93, DOI 10.1007/s11011-013-9467-2; Ramkumar K, 2008, NEUROCHEM RES, V33, P1651, DOI 10.1007/s11064-007-9511-x; Sarris J, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-107; Shors TJ, 1997, SYNAPSE, V26, P209, DOI 10.1002/(SICI)1098-2396(199707)26:3<209::AID-SYN2>3.0.CO;2-B; Sousa N, 2000, NEUROSCIENCE, V97, P253, DOI 10.1016/S0306-4522(00)00050-6; Srikumar BN, 2007, PSYCHOPHARMACOLOGY, V193, P363, DOI 10.1007/s00213-007-0801-4; Srikumar BN, 2006, NEUROSCIENCE, V143, P679, DOI 10.1016/j.neuroscience.2006.08.041; Sunanda, 2000, NEUROCHEM RES, V25, P1547, DOI 10.1023/A:1026606201069; Tang YP, 2001, NEUROPHARMACOLOGY, V41, P779, DOI 10.1016/S0028-3908(01)00122-8; Teather LA, 2002, EUR J NEUROSCI, V16, P2405, DOI 10.1046/j.1460-9568.2002.02416.x; Then FS, 2015, NEUROLOGY, V84, P2169, DOI 10.1212/WNL.0000000000001605; Valero J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016832; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Veena J, 2011, PSYCHOPHARMACOLOGY, V217, P239, DOI 10.1007/s00213-011-2279-3; Veena J, 2009, NEUROSCI LETT, V455, P178, DOI 10.1016/j.neulet.2009.03.059; Veena J, 2009, J NEUROSCI RES, V87, P831, DOI 10.1002/jnr.21907; Vouimba RM, 2004, EUR J NEUROSCI, V19, P1887, DOI 10.1111/j.1460-9568.2004.03294.x; Vyas A, 2002, J NEUROSCI, V22, P6810; White JH, 2015, DISABIL REHABIL, V37, P593, DOI 10.3109/09638288.2014.935876; Wright RL, 2008, BEHAV BRAIN RES, V187, P41, DOI 10.1016/j.bbr.2007.08.025; Yang JL, 2007, NEUROBIOL LEARN MEM, V87, P257, DOI 10.1016/j.nlm.2006.09.001; Yu LL, 2016, WORLD NEUROSURG, V86, P173, DOI 10.1016/j.wneu.2015.09.071	76	30	33	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG	2017	95	8					1602	1610		10.1002/jnr.23992			9	Neurosciences	Neurosciences & Neurology	EX7OU	WOS:000403438300008	27862185				2021-06-18	
J	Adams, H; Donnelly, J; Czosnyka, M; Kolias, AG; Helmy, A; Menon, DK; Smielewski, P; Hutchinson, PJ				Adams, Hadie; Donnelly, Joseph; Czosnyka, Marek; Kolias, Angelos G.; Helmy, Adel; Menon, David K.; Smielewski, Peter; Hutchinson, Peter J.			Temporal profile of intracranial pressure and cerebrovascular reactivity in severe traumatic brain injury and association with fatal outcome: An observational study	PLOS MEDICINE			English	Article							CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; BLOOD-FLOW; DECOMPRESSIVE CRANIECTOMY; TIME-COURSE; AUTOREGULATION; HYPERTENSION; EPIDEMIOLOGY; HYPERVENTILATION; CIRCULATION	Background Both intracranial pressure (ICP) and the cerebrovascular pressure reactivity represent the dysregulation of pathways directly involved in traumatic brain injury (TBI) pathogenesis and have been used to inform clinical management. However, how these parameters evolve over time following injury and whether this evolution has any prognostic importance have not been studied. Methods and findings We analysed the temporal profile of ICP and pressure reactivity index (PRx), examined their relation to TBI-specific mortality, and determined if the prognostic relevance of these parameters was affected by their temporal profile using mixed models for repeated measures of ICP and PRx for the first 240 hours from the time of injury. A total of 601 adults with TBI, admitted between September 2002 to January 2016, and with high-resolution continuous monitoring from a single centre, were studied. At 6 months postinjury, 133 (19%) patients had a fatal outcome; of those, 88 (78%) died from nonsurvivable TBI or brain death. The difference in mean ICP between those with a fatal outcome and functional survivors was only significant for the first 168 hours after injury (all p < 0.05). For PRx, those patients with a fatal outcome also had a higher (more impaired) PRx throughout the first 120 hours after injury (all p < 0.05). The separation of ICP and PRx was greatest in the first 72 hours after injury. Mixed models demonstrated that the explanatory power of the PRx decreases over time; therefore, the prognostic weight assigned to PRx should similarly decrease. However, the ability of ICP to predict a fatal outcome remained relatively stable over time. As control of ICP is the central purpose of TBI management, it is likely that some of the information that is reflected in the natural history of ICP changes is no longer apparent because of therapeutic intervention. Conclusions We demonstrated the temporal evolution of ICP and PRx and their relationship with fatal outcome, indicating a potential early prognostic and therapeutic window. The combination of dynamic monitoring variables and their time profile improved prediction of outcome. Therefore, time-driven dynamic modelling of outcome in patients with severe TBI may allow for more accurate and clinically useful prediction models. Further research is needed to confirm and expand on these findings.	[Adams, Hadie; Donnelly, Joseph; Czosnyka, Marek; Kolias, Angelos G.; Helmy, Adel; Smielewski, Peter; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Cambridge, England	Adams, H (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge, England.	ha356@cam.ac.uk	Donnelly, Joseph/E-9235-2018; Helmy, Adel/AAS-3084-2020; Donnelly, Joseph/N-6803-2019	Donnelly, Joseph/0000-0002-6502-8069; Helmy, Adel/0000-0002-0531-0556; Donnelly, Joseph/0000-0002-6502-8069; Smielewski, Peter/0000-0001-5096-3938; Kolias, Angelos/0000-0003-3992-0587	Senior Investigator award from the NIHR; European Union Seventh Framework Program grant (CENTER-TBI) [602150]; Research Professorship from the NIHR; NIHR Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0601025, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013] Funding Source: researchfish	DKM is supported by a Senior Investigator award from the NIHR and a European Union Seventh Framework Program grant (CENTER-TBI; grant no. 602150). PJH is supported by a Research Professorship from the NIHR, the NIHR Cambridge Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ameloot K, 2015, RESUSCITATION, V90, P121, DOI 10.1016/j.resuscitation.2015.03.001; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Dias C, 2015, NEUROCRIT CARE, V23, P92, DOI 10.1007/s12028-014-0103-8; Dias C, 2015, NEUROCRIT CARE, V22, P192, DOI 10.1007/s12028-014-0045-1; Donnelly J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1293-6; Donnelly J, 2015, NEUROCRIT CARE, V22, P20, DOI 10.1007/s12028-014-0042-4; Fanelli V, 2015, INTENSIVE CARE MED E, V3, pA509; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GUILLAUME J, 1951, PRESSE MED, V59, P953; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; JENNETT B, 1975, LANCET, V1, P480; Johnson U, 2014, NEUROCRIT CARE; Katzenberger RJ, 2015, FLY, V9, P68, DOI 10.1080/19336934.2015.1085623; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Lundberg N., 1959, ACTA PSYCHIAT SCAND, V36, P1; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Moons KGM, 2015, ADV ANAT PATHOL, V22, P303, DOI 10.1097/PAP.0000000000000072; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Ogawa Y, 2010, ANESTH ANALG, V111, P1279, DOI 10.1213/ANE.0b013e3181f42fc0; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pfeifer R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148844; Pfister D, 2008, CRIT CARE, V12, DOI 10.1186/cc6891; R Development Core Team, 2013, R LANG ENV STAT COMP; Rangel-Castilla L, 2010, J NEUROTRAUM, V27, P1853, DOI 10.1089/neu.2010.1339; ROBERTSON CS, 1989, J NEUROSURG, V71, P673, DOI 10.3171/jns.1989.71.5.0673; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Salam Adil, 2003, Respir Care, V48, P1033; Salehpour F, 2011, J CRIT CARE, V26, P352, DOI 10.1016/j.jcrc.2010.12.005; Schramm P, 2011, J NEUROSURG ANESTH, V23, P41, DOI 10.1097/ANA.0b013e3181f35854; Sekhon MS, 2015, NEUROCRIT CARE, V23, P210, DOI 10.1007/s12028-015-0141-x; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Souter MJ, 1999, CRIT CARE MED, V27, P177, DOI 10.1097/00003246-199901000-00048; Stein DM, 2013, NEUROCRIT CARE, V18, P332, DOI 10.1007/s12028-013-9832-3; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Sykora M, 2016, CRIT CARE MED, V44, P1173, DOI 10.1097/CCM.0000000000001624; Taccone FS, 2010, NEUROCRIT CARE, V12, P35, DOI 10.1007/s12028-009-9289-6; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	61	30	30	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	JUL	2017	14	7							e1002353	10.1371/journal.pmed.1002353			21	Medicine, General & Internal	General & Internal Medicine	FC1QA	WOS:000406611200023	28742817	DOAJ Gold, Green Published			2021-06-18	
J	Hoshizaki, TB; Post, A; Kendall, M; Cournoyer, J; Rousseau, P; Gilchrist, MD; Brien, S; Cusimano, M; Marshall, S				Hoshizaki, T. Blaine; Post, Andrew; Kendall, Marshall; Cournoyer, Janie; Rousseau, Philippe; Gilchrist, Michael D.; Brien, Susan; Cusimano, Michael; Marshall, Shawn			The development of a threshold curve for the understanding of concussion in sport	TRAUMA-ENGLAND			English	Article						Concussion; mild traumatic brain injury (mTBI); Wayne State Concussion Tolerance Curve; brain injury	BRAIN-INJURY; ACCIDENT RECONSTRUCTION; PROFESSIONAL FOOTBALL; BIOMECHANICS; ACCELERATION; PREDICTION; MECHANISMS; IMPACTS	Much of what is known concerning human brain injury thresholds is based upon impacts to cadavers and animal models that were used to generate the Wayne State Concussion Tolerance Curve (WSTC) and similar curves. These curves are the foundation for predictive metrics used in standard development as well as helmet design. These curves were based upon a very narrow range of impacts; impacts whose characteristics differ greatly from how the head is impacted in sport. This research examines the uses of time-based curves like the WSTC in the context of understanding mechanisms of brain injury and head protection. Published linear/rotational acceleration magnitude/duration data from Hybrid III laboratory reconstructions of brain injury events were plotted. This research further develops the understanding of injury thresholds in comparison to threshold curves such as the WSTC and Brain Injury Curve Leuven. The data demonstrate the relationships between magnitude and duration of dynamic response on minor traumatic brain injury (mTBI) in sport.	[Hoshizaki, T. Blaine; Post, Andrew; Kendall, Marshall; Cournoyer, Janie; Rousseau, Philippe; Gilchrist, Michael D.; Brien, Susan] Univ Ottawa, Human Kinet, Ottawa, ON, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland; [Brien, Susan] Hull Hosp, Gatineau, PQ, Canada; [Cusimano, Michael] St Michaels Hosp, Toronto, ON, Canada; [Marshall, Shawn] Ottawa Hosp, Res Inst, Ottawa, ON, Canada	Post, A (corresponding author), 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca	Cusimano, Michael/X-4059-2019				Auer C, 2001, INT SOC BIOM 18 C ZU, P1; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Cournoyer J, 2014, SPORT CONC C CHIC IL; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2007, THESIS; Fahlstedt M, 2012, IRCOBI, P800; Fernandes FAO, 2015, P I MECH ENG H, V229, P592, DOI 10.1177/0954411915592906; Forero Rueda MA, 2013, COMPUT METHOD BIOMEC, V14, P1021; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gennarelli TA, 1972, 720970 SAE; Gilchrist MD, 2003, KEY ENG MATER, V245-2, P417, DOI 10.4028/www.scientific.net/KEM.245-246.417; GURDJIAN E S, 1964, J Trauma, V4, P309; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HARDY WN, 1994, INT J IMPACT ENG, V15, P561, DOI 10.1016/0734-743X(94)80034-7; Hitosugi M, 2014, BIOMED RES-TOKYO, V35, P339, DOI 10.2220/biomedres.35.339; Hodgson VR, 1970, 700901 SAE; Holbourn AHS, 1943, LANCET, V2, P438; Hoshizaki B, 2013, J NEUROL NEUROPHYS, V5, P1; Kendall M, 2013, IRCOBI, P430; Kendall M., 2016, THESIS; King A.I., 2003, IRCOBI C LISB PORT, P1; MARTLAND HS, 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Morrison III B., 2003, 20032200066 SAE; Newman JA, 1998, BIOM HLTH R, V21, P200; O'Donoghue D, 1999, THESIS; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Ono K., 1980, 801303 SAE; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4028983; Post A, 2015, NEUROSURGERY, V76, P81, DOI 10.1227/NEU.0000000000000554; Post A, 2015, J MECH BEHAV BIOMED, V41, P325, DOI 10.1016/j.jmbbm.2014.07.034; Post A, 2012, TRAUMA, V14, P327, DOI 10.1177/1460408612446573; Post A, 2013, COMPUT METHOD BIOMEC, V16, P511, DOI 10.1080/10255842.2011.627559; Post A, 2012, J BIOMECH, V45, P679, DOI 10.1016/j.jbiomech.2011.12.005; Rousseau P., 2014, THESIS; Rousseau P, 2015, SPORT BIOMECH, V14, P57, DOI 10.1080/14763141.2015.1025236; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Sano K, 1972, Scand J Rehabil Med, V4, P47; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Stapp JP, 1970, IMPACT INJURY CRASH, P308; Van Lierde C, 2005, THESIS; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; WILLINGER R, 1994, ACCIDENT ANAL PREV, V26, P767, DOI 10.1016/0001-4575(94)90053-1; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	59	30	30	1	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1460-4086	1477-0350		TRAUMA	Trauma	JUL	2017	19	3					196	206		10.1177/1460408616676503			11	Emergency Medicine	Emergency Medicine	EX6EL	WOS:000403335300004					2021-06-18	
J	Liu, WC; Wen, L; Xie, T; Wang, H; Gong, JB; Yang, XF				Liu, Wen-Chao; Wen, Liang; Xie, Tao; Wang, Hao; Gong, Jiang-Biao; Yang, Xiao-Feng			Therapeutic effect of erythropoietin in patients with traumatic brain injury: a meta-analysis of randomized controlled trials	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; erythropoietin; favorable neurological outcome; mortality; deep vein thrombosis; meta-analysis	EPOETIN-ALPHA; HEAD-INJURY; EFFICACY; NEUROPROTECTION; MORTALITY; SURVIVAL; STROKE; DAMAGE	OBJECTIVE Erythropoietin (EPO) exerts a neuroprotective effect in animal models of traumatic brain injury (TBI). However, its effectiveness in human patients with TBI is unclear. In this study, the authors conducted the first meta-analysis to assess the effectiveness and safety of EPO in patients with TBI. METHODS In December 2015, a systematic search was performed of PubMed, Web of Science, MEDLINE, Embase, the Cochrane Library databases, and Google Scholar. Only English-language publications of randomized controlled trials (RCTs) using EPO in patients with TBI were selected for analysis. The assessed outcomes included mortality, favorable neurological outcome, hospital stay, and associated adverse effects. Continuous variables were presented as mean difference (MD) with a 95% confidence interval (CI). Dichotomous variables were presented as risk ratio (RR) or risk difference (RD) with a 95% Cl. Statistical heterogeneity was examined using both I-2 and chi-square tests. RESULTS Of the 346 studies identified in the search, 5 RCTs involving 915 patients met the inclusion criteria. The overall results demonstrated that EPO significantly reduced mortality (RR 0.69, 95% CI 0.49-0.96, p = 0.03) and shortened the hospitalization time (MD -7.59, 95% CI -9.71 to -5.46, p < 0.0001) for patients with TBI. Pooled results of favorable outcome (RR 1.00, 95% CI 0.88-1.15, p = 0.97) and deep vein thrombosis (DVT; RD 0.00, 95% CI -0.05 to 0.05, p = 1.00) did not show a significant difference. CONCLUSIONS The authors suggested that EPO is beneficial for patients with TBI in terms of reducing mortality and shortening hospitalization time without increasing the risk of DVT. However, its effect on improving favorable neurological outcomes did not reach statistical significance. Therefore, more well-designed RCTs are necessary to ascertain the optimum dosage and time window of EPO treatment for patients with TBI.	[Liu, Wen-Chao; Wen, Liang; Wang, Hao; Gong, Jiang-Biao; Yang, Xiao-Feng] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Neurosurg, 79 Qingchun Rd, Hangzhou 310000, Zhejiang, Peoples R China; [Xie, Tao] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China	Yang, XF (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Neurosurg, 79 Qingchun Rd, Hangzhou 310000, Zhejiang, Peoples R China.	zjcswk@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81470052, 81271357]	This project was supported by grants (81470052 and 81271357) from the National Natural Science Foundation of China.	Abrishamkar S, 2012, J RES MED SCI, V17, P51; Aloizos S, 2015, TURK NEUROSURG, V25, P552, DOI 10.5137/1019-5149.JTN.9685-14.4; Asadi B, 2013, INT J PREVENTIVE MED, V4, pS306; Bennett CL, 2008, JAMA-J AM MED ASSOC, V299, P914, DOI 10.1001/jama.299.8.914; Bouzat P, 2011, CRIT CARE MED, V39, P2099, DOI 10.1097/CCM.0b013e31821cb7b2; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Corwin HL, 2002, JAMA-J AM MED ASSOC, V288, P2827, DOI 10.1001/jama.288.22.2827; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; Grasso G, 2007, DRUG NEWS PERSPECT, V20, P315, DOI 10.1358/dnp.2007.20.5.1120219; Grasso G, 2015, WORLD NEUROSURG, V84, P1491, DOI 10.1016/j.wneu.2015.05.056; Hellewell SC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-156; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; JENNETT B, 1975, LANCET, V1, P480; Jerndal M, 2010, J CEREBR BLOOD F MET, V30, P961, DOI 10.1038/jcbfm.2009.267; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; MATTHEWS DSF, 1995, J NEUROL NEUROSUR PS, V59, P359, DOI 10.1136/jnnp.59.4.359; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nirula R, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/209848; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Peng WJ, 2014, J NEUROSURG, V121, P653, DOI 10.3171/2014.6.JNS132577; Phrommintikul A, 2007, LANCET, V369, P381, DOI 10.1016/S0140-6736(07)60194-9; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Schober ME, 2014, J NEUROTRAUM, V31, P358, DOI 10.1089/neu.2013.2922; Singh AK, 2010, CURR OPIN NEPHROL HY, V19, P420, DOI 10.1097/MNH.0b013e32833cf1d6; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Talving P, 2012, ARCH SURG-CHICAGO, V147, P251, DOI 10.1001/archsurg.2011.1838; Talving P, 2010, ANN SURG, V251, P1, DOI 10.1097/SLA.0b013e3181b844fa; Tsai TH, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0761-8; Turaga Kiran K, 2007, J Intensive Care Med, V22, P270, DOI 10.1177/0885066607304437; Velly L, 2010, PHARMACOL THERAPEUT, V128, P445, DOI 10.1016/j.pharmthera.2010.08.002; Yip HK, 2011, CRIT CARE, V15, DOI 10.1186/cc10002	38	30	33	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2017	127	1					8	15		10.3171/2016.4.JNS152909			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EY6JB	WOS:000404087500002	27367243				2021-06-18	
J	Salehpour, F; Rasta, SH				Salehpour, Farzad; Rasta, Seyed Hossein			The potential of transcranial photobiomodulation therapy for treatment of major depressive disorder	REVIEWS IN THE NEUROSCIENCES			English	Article						cerebral blood flow; depression; near-infrared; photobiomodulation; pulsed light; prefrontal cortex	DIRECT-CURRENT STIMULATION; INFRARED-LASER THERAPY; TRAUMATIC BRAIN-INJURY; LEVEL LIGHT THERAPY; CEREBRAL-BLOOD-FLOW; PREFRONTAL CORTEX; MOUSE MODEL; OPTICAL-PROPERTIES; MITOCHONDRIAL; METAANALYSIS	Major depressive disorder is a common debilitating mood disorder that affects quality of life. Prefrontal cortex abnormalities, an imbalance in neurotransmitters, neuroinflammation, and mitochondrial dysfunction are the major factors in the etiology of major depressive disorder. Despite the efficacy of pharmacotherapy in the treatment of major depressive disorder, 30%-40% of patients do not respond to antidepressants. Given this, exploring the alternative therapies for treatment or prevention of major depressive disorder has aroused interest among scientists. Transcranial photobiomodulation therapy is the use of low-power lasers and light-emitting diodes in the far-red to near-infrared optical region for stimulation of neuronal activities. This non-invasive modality improves the metabolic capacity of neurons due to more oxygen consumption and ATP production. Beneficial effects of transcranial photobiomodulation therapy in the wide range of neurological and psychological disorders have been already shown. In this review, we focus on some issues relating to the application of photobiomodulation therapy for major depressive disorder. There is some evidence that transcranial photobiomodulation therapy using near-infrared light on 10-Hz pulsed mode appears to be a hopeful technique for treatment of major depressive disorder. However, further studies are necessary to find the safety of this method and to determine its effective treatment protocol.	[Salehpour, Farzad; Rasta, Seyed Hossein] Tabriz Univ Med Sci, Dept Med Phys, Attar Neyshapouri St,Azadi Ave, Tabriz 5166614766, Iran; [Rasta, Seyed Hossein] Tabriz Univ Med Sci, Dept Med Bioengn, Tabriz 5166614766, Iran; [Rasta, Seyed Hossein] Univ Aberdeen, Sch Med Sci, Aberdeen AB24 5DT, Scotland; [Salehpour, Farzad] Tabriz Univ Med Sci, Neurosci Res Ctr NSRC, Tabriz 5166614766, Iran	Rasta, SH (corresponding author), Tabriz Univ Med Sci, Dept Med Phys, Attar Neyshapouri St,Azadi Ave, Tabriz 5166614766, Iran.; Rasta, SH (corresponding author), Tabriz Univ Med Sci, Dept Med Bioengn, Tabriz 5166614766, Iran.; Rasta, SH (corresponding author), Univ Aberdeen, Sch Med Sci, Aberdeen AB24 5DT, Scotland.	s.h.rasta@abdn.ac.uk	Rasta, Seyed Hossein/L-6626-2017	Rasta, Seyed Hossein/0000-0003-0351-5176; salehpour, farzad/0000-0002-7070-8835			Abdo A, 2007, P ANN INT IEEE EMBS, P1723, DOI 10.1109/IEMBS.2007.4352642; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Antunes F, 2004, P NATL ACAD SCI USA, V101, P16774, DOI 10.1073/pnas.0405368101; BARKER AT, 1985, LANCET, V1, P1106; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; BEAUVOIT B, 1994, BIOPHYS J, V67, P2501, DOI 10.1016/S0006-3495(94)80740-4; Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096; Berlim MT, 2013, J PSYCHIATR RES, V47, P1, DOI 10.1016/j.jpsychires.2012.09.025; Blanco NJ, 2017, J NEUROPSYCHOL, V11, P14, DOI 10.1111/jnp.12074; Bradford A, 2005, J PHOTOCH PHOTOBIO B, V81, P9, DOI 10.1016/j.jphotobiol.2005.05.005; Brambilla P, 2005, PHARMACOPSYCHIATRY, V38, P69, DOI 10.1055/s-2005-837806; Brunoni AR, 2016, BRIT J PSYCHIAT, V208, P522, DOI 10.1192/bjp.bp.115.164715; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Carney S, 2003, LANCET, V361, P799; Cassano Paolo, 2015, Psychiatry J, V2015, P352979, DOI 10.1155/2015/352979; Cassano P, 2016, NEUROPHOTONICS, V3, DOI 10.1117/1.NPh.3.3.031404; Chen ACH, 2011, PHOTOMED LASER SURG, V29, P383, DOI 10.1089/pho.2010.2837; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Cusin C, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-14; de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Disner SG, 2016, BRAIN STIMUL, V9, P780, DOI 10.1016/j.brs.2016.05.009; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Duggett N.A., 2014, BIOL MED, V6, P1; Elhwuegi AS, 2004, PROG NEURO-PSYCHOPH, V28, P435, DOI 10.1016/j.pnpbp.2003.11.018; Fahim C, 2004, BRAIN COGNITION, V54, P161; Gawryluk JW, 2011, INT J NEUROPSYCHOPH, V14, P123, DOI 10.1017/S1461145710000805; Goldapple K, 2004, ARCH GEN PSYCHIAT, V61, P34, DOI 10.1001/archpsyc.61.1.34; Grillo SL, 2013, J PHOTOCH PHOTOBIO B, V123, P13, DOI 10.1016/j.jphotobiol.2013.02.015; Hamblin M.R., 2006, BIOMED OPT, V6140; Hamblin M.R., 2008, BIOMED OPT, V6846; Hamblin MR, 2016, BBA CLIN, V6, P113, DOI 10.1016/j.bbacli.2016.09.002; Hamon M, 2013, PROG NEURO-PSYCHOPH, V45, P54, DOI 10.1016/j.pnpbp.2013.04.009; Hashmi JT, 2010, LASER SURG MED, V42, P450, DOI 10.1002/lsm.20950; Henderson TA, 2015, NEUROPSYCH DIS TREAT, V11, P2191, DOI 10.2147/NDT.S78182; Hennessy M, 2017, J OPTICS-UK, V19, DOI 10.1088/2040-8986/19/1/013003; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Huang ZG, 2016, MATH PROBL ENG, V2016, DOI 10.1155/2016/5087237; Hwang J, 2016, LASER MED SCI, P1; Iaccarino HF, 2016, NATURE, V540, P230, DOI 10.1038/nature20587; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Iosifescu DV, 2008, BIOL PSYCHIAT, V63, P1127, DOI 10.1016/j.biopsych.2007.11.020; Jacques SL, 2013, PHYS MED BIOL, V58, pR37, DOI 10.1088/0031-9155/58/11/R37; Jagdeo JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047460; Johnstone DM, 2014, NEUROSCIENCE, V274, P93, DOI 10.1016/j.neuroscience.2014.05.023; Kalu UG, 2012, PSYCHOL MED, V42, P1791, DOI 10.1017/S0033291711003059; Karu T, 2000, PROC SPIE, V4159, P1, DOI 10.1117/12.405918; KARU TI, 1990, PHOTOCHEM PHOTOBIOL, V52, P1089, DOI 10.1111/j.1751-1097.1990.tb08450.x; Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127580; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lee BH, 2007, J AFFECT DISORDERS, V101, P239, DOI 10.1016/j.jad.2006.11.005; Litscher D, 2013, INT J PHOTOENERGY, V2013, DOI 10.1155/2013/575798; Mechan AO, 2011, BRIT J NUTR, V105, P1150, DOI 10.1017/S0007114510004940; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Mohammed H.S., 2016, LASER MED SCI, V31, P1; Morries LD, 2015, NEUROPSYCH DIS TREAT, V11, P2159, DOI 10.2147/NDT.S65809; Muili KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030655; Naeser MA, 2014, J NEUROTRAUM, V31, P1008, DOI 10.1089/neu.2013.3244; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; O'Reardon JP, 1998, PSYCHIAT ANN, V28, P633, DOI 10.3928/0048-5713-19981101-08; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Passarella S, 1989, J Photochem Photobiol B, V3, P642, DOI 10.1016/1011-1344(89)80090-9; Passarella S, 2014, J PHOTOCH PHOTOBIO B, V140, P344, DOI 10.1016/j.jphotobiol.2014.07.021; Peoples C, 2012, PARKINSONISM RELAT D, V18, P469, DOI 10.1016/j.parkreldis.2012.01.005; Petrie S.R., 2016, QUAL PRIM CARE, V24, P33; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Rasta SH, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.11.116005; Rezin GT, 2008, NEUROCHEM INT, V53, P395, DOI 10.1016/j.neuint.2008.09.012; Rojas JC, 2012, J ALZHEIMERS DIS, V32, P741, DOI 10.3233/JAD-2012-120817; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Salehpour F, 2016, LASER SURG MED, V48, P695, DOI 10.1002/lsm.22542; Salehpour F, 2016, LASER SURG MED, V48, P455; Salgado ASI, 2015, LASER MED SCI, V30, P339, DOI 10.1007/s10103-014-1669-2; Santana-Blank L, 2016, PHOTOMED LASER SURG, V34, P93, DOI 10.1089/pho.2015.4015; Santana-Blank L, 2010, PHOTOMED LASER SURG, V28, pS41, DOI 10.1089/pho.2009.2647; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Shumake J, 2003, Behav Cogn Neurosci Rev, V2, P198, DOI 10.1177/1534582303259057; Smith KC, 2007, PHOTOCHEM PHOTOBIOL, V3, P1539; Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910; Souery D, 1999, EUR NEUROPSYCHOPHARM, V9, P83, DOI 10.1016/S0924-977X(98)00004-2; Stahl SM, 2009, STAHLS ILLUSTRATED A; Szundi I, 2001, BIOCHEMISTRY-US, V40, P2332, DOI 10.1021/bi002220v; Taddeucci A, 1996, J Biomed Opt, V1, P117, DOI 10.1117/12.227816; Tagliari B, 2010, METAB BRAIN DIS, V25, P169, DOI 10.1007/s11011-010-9194-x; Tian FH, 2016, LASER SURG MED, V48, P343, DOI 10.1002/lsm.22471; Tuby H, 2011, LASER SURG MED, V43, P401, DOI 10.1002/lsm.21063; Uccelli A, 2011, BEST PRACT RES CL HA, V24, P59, DOI 10.1016/j.beha.2011.01.004; Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938; Videbech P, 2000, ACTA PSYCHIAT SCAND, V101, P11, DOI 10.1034/j.1600-0447.2000.101001011.x; Weiner RD, 2000, ARCH GEN PSYCHIAT, V57, P591, DOI 10.1001/archpsyc.57.6.591; Wu XJ, 2012, LASER SURG MED, V44, P227, DOI 10.1002/lsm.22004; Xuan WJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.108003; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547; Zunszain Patricia A, 2013, Curr Top Behav Neurosci, V14, P135, DOI 10.1007/7854_2012_211	103	30	30	0	14	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	JUN	2017	28	4					441	453		10.1515/revneuro-2016-0087			13	Neurosciences	Neurosciences & Neurology	EW6MD	WOS:000402623700009	28231069				2021-06-18	
J	DeVience, SJ; Lu, X; Proctor, J; Rangghran, P; Melhem, ER; Gullapalli, R; Fiskum, GM; Mayer, D				DeVience, Stephen J.; Lu, Xin; Proctor, Julie; Rangghran, Parisa; Melhem, Elias R.; Gullapalli, Rao; Fiskum, Gary M.; Mayer, Dirk			Metabolic imaging of energy metabolism in traumatic brain injury using hyperpolarized [1-C-13] pyruvate	SCIENTIFIC REPORTS			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; IN-VIVO; LACTATE; MODELS; RATIO	Traumatic brain injury (TBI) is known to cause perturbations in the energy metabolism of the brain, but current tests of metabolic activity are only indirect markers of energy use or are highly invasive. Here we show that hyperpolarized C-13 magnetic resonance spectroscopic imaging (MRSI) can be used as a direct, non-invasive method for studying the effects of TBI on energy metabolism. Measurements were performed on rats with moderate TBI induced by controlled cortical impact on one cerebral hemisphere. Following injection of hyperpolarized [1-C-13] pyruvate, the resulting C-13-bicarbonate signal was found to be 24 +/- 6% lower in the injured hemisphere compared with the non-injured hemisphere, while the hyperpolarized bicarbonate-to-lactate ratio was 33 +/- 8% lower in the injured hemisphere. In a control group, no significant difference in signal was found between sides of the brain. The results suggest an impairment in mitochondrial pyruvate metabolism, resulting in a decrease in aerobic respiration at the location of injury following TBI.	[DeVience, Stephen J.; Lu, Xin; Melhem, Elias R.; Gullapalli, Rao; Mayer, Dirk] Univ Maryland, Dept Diagnost Radiol & Nucl Med, Sch Med, 22 S Greene St, Baltimore, MD 21201 USA; [DeVience, Stephen J.; Lu, Xin; Melhem, Elias R.; Gullapalli, Rao; Mayer, Dirk] Univ Maryland, Ctr Metab Imaging Therapeut, Med Ctr, 22 S Greene St, Baltimore, MD 21201 USA; [Proctor, Julie; Rangghran, Parisa; Fiskum, Gary M.] Univ Maryland, Dept Anesthesiol, Sch Med, 22 S Greene St, Baltimore, MD 21201 USA; [Proctor, Julie; Rangghran, Parisa; Fiskum, Gary M.] Univ Maryland, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, 22 S Greene St, Baltimore, MD 21201 USA; [Fiskum, Gary M.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA	Mayer, D (corresponding author), Univ Maryland, Dept Diagnost Radiol & Nucl Med, Sch Med, 22 S Greene St, Baltimore, MD 21201 USA.; Mayer, D (corresponding author), Univ Maryland, Ctr Metab Imaging Therapeut, Med Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	dmayer@som.umaryland.edu	DeVience, Stephen J/D-7274-2012; Mayer, Dirk/AAJ-5906-2020	DeVience, Stephen J/0000-0003-3142-7296; Mayer, Dirk/0000-0001-7557-9019	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS096575, R01 DK106395]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK106395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS096575] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grants R21 NS096575 and R01 DK106395.	Ardenkjaer-Larsen JH, 2003, P NATL ACAD SCI USA, V100, P10158, DOI 10.1073/pnas.1733835100; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Coronado VG, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P84; Day SE, 2007, NAT MED, V13, P1382, DOI 10.1038/nm1650; Day SE, 2011, MAGN RESON MED, V65, P557, DOI 10.1002/mrm.22698; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; George EO, 2014, J NEUROTRAUM, V31, P1018, DOI 10.1089/neu.2013.3224; Golman K, 2006, CANCER RES, V66, P10855, DOI 10.1158/0008-5472.CAN-06-2564; Golman K, 2006, P NATL ACAD SCI USA, V103, P11270, DOI 10.1073/pnas.0601319103; Guglielmetti C., 2016, P INT SOC MAG RESON, V24, P863; Hurd RE, 2013, MAGN RESON MED, V70, P936, DOI 10.1002/mrm.24544; Hurd RE, 2010, MAGN RESON MED, V63, P1137, DOI 10.1002/mrm.22364; Jalloh I, 2015, METAB BRAIN DIS, V30, P615, DOI 10.1007/s11011-014-9628-y; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; Kettunen MI, 2010, MAGN RESON MED, V63, P872, DOI 10.1002/mrm.22276; Kolias Angelos G, 2013, Pract Neurol, V13, P228, DOI 10.1136/practneurol-2012-000268; Mayer D, 2011, MAGN RESON MED, V65, P1228, DOI 10.1002/mrm.22707; McKenna MC, 2015, NEUROCHEM RES, V40, P2527, DOI 10.1007/s11064-015-1600-7; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nelson SJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006070; Park JM, 2016, NMR BIOMED, V29, P650, DOI 10.1002/nbm.3509; Park JM, 2013, NEURO-ONCOLOGY, V15, P433, DOI 10.1093/neuonc/nos319; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Serrao EM, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00059; Sharma Pushpa, 2009, J Emerg Trauma Shock, V2, P67, DOI 10.4103/0974-2700.50739; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	34	30	30	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAY 15	2017	7								1907	10.1038/s41598-017-01736-x			7	Multidisciplinary Sciences	Science & Technology - Other Topics	FX2OT	WOS:000425901600003	28507314	DOAJ Gold, Green Published			2021-06-18	
J	Jagielska, A; Lowe, AL; Makhija, E; Wroblewska, L; Guck, J; Franklin, RJM; Shivashankar, GV; Van Vliet, KJ				Jagielska, Anna; Lowe, Alexis L.; Makhija, Ekta; Wroblewska, Liliana; Guck, Jochen; Franklin, Robin J. M.; Shivashankar, G. V.; Van Vliet, Krystyn J.			Mechanical Strain Promotes Oligodendrocyte Differentiation by Global Changes of Gene Expression	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						oligodendrocytes; oligodendrocyte precursor cell (OPC); oligodendrocyte differentiation; mechanical strain; multiple sclerosis (MS); mechanotransduction; chromatin remodeling; cell nucleus shape	CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS LESIONS; TRAUMATIC BRAIN-INJURY; EXTRACELLULAR-MATRIX; MORPHOLOGICAL-DIFFERENTIATION; PRECURSOR DIFFERENTIATION; PROGENITOR CELLS; AXONAL INJURY; GROWTH CONES; STEM-CELLS	Differentiation of oligodendrocyte progenitor cells (OPC) to oligodendrocytes and subsequent axon myelination are critical steps in vertebrate central nervous system (CNS) development and regeneration. Growing evidence supports the significance of mechanical factors in oligodendrocyte biology. Here, we explore the effect of mechanical strains within physiological range on OPC proliferation and differentiation, and strain-associated changes in chromatin structure, epigenetics, and gene expression. Sustained tensile strain of 10-15% inhibited OPC proliferation and promoted differentiation into oligodendrocytes. This response to strain required specific interactions of OPCs with extracellular matrix ligands. Applied strain induced changes in nuclear shape, chromatin organization, and resulted in enhanced histone deacetylation, consistent with increased oligodendrocyte differentiation. This response was concurrent with increased mRNA levels of the epigenetic modifier histone deacetylase Hdac11. Inhibition of HDAC proteins eliminated the strain-mediated increase of OPC differentiation, demonstrating a role of HDACs in mechanotransduction of strain to chromatin. RNA sequencing revealed global changes in gene expression associated with strain. Specifically, expression of multiple genes associated with oligodendrocyte differentiation and axon-oligodendrocyte interactions was increased, including cell surface ligands (Ncam, ephrins), cyto-and nucleo-skeleton genes (Fyn, actinins, myosin, nesprin, Sun1), transcription factors (Sox10, Zfp191, Nkx2.2), and myelin genes (Cnp, Plp, Mag). These findings show how mechanical strain can be transmitted to the nucleus to promote oligodendrocyte differentiation, and identify the global landscape of signaling pathways involved in mechanotransduction. These data provide a source of potential new therapeutic avenues to enhance OPC differentiation in vivo.	[Jagielska, Anna; Van Vliet, Krystyn J.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Lowe, Alexis L.] Wellesley Coll, Dept Neurosci, Wellesley, MA 02181 USA; [Makhija, Ekta; Shivashankar, G. V.] Natl Univ Singapore, Mechanobiol Inst, Singapore, Singapore; [Wroblewska, Liliana; Van Vliet, Krystyn J.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Guck, Jochen] Tech Univ Dresden, Biotechnol Ctr, Dresden, Germany; [Franklin, Robin J. M.] Univ Cambridge, Wellcome Trust Med Res Council, Cambridge Stem Cell Inst, Cambridge, England; [Franklin, Robin J. M.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England; [Makhija, Ekta; Van Vliet, Krystyn J.] Singapore MIT Alliance Res & Technol, BioSyst & Micromech Interdisciplinary Res Grp, Singapore, Singapore; [Wroblewska, Liliana] Pfizer, Cambridge, MA USA	Van Vliet, KJ (corresponding author), MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.; Van Vliet, KJ (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Van Vliet, KJ (corresponding author), Singapore MIT Alliance Res & Technol, BioSyst & Micromech Interdisciplinary Res Grp, Singapore, Singapore.	krystyn@mit.edu	Guck, Jochen/B-4412-2014	Guck, Jochen/0000-0002-1453-6119; Franklin, Robin/0000-0001-6522-2104	National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG4855A1/1]; Human Frontiers Science ProgramHuman Frontier Science Program [RGP0015/2009-C]; National Research Foundation of Singapore through Singapore-MIT Alliance for Research and Technology (SMART), BioSystems and Micromechanics (BioSyM) interdisciplinary research group; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_12009] Funding Source: researchfish	We gratefully acknowledge funding from the National Multiple Sclerosis Society (RG4855A1/1), the Human Frontiers Science Program (RGP0015/2009-C), and the National Research Foundation of Singapore through the Singapore-MIT Alliance for Research and Technology (SMART), BioSystems and Micromechanics (BioSyM) interdisciplinary research group.	Ahmed WW, 2013, LAB CHIP, V13, P570, DOI 10.1039/c2lc41109a; Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Arulmoli J, 2015, SCI REP-UK, V5, DOI 10.1038/srep08499; Baer AS, 2009, BRAIN, V132, P465, DOI 10.1093/brain/awn334; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; Bauer NG, 2009, GLIA, V57, P1691, DOI 10.1002/glia.20885; Betz T, 2011, P NATL ACAD SCI USA, V108, P13420, DOI 10.1073/pnas.1106145108; BLAKEMORE WF, 1974, NATURE, V249, P577, DOI 10.1038/249577a0; BRAY D, 1979, J CELL SCI, V37, P391; Bray D, 1984, BIOPHYS J, V102, P379; Buttery PC, 1999, MOL CELL NEUROSCI, V14, P199, DOI 10.1006/mcne.1999.0781; Camara J, 2009, J CELL BIOL, V185, P699, DOI 10.1083/jcb.200807010; Chalut KJ, 2012, BIOPHYS J, V103, P2060, DOI 10.1016/j.bpj.2012.10.015; Chambliss AB, 2013, SCI REP-UK, V3, DOI 10.1038/srep01087; Chew LJ, 2009, J NEUROSCI RES, V87, P3277, DOI 10.1002/jnr.22128; Christ AF, 2010, J BIOMECH, V43, P2986, DOI 10.1016/j.jbiomech.2010.07.002; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Colognato H, 2004, J CELL BIOL, V167, P365, DOI 10.1083/jcb.200404076; Colognato H, 2007, DEVELOPMENT, V134, P1723, DOI 10.1242/dev.02819; Cullen DK, 2007, BRAIN RES, V1158, P103, DOI 10.1016/j.brainres.2007.04.070; Dahl KN, 2008, CIRC RES, V102, P1307, DOI 10.1161/CIRCRESAHA.108.173989; Driscoll TP, 2015, BIOPHYS J, V108, P2783, DOI 10.1016/j.bpj.2015.05.010; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Fisher E, 2007, ANN NEUROL, V62, P219, DOI 10.1002/ana.21113; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Franklin RJM, 1999, J NEUROSCI RES, V58, P207, DOI 10.1002/(SICI)1097-4547(19991015)58:2<207::AID-JNR1>3.0.CO;2-1; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Franze K, 2013, ANNU REV BIOMED ENG, V15, P227, DOI 10.1146/annurev-bioeng-071811-150045; Franze K, 2013, DEVELOPMENT, V140, P3069, DOI 10.1242/dev.079145; Franze K, 2011, SOFT MATTER, V7, P3147, DOI 10.1039/c0sm01017k; Franze K, 2010, REP PROG PHYS, V73, DOI 10.1088/0034-4885/73/9/094601; Franze K, 2009, BIOPHYS J, V97, P1883, DOI 10.1016/j.bpj.2009.07.033; Fuhs T, 2013, CYTOSKELETON, V70, P44, DOI 10.1002/cm.21080; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Graham DM, 2016, CURR OPIN CELL BIOL, V40, P98, DOI 10.1016/j.ceb.2016.03.006; Harlow DE, 2014, EXP NEUROL, V251, P39, DOI 10.1016/j.expneurol.2013.10.017; Hernandez M, 2016, J NEUROSCI, V36, P806, DOI 10.1523/JNEUROSCI.2873-15.2016; Hubner MR, 2010, ANNU REV BIOPHYS, V39, P471, DOI 10.1146/annurev.biophys.093008.131348; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jagielska A, 2012, STEM CELLS DEV, V21, P2905, DOI 10.1089/scd.2012.0189; Kippert A, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-71; Kuhlmann T, 2008, BRAIN, V131, P1749, DOI 10.1093/brain/awn096; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Laursen LS, 2009, J NEUROSCI, V29, P9174, DOI 10.1523/JNEUROSCI.5942-08.2009; Lindqvist N, 2010, INVEST OPHTH VIS SCI, V51, P1683, DOI 10.1167/iovs.09-4159; Linneberg C, 2015, ASN NEURO, V7, DOI 10.1177/1759091415602859; Liu H, 2009, GLIA, V57, P1, DOI 10.1002/glia.20729; Liu J, 2010, TRENDS NEUROSCI, V33, P193, DOI 10.1016/j.tins.2010.01.007; Lourenco T, 2016, SCI REP-UK, V6, DOI 10.1038/srep21563; Lu Y, 2010, FASEB J, V24; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Makhija E, 2016, P NATL ACAD SCI USA, V113, pE32, DOI 10.1073/pnas.1513189113; Mammoto A, 2012, J CELL SCI, V125, P3061, DOI 10.1242/jcs.093005; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Mendez MG, 2012, INT J BIOCHEM CELL B, V44, P728, DOI 10.1016/j.biocel.2012.02.003; Milner R, 1997, GLIA, V21, P350; Milstein JN, 2011, J R SOC INTERFACE, V8, P1673, DOI 10.1098/rsif.2011.0371; Moshayedi P, 2014, BIOMATERIALS, V35, P3919, DOI 10.1016/j.biomaterials.2014.01.038; Moshayedi P, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/19/194114; Nave KA, 2014, ANNU REV CELL DEV BI, V30, P503, DOI 10.1146/annurev-cellbio-100913-013101; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Palser AL, 2009, J NEUROSCI RES, V87, P3356, DOI 10.1002/jnr.22248; Payne SC, 2012, INVEST OPHTH VIS SCI, V53, P6093, DOI 10.1167/iovs.12-10080; Poitelon Y, 2016, NAT NEUROSCI, V19, P879, DOI 10.1038/nn.4316; Relvas JB, 2001, CURR BIOL, V11, P1039, DOI 10.1016/S0960-9822(01)00292-5; Rosenberg SS, 2008, P NATL ACAD SCI USA, V105, P14662, DOI 10.1073/pnas.0805640105; Roux KJ, 2009, P NATL ACAD SCI USA, V106, P2194, DOI 10.1073/pnas.0808602106; Rusielewicz T, 2014, GLIA, V62, P580, DOI 10.1002/glia.22627; Saha K, 2008, BIOPHYS J, V95, P4426, DOI 10.1529/biophysj.108.132217; Schregel K, 2012, P NATL ACAD SCI USA, V109, P6650, DOI 10.1073/pnas.1200151109; Schwartz MA, 2008, CURR OPIN CELL BIOL, V20, P551, DOI 10.1016/j.ceb.2008.05.005; Sherman DL, 2005, NAT REV NEUROSCI, V6, P683, DOI 10.1038/nrn1743; Shimizu T, 2017, GLIA, V65, P360, DOI 10.1002/glia.23096; Shivashankar GV, 2011, ANNU REV BIOPHYS, V40, P361, DOI 10.1146/annurev-biophys-042910-155319; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2009, PROG NEUROBIOL, V89, P231, DOI 10.1016/j.pneurobio.2009.07.006; SOBEL RA, 1989, AM J PATHOL, V135, P161; Song J, 2001, MOL CELL NEUROSCI, V17, P624, DOI 10.1006/mcne.2001.0974; Stoffels JMJ, 2013, BRAIN, V136, P116, DOI 10.1093/brain/aws313; Urbanski MM, 2016, SCI REP-UK, V6, DOI 10.1038/srep33751; VanEssen DC, 1997, NATURE, V385, P313, DOI 10.1038/385313a0; Wang HB, 2008, J CELL BIOL, V182, P1171, DOI 10.1083/jcb.200802091; Wang HB, 2012, J NEUROSCI RES, V90, P1547, DOI 10.1002/jnr.23036; Wang N, 2009, NAT REV MOL CELL BIO, V10, P75, DOI 10.1038/nrm2594; Wu J, 2013, NUCLEIC ACIDS RES, V41, P5149, DOI 10.1093/nar/gkt216; Zeiger A., 2013, THESIS; Zeiger AS, 2016, PHYS BIOL, V13, DOI 10.1088/1478-3975/13/4/046006; Zuchero JB, 2015, DEV CELL, V34, P152, DOI 10.1016/j.devcel.2015.06.011	94	30	30	0	9	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	APR 20	2017	11								93	10.3389/fncel.2017.00093			16	Neurosciences	Neurosciences & Neurology	EX4DS	WOS:000403184200001	28473753	DOAJ Gold, Green Published			2021-06-18	
J	Jha, RM; Puccio, AM; Okonkwo, DO; Zusman, BE; Park, SY; Wallisch, J; Empey, PE; Shutter, LA; Clark, RSB; Kochanek, PM; Conley, YP				Jha, Ruchira M.; Puccio, Ava M.; Okonkwo, David O.; Zusman, Benjamin E.; Park, Seo-Young; Wallisch, Jessica; Empey, Philip E.; Shutter, Lori A.; Clark, Robert S. B.; Kochanek, Patrick M.; Conley, Yvette P.			ABCC8 Single Nucleotide Polymorphisms are Associated with Cerebral Edema in Severe TBI	NEUROCRITICAL CARE			English	Article						ABCC8; Cerebral edema; Traumatic brain injury; Single nucleotide polymorphism (SNP); Sulfonylurea receptor-1 (Sur1)	SULFONYLUREA RECEPTOR 1; TRAUMATIC BRAIN-INJURY; CONGENITAL HYPERINSULINISM; GENETIC-VARIATION; AQUAPORIN-4; GLYBURIDE; PRESSURE; DNA	Cerebral edema (CE) in traumatic brain injury (TBI) is the consequence of multiple underlying mechanisms and is associated with unfavorable outcomes. Genetic variability in these pathways likely explains some of the clinical heterogeneity observed in edema development. A role for sulfonylurea receptor-1 (Sur1) in CE is supported. However, there are no prior studies examining the effect of genetic variability in the Sur1 gene (ABCC8) on the development of CE. We hypothesize that ABCC8 single nucleotide polymorphisms (SNPs) are predictive of CE. DNA was extracted from 385 patients. SNPs in ABCC8 were genotyped using the Human Core Exome v1.2 (Illumina). CE measurements included acute CT edema, mean and peak intracranial pressure (ICP), and need for decompressive craniotomy. Fourteen SNPs with minor allele frequency > 0.2 were identified. Four SNPS rs2283261, rs3819521, rs2283258, and rs1799857 were associated with CE measures. In multiple regression models, homozygote-variant genotypes in rs2283261, rs3819521, and rs2283258 had increased odds of CT edema (OR 2.45, p = 0.007; OR 2.95, p = 0.025; OR 3.00, p = 0.013), had higher mean (beta = 3.13, p = 0.000; beta = 2.95, p = 0.005; beta = 3.20, p = 0.008), and peak ICP (beta = 8.00, p = 0.001; beta = 7.64, p = 0.007; beta = 6.89, p = 0.034). The homozygote wild-type genotype of rs1799857 had decreased odds of decompressive craniotomy (OR 0.47, p = 0.004). This is the first report assessing the impact of ABCC8 genetic variability on CE development in TBI. Minor allele ABCC8 SNP genotypes had increased risk of CE, while major SNP alleles were protective-potentially suggesting an evolutionary advantage. These findings could guide risk stratification, treatment responders, and the development of novel targeted or gene-based therapies against CE in TBI and other neurological disorders.	[Jha, Ruchira M.; Wallisch, Jessica; Shutter, Lori A.; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, 3550 Terrace St, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Puccio, Ava M.; Okonkwo, David O.; Zusman, Benjamin E.; Shutter, Lori A.] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Shutter, Lori A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Wallisch, Jessica; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA; [Park, Seo-Young] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA; [Park, Seo-Young] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA USA; [Jha, Ruchira M.; Empey, Philip E.; Kochanek, Patrick M.; Conley, Yvette P.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA	Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, 3550 Terrace St, Pittsburgh, PA 15261 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA.	ruchirajha@gmail.com	Shutter, Lori A/G-2957-2013; Empey, Philip/L-9604-2019	Empey, Philip/0000-0001-7474-2339; Wallisch, Jessica/0000-0002-7908-9479; Shutter, Lori/0000-0002-1390-0628; Jha, Ruchira/0000-0002-3047-7649; Conley, Yvette/0000-0002-1784-6067	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [KL2 TR000146, R00 NR013176, R01 NR013342, T32 HD040686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS069498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013342, R00NR013176] Funding Source: NIH RePORTER	We are grateful to NIH Grant Nos. KL2 TR000146 (RMJ), R00 NR013176 (YPC), R01 NR013342 (YPC) and T32 HD040686 (JW) for their generous support.	Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aittoniemi J, 2009, PHILOS T R SOC B, V364, P257, DOI 10.1098/rstb.2008.0142; Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916; Carter KW, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-60; Chen JH, 2016, INT J MOL MED, V37, P1059, DOI 10.3892/ijmm.2016.2506; Conley YP, 2014, J NEUROTRAUM, V31, P34, DOI 10.1089/neu.2013.2855; Cousar JL, 2013, NEUROCRIT CARE, V19, P192, DOI 10.1007/s12028-013-9881-7; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Dardiotis E, 2011, PHARMACOGENET GENOM, V21, P136, DOI 10.1097/FPC.0b013e328343ab15; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Denton JS, 2012, TRENDS ENDOCRIN MET, V23, P41, DOI 10.1016/j.tem.2011.09.004; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Flanagan SE, 2009, HUM MUTAT, V30, P170, DOI 10.1002/humu.20838; Glaser B, 1999, DIABETES, V48, P1652, DOI 10.2337/diabetes.48.8.1652; Hardy OT, 2007, J PEDIATR-US, V150, P140, DOI 10.1016/j.jpeds.2006.08.028; Huang LQ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-102; Jha R, 2016, NEUROLOGY, V86; Kimberly WT, 2014, NEUROCRIT CARE, V20, P193, DOI 10.1007/s12028-013-9917-z; Knight JC, 2003, CLIN SCI, V104, P493, DOI 10.1042/CS20020304; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Liang FY, 2015, NEUROSCI LETT, V598, P29, DOI 10.1016/j.neulet.2015.05.006; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Martinez-Valverde T, 2015, J NEUROTRAUM, V32, P1478, DOI 10.1089/neu.2014.3706; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narum SR, 2006, CONSERV GENET, V7, P783, DOI 10.1007/s10592-005-9056-y; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Proverbio MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068740; Remedy Pharmaceuticals Inc., 2016, PHAS 1 RAND DOUBL BL, P1; Ritter AC, 2016, EPILEPSIA, V57, P984, DOI 10.1111/epi.13397; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sheth KN, 2016, NEUROCRIT CARE, V24, P132, DOI 10.1007/s12028-015-0189-7; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Stanley CA, 2004, J CLIN ENDOCR METAB, V89, P288, DOI 10.1210/jc.2003-030965; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; Yao XM, 2015, J NEUROTRAUM, V32, P1458, DOI 10.1089/neu.2014.3675	40	30	30	1	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2017	26	2					213	224		10.1007/s12028-016-0309-z			12	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	EN5EV	WOS:000396029300009	27677908	Green Accepted			2021-06-18	
J	Lin, C; Chao, HL; Li, Z; Xu, XP; Liu, YL; Bao, ZY; Hou, LJ; Liu, Y; Wang, XM; You, YP; Liu, N; Ji, J				Lin, Chao; Chao, Honglu; Li, Zheng; Xu, Xiupeng; Liu, Yinlong; Bao, Zhongyuan; Hou, Lijun; Liu, Yan; Wang, Xiaoming; You, Yongping; Liu, Ning; Ji, Jing			Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Inflammation; NLRP3; omega-3 FAs	INTRACEREBRAL HEMORRHAGE; INSULIN-SECRETION; CLINICAL-TRIALS; FATTY-ACIDS; ER STRESS; SUPPLEMENTATION; TARGET; CELLS; MODEL; GPR40	Omega-3 fatty acids (omega-3 FAS) attenuate inflammation and improve neurological outcome in response to traumatic brain injury (TBI), but the specific anti-inflammatory mechanisms remain to be elucidated. Here we found that NLRP3 inflammasome and subsequent pro-inflammatory cytokines were activated in human brains after TBI. Rats treated with omega-3 FM had significantly less TBI-induced caspase-1 cleavage and IL-1 beta secretion than those with vehicle. G protein-coupled receptor 40 (GPR40) was observed to be involved in this anti-inflammation. GW1100, a GPR40 inhibitor, eliminated the anti-inflammatory effect of omega-3 FAs after TBI. beta-Arrestin-2 (ARRB2), a downstream scaffold protein of GPR40, was activated to inhibit inflammation via directly binding with NLRP3 in the omega-3 FAs treatment group. Interestingly, we also observed that omega-3 FAs prevented NLRP3 mitochondrial localization, which was reversed by GW1100. Furthermore, omega-3 FAs markedly ameliorated neuronal death and behavioral deficits after TBI, while GW1100 significantly suppressed this effect. Collectively, these data indicate that the GPR40-mediated pathway is involved in the inhibitory effects of omega-3 FAs on TBI-induced inflammation and ARRB2 is activated to interact with NLRP3. (C) 2017 Published by Elsevier Inc.	[Lin, Chao; Chao, Honglu; Li, Zheng; Xu, Xiupeng; Liu, Yinlong; Bao, Zhongyuan; You, Yongping; Liu, Ning; Ji, Jing] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Hou, Lijun] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Liu, Yan] Nanjing Med Univ, Sch Pharm, Inst Stem Cell & Neural Regenerat, Nanjing, Jiangsu, Peoples R China; [Wang, Xiaoming] Nanjing Med Univ, Dept Immunol, Nanjing, Jiangsu, Peoples R China	Liu, N; Ji, J (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	liuning_0853@163.com; jijing@njmu.edu.cn			Jiangsu Innovation Project, China Scholarship Council [201508320270]; Provincial Initiative Program for Excellency Disciplines [20142101]; Jiangsu Province's Key Discipline of Medicine [XK201117]; Jiangsu Province; Outstanding Youth of Jiangsu Province [BK20160047, BK20160044]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471269, 81300998, 31570881]; Priority Academic Program Development of Jiangsu Higher Education Institutions (2016, PAPD)	`This study was supported by Jiangsu Innovation Project, China Scholarship Council (201508320270), the Provincial Initiative Program for Excellency Disciplines (20142101, Chao Lin), Jiangsu Province's Key Discipline of Medicine (XK201117), Jiangsu Province and the Priority Academic Program Development of Jiangsu Higher Education Institutions (2016, PAPD), Outstanding Youth of Jiangsu Province (BK20160047 and BK20160044), and National Natural Science Foundation of China (81471269, 81300998, and 31570881)	Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Briscoe CP, 2006, BRIT J PHARMACOL, V148, P619, DOI 10.1038/sj.bjp.0706770; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Hashimoto M, 2002, J NEUROCHEM, V81, P1084, DOI 10.1046/j.1471-4159.2002.00905.x; Hoque R, 2014, GASTROENTEROLOGY, V146, P1763, DOI 10.1053/j.gastro.2014.03.014; Innis SM, 2007, J NUTR, V137, P855; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jones ML, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.103754; Khan M.Z., 2015, NEUROPHARMACOLOGY; Kumar Parvathy R, 2014, J Tradit Complement Med, V4, P89, DOI 10.4103/2225-4110.130374; Lebeaupin C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.248; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lewis M, 2013, AM J EMERG MED, V31, DOI 10.1016/j.ajem.2012.05.014; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lin C., 2016, J PINEAL RES; Lin C, 2015, SCI REP-UK, V5, DOI 10.1038/srep13442; Lin C, 2013, J NEUROSURG, V118, P364, DOI 10.3171/2012.9.JNS12702; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Nakamoto K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081563; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Potts Mathew B, 2006, NeuroRx, V3, P143; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Stonehouse W, 2014, NUTRIENTS, V6, P2730, DOI 10.3390/nu6072730; Subramanian N, 2013, CELL, V153, P348, DOI 10.1016/j.cell.2013.02.054; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang WJ, 2013, ECOSPHERE, V4, DOI 10.1890/ES13-00040.1; Wang XQ, 2014, NAT IMMUNOL, V15, P1126, DOI 10.1038/ni.3015; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Xi G, 2002, ACT NEUR S, V81, P253; Yan YQ, 2013, IMMUNITY, V38, P1154, DOI 10.1016/j.immuni.2013.05.015; Yuan BQ, 2015, J NEUROIMMUNOL, V287, P71, DOI 10.1016/j.jneuroim.2015.08.002; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	39	30	32	1	18	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2017	290						115	122		10.1016/j.expneurol.2017.01.005			8	Neurosciences	Neurosciences & Neurology	EM5QR	WOS:000395368000011	28077335				2021-06-18	
J	Posti, JP; Hossain, I; Takala, RSK; Liedes, H; Newcombe, V; Outtrim, J; Katila, AJ; Frantzen, J; Ala-Seppala, H; Coles, JP; Kyllonen, A; Maanpaa, HR; Tallus, J; Hutchinson, PJ; van Gils, M; Menon, DK; Tenovuo, O				Posti, Jussi P.; Hossain, Iftakher; Takala, Riikka S. K.; Liedes, Hilkka; Newcombe, Virginia; Outtrim, Joanne; Katila, Ari J.; Frantzen, Janek; Ala-Seppala, Henna; Coles, Jonathan P.; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi; Hutchinson, Peter J.; van Gils, Mark; Menon, David K.; Tenovuo, Olli		TBIcare Investigators	Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 Are Not Specific Biomarkers for Mild CT-Negative Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; GFAP; orthopedic injury; TBI; UCH-L1	CEREBROSPINAL-FLUID; SERUM-LEVELS; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; DIAGNOSTIC MARKER; HEAD-INJURY; GFAP; PLASMA; S100B; L1	Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) have been studied as potential biomarkers of mild traumatic brain injury (mTBI). We report the levels of GFAP and UCH-L1 in patients with acute orthopedic injuries without central nervous system involvement, and relate them to the type of extracranial injury, head magnetic resonance imaging (MRI) findings, and levels of GFAP and UCH-L1 in patients with CT-negative mTBI. Serum UCH-L1 and GFAP were longitudinally measured from 73 patients with acute orthopedic injury on arrival and on days 1, 2, 3, 7 after admission, and on the follow-up visit 3-10 months after the injury. The injury types were recorded, and 71% patients underwent also head MRI. The results were compared with those found in patients with CT-negativemTBI (n = 93). The levels of GFAP were higher in patients with acute orthopedic trauma than in patients with CT-negative mTBI (p = 0.026) on arrival; however, no differences were found on the following days. The levels of UCH-L1 were not significantly different between these two groups at any measured point of time. Levels of GFAP and UCH-L1 were not able to distinguish patients with CT-negative mTBI from patients with orthopedic trauma. Patients with orthopedic trauma and high levels of UCH-L1 or GFAP values may be falsely diagnosed as having a concomitant mTBI, predisposing them to unwarranted diagnostics and unnecessary brain imaging. This casts a significant doubt on the diagnostic value of GFAP and UCH-L1 in cases with mTBI.	[Posti, Jussi P.; Frantzen, Janek] Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, POB 52, FI-20521 Turku, Finland; [Posti, Jussi P.; Frantzen, Janek; Tenovuo, Olli] Turku Univ Hosp, Dept Rehabil & Brain Trauma, Div Clin Neurosci, Turku, Finland; [Posti, Jussi P.; Hossain, Iftakher; Ala-Seppala, Henna; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi; Tenovuo, Olli] Univ Turku, Dept Neurol, Turku, Finland; [Takala, Riikka S. K.; Katila, Ari J.] Turku Univ Hosp, Perioperat Serv, Intens Care Med & Pain Management, Turku, Finland; [Takala, Riikka S. K.; Katila, Ari J.] Univ Turku, Turku, Finland; [Liedes, Hilkka; van Gils, Mark] VTT Tech Res Ctr Finland Ltd, Med Syst, Tampere, Finland; [Newcombe, Virginia; Outtrim, Joanne; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge, England; [Coles, Jonathan P.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England	Posti, JP (corresponding author), Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, POB 52, FI-20521 Turku, Finland.	jussi.posti@utu.fi	Posti, Jussi P./Y-2908-2019	Posti, Jussi P./0000-0002-5925-5193; Liedes, Hilkka/0000-0003-4655-7675; Ala-Seppala, Henna/0000-0002-1577-3028; Newcombe, Virginia/0000-0001-6044-9035; van Gils, Mark/0000-0002-0029-1771	European Commission under the 7th Framework Programme [FP7-270259-TBIcare]; personal Government's Special Financial Transfer tied to academic research in Health Sciences; Maire Taponen Foundation; Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship; National Institute for Health Research (NIHR) Research Fellowship; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013, ACF-2009-14-007] Funding Source: researchfish	This work was partially funded by the European Commission under the 7th Framework Programme (FP7-270259-TBIcare), personal Government's Special Financial Transfer tied to academic research in Health Sciences (J.P.P. and R.S.K.T.), personal EVO funding and grant from Maire Taponen Foundation (J.P.P.), Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship (V.N.), National Institute for Health Research (NIHR) Research Fellowship (P.J.H.) The authors thank research nurses Patricia Bertenyi and Satu Timlin for their valuable contribution to this study.	BAKAY RAE, 1986, NEUROSURGERY, V18, P376, DOI 10.1227/00006123-198603000-00026; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Cape E, 2014, J PSYCHOSOM RES, V77, P219, DOI 10.1016/j.jpsychores.2014.06.014; Carlson AP, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.8.FOCUS10182; Carotti S, 2008, LIVER TRANSPLANT, V14, P806, DOI 10.1002/lt.21436; Chen FJ, 2010, P NATL ACAD SCI USA, V107, P1636, DOI 10.1073/pnas.0911516107; Chuang D, 2005, ANZ J SURG, V75, P813, DOI 10.1111/j.1445-2197.2005.03530.x; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Fellenberg J, 2010, INT J CANCER, V127, P1804, DOI 10.1002/ijc.25205; Gurnett CA, 2003, EPILEPSIA, V44, P1455, DOI 10.1046/j.1528-1157.2003.21603.x; Hainfellner JA, 2001, J NEUROPATH EXP NEUR, V60, P449, DOI 10.1093/jnen/60.5.449; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hsu SH, 2010, CLIN CHIM ACTA, V411, P1920, DOI 10.1016/j.cca.2010.07.035; Ilhan A, 2011, J CLIN ONCOL, V29, pE756, DOI 10.1200/JCO.2011.36.6401; Isokuortti H, 2014, INJURY, V45, P1340, DOI 10.1016/j.injury.2014.04.012; JESSEN KR, 1984, J NEUROCYTOL, V13, P187, DOI 10.1007/BF01148114; Jung CS, 2007, BRAIN, V130, P3336, DOI 10.1093/brain/awm263; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kiviniemi A, 2015, J NEURO-ONCOL, V124, P237, DOI 10.1007/s11060-015-1829-7; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Meyer-Schwesinger C, 2009, J PATHOL, V217, P452, DOI 10.1002/path.2446; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Mondello S, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-85; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Olsson B, 2011, PROG NEUROBIOL, V95, P520, DOI 10.1016/j.pneurobio.2011.04.006; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Ren CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep24588; Riol H, 1997, J NEUROSCI RES, V48, P53; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; VIALE G, 1991, VIRCHOWS ARCH A, V418, P339, DOI 10.1007/BF01600164; VIALE G, 1988, AM J PATHOL, V133, P363; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	54	30	30	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	7					1427	1438		10.1089/neu.2016.4442			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ER0FB	WOS:000398461600012	27841729				2021-06-18	
J	Obenaus, A; Ng, M; Orantes, AM; Kinney-Lang, E; Rashid, F; Hamer, M; DeFazio, RA; Tang, J; Zhang, JH; Pearce, WJ				Obenaus, Andre; Ng, Michelle; Orantes, Amanda M.; Kinney-Lang, Eli; Rashid, Faisal; Hamer, Mary; DeFazio, Richard A.; Tang, Jiping; Zhang, John H.; Pearce, William J.			Traumatic brain injury results in acute rarefication of the vascular network	SCIENTIFIC REPORTS			English	Article							CEREBRAL-BLOOD-FLOW; CEREBROVASCULAR REACTIVITY; FRACTAL ANALYSIS; RAT; MICROCIRCULATION; VISUALIZATION; MICROVESSELS; RECOVERY; DYNAMICS; FEATURES	The role of the cerebrovascular network and its acute response to TBI is poorly defined and emerging evidence suggests that cerebrovascular reactivity is altered. We explored how cortical vessels are physically altered following TBI using a newly developed technique, vessel painting. We tested our hypothesis that a focal moderate TBI results in global decrements to structural aspects of the vasculature. Rats (naive, sham-operated, TBI) underwent a moderate controlled cortical impact. Animals underwent vessel painting perfusion to label the entire cortex at 1 day post TBI followed by whole brain axial and coronal images using a wide-field fluorescence microscope. Cortical vessel network characteristics were analyzed for classical angiographic features (junctions, lengths) wherein we observed significant global (both hemispheres) reductions in vessel junctions and vessel lengths of 33% and 22%, respectively. Biological complexity can be quantified using fractal geometric features where we observed that fractal measures were also reduced significantly by 33%, 16% and 13% for kurtosis, peak value frequency and skewness, respectively. Acutely after TBI there is a reduction in vascular network and vascular complexity that are exacerbated at the lesion site and provide structural evidence for the bilateral hemodynamic alterations that have been reported in patients after TBI.	[Obenaus, Andre; Ng, Michelle; Kinney-Lang, Eli; Rashid, Faisal; Hamer, Mary] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; [Orantes, Amanda M.] Loma Linda Univ, Mol & Integrat Physiol, Loma Linda, CA 92350 USA; [Tang, Jiping; Zhang, John H.; Pearce, William J.] Loma Linda Univ, Sch Med, Physiol & Pharmacol, Loma Linda, CA 92350 USA; [Zhang, John H.] Loma Linda Univ, Sch Med, Anesthesiol, Loma Linda, CA 92350 USA; [Zhang, John H.] Loma Linda Univ, Sch Med, Neurosurg, Loma Linda, CA USA; [DeFazio, Richard A.] Univ Michigan, Ann Arbor, MI 48101 USA; [Pearce, William J.] Loma Linda Univ, Ctr Perinatal Biol, Loma Linda, CA 92350 USA	Obenaus, A (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA.	aobenaus@llu.edu		Pearce, William/0000-0002-5331-5677	NIH Program Project grant from NINDS [1P01NS082184]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD083132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076945, P01NS082184] Funding Source: NIH RePORTER	These studies were supported by an NIH Program Project grant from NINDS (1P01NS082184, Project 3). The authors also thank S Padmabharathi Pothirajan for MRI data acquisition.	Ab Hamid F., 2015, CURRENT EYE RES, P1; Belayev L, 2007, BRAIN RES, V1157, P146, DOI 10.1016/j.brainres.2007.04.077; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Boulouis G, 2016, SEMIN NEUROL, V36, P233, DOI 10.1055/s-0036-1581993; DeFazio RA, 2011, TRANSL STROKE RES, V2, P112, DOI 10.1007/s12975-010-0044-2; Di Ieva A, 2015, NEUROSCIENTIST, V21, P30, DOI 10.1177/1073858413513928; Di Ieva A, 2014, NEUROSCIENTIST, V20, P403, DOI 10.1177/1073858413513927; Di Ieva A, 2011, MICROVASC RES, V81, P222, DOI 10.1016/j.mvr.2010.12.006; Donnelly J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1293-6; Donovan V, 2012, NEUROIMAGE-CLIN, V1, P18, DOI 10.1016/j.nicl.2012.08.001; Esen F, 2011, MICROVASC RES, V82, P291, DOI 10.1016/j.mvr.2011.07.012; Gaustad JV, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-388; Ghanavati S, 2014, NEUROIMAGE, V95, P117, DOI 10.1016/j.neuroimage.2014.03.044; Ghosh N, 2012, J CEREBR BLOOD F MET, V32, P2161, DOI 10.1038/jcbfm.2012.121; HAACKE EM, 2002, IMAGE ANAL STEREOL, V21, P107; Hamel E, 2016, CELL MOL NEUROBIOL, V36, P219, DOI 10.1007/s10571-015-0285-4; Harris NG, 2016, EXP NEUROL, V277, P124, DOI 10.1016/j.expneurol.2015.12.020; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Hughes S, 2014, METHODS MOL BIOL, V1135, P127, DOI 10.1007/978-1-4939-0320-7_12; Immonen R, 2010, J CEREBR BLOOD F MET, V30, P1318, DOI 10.1038/jcbfm.2010.15; Joshi VS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088061; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Lauwers F, 2008, NEUROIMAGE, V39, P936, DOI 10.1016/j.neuroimage.2007.09.024; Lavinio A, 2008, ACTA NEUROCHIR SUPPL, V102, P3, DOI 10.1007/978-3-211-85578-2_1; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Li YW, 2008, NAT PROTOC, V3, P1703, DOI 10.1038/nprot.2008.172; Lorthois S, 2010, J THEOR BIOL, V262, P614, DOI 10.1016/j.jtbi.2009.10.037; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Obenaus A., 2015, ENCY MENTAL HLTH, P329; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Ong YT, 2014, DEMENT GER COGN D EX, V4, P305, DOI 10.1159/000363286; Ostergaard L, 2014, J CEREBR BLOOD F MET, V34, P1585, DOI 10.1038/jcbfm.2014.131; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Perez-Barcena J, 2015, J NEUROL SCI, V353, P38, DOI 10.1016/j.jns.2015.03.044; Pluta RM, 2005, PHARMACOL THERAPEUT, V105, P23, DOI 10.1016/j.pharmthera.2004.10.002; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; Robertson RT, 2015, HISTOCHEM CELL BIOL, V143, P225, DOI 10.1007/s00418-014-1301-3; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Sangiorgi S, 2013, J NEUROSURG, V118, P763, DOI 10.3171/2012.11.JNS12627; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Scholten AC, 2016, J NEUROTRAUM, V33, P1969, DOI 10.1089/neu.2015.4252; Stankovic ND, 2016, ACTA NEUROPATHOL, V131, P347, DOI 10.1007/s00401-015-1524-y; Talu S, 2013, CURR EYE RES, V38, P781, DOI 10.3109/02713683.2013.779722; Traversi C, 2008, CLIN EXP OPHTHALMOL, V36, P323, DOI 10.1111/j.1442-9071.2008.01766.x; Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009; Varsos GV, 2014, NEUROCRIT CARE, V21, P266, DOI 10.1007/s12028-014-9971-1; Veenith TV, 2016, JAMA NEUROL, V73, P542, DOI 10.1001/jamaneurol.2016.0091; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Walker EJ, 2011, JOVE-J VIS EXP, DOI 10.3791/2958; Wu JP, 2014, NEUROIMAGE, V87, P199, DOI 10.1016/j.neuroimage.2013.10.036; Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385	55	30	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAR 19	2017	7								239	10.1038/s41598-017-00161-4			14	Multidisciplinary Sciences	Science & Technology - Other Topics	EO9AS	WOS:000396982200016	28331228	DOAJ Gold, Green Published			2021-06-18	
J	Acosta, SA; Tajiri, N; Sanberg, PR; Kaneko, Y; Borlongan, CV				Acosta, Sandra A.; Tajiri, Naoki; Sanberg, Paul R.; Kaneko, Yuji; Borlongan, Cesar V.			Increased Amyloid Precursor Protein and Tau Expression Manifests as Key Secondary Cell Death in Chronic Traumatic Brain Injury	JOURNAL OF CELLULAR PHYSIOLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; ALZHEIMERS-DISEASE; HEAD-INJURY; MICROGLIAL ACTIVATION; COGNITIVE DEFICITS; HIPPOCAMPAL NEUROGENESIS; TRANSGENIC MICE; AXONAL DAMAGE; BETA; RATS	In testing the hypothesis of Alzheimer's disease (AD)-like pathology in late stage traumatic brain injury (TBI), we evaluated AD pathological markers in late stage TBI model. Sprague-Dawley male rats were subjected to moderate controlled cortical impact (CCI) injury, and 6 months later euthanized and brain tissues harvested. Results from H&E staining revealed significant 33% and 10% reduction in the ipsilateral and contralateral hippocampal CA3 interneurons, increased MHCII-activated inflammatory cells in many gray matter (8-20-fold increase) and white matter (6-30-fold increased) regions of both the ipsilateral and contralateral hemispheres, decreased cell cycle regulating protein marker by 1.6- and 1-fold in the SVZ and a 2.3- and 1.5-fold reductions in the ipsilateral and contralateral dentate gyrus, diminution of immature neuronal marker by two- and onefold in both the ipsilateral and contralateral SVZ and dentate gyrus, and amplified amyloid precursor protein (APP) distribution volumes in white matter including corpus callosum, fornix, and internal capsule (4-38-fold increase), as well as in the cortical gray matter, such as the striatum hilus, SVZ, and dentate gyrus (6-40-fold increase) in TBI animals compared to controls (P's<0.001). Surrogate AD-like phenotypic markers revealed a significant accumulation of phosphorylated tau (AT8) and oligomeric tau (T22) within the neuronal cell bodies in ipsilateral and contralateral cortex, and dentate gyrus relative to sham control, further supporting the rampant neurodegenerative pathology in TBI secondary cell death. These findings indicate that AD-like pathological features may prove to be valuable markers and therapeutic targets for late stage TBI. J. Cell. Physiol. 232: 665-677, 2017. (c) 2016 Wiley Periodicals, Inc.	[Acosta, Sandra A.; Tajiri, Naoki; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33620 USA; [Sanberg, Paul R.] Univ S Florida, Dept Neurosurg & Brain Repair, Off Res & Innovat, Tampa, FL USA	Borlongan, CV (corresponding author), Univ S Florida, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Tajiri, Naoki/K-1230-2012	Tajiri, Naoki/0000-0003-2189-662X	Department of Defense USAUnited States Department of Defense [W81XWH-11-1-0634]	Contract grant sponsor: Department of Defense USA;; Contract grant number: W81XWH-11-1-0634.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Chen YZ, 2003, J CELL BIOL, V163, P27, DOI 10.1083/jcb.200304003; Cho SH, 2011, J BIOL CHEM, V286, P32713, DOI 10.1074/jbc.M111.254268; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Gottlieb S, 2000, BRIT MED J, V321, P1100; HAASS C, 1991, J NEUROSCI, V11, P3783; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; He P, 2007, J CELL BIOL, V178, P829, DOI 10.1083/jcb.200705042; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; Lim GP, 2001, J NEUROSCI, V21, P8370; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; Marshall SA, 2013, NEUROBIOL DIS, V54, P239, DOI 10.1016/j.nbd.2012.12.016; MAYHEW TM, 1991, EXP PHYSIOL, V76, P639, DOI 10.1113/expphysiol.1991.sp003533; MCLAURIN J, 1995, NEUROPATH APPL NEURO, V21, P302, DOI 10.1111/j.1365-2990.1995.tb01064.x; Mizuno T, 2011, AM J PATHOL, V179, P2016, DOI 10.1016/j.ajpath.2011.06.011; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nakashiba T, 2008, SCIENCE, V319, P1260, DOI 10.1126/science.1151120; O'Keefe GM, 2002, J NEUROVIROL, V8, P496, DOI 10.1080/13550280290100941; Park MS, 2014, J EXERC REHABIL, V10, P148, DOI 10.12965/jer.140109; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reddy PH, 2010, J ALZHEIMERS DIS, V20, pS499, DOI 10.3233/JAD-2010-100504; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SCOVILLE WB, 1954, J NEUROSURG, V11, P64, DOI 10.3171/jns.1954.11.1.0064; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sheng JG, 2003, NEUROBIOL DIS, V14, P133, DOI 10.1016/S0969-9961(03)00069-X; Soldatovic-Stajic B, 2014, EUR REV MED PHARMACO, V18, P1632; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zhao J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-150	71	30	30	0	81	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9541	1097-4652		J CELL PHYSIOL	J. Cell. Physiol.	MAR	2017	232	3					665	677		10.1002/jcp.25629			13	Cell Biology; Physiology	Cell Biology; Physiology	EC9MO	WOS:000388468900022	27699791	Other Gold, Green Published			2021-06-18	
J	Janssen, PHH; Mandrekar, J; Mielke, MM; Ahlskog, JE; Boeve, BF; Josephs, K; Savica, R				Janssen, Pieter H. H.; Mandrekar, Jay; Mielke, Michelle M.; Ahlskog, J. Eric; Boeve, Bradley F.; Josephs, Keith; Savica, Rodolfo			High School Football and Late-Life Risk of Neurodegenerative Syndromes, 1956-1970	MAYO CLINIC PROCEEDINGS			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; MEDICAL-RECORDS LINKAGE; HEAD TRAUMA; EPIDEMIOLOGY; DISEASE; SCLEROSIS; EXERCISE; DEMENTIA; INJURY	Objective: To assess whether athletes who played American varsity high school football between 1956 and 1970 have an increased risk of neurodegenerative diseases later in life. Patients and Methods: We identified all male varsity football players between 1956 and 1970 in the public high schools of Rochester, Minnesota, and nonefootball-playing male varsity swimmers, wrestlers, and basketball players. Using the medical records linkage system of the Rochester Epidemiology Project, we ascertained the incidence of late-life neurodegenerative diseases: dementia, parkinsonism, and amyotrophic lateral sclerosis. We also recorded medical record-documented head trauma during high school years. Results: We identified 296 varsity football players and 190 athletes engaging in other sports. Football players had an increased risk of medically documented head trauma, especially if they played football for more than 1 year. Compared with nonfootball athletes, football players did not have an increased risk of neurodegenerative disease overall or of the individual conditions of dementia, parkinsonism, and amyotrophic lateral sclerosis. Conclusion: In this community-based study, varsity high school football players from 1956 to 1970 did not have an increased risk of neurodegenerative diseases compared with athletes engaged in other varsity sports. This was from an era when there was a generally nihilistic view of concussion dangers, less protective equipment, and no prohibition of spearing (head-first tackling). However, the size and strength of players from previous eras may not be comparable with that of current high school athletes. (C) 2016 Mayo Foundation for Medical Education and Research	[Janssen, Pieter H. H.] Radboud Univ Nijmegen, Nijmegen, Netherlands; [Janssen, Pieter H. H.; Mielke, Michelle M.; Ahlskog, J. Eric; Boeve, Bradley F.; Josephs, Keith; Savica, Rodolfo] Mayo Clin, Coll Med, Dept Neurol, Rochester, MN USA; [Mandrekar, Jay; Mielke, Michelle M.; Savica, Rodolfo] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA	Savica, R (corresponding author), Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA.	savica.rodolfo@mayo.edu		Mielke, Michelle/0000-0001-7177-1185	Rochester Epidemiology Project [R01-AG034676]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034676] Funding Source: NIH RePORTER	This study was made possible by the Rochester Epidemiology Project (grant number R01-AG034676; Principal Investigators: Walter A. Rocca, MD, MPH, and Jennifer St Sauver, PhD).	Abel EL, 2007, PERCEPT MOTOR SKILL, V104, P1251, DOI 10.2466/PMS.104.4.1251-1254; Ahlskog JE, 2011, MAYO CLIN PROC, V86, P876, DOI 10.4065/mcp.2011.0252; Ahlskog JE, 2011, NEUROLOGY, V77, P288, DOI 10.1212/WNL.0b013e318225ab66; Albin RL, 2016, NEUROLOGY, V86, P1929, DOI 10.1212/01.wnl.0000484015.90990.ab; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; CLARKE KS, 1979, MED SCI SPORT EXER, V11, P138; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Goodwin Linda, 2006, J Insur Med, V38, P300; Kokkinos Peter, 2012, ISRN Cardiol, V2012, P718789, DOI 10.5402/2012/718789; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Rocca WA, 2012, MAYO CLIN PROC, V87, P1202, DOI 10.1016/j.mayocp.2012.08.012; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; St Sauver JL, 2012, MAYO CLIN PROC, V87, P151, DOI 10.1016/j.mayocp.2011.11.009; St Sauver JL, 2011, AM J EPIDEMIOL, V173, P1059, DOI 10.1093/aje/kwq482; Vanacore N, 2006, PARKINSONISM RELAT D, V12, P327, DOI 10.1016/j.parkreldis.2005.11.007	21	30	31	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0025-6196	1942-5546		MAYO CLIN PROC	Mayo Clin. Proc.	JAN	2017	92	1					66	71		10.1016/j.mayocp.2016.09.004			6	Medicine, General & Internal	General & Internal Medicine	EK4QQ	WOS:000393912300014	27979411	Green Accepted			2021-06-18	
J	Scheiman, MM; Talasan, H; Mitchell, GL; Alvarez, TL				Scheiman, Mitchell M.; Talasan, Henry; Mitchell, G. Lynn; Alvarez, Tara L.			Objective Assessment of Vergence after Treatment of Concussion-Related CI: A Pilot Study	OPTOMETRY AND VISION SCIENCE			English	Article						convergence insufficiency; vision therapy; concussion; vision rehabilitation	RANDOMIZED CLINICAL-TRIAL; INSUFFICIENCY SYMPTOM SURVEY; CONVERGENCE INSUFFICIENCY; DISPARITY VERGENCE; PEAK VELOCITY; EYE-MOVEMENTS; DYSFUNCTIONS; FREQUENCY; DYNAMICS; CHILDREN	Purpose. To evaluate changes in objective measures of disparity vergence after office-based vision therapy (OBVT) for concussion-related convergence insufficiency (CI) and determine the feasibility of using this objective assessment as an outcome measure in a clinical trial. Methods. This was a prospective, observational trial. All participants were treated with weekly OBVT with home reinforcement. Participants included two adolescents and three young adults with concussion-related, symptomatic CI. The primary outcome measure was average peak velocity for 4 degrees symmetrical convergence steps. Other objective outcome measures of disparity vergence included time to peak velocity, latency, accuracy, settling time, and main sequence. We also evaluated saccadic eye movements using the same outcome measures. Changes in clinical measures (near point of convergence, positive fusional vergence at near, Convergence Insufficiency Symptom Survey [CISS] score) were evaluated. Results. There were statistically significant and clinically meaningful changes in all clinical measures for convergence. Four of the five subjects met clinical success criteria. For the objective measures, we found a statistically significant increase in peak velocity, response accuracy to 4 degrees symmetrical convergence and divergence step stimuli, and the main sequence ratio for convergence step stimuli. Objective saccadic eye movements (5 and 10 degrees) appeared normal pre-OBVT and did not show any significant change after treatment. Conclusions. This is the first report of the use of objective measures of disparity vergence as outcome measures for concussion-related convergence insufficiency. These measures provide additional information that is not accessible with clinical tests about underlying physiological mechanisms leading to changes in clinical findings and symptoms. The study results also demonstrate that patients with concussion can tolerate the visual demands (over 200 vergence and versional eye movements) during the 25-minute testing time and suggest that these measures could be used in a large-scale randomized clinical trial of concussion-related CI as outcome measures.	[Scheiman, Mitchell M.] Salus Univ, Penn Coll Optometry, 8360 Old York Rd, Elkins Pk, PA 19027 USA; [Talasan, Henry; Alvarez, Tara L.] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA; [Mitchell, G. Lynn] Ohio State Univ, Coll Optometry, 338 W 10th Ave, Columbus, OH 43210 USA	Scheiman, MM (corresponding author), Salus Univ, Penn Coll Optometry, 8360 Old York Rd, Elkins Pk, PA 19027 USA.	mscheiman@salus.edu	Mitchell, Gladys/E-7973-2012	Alvarez, Tara/0000-0002-8797-1613; Scheiman, Mitchell/0000-0002-9274-5696	NSF MRINational Science Foundation (NSF)NSF - Office of the Director (OD) [CBET 1428425]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01EY023261]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY023261] Funding Source: NIH RePORTER	This research was supported in part by NSF MRI CBET 1428425 to T.L.A. and NIH 1R01EY023261 to T.L.A. and M.S.	Alvarez TL, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00419; Alvarez TL, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00050; Alvarez TL, 2013, INVEST OPHTH VIS SCI, V54, P4122, DOI 10.1167/iovs.13-11797; Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Alvarez TL, 2010, OPTOMETRY VISION SCI, V87, P985, DOI 10.1097/OPX.0b013e3181fef1aa; Alvarez TL, 2000, VISION RES, V40, P341, DOI 10.1016/S0042-6989(99)00175-3; Alvarez TL, 2005, J VISION, V5, P640, DOI 10.1167/5.7.4; Alvarez TL, 2002, CAH PSYCHOL COGN, V21, P243; Alvarez TL, 1998, J NEUROPHYSIOL, V79, P37; Alvarez TL, 1999, ANN BIOMED ENG, V27, P380, DOI 10.1114/1.162; BAHILL AT, 1982, BIOL CYBERN, V45, P1, DOI 10.1007/BF00387207; Barnhardt C, 2012, OPTOMETRY VISION SCI, V89, P1512, DOI 10.1097/OPX.0b013e318269c8f9; Borsting EJ, 2003, OPTOMETRY VISION SCI, V80, P832, DOI 10.1097/00006324-200312000-00014; Borsting Eric, 2003, Optometry, V74, P25; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Bucci MP, 2004, EXP BRAIN RES, V157, P286, DOI 10.1007/s00221-004-1842-0; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chen YF, 2010, J MED BIOL ENG, V30, P1; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Godwin Marshall, 2003, BMC Med Res Methodol, V3, P28, DOI 10.1186/1471-2288-3-28; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Guo Y, 2011, JOVE-J VIS EXP, P49; Han SJ, 2010, OPHTHAL PHYSL OPT, V30, P95, DOI 10.1111/j.1475-1313.2009.00681.x; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; HSU FK, 1976, COMPUT PROG BIOMED, V6, P108, DOI 10.1016/0010-468X(76)90032-5; Jainta S, 2011, VISION RES, V51, P1845, DOI 10.1016/j.visres.2011.06.014; JONES R, 1980, AM J OPTOM PHYS OPT, V57, P640; Kim E, 2011, IEEE ENG MED BIO, P1664, DOI 10.1109/IEMBS.2011.6090479; Kim EH, 2012, CURR EYE RES, V37, P1054, DOI 10.3109/02713683.2012.694551; Kim EH, 2012, VISION RES, V63, P9, DOI 10.1016/j.visres.2012.04.013; Kim EH, 2010, INVEST OPHTH VIS SCI, V51, P4017, DOI 10.1167/iovs.09-4560; KOTULAK JC, 1987, VISION RES, V27, P1797, DOI 10.1016/0042-6989(87)90108-8; Lee YY, 2012, J EYE MOVEMENT RES, V5; Leigh R.J., 2015, NEUROLOGY EYE MOVEME; Letourneau JE., 1988, CAN J OPTOM, V50, P194; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; MAYS LE, 1984, J NEUROPHYSIOL, V51, P1091; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Porcar E, 1997, OPTOMETRY VISION SCI, V74, P111, DOI 10.1097/00006324-199702000-00023; Rambold H, 2005, ANN NY ACAD SCI, V1039, P567, DOI 10.1196/annals.1325.069; Rouse M, 2009, OPTOMETRY VISION SCI, V86, P357, DOI 10.1097/OPX.0b013e3181989252; Rouse MW, 1999, OPTOMETRY VISION SCI, V76, P643, DOI 10.1097/00006324-199909000-00022; Sander T, 2009, BRAIN, V132, P103, DOI 10.1093/brain/awn306; Scheiman M, 2005, BRIT J OPHTHALMOL, V89, P1318, DOI 10.1136/bjo.2005.068197; Scheiman M, 2005, OPTOMETRY VISION SCI, V82, P583, DOI 10.1097/01.opx.0000171331.36871.2f; Scheiman M, 2005, ARCH OPHTHALMOL-CHIC, V123, P14, DOI 10.1001/archopht.123.1.14; Scheiman M, 2014, OPTOM VIS PERF, V2, P10; Scheiman M., 2014, CLIN MANAGEMENT BINO, V4th; Scheiman M, 2011, INVEST OPHTHALMOL VI, V53; Scheiman M, 2008, ARCH OPHTHALMOL-CHIC, V126, P1336, DOI 10.1001/archopht.126.10.1336; Scheiman M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006768.pub2; SEMMLOW JL, 1993, OPHTHAL PHYSL OPT, V13, P48, DOI 10.1111/j.1475-1313.1993.tb00426.x; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Talasan H, 2016, J VISION, V16, DOI 10.1167/16.1.7; Thiagarajan P, 2013, J REHABIL RES DEV, V50, P1223, DOI 10.1682/JRRD.2012.12.0235; Yuan WH, 1999, IEEE T BIO-MED ENG, V46, P1191, DOI 10.1109/10.790495; ZEE DS, 1992, J NEUROPHYSIOL, V68, P1624	58	30	30	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	JAN	2017	94	1					74	88		10.1097/OPX.0000000000000936			15	Ophthalmology	Ophthalmology	EM5ZZ	WOS:000395393900011	27464574	Green Accepted			2021-06-18	
J	Sun, LH; Perakyla, J; Holm, K; Haapasalo, J; Lehtimaki, K; Ogawa, KH; Peltola, J; Hartikainen, KM				Sun, Lihua; Perakyla, Jari; Holm, Katri; Haapasalo, Joonas; Lehtimaki, Kai; Ogawa, Keith H.; Peltola, Jukka; Hartikainen, Kaisa M.			Vagus nerve stimulation improves working memory performance	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Attention; Cognition; Executive functions; Frontal alpha asymmetry; Vagus nerve stimulation	TREATMENT-RESISTANT DEPRESSION; EMOTION-ATTENTION INTERACTION; ANTERIOR THALAMIC NUCLEI; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; SELECTIVE ATTENTION; LOCUS-COERULEUS; ALZHEIMERS-DISEASE; VAGAL-STIMULATION; PARTIAL SEIZURES	Vagus nerve stimulation (VNS) is used for treating refractory epilepsy and major depression. While the impact of this treatment on seizures has been established, its impact on human cognition remains equivocal. The goal of this study is to elucidate the immediate effects of vagus nerve stimulation on attention, cognition, and emotional reactivity in patients with epilepsy. Twenty patients (12 male and 8 female; 45 +/- 13years old) treated with VNS due to refractory epilepsy participated in the study. Subjects performed a computer-based test of executive functions embedded with emotional distractors while their brain activity was recorded with electroencephalography. Subjects' cognitive performance, early visual event-related potential N1, and frontal alpha asymmetry were studied when cyclic vagus nerve stimulation was on and when it was off. We found that vagus nerve stimulation improved working memory performance as seen in reduced errors on a subtask that relied on working memory, odds ratio (OR)=0.63 (95% confidence interval, CI [0.47, 0.85]) and increased N1 amplitude, F(1, 15)=10.17, p=.006. In addition, vagus nerve stimulation resulted in longer reaction time, F(1, 16)=8.23, p=.019, and greater frontal alpha asymmetry, F(1, 16)=11.79, p=.003, in response to threat-related distractors. This is the first study to show immediate improvement in working memory performance in humans with clinically relevant vagus nerve stimulation. Furthermore, vagus nerve stimulation had immediate effects on emotional reactivity evidenced in behavior and brain physiology.	[Sun, Lihua; Perakyla, Jari; Holm, Katri; Hartikainen, Kaisa M.] Tampere Univ Hosp, Behav Neurol Res Unit, Tampere, Finland; [Perakyla, Jari; Holm, Katri; Peltola, Jukka; Hartikainen, Kaisa M.] Univ Tampere, Fac Med & Life Sci, Tampere, Finland; [Haapasalo, Joonas; Lehtimaki, Kai; Peltola, Jukka] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland; [Ogawa, Keith H.] St Marys Coll Calif, John Magaddino Neurosci Lab, Moraga, CA USA	Hartikainen, KM (corresponding author), Tampere Univ Hosp, Behav Neurol Res Unit, Tampere, Finland.	kaisa.hartikainen@uta.fi		Sun, Lihua/0000-0002-9931-9497; Hartikainen, Kaisa/0000-0001-7278-9635	Academy of FinlandAcademy of FinlandEuropean Commission; Competitive Research Fund of Pirkanmaa Hospital District	This work was supported by the Academy of Finland and the Competitive Research Fund of Pirkanmaa Hospital District.	Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; ASTONJONES G, 1991, PROG BRAIN RES, V88, P47; Awh E, 2006, NEUROSCIENCE, V139, P201, DOI 10.1016/j.neuroscience.2005.08.023; BENMENACHEM E, 1994, EPILEPSIA, V35, P616, DOI 10.1111/j.1528-1157.1994.tb02482.x; Bishop SJ, 2008, ANN NY ACAD SCI, V1129, P141, DOI 10.1196/annals.1417.016; Chamberlain SR, 2006, PSYCHOPHARMACOLOGY, V188, P397, DOI 10.1007/s00213-006-0391-6; CLARK KB, 1995, NEUROBIOL LEARN MEM, V63, P213, DOI 10.1006/nlme.1995.1024; Clark KB, 1999, NAT NEUROSCI, V2, P94; DALGLEISH T, 1990, CLIN PSYCHOL REV, V10, P589, DOI 10.1016/0272-7358(90)90098-U; Davidson R.J., 1995, CEREBRAL ASYMMETRY E, P361; Dodrill CB, 2001, EPILEPSY BEHAV, V2, P46, DOI 10.1006/ebeh.2000.0148; Elger G, 2000, EPILEPSY RES, V42, P203, DOI 10.1016/S0920-1211(00)00181-9; Goddard AW, 2010, DEPRESS ANXIETY, V27, P339, DOI 10.1002/da.20642; Grimonprez A, 2015, NEUROSCI BIOBEHAV R, V56, P26, DOI 10.1016/j.neubiorev.2015.06.019; Grimonprez A, 2015, J PSYCHIATR RES, V68, P1, DOI 10.1016/j.jpsychires.2015.05.002; Hartikainen KM, 2007, NEUROREPORT, V18, P1929, DOI 10.1097/WNR.0b013e3282f1ca18; Hartikainen KM, 2014, J CLIN EXP NEUROPSYC, V36, P540, DOI 10.1080/13803395.2014.913554; Hartikainen KM, 2012, NEUROREPORT, V23, P447, DOI 10.1097/WNR.0b013e3283531e74; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hartikainen KM, 2010, NEUROREPORT, V21, P344, DOI 10.1097/WNR.0b013e328336eeb3; Hartikainen KM, 2000, NEUROPSYCHOLOGIA, V38, P1576, DOI 10.1016/S0028-3932(00)00072-5; Hassert DL, 2004, BEHAV NEUROSCI, V118, P79, DOI 10.1037/0735-7044.118.1.79; Javed A, 2015, SEIZURE-EUR J EPILEP, V29, P34, DOI 10.1016/j.seizure.2015.03.013; KALIA M, 1982, J COMP NEUROL, V211, P248, DOI 10.1002/cne.902110304; Kindt M, 2001, J PSYCHOPATHOL BEHAV, V23, P193, DOI 10.1023/A:1010921405496; Klinkenberg S, 2012, CLIN NEUROL NEUROSUR, V114, P336, DOI 10.1016/j.clineuro.2011.11.016; Liimatainen J, 2016, INTERACT CARDIOV TH, V23, P630, DOI 10.1093/icvts/ivw170; Luck SJ, 1998, P NATL ACAD SCI USA, V95, P825, DOI 10.1073/pnas.95.3.825; MACLEOD C, 1988, Q J EXP PSYCHOL-A, V40, P653, DOI 10.1080/14640748808402292; Maki-Marttunen V, 2017, J NEUROTRAUM, V34, P400, DOI 10.1089/neu.2015.4390; Maki-Marttunen V, 2015, J NEUROTRAUM, V32, P272, DOI 10.1089/neu.2014.3557; Maki-Marttunen V, 2014, NEUROREPORT, V25, P1038, DOI 10.1097/WNR.0000000000000223; MANGUN GR, 1991, J EXP PSYCHOL HUMAN, V17, P1057, DOI 10.1037/0096-1523.17.4.1057; Marangell LB, 2002, BIOL PSYCHIAT, V51, P280, DOI 10.1016/S0006-3223(01)01343-9; McGlone J, 2008, CAN J NEUROL SCI, V35, P287, DOI 10.1017/S0317167100008854; Merrill CA, 2006, J CLIN PSYCHIAT, V67, P1171, DOI 10.4088/JCP.v67n0801; O'Dell TJ, 2015, LEARN MEMORY, V22, P461, DOI 10.1101/lm.031088.113; PENRY JK, 1990, EPILEPSIA, V31, pS40, DOI 10.1111/j.1528-1157.1990.tb05848.x; Perez-Edgar K, 2013, BRAIN COGNITION, V82, P337, DOI 10.1016/j.bandc.2013.05.009; Raedt R, 2011, J NEUROCHEM, V117, P461, DOI 10.1111/j.1471-4159.2011.07214.x; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Rush AJ, 2000, BIOL PSYCHIAT, V47, P276, DOI 10.1016/S0006-3223(99)00304-2; Sackeim HA, 2001, NEUROPSY NEUROPSY BE, V14, P53; Sackeim HA, 2001, NEUROPSYCHOPHARMACOL, V25, P713, DOI 10.1016/S0893-133X(01)00271-8; Sjogren MJC, 2002, J CLIN PSYCHIAT, V63, P972, DOI 10.4088/JCP.v63n1103; Sun LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149525; Sun LH, 2015, NEUROPSYCHOLOGIA, V78, P88, DOI 10.1016/j.neuropsychologia.2015.10.001; Van Bockstaele EJ, 1999, J COMP NEUROL, V412, P410, DOI 10.1002/(SICI)1096-9861(19990927)412:3<410::AID-CNE3>3.0.CO;2-F; van Stegeren AH, 2008, ACTA PSYCHOL, V127, P532, DOI 10.1016/j.actpsy.2007.10.004; Vonck K, 2014, NEUROSCI BIOBEHAV R, V45, P63, DOI 10.1016/j.neubiorev.2014.05.005; Vuilleumier P, 2001, NEUROREPORT, V12, P1119, DOI 10.1097/00001756-200105080-00014	51	30	31	1	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2017	39	10					954	964		10.1080/13803395.2017.1285869			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	FN2VJ	WOS:000415853000004	28492363				2021-06-18	
J	Kraus, N; Thompson, EC; Krizman, J; Cook, K; White-Schwoch, T; LaBella, CR				Kraus, Nina; Thompson, Elaine C.; Krizman, Jennifer; Cook, Katherine; White-Schwoch, Travis; LaBella, Cynthia R.			Auditory biological marker of concussion in children	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; SPEECH-PERCEPTION; PITCH DISCRIMINATION; FOOTBALL PLAYERS; HEARING-LOSS; HEAD-INJURY; NOISE; PLASTICITY; INDIVIDUALS; PERFORMANCE	Concussions carry devastating potential for cognitive, neurologic, and socio-emotional disease, but no objective test reliably identifies a concussion and its severity. A variety of neurological insults compromise sound processing, particularly in complex listening environments that place high demands on brain processing. The frequency-following response captures the high computational demands of sound processing with extreme granularity and reliably reveals individual differences. We hypothesize that concussions disrupt these auditory processes, and that the frequency-following response indicates concussion occurrence and severity. Specifically, we hypothesize that concussions disrupt the processing of the fundamental frequency, a key acoustic cue for identifying and tracking sounds and talkers, and, consequently, understanding speech in noise. Here we show that children who sustained a concussion exhibit a signature neural profile. They have worse representation of the fundamental frequency, and smaller and more sluggish neural responses. Neurophysiological responses to the fundamental frequency partially recover to control levels as concussion symptoms abate, suggesting a gain in biological processing following partial recovery. Neural processing of sound correctly identifies 90% of concussion cases and clears 95% of control cases, suggesting this approach has practical potential as a scalable biological marker for sports-related concussion and other types of mild traumatic brain injuries.	[Kraus, Nina; Thompson, Elaine C.; Krizman, Jennifer; White-Schwoch, Travis] Northwestern Univ, Auditory Neurosci Lab, Evanston, IL 60208 USA; [Kraus, Nina; Thompson, Elaine C.; Krizman, Jennifer; White-Schwoch, Travis] Northwestern Univ, Dept Commun Sci, Evanston, IL 60208 USA; [Kraus, Nina] Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; [Kraus, Nina] Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, Chicago, IL 60611 USA; [Cook, Katherine; LaBella, Cynthia R.] Ann & Robert H Lurie Childrens Hosp Chicago, Div Pediat Orthopaed Surg & Sports Med, Chicago, IL 60611 USA; [Cook, Katherine; LaBella, Cynthia R.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA	Kraus, N (corresponding author), Northwestern Univ, Auditory Neurosci Lab, Evanston, IL 60208 USA.; Kraus, N (corresponding author), Northwestern Univ, Dept Commun Sci, Evanston, IL 60208 USA.; Kraus, N (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA.; Kraus, N (corresponding author), Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, Chicago, IL 60611 USA.	nkraus@northwestern.edu			Knowles Hearing Center	Supported by the Knowles Hearing Center. We thank Trent Nicol for his comments on this manuscript, Greta Weber, Jamie Burgess, PhD, and Kelly Trainor, APN, for their assistance with this project, and colleagues in the Auditory Neuroscience Laboratory and the Institute for Sports Medicine.	Anderson S, 2013, HEARING RES, V300, P18, DOI 10.1016/j.heares.2013.03.006; Anderson S, 2012, J NEUROSCI, V32, P14156, DOI 10.1523/JNEUROSCI.2176-12.2012; Anderson S, 2010, J NEUROSCI, V30, P4922, DOI 10.1523/JNEUROSCI.0107-10.2010; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Bajo VM, 2010, NAT NEUROSCI, V13, P253, DOI 10.1038/nn.2466; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Carcagno S, 2011, JARO-J ASSOC RES OTO, V12, P89, DOI 10.1007/s10162-010-0236-1; Carman AJ, 2015, NAT REV NEUROL, V11, P230, DOI 10.1038/nrneurol.2015.30; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cramer SC, 2011, BRAIN, V134, P1591, DOI 10.1093/brain/awr039; Dehaene-Lambertz G, 2002, SCIENCE, V298, P2013, DOI 10.1126/science.1077066; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Doupe AJ, 1999, ANNU REV NEUROSCI, V22, P567, DOI 10.1146/annurev.neuro.22.1.567; DUBNO JR, 1984, J ACOUST SOC AM, V76, P87, DOI 10.1121/1.391011; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Folmer RL, 2011, INT J PSYCHOPHYSIOL, V82, P4, DOI 10.1016/j.ijpsycho.2011.03.005; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Gosselin N, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12253; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; Joyce AS, 2015, MED SCI SPORT EXER, V47, P1119, DOI 10.1249/MSS.0000000000000534; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kraus N, 2005, TRENDS NEUROSCI, V28, P176, DOI 10.1016/j.tins.2005.02.003; Kraus N, 2015, TRENDS COGN SCI, V19, P642, DOI 10.1016/j.tics.2015.08.017; Krizman J, 2012, P NATL ACAD SCI USA, V109, P7877, DOI 10.1073/pnas.1201575109; Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845-09.2009; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maro II, 2014, EAR HEARING, V35, P306, DOI 10.1097/01.aud.0000439101.07257.ed; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGee T, 1996, EAR HEARING, V17, P419, DOI 10.1097/00003446-199610000-00008; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Munjal SK, 2010, J TRAUMA, V68, P13, DOI 10.1097/TA.0b013e3181c9f274; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Pruitt DT, 2016, J NEUROTRAUM, V33, P871, DOI 10.1089/neu.2015.3972; ROSEN S, 1992, PHILOS T ROY SOC B, V336, P367, DOI 10.1098/rstb.1992.0070; Sanchez JT, 2007, J NEUROSCI, V27, P1954, DOI 10.1523/JNEUROSCI.2894-06.2007; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Shaheen LA, 2015, JARO-J ASSOC RES OTO, V16, P727, DOI 10.1007/s10162-015-0539-3; Skoe E, 2015, CEREB CORTEX, V25, P1415, DOI 10.1093/cercor/bht311; Skoe E, 2010, EAR HEARING, V31, P302, DOI 10.1097/AUD.0b013e3181cdb272; Song JH, 2011, J COGNITIVE NEUROSCI, V23, P2268, DOI 10.1162/jocn.2010.21556; Turgeon C, 2011, EAR HEARING, V32, P667, DOI 10.1097/AUD.0b013e31821209d6; van der Roer N, 2006, SPINE, V31, P578, DOI 10.1097/01.brs.0000201293.57439.47; Wehr M, 2003, NATURE, V426, P442, DOI 10.1038/nature02116; White-Schwoch T, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002196; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767; Ziegler JC, 2005, P NATL ACAD SCI USA, V102, P14110, DOI 10.1073/pnas.0504446102	47	30	30	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	DEC 22	2016	6								39009	10.1038/srep39009			10	Multidisciplinary Sciences	Science & Technology - Other Topics	EF4NC	WOS:000390304800001	28005070	DOAJ Gold, Green Published			2021-06-18	
J	Buckley, TA; Vallabhajosula, S; Oldham, JR; Munkasy, BA; Evans, KM; Krazeise, DA; Ketcham, CJ; Hall, EE				Buckley, Thomas A.; Vallabhajosula, Srikant; Oldham, Jessie R.; Munkasy, Barry A.; Evans, Kelsey M.; Krazeise, David A.; Ketcham, Caroline J.; Hall, Eric E.			Evidence of a conservative gait strategy in athletes with a history of concussions	JOURNAL OF SPORT AND HEALTH SCIENCE			English	Article						Balance; Brain injury; Gait performance; Locomotion; Mild traumatic; Postural control; Postural stability; Variability	TRAUMATIC BRAIN-INJURY; GAITRITE(R) WALKWAY SYSTEM; HEART-RATE-VARIABILITY; HIGH-SCHOOL; POSTURAL-CONTROL; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; CEREBRAL CONCUSSION; LENGTH VARIABILITY; BALANCE CONTROL	Background: A history of 3 or more concussions is frequently associated with numerous short-and long-term neuropathologies. Impairments in postural control are a known acute consequence of concussion; however, limited evidence exists on the effects of multiple concussions on gait. The purpose of this study was to assess gait stepping characteristics in collegiate aged student-athletes based on concussion history. Methods: There were 63 participants divided into 3 even groups based on concussion history: >= 3 concussions, 1-2 concussions, and 0 concussion. All participants completed 10 trials of gait on a 4.9 m instrumented walkway. The dependent variables of interest included both gait stepping characteristics (step velocity, length, and width, double support time, and the percentage of the gait cycle in stance) and coefficient of variability (CoV) measures (step length, time, and width). The gait stepping characteristics were compared first with a MANOVA with follow-up 1-way ANOVAs and Tukey post hoc tests as appropriate. The CoV measures were compared with 1-way ANOVAs and Tukey post hoc tests. Results: There were main effects for group for step velocity, length, width, and double support time. Overall, the 0 concussion group displayed typical healthy young gait parameters and performed significantly better than either concussion group. The 0 concussion group had a significantly greater step length CoV, but there were no differences in the step time or width CoV. Conclusion: This finding provides evidence of subtle impairments in postural control during gait among individuals with prior history of concussion which could be an early indicator of future neurological deficiencies. The limited difference in the variability measures is consistent with prior static stance studies and could suggest the individuals constrain their motor systems to reduce variability. Taken together, these findings suggest a conservative gait strategy which is adopted by individuals with a history of concussions. (C) 2016 Production and hosting by Elsevier B.V. on behalf of Shanghai University of Sport. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Buckley, Thomas A.; Oldham, Jessie R.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA; [Vallabhajosula, Srikant] Elon Univ, Dept Phys Therapy Educ, Elon, NC 27244 USA; [Munkasy, Barry A.; Evans, Kelsey M.] Georgia Southern Univ, Dept Hlth & Kinesiol, Statesboro, GA 30460 USA; [Krazeise, David A.] Stetson Univ, Dept Intercollegiate Athlet, Deland, FL 32723 USA; [Ketcham, Caroline J.; Hall, Eric E.] Elon Univ, Dept Exercise Sci, Elon, NC 27244 USA	Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA.	TBuckley@UDel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; Vallabhajosula, Srikant/0000-0002-7984-1106; Oldham, Jessie/0000-0003-2801-2110; Ketcham, Caroline/0000-0002-6713-130X	NIH/NINDS grant [1R15NS070744-01A1]; Georgia Southern University Faculty Development grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS070744] Funding Source: NIH RePORTER	This project was funded, in part, by an NIH/NINDS grant (1R15NS070744-01A1) and a Georgia Southern University Faculty Development grant. Two authors, Drs. Buckley and Munkasy, arc primary investigators on both grants. The funding agency had no role in the development of the manuscript, the interpretation of the results, or the decision where to submit the manuscript.	Acharya UR, 2006, MED BIOL ENG COMPUT, V44, P1031, DOI 10.1007/s11517-006-0119-0; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Caderby T, 2013, GAIT POSTURE, V37, P144, DOI 10.1016/j.gaitpost.2012.06.012; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Gosselin N, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12253; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guzzetti S, 2001, AUTON NEUROSCI-BASIC, V90, P102, DOI 10.1016/S1566-0702(01)00274-0; Hass CJ, 2004, ARCH PHYS MED REHAB, V85, P1593, DOI 10.1016/j.apmr.2004.01.020; Hausdorff JM, 2009, CHAOS, V19, DOI 10.1063/1.3147408; Hausdorff JM, 1998, MOVEMENT DISORD, V13, P428, DOI 10.1002/mds.870130310; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Inc CS, 2013, GAITRITE EL WALKW TE; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Karantzoulis S, 2013, NEUROPSYCHOL REV, V23, P350, DOI 10.1007/s11065-013-9243-4; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Littleton A, 2013, J SPORT HEALTH SCI, V2, P227, DOI 10.1016/j.jshs.2013.04.003; Lord S, 2011, GAIT POSTURE, V34, P443, DOI 10.1016/j.gaitpost.2011.07.010; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; Mbourou GA, 2003, GERONTOLOGY, V49, P21, DOI 10.1159/000066506; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Menz HB, 2004, GAIT POSTURE, V20, P20, DOI 10.1016/S0966-6362(03)00068-7; Nakamura T, 1996, GERONTOLOGY, V42, P108, DOI 10.1159/000213780; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Owings TM, 2003, J BIOMECH, V36, P1215, DOI 10.1016/S0021-9290(03)00108-8; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Powers KC, 2014, GAIT POSTURE, V39, P728, DOI 10.1016/j.gaitpost.2013.10.005; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Preatoni E, 2013, SPORT BIOMECH, V12, P69, DOI 10.1080/14763141.2012.738700; Preatoni E, 2010, J SPORT SCI, V28, P1327, DOI 10.1080/02640414.2010.507250; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Roemmich RT, 2012, GAIT POSTURE, V36, P340, DOI 10.1016/j.gaitpost.2012.01.018; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Silverberg ND, 2013, J NEUROTRAUM, V30, P1398, DOI 10.1089/neu.2012.2827; Slobounov S, 2012, CLIN NEUROPHYSIOL, V123, P1755, DOI 10.1016/j.clinph.2011.12.022; Socie MJ, 2013, MULT SCLER INT, V2013, DOI 10.1155/2013/645197; Solomon GS, 2013, ARCH CLIN NEUROPSYCH, V28, P9, DOI 10.1093/arclin/acs108; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Spira JL, 2014, J NEUROTRAUM, V31, P1823, DOI 10.1089/neu.2014.3363; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Webster KE, 2005, GAIT POSTURE, V22, P317, DOI 10.1016/j.gaitpost.2004.10.005	72	30	30	0	14	SHANGHAI UNIV SPORT	SHANGHAI	EDITORIAL BOARD, 650 QINGYUANHUAN RD, SHANGHAI, 200438, PEOPLES R CHINA	2095-2546	2213-2961		J SPORT HEALTH SCI	J. Sport Health Sci.	DEC	2016	5	4					417	423		10.1016/j.jshs.2015.03.010			7	Hospitality, Leisure, Sport & Tourism; Sport Sciences	Social Sciences - Other Topics; Sport Sciences	EJ0UA	WOS:000392924800011	30356549	DOAJ Gold, Green Published			2021-06-18	
J	Iverson, GL; Atkins, JE; Zafonte, R; Berkner, PD				Iverson, Grant L.; Atkins, Joseph E.; Zafonte, Ross; Berkner, Paul D.			Concussion History in Adolescent Athletes with Attention-Deficit Hyperactivity Disorder	JOURNAL OF NEUROTRAUMA			English	Article						adolescents; attention-deficit hyperactivity disorder; concussion; mild traumatic brain injury; surveillance	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; DEFICIT/HYPERACTIVITY DISORDER; PSYCHIATRIC-ILLNESS; NONFATAL INJURIES; CHILDREN; POPULATION; PREDICTORS; COHORT	Little is known about the rate of concussions in adolescents with attention-deficit hyperactivity disorder (ADHD). We hypothesized that high school athletes with ADHD would report a greater history of concussion than students without ADHD. A total of 6529 adolescent and young adult student athletes, between the ages of 13 and 19 years (mean, 15.9; standard deviation, 1.3), completed a preseason health survey in 2010. Of those with ADHD, 26.1% reported a history of one or more concussions, compared to 17.1% of those without ADHD (p < 0.00001; odds ratio [OR], 1.71). Stratified by gender, 27.0% of boys with ADHD reported a history of one or more concussions, compared to 20.0% of boys without ADHD (p < 0.004; OR, 1.48), and 23.6% of girls with ADHD reported a history of one or more concussions, compared to 13.6% of girls without ADHD (p < 0.003; OR, 1.97). Of those with ADHD, 9.8% reported a history of two or more concussions, compared to 5.5% of those without ADHD (p < 0.0003; OR, 1.87). Stratified by gender, 10.0% of boys with ADHD reported a history of two or more concussions, compared to 6.7% of boys without ADHD (p < 0.033; OR, 1.54), and 9.1% of girls with ADHD reported a history of two or more concussions, compared to 3.8% of girls without ADHD (p < 0.006; OR, 2.51). In this large-scale, retrospective survey study, boys and girls with ADHD were significantly more likely to report a history of concussion. Additional research is needed to determine whether students with ADHD are more susceptible to injury (i.e., have a lower threshold) or have different recovery trajectories.	[Iverson, Grant L.; Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] MassGen Hosp Children Sport Concuss Program, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.; Zafonte, Ross] Spaulding Rehabil Hosp, Charlestown, MA USA; [Atkins, Joseph E.] Colby Coll, Dept Psychol, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Hlth Serv, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Dept Biol, Waterville, ME 04901 USA	Iverson, GL (corresponding author), Harvard Med Sch, Dept Phys Med & Rehabil, Ctr Hlth & Rehabil, 79-96 Thirteenth St, Charlestown, MA 02129 USA.	giverson@mgh.harvard.edu		Iverson, Grant/0000-0001-7348-9570	Goldfarb Center for Public Policy; Civic Engagement/Colby College; Bill and Joan Alfond Foundation; Harvard Integrated Program to Protect and Improve the Health of NFLPA Members	This work was funded, in part, by the Goldfarb Center for Public Policy and Civic Engagement/Colby College and the Bill and Joan Alfond Foundation. R.Z. was supported, in part, by the Harvard Integrated Program to Protect and Improve the Health of NFLPA Members.	Adeyemo BO, 2014, J ATTEN DISORD, V18, P576, DOI 10.1177/1087054714543371; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Kaya A, 2008, J INT MED RES, V36, P9, DOI 10.1177/147323000803600102; Keenan HT, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1984; Lam L T, 2002, J Atten Disord, V6, P77, DOI 10.1177/108705470200600204; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Merrill RM, 2009, ADV MED SCI-POLAND, V54, P20, DOI 10.2478/v10039-009-0022-7; Pastor PN, 2006, AMBUL PEDIATR, V6, P38, DOI 10.1016/j.ambp.2005.07.002; PASTOR PN, 2008, VITAL HLTH STAT, V10, P1; Sabuncuoglu O, 2005, DENT TRAUMATOL, V21, P249, DOI 10.1111/j.1600-9657.2005.00317.x; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Shilon Y, 2012, CHILD CARE HLTH DEV, V38, P366, DOI 10.1111/j.1365-2214.2011.01278.x; Swensen, 2004, J ADOLESCENT HEALTH, V35, DOI [DOI 10.1016/J.JAD0HEALTH.2003.12.003, 10.1016/j.jadohealth.2003.12.003]; Xiang HY, 2005, AM J PUBLIC HEALTH, V95, P1970, DOI 10.2105/AJPH.2004.057505	24	30	30	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2016	33	23					2077	2080		10.1089/neu.2014.3424			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ED2JG	WOS:000388669800002	25375785				2021-06-18	
J	Pyne, JM; Constans, JI; Wiederhold, MD; Gibson, DP; Kimbrell, T; Kramer, TL; Pitcock, JA; Han, XT; Williams, DK; Chartrand, D; Gevirtz, RN; Spira, J; Wiederhold, BK; McCraty, R; McCune, TR				Pyne, Jeffrey M.; Constans, Joseph I.; Wiederhold, Mark D.; Gibson, Douglas P.; Kimbrell, Timothy; Kramer, Teresa L.; Pitcock, Jeffery A.; Han, Xiaotong; Williams, D. Keith; Chartrand, Don; Gevirtz, Richard N.; Spira, James; Wiederhold, Brenda K.; McCraty, Rollin; McCune, Thomas R.			Heart rate variability: Pre-deployment predictor of post-deployment PTSD symptoms	BIOLOGICAL PSYCHOLOGY			English	Article						Post traumatic stress disorder (PTSD); military; risk factors; combat stress; prediction; longitudinal; heart rate variability	POSTTRAUMATIC-STRESS-DISORDER; CARDIAC VAGAL TONE; PSYCHOPHYSIOLOGICAL REACTIVITY; RISK-FACTORS; RESILIENCE; VETERANS; US; ASSOCIATION; DEPRESSION; IRAQ	Heart rate variability is a physiological measure associated with autonomic nervous system activity. This study hypothesized that lower pre-deployment HRV would be associated with higher post-deployment post-traumatic stress disorder (PTSD) symptoms. Three-hundred-forty-three Army National Guard soldiers enrolled in the Warriors Achieving Resilience (WAR) study were analyzed. The primary outcome was PTSD symptom severity using the PTSD Checklist Military version (PCL) measured at baseline, 3- and 12-month post-deployment. Heart rate variability predictor variables included: high frequency power (HF) and standard deviation of the normal cardiac inter-beat interval (SDNN). Generalized linear mixed models revealed that the pre-deployment PCL*ln(HF) interaction term was significant (p < 0.0001). Pre-deployment SDNN was not a significant predictor of post-deployment PCL. Covariates included age, pre-deployment PCL, race/ethnicity, marital status, tobacco use, childhood abuse, pre-deployment traumatic brain injury, and previous combat zone deployment. Pre-deployment heart rate variability predicts post-deployment PTSD symptoms in the context of higher pre-deployment PCL scores. Published by Elsevier B.V.	[Pyne, Jeffrey M.; Kimbrell, Timothy; Pitcock, Jeffery A.; Han, Xiaotong] Cent Arkansas Vet Healthcare Syst, Ctr Mental Hlth Outcomes Res, North Little Rock, AR 72114 USA; [Pyne, Jeffrey M.; Constans, Joseph I.; Kimbrell, Timothy; Han, Xiaotong] Cent Arkansas Vet Healthcare Syst, South Cent Mental Illness Educ & Clin Ctr, North Little Rock, AR 72114 USA; [Pyne, Jeffrey M.; Kramer, Teresa L.; Han, Xiaotong] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Div Hlth Serv Res, Little Rock, AR 72205 USA; [Constans, Joseph I.] Southeastern Louisiana Vet Hlth Care Syst 629 11F, POB 61011, New Orleans, LA 70161 USA; [Constans, Joseph I.] Tulane Univ, New Orleans, LA 70118 USA; [Wiederhold, Mark D.; Wiederhold, Brenda K.] Virtual Real Med Ctr, 9565 Waples St,Suite 200, San Diego, CA 92121 USA; [Gibson, Douglas P.] Virginia Army Natl Guard, Off State Surgeon, BLDG 1310,Ft Pickett, Blackstone, VA 23824 USA; [Williams, D. Keith] Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA; [Chartrand, Don] Ease Interactive Inc, San Diego, CA USA; [Gevirtz, Richard N.] Alliant Int Univ, 10455 Pomerado Rd, San Diego, CA 92131 USA; [Spira, James] Univ Hawaii, Sch Med, US Dept Vet Affairs, Natl Ctr PTSD, Honolulu, HI 96819 USA; [Spira, James] Univ Hawaii, Sch Med, Dept Psychiat, Honolulu, HI 96819 USA; [McCraty, Rollin] Inst HeartMath, 14700 West Pk Ave, Boulder Creek, CA 95006 USA	Pyne, JM (corresponding author), 2200 Ft Roots Dr 152-NLR, North Little Rock, AR USA.	jmpyne@uams.edu	Wiederhold, Brenda K/Z-1993-2019; Pyne, Jeffrey/AAA-9280-2019	Wiederhold, Brenda K/0000-0002-3320-0303; 	Military Operational Medical Research Program [PT074626]; South Central Mental Illness and Research Educational and Clinical Center (MIRECC); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 GM103425-09, UL1TR000039, KL2TR000063]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000039, KL2TR000063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103425] Funding Source: NIH RePORTER	This work was supported by grants from the Military Operational Medical Research Program (PT074626), South Central Mental Illness and Research Educational and Clinical Center (MIRECC), and National Institutes of Health (P20 GM103425-09, UL1TR000039, KL2TR000063).	Agelink MW, 2002, PSYCHIAT RES, V113, P139, DOI 10.1016/S0165-1781(02)00225-1; Beevers CG, 2011, AM J PSYCHIAT, V168, P735, DOI 10.1176/appi.ajp.2011.10091309; Billman GE, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00026; BLANCHARD EB, 1991, J NERV MENT DIS, V179, P97, DOI 10.1097/00005053-199102000-00006; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Brady RE, 2015, J TRAUMA DISSOCIATIO, V16, P551, DOI 10.1080/15299732.2015.1021505; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Camm AJ, 1996, EUR HEART J, V17, P354; Chalmers JA, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00080; Cohen H, 2006, AUTON NEUROSCI-BASIC, V128, P1, DOI 10.1016/j.autneu.2005.06.007; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Constans JI, 2014, J ABNORM PSYCHOL, V123, P81, DOI 10.1037/a0035100; Cooper TM, 2015, BRAIN BEHAV IMMUN, V49, P94, DOI 10.1016/j.bbi.2014.12.017; Eckberg DL, 1997, CIRCULATION, V96, P3224, DOI 10.1161/01.CIR.96.9.3224; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Forneris CA, 2004, MIL MED, V169, P307, DOI 10.7205/MILMED.169.4.307; Geisler FCM, 2013, BIOL PSYCHOL, V93, P279, DOI 10.1016/j.biopsycho.2013.02.013; Ginsberg JP, 2010, ALTERN THER HEALTH M, V16, P52; GROSSMAN P, 1993, PSYCHOPHYSIOLOGY, V30, P486, DOI 10.1111/j.1469-8986.1993.tb02072.x; Guthrie RM, 2005, AM J PSYCHIAT, V162, P283, DOI 10.1176/appi.ajp.162.2.283; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hoge EA, 2007, DEPRESS ANXIETY, V24, P139, DOI 10.1002/da.20175; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Jarczok M. N., 2015, PUBLIC LIB SCI, V10; Kardiner A., 1941, TRAUMATIC NEUROSES W; Keane TM, 1998, J CONSULT CLIN PSYCH, V66, P914, DOI 10.1037/0022-006X.66.6.914; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; Koffel E, 2013, J ANXIETY DISORD, V27, P512, DOI 10.1016/j.janxdis.2013.07.003; Kok BC, 2012, J NERV MENT DIS, V200, P444, DOI 10.1097/NMD.0b013e3182532312; Marmar CR, 2006, ANN NY ACAD SCI, V1071, P1, DOI 10.1196/annals.1364.001; McCraty R., 2014, PSYCHOL CLIN SETTING, V5, P1090, DOI DOI 10.3389/FPSYG.2014.01090.EC0LLECTI0N; Meakins JC, 1918, HEART-J STUD CIRC, V7, P17; Minassian A, 2015, JAMA PSYCHIAT, V72, P979, DOI 10.1001/jamapsychiatry.2015.0922; National Institute of Mental Health, 2011, NIMH RES DOM CRIT RD; Newton-Cheh C, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S7; Orr SP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-8; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Phillips CJ, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-52; PITMAN RK, 1987, ARCH GEN PSYCHIAT, V44, P970; Pole N, 2009, BIOL PSYCHIAT, V65, P235, DOI 10.1016/j.biopsych.2008.07.015; Porges SW, 2007, BIOL PSYCHOL, V74, P116, DOI 10.1016/j.biopsycho.2006.06.009; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.2307/2335739; Rusiecki JA, 2012, EPIGENOMICS-UK, V4, P29, DOI [10.2217/EPI.11.116, 10.2217/epi.11.116]; Sandweiss DA, 2011, ARCH GEN PSYCHIAT, V68, P496, DOI 10.1001/archgenpsychiatry.2011.44; Schafer JL., 1997, ANAL INCOMPLETE MULT; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Shephard B., 2003, WAR NERVES SOLDIERS; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sundin J, 2014, BRIT J PSYCHIAT, V204, P202, DOI 10.1192/bjp.bp.113.129569; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; Thayer JF, 2009, ANN BEHAV MED, V37, P141, DOI 10.1007/s12160-009-9101-z; Tsuji H, 1996, CIRCULATION, V94, P2850, DOI 10.1161/01.CIR.94.11.2850; U.S. Department of Defense Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; van Zuiden M, 2012, BIOL PSYCHIAT, V71, P309, DOI 10.1016/j.biopsych.2011.10.026; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Wald I, 2013, JAMA PSYCHIAT, V70, P401, DOI 10.1001/2013.jamapsychiatry.188; Warner CH, 2011, ARCH GEN PSYCHIAT, V68, P1065, DOI 10.1001/archgenpsychiatry.2011.112; Weathers F.W., 1993, 9 ANN C ISTSS; Wolfe J, 2000, J CLIN PSYCHOL, V56, P1371, DOI 10.1002/1097-4679(200010)56:10<1371::AID-JCLP8>3.3.CO;2-O; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	62	30	30	0	26	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0301-0511	1873-6246		BIOL PSYCHOL	Biol. Psychol.	DEC	2016	121		A				91	98		10.1016/j.biopsycho.2016.10.008			8	Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental	Psychology; Behavioral Sciences	EE3SK	WOS:000389518500011	27773678	Green Accepted			2021-06-18	
J	Ewing-Cobbs, L; Johnson, CP; Juranek, J; DeMaster, D; Prasad, M; Duque, G; Kramer, L; Cox, CS; Swank, PR				Ewing-Cobbs, Linda; Johnson, Chad Parker; Juranek, Jenifer; DeMaster, Dana; Prasad, Mary; Duque, Gerardo; Kramer, Larry; Cox, Charles S.; Swank, Paul R.			Longitudinal diffusion tensor imaging after pediatric traumatic brain injury: Impact of age at injury and time since injury on pathway integrity	HUMAN BRAIN MAPPING			English	Article						tract-based spatial statistics; fractional anisotropy; radial diffusivity; axial diffusivity; children; microstructure; neurodegeneration; dysmyelination; chronic	WHITE-MATTER; CORPUS-CALLOSUM; FRACTIONAL ANISOTROPY; UNCINATE FASCICULUS; CHILDREN; ADOLESCENTS; CHILDHOOD; RECOVERY; MODERATE; MICROSTRUCTURE	Following pediatric traumatic brain injury (TBI), longitudinal diffusion tensor imaging may characterize alterations in initial recovery and subsequent trajectory of white matter development. Our primary aim examined effects of age at injury and time since injury on pathway microstructure in children ages 6-15 scanned 3 and 24 months after TBI. Microstructural values generated using tract-based spatial statistics extracted from core association, limbic, and projection pathways were analyzed using general linear mixed models. Relative to children with orthopedic injury, the TBI group had lower fractional anisotropy (FA) bilaterally in all seven pathways. In left-hemisphere association pathways, school-aged children with TBI had the lowest initial pathway integrity and showed the greatest increase in FA over time suggesting continued development despite incomplete recovery. Adolescents showed limited change in FA and radial diffusivity and had the greatest residual deficit suggesting relatively arrested development. Radial diffusivity was persistently elevated in the TBI group, implicating dysmyelination as a core contributor to chronic post-traumatic neurodegenerative changes. The secondary aim compared FA values over time in the total sample, including participants contributing either one or two scans to the analysis, to the longitudinal cases contributing two scans. For each pathway, FA values and effect sizes were very similar and indicated extremely small differences in measurement of change over time in the total and longitudinal samples. Statistical approaches incorporating missing data may reliably estimate the effects of TBI and provide increased power to identify whether pathways show neurodegeneration, arrested development, or continued growth following pediatric TBI. Hum Brain Mapp 37:3929-3945, 2016. (c) 2016 Wiley Periodicals, Inc.	[Ewing-Cobbs, Linda; Johnson, Chad Parker; Juranek, Jenifer; DeMaster, Dana; Prasad, Mary; Duque, Gerardo] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Houston, TX 77030 USA; [Ewing-Cobbs, Linda; Johnson, Chad Parker; Juranek, Jenifer; DeMaster, Dana; Prasad, Mary; Duque, Gerardo] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, Houston, TX 77030 USA; [Kramer, Larry] Univ Texas Hlth Sci Ctr Houston, Diagnost & Intervent Radiol, Houston, TX 77030 USA; [Cox, Charles S.] Univ Texas Hlth Sci Ctr Houston, Pediat Surg, Houston, TX 77030 USA; [Swank, Paul R.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA	Ewing-Cobbs, L (corresponding author), Dept Pediat, 7000 Fannin St,Suite 2401, Houston, TX 77030 USA.	Linda.ewing-cobbs@uth.tmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS046308]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046308] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant number: R01 NS046308.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Andersson J. L. R., 2007, TR07JA2 FMRIB CTR; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Catani M., 2012, ATLAS HUMAN BRAIN CO; Cohen J, 1998, STAT POWER ANAL BEHA; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Dennis EL, 2013, INT J DEV NEUROSCI, V31, P525, DOI 10.1016/j.ijdevneu.2013.05.007; Dennis EL, 2013, NEUROIMAGE, V64, P671, DOI 10.1016/j.neuroimage.2012.09.004; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Durlak JA, 2009, J PEDIATR PSYCHOL, V34, P917, DOI 10.1093/jpepsy/jsp004; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Hasan KM, 2009, BRAIN RES, V1276, P67, DOI 10.1016/j.brainres.2009.04.025; Hasan KM, 2003, MAGNET RESON MED, V50, P589, DOI 10.1002/mrm.10552; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Johnson CP, 2011, J INT NEUROPSYCH SOC, V17, P663, DOI 10.1017/S1355617711000464; Johnson CP, 2015, NEUROIMAGE-CLIN, V9, P668, DOI 10.1016/j.nicl.2015.10.009; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Krogsrud SK, 2016, NEUROIMAGE, V124, P473, DOI 10.1016/j.neuroimage.2015.09.017; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Lipsey M. W., 1990, DESIGN SENSITIVITY S; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Mori S., 2005, MRI ATLAS HUMAN WHIT; Park HJ, 2013, SCIENCE, V342, P579, DOI 10.1126/science.1238411; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Roberts RM, 2014, DEV NEUROPSYCHOL, V39, P600, DOI 10.1080/87565641.2014.973958; Rosema S, 2015, J NEUROTRAUM, V32, P976, DOI 10.1089/neu.2014.3567; Scheibel RS, 2011, SOC NEUROSCI-UK, V6, P582, DOI 10.1080/17470919.2011.588844; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Simmonds DJ, 2014, NEUROIMAGE, V92, P356, DOI 10.1016/j.neuroimage.2013.12.044; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; TEASDALE G, 1974, LANCET, V2, P81; Urger SE, 2015, J CHILD NEUROL, V30, P9, DOI 10.1177/0883073813520503; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wilde EA, 2009, J CLIN EXP NEUROPSYC, V31, P205, DOI 10.1080/13803390802098118; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yu QW, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00228	62	30	31	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	NOV	2016	37	11					3929	3945		10.1002/hbm.23286			17	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DZ7VM	WOS:000386075900018	27329317	Green Published, Green Accepted			2021-06-18	
J	Claassen, J; Velazquez, A; Meyers, E; Witsch, J; Falo, MC; Park, S; Agarwal, S; Schmidt, JM; Schiff, ND; Sitt, JD; Naccache, L; Connolly, ES; Frey, HP				Claassen, Jan; Velazquez, Angela; Meyers, Emma; Witsch, Jens; Falo, M. Cristina; Park, Soojin; Agarwal, Sachin; Schmidt, J. Michael; Schiff, Nicholas D.; Sitt, Jacobo D.; Naccache, Lionel; Connolly, E. Sander; Frey, Hans-Peter			Bedside Quantitative Electroencephalography Improves Assessment of Consciousness in Comatose Subarachnoid Hemorrhage Patients	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NONCONVULSIVE SEIZURES; VEGETATIVE STATE; OF-LIFE; DISORDERS; PROPOFOL; CARE; AWARENESS; OSCILLATIONS; INFORMATION	Objective: Accurate behavioral assessments of consciousness carry tremendous significance in guiding management, but are extremely challenging in acutely brain-injured patients. We evaluated whether electroencephalography (EEG) and multimodality monitoring parameters may facilitate assessment of consciousness in patients with subarachnoid hemorrhage. Methods: A retrospective analysis was performed of 83 consecutively treated adults with subarachnoid hemorrhage. All patients were initially comatose and had invasive brain monitoring placed. Behavioral assessments were performed during daily interruption of sedation and categorized into 3 groups based on their best examination as (1) comatose, (2) arousable (eye opening or attending toward a stimulus), and (3) aware (command following). EEG features included spectral power and complexity measures. Comparisons were made using bootstrapping methods and partial least squares regression. Results: We identified 389 artifact-free EEG clips following behavioral assessments. Increasing central gamma, posterior alpha, and diffuse theta-delta oscillations differentiated patients who were arousable from those in coma. Command following was characterized by a further increase in central gamma and posterior alpha, as well as an increase in alpha permutation entropy. These EEG features together with basic neurological examinations (eg, pupillary light reflex) contributed heavily to a linear model predicting behavioral state, whereas brain physiology measures (eg, brain oxygenation), structural injury, and clinical course added less. Interpretation: EEG measures of behavioral states provide distinctive signatures that complement behavioral assessments of patients with subarachnoid hemorrhage shortly after the injury. Our data support the hypothesis that impaired connectivity of cortex with both central thalamus and basal forebrain underlies decreasing levels of consciousness.	[Claassen, Jan; Velazquez, Angela; Meyers, Emma; Witsch, Jens; Falo, M. Cristina; Park, Soojin; Agarwal, Sachin; Schmidt, J. Michael; Frey, Hans-Peter] Columbia Univ, Dept Neurol, New York, NY USA; [Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA; [Sitt, Jacobo D.; Naccache, Lionel] Natl Inst Hlth & Med Res, Inst Brain & Spinal Cord Res Ctr, Paris, France; [Connolly, E. Sander] Columbia Univ, Dept Neurosurg, New York, NY USA	Claassen, J (corresponding author), Columbia Univ, Neurol Inst, 177 Ft Washington Ave,MHB 8 Ctr,Room 300, New York, NY 10032 USA.	jc1439@columbia.edu	Claassen, Jan/AAA-5451-2020; Sitt, Jacobo/A-9834-2015; Witsch, Jens/AAL-3997-2020	Sitt, Jacobo/0000-0002-3878-4846; Witsch, Jens/0000-0001-8924-851X; Schmidt, J. Michael/0000-0001-8141-2944; naccache, lionel/0000-0002-2874-1009	NIH National Library of MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM011826]; NIH National Center for Advancing Translational Sciences [UL1 TR000040, UL1 RR024156]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000040] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024156] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM011826] Funding Source: NIH RePORTER	This work was supported by the NIH National Library of Medicine (R01LM011826, J.C.) and NIH National Center for Advancing Translational Sciences (UL1 TR000040 [formerly the National Center for Research Resources, UL1 RR024156], J.C.).	Bandt C, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.174102; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Barry RJ, 2007, CLIN NEUROPHYSIOL, V118, P2765, DOI 10.1016/j.clinph.2007.07.028; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Boly M, 2012, J NEUROSCI, V32, P7082, DOI 10.1523/JNEUROSCI.3769-11.2012; Breshears JD, 2010, P NATL ACAD SCI USA, V107, P21170, DOI 10.1073/pnas.1011949107; Ching SN, 2010, P NATL ACAD SCI USA, V107, P22665, DOI 10.1073/pnas.1017069108; Choi HA, 2015, NEUROCRIT CARE, V22, P423, DOI 10.1007/s12028-014-0073-x; Cimenser A, 2011, P NATL ACAD SCI USA, V108, P8832, DOI 10.1073/pnas.1017041108; Claassen J, 2014, ANN NEUROL, V75, P771, DOI 10.1002/ana.24166; Claassen J, 2013, ANN NEUROL, V74, P53, DOI 10.1002/ana.23859; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Farzan F, 2010, BRAIN, V133, P1505, DOI 10.1093/brain/awq046; Forgacs PB, 2015, ANN NEUROL, V77, P185, DOI 10.1002/ana.24311; Forgacs PB, 2014, ANN NEUROL, V76, P869, DOI 10.1002/ana.24283; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Gosseries O, 2011, FUNCT NEUROL, V26, P25; Hall SD, 2010, CLIN NEUROPHYSIOL, V121, P549, DOI 10.1016/j.clinph.2009.11.084; JAHNSEN H, 1984, ARCH ITAL BIOL, V122, P73; John ER, 2001, CONSCIOUS COGN, V10, P165, DOI 10.1006/ccog.2001.0507; King JR, 2013, CURR BIOL, V23, P1914, DOI 10.1016/j.cub.2013.07.075; Komotar RJ, 2009, NEUROSURGERY, V64, pN10, DOI 10.1227/01.neu.0000351422.52956.17; Komotar RJ, 2009, NEUROSURGERY, V64, P397, DOI 10.1227/01.NEU.0000338946.42939.C7; Leon-Carrion J, 2012, BRAIN RES, V1476, P22, DOI 10.1016/j.brainres.2012.03.055; Lerch C, 2006, NEUROCRIT CARE, V5, P85, DOI 10.1385/NCC:5:2:85; Llinas R, 1998, PHILOS T ROY SOC B, V353, P1841, DOI 10.1098/rstb.1998.0336; Lule D, 2009, PROG BRAIN RES, V177, P339, DOI 10.1016/S0079-6123(09)17723-3; Mikell CB, 2015, STROKE, V46, P49, DOI 10.1161/STROKEAHA.114.007645; Mitra P., 2008, OBSERVED BRAIN DYNAM; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159; Posner J., 2007, PLUM POSNERS DIAGNOS, V4; Purdon PL, 2013, P NATL ACAD SCI USA, V110, pE1142, DOI 10.1073/pnas.1221180110; Riker RR, 2014, NEUROCRIT CARE, V21, P27, DOI 10.1007/s12028-014-0025-5; Schiff N. D, 2016, BRAIN FUNCTION RESPO, P195, DOI [DOI 10.1007/978-3-319-21425-2_15, 10.1007/978-3-319-21425-2_15]; Schiff ND, 2014, CURR OPIN NEUROBIOL, V25, P7, DOI 10.1016/j.conb.2013.10.007; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141; Sohal VS, 2012, BIOL PSYCHIAT, V71, P1039, DOI 10.1016/j.biopsych.2012.01.024; Supp GG, 2011, CURR BIOL, V21, P1988, DOI 10.1016/j.cub.2011.10.017; Suwatcharangkoon S, 2016, JAMA NEUROL, V73, P28, DOI 10.1001/jamaneurol.2015.3188; Tallon-Baudry C, 2009, FRONT BIOSCI-LANDMRK, V14, P321, DOI 10.2741/3246; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Vinck M, 2010, NEUROIMAGE, V51, P112, DOI 10.1016/j.neuroimage.2010.01.073; Williams ST, 2013, ELIFE, V2, DOI 10.7554/eLife.01157	54	30	31	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	OCT	2016	80	4					541	553		10.1002/ana.24752			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ED0XZ	WOS:000388568700007	27472071	Green Accepted			2021-06-18	
J	Phang, I; Zoumprouli, A; Papadopoulos, MC; Saadoun, S				Phang, Isaac; Zoumprouli, Argyro; Papadopoulos, Marios C.; Saadoun, Samira			Microdialysis to Optimize Cord Perfusion and Drug Delivery in Spinal Cord Injury	ANNALS OF NEUROLOGY			English	Article							ACUTE BRAIN-INJURY; CEREBRAL MICRODIALYSIS; INTRASPINAL PRESSURE; METHYLPREDNISOLONE; MANAGEMENT; SYSTEM; TRIAL; MATER; DURA	Objective: There is lack of monitoring from the injury site to guide management of patients with acute traumatic spinal cord injury. Here, we describe a bedside microdialysis monitoring technique for optimizing spinal cord perfusion and drug delivery at the injury site. Methods: Fourteen patients were recruited within 72 hours of severe spinal cord injury. We inserted intradurally at the injury site a pressure probe, to monitor continuously spinal cord perfusion pressure, and a microdialysis catheter, to monitor hourly glycerol, glutamate, glucose, lactate, and pyruvate. The pressure probe and microdialysis catheter were placed on the surface of the injured cord. Results: Microdialysis monitoring did not cause serious complications. Spinal cord perfusion pressure 90 to 100mm Hg and tissue glucose > 4.5mM minimized metabolic derangement at the injury site. Increasing spinal cord perfusion pressure by similar to 10mm Hg increased the entry of intravenously administered dexamethasone at the injury site 3-fold. Interpretation: This study determined the optimum spinal cord perfusion pressure and optimum tissue glucose concentration at the injury site. We also identified spinal cord perfusion pressure as a key determinant of drug entry into the injured spinal cord. Our findings challenge current guidelines, which recommend maintaining mean arterial pressure at 85 to 90mm Hg for a week after spinal cord injury. We propose that future drug trials for spinal cord injury include pressure and microdialysis monitoring to optimize spinal cord perfusion and maximize drug delivery at the injury site.	[Phang, Isaac; Papadopoulos, Marios C.; Saadoun, Samira] St Georges Univ London, Acad Neurosurg Unit, London, England; [Zoumprouli, Argyro] St George Hosp, Neurointens Care Unit, London, England	Saadoun, S (corresponding author), St Georges Univ London, Room 0-136,Jenner Wing, London SW17 0RE, England.	ssaadoun@sgul.ac.uk		Papadopoulos, Marios/0000-0001-9174-4176; Zoumprouli, Argyro/0000-0003-0890-690X; Saadoun, Samira/0000-0002-5480-5678	Wings for Life Spinal Cord Research Foundation; Fletcher Fund; Neurosciences Research Foundation; London Deanery	Supported by research funds from Wings for Life Spinal Cord Research Foundation (S.S., M.C.P.), Fletcher Fund (M.C.P.), Neurosciences Research Foundation (M.C.P., I.P.), and London Deanery (I.P.).	Abrahamsson P, 2016, J SURG RES, V200, P480, DOI 10.1016/j.jss.2015.09.009; Abrahamsson P, 2011, CLIN PHYSIOL FUNCT I, V31, P175, DOI 10.1111/j.1475-097X.2010.00995.x; BALIS FM, 1987, J CLIN ONCOL, V5, P202, DOI 10.1200/JCO.1987.5.2.202; BERNARDS CM, 1990, ANESTHESIOLOGY, V73, P1214, DOI 10.1097/00000542-199012000-00020; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Dahyot-Fizelier C, 2013, ANTIMICROB AGENTS CH, V57, P2738, DOI 10.1128/AAC.02570-12; Fehlings MG, 2016, SPINAL CORD, V54, P8, DOI 10.1038/sc.2015.95; Fehlings MG, 2010, SPINE, V35, pS166, DOI 10.1097/BRS.0b013e3181f386f6; Frasca D, 2014, ANTIMICROB AGENTS CH, V58, P1019, DOI 10.1128/AAC.01760-13; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Inoue T, 2014, J NEUROTRAUM, V31, P284, DOI 10.1089/neu.2013.3061; Kitagawa R, 2013, NEUROSURG CLIN N AM, V24, P417, DOI 10.1016/j.nec.2013.02.002; Kobayakawa K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009430; Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158; Okon EB, 2013, J NEUROTRAUM, V30, P1564, DOI 10.1089/neu.2013.2956; Papadopoulos MC, 2015, NEUROSURGERY, V77, pE500, DOI 10.1227/NEU.0000000000000862; Phang I, 2016, J NEUROSURG-SPINE, V25, P398, DOI 10.3171/2016.1.SPINE151317; Phang I, 2016, SPINE, V41, pE605, DOI 10.1097/BRS.0000000000001334; Phang I, 2015, NEUROCRIT CARE, V23, P414, DOI 10.1007/s12028-015-0153-6; Phang I, 2015, J NEUROTRAUM, V32, P865, DOI 10.1089/neu.2014.3668; Plock N, 2005, EUR J PHARM SCI, V25, P1, DOI 10.1016/j.ejps.2005.01.017; QUAN N, 1989, BRAIN RES BULL, V22, P621, DOI 10.1016/0361-9230(89)90080-4; Saadoun S, 2016, BRIT J NEUROSURG, V30, P1; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Shannon RJ, 2014, BRIT J CLIN PHARMACO, V78, P981, DOI 10.1111/bcp.12414; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Vandenabeele F, 1996, J ANAT, V189, P417; Varsos GV, 2015, J NEUROSURG-SPINE, V23, P763, DOI 10.3171/2015.3.SPINE14870; Walters BC, 2013, NEUROSURGERY, V60, P82, DOI 10.1227/01.neu.0000430319.32247.7f; Werndle MC, 2016, ACTA NEUROCHIR SUPPL, V122, P323, DOI 10.1007/978-3-319-22533-3_64; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028; Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038	36	30	30	2	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	OCT	2016	80	4					522	531		10.1002/ana.24750			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ED0XZ	WOS:000388568700005	27463064	Green Accepted			2021-06-18	
J	Silverberg, ND; Iverson, GL; McCrea, M; Apps, JN; Hammeke, TA; Thomas, DG				Silverberg, Noah D.; Iverson, Grant L.; McCrea, Michael; Apps, Jennifer N.; Hammeke, Thomas A.; Thomas, Danny G.			Activity-Related Symptom Exacerbations After Pediatric Concussion	JAMA PEDIATRICS			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; BED REST; ADOLESCENTS; CHILDREN; RECOVERY; EXERCISE; TRIAL; YOUTH	IMPORTANCE Recovery from concussion generally follows a trajectory of gradual improvement, but symptoms can abruptly worsen with exertion. This phenomenon is poorly understood. OBJECTIVES To characterize the incidence, course, and clinical significance of symptom exacerbations (spikes) in children after concussion. DESIGN, SETTING, AND PARTICIPANTS This secondary analysis of clinical trial data analyzes 63 eligible participants prospectively recruited from an emergency department who were asked to complete a postconcussion symptom scale and record their activities in a structured diary for the next 10 days. They completed standardized assessments of symptoms (postconcussion symptom scale), cognition (Immediate Post-Concussion Assessment and Cognitive Testing), and balance (Balance Error Scoring System) 10 days following the injury. Eligible participants were aged 11 to 18 years and sustained a concussion (according to the Centers for Disease Control and Prevention criteria) that did not result in an abnormal computed tomography scan or require hospital admission. The trial was conducted from May 2010 to December 2012, and the analysis was conducted from November 2015 to February 2016. MAIN OUTCOME AND MEASURE The occurrence of symptom spikes, defined as an increase of 10 or more points on the postconcussion symptom scale over consecutive days. RESULTS Of the 63 participants, there were 41 boys (65.1%) and 22 girls (34.9%), and the mean (SD) age was 13.8 (1.8) years. Symptom spikes occurred in one-third of the sample (20 participants [31.7%]). Symptom spikes tended to partially resolve within 24 hours. An abrupt increase in mental activity (ie, returning to school and extracurricular activities) from one day to the next increased the risk of a symptom spike (relative risk, 0.81; 95% CI, 0.21-3.21), but most symptom spikes were not preceded by a documented increase in physical or mental activity. Patients with symptom spikes were initially more symptomatic in the emergency department and throughout the observation period but did not differ from the group without symptom spikes on cognition or balance 10 days following injury. CONCLUSIONS AND RELEVANCE Certain patients appeared susceptible to high and variable symptom reporting. Symptom spikes may not themselves be detrimental to recovery. The present findings support clinical guidelines for adolescents to return to school and activities gradually after concussion.	[Silverberg, Noah D.] Univ British Columbia, Dept Med, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah D.; Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Silverberg, Noah D.; Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Silverberg, Noah D.; Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGen Hosp, Children Sports Concuss Program, Boston, MA USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Clement J Zablocki VA Med Ctr, Milwaukee, WI 53226 USA; [Apps, Jennifer N.; Hammeke, Thomas A.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA; [Thomas, Danny G.] Med Coll Wisconsin, Dept Pediat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA	Thomas, DG (corresponding author), Childrens Hosp Wisconsin, Dept Pediat, Emergency Med, Corp Ctr, 999 N 92nd St,Ste C550, Milwaukee, WI 53226 USA.	dthomas@mcw.edu		Iverson, Grant/0000-0001-7348-9570; Thomas, Danny/0000-0002-7470-9835	Injury Research Center of the Medical College of Wisconsin; Vancouver Coastal Health Research Institute; Mooney-Reed Charitable Foundation	Dr Thomas received the Advancing A Healthier Wisconsin Seed Grant from the Injury Research Center of the Medical College of Wisconsin. Dr Silverberg received salary support from the Vancouver Coastal Health Research Institute. Dr Iverson received funding from the Mooney-Reed Charitable Foundation.	ANDREASSEN J, 1957, ACTA MED SCAND, V158, P239; [Anonymous], HEADS UP HLTH CAR PR; Aubry M, 2002, BRIT J SPORT MED, V36, P6; Balasundaram AP, 2013, PHYS THER SPORT, V14, P253, DOI 10.1016/j.ptsp.2013.06.002; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bratteby LE, 1997, EUR J CLIN NUTR, V51, P585, DOI 10.1038/sj.ejcn.1600449; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Buckley T, J HEAD TRAUMA REHABI, DOI [10.1097/HRT.0000000000000165, DOI D10.1097/HRT.0000000000000165]; Covassin T, 2013, BRAIN INJURY, V27, P1589, DOI 10.3109/02699052.2013.823656; Craton N, 2014, CURR SPORT MED REP, V13, P201, DOI 10.1249/JSR.0000000000000072; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Dematteo C, 2015, MED SCI SPORT EXER, V47, P2283, DOI 10.1249/MSS.0000000000000682; DeMatteo C, 2015, CLIN PEDIATR, V54, P152, DOI 10.1177/0009922814558256; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Henry CJK, 2004, AM J HUM BIOL, V16, P346, DOI 10.1002/ajhb.20022; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mihalik JP, 2013, CLIN J SPORT MED, V23, P343, DOI 10.1097/JSM.0b013e318295a834; Moor HM, 2015, INT J SPORTS PHYS TH, V10, P225; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Schofield W N, 1985, Hum Nutr Clin Nutr, V39 Suppl 1, P5; Silverberg ND, 2016, CLIN J SPORT MED, V26, P226, DOI 10.1097/JSM.0000000000000241; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Symonds CP, 1928, BRIT MED J, V1928, P829, DOI 10.1136/bmj.2.3540.829; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966	32	30	30	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	OCT	2016	170	10					946	953		10.1001/jamapediatrics.2016.1187			8	Pediatrics	Pediatrics	DZ2AB	WOS:000385643000013	27479847	Bronze			2021-06-18	
J	Coulson-Thomas, VJ; Lauer, ME; Soleman, S; Zhao, C; Hascall, VC; Day, AJ; Fawcett, JW				Coulson-Thomas, Vivien J.; Lauer, Mark E.; Soleman, Sara; Zhao, Chao; Hascall, Vincent C.; Day, Anthony J.; Fawcett, James W.			Tumor Necrosis Factor-stimulated Gene-6 (TSG-6) Is Constitutively Expressed in Adult Central Nervous System (CNS) and Associated with Astrocyte-mediated Glial Scar Formation following Spinal Cord Injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						astrocyte; glycosaminoglycan; hyaluronan; inflammation; proteoglycan; glial scar	INTER-ALPHA-INHIBITOR; SMOOTH-MUSCLE-CELLS; ANTIINFLAMMATORY PROTEIN TSG-6; HEAVY-CHAIN TRANSFER; HYALURONAN-BINDING PROTEINS; FIBRILLARY ACIDIC PROTEIN; HUMAN AMNIOTIC MEMBRANE; REACTIVE ASTROCYTES; EXTRACELLULAR-MATRIX; CD44 EXPRESSION	Tumor necrosis factor (TNF)-stimulated gene-6 (TSG-6) binds to hyaluronan and can reorganize/stabilize its structure, also enhancing the binding of this glycosaminoglycan to its cell surface receptor, CD44. TSG-6 is rapidly up-regulated in response to inflammatory cytokines protecting tissues from the damaging effects of inflammation. Despite TSG-6 treatment having been shown to improve outcomes in an experimental model of traumatic brain injury, TSG-6 expression has not been extensively studied in the central nervous system (CNS). We hereby analyzed the expression profile of TSG-6 in the developing CNS and following injury. We show that TSG-6 is expressed in the rat CNS by GFAP(+) and CD44(+) astrocytes, solely in the mature brain and spinal cord, and is not present during the development of the CNS. TSG-6(-/-) mice present a reduced number of GFAP(+) astrocytes when compared with the littermate TSG-6(+/-) mice. TSG-6 expression is drastically up-regulated after injury, and the TSG-6 protein is present within the glial scar, potentially coordinating and stabilizing the formation of this hyaluronan-rich matrix. This study shows that TSG-6 is expressed in the CNS, suggesting a role for TSG-6 in astrocyte activation and tissue repair. We hypothesize that within this context TSG-6 could participate in the formation of the glial scar and confer anti-inflammatory properties. Further studies are required to elucidate the therapeutic potential of targeting TSG-6 after CNS injury to promote its protective effects while reducing the inhibitory properties of the glial scar in axon regeneration.	[Coulson-Thomas, Vivien J.; Soleman, Sara; Fawcett, James W.] Univ Cambridge, John Van Geest Cambridge Ctr Brain Repair, ED Adrian Bldg,Forvie Site,Robinson Way, Cambridge CB2 0PY, England; [Lauer, Mark E.; Hascall, Vincent C.] Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; [Zhao, Chao] Univ Cambridge, Wellcome Trust Med Res Council Cambridge Stem Cel, Clifford Allbutt Bldg, Cambridge CB2 0AH, England; [Zhao, Chao] Univ Cambridge, Dept Clin Neurosci, Clifford Allbutt Bldg, Cambridge CB2 0AH, England; [Day, Anthony J.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	Coulson-Thomas, VJ (corresponding author), Univ Houston, Coll Optometry, 505 J Davis Armistead Bldg,Rm 2103, Houston, TX 77204 USA.; Day, AJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.; Fawcett, JW (corresponding author), Univ Cambridge, John van Geest Ctr Brain Repair, Forvie Site,Robinson Way, Cambridge CB2 0PY, England.	vcoulsonthomas@gmail.com; anthony.day@manchester.ac.uk; jf108@cam.ac.uk	Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134	European Research Council ECMneuro; National Institutes of Health NHLBI Award [PO1HL107147]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL107147] Funding Source: NIH RePORTER; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_12009] Funding Source: researchfish	This work was supported by the European Research Council ECMneuro and National Institutes of Health NHLBI Award PO1HL107147. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Asher RA, 2000, J NEUROSCI, V20, P2427; Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; Baranova NS, 2014, J BIOL CHEM, V289, P30481, DOI 10.1074/jbc.M114.568154; Baranova NS, 2013, J BIOL CHEM, V288, P29642, DOI 10.1074/jbc.M113.477422; Baranova NS, 2011, J BIOL CHEM, V286, P25675, DOI 10.1074/jbc.M111.247395; Beltran SR, 2015, J PERIODONTOL, V86, P62, DOI 10.1902/jop.2014.140187; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Bignami A, 1984, J Neurosurg Sci, V28, P127; Bogdani M, 2014, DIABETES, V63, P2727, DOI 10.2337/db13-1658; Bollyky PL, 2011, P NATL ACAD SCI USA, V108, P7938, DOI 10.1073/pnas.1017360108; Bollyky PL, 2009, J LEUKOCYTE BIOL, V86, P567, DOI 10.1189/jlb.0109001; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Briggs DC, 2015, J BIOL CHEM, V290, P28708, DOI 10.1074/jbc.M115.669838; Buggey H, 2013, THESIS; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Choi S, 2009, ASN NEURO, V1, DOI 10.1042/AN20090009; Coulson-Thomas VJ, 2016, OCUL SURF, V14, P121, DOI 10.1016/j.jtos.2015.11.004; Coulson-Thomas VJ, 2014, J BIOL CHEM, V289, P23465, DOI 10.1074/jbc.M114.557447; Coulson-Thomas YA, 2008, J NEUROSCI METH, V171, P19, DOI 10.1016/j.jneumeth.2008.01.030; Cragnolini AB, 2009, GLIA, V57, P1386, DOI 10.1002/glia.20857; DAHL D, 1976, BRAIN RES, V116, P150, DOI 10.1016/0006-8993(76)90257-2; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; Dyer DP, 2016, J BIOL CHEM, V291, P12627, DOI 10.1074/jbc.M116.720953; Dyer DP, 2014, J IMMUNOL, V192, P2177, DOI 10.4049/jimmunol.1300194; Evanko SP, 2012, MATRIX BIOL, V31, P90, DOI 10.1016/j.matbio.2011.10.004; Fawcett JW, 2006, J NEUROTRAUM, V23, P371, DOI 10.1089/neu.2006.23.371; Fawcett JW, 2006, ADV EXP MED BIOL, V557, P11; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Fujimoto T, 2002, AM J PATHOL, V160, P1495, DOI 10.1016/S0002-9440(10)62575-8; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; GIRGRAH N, 1991, J NEUROPATH EXP NEUR, V50, P779, DOI 10.1097/00005072-199111000-00009; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; HATHCOCK KS, 1993, J IMMUNOL, V151, P6712; He H, 2014, INVEST OPHTH VIS SCI, V55, P1647, DOI 10.1167/iovs.13-13094; He H, 2009, J BIOL CHEM, V284, P20136, DOI 10.1074/jbc.M109.021881; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Higman VA, 2014, J BIOL CHEM, V289, P5619, DOI 10.1074/jbc.M113.542357; Hull RL, 2012, J HISTOCHEM CYTOCHEM, V60, P749, DOI 10.1369/0022155412457048; HUTTON LA, 1992, J NEUROSCI RES, V32, P375, DOI 10.1002/jnr.490320309; Jain M, 1996, J CLIN INVEST, V97, P596, DOI 10.1172/JCI118455; Jaworski DM, 1999, EXP NEUROL, V157, P327, DOI 10.1006/exnr.1999.7062; Kandel ER, 2000, SCIENCE, V290, P1113, DOI 10.1126/science.290.5494.1113; Khan AI, 2004, J IMMUNOL, V173, P7594, DOI 10.4049/jimmunol.173.12.7594; Kota DJ, 2013, DIABETES, V62, P2048, DOI 10.2337/db12-0931; KUMAR S, 1993, MOL BRAIN RES, V17, P163, DOI 10.1016/0169-328X(93)90086-5; Kuznetsova SA, 2006, J CELL SCI, V119, P4499, DOI 10.1242/jcs.03171; Lauer M. E., 2015, INT J CELL BIOL; Lauer ME, 2015, J BIOL CHEM, V290, P23124, DOI 10.1074/jbc.M115.663823; Lauer ME, 2015, METHODS MOL BIOL, V1229, P543, DOI 10.1007/978-1-4939-1714-3_42; Lauer ME, 2014, J BIOL CHEM, V289, P29171, DOI 10.1074/jbc.M114.600809; Lauer ME, 2014, J BIOL CHEM, V289, P6791, DOI 10.1074/jbc.M113.512491; Lauer ME, 2013, J BIOL CHEM, V288, P205, DOI 10.1074/jbc.M112.403998; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lemons ML, 2001, J NEUROSCI, V21, P4772, DOI 10.1523/JNEUROSCI.21-13-04772.2001; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Mahoney DJ, 2008, J BIOL CHEM, V283, P25952, DOI 10.1074/jbc.M802138200; Mahoney DJ, 2011, ARTHRITIS RHEUM-US, V63, P1034, DOI 10.1002/art.30201; Maina V, 2009, J LEUKOCYTE BIOL, V86, P123, DOI 10.1189/jlb.0608345; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; Marson A, 2009, GLYCOBIOLOGY, V19, P1537, DOI 10.1093/glycob/cwp132; McKeon RJ, 1999, J NEUROSCI, V19, P10778; Metea MR, 2006, GLIA, V54, P650, DOI 10.1002/glia.20352; Milner CM, 2006, BIOCHEM SOC T, V34, P446, DOI 10.1042/BST0340446; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; MORETTO G, 1993, J NEUROPATH EXP NEUR, V52, P419, DOI 10.1097/00005072-199307000-00009; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Nagy N, 2015, J CLIN INVEST, V125, P3928, DOI 10.1172/JCI79271; Nagyeri G, 2011, J BIOL CHEM, V286, P23559, DOI 10.1074/jbc.M111.222026; Naruse M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053109; Niclou SP, 2006, J NEUROTRAUM, V23, P409, DOI 10.1089/neu.2006.23.409; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; Oh JY, 2010, P NATL ACAD SCI USA, V107, P16875, DOI 10.1073/pnas.1012451107; Oh JW, 1998, J IMMUNOL, V161, P4992; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Park Y, 2016, BIOCHEMISTRY-US, V55, P262, DOI 10.1021/acs.biochem.5b01148; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; Rodriguez-Grande B, 2014, J CEREBR BLOOD F MET, V34, P480, DOI 10.1038/jcbfm.2013.224; RUDGE JS, 1994, EUR J NEUROSCI, V6, P693, DOI 10.1111/j.1460-9568.1994.tb00981.x; Scavenius C, 2016, J BIOL CHEM, V291, P4658, DOI 10.1074/jbc.M115.678748; Shinoe T, 2010, J NEUROCHEM, V115, P1633, DOI 10.1111/j.1471-4159.2010.07072.x; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith PD, 2015, EXP NEUROL, V274, P100, DOI 10.1016/j.expneurol.2015.08.004; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Spasova MS, 2014, EXP BIOL MED, V239, P724, DOI 10.1177/1535370213519195; Swaidani S, 2013, J BIOL CHEM, V288, P412, DOI 10.1074/jbc.M112.389874; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tan KT, 2011, J EUR ACAD DERMATOL, V25, P317, DOI 10.1111/j.1468-3083.2010.03792.x; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Wang H, 2015, EUR J PHARMACOL, V751, P42, DOI 10.1016/j.ejphar.2015.01.040; Wang Y, 1998, ACTA NEUROPATHOL, V96, P357, DOI 10.1007/s004010050906; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; Ye L, 1997, CIRC RES, V81, P289, DOI 10.1161/01.RES.81.3.289; YOKOYAMA M, 1993, EXP NEUROL, V124, P377, DOI 10.1006/exnr.1993.1209; Zhang SZ, 2012, J BIOL CHEM, V287, P12433, DOI 10.1074/jbc.M112.342873; Zhuo LS, 2006, J BIOL CHEM, V281, P20303, DOI 10.1074/jbc.M506703200	115	30	33	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2016	291	38					19939	19952		10.1074/jbc.M115.710673			14	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	DV9EO	WOS:000383243100018	27435674	Other Gold, Green Published			2021-06-18	
J	Bayen, E; Jourdan, C; Ghout, I; Darnoux, E; Azerad, S; Vallat-Azouvi, C; Weiss, JJ; Aegerter, P; Pradat-Diehl, P; Joel, ME; Azouvi, P				Bayen, Eleonore; Jourdan, Claire; Ghout, Idir; Darnoux, Emmanuelle; Azerad, Sylvie; Vallat-Azouvi, Claire; Weiss, Jean-Jacques; Aegerter, Philippe; Pradat-Diehl, Pascale; Joel, Marie-Eve; Azouvi, Philippe			Objective and Subjective Burden of Informal Caregivers 4 Years After a Severe Traumatic Brain Injury: Results From the PariS-TBI Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						GOS-E; informal care; informal care time; objective burden; subjective burden; Zarit Burden Inventory	WILLINGNESS-TO-PAY; MENTAL-HEALTH; HEAD-INJURY; LIFE SATISFACTION; FAMILY CAREGIVERS; SOCIAL SUPPORT; ECONOMIC VALUATION; FOLLOW-UP; CARE; REHABILITATION	Objective: Prospective assessment of informal caregiver (IC) burden 4 years after the traumatic brain injury of a relative. Setting: Longitudinal cohort study (metropolitan Paris, France). Participants: Home dwelling adults (N = 98) with initially severe traumatic brain injury and their primary ICs. Main Outcome Measures: Informal caregiver objective burden (Resource Utilization in Dementia measuring Informal Care Time [ICT]), subjective burden (Zarit Burden Inventory), monetary self-valuation of ICT (Willingness-to-pay, Willingness-to-accept). Results: Informal caregivers were women (81%) assisting men (80%) of mean age of 37 years. Fifty-five ICs reported no objective burden (ICT = 0) and no/low subjective burden (average Zarit Burden Inventory = 12.1). Forty-three ICs reported a major objective burden (average ICT = 5.6 h/d) and a moderate/severe subjective burden (average Zarit Burden Inventory = 30.3). In multivariate analyses, higher objective burden was associated with poorer Glasgow Outcome Scale-Extended scores, with more severe cognitive disorders (Neurobehavioral Rating Scale-revised) and with no coresidency status; higher subjective burden was associated with poorer Glasgow Outcome Scale-Extended scores, more Neurobehavioral Rating Scale-revised disorders, drug-alcohol abuse, and involvement in litigation. Economic valuation showed that on average, ICs did not value their ICT as free and preferred to pay a mean Willingness-to-pay = (sic) 17 per hour to be replaced instead of being paid for providing care themselves (Willingness-to-accept = (sic) 12). Conclusion: Four years after a severe traumatic brain injury, 44% of ICs experienced a heavy multidimensional burden.	[Bayen, Eleonore; Pradat-Diehl, Pascale] Grp Hosp Pitie Salpetriere, AP HP, Serv Med Phys & Readaptat, Paris, France; [Bayen, Eleonore; Joel, Marie-Eve] Univ Paris 09, LEDa, LEGOS Lab Econ & Gest Org Sante, Paris, France; [Vallat-Azouvi, Claire; Pradat-Diehl, Pascale] Univ Paris 06, ER 6, Paris, France; [Jourdan, Claire; Vallat-Azouvi, Claire; Azouvi, Philippe] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, Garches, France; [Jourdan, Claire; Azouvi, Philippe] Univ Versailles St Quentin, EA 4497, Guyancourt, France; [Ghout, Idir; Azerad, Sylvie; Aegerter, Philippe] Hop Ambroise Pare, AP HP, Unite Rech Clin Paris Ouest, Boulogne, France; [Aegerter, Philippe] Univ Versailles St Quentin, UPRES EA 2506, Guyancourt, France; [Darnoux, Emmanuelle; Weiss, Jean-Jacques] Ctr Ressources Francilien Traumatisme Cranien, Paris, France	Bayen, E (corresponding author), Hop La Pitie Salpetriere, Antenne UEROS UGECAMIF, Serv Med Phys & Readaptat, 47 Blvd Hop, F-75013 Paris, France.	bayen.eleonore@gmail.com		AEGERTER, Philippe/0000-0002-9156-5028	French Ministry of Health (Programme Hospitalier de Recherche Clinique) [AOM-04-084]; AP-HP (Departement de la Recherche Clinique et du Developpement); Institut de Recherche en Sante Publique (IReSP); Caisse Nationale de Solidarite pour l'Autonomie (CNSA); Societe Francaise de Medecine Physique et de Readaptation (SOFMER); Fondation des "Gueules Cassees"; Institut du Cerveau et de la Moelle Epiniere (IHU-A-ICM)	This constitution of the cohort was funded by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2004, AOM-04-084) and sponsored by AP-HP (Departement de la Recherche Clinique et du Developpement). The 4-year follow-up of this study was funded by a grant from the Institut de Recherche en Sante Publique (IReSP).; The authors thank all members of the CRFTC Steering Committee (Centre Ressource Francilien des Traumatises Craniens) for their valuable help. Additional support was obtained from the Caisse Nationale de Solidarite pour l'Autonomie (CNSA), the Societe Francaise de Medecine Physique et de Readaptation (SOFMER), the Fondation des "Gueules Cassees," and the Institut du Cerveau et de la Moelle Epiniere (IHU-A-ICM).	Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Ardolino A, 2012, INJURY, V43, P1662, DOI 10.1016/j.injury.2012.05.008; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Bayen E, 2013, NEUROLOGIES, V16, P273; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; Boschen K, 2007, NEUROREHABILITATION, V22, P19; BRAITHWAITE V, 1992, RES AGING, V14, P3, DOI 10.1177/0164027592141001; Brehaut JC, 2004, PEDIATRICS, V114, P182; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brouwer WBF, 1999, INT J TECHNOL ASSESS, V15, P147, DOI 10.1017/S0266462399152346; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Butera-Prinzi F, 2010, NEUROREHABILITATION, V27, P31, DOI 10.3233/NRE-2010-0579; Corrigan JA, 2008, ARCH PHYS MED REHAB, V89, P912, DOI 10.1016/j.apmr.2007.12.027; Davin B, 2012, CAHIERS ANN GERONTOL, V4, P236; Dixon S, 2006, PHARMACOECONOMICS, V24, P43, DOI 10.2165/00019053-200624010-00004; Doyle ST, 2013, BRAIN INJURY, V27, P1441, DOI 10.3109/02699052.2013.826505; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Flachaire E, 2013, THEOR DECIS, V74, P431, DOI 10.1007/s11238-012-9295-6; Gan C, 2010, NEUROREHABILITATION, V27, P5, DOI 10.3233/NRE-2010-0577; Gerves C, 2013, VALUE HEALTH, V16, P745, DOI 10.1016/j.jval.2013.03.1629; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Harvey K, 2008, ACTA PSYCHIAT SCAND, V117, P164, DOI 10.1111/j.1600-0447.2007.01148.x; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; HOENIG J, 1966, PSYCHIAT NEUROL, V152, P281; Institut National de la Statistique et des Etudes Economiques (INSEE), 2008, ENQ JAND SANT 2008 A; Jackson D, 2013, J REHABIL MED, V45, P653, DOI 10.2340/16501977-1178; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2013, NEUROREHAB NEURAL RE, V27, P35, DOI 10.1177/1545968312440744; Kadushin G, 2004, HEALTH SOC WORK, V29, P219, DOI 10.1093/hsw/29.3.219; Katz S, 2005, BRAIN INJURY, V19, P59, DOI 10.1080/02699050410001719970; Ketchum JM, 2012, NEUROREHABILITATION, V30, P23, DOI 10.3233/NRE-2012-0724; Koopmanschap MA, 2008, PHARMACOECONOMICS, V26, P269, DOI 10.2165/00019053-200826040-00001; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreutzer JS, 2007, NEUROREHABILITATION, V22, P53; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; MAHONEY F I, 1965, Md State Med J, V14, P61; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mazaux J-M, 2006, Rev Stomatol Chir Maxillofac, V107, P287, DOI 10.1016/S0035-1768(06)77051-6; Misic-Pavkov G, 2012, EUR REV MED PHARMACO, V16, P1806; Mulvaney-Day NE, 2005, J MENT HEALTH POLICY, V8, P71; Park EO, 2014, NURS INQ, V21, P140, DOI 10.1111/nin.12032; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Ramkumar NA, 2010, NEUROREHABILITATION, V27, P105, DOI 10.3233/NRE-2010-0585; RANKIN ED, 1994, GERONTOLOGIST, V34, P828, DOI 10.1093/geront/34.6.828; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Seel RT, 2012, ARCH PHYS MED REHAB, V93, pS138, DOI 10.1016/j.apmr.2012.04.021; Soberg HL, 2012, ARCH PHYS MED REHAB, V93, P765, DOI 10.1016/j.apmr.2011.08.050; Stejskal TM, 2012, NEUROREHABILITATION, V31, P75, DOI 10.3233/NRE-2012-0776; Tate R.L., 2006, BRAIN IMPAIR, V7, P1, DOI DOI 10.1375/brim.7.1.1; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; TOBIN J, 1958, ECONOMETRICA, V26, P24, DOI 10.2307/1907382; van den Berg B, 2005, HEALTH ECON, V14, P169, DOI 10.1002/hec.893; van den Berg B, 2005, HEALTH ECON, V14, P363, DOI 10.1002/hec.980; van den Berg B, 2008, VALUE HEALTH, V11, P1041, DOI 10.1111/j.1524-4733.2008.00357.x; van den Berg B, 2006, HEALTH ECON, V15, P447, DOI 10.1002/hec.1075; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; Vulekovic Petar, 2008, Med Pregl, V61, P471; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wimo A, 1998, HLTH EC DEMENTIA, P465; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; Wood RL, 2008, BRAIN INJURY, V22, P905, DOI 10.1080/02699050802491271; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	74	30	30	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2016	31	5					E59	E67		10.1097/HTR.0000000000000079			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DX2ZY	WOS:000384243600007	24992640				2021-06-18	
J	Phang, I; Zoumprouli, A; Saadoun, S; Papadopoulos, MC				Phang, Isaac; Zoumprouli, Argyro; Saadoun, Samira; Papadopoulos, Marios C.			Safety profile and probe placement accuracy of intraspinal pressure monitoring for traumatic spinal cord injury: Injured Spinal Cord Pressure Evaluation study	JOURNAL OF NEUROSURGERY-SPINE			English	Article						critical care; monitoring; paralysis; perfusion pressure; spinal cord injury; trauma	PERFUSION-PRESSURE; MANAGEMENT; DEVICE; INDEX	OBJECTIVE A novel technique for monitoring intraspinal pressure and spinal cord perfusion pressure in patients with traumatic spinal cord injury was recently described. This is analogous to monitoring intracranial pressure and cerebral perfusion pressure in patients with traumatic brain injury. Because intraspinal pressure monitoring is a new technique, its safety profile and impact on early patient care and long-term outcome after traumatic spinal cord injury are unknown. The object of this study is to review all patients who had intraspinal pressure monitoring to date at the authors' institution in order to define the accuracy of intraspinal pressure probe placement and the safety of the technique. METHODS At the end of surgery to fix spinal fractures, a pressure probe was inserted intradurally to monitor intraspinal pressure at the injury site. Postoperatively, CT scanning was performed within 48 hours and MRI at 2 weeks and 6 months. Neurointensive care management and complications were reviewed. The American Spinal Injury Association Impairment Scale (AIS) grade was determined on admission and at 2 to 4 weeks and 12 to 18 months postoperation. RESULTS To date, 42 patients with severe traumatic spinal cord injuries (AIS Grades A-C) had undergone intraspinal pressure monitoring. Monitoring started within 72 hours of injury and continued for up to a week. Based on postoperative CT and MRI, the probe position was acceptable in all patients, i.e., the probe was located at the site of maximum spinal cord swelling. Complications were probe displacement in 1 of 42 patients (2.4%), CSF leakage that required wound resuturing in 3 of 42 patients (7.1%), and asymptomatic pseudomeningocele that was diagnosed in 8 of 42 patients (19.0%). Pseudomeningocele was diagnosed on MRI and resolved within 6 months in all patients. Based on the MRI and neurological examination results, there were no serious probe-related complications such as meningitis, wound infection, hematoma, wound breakdown, or neurological deterioration. Within 2 weeks postoperatively, 75% of patients were extubated and 25% underwent tracheostomy. Norepinephrine was used to support blood pressure without complications. Overall, the mean intraspinal pressure was around 20 mm Hg, and the mean spinal cord perfusion pressure was around 70 mm Hg. In laminectomized patients, the intraspinal pressure was significantly higher in the supine than lateral position by up to 18 mm Hg after thoracic laminectomy and 8 mm Hg after cervical laminectomy. At 12 to 18 months, 11.4% of patients had improved by 1 AIS grade and 14.3% by at least 2 AIS grades. CONCLUSIONS These data suggest that after traumatic spinal cord injury intradural placement of the pressure probe is accurate and intraspinal pressure monitoring is safe for up to a week. In patients with spinal cord injury who had laminectomy, the supine position should be avoided in order to prevent rises in intraspinal pressure.	[Phang, Isaac; Saadoun, Samira; Papadopoulos, Marios C.] St Georges Univ London, Acad Neurosurg Unit, London, England; [Zoumprouli, Argyro] St George Hosp, Neurointens Care Unit, London, England	Papadopoulos, MC (corresponding author), St George Hosp, Dept Neurosurg, Atkinson Morley Wing, London SW17 0QT, England.	mpapadop@sgul.ac.uk		Zoumprouli, Argyro/0000-0003-0890-690X; Saadoun, Samira/0000-0002-5480-5678; Papadopoulos, Marios/0000-0001-9174-4176	Wings for Life Spinal Cord Research Foundation; Fletcher Fund/Neurosciences Research Foundation; London Deanery	We thank the neurosurgeons at St. George's Hospital, King's College Hospital, and Hurstwood Park Neurological Centre for help with patient recruitment. We also thank the neuroanesthesia, operating room, and NICU staff at St. George's Hospital for help with data collection. This study was supported by Wings for Life Spinal Cord Research Foundation (M.C.P. and S.S.), Fletcher Fund/Neurosciences Research Foundation (M.C.P.), and London Deanery (I.P.).	Ackerman P, 2010, SPINAL CORD, V48, P380, DOI 10.1038/sc.2009.140; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Bekar A, 2009, J CLIN NEUROSCI, V16, P236, DOI 10.1016/j.jocn.2008.02.008; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Call MS, 2011, J TRAUMA, V71, P1673, DOI 10.1097/TA.0b013e31821e87c2; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Como JJ, 2005, J TRAUMA, V59, P912, DOI 10.1097/01.ta.0000187660.03742.a6; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; Czosnyka Marek, 2007, Neurosurg Focus, V22, pE10; Ditunno JF, 2000, SPINAL CORD, V38, P234, DOI 10.1038/sj.sc.3100993; Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037; Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3; Hunter JD, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3325; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; Inoue T, 2014, J NEUROTRAUM, V31, P284, DOI 10.1089/neu.2013.3061; Koskinen LOD, 2013, ACTA NEUROCHIR, V155, P2141, DOI 10.1007/s00701-013-1856-0; Krogh K, 2006, SPINAL CORD, V44, P625, DOI 10.1038/sj.sc.3101887; Papadopoulos MC, 2015, NEUROSURGERY, V77, pE500, DOI 10.1227/NEU.0000000000000862; Phang I, 2015, NEUROCRIT CARE, V23, P414, DOI 10.1007/s12028-015-0153-6; Phang I, 2015, J NEUROTRAUM, V32, P865, DOI 10.1089/neu.2014.3668; Rebuck JA, 2000, J NEUROL NEUROSUR PS, V69, P381, DOI 10.1136/jnnp.69.3.381; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; van Middendorp JJ, 2013, J NEUROTRAUM, V30, P1781, DOI 10.1089/neu.2013.2932; Varsos GV, 2015, J NEUROSURG-SPINE, V23, P763, DOI 10.3171/2015.3.SPINE14870; Walters BC, 2013, NEUROSURGERY, V60, P82, DOI 10.1227/01.neu.0000430319.32247.7f; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028; Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038	27	30	31	1	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	SEP	2016	25	3					398	405		10.3171/2016.1.SPINE151317			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DT8YR	WOS:000381782200016	27129044	Bronze, Green Accepted			2021-06-18	
J	Leeper, CM; Kutcher, M; Nasr, I; McKenna, C; Billiar, T; Neal, M; Sperry, J; Gaines, BA				Leeper, Christine M.; Kutcher, Matthew; Nasr, Isam; McKenna, Christine; Billiar, Timothy; Neal, Matthew; Sperry, Jason; Gaines, Barbara A.			Acute traumatic coagulopathy in a critically injured pediatric population: Definition, trend over time, and outcomes	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	29th Annual Scientific Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 09-16, 2016	San Antonio, TX	Eastern Assoc Surg Trauma		Acute traumatic coagulopathy; pediatric; international normalized ratio; mortality; transfusion	INTERNATIONAL NORMALIZED RATIO; FROZEN PLASMA TRANSFUSION; MULTIPLE ORGAN FAILURE; BRAIN-INJURY; HEAD TRAUMA; CHILDREN; MORTALITY; ADMISSION; PREDICTS; MODERATE	BACKGROUND: While our understanding of acute traumatic coagulopathy (ATC) in adults is advancing, the pediatric literature on ATC is limited. Children have a unique injury profile and physiologic response to trauma; however, the impact of this phenomenon on ATC has not been fully elucidated. METHODS: We performed a retrospective review of our trauma registry from 2005 to 2014. Level 1 trauma patients age 0 year to 17 years requiring admission to the intensive care unit were included. Variables included admission vital signs and laboratory studies, product transfusion, injuries, and mortality. Youden index was used to determine optimum cutoff point for admission international normalized ratio (INR) as a predictor of mortality. Logistic regression modeling was used to determine independent predictors of mortality adjusting for hypotension, hypothermia, acidosis, injury severity, hemorrhage, and head injury. chi (2) tests were performed evaluating for association between mortality and 24-hour INR as well as between transfusion and INR correction. RESULTS: A total of 776 patients were analyzed: 29.2% (n = 227) had an admission INR of 1.3 or greater, and 13.3% (n = 103) had an admission INR of 1.5 or greater. Youden index demonstrated optimum cutoff at INR of 1.3 or greater to distinguish survivors and nonsurvivors. Overall mortality rate was 11.1% (n = 86). Elevated INR was independently associated with mortality (odds ratio, 3.77; p < 0.001) after controlling for other predictors in regression modeling. Death was also associated with elevated INR at 24 hours and worsening INR trend over time. Patients who received plasma were equally likely to normalize their INR compared with those who were not transfused (p = nonsignificant). Findings were consistent across age groups. CONCLUSION: INR likely serves as a marker of systemic dysregulation rather than a treatment target in ATC. Elevated admission INR, elevated INR at 24 hours, and overall trend in INR strongly predict mortality in a diverse pediatric trauma population; however, product transfusion did not influence the INR trend or clinical outcome. Further research is warranted to evaluate potential upstream mediators of ATC and targets for intervention in pediatric trauma patients. (J Trauma Acute Care Surg. 2016; 81: 34-41. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.)	[Leeper, Christine M.; Kutcher, Matthew; Billiar, Timothy; Neal, Matthew; Sperry, Jason] Univ Pittsburgh, Dept Surg, Div Gen Surg & Trauma, Med Ctr, Pittsburgh, PA 15224 USA; [Leeper, Christine M.; McKenna, Christine; Gaines, Barbara A.] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Nasr, Isam] Johns Hopkins Univ Hosp, Div Pediat Surg, Baltimore, MD 21287 USA	Gaines, BA (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, UPMC, 7th Floor,Fac Pavil,One Childrens Hosp Dr, Pittsburgh, PA 15224 USA.	Barbara.Gaines@chp.edu		Kutcher, Matthew/0000-0003-4566-5359			Abdel-Wahab OI, 2006, TRANSFUSION, V46, P1279, DOI 10.1111/j.1537-2995.2006.00891.x; Acker SN, 2015, J PEDIATR SURG, V50, P331, DOI 10.1016/j.jpedsurg.2014.08.009; Adamsbaum C, 2010, PEDIATRICS, V126, P546, DOI 10.1542/peds.2009-3647; Affonseca CA, 2007, J PEDIAT-BRAZIL, V83, P274, DOI [10.1590/S0021-75572007000400014, 10.2223/JPED.1639]; Agren A, 2013, SCAND J CLIN LAB INV, V73, P214, DOI 10.3109/00365513.2013.765960; Attard C, 2013, J THROMB HAEMOST, V11, P1850, DOI 10.1111/jth.12372; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Calkins CM, 2002, J TRAUMA, V53, P1058, DOI 10.1097/00005373-200212000-00005; Centers for Disease Control and Prevention, 2014, REP C TRAUM BRAIN IN; Centers for Disease Control and Prevention, 2013, 10 LEAD CAUS DEATH A; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Christiaans SC, 2014, SHOCK, V41, P476, DOI 10.1097/SHK.0000000000000151; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Davis JW, 2004, J TRAUMA, V57, P1173, DOI 10.1097/01.TA.0000151257.79108.FB; DZIK WH, 2009, ROSSIS PRINCIPLES TR, P575; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Esmon CT, 2011, J THROMB HAEMOST, V9, P182, DOI 10.1111/j.1538-7836.2011.04323.x; Eswald MB, 2010, TXB PEDIAT EMERGENCY, V6, P1009; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Frith D, 2010, SURG-J R COLL SURG E, V8, P159, DOI 10.1016/j.surge.2009.10.022; Gardner AR, 2015, J TRAUMA ACUTE CARE, V78, P1143, DOI 10.1097/TA.0000000000000658; Gonzalez E, 2014, SCAND J SURG, V103, P89, DOI 10.1177/1457496914531927; Hendrickson JE, 2012, J PEDIAT, V160; Holland LL, 2006, AM J CLIN PATHOL, V126, P133, DOI 10.1309/NQXHUG7HND78LFFK; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Janus J, 2010, AM FAM PHYSICIAN, V81, P1462; Kleinman ME, 2010, PEDIATRICS, V126, pE1361, DOI 10.1542/peds.2010-2972D; Lao ZQ, 2012, INT J PREVENTIVE MED, V3, P303; Leeper C, 2015, J TRAUMA ACUTE CARE; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Maegele M, 2014, SHOCK, V41, P21, DOI 10.1097/SHK.0000000000000088; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; Peltan ID, 2015, CRIT CARE MED, V43, P1429, DOI 10.1097/CCM.0000000000000981; Rowell SE, 2014, J TRAUMA ACUTE CARE, V77, P846, DOI 10.1097/TA.0000000000000459; Soundar EP, 2014, J INTENSIVE CARE, V2, DOI 10.1186/s40560-014-0064-1; Stewart CL, 2013, J PEDIATR SURG, V48, P2106, DOI 10.1016/j.jpedsurg.2013.05.009; Suominen P, 1998, INJURY, V29, P425; Swanson CA, 2010, J TRAUMA, V68, P1072, DOI 10.1097/TA.0b013e3181d7a6f2; Melo JRT, 2009, CHILD NERV SYST, V25, P1077, DOI 10.1007/s00381-009-0924-5; Upperman JS, 2010, J TRAUMA, V69, P1304, DOI 10.1097/TA.0b013e3181fa4858; Vallipakorn SAO, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-60; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; Vogel AM, 2013, J PEDIATR SURG, V48, P1371, DOI 10.1016/j.jpedsurg.2013.03.036; Whittaker B, 2013, SHOCK, V39, P421, DOI 10.1097/SHK.0b013e31828e08cb; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	48	30	32	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2016	81	1					34	41		10.1097/TA.0000000000001002			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DS5BV	WOS:000380796400007	26886002				2021-06-18	
J	Li, W; Risacher, SL; McAllister, TW; Saykin, AJ				Li, Wei; Risacher, Shannon L.; McAllister, Thomas W.; Saykin, Andrew J.			Traumatic brain injury and age at onset of cognitive impairment in older adults	JOURNAL OF NEUROLOGY			English	Article						Alzheimer's disease; Dementia; MCI; Traumatic brain injury; Age at onset	ALZHEIMERS-DISEASE; HEAD-INJURY; DEMENTIA; RISK; CORE; PROTEIN; UPDATE; MILD	There is a deficiency of knowledge regarding how traumatic brain injury (TBI) is associated with age at onset (AAO) of cognitive impairment in older adults. Participants with a TBI history were identified from the Alzheimer's disease neuroimaging initiative (ADNI 1/GO/2) medical history database. Using an analysis of covariance (ANCOVA) model, the AAO was compared between those with and without TBI, and potential confounding factors were controlled. The AAO was also compared between those with mild TBI (mTBI) and moderate or severe TBI (sTBI). Lastly, the effects of mTBI were analyzed on the AAO of participants with clinical diagnoses of either mild cognitive impairment (MCI) or Alzheimer's disease (AD). The AAO for a TBI group was 68.2 +/- 1.1 years [95 % confidence interval (CI) 66.2-70.3, n = 62], which was significantly earlier than the AAO for the non-TBI group of 70.9 +/- 0.2 years (95 % CI 70.5-71.4, n = 1197) (p = 0.013). Participants with mTBI history showed an AAO of 68.5 +/- 1.1 years (n = 56), which was significantly earlier than the AAO for the non-TBI group (p = 0.032). Participants with both MCI and mTBI showed an AAO of 66.5 +/- 1.3 years (95 % CI 63.9-69.1, n = 45), compared to 70.6 +/- 0.3 years for the non-TBI MCI group (95 % CI 70.1-71.1, n = 935) (p = 0.016). As a conclusion, a history of TBI may accelerate the AAO of cognitive impairment by two or more years. These results were consistent with reports of TBI as a significant risk factor for cognitive decline in older adults, and TBI is associated with an earlier AAO found in patients with MCI or AD.	[Li, Wei] Indiana Univ Purdue Univ, Sch Hlth & Rehabil Sci, 2039 N Capitol Ave, Indianapolis, IN 46202 USA; [Risacher, Shannon L.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, Indiana Alzheimer Dis Ctr, 355 W 16th St,Suite 4100, Indianapolis, IN 46202 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, 355 W 16th St,Suite 4800, Indianapolis, IN 46202 USA	Li, W (corresponding author), Indiana Univ Purdue Univ, Sch Hlth & Rehabil Sci, 2039 N Capitol Ave, Indianapolis, IN 46202 USA.	wl23@iu.edu	Risacher, Shannon/AAI-2141-2019; Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG19771, K01 AG049050]; Indiana Alzheimer Disease Center; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG049050, U01AG024904, R01AG019771, P30AG010133] Funding Source: NIH RePORTER	Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). Analyses in the present report were supported by NIA R01 AG19771 (to AJS), NIA K01 AG049050 (SLR), and funding from Indiana Alzheimer Disease Center.	Almeida OP, 2015, INT J GERIATR PSYCH, V30, P1215, DOI 10.1002/gps.4276; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Bruce DG, 2001, DIABETES RES CLIN PR, V53, P165, DOI 10.1016/S0168-8227(01)00266-2; Cheng PY, 2012, J DIABETES COMPLICAT, V26, P382, DOI 10.1016/j.jdiacomp.2012.06.003; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Deutsch MB, 2015, DEMENT GERIATR COGN, V39, P143, DOI 10.1159/000369787; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Jack CR, 2010, ALZHEIMERS DEMENT, V6, P212, DOI 10.1016/j.jalz.2010.03.004; Jagust WJ, 2010, ALZHEIMERS DEMENT, V6, P221, DOI 10.1016/j.jalz.2010.03.003; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Kloppenborg RP, 2008, EUR J PHARMACOL, V585, P97, DOI 10.1016/j.ejphar.2008.02.049; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; PISHKIN V, 1985, ALCOHOL CLIN EXP RES, V9, P400, DOI 10.1111/j.1530-0277.1985.tb05571.x; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Saykin AJ, 2010, ALZHEIMERS DEMENT, V6, P265, DOI 10.1016/j.jalz.2010.03.013; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Trojanowski JQ, 2010, ALZHEIMERS DEMENT, V6, P230, DOI 10.1016/j.jalz.2010.03.008; Wang HK, 2015, NEUROSCIENCE, V300, P94, DOI 10.1016/j.neuroscience.2015.05.013; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Weiner MW, 2010, ALZHEIMERS DEMENT, V6, P202, DOI 10.1016/j.jalz.2010.03.007	34	30	32	0	9	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	JUL	2016	263	7					1280	1285		10.1007/s00415-016-8093-4			6	Clinical Neurology	Neurosciences & Neurology	DQ4PH	WOS:000379185300003	27007484	Green Accepted			2021-06-18	
J	Poole, VN; Robinson, ME; Singleton, O; DeGutis, J; Milberg, WP; McGlinchey, RE; Salat, DH; Esterman, M				Poole, Victoria N.; Robinson, Meghan E.; Singleton, Omar; DeGutis, Joseph; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.; Esterman, Michael			Intrinsic functional connectivity predicts individual differences in distractibility	NEUROPSYCHOLOGIA			English	Article						Attention; Distraction; Functional connectivity; Support vector regression; Resting-State fMRI	DEFAULT-MODE NETWORK; TRANSCRANIAL MAGNETIC STIMULATION; TRAUMATIC BRAIN-INJURY; FRONTAL EYE FIELD; RESTING-STATE; ATTENTIONAL CAPTURE; VISUAL-ATTENTION; TOP-DOWN; PSYCHOLOGICAL SYMPTOMS; INTERFERENCE CONTROL	Distractor suppression, the ability to filter and ignore task-irrelevant information, is critical for efficient task performance. While successful distractor suppression relies on a balance of activity in neural networks responsible for attention maintenance (dorsal attention network; DAN), reorientation (ventral attention network; VAN), and internal thought (default mode network, DMN), the degree to which intrinsic connectivity within and between these networks contributes to individual differences in distractor suppression ability is not well-characterized. For the purposes of understanding these interactions, the current study collected resting-state fMRI data from 32 Veterans and, several months later (7 5 months apart), performance on the additional singleton paradigm, a measure of distractor suppression. Using multivariate support vector regression models composed of resting state connectivity between regions of the DAN, VAN, and DMN, and a leave-one-subject-out cross-validation procedure, we were able to predict an individual's task performance, yielding a significant correlation between the actual and predicted distractor suppression (r=0.48, p=0.0053). Network-level analyses revealed that greater within-network DMN connectivity was predictive of better distractor suppression, while greater connectivity between the DMN and attention networks was predictive of poorer distractor suppression. The strongest connection hubs were determined to be the right frontal eye field and temporoparietal junction of the DAN and VAN, respectively, and medial (ventromedial prefrontal and posterior cingulate cortices) and bilateral prefrontal regions of the DMN. These results are amongst a small but growing number of studies demonstrating that resting state connectivity is related to stable individual differences in cognitive ability, and suggest that greater integrity and independence of the DMN is related to better attentional ability. Published by Elsevier Ltd.	[Poole, Victoria N.; Robinson, Meghan E.; DeGutis, Joseph; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.; Esterman, Michael] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, VA RR&D TBI Ctr Excellence, 150 S Huntington Ave, Boston, MA 02130 USA; [Poole, Victoria N.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA; [Poole, Victoria N.; DeGutis, Joseph; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.] Harvard Univ, Sch Med, Boston, MA USA; [Poole, Victoria N.; Robinson, Meghan E.; Salat, David H.; Esterman, Michael] VA Boston Healthcare Syst, Neuroimaging Res Vet NeRVe Ctr, 150 S Huntington Ave, Boston, MA 02130 USA; [Poole, Victoria N.; Singleton, Omar; DeGutis, Joseph; Esterman, Michael] VA Boston Healthcare Syst, Boston Attent & Learning Lab BAL1LAB, 150 S Huntington Ave, Boston, MA 02130 USA; [Robinson, Meghan E.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr GRECC, 150 S Huntington Ave, Boston, MA 02130 USA; [Salat, David H.] AA Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Esterman, Michael] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA	Poole, VN (corresponding author), VA Boston Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA.	vpoole@bidmc.harvard.edu	McGlinchey, Regina E/R-1971-2016	Poole, Victoria/0000-0003-0974-2564	Translational Research Center for TBI and Stress Disorders (TRACTS); VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B9254-C]; Department of Veterans Affairs Clinical Sciences Research and DevelopmentUS Department of Veterans Affairs [1IK2CX000706-01A2]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32AG023480]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG023480] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK2CX000706] Funding Source: NIH RePORTER	This research was supported by the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B9254-C), a Career Development award to M. E. from the Department of Veterans Affairs Clinical Sciences Research and Development (1IK2CX000706-01A2), and an institutional training award to V. P. from National Institutes of Health (T32 Grant 5T32AG023480).	Anderson BA, 2011, P NATL ACAD SCI USA, V108, P10367, DOI 10.1073/pnas.1104047108; Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Anticevic A, 2012, TRENDS COGN SCI, V16, P584, DOI 10.1016/j.tics.2012.10.008; Balthazar MLF, 2014, HUM BRAIN MAPP, V35, P1237, DOI 10.1002/hbm.22248; Bishop SJ, 2009, NAT NEUROSCI, V12, P92, DOI 10.1038/nn.2242; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bourel-Ponchel E, 2011, EUR J PAEDIATR NEURO, V15, P123, DOI 10.1016/j.ejpn.2010.08.008; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buschman TJ, 2007, SCIENCE, V315, P1860, DOI 10.1126/science.1138071; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; Clapp WC, 2012, NEUROBIOL AGING, V33, P134, DOI 10.1016/j.neurobiolaging.2010.01.012; Cole MW, 2012, J NEUROSCI, V32, P8988, DOI 10.1523/JNEUROSCI.0536-12.2012; Connor CE, 2004, CURR BIOL, V14, pR850, DOI 10.1016/j.cub.2004.09.041; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; De Havas JA, 2012, NEUROIMAGE, V59, P1745, DOI 10.1016/j.neuroimage.2011.08.026; DeGutis J, 2015, J INT NEUROPSYCH SOC, V21, P342, DOI 10.1017/S1355617715000235; Eglin M, 1989, J Cogn Neurosci, V1, P372, DOI 10.1162/jocn.1989.1.4.372; Esterman M, 2015, NEUROIMAGE, V111, P542, DOI 10.1016/j.neuroimage.2015.01.044; Esterman M, 2014, J NEUROSCI, V34, P1724, DOI 10.1523/JNEUROSCI.2658-13.2014; Esterman M, 2013, J INT NEUROPSYCH SOC, V19, P835, DOI 10.1017/S135561771300057X; Esterman M, 2013, CEREB CORTEX, V23, P2712, DOI 10.1093/cercor/bhs261; Esterman M, 2010, NEUROIMAGE, V50, P572, DOI 10.1016/j.neuroimage.2009.10.092; Finn ES, 2015, NAT NEUROSCI, V18, P1664, DOI 10.1038/nn.4135; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; FOLK CL, 1992, J EXP PSYCHOL HUMAN, V18, P1030, DOI 10.1037//0096-1523.18.4.1030; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Forstmann BU, 2008, J COGNITIVE NEUROSCI, V20, P1854, DOI 10.1162/jocn.2008.20122; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Friedman NP, 2004, J EXP PSYCHOL GEN, V133, P101, DOI 10.1037/0096-3445.133.1.101; Halko MA, 2014, J NEUROSCI, V34, P12049, DOI 10.1523/JNEUROSCI.1776-14.2014; Haufe S, 2014, NEUROIMAGE, V87, P96, DOI 10.1016/j.neuroimage.2013.10.067; Hung J, 2011, J NEUROSCI, V31, P15904, DOI 10.1523/JNEUROSCI.2626-11.2011; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kucyi A, 2014, NEUROIMAGE, V100, P471, DOI 10.1016/j.neuroimage.2014.06.044; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Leber AB, 2010, J NEUROSCI, V30, P11458, DOI 10.1523/JNEUROSCI.0809-10.2010; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Lippa SM, 2015, J TRAUMA STRESS, V28, P25, DOI 10.1002/jts.21979; Maki-Marttunen V, 2015, J NEUROTRAUM, V32, P272, DOI 10.1089/neu.2014.3557; Mayer JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048586; Mennes M, 2010, NEUROIMAGE, V50, P1690, DOI 10.1016/j.neuroimage.2010.01.002; Moser JS, 2012, EMOTION, V12, P213, DOI 10.1037/a0026156; Reineberg AE, 2015, NEUROIMAGE, V104, P69, DOI 10.1016/j.neuroimage.2014.09.045; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Rosenberg MD, 2016, NAT NEUROSCI, V19, P165, DOI 10.1038/nn.4179; Rosenberg MD, 2015, NEUROIMAGE, V114, P249, DOI 10.1016/j.neuroimage.2015.03.032; Sala-Llonch R, 2012, CORTEX, V48, P1187, DOI 10.1016/j.cortex.2011.07.006; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; Serences JT, 2005, PSYCHOL SCI, V16, P114, DOI 10.1111/j.0956-7976.2005.00791.x; Sheline YI, 2010, BIOL PSYCHIAT, V67, P584, DOI 10.1016/j.biopsych.2009.08.024; Shen X, 2013, NEUROIMAGE, V82, P403, DOI 10.1016/j.neuroimage.2013.05.081; Spreng RN, 2010, J COGNITIVE NEUROSCI, V22, P1112, DOI 10.1162/jocn.2009.21282; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Theeuwes J, 2004, PSYCHON B REV, V11, P65, DOI 10.3758/BF03206462; Theeuwes J, 1998, J EXP PSYCHOL HUMAN, V24, P1342, DOI 10.1037/0096-1523.24.5.1342; THEEUWES J, 1992, PERCEPT PSYCHOPHYS, V51, P599, DOI 10.3758/BF03211656; Theeuwes J, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0055; Theeuwes J, 2010, ACTA PSYCHOL, V135, P77, DOI 10.1016/j.actpsy.2010.02.006; Uddin LQ, 2008, J NEUROSCI METH, V169, P249, DOI 10.1016/j.jneumeth.2007.11.031; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Visintin E, 2015, BEHAV BRAIN RES, V278, P315, DOI 10.1016/j.bbr.2014.10.002; Vossel S, 2014, NEUROSCIENTIST, V20, P150, DOI 10.1177/1073858413494269; Weathers F.W., 1994, PCL C FOR DSM 4; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Wotruba D, 2014, SCHIZOPHRENIA BULL, V40, P1095, DOI 10.1093/schbul/sbt161; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011	72	30	31	2	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JUN	2016	86						176	182		10.1016/j.neuropsychologia.2016.04.023			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	DP4GC	WOS:000378453400018	27132070				2021-06-18	
J	Srinivasan, A; Aggarwal, A; Gaudihalli, S; Mohanty, M; Dhandapani, M; Singh, H; Mukherjee, KK; Dhandapani, S				Srinivasan, Anirudh; Aggarwal, Ashish; Gaudihalli, Sachin; Mohanty, Manju; Dhandapani, Manju; Singh, Harminder; Mukherjee, Kanchan K.; Dhandapani, Sivashanmugam			Impact of Early Leukocytosis and Elevated High-Sensitivity C-Reactive Protein on Delayed Cerebral Ischemia and Neurologic Outcome After Subarachnoid Hemorrhage	WORLD NEUROSURGERY			English	Article						DCI; Early inflammatory response; GOS; hs-CRP; Ictus; New infarct; Outcome; TLC	INTERCELLULAR-ADHESION MOLECULE-1; TRAUMATIC BRAIN INJURY; HEAD-INJURY; VASOSPASM; SERUM; DEFICITS; DAMAGE; COUNT	BACKGROUND: The role of inflammatory response in the pathophysiology of subarachnoid hemorrhage (SAH) is being increasingly recognized. This study analyzed the impact of cellular and biochemical markers of early inflammatory response to ictus on outcome after SAH. METHODS: Patients with SAH were prospectively studied for markers of early cellular, biochemical, and cytotoxic inflammatory response, including total leukocyte count (TLC), high-sensitivity C-reactive protein (hs-CRP), and lactate dehydrogenase. The relationship of these markers to delayed cerebral ischemia (DCI), new infarct, and Glasgow Outcome Scale (GOS) score at 3 months was studied. RESULTS: The study comprised 246 patients. Of patients, 94 who developed DCI had a significantly higher TLC [+/- SD] (11.2 3 10(3)/mm(3) [+/- 4.0] vs. 9.4 x 10(3)/mm(3) [+/- 2.9], P = 0.001) and 62 with new infarct had significantly higher TLC (11.0 X 10(3)/mm(3) [+/- 3.6] vs. 9.8 X 10(3)/mm(3) [+/- 3.4], P = 0.05). GOS score had a significant inverse relationship to TLC at admission. The mean TLC [+/- SD] was 12.7 x 10(3)/mm(3) [+/- 4.2], 11.7 x 10(3)/mm(3) [+/- 3.1], 10.2 x 10(3)/mm(3) [+/- 3.4], and 9.3 x 10(3)/mm(3) [+/- 2.8] among patients with GOS scores of 1, 3, 4, and 5 (P < 0.001). hs-CRP showed a trend of an inverse relationship to GOS score in univariate analysis. Lactate dehydrogenase had no relationship with any outcome parameter. In multivariate analysis, higher admission TLC had a significant association with DCI (P = 0.01) and poorer GOS score (P < 0.001), and higher hs-CRP had a significant association with poorer GOS score (P = 0.05). CONCLUSIONS: A leukocytosis response to ictus seems to have a significant independent association with both DCI and poor GOS score, and hs-CRP level had a significant independent association with poor GOS score, indicating preeminence of early cellular response in SAH pathophysiology.	[Srinivasan, Anirudh; Aggarwal, Ashish; Gaudihalli, Sachin; Mohanty, Manju; Mukherjee, Kanchan K.; Dhandapani, Sivashanmugam] Post Grad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India; [Dhandapani, Manju] Post Grad Inst Med Educ & Res, Natl Inst Nursing Educ, Chandigarh, India; [Singh, Harminder] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA	Dhandapani, S (corresponding author), Post Grad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India.	ssdhandapani.neurosurg@gmail.com	Dhandapani, Sivashanmugam/I-2395-2013	Dhandapani, Sivashanmugam/0000-0002-3497-4255; Dhandapani, Manju/0000-0003-3351-3841			Aggarwal A, 2013, J NEUROSCI RURAL PRA, V4, P257, DOI 10.4103/0976-3147.118762; Badjatia N, 2011, STROKE, V42, P2436, DOI 10.1161/STROKEAHA.111.614685; Dhandapani M, 2014, J CLIN NURS, V23, P1114, DOI 10.1111/jocn.12396; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Dhandapani S S, 2012, Asian J Neurosurg, V7, P17, DOI 10.4103/1793-5482.95690; Dhandapani SS, 2007, INDIAN J NEUROTRAUM, V4, P35, DOI 10.1016/S0973-0508(07)80009-8; Dhandapani Sivashanmugam, 2015, Surg Neurol Int, V6, pS543, DOI 10.4103/2152-7806.168067; Dhandapani S, 2015, WORLD NEUROSURG, V84, P1244, DOI 10.1016/j.wneu.2015.05.058; Dhandapani S, 2015, NEUROL INDIA, V63, P531, DOI 10.4103/0028-3886.162026; Dhandapani S, 2015, ACTA NEUROCHIR, V157, P399, DOI 10.1007/s00701-014-2297-0; Dhandapani S, 2014, J CLIN NEUROSCI, V21, P745, DOI 10.1016/j.jocn.2013.07.038; Dhandapani S, 2013, NEUROL INDIA, V61, P406, DOI 10.4103/0028-3886.117616; Dhandapani S, 2013, ACTA NEUROCHIR, V155, P237, DOI 10.1007/s00701-012-1571-2; Fountas KN, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS08311; Hadjivassiliou M, 2001, NEUROLOGY, V56, P1672, DOI 10.1212/WNL.56.12.1672; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hong CM, 2014, BIOMARKERS, V19, P95, DOI 10.3109/1354750X.2014.881418; Hutter BO, 1999, ACT NEUR S, V72, P157; Hwang SH, 2013, J KOREAN NEUROSURG S, V54, P289, DOI 10.3340/jkns.2013.54.4.289; Jeon YT, 2012, J NEUROSURG ANESTH, V24, P317, DOI 10.1097/ANA.0b013e31826047a2; Juvela S, 2012, ACTA NEUROCHIR, V154, P397, DOI 10.1007/s00701-011-1243-7; Kaynar MY, 2004, J NEUROSURG, V101, P1030, DOI 10.3171/jns.2004.101.6.1030; Kratz A., 2012, HARRISONS PRINCIPLES, V18th ed, P3585; Kubo Y, 2008, SURG NEUROL, V69, P592, DOI 10.1016/j.surneu.2008.02.014; LONGSTRETH WT, 1993, NEUROLOGY, V43, P712, DOI 10.1212/WNL.43.4.712; Mack WJ, 2002, J NEUROSURG, V96, P71, DOI 10.3171/jns.2002.96.1.0071; Maiuri F, 1987, J Neurosurg Sci, V31, P45; McGirt MJ, 2003, J NEUROSURG, V98, P1222, DOI 10.3171/jns.2003.98.6.1222; Muroi C, 2013, NEUROSURGERY, V72, P367, DOI 10.1227/NEU.0b013e31828048ce; NEILDWYER G, 1974, BRAIN, V97, P79, DOI 10.1093/brain/97.1.79; Nissen JJ, 2000, ACT NEUR S, V76, P55; Nordestgaard BG, 2009, NUTR METAB CARDIOVAS, V19, P521, DOI 10.1016/j.numecd.2009.07.005; PARKINSON D, 1984, SURG NEUROL, V21, P132, DOI 10.1016/0090-3019(84)90330-6; Provencio JJ, 2010, NEUROCRIT CARE, V12, P244, DOI 10.1007/s12028-009-9308-7; Rothoerl RD, 2006, J NEUROSURG ANESTH, V18, P68, DOI 10.1097/01.ana.0000181693.30750.af; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Tewari M, 2015, ANN NEUROSCI, V22, P78, DOI 10.5214/ans.0972.7531.220205; Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275	38	30	33	2	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2016	90						91	95		10.1016/j.wneu.2016.02.049			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DS1MS	WOS:000380360500013	26898490				2021-06-18	
J	Bragin, A; Li, L; Almajano, J; Alvarado-Rojas, C; Reid, AY; Staba, RJ; Engel, J				Bragin, Anatol; Li, Lin; Almajano, Joyel; Alvarado-Rojas, Catalina; Reid, Aylin Y.; Staba, Richard J.; Engel, Jerome, Jr.			Pathologic electrographic changes after experimental traumatic brain injury	EPILEPSIA			English	Article						Traumatic brain injury; Epileptogenesis; Pathologic high frequency oscillations; Seizure; Electroencephalography; Spindles; Repetitive HFOs and spikes	HIGH-FREQUENCY OSCILLATIONS; FLUID PERCUSSION INJURY; SPIKE-WAVE DISCHARGES; SPRAGUE-DAWLEY RATS; POSTTRAUMATIC EPILEPSY; SLEEP SPINDLES; STATUS EPILEPTICUS; ENTORHINAL CORTEX; ABSENCE EPILEPSY; SEIZURES	Objective: To investigate possible electroencephalography (EEG) correlates of epileptogenesis after traumatic brain injury (TBI) using the fluid percussion model. Methods: Experiments were conducted on adult 2- to 4-month-old male Sprague-Dawley rats. Two groups of animals were studied: (1) the TBI group with depth and screw electrodes implanted immediately after the fluid percussion injury (FPI) procedure, and (2) a naive age-matched control group with the same electrode implantation montage. Pairs of tungsten microelectrodes (50 lm outer diameter) and screw electrodes were implanted in neocortex inside the TBI core, areas adjacent to TBI, and remote areas. EEG activity, recorded on the day of FPI, and continuously for 2 weeks, was analyzed for possible electrographic biomarkers of epileptogenesis. Video-EEG monitoring was also performed continuously in the TBI group to capture electrographic and behavioral seizures until the caps came off (28-189 days), and for 1 week, at 2, 3, and 6 months of age, in the control group. Results: Pathologic high-frequency oscillations (pHFOs) with a central frequency between 100 and 600 Hz, were recorded from microelectrodes, beginning during the first two post-FPI weeks, in 7 of 12 animals in the TBI group (58%) and never in the controls. pHFOs only occurred in cortical areas within or adjacent to the TBI core. These were associated with synchronous multiunit discharges and popSpikes, duration 1540 msec. Repetitive pHFOs and EEG spikes (rHFOSs) formed paroxysmal activity, with a unique arcuate pattern, in the frequency band 10-16 Hz in the same areas as isolated pHFOs, and these events were also recorded by screw electrodes. Although loss of caps prevented long-term recordings from all rats, pHFOs and rHFOSs occurred during the first 2 weeks in all four animals that later developed seizures, and none of the rats without these events developed late seizures. Significance: pHFOs, similar to those associated with epileptogenesis in the status rat model of epilepsy, may also reflect epileptogenesis after FPI. rHFOSs could be noninvasive biomarkers of epileptogenesis.	[Bragin, Anatol; Li, Lin; Almajano, Joyel; Alvarado-Rojas, Catalina; Reid, Aylin Y.; Staba, Richard J.; Engel, Jerome, Jr.] Univ Calif Los Angeles, Dept Neurol, 710 Wetwood Plaza, Los Angeles, CA 90095 USA; [Bragin, Anatol; Engel, Jerome, Jr.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA; [Engel, Jerome, Jr.] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA USA; [Engel, Jerome, Jr.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Med, Los Angeles, CA USA	Bragin, A; Engel, J (corresponding author), Univ Calif Los Angeles, Dept Neurol, 710 Wetwood Plaza, Los Angeles, CA 90095 USA.	abragin@mednet.ucla.edu; engel@ucla.edu	Li, Lin/V-4460-2019; Staba, Richard/AAN-3149-2021	LI, LIN/0000-0002-9996-9377; Alvarado-Rojas, Catalina/0000-0002-2315-5692; Reid, Aylin Yasmin/0000-0001-6855-9669	National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS065877, NS071048]; Citizens United for Research in Epilepsy [NS033310, NS080181]; Alberta Innovates-Health Solutions; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065877, P20NS080181, R37NS033310, R01NS071048, R01NS033310] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) grants NS065877 (AB); NS071048 and Citizens United for Research in Epilepsy (RS); NS033310 and NS080181 (JE). AYR was supported by a Clinical Fellowship award from Alberta Innovates-Health Solutions.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Andrillon T, 2011, J NEUROSCI, V31, P17821, DOI 10.1523/JNEUROSCI.2604-11.2011; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bartho P, 2014, NEURON, V82, P1367, DOI 10.1016/j.neuron.2014.04.046; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Bragin A, 1999, EPILEPSIA, V40, P127, DOI 10.1111/j.1528-1157.1999.tb02065.x; Bragin A, 2004, EPILEPSIA, V45, P1017, DOI 10.1111/j.0013-9580.2004.17004.x; Bragin A, 2002, J NEUROSCI, V22, P2012, DOI 10.1523/JNEUROSCI.22-05-02012.2002; Bragin A, 2000, EPILEPSIA, V41, pS144, DOI 10.1111/j.1528-1157.2000.tb01573.x; Bragin A, 2007, EPILEPSIA, V48, P35, DOI 10.1111/j.1528-1167.2007.01287.x; Bragin A, 2011, EPILEPSIA, V52, P45, DOI 10.1111/j.1528-1167.2010.02896.x; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Giza CC, 2010, EPILEPSY MECH MODELS, P181; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Kandel A, 1997, J NEUROSCI, V17, P6783; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Mazarati A, 2002, EPILEPSIA, V43, P74, DOI 10.1046/j.1528-1157.43.s.5.25.x; Molle M, 2009, EUR J NEUROSCI, V29, P1071, DOI 10.1111/j.1460-9568.2009.06654.x; Moeller F, 2013, EPILEPSIA, V54, pE103, DOI 10.1111/epi.12243; Pearce PS, 2014, EPILEPSY BEHAV, V32, P121, DOI 10.1016/j.yebeh.2014.01.004; Pinault D, 2006, J PHYSIOL-LONDON, V574, P209, DOI 10.1113/jphysiol.2006.108498; Rodgers KM, 2015, J NEUROSCI, V35, P9194, DOI 10.1523/JNEUROSCI.0919-15.2015; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Sitnikova E, 2014, BRAIN RES, V1543, P290, DOI 10.1016/j.brainres.2013.11.001; Staba RJ, 2002, J NEUROPHYSIOL, V88, P1743, DOI 10.1152/jn.2002.88.4.1743; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Thapa A, 2010, SEIZURE-EUR J EPILEP, V19, P211, DOI 10.1016/j.seizure.2010.02.004; vanLuijtelaar ELJM, 1997, ACTA NEUROBIOL EXP, V57, P113; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; WILLOUGHBY JO, 1992, LAB ANIM SCI, V42, P551	38	30	30	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	MAY	2016	57	5					735	745		10.1111/epi.13359			11	Clinical Neurology	Neurosciences & Neurology	DR8ID	WOS:000380140700010	27012461	Green Accepted, Green Published			2021-06-18	
J	Fidan, E; Lewis, J; Kline, AE; Garman, RH; Alexander, H; Cheng, JP; Bondi, CO; Clark, RSB; Dezfulian, C; Kochanek, PM; Kagan, VE; Bayir, H				Fidan, Emin; Lewis, Jesse; Kline, Anthony E.; Garman, Robert H.; Alexander, Henry; Cheng, Jeffrey P.; Bondi, Corina O.; Clark, Robert S. B.; Dezfulian, Cameron; Kochanek, Patrick M.; Kagan, Valerian E.; Bayir, Huelya			Repetitive Mild Traumatic Brain Injury in the Developing Brain: Effects on Long-Term Functional Outcome and Neuropathology	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; development; head injury; microglia	CLOSED-HEAD INJURY; POSTTRAUMATIC-STRESS-DISORDER; FLUID PERCUSSION INJURY; DYNAMIC STRETCH INJURY; AXONAL INJURY; HIGH-SCHOOL; COGNITIVE IMPAIRMENT; NORMOBARIC HYPEROXIA; SODIUM-CHANNELS; RAT HIPPOCAMPUS	Although accumulating evidence suggests that repetitive mild TBI (rmTBI) may cause long-term cognitive dysfunction in adults, whether rmTBI causes similar deficits in the immature brain is unknown. Here we used an experimental model of rmTBI in the immature brain to answer this question. Post-natal day (PND) 18 rats were subjected to either one, two, or three mild TBIs (mTBI) or an equivalent number of sham insults 24 h apart. After one or two mTBIs or sham insults, histology was evaluated at 7 days. After three mTBIs or sham insults, motor (d1-5), cognitive (d11-92), and histological (d21-92) outcome was evaluated. At 7 days, silver degeneration staining revealed axonal argyrophilia in the external capsule and corpus callosum after a single mTBI, with a second impact increasing axonal injury. Iba-1 immunohistochemistry showed amoeboid shaped microglia within the amygdalae bilaterally after mTBI. After three mTBI, there were no differences in beam balance, Morris water maze, and elevated plus maze performance versus sham. The rmTBI rats, however, showed impairment in novel object recognition and fear conditioning. Axonal silver staining was observed only in the external capsule on d21. Iba-1 staining did not reveal activated microglia on d21 or d92. In conclusion, mTBI results in traumatic axonal injury and microglial activation in the immature brain with repeated impact exacerbating axonal injury. The rmTBI in the immature brain leads to long-term associative learning deficit in adulthood. Defining the mechanisms damage from rmTBI in the developing brain could be vital for identification of therapies for children.	[Fidan, Emin; Lewis, Jesse; Kline, Anthony E.; Alexander, Henry; Cheng, Jeffrey P.; Bondi, Corina O.; Clark, Robert S. B.; Dezfulian, Cameron; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15224 USA; [Kline, Anthony E.; Cheng, Jeffrey P.; Bondi, Corina O.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15224 USA; [Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15224 USA; [Garman, Robert H.] Vet Pathol Inc, Murrysville, PA USA; [Clark, Robert S. B.; Dezfulian, Cameron; Kochanek, Patrick M.; Bayir, Huelya] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Bayir, H (corresponding author), Univ Pittsburgh, Dept Crit Care Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA.; Bayir, H (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	bayihx@ccm.upmc.edu		Bondi, Corina/0000-0002-5733-4912; Kagan, Valerian E./0000-0002-7245-1885	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005, R01NS076511, R01NS084967, R01NS084604, R01NS061817] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD069620, HD069620] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS060005, NS076511, R01 NS061817, NS060005, R01 NS076511, NS084967, NS084604, NS061817, R01 NS084604] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U19AIO68021] Funding Source: Medline		Ahn ES, 2008, J NEUROSURG, V108, P124, DOI 10.3171/JNS/2008/108/01/0124; Anderson V, 2012, J HEAD TRAUMA REHAB, V27, P199, DOI 10.1097/HTR.0b013e31821a9d2b; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Dunkley C, 2011, EPILEPSY RES, V93, P96, DOI 10.1016/j.eplepsyres.2010.11.002; Eder C, 1998, J NEUROSCI, V18, P7127; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Ellis EF, 2007, J NEUROCHEM, V101, P1463, DOI 10.1111/j.1471-4159.2007.04515.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; IZUMI Y, 1995, SYNAPSE, V20, P19, DOI 10.1002/syn.890200104; JACKSON PS, 1993, J NEUROPHYSIOL, V70, P1412; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kochanek PM, 2010, JAMA-J AM MED ASSOC, V303, P2190, DOI 10.1001/jama.2010.715; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Landers MS, 2012, DEV NEUROSCI-BASEL, V34, P101, DOI 10.1159/000336732; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Liaury K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-56; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; O'Brien N, 2006, BEHAV BRAIN RES, V170, P156, DOI 10.1016/j.bbr.2006.02.008; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Paxinos G, 1998, CHEMOARCHITECTONIC A; Perlson E, 2010, TRENDS NEUROSCI, V33, P335, DOI 10.1016/j.tins.2010.03.006; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Puccio AM, 2009, J NEUROTRAUM, V26, P1241, DOI [10.1089/neu.2008.0624, 10.1089/neu.2008-0624]; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Shechner T, 2014, BIOL PSYCHOL, V100, P1, DOI 10.1016/j.biopsycho.2014.04.001; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 1999, J NEUROSCI, V19, P4263; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Veenith TV, 2014, J CEREBR BLOOD F MET, V34, P1622, DOI 10.1038/jcbfm.2014.123; Walson KH, 2011, CRIT CARE MED, V39, P335, DOI 10.1097/CCM.0b013e3181ffda0e; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	89	30	32	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2016	33	7					641	651		10.1089/neu.2015.3958			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DI6QK	WOS:000373624700003	26214116	Green Published			2021-06-18	
J	Kassam, I; Gagnon, F; Cusimano, MD				Kassam, Irfahan; Gagnon, France; Cusimano, Michael D.			Association of the APOE-epsilon 4 allele with outcome of traumatic brain injury in children and youth: a meta-analysis and meta-regression	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							APOLIPOPROTEIN-E POLYMORPHISM; SEVERE HEAD-INJURY; APOE GENOTYPE; EPSILON-4 CARRIERS; EARLY-STAGE; RECOVERY; MODERATE; IMPACT; GENE; SEVERITY	Objective To disentangle the temporal relationship between the APOE-epsilon 4 allele and outcomes of paediatric traumatic brain injury (TBI). Methods PubMed, EMBASE, Web of Science, MEDLINE, PsychINFO and HuGE Navigator Genopedia databases were searched from their inception up to January 2015 without language limitations. Included studies were analysed under a dominant genetic model to assess the association between the APOE-epsilon 4 allele and poor outcomes of paediatric TBI at 6 months. Metaregression was used to assess trends over time. Results Of the 325 initially identified records, 6 studies were selected and analysed based on inclusion/exclusion criteria. A total of 358 cases of paediatric TBI were included. 2 studies assessed outcomes at multiple time points ranging from 3 to 36 months; 4 studies assessed outcomes at a single time point (either 6 or 12 months). At 6 months, there is 2.36 (95% CI 1.26 to 4.42; p=0.007) times higher odds of poor outcome following TBI in children with at least one APOE-epsilon 4 allele, compared with the children without. Further, the adjusted odds suggested an increasing trend of 7% per month (95% CI -9 to 25; p=0.359). Conclusions This meta-analysis provides cumulative evidence that the APOE-epsilon 4 allele is important to the prognosis of paediatric TBI, but may have a different effect compared with adult TBI; moreover, this effect may be time dependent.	[Kassam, Irfahan; Gagnon, France; Cusimano, Michael D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5T 3M7, Canada; [Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Div Neurosurg,Keenan Res Ctr, 30 Bond St, Toronto, ON M5T 3M7, Canada	Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Div Neurosurg,Keenan Res Ctr, 30 Bond St, Toronto, ON M5T 3M7, Canada.	injuryprevention@smh.ca	Kassam, Irfahan/D-6713-2017; Cusimano, Michael/X-4059-2019	Kassam, Irfahan/0000-0002-6150-5614; 	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [GET-101831, TIR-103946]; Ontario Neurotrauma Foundation	FG holds a Canada Research Chair, and is supported by the Canadian Institutes of Health Research Strategic Training grant in Genetic Epidemiology #GET-101831. MDC is supported by the Canadian Institutes of Health Research Strategic Training grant in Applied Injury Research #TIR-103946, and the Ontario Neurotrauma Foundation.	ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Barlow KM, 2013, HAND CLINIC, V112, P891, DOI 10.1016/B978-0-444-52910-7.00011-8; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Brichtova E, 2008, CHILD NERV SYST, V24, P349, DOI 10.1007/s00381-007-0459-6; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Colegrave N, 2003, BEHAV ECOL, V14, P446, DOI 10.1093/beheco/14.3.446; Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x; ECMap, BRAIN DEV; Engels WR, 2009, GENETICS, V183, P1431, DOI 10.1534/genetics.109.108977; Geifman N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081114; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Hiekkanen H, 2009, BRAIN INJURY, V23, P396, DOI 10.1080/02699050902926259; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; James ML, 2009, J STROKE CEREBROVASC, V18, P144, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.012; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang Y, 2008, ACTA NEUROCHIR SUPPL, V105, P233; Jiang Y, 2007, J NEUROTRAUM, V24, P1802, DOI 10.1089/neu.2007.0299; Karch A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084405; Kay AD, 2003, J NEUROTRAUM, V20, P243, DOI 10.1089/089771503321532824; Kurowski B, 2012, J PEDIATR REHAB MED, V5, P217, DOI 10.3233/PRM-2012-0214; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Lehman SM, 2005, CRIT CARE MED, V33, pA106, DOI 10.1097/00003246-200512002-00379; Levine M, 2001, PHARMACOTHERAPY, V21, P405, DOI 10.1592/phco.21.5.405.34503; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Linton KF, 2014, BRAIN INJURY, P1; Little J, HUGENET HUGE REV HDB; Little J, 2009, ANN INTERN MED, V150, P206, DOI 10.7326/0003-4819-150-3-200902030-00011; Lo TYM, 2009, CHILD NERV SYST, V25, P47, DOI 10.1007/s00381-008-0723-4; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Mahley RW, 2012, NEURON, V76, P871, DOI 10.1016/j.neuron.2012.11.020; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Noe E, 2010, BRAIN INJURY, V24, P886, DOI 10.3109/02699051003724952; Olivecrona M, 2010, J NEUROSURG, V112, P1113, DOI 10.3171/2009.8.JNS09636; Olivecrona Z, 2012, ACTA NEUROCHIR, V154, P675, DOI 10.1007/s00701-012-1292-6; Ost M, 2008, ACTA ANAESTH SCAND, V52, P1364, DOI 10.1111/j.1399-6576.2008.01675.x; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; RALL SC, 1982, J BIOL CHEM, V257, P4171; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Trikalinos TA, 2006, AM J EPIDEMIOL, V163, P300, DOI 10.1093/aje/kwj046; Wang H, 2013, EXP NEUROL, V241, P67, DOI 10.1016/j.expneurol.2012.11.027; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006; ZANNIS VI, 1981, AM J HUM GENET, V33, P11; Zeng S, 2014, GENET TEST MOL BIOMA, V18, P202, DOI 10.1089/gtmb.2013.0421; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zintzaras E, 2010, EUR J EPIDEMIOL, V25, P553, DOI 10.1007/s10654-010-9467-z	64	30	31	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2016	87	4					433	440		10.1136/jnnp-2015-310500			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	DG7WI	WOS:000372294000014	25904811				2021-06-18	
J	Raj, R; Mikkonen, ED; Kivisaari, R; Skrifvars, MB; Korja, M; Siironen, J				Raj, Rahul; Mikkonen, Era D.; Kivisaari, Riku; Skrifvars, Markus B.; Korja, Miikka; Siironen, Jari			Mortality in Elderly Patients Operated for an Acute Subdural Hematoma: A Surgical Case Series	WORLD NEUROSURGERY			English	Article						Acute subdural hematoma; Craniotomy; Elderly; Mortality; Prognosis; Prognostic factors; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; EPIDEMIOLOGY; COMA; AGE	BACKGROUND: Surgery for elderly patients with acute subdural hematomas (ASDH) is controversial, because postoperative mortality rates are reported to be high and long-term outcomes unknown. Thus, we aimed to describe midterm and long-term mortality rates of elderly patients operated for an ASDH. METHODS: We reviewed all consecutive >= 75-year-old patients operated on for an ASDH between 2009 and 2012. We recorded data on preadmission functional status (independent or dependent) and use of antithrombotic medication. Patients were followed up a median of 4.2 years (range, 2.5-6.4 years). RESULTS: Forty-four patients were included. The majority of the patients (70%) were independent and taking antithrombotic medication (77%). Independent patients had a 1-year mortality of 42%, compared to 69% for dependent patients; 56% of patients taking antithrombotics and 30% of those without antithrombotics died within the first postoperative year. All patients with an admission Glasgow coma scale score of 3-8 died within the first postoperative year, if they used antithrombotics or were dependent before the injury. Of all 1-year survivors, 77% were alive at the end of follow-up. CONCLUSION: In this first surgical case series of 75-year-old or older patients with ASDH, the overall mortality rate appears to be relatively low, especially for preoperatively conscious and independent patients without antithrombotic medication. Patients alive at 1-year after surgery had a life expectancy comparable to their age-matched peers. The prognosis seems to be detrimental for preoperatively unconscious patients who were functionally dependent or used antithrombotic medication before the injury.	[Raj, Rahul; Mikkonen, Era D.; Kivisaari, Riku; Korja, Miikka; Siironen, Jari] Univ Helsinki, Dept Neurosurg, Helsinki, Finland; [Skrifvars, Markus B.] Univ Helsinki, Div Intens Care, Helsinki, Finland; Helsinki Univ Hosp, Helsinki, Finland	Raj, R (corresponding author), Univ Helsinki, Dept Neurosurg, Helsinki, Finland.	rahul.br.raj@icloud.com	Korja, Miikka/E-4292-2016; Raj, Rahul/K-7693-2012	Korja, Miikka/0000-0002-4463-6954; Raj, Rahul/0000-0003-4243-9591; Mikkonen, Era Daniel/0000-0003-1379-0235	Finska Lakaresallskapet, Medicinska Understodsforeningen Liv och Halsa; Maud Kuistila Memorial foundation	The study was funded by grants from Finska Lakaresallskapet, Medicinska Understodsforeningen Liv och Halsa, and the Maud Kuistila Memorial foundation.	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Hanif S, 2009, Ir Med J, V102, P255; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P191, DOI 10.1007/BF01808958; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; Herou E, 2015, WORLD NEUROSURG, V83, P996, DOI 10.1016/j.wneu.2015.02.023; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Raj R, 2014, CRIT CARE, V18, DOI 10.1186/cc13814; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Taussky P, 2012, WORLD NEUROSURG, V78, P306, DOI 10.1016/j.wneu.2011.10.030; TEASDALE G, 1974, LANCET, V2, P81	27	30	31	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	APR	2016	88						592	597		10.1016/j.wneu.2015.10.095			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DK1CI	WOS:000374649700077	26548818	Green Published			2021-06-18	
J	Slomine, BS; Silverstein, FS; Christensen, JR; Holubkov, R; Page, K; Dean, JM; Moler, FW				Slomine, Beth S.; Silverstein, Faye S.; Christensen, James R.; Holubkov, Richard; Page, Kent; Dean, J. Michael; Moler, Frank W.		THAPCA Trial Grp	Neurobehavioral Outcomes in Children After Out-of-Hospital Cardiac Arrest	PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; TERM NEUROPSYCHOLOGICAL OUTCOMES; PEDIATRIC INTENSIVE-CARE; CARDIOPULMONARY-RESUSCITATION; FOLLOW-UP; LIFE; PLASTICITY; SURVIVAL; BEHAVIOR; AGE	OBJECTIVE: This study examined 12-month neurobehavioral outcomes in children who survived out-of-hospital cardiac arrest (OH-CA), were comatose after resuscitation, and were enrolled in a clinical trial to evaluate targeted temperature management to hypothermia (33.0 degrees C) or normothermia (36.8 degrees C) (Therapeutic Hypothermia after Pediatric Cardiac Arrest, Out-of-Hopsital [ THAPCA-OH]; NCT00878644). METHODS: Baseline functioning was assessed by caregiver responses on the Vineland Adaptive Behavior Scales-Second Edition (VABS-II) soon after OH-CA (based on functioning before OH-CA); children with broadly normal baseline functioning (VABS-II >= 70) were included in the THAPCA-OH primary outcome. VABS-II was completed again 12 months later. Then, face-to-face cognitive evaluations were completed. Analyses evaluated changes in VABS-II composite, domain, and subdomain scores and cognitive functioning at follow-up. RESULTS: Ninety-six of 295 enrolled children were alive at 12 months; 87 of 96 had broadly normal baseline functioning (VABS-II >= 70). Follow-up was obtained on 85/87. Forty-two of 85 had VABS-II >= 70 at 12 months. VABS-II composite, domain, and subdomain scores declined significantly between baseline and 12-month follow-up (P<.001). Declines were greatest in older children. Most children displayed well below average cognitive functioning. Older age at cardiac arrest and higher baseline VABS-II scores were predictive of greater decline in neurobehavioral function. Treatment with hypothermia did not influence neurobehavioral outcomes. CONCLUSIONS: This is the largest study exploring long-term neurobehavioral outcomes in children surviving OH-CA who were comatose after resuscitation. Results revealed significant neurobehavioral morbidity across multiple functional domains, based both on caregiver reports and performance on objective cognitive measures, in survivors 1 year later.	[Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, 707 N Broadway, Baltimore, MD 21205 USA; [Christensen, James R.] Kennedy Krieger Inst, Dept Phys Med & Rehabil, Baltimore, MD USA; [Slomine, Beth S.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA; [Slomine, Beth S.; Christensen, James R.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD USA; [Christensen, James R.] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; [Silverstein, Faye S.; Moler, Frank W.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Silverstein, Faye S.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA; [Holubkov, Richard; Page, Kent; Dean, J. Michael] Univ Utah, Dept Pediat, Salt Lake City, UT USA	Slomine, BS (corresponding author), Kennedy Krieger Inst, Dept Neuropsychol, 707 N Broadway, Baltimore, MD 21205 USA.	slomine@kennedykrieger.org		Holubkov, Richard/0000-0003-0431-3381	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01HL094345, U01HL094339]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA;  [UL1TR000003];  [P30HD040677];  [P30HD062171];  [U07MC09174];  [UL1 RR 024986];  [UL1 TR 000433]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD079123, UG1HD050096, U01HD049934, P30HD062171, P30HD040677, U10HD050012, U10HD049981, U10HD050096, U10HD049983] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U10HD049945, R34HD050531, R21HD044955] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000003, KL2TR000434, UL1TR000433] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024987, UL1RR024986] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094339, U01HL094345] Funding Source: NIH RePORTER	Primary support for the conduct of the Therapeutic Hypothermia after Pediatric Cardiac Arrest, Out-of-Hospital Trial was funding from National Institutes of Health U01HL094345 (Dr Moler) and U01HL094339 (Dr Dean). Additional support from the following federal grants contributed to the planning of the Therapeutic Hypothermia after Pediatric Cardiac Arrest Trials: Eunice Kennedy Shriver National Institute of Child Health and Development, Bethesda, MD, HD044955 (Dr Moler) and HD050531 (Dr Moler). In part, support was from the participation of the following research networks: Pediatric Emergency Care Applied Research Network from cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008; and the Collaborative Pediatric Critical Care Research Network from cooperative agreements U10HD500009, U10HD050096, U10HD049981, U10HD049945, U10HD049983, U10HD050012, and U01HD049934. At several centers, clinical research support was supplemented by the following grants or cooperative agreements: UL1TR000003, P30HD040677, P30HD062171, U07MC09174, UL1 RR 024986, and UL1 TR 000433. Funded by the National Institutes of Health (NIH).	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Horisberger T, 2002, INTENS CARE MED, V28, P365, DOI 10.1007/s00134-001-1188-z; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; KRIEL RL, 1994, PEDIATR NEUROL, V10, P207, DOI 10.1016/0887-8994(94)90024-8; Li GH, 1999, J TRAUMA, V47, P1, DOI 10.1097/00005373-199907000-00001; Lux AL, 2005, LANCET NEUROL, V4, P712, DOI 10.1016/S1474-4422(05)70199-X; Maryniak A, 2008, RESUSCITATION, V77, P46, DOI 10.1016/j.resuscitation.2007.10.024; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Ment LR, 2003, JAMA-J AM MED ASSOC, V289, P705, DOI 10.1001/jama.289.6.705; Moler FW, 2015, NEW ENGL J MED, V372, P1898, DOI 10.1056/NEJMoa1411480; Moler FW, 2009, CRIT CARE MED, V37, P2259, DOI 10.1097/CCM.0b013e3181a00a6a; Mullen E. M., 1995, MULLEN SCALES EARLY; Recla M, 2013, BRAIN INJURY, V27, P862, DOI 10.3109/02699052.2013.775499; Sparrow S, 2005, VINELAND ADAPTIVE BE; Suominen PK, 2014, RESUSCITATION, V85, P1059, DOI 10.1016/j.resuscitation.2014.03.307; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; van Zellem L, 2015, PEDIATR CRIT CARE ME, V16, P693, DOI 10.1097/PCC.0000000000000452; van Zellem L, 2015, INTENS CARE MED, V41, P1057, DOI 10.1007/s00134-015-3789-y; Wechsler D., 2011, WECHLSER ABBREVIATED; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Young KD, 2004, PEDIATRICS, V114, P157, DOI 10.1542/peds.114.1.157; ZARITSKY A, 1995, RESUSCITATION, V30, P95, DOI 10.1016/0300-9572(95)00884-V	28	30	30	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2016	137	4							e20153412	10.1542/peds.2015-3412			9	Pediatrics	Pediatrics	DI0OU	WOS:000373197500038	26940987	Bronze, Green Published, Green Accepted			2021-06-18	
J	Gao, X; Wang, XT; Xiong, WH; Chen, JH				Gao, Xiang; Wang, Xiaoting; Xiong, Wenhui; Chen, Jinhui			In vivo reprogramming reactive glia into iPSCs to produce new neurons in the cortex following traumatic brain injury	SCIENTIFIC REPORTS			English	Article							CONTROLLED CORTICAL IMPACT; PLURIPOTENT STEM-CELLS; CARDIAC FIBROBLASTS; NERVOUS-SYSTEM; SOX2 FUNCTIONS; DENTATE GYRUS; RAT; NEUROGENESIS; HIPPOCAMPUS; ASTROCYTES	Traumatic brain injury (TBI) results in a significant amount of cell death in the brain. Unfortunately, the adult mammalian brain possesses little regenerative potential following injury and little can be done to reverse the initial brain damage caused by trauma. Reprogramming adult cells to generate induced pluripotent stem cell (iPSCs) has opened new therapeutic opportunities to generate neurons in a non-neurogenic regions in the cortex. In this study we showed that retroviral mediated expression of four transcription factors, Oct4, Sox2, Klf4, and c-Myc, cooperatively reprogrammed reactive glial cells into iPSCs in the adult neocortex following TBI. These iPSCs further differentiated into a large number of neural stem cells, which further differentiated into neurons and glia in situ, and filled up the tissue cavity induced by TBI. The induced neurons showed a typical neuronal morphology with axon and dendrites, and exhibited action potential. Our results report an innovative technology to transform reactive glia into a large number of functional neurons in their natural environment of neocortex without embryo involvement and without the need to grow cells outside the body and then graft them back to the brain. Thus this technology offers hope for personalized regenerative cell therapies for repairing damaged brain.	[Gao, Xiang; Wang, Xiaoting; Xiong, Wenhui; Chen, Jinhui] Indiana Univ, Stark Neurosci Res Inst, Dept Neurosurg, Spinal Cord & Brain Injury Res Grp, 320 W 15th St, Indianapolis, IN 46202 USA	Chen, JH (corresponding author), Indiana Univ, Stark Neurosci Res Inst, Dept Neurosurg, Spinal Cord & Brain Injury Res Grp, 320 W 15th St, Indianapolis, IN 46202 USA.	chen204@iupui.edu			Indiana Spinal Cord & Brain Injury Research [SCBI 200-12]; Ralph W. and Grace M. Showalter Research Award; Indiana University Biological Research Grant; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RR025761, 1R21NS072631-01A]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001108] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631] Funding Source: NIH RePORTER	The retroviral vector expressing hOKSM was a gift from Dr. Wen-Shu Wu. This work was supported by funding from the Indiana Spinal Cord & Brain Injury Research Grants (SCBI 200-12), the Ralph W. and Grace M. Showalter Research Award, Indiana University Biological Research Grant, NIH grants RR025761 and 1R21NS072631-01A.	About I, 2000, AM J PATHOL, V157, P287, DOI 10.1016/S0002-9440(10)64539-7; Andressen C, 2001, STEM CELLS, V19, P419, DOI 10.1634/stemcells.19-5-419; Carlson SW, 2014, J NEUROPATH EXP NEUR, V73, P734, DOI 10.1097/NEN.0000000000000092; Chen JH, 2004, P NATL ACAD SCI USA, V101, P16357, DOI 10.1073/pnas.0406795101; Choo AB, 2008, STEM CELLS, V26, P1454, DOI 10.1634/stemcells.2007-0576; Chung S, 2006, J NEUROCHEM, V97, P1467, DOI 10.1111/j.1471-4159.2006.03841.x; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Episkopou V, 2005, TRENDS NEUROSCI, V28, P219, DOI 10.1016/j.tins.2005.03.003; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Guo ZY, 2014, CELL STEM CELL, V14, P188, DOI 10.1016/j.stem.2013.12.001; Gupta Y K, 2006, Indian J Physiol Pharmacol, V50, P7; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Jayawardena TM, 2012, CIRC RES, V110, P1465, DOI 10.1161/CIRCRESAHA.112.269035; Jiang Taipeng, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P392; Kelly Kevin M, 2004, Epilepsy Curr, V4, P160, DOI 10.1111/j.1535-7597.2004.44015.x; Knoepfler PS, 2009, STEM CELLS, V27, P1050, DOI 10.1002/stem.37; Kochanek PM, 1998, SEMIN CLIN NEUROPSYC, P176; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lee MO, 2013, P NATL ACAD SCI USA, V110, pE3281, DOI 10.1073/pnas.1303669110; Li R, 2013, PROTEIN CELL, V4, P415, DOI 10.1007/s13238-013-2089-y; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Ma DK, 2009, CELL RES, V19, P672, DOI 10.1038/cr.2009.56; Magavi S. S. P., 2003, J NEUROSCI, V25, P10729; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Minino Arialdi M, 2006, Natl Vital Stat Rep, V54, P1; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; Nishimura K, 2013, BIOL PHARM BULL, V36, P171, DOI 10.1248/bpb.b12-00929; Niu WZ, 2013, NAT CELL BIOL, V15, P1164, DOI 10.1038/ncb2843; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Prigatano GP, 2005, ACT NEUR S, V93, P39; Qian L, 2012, NATURE, V485, P593, DOI 10.1038/nature11044; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Rakic P, 2006, SCIENCE, V313, P928, DOI 10.1126/science.1131713; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schuldiner M, 2003, STEM CELLS, V21, P257, DOI 10.1634/stemcells.21-3-257; Song KH, 2012, NATURE, V485, P599, DOI 10.1038/nature11139; Stallcup WB, 2002, J NEUROCYTOL, V31, P423, DOI 10.1023/A:1025731428581; Stiles J, 2005, TRENDS COGN SCI, V9, P136, DOI 10.1016/j.tics.2005.01.002; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takahashi K, 2013, DEVELOPMENT, V140, P2457, DOI 10.1242/dev.092551; Tanabe K, 2013, P NATL ACAD SCI USA, V110, P12172, DOI 10.1073/pnas.1310291110; Tang C, 2011, NAT BIOTECHNOL, V29, P829, DOI 10.1038/nbt.1947; Thomson M, 2011, CELL, V145, P875, DOI 10.1016/j.cell.2011.05.017; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Yamanaka S, 2012, CELL STEM CELL, V10, P678, DOI 10.1016/j.stem.2012.05.005; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314	70	30	32	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAR 9	2016	6								22490	10.1038/srep22490			13	Multidisciplinary Sciences	Science & Technology - Other Topics	DF8IF	WOS:000371600400001	26957147	DOAJ Gold, Green Published			2021-06-18	
J	Guardado, P; Olivera, A; Rusch, HL; Roy, M; Martin, C; Lejbman, N; Lee, H; Gill, JM				Guardado, Pedro; Olivera, Anlys; Rusch, Heather L.; Roy, Michael; Martin, Christiana; Lejbman, Natasha; Lee, Hwyunhwa; Gill, Jessica M.			Altered gene expression of the innate immune, neuroendocrine, and nuclear factor-kappa B (NF-kappa B) systems is associated with posttraumatic stress disorder in military personnel	JOURNAL OF ANXIETY DISORDERS			English	Article						Gene expression; Innate immune; Neuroendocrine; NF-kappa B; PTSD; Trauma	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; COMBAT VETERANS; IMPROVED SLEEP; ANIMAL-MODEL; PTSD RISK; SYMPTOMS; MEMORY; HIPPOCAMPAL; DEPRESSION	Whole transcriptome analysis provides an unbiased examination of biological activity, and likely, unique insight into the mechanisms underlying posttraumatic stress disorder (PTSD) and comorbid depression and traumatic brain injury. This study compared gene-expression profiles in military personnel with PTSD (n =28) and matched controls without PTSD (n =27) using HG-U133 Plus 2.0 microarrays (Affymetrix), which contain 54,675 probe sets representing more than 38,500 genes. Analysis of expression profiles revealed 203 differentially expressed genes in PTSD, of which 72% were upregulated. Using Partek Genomics Suite 6.6, differentially expressed transcription clusters were filtered based on a selection criterion of <= 1.5 relative fold change at a false discovery rate of <= 5%. Ingenuity Pathway Analysis (Qiagen) of the differentially expressed genes indicated a dysregulation of genes associated with the innate immune, neuroendocrine, and NF-kappa B systems. These findings provide novel insights that may lead to new pharmaceutical agents for PTSD treatments and help mitigate mental and physical comorbidity risk. (c) 2016 Published by Elsevier Ltd.	[Guardado, Pedro; Olivera, Anlys; Rusch, Heather L.; Martin, Christiana; Lejbman, Natasha; Gill, Jessica M.] NINR, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Rusch, Heather L.] Henry M Jackson Fdn Adv Mil Med, 6720A Rockledge Dr 100, Bethesda, MD 20817 USA; [Roy, Michael] Uniformed Serv Univ Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Lee, Hwyunhwa] Univ Nevada, Sch Nursing, 4505 South Maryland Pkwy, Las Vegas, NV 89154 USA	Gill, JM (corresponding author), 1 Cloister Court 256, Bethesda, MD 20892 USA.	gillj@mail.nih.gov	Gill, Gill M/Q-2020-2017	Martin, Christiana/0000-0002-4484-6134; Rusch, Heather/0000-0002-4061-8628			Acheson DT, 2012, NEUROPHARMACOLOGY, V62, P674, DOI 10.1016/j.neuropharm.2011.04.029; Anderson G, 2015, ADV INTEGR MED, V2, P31, DOI 10.1016/j.aimed.2014.12.007; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; Beck IME, 2009, ENDOCR REV, V30, P830, DOI 10.1210/er.2009-0013; Breen MS, 2015, MOL PSYCHIAT; Buckenmaier C, 2010, CURR PAIN HEADACHE R, V14, P1, DOI 10.1007/s11916-009-0090-1; Cohen H, 2014, EUR NEUROPSYCHOPHARM, V24, P1925, DOI 10.1016/j.euroneuro.2014.09.009; Cohen H, 2011, NEUROPSYCHOPHARMACOL, V36, P2286, DOI 10.1038/npp.2011.118; de Kloet CS, 2007, MOL PSYCHIATR, V12, P443, DOI 10.1038/sj.mp.4001934; Deppermann S, 2014, NEUROSCIENCE, V283, P166, DOI 10.1016/j.neuroscience.2014.08.037; Edwards R. D., 2010, NATL BUREAU EC RES W, V38; Fuchikami M, 2016, PROG NEURO-PSYCHOPH, V64, P320, DOI 10.1016/j.pnpbp.2015.03.010; Garate I, 2013, BIOL PSYCHIAT, V73, P32, DOI 10.1016/j.biopsych.2012.07.005; Gill J, 2014, PSYCHIAT RES, V216, P116, DOI 10.1016/j.psychres.2014.01.046; Gill J, 2010, BIOL PSYCHIAT, V68, P999, DOI 10.1016/j.biopsych.2010.07.033; Gill J, 2008, J TRAUMA STRESS, V21, P530, DOI 10.1002/jts.20372; Gill JM, 2013, J PSYCHOSOM RES, V74, P301, DOI 10.1016/j.jpsychores.2012.10.013; Gill JM, 2009, PERSPECT PSYCHIATR C, V45, P262, DOI 10.1111/j.1744-6163.2009.00229.x; Glatt SJ, 2013, AM J MED GENET B, V162B, P313, DOI 10.1002/ajmg.b.32167; Gupte R, 2013, P NATL ACAD SCI USA, V110, P14616, DOI 10.1073/pnas.1309898110; Heinzelmann M., 2014, MILITARY PERSONNEL B; Heinzelmann M, 2014, SLEEP MED, V15, P1565, DOI 10.1016/j.sleep.2014.08.004; Heinzelmann M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00198; Hollifield M, 2013, MOL MED REP, V8, P238, DOI 10.3892/mmr.2013.1475; Irwin MR, 2011, NAT REV IMMUNOL, V11, P625, DOI 10.1038/nri3042; Jovanovic T., 2015, BIOL PSYCHIAT, V11, P954; Kubo Y, 2012, PHARMACOL BIOCHEM BE, V102, P495, DOI 10.1016/j.pbb.2012.06.017; Labarthe A, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00163; Laudenslager ML, 1998, BRAIN BEHAV IMMUN, V12, P74, DOI 10.1006/brbi.1997.0513; Liberzon I, 2014, JAMA PSYCHIAT, V71, P1174, DOI 10.1001/jamapsychiatry.2014.999; Livingston WS, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00059; Logue MW, 2015, PSYCHONEUROENDOCRINO, V57, P1, DOI 10.1016/j.psyneuen.2015.03.016; McGowan Patrick O, 2013, Front Psychiatry, V4, P110, DOI 10.3389/fpsyt.2013.00110; Mehta D, 2012, NEUROPHARMACOLOGY, V62, P654, DOI 10.1016/j.neuropharm.2011.03.009; Miller GE, 2008, BIOL PSYCHIAT, V64, P266, DOI 10.1016/j.biopsych.2008.03.017; Morris P, 2004, PSYCHONEUROENDOCRINO, V29, P269, DOI 10.1016/S0306-4530(03)00027-1; MULLER KE, 1992, J AM STAT ASSOC, V87, P1209, DOI 10.2307/2290663; MULLER KE, 1992, NEUROTOXICOL TERATOL, V14, P211, DOI 10.1016/0892-0362(92)90019-7; Pace TWW, 2006, AM J PSYCHIAT, V163, P1630, DOI 10.1176/appi.ajp.163.9.1630; Pace TWW, 2011, BRAIN BEHAV IMMUN, V25, P6, DOI 10.1016/j.bbi.2010.10.003; Ramos BP, 2005, BIOL PSYCHIAT, V58, P894, DOI 10.1016/j.biopsych.2005.05.022; Rusch HL, 2015, J CLIN SLEEP MED, V11, P615, DOI 10.5664/jcsm.4770; Sarapas C, 2011, DIS MARKERS, V30, P101, DOI [10.1155/2011/328054, 10.3233/DMA-2011-0764]; Shvil E, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0358-3; Smith AK, 2011, AM J MED GENET B, V156B, P700, DOI 10.1002/ajmg.b.31212; Sternberg EM, 2006, NAT REV IMMUNOL, V6, P318, DOI 10.1038/nri1810; Suh HS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-37; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; Tylee DS, 2015, PSYCHONEUROENDOCRINO, V51, P472, DOI 10.1016/j.psyneuen.2014.09.024; Tylee DS, 2013, AM J MED GENET B, V162, P595, DOI 10.1002/ajmg.b.32150; Uddin M, 2010, P NATL ACAD SCI USA, V107, P9470, DOI 10.1073/pnas.0910794107; Uher R, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00048; van Liempt S, 2013, PSYCHONEUROENDOCRINO, V38, P155, DOI 10.1016/j.psyneuen.2012.05.015; van Liempt S, 2011, PSYCHONEUROENDOCRINO, V36, P1361, DOI 10.1016/j.psyneuen.2011.03.009; Van Voorhees EE, 2014, AGGRESSIVE BEHAV, V40, P582, DOI 10.1002/ab.21554; van Zuiden M, 2013, BRAIN BEHAV IMMUN, V30, P12, DOI 10.1016/j.bbi.2012.08.015; van Zuiden M, 2012, PSYCHONEUROENDOCRINO, V37, P1822, DOI 10.1016/j.psyneuen.2012.03.018; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Williams SG, 2015, SLEEP BREATH, V19, P175, DOI 10.1007/s11325-014-0984-y; Wilson CB, 2014, BEHAV BRAIN RES, V268, P72, DOI 10.1016/j.bbr.2014.03.029; Xing GQ, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00196; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zimmerman G, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.4; Zoladz PR, 2013, NEUROSCI BIOBEHAV R, V37, P860, DOI 10.1016/j.neubiorev.2013.03.024	65	30	30	1	22	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6185	1873-7897		J ANXIETY DISORD	J. Anxiety Disord.	MAR	2016	38						9	20		10.1016/j.janxdis.2015.12.004			12	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	DF6EQ	WOS:000371449100002	26751122				2021-06-18	
J	Astrand, R; Rosenlund, C; Unden, J				Astrand, Ramona; Rosenlund, Christina; Unden, Johan		SNC	Scandinavian guidelines for initial management of minor and moderate head trauma in children	BMC MEDICINE			English	Article						Guidelines; Prediction rule; Children; Mild; moderate; head trauma; Brain injury; Computed tomography; Evidence-based; GRADE	CRANIAL COMPUTED-TOMOGRAPHY; GLASGOW COMA SCALE; NOMINAL GROUP TECHNIQUE; BRAIN-INJURY; INTRACRANIAL INJURY; PEDIATRIC-PATIENTS; SKULL FRACTURE; DECISION RULE; REQUIRE HOSPITALIZATION; ROUTINE HOSPITALIZATION	Background: The management of minor and moderate head trauma in children differs widely between countries. Presently, there are no existing guidelines for management of these children in Scandinavia. The purpose of this study was to produce new evidence-based guidelines for the initial management of head trauma in the paediatric population in Scandinavia. The primary aim was to detect all children in need of neurosurgical intervention. Detection of any traumatic intracranial injury on CT scan was an important secondary aim. Methods: General methodology according to the Appraisal of Guidelines for Research and Evaluation (AGREE) II and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used. Systematic evidence-based review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology and based upon relevant clinical questions with respect to patient-important outcomes. Quality ratings of the included studies were performed using Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 and Centre of Evidence Based Medicine (CEBM)-2 tools. Based upon the results, GRADE recommendations, a guideline, discharge instructions and in-hospital observation instructions were drafted. For elements with low evidence, a modified Delphi process was used for consensus, which included relevant clinical stakeholders. Results: The guidelines include criteria for selecting children for CT scans, in-hospital observation or early discharge, and suggestions for monitoring routines and discharge advice for children and guardians. The guidelines separate mild head trauma patients into high-, medium-and low-risk categories, favouring observation for mild, low-risk patients as an attempt to reduce CT scans in children. Conclusions: We present new evidence and consensus based Scandinavian Neurotrauma Committee guidelines for initial management of minor and moderate head trauma in children. These guidelines should be validated before extensive clinical use and updated within four years due to rapid development of new diagnostic tools within paediatric neurotrauma.	[Astrand, Ramona] Rigshosp, Dept Neurosurg, Neuroctr 2091, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; [Rosenlund, Christina] Odense Univ Hosp, Dept Neurosurg, Sdr Blvd 29, DK-5000 Odense C, Denmark; [Unden, Johan] Skane Univ Hosp, Inst Clin Sci, Dept Intens Care & Perioperat Med, Sodra Forstadsgatan 101, S-20502 Malmo, Sweden	Unden, J (corresponding author), Skane Univ Hosp, Inst Clin Sci, Dept Intens Care & Perioperat Med, Sodra Forstadsgatan 101, S-20502 Malmo, Sweden.	dr.johan.unden@gmail.com		Marklund, Niklas/0000-0002-9797-5626; Sundstrom, Terje/0000-0002-6503-7141			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; AGREE Next Steps Consortium, 2009, AGREE 2 INSTR; Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Astrand R, 2006, ACTA NEUROL SCAND, V113, P262, DOI 10.1111/j.1600-0404.2005.00573.x; Astrand R, 2011, CLIN CHIM ACTA, V412, P2190, DOI 10.1016/j.cca.2011.08.009; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Aziz H, 2013, J TRAUMA ACUTE CARE, V75, P550, DOI 10.1097/TA.0b013e3182a53a77; Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Bergman DA, 1999, PEDIATRICS, V104, P1407; Boran BO, 2006, PEDIATR NEUROSURG, V42, P203, DOI 10.1159/000092355; Bouvier D, 2012, CLIN CHEM, V58, P1116, DOI 10.1373/clinchem.2011.180828; Bouvier D, 2011, CLIN BIOCHEM, V44, P927, DOI 10.1016/j.clinbiochem.2011.05.004; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brooks JC, 2015, ARCH PHYS MED REHAB, V96, P1000, DOI 10.1016/j.apmr.2015.02.002; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Center for Disease Control and Prevention and American College of Emergency Physicians, 2008, HEADS SER WHAT EXP C; CHAN KH, 1990, J NEUROSURG, V72, P189, DOI 10.3171/jns.1990.72.2.0189; CHAN KH, 1990, CHILD NERV SYST, V6, P27, DOI 10.1007/BF00262262; Chiappelli F, 2010, EVIDENCE BASED PRACT, DOI [10.1007/978-3-642-05025-1_2, DOI 10.1007/978-3-642-05025-1_2]; Colvin JD, 2013, ARCH DIS CHILD, V98, P934, DOI 10.1136/archdischild-2012-303588; Da Dalt L, 2006, EUR J PEDIATR, V165, P142, DOI 10.1007/s00431-005-0019-6; Da Dalt L, 2007, J PEDIATR-US, V150, P274, DOI 10.1016/j.jpeds.2006.11.060; DAVIES RL, 1995, PEDIATRICS, V95, P345; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Dawson EC, 2012, PEDIATR NEUROSURG, V48, P221, DOI 10.1159/000346697; Dayan PS, 2015, PEDIATRICS, V135, P504, DOI 10.1542/peds.2014-2695; Dayan PS, 2014, ANN EMERG MED, V64, P153, DOI 10.1016/j.annemergmed.2014.02.003; Dayan PS, 2014, ANN EMERG MED, V63, P657, DOI 10.1016/j.annemergmed.2014.01.009; Dias MS, 1999, PEDIATR NEUROSURG, V30, P232, DOI 10.1159/000028803; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Durham SR, 2006, J NEUROSURG, V105, P365, DOI 10.3171/ped.2006.105.5.365; Edwards AD, 2011, PEDIATR RADIOL, V41, P1353, DOI 10.1007/s00247-011-2147-7; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Garcia JJG, 2009, AN PEDIATR, V71, P31, DOI 10.1016/j.anpedi.2009.03.009; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Goldet Gabrielle, 2013, J Evid Based Med, V6, P50, DOI 10.1111/jebm.12018; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P173, DOI 10.1016/j.jclinepi.2012.08.001; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P395, DOI 10.1016/j.jclinepi.2010.09.012; Guzel A, 2009, PEDIATR NEUROSURG, V45, P262, DOI 10.1159/000228984; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; Hall P, 2005, LAKARTIDNINGEN, V102, P220; Hall P, 2005, LAKARTIDNINGEN, V102, P217; Hall Per, 2005, Lakartidningen, V102, P214; Hallen M, 2010, J TRAUMA, V69, P284, DOI 10.1097/TA.0b013e3181ca060b; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Heskestad B, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-6; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Holsti M, 2005, PEDIATR EMERG CARE, V21, P639, DOI 10.1097/01.pec.0000181426.25342.a9; Howick J., OXFORD 2011 LEVELS E; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Hutchings Andrew, 2006, J Health Serv Res Policy, V11, P218, DOI 10.1258/135581906778476553; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ismail R, 2016, J GLAUCOMA, V25, P539, DOI 10.1097/IJG.0000000000000301; KADISH HA, 1995, ANN EMERG MED, V26, P37, DOI 10.1016/S0196-0644(95)70235-0; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Klemetti S, 2009, PEDIATR EMERG CARE, V25, P811, DOI 10.1097/PEC.0b013e3181c32e74; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lee LK, 2014, JAMA PEDIATR, V168, P837, DOI 10.1001/jamapediatrics.2014.361; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Lossius HM, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-80; da Silva PSL, 2008, J TRAUMA, V65, P1293, DOI 10.1097/TA.0b013e318156866c; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Makdissi M, 2014, AUST FAM PHYSICIAN, V43, P94; Mandera M, 2000, CHILD NERV SYST, V16, P156, DOI 10.1007/s003810050484; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; Munivenkatappa A, 2013, J PEDIATR NEUROSCI, V8, P183, DOI 10.4103/1817-1745.123659; Munoz-Sanchez M, 2005, CHILD NERV SYST, V21, P128, DOI 10.1007/s00381-004-1036-x; Murgio A, 2001, CHILD NERV SYST, V17, P257, DOI 10.1007/s003810000403; Ng SM, 2002, J PAEDIATR CHILD H, V38, P388, DOI 10.1046/j.1440-1754.2002.00012.x; Nigrovic LE, 2015, PEDIATRICS, V136, pE227, DOI 10.1542/peds.2014-3588; Nigrovic LE, 2013, ANN EMERG MED, V61, P389, DOI 10.1016/j.annemergmed.2012.08.030; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Odgaard L, 2015, CLIN EPIDEMIOL, V7, P225, DOI 10.2147/CLEP.S78141; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2004, PEDIATRICS, V113, pE507, DOI 10.1542/peds.113.6.e507; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Perheentupa U, 2010, INT J PEDIATR OTORHI, V74, P1245, DOI 10.1016/j.ijporl.2010.07.023; Powell EC, 2015, PEDIATRICS, V135, pE851, DOI 10.1542/peds.2014-2858; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; Ratan SK, 2001, CLIN PEDIATR, V40, P375, DOI 10.1177/000992280104000702; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; Roguski M, 2015, J NEUROSURG-PEDIATR, V15, P529, DOI 10.3171/2014.10.PEDS14128; Rollins MD, 2011, J PEDIATR SURG, V46, P1342, DOI 10.1016/j.jpedsurg.2010.12.019; *ROYAL COLL RAD, 2008, STAND RAD INV SUSP N; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Schnellinger MG, 2010, CLIN PEDIATR, V49, P569, DOI 10.1177/0009922809352375; Schonfeld D, 2013, ANN EMERG MED, V62, P597, DOI 10.1016/j.annemergmed.2013.06.020; Schunemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Shane SA, 1997, PEDIATR EMERG CARE, V13, P198, DOI 10.1097/00006565-199706000-00006; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Spencer MT, 2003, AM J EMERG MED, V21, P111, DOI 10.1053/ajem.2003.50031; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Te Ao B, 2014, NEUROLOGY, V83, P1645, DOI 10.1212/WNL.0000000000000933; TEASDALE G, 1974, LANCET, V2, P81; Melo JRT, 2008, ARQ NEURO-PSIQUIAT, V66, P708, DOI 10.1590/S0004-282X2008000500019; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; van Teijlingen E, 2006, J FAM PLAN REPROD H, V32, P249, DOI 10.1783/147118906778586598; Vestergaard V, 2014, ACTA NEUROL SCAND, V129, P168, DOI 10.1111/ane.12158; Wang MY, 2000, NEUROSURGERY, V46, P1093, DOI 10.1097/00006123-200005000-00014; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550	126	30	30	0	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1741-7015			BMC MED	BMC Med.	FEB 18	2016	14								33	10.1186/s12916-016-0574-x			19	Medicine, General & Internal	General & Internal Medicine	DE1QO	WOS:000370401700001	26888597	DOAJ Gold, Green Published			2021-06-18	
J	Guley, NH; Rogers, JT; Del Mar, NA; Deng, YP; Islam, RM; D'Surney, L; Ferrell, J; Deng, BW; Hines-Beard, J; Bu, W; Ren, HL; Elberger, AJ; Marchetta, JG; Rex, TS; Honig, MG; Reiner, A				Guley, Natalie H.; Rogers, Joshua T.; Del Mar, Nobel A.; Deng, Yunping; Islam, Rafiqul M.; D'Surney, Lauren; Ferrell, Jessica; Deng, Bowei; Hines-Beard, Jessica; Bu, Wei; Ren, Huiling; Elberger, Andrea J.; Marchetta, Jeffrey G.; Rex, Tonia S.; Honig, Marcia G.; Reiner, Anton			A Novel Closed-Head Model of Mild Traumatic Brain Injury Using Focal Primary Overpressure Blast to the Cranium in Mice	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; mild TBI; motor deficits; overpressure blast; visual deficits	CONTROLLED CORTICAL IMPACT; POSTTRAUMATIC-STRESS-DISORDER; STRIATAL PROJECTION NEURON; FLUID PERCUSSION INJURY; GAMMA PKC-GAMMA; MOUSE MODEL; CONTRAST SENSITIVITY; AXONAL INJURY; ANIMAL-MODEL; OPTIC-NERVE	Mild traumatic brain injury (TBI) from focal head impact is the most common form of TBI in humans. Animal models, however, typically use direct impact to the exposed dura or skull, or blast to the entire head. We present a detailed characterization of a novel overpressure blast system to create focal closed-head mild TBI in mice. A high-pressure air pulse limited to a 7.5mm diameter area on the left side of the head overlying the forebrain is delivered to anesthetized mice. The mouse eyes and ears are shielded, and its head and body are cushioned to minimize movement. This approach creates mild TBI by a pressure wave that acts on the brain, with minimal accompanying head acceleration-deceleration. A single 20-psi blast yields no functional deficits or brain injury, while a single 25-40psi blast yields only slight motor deficits and brain damage. By contrast, a single 50-60psi blast produces significant visual, motor, and neuropsychiatric impairments and axonal damage and microglial activation in major fiber tracts, but no contusive brain injury. This model thus reproduces the widespread axonal injury and functional impairments characteristic of closed-head mild TBI, without the complications of systemic or ocular blast effects or head acceleration that typically occur in other blast or impact models of closed-skull mild TBI. Accordingly, our model provides a simple way to examine the biomechanics, pathophysiology, and functional deficits that result from TBI and can serve as a reliable platform for testing therapies that reduce brain pathology and deficits.	[Guley, Natalie H.; Rogers, Joshua T.; Del Mar, Nobel A.; Deng, Yunping; Islam, Rafiqul M.; D'Surney, Lauren; Ferrell, Jessica; Deng, Bowei; Bu, Wei; Ren, Huiling; Elberger, Andrea J.; Honig, Marcia G.; Reiner, Anton] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA; [D'Surney, Lauren; Hines-Beard, Jessica; Rex, Tonia S.; Reiner, Anton] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN 38163 USA; [Hines-Beard, Jessica; Rex, Tonia S.] Vanderbilt Univ, Dept Ophthalmol & Visual Sci, 221 Kirkland Hall, Nashville, TN 37235 USA; [Marchetta, Jeffrey G.] Univ Memphis, Dept Mech Engn, Memphis, TN 38152 USA; [Islam, Rafiqul M.] Bangladesh Agr Univ, Dept Anat & Histol, Mymensingh, Bangladesh	Reiner, A (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA.	areiner@uthsc.edu	Reiner, Anton/AAG-8860-2020	Reiner, Anton/0000-0002-2146-5232	NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY022349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS081370] Funding Source: NIH RePORTER; NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY-005298, EY-022349] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-081370] Funding Source: Medline		ABE H, 1993, OPHTHALMOLOGICA, V207, P100, DOI 10.1159/000310413; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Akimov NP, 2012, BEHAV BRAIN RES, V226, P601, DOI 10.1016/j.bbr.2011.09.030; Al-Hashmi AM, 2011, EXP BRAIN RES, V215, P293, DOI 10.1007/s00221-011-2896-4; Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Bareyre FM, 2005, NAT MED, V11, P1355, DOI 10.1038/nm1331; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Blumbergs P.C., 2008, GREENFIELDS NEUROPAT, P733; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bose P, 2013, J NEUROTRAUM, V30, P1177, DOI 10.1089/neu.2012.2740; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bricker-Anthony C, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0192-5; Bricker-Anthony C, 2014, INVEST OPHTH VIS SCI, V55, P4853, DOI 10.1167/iovs.14-14353; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Cuthbertson S, 2003, INVEST OPHTH VIS SCI, V44, P3713, DOI 10.1167/iovs.02-1207; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; de la Cuadra Patricio, 2007, Journal of Flow Visualization and Image Processing, V14, P355, DOI 10.1615/JFlowVisImageProc.v14.i4.20; Deng YP, 2013, NEUROBIOL DIS, V60, P89, DOI 10.1016/j.nbd.2013.08.009; DILEO MAS, 1992, DIABETES CARE, V15, P620, DOI 10.2337/diacare.15.5.620; DRAGER UC, 1980, J COMP NEUROL, V191, P383, DOI 10.1002/cne.901910306; Drai D, 2001, NEUROSCI BIOBEHAV R, V25, P409, DOI 10.1016/S0149-7634(01)00022-7; Drai D, 2000, J NEUROSCI METH, V96, P119, DOI 10.1016/S0165-0270(99)00194-6; Ebneter A, 2010, INVEST OPHTH VIS SCI, V51, P6448, DOI 10.1167/iovs.10-5284; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Franklin K. B. J., 2012, MOUSE BRAIN STEREOTA; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gorski JA, 2002, J NEUROSCI, V22, P6309; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Hashemi H, 2012, OPHTHALMOLOGY, V119, P541, DOI 10.1016/j.ophtha.2011.08.030; Heffernan ME, 2013, J NEUROTRAUM, V30, P1007, DOI 10.1089/neu.2012.2366; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Hua Y, 2014, J COMPUT NONLIN DYN, V9, DOI 10.1115/1.4026156; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Jasnow AM, 2013, J NEUROSCI, V33, P10396, DOI 10.1523/JNEUROSCI.5539-12.2013; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jovanovic Milos, 2012, Acta Chir Iugosl, V59, P73; Kafkafi N, 2003, BEHAV NEUROSCI, V117, P464, DOI 10.1037/0735-7044.117.3.464; Kafkafi N, 2001, J NEUROSCI METH, V109, P111, DOI 10.1016/S0165-0270(01)00392-2; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kim KK, 2009, J BIOL CHEM, V284, P31052, DOI 10.1074/jbc.M109.052969; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; King CE, 1997, NEUROREPORT, V8, P1663; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovacs SK, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00047; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Laksari K, 2014, J MECH BEHAV BIOMED, V32, P132, DOI 10.1016/j.jmbbm.2013.12.021; Lamy Michael, 2011, Ann Adv Automot Med, V55, P125; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Lieu A, 2013, J NEUROIMMUNOL, V256, P43, DOI 10.1016/j.jneuroim.2013.01.003; Lipkind D, 2004, J APPL PHYSIOL, V97, P347, DOI 10.1152/japplphysiol.00148.2004; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MARMOR MF, 1986, BRIT J OPHTHALMOL, V70, P553, DOI 10.1136/bjo.70.7.553; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meade CA, 2000, EXP NEUROL, V166, P307, DOI 10.1006/exnr.2000.7530; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Miller G, 2011, SCIENCE, V333, P517, DOI 10.1126/science.333.6042.517; Miller G, 2011, SCIENCE, V333, P514, DOI 10.1126/science.333.6042.514; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MULLER M, 1988, EXP BRAIN RES, V71, P611, DOI 10.1007/BF00248754; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Ono I., 1980, 24 STAPP CAR CRASH C; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Osier N. D., 2015, J NEUROTRAUMA; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; Redell JB, 2007, NEUROSCI LETT, V413, P36, DOI 10.1016/j.neulet.2006.11.060; Reiner A, 2012, NEUROBIOL DIS, V47, P75, DOI 10.1016/j.nbd.2012.03.025; Reiner A, 2007, J COMP NEUROL, V505, P603, DOI 10.1002/cne.21515; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saito N, 2002, J BIOCHEM, V132, P683, DOI 10.1093/oxfordjournals.jbchem.a003274; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Swan AA, 2011, J NEUROTRAUM, V28, P431, DOI 10.1089/neu.2010.1519; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Taylor PA, 2014, BRAIN INJURY, V28, P879, DOI 10.3109/02699052.2014.888478; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Weinberger S, 2011, NATURE, V477, P390, DOI 10.1038/477390a; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zakaria N, 2012, BRAIN RES, V1467, P81, DOI 10.1016/j.brainres.2012.05.046	155	30	30	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2016	33	4					403	422		10.1089/neu.2015.3886			20	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DD2NH	WOS:000369758800009	26414413	Green Published			2021-06-18	
J	Chang, CY; Lui, TN; Lin, JW; Lin, YL; Hsing, CH; Wang, JJ; Chen, RM				Chang, Chia-Yu; Lui, Tai-Ngar; Lin, Jia-Wei; Lin, Yi-Ling; Hsing, Chung-Hsi; Wang, Jhi-Joung; Chen, Ruei-Ming			Roles of microRNA-1 in hypoxia-induced apoptotic insults to neuronal cells	ARCHIVES OF TOXICOLOGY			English	Article						Hypoxia; Neural apoptosis; miR-1; HSP-70; Intrinsic mechanism	HEAT-SHOCK PROTEINS; TUMOR HYPOXIA; BRAIN-INJURY; BAX; ACTIVATION; EXPRESSION; MIR-1; HSP70; MITOCHONDRIA; OSTEOBLASTS	Hypoxia is a common occurrence in brain tumors and traumatic brain injury. microRNA (miR)-1 participates in the regulation of brain development and neuronal function. Interestingly, miR-1 can mediate ischemia-induced injury to cardiomyocytes. This study was designed to evaluate the roles of miR-1 in hypoxia-induced insults to neurons and the possible mechanisms. Exposure of neuro-2a cells to oxygen/glucose deprivation (OGD) or cobalt chloride decreased cell viability and induced cell apoptosis in time-dependent manners. In parallel, OGD caused augmentation of cellular Bax and cytochrome c levels, a reduction in the mitochondrial membrane potential (MMP), activation of caspase-3, and fragmentation of DNA. miR-1 was induced in neuro-2a cells by OGD. Knocking down miR-1 expression using specific antisense inhibitors significantly alleviated OGD-induced neuronal death. Administration of OGD to neuro-2a cells induced heat-shock protein (HSP)-70 messenger (m)RNA and protein expressions. A bioinformatic search revealed that miR-1-specific binding elements exist in the 3'-untranslated region of HSP-70 mRNA. Overexpression of miR-1 simultaneously attenuated OGD-induced HSP-70 mRNA and protein expressions. In comparison, knocking down miR-1 expression synergistically enhanced OGD-induced HSP-70 mRNA. As to the mechanism, reducing miR-1 expression lowered OGD-induced alterations in the MMP, caspase-3 activation, DNA fragmentation, and cell apoptosis. Taken together, this study shows that miR-1 can target HSP-70 expression and consequently mediate hypoxia-induced apoptotic insults to neuro-2a cells via an intrinsic Bax-mitochondrion-caspase protease pathway.	[Chang, Chia-Yu] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; [Chang, Chia-Yu; Lin, Jia-Wei; Chen, Ruei-Ming] Taipei Med Univ, Ctr Comprehens Canc, Taipei 110, Taiwan; [Lui, Tai-Ngar] Taipei Med Univ, Wan Fang Hosp, Dept Neurosurg, Taipei 110, Taiwan; [Lin, Yi-Ling; Chen, Ruei-Ming] Taipei Med Univ, Wan Fang Hosp, Brain Dis Res Ctr, Taipei 110, Taiwan; [Lin, Yi-Ling; Chen, Ruei-Ming] Taipei Med Univ, Wan Fang Hosp, Dept Anesthesiol, Taipei 110, Taiwan; [Hsing, Chung-Hsi; Wang, Jhi-Joung] Chi Mei Med Ctr, Dept Anesthesiol, Tainan, Taiwan; [Chen, Ruei-Ming] Taipei Med Univ, Grad Inst Med Sci, 250 Wu Xing St, Taipei 110, Taiwan; [Chen, Ruei-Ming] Taipei Med Univ Hosp, Anesthet & Toxicol Res Ctr, Taipei, Taiwan	Chen, RM (corresponding author), Taipei Med Univ, Grad Inst Med Sci, 250 Wu Xing St, Taipei 110, Taiwan.	rmchen@tmu.edu.tw			Chi-Mei Medical Center, Tainan, Taiwan [100CM-TMU-13-3]; Wan-Fang Hospital [101wf-eva-06]; National Science CouncilMinistry of Science and Technology, Taiwan [NSC101-2314-B-038-008-MY3, NSC101-2314-B-038-003-MY3]; Health and Welfare Surcharge of Tobacco Products, Taipei, Taiwan [MOHW103-TD-B-111-01]	This project was supported by grants from the Chi-Mei Medical Center (100CM-TMU-13-3), Tainan, Taiwan; Wan-Fang Hospital (101wf-eva-06), the National Science Council (NSC101-2314-B-038-008-MY3; NSC101-2314-B-038-003-MY3), and Health and Welfare Surcharge of Tobacco Products (MOHW103-TD-B-111-01), Taipei, Taiwan.	ABE K, 1993, J CEREBR BLOOD F MET, V13, P773, DOI 10.1038/jcbfm.1993.98; Ariffin AB, 2014, CANCER RES, V74, P2655, DOI 10.1158/0008-5472.CAN-13-3696; Axelson H, 2005, SEMIN CELL DEV BIOL, V16, P554, DOI 10.1016/j.semcdb.2005.03.007; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755; Chan SY, 2010, CELL CYCLE, V9, P1072, DOI 10.4161/cc.9.6.11006; Chang HC, 2011, J CEREBR BLOOD F MET, V31, P842, DOI 10.1038/jcbfm.2010.180; Chen RM, 2010, J BONE MINER RES, V25, P2193, DOI 10.1002/jbmr.121; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chio CC, 2013, ARCH TOXICOL, V87, P459, DOI 10.1007/s00204-012-0965-5; Chuang CY, 2011, ARCH TOXICOL, V85, P209, DOI 10.1007/s00204-010-0585-x; Fatemi A, 2009, CLIN PERINATOL, V36, P835, DOI 10.1016/j.clp.2009.07.011; Gerstner ER, 2009, NAT REV CLIN ONCOL, V6, P229, DOI 10.1038/nrclinonc.2009.14; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Jana A, 2009, J NEUROL SCI, V278, P5, DOI 10.1016/j.jns.2008.12.010; Jensen RL, 2009, J NEURO-ONCOL, V92, P317, DOI 10.1007/s11060-009-9827-2; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lee ST, 2009, BRIT J ANAESTH, V102, P80, DOI 10.1093/bja/aen322; Liao MH, 2014, BRIT J NUTR, V111, P55, DOI 10.1017/S0007114513002043; Lin JW, 2012, NEURO-ONCOLOGY, V14, P302, DOI 10.1093/neuonc/nor217; Lin YL, 2010, J NUTR, V140, P2187, DOI 10.3945/jn.110.123505; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Mazzeo AT, 2007, J NEUROL SCI, V261, P1, DOI 10.1016/j.jns.2007.04.026; Murphy ME, 2013, CARCINOGENESIS, V34, P1181, DOI 10.1093/carcin/bgt111; Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022; Negrini M, 2009, CURR OPIN CELL BIOL, V21, P470, DOI 10.1016/j.ceb.2009.03.002; Okouchi M, 2007, ANTIOXID REDOX SIGN, V9, P1059, DOI 10.1089/ars.2007.1511; Pagliari LJ, 2005, P NATL ACAD SCI USA, V102, P17975, DOI 10.1073/pnas.0506712102; Patterson AJ, 2010, CURR MOL MED, V10, P653; Qi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069509; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Saleh A, 2000, NAT CELL BIOL, V2, P476; Shi Q, 2007, CELL MOL IMMUNOL, V4, P53; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Townley-Tilson WHD, 2010, INT J BIOCHEM CELL B, V42, P1252, DOI 10.1016/j.biocel.2009.03.002; Tsan MF, 2009, J LEUKOCYTE BIOL, V85, P905, DOI 10.1189/jlb.0109005; Varendi K, 2014, CELL MOL LIFE SCI, V71, P4443, DOI 10.1007/s00018-014-1628-x; Wang H, 2006, BRAIN RES, V1114, P212, DOI 10.1016/j.brainres.2006.07.056; Wang PF, 2014, J IMMUNOL, V192, P4783, DOI 10.4049/jimmunol.1303108; Wei JD, 2012, J ORTHOP RES, V30, P1058, DOI 10.1002/jor.22046; Wu TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072404; Xu CQ, 2007, J CELL SCI, V120, P3045, DOI 10.1242/jcs.010728; Zhang Y, 2010, CELL PHYSIOL BIOCHEM, V26, P991, DOI 10.1159/000324012	44	30	31	0	19	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5761	1432-0738		ARCH TOXICOL	Arch. Toxicol.	JAN	2016	90	1					191	202		10.1007/s00204-014-1364-x			12	Toxicology	Toxicology	DD8SJ	WOS:000370196900010	25238743				2021-06-18	
J	Tichy, J; Spechtmeyer, S; Mittelbronn, M; Hattingen, E; Rieger, J; Senft, C; Foerch, C				Tichy, Julia; Spechtmeyer, Sabrina; Mittelbronn, Michel; Hattingen, Elke; Rieger, Johannes; Senft, Christian; Foerch, Christian			Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma	JOURNAL OF NEURO-ONCOLOGY			English	Article						Glioblastoma; GFAP; Serum; Diagnostic marker; Biomarker	MGMT PROMOTER METHYLATION; TRAUMATIC BRAIN-INJURY; PROGNOSTIC VALUE; PLASMA-LEVELS; TUMOR VOLUME; TEMOZOLOMIDE; EXPRESSION; BIOMARKER	Glioblastoma (GBM) is the most common malignant primary brain tumor. Although clinical presentation and brain imaging might be suggestive, histopathological evaluation by means of a brain biopsy is routinely performed to establish the diagnosis. A serum marker indicative of GBM may simplify the diagnostic work-up of patients suspected to having a brain tumor. We prospectively examined 113 patients with newly diagnosed single supratentorial or infratentorial space-occupying brain lesions. Glial fibrillary acidic protein (GFAP) levels were determined from venous blood samples via a prototype ELISA assay prior to any invasive procedures. Serum levels of GFAP were correlated with histopathological findings and MRI parameters. GFAP values were significantly higher in GBM patients (n = 33) compared to all other tumors (p < 0.001). A GFAP serum concentration of a parts per thousand yen0.01 A mu g/L revealed a sensitivity of 85 % and a specificity of 70 % for differentiating GBM from other entities. By applying a GFAP cut-off point of 0.20 A mu g/L, specificity was maximized (99 %), but sensitivity dropped to 27 %. In GBM patients, serum GFAP values were significantly correlated with tumor volume. GBM patients with high GFAP levels showed more in vivo GFAP expression as well as more necrosis and perilesional edema compared to GBM patients having low or non-detectable GFAP levels. GFAP serum concentrations differentiated between patients with GBM and patients with cerebral mass lesions of other entities with a moderate diagnostic accuracy. Serum GFAP levels in GBM patients were positively correlated with tumor volume and histopathological tumor characteristics.	[Tichy, Julia; Spechtmeyer, Sabrina; Foerch, Christian] Goethe Univ Frankfurt, Dept Neurol, D-60054 Frankfurt, Germany; [Tichy, Julia; Rieger, Johannes] Goethe Univ Frankfurt, Dr Senckenberg Inst Neurooncol, D-60054 Frankfurt, Germany; [Tichy, Julia; Mittelbronn, Michel] Goethe Univ Frankfurt, Neurol Inst, Edinger Inst, D-60054 Frankfurt, Germany; [Mittelbronn, Michel] German Canc Consortium DKTK, Heidelberg, Germany; [Mittelbronn, Michel] German Canc Res Ctr, Heidelberg, Germany; [Hattingen, Elke] Goethe Univ Frankfurt, Inst Neuroradiol, D-60054 Frankfurt, Germany; [Senft, Christian] Goethe Univ Frankfurt, Dept Neurosurg, D-60054 Frankfurt, Germany; [Tichy, Julia] Goethe Univ Hosp Frankfurt, Dr Senckenberg Inst Neurooncol, Dept Neurol, Schleusenweg 2-16, D-60528 Frankfurt, Germany	Tichy, J (corresponding author), Goethe Univ Frankfurt, Dept Neurol, D-60054 Frankfurt, Germany.; Tichy, J (corresponding author), Goethe Univ Frankfurt, Dr Senckenberg Inst Neurooncol, D-60054 Frankfurt, Germany.; Tichy, J (corresponding author), Goethe Univ Frankfurt, Neurol Inst, Edinger Inst, D-60054 Frankfurt, Germany.; Tichy, J (corresponding author), Goethe Univ Hosp Frankfurt, Dr Senckenberg Inst Neurooncol, Dept Neurol, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	julia.tichy@kgu.de	Hattingen, Elke/D-7880-2015; Senft, Christian/F-4252-2010	Senft, Christian/0000-0003-1288-6913; Mittelbronn, Michel/0000-0002-2998-052X; Hattingen, Elke/0000-0002-8392-9004			Brommeland T, 2007, ACTA NEUROL SCAND, V116, P380, DOI 10.1111/j.1600-0404.2007.00889.x; Brunkhorst R, 2010, TRANSL STROKE RES, V1, P246, DOI 10.1007/s12975-010-0040-6; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Foerch C, 2012, CLIN CHEM, V58, P237, DOI 10.1373/clinchem.2011.172676; Perez-Larraya JG, 2014, CANCER-AM CANCER SOC, V120, P3972, DOI 10.1002/cncr.28949; Harter PN, 2010, NEUROPATH APPL NEURO, V36, P623, DOI 10.1111/j.1365-2990.2010.01100.x; Jung CS, 2007, BRAIN, V130, P3336, DOI 10.1093/brain/awm263; Jung CS, 2011, HISTOL HISTOPATHOL, V26, P1327, DOI 10.14670/HH-26.1327; Kiviniemi A, 2015, J NEURO-ONCOL, V124, P237, DOI 10.1007/s11060-015-1829-7; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Larsson IM, 2014, RESUSCITATION, V85, P1654, DOI 10.1016/j.resuscitation.2014.09.007; Lyubimova NV, 2011, B EXP BIOL MED+, V150, P732, DOI 10.1007/s10517-011-1236-9; Lyubimova NV, 2013, KLIN LAB DIAGN, V71-72, P40; Mayer CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062101; Nduom EK, 2013, J NEUROSURG, V119, P427, DOI 10.3171/2013.3.JNS122226; Noreen F, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju161; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Okonogi N, 2015, ANTICANCER RES, V35, P1229; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Petzold A, 2015, BRAIN RES, V1600, P17, DOI 10.1016/j.brainres.2014.12.027; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Wang K, 2014, ASIAN PAC J CANCER P, V15, P10893, DOI 10.7314/APJCP.2014.15.24.10893; Weise LM, 2014, STEREOT FUNCT NEUROS, V92, P129, DOI 10.1159/000360582; Weller M, 2015, CLIN CANCER RES, V21, P2057, DOI 10.1158/1078-0432.CCR-14-2737; Wilhelmsson U, 2003, ONCOGENE, V22, P3407, DOI 10.1038/sj.onc.1206372; YUNG WKA, 1985, J NEURO-ONCOL, V3, P35	29	30	32	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-594X	1573-7373		J NEURO-ONCOL	J. Neuro-Oncol.	JAN	2016	126	2					361	369		10.1007/s11060-015-1978-8			9	Oncology; Clinical Neurology	Oncology; Neurosciences & Neurology	DB7WS	WOS:000368728300017	26518540				2021-06-18	
J	Turner-Stokes, L; Williams, H; Bill, A; Bassett, P; Sephton, K				Turner-Stokes, Lynne; Williams, Heather; Bill, Alan; Bassett, Paul; Sephton, Keith			Cost-efficiency of specialist inpatient rehabilitation for working-aged adults with complex neurological disabilities: a multicentre cohort analysis of a national clinical data set	BMJ OPEN			English	Article							UNIFORM DATA SYSTEM; TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; PROGRAMS; CARE; DEPENDENCY; OUTCOMES; CASEMIX; SCORE; STAY	Objectives: To evaluate functional outcomes, care needs and cost-efficiency of specialist rehabilitation for a multicentre cohort of inpatients with complex neurological disability, comparing different diagnostic groups across 3 levels of dependency. Design: A multicentre cohort analysis of prospectively collected clinical data from the UK Rehabilitation Outcomes Collaborative (UKROC) national clinical database, 2010-2015. Setting: All 62 specialist (levels 1 and 2) rehabilitation services in England. Participants: Working-aged adults (16-65 years) with complex neurological disability. Inclusion criteria: all episodes with length of stay (LOS) 8-400 days and complete outcome measures recorded on admission and discharge. Total N= 5739: acquired brain injury n= 4182 (73%); spinal cord injury n= 506 (9%); peripheral neurological conditions n= 282 (5%); progressive conditions n= 769 (13%). Intervention: Specialist inpatient multidisciplinary rehabilitation. Outcome measures: Dependency and care costs: Northwick Park Dependency Scale/ Care Needs Assessment (NPDS/ NPCNA). Functional independence: UK Functional Assessment Measure (UK Functional Independence Measure (FIM)+ FAM). Cost-efficiency: (1) time taken to offset rehabilitation costs by savings in NPCNA-estimated costs of ongoing care, (2) FIM efficiency (FIM gain/ LOS days), (3) FIM+ FAM efficiency (FIM+ FAM gain/ LOS days). Patients were analysed in 3 groups of dependency. Results: Mean LOS 90.1 (SD 66) days. All groups showed significant reduction in dependency between admission and discharge on all measures (paired t tests: p< 0.001). Mean reduction in `weekly care costs' was greatest in the high-dependency group at xi 760/ week (95% CI 726 to 794)), compared with the medium-dependency (xi 408/ week (95% CI 370 to 445)), and low-dependency ( 130/ week (95% CI 82 to 178)), groups. Despite longer LOS, time taken to offset the cost of rehabilitation was 14.2 (95% CI 9.9 to 18.8) months in the high-dependency group, compared with 22.3 (95% CI 16.9 to 29.2) months (medium dependency), and 27.7 (95% CI 15.9 to 39.7) months (low dependency). FIM efficiency appeared greatest in medium-dependency patients (0.54), compared with the low-dependency (0.37) and high-dependency (0.38) groups. Broadly similar patterns were seen across all 4 diagnostic groups. Conclusions: Specialist rehabilitation can be highly cost-efficient for all neurological conditions, producing substantial savings in ongoing care costs, especially in high-dependency patients.	[Turner-Stokes, Lynne] Kings Coll London, Fac Life Sci & Med, Dept Palliat Care Policy & Rehabil, London, England; [Turner-Stokes, Lynne; Williams, Heather; Bill, Alan; Sephton, Keith] Northwick Pk Hosp & Clin Res Ctr, Reg Hyper Acute Rehabil Unit, Harrow, Middx, England; [Bassett, Paul] Statsconsultancy Ltd, London, England	Turner-Stokes, L (corresponding author), Kings Coll London, Fac Life Sci & Med, Dept Palliat Care Policy & Rehabil, London, England.; Turner-Stokes, L (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Reg Hyper Acute Rehabil Unit, Harrow, Middx, England.	lynne.turner-stokes@dial.pipex.com	Turner-Stokes, Lynne/F-4418-2012	Turner-Stokes, Lynne/0000-0002-3302-9462; Bassett, Paul/0000-0001-7830-4563	National Institute for Health Research (NIHR) under Programme Grants for Applied Research programme [RP-PG-0407-10 185]; Dunhill Medical TrustDunhill Medical Trust; National Institute for Health ResearchNational Institute for Health Research (NIHR) [RP-PG-0407-10185] Funding Source: researchfish	This article presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research programme (RP-PG-0407-10 185). Financial support for the preparation of this manuscript was also provided by the Dunhill Medical Trust.	[Anonymous], 2015, SPEC NEUR SERV PROV; [Anonymous], 2005, NATL SERV FRAM LONG; [Anonymous], 2013, GUID HEALTHC SYST EN; [Anonymous], 2003, NEUR A BRIEF REV NUM; Bottemiller KL, 2006, REHABIL NURS, V31, P22, DOI 10.1002/j.2048-7940.2006.tb00006.x; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; Granger CV, 2012, AM J PHYS MED REHAB, V91, P289, DOI 10.1097/PHM.0b013e31824ad2fd; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Granger CV, 2009, AM J PHYS MED REHAB, V88, P961, DOI [10.1097/PHM.0b013e3181c1ec38, 10.1097/PHM.0b013e3181clec38]; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; Khan F, 2009, MULT SCLER J, V15, P869, DOI 10.1177/1352458509105230; Khan F, 2010, J CLIN MED RES, V2, P91; Khan F, 2007, COCHRANE DB SYST REV, V8; Oddy M, 2013, BRAIN INJURY, V27, P1500, DOI 10.3109/02699052.2013.830332; Office for National Statistics, 2014, 2012 BAS PER COH LIF; Porter ME, 2006, REDEFINING HLTH CARE; Siegert RJ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004231; Siegert RJ, 2010, J REHABIL MED, V42, P936, DOI 10.2340/16501977-0602; Stineman MG, 2001, MED CARE, V39, P123, DOI 10.1097/00005650-200102000-00003; Turner-Stokes L, 2006, J NEUROL NEUROSUR PS, V77, P634, DOI 10.1136/jnnp.2005.073411; Turner-Stokes L, 2004, CLIN MED, V4, P10, DOI 10.7861/clinmedicine.4-1-10; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Turner-Stokes L, 1999, CLIN REHABIL, V13, P253, DOI 10.1191/026921599677787870; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Turner-Stokes L, 1998, CLIN REHABIL, V12, P304, DOI 10.1191/026921598669173600; Turner-Stokes L, 2015, RPPG040710185 NIH RE; Turner-Stokes L, 2007, BRAIN INJURY, V21, P1015, DOI 10.1080/02699050701591445; Turner-Stokes L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132275; Turner-Stokes L, 2013, DISABIL REHABIL, V35, P1885, DOI 10.3109/09638288.2013.766271; Turner-Stokes L, 2012, CLIN REHABIL, V26, P264, DOI 10.1177/0269215511417467	31	30	31	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2016	6	2								10.1136/bmjopen-2015-010238			13	Medicine, General & Internal	General & Internal Medicine	DT5HX	WOS:000381514500105	26911586	DOAJ Gold, Green Published			2021-06-18	
J	Whiteneck, GG; Cuthbert, JP; Corrigan, JD; Bogner, JA				Whiteneck, Gale G.; Cuthbert, Jeffery P.; Corrigan, John D.; Bogner, Jennifer A.			Risk of Negative Outcomes After Traumatic Brain Injury: A Statewide Population-Based Survey	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						activities of daily living; epidemiology; health status; mild cognitive impairment; mild traumatic brain injury; postconcussive symptoms; quality of life; surveys; traumatic brain injury	UNITED-STATES; MILD; RELIABILITY; VALIDITY; PREVALENCE; HISTORY; COHORT	Objective: To investigate the rates of negative outcomes associated with all severities of traumatic brain injury (TBI), treated in all settings or not treated at all, in comparison to the general population. Participants: Coloradoans without injury, with injury but no TBI, with mild TBI but no loss of consciousness (LOC), mild TBI with LOC, moderate TBI, or severe TBI. Design: Statewide population-based survey. Main measures: Computer-assisted, modified Ohio State University TBI Identification Method; Behavioral Risk Factor Surveillance System and National Health Interview Survey questions; Satisfaction with Life Scale; and postconcussive symptoms. Results: Up to 42.5% of participants reported a lifetime history of at least 1 TBI. Multiple negative outcomes were found to increase in prevalence in a stepwise fashion in association with greater TBI severity, with the clearest patterns observed for disability, poor life satisfaction, and impaired memory. Conclusions: Traumatic brain injury was found to be associated with disability and other negative outcomes in a general population survey. This study does not allow us to examine the proximate causes of disability, but it suggests that TBI may serve to both cause disability directly and exacerbate the influence of other etiologies. These relations should be examined in subsequent studies.	[Whiteneck, Gale G.; Cuthbert, Jeffery P.] Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA; [Corrigan, John D.; Bogner, Jennifer A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Whiteneck, GG (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	gale@craig-hospital.org			Colorado Injury Control Research Center through Centers for Disease Control and Prevention [R49 CE001168]; National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education, TBI Model System Centers grantsUS Department of Education [H133A070029]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001168] Funding Source: NIH RePORTER	This publication was supported by the Colorado Injury Control Research Center through grant number R49 CE001168 from the Centers for Disease Control and Prevention and the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education, TBI Model System Centers grants to Ohio State University (H133A070029). The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the National Institute on Disability and Rehabilitation Research.	Adams P F, 1992, Vital Health Stat 10, P1; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; [Anonymous], 2012, SAS 9 3; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; Battaglia M.P., 2000, P 25 ANN SAS US GROU; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bureau of Health Statistics and Data Management, 1998, NEW HAMPSH BEH RISK; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; Caplan B, 1996, J HEAD TRAUMA REHAB, V11, P1; Centers for Disease Control and Prevention, 2000, BRFSS 2000 SURV DAT; Centers for Disease Control and Prevention, 2007, 2007 BEH RISK FACT S; Centers for Disease Control and Prevention, 1994, NAT HLTH INT SURV 19; Centers for Disease Control and Prevention, 2013, DIS HLTH DAT SYST ME; Centers for Disease Control and Prevention Department of Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; Coronado V. G., 2012, BRAIN INJURY MED, P45; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Corrigan JD, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1315; Cuthbert JP, 2016, J HEAD TRAUMA REHAB, V31, pE36, DOI 10.1097/HTR.0000000000000075; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diener E., 2006, UNDERSTANDING SCORES; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Health Statistics Section, 2001, COL BEH RISK FACT SU; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2009, GULF WAR HLTH, V7; Izrael D, 2000, 25 ANN SAS US GROUP; Izrael D, 2009, SAS GLOB FOR; Kalton G., 2003, J OFF STAT, V19, P81; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; McKinlay A, 2014, J HEAD TRAUMA REHAB, V29, P498, DOI 10.1097/HTR.0000000000000001; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Rosenthal M., 1999, REHABILITATION ADULT; Rosenthal M, 1993, J HEAD TRAUMA REHAB, V8, P1; Selassie A, 2003, S CAROLINA TRAUMATIC; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sosin DM, 1996, BRAIN INJURY, V10, P47; StataCorp LP. STATA. College Station, 2011, STAT STAT SOFTW REL; Thurman D, 1996, W J MED, V165, P196; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Whiteneck G, J HEAD TRAU IN PRESS; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	52	30	30	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2016	31	1					E43	E54		10.1097/HTR.0000000000000141			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DK9CN	WOS:000375228000005	25931188				2021-06-18	
J	Ghasemzadeh, A; Mundinger, GS; Swanson, EW; Utria, AF; Dorafshar, AH				Ghasemzadeh, Ali; Mundinger, Gerhard S.; Swanson, Edward W.; Utria, Alan F.; Dorafshar, Amir H.			Treatment of Pediatric Condylar Fractures: A 20-Year Experience	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							MANDIBLE FRACTURES; OPEN REDUCTION; FOLLOW-UP; CHILDREN; CLASSIFICATION; DEMOGRAPHICS; MANAGEMENT; INJURIES; FIXATION; PATTERNS	Background: The purpose of this study was to define patterns of injury and treatment for condylar and subcondylar fractures and evaluate short-term outcomes in the pediatric population. Methods: A retrospective chart review was performed on pediatric patients with mandibular condylar fractures who presented between 1990 and 2010. Computed tomographic imaging was reviewed for all patients to assess fracture characteristics. Mandibular fractures were codified using the Strasbourg Osteosynthesis Research Group and Lindahl classification methods. Results: Sixty-four patients with 92 condylar fractures were identified. Of these patients, 29 had isolated condylar fracture and 35 had a condylar fracture associated with an additional mandibular arch fracture. The most common fracture patterns were diacapitular fracture in the Strasbourg Osteosynthesis Research Group system (n = 46) and vertical condylar head fracture in the Lindahl system (n = 14). Condylar fracture with additional mandibular arch fractures were treated with maxillomandibular fixation more often than patients with condylar fracture [n = 40 (74.1 percent) versus n = 14 (25.9 percent); p = 0.004]. No condylar fracture was treated in an open fashion. Forty-three patients returned for follow-up. The median follow-up period was 81 days (interquartile range, 35 to 294 days). Ten patients had complications (23.3 percent). The most common complication was malocclusion (n = 5). Nine of 10 patients with complications had condylar fracture with an additional mandibular arch fracture. Conclusions: Closed treatment of condylar fractures yields satisfactory results in pediatric patients. Pediatric patients with condylar fractures combined with additional arch fractures experience a higher rate of unfavorable outcomes.	[Ghasemzadeh, Ali; Mundinger, Gerhard S.; Swanson, Edward W.; Utria, Alan F.; Dorafshar, Amir H.] Johns Hopkins Univ Hosp, Dept Plast & Reconstruct Surg, Baltimore, MD 21287 USA	Dorafshar, AH (corresponding author), Johns Hopkins Univ Hosp, Dept Plast & Reconstruct Surg, JHOC 8150,600 North Wolfe St, Baltimore, MD 21287 USA.	adorafs1@jhmi.edu	Dorafshar, Amir/AAP-2657-2021	Susarla, Srinivas/0000-0003-0155-8260; Utria, Alan/0000-0003-2431-7611; Dorafshar, Amir/0000-0001-7045-3601; Ghasemzadeh, Ali/0000-0001-6605-4835	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM007309] Funding Source: Medline		Bos RRM, 1999, BRIT J ORAL MAX SURG, V37, P87; Cenzi R, 2009, J CRANIOFAC SURG, V20, P24, DOI [10.1097/SCS.0b013e31819032a3, 10.1097/scs.0b013e31819032a3]; Deleyiannis FWB, 2006, ANN PLAS SURG, V57, P495, DOI 10.1097/01.sap.0000226943.79337.bf; Dodson Thomas B, 2005, Oral Maxillofac Surg Clin North Am, V17, P447, DOI 10.1016/j.coms.2005.06.001; Ellis E, 2005, J ORAL MAXIL SURG, V63, P115, DOI 10.1016/j.joms.2004.02.019; Goth S, 2012, J CRANIOFAC SURG, V23, P47, DOI 10.1097/SCS.0b013e318240c8ab; Grunwaldt L, 2011, PLAST RECONSTR SURG, V128, P1263, DOI 10.1097/PRS.0b013e318230c8cf; Lekven N, 2011, J ORAL MAXIL SURG, V69, P2853, DOI 10.1016/j.joms.2011.03.019; LINDAHL L, 1977, INT J ORAL MAXILLOF, V6, P12, DOI 10.1016/S0300-9785(77)80067-7; Loukota RA, 2005, BRIT J ORAL MAX SURG, V43, P72, DOI 10.1016/j.bjoms.2004.08.018; Pereira MD, 1995, J CRANIO MAXILL SURG, V23, P369, DOI 10.1016/S1010-5182(05)80132-5; Schiel S, 2013, J ORAL MAXIL SURG, V71, P1220, DOI 10.1016/j.joms.2013.03.023; Smartt JM, 2005, PLAST RECONSTR SURG, V116, p28E, DOI 10.1097/01.prs.0000173445.10908.f8; Smith DM, 2013, PLAST RECONSTR SURG, V131, P1348, DOI 10.1097/PRS.0b013e31828bd503; Thoren H, 1997, BRIT J ORAL MAX SURG, V35, P306, DOI 10.1016/S0266-4356(97)90401-0; Thoren H, 2001, J ORAL MAXIL SURG, V59, P768, DOI 10.1053/joms.2001.23369; Wheeler J, 2011, CRANIOMAX TRAUM REC, V4, P43, DOI 10.1055/s-0031-1272901	17	30	31	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	DEC	2015	136	6					1279	1288		10.1097/PRS.0000000000001811			10	Surgery	Surgery	CW6LJ	WOS:000365108700002	26595021	Green Accepted			2021-06-18	
J	Reeser, JC; Gregory, A; Berg, RL; Comstock, RD				Reeser, Jonathan C.; Gregory, Andrew; Berg, Richard L.; Comstock, R. Dawn			A Comparison of Women's Collegiate and Girls' High School Volleyball Injury Data Collected Prospectively Over a 4-Year Period	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						volleyball; injury surveillance; injury patterns; high school athletes; collegiate athletes	STATES HIGH-SCHOOL; SPORTS INJURIES; PROSPECTIVE COHORT; KNEE INJURIES; RISK-FACTORS; EPIDEMIOLOGY; CONCUSSIONS; MECHANISMS; PREVENTION	Background: There is a relative paucity of research examining the sport-specific injury epidemiology of high school and collegiate volleyball athletes. Moreover, differences in study methodology frequently limit our ability to compare and contrast injury data collected from selected populations. Hypothesis: There are differences between the injury patterns characteristic of high school and collegiate female volleyball athletes. Study Design: Retrospective clinical review. Level of Evidence: Level 3. Methods: We statistically analyzed injury incidence and outcome data collected over a 4-year interval (2005-2006 to 2008-2009) by 2 similar injury surveillance systems, the National Collegiate Athletic Association's Injury Surveillance System (NCAA ISS) and the High School Reporting Injuries Online (HS RIO). We compared diagnoses, anatomic distribution of injuries, mechanisms of injury, and time lost from training or competition between high school and collegiate volleyball athletes. Results: The overall volleyball-related injury rate was significantly greater among collegiate athletes than among high school athletes during both competition (injury rate ratio, 2.9; 95% CI, 2.5-3.4) and practice (injury rate ratio, 3.5; 95% CI, 3.1-3.9). Collegiate athletes had a higher rate of ankle sprain, knee injury, and shoulder injury. Concussions represented a relatively high percentage of injuries in both populations (5.0% of total NCAA ISS injuries vs 4.8% of total HS RIO injuries, respectively). Conclusion: The data suggest that although similar, there were distinct differences between the injury patterns of the 2 populations. Compared with high school volleyball players, collegiate athletes have a higher rate of acute time loss injury as well as overuse time loss injury (particularly patellar tendinosis). Concussions represented a significant and worrisome component of the injury pattern for both study populations.	[Reeser, Jonathan C.; Berg, Richard L.] Marshfield Clin Res Fdn, Marshfield, WI USA; [Gregory, Andrew] Vanderbilt Sports Med Med Ctr East, Nashville, TN USA; [Comstock, R. Dawn] Univ Colorado, Sch Med, Colorado Sch Publ Hlth Epidemiol, Pediat Pediat Injury Prevent Educ & Res PIPER Pro, Aurora, CO 80309 USA	Reeser, JC (corresponding author), Marshfield Res Fdn, 1000 North Oak Ave, Marshfield, WI 54449 USA.	jreeser@charter.net			Marshfield Clinic Research Foundation	This study was funded by personal research funds provided to JCR from the Marshfield Clinic Research Foundation.	Aagaard H, 1997, INT J SPORTS MED, V18, P217, DOI 10.1055/s-2007-972623; Agel J, 2004, J ATHL TRAINING, V42, P295; Bahr R, 1997, SCAND J MED SCI SPOR, V7, P166, DOI 10.1111/j.1600-0838.1997.tb00134.x; BAHR R, 1994, AM J SPORT MED, V22, P595, DOI 10.1177/036354659402200505; Belechri M, 2001, EUR J EPIDEMIOL, V17, P1005, DOI 10.1023/A:1020078522493; Bonza JE, 2013, J ATHL TRAINING, V44, P76; Clarsen B, 2013, BRIT J SPORT MED, V47, P495, DOI 10.1136/bjsports-2012-091524; DELOES M, 1995, INT J SPORTS MED, V16, P134, DOI 10.1055/s-2007-972980; FERRETTI A, 1986, SPORTS MED, V3, P289, DOI 10.2165/00007256-198603040-00005; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Lian OB, 2005, AM J SPORT MED, V33, P561, DOI 10.1177/0363546504270454; Maffulli N, 1996, BRIT J SPORT MED, V30, P218, DOI 10.1136/bjsm.30.3.218; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Pollard KA, 2011, CLIN PEDIATR, V50, P844, DOI 10.1177/0009922811406262; Rauh MJ, 2007, J ATHL TRAINING, V42, P486; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Reeser JC, 2006, BRIT J SPORT MED, V40, P594, DOI 10.1136/bjsm.2005.018234; Reeser JC, 2010, PM&R, V2, P27, DOI 10.1016/j.pmrj.2009.11.010; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; SOLGARD L, 1995, BRIT J SPORT MED, V29, P200, DOI 10.1136/bjsm.29.3.200; Swenson DM, 2013, CLIN J SPORT MED, V23, P190, DOI 10.1097/JSM.0b013e31827d21fe; Swenson DM, 2013, MED SCI SPORT EXER, V45, P462, DOI 10.1249/MSS.0b013e318277acca; Verhagen EALM, 2004, BRIT J SPORT MED, V38, P477, DOI 10.1136/bjsm.2003.005785; Vetter RE, 2010, J STRENGTH COND RES, V24, P587, DOI 10.1519/JSC.0b013e3181c7c2eb; Vrbanic TSL, 2007, COLLEGIUM ANTROPOL, V31, P253; Yardt EE, 2008, AM J SPORT MED, V36, P57, DOI 10.1177/0363546507307507	28	30	30	1	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	NOV-DEC	2015	7	6					504	510		10.1177/1941738115600143			7	Sport Sciences	Sport Sciences	V20OH	WOS:000214895400005	26502443	Green Published			2021-06-18	
J	Ceccanti, M; Hamilton, D; Coriale, G; Carito, V; Aloe, L; Chaldakov, G; Romeo, M; Ceccanti, M; Iannitelli, A; Fiore, M				Ceccanti, Mauro; Hamilton, Derek; Coriale, Giovanna; Carito, Valentina; Aloe, Luigi; Chaldakov, George; Romeo, Marina; Ceccanti, Marco; Iannitelli, Angela; Fiore, Marco			Spatial learning in men undergoing alcohol detoxification	PHYSIOLOGY & BEHAVIOR			English	Article						Virtual Morris maze; Ethanol detoxification	MORRIS WATER MAZE; TRAUMATIC BRAIN-INJURY; SOCIAL DRINKERS; SEX-DIFFERENCES; MEMORY-SYSTEMS; ADULT RATS; NAVIGATION; TASK; DEFICITS; ETHANOL	Alcohol dependence is a major public health problem worldwide. Brain and behavioral disruptions including changes in cognitive abilities are common features of alcohol addiction. Thus, the present study was aimed to investigate spatial learning and memory in 29 alcoholic men undergoing alcohol detoxification by using a virtual Morris maze task. As age-matched controls we recruited 29 men among occasional drinkers without history of alcohol dependence and/or alcohol related diseases and with a negative blood alcohol level at the time of testing. We found that the responses to the virtual Morris maze are impaired in men undergoing alcohol detoxification. Notably they showed increased latencies in the first movement during the trials, increased latencies in retrieving the hidden platform and increased latencies in reaching the visible platform. These findings were associated with reduced swimming time in the target quadrant of the pool where the platform had been during the 4 hidden platform trials of the learning phase compared to controls. Such increasing latency responses may suggest motor control, attentional and motivational deficits due to alcohol detoxification. (C) 2015 Elsevier Inc. All rights reserved.	[Ceccanti, Mauro; Coriale, Giovanna; Romeo, Marina] Univ Roma La Sapienza, Dept Clin Med, Ctr Alcohol Abuse Ctr Riferimento Alcol Reg Lazio, Rome, Italy; [Hamilton, Derek] Univ New Mexico, Albuquerque, NM 87131 USA; [Carito, Valentina; Aloe, Luigi; Fiore, Marco] Natl Res Council IBCN CNR, Inst Cell Biol & Neurobiol, Rome, Italy; [Chaldakov, George; Ceccanti, Marco] Med Univ, Div Cell Biol, BG-9002 Varna, Bulgaria; [Iannitelli, Angela] Univ Aquila, Dept Hlth Sci, I-67100 Laquila, Italy	Fiore, M (corresponding author), CNR, Ist Biol Cellulare & Neurobiol, Via Fosso di Fiorano 64, I-00143 Rome, Italy.	marco.fiore@cnr.it	Hamilton, Derek A/H-4447-2013; Fiore, Marco/B-6112-2015; Iannitelli, Angela/AAM-7689-2020	Hamilton, Derek A/0000-0001-7021-3288; Fiore, Marco/0000-0001-6806-9715; Ceccanti, Marco/0000-0001-8897-3736; CECCANTI, Mauro/0000-0001-9981-8715			Abernathy K, 2010, INT REV NEUROBIOL, V91, P289, DOI 10.1016/S0074-7742(10)91009-X; Aminoff EM, 2013, TRENDS COGN SCI, V17, P379, DOI 10.1016/j.tics.2013.06.009; Astur RS, 2004, BEHAV BRAIN RES, V151, P103, DOI 10.1016/j.bbr.2003.08.024; Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Beatty WW, 1996, J STUD ALCOHOL, V57, P136, DOI 10.15288/jsa.1996.57.136; Boccia M, 2014, NEUROPSYCHOL REV, V24, P236, DOI 10.1007/s11065-014-9247-8; Boulouard M, 2002, BEHAV BRAIN RES, V136, P239, DOI 10.1016/S0166-4328(02)00134-1; Brandt T, 2005, BRAIN, V128, P2732, DOI 10.1093/brain/awh617; Brown SA, 2000, ALCOHOL CLIN EXP RES, V24, P164, DOI 10.1111/j.1530-0277.2000.tb04586.x; Bueters T, 2008, EXP NEUROL, V209, P114, DOI 10.1016/j.expneurol.2007.09.005; Coriale G, 2012, ADDICT BEHAV, V37, P1224, DOI 10.1016/j.addbeh.2012.05.018; Cornwell BR, 2010, AM J PSYCHIAT, V167, P836, DOI 10.1176/appi.ajp.2009.09050614; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Driscoll I, 2005, HORM BEHAV, V47, P326, DOI 10.1016/j.yhbeh.2004.11.013; Fajnerova I, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00157; Fein G, 2006, ALCOHOL CLIN EXP RES, V30, P1538, DOI 10.1111/j.1530-0277.2006.00185.x; Fiore M, 2002, NEUROTOXICOL TERATOL, V24, P179, DOI 10.1016/S0892-0362(01)00214-8; Fiore M, 2000, BEHAV BRAIN RES, V112, P165, DOI 10.1016/S0166-4328(00)00180-7; First MB., 1997, STRUCTURED CLIN INTE; Goodrich-Hunsaker NJ, 2010, HIPPOCAMPUS, V20, P481, DOI 10.1002/hipo.20651; Gordan ML, 2012, BEHAV BRAIN RES, V235, P7, DOI 10.1016/j.bbr.2012.07.027; Hamilton DA, 2003, BEHAV BRAIN RES, V143, P85, DOI 10.1016/S0166-4328(03)00028-7; Hamilton DA, 2009, BEHAV PROCESS, V81, P154, DOI 10.1016/j.beproc.2008.12.003; Hartley T, 2005, TRENDS NEUROSCI, V28, P169, DOI 10.1016/j.tins.2005.02.004; Harvanko AM, 2012, J ADDICT MED, V6, P106, DOI 10.1097/ADM.0b013e31823ae56d; He J, 2005, EUR J NEUROSCI, V21, P2711, DOI 10.1111/j.1460-9568.2005.04120.x; Heinz AJ, 2011, NAT REV NEUROSCI, V12, P400, DOI 10.1038/nrn3042; KRAMER JH, 1991, J CLIN EXP NEUROPSYC, V13, P455, DOI 10.1080/01688639108401063; Maguire EA, 1999, CURR OPIN NEUROBIOL, V9, P171, DOI 10.1016/S0959-4388(99)80023-3; Markwiese BJ, 1998, ALCOHOL CLIN EXP RES, V22, P416, DOI 10.1097/00000374-199804000-00018; Matthews DB, 2004, NEUROBIOL LEARN MEM, V82, P299, DOI 10.1016/j.nlm.2004.06.007; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nam HW, 2013, MOL CELLS, V36, P195, DOI 10.1007/s10059-013-0192-9; Oscar-Berman M, 2003, ALCOHOL RES HEALTH, V27, P125; Oscar-Berman M, 1987, Recent Dev Alcohol, V5, P59; Oscar-Berman M, 1990, NIDA Res Monogr, V101, P136; Oscar-Berman M, 2007, NEUROPSYCHOL REV, V17, P239, DOI 10.1007/s11065-007-9038-6; Pasqualotto A, 2012, NEUROSCI BIOBEHAV R, V36, P1179, DOI 10.1016/j.neubiorev.2012.01.008; Rajendran P, 2004, ANN NY ACAD SCI, V1021, P441, DOI 10.1196/annals.1308.060; Rich NJ, 2010, J NEUROSCI RES, V88, P2933, DOI 10.1002/jnr.22443; Scaife JC, 2009, PHARMACOL BIOCHEM BE, V93, P354, DOI 10.1016/j.pbb.2009.05.015; Schottenbauer MA, 2007, AGING NEUROPSYCHOL C, V14, P505, DOI 10.1080/13825580600681305; Schulte T, 2012, ALCOHOL CLIN EXP RES, V36, P2017, DOI 10.1111/j.1530-0277.2012.01831.x; Sircar R, 2005, ALCOHOL CLIN EXP RES, V29, P1402, DOI 10.1097/01.alc.0000175012.77756.d9; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; Sneider J.T., 2013, J ADDICTION A; Sneider J. T., 2013, J ADDICTION RES T S7; Sneider JT, 2011, PERCEPT MOTOR SKILL, V113, P461, DOI 10.2466/04.22.24.27.PMS.113.5.461-480; Sobell L. C., 1992, TIMELINE FOLLOW BACK; SULLIVAN EV, 1992, BIOL PSYCHIAT, V32, P312, DOI 10.1016/0006-3223(92)90036-Y; Tabakoff B, 2013, PHARMACOL BIOCHEM BE, V113, P20, DOI 10.1016/j.pbb.2013.10.009; Trudell J. R., 2014, TRENDS PHARM SCI; Weissenborn R, 2003, PSYCHOPHARMACOLOGY, V165, P306, DOI 10.1007/s00213-002-1281-1	55	30	30	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	OCT 1	2015	149						324	330		10.1016/j.physbeh.2015.06.034			7	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	CO2ZR	WOS:000359026400044	26143187				2021-06-18	
J	Steuer, J; Bjorck, M; Sonesson, B; Resch, T; Dias, N; Hultgren, R; Tunesi, R; Wanhainen, A; Lachat, M; Pfammatter, T				Steuer, J.; Bjorck, M.; Sonesson, B.; Resch, T.; Dias, N.; Hultgren, R.; Tunesi, R.; Wanhainen, A.; Lachat, M.; Pfammatter, T.			Editor's Choice - Durability of Endovascular Repair in Blunt Traumatic Thoracic Aortic Injury: Long-Term Outcome from Four Tertiary Referral Centers	EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY			English	Article						Blunt injury; Endovascular technique; Thoracic aorta	AMERICAN-ASSOCIATION; STENT-GRAFT; MULTICENTER; EXPERIENCE; SURGERY; TRIAL	Objectives: To analyze the early and long-term survival and re-intervention rate in patients undergoing TEVAR for blunt traumatic thoracic aortic injury. Methods: This was a consecutive case series. Between the years 2001 and 2010, a total of 74 patients underwent TEVAR for blunt traumatic thoracic aortic injury at four tertiary referral centers, three in Sweden and one in Switzerland. The median age of the patients was 41 years, and 16% were women. Demographic, procedural, and outcome data were collected and reviewed retrospectively. The patients were followed up during 2013-2014. Results: Early (30 day) mortality was 9% (7 patients), with only two cases directly related to the aortic injury; in hospital mortality was 14% as three patients died during the primary hospital admission within the first 6 months. Most patients had sustained severe injuries to other organ systems, and among all in hospital deaths brain injury was the predominant cause. Five year survival in the whole group was 81%. Re-intervention was needed in 16% (12 patients) during the first year, half of them within the first month. Only one patient underwent re-intervention more than 1 year after the initial procedure. Infolding and partial stentgraft collapse was the reason for the secondary procedure in five of the 13 patients; in three it occurred within 3 weeks of the acute TEVAR. Conclusion: TEVAR allows rapid and effective therapy in trauma patients with blunt aortic injury. The outcome is dependent on the severity of the concomitant injuries. The treatment is durable during the first decade after the procedure, but even longer follow up is needed to determine the impact of TEVAR in young patients on the degenerative changes that take place in the aging aorta. (C) 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.	[Steuer, J.; Bjorck, M.; Wanhainen, A.] Uppsala Univ, Dept Surg Sci, Vasc Surg, Uppsala, Sweden; [Steuer, J.; Tunesi, R.; Lachat, M.] Univ Zurich Hosp, Cardiovasc Surg Clin, CH-8091 Zurich, Switzerland; [Steuer, J.] Stockholm South Hosp, Dept Surg, SE-11883 Stockholm, Sweden; [Sonesson, B.; Resch, T.; Dias, N.] Skane Univ Hosp, Vasc Ctr, Malmo, Sweden; [Hultgren, R.] Karolinska Univ Hosp, Dept Vasc Surg, Stockholm, Sweden; [Pfammatter, T.] Univ Zurich Hosp, Inst Diagnost & Intervent Radiol, CH-8091 Zurich, Switzerland	Steuer, J (corresponding author), Stockholm South Hosp, Vasc Surg Sect, Dept Surg, SE-11883 Stockholm, Sweden.	joste@live.se	Resch, Tim/AAW-9630-2020; Lachat, Mario/G-4826-2011; Hultgren, Rebecka/K-8738-2012	Lachat, Mario/0000-0001-7812-2110; Hultgren, Rebecka/0000-0002-8869-0493; Dias, Nuno/0000-0002-6907-6148			Azizzadeh A, 2013, J VASC SURG, V57, P108, DOI 10.1016/j.jvs.2012.05.110; Azizzadeh A, 2009, J VASC SURG, V49, P1403, DOI 10.1016/j.jvs.2009.02.234; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; COPES WS, 1988, J TRAUMA, V28, P78, DOI 10.1097/00005373-198801000-00011; Demetriades D, 2008, J TRAUMA, V64, P561, DOI 10.1097/TA.0b013e3181641bb3; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; Forbes TL, 2010, J VASC SURG, V52, P45, DOI 10.1016/j.jvs.2010.01.094; Jonker FHW, 2010, J ENDOVASC THER, V17, P725, DOI 10.1583/10-3130.1; Khoynezhad A, 2013, J VASC SURG, V57, P899, DOI 10.1016/j.jvs.2012.10.099; Lachat M, 2002, EUR J CARDIO-THORAC, V21, P959, DOI 10.1016/S1010-7940(02)00062-3; Martinelli O, 2013, J VASC SURG, V58, P832, DOI 10.1016/j.jvs.2013.02.243; Mattox KL, 2008, J TRAUMA, V64, P570; Mitchell RS, 2002, J ENDOVASC THER, V9, P98; Neschis DG, 2008, NEW ENGL J MED, V359, P1708, DOI 10.1056/NEJMra0706159; Orend KH, 2007, EUR J VASC ENDOVASC, V34, P666, DOI 10.1016/j.ejvs.2007.06.022; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; Rabin J, 2014, ANN THORAC SURG, V98, P46, DOI 10.1016/j.athoracsur.2014.04.025; Rabin J, 2014, J THORAC CARDIOV SUR, V147, P143, DOI 10.1016/j.jtcvs.2013.08.053; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; Starnes BW, 2012, J VASC SURG, V55, P47, DOI 10.1016/j.jvs.2011.07.073; Steuer J, 2012, J VASC SURG, V56, P973, DOI 10.1016/j.jvs.2012.03.259; Watson J, 2013, J VASC SURG, V58, P380, DOI 10.1016/j.jvs.2013.01.045	22	30	31	0	4	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1078-5884	1532-2165		EUR J VASC ENDOVASC	Eur. J. Vasc. Endovasc. Surg.	OCT	2015	50	4					460	465		10.1016/j.ejvs.2015.05.012			6	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	CS1XK	WOS:000361862000011	26143100	Bronze			2021-06-18	
J	Sun, LQ; Gao, JL; Zhao, MM; Cui, JZ; Li, YX; Yang, XJ; Jing, XB; Wu, ZX				Sun, Liqian; Gao, Junling; Zhao, Manman; Cui, Jianzhong; Li, Youxiang; Yang, Xinjian; Jing, Xiaobin; Wu, Zhongxue			A novel cognitive impairment mechanism that astrocytic p-connexin 43 promotes neuronic autophagy via activation of P2X7R and down-regulation of GLT-1 expression in the hippocampus following traumatic brain injury in rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Cognitive function; Hippocampus; Autophagy; Hippocampal slices	FOCAL CEREBRAL-ISCHEMIA; RECEPTORS; MODEL; NEUROPROTECTION; HEMICHANNELS; STIMULATION; INVOLVEMENT; DEFICITS; CELLS	Connexin 43 (Cx43) is one of the major gap junction proteins in astrocytes. Our previous studies reported that astrocytic phosphorylated Cx43 (p-CX43) regulated neuronic autophagy levels in the rat hippocampus after traumatic brain injury (TBI). In this study, we explored the underlying molecular mechanism by which gap junctional intercellular communication influenced neuronic autophagy and therefore initiated cognitive and memory impairments after TBI. The gap junctional blocker carbenoxolone (CBX) or autophagy inhibitor 3-methyladenine (3-MA) reduced latencies, as compared to TBI rats. Similarly, CBX or 3-MA restored long-term potentiation (LTP), relative to TBI hippocampal slices. Immunoblotting analysis showed that the expression of autophagy-related gene Beclin-1 in the hippocampus post-TBI were decreased in response to treatment with CBX, the P2X7 receptor (P2X7R) antagonist Oxidized ATP (OxATP) or ceftriaxone (Cef) which increased the expression and activity of the glutamate transporter (GLT-1) in the central nervous system (CNS). Moreover, CBX or OxATP pretreatment increased GLT-1 level in the rat hippocampus after TBI. However, CBX pretreatment suppressed P2X7R expression whereas maintained P2X7 level post-TBI. Confocal images revealed that p-CX43, P2X7 and GLT-1 strongly colocalized with glial fibrillary acidic protein (GFAP). Taken together, these results implied that Cx43, might induce neuronic autophagy by activation of P2X7R and reduce the expression of GLT-1 in the hippocampus, promoting TBI-induced cognitive deficits repair. Therefore, control of this communication may be serve as therapeutic strategies for intervention against TBI. (C) 2015 Elsevier B.V. All rights reserved.	[Sun, Liqian; Li, Youxiang; Yang, Xinjian; Wu, Zhongxue] Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing 100050, Peoples R China; [Sun, Liqian; Li, Youxiang; Yang, Xinjian; Wu, Zhongxue] Capital Med Univ, Beijing Tiantan Hosp, Beijing 100050, Peoples R China; [Gao, Junling; Zhao, Manman] North China Univ Sci & Technol, Sch Basic Med Sci, Dept Histol & Embryol, Tangshan 063000, Hebei, Peoples R China; [Cui, Jianzhong] Tangshan Gongren Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China; [Jing, Xiaobin] Tangshan Ophthalmol Hosp, Dept Ophthalmol, Tangshan 063000, Hebei, Peoples R China	Wu, ZX (corresponding author), Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, 6 Tiantan Xili, Beijing 100050, Peoples R China.	zhongxuewu@yeah.net		Yang, Xinjian/0000-0001-7306-0125; Gao, Junling/0000-0001-5267-5884	Beijing Postdoctoral Research FoundationChina Postdoctoral Science Foundation [2015ZZ-49]; Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	The present study was supported by a grant from the Project supported by Beijing Postdoctoral Research Foundation (no. 2015ZZ-49) the Natural Science Foundation of Hebei Province (no. H2014105079). The authors would like to acknowledge the technical assistance of Junling Gao and Manman Zhao.	Caplan L. R., 1997, PRIMER CEREBROVASCUL; Figiel M, 2007, MOL CELL NEUROSCI, V35, P130, DOI 10.1016/j.mcn.2007.02.009; Giaume C, 1996, TRENDS NEUROSCI, V19, P319, DOI 10.1016/0166-2236(96)10046-1; Khorasani MZ, 2009, PAK J PHARM SCI, V22, P349; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Knight MM, 2009, J ANAT, V214, P275, DOI 10.1111/j.1469-7580.2008.01021.x; Krieglstein J, 1997, EUR J PHARM SCI, V5, P181, DOI 10.1016/S0928-0987(97)00276-5; Lai Y, 2007, J CEREB BLOOD FLOW M, V28, P540; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Milad MR, 2004, BEHAV NEUROSCI, V118, P389, DOI 10.1037/0735-7044.118.2.389; Morioka N, 2008, GLIA, V56, P528, DOI 10.1002/glia.20634; Odero GL, 2010, NEUROSCIENCE, V169, P532, DOI 10.1016/j.neuroscience.2010.04.004; Ohsumi A, 2010, J NEUROTRAUM, V27, P1255, DOI 10.1089/neu.2009.1234; Pannicke T, 2000, J NEUROSCI, V20, P5965, DOI 10.1523/JNEUROSCI.20-16-05965.2000; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Sun L, 2013, NEUROL SCI, P1; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Yanagisawa D, 2008, BIOL PHARM BULL, V31, P1121, DOI 10.1248/bpb.31.1121; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0	26	30	34	2	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	SEP 15	2015	291						315	324		10.1016/j.bbr.2015.05.049			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	CN5FI	WOS:000358454800039	26031379				2021-06-18	
J	Kurowski, BG; Pomerantz, WJ; Schaiper, C; Ho, MN; Gittelman, MA				Kurowski, Brad G.; Pomerantz, Wendy J.; Schaiper, Courtney; Ho, Mona; Gittelman, Michael A.			Impact of preseason concussion education on knowledge, attitudes, and behaviors of high school athletes	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	19th Annual Meeting of the Injury Free Coalition for Kids	DEC 05-07, 2014	Fort Lauderdale, FL			Concussion; education; athlete; adolescent; brain injury	4TH INTERNATIONAL-CONFERENCE; SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURIES; CONSENSUS STATEMENT; FOOTBALL PLAYERS; NOVEMBER 2012; HEAD-INJURY; CDC HEADS; COLLEGIATE; ZURICH	BACKGROUND: The benefit of preseason concussion education on athletes' knowledge, attitudes, and behaviors is unclear. The purpose of the study was to determine the influence of preseason concussion education on knowledge and self-reported attitudes and reporting behaviors. We hypothesized that preseason education would lead to better knowledge and self-reported attitudes and better reporting of concussion symptoms during the season. METHODS: This study involved a prospective cohort comparing the benefits of a preseason lectured-based concussion education session at one high school with a control school. Participants included males and females age 13 years to 18 years from two community high schools who were participating in higher concussion risk, fall or winter sports (football, soccer, wrestling, and basketball). The education school and control school included 234 and 262 participants, respectively. Outcomes were a preseason and postseason survey assessing knowledge and self-reported attitudes about concussions and an end-of-season questionnaire assessing concussion reporting behaviors during the season. RESULTS: Total scores on the combined (p < 0.0001), knowledge-based (p = 0.016), and behavioral-based (p < 0.0001) questions demonstrated statistically significant improvement in the education group. Scores peaked immediately after education but dissipated at the end of the season. There was a lower proportion in the education school (72%) compared with the control school (88%) that reported continued play despite having concussion symptoms during the season (p = 0.025). A similar proportion of athletes diagnosed with concussion during the season in the education (27%) and control schools (23%) reported returning to play before symptoms resolved (p = 0.81). CONCLUSION: These findings suggest that a didactic-based preseason concussion education likely has minimal benefits. Other factors besides knowledge are likely influencing student-athlete concussion reporting behavior. Future research focused on changing the culture of concussion reporting is needed. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.	[Kurowski, Brad G.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Phys Med & Rehabil, Cincinnati, OH USA; [Pomerantz, Wendy J.; Ho, Mona; Gittelman, Michael A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Emergency Med, Cincinnati, OH USA; [Kurowski, Brad G.; Pomerantz, Wendy J.; Schaiper, Courtney; Gittelman, Michael A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA; [Kurowski, Brad G.; Pomerantz, Wendy J.; Schaiper, Courtney; Gittelman, Michael A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Comprehens Childrens Injury Ctr, Cincinnati, OH USA	Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org			Ohio Department of Public Safety; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2K12 HD001097-16]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD074683-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683, K12HD001097] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER	This work was supported in part by (1) Ohio Department of Public Safety, (2) National Institutes of Health grant 2K12 HD001097-16, and (3) National Institute of Child Health and Human Development grant 1K23HD074683-01A1. Funding from these organizations supported the institutions/investigators in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation of the manuscript for publication.	[Anonymous], 2013, HEADS 10 YEARS ANN V; Bramley HP, 2011, CLIN PEDIAT PHILA, V51, P332; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Delaney JS, 2015, CLIN J SPORT MED, V25, P113, DOI 10.1097/JSM.0000000000000112; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Herring SA, 2011, MED SCI SPORTS EXERC, V43, P2412; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kay MC, 2014, J SPORT REHABIL; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kinzie MB, 2005, PATIENT EDUC COUNS, V56, P3, DOI 10.1016/j.pec.2004.02.005; Kroshus E, 2014, CLIN J SPORT MED; Kroshus E, 2014, HEALTH EDUC BEHAV, V42, P153; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kurowski B, 2014, J TRAUMA ACUTE CARE, V77, pS12, DOI 10.1097/TA.0000000000000316; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Mannings C, 2014, J TRAUMA ACUTE CARE, V77, pS18, DOI 10.1097/TA.0000000000000371; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Meier TB, 2014, J SCI MED SPORT; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; O'Donoghue EM., 2009, ATHLETIC TRAINING SP, V1, DOI [DOI 10.3928/19425864-20090427-07, 10.3928/19425864-20090427-07]; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Robert G, 2014, SPORTS RELATED CONCU; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; Silverberg ND, 2013, J NEUROTRAUM, V30, P1398, DOI 10.1089/neu.2012.2827; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Theye Fred, 2004, Clin Med Res, V2, P165; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	51	30	30	0	33	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2015	79	3		1			S21	S28		10.1097/TA.0000000000000675			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DJ7FH	WOS:000374376800005	26308118	Green Accepted			2021-06-18	
J	Martinez-Morillo, E; Childs, C; Garcia, BP; Menendez, FVA; Romaschin, AD; Cervellin, G; Lippi, G; Diamandis, EP				Martinez-Morillo, Eduardo; Childs, Charmaine; Prieto Garcia, Belen; Alvarez Menendez, Francisco V.; Romaschin, Alexander D.; Cervellin, Gianfranco; Lippi, Giuseppe; Diamandis, Eleftherios P.			Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury	CLINICAL CHEMISTRY AND LABORATORY MEDICINE			English	Article						biomarker; brain injury; cerebrospinal fluid; neurofilament; serum; stroke	SUBARACHNOID HEMORRHAGE; INTRACEREBRAL HEMORRHAGE; COMMERCIAL IMMUNOASSAYS; CEREBROSPINAL-FLUID; RESEARCHERS BEWARE; CHAIN LEVELS; BIOMARKERS; STROKE; DISEASE; DAMAGE	Background: Brain injury is a medical emergency that needs to be diagnosed and treated promptly. Several proteins have been studied as biomarkers of this medical condition. The aims of this study were to: 1) evaluate the selectivity and precision of a commercial ELISA kit for neurofilament medium polypeptide (NFM) protein; and 2) evaluate the concentration in cerebrospinal fluid (CSF) and serum of healthy individuals and patients with brain damage. Methods: An ELISA from Elabscience was used. The selectivity was evaluated using size-exclusion chromatography and mass spectrometry. Intra-and inter-batch coefficients of variation (CV) were also studied. Fifty-one CSF samples from 36 age-matched patients with hemorrhagic stroke (HS) (n = 30), ischemic stroke (IS) (n = 11) and healthy individuals (n = 10) were assayed. In addition, serum samples from healthy volunteers (n = 47), 68 serum samples from seven patients with HS, 106 serum samples from 12 patients with traumatic brain injury (TBI) and 68 serum samples from 68 patients with mild traumatic brain injury (mTBI) were also analyzed. Results: NFM was identified in the chromatographic fraction with highest immunoreactivity. The intra-and inter-batch CVs were <= 10% and <= 13%, respectively. The CSF-NFM concentration in HS was significantly higher (p < 0.0001) than in IS and controls. Serum NFM concentration ranged from 0.26 to 8.57 ng/mL in healthy individuals (median = 2.29), from 0.97 to 42.4 ng/mL in HS (median = 10.8) and from 3.48 to 45.4 ng/mL in TBI (median = 14.7). Finally, 44% of patients with mTBI had increased NFM concentration, with significantly higher levels (p = 0.01) in patients with polytrauma. Conclusions: To our knowledge this is the first study describing increased NFM levels in CSF and serum from patients with brain damage.	[Diamandis, Eleftherios P.] Mt Sinai Hosp, Pathol & Lab Med Dept, Toronto, ON M5T 3L9, Canada; [Diamandis, Eleftherios P.] Univ Hlth Network, Dept Clin Biochem, Toronto, ON, Canada; [Martinez-Morillo, Eduardo] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5T 3L9, Canada; [Martinez-Morillo, Eduardo] Hosp Univ Cent Asturias, Lab Med, Dept Clin Biochem, Oviedo, Spain; [Childs, Charmaine] Sheffield Hallam Univ, Fac Hlth & Wellbeing, Ctr Hlth & Social Care Res, Sheffield S1 1WB, S Yorkshire, England; [Prieto Garcia, Belen; Alvarez Menendez, Francisco V.] Hosp Univ Cent Asturias, Lab Med, Dept Clin Biochem, Oviedo, Spain; [Romaschin, Alexander D.] Univ Toronto, St Michaels Hosp, Dept Lab Med & Pathobiol, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Cervellin, Gianfranco] Acad Hosp Parma, Emergency Dept, Parma, Italy; [Lippi, Giuseppe] Acad Hosp Parma, Lab Clin Chem & Hematol, Parma, Italy	Diamandis, EP (corresponding author), Mt Sinai Hosp, Pathol & Lab Med Dept, Suite 6-201,Box 32,60 Murray St, Toronto, ON M5T 3L9, Canada.	ediamandis@mtsinai.on.ca	Lippi, Giuseppe/X-7198-2018	Lippi, Giuseppe/0000-0001-9523-9054; Diamandis, Eleftherios/0000-0002-1589-820X			Arlen RK, 2007, NEW RES NEUROFILAMEN; Brea D, 2009, CLIN CHEM LAB MED, V47, P1513, DOI 10.1515/CCLM.2009.337; Cai JY, 2013, CLIN CHIM ACTA, V424, P182, DOI 10.1016/j.cca.2013.06.019; Cervellin G, 2012, CLIN BIOCHEM, V45, P408, DOI 10.1016/j.clinbiochem.2012.01.006; Childs C, 2013, CLIN CHEM LAB MED, V51, pE195, DOI 10.1515/cclm-2013-0216; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Gresle MM, 2014, J NEUROL NEUROSUR PS, V85, P1209, DOI 10.1136/jnnp-2013-306789; Kuhle J, 2015, J NEUROL NEUROSUR PS, V86, P273, DOI 10.1136/jnnp-2013-307454; Kuhle J, 2010, J NEUROIMMUNOL, V220, P114, DOI 10.1016/j.jneuroim.2010.01.004; Liem RKH, 2009, J CLIN INVEST, V119, P1814, DOI 10.1172/JCI38003; Martinez-Morillo E, 2014, J PROTEOME RES, V13, P969, DOI 10.1021/pr401111h; Martinez-Morillo E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045676; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Moritz S, 2010, J NEUROSURG ANESTH, V22, P21, DOI 10.1097/ANA.0b013e3181bdf50d; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Petzold A, 2005, J NEUROTRAUM, V22, P407, DOI 10.1089/neu.2005.22.407; Prassas I, 2014, CLIN CHEM LAB MED, V52, P765, DOI 10.1515/cclm-2013-1078; Rifai N, 2012, CLIN CHEM, V58, P1387, DOI 10.1373/clinchem.2012.192351; Schiavi Paolo, 2012, Acta Biomed, V83, P5; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Zanier ER, 2011, J NEUROL NEUROSUR PS, V82, P157, DOI 10.1136/jnnp.2009.177667	23	30	31	1	19	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1434-6621	1437-4331		CLIN CHEM LAB MED	Clin. Chem. Lab. Med.	SEP	2015	53	10					1575	1584		10.1515/cclm-2014-0908			10	Medical Laboratory Technology	Medical Laboratory Technology	CQ8IT	WOS:000360851500023	25720124	Green Accepted			2021-06-18	
J	Taylor, HG; Orchinik, LJ; Minich, N; Dietrich, A; Nuss, K; Wright, M; Bangert, B; Rusin, J; Yeates, KO				Taylor, H. Gerry; Orchinik, Leah J.; Minich, Nori; Dietrich, Ann; Nuss, Kathryn; Wright, Martha; Bangert, Barbara; Rusin, Jerome; Yeates, Keith Owen			Symptoms of Persistent Behavior Problems in Children With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						child; brain; injury; neurobehavioral manifestations; traumatic mild	POST-CONCUSSIVE SYNDROME; CLOSED-HEAD-INJURY; 1ST 6 MONTHS; POSTCONCUSSIVE SYMPTOMS; YOUNG-CHILDREN; ADOLESCENTS; OUTCOMES; TERM	Objective: To investigate the effects of mild traumatic brain injury (mTBI) in children on symptom ratings of behavior problems across the first-year postinjury. Setting: Emergency departments of 2 regional children's hospitals. Participants: Parents of 176 children with mTBI and 90 children with orthopedic injury aged 8 to 15 years. Design: Group comparisons of postinjury parent and teacher ratings of child behavior problems controlling for background factors. Main Measures: Child Behavior Checklist and Teacher's Report Form. Results: For younger but not older children in the sample, children with mTBI compared with children with orthopedic injury had higher postinjury ratings on the Child Behavior Checklist Total Behavior Problem scale (t(264)=3.34, P<.001) and higher rates of T-scores of 60 or more on this scale (odds ratio=3.00; 95% confidence interval, 1.33-6.77; P=.008). For children with mTBI, hospitalization, motor vehicle accidents, loss of consciousness, and magnetic resonance imaging abnormality were associated with higher parent or teacher ratings. Conclusions: School-aged children with mTBI are at risk for persistent symptoms of behavior problems, especially if mTBI is more severe or occurs at a younger age. The findings justify monitoring of behavior long after injury and further research to identify risk factors for these symptoms and their association with clinical disorders.	[Taylor, H. Gerry; Minich, Nori; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Orchinik, Leah J.] Case Western Reserve Univ, Dept Psychol Sci, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, WO Walker Bldg,Ste 3150,10524 Euclid Ave, Cleveland, OH 44106 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Ctr Biobehav Hlth, Res Inst, Columbus, OH USA; [Yeates, Keith Owen] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA	Taylor, HG (corresponding author), Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, WO Walker Bldg,Ste 3150,10524 Euclid Ave, Cleveland, OH 44106 USA.	hgt2@case.edu	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD39834, K02HD44099]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	This research was funded by project grants R01HD39834 and K02HD44099 from the National Institute of Child Health and Human Development to Dr Yeates. The authors thank Lauren Ayr, Anne Birnbaum, Amy Clemens, Taryn Fay, Amanda Lininger, Katie Pestro, Elizabeth Roth, Elizabeth Shaver, and Heidi Walker for their assistance in carrying out this project.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Faul M., 2002, TRAUMATIC BRAIN INJU; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hawkins DM, 2004, J CHEM INF COMP SCI, V44, P1, DOI 10.1021/ci0342472; Keightley ML, 2014, ARCH PHYS MED REHAB, V93, P5192; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Petty CR, 2008, J ANXIETY DISORD, V22, P532, DOI 10.1016/j.janxdis.2007.04.003; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; Tabachnick BG, 1983, USING MULTIVARIATE S; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wechsler D., 2011, WECHLSER ABBREVIATED; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	45	30	30	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2015	30	5					302	310		10.1097/HTR.0000000000000106			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JE	WOS:000369605400008	25629259	Green Accepted			2021-06-18	
J	Cepeda, S; Gomez, PA; Castano-Leon, AM; Martinez-Perez, R; Munarriz, PM; Lagares, A				Cepeda, Santiago; Gomez, Pedro A.; Castano-Leon, Ana Maria; Martinez-Perez, Rafael; Munarriz, Pablo M.; Lagares, Alfonso			Traumatic Intracerebral Hemorrhage: Risk Factors Associated with Progression	JOURNAL OF NEUROTRAUMA			English	Article						contusion; intracerebral hematoma; progressive hemorrhagic injury; TBI; TICH	SEVERE HEAD-INJURY; BRAIN-INJURY; INTRACRANIAL HEMORRHAGE; COMPUTERIZED-TOMOGRAPHY; CONTUSIONS; COAGULOPATHY; HEMATOMA; LESION; THROMBOCYTOPENIA; PREDICTORS	The increase in the volume of a traumatic intracerebral hemorrhage (TICH) is a widely studied phenomenon that has a direct impact on the prognosis of patients. The objective of this study was to identify the risk factors associated with the progression of TICH. We retrospectively analyzed the records of 1970 adult patients >15 years of age who were consecutively admitted after sustaining a closed severe traumatic brain injury (TBI) between January 1987 and November 2013 at a single center. Beginning in 2007, patients with moderate TBIs were also included. A total of 782 patients exhibited one or more TICH on the initial CT scan, and met the selection criteria. The main outcome variable was the presence or absence of progression of the TICH. Univariate and multivariate statistical analyses were performed. Factors independently associated with the growth of TICH obtained through logistic regression included the following: an initial volume <5cc (odds ratio [OR] 2.42, p<0.001), cisternal compression (OR 1.95, p<0.001), decompressive craniectomy (OR 2.18, p<0.001), age (mean 37.67 vs. 42.95 years; OR 1.01, p<0.001), falls as mechanism of trauma (OR 1.72, p=0.001), multiple TICHs (OR 1.56, p=0.007), and hypoxia (OR 1.56, p=0.02). TICH progression occurred with a frequency of 63% in our study. We showed that there was a correlation between TICH growth and some variables, such as multiple TICHs, a lower initial volume, acute subdural hematoma, cisternal compression, older patient age, hypoxia, falls, and decompressive craniectomy.	[Cepeda, Santiago; Gomez, Pedro A.; Castano-Leon, Ana Maria; Martinez-Perez, Rafael; Munarriz, Pablo M.; Lagares, Alfonso] Univ Complutense Madrid, Hosp 12 Octubre, Dept Neurosurg, Madrid, Spain	Cepeda, S (corresponding author), Hosp 12 Octubre, Dept Neurosurg, Avda Cordoba S-N, E-28041 Madrid, Spain.	cepeda_santiago@hotmail.com	MARTINEZ-PEREZ, Rafael/AAR-5874-2020; Castano-Leon, Ana M/ABF-6322-2020; MARTINEZ-PEREZ, Rafael/AAO-7328-2020; Gomez, Pedro/N-5051-2019; Lagares, Alfonso/B-2969-2011; Munarriz, Pablo M/S-3398-2018; Martinez-Perez, Rafael/E-2408-2014; Cepeda, Santiago/AAE-3200-2021	MARTINEZ-PEREZ, Rafael/0000-0002-2896-2346; Castano-Leon, Ana M/0000-0002-7918-5049; Gomez, Pedro/0000-0002-4185-5238; Lagares, Alfonso/0000-0003-3996-0554; Munarriz, Pablo M/0000-0002-9888-7046; Martinez-Perez, Rafael/0000-0002-2896-2346; Cepeda, Santiago/0000-0003-1667-8548	Mutua Madrilena Foundation (Spain) [2010-007]	This study was funded by grant no. 2010-007 from the Mutua Madrilena Foundation (Spain) to Pedro A. Gomez.	Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chang EF, 2007, NEUROSURGERY, V61, P222, DOI [10.1227/01.NEU.0000197101.68538.E6, 10.1227/01.neu.0000279217.45881.69]; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; Gean A, 1994, IMAGING HEAD TRAUMA; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gomez PA, 1999, NEUROCIRUGIA, V10, P297; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Iaccarino C, 2014, J NEUROSURG, V120, P908, DOI 10.3171/2013.12.JNS131090; Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Marion DW, 2006, NEUROSURGERY, V58, P655; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Singounas E G, 1992, J Neurosurg Sci, V36, P201; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Study Group on Head Injury of the Italian Society for Neurosurgery, 1996, J NEUROSURG SCI, V40, P11; Sturiale CL, 2012, J NEUROTRAUM, V29, P2723, DOI 10.1089/neu.2012.2556; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Wu JJ, 1999, J TRAUMA, V47, P39, DOI 10.1097/00005373-199907000-00009; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109	44	30	35	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2015	32	16					1246	1253		10.1089/neu.2014.3808			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CU9RU	WOS:000363883400009	25752340				2021-06-18	
J	Datto, JP; Bastidas, JC; Miller, NL; Shah, AK; Arheart, KL; Marcillo, AE; Dietrich, WD; Pearse, DD				Datto, Jeffrey P.; Bastidas, Johana C.; Miller, Nicole L.; Shah, Anna K.; Arheart, Kristopher L.; Marcillo, Alexander E.; Dietrich, W. Dalton; Pearse, Damien D.			Female Rats Demonstrate Improved Locomotor Recovery and Greater Preservation of White and Gray Matter after Traumatic Spinal Cord Injury Compared to Males	JOURNAL OF NEUROTRAUMA			English	Article						BBB; CatWalk; gender; GridWalk; spinal cord injury	OLFACTORY ENSHEATHING GLIA; GENDER-RELATED DIFFERENCES; FUNCTIONAL RECOVERY; SCHWANN-CELLS; BRAIN-INJURY; PROGESTERONE NEUROPROTECTION; MEDIATED NEUROPROTECTION; NERVOUS-SYSTEM; ESTROGEN; TESTOSTERONE	The possibility of a gender-related difference in recovery after spinal cord injury (SCI) remains a controversial subject. Current empirical animal research lacks sizable test groups to definitively determine whether significant differences exist. Evaluating locomotor recovery variances between sexes following a precise, clinically relevant spinal cord contusion model can provide valuable insight into a possible gender-related advantage in outcome post-SCI. In the current study, we hypothesized that by employing larger sample sizes in a reproducible contusive SCI paradigm, subtle distinctions in locomotor recovery between sexes, if they exist, would be elucidated through a broad range of behavioral tests. During 13 weeks of functional assessment after a thoracic (T8) contusive SCI in rat, significant differences owing to gender existed for the Basso, Beattie, and Bresnahan score and CatWalk hindlimb swing, support four, and single stance analyses. Significant differences in locomotor performance were noticeable as early as 4 weeks post-SCI. Stereological tissue-volume analysis determined that females, more so than males, also exhibited greater volumes of preserved gray and white matter within the injured cord segment as well as more spared ventral white matter area at the center of the lesion. The stereological tissue analysis differences favoring females directly correlated with the female rats' greater functional improvement observed at endpoint.	[Datto, Jeffrey P.; Bastidas, Johana C.; Miller, Nicole L.; Shah, Anna K.; Marcillo, Alexander E.; Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33101 USA; [Arheart, Kristopher L.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33101 USA; [Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33101 USA; [Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Neurosci Program, Miami, FL 33101 USA; [Pearse, Damien D.] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33101 USA	Pearse, DD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Lois Pope Life Ctr, Locator Code R-48,POB 016960, Miami, FL 33101 USA.	DPearse@miamiproject.med.miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X	Department of Defense Congressionally Directed Medical Research Programs SCIRP [W81XWH-10-1-0793]; Miami Project to Cure Paralysis; Buoniconti Fund	The authors thank Denise Koivisto, Eva Juarez, Alex Basagoitia, Ronald Zambrano, Miguel Martinez, and Ramon German for help with animal care; Paulo Diaz for surgical assistance; Carlos Concepcion, Layne Keathly, Isabel Lee, Jingwen Yang, and Vivien Chen for critical review and proofreading of the manuscript; Dr. Richard Morris for guidance and help with statistical analysis; Lindsay Connor for data analysis; and Leah Colucci and Hanna Mathers for data organization, quality assurance review of the CatWalk data, and proofreading of the manuscript. This research was supported by The Department of Defense Congressionally Directed Medical Research Programs SCIRP (Award No. W81XWH-10-1-0793), The Miami Project to Cure Paralysis, and The Buoniconti Fund.	Al-Habib AF, 2011, J NEUROTRAUM, V28, P1431, DOI 10.1089/neu.2009.1157; Antunes F, 2001, FREE RADICAL BIO MED, V30, P1008, DOI 10.1016/S0891-5849(01)00493-2; Bagetta G, 2004, NEUROSCI LETT, V368, P87, DOI 10.1016/j.neulet.2004.06.062; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Battistuzzo CR, 2012, J NEUROTRAUM, V29, P1600, DOI 10.1089/neu.2011.2199; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Belviranli M, 2012, NEUROSCIENCE, V227, P1, DOI 10.1016/j.neuroscience.2012.09.036; Benowitz LI, 2011, CURR OPIN NEUROL, V24, P577, DOI 10.1097/WCO.0b013e32834c208d; Bialek M, 2004, POL J PHARMACOL, V56, P509; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Byers JS, 2012, J COMP NEUROL, V520, P2683, DOI 10.1002/cne.23066; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; Everitt BS, 2002, CAMBRIDGE DICT STAT; Fargo KN, 2009, DEV NEUROBIOL, V69, P825, DOI 10.1002/dneu.20743; Farooque M, 2006, SPINAL CORD, V44, P182, DOI 10.1038/sj.sc.3101816; Fee DB, 2007, BRAIN RES, V1137, P146, DOI 10.1016/j.brainres.2006.12.024; Furlan JC, 2005, J NEUROTRAUM, V22, P368, DOI 10.1089/neu.2005.22.368; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Greenwald BD, 2001, ARCH PHYS MED REHAB, V82, P1181, DOI 10.1053/apmr.2001.24891; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; Hammond J, 2001, J NEUROCHEM, V77, P1319, DOI 10.1046/j.1471-4159.2001.00345.x; Hauben E, 2002, EUR J NEUROSCI, V16, P1731, DOI 10.1046/j.1460-9568.2002.02241.x; Jung SY, 2014, EXP THER MED, V7, P587, DOI 10.3892/etm.2013.1451; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Kay E, 2010, PM&R, V2, P504, DOI 10.1016/j.pmrj.2010.03.010; Kwon BK, 2011, J NEUROTRAUM, V28, P1545, DOI 10.1089/neu.2009.1149; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Little CM, 2009, J COMP NEUROL, V512, P359, DOI 10.1002/cne.21885; McAllister C, 2010, J NEUROSCI, V30, P7326, DOI 10.1523/JNEUROSCI.1180-10.2010; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Morinaga A, 2011, EXP NEUROL, V228, P298, DOI 10.1016/j.expneurol.2011.01.011; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Pearse D, 2010, CURR OPIN INVEST DR, V11, P1207; Pearse DD, 2007, GLIA, V55, P976, DOI 10.1002/glia.20490; Pearse DD, 2005, J NEUROTRAUM, V22, P680, DOI 10.1089/neu.2005.22.680; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; Perreau VM, 2004, GENE EXPRESSION, V12, P107, DOI 10.3727/000000005783992115; Petrovska S, 2012, J PHYSIOL BIOCHEM, V68, P455, DOI 10.1007/s13105-012-0159-x; Rabchevsky AG, 2011, PHARMACOL THERAPEUT, V132, P15, DOI 10.1016/j.pharmthera.2011.05.001; Andrade MSR, 2010, BRAIN RES, V1346, P266, DOI 10.1016/j.brainres.2010.05.070; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Samantaray S., 2010, OPEN DRUG DISCOV J, V2, P174; Samantaray S, 2011, NEUROCHEM RES, V36, P1809, DOI 10.1007/s11064-011-0498-y; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P86, DOI 10.1111/j.1749-6632.2009.05360.x; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P90, DOI 10.1111/j.1749-6632.2009.05357.x; Schaal SM, 2007, CELL TRANSPLANT, V16, P207, DOI 10.3727/000000007783464768; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Singh A, 2011, NEUROREHAB NEURAL RE, V25, P24, DOI 10.1177/1545968310378510; Singh M, 2006, EXP BIOL MED, V231, P514; Sipski ML, 2004, ARCH PHYS MED REHAB, V85, P1826, DOI 10.1016/j.apmr.2004.04.031; Siriphorn A, 2010, J NEUROCHEM, V115, P864, DOI 10.1111/j.1471-4159.2010.06770.x; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sribnick EA, 2010, J NEUROSCI RES, V88, P1738, DOI 10.1002/jnr.22337; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Swartz KR, 2007, J NEUROTRAUM, V24, P473, DOI 10.1089/neu.2006.0167; Tajiri N, 2010, BRAIN RES, V1310, P200, DOI 10.1016/j.brainres.2009.10.075; Takami T, 2002, J NEUROSCI, V22, P6670; Tehranipour M, 2010, J MOTOR BEHAV, V42, P151, DOI 10.1080/00222891003697921; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Ung RV, 2007, SPINAL CORD, V45, P367, DOI 10.1038/sj.sc.3101970; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; Vickers A J, 2001, BMC Med Res Methodol, V1, P6, DOI 10.1186/1471-2288-1-6; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057	76	30	30	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 1	2015	32	15					1146	1157		10.1089/neu.2014.3702			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0JK	WOS:000363936800002	25715192	Green Published			2021-06-18	
J	Hammond, FM; Barrett, RS; Shea, T; Seel, RT; McAlister, TW; Kaelin, D; Ryser, DK; Corrigan, JD; Cullen, N; Horn, SD				Hammond, Flora M.; Barrett, Ryan S.; Shea, Timothy; Seel, Ronald T.; McAlister, Thomas W.; Kaelin, Darryl; Ryser, David K.; Corrigan, John D.; Cullen, Nora; Horn, Susan D.			Psychotropic Medication Use During Inpatient Rehabilitation for Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Amantadine; Antidepressive agents; Antipsychotic agents; Brain injuries; Central nervous system stimulants; Drug therapy; Medication therapy management; Patient care; Physician's practice patterns; Polypharmacy; Rehabilitation	PLACEBO-CONTROLLED TRIAL; PROPENSITY ADJUSTMENT; METHYLPHENIDATE; AMANTADINE; HALOPERIDOL; AGITATION; RECOVERY; SEQUELAE	Objective: To describe psychotropic medication administration patterns during inpatient rehabilitation for traumatic brain injury (TBI) and their relation to patient preinjury and injury characteristics. Design: Prospective observational cohort. Setting: Multiple acute inpatient rehabilitation units or hospitals. Participants: Individuals with TBI (N=2130; complicated mild, moderate, or severe) admitted for inpatient rehabilitation. Interventions: Not applicable. Main Outcome Measures: Not applicable. Results: Most frequently administered were narcotic analgesics (72% of sample), followed by antidepressants (67%), anticonvulsants (47%), anxiolytics (33%), hypnotics (30%), stimulants (28%), antipsychotics (25%), antiparkinson agents (25%), and miscellaneous psychotropics (18%). The psychotropic agents studied were administered to 95% of the sample, with 8.5% receiving only 1 and 31.8% receiving >= 6. Degree of psychotropic medication administration varied widely between sites. Univariate analyses indicated younger patients were more likely to receive anxiolytics, antidepressants, antiparkinson agents, stimulants, antipsychotics, and narcotic analgesics, whereas those older were more likely to receive anticonvulsants and miscellaneous psychotropics. Men were more likely to receive antipsychotics. All medication classes were less likely administered to Asians and more likely administered to those with more severe functional impairment. Use of anticonvulsants was associated with having seizures at some point during acute care or rehabilitation stays. Narcotic analgesics were more likely for those with history of drug abuse, history of anxiety and depression (premorbid or during acute care), and severe pain during rehabilitation. Psychotropic medication administration increased rather than decreased during the course of inpatient rehabilitation in each of the medication categories except for narcotics. This observation was also true for medication administration within admission functional levels (defined by cognitive FIM scores), except for those with higher admission FIM cognitive scores. Conclusions: Many psychotropic medications are used during inpatient rehabilitation. In general, lower admission FIM cognitive score groups were administered more of the medications under investigation compared with those with higher cognitive function at admission. Considerable site variation existed regarding medications administered. The current investigation provides baseline data for future studies of effectiveness. (C) 2015 by the American Congress of Rehabilitation Medicine	[Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.; McAlister, Thomas W.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Barrett, Ryan S.; Horn, Susan D.] Inst Clin Outcomes Res, Salt Lake City, UT USA; [Shea, Timothy; Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Seel, Ronald T.] Shepherd Ctr, Crawford Res Inst, Atlanta, GA USA; [Kaelin, Darryl] Univ Louisville, Sch Med, Louisville, KY 40292 USA; [Kaelin, Darryl] Frazier Rehabil Inst, Louisville, KY USA; [Ryser, David K.] Intermt Med Ctr, Salt Lake City, UT USA; [Cullen, Nora] Toronto Rehabil Inst, Toronto, ON, Canada	Hammond, FM (corresponding author), 4141 Shore Dr, Indianapolis, IN 46254 USA.	flora.hammond@rhin.com		Cullen, Nora/0000-0001-6359-9418	National Institutes of Health, National Center for Medical Rehabilitation ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01HD050439-01]; National Institute on Disability and Rehabilitation Research [H133A080023]; Ontario Neurotrauma Foundation [2007-ABI-ISIS-525]; American Congress of Rehabilitation Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439] Funding Source: NIH RePORTER	Supported by the National Institutes of Health, National Center for Medical Rehabilitation Research (grant no. 1R01HD050439-01); National Institute on Disability and Rehabilitation Research (grant no. H133A080023); and Ontario Neurotrauma Foundation (grant no. 2007-ABI-ISIS-525).; Publication of this article was supported by the American Congress of Rehabilitation Medicine.	Balon R, 2006, AM J PSYCHIAT, V163, P1504, DOI 10.1176/appi.ajp.163.9.1504; Bogner J, 2015, ARCH PHYS MED REHAB, V96, pS274, DOI 10.1016/j.apmr.2015.04.020; Burnett DM, 1999, NEUROREHABILITATION, V13, P165; Corrigan JD, 2015, ARCH PHYS MED REHAB, V96, pS209, DOI 10.1016/j.apmr.2015.03.026; EDWARDS JG, 2004, SEMINARS CLIN PSYCHO, P573; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P177, DOI 10.1097/00001199-200303000-00008; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Forchheimer MB, 2011, ARCH PHYS MED REHAB, V92, P419, DOI 10.1016/j.apmr.2010.08.029; Francisco GE, 2007, BRAIN INJURY, V21, P1007, DOI 10.1080/02699050701559558; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Heinemann AW, 1994, TOP STROKE REHABIL, V1, P1; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Horn SD, 2015, ARCH PHYS MED REHAB, V96, pS178, DOI 10.1016/j.apmr.2014.09.042; Horn SD, 2015, ARCH PHYS MED REHAB, V96, pS304, DOI 10.1016/j.apmr.2014.11.030; Leon AC, 2007, STAT MED, V26, P110, DOI 10.1002/sim.2458; Leon AC, 2007, STAT MED, V26, P2650, DOI 10.1002/sim.2732; Madeira G, 2007, LARYNGOL OTOL RHINOL, V128, P145; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Murphy MP, 2014, REHABIL NURS, V39, P113, DOI 10.1002/rnj.89; Mysiw WJ, 2006, BRAIN INJURY, V20, P905, DOI 10.1080/02699050600743972; Ontario Neurotrauma Foundation, EV BAS REV MOD SEV A; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Schneider WN, 1999, BRAIN INJURY, V13, P863; Seel RT, 2015, ARCH PHYS MED REHAB, V96, pS197, DOI 10.1016/j.apmr.2015.02.034; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Talsky A, 2010, BCMJ, V53, P26, DOI DOI 10.1089/SCD.2015.0160; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2010, EUR J PHYS REHAB MED, V46, P557; Yasseen B, 2008, BRAIN INJURY, V22, P752, DOI 10.1080/02699050802320132; Zafonte RD, 2000, J HEAD TRAUMA REHAB, V15, P1179, DOI 10.1097/00001199-200010000-00014	34	30	30	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2015	96	8		3			S256	S273		10.1016/j.apmr.2015.01.025			18	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CO3CV	WOS:000359035100008	26212402	Green Accepted			2021-06-18	
J	Horn, SD; Corrigan, JD; Bogner, J; Hammond, FM; Seel, RT; Smout, RJ; Barrett, RS; Dijkers, MP; Whiteneck, GG				Horn, Susan D.; Corrigan, John D.; Bogner, Jennifer; Hammond, Flora M.; Seel, Ronald T.; Smout, Randall J.; Barrett, Ryan S.; Dijkers, Marcel. P.; Whiteneck, Gale G.			Traumatic Brain Injury-Practice Based Evidence Study: Design and Patients, Centers, Treatments, and Outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference of the American-Congress-of-Rehabilitation-Medicine	OCT 10, 2014	Toronto, CANADA	Amer Congress Rehabil Med		Brain injuries; Comparative effectiveness research; Rehabilitation	SYSTEMS NATIONAL DATABASE; INPATIENT REHABILITATION; REPRESENTATIVENESS; SEVERITY; SCIREHAB; AGE	Objectives: To describe study design, patients, centers, treatments, and outcomes of a traumatic brain injury (TBI) practice-based evidence (PBE) study and to evaluate the generalizability of the findings to the U.S. TBI inpatient rehabilitation population. Design: Prospective, longitudinal, observational study. Setting: Ten inpatient rehabilitation centers. Participants: Patients (N=2130) enrolled between October 2008 and September 2011 and admitted for inpatient rehabilitation after an index TBI injury. Interventions: Not applicable. Main Outcome Measures: Return to acute care during rehabilitation, rehabilitation length of stay, FIM at discharge, residence at discharge, and 9 months postdischarge rehospitalization, FIM, participation, and subjective well-being. Results: The level of admission FIM cognitive score was found to create relatively homogeneous subgroups for the subsequent analysis of best treatment combinations. There were significant differences in patient and injury characteristics, treatments, rehabilitation course, and outcomes by admission FIM cognitive subgroups. TBI-PBE study patients were overall similar to U.S. national TBI inpatient rehabilitation populations. Conclusions: This TBI-PBE study succeeded in capturing naturally occurring variation in patients and treatments, offering opportunities to study best treatments for specific patient impairments. Subsequent articles in this issue report differences between patients and treatments and associations with outcomes in greater detail. (C) 2015 by the American Congress of Rehabilitation Medicine	[Horn, Susan D.; Smout, Randall J.; Barrett, Ryan S.] Int Sever Informat Syst Inc, Inst Clin Outcomes Res, Salt Lake City, UT USA; [Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Seel, Ronald T.] Shepherd Ctr, Crawford Res Inst, Atlanta, GA USA; [Dijkers, Marcel. P.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Whiteneck, Gale G.] Craig Hosp, Res Dept, Englewood, CO USA	Horn, SD (corresponding author), Univ Utah, Sch Med, Dept Populat Hlth Sci, Hlth Syst Innovat & Res Program, Williams Bldg,Rm 1N461,295 Chipeta Way, Salt Lake City, UT 84108 USA.	susan.horn@hsc.utah.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439-01, R01 HD050439] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439] Funding Source: NIH RePORTER		AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Beaulieu CL, 2015, ARCH PHYS MED REHAB, V96, pS222, DOI 10.1016/j.apmr.2014.10.028; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; Chesnut R, 1999, AHCPR PUBLICATION; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; Dijkers M, 2013, NEUROREHABILITATION, V32, P233, DOI 10.3233/NRE-130841; Dijkers MP, 2013, ARCH PHYS MED REHAB, V94, pS61, DOI 10.1016/j.apmr.2012.11.048; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; High WM., 2004, REHABILITATION TRAUM, P14; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2002, J PEDIATR-US, V141, P496, DOI 10.1067/mpd.2002.126925; Horn SD, 2013, ARCH PHYS MED REHAB, V94, pS75, DOI 10.1016/j.apmr.2012.10.036; Horn SD, 2012, ARCH PHYS MED REHAB, V93, pS127, DOI 10.1016/j.apmr.2011.10.031; Krumholz HM, 2011, JAMA-J AM MED ASSOC, V306, P754, DOI 10.1001/jama.2011.1170; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Seel RT, 2015, ARCH PHYS MED REHAB, V96, pS197, DOI 10.1016/j.apmr.2015.02.034; Whiteneck GG, 2013, ARCH PHYS MED REHAB, V94, pS67, DOI 10.1016/j.apmr.2012.12.022; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007	28	30	30	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2015	96	8		3			S178	S196		10.1016/j.apmr.2014.09.042			19	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CO3CV	WOS:000359035100002	26212396	Bronze, Green Accepted			2021-06-18	
J	Kobeissy, FH; Liu, MC; Yang, ZH; Zhang, ZQ; Zheng, WR; Glushakova, O; Mondello, S; Anagli, J; Hayes, RL; Wang, KKW				Kobeissy, Firas H.; Liu, Ming Cheng; Yang, Zhihui; Zhang, Zhiqun; Zheng, Wenrong; Glushakova, Olena; Mondello, Stefania; Anagli, John; Hayes, Ronald L.; Wang, Kevin K. W.			Degradation of beta II-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions	MOLECULAR NEUROBIOLOGY			English	Article						Cell death; Neurodegeneration; Protease; TBI; beta II-Spectrin apoptotic; Calpain-2; Caspase-3	CULTURED HIPPOCAMPAL SLICES; CALCIUM-DEPENDENT PROTEASE; DIFFUSE AXONAL INJURY; ALPHA-II; CEREBROSPINAL-FLUID; BREAKDOWN PRODUCTS; NEURONAL APOPTOSIS; MEMBRANE SKELETON; PROTEOLYSIS; ANKYRIN	A major consequence of traumatic brain injury (TBI) is the rapid proteolytic degradation of structural cytoskeletal proteins. This process is largely reflected by the interruption of axonal transport as a result of extensive axonal injury leading to neuronal cell injury. Previous work from our group has described the extensive degradation of the axonally enriched cytoskeletal alpha II-spectrin protein which results in molecular signature breakdown products (BDPs) indicative of injury mechanisms and to specific protease activation both in vitro and in vivo. In the current study, we investigated the integrity of beta II-spectrin protein and its proteolytic profile both in primary rat cerebrocortical cell culture under apoptotic, necrotic, and excitotoxic challenge and extended to in vivo rat model of experimental TBI (controlled cortical impact model). Interestingly, our results revealed that the intact 260-kDa beta II-spectrin is degraded into major fragments (beta II-spectrin breakdown products (beta sBDPs)) of 110, 108, 85, and 80 kDa in rat brain (hippocampus and cortex) 48 h post-injury. These beta sBDP profiles were further characterized and compared to an in vitro beta II-spectrin fragmentation pattern of naive rat cortex lysate digested by calpain-2 and caspase-3. Results revealed that beta II-spectrin was degraded into major fragments of 110/85 kDa by calpain-2 activation and 108/80 kDa by caspase-3 activation. These data strongly support the hypothesis that in vivo activation of multiple protease system induces structural protein proteolysis involving beta II-spectrin proteolysis via a specific calpain and/or caspase-mediated pathway resulting in a signature, protease-specific beta sBDPs that are dependent upon the type of neural injury mechanism. This work extends on previous published work that discusses the interplay spectrin family (alpha II-spectrin and beta II-spectrin) and their susceptibility to protease proteolysis and their implication to neuronal cell death mechanisms.	[Kobeissy, Firas H.; Liu, Ming Cheng; Yang, Zhihui; Zhang, Zhiqun; Zheng, Wenrong; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA; [Glushakova, Olena; Anagli, John; Hayes, Ronald L.] Banyan Biomarkers Inc, Banyan Lab, Alachua, FL 32615 USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, I-98125 Messina, Italy; [Kobeissy, Firas H.] Amer Univ Beirut, Dept Biochem & Mol Genet, Fac Med, Beirut, Lebanon	Kobeissy, FH (corresponding author), Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA.	firasko@gmail.com; kwang@ufl.edu	Mondello, Stefania/A-1813-2012; Kobeissy, Firas/E-7042-2017	Mondello, Stefania/0000-0002-8587-3614; Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01, R01 NS052831-01]; Department of DefenseUnited States Department of Defense [DAMD17-03-1-0066]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052831, R01NS049175] Funding Source: NIH RePORTER	We would like to thank Dr. Hussam Jourdi for his critical and thorough discussion. Special thanks to Mr. Danny Johnson for his technical support in animal surgeries and tissue collection. This work was supported by the National Institutes of Health grants R01 NS049175-01 and R01 NS052831-01 and the Department of Defense grant DAMD17-03-1-0066. KKW and RLH hold equity in Banyan Biomarkers, Inc., a company commercializing technology of detecting brain injury biomarkers. RLH and OG are employees at Banyan Biomarkers Inc.	AZUMA M, 1991, CURR EYE RES, V10, P657, DOI 10.3109/02713689109013857; BACKMAN L, 1991, J BIOL CHEM, V266, P3835; Baskin-Bey ES, 2007, AM J TRANSPLANT, V7, P218, DOI 10.1111/j.1600-6143.2006.01595.x; Beneke R, 2005, EUR J APPL PHYSIOL, V95, P307, DOI 10.1007/s00421-005-0010-y; BENNETT M, 1995, IRISH MED J, V88, P59; Bennett V, 2001, PHYSIOL REV, V81, P1353; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cb.09.110193.000331; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Buki A, 2000, J NEUROSCI, V20, P2825; Chen ZM, 2005, NEUROSCI LETT, V376, P166, DOI 10.1016/j.neulet.2004.11.051; Chiesa R, 1998, J NEUROCHEM, V70, P1474; Croall DE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-218; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Czogalla A, 2007, MOL MEMBR BIOL, V24, P215, DOI 10.1080/09687860601102427; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; De Matteis MA, 2000, J CELL SCI, V113, P2331; DELCERRO S, 1994, NEUROSCI LETT, V167, P149, DOI 10.1016/0304-3940(94)91049-9; DISTASI AMM, 1991, NEURON, V6, P445, DOI 10.1016/0896-6273(91)90252-U; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Garbe DS, 2007, DEVELOPMENT, V134, P273, DOI 10.1242/dev.02653; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Glantz SB, 2007, BIOCHEMISTRY-US, V46, P502, DOI 10.1021/bi061504y; GOODMAN SR, 1980, J BIOL CHEM, V255, P8082; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; Hayes NVL, 2000, J CELL SCI, V113, P2023; Hoglen NC, 2007, LIVER TRANSPLANT, V13, P361, DOI 10.1002/lt.21016; HU RJ, 1991, J BIOL CHEM, V266, P18200; Huh GY, 2001, NEUROSCI LETT, V316, P41, DOI 10.1016/S0304-3940(01)02371-0; IVY G, 1988, BRAIN RES, V459, P233, DOI 10.1016/0006-8993(88)90639-7; Jourdi H, 2005, NEUROCHEM INT, V46, P31, DOI 10.1016/j.neuint.2004.07.002; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kizhatil K, 2009, EXP EYE RES, V88, P55, DOI 10.1016/j.exer.2008.09.022; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kondo K, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-147; Koumura A, 2008, NEUROSCIENCE, V157, P309, DOI 10.1016/j.neuroscience.2008.09.007; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu MC, 2010, ASN NEURO, V3; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lofvenberg L, 1999, FEBS LETT, V443, P89, DOI 10.1016/S0014-5793(98)01697-4; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Nath R, 2000, NEUROCHEM INT, V36, P119, DOI 10.1016/S0197-0186(99)00112-6; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pockros PJ, 2007, HEPATOLOGY, V46, P324, DOI 10.1002/hep.21664; Poordad F Fred, 2004, Curr Opin Investig Drugs, V5, P1198; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rolius R, 2010, CELL MOL BIOL LETT, V15, P395, DOI 10.2478/s11658-010-0015-3; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SEUBERT P, 1989, NEUROSCIENCE, V31, P195, DOI 10.1016/0306-4522(89)90041-9; Shirasaki Y, 2005, BIOORGAN MED CHEM, V13, P4473, DOI 10.1016/j.bmc.2005.04.059; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Stankewich MC, 2011, J CELL SCI, V124, P3956, DOI 10.1242/jcs.080374; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Ursitti JA, 2001, DEV BRAIN RES, V129, P81, DOI 10.1016/S0165-3806(01)00160-2; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Zhang CS, 2013, J CELL BIOL, V203, P437, DOI 10.1083/jcb.201308116; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z	86	30	30	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	AUG	2015	52	1					696	709		10.1007/s12035-014-8898-z			14	Neurosciences	Neurosciences & Neurology	CN3QO	WOS:000358341600060	25270371	Green Accepted			2021-06-18	
J	Oeur, RA; Karton, C; Post, A; Rousseau, P; Hoshizaki, TB; Marshall, S; Brien, SE; Smith, A; Cusimano, MD; Gilchrist, MD				Oeur, R. Anna; Karton, Clara; Post, Andrew; Rousseau, Philippe; Hoshizaki, T. Blaine; Marshall, Shawn; Brien, Susan E.; Smith, Aynsley; Cusimano, Michael D.; Gilchrist, Michael D.			A comparison of head dynamic response and brain tissue stress and strain using accident reconstructions for concussion, concussion with persistent postconcussive symptoms, and subdural hematoma	JOURNAL OF NEUROSURGERY			English	Article						accident reconstruction; traumatic brain injury; concussion; finite element modeling; Hybrid III headform; subdural hematoma; persistent postconcussive symptoms	CHRONIC TRAUMATIC ENCEPHALOPATHY; FINITE-ELEMENT-ANALYSIS; MULTIBODY DYNAMICS; INJURY CRITERIA; FE MODEL; IMPACT; FALLS; BIOMECHANICS; PREDICTORS	OBJECT Concussions typically resolve within several days, but in a few cases the symptoms last for a month or longer and are termed persistent postconcussive symptoms (PPCS). These persisting symptoms may also be associated with more serious brain trauma similar to subdural hematoma (SDH). The objective of this study was to investigate the head dynamic and brain tissue responses of injury reconstructions resulting in concussion, PPCS, and SDH. METHODS Reconstruction cases were obtained from sports medicine clinics and hospitals. All subjects received a direct blow to the head resulting in symptoms. Those symptoms that resolved in 9 days or fewer were defined as concussions (n = 3). Those with symptoms lasting longer than 18 months were defined as PPCS (n = 3), and 3 patients presented with SDHs (n = 3). A Hybrid III headform was used in reconstruction to obtain linear and rotational accelerations of the head. These dynamic response data were then input into the University College Dublin Brain Trauma Model to calculate maximum principal strain and von Mises stress. A Kruskal-Wallis test followed by Tukey post hoc tests were used to compare head dynamic and brain tissue responses between injury groups. Statistical significance was set at p < 0.05. RESULTS A significant difference was identified for peak resultant linear and rotational acceleration between injury groups. Post hoc analyses revealed the SDH group had higher linear and rotational acceleration responses (316 g and 23,181 rad/sec(2), respectively) than the concussion group (149 g and 8111 rad/sec(2), respectively; p < 0.05). No significant differences were found between groups for either brain tissue measures of maximum principal strain or von Mises stress. CONCLUSIONS The reconstruction of accidents resulting in a concussion with transient symptoms (low severity) and SDHs revealed a positive relationship between an increase in head dynamic response and the risk for more serious brain injury. This type of relationship was not found for brain tissue stress and strain results derived by finite element analysis. Future research should be undertaken using a larger sample size to confirm these initial findings. Understanding the relationship between the head dynamic and brain tissue response and the nature of the injury provides important information for developing strategies for injury prevention.	[Oeur, R. Anna; Karton, Clara; Post, Andrew; Rousseau, Philippe; Hoshizaki, T. Blaine] Univ Ottawa, Sch Human Kinet, Ottawa, ON K1S 5S9, Canada; [Marshall, Shawn] Ottawa Hosp, Res Inst, Clin Epidemiol, Ottawa, ON, Canada; [Brien, Susan E.] Ctr Sante & Serv Sociaux CSSS Gatineau Hull Site, Dept Neurosurg, Quebec City, PQ, Canada; [Smith, Aynsley] Mayo Clin, Dept Orthoped & Phys Med & Rehabil, Rochester, MN USA; [Cusimano, Michael D.] St Michaels Hosp, Injury Prevent Res Off, Toronto, ON, Canada; [Cusimano, Michael D.] St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland	Oeur, RA (corresponding author), Univ Ottawa, Neurotrauma Impact Sci Lab, 200 Lees Ave,A-106, Ottawa, ON K1S 5S9, Canada.	anna.oeur@uottawa.ca	Cusimano, Michael/X-4059-2019; Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946] Funding Source: Medline		Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bohannon RW, 1997, AGE AGEING, V26, P15, DOI 10.1093/ageing/26.1.15; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2009, INT J CRASHWORTHINES, V14, P503, DOI 10.1080/13588260902826554; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gennarelli T.A., 1971, P 15 STAPP CAR CRASH, V39, P797; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gilchrist MD, 2008, FORENSIC SCI INT, V177, P52, DOI 10.1016/j.forsciint.2007.10.010; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hodgson VR, 1983, P 27 STAPP CAR CRASH, P225; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Karton C, 2013, 1 INT C HELM PERF DE, pA3; Kendall M, 2012, 2012 INT RES COUNC B; King AI, IS HEAD INJURY CAUSE; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Lamy Michael, 2011, Ann Adv Automot Med, V55, P125; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Nahum AM, 1977, 21ST P STAPP CAR CRA, P303; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A, 2013, THESIS U OTTAWA CANA; Post A, 2013, COMPUT METHOD BIOMEC, V16, P511, DOI 10.1080/10255842.2011.627559; Post A, 2012, P I MECH ENG P-J SPO, V226, P290, DOI 10.1177/1754337112436629; Post A, 2012, J BIOMECH, V45, P679, DOI 10.1016/j.jbiomech.2011.12.005; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Tator CH, 2012, J CLIN SPORT PSYCHOL, V6, P293, DOI 10.1123/jcsp.6.3.293; Trosseille X, DEV FEM HUMAN HEAD A; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; Ward C, FINITE ELEMENT MODEL; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	30	30	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2015	123	2					415	422		10.3171/2014.10.JNS14440			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CS6OV	WOS:000362200800019	25909574	Bronze			2021-06-18	
J	Yoo, C; Yong, MH; Chung, J; Yang, Y				Yoo, Chanuk; Yong, Mi-hyun; Chung, Jaeyeop; Yang, Yeongae			Effect of computerized cognitive rehabilitation program on cognitive function and activities of living in stroke patients	JOURNAL OF PHYSICAL THERAPY SCIENCE			English	Article						Computerized cognitive rehabilitation; Cognitive function; Activities of daily living	TRAUMATIC BRAIN-INJURY; THERAPY	[Purpose] The objective of this study was to examine the effect of cognitive rehabilitation using a computer on cognitive function and activities of daily living in stroke patients presenting impairment of cognitive function. [Subjects] Forty-six stroke patients were divided into two groups ( a training group and control group) through random assignment. [Methods] The training group received rehabilitation therapy and an additional computerized cognitive rehabilitation program using The RehaCom software 30 minutes/day, 5 times/week for 5 weeks. The control group received only rehabilitation therapy including physical and occupational therapy. A comparative analysis on all subjects was conducted before and after the experiment using a cognitive test and activities of daily living test. [Results] After 5 weeks of therapy, the training group presented statistically significant improvement in cognitive function assessment items of digit span, visual span, visual learning, auditory continuous performance, visual continuous performance, and others compared with the control group but did not present statistically significant improvement in activities of daily living. [Conclusion] It was revealed through this study that computerized cognitive rehabilitation with the RehaCom program results in improvement in cognitive function and can be used as a treatment tool beneficial to stroke patients presenting cognitive impairment.	[Yoo, Chanuk] Hanlyo Univ, Dept Occupat Therapy, Gwangyang Si, South Korea; [Yong, Mi-hyun] Kyungwoon Univ, Coll Hlth, Dept Occupat Therapy, Gumi Si, South Korea; [Chung, Jaeyeop] Kyongbuk Sci Coll, Dept Occupat Therapy, Gimcheon, South Korea; [Yang, Yeongae] Inje Univ, Coll Biomed Sci & Engn, Dept Occupat Therapy, Gimhae, South Korea	Yang, Y (corresponding author), Inje Univ, Coll Biomed Sci & Engn, Dept Occupat Therapy, Gimhae, South Korea.	otyya62@inje.ac.kr					Chen SHA, 1997, BRAIN INJURY, V11, P197; DAM M, 1993, STROKE, V24, P1186, DOI 10.1161/01.STR.24.8.1186; Dickson HG, 1995, SCAND J REHABIL MED, V27, P253; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; Gontkovsky ST, 2002, NEUROREHABILITATION, V17, P195; Gunther VK, 2003, AGING MENT HEALTH, V7, P200, DOI 10.1080/1360786031000101175; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Lee IH, 2012, J PHYS THER SCI, V24, P503, DOI 10.1589/jpts.24.503; Lee YM, 2013, J PHYS THER SCI, V25, P1475, DOI 10.1589/jpts.25.1475; MCALLISTER TW, 1981, COMPR PSYCHIAT, V22, P572, DOI 10.1016/0010-440X(81)90006-7; Palmese CA, 2000, BRAIN INJURY, V14, P535; Patel MD, 2002, J AM GERIATR SOC, V50, P700, DOI 10.1046/j.1532-5415.2002.50165.x; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489	13	30	33	0	7	SOC PHYSICAL THERAPY SCIENCE	TOKYO	C/O PUBLICATION CENTER, 1-24-12 SUGAMO, TOSHIMA-KU, TOKYO, 170-0002, JAPAN	0915-5287	2187-5626		J PHYS THER SCI	J. Phys. Ther. Sci.	AUG	2015	27	8					2487	2489		10.1589/jpts.27.2487			3	Rehabilitation	Rehabilitation	CP6SX	WOS:000360019600018	26355244	Bronze, Green Published			2021-06-18	
J	Mayer, AR; Ling, JM; Allen, EA; Klimaj, SD; Yeo, RA; Hanlon, FM				Mayer, Andrew R.; Ling, Josef M.; Allen, Elena A.; Klimaj, Stefan D.; Yeo, Ronald A.; Hanlon, Faith M.			Static and Dynamic Intrinsic Connectivity following Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						functional; ICA; mild TBI; resting state networks; RSFC	DEFAULT-MODE NETWORK; FUNCTIONAL CONNECTIVITY; CONCUSSED INDIVIDUALS; HEAD MOTION; TIME; MRI; DISRUPTION; RELEVANCE; ATTENTION; VETERANS	Mild traumatic brain injury (mTBI) is the most common neurological disorder and is typically characterized by temporally limited cognitive impairment and emotional symptoms. Previous examinations of intrinsic resting state networks in mTBI have primarily focused on abnormalities in static functional connectivity, and deficits in dynamic functional connectivity have yet to be explored in this population. Resting-state data was collected on 48 semi-acute (mean=14 days post-injury) mTBI patients and 48 matched healthy controls. A high-dimensional independent component analysis (N=100) was utilized to parcellate intrinsic connectivity networks (ICN), with a priori hypotheses focusing on the default-mode network (DMN) and sub-cortical structures. Dynamic connectivity was characterized using a sliding window approach over 126 temporal epochs, with standard deviation serving as the primary outcome measure. Finally, distribution-corrected z-scores (DisCo-Z) were calculated to investigate changes in connectivity in a spatially invariant manner on a per-subject basis. Following appropriate correction for multiple comparisons, no significant group differences were evident on measures of static or dynamic connectivity within a priori ICN. Reduced (HC>mTBI patients) static connectivity was observed in the DMN at uncorrected (p<0.005) thresholds. Finally, a trend (p=0.07) for decreased dynamic connectivity in patients across all ICN was observed during spatially invariant analyses (DisCo-Z). In the semi-acute phase of recovery, mTBI was not reliably associated with abnormalities in static or dynamic functional connectivity within the DMN or sub-cortical structures.	[Mayer, Andrew R.; Ling, Josef M.; Allen, Elena A.; Klimaj, Stefan D.; Hanlon, Faith M.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.; Yeo, Ronald A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall 1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Klimaj, Stefan/AAV-4060-2020		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21-NS064464-01A1, 3R21NS064464-01A1S1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (grant numbers R21-NS064464-01A1, 3R21NS064464-01A1S1 to A.M). Special thanks to Diana South and Cathy Smith for assistance with data collection.	Allen EA, 2014, CEREB CORTEX, V24, P663, DOI 10.1093/cercor/bhs352; Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chang C, 2010, NEUROIMAGE, V50, P81, DOI 10.1016/j.neuroimage.2009.12.011; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Franco AR, 2013, BRAIN CONNECT, V3, P363, DOI 10.1089/brain.2012.0134; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Heffernan ME, 2013, J NEUROTRAUM, V30, P1007, DOI 10.1089/neu.2012.2366; Hellyer PJ, 2014, J NEUROSCI, V34, P451, DOI 10.1523/JNEUROSCI.1853-13.2014; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Hutchison RM, 2013, HUM BRAIN MAPP, V34, P2154, DOI 10.1002/hbm.22058; Hutchison RM, 2012, FRONT NEUROANAT, V6, P1, DOI 10.3389/fnana.2012.00029; Hyder F, 2006, J CEREBR BLOOD F MET, V26, P865, DOI 10.1038/sj.jcbfm.9600263; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kiviniemi V, 2009, HUM BRAIN MAPP, V30, P3865, DOI 10.1002/hbm.20813; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Mangia S, 2009, J CEREBR BLOOD F MET, V29, P441, DOI 10.1038/jcbfm.2008.134; Margulies DS, 2010, MAGN RESON MATER PHY, V23, P289, DOI 10.1007/s10334-010-0228-5; Mayer A. R., 2014, HUM BRAIN MAPP; Mayer AR, 2007, J INT NEUROPSYCH SOC, V13, P839, DOI 10.1017/S1355617707071081; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Oleksiak M, 2012, J REHABIL RES DEV, V49, P995, DOI 10.1682/JRRD.2011.01.0001; Pawela CP, 2010, NEUROIMAGE, V49, P2467, DOI 10.1016/j.neuroimage.2009.09.054; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Sarno S, 2003, BRAIN INJURY, V17, P413, DOI 10.1080/0269905031000070161; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stamatakis EA, 2002, J NUCL MED, V43, P476; Starck T, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00802; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	58	30	32	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2015	32	14					1046	1055		10.1089/neu.2014.3542			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0TB	WOS:000363965000002	25318005	Green Published			2021-06-18	
J	Yang, YH; Khan, Z; Ma, C; Lim, HJ; Callahan, LAS				Yang, Yueh-Hsun; Khan, Zara; Ma, Cheng; Lim, Hyun Ju; Callahan, Laura A. Smith			Optimization of adhesive conditions for neural differentiation of murine embryonic stem cells using hydrogels functionalized with continuous Ile-Lys-Val-Ala-Val concentration gradients	ACTA BIOMATERIALIA			English	Article						Neural differentiation; Embryonic stem cell; Tissue engineering; Gradient hydrogel; Combinatorial methods	MARROW STROMAL CELLS; SPINAL-CORD-INJURY; NEURITE EXTENSION; OSTEOGENIC DIFFERENTIATION; LAMININ PEPTIDE; MATRIX; TRANSPLANTATION; NANOFIBERS; CULTURE; GROWTH	Stem cell therapies, which aim to restore neurological function after central nervous system injury, have shown increased efficacy when a tissue engineering matrix is implanted with cells compared to implantation of the cells alone. However, much work still needs to be done to characterize materials that can be used to facilitate and direct the differentiation of implanted cells. In the current study, polyethylene glycol hydrogels functionalized with continuous Ile-Lys-Val-Ala-Val (IKVAV) concentration gradients were fabricated and utilized to systematically study and optimize the adhesive conditions for neural differentiation of mouse embryonic stem cells in two- and three-dimensional environments. The results suggest that 570 mu M and 60 mu M are the optimal IKVAV concentrations for 2D and 3D neural differentiation, respectively, to maximize mRNA expression of neuron-specific markers and neurite extension while minimizing apoptotic activities in cultured cells compared to those exposed to higher IKVAV concentrations. The combinatorial approach presented in this work demonstrates that hydrogels functionalized with bioactive peptides provide a defined and tunable platform that can be employed to characterize and improve culture conditions for superior survival, maturation and integration of implanted cells, leading to enhanced restoration of neurological function for those receiving stem cell therapies after traumatic brain and spinal cord injuries. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Yang, Yueh-Hsun; Khan, Zara; Ma, Cheng; Lim, Hyun Ju; Callahan, Laura A. Smith] Univ Texas Med Sch Houston, Vivian L Smith Dept Neurosurg, Houston, TX USA; [Yang, Yueh-Hsun; Khan, Zara; Ma, Cheng; Lim, Hyun Ju; Callahan, Laura A. Smith] Univ Texas Brown Fdn Inst Mol Med, Ctr Stem Cell & Regenerat Med, Houston, TX USA; [Callahan, Laura A. Smith] Univ Texas Hlth Sci Ctr Houston, Dept Nanomed & Biomed Engn, Houston, TX 77030 USA; [Callahan, Laura A. Smith] Univ Texas Hlth Sci Ctr Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA	Callahan, LAS (corresponding author), Univ Texas Hlth Sci Ctr Houston, Vivian L Smith Dept Neurosurg, Ctr Stem Cells & Regenerat Med, 1825 Pressler St Suite 630F, Houston, TX 77030 USA.	laura.a.smithcallahan@uth.tmc.edu	Callahan, Laura Smith/R-1424-2017; Yang, Yueh-Hsun/I-9300-2014	Callahan, Laura Smith/0000-0001-9234-1053; Khan, Zara/0000-0002-7624-6379; Yang, Yueh-Hsun/0000-0003-0298-8641	Vivian L. Smith Department of Neurosurgery; William Stamps Farish Fund	The authors gratefully acknowledge research funding from Vivian L. Smith Department of Neurosurgery and William Stamps Farish Fund, which enabled this work.	[Anonymous], 2014, J SPINAL CORD MED, V37, P659; Arimura N, 2005, NEURON, V48, P881, DOI 10.1016/j.neuron.2005.11.007; Barros CS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005108; Callahan LAS, 2013, BIOMATER SCI-UK, V1, P537, DOI 10.1039/c3bm00161j; Callahan LAS, 2013, BIOMATERIALS, V34, P9089, DOI 10.1016/j.biomaterials.2013.08.028; Callahan LAS, 2013, ACTA BIOMATER, V9, P6095, DOI 10.1016/j.actbio.2012.12.028; Chan EP, 2012, SOFT MATTER, V8, P1492, DOI 10.1039/c1sm06514a; Chatterjee K, 2010, BIOMATERIALS, V31, P5051, DOI 10.1016/j.biomaterials.2010.03.024; Cruise GM, 1998, BIOMATERIALS, V19, P1287, DOI 10.1016/S0142-9612(98)00025-8; D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180; Dodla MC, 2006, J BIOMED MATER RES A, V78A, P213, DOI 10.1002/jbm.a.30747; FEDEROFF HJ, 1993, DIABETES, V42, P509, DOI 10.2337/diabetes.42.4.509; Fujimoto Y, 2012, STEM CELLS, V30, P1163, DOI 10.1002/stem.1083; Gallant ND, 2007, ADV MATER, V19, P965, DOI 10.1002/adma.200602221; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gunn JW, 2005, J BIOMED MATER RES A, V72A, P91, DOI 10.1002/jbm.a.30203; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jin KL, 2010, J CEREBR BLOOD F MET, V30, P534, DOI 10.1038/jcbfm.2009.219; Lam J, 2015, ADV HEALTHC MATER, V4, P534, DOI 10.1002/adhm.201400410; Lampe KJ, 2010, J BIOMED MATER RES A, V94A, P1162, DOI 10.1002/jbm.a.32787; Li QQ, 2014, J BIOMED MATER RES A, V102, P1991, DOI 10.1002/jbm.a.34876; Li XW, 2014, STEM CELL TRANSL MED, V3, P662, DOI 10.5966/sctm.2013-0015; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; Lu SX, 2000, MACROMOLECULES, V33, P2509, DOI 10.1021/ma9915024; Lutolf MP, 2003, ADV MATER, V15, P888, DOI 10.1002/adma.200304621; Mahoney MJ, 2006, BIOMATERIALS, V27, P2265, DOI 10.1016/j.biomaterials.2005.11.007; McKinnon DD, 2013, BIOMATER SCI-UK, V1, P460, DOI 10.1039/c3bm00166k; MERRILL EW, 1993, BIOMATERIALS, V14, P1117, DOI 10.1016/0142-9612(93)90154-T; NOMIZU M, 1995, FEBS LETT, V365, P227, DOI 10.1016/0014-5793(95)00475-O; Osanai T, 2010, NEUROSURGERY, V66, P1140, DOI 10.1227/01.NEU.0000369610.76181.CF; Pan LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104335; Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/NMAT2441, 10.1038/nmat2441]; Shi Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Smith LA, 2009, TISSUE ENG PT A, V15, P1855, DOI 10.1089/ten.tea.2008.0227; Smith LA, 2009, BIOMATERIALS, V30, P2516, DOI 10.1016/j.biomaterials.2009.01.009; Sobek J, 2006, COMB CHEM HIGH T SCR, V9, P365, DOI 10.2174/138620706777452429; Sur S, 2014, BIOMATER SCI-UK, V2, P903, DOI 10.1039/c3bm60228a; Sur S, 2012, BIOMATERIALS, V33, P545, DOI 10.1016/j.biomaterials.2011.09.093; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; Thid D, 2008, J BIOMED MATER RES A, V84A, P940, DOI 10.1002/jbm.a.31358; Thid D, 2007, LANGMUIR, V23, P11693, DOI 10.1021/la701159u; Titomanlio L, 2011, STEM CELLS DEV, V20, P865, DOI 10.1089/scd.2010.0302; Tse JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015978; Tsuji O, 2010, P NATL ACAD SCI USA, V107, P12704, DOI 10.1073/pnas.0910106107; Yang YH, 2011, TISSUE ENG PT A, V17, P2025, DOI [10.1089/ten.TEA.2010.0415, 10.1089/ten.tea.2010.0415]; Yang YH, 2012, STEM CELL TRANSL MED, V1, P843, DOI 10.5966/sctm.2012-0083; Yasuda H, 2010, J NEUROSURG, V112, P336, DOI 10.3171/2009.2.JNS08495; Yliperttula M, 2008, EUR J PHARM SCI, V35, P151, DOI 10.1016/j.ejps.2008.04.012; Zustiak SP, 2013, BIOTECHNOL PROGR, V29, P1255, DOI 10.1002/btpr.1761; Zustiak SP, 2010, ACTA BIOMATER, V6, P3404, DOI 10.1016/j.actbio.2010.03.040	51	30	30	0	35	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	JUL 15	2015	21						55	62		10.1016/j.actbio.2015.04.031			8	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CK9FR	WOS:000356546500005	25931018				2021-06-18	
J	Haberg, AK; Olsen, A; Moen, KG; Schirmer-Mikalsen, K; Visser, E; Finnanger, TG; Evensen, KAI; Skandsen, T; Vik, A; Eikenes, L				Haberg, A. K.; Olsen, A.; Moen, K. G.; Schirmer-Mikalsen, K.; Visser, E.; Finnanger, T. G.; Evensen, K. A. I.; Skandsen, T.; Vik, A.; Eikenes, L.			White matter microstructure in chronic moderate-to-severe traumatic brain injury: Impact of acute-phase injury-related variables and associations with outcome measures	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						MRI; head injury; intensive care unit; executive function; BRIEF	DIFFUSE AXONAL INJURY; CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; CORPUS-CALLOSUM; WALLERIAN DEGENERATION; INTRACRANIAL-PRESSURE; COGNITIVE IMPAIRMENT; TENSOR TRACTOGRAPHY; VOXELWISE ANALYSIS; LONGITUDINAL MRI	This study examines how injury mechanisms and early neuroimaging and clinical measures impact white matter (WM) fractional anisotropy (FA), mean diffusivity (MD), and tract volumes in the chronic phase of traumatic brain injury (TBI) and how WM integrity in the chronic phase is associated with different outcome measures obtained at the same time. Diffusion tensor imaging (DTI) at 3 T was acquired more than 1 year after TBI in 49 moderate-to-severe-TBI survivors and 50 matched controls. DTI data were analyzed with tract-based spatial statistics and automated tractography. Moderate-to-severe TBI led to widespread FA decreases, MD increases, and tract volume reductions. In severe TBI and in acceleration/deceleration injuries, a specific FA loss was detected. A particular loss of FA was also present in the thalamus and the brainstem in all grades of diffuse axonal injury. Acute-phase Glasgow Coma Scale scores, number of microhemorrhages on T2*, lesion volume on fluid-attenuated inversion recovery, and duration of posttraumatic amnesia were associated with more widespread FA loss and MD increases in chronic TBI. Episodes of cerebral perfusion pressure <70 mmHg were specifically associated with reduced MD. Neither episodes of intracranial pressure >20 mmHg nor acute-phase Rotterdam CT scores were associated with WM changes. Glasgow Outcome Scale Extended scores and performance-based cognitive control functioning were associated with FA and MD changes, but self-reported cognitive control functioning was not. In conclusion, FA loss specifically reflects the primary injury severity and mechanism, whereas FA and MD changes are associated with objective measures of general and cognitive control functioning. (c) 2014 Wiley Periodicals, Inc.	[Haberg, A. K.; Moen, K. G.; Skandsen, T.; Vik, A.] Norwegian Univ Sci & Technol, Dept Neurosci, N-7491 Trondheim, Norway; [Haberg, A. K.] Univ Trondheim Hosp, St Olavs Hosp, Dept Med Imaging, Trondheim, Norway; [Olsen, A.; Schirmer-Mikalsen, K.; Eikenes, L.] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway; [Olsen, A.; Skandsen, T.] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Moen, K. G.; Vik, A.] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway; [Schirmer-Mikalsen, K.] Univ Trondheim Hosp, St Olavs Hosp, Dept Anaesthesia & Intens Care, Trondheim, Norway; [Visser, E.] Univ Oxford, John Radcliffe Hosp, FMRIB Ctr, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England; [Finnanger, T. G.] Norwegian Univ Sci & Technol, Fac Med, Reg Ctr Child & Youth Mental Hlth & Child Welfare, N-7491 Trondheim, Norway; [Finnanger, T. G.] Univ Trondheim Hosp, St Olavs Hosp, Div Mental Healthcare, Dept Child & Adolescent Psychiat, Trondheim, Norway; [Evensen, K. A. I.] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, N-7491 Trondheim, Norway; [Evensen, K. A. I.] Norwegian Univ Sci & Technol, Dept Lab Med, Childrens & Womens Hlth, N-7491 Trondheim, Norway; [Evensen, K. A. I.] Trondheim Municipal, Dept Physiotherapy, Trondheim, Norway	Haberg, AK (corresponding author), Norwegian Univ Sci & Technol, Fac Med, Dept Neurosci, Post Box 8905, N-7491 Trondheim, Norway.	asta.haberg@ntnu.no	Olsen, Alexander/A-7539-2010; Olsen, Alexander/P-5235-2019	Olsen, Alexander/0000-0001-8691-3860; Evensen, Kari Anne I./0000-0002-0129-0164	Norwegian Research CouncilResearch Council of NorwayEuropean Commission; Norwegian National Advisory Unit for Functional MRI	Contract grant sponsor: Norwegian Research Council; Contract grant sponsor: Norwegian National Advisory Unit for Functional MRI.	ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Back SA, 2006, MENT RETARD DEV D R, V12, P129, DOI 10.1002/mrdd.20107; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bayly PV, 2012, ANNU REV BIOMED ENG, V14, P369, DOI [10.1146/annurev-bioeng-071811-150032, 10.1146/annurev.bioeng-071811-150032]; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bendlin BB, 2010, DEV NEUROPSYCHOL, V35, P257, DOI 10.1080/87565641003696775; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Borch K, 2010, ACTA PAEDIATR, V99, P1489, DOI 10.1111/j.1651-2227.2010.01856.x; Brandstack N, 2013, RADIOLOGY, V267, P231, DOI 10.1148/radiol.12112570; Brezova V, 2014, NEUROIMAGE-CLIN, V5, P128, DOI 10.1016/j.nicl.2014.03.012; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Cook P. A., 2006, 14 SCI M INT SOC MAG, P2759; Davceva N, 2012, J FORENSIC LEG MED, V19, P480, DOI 10.1016/j.jflm.2012.04.022; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Deng BM, 2013, AM J ALZHEIMERS DIS, V28, P154, DOI 10.1177/1533317512470207; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Eikenes L, 2012, PEDIATR RES, V72, P649, DOI 10.1038/pr.2012.129; Eikenes L, 2011, NEUROIMAGE, V54, P1774, DOI 10.1016/j.neuroimage.2010.10.037; FAZEKAS F, 1993, NEUROLOGY, V43, P1683, DOI 10.1212/WNL.43.9.1683; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1994, RADIOLOGY, V191, P1; Holland D, 2010, NEUROIMAGE, V50, P175, DOI 10.1016/j.neuroimage.2009.11.044; Isquith PK, 2013, APPL NEUROPSYCH-CHIL, V2, P125, DOI 10.1080/21622965.2013.748389; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Karamanos E, 2014, AM J SURG, V208, P363, DOI 10.1016/j.amjsurg.2013.10.026; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Kurki TJI, 2013, J MAGN RESON IMAGING, V38, P46, DOI 10.1002/jmri.23901; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; Leunissen I, 2014, HUM BRAIN MAPP, V35, P2459, DOI 10.1002/hbm.22341; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marshman LAG, 2013, J CLIN NEUROSCI, V20, P1475, DOI 10.1016/j.jocn.2012.11.022; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Mori S., 2005, MRI ATLAS HUMAN WHIT; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Nir TM, 2013, NEUROIMAGE-CLIN, V3, P180, DOI 10.1016/j.nicl.2013.07.006; Olsen A, 2014, CEREB CORTEX; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Power JD, 2013, CURR OPIN NEUROBIOL, V23, P223, DOI 10.1016/j.conb.2012.12.009; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rao V, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-78; Roth R, 2005, BEHAV RAING INVENTOR; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Schirmer-Mikalsen K, 2013, ACTA ANAESTH SCAND, V57, P46, DOI 10.1111/j.1399-6576.2012.02785.x; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Spitz G, 2013, BRAIN TOPOGR, V26, P648, DOI 10.1007/s10548-013-0283-0; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806; TEASDALE G, 1974, LANCET, V2, P81; Toplak ME, 2013, J CHILD PSYCHOL PSYC, V54, P131, DOI 10.1111/jcpp.12001; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Vernooij MW, 2008, J CEREBR BLOOD F MET, V28, P412, DOI 10.1038/sj.jcbfm.9600526; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Visser E, 2011, NEUROIMAGE, V54, P303, DOI 10.1016/j.neuroimage.2010.07.038; White H, 2008, ANESTH ANALG, V107, P979, DOI 10.1213/ane.0b013e31817e7b1a; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	92	30	31	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUL	2015	93	7			SI		1109	1126		10.1002/jnr.23534			18	Neurosciences	Neurosciences & Neurology	CI5TO	WOS:000354822900013	25641684	Other Gold			2021-06-18	
J	Reneker, JC; Moughiman, MC; Cook, CE				Reneker, Jennifer C.; Moughiman, M. Clay; Cook, Chad E.			The diagnostic utility of clinical tests for differentiating between cervicogenic and other causes of dizziness after a sports-related concussion: An international Delphi study	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Sports-related concussion; Cervical dizziness differential diagnosis; Delphi method	PROFESSIONAL FOOTBALL; WHIPLASH INJURY; PEOPLE; PAIN; DISTURBANCES; UNSTEADINESS; BIOMECHANICS; DISORDERS; STATEMENT; SEVERITY	Objectives: Dizziness after a sports-related concussion is very common and is associated with prolonged recovery. The events in sports that cause concussion include strong mechanical forces exerted to the head and neck, potentially injuring the cervical region, the peripheral vestibular and central nervous system, all of which can contribute to a sensation of dizziness. The purpose of this study was to identify proper clinically administered tests and measures that are useful in differentiating between cervicogenic and other causes of dizziness after a sports-related concussion. Design: The Delphi method. Methods: The workgroup identified the initial list of suggested clinical tests and the initial list of content experts on dizziness and/or concussion through a search of peer-reviewed and grey literature. The respondent group included all invited experts who opted to participate. A sequential three-round process was used for elicitation of consensus opinions from the targeted content experts. Results: The respondent group included 25 members from several medical disciplines who were experts in concussion and dizziness. At the conclusion of the study, ten clinical tests achieved the designation of strong clinical utility, six were determined to have weak clinical utility and seven achieved no consensus among the experts. Conclusions: The majority of clinical tests identified as having strong clinical utility are tests used to identify dizziness originating from the vestibular or central nervous system. No clinical tests specific for the cervical region achieved consensus. Expert opinion from different medical professions and even within professions was widely divergent regarding the utility of clinical tests to assess cervical dysfunction. Published by Elsevier Ltd on behalf of Sports Medicine Australia.	[Reneker, Jennifer C.; Cook, Chad E.] Walsh Univ, Div Phys Therapy, North Canton, OH USA; [Reneker, Jennifer C.; Moughiman, M. Clay] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Community Based Outpatient Therapy, Akron, OH USA	Reneker, JC (corresponding author), 2020 East Maple St NE, North Canton, OH 44720 USA.	JReneker@Walsh.edu	Reneker, Jennifer/N-2038-2016	Reneker, Jennifer/0000-0003-3617-5681			Al-Saif A, 2012, J AM SCI, V8, P483; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Ardic FN, 2006, OTOL NEUROTOL, V27, P676; Bossuyt PMM, 2012, CLIN CHEM, V58, P1636, DOI 10.1373/clinchem.2012.182576; Colledge NR, 1996, BMJ-BRIT MED J, V313, P788; DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458; Hansson EE, 2006, J REHABIL MED, V38, P387, DOI 10.1080/16501970600768992; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Malmstrom EM, 2007, DISABIL REHABIL, V29, P1193, DOI 10.1080/09638280600948383; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Nacci A, 2011, ACTA OTORHINOLARYNGO, V31, P378; Powell C, 2003, J ADV NURS, V41, P376, DOI 10.1046/j.1365-2648.2003.02537.x; Reid SA, 2008, MANUAL THER, V13, P357, DOI 10.1016/j.math.2007.03.006; Reid SA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-201; Schneider K, 2009, CLIN J SPORT MED, V19, P265; Schneider K, 2012, CLIN J SPORT MED, V22, P295; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Treleaven J, 2008, MANUAL THER, V13, P2, DOI 10.1016/j.math.2007.06.003; Treleaven J, 2011, SPINE, V36, pS211, DOI 10.1097/BRS.0b013e3182387f78; Tuo Kwo-Shieng, 2006, J Chin Med Assoc, V69, P591; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Wells C, 2014, PHYS THER, V94, P792, DOI 10.2522/ptj.20130030; Wrisley DM, 2000, J ORTHOP SPORT PHYS, V30, P755, DOI 10.2519/jospt.2000.30.12.755	28	30	32	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	JUL	2015	18	4					366	372		10.1016/j.jsams.2014.05.002			7	Sport Sciences	Sport Sciences	CL3HL	WOS:000356840900002	24933505				2021-06-18	
J	Robertson, K; Schmitter-Edgecombe, M				Robertson, Kayela; Schmitter-Edgecombe, Maureen			Self-awareness and traumatic brain injury outcome	BRAIN INJURY			English	Article						Awareness; community integration; outcome; rehabilitation; self-awareness; traumatic brain injury	EPISODIC MEMORY; POSTTRAUMATIC AMNESIA; REHABILITATION; DEFICITS; PREDICTIONS; PERFORMANCE; METAMEMORY; IMPAIRMENT; ACCURACY; FLUENCY	Primary objective: Impaired self-awareness following a traumatic brain injury (TBI) can reduce the effectiveness of rehabilitation, resulting in poorer outcomes. However, little is understood about how the multi-dimensional aspects of self-awareness may differentially change with recovery and impact outcome. Thus, this study examined four self-awareness variables represented in the Dynamic Comprehensive Model of Awareness: metacognitive awareness, anticipatory awareness, error-monitoring and self-regulation. Research design: This study evaluated change of the self-awareness measures with recovery from TBI and whether the self-awareness measures predicted community re-integration at follow-up. Methods and procedures: Participants were 90 individuals with moderate-to-severe TBI who were tested acutely following injury and 90 age-matched controls. Forty-nine of the TBI participants and 49 controls were re-tested after 6 months. Main outcome and results: Results revealed that the TBI group's error-monitoring performance was significantly poorer than controls at both baseline and follow-up. Regression analyses revealed that the self-awareness variables at follow-up were predictive of community re-integration, with error-monitoring being a unique predictor. Conclusions: The results highlight the importance of error-monitoring and suggest that interventions targeted at improving error-monitoring may be particularly beneficial. Understanding the multi-dimensional nature of self-awareness will further improve rehabilitation efforts and understanding of the theoretical basis of self-awareness.	[Robertson, Kayela; Schmitter-Edgecombe, Maureen] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Robertson, K (corresponding author), Washington State Univ, Dept Psychol, POB 644820, Pullman, WA 99164 USA.	k.robertson@email.wsu.edu			NINSD [R01-N5047690]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047690] Funding Source: NIH RePORTER	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This work was supported by a grant from NINSD R01-N5047690.	Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Anderson JW, 2010, J CLIN EXP NEUROPSYC, V32, P505, DOI 10.1080/13803390903224944; Anderson JW, 2009, J CLIN EXP NEUROPSYC, V31, P425, DOI 10.1080/13803390802232667; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Barco PP, 1991, TRAINING AWARENESS C; Beatty WW, 1998, MULT SCLER, V4, P40; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DEVOLDER PA, 1990, PSYCHOL AGING, V5, P291, DOI 10.1037/0882-7974.5.2.291; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; FitzGerald M. C., 2012, IRISH J PSYCHOL, V33, P78, DOI [DOI 10.1080/03033910.2012.708898, 10.1080/03033910.2012.708898]; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Hartman-Maeir A, 2002, J REHABIL MED, V34, P158, DOI 10.1080/16501970213236; HERTZOG C, 1990, PSYCHOL AGING, V5, P215, DOI 10.1037/0882-7974.5.2.215; Hoerold D, 2013, NEUROPSYCHOLOGIA, V51, P385, DOI 10.1016/j.neuropsychologia.2012.11.019; Kennedy MRT, 2003, J SPEECH LANG HEAR R, V46, P98, DOI 10.1044/1092-4388(2003/008); Kennedy MRT, 2000, J SPEECH LANG HEAR R, V43, P1072, DOI 10.1044/jslhr.4305.1072; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; Leung DPK, 2011, INT J REHABIL RES, V34, P187, DOI 10.1097/MRR.0b013e3283487f31; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Majdan A, 1996, J CLIN EXP NEUROPSYC, V18, P416, DOI 10.1080/01688639608408998; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; McPherson KM, 2009, CLIN REHABIL, V23, P296, DOI 10.1177/0269215509102980; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ownsworth T, 2004, NEUROPSYCHOL REHABIL, V14, P535, DOI 10.1080/09602010343000538; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Pigatano GP, 1991, AWARENESS DEFICIT BR; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Schmidt J, 2013, NEUROREHAB NEURAL RE, V27, P316, DOI 10.1177/1545968312469838; Schmitter-Edgecombe M, 2004, BRAIN INJURY, V18, P997, DOI 10.1080/02699050410001719934; Schmitter-Edgecombe M, 2008, J CLIN EXP NEUROPSYC, V30, P212, DOI 10.1080/13803390701363803; Schmitter-Edgecombe M, 2011, J CLIN EXP NEUROPSYC, V33, P218, DOI 10.1080/13803395.2010.507184; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Simmond M, 2003, BRIT J OCCUPATIONAL, V66, P447, DOI DOI 10.1177/030802260306601003; TEASDALE G, 1974, LANCET, V2, P81; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009	51	30	30	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2015	29	7-8					848	858		10.3109/02699052.2015.1005135			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CO0BJ	WOS:000358814800009	25915097	Green Accepted			2021-06-18	
J	Rodgers, KM; Dudek, FE; Barth, DS				Rodgers, Krista M.; Dudek, F. Edward; Barth, Daniel S.			Progressive, Seizure-Like, Spike-Wave Discharges Are Common in Both Injured and Uninjured Sprague-Dawley Rats: Implications for the Fluid Percussion Injury Model of Post-Traumatic Epilepsy	JOURNAL OF NEUROSCIENCE			English	Article						absence; acquired epilepsy; epilepsy; fluid percussion; genetic epilepsy; seizure	COMPLEX PARTIAL SEIZURES; PHOTOTHROMBOTIC BRAIN INFARCTION; GENETIC ABSENCE EPILEPSY; TEMPORAL-LOBE EPILEPSY; LONG-EVANS RATS; ELECTRICAL-STIMULATION; STATUS EPILEPTICUS; AWAKE RATS; EEG; NETWORKS	Variable-duration oscillations and repetitive, high-voltage spikes have been recorded in the electrocorticogram (ECoG) of rats weeks and months after fluid percussion injury (FPI), a model of traumatic brain injury. These ECoG events, which have many similarities to spike-wave-discharges (SWDs) and absence seizures, have been proposed to represent nonconvulsive seizures characteristic of post-traumatic epilepsy (PTE). The present study quantified features of SWD episodes in rats at different time points after moderate to severe FPI, and compared them with age-matched control rats. Control and FPI-injured rats at 1 year of age displayed large-amplitude and frequent SWD events at frontal and parietal recording sites. At 3-6 months, SWDs were shorter in duration and less frequent; extremely brief SWDs (i.e., "larval") were detected as early as 1 month. The onset of the SWDs was nearly always synchronous across electrodes and of larger amplitude in frontal regions. A sensory stimulus, such as a click, immediately and consistently stopped the occurrence of the SWDs. SWDs were consistently accompanied by behavioral arrest. All features of SWDs in control and experimental (FPI) rats were indistinguishable. None of the FPI-treated rats developed nonconvulsive or convulsive seizures that could be distinguished electro-graphically or behaviorally from SWDs. Because SWDs have features similar to genetic absence seizures, these results challenge the hypothesis that SWDs after FPI reflect PTE.	[Rodgers, Krista M.; Barth, Daniel S.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA; [Dudek, F. Edward] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT 84108 USA	Barth, DS (corresponding author), Univ Colorado, Dept Psychol & Neurosci, Campus Box 345, Boulder, CO 80309 USA.	daniel.barth@colorado.edu	Rodgers, Krista/AAC-5063-2020	RODGERS, KRISTA/0000-0003-4393-6389	US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [PR100040]; Epitel	This work was supported by the US Army Medical Research and Material Command (Grant PR100040).; F.E.D. has equity interest in and receives consultant fees from Epitel, which is a company that makes telemetric recording devices; however, this work did not use these devices. The remaining authors declare no competing financial interests.	Afra P, 2008, EPILEPSIA, V49, P677, DOI 10.1111/j.1528-1167.2007.01420.x; Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; ALDINIO C, 1985, METHOD FIND EXP CLIN, V7, P563; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; BERTRAM EH, 1994, BRAIN RES, V661, P157, DOI 10.1016/0006-8993(94)91192-4; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; BUZSAKI G, 1990, NEUROSCIENCE, V36, P1, DOI 10.1016/0306-4522(90)90345-5; BUZSAKI G, 1990, NEUROSCIENCE, V38, P323, DOI 10.1016/0306-4522(90)90031-X; Campbell John N, 2014, Int J Neurol Brain Disord, V1, P1; COENEN AML, 1987, EPILEPSY RES, V1, P297, DOI 10.1016/0920-1211(87)90005-2; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Danober L, 1998, PROG NEUROBIOL, V55, P27, DOI 10.1016/S0301-0082(97)00091-9; DEVINSKY O, 1988, NEUROLOGY, V38, P1347, DOI 10.1212/WNL.38.9.1347; Dudek FE, 2010, EPILEPSY CURR, V10, P91, DOI 10.1111/j.1535-7511.2010.01368.x; Eastman CL, 2015, EXP NEUROL, V264, P150, DOI 10.1016/j.expneurol.2014.12.010; Engel J, 2013, SEIZURES EPILEPSY, V83; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; HAMMOND EJ, 1979, EPILEPSIA, V20, P511, DOI 10.1111/j.1528-1157.1979.tb04833.x; Huang HY, 2012, EPILEPSIA, V53, P2005, DOI 10.1111/j.1528-1167.2012.03664.x; Jenssen S, 2006, EPILEPSIA, V47, P1499, DOI 10.1111/j.1528-1167.2006.00622.x; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; KAPLAN BJ, 1985, EXP NEUROL, V88, P425, DOI 10.1016/0014-4886(85)90204-3; Kelly KM, 2006, EXP NEUROL, V201, P495, DOI 10.1016/j.expneurol.2006.05.006; Kelly KM, 2001, EPILEPSY RES, V47, P189, DOI 10.1016/S0920-1211(01)00294-7; Kendirli MT, 2014, EPILEPSIA, V55, P1969, DOI 10.1111/epi.12854; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Kim Daeyoung, 2011, J Epilepsy Res, V1, P57, DOI 10.14581/jer.11011; KLEINLOGEL H, 1985, NEUROPSYCHOBIOLOGY, V13, P206, DOI 10.1159/000118189; LOTHMAN EW, 1993, EPILEPSIA, V34, pS59, DOI 10.1111/j.1528-1157.1993.tb05907.x; Luttjohann A, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00016; Meeren H, 2005, ARCH NEUROL-CHICAGO, V62, P371, DOI 10.1001/archneur.62.3.371; Meeren HKM, 2002, J NEUROSCI, V22, P1480, DOI 10.1523/JNEUROSCI.22-04-01480.2002; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Orru G, 2012, NEUROSCI BIOBEHAV R, V36, P1140, DOI 10.1016/j.neubiorev.2012.01.004; Pearce PS, 2014, EPILEPSY BEHAV, V32, P121, DOI 10.1016/j.yebeh.2014.01.004; Pearl P.L., 2008, PEDIAT EPILEPSY, P323; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; ROBINSON PF, 1980, BRAIN RES, V201, P452, DOI 10.1016/0006-8993(80)91052-5; Rodgers KM, 2012, J NEUROTRAUM, V29, P1886, DOI 10.1089/neu.2011.2273; Sato S., 1983, PEDIAT EPILEPTOLOGY, P65; SEMBA K, 1984, NEUROSCIENCE, V12, P761, DOI 10.1016/0306-4522(84)90168-4; SEMBA K, 1980, BRAIN RES, V195, P281, DOI 10.1016/0006-8993(80)90065-7; Shaw FZ, 2004, J NEUROPHYSIOL, V91, P63, DOI 10.1152/jn.00487.2003; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; THEODORE WH, 1994, NEUROLOGY, V44, P1403, DOI 10.1212/WNL.44.8.1403; THEODORE WH, 1983, NEUROLOGY, V33, P1115; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Van Hese P, 2003, PHYS MED BIOL, V48, P1685; Van Hese P, 2009, IEEE T BIO-MED ENG, V56, P706, DOI 10.1109/TBME.2008.2008858; VANDERWOLF CH, 1975, J COMP PHYSIOL PSYCH, V88, P300, DOI 10.1037/h0076211; VERGNES M, 1982, NEUROSCI LETT, V33, P97, DOI 10.1016/0304-3940(82)90136-7; Wiest MC, 2003, NAT NEUROSCI, V6, P913, DOI 10.1038/nn1107; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; WILLIAMSON PD, 1985, ANN NEUROL, V18, P497, DOI 10.1002/ana.410180413	61	30	32	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 17	2015	35	24					9194	9204		10.1523/JNEUROSCI.0919-15.2015			11	Neurosciences	Neurosciences & Neurology	CN2KU	WOS:000358250700021	26085641	Bronze, Green Published			2021-06-18	
J	Sheth, SA; Iavarone, AT; Liebeskind, DS; Won, SJ; Swanson, RA				Sheth, Sunil A.; Iavarone, Anthony T.; Liebeskind, David S.; Won, Seok Joon; Swanson, Raymond A.			Targeted Lipid Profiling Discovers Plasma Biomarkers of Acute Brain Injury	PLOS ONE			English	Article							FIBRILLARY ACIDIC PROTEIN; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; INFARCT VOLUME; WHITE-MATTER; SPHINGOLIPIDS; INTERVENTION; ASSOCIATION; GUIDELINES; PROGNOSIS	Prior efforts to identify a blood biomarker of brain injury have relied almost exclusively on proteins; however their low levels at early time points and poor correlation with injury severity have been limiting. Lipids, on the other hand, are the most abundant molecules in the brain and readily cross the blood-brain barrier. We previously showed that certain sphingolipid (SL) species are highly specific to the brain. Here we examined the feasibility of using SLs as biomarkers for acute brain injury. A rat model of traumatic brain injury (TBI) and a mouse model of stroke were used to identify candidate SL species though our mass-spectrometry based lipid profiling approach. Plasma samples collected after TBI in the rat showed large increases in many circulating SLs following injury, and larger lesions produced proportionately larger increases. Plasma samples collected 24 hours after stroke in mice similarly revealed a large increase in many SLs. We constructed an SL score (sum of the two SL species showing the largest relative increases in the mouse stroke model) and then evaluated the diagnostic value of this score on a small sample of patients (n = 14) who presented with acute stroke symptoms. Patients with true stroke had significantly higher SL scores than patients found to have non-stroke causes of their symptoms. The SL score correlated with the volume of ischemic brain tissue. These results demonstrate the feasibility of using lipid biomarkers to diagnose brain injury. Future studies will be needed to further characterize the diagnostic utility of this approach and to transition to an assay method applicable to clinical settings.	[Sheth, Sunil A.; Liebeskind, David S.] Univ Calif Los Angeles, Comprehens Stroke Ctr, Los Angeles, CA 90095 USA; [Sheth, Sunil A.; Liebeskind, David S.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Iavarone, Anthony T.] Univ Calif Berkeley, Chem Mass Spectrometry Facil QB3, Berkeley, CA 94720 USA; [Won, Seok Joon; Swanson, Raymond A.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94143 USA; [Won, Seok Joon; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA	Sheth, SA (corresponding author), Univ Calif Los Angeles, Comprehens Stroke Ctr, Los Angeles, CA 90095 USA.	ssheth@post.harvard.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS041421]; Department of Defense (RAS) [W81XWH-13-2-0091]; Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041421, R01NS081149] Funding Source: NIH RePORTER	This study was supported by the NIH (NS041421), Department of Defense (RAS, grant W81XWH-13-2-0091) and the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams HP, 2007, CIRCULATION, V115, pE478, DOI 10.1161/CIRCULATIONAHA.107.181486; Adibhatla RM, 2006, AAPS J, V8, pE314; Ahmad O, 2012, CEREBROVASC DIS, V33, P47, DOI 10.1159/000332810; Anand N, 2005, CEREBROVASC DIS; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Dassan P, 2009, CEREBROVASC DIS, V27, P295, DOI 10.1159/000199468; del Zoppo GJ, 2009, STROKE, V40, P2945, DOI 10.1161/STROKEAHA.109.192535; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; Hamilton JA, 2007, J MOL NEUROSCI, V33, P2, DOI 10.1007/s12031-007-0060-1; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Jain M, 2014, AM J PHYSIOL-ENDOC M, V306, pE854, DOI 10.1152/ajpendo.00371.2013; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Kihara Y, 2009, P NATL ACAD SCI USA, V106, P21807, DOI 10.1073/pnas.0906891106; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kuntz M, 2014, J CEREBR BLOOD F MET, V34, P95, DOI 10.1038/jcbfm.2013.169; Laskowitz DT, 2009, STROKE, V40, P77, DOI 10.1161/STROKEAHA.108.516377; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Mapstone M, 2014, NAT MED, V20, P415, DOI 10.1038/nm.3466; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Merrill AH, 2009, J LIPID RES, V50, pS97, DOI 10.1194/jlr.R800073-JLR200; Nickel CH, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-7; Nicoli F, 2014, NEURORADIOLOGY, V56, P117, DOI 10.1007/s00234-013-1310-2; Niedermeyer THJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044913; O'Brien J. S, 1965, J LIPID RES; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Quehenberger O, 2010, J LIPID RES, V51, P3299, DOI 10.1194/jlr.M009449; ROUSER G, 1965, J AM OIL CHEM SOC, V42, P404, DOI 10.1007/BF02635576; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; Shaner RL, 2009, J LIPID RES, V50, P1692, DOI 10.1194/jlr.D800051-JLR200; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; van den Boorn JG, 2011, NAT BIOTECHNOL, V29, P325, DOI 10.1038/nbt.1830; Whiteley W, 2009, STROKE, V40, pE380, DOI 10.1161/STROKEAHA.108.528752; Won SJ, 2011, ANN NEUROL, V70, P583, DOI 10.1002/ana.22538; Wunderlich MT, 2006, EUR J NEUROL, V13, P1118, DOI 10.1111/j.1468-1331.2006.01435.x; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197	38	30	30	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2015	10	6							e0129735	10.1371/journal.pone.0129735			15	Multidisciplinary Sciences	Science & Technology - Other Topics	CK6HU	WOS:000356329900098	26076478	DOAJ Gold, Green Published			2021-06-18	
J	Johansson, B; Wentzel, AP; Andrell, P; Mannheimer, C; Ronnback, L				Johansson, B.; Wentzel, A. -P.; Andrell, P.; Mannheimer, C.; Ronnback, L.			Methylphenidate reduces mental fatigue and improves processing speed in persons suffered a traumatic brain injury	BRAIN INJURY			English	Article						Cognition; mental fatigue; methylphenidate; pain; TBI	SF-36 HEALTH SURVEY; POST-CONCUSSION SYMPTOMS; QUALITY-OF-LIFE; DOUBLE-BLIND; CHRONIC PAIN; HEAD-INJURY; CONTROLLED-TRIAL; MILD; PLACEBO; RELIABILITY	Objective: Post-traumatic brain injury symptoms, such as mental fatigue, have considerable negative impacts on quality-of-life. In the present study the effects of methylphenidate in two different dosages were assessed with regard to mental fatigue, pain and cognitive functions in persons who had suffered a traumatic brain injury. Methods: Fifty-one subjects were included and 44 completed the study. The treatment continued for 12 weeks, including three treatment periods with no medication for 4 weeks, administration of low dose methylphenidate (up to 5 mg x 3) for 4 weeks and normal dose methylphenidate (up to 20 mg x 3) for a further 4 weeks. The patients were randomized into three groups where all groups were given all treatments. Results: Significantly reduced mental fatigue, assessed with the Mental Fatigue Scale (MFS) and increased information processing speed (coding, WAIS-III), were detected. The SF-36 vitality and social functioning scales were also improved significantly. Pain was not reduced by methylphenidate. The positive effects of treatment were dose-dependent, with the most prominent effects being at 60 mg methylphenidate/day spread over three doses. Observed side-effects were increased blood pressure and increased heart rate. Conclusions: Methylphenidate was generally well-tolerated and it improved long-lasting mental fatigue and processing speed after traumatic brain injury.	[Johansson, B.; Ronnback, L.] Univ Gothenburg, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol, S-41345 Gothenburg, Sweden; [Wentzel, A. -P.; Andrell, P.] Univ Gothenburg, Sahlgrenska Acad, Multidisciplinary Pain Ctr, Dept Mol & Clin Med, S-41345 Gothenburg, Sweden; [Wentzel, A. -P.; Mannheimer, C.] Kungalv Hosp, Multidisciplinary Pain Ctr, Kungalv, Sweden	Johansson, B (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Dubbsgatan 14, S-41345 Gothenburg, Sweden.	birgitta.johansson@neuro.gu.se		, Birgitta/0000-0003-0240-1142	Health & Medical Care Committee of the Region, Vastra Gotaland	The authors report no conflicts of interest. The study was funded by grants from The Health & Medical Care Committee of the Region, Vastra Gotaland.	Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; Alban JP, 2004, AM J PHYS MED REHAB, V83, P131, DOI 10.1097/01.phm.0000112308.68586.1d; Altman D, 1991, PRACTICAL STAT MED R; ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jamora CW, 2013, BRAIN INJURY, V27, P1134, DOI 10.3109/02699052.2013.804196; Johansson B, 2014, BRAIN INJURY, V28, P304, DOI 10.3109/02699052.2013.865267; Johansson B., 2014, TRAUMATIC BRAIN INJU; Johansson B., 2014, INT J PHYS MED REHAB, V2, P1, DOI [10.4172/2329-9096.1000182, DOI 10.4172/2329-9096.1000182]; Johansson Birgitta, 2012, ISRN Psychiatry, V2012, P686425, DOI 10.5402/2012/686425; Johansson B, 2012, ACTA NEUROPSYCHIATR, V24, P266, DOI 10.1111/j.1601-5215.2012.00678.x; Johansson B, 2010, BRAIN INJURY, V24, P2, DOI 10.3109/02699050903452961; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; LINDQVIST G, 1993, ACTA PSYCHIAT SCAND, V88, P5, DOI 10.1111/j.1600-0447.1993.tb05611.x; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rodholm M, 2001, ACTA NEUROL SCAND, V103, P379, DOI 10.1034/j.1600-0404.2001.103006379.x; Senn S, 2002, CROSS OVER TRIALS CL; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Sullivan M, 1998, J CLIN EPIDEMIOL, V51, P1105, DOI 10.1016/S0895-4356(98)00102-4; Sullivan M, 1982, SOC SCI MED, V41, P1349; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895-4356(98)00081-X; Wechsler D., 2003, WECHSLER ADULT INTEL; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632	42	30	30	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2015	29	6					758	765		10.3109/02699052.2015.1004747			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CL8RL	WOS:000357241700011	25794299				2021-06-18	
J	Simavli, S; Thompson, IR; Maguire, CA; Gill, JC; Carroll, RS; Wolfe, A; Kaiser, UB; Navarro, VM				Simavli, Serap; Thompson, Iain R.; Maguire, Caroline A.; Gill, John C.; Carroll, Rona S.; Wolfe, Andrew; Kaiser, Ursula B.; Navarro, Victor M.			Substance P Regulates Puberty Onset and Fertility in the Female Mouse	ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; LUTEINIZING-HORMONE RELEASE; NEUROKININ-B; HYPOGONADOTROPIC HYPOGONADISM; GONADOTROPIN-SECRETION; CONTAINING NEURONS; RAT HYPOTHALAMUS; TACR3 MUTATIONS; ARCUATE NUCLEUS; KISS-1 PEPTIDE	Puberty is a tightly regulated process that leads to reproductive capacity. Kiss1 neurons are crucial in this process by stimulating GnRH, yet how Kiss1 neurons are regulated remains unknown. Substance P (SP), an important neuropeptide in pain perception, induces gonadotropin release in adult mice in a kisspeptin-dependent manner. Here, we assessed whether SP, through binding to its receptor NK1R (neurokinin 1 receptor), participates in the timing of puberty onset and fertility in the mouse. We observed that 1) selective NK1R agonists induce gonadotropin release in prepubertal females; 2) the expression of Tac1 (encoding SP) and Tacr1 (NK1R) in the arcuate nucleus is maximal before puberty, suggesting increased SP tone; 3) repeated exposure to NK1R agonists prepubertally advances puberty onset; and 4) female Tac1(-/-) mice display delayed puberty; moreover, 5) SP deficiency leads to subfertility in females, showing fewer corpora lutea and antral follicles and leading to decreased litter size. Thus, our findings support a role for SP in the stimulation of gonadotropins before puberty, acting via Kiss1 neurons to stimulate GnRH release, and its involvement in the attainment of full reproductive capabilities in female mice.	[Simavli, Serap; Thompson, Iain R.; Maguire, Caroline A.; Gill, John C.; Carroll, Rona S.; Kaiser, Ursula B.; Navarro, Victor M.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; [Wolfe, Andrew] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA	Navarro, VM (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, Boston, MA 02115 USA.	vnavarro@partners.org	Simavli, Serap/ABG-2440-2020		Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54 HD028138]; National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD019938]; NIH GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K99 HD071970]; Charles H. Hood Foundation for Child Health Research Program; Microgrant Program from The Biomedical Research Institute; Center for Faculty Development and Diversity's Office for Research Careers at the Brigham and Women's Hospital; TUBITAK (The Scientific and Technological Research Council of Turkey)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [2219]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K99HD071970, R00HD071970, R01HD019938, R37HD019938, K99HD079663, U54HD028138] Funding Source: NIH RePORTER	This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development through Cooperative Agreement U54 HD028138 as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research grants from the National Institute of Health (NIH) Grant R01 HD019938 (to U.B.K.). V.M.N. was supported by NIH Grant K99 HD071970, Charles H. Hood Foundation for Child Health Research Program and the Microgrant Program from The Biomedical Research Institute and the Center for Faculty Development and Diversity's Office for Research Careers at the Brigham and Women's Hospital. S.S. was supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Grant 2219.	Abreu AP, 2013, NEW ENGL J MED, V368, P2467, DOI 10.1056/NEJMoa1302160; ARISAWA M, 1990, NEUROENDOCRINOLOGY, V51, P523, DOI 10.1159/000125386; BLENDONOHY P M, 1991, Brain Injury, V5, P63, DOI 10.3109/02699059108998513; Cao YQ, 1998, NATURE, V392, P390; COIRO V, 1992, METABOLISM, V41, P689, DOI 10.1016/0026-0495(92)90305-T; Darmani NA, 2008, BRAIN RES, V1214, P58, DOI 10.1016/j.brainres.2008.03.077; de Croft S, 2013, ENDOCRINOLOGY, V154, P2750, DOI 10.1210/en.2013-1231; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; de Roux N, 2003, P NATL ACAD SCI USA, V100, P10972, DOI 10.1073/pnas.1834399100; Debeljuk L, 2006, PEPTIDES, V27, P736, DOI 10.1016/j.peptides.2005.08.002; Debeljuk L, 2003, PEPTIDES, V24, P1445, DOI 10.1016/j.peptides.2003.09.009; Ebner K, 2006, AMINO ACIDS, V31, P251, DOI 10.1007/s00726-006-0335-9; Funes S, 2003, BIOCHEM BIOPH RES CO, V312, P1357, DOI 10.1016/j.bbrc.2003.11.066; Gabrielian Levon, 2013, Acta Neurochir Suppl, V118, P201, DOI 10.1007/978-3-7091-1434-6_37; Garcia-Galiano D, 2012, ENDOCRINOLOGY, V153, P316, DOI 10.1210/en.2011-1260; Gianetti E, 2010, J CLIN ENDOCR METAB, V95, P2857, DOI 10.1210/jc.2009-2320; Gill JC, 2012, ENDOCRINOLOGY, V153, P4883, DOI 10.1210/en.2012-1529; Gill JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011911; Gottsch ML, 2004, ENDOCRINOLOGY, V145, P4073, DOI 10.1210/en.2004-0431; Grachev P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044344; Hrabovszky E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072369; KALRA PS, 1992, ENDOCRINOLOGY, V131, P1195, DOI 10.1210/en.131.3.1195; Kaulfers AMD, 2010, J PEDIATR-US, V157, P894, DOI 10.1016/j.jpeds.2010.07.004; Kerdelhue B, 2000, NEUROENDOCRINOLOGY, V71, P228, DOI 10.1159/000054540; Kerdelhue B, 2006, NEUROENDOCRINOL LETT, V27, P359; Lapatto R, 2007, ENDOCRINOLOGY, V148, P4927, DOI 10.1210/en.2007-0078; Lasaga M, 2011, PEPTIDES, V32, P1972, DOI 10.1016/j.peptides.2011.07.009; Lehman MN, 2010, ENDOCRINOLOGY, V151, P3479, DOI 10.1210/en.2010-0022; Martin C, 2014, J NEUROSCI, V34, P6047, DOI 10.1523/JNEUROSCI.3003-13.2014; Navarro VM, 2015, ENDOCRINOLOGY, V156, P627, DOI 10.1210/en.2014-1651; Navarro Victor M, 2012, Front Endocrinol (Lausanne), V3, P48, DOI 10.3389/fendo.2012.00048; Navarro VM, 2012, J NEUROSCI, V32, P2388, DOI 10.1523/JNEUROSCI.4288-11.2012; Navarro VM, 2004, ENDOCRINOLOGY, V145, P4565, DOI 10.1210/en.2004-0413; Navarro VM, 2004, J PHYSIOL-LONDON, V561, P379, DOI 10.1113/jphysiol.2004.072298; Noel SD, 2014, FASEB J, V28, P1924, DOI 10.1096/fj.13-240630; OHTSUKA S, 1987, ACTA ENDOCRINOL-COP, V115, P247, DOI 10.1530/acta.0.1150247; Ojeda SR, 2014, NAT REV ENDOCRINOL, V10, P67, DOI 10.1038/nrendo.2013.233; Pinilla L, 2012, PHYSIOL REV, V92, P1235, DOI 10.1152/physrev.00037.2010; RANCE NE, 1991, ENDOCRINOLOGY, V128, P2239, DOI 10.1210/endo-128-5-2239; Ruiz-Pino F, 2015, ENDOCRINOLOGY, V156, P576, DOI 10.1210/en.2014-1026; SAHU A, 1992, ENDOCRINOLOGY, V130, P1571, DOI 10.1210/en.130.3.1571; Seminara SB, 2003, NEW ENGL J MED, V349, P1614, DOI 10.1056/NEJMoa035322; Topaloglu AK, 2009, NAT GENET, V41, P354, DOI 10.1038/ng.306; Traczyk W Z, 1992, J Physiol Pharmacol, V43, P279; True C, 2015, ENDOCRINOLOGY, V156, P1386, DOI 10.1210/en.2014-1862; TSURUO Y, 1984, BRAIN RES, V305, P331, DOI 10.1016/0006-8993(84)90439-6; TSURUO Y, 1991, NEUROENDOCRINOLOGY, V53, P236, DOI 10.1159/000125724; van Herck H, 1998, LAB ANIM-UK, V32, P377, DOI 10.1258/002367798780599794; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Yang JJ, 2012, ENDOCRINOLOGY, V153, P1498, DOI 10.1210/en.2011-1949; Young J, 2010, J CLIN ENDOCR METAB, V95, P2287, DOI 10.1210/jc.2009-2600; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39	52	30	30	1	7	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	JUN	2015	156	6					2313	2322		10.1210/en.2014-2012			10	Endocrinology & Metabolism	Endocrinology & Metabolism	CN4YB	WOS:000358435400036	25856429	Bronze, Green Published			2021-06-18	
J	Stemper, BD; Shah, AS; Pintar, FA; McCrea, M; Kurpad, SN; Glavaski-Joksimovic, A; Olsen, C; Budde, MD				Stemper, Brian D.; Shah, Alok S.; Pintar, Frank A.; McCrea, Michael; Kurpad, Shekar N.; Glavaski-Joksimovic, Aleksandra; Olsen, Christopher; Budde, Matthew D.			Head Rotational Acceleration Characteristics Influence Behavioral and Diffusion Tensor Imaging Outcomes Following Concussion	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury (mTBI); Diffusion tensor imaging (DTI); Behavioral assessments; Biomechanics	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; WHITE-MATTER INTEGRITY; FINITE-ELEMENT MODEL; HIGH-SCHOOL FOOTBALL; ELEVATED PLUS-MAZE; PROFESSIONAL FOOTBALL; ANIMAL-MODEL; RECURRENT CONCUSSION	A majority of traumatic brain injuries (TBI) in motor vehicle crashes and sporting environments are mild and caused by high-rate acceleration of the head. For injuries caused by rotational acceleration, both magnitude and duration of the acceleration pulse were shown to influence injury outcomes. This study incorporated a unique rodent model of rotational acceleration-induced mild TBI (mTBI) to quantify independent effects of magnitude and duration on behavioral and neuroimaging outcomes. Ninety-two Sprague-Dawley rats were exposed to head rotational acceleration at peak magnitudes of 214 or 350 krad/s(2) and acceleration pulse durations of 1.6 or 3.4 ms in a full factorial design. Rats underwent a series of behavioral tests including the Composite Neuroscore (CN), Elevated Plus Maze (EPM), and Morris Water Maze (MWM). Ex vivo diffusion tensor imaging (DTI) of the fixed brains was conducted to assess the effects of rotational injury on brain microstructure as revealed by the parameter fractional anisotropy (FA). While the injury did not cause significant locomotor or cognitive deficits measured with the CN and MWM, respectively, a main effect of duration was consistently observed for the EPM. Increased duration caused significantly greater activity and exploratory behaviors measured as open arm time and number of arm changes. DTI demonstrated significant effects of both magnitude and duration, with the FA of the amygdala related to both the magnitude and duration. Increased duration also caused FA changes at the interface of gray and white matter. Collectively, the findings demonstrate that the consequences of rotational acceleration mTBI were more closely associated with duration of the rotational acceleration impulse, which is often neglected as an independent factor, and highlight the need for animal models of TBI with strong biomechanical foundations to associate behavioral outcomes with brain microstructure.	[Stemper, Brian D.; Shah, Alok S.; Pintar, Frank A.; McCrea, Michael; Kurpad, Shekar N.; Glavaski-Joksimovic, Aleksandra; Olsen, Christopher; Budde, Matthew D.] Med Coll Wisconsin, Dept Neurosurg, Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53226 USA	Stemper, BD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53226 USA.	bstemper@mcw.edu	Olsen, Christopher/G-9595-2013; Stemper, Brian/AAX-7611-2020; Kurpad, Shekar/V-2188-2019	Olsen, Christopher/0000-0003-2700-0310; 	Merit Review Award from the United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service Program [I01 RX000380]; Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin endowment at the Medical College of Wisconsin [5520207]; Department of Neurosurgery, Medical College of Wisconsin; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R21DA039276] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000380] Funding Source: NIH RePORTER	This work was supported in part by Merit Review Award number I01 RX000380 from the United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service Program (PI: FAP), the Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin endowment at the Medical College of Wisconsin (5520207 to MDB), and the Department of Neurosurgery, Medical College of Wisconsin. The authors acknowledge the considerable contributions of Rachel Chiariello, Natasha Wilkins, and Andrea Winegar.	ABEL JM, 1978, 22 STAPP CAR CRASH C, P35; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Baykara B, 2012, TURK NEUROSURG, V22, P604, DOI 10.5137/1019-5149.JTN.5633-11.1; Bolouri H, 2012, ACTA NEUROL SCAND, V125, P241, DOI 10.1111/j.1600-0404.2011.01614.x; Bortolato M, 2009, NEUROPSYCHOPHARMACOL, V34, P2746, DOI 10.1038/npp.2009.118; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Budde MD, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00003; Budde MD, 2012, NEUROIMAGE, V63, P1, DOI 10.1016/j.neuroimage.2012.06.042; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Davidsson Johan, 2011, Front Neurol, V2, P41, DOI 10.3389/fneur.2011.00041; DECKER MW, 1995, NEUROBIOL LEARN MEM, V64, P156, DOI 10.1006/nlme.1995.1055; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Fan LW, 2008, EUR J NEUROSCI, V27, P1475, DOI 10.1111/j.1460-9568.2008.06121.x; Fijalkowski RJ, 2007, P INT IRCOBI C BIOM, P161; Fijalkowski RJ, 2007, BIOMED SCI INSTRUM, V43, P18; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Fijalkowski RJ, 2006, BIOMED SCI INSTRUM, V42, P108; Fijalkowski RJ, 2009, STAPP CAR CRASH JO, V53, P193; Fijalkowski RJ, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3078182; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Gao W, 2013, NEUROSCI LETT, V533, P50, DOI 10.1016/j.neulet.2012.11.020; Gennarelli T. A., 1972, 16 STAPP CAR CRASH C, P296; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gennarelli TA, 2003, ANN P ASS ADV AUTOMO, P624; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Hayasaka S, 2003, NEUROIMAGE, V20, P2343, DOI 10.1016/j.neuroimage.2003.08.003; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; Higgins L. S., 1967, 11 STAPP CAR CRASH C, P57; Hirsch Arthur E., 1970, STAPP CAR CRASH J, P144; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jespersen SN, 2013, NMR BIOMED, V26, P1647, DOI 10.1002/nbm.2999; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; King PR, 2012, J CLIN PSYCHOL MED S, V19, P376, DOI 10.1007/s10880-012-9345-9; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lamy M, 2013, MED BIOL ENG COMPUT, V51, P353, DOI 10.1007/s11517-012-1004-7; Lindemann Sven, 2007, Physiol Behav, V91, P551, DOI 10.1016/j.physbeh.2007.04.008; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2000, STANDARDIZED ASSESSM; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; Meyer JS, 2008, ANN NY ACAD SCI, V1139, P151, DOI 10.1196/annals.1432.029; Moller C, 1997, BRAIN RES, V760, P94, DOI 10.1016/S0006-8993(97)00308-9; MOSER E, 1993, J NEUROSCI, V13, P3916; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; Napieralski JA, 1998, EXP NEUROL, V154, P80, DOI 10.1006/exnr.1998.6893; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Ommaya AK, 1967, 11 STAPP CAR CRASH C, P73; Ono K., 1980, 24 STAPP CAR CRASH C, P103; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Primeaux SD, 1999, PHYSIOL BEHAV, V67, P41, DOI 10.1016/S0031-9384(99)00027-X; Ramamoorthy R, 2008, BEHAV PHARMACOL, V19, P29, DOI 10.1097/FBP.0b013e3282f3cfd4; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Simpson D. A., 2005, HEAD INJURY, P143; Sun SW, 2003, MAGN RESON MED, V50, P743, DOI 10.1002/mrm.10605; Thiabault LE, 1990, 34 ANN P ASS ADV AUT, V34, P337; UNTERHARNSCHEIDT F, 1969, ACTA NEUROPATHOL, V12, P200, DOI 10.1007/BF00692508; Ventura-Silva AP, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00032; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Wiest-Daessle N, 2007, LECT NOTES COMPUT SC, V4792, P344; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zhang H, 2007, LECT NOTES COMPUT SC, V4792, P211; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501	102	30	32	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	MAY	2015	43	5					1071	1088		10.1007/s10439-014-1171-9			18	Engineering, Biomedical	Engineering	CH1KM	WOS:000353780300002	25344352	Green Accepted			2021-06-18	
J	Zetterberg, H; Blennow, K				Zetterberg, Henrik; Blennow, Kaj			Fluid markers of traumatic brain injury	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article							CEREBROSPINAL-FLUID; MILD; TAU; BIOMARKERS; PROTEOLYSIS; IMPAIRMENT; CONCUSSION; SYMPTOMS	Traumatic brain injury (TBI) occurs when an external force traumatically injures the brain. Whereas severe TBI can be diagnosed using a combination of clinical signs and standard neuroimaging techniques, mild TBI (also called concussion) is more difficult to detect This is where fluid markers of injury to different cell types and subcellular compartments in the central nervous system come into play. These markers are often proteins, peptides or other molecules with selective or high expression in the brain, which can be measured in the cerebrospinal fluid or blood as they leak out or get secreted in response to the injury. Here, we review the literature on fluid markers of neuronal, axonal and astroglial injury to diagnose mild TBI and to predict clinical outcome in patients with head trauma. We also discuss chronic traumatic encephalopathy, a progressive neurodegenerative disease in individuals with a history of multiple mild TBIs in a biomarker context This article is part of a Special Issue entitled Traumatic Brain Injury'. (C) 2015 Elsevier Inc. All rights reserved.	[Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Clin Neurochem Lab, Inst Neurosci & Physiol, S-43180 Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, London, England	Zetterberg, H (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, S-43180 Molndal, Sweden.	henrik.zetterberg@gu.se			Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish State Support for Clinical Research; Torsten Soderberg Foundation; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; Wolfson Foundation	Work in the authors' laboratories is supported by the Swedish Research Council, the Swedish State Support for Clinical Research, the Torsten Soderberg Foundation, the Knut and Alice Wallenberg Foundation and the Wolfson Foundation.	Blennow K., 2015, NAT MED IN PRESS; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Devic I, 2011, BRAIN, V134, DOI 10.1093/brain/awr015; Hesse C, 2001, NEUROSCI LETT, V297, P187, DOI 10.1016/S0304-3940(00)01697-9; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kawai N, 2013, BRAIN INJURY, V27, P1026, DOI 10.3109/02699052.2013.794963; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Lemoine J, 2012, EXPERT REV MOL DIAGN, V12, P333, DOI [10.1586/erm.12.32, 10.1586/ERM.12.32]; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McMahon P.J., 2015, J NEUROTRAU IN PRESS; Neselius S., 2015, KNEE SURG S IN PRESS; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shi M, 2011, J ALZHEIMERS DIS, V27, P299, DOI 10.3233/JAD-2011-110731; Siman R., 2015, J NEUROTRAU IN PRESS; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zetterberg H, 2010, EUR NEUROL, V63, P326, DOI 10.1159/000311703	33	30	30	0	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAY	2015	66		B		SI		99	102		10.1016/j.mcn.2015.02.003			4	Neurosciences	Neurosciences & Neurology	CK7FT	WOS:000356398900005	25659491				2021-06-18	
J	Dromerick, AW; Edwardson, MA; Edwards, DF; Giannetti, ML; Barth, J; Brady, KP; Chan, E; Tan, MT; Tamboli, I; Chia, R; Orquiza, M; Padilla, RM; Cheema, AK; Mapstone, ME; Fiandaca, MS; Federoff, HJ; Newport, EL				Dromerick, Alexander W.; Edwardson, Matthew A.; Edwards, Dorothy F.; Giannetti, Margot L.; Barth, Jessica; Brady, Kathaleen P.; Chan, Evan; Tan, Ming T.; Tamboli, Irfan; Chia, Ruth; Orquiza, Michael; Padilla, Robert M.; Cheema, Amrita K.; Mapstone, Mark E.; Fiandaca, Massimo S.; Federoff, Howard J.; Newport, Elissa L.			Critical periods after stroke study: translating animal stroke recovery experiments into a clinical trial	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						stroke rehabilitation; cerebrovascular disorders; critical period; motor recovery; multi-omics; adaptive randomization	UPPER-EXTREMITY FUNCTION; CONSTRAINT-INDUCED MOVEMENT; RESEARCH ARM TEST; EARLY REHABILITATION; INTERRATER RELIABILITY; REACHING MOVEMENTS; TRUNK RESTRAINT; GENE-EXPRESSION; TRAUMATIC BRAIN; TIME-COURSE	Introduction: Seven hundred ninety-five thousand Americans will have a stroke this year, and half will have a chronic hemiparesis. Substantial animal literature suggests that the mammalian brain has much potential to recover from acute injury using mechanisms of neuroplasticity, and that these mechanisms can be accessed using training paradigms and neurotransmitter manipulation. However, most of these findings have not been tested or confirmed in the rehabilitation setting, in large part because of the challenges in translating a conceptually straightforward laboratory experiment into a meaningful and rigorous clinical trial in humans. Through presentation of methods for a Phase II trial, we discuss these issues and describe our approach. Methods: In rodents there is compelling evidence for timing effects in rehabilitation; motor training delivered at certain times after stroke may be more effective than the same training delivered earlier or later, suggesting that there is a critical or sensitive period for strongest rehabilitation training effects. If analogous critical/sensitive periods can be identified after human stroke, then existing clinical resources can be better utilized to promote recovery. The Critical Periods after Stroke Study (CPASS) is a phase II randomized, controlled trial designed to explore whether such a sensitive period exists. We will randomize 64 persons to receive an additional 20 h of upper extremity therapy either immediately upon rehab admission, 2-3 months after stroke onset, 6 months after onset, or to an observation-only control group. The primary outcome measure will be the Action Research Arm Test (ARAT) at 1 year. Blood will be drawn at up to 3 time points for later biomarker studies. Conclusion: CPASS is an example of the translation of rodent motor recovery experiments into the clinical setting; data obtained from this single site randomized controlled trial will be used to finalize the design of a Phase III trial.	[Dromerick, Alexander W.; Edwardson, Matthew A.; Giannetti, Margot L.; Barth, Jessica; Brady, Kathaleen P.; Chan, Evan; Newport, Elissa L.] Georgetown Univ, Ctr Brain Plast & Recovery, Dept Rehabil Med, Washington, DC USA; [Dromerick, Alexander W.; Edwardson, Matthew A.; Giannetti, Margot L.; Barth, Jessica; Brady, Kathaleen P.; Chan, Evan; Newport, Elissa L.] MedStar Natl Rehabil Hosp, Washington, DC USA; [Dromerick, Alexander W.; Edwardson, Matthew A.; Fiandaca, Massimo S.; Federoff, Howard J.; Newport, Elissa L.] Georgetown Univ, Dept Neurol, Washington, DC USA; [Edwards, Dorothy F.] Univ Wisconsin, Dep Kinesiol & Occupat Therapy, Madison, WI USA; [Tan, Ming T.] Georgetown Univ, Dept Biostat, Washington, DC USA; [Tamboli, Irfan; Chia, Ruth; Orquiza, Michael; Padilla, Robert M.; Fiandaca, Massimo S.; Federoff, Howard J.] Georgetown Univ, Dept Neurosci, Washington, DC USA; [Cheema, Amrita K.] Georgetown Univ, Dept Oncol, Washington, DC USA; [Cheema, Amrita K.] Georgetown Univ, Dept Biochem, Washington, DC USA; [Mapstone, Mark E.] Univ Rochester, Dept Neurol, Rochester, NY USA	Dromerick, AW (corresponding author), MedStar Natl Rehabil Hosp, Ctr Brain Plast & Res, Dept Rehabil Med, 102 Irving St NW, Washington, DC USA.	alexander.w.dromerick@gunet.georgetown.edu	Chia, Ruth/AAF-4900-2021; Edwards, Dorothy/L-6720-2016	Chia, Ruth/0000-0002-4709-7423; Fiandaca, Massimo/0000-0002-8376-1934; Giannetti, Margot/0000-0002-5259-9081; Edwardson, Matthew/0000-0002-0327-5531	Center for Brain Plasticity and Recovery at Georgetown University; MedStar National Rehabilitation Hospital; National Institute for Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1U10N5086513]; National Institute for Deafness and Communicative DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K18 DC014558]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K18DC014558] Funding Source: NIH RePORTER	This work is supported by the Center for Brain Plasticity and Recovery at Georgetown University and MedStar National Rehabilitation Hospital, the National Institute for Neurological Diseases and Stroke (1U10N5086513) and the National Institute for Deafness and Communicative Disorders (K18 DC014558).	ATKINSON AC, 1982, BIOMETRIKA, V69, P61, DOI 10.2307/2335853; Baum C.M., 2008, ACTIVITY CARD SORT, V2nd ed.; Bavelier D, 2010, J NEUROSCI, V30, P14964, DOI 10.1523/JNEUROSCI.4812-10.2010; Bernhardt J, 2008, STROKE, V39, P390, DOI 10.1161/STROKEAHA.107.492363; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Carey LM, 2015, INT J STROKE, V10, P636, DOI 10.1111/ijs.12190; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; Carter AR, 2010, CURR NEUROL NEUROSCI, V10, P158, DOI 10.1007/s11910-010-0091-9; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; De Weerdt W, 1985, PHYSIOTHER CAN, V37, P65, DOI DOI 10.3138/PTC.37.2.065; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dromerick AW, 2009, NEUROLOGY, V73, P195, DOI 10.1212/WNL.0b013e3181ab2b27; Dromerick Alexander W, 2006, NeuroRx, V3, P428, DOI 10.1016/j.nurx.2006.07.004; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; FEIGENSON JS, 1977, STROKE, V8, P8; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Gagnon D, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-151; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Han C, 2013, CLIN REHABIL, V27, P75, DOI 10.1177/0269215512447223; Hensch TK, 2005, CURR TOP DEV BIOL, V69, P215, DOI 10.1016/S0070-2153(05)69008-4; Hess E. H., 1973, IMPRINTING EARLY EXP; Hsieh CL, 1998, AGE AGEING, V27, P107, DOI 10.1093/ageing/27.2.107; Hubbard IJ, 2015, NEUROREHAB NEURAL RE, V29, P703, DOI 10.1177/1545968314562647; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Ingvaldsen RP, 1997, HUM MOVEMENT SCI, V16, P705, DOI 10.1016/S0167-9457(97)00022-5; JOHNSON JS, 1989, COGNITIVE PSYCHOL, V21, P60, DOI 10.1016/0010-0285(89)90003-0; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P406, DOI 10.1016/S0003-9993(95)80568-0; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kollen BJ, 2009, STROKE, V40, pE89, DOI 10.1161/STROKEAHA.108.533828; KOTILA M, 1984, STROKE, V15, P1039, DOI 10.1161/01.STR.15.6.1039; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Lang CE, 2006, ARCH PHYS MED REHAB, V87, P1605, DOI 10.1016/j.apmr.2006.09.003; Lang CE, 2009, ARCH PHYS MED REHAB, V90, P1692, DOI 10.1016/j.apmr.2009.04.005; LAWSON REED, 1963, OHIO JOUR SCI, V63, P87; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Lin JH, 2009, PHYS THER, V89, P840, DOI 10.2522/ptj.20080285; Liu N, 2014, STROKE, V45, P3502, DOI 10.1161/STROKEAHA.114.005661; Lum PS, 2009, TOP STROKE REHABIL, V16, P237, DOI 10.1310/tsr1604-237; Lum PS, 2004, IEEE T NEUR SYS REH, V12, P186, DOI 10.1109/TNSRE.2004.827225; Mapstone M, 2014, NAT MED, V20, P415, DOI 10.1038/nm.3466; MARLER P, 1970, AM SCI, V58, P669; Mathiowetz V., 1992, MEASUREMENT NEUROLOG, P171; Maulden SA, 2005, ARCH PHYS MED REHAB, V86, pS34, DOI 10.1016/j.apmr.2005.08.119; Mead GE, 2000, J NEUROL NEUROSUR PS, V68, P558, DOI 10.1136/jnnp.68.5.558; Medical Research Council, 1976, AIDS EX PER NERV SYS; Meinert C.L., 1986, CLIN TRIALS DESIGN C; Mesulam M., 1985, PRINCIPLES BEHAV NEU; Michaelsen SM, 2006, STROKE, V37, P186, DOI 10.1161/01.STR.0000196940.20446.c9; Michaelsen SM, 2004, STROKE, V35, P1914, DOI 10.1161/01.STR.0000132569.33572.75; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P852, DOI 10.1016/0003-9993(94)90108-2; Nave AH, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-197; NEWPORT EL, 1990, COGNITIVE SCI, V14, P11, DOI 10.1207/s15516709cog1401_2; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ostwald SK, 2009, TOP STROKE REHABIL, V16, P80, DOI 10.1310/tsr1601-80; Page SJ, 2001, J REHABIL RES DEV, V38, P583; Paolucci S, 2000, ARCH PHYS MED REHAB, V81, P695, DOI 10.1053/apmr.2000.5583; Pollock A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001920.pub2; Rossi PW, 1997, J NEUROL REHABIL, V11, P27; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; SIGNORINI DF, 1993, STAT MED, V12, P2343, DOI 10.1002/sim.4780122410; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; Skinner BF., 1938, BEHAV ORGANISMS EXPT; Stark SL, 2005, ARCH PHYS MED REHAB, V86, P344, DOI 10.1016/j.apmr.2004.03.020; SUNDERLAND A, 1992, J NEUROL NEUROSUR PS, V55, P530, DOI 10.1136/jnnp.55.7.530; Tang Y, 2006, J CEREBR BLOOD F MET, V26, P1089, DOI 10.1038/sj.jcbfm.9600264; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; Taub E., 2011, MOTOR ACTIVITY LOG M; Thorndike E. L., 1898, PSYCHOL REV MONOGRAP, V8; Uswatte G, 2006, NEUROLOGY, V67, P1189, DOI 10.1212/01.wnl.0000238164.90657.c2; van der Lee JH, 2002, CLIN REHABIL, V16, P646, DOI 10.1191/0269215502cr534oa; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wade D. T., 1992, MEASURE MOTOR IMPAIR, P154; Wade D. T., 1992, MEASUREMENTS NEUROLO, P155; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; Ween JE, 1996, NEUROLOGY, V47, P388, DOI 10.1212/WNL.47.2.388; Whitall J, 2000, STROKE, V31, P2390, DOI 10.1161/01.STR.31.10.2390; Winstein CJ, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-5; Woldag H, 2010, J REHABIL MED, V42, P582, DOI 10.2340/16501977-0558; Wolf SL, 2010, STROKE, V41, P2309, DOI 10.1161/STROKEAHA.110.588723; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Wong D. L., 2001, WONGS ESSENTIALS PED; WYLIE CM, 1970, GERIATRICS, V25, P107; YESAVAGE JA, 1988, PSYCHOPHARMACOL BULL, V24, P709; Yuan A., 2014, J CLIN TRIALS, V4, P181, DOI [10.4172/2167-0870.1000181, DOI 10.4172/2167-0870.1000181]; Zhou XM, 2011, J NEUROSCI, V31, P5625, DOI 10.1523/JNEUROSCI.6470-10.2011	97	30	31	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	APR 29	2015	9								231	10.3389/fnhum.2015.00231			13	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	CK1ZA	WOS:000356007300002	25972803	DOAJ Gold, Green Published			2021-06-18	
J	Tsitsilonis, S; Seemann, R; Misch, M; Wichlas, F; Haas, NP; Schmidt-Bleek, K; Kleber, C; Schaser, KD				Tsitsilonis, Serafeim; Seemann, Ricarda; Misch, Martin; Wichlas, Florian; Haas, Norbert P.; Schmidt-Bleek, Katharina; Kleber, Christian; Schaser, Klaus-Dieter			The effect of traumatic brain injury on bone healing: an experimental study in a novel in vivo animal model	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Fracture healing; Animal model; Heterotopic ossification; Callus formation	CORTICAL IMPACT INJURY; RAT MODEL; FRACTURE; MICROCIRCULATION; EXPRESSION	Introduction: Among many factors determining the outcome of complex fractures in polytrauma patients, the role of traumatic brain injury (TBI) remains only partly understood. The aim of the present study was to examine the effect of traumatic brain injury on bone healing through the establishment of a novel standardised animal model that sequentially combines traumatic brain injury (TBI) with a long bone injury. Materials and methods: Thirty-six female twelve-week old C57/BL6 mice were randomised in two groups (fracture (Fx)-group and combined-trauma (Fx/TBI) group). The methods of the Control Cortical Impact Injury for induction of TBI and of the femoral osteotomy, fixed with an external fixator for the simulation of the long bone fracture, were combined. No TBI was induced in the Fx-group. Bone healing was examined using in vivo micro-CT measurements over a period of three weeks. Results: The severity of the TBI was sufficient to stimulate a significantly increased callus formation in the Fx/TBI-group with an acceptable mortality rate. The micro-CT analysis of fracture healing displayed a significantly increased callus volume in the Fx/TBI-group already from the second postoperative week. This difference remained significant throughout the entire study period. Discussion: The successful and standardised combination of TBI and fracture in a mouse model allows systematic and quantitative in vivo analysis of underlying pathways that trigger the mutual interaction between musculoskeletal trauma and brain injury, as well as, corresponding differences in fracture healing using micro-CT methods. Conclusion: The present study offers three new aspects: a standardised model for combined injury of TBI and femoral osteotomy; direct and serial in vivo imaging and quantification of fracture healing response using micro-CT; testing of potentially beneficial therapeutic regimens for fracture treatment in presence of TBI. Thus this model provides a valuable basic approach for the study of the amplifying effect of TBI on callus formation seen in patients with craniocerebral injury and concomitant skeletal trauma. (C) 2015 Elsevier Ltd. All rights reserved.	[Tsitsilonis, Serafeim; Seemann, Ricarda; Wichlas, Florian; Haas, Norbert P.; Kleber, Christian; Schaser, Klaus-Dieter] Charite, Ctr Musculoskeletal Surg, D-13353 Berlin, Germany; [Tsitsilonis, Serafeim; Kleber, Christian] Berlin Brandenburg Ctr Regenerat Therapies, D-13353 Berlin, Germany; [Misch, Martin] Charite, Dept Neurosurg, D-13353 Berlin, Germany; [Schmidt-Bleek, Katharina] Charite, Julius Wolff Inst, D-13353 Berlin, Germany	Tsitsilonis, S (corresponding author), Charite, Ctr Musculoskeletal Surg, Augustenburger Pl 1, D-13353 Berlin, Germany.	serafeim.tsitsilonis@charite.de	Schmidt-Bleek, Katharina/O-9816-2015	Misch, Martin/0000-0001-5283-5753; Seemann, Ricarda/0000-0001-5752-070X			Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Cadosch D, 2010, J BONE JOINT SURG AM, V92A, P645, DOI 10.2106/JBJS.I.00097; GARLAND DE, 1988, CLIN ORTHOP RELAT R, P86; Giannoudis PV, 2006, INJURY, V37, pS18, DOI 10.1016/j.injury.2006.08.020; Hannouche D, 2001, J BONE JOINT SURG BR, V83B, P157, DOI 10.1302/0301-620X.83B2.12106; Kushwaha V P, 1998, J Am Acad Orthop Surg, V6, P298; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Mirzayan MJ, 2012, EXP TOXICOL PATHOL, V64, P133, DOI 10.1016/j.etp.2010.07.007; Morley J, 2005, INJURY, V36, P363, DOI 10.1016/j.injury.2004.08.028; Probst C, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/136020; Schaser KD, 2005, J ORTHOP RES, V23, P231, DOI 10.1016/j.orthres.2004.05.009; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; Trentz OA, 2005, CRIT CARE MED, V33, P399, DOI 10.1097/01.CCM.0000152221.87477.21; Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319	20	30	33	1	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	APR	2015	46	4					661	665		10.1016/j.injury.2015.01.044			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	CD7MZ	WOS:000351275900025	25682315				2021-06-18	
J	Gatson, JW; Simpkins, JW; Uteshev, VV				Gatson, Joshua W.; Simpkins, James W.; Uteshev, Victor V.			High therapeutic potential of positive allosteric modulation of alpha 7 nAChRs in a rat model of traumatic brain injury: Proof-of-concept	BRAIN RESEARCH BULLETIN			English	Article						Nicotinic; PNU120596; PNU-120596; Alpha7; Choline; Traumatic brain injury	NICOTINIC ACETYLCHOLINE-RECEPTOR; ACH RECEPTORS; FREE CHOLINE; IN-VITRO; ACTIVATION; PNU-120596; AGONIST; HIPPOCAMPUS; MEMORY; NEUROPROTECTION	There are currently no clinically efficacious drug therapies to treat brain damage secondary to traumatic brain injury (TBI). In this proof-of-concept study, we used a controlled cortical impact model of TBI in young adult rats to explore a novel promising approach that utilizes PNU-120596, a previously reported highly selective Type-II positive allosteric modulator (alpha-PAM) of alpha 7 nicotinic acetylcholine receptors (nAChRs). alpha 7-PAMs enhance and prolong alpha 7 nAChR activation, but do not activate alpha 7 nAChRs when administered without an agonist. The rational basis for the use of an alpha 7-PAM as a post-TBI treatment is tripartite and arises from: (1) the intrinsic ability of brain injury to elevate extracellular levels of choline (a ubiquitous cell membrane-building material and a selective endogenous agonist of alpha 7 nAChRs) due to the breakdown of cell membranes near the site and time of injury; (2) the ubiquitous expression of functional alpha 7 nAChRs in neuronal and glial/immune brain cells; and (3) the potent neuroprotective and anti-inflammatory effects of alpha 7 nAChR activation. Therefore, both neuroprotective and anti-inflammatory effects can be achieved post-TBI by targeting only a single player (i.e., the alpha 7 nAChR) using alpha 7-PAM5 to enhance the activation of alpha 7 nAChRs by injury-elevated extracellular choline. Our data support this hypothesis and demonstrate that subcutaneous administration of PNU-120596 post-TBI in young adult rats significantly reduces both brain cell damage and reactive gliosis. Therefore, our results introduce post-TBI systemic administration of alpha 7-PAMs as a promising therapeutic intervention that could significantly restrict brain injury post-TBI and facilitate recovery of TBI patients. (C) 2015 Elsevier Inc. All rights reserved.	[Gatson, Joshua W.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dept Neurosurg, Dallas, TX 75390 USA; [Simpkins, James W.] W Virginia Univ, Ctr Basic & Translat Stroke Res, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; [Uteshev, Victor V.] Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76248 USA	Uteshev, VV (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie Blvd, Ft Worth, TX 76248 USA.	Victor.Uteshev@unthsc.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK082625]; NIDA Research Resources Drug Supply Program [PNU-120596]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK082625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG027956] Funding Source: NIH RePORTER	This study was supported by a grant DK082625 from the National Institute of Health to VVU. We thank the NIDA Research Resources Drug Supply Program for PNU-120596.	Akaike A, 2010, J MOL NEUROSCI, V40, P211, DOI 10.1007/s12031-009-9236-1; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; ARENDASH GW, 1995, BRAIN RES, V674, P252, DOI 10.1016/0006-8993(94)01449-R; Bertrand N, 1996, NEUROCHEM INT, V28, P293, DOI 10.1016/0197-0186(95)00086-0; Breese CR, 1997, J COMP NEUROL, V387, P385, DOI 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X; Brown KL, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00166; Callahan PM, 2013, NEUROPHARMACOLOGY, V67, P201, DOI 10.1016/j.neuropharm.2012.10.019; Dinklo T, 2011, J PHARMACOL EXP THER, V336, P560, DOI 10.1124/jpet.110.173245; DJURICIC B, 1991, J CEREBR BLOOD F MET, V11, P308, DOI 10.1038/jcbfm.1991.63; Egea J, 2007, NEUROSCIENCE, V145, P866, DOI 10.1016/j.neuroscience.2006.12.036; Felix R, 1997, NEUROSCIENCE, V81, P1009, DOI 10.1016/S0306-4522(97)00224-8; Freedman R, 2000, J CHEM NEUROANAT, V20, P299, DOI 10.1016/S0891-0618(00)00109-5; Freitas K, 2013, BRIT J PHARMACOL, V169, P567, DOI 10.1111/j.1476-5381.2012.02226.x; Freitas K, 2013, J PHARMACOL EXP THER, V344, P264, DOI 10.1124/jpet.112.197871; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Gronlien JH, 2007, MOL PHARMACOL, V72, P715, DOI 10.1124/mol.107.035410; Guan Y.Z., 2014, MOL NEUROBIOL; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Gusev AG, 2010, J PHARMACOL EXP THER, V332, P588, DOI 10.1124/jpet.109.162099; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Harris JG, 2004, NEUROPSYCHOPHARMACOL, V29, P1378, DOI 10.1038/sj.npp.1300450; Hartmann J, 2008, NEUROCHEM INT, V52, P972, DOI 10.1016/j.neuint.2007.10.008; Hurst RS, 2005, J NEUROSCI, V25, P4396, DOI 10.1523/JNEUROSCI.5269-04.2005; JOPE RS, 1991, NEUROCHEM RES, V16, P1219, DOI 10.1007/BF00966699; De Rosa MJ, 2009, LIFE SCI, V85, P444, DOI 10.1016/j.lfs.2009.07.010; Kalappa BI, 2013, BRIT J PHARMACOL, V169, P1862, DOI 10.1111/bph.12247; Kalappa BI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013964; Kiewert C, 2010, BRAIN RES, V1312, P101, DOI 10.1016/j.brainres.2009.11.068; Kitagawa H, 2003, NEUROPSYCHOPHARMACOL, V28, P542, DOI 10.1038/sj.npp.1300028; Klein J, 1998, NEUROCHEM INT, V32, P479, DOI 10.1016/S0197-0186(97)00127-7; Lendvai B, 2013, BRAIN RES BULL, V93, P86, DOI 10.1016/j.brainresbull.2012.11.003; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Li YX, 1999, BRAIN RES, V830, P218, DOI 10.1016/S0006-8993(99)01372-4; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Malysz J, 2009, J PHARMACOL EXP THER, V330, P257, DOI 10.1124/jpet.109.151886; McLean SL, 2012, J PSYCHOPHARMACOL, V26, P1265, DOI 10.1177/0269881111431747; Munro G, 2012, BRIT J PHARMACOL, V167, P421, DOI 10.1111/j.1476-5381.2012.02003.x; Olincy A, 2006, ARCH GEN PSYCHIAT, V63, P630, DOI 10.1001/archpsyc.63.6.630; Papke RL, 1996, NEUROSCI LETT, V213, P201; Papke RL, 2002, BRIT J PHARMACOL, V137, P49, DOI 10.1038/sj.bjp.0704833; Parada E., 2013, ANTIOXID REDOX SIGNA; Quick MW, 2002, J NEUROBIOL, V53, P457, DOI 10.1002/neu.10109; Quik M, 2009, BIOCHEM PHARMACOL, V78, P677, DOI 10.1016/j.bcp.2009.05.003; Sarter M, 2005, NAT REV NEUROSCI, V6, P48, DOI 10.1038/nrn1588; SCREMIN OU, 1991, STROKE, V22, P643, DOI 10.1161/01.STR.22.5.643; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Sun F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073581; Thomsen MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027014; Thomsen MS, 2010, CURR PHARM DESIGN, V16, P323, DOI 10.2174/138161210790170094; Timmermann DB, 2007, J PHARMACOL EXP THER, V323, P294, DOI 10.1124/jpet.107.120436; Uteshev VV, 2014, EUR J PHARMACOL, V727, P181, DOI 10.1016/j.ejphar.2014.01.072; Uteshev VV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032951; Uteshev VV, 2012, ADV EXP MED BIOL, V740, P603, DOI 10.1007/978-94-007-2888-2_27; Uteshev VV, 2003, J NEUROPHYSIOL, V89, P1797, DOI 10.1152/jn.00943.2002; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Wallace TL, 2011, BIOCHEM PHARMACOL, V82, P891, DOI 10.1016/j.bcp.2011.06.034; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whiteaker P, 1999, EUR J NEUROSCI, V11, P2689, DOI 10.1046/j.1460-9568.1999.00685.x; Woodruff TM, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-11; Zapata A, 1998, J NEUROSCI, V18, P3597	64	30	30	1	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	MAR	2015	112						35	41		10.1016/j.brainresbull.2015.01.008			7	Neurosciences	Neurosciences & Neurology	CE6TF	WOS:000351970400005	25647232	Green Accepted			2021-06-18	
J	Papa, L; Robertson, CS; Wang, KKW; Brophy, GM; Hannay, HJ; Heaton, S; Schmalfuss, I; Gabrielli, A; Hayes, R; Robicsek, SA				Papa, Linda; Robertson, Claudia S.; Wang, Kevin K. W.; Brophy, Gretchen M.; Hannay, H. Julia; Heaton, Shelley; Schmalfuss, Ilona; Gabrielli, Andrea; Hayes, Ronald L.; Robicsek, Steven A.			Biomarkers Improve Clinical Outcome Predictors of Mortality Following Non-Penetrating Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Biomarkers; Severe traumatic brain injury; Mortality; Microtubual associated protein (MAP-2); S100B; Alpha-spectrin breakdown products (SBDPs); Ubiquitin C-terminal hydrolase (UCH-L1)	NEURON-SPECIFIC-ENOLASE; MICROTUBULE-ASSOCIATED PROTEIN-2; SPECTRIN BREAKDOWN PRODUCTS; C-TERMINAL HYDROLASE-L1; II-SPECTRIN; CEREBROSPINAL-FLUID; S-100B PROTEIN; SERUM S100B; HEAD-INJURY; DAMAGE	This study assessed whether early levels of biomarkers measured in CSF within 24-h of severe TBI would improve the clinical prediction of 6-months mortality. This prospective study conducted at two Level 1 Trauma Centers enrolled adults with severe TBI (GCS a parts per thousand currency sign8) requiring a ventriculostomy as well as control subjects. Ventricular CSF was sampled within 24-h of injury and analyzed for seven candidate biomarkers (UCH-L1, MAP-2, SBDP150, SBDP145, SBDP120, MBP, and S100B). The International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) scores (Core, Extended, and Lab) were calculated for each patient to determine risk of 6-months mortality. The IMPACT models and biomarkers were assessed alone and in combination. There were 152 patients enrolled, 131 TBI patients and 21 control patients. Thirty six (27 %) patients did not survive to 6 months. Biomarkers were all significantly elevated in TBI versus controls (p < 0.001). Peak levels of UCH-L1, SBDP145, MAP-2, and MBP were significantly higher in non-survivors (p < 0.05). Of the seven biomarkers measured at 12-h post-injury MAP-2 (p = 0.004), UCH-L1 (p = 0.024), and MBP (p = 0.037) had significant unadjusted hazard ratios. Of the seven biomarkers measured at the earliest time within 24-h, MAP-2 (p = 0.002), UCH-L1 (p = 0.016), MBP (p = 0.021), and SBDP145 (0.029) had the most significant elevations. When the IMPACT Extended Model was combined with the biomarkers, MAP-2 contributed most significantly to the survival models with sensitivities of 97-100 %. These data suggest that early levels of MAP-2 in combination with clinical data provide enhanced prognostic capabilities for mortality at 6 months.	[Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL 32806 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci & Neurosurg, Richmond, VA USA; [Hannay, H. Julia] Univ Houston, Dept Psychol, Houston, TX USA; [Heaton, Shelley] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Schmalfuss, Ilona] Univ Florida, Dept Radiol, Gainesville, FL 32610 USA; [Schmalfuss, Ilona] NF SG Vet Adm, Gainesville, FL USA; [Gabrielli, Andrea; Robicsek, Steven A.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Banyan Labs, Alachua, FL USA	Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, 86 W Underwood S-200, Orlando, FL 32806 USA.	lpstat@aol.com; claudiar@bcm.edu; kawangwang17@gmail.com; gbrophy@vcu.edu; psycqs@central.uh.edu; sheaton@phhp.ufl.edu; schmai@radiology.ufl.edu; agabrielli@anest.ufl.edu; rhayes@banyanbio.com; robicsek@me.com		Brophy, Gretchen/0000-0002-4749-2693; Wang, Kevin/0000-0002-9343-6473; Hannay, H. Julia/0000-0001-7023-912X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS052831]	This study was funded by NIH RO1 NS052831 "Biochemical Markers of Severe Traumatic Brain Injury''. Drs. Brophy and Papa are consultants of Banyan Biomarkers, Inc. but receive no stocks or royalties from the company and will not benefit financially from this publication. Dr. Hayes and Wang own stock, receive royalties from Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research or work reported in this publication.	Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Cooper E. H., 1994, International Journal of Biological Markers, V9, P205; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DIEZGUERRA FJ, 1993, EUR J BIOCHEM, V215, P181, DOI 10.1111/j.1432-1033.1993.tb18021.x; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Faul M., 2010, EMERGENCY DEP VISITS; Ferguson I, 2011, ANN EMERG MED, V58, pS213, DOI 10.1016/j.annemergmed.2011.06.133; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; HAIMOTO H, 1987, LAB INVEST, V57, P489; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hunter CL, 2013, AM J EMERG MED, V31, P64, DOI 10.1016/j.ajem.2012.05.034; IBERTI TJ, 1990, CRIT CARE MED, V18, P275, DOI 10.1097/00003246-199003000-00005; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Khan SH, 1998, ACT NEUR S, V71, P50; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mondello S, 2012, BRAIN INJURY, V26, P1629, DOI 10.3109/02699052.2012.700083; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Papa L., 2012, PROTEOMICS HUMAN DIS; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; USUI A, 1989, CLIN CHEM, V35, P1942; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Xiong H, 2000, Sheng Li Ke Xue Jin Zhan, V31, P217; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217; Zhang ZQ, 2011, TRANSL STROKE RES, V2, P455, DOI 10.1007/s12975-011-0137-6	61	30	31	0	12	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2015	22	1					52	64		10.1007/s12028-014-0028-2			13	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	CA3FH	WOS:000348791300008	25052159				2021-06-18	
J	Kim, N; Kim, JY; Yenari, MA				Kim, N.; Kim, J. Y.; Yenari, M. A.			PHARMACOLOGICAL INDUCTION OF THE 70-kDa HEAT SHOCK PROTEIN PROTECTS AGAINST BRAIN INJURY	NEUROSCIENCE			English	Article						animal studies; traumatic brain injury; therapeutic approaches	LEUKEMIA CELLS; INHIBITORS; HEAT-SHOCK-PROTEIN-70; OVEREXPRESSION; INFLAMMATION; MECHANISMS; APOPTOSIS; ISCHEMIA; SURVIVAL; NEURONS	The 70-kDa heat shock protein (HSP70) is known to protect the brain from injury through multiple mechanisms. We investigated the effect of pharmacological HSP70 induction in experimental traumatic brain injury (TBI). 3-month-old male C57/B6 mice were given 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) intraperitoneally (IP, 2 mg/kg) or intracerebroventricularly (ICV, 1 mu g/kg) to determine whether HSP70 could be induced in the brain. Mice were subjected to TBI via cortical controlled impact, and were treated with 17-AAG (or vehicle) IP according to one of two treatment regimens: (1) 2 mg/kg at the time of injury, (2) a total of three doses (4 mg/kg) at 2 and 1 d prior to TBI and again at the time of injury. Brains were assessed for HSP70 induction, hemorrhage volume at 3 d, and lesion size at 14 d post-injury. Immunohistochemistry showed that both IP and ICV administration of 17-AAG increased HSP70 expression primarily in microglia and in a few neurons by 24 h but not in astrocytes. 17-AAG induced HSP70 in injured brain tissue as early as 6 h, peaking at 48 h and largely subsiding by 72 h after IP injection. Both treatment groups showed decreased hemorrhage volume relative to untreated mice as well as improved neurobehavioral outcomes. These observations indicate that pharmacologic HSP70 induction may prove to be a promising treatment for TBI. Published by Elsevier Ltd. on behalf of IBRO.	[Yenari, M. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Yenari, MA (corresponding author), Neurol 127,VAMC 4150 Clement St, San Francisco, CA 94121 USA.	nuri@berkeley.edu; jongyoul74@gmail.com; yenari@alum.mit.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS40516]; Department of DefenseUnited States Department of Defense; Veteran's Merit Award; American Heart Association Western States Affiliate Postdoctoral FellowshipAmerican Heart Association [13POST14810019]; Northern California Institute for Research and Education; resources of the Veterans Affairs Medical Center, San Francisco, California; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040516] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health (NS40516), Department of Defense and the Veteran's Merit Award to MY, an American Heart Association Western States Affiliate Postdoctoral Fellowship (13POST14810019) to JYK. Grants to MY and JYK were administered by the Northern California Institute for Research and Education, and supported by resources of the Veterans Affairs Medical Center, San Francisco, California. The authors wish to thank Dr. Linda Noble-Haeusslein for helpful discussion and advice.	Adachi M, 2009, PLOS ONE, V4, pA57, DOI 10.1371/journal.pone.0007719; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Chakraborty PK, 2008, CANCER SCI, V99, P1109, DOI 10.1111/j.1349-7006.2008.00809.x; Chatterjee A, 2008, AM J PHYSIOL-LUNG C, V294, pL755, DOI 10.1152/ajplung.00350.2007; Chatterjee A, 2007, AM J RESP CRIT CARE, V176, P667, DOI 10.1164/rccm.200702-291OC; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Giffard RG, 2004, J EXP BIOL, V207, P3213, DOI 10.1242/jeb.01034; Giffard RG, 2004, J NEUROSURG ANESTH, V16, P53, DOI 10.1097/00008506-200401000-00010; Giffard RG, 2008, ANESTHESIOLOGY, V109, P339, DOI 10.1097/ALN.0b013e31817f4ce0; Henderson B, 2010, CELL BIOCHEM FUNCT, V28, P1, DOI 10.1002/cbf.1609; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; Kelly S, 2002, ANN NEUROL, V52, P160, DOI 10.1002/ana.10264; Kelly Stephen, 2002, Curr Med Res Opin, V18 Suppl 2, ps55, DOI 10.1185/030079902125000732; Kim JY, 2013, NEUROBIOL DIS, V58, P289, DOI 10.1016/j.nbd.2013.06.012; Kim Nuri, 2012, Inflammopharmacology, V20, P177, DOI 10.1007/s10787-011-0115-3; Komotar RJ, 2007, NAT PROTOC, V2, P2345, DOI 10.1038/nprot.2007.359; Kwon HM, 2008, NEUROL RES, V30, P740, DOI 10.1179/174313208X289615; Lee JE, 2004, NEUROREPORT, V15, P499, DOI 10.1097/00001756-200403010-00023; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; Madrigal-Matute J, 2010, CARDIOVASC RES, V86, P330, DOI 10.1093/cvr/cvq046; Manaenko A, 2010, NEUROCHEM INT, V57, P844, DOI 10.1016/j.neuint.2010.09.001; Porter JR, 2009, CURR TOP MED CHEM, V9, P1386, DOI 10.2174/156802609789895719; Poulaki V, 2007, FASEB J, V21, P2113, DOI 10.1096/fj.06-7637com; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.0.CO;2-3; Sausville EA, 2003, CURR CANCER DRUG TAR, V3, P377, DOI 10.2174/1568009033481831; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004; Tavernier E, 2012, J CANCER RES CLIN, V138, P1753, DOI 10.1007/s00432-012-1247-6; Turturici G, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/618127; Vaishampayan UN, 2010, CLIN CANCER RES, V16, P3795, DOI 10.1158/1078-0432.CCR-10-0503; Wang GH, 2011, J NEUROCHEM, V117, P703, DOI 10.1111/j.1471-4159.2011.07239.x; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yenari MA, 2005, ANN NY ACAD SCI, V1053, P74, DOI 10.1196/annals.1344.007; Zhang JJ, 2013, CLIN EXP MED, V13, P323, DOI 10.1007/s10238-012-0208-3	34	30	33	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JAN 22	2015	284						912	919		10.1016/j.neuroscience.2014.11.010			8	Neurosciences	Neurosciences & Neurology	AW4HZ	WOS:000346243100081	25446362	Green Accepted			2021-06-18	
J	Czorlich, P; Skevas, C; Knospe, V; Vettorazzi, E; Richard, G; Wagenfeld, L; Westphal, M; Regelsberger, J				Czorlich, Patrick; Skevas, Christos; Knospe, Volker; Vettorazzi, Eik; Richard, Gisbert; Wagenfeld, Lars; Westphal, Manfred; Regelsberger, Jan			Terson syndrome in subarachnoid hemorrhage, intracerebral hemorrhage, and traumatic brain injury	NEUROSURGICAL REVIEW			English	Article						Terson syndrome; Intraocular hemorrhage; Subarachnoid hemorrhage; Traumatic brain injury; Intracerebral hemorrhage	NERVE SHEATH HEMORRHAGE; 60 CONSECUTIVE PATIENTS; VITREOUS HEMORRHAGE; INTRAOCULAR HEMORRHAGES; INTRACRANIAL-PRESSURE; MOYAMOYA-DISEASE; VITRECTOMY; INJECTION; ANEURYSMS	This prospective trial was designed to evaluate the incidence of Terson syndrome in patients suffering from subarachnoid hemorrhage, intracerebral hemorrhage, or traumatic brain injury and whether consequences necessarily derive from the intraocular hemorrhage itself. Two ophthalmologic examinations were performed to identify patients with Terson syndrome. Data on initial Glasgow Coma Scale, Hunt and Hess and Fisher grades, aneurysm site and diameter, and volume of hemorrhage in intracerebral hemorrhage patients were correlated to the location and course of Terson syndrome. Follow-up was performed after 3 months, including clinical and ophthalmologic investigations. The data showed that 16 of 83 subarachnoid hemorrhage patients (19.3 %), 2 of 22 intracerebral hemorrhage patients (9.1 %), and 1 of 32 traumatic brain injury patients (3.1 %) suffered from Terson syndrome. Low Glasgow Coma Scale (p = 0.002), high Hunt and Hess grade (p < 0.001), and high Fisher grade (p = 0.002) were found to be associated with a higher incidence of Terson syndrome. The neurological outcome in subarachnoid hemorrhage patients suffering from Terson syndrome was worse compared with that of subarachnoid hemorrhage patients without Terson syndrome (p = 0.005), and vitrectomy was performed in seven eyes of six patients due to poor visual acuity. Terson syndrome is underestimated in patients with subarachnoid hemorrhage and a rare pathology in intracerebral hemorrhage as well as in traumatic brain injury patients. Spontaneous regression of the intraocular hemorrhage may be seen, but in half of the patients, vitrectomy is necessary to prevent permanent visual deterioration.	[Czorlich, Patrick; Westphal, Manfred; Regelsberger, Jan] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, D-20246 Hamburg, Germany; [Skevas, Christos; Knospe, Volker; Richard, Gisbert; Wagenfeld, Lars] Univ Med Ctr Hamburg Eppendorf, Dept Ophthalmol, D-20246 Hamburg, Germany; [Vettorazzi, Eik] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, D-20246 Hamburg, Germany	Czorlich, P (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany.	p.czorlich@uke.de	Czorlich, Patrick/H-8934-2019; Vettorazzi, Eik/B-8130-2019	Vettorazzi, Eik/0000-0002-3737-6402			Arakawa Y, 2000, NEUROL MED-CHIR, V40, P480, DOI 10.2176/nmc.40.480; Augsten R, 2007, KLIN MONATSBL AUGENH, V224, P674, DOI 10.1055/s-2007-963325; Baker ML, 2008, J CLIN NEUROSCI, V15, P313, DOI 10.1016/j.jocn.2006.09.011; CASTREN JA, 1963, ACTA OPHTHALMOL, V41, P430; FAHMY JA, 1973, ACTA OPHTHALMOL, V51, P289; Fountas KN, 2008, J NEUROSURG, V109, P439, DOI 10.3171/JNS/2008/109/9/0439; Frizzel RT, 1997, NEUROSURGERY, V41, P33; Frizzell RT, 1997, NEUROSURGERY, V41, P529, DOI 10.1097/00006123-199709000-00004; GARFINKLE AM, 1992, J NEUROSURG, V76, P766, DOI 10.3171/jns.1992.76.5.0766; Gauntt CD, 2007, J NEURO-OPHTHALMOL, V27, P193, DOI 10.1097/WNO.0b013e31814b22dc; Gibran S, 2002, BRIT J OPHTHALMOL, V86, P353, DOI 10.1136/bjo.86.3.353; Hoving EW, 2009, J NEUROSURG, V110, P858, DOI 10.3171/2008.6.17610; Jr Hegdes TR, 1955, AMA ARCH OPHTHALMOL, V54, P425; Kim HS, 2012, J KOREAN NEUROSURG S, V51, P367, DOI 10.3340/jkns.2012.51.6.367; Kuhn F, 1998, OPHTHALMOLOGY, V105, P472, DOI 10.1016/S0161-6420(98)93030-5; Litten M, 1881, BERLINER KLIN WOCHEN, V18, P23; MANSCHOT WA, 1954, AM J OPHTHALMOL, V38, P501, DOI 10.1016/0002-9394(54)90700-X; Medele RJ, 1998, J NEUROSURG, V88, P851, DOI 10.3171/jns.1998.88.5.0851; Mena OJ, 2011, AM J FOREN MED PATH, V32, P55, DOI 10.1097/PAF.0b013e3181edee5b; MULLER PJ, 1974, J NEUROSURG, V41, P160, DOI 10.3171/jns.1974.41.2.0160; Naseri A, 2001, NEUROLOGY, V57, P364, DOI 10.1212/WNL.57.2.364; Ogawa T, 2001, OPHTHALMOLOGY, V108, P1654, DOI 10.1016/S0161-6420(01)00673-X; Pfausler B, 1996, J NEUROSURG, V85, P392, DOI 10.3171/jns.1996.85.3.0392; SHAW HE, 1975, AM J OPHTHALMOL, V80, P207, DOI 10.1016/0002-9394(75)90134-8; SHAW HE, 1977, ANN OPHTHALMOL, V9, P1403; Stiebel-Kalish H, 2004, RETINA-J RET VIT DIS, V24, P36, DOI 10.1097/00006982-200402000-00006; Stienen MN, 2012, CLIN NEUROL NEUROSUR, V114, P535, DOI 10.1016/j.clineuro.2011.10.034; Sung W, 2011, ACTA OPHTHALMOL, V89, P544, DOI 10.1111/j.1755-3768.2009.01735.x; Swallow CE, 1998, AM J NEURORADIOL, V19, P743; Takkar A, 2013, NEUROLOGY, V81, pE40, DOI 10.1212/WNL.0b013e31829e6f13; Terson A, 1990, CLIN OPHTHALMOL, V6, P309; TOOSI SH, 1987, ANN OPHTHALMOL, V19, P7; VANDERLINDEN RG, 1974, J NEUROSURG, V41, P167, DOI 10.3171/jns.1974.41.2.0167; WALSH FB, 1951, AM J OPHTHALMOL, V34, P509, DOI 10.1016/0002-9394(51)90294-2; WEAVER RG, 1961, AM J OPHTHALMOL, V52, P257, DOI 10.1016/0002-9394(61)91122-9; Wietholter S, 1998, ZBL NEUROCHIR, V59, P166	36	30	32	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JAN	2015	38	1					129	136		10.1007/s10143-014-0564-4			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AX8MD	WOS:000347162600023	25173620				2021-06-18	
J	Dean, PJA; Sato, JR; Vieira, G; McNamara, A; Sterr, A				Dean, Philip J. A.; Sato, Joao R.; Vieira, Gilson; McNamara, Adam; Sterr, Annette			Multimodal imaging of mild traumatic brain injury and persistent postconcussion syndrome	BRAIN AND BEHAVIOR			English	Article						Cognitive tasks; mild traumatic brain injury; neuroimaging	DEFAULT MODE NETWORK; POST-CONCUSSION SYMPTOMS; DIFFUSE AXONAL INJURY; WORKING-MEMORY; HEAD-INJURY; UNITED-STATES; FUNCTIONAL NETWORKS; PERFORMANCE; ACTIVATION; CONNECTIVITY	Background: Persistent postconcussion syndrome (PCS) occurs in around 5-10% of individuals after mild traumatic brain injury (mTBI), but research into the underlying biology of these ongoing symptoms is limited and inconsistent. One reason for this could be the heterogeneity inherent to mTBI, with individualized injury mechanisms and psychological factors. A multimodal imaging study may be able to characterize the injury better. Aim: To look at the relationship between functional (fMRI), structural (diffusion tensor imaging), and metabolic (magnetic resonance spectroscopy) data in the same participants in the long term (>1year) after injury. It was hypothesized that only those mTBI participants with persistent PCS would show functional changes, and that these changes would be related to reduced structural integrity and altered metabolite concentrations. Methods: Functional changes associated with persistent PCS after mTBI (>1year postinjury) were investigated in participants with and without PCS (both n=8) and non-head injured participants (n=9) during performance of working memory and attention/processing speed tasks. Correlation analyses were performed to look at the relationship between the functional data and structural and metabolic alterations in the same participants. Results: There were no behavioral differences between the groups, but participants with greater PCS symptoms exhibited greater activation in attention-related areas (anterior cingulate), along with reduced activation in temporal, default mode network, and working memory areas (left prefrontal) as cognitive load was increased from the easiest to the most difficult task. Functional changes in these areas correlated with reduced structural integrity in corpus callosum and anterior white matter, and reduced creatine concentration in right dorsolateral prefrontal cortex. Conclusion: These data suggest that the top-down attentional regulation and deactivation of task-irrelevant areas may be compensating for the reduction in working memory capacity and variation in white matter transmission caused by the structural and metabolic changes after injury. This may in turn be contributing to secondary PCS symptoms such as fatigue and headache. Further research is required using multimodal data to investigate the mechanisms of injury after mTBI, but also to aid individualized diagnosis and prognosis.	[Dean, Philip J. A.; McNamara, Adam; Sterr, Annette] Univ Surrey, Sch Psychol, Guildford GU2 7XH, Surrey, England; [Sato, Joao R.] Univ Fed ABC, Ctr Math Computat & Cognit, Sao Paulo, Brazil; [Sato, Joao R.; Vieira, Gilson] Univ Sao Paulo, Fac Med, Dept Radiol, NIF LIM44, Sao Paulo, Brazil	Dean, PJA (corresponding author), Univ Surrey, Sch Psychol, Guildford GU2 7XH, Surrey, England.	p.dean@surrey.ac.uk	Vieira, Gilson/H-9984-2015	Vieira, Gilson/0000-0001-5877-2810; Dean, Philip/0000-0002-2362-513X; Sterr, Annette/0000-0003-4490-985X	Wingate Foundation Scholarship, UK; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0200128] Funding Source: researchfish	This work was supported by a Wingate Foundation Scholarship, UK.	APA, 1994, DIAGN STA MAN MENT D; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen CJ, 2012, RADIOLOGY, V264, P844, DOI 10.1148/radiol.12112154; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Oliveira PPD, 2010, J ALZHEIMERS DIS, V19, P1263, DOI 10.3233/JAD-2010-1322; Dean PJA, 2013, NEUROREPORT, V24, P677, DOI 10.1097/WNR.0b013e3283637aa4; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Elbin RJ, 2012, BRAIN INJURY, V26, P1217, DOI 10.3109/02699052.2012.672788; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Fos L A, 2000, Appl Neuropsychol, V7, P140, DOI 10.1207/S15324826AN0703_4; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Gonzalez PG, 2011, PM&R, V3, pS413, DOI 10.1016/j.pmrj.2011.08.536; Goodacre S, 2008, EMERG MED J, V25, P556, DOI 10.1136/emj.2007.055723; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lazeron RHC, 2003, J NEUROL SCI, V213, P29, DOI 10.1016/S0022-510X(03)00144-8; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Medaglia JD, 2012, HUM BRAIN MAPP, V33, P979, DOI 10.1002/hbm.21264; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; NCIPC, 2003, REP C MILD TRAUM BRA; Nelson HE, 1982, NATL ADULT READING T; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sato JR, 2009, NEUROIMAGE, V46, P105, DOI 10.1016/j.neuroimage.2009.01.032; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Stulemeijer M, 2010, J NEUROTRAUM, V27, P1585, DOI 10.1089/neu.2010.1298; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Terry DP, 2012, BRAIN INJURY, V26, P1684, DOI 10.3109/02699052.2012.722259; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; World Health Organization, 1992, ICD 10 INT STAT CLAS; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125	90	30	32	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	JAN	2015	5	1							e00292	10.1002/brb3.292			17	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	CA6OO	WOS:000349034700006	25722949	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Lazarus, RC; Buonora, JE; Jacobowitz, DM; Mueller, GP				Lazarus, Rachel C.; Buonora, John E.; Jacobowitz, David M.; Mueller, Gregory P.			Protein carbonylation after traumatic brain injury: cell specificity, regional susceptibility, and gender differences	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Carbonylation; Reactive oxygen species; Reactive carbonyl species; Traumatic brain injury; Median eminence; Dorsal third ventricle; Astrocytes; Ependymal cells; Free radicals	ALZHEIMERS-DISEASE BRAIN; OXIDATIVE STRESS; LIPID-PEROXIDATION; PROTEOMIC IDENTIFICATION; HYPOTHALAMIC TANYCYTES; ASTROCYTES; PROGESTERONE; ACCUMULATION; DYSFUNCTION; METABOLISM	Protein carbonylation is a well-documented and quantifiable consequence of oxidative stress in several neuropathologies, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Although oxidative stress is a hallmark of traumatic brain injury (TB!), little work has explored the specific neural regions and cell types in which protein carbonylation occurs. Furthermore, the effect of gender on protein carbonylation after TBI has not been studied. The present investigation was designed to determine the regional and cell specificity of TBI-induced protein carbonylation and how this response to injury is affected by gender. Immunohistochemistry was used to visualize protein carbonylation in the brains of adult male and female Sprague-Dawley rats subjected to controlled cortical impact (CCI) as an injury model of TBI. Cell-specific markers were used to colocalize the presence of carbonylated proteins in specific cell types, including astrocytes, neurons, microglia, and oligodendrocytes. Results also indicated that the injury lesion site, ventral portion of the dorsal third ventricle, and ventricular lining above the median eminence showed dramatic increases in protein carbonylation after injury. Specifically, astrocytes and limited regions of ependymal cells adjacent to the dorsal third ventricle and the median eminence were most susceptible to postinjury protein carbonylation. However, these patterns of differential susceptibility to protein carbonylation were gender dependent, with males showing significantly greater protein carbonylation at sites distant from the lesion. Proteomic analyses were also conducted and determined that the proteins most affected by carbonylation in response to TBI include glial fibrillary acidic protein, dihydropyrimidase-related protein 2, fructose-bisphosphate aldolase C, and fructose-bisphosphate aldolase A. Many other proteins, however, were not carbonylated by CCI. These findings indicate that there is both regional and protein specificity in protein carbonylation after TBI. The marked increase in carbonylation seen in ependymal layers distant from the lesion suggests a mechanism involving the transmission of a cerebral spinal fluid-borne factor to these sites. Furthermore, this process is affected by gender, suggesting that hormonal mechanisms may serve a protective role against oxidative stress. Published by Elsevier Inc.	[Lazarus, Rachel C.; Buonora, John E.; Jacobowitz, David M.; Mueller, Gregory P.] Uniformed Serv Univ Hlth Sci, Program Neurosci, Bethesda, MD 20814 USA; [Jacobowitz, David M.; Mueller, Gregory P.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Mueller, Gregory P.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Mueller, GP (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Gregory.mueller@usuhs.edu			Uniformed Services University of the Health Services [T0702554, R07028414]; TriService Nursing Research Program [N12-P12]	The authors thank Dr. Regina Day for her assistance in preparation of this publication. Support for this work included funding from the Uniformed Services University of the Health Services (T0702554 and R07028414) and TriService Nursing Research Program (N12-P12). The views expressed are the private views of the authors and do not necessary reflect the official policy or position of the Uniformed Services University of the Health Sciences, the Department of the Army, the Department of Defense, or the United States government.	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Azimzadeh O, 2011, PROTEOMICS, V11, P3299, DOI 10.1002/pmic.201100178; Barrett P, 2006, J ENDOCRINOL, V191, P687, DOI 10.1677/joe.1.06929; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Bizzozero OA, 2005, J NEUROSCI RES, V81, P687, DOI 10.1002/jnr.20587; Bosken J. M., 2012, SPRINGER PROTOCOLS H; Butterfield DA, 2012, ANTIOXID REDOX SIGN, V17, P1610, DOI 10.1089/ars.2011.4109; Carini M., 2010, MASS SPECTROMETRIC S, P173; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Clausen F., 2004, ACTA U UPSALIENSIS C, V77; Conrad C. C., 1999, BIOL PROCED ONLINE, V2, P39; Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x; Del Bigio MR, 2010, ACTA NEUROPATHOL, V119, P55, DOI 10.1007/s00401-009-0624-y; Desagher S, 1996, J NEUROSCI, V16, P2553; Devi L, 2006, J NEUROSCI, V26, P9057, DOI 10.1523/JNEUROSCI.1469-06.2006; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Faul M., 2010, INJ PREV, V16; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Ikegami K, 2010, CELL STRUCT FUNCT, V35, P15, DOI 10.1247/csf.09027; Irwin RW, 2008, ENDOCRINOLOGY, V149, P3167, DOI 10.1210/en.2007-1227; Johanson C, 2011, TOXICOL PATHOL, V39, P186, DOI 10.1177/0192623310394214; Kavakli HS, 2010, SCI RES ESSAYS, V5, P2832; Kent T., 2008, 1 BAYL COLL MED; Kernt M, 2013, J GLAUCOMA, V22, P404, DOI 10.1097/IJG.0b013e31824caf90; Lee DA, 2012, NAT NEUROSCI, V15, P700, DOI 10.1038/nn.3079; Luoma JI, 2011, STEROIDS, V76, P845, DOI 10.1016/j.steroids.2011.02.013; Lushchak VI, 2012, OXIDATIVE STRESS IN AQUATIC ECOSYSTEMS, P420; Mackay GM, 2006, EUR J NEUROL, V13, P30, DOI 10.1111/j.1468-1331.2006.01220.x; Merkulova M, 2011, AM J PHYSIOL-CELL PH, V300, pC1442, DOI 10.1152/ajpcell.00076.2010; NAVARRO A, 1995, HISTOL HISTOPATHOL, V10, P861; NOBLE PG, 1994, BRAIN RES, V633, P83, DOI 10.1016/0006-8993(94)91525-3; Oikawa S, 2014, FREE RADICAL RES, V48, P694, DOI 10.3109/10715762.2014.901509; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Papadopoulos MC, 1998, NEUROSCIENCE, V82, P915; Peruzzo B, 2004, CELL TISSUE RES, V317, P147, DOI 10.1007/s00441-004-0899-1; Peuchen S, 1997, PROG NEUROBIOL, V52, P261, DOI 10.1016/S0301-0082(97)00010-5; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Rangarajan ES, 2010, J BIOL CHEM, V285, P11983, DOI 10.1074/jbc.M109.092049; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rodriguez EM, 2005, INT REV CYTOL, V247, P89, DOI 10.1016/S0074-7696(05)47003-5; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Rzigalinski B.A., 2011, NANOMEDICINE HLTH DI, P100; Schinder AF, 1996, J NEUROSCI, V16, P6125; Selley ML, 1998, FREE RADICAL BIO MED, V25, P169, DOI 10.1016/S0891-5849(98)00021-5; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Simpson EP, 2004, NEUROLOGY, V62, P1758, DOI 10.1212/WNL.62.10.1758; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Sugino N, 1996, ENDOCRINOLOGY, V137, P749, DOI 10.1210/en.137.2.749; Sultana R, 2010, J ALZHEIMERS DIS, V19, P341, DOI 10.3233/JAD-2010-1222; Suzuki Y, 2003, J NEUROCHEM, V86, P1042, DOI 10.1046/j.1471-4159.2003.01920.x; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zheng JZ, 2010, J NEUROSCI RES, V88, P3376, DOI 10.1002/jnr.22488	61	30	30	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JAN	2015	78						89	100		10.1016/j.freeradbiomed.2014.10.507			12	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AZ4GB	WOS:000348178700009	25462645	Other Gold			2021-06-18	
J	Liu, SG; Ren, PY; Wang, GY; Yao, SX; He, XJ				Liu, Shu-Guang; Ren, Peng-Yu; Wang, Guo-Yu; Yao, Shu-Xin; He, Xi-Jing			Allicin protects spinal cord neurons from glutamate-induced oxidative stress through regulating the heat shock protein 70/inducible nitric oxide synthase pathway	FOOD & FUNCTION			English	Article							RAT CORTICAL-NEURONS; ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; KAPPA-B ACTIVATION; LIPID-PEROXIDATION; PARKINSONS-DISEASE; SECONDARY INJURY; CONTUSION INJURY; IN-VITRO; EXPRESSION	Allicin, the main biologically active compound derived from garlic, exerts a broad spectrum of pharmacological activities and is considered to have therapeutic potential in many neurological disorders. Using an in vitro spinal cord injury model induced by glutamate treatment, we sought to investigate the neuroprotective effects of allicin in primary cultured spinal cord neurons. We found that allicin treatment significantly attenuated glutamate-induced lactate dehydrogenase (LDH) release, loss of cell viability and apoptotic neuronal death. This protection was associated with reduced oxidative stress, as evidenced by decreased reactive oxygen species (ROS) generation, reduced lipid peroxidation and preservation of antioxidant enzyme activities. The results of western blot analysis showed that allicin decreased the expression of inducible nitric oxide synthase (iNOS), but had no effects on the expression of neuronal NOS (nNOS) following glutamate exposure. Moreover, allicin treatment significantly increased the expression of heat shock protein 70 (HSP70) at both mRNA and protein levels. Knockdown of HSP70 by specific targeted small interfere RNA (siRNA) not only mitigated allicin-induced protective activity, but also partially nullified its effects on the regulation of iNOS. Collectively, these data demonstrate that allicin treatment may be an effective therapeutic strategy for spinal cord injury, and that the potential underlying mechanism involves HSP70/iNOS pathway-mediated inhibition of oxidative stress.	[Liu, Shu-Guang; Wang, Guo-Yu; He, Xi-Jing] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Dept Orthopaed, Xian 710004, Shaanxi, Peoples R China; [Ren, Peng-Yu] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 3, Dept Neurosurg, Xian 710068, Shaanxi, Peoples R China; [Liu, Shu-Guang; Yao, Shu-Xin] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp, Dept Orthopaed,Hong Hui Hosp, Xian 710004, Shaanxi, Peoples R China	He, XJ (corresponding author), Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Dept Orthopaed, Xian 710004, Shaanxi, Peoples R China.	hexijing_xjtu@163.com	He, Xijing/AAE-7424-2021	He, Xijing/0000-0002-0465-5376			Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Ayala GX, 2008, NEUROPHARMACOLOGY, V55, P1383, DOI 10.1016/j.neuropharm.2008.08.035; Bayan L, 2014, AVICENNA J PHYTOMEDI, V4, P1; Bruck R, 2005, LIVER INT, V25, P613, DOI 10.1111/j.1478-3231.2005.01050.x; Cao HQ, 2013, NEUROSCI BULL, V29, P94, DOI 10.1007/s12264-012-1277-8; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI [10.1089/neu.2008.0870, 10.1089/neu.2008-0870]; Chan JYY, 2013, PHYTOTHER RES, V27, P637, DOI 10.1002/ptr.4796; Chan JYH, 2004, CIRCULATION, V110, P3560, DOI 10.1161/01.CIR.0000143082.63063.33; Chang CC, 2014, NEUROBIOL DIS, V62, P241, DOI 10.1016/j.nbd.2013.10.012; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2013, CELL SIGNAL, V25, P2863, DOI 10.1016/j.cellsig.2013.09.004; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Chen W, 2014, NEUROCHEM INT, V68, P28, DOI 10.1016/j.neuint.2014.01.015; Chiesa R, 2004, ANN VASC SURG, V18, P514, DOI 10.1007/s10016-004-0072-z; CRAWFORD ES, 1986, J VASC SURG, V3, P389, DOI 10.1067/mva.1986.avs0030389; Dawson TM, 1996, ANNU REV MED, V47, P219, DOI 10.1146/annurev.med.47.1.219; Die J, 2010, BRAIN RES, V1346, P251, DOI 10.1016/j.brainres.2010.05.068; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; Evans CG, 2010, J MED CHEM, V53, P4585, DOI 10.1021/jm100054f; Fujisawa H, 2008, J AGR FOOD CHEM, V56, P4229, DOI 10.1021/jf8000907; Garcia Y, 2013, ANIMAL, V7, P1651, DOI 10.1017/S1751731113001134; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; Hamaishi M, 2009, ANN VASC SURG, V23, P128, DOI 10.1016/j.avsg.2008.05.010; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2009, J NEUROCHEM, V111, P1348, DOI 10.1111/j.1471-4159.2009.06395.x; Heneka MT, 2001, J NEUROIMMUNOL, V114, P8, DOI 10.1016/S0165-5728(01)00246-6; Horev-Azaria L, 2009, EUR J NUTR, V48, P67, DOI 10.1007/s00394-008-0762-3; Hunter R, 2005, ANN NY ACAD SCI, V1056, P234, DOI 10.1196/annals.1352.011; In JH, 2003, MOL CELLS, V15, P406; Isaka M, 2006, J VASC SURG, V43, P1257, DOI 10.1016/j.jvs.2006.02.017; Izigov N, 2011, FREE RADICAL BIO MED, V50, P1131, DOI 10.1016/j.freeradbiomed.2011.01.028; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Kakinohana M, 2011, STROKE, V42, P2302, DOI 10.1161/STROKEAHA.110.600429; Kao MC, 2004, ANESTH ANALG, V99, P580, DOI 10.1213/01.ANE.0000130391.62612.3E; Kiyoshima T, 2003, ANESTH ANALG, V96, P839, DOI 10.1213/01.ANE.0000047268.41102.D4; Lam T, 2013, SPINAL CORD, V51, P656, DOI 10.1038/sc.2013.71; Lawson LD, 2005, J AGR FOOD CHEM, V53, P6254, DOI 10.1021/jf050536+; Lawson LD, 2005, J AGR FOOD CHEM, V53, P1974, DOI 10.1021/jf048323s; Liu CL, 2002, CHINESE MED J-PEKING, V115, P740; Liu NK, 2006, ANN NEUROL, V59, P606, DOI 10.1002/ana.20798; Liu Philip K., 2001, Current Topics in Medicinal Chemistry, V1, P483, DOI 10.2174/1568026013394688; Miron T, 2000, BBA-BIOMEMBRANES, V1463, P20, DOI 10.1016/S0005-2736(99)00174-1; Okada Y, 2005, REDOX REP, V10, P96, DOI 10.1179/135100005X38851; Patury S, 2009, CURR TOP MED CHEM, V9, P1337, DOI 10.2174/156802609789895674; Ross ME, 1996, METHOD ENZYMOL, V269, P408; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Santoscopy C, 2002, NEUROSCI LETT, V330, P94, DOI 10.1016/S0304-3940(02)00716-4; Sela U, 2008, NUTR CANCER, V60, P412, DOI 10.1080/01635580701733083; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Staba EJ, 2001, J NUTR, V131, p1118S, DOI 10.1093/jn/131.3.1118S; Tabayashi K, 2005, SURG TODAY, V35, P1, DOI 10.1007/s00595-004-2889-z; Temiz C, 2013, TURK NEUROSURG, V23, P67, DOI 10.5137/1019-5149.JTN.6825-12.1; van Duijnhoven N, 2010, EUR J APPL PHYSIOL, V109, P1059, DOI 10.1007/s00421-010-1398-6; Witt SN, 2010, BIOPOLYMERS, V93, P218, DOI 10.1002/bip.21302; Yang JY, 2007, SPINAL CORD, V45, P731, DOI 10.1038/sj.sc.3102036; Yune TY, 2009, J NEUROCHEM, V110, P1276, DOI 10.1111/j.1471-4159.2009.06214.x; Yune TY, 2004, J NEUROTRAUM, V21, P1778, DOI 10.1089/0897715042664858; Zhou LS, 2013, BRAIN RES, V1517, P150, DOI 10.1016/j.brainres.2013.04.007; Zhou YF, 2014, BRAIN RES BULL, V100, P14, DOI 10.1016/j.brainresbull.2013.10.013; Zhu JW, 2012, NEUROCHEM INT, V61, P640, DOI 10.1016/j.neuint.2012.06.021	63	30	31	1	19	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2042-6496	2042-650X		FOOD FUNCT	Food Funct.		2015	6	1					321	330		10.1039/c4fo00761a			10	Biochemistry & Molecular Biology; Food Science & Technology	Biochemistry & Molecular Biology; Food Science & Technology	AX9QB	WOS:000347235900032	25473931				2021-06-18	
J	Rusch, HL; Guardado, P; Baxter, T; Mysliwiec, V; Gill, JM				Rusch, Heather L.; Guardado, Pedro; Baxter, Tristin; Mysliwiec, Vincent; Gill, Jessica M.			Improved Sleep Quality is Associated with Reductions in Depression and PTSD Arousal Symptoms and Increases in IGF-1 Concentrations	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						BDNF; depression; IGF-1; insomnia; military; PTSD; sleep quality; mTBI; trauma	GROWTH-FACTOR-I; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; NEUROTROPHIC FACTOR; CLINICIAN; INSOMNIA; HOMEOSTASIS; DISTURBANCE; NIGHTMARES	Study Objectives: One-third of deployed military personnel will be diagnosed with insomnia, placing them at high risk for comorbid depression, posttraumatic stress disorder (PTSD), and medical conditions. The disruption of trophic factors has been implicated in these comorbid conditions, which can impede postdeployment recovery. This study determined if improved sleep quality is associated with (1) reductions in depression and posttraumatic symptoms, as well as enrichments in health-related quality of life (HRQOL), and (2) changes in plasma concentrations of brain derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1). Methods: Forty-four military personnel diagnosed with insomnia underwent clinical evaluations and blood draws at pretreatment and at posttreatment following cognitive behavioral therapy for insomnia and automatic positive airway pressure treatment. Participants were classified as sleep improved (n = 28) or sleep declined (n = 16) based on their change in pretreatment to posttreatment Pittsburgh Sleep Quality Index (PSQI) score. Both groups were compared on outcomes of depression, PTSD, HRQOL, BDNF, and IGF-1. Results: Paired t-tests of the sleep improved group revealed significant declines in depression (p = 0.005) and posttraumatic arousal (p = 0.006) symptoms, and a significant increase in concentrations of IGF-1 (p = 0.009). The sleep declined group had no relevant change in psychiatric symptoms or trophic factors, and had further declines on five of eight dimensions of HRQOL. Between-group change score differences were significant at p < 0.05. Conclusions: These findings suggest that interventions, which successfully improve sleep quality, are an effective means to reduce the depression and posttraumatic arousal symptoms common to military personnel, as well as increase protective trophic factors implicated in these conditions.	[Rusch, Heather L.; Guardado, Pedro; Gill, Jessica M.] NINR, NIH, Bethesda, MD 20892 USA; [Rusch, Heather L.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Baxter, Tristin; Mysliwiec, Vincent] Madigan Army Med Ctr, Tacoma, WA 98431 USA	Rusch, HL (corresponding author), 1 Cloister Court,Bldg 60 259, Bethesda, MD 20892 USA.	heather.rusch@nih.gov	Gill, Gill M/Q-2020-2017	Rusch, Heather/0000-0002-4061-8628	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000027] Funding Source: NIH RePORTER	This was not an industry supported study. The authors have indicated no financial conflicts of interest. The work was performed at the Madigan Army Medical Center, Tacoma, WA. Support for this work included funding from Department of Defense in the Center for Neuroscience and Regenerative Medicine.	Andero R, 2014, PROG MOL BIOL TRANSL, V122, P169, DOI 10.1016/B978-0-12-420170-5.00006-4; Angelucci F, 2014, BRAIN COGNITION, V84, P118, DOI 10.1016/j.bandc.2013.11.012; [Anonymous], 2005, INT CLASSLEEP DIS; Bachmann V, 2012, SLEEP, V35, P335, DOI 10.5665/sleep.1690; Bonne O, 2011, J CLIN PSYCHIAT, V72, P1124, DOI 10.4088/JCP.09m05106blu; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; Britton WB, 2012, PSYCHOTHER PSYCHOSOM, V81, P296, DOI 10.1159/000332755; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cho HJ, 2008, AM J PSYCHIAT, V165, P1543, DOI 10.1176/appi.ajp.2008.07121882; Creyghton Wouter M, 2004, Semin Vasc Med, V4, P167, DOI 10.1055/s-2004-835375; Escamilla M, 2012, CURR PSYCHIAT REP, V14, P529, DOI 10.1007/s11920-012-0306-7; Gehrman P, 2013, SLEEP, V36, P1009, DOI 10.5665/sleep.2798; Giese M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076050; Gomez-Merino D, 2005, NEUROIMMUNOMODULAT, V12, P164, DOI 10.1159/000084849; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoyos CM, 2014, SLEEP, V37, P733, DOI 10.5665/sleep.3580; JARRETT DB, 1990, BIOL PSYCHIAT, V27, P497, DOI 10.1016/0006-3223(90)90441-4; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johnson-Farley NN, 2006, J PHARMACOL EXP THER, V316, P1062, DOI 10.1124/jpet.105.094433; Koffel E, 2013, J ANXIETY DISORD, V27, P512, DOI 10.1016/j.janxdis.2013.07.003; Molendijk ML, 2011, MOL PSYCHIATR, V16, P1088, DOI 10.1038/mp.2010.98; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Mysliwiec V, 2013, CHEST, V144, P549, DOI 10.1378/chest.13-0088; Nakamura Y, 2011, J PSYCHOSOM RES, V70, P335, DOI 10.1016/j.jpsychores.2010.09.007; Paslakis G, 2012, MED HYPOTHESES, V79, P222, DOI 10.1016/j.mehy.2012.04.045; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558; Pigeon WR, 2013, J PSYCHOSOM RES, V75, P546, DOI 10.1016/j.jpsychores.2013.09.004; Pittenger C, 2008, NEUROPSYCHOPHARMACOL, V33, P88, DOI 10.1038/sj.npp.1301574; Rajpathak SN, 2009, DIABETES-METAB RES, V25, P3, DOI 10.1002/dmrr.919; Rosario ER, 2013, J HEAD TRAUMA REHAB, V28, P390, DOI 10.1097/HTR.0b013e318250eac6; Rush AJ, 1998, BIOL PSYCHIAT, V44, P3, DOI 10.1016/S0006-3223(98)00092-4; Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8; Schilling C, 2011, J CLIN PSYCHOPHARM, V31, P390, DOI 10.1097/JCP.0b013e3182189d86; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Siebern AT, 2011, PSYCHOL RES BEHAV MA, V4, P21, DOI 10.2147/PRBM.S10041; Suzuki G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089455; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Weber-Hamann B, 2009, PHARMACOPSYCHIATRY, V42, P23, DOI 10.1055/s-0028-1085442; Williams J, 2013, CHEST, V143, P554, DOI 10.1378/chest.12-0731	43	30	30	0	14	AMER ACAD SLEEP MEDICINE	WESTCHESTER	ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA	1550-9389	1550-9397		J CLIN SLEEP MED	J. Clin. Sleep Med.		2015	11	6					615	623	PII jc-00412-14	10.5664/jcsm.4770			9	Clinical Neurology	Neurosciences & Neurology	CY3BZ	WOS:000366284500007	25766717	Green Published, Bronze			2021-06-18	
J	Siracusa, R; Paterniti, I; Impellizzeri, D; Cordaro, M; Crupi, R; Navarra, M; Cuzzocrea, S; Esposito, E				Siracusa, Rosalba; Paterniti, Irene; Impellizzeri, Daniela; Cordaro, Marika; Crupi, Rosalia; Navarra, Michele; Cuzzocrea, Salvatore; Esposito, Emanuela			The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Autophagy; luteolin; neuroinflammation; neuroprotection; palmitoylethanolamide; Parkinson's disease	FATTY-ACID AMIDE; TRAUMATIC BRAIN-INJURY; MOUSE MODEL; KAPPA-B; N-PALMITOYLETHANOLAMIDE; ALPHA-SYNUCLEIN; ANANDAMIDE; FLAVONOIDS; INFLAMMATION; ACTIVATION	Parkinson's disease (PD) is a disorder resulted by degeneration of dopaminergic neurons. To counteract the neuroinflammation and oxidative stress of PD, we decided to test a new composite constituted by palmitoylethanolamide (PEA) and luteolin (Lut), in a mass ratio of 10: 1, respectively (co-ultraPEALut). In this study the neuroprotective property of the new compound was investigated. For the in vivo model of PD, mice received four injections of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Starting 24 h after the first administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), we treated animals with co-ultraPEALut daily until 7 days. On day 8, brains were processed for Western blotting and immunohistochemical analysis. Treatment with co-ultraPEALut reduced the specific markers of PD (tyrosine hydroxylase immunopositive), and the increased levels of activated astrocytes and pro-inflammatory cytokines as well as inducible nitric oxide synthase. Further, the possible association of autophagy with the beneficial effects of co-ultraPEALut. Western blot analysis and immunofluorescence staining showed that co-ultraPEALut administration increased autophagy process. These data were confirmed by an in vitro model, using SH-SY5Y neuroblastoma cells. Western blot analysis showed that co-ultraPEALut pre-treatment maintained high Beclin-1 and p62 expression, while continued to inhibit the p70S6K expression. Altogether, these results put forward that treatment with co-ultraPEALut is able to modulate both the neuroinflammatory process and the autophagic pathway involved in PD, actions which may underlie its neuroprotective effect.	[Siracusa, Rosalba; Paterniti, Irene; Impellizzeri, Daniela; Cordaro, Marika; Crupi, Rosalia; Cuzzocrea, Salvatore; Esposito, Emanuela] Univ Messina, Dept Biol & Environm Sci, I-98166 Messina, Italy; [Navarra, Michele] Univ Messina, Pharmacobiol Dept, I-98166 Messina, Italy; [Cuzzocrea, Salvatore] St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Esposito, E (corresponding author), Univ Messina, Dept Biol & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy.	eesposito@unime.it	Crupi, Rosalia/U-4364-2019; Cordaro, Marika/K-7329-2016	Cordaro, Marika/0000-0002-3980-0043; Cuzzocrea, Salvatore/0000-0001-6131-3690; Crupi, Rosalia/0000-0002-7629-3132; Siracusa, Rosalba/0000-0001-7868-2505; Impellizzeri, Daniela/0000-0001-9492-3161	 [PON 01_02512]	The authors would like to thank Maria Antonietta Medici for her excellent technical assistance during this study and Mr. Francesco Soraci for his secretarial and administrative assistance and Miss Valentina Malvagni for her editorial assistance with the manuscript. This study was supported by PON 01_02512.	Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1; Bouchard JF, 2003, LIFE SCI, V72, P1859, DOI 10.1016/S0024-3205(02)02474-8; Calignano A, 2001, EUR J PHARMACOL, V419, P191, DOI 10.1016/S0014-2999(01)00988-8; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Capasso R, 2001, BRIT J PHARMACOL, V134, P945, DOI 10.1038/sj.bjp.0704339; Capuano A, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-43; Chen CC, 2004, MOL PHARMACOL, V66, P683; Cordaro M, 2015, J NEUROTRAUMA; Crupi R, 2013, CNS NEUROL DISORD-DR, V12, P989, DOI 10.2174/18715273113129990084; Cui YW, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-42; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; De Petrocellis L, 2002, FUND CLIN PHARMACOL, V16, P297, DOI 10.1046/j.1472-8206.2002.00094.x; Di Marzo V, 2001, BIOCHEM J, V358, P249, DOI 10.1042/0264-6021:3580249; Esposito E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041880; Esposito E, 2011, BRAIN BEHAV IMMUN, V25, P1099, DOI 10.1016/j.bbi.2011.02.006; Franklin A, 2003, J NEUROSCI, V23, P7767; Genovese T, 2008, J PHARMACOL EXP THER, V326, P12, DOI 10.1124/jpet.108.136903; Ghosh A, 2007, P NATL ACAD SCI USA, V104, P18754, DOI 10.1073/pnas.0704908104; Hald A, 2005, EXP NEUROL, V193, P279, DOI 10.1016/j.expneurol.2005.01.013; Hansen HS, 2009, BIOCHEM PHARMACOL, V78, P553, DOI 10.1016/j.bcp.2009.04.024; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6; Hsieh CF, 2008, OPT LETT, V33, P1174, DOI 10.1364/OL.33.001174; Jaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kumazawa Y, 2006, CURR PHARM DESIGN, V12, P4271, DOI 10.2174/138161206778743565; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lambert DM, 2001, EPILEPSIA, V42, P321, DOI 10.1046/j.1528-1157.2001.41499.x; Levy OA, 2009, APOPTOSIS, V14, P478, DOI 10.1007/s10495-008-0309-3; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Liu F, 2012, IMMUNOL REV, V246, P239, DOI 10.1111/j.1600-065X.2012.01107.x; Liu KY, 2013, NEUROCHEM RES, V38, P201, DOI 10.1007/s11064-012-0909-8; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Lynch-Day MA, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009357; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; McGeer Patrick L, 2002, Sci Aging Knowledge Environ, V2002, pre3, DOI 10.1126/sageke.2002.29.re3; Middleton E, 2000, PHARMACOL REV, V52, P673; Miller RL, 2009, NEUROCHEM RES, V34, P55, DOI 10.1007/s11064-008-9656-2; Mizushima N, 2010, FEBS LETT, V584, P1279, DOI 10.1016/j.febslet.2010.02.053; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Muccioli GG, 2008, NEUROPHARMACOLOGY, V54, P16, DOI 10.1016/j.neuropharm.2007.05.015; Muramatsu Y, 2003, J NEURAL TRANSM, V110, P1129, DOI 10.1007/s00702-003-0021-y; Nagatsu T, 2000, J NEURAL TRANSM-SUPP, P143; Ola MS, 2011, MOL CELL BIOCHEM, V351, P41, DOI 10.1007/s11010-010-0709-x; Ouchi Y, 2005, ANN NEUROL, V57, P168, DOI 10.1002/ana.20338; Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819; Paterniti I, 2014, CNS NEUROL DISORD-DR, V13, P1530, DOI 10.2174/1871527313666140806124322; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-91; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Schulz JB, 2004, CELL TISSUE RES, V318, P135, DOI 10.1007/s00441-004-0954-y; Seelinger G, 2008, PLANTA MED, V74, P1667, DOI 10.1055/s-0028-1088314; Sheerin AH, 2004, EPILEPSIA, V45, P1184, DOI 10.1111/j.0013-9580.2004.16604.x; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Song X, 1997, NEUROTOXICOLOGY, V18, P341; Spilman P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009979; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Winklhofer KF, 2010, BBA-MOL BASIS DIS, V1802, P29, DOI 10.1016/j.bbadis.2009.08.013; Xagorari A, 2001, J PHARMACOL EXP THER, V296, P181; Xilouri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005515; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang QA, 2010, NEUROSCIENTIST, V16, P335, DOI 10.1177/1073858409357118	66	30	30	0	6	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2015	14	10					1350	1366		10.2174/1871527314666150821102823			17	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CX6JW	WOS:000365808000018	26295827				2021-06-18	
J	Logsdon, AF; Turner, RC; Lucke-Wold, BP; Robson, MJ; Naser, ZJ; Smith, KE; Matsumoto, RR; Huber, JD; Rosen, CL				Logsdon, Aric Flint; Turner, Ryan Coddington; Lucke-Wold, Brandon Peter; Robson, Matthew James; Naser, Zachary James; Smith, Kelly Elizabeth; Matsumoto, Rae Reiko; Huber, Jason Delwyn; Rosen, Charles Lee			Altering endoplasmic reticulum stress in a model of blast-induced traumatic brain injury controls cellular fate and ameliorates neuropsychiatric symptoms	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						blast-induced traumatic brain injury; blood-brain barrier; endoplasmic reticulum stress; salubrinal; CHOP; apoptosis; prefrontal cortex	UNFOLDED PROTEIN RESPONSE; ER STRESS; AXONAL INJURY; APOPTOSIS; ACTIVATION; BCL-2; CASPASE-12; EXPRESSION; HEAD; INHIBITION	Neuronal injury following blast-induced traumatic brain injury (bTBI) increases the risk for neuropsychiatric disorders, yet the pathophysiology remains poorly understood. Blood-brain-barrier (BBB) disruption, endoplasmic reticulum (ER) stress, and apoptosis have all been implicated in bTBI. Microvessel compromise is a primary effect of bTBI and is postulated to cause subcellular secondary effects such as ER stress. What remains unclear is how these secondary effects progress to personality disorders in humans exposed to head trauma. To investigate this we exposed male rats to a clinically relevant bTBI model we have recently developed. The study examined initial BBB disruption using Evan's blue (EB), ER stress mechanisms, apoptosis and impulsive-like behavior measured with elevated plus maze (EPM). Large BBB openings were observed immediately following bTBI, and persisted for at least 6 h. Data showed increased mRNA abundance of stress response genes at 3 h, with subsequent increases in the ER stress markers C/EBP homologous protein (CHOP) and growth arrest and DNA damage-inducible protein 34 (GADD34) at 24 h. Caspase-12 and Caspase-3 were both cleaved at 24 h following bTBI. The ER stress inhibitor, salubrinal (SAL), was administered (1 mg/kg i.p.) to investigate its effects on neuronal injury and impulsive-like behavior associated with bTBI. SAL reduced CHOP protein expression, and diminished Caspase-3 cleavage, suggesting apoptosis attenuation. Interestingly, SAL also ameliorated impulsive-like behavior indicative of head trauma. These results suggest SAL plays a role in apoptosis regulation and the pathology of chronic disease. These observations provide evidence that bTBI involves ER stress and that the unfolded protein response (UPR) is a promising molecular target for the attenuation of neuronal injury.	[Logsdon, Aric Flint; Robson, Matthew James; Smith, Kelly Elizabeth; Matsumoto, Rae Reiko; Huber, Jason Delwyn] W Virginia Univ, Sch Pharm, Dept Pharmaceut Sci, Morgantown, WV 26506 USA; [Logsdon, Aric Flint; Turner, Ryan Coddington; Lucke-Wold, Brandon Peter; Huber, Jason Delwyn; Rosen, Charles Lee] W Virginia Univ, Hlth Sci Ctr, Ctr Neurosci, Morgantown, WV 26506 USA; [Logsdon, Aric Flint; Turner, Ryan Coddington; Lucke-Wold, Brandon Peter; Naser, Zachary James; Huber, Jason Delwyn; Rosen, Charles Lee] W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA; [Robson, Matthew James] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37235 USA; [Matsumoto, Rae Reiko] Touro Univ Calif, Coll Pharm, Deans Off, Vallejo, CA USA	Rosen, CL (corresponding author), W Virginia Univ, Hlth Sci Ctr, Sch Med, Dept Neurosurg, Med Ctr Dr,Suite 4300,POB 9183, Morgantown, WV 26506 USA.	crosen@hsc.wvu.edu	Robson, Matthew/H-3127-2013	Robson, Matthew/0000-0002-3277-3062; Fraser, Kelly/0000-0003-1563-050X; Turner, Ryan/0000-0001-5523-0645	Mary Babb Randolph Cancer Center; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 RR016550, P30 RR032138/GM103488, P20 RR016477]; West Virginia University Health Sciences Center Office of Research and Graduate Education; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32GM08174]	We thank Dr. James P. O'Callaghan and Dr. Diane B. Miller of the Center for Disease Control (CDC) and the National Institute for Occupational Safety and Health (NIOSH). The authors also acknowledge the work done by Zhenjun Tan, Corey Brown and Diana Richardson. The authors are grateful for the assistance of Dr. Robert T.T. Gettens and Nicholas St. John of Western New England University for the design of the blast model and Mr. Peter Bennett and Mr. James Edward Robson for model construction. Imaging experiments and image analysis were performed in the West Virginia University Microscope Imaging Facility, which has been supported by the Mary Babb Randolph Cancer Center and NIH grants P20 RR016550, P30 RR032138/GM103488 and P20 RR016477. This work was supported by a Research Funding and Development (RFDG) grant from the West Virginia University Health Sciences Center Office of Research and Graduate Education (to Jason Delwyn Huber and Charles Lee Rosen) and a training grant from the National Institutes of Health (to Ryan Coddington Turner) (5T32GM08174).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Badiola N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.31; Beerten J, 2012, CURR TOP MED CHEM, V12, P2470; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Bernales S, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00005; Bidzan L, 2012, MED SCI MONITOR, V18, pCR182, DOI 10.12659/MSM.882523; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chen Y, 2013, J NEUROPSYCH CLIN N, V25, P103, DOI 10.1176/appi.neuropsych.12030058; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00119; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Costa RO, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.04.011; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Farrell-Carnahan L, 2013, MIL MED, V178, P951, DOI 10.7205/MILMED-D-13-00037; Galehdar Z, 2010, J NEUROSCI, V30, P16938, DOI 10.1523/JNEUROSCI.1598-10.2010; Gao B, 2013, ACTA PHARMACOL SIN, V34, P657, DOI 10.1038/aps.2013.34; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gurkoff G, 2013, PHARMACEUTICALS, V6, P788, DOI 10.3390/ph6070788; Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976; Ho YS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036752; Johnson EM, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00044; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kaya M, 2011, METHODS MOL BIOL, V763, P369, DOI 10.1007/978-1-61779-191-8_25; Kessel D, 2006, BIOCHEM BIOPH RES CO, V346, P1320, DOI 10.1016/j.bbrc.2006.06.056; Liu CL, 2012, J GERIATR CARDIOL, V9, P258, DOI 10.3724/SP.J.1263.2012.02292; Liu Y, 2014, CAN J CARDIOL, V30, P368, DOI 10.1016/j.cjca.2013.11.001; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Methippara M, 2012, NEUROSCIENCE, V209, P108, DOI 10.1016/j.neuroscience.2012.02.016; Mosienko V, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.44; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Nijholt DAT, 2012, J PATHOL, V226, P693, DOI 10.1002/path.3969; O'Callaghan JP, 2004, J NEUROSCI METH, V135, P159, DOI 10.1016/j.jneumeth.2003.12.006; Osada N, 2009, NEUROCHEM INT, V54, P403, DOI 10.1016/j.neuint.2009.01.010; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Plattner F, 2006, J BIOL CHEM, V281, P25457, DOI 10.1074/jbc.M603469200; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Rubovitch V, 2011, NEUROCHEM INT, V58, P443, DOI 10.1016/j.neuint.2011.01.009; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Salminen A, 2010, AGEING RES REV, V9, P211, DOI 10.1016/j.arr.2010.04.003; Scheper W, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007641; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Yang FW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057869; Yen LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068595; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhang Y, 2014, PHYSIOL BEHAV, V131, P41, DOI 10.1016/j.physbeh.2014.04.014; Zhu F, 2013, INT J NUMER METH BIO, V29, P392, DOI 10.1002/cnm.2518; Zhu Feng, 2010, Stapp Car Crash J, V54, P211	66	30	30	0	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	DEC 10	2014	8								421	10.3389/fncel.2014.00421			14	Neurosciences	Neurosciences & Neurology	AX9QG	WOS:000347236400002	25540611	DOAJ Gold, Green Published			2021-06-18	
J	Bao, TH; Miao, W; Han, JH; Yin, M; Yan, Y; Wang, WW; Zhu, YH				Bao, Tian-hao; Miao, Wei; Han, Jian-hong; Yin, Mei; Yan, Yong; Wang, Wei-wei; Zhu, Yu-hong			Spontaneous Running Wheel Improves Cognitive Functions of Mouse Associated with miRNA Expressional Alteration in Hippocampus Following Traumatic Brain Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Spontaneous running wheel; Cognitive functions; miRNA	EXERCISE; MICRORNAS; TARGETS; GENE	Traumatic brain injury (TBI) is an insult to the brain that results in impairments of cognitive and physical functioning. Both of human research and animal studies demonstrate that spontaneous exercise can facilitate neuronal plasticity and improve cognitive function in normal or TBI rodent models. However, the possible mechanisms underlying are still not well known. We postulated that spontaneous running wheel (RW) altered microRNA (miRNA) expressions in hippocampus of mice following TBI, which might be associated with the improvement in cognitive functions. In the present study, acquisition of spatial learning and memory retention was assessed by using the Morris water maze (MWM) test on days 15 post RW exercise. Then, microarray analyses in miRNA files were employed, and the expressional changes of miRNAs in the hippocampus of mice were detected. The results showed that spontaneous RW exercise (i) recovered the hippocampus-related cognitive deficits induced by TBI, (ii) altered hippocampal expressions of miRNAs in both of sham and TBI mice, and (iii) miR-21 or miR-34a was associated with the recovery process. The present results indicated that an epigenetic mechanism might be involved in voluntary exercise-induced cognitive improvement of mice that suffered from TBI.	[Bao, Tian-hao; Miao, Wei; Han, Jian-hong; Yin, Mei; Yan, Yong; Zhu, Yu-hong] Kunming Med Univ, Affiliated Hosp 2, Dept Neurol, Kunming 650031, Peoples R China; [Bao, Tian-hao] Psychiat Hosp Yunnan Prov, Kunming 650224, Peoples R China; [Wang, Wei-wei] Kunming Med Univ, Affiliated Hosp 2, Dept Cardiol, Kunming 650031, Peoples R China	Zhu, YH (corresponding author), Kunming Med Univ, Affiliated Hosp 2, Dept Neurol, Kunming 650031, Peoples R China.	zhuyuhong2014@126.com					Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Koo HM, 2013, J PHYS THER SCI, V25, P1103, DOI 10.1589/jpts.25.1103; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Mooren FC, 2014, AM J PHYSIOL-HEART C, V306, pH557, DOI 10.1152/ajpheart.00711.2013; Ntanasis-Stathopoulos J, 2013, J MUSCULOSKEL NEURON, V13, P133; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Radom-Aizik S, 2014, BRAIN BEHAV IMMUN, V39, P121, DOI 10.1016/j.bbi.2014.01.003; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Roemer K, 2010, CELL CYCLE, V9, P3438, DOI 10.4161/cc.9.17.13001; Rosi S, 2012, HIPPOCAMPUS, V22, P544, DOI 10.1002/hipo.20920; Szabo Z, 2010, BRAIN RES, V1341, P25, DOI 10.1016/j.brainres.2009.01.035; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; VanLeeuwen JE, 2010, J NEUROSCI RES, V88, P650, DOI 10.1002/jnr.22216; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Zacharewicz E, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00266; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	29	30	30	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	DEC	2014	54	4					622	629		10.1007/s12031-014-0344-1			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AW0PP	WOS:000345995700004	24920273				2021-06-18	
J	Kamat, R; Weinborn, M; Kellogg, EJ; Bucks, RS; Velnoweth, A; Woods, SP				Kamat, Rujvi; Weinborn, Michael; Kellogg, Emily J.; Bucks, Romola S.; Velnoweth, Aimee; Woods, Steven Paul			Construct Validity of the Memory for Intentions Screening Test (MIST) in Healthy Older Adults	ASSESSMENT			English	Article						aging; prospective memory; construct validity; geropsychology; neuropsychological assessment	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; HIV-INFECTION; AGE; DEFICITS; TASK; TIME; RETRIEVAL; SCHIZOPHRENIA; INDIVIDUALS	The Memory for Intentions Screening Test (MIST) is a clinical measure of prospective memory. There is emerging support for the sensitivity and ecological relevance of the MIST in clinical populations. In the present study, the construct validity of the MIST was evaluated in 40 younger (18-30 years), 24 young-old (60-69 years), and 37 old-old (70+ years) healthy adults. Consistent with expectations derived from the prospective memory and aging literature, older adults demonstrated lower scores on the MIST's primary scale scores (particularly on the time-based scale), but slightly better performance on the seminaturalistic 24-hour trial. Among the healthy older adults, the MIST showed evidence of both convergent (e.g., verbal fluency) and divergent (e.g., visuoperception) correlations with standard clinical tests, although the magnitude of those correlations were comparable across the time-and event-based scales. Together, these results support the discriminant and convergent validity of the MIST as a measure of prospective memory in healthy older adults.	[Kamat, Rujvi; Kellogg, Emily J.; Woods, Steven Paul] Univ Calif San Diego, San Diego, CA 92103 USA; [Kamat, Rujvi] San Diego State Univ, San Diego, CA 92182 USA; [Weinborn, Michael; Bucks, Romola S.; Velnoweth, Aimee; Woods, Steven Paul] Univ Western Australia, Perth, WA 6009, Australia	Woods, SP (corresponding author), Univ Calif San Diego, Dept Psychiat, 220 Dickinson St,Suite B,MC8231, San Diego, CA 92103 USA.	spwoods@ucsd.edu	Bucks, Romola S/B-9164-2011; Weinborn, Michael/H-6068-2014	Bucks, Romola S/0000-0002-4207-4724; Weinborn, Michael/0000-0001-7094-9930; Woods, Steven Paul/0000-0003-0776-4233	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH062512, R01MH073419, R25MH081482] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30 MH062512, R01-MH073419, R01 MH073419, R25 MH081482] Funding Source: Medline		Benson Aaron D, 2005, Prim Care Companion J Clin Psychiatry, V7, P62; Benton A., 1994, MULTILINGUAL APHASIA; Braver TS, 2001, NEUROIMAGE, V14, P48, DOI 10.1006/nimg.2001.0791; Burgess PW, 2011, NEUROPSYCHOLOGIA, V49, P2246, DOI 10.1016/j.neuropsychologia.2011.02.014; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Burgess PW, 2003, NEUROPSYCHOLOGIA, V41, P906, DOI 10.1016/S0028-3932(02)00327-5; Carey CL, 2006, J CLIN EXP NEUROPSYC, V28, P536, DOI 10.1080/13803390590949494; Doyle K, 2012, AIDS BEHAV, V16, P2309, DOI 10.1007/s10461-011-0121-x; Doyle KL, 2013, J CLIN EXP NEUROPSYC, V35, P359, DOI 10.1080/13803395.2013.776010; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gupta S, 2010, J CLIN EXP NEUROPSYC, V32, P898, DOI 10.1080/13803391003596470; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; Iudicello JE, 2011, CLIN NEUROPSYCHOL, V25, P269, DOI 10.1080/13854046.2010.546812; Jimura K, 2010, CEREB CORTEX, V20, P1420, DOI 10.1093/cercor/bhp206; Karantzoulis S, 2009, J INT NEUROPSYCH SOC, V15, P407, DOI 10.1017/S1355617709090596; Kausler D. H., 1994, LEARNING MEMORY NORM; Kliegel M, 2002, PSYCHOL BEITR, V44, P303, DOI DOI 10.1037/0012-1649.44.2.612; Kliegel M, 2008, DEV PSYCHOL, V44, P612, DOI 10.1037/0012-1649.44.2.612; Martin T., 2007, APPL COGNITIVE PSYCH, V14, P127; MAYLOR EA, 1990, Q J EXP PSYCHOL-A, V42, P471, DOI 10.1080/14640749008401233; McDaniel M. A., 2007, PROSPECTIVE MEMORY O; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; McDaniel MA, 2011, NEUROPSYCHOLOGIA, V49, P2147, DOI 10.1016/j.neuropsychologia.2010.12.029; McFarland CP, 2009, NEUROPSYCHOLOGIA, V47, P1660, DOI 10.1016/j.neuropsychologia.2009.02.023; Miller GA, 2001, J ABNORM PSYCHOL, V110, P40, DOI 10.1037//0021-843X.110.1.40; MILLER MB, 1995, J ABNORM PSYCHOL, V104, P251, DOI 10.1037/0021-843X.104.2.251; Moscovitch M., 1994, NEUROPSYCHOLOGY, V8, P524, DOI DOI 10.1037/0894-4105.8.4.524; Old SR, 2008, PSYCHOL AGING, V23, P104, DOI 10.1037/0882-7974.23.1.104; Park DC, 1997, PSYCHOL AGING, V12, P314, DOI 10.1037/0882-7974.12.2.314; PATTON GW, 1993, EXP AGING RES, V19, P165, DOI 10.1080/03610739308253929; Piatt AL, 1999, NEUROPSYCHOLOGIA, V37, P1499, DOI 10.1016/S0028-3932(99)00066-4; Pirogovsky E, 2012, J INT NEUROPSYCH SOC, V18, P986, DOI 10.1017/S1355617712000781; POWER C, 1995, J ACQ IMMUN DEF SYND, V8, P273, DOI 10.1097/00042560-199503010-00008; Psychological Corporation, 1997, WAIS 3 WMS 3 TECHN M; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Raskin S., 2010, MIST MEMORY INTENTIO; Raskin SA, 2011, NEUROPSYCHOLOGY, V25, P201, DOI 10.1037/a0020999; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rendell PG, 1999, J GERONTOL B-PSYCHOL, V54, pP256, DOI 10.1093/geronb/54B.4.P256; Rendell PG, 2000, APPL COGNITIVE PSYCH, V14, pS43, DOI 10.1002/acp.770; Reynolds JR, 2009, CEREB CORTEX, V19, P1208, DOI 10.1093/cercor/bhn164; Royall DR, 1998, J NEUROL NEUROSUR PS, V64, P588, DOI 10.1136/jnnp.64.5.588; Schmitter-Edgecombe M, 2009, NEUROPSYCHOLOGY, V23, P168, DOI 10.1037/a0014186; Scullin MK, 2011, MEM COGNITION, V39, P1232, DOI 10.3758/s13421-011-0106-z; Simons JS, 2006, NEUROPSYCHOLOGIA, V44, P1388, DOI 10.1016/j.neuropsychologia.2006.01.005; Singer T, 2003, PSYCHOL AGING, V18, P318, DOI 10.1037/0882-7974.18.2.318; Smits CHM, 1997, J AGING HEALTH, V9, P204, DOI 10.1177/089826439700900204; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Twamley EW, 2008, SCHIZOPHR RES, V106, P42, DOI 10.1016/j.schres.2007.10.030; Weber E, 2011, J CLIN EXP NEUROPSYC, V33, P1108, DOI 10.1080/13803395.2011.604027; Weinborn M, 2011, ARCH CLIN NEUROPSYCH, V26, P746, DOI 10.1093/arclin/acr071; Wilson B., 2004, J INT NEUROPSYCH SOC, V10, P44; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Woods S. P., 2012, J INT NEUROPSYCH SOC, V18, P143; Woods SP, 2008, CLIN NEUROPSYCHOL, V22, P864, DOI 10.1080/13854040701595999; Woods SP, 2008, ARCH CLIN NEUROPSYCH, V23, P257, DOI 10.1016/j.acn.2007.12.006; Woods SP, 2008, NEUROPSYCHOLOGY, V22, P110, DOI 10.1037/0894-4105.22.1.110; Woods SP, 2007, SCHIZOPHR RES, V90, P344, DOI 10.1016/j.schres.2006.11.005; Woods SP, 2011, REHABIL PSYCHOL, V56, P77, DOI 10.1037/a0022753; Woods SP, 2010, J CLIN EXP NEUROPSYC, V32, P398, DOI 10.1080/13803390903130737; Woods SP, 2009, J INT NEUROPSYCH SOC, V15, P42, DOI 10.1017/S1355617708090012; Zogg JB, 2011, ARCH CLIN NEUROPSYCH, V26, P250, DOI 10.1093/arclin/acr020; Zogg JB, 2010, CLIN NEUROPSYCHOL, V24, P945, DOI 10.1080/13854046.2010.501343	67	30	30	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	DEC	2014	21	6					742	753		10.1177/1073191114530774			12	Psychology, Clinical	Psychology	AX0LS	WOS:000346644500011	24752386	Green Accepted			2021-06-18	
J	Kamradt, JM; Ullsperger, JM; Nikolas, MA				Kamradt, Jaclyn M.; Ullsperger, Josie M.; Nikolas, Molly A.			Executive Function Assessment and Adult Attention-Deficit/Hyperactivity Disorder: Tasks Versus Ratings on the Barkley Deficits in Executive Functioning Scale	PSYCHOLOGICAL ASSESSMENT			English	Article						adult attention-deficit/hyperactivity disorder; neuropsychological functioning; executive functioning; tasks; ratings	PERFORMANCE-BASED MEASURES; TRAUMATIC BRAIN-INJURY; MAJOR LIFE ACTIVITIES; DUAL PATHWAY MODEL; NEUROPSYCHOLOGICAL PERFORMANCE; HYPERACTIVITY DISORDER; ECOLOGICAL VALIDITY; GENERAL-POPULATION; EF TESTS; ADHD	Adults with attention-deficit/hyperactivity disorder (ADHD) exhibit variable impairments on executive function (EF) tasks. Due to this variability, ratings of EF (rather than tasks) have been proposed as an alternative method that better captures symptom severity and impairment among adults with ADHD. However, few studies have jointly examined performance across multiple neuropsychological domains and EF ratings as predictors of severity and impairment among adults with ADHD. Adults (N = 273) ages 18-38 years (M = 22.6 years, 55.3% male, 62.2% with ADHD) completed a comprehensive diagnostic and neurocognitive assessment, which included self and informant ratings of ADHD symptom severity and EF and tasks of arousal/activation, response inhibition, set shifting, interference control, and working memory. Hierarchical linear regression models indicated that tasks of arousal/activation and response inhibition uniquely predicted ADHD symptom dimensions and related impairments. Over and above EF task performance, EF ratings of time management significantly predicted increased inattention (beta = .209, p < .001, Delta R-2 = 3.9%), whereas ratings of restraint predicted increased hyperactivity/impulsivity (beta = .259, p < .001, Delta R-2 = 6.4%). Furthermore, EF ratings of time management, restraint, and emotion regulation incrementally accounted for variance in relationship, professional, and daily living impairments over and above EF task performance (Delta R-2 range = 1.7-7.7%). Results may help refine neurobiological theories and assessment of adult ADHD.	[Kamradt, Jaclyn M.; Ullsperger, Josie M.; Nikolas, Molly A.] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA	Kamradt, JM (corresponding author), Univ Iowa, Dept Psychol, Iowa City, IA 52240 USA.	jaclyn-kamradt@uiowa.edu	Nikolas, Molly/AAE-9359-2019				Adler L, 2004, PSYCHIAT CLIN N AM, V27, P187, DOI 10.1016/j.psc.2003.12.003; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596.910646, DOI 10.1176/APPI.BOOKS.9780890425596.910646]; Antshel KM, 2010, PSYCHOL MED, V40, P1909, DOI 10.1017/S0033291709992273; Barkley R.A., 2011, BARKLEY ADULT ADHD R; Barkley R.A., 2011, BARKLEY FUNCTIONAL I; Barkley RA, 2006, J AM ACAD CHILD PSY, V45, P192, DOI 10.1097/01.chi.0000189134.97436.e2; Barkley RA, 2002, J CLIN PSYCHIAT, V63, P10; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Barkley RA, 2011, BARKLEY DEFICITS EXE; Barkley RA, 2011, DEV NEUROPSYCHOL, V36, P137, DOI 10.1080/87565641.2010.549877; Barkley RA, 2011, J PSYCHOPATHOL BEHAV, V33, P137, DOI 10.1007/s10862-011-9217-x; Barkley RA, 2010, ARCH CLIN NEUROPSYCH, V25, P157, DOI 10.1093/arclin/acq014; Bidwell LC, 2007, BIOL PSYCHIAT, V62, P991, DOI 10.1016/j.biopsych.2007.04.003; Biederman J, 2007, J NERV MENT DIS, V195, P240, DOI 10.1097/01.nmd.0000243968.06789.73; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Boonstra AM, 2005, PSYCHOL MED, V35, P1097, DOI 10.1017/S003329170500499X; Brown T.E., 2006, INT J DISABIL DEV ED, V53, P35, DOI DOI 10.1080/10349120500510024; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Conners C. K., 2002, CONNERS CONTINUOUS P; Cornish KM, 2005, MOL PSYCHIATR, V10, P686, DOI 10.1038/sj.mp.4001641; Crosbie J, 2013, J ABNORM CHILD PSYCH, V41, P497, DOI 10.1007/s10802-012-9693-9; Crosbie J, 2001, AM J PSYCHIAT, V158, P1884, DOI 10.1176/appi.ajp.158.11.1884; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Faraone SV, 2000, BIOL PSYCHIAT, V48, P9, DOI 10.1016/S0006-3223(00)00889-1; Gansler DA, 1998, J NERV MENT DIS, V186, P776, DOI 10.1097/00005053-199812000-00006; Gau SSF, 2010, J CHILD PSYCHOL PSYC, V51, P838, DOI 10.1111/j.1469-7610.2010.02215.x; Goos LM, 2009, AM J PSYCHIAT, V166, P711, DOI 10.1176/appi.ajp.2009.08040621; Jensen PS, 2001, J DEV BEHAV PEDIATR, V22, P60, DOI 10.1097/00004703-200102000-00008; Johnson DE, 2001, ARCH CLIN NEUROPSYCH, V16, P587; Jung RE, 2000, CLIN NEUROPSYCHOL, V14, P535, DOI 10.1076/clin.14.4.535.7198; Kessler RC, 2005, PSYCHOL MED, V35, P245, DOI 10.1017/S0033291704002892; Kessler RC, 2010, ARCH GEN PSYCHIAT, V67, P1168, DOI 10.1001/archgenpsychiatry.2010.146; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Lahey BB, 2005, ARCH GEN PSYCHIAT, V62, P896, DOI 10.1001/archpsyc.62.8.896; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Logan Gordon D., 1994, P189; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P52, DOI 10.1076/chin.8.1.52.8719; Mannuzza S, 2000, CHILD ADOL PSYCH CL, V9, P711; Nigg JT, 2012, J CLIN CHILD ADOLESC, V41, P524, DOI 10.1080/15374416.2012.686870; Nigg JT, 2005, J ABNORM PSYCHOL, V114, P706, DOI 10.1037/0021-843X.114.3.706; Nigg JT, 2005, BIOL PSYCHIAT, V57, P1224, DOI 10.1016/j.biopsych.2004.08.025; Nikolas MA, 2013, NEUROPSYCHOLOGY, V27, P107, DOI 10.1037/a0030685; Sandson TA, 2000, J LEARN DISABIL, V33, P83, DOI 10.1177/002221940003300111; Schoechlin C, 2005, ARCH CLIN NEUROPSYCH, V20, P727, DOI 10.1016/j.acn.2005.04.005; Seidman LJ, 2006, CLIN PSYCHOL REV, V26, P466, DOI 10.1016/j.cpr.2006.01.004; Sergeant JA, 2003, NEUROSCI BIOBEHAV R, V27, P583, DOI 10.1016/j.neubiorev.2003.08.004; Shaw P, 2007, P NATL ACAD SCI USA, V104, P19649, DOI 10.1073/pnas.0707741104; Sonuga-Barke EJS, 2010, J AM ACAD CHILD PSY, V49, P345, DOI 10.1016/j.jaac.2009.12.018; Sonuga-Barke EJS, 2002, BEHAV BRAIN RES, V130, P29, DOI 10.1016/S0166-4328(01)00432-6; Toplak ME, 2013, J CHILD PSYCHOL PSYC, V54, P131, DOI 10.1111/jcpp.12001; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; Torralva T, 2013, J ATTEN DISORD, V17, P11, DOI 10.1177/1087054710389988; van Lieshout M, 2013, CLIN PSYCHOL REV, V33, P539, DOI 10.1016/j.cpr.2013.02.003; Wechsler D., 1999, MANUAL WECHSLER ABBR; Wechsler D., 2008, MANUAL WECHSLER ADUL; WEYANDT LL, 1995, J PSYCHOPATHOL BEHAV, V17, P293, DOI 10.1007/BF02229304; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Woods SP, 2002, CLIN NEUROPSYCHOL, V16, P12, DOI 10.1076/clin.16.1.12.8336	62	30	30	0	36	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	DEC	2014	26	4					1095	1105		10.1037/pas0000006			11	Psychology, Clinical	Psychology	AX1HK	WOS:000346698200004	24885846				2021-06-18	
J	Sweet, JA; Eakin, KC; Munyon, CN; Miller, JP				Sweet, Jennifer A.; Eakin, Katharine C.; Munyon, Charles N.; Miller, Jonathan P.			Improved Learning and Memory With Theta-Burst Stimulation of the Fornix in Rat Model of Traumatic Brain Injury	HIPPOCAMPUS			English	Article						brain stimulation; fornix; hippocampus; theta-burst stimulation; traumatic brain injury	LONG-TERM POTENTIATION; GLOBUS-PALLIDUS INTERNUS; FLUID PERCUSSION INJURY; MORRIS WATER MAZE; ELECTRICAL-STIMULATION; WORKING-MEMORY; PARKINSONS-DISEASE; SEPTAL STIMULATION; SPATIAL MEMORY; NUCLEUS	Objective: Learning and memory deficits are a source of considerable morbidity after traumatic brain injury (TBI). We investigated the effect of different patterns of hippocampal stimulation via a fornix electrode on cognitively demanding tasks after TBI. Methods: Male Sprague-Dawley rats underwent fluid-percussion injury and were compared with sham-operated rats. Electrodes were implanted into the fornix and hippocampus, and stimulation of the fornix produced robust evoked potentials in the hippocampus. A 60-s delayed non-match-to-sample (DNMS) swim T-maze was serially performed using four stimulation patterns: no stimulation (No Stim), low-frequency stimulation (LFS, 5 Hz), high-frequency stimulation (HFS, 130 Hz), and theta-burst stimulation (TBS, 200 Hz in 50 ms trains, five trains per second; 60 mu A biphasic pulses). In a separate cohort of sham and injured animals, Morris water maze (MWM) was performed with or without TBS. Results: In the DNMS swim T-maze, LFS and HFS did not significantly improve performance after TBI. However, there was a significant difference in performance between TBI+No Stim and TBI+TBS groups (P<0.05) with no significant difference between Sham+No Stim and TBI+TBS. In the MWM, latency in the TBI+TBS group was significantly different from TBI+No Stim starting on day 2 (P<0.05) and was not different from Sham+No Stim. The TBI+TBS group performed significantly more platform crossings in the probe trial (P<0.01) and exhibited improved search strategy starting on day 3 (P<0.05) compared with TBI+No Stim. Conclusions: Deficits in learning and memory after TBI are improved with TBS of the hippocampus. HFS and LFS do not appear to produce as great an effect as TBS. (c) 2014 Wiley Periodicals, Inc.	[Sweet, Jennifer A.; Eakin, Katharine C.; Munyon, Charles N.; Miller, Jonathan P.] Case Western Reserve Univ, Dept Neurol Sur, Cleveland, OH 44106 USA	Miller, JP (corresponding author), Case Western Reserve Univ, Dept Neurol Sur, 10900 Euclid Ave, Cleveland, OH 44106 USA.	jonathan.miller@UHHospitals.org		Miller, Jonathan/0000-0001-5441-1751			BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; Birdno MJ, 2012, J NEUROPHYSIOL, V107, P364, DOI 10.1152/jn.00906.2010; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Champagne D, 2002, NEUROSCIENCE, V114, P641, DOI 10.1016/S0306-4522(02)00313-5; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Coubes P, 2004, J NEUROSURG, V101, P189, DOI 10.3171/jns.2004.101.2.0189; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; De Ridder D, 2013, WORLD NEUROSURG, V80, P642, DOI 10.1016/j.wneu.2013.01.040; De Ridder D, 2010, J NEUROSURG, V112, P1289, DOI 10.3171/2009.10.JNS09298; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dudchenko PA, 2013, NEUROSCI BIOBEHAV R, V37, P2111, DOI 10.1016/j.neubiorev.2012.03.003; Eakin K.C., 2012, J NEUROTRAUM, V29, P1; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Fisher R, 2010, EPILEPSIA, V51, P899, DOI 10.1111/j.1528-1167.2010.02536.x; Follett KA, 2010, NEW ENGL J MED, V362, P2077, DOI 10.1056/NEJMoa0907083; Grover LM, 2009, LEARN MEMORY, V16, P69, DOI 10.1101/lm.1179109; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; Halpern CH, 2008, J NEUROSURG, V109, P625, DOI 10.3171/JNS/2008/109/10/0625; Hamani C, 2008, ANN NEUROL, V63, P119, DOI 10.1002/ana.21295; HAMPSON RE, 1993, BEHAV NEUROSCI, V107, P715, DOI 10.1037/0735-7044.107.5.715; HOLT L, 1983, BEHAV NEURAL BIOL, V39, P7, DOI 10.1016/S0163-1047(83)90552-6; HOLT L, 1985, BEHAV NEUROSCI, V99, P60, DOI 10.1037/0735-7044.99.1.60; Koubeissi MZ, 2013, ANN NEUROL, V74, P223, DOI 10.1002/ana.23915; Lacruz ME, 2010, NEUROSCIENCE, V170, P623, DOI 10.1016/j.neuroscience.2010.06.042; Laxton AW, 2010, ANN NEUROL, V68, P521, DOI 10.1002/ana.22089; Lee DJ, 2013, J NEUROTRAUM, V30, P131, DOI 10.1089/neu.2012.2646; LEGENDY CR, 1985, J NEUROPHYSIOL, V53, P926; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; Nakao K, 2003, SYNAPSE, V47, P163, DOI 10.1002/syn.10168; Nuttin B, 1999, LANCET, V354, P1526, DOI 10.1016/S0140-6736(99)02376-4; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Plaha P, 2006, BRAIN, V129, P1732, DOI 10.1093/brain/awl127; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Shirvalkar PR, 2010, P NATL ACAD SCI USA, V107, P7054, DOI 10.1073/pnas.0911184107; SIMON P, 1994, BEHAV BRAIN RES, V61, P59, DOI 10.1016/0166-4328(94)90008-6; Smith GS, 2012, NEUROPSYCHOPHARMACOL, V37, P1, DOI 10.1038/npp.2011.233; Soriano-Mas C, 2005, BEHAV BRAIN RES, V160, P141, DOI 10.1016/j.bbr.2004.11.025; Stone SSD, 2011, J NEUROSCI, V31, P13469, DOI 10.1523/JNEUROSCI.3100-11.2011; Suthana N, 2012, NEW ENGL J MED, V366, P502, DOI 10.1056/NEJMoa1107212; Toda H, 2008, J NEUROSURG, V108, P132, DOI 10.3171/JNS/2008/108/01/0132; Toth Z, 1997, J NEUROSCI, V17, P8106; TREIT D, 1988, PHARMACOL BIOCHEM BE, V31, P959, DOI 10.1016/0091-3057(88)90413-3; TURNBULL J, 1994, CAN J NEUROL SCI, V21, P100, DOI 10.1017/S0317167100049003; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Zhang JY, 2012, EXP NEUROL, V233, P575, DOI 10.1016/j.expneurol.2011.07.007; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	53	30	30	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1050-9631	1098-1063		HIPPOCAMPUS	Hippocampus	DEC	2014	24	12					1592	1600		10.1002/hipo.22338			9	Neurosciences	Neurosciences & Neurology	AU0TE	WOS:000345336600017	25087862				2021-06-18	
J	Muroski, ME; Morgan, TJ; Levenson, CW; Strouse, GF				Muroski, Megan E.; Morgan, Thomas J., Jr.; Levenson, Cathy W.; Strouse, Geoffrey F.			A Gold Nanoparticle Pentapeptide: Gene Fusion To Induce Therapeutic Gene Expression in Mesenchymal Stem Cells	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY			English	Article							STABLE TRANSGENE EXPRESSION; PENETRATING PEPTIDES; IN-VIVO; NONVIRAL VECTORS; DELIVERY; TRANSFECTION; SURFACE; SIRNA; SIZE; TRANSDUCTION	Mesenchymal stem cells (MSC) have been identified as having great potential as autologous cell therapeutics to treat traumatic brain injury and spinal injury as well as neuronal and cardiac ischemic events. All future clinical applications of MSC cell therapies must allow the MSC to be harvested, transfected, and induced to express a desired protein or selection of proteins to have medical benefit. For the full potential of MSC cell therapy to be realized, it is desirable to systematically alter the protein expression of therapeutically beneficial biomolecules in harvested MSC cells with high fidelity in a single transfection event. We have developed a delivery platform on the basis of the use of a solid gold nanoparticle that has been surface modified to produce a fusion containing a zwitterionic, pentapeptide designed from Bax inhibiting peptide (Ku70) to enhance cellular uptake and a linearized expression vector to induce enhanced expression of brain-derived neurotrophic factor (BDNF) in rat-derived MSCs. Ku70 is observed to effect >80% transfection following a single treatment of femur bone marrow isolated rat MSCs with efficiencies for the delivery of a 6.6 kbp gene on either a Au nanoparticle (NP) or CdSe/ZnS quantum dot (QD). Gene expression is observed within 4 d by optical measurements, and secretion is observed within 10 d by Western Blot analysis. The combination of being able to selectively engineer the NP, to colocalize biological agents, and to enhance the stability of those agents has provided the strong impetus to utilize this novel class of materials to engineer primary MSCs.	[Muroski, Megan E.; Strouse, Geoffrey F.] Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; [Morgan, Thomas J., Jr.; Levenson, Cathy W.; Strouse, Geoffrey F.] Florida State Univ, Coll Med, Tallahassee, FL 32306 USA	Strouse, GF (corresponding author), Florida State Univ, Dept Chem & Biochem, 95 Chieftan Way, Tallahassee, FL 32306 USA.	Strouse@chem.fsu.edu		Levenson, Cathy W/0000-0003-4463-3136; /0000-0002-6491-1589	National Science FoundationNational Science Foundation (NSF) [CHE-0911080]; Florida State University Office of Research Planning grant [CRC-PG 075000-140]	We wish to acknowledge the National Science Foundation under CHE-0911080 for support of the research as well as the Florida State University Office of Research Planning grant CRC-PG 075000-140.	Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067; Albanese A, 2011, ACS NANO, V5, P5478, DOI 10.1021/nn2007496; Aluigi M, 2006, STEM CELLS, V24, P454, DOI 10.1634/stemcells.2005-0198; Aronovich EL, 2011, HUM MOL GENET, V20, pR14, DOI 10.1093/hmg/ddr140; Barrow Katie A., 2006, V329, P283; Bernstein HS, 2012, PEDIATR RES, V71, P491, DOI 10.1038/pr.2011.61; Breshike CJ, 2013, J PHYS CHEM C, V117, P23942, DOI 10.1021/jp407259r; Chen CY, 2011, MOL PHARMACEUT, V8, P1505, DOI 10.1021/mp100368d; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen LQ, 2012, ANAL CHEM, V84, P3099, DOI 10.1021/ac202810b; Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o; Choi HS, 2010, MOL IMAGING, V9, P291, DOI 10.2310/7290.2010.00031; Chompoosor A, 2008, BIOCONJUGATE CHEM, V19, P1342, DOI 10.1021/bc8000694; Choudhary S, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/264350; Chugh A, 2010, IUBMB LIFE, V62, P183, DOI 10.1002/iub.297; Cumberland SL, 2002, LANGMUIR, V18, P269, DOI 10.1021/la011278n; Deng DW, 2013, BIOSENS BIOELECTRON, V49, P216, DOI 10.1016/j.bios.2013.05.018; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Fang B, 2013, BIOCHIMIE, V95, P251, DOI 10.1016/j.biochi.2012.09.020; Ferreira E, 2008, GENE THER, V15, P537, DOI 10.1038/gt.2008.9; Flanagan M, 2011, CANCER GENE THER, V18, P579, DOI 10.1038/cgt.2011.27; Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+; Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001; Gandra N, 2013, ANGEW CHEM INT EDIT, V52, P11278, DOI 10.1002/anie.201301113; Giljohann DA, 2009, J AM CHEM SOC, V131, P2072, DOI 10.1021/ja808719p; Glover DJ, 2005, NAT REV GENET, V6, P299, DOI 10.1038/nrg1577; Gomez JA, 2007, BIOCHEM SOC T, V35, P797, DOI 10.1042/BST0350797; Greco SJ, 2012, THER DELIV, V3, P997, DOI 10.4155/TDE.12.69; Gresch O, 2012, METHODS MOL BIOL, V801, P65, DOI 10.1007/978-1-61779-352-3_5; Guo ST, 2010, ACS NANO, V4, P5505, DOI 10.1021/nn101638u; Haes AJ, 2005, MRS BULL, V30, P368, DOI 10.1557/mrs2005.100; Hakkinen H, 2012, NAT CHEM, V4, P443, DOI [10.1038/NCHEM.1352, 10.1038/nchem.1352]; Hamm A, 2002, TISSUE ENG, V8, P235, DOI 10.1089/107632702753725003; Hong R, 2006, J AM CHEM SOC, V128, P1078, DOI 10.1021/ja056726i; Honmou O, 2012, TRENDS MOL MED, V18, P292, DOI 10.1016/j.molmed.2012.02.003; Jain PK, 2006, J AM CHEM SOC, V128, P2426, DOI 10.1021/ja056769z; Jang JH, 2011, MOL THER, V19, P1407, DOI 10.1038/mt.2011.111; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; Kawano T, 2006, J CONTROL RELEASE, V111, P382, DOI 10.1016/j.jconrel.2005.12.022; Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y; Kim JH, 2005, EXP MOL MED, V37, P36; Kogot JM, 2008, J AM CHEM SOC, V130, P16156, DOI 10.1021/ja8064717; Lee JS, 2009, NANO LETT, V9, P2402, DOI 10.1021/nl9009793; Lei Y, 2008, BIOCONJUGATE CHEM, V19, P421, DOI 10.1021/bc0700685; Len J. G., 2012, NANOMED-NANOTECHNOL, V8, P767; Levy R, 2004, J AM CHEM SOC, V126, P10076, DOI 10.1021/ja0487269; Liew CG, 2007, STEM CELLS, V25, P1521, DOI 10.1634/stemcells.2006-0634; Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1; Locke M, 2011, TISSUE ENG PART C-ME, V17, P949, DOI [10.1089/ten.tec.2011.0153, 10.1089/ten.TEC.2011.0153]; Madeira C, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/735349; Mansouri S, 2004, EUR J PHARM BIOPHARM, V57, P1, DOI 10.1016/S0939-6411(03)00155-3; Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004; Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d; Muroski ME, 2012, J AM CHEM SOC, V134, P19722, DOI 10.1021/ja307502x; Murphy CJ, 2008, ACCOUNTS CHEM RES, V41, P1721, DOI 10.1021/ar800035u; Nadri S, 2007, INT J DEV BIOL, V51, P723, DOI 10.1387/ijdb.072352ns; Oh E, 2010, LANGMUIR, V26, P7604, DOI 10.1021/la904438s; Park JS, 2010, BIOMATERIALS, V31, P124, DOI 10.1016/j.biomaterials.2009.09.023; Peister A, 2004, GENE THER, V11, P224, DOI 10.1038/sj.gt.3302163; Peng LH, 2011, DRUG DISCOV TODAY, V16, P957, DOI 10.1016/j.drudis.2011.07.009; Pouton CW, 2001, ADV DRUG DELIVER REV, V46, P187, DOI 10.1016/S0169-409X(00)00133-2; Reagan MR, 2011, STEM CELLS, V29, P920, DOI 10.1002/stem.645; Ren GW, 2012, STEM CELL TRANSL MED, V1, P51, DOI 10.5966/sctm.2011-0019; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559; Samper E, 2013, STEM CELL REV REP, V9, P266, DOI 10.1007/s12015-012-9353-z; Sandhu KK, 2002, BIOCONJUGATE CHEM, V13, P3, DOI 10.1021/bc015545c; Santos JL, 2011, CURR GENE THER, V11, P46; Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b; Scheibe F, 2012, GENE THER, V19, P550, DOI 10.1038/gt.2011.139; Seferos DS, 2007, J AM CHEM SOC, V129, P15477, DOI 10.1021/ja0776529; Seth P, 2005, CANCER BIOL THER, V4, P512, DOI 10.4161/cbt.4.5.1705; Shah K, 2012, ADV DRUG DELIVER REV, V64, P739, DOI 10.1016/j.addr.2011.06.010; Silva FH, 2006, MED HYPOTHESES, V67, P922, DOI 10.1016/j.mehy.2006.01.065; Sokolova IB, 2011, B EXP BIOL MED+, V151, P130, DOI 10.1007/s10517-011-1274-3; Song HP, 2010, BIOMATERIALS, V31, P769, DOI 10.1016/j.biomaterials.2009.09.085; Sykova E, 2007, PROG BRAIN RES, V161, P367, DOI 10.1016/S0079-6123(06)61026-1; Tawonsawatruk Tulyapruek, 2012, J Med Assoc Thai, V95 Suppl 10, pS189; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; Trounson A, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-29; Woehrle GH, 2005, J AM CHEM SOC, V127, P2172, DOI 10.1021/ja0457718; Wuelfing WP, 1998, J AM CHEM SOC, V120, P12696, DOI 10.1021/ja983183m; Ye Zhaohui, 2008, V430, P243, DOI 10.1007/978-1-59745-182-6_17; Yi T, 2012, ARCH PHARM RES, V35, P213, DOI 10.1007/s12272-012-0202-z; Zeng JM, 2007, STEM CELLS, V25, P1055, DOI 10.1634/stemcells.2006-0616; Zhu ZJ, 2012, ANAL CHEM, V84, P4321, DOI 10.1021/ac203408v	86	30	31	2	97	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0002-7863	1520-5126		J AM CHEM SOC	J. Am. Chem. Soc.	OCT 22	2014	136	42					14763	14771		10.1021/ja505190q			9	Chemistry, Multidisciplinary	Chemistry	AR6ID	WOS:000343686500031	25198921				2021-06-18	
J	Viscomi, MT; Molinari, M				Viscomi, Maria Teresa; Molinari, Marco			Remote Neurodegeneration: Multiple Actors for One Play	MOLECULAR NEUROBIOLOGY			English	Article						Remote damage; Inflammation; Apoptosis; Nitrergic system; Endocannabinoid system	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; AXOTOMIZED RUBROSPINAL NEURONS; LATERAL GENICULATE-NUCLEUS; CENTRAL-NERVOUS-SYSTEM; INFERIOR OLIVARY NEURONS; MESSENGER-RNA EXPRESSION; RETROGRADE TRANSSYNAPTIC DEGENERATION; CELL-DEATH; NITRIC-OXIDE	Remote neurodegeneration significantly influences the clinical outcome in many central nervous system (CNS) pathologies, such as stroke, multiple sclerosis, and traumatic brain and spinal cord injuries. Because these processes develop days or months after injury, they are accompanied by a therapeutic window of opportunity. The complexity and clinical significance of remote damage is prompting many groups to examine the factors of remote degeneration. This research is providing insights into key unanswered questions, opening new avenues for innovative neuroprotective therapies. In this review, we evaluate data from various remote degeneration models to describe the complexity of the systems that are involved and the importance of their interactions in reducing damage and promoting recovery after brain lesions. Specifically, we recapitulate the current data on remote neuronal degeneration, focusing on molecular and cellular events, as studied in stroke and brain and spinal cord injury models. Remote damage is a multifactorial phenomenon in which many components become active in specific time frames. Days, weeks, or months after injury onset, the interplay between key effectors differentially affects neuronal survival and functional outcomes. In particular, we discuss apoptosis, inflammation, oxidative damage, and autophagy-all of which mediate remote degeneration at specific times. We also review current findings on the pharmacological manipulation of remote degeneration mechanisms in reducing damage and sustaining outcomes. These novel treatments differ from those that have been proposed to limit primary lesion site damage, representing new perspectives on neuroprotection.	[Viscomi, Maria Teresa; Molinari, Marco] Santa Lucia Fdn IRCCS, Expt Neurorehabil Lab, I-00143 Rome, Italy	Viscomi, MT (corresponding author), Santa Lucia Fdn IRCCS, Expt Neurorehabil Lab, Via Fosso di Fiorano 65, I-00143 Rome, Italy.	mt.viscomi@hsantalucia.it; m.molinari@hsantalucia.it	Molinari, Marco/A-9624-2010; Viscomi, Maria Teresa/AAL-6625-2021; Viscomi, Maria Teresa/G-4173-2011	Molinari, Marco/0000-0001-9808-9688; Viscomi, Maria Teresa/0000-0002-9096-4967	Italian Ministry of Health (Ricerca Corrente)Ministry of Health, Italy; Wings for Life Spinal Cord Research Foundation; International Foundation for Research in Paraplegia (IFP); Italian Ministry of HealthMinistry of Health, Italy [GR10.184]	This work was supported by the Italian Ministry of Health (Ricerca Corrente - MM), by the Wings for Life Spinal Cord Research Foundation (M. T. V.), by the International Foundation for Research in Paraplegia (IFP) (M. T. V.), and by the program Young Researchers of Italian Ministry of Health (GR10.184; M. T. V.). We thank Prof. G. Bernardi for his continuous support and encouragement. The professional editorial work of Blue Pencil Science is also acknowledged.	Abe N, 2008, CURR OPIN NEUROBIOL, V18, P276, DOI 10.1016/j.conb.2008.06.005; Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; Al-Abdulla NA, 1998, AM J PATHOL, V153, P447, DOI 10.1016/S0002-9440(10)65588-5; Al-Abdulla NA, 2002, NEUROSCIENCE, V115, P7, DOI 10.1016/S0306-4522(02)00363-9; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Ambron RT, 1996, MOL NEUROBIOL, V13, P61, DOI 10.1007/BF02740752; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Arevalo-Martin A, 2010, NEUROBIOL DIS, V38, P304, DOI 10.1016/j.nbd.2010.02.002; Bahr BA, 2006, EXPERT OPIN INV DRUG, V15, P351, DOI 10.1517/13543784.15.4.351; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bari M, 2006, MINI-REV MED CHEM, V6, P257, DOI 10.2174/138955706776073466; Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x; BARRIONUEVO G, 1978, ELECTROEN CLIN NEURO, V44, P232, DOI 10.1016/0013-4694(78)90269-9; Barron KD, 2004, J NEUROL SCI, V220, P119, DOI 10.1016/j.jns.2004.03.009; BARRON KD, 1967, J NEUROPATH EXP NEUR, V26, P300, DOI 10.1097/00005072-196704000-00007; Bartolomeo P, 2011, CORTEX, V47, P1010, DOI 10.1016/j.cortex.2010.11.007; Ben Taib Nordeyn Oulad, 2009, J Neurosurg, V111, P796, DOI 10.3171/2008.2.17679; Bermudez-Silva FJ, 2010, PHARMACOL BIOCHEM BE, V95, P375, DOI 10.1016/j.pbb.2010.03.012; Bezprozvanny I, 2009, TRENDS MOL MED, V15, P89, DOI 10.1016/j.molmed.2009.01.001; BIALOWAS J, 1984, J HIRNFORSCH, V25, P417; BIRBAMER G, 1992, AM J NEURORADIOL, V13, P1501; Bisicchia E, 2013, CELL MOL LIFE SCI, V70, P2191, DOI 10.1007/s00018-012-1253-5; Block F, 2005, PROG NEUROBIOL, V75, P342, DOI 10.1016/j.pneurobio.2005.03.004; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bove J, 2011, NAT REV NEUROSCI, V12, P437, DOI 10.1038/nrn3068; Braeuninger Stefan, 2009, Exp Transl Stroke Med, V1, P8, DOI 10.1186/2040-7378-1-8; Bregman BS, 1998, EXP NEUROL, V149, P13, DOI 10.1006/exnr.1997.6669; Briggs F, 2008, CURR OPIN NEUROBIOL, V18, P403, DOI 10.1016/j.conb.2008.09.002; BROWN LT, 1974, J COMP NEUROL, V154, P169, DOI 10.1002/cne.901540205; Buffo A, 2003, EUR J NEUROSCI, V18, P2146, DOI 10.1046/j.1460-9568.2003.02940.x; Buffo A, 1998, NEUROSCIENCE, V85, P587, DOI 10.1016/S0306-4522(98)00049-9; Buffon F, 2005, J CEREBR BLOOD F MET, V25, P641, DOI 10.1038/sj.jcbfm.9600054; Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0; Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605; Burnstock G, 2013, ADV EXP MED BIOL, V986, P1, DOI 10.1007/978-94-007-4719-7_1; Burnstock G, 2011, PROG NEUROBIOL, V95, P229, DOI 10.1016/j.pneurobio.2011.08.006; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Calabrese V, 2009, ANTIOXID REDOX SIGN, V11, P2717, DOI [10.1089/ars.2009.2721, 10.1089/ARS.2009.2721]; Carter AR, 2012, NEUROREHAB NEURAL RE, V26, P7, DOI 10.1177/1545968311411054; CASTRO AJ, 1978, J COMP NEUROL, V178, P611, DOI 10.1002/cne.901780402; Cavalli V, 2005, J CELL BIOL, V168, P775, DOI 10.1083/jcb.200410136; Chen HJ, 2012, REV NEUROSCIENCE, V23, P279, DOI 10.1515/revneuro-2012-0001; Chen HC, 2013, J SURG RES, V179, pE203, DOI 10.1016/j.jss.2012.02.023; CHEN S, 1994, EXP NEUROL, V126, P270, DOI 10.1006/exnr.1994.1064; Chen XH, 2011, J NEUROIMMUNOL, V235, P1, DOI 10.1016/j.jneuroim.2011.04.006; Chen X, 2011, BRAIN RES, V1382, P298, DOI 10.1016/j.brainres.2011.01.045; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Cho DC, 2011, J KOREAN NEUROSURG S, V49, P83, DOI 10.3340/jkns.2011.49.2.83; Cho Y, 2013, CELL, V155, P894, DOI 10.1016/j.cell.2013.10.004; Chrousos George P, 2005, Sci STKE, V2005, ppe48, DOI 10.1126/stke.3042005pe48; Derkinderen P, 2003, J NEUROSCI, V23, P2371; Di Marzo V, 2008, REV PHYSIOL BIOCH P, V160, P1, DOI 10.1007/112_0505; Di Marzo V, 2005, NAT NEUROSCI, V8, P585, DOI 10.1038/nn1457; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; Dihne M, 2002, STROKE, V33, P3006, DOI 10.1161/01.STR.0000039406.64644.CB; Dihne M, 2001, BRAIN RES, V889, P165, DOI 10.1016/S0006-8993(00)03129-2; El Manira A, 2010, PHYSIOLOGY, V25, P230, DOI 10.1152/physiol.00007.2010; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Esiri MM, 2007, J NEUROIMMUNOL, V184, P4, DOI 10.1016/j.jneuroim.2006.11.013; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030; FERINGA ER, 1988, EXP NEUROL, V100, P112, DOI 10.1016/0014-4886(88)90205-1; Fernandez-Ruiz J, 2008, MOL CELL ENDOCRINOL, V286, pS91, DOI 10.1016/j.mce.2008.01.001; Fernandez-Ruiz J, 2010, EXPERT OPIN THER TAR, V14, P387, DOI 10.1517/14728221003709792; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Fimia GM, 2010, CELL MOL LIFE SCI, V67, P1581, DOI 10.1007/s00018-010-0284-z; Fitzek C, 2004, EUR J RADIOL, V49, P198, DOI 10.1016/S0720-048X(03)00132-3; Florenzano F, 2008, PROG NEUROBIOL, V84, P40, DOI 10.1016/j.pneurobio.2007.10.004; Florenzano F, 2002, NEUROSCIENCE, V115, P425, DOI 10.1016/S0306-4522(02)00397-4; FRY FJ, 1972, J COMP NEUROL, V144, P1, DOI 10.1002/cne.901440102; Fukuoka T, 1997, BRAIN RES, V767, P250, DOI 10.1016/S0006-8993(97)00715-4; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479; Galve-Roperh I, 2008, CURR PHARM DESIGN, V14, P2279, DOI 10.2174/138161208785740117; Garcia-Ovejero D, 2009, NEUROBIOL DIS, V33, P57, DOI 10.1016/j.nbd.2008.09.015; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gomes JA, 2005, CRIT CARE MED, V33, P1214, DOI 10.1097/01.CCM.0000166389.85273.38; Gonzalez C, 2011, DIABETES-METAB RES, V27, P331, DOI 10.1002/dmrr.1176; Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x; GOTO N, 1981, ACTA NEUROPATHOL, V54, P275, DOI 10.1007/BF00697000; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; Han S, 2013, J MED CHEM, V56, P8224, DOI 10.1021/jm4005626; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hendrickson ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046918; Herve D, 2005, J NEUROL NEUROSUR PS, V76, P200, DOI 10.1136/jnnp.2004.041012; Hohlfeld R, 2007, NEUROLOGY, V68, pS58, DOI 10.1212/01.wnl.0000275234.43506.9b; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Ibanez CF, 2007, TRENDS CELL BIOL, V17, P519, DOI 10.1016/j.tcb.2007.09.003; Inoue Y, 2010, SEMIN CELL DEV BIOL, V21, P664, DOI 10.1016/j.semcdb.2010.03.009; Jindahra P, 2012, BRAIN, V135, P534, DOI 10.1093/brain/awr324; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Kanno H, 2009, AUTOPHAGY, V5, P390, DOI 10.4161/auto.5.3.7724; Kanno H, 2009, NEUROBIOL DIS, V33, P143, DOI 10.1016/j.nbd.2008.09.009; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Khaing ZZ, 2012, J NEUROTRAUM, V29, P488, DOI 10.1089/neu.2011.2106; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kino T, 2009, CELL MOL LIFE SCI, V66, P3435, DOI 10.1007/s00018-009-0098-z; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kobayashi NR, 1997, J NEUROSCI, V17, P9583; Kojika S, 1996, LEUKEMIA, V10, P994; Kolodziejak A, 2000, J PHYSIOL PHARMACOL, V51, P41; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kwon BK, 2004, EXP NEUROL, V189, P45, DOI 10.1016/j.expneurol.2004.05.034; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; Lam TI, 2013, NEUROREHAB NEURAL RE, V27, P889, DOI 10.1177/1545968313491003; Lee HC, 2007, SURG NEUROL, V68, pS37, DOI 10.1016/j.surneu.2007.06.085; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; LIEBERMAN AR, 1974, J ANAT, V118, P384; Lingor P, 2012, CELL TISSUE RES, V349, P289, DOI 10.1007/s00441-012-1362-3; LIPTON SA, 1994, PROG BRAIN RES, V103, P359; LITTLE JW, 1985, PARAPLEGIA, V23, P39, DOI 10.1038/sc.1985.7; Liu PH, 2003, EXP NEUROL, V179, P111, DOI 10.1006/exnr.2002.8057; Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Maccarrone M, 2006, THROMB HAEMOSTASIS, V95, P117, DOI 10.1160/TH05-06-0413; Mandolesi G, 2005, CURR BIOL, V15, P2119, DOI 10.1016/j.cub.2005.10.045; Martin LJ, 2011, J NEUROSCI, V31, P359, DOI 10.1523/JNEUROSCI.2225-10.2011; Martin LJ, 2003, J NEUROCHEM, V85, P234, DOI 10.1046/j.1471-4159.2003.01659.x; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; MATTHEWS MA, 1973, J NEUROCYTOL, V2, P265, DOI 10.1007/BF01104030; Matysiak M, 2008, MULT SCLER J, V14, P919, DOI 10.1177/1352458508090666; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; MCBRIDE RL, 1989, J NEUROPATH EXP NEUR, V48, P568, DOI 10.1097/00005072-198909000-00007; Meijer Alfred J., 2006, Molecular Aspects of Medicine, V27, P411, DOI 10.1016/j.mam.2006.08.002; Missitzi J, 2011, J PHYSIOL-LONDON, V589, P297, DOI 10.1113/jphysiol.2010.200600; Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004; Molina-Holgado F, 2005, MOL CELL NEUROSCI, V28, P189, DOI 10.1016/j.mcn.2004.09.004; Molinari M, 2013, HDB CEREBELLUM CEREB, P1579; Mori F, 1997, EXP NEUROL, V143, P45, DOI 10.1006/exnr.1996.6318; Mu XJ, 2000, J NEUROTRAUM, V17, P773, DOI 10.1089/neu.2000.17.773; Nakamura T, 2012, EXP NEUROL, V238, P12, DOI 10.1016/j.expneurol.2012.06.032; Nielson JL, 2011, J COMP NEUROL, V519, P2852, DOI 10.1002/cne.22661; Nielson JL, 2010, J NEUROSCI, V30, P11516, DOI 10.1523/JNEUROSCI.1433-10.2010; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Nordeyn OBT, 2005, J PHYSIOL-LONDON, V567, P293, DOI 10.1113/jphysiol.2005.088229; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Novikova LN, 2002, J COMP NEUROL, V452, P255, DOI 10.1002/cne.10381; Oddi S, 2012, J MOL MED, V90, P371, DOI 10.1007/s00109-011-0846-z; Oulad Ben Taib N, 2006, BRAIN RES, V1090, P110; Pacher P, 2005, NEUROPHARMACOLOGY, V48, P1130, DOI 10.1016/j.neuropharm.2004.12.005; Pacher P, 2011, PROG LIPID RES, V50, P193, DOI 10.1016/j.plipres.2011.01.001; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pacher P, 2009, SEMIN IMMUNOPATHOL, V31, P63, DOI 10.1007/s00281-009-0145-8; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Pearson-Fuhrhop KM, 2012, CURR OPIN NEUROL, V25, P682, DOI 10.1097/WCO.0b013e32835a360a; Pereira JE, 2009, EXP NEUROL, V220, P71, DOI 10.1016/j.expneurol.2009.07.030; Perry RB, 2012, NEURON, V75, P294, DOI 10.1016/j.neuron.2012.05.033; Perry RBT, 2009, SEMIN CELL DEV BIOL, V20, P600, DOI 10.1016/j.semcdb.2009.04.014; Pertwee RG, 2005, AAPS J, V7, pE625, DOI 10.1208/aapsj070364; Pertwee RG, 2005, HANDB EXP PHARMACOL, V168, P1; PINCHING AJ, 1971, J CELL SCI, V8, P253; Pinzon A, 2008, BRAIN RES, V1243, P146, DOI 10.1016/j.brainres.2008.09.047; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Puyal J, 2012, NEUROSCIENTIST, V18, P224, DOI 10.1177/1073858411404948; Raisman Geoffrey, 2012, Handb Clin Neurol, V109, P541, DOI 10.1016/B978-0-444-52137-8.00033-4; Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rigaud M, 2009, ANESTHESIOLOGY, V111, P381, DOI 10.1097/ALN.0b013e3181ae6212; Rishal I, 2014, NAT REV NEUROSCI, V15, P32, DOI 10.1038/nrn3609; Rishal I, 2010, EXP NEUROL, V223, P5, DOI 10.1016/j.expneurol.2009.08.010; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; ROTH EJ, 1991, PARAPLEGIA, V29, P582, DOI 10.1038/sc.1991.86; Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865; RUIGROK TJH, 1990, EUR J MORPHOL, V28, P224; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Sagredo Onintza, 2012, Recent Pat CNS Drug Discov, V7, P41; SAKAI T, 1994, BRAIN DEV-JPN, V16, P229, DOI 10.1016/0387-7604(94)90075-2; Sanchez AJ, 2012, CLIN IMMUNOL, V142, P57, DOI 10.1016/j.clim.2011.02.010; Saxon DW, 1996, J COMP NEUROL, V371, P41; SAXON DW, 1994, NEUROREPORT, V5, P809, DOI 10.1097/00001756-199403000-00018; Sayer Faisal T, 2006, Spine J, V6, P335, DOI 10.1016/j.spinee.2005.11.001; Scotter EL, 2010, BRIT J PHARMACOL, V160, P480, DOI 10.1111/j.1476-5381.2010.00735.x; SEGER R, 1995, FASEB J, V9, P726; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Sharma Alok, 2012, J Assoc Physicians India, V60 Suppl, P13; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Soblosky JS, 2001, BEHAV BRAIN RES, V119, P1, DOI 10.1016/S0166-4328(00)00328-4; Sofroniew M V, 1988, J Chem Neuroanat, V1, P327; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Souza JM, 2008, FREE RADICAL BIO MED, V45, P357, DOI 10.1016/j.freeradbiomed.2008.04.010; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Sung YJ, 2001, J NEUROBIOL, V47, P67, DOI 10.1002/neu.1016; TETZLAFF W, 1991, J NEUROSCI, V11, P2528; Thippeswamy T, 2006, HISTOL HISTOPATHOL, V21, P445, DOI 10.14670/HH-21.445; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tohda C, 2011, PHARMACOL THERAPEUT, V132, P57, DOI 10.1016/j.pharmthera.2011.05.006; Tseng GF, 1996, BRAIN RES, V715, P32, DOI 10.1016/0006-8993(95)01418-7; Uchino A, 2006, EUR RADIOL, V16, P592, DOI 10.1007/s00330-005-0014-3; van der Stelt M, 2005, NEUROMOL MED, V7, P37, DOI 10.1385/NMM:7:1-2:037; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Velayudhan L, 2013, CURR PHARM DESIGN, V33, P755; Viscomi MT, 2008, CEREBELLUM, V7, P401, DOI 10.1007/s12311-008-0042-z; Viscomi MT, 2008, NEUROSCIENCE, V154, P1267, DOI 10.1016/j.neuroscience.2008.04.024; Viscomi MT, 2010, EXP NEUROL, V224, P56, DOI 10.1016/j.expneurol.2010.03.023; Viscomi MT, 2009, CEREBELLUM, V8, P184, DOI 10.1007/s12311-009-0107-7; Viscomi MT, 2012, MOL NEUROBIOL, V46, P513, DOI 10.1007/s12035-012-8296-3; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Viscomi MT, 2009, J NEUROSCI, V29, P4564, DOI 10.1523/JNEUROSCI.0786-09.2009; Viscomi MT, 2004, NEUROSCIENCE, V123, P393, DOI 10.1016/j.neuroscience.2003.09.030; Volonte C, 2003, CNS NEUROL DISORD-DR, V2, P403, DOI 10.2174/1568007033482643; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Wang MD, 2011, TISSUE ENG PART B-RE, V17, P177, DOI [10.1089/ten.TEB.2010.0648, 10.1089/ten.teb.2010.0648]; Wang YJ, 2002, J NEUROTRAUM, V19, P1487, DOI 10.1089/089771502320914714; Wannier-Morino P, 2008, BRAIN RES, V1217, P96, DOI 10.1016/j.brainres.2007.11.019; Weaver LC, 2005, J NEUROTRAUM, V22, P1375, DOI 10.1089/neu.2005.22.1375; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Xiao M, 2007, NEUROBIOL DIS, V26, P363, DOI 10.1016/j.nbd.2007.01.012; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Xing SH, 2012, AUTOPHAGY, V8, P63, DOI 10.4161/auto.8.1.18217; Xu M, 2005, BRAIN RES, V1055, P137, DOI 10.1016/j.brainres.2005.07.003; Xu M, 2000, EXP NEUROL, V161, P472, DOI 10.1006/exnr.1999.7278; Xue MZ, 2010, AM J PATHOL, V176, P1193, DOI 10.2353/ajpath.2010.090361; Yamada K, 1998, AM J ROENTGENOL, V171, P813, DOI 10.2214/ajr.171.3.9725322; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yucel Y, 2008, PROG BRAIN RES, V173, P465, DOI 10.1016/S0079-6123(08)01132-1; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zarruk JG, 2012, STROKE, V43, P211, DOI 10.1161/STROKEAHA.111.631044; Zhou LQ, 1999, NEUROREPORT, V10, P3417, DOI 10.1097/00001756-199911080-00029	241	30	33	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	OCT	2014	50	2					368	389		10.1007/s12035-013-8629-x			22	Neurosciences	Neurosciences & Neurology	AQ9GV	WOS:000343157900010	24442481				2021-06-18	
J	Dohi, K; Kraemer, BC; Erickson, MA; McMillan, PJ; Kovac, A; Flachbartova, Z; Hansen, KM; Shah, GN; Sheibani, N; Salameh, T; Banks, WA				Dohi, Kenji; Kraemer, Brian C.; Erickson, Michelle A.; McMillan, Pamela J.; Kovac, Andrej; Flachbartova, Zuzana; Hansen, Kim M.; Shah, Gul N.; Sheibani, Nader; Salameh, Therese; Banks, William A.			Molecular Hydrogen in Drinking Water Protects against Neurodegenerative Changes Induced by Traumatic Brain Injury	PLOS ONE			English	Article							INDUCED OXIDATIVE DAMAGE; BARRIER; TRANSPORT; PERICYTES; MATRIX-METALLOPROTEINASE-9; PERMEABILITY; EXPRESSION; CYTOKINES; ALPHA	Traumatic brain injury (TBI) in its various forms has emerged as a major problem for modern society. Acute TBI can transform into a chronic condition and be a risk factor for neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, probably through induction of oxidative stress and neuroinflammation. Here, we examined the ability of the antioxidant molecular hydrogen given in drinking water (molecular hydrogen water; mHW) to alter the acute changes induced by controlled cortical impact (CCI), a commonly used experimental model of TBI. We found that mHW reversed CCI-induced edema by about half, completely blocked pathological tau expression, accentuated an early increase seen in several cytokines but attenuated that increase by day 7, reversed changes seen in the protein levels of aquaporin-4, HIF-1, MMP-2, and MMP-9, but not for amyloid beta peptide 1-40 or 1-42. Treatment with mHW also reversed the increase seen 4 h after CCI in gene expression related to oxidation/carbohydrate metabolism, cytokine release, leukocyte or cell migration, cytokine transport, ATP and nucleotide binding. Finally, we found that mHW preserved or increased ATP levels and propose a new mechanism for mHW, that of ATP production through the Jagendorf reaction. These results show that molecular hydrogen given in drinking water reverses many of the sequelae of CCI and suggests that it could be an easily administered, highly effective treatment for TBI.	[Dohi, Kenji; Kraemer, Brian C.; Erickson, Michelle A.; Kovac, Andrej; Hansen, Kim M.; Salameh, Therese; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA; [Dohi, Kenji] Jikei Univ, Sch Med, Dept Emergency Med, Tokyo, Japan; [Kraemer, Brian C.; Kovac, Andrej; Hansen, Kim M.; Salameh, Therese; Banks, William A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA; [Kraemer, Brian C.; McMillan, Pamela J.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA; [McMillan, Pamela J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Flachbartova, Zuzana] Univ Vet Med & Pharm, Dept Microbiol & Immunol, Lab Biomed Microbiol & Immunol, Kosice, Slovakia; [Shah, Gul N.] St Louis Univ, Sch Med, Edward Doisy Res Ctr, Div Endocrinol,Dept Internal Med, St Louis, MO USA; [Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA	Banks, WA (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.	wabanks1@uw.edu	Erickson, Michelle/U-7754-2019; Banks, William A/K-1330-2017; Sheibani, Nader/AAG-2379-2020; Erickson, Michelle/G-4815-2014	Banks, William A/0000-0002-0496-3619; Sheibani, Nader/0000-0003-2723-9217; Erickson, Michelle/0000-0002-2575-1594; dohi, kenji/0000-0002-4451-0382	Kiban C grant [23592683]; VA Merit ReviewUS Department of Veterans Affairs [RO-1 AG029839, R0-1 NS064131];  [RO-1 DK083485]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23592683] Funding Source: KAKEN; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA014520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK083485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32ES019851, P30ES013508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG029839] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002619] Funding Source: NIH RePORTER	KD was supported by Kiban C grant number 23592683. WAB was supported by VA Merit Review; RO-1 AG029839. WAB and GNS was supported by RO-1 DK083485. BCK was supported by VA Merit Review; R0-1 NS064131. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banks William A., 1997, V73, P353; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Erickson MA, 2012, J ALZHEIMERS DIS, V28, P951, DOI 10.3233/JAD-2011-111517; Guthrie CR, 2009, HUM MOL GENET, V18, P1825, DOI 10.1093/hmg/ddp099; Halliday MR, 2013, JAMA NEUROL, V70, P1198, DOI 10.1001/jamaneurol.2013.3841; Hawkins BE, 2013, J BIOL CHEM; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; JAGENDORF AT, 1966, P NATL ACAD SCI USA, V55, P170, DOI 10.1073/pnas.55.1.170; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Keep RF, 2012, TRANSL STROKE RES, V3, P263, DOI 10.1007/s12975-012-0152-2; Kovac A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-139; Miyamoto K, 2014, J MOL NEUROSCI; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Pan WH, 2006, J NEUROIMMUNOL, V174, P119, DOI 10.1016/j.jneuroim.2006.02.006; Pan WH, 1997, NEUROSCI BIOBEHAV R, V21, P603, DOI 10.1016/S0149-7634(96)00047-4; Pan WH, 1996, AM J PHYSIOL-ENDOC M, V271, pE636; Pan WH, 2000, EXP NEUROL, V170, P357, DOI 10.1006/exnr.2001.7702; Pan WH, 1998, BRAIN RES, V788, P87, DOI 10.1016/S0006-8993(97)01525-4; Price TO, 2012, ENDOCRINOLOGY, V153, P362, DOI 10.1210/en.2011-1638; Reyes TM, 1999, BRAIN RES, V851, P215, DOI 10.1016/S0006-8993(99)02189-7; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Shah GN, 2013, J PHARMACOL EXP THER, V344, P637, DOI 10.1124/jpet.112.201400; Silverberg GD, 2010, J NEUROPATH EXP NEUR, V69, P1034, DOI 10.1097/NEN.0b013e3181f46e25; Soustiel JF, 2010, NEUROTHERAPEUTICS, V7, P13, DOI 10.1016/j.nurt.2009.11.001; Verma S, 2006, BRAIN BEHAV IMMUN, V20, P449, DOI 10.1016/j.bbi.2005.10.005; Wick Jeannette Y, 2012, Consult Pharm, V27, P392, DOI 10.4140/TCP.n.2012.392	33	30	32	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2014	9	9							e108034	10.1371/journal.pone.0108034			16	Multidisciplinary Sciences	Science & Technology - Other Topics	AQ0SJ	WOS:000342492700070	25251220	DOAJ Gold, Green Published			2021-06-18	
J	Sweeney, ZK; Fu, JP; Wiedmann, B				Sweeney, Zachary K.; Fu, Jiping; Wiedmann, Brigitte			From Chemical Tools to Clinical Medicines: Nonimmunosuppressive Cyclophilin Inhibitors Derived from the Cyclosporin and Sanglifehrin Scaffolds	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; HEPATITIS-C-VIRUS; MYOCARDIAL REPERFUSION INJURY; IMPROVED BINDING-AFFINITY; TRAUMATIC BRAIN-INJURY; REPLICATION IN-VITRO; X-RAY-STRUCTURE; IMMUNOSUPPRESSIVE ACTIVITY; CRYSTAL COMPLEX; N-METHYL-4-ISOLEUCINE CYCLOSPORINE	The cyclophilins are widely expressed enzymes that catalyze the interconversion of the cis and trans peptide bonds of prolines. The immunosuppressive natural products cyclosporine A and sanglifehrin A inhibit the enzymatic activity of the cyclophilins. Chemical modification of both the cyclosporine and sanglifehrin scaffolds has produced many analogues that inhibit cyclophilins in vitro but have reduced immunosuppressive properties. Three nonimmunosuppressive cyclophilin inhibitors (alisporivir, SCY-635, and NIM811) have demonstrated clinical efficacy for the treatment of hepatitis C infection. Additional candidates are in various stages of preclinical development for the treatment of hepatitis C or myocardial reperfusion injury. Recent publications suggest that cyclophilin inhibitors may have utility for the treatment of diverse viral infections, inflammatory indications, and cancer. In this review, we document the structureactivity relationships of the nonimmunosuppressive cyclosporins and sanglifehrins in clinical and preclinical development. Aspects of the pharmacokinetic behavior and chemical biology of these drug candidates are also described.	[Sweeney, Zachary K.; Fu, Jiping; Wiedmann, Brigitte] Novartis Inst BioMed Res, Emeryville, CA 94608 USA	Sweeney, ZK (corresponding author), Novartis Inst BioMed Res, 4560 Horton St, Emeryville, CA 94608 USA.	zachary.sweeney@novartis.com			NovartisNovartis	This work was funded by Novartis. We thank Heinz Moser, Javier De Vicente, James Sutton, and the reviewers for critical evaluations of the manuscript.	Aciro C., 2013, International Patent, Patent No. [WO 2013185090 A1 20131212, 2013185090]; Aciro C., 2013, International Patent, Patent No. [WO 2013185103 A1 20131212, 2013185103]; Akhlaghi F, 2002, CLIN PHARMACOKINET, V41, P615, DOI 10.2165/00003088-200241090-00001; Alex A, 2011, MEDCHEMCOMM, V2, P669, DOI 10.1039/c1md00093d; Amundsen R, 2010, DRUG METAB DISPOS, V38, P1499, DOI 10.1124/dmd.110.032268; Appleby T., 2012, International Patent, Patent No. [WO 2012078915 A1 20120614, 2012078915]; AWNI WM, 1985, DRUG METAB DISPOS, V13, P127; Baugh J, 2012, BIOL CHEM, V393, P579, DOI 10.1515/hsz-2012-0151; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Bobardt M, 2013, J HEPATOL, V58, P16, DOI 10.1016/j.jhep.2012.08.007; Bockus AT, 2013, CURR TOP MED CHEM, V13, P821, DOI 10.2174/1568026611313070005; BOREL JF, 1989, PHARMACOL REV, V41, P239; Bua J, 2004, BIOORG MED CHEM LETT, V14, P4633, DOI 10.1016/j.bmcl.2004.07.003; Carling W. R., 2012, Patent No. [WO 2012/051193, 2012051193]; Chatterji U, 2005, J BIOL CHEM, V280, P40293, DOI 10.1074/jbc.M506314200; Choi JW, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000750; Coelmont L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013687; COLOMBANI PM, 1985, SCIENCE, V228, P337, DOI 10.1126/science.3885394; Davis TL, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000439; EBERLE MK, 1995, J MED CHEM, V38, P1853, DOI 10.1021/jm00011a004; El-Sheikh AAK, 2013, TRANSL RES, V162, P398, DOI 10.1016/j.trsl.2013.08.003; Elrod JW, 2013, CIRC J, V77, P1111, DOI 10.1253/circj.CJ-13-0321; Evers M, 2003, BIOORG MED CHEM LETT, V13, P4415, DOI 10.1016/j.bmcl.2003.09.042; Fang F, 2010, J MOL ENDOCRINOL, V44, P319, DOI 10.1677/JME-09-0140; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Flisiak R, 2012, EXPERT OPIN INV DRUG, V21, P375, DOI 10.1517/13543784.2012.658641; Frausto SD, 2013, VIRUSES-BASEL, V5, P1684, DOI 10.3390/v5071684; Friedenberg WR, 2006, CANCER-AM CANCER SOC, V106, P830, DOI 10.1002/cncr.21666; Gaither LA, 2010, VIROLOGY, V397, P43, DOI 10.1016/j.virol.2009.10.043; Galat A, 2004, PROTEINS, V56, P808, DOI 10.1002/prot.20156; Galat A, 2010, CELL MOL LIFE SCI, V67, P3467, DOI 10.1007/s00018-010-0437-0; Gallay PA, 2013, DRUG DES DEV THER, V7, P105, DOI 10.2147/DDDT.S30946; Garcia-Rivera JA, 2012, ANTIMICROB AGENTS CH, V56, P5113, DOI 10.1128/AAC.00919-12; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Gill RS, 2012, SHOCK, V37, P341, DOI 10.1097/SHK.0b013e31824bc9ab; Goto K, 2006, BIOCHEM BIOPH RES CO, V343, P879, DOI 10.1016/j.bbrc.2006.03.059; Gregory MA, 2011, ANTIMICROB AGENTS CH, V55, P1975, DOI 10.1128/AAC.01627-10; Guichou J.-F., 2011, Patent, Patent No. [WO2011076784, 2011076784]; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; Hartel C, 2006, SCAND J IMMUNOL, V63, P26, DOI 10.1111/j.1365-3083.2006.01702.x; Hegmans A., 2012, Patent No. [WO2012-079172 A1, 2012079172, WO 2012079172A1]; Heine SJ, 2011, J INFLAMM RES, V4, P93, DOI 10.2147/JIR.S20733; Heusler K, 2001, SWISS MED WKLY, V131, P299; Hokari M, 2010, J PHARM PHARMACOL, V62, P485, DOI 10.1211/jpp.62.04.0011; Hopkins S, 2012, VIRUSES-BASEL, V4, P2558, DOI 10.3390/v4112558; Hopkins S, 2012, J HEPATOL, V57, P47, DOI 10.1016/j.jhep.2012.02.024; Hopkins S, 2010, ANTIMICROB AGENTS CH, V54, P660, DOI 10.1128/AAC.00660-09; Hubler F, 2000, TETRAHEDRON LETT, V41, P7193, DOI 10.1016/S0040-4039(00)01267-3; Immecke SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018406; Ito K, 2013, MOLECULES, V18, P3502, DOI 10.3390/molecules18033502; Jiang L., 2012, ANN M AM ASS STUD LI; Jin L, 2002, P NATL ACAD SCI USA, V99, P13522, DOI 10.1073/pnas.212504399; Kallen J, 2005, J BIOL CHEM, V280, P21965, DOI 10.1074/jbc.M501623200; Karlgren M, 2012, PHARM RES-DORDR, V29, P411, DOI 10.1007/s11095-011-0564-9; Ko SY, 1997, HELV CHIM ACTA, V80, P695, DOI 10.1002/hlca.19970800307; Kobayashi M., 2006, [No title captured], Patent No. [2006/054801, 2006054801]; Kolitz JE, 2010, BLOOD, V116, P1413, DOI 10.1182/blood-2009-07-229492; Korde AS, 2007, J NEUROTRAUM, V24, P895, DOI 10.1089/neu.2006.0122; Kovacs S. J., 2012, DIG DIS WEEK; LAWEN A, 1991, J BIOL CHEM, V266, P15567; Lawitz E, 2011, ANTIVIR RES, V89, P238, DOI 10.1016/j.antiviral.2011.01.003; Lee J, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-97; Li K., 2011, [No title captured], Patent No. [WO2011-070364 A1, 2011070364]; Lin K, 2011, ANTIVIRAL DRUGS: FROM BASIC DISCOVERY THROUGH CLINICAL TRIALS, P317; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Loor F, 2002, J MED CHEM, V45, P4598, DOI 10.1021/jm0109863; Malesevic M, 2013, J MED CHEM, V56, P7302, DOI 10.1021/jm4007577; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mikol V, 1998, J MOL BIOL, V283, P451, DOI 10.1006/jmbi.1998.2109; MIKOL V, 1993, J MOL BIOL, V234, P1119, DOI 10.1006/jmbi.1993.1664; Moss S., 2012, Patent, Patent No. [WO2012/131371 (Al), 2012131371, 2012/131371]; Moss S.J., 2012, Int. Patent Appl., Patent No. [WO 2012/131377 A1, 2012131377]; Moss SJ, 2012, MEDCHEMCOMM, V3, P938, DOI 10.1039/c1md00227a; Neya M., 2007, New Cyclic Peptide Compounds, Patent No. [WO 2007/049803, 2007049803]; Nicolas V, 2010, PKUK 2010 BRIST UK; ODONOHUE MF, 1995, PROTEIN SCI, V4, P2191, DOI 10.1002/pro.5560041025; Ogimura E, 2011, BIOCHEM BIOPH RES CO, V416, P313, DOI 10.1016/j.bbrc.2011.11.032; Owens C. M., 2013, ANN M EUR ASS STUD L; Owens C. M., 2011, ANN M AASLD SAN FRAN; Paeshuyse J, 2006, HEPATOLOGY, V43, P761, DOI 10.1002/hep.21102; PAPAGEORGIOU C, 1994, J MED CHEM, V37, P3674, DOI 10.1021/jm00048a002; PAPAGEORGIOU C, 1994, BIOORG MED CHEM LETT, V4, P267, DOI 10.1016/S0960-894X(01)80127-X; Papageorgiou C, 1997, BIOORGAN MED CHEM, V5, P187, DOI 10.1016/S0968-0896(96)00204-0; Papageorgiou C, 1996, BIOORG MED CHEM LETT, V6, P23, DOI 10.1016/0960-894X(95)00553-6; Peel M, 2013, RSC DRUG DISCOV, V32, P384, DOI 10.1039/9781849737814-00384; Peel M, 2013, BIOORG MED CHEM LETT, V23, P4485, DOI 10.1016/j.bmcl.2013.05.101; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; Pushkarsky T, 2005, J BIOL CHEM, V280, P27866, DOI 10.1074/jbc.M503770200; Puyang XL, 2010, ANTIMICROB AGENTS CH, V54, P1981, DOI 10.1128/AAC.01236-09; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; RADEKE HH, 1992, INT J IMMUNOPHARMACO, V14, P595, DOI 10.1016/0192-0561(92)90120-A; Rasola A, 2007, APOPTOSIS, V12, P815, DOI 10.1007/s10495-007-0723-y; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Rehman H, 2008, J PHARMACOL EXP THER, V327, P699, DOI 10.1124/jpet.108.143578; Rehman H, 2011, TRANSPLANTATION, V91, P406, DOI 10.1097/TP.0b013e318204bdb2; ROSEN MK, 1992, BIOORG MED CHEM LETT, V2, P747, DOI 10.1016/S0960-894X(00)80405-9; SAKAMOTO K, 1993, J ANTIBIOT, V46, P1788, DOI 10.7164/antibiotics.46.1788; Sanglier JJ, 1999, J ANTIBIOT, V52, P466, DOI 10.7164/antibiotics.52.466; Sawada M., 2012, ANN M AM ASS STUD LI; Schaerfer C, 2013, J MED CHEM, V56, P2016, DOI 10.1021/jm3016816; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Scribner A, 2010, BIOORG MED CHEM LETT, V20, P6542, DOI 10.1016/j.bmcl.2010.09.036; Sedrani R, 2003, J AM CHEM SOC, V125, P3849, DOI 10.1021/ja021327y; SEEBACH D, 1993, HELV CHIM ACTA, V76, P1564, DOI 10.1002/hlca.19930760415; SEEBACH D, 1991, HELV CHIM ACTA, V74, P197, DOI 10.1002/hlca.19910740121; Shitara Y, 2009, DRUG METAB DISPOS, V37, P1172, DOI 10.1124/dmd.108.025544; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; Steadman V. A., 2013, International Patent, Patent No. [WO 2013185093 A1 20131212, 2013185093]; Stemmy EJ, 2011, AM J RESP CELL MOL, V45, P991, DOI 10.1165/rcmb.2011-0007OC; Su Z., 2012, [No title captured], Patent No. [WO2012-075494 A1, 2012075494]; Su Z., 2012, Patent No. [WO 2012/009715, 2012009715]; Su Z., 2013, Patent No. [WO 2013/028615, 2013028615]; Su Z., 2012, [No title captured], Patent No. [WO 2012021796 A2, 2012021796]; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Taylor P, 1997, PROG BIOPHYS MOL BIO, V67, P155, DOI 10.1016/S0079-6107(97)00014-X; TERAOKA S, 1988, TRANSPLANT P, V20, P868; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; TRABER R, 1987, HELV CHIM ACTA, V70, P13, DOI 10.1002/hlca.19870700103; Vuagniaux G., 2011, Use of Cyclo-undecadepsipeptide Compounds, Patent No. [WO 2011/141891, 2011141891]; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Wang H, 2011, J GASTROEN HEPATOL, V26, P558, DOI 10.1111/j.1440-1746.2010.06406.x; Wang WL, 2011, MED HYPOTHESES, V77, P734, DOI 10.1016/j.mehy.2011.07.026; Wenger R. M., 2000, Novel Cyclosporin with Improved Activity Profile, Patent No. [WO 00/01715, 0001715]; Wenger R.M., 2011, Cydoundecadepsipeptide Compounds and Use of Said Compounds as a Medicament, Patent No. [US 2011/212057, 2011212057]; Wenger R.M., 1986, PROG CLIN BIOCH MED, P157; WENGER RM, 1994, FEBS LETT, V340, P255, DOI 10.1016/0014-5793(94)80149-5; WENGER RM, 1984, HELV CHIM ACTA, V67, P502, DOI 10.1002/hlca.19840670220; WENGER RM, 1985, ANGEW CHEM INT EDIT, V24, P77, DOI 10.1002/anie.198500773; Wissing ER, 2010, NEUROMUSCULAR DISORD, V20, P753, DOI 10.1016/j.nmd.2010.06.016; Wring S., 2010, EUR ASS STUD LIV M; Yamanaka T., 2008, New Cyclic Peptide Compounds, Patent No. [WO 2008/139986, 2008139986]; Yurchenko V, 2006, IMMUNOLOGY, V117, P301, DOI 10.1111/j.1365-2567.2005.02316.x; Yurchenko V, 2010, CLIN EXP IMMUNOL, V160, P305, DOI 10.1111/j.1365-2249.2010.04115.x; ZEDERLUTZ G, 1994, J CHROMATOGR B, V662, P301, DOI 10.1016/0378-4347(94)00211-8; Zeisel MB, 2013, J HEPATOL, V58, P375, DOI 10.1016/j.jhep.2012.09.022; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; Zhang JY, 2003, J BIOL CHEM, V278, P7459, DOI 10.1074/jbc.M207976200; Zhong Z, 2007, AM J TRANSPLANT, V7, P1103, DOI 10.1111/j.1600-6143.2007.01770.x	141	30	31	0	22	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	SEP 11	2014	57	17					7145	7159		10.1021/jm500223x			15	Chemistry, Medicinal	Pharmacology & Pharmacy	AO8QN	WOS:000341619400001	24831536				2021-06-18	
J	Gullotti, DM; Beamer, M; Panzer, MB; Chen, YC; Patel, TP; Yu, A; Jaumard, N; Winkelstein, B; Bass, CR; Morrison, B; Meaney, DF				Gullotti, David M.; Beamer, Matthew; Panzer, Matthew B.; Chen, Yung Chia; Patel, Tapan P.; Yu, Allen; Jaumard, Nicolas; Winkelstein, Beth; Bass, Cameron R.; Morrison, Barclay; Meaney, David F.			Significant Head Accelerations Can Influence Immediate Neurological Impairments in a Murine Model of Blast-Induced Traumatic Brain Injury	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						blast; traumatic brain injury; biomechanics; acceleration; overpressure	INTRACRANIAL-PRESSURE RESPONSE; BEHAVIORAL DEFICITS; MOUSE MODEL; RAT; WAVE; OVERPRESSURE; RANGE	Although blast-induced traumatic brain injury (bTBI) is well recognized for its significance in the military population, the unique mechanisms of primary bTBI remain undefined. Animate models of primary bTBI are critical for determining these potentially unique mechanisms, but the biomechanical characteristics of many bTBI models are poorly understood. In this study, we examine some common shock tube configurations used to study blast-induced brain injury in the laboratory and define the optimal configuration to minimize the effect of torso overpressure and blast-induced head accelerations. Pressure transducers indicated that a customized animal holder successfully reduced peak torso overpressures to safe levels across all tested configurations. However, high speed video imaging acquired during the blast showed significant head accelerations occurred when animals were oriented perpendicular to the shock tube axis. These findings of complex head motions during blast are similar to previous reports [Goldstein et al., 2012, "Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model," Sci. Transl. Med., 4(134), 134ra160; Sundaramurthy et al., 2012, " Blast-Induced Biomechanical Loading of the Rat: An Experimental and Anatomically Accurate Computational Blast Injury Model," J. Neurotrauma, 29(13), pp. 2352-2364; Svetlov et al., 2010, "Morphologic and Biochemical Characterization of Brain Injury in a Model of Controlled Blast Overpressure Exposure," J. Trauma, 69(4), pp. 795-804]. Under the same blast input conditions, minimizing head acceleration led to a corresponding elimination of righting time deficits. However, we could still achieve righting time deficits under minimal acceleration conditions by significantly increasing the peak blast overpressure. Together, these data show the importance of characterizing the effect of blast overpressure on head kinematics, with the goal of producing models focused on understanding the effects of blast overpressure on the brain without the complicating factor of superimposed head accelerations.	[Gullotti, David M.; Beamer, Matthew; Chen, Yung Chia; Patel, Tapan P.; Jaumard, Nicolas; Winkelstein, Beth; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Panzer, Matthew B.; Yu, Allen; Bass, Cameron R.] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Winkelstein, Beth; Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Morrison, Barclay] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.		Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Patel, Tapan/0000-0001-8959-6645; Meaney, David/0000-0002-0954-4122	Department of the Army [W911F-10-1-0526]	Funding for this project was provided by the Department of the Army Grant No. W911F-10-1-0526. We would also like to thank Edward W. Vogel III, Christopher D. Hue, and Gwen B. Effgen from Columbia University for their input and help with high speed video acquisition. Finally, we would like to thank Anthony Choo, Rosalind Mott, and Tanya Merdiushev for their input to the project.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Arun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033798; Arun P, 2012, NEUROREPORT, V23, P342, DOI 10.1097/WNR.0b013e328351b58d; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; FRIEDLANDER FG, 1946, PROC R SOC LON SER-A, V186, P322, DOI 10.1098/rspa.1946.0046; Ganpule S, 2013, BIOMECH MODEL MECHAN, V12, P511, DOI 10.1007/s10237-012-0421-8; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Leonardi AD, 2013, ANN BIOMED ENG, V41, P2488, DOI 10.1007/s10439-013-0850-2; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Liu H, 2012, INT J MED SCI, V9, P655, DOI 10.7150/ijms.5004; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Orman JA, 2012, J TRAUMA ACUTE CARE, V73, pS496, DOI 10.1097/TA.0b013e318275473c; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Shah Ms Alok S, 2012, Biomed Sci Instrum, V48, P393; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taniellan T., 2008, MG720CCF; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Yu A. W., 2012, BIOM ENG SOC ANN M B; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	30	30	0	12	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	SEP	2014	136	9							091004	10.1115/1.4027873			11	Biophysics; Engineering, Biomedical	Biophysics; Engineering	AN5GC	WOS:000340617700004	24950710				2021-06-18	
J	Leon, I; Garcia-Garcia, J; Roldan-Tapia, L				Leon, Irene; Garcia-Garcia, Juan; Roldan-Tapia, Lola			Estimating Cognitive Reserve in Healthy Adults Using the Cognitive Reserve Scale	PLOS ONE			English	Article							NEURONORMA PROJECT NORMS; TRAUMATIC BRAIN-INJURY; LEISURE ACTIVITIES; NEUROPSYCHOLOGICAL PERFORMANCE; INTERINDIVIDUAL VARIABILITY; VISUOSPATIAL SPAN; ALZHEIMER-DISEASE; NEURAL BASIS; VERBAL SPAN; LIFE-STYLE	The concept of cognitive reserve emerged from observed disparities between brain pathology and clinical symptoms. It may explain better neuropsychological performance in healthy individuals. The objectives of this study were to measure reserve in healthy subjects using a new Cognitive Reserve Scale (CRS), analyze the internal consistency of the CRS, and analyze validity evidence. A total of 117 healthy individuals were divided into two groups: 87 adults (aged 18-64 years) and 30 elderly adults (>= 65 years). All subjects completed the CRS and a comprehensive neuropsychological battery. The internal consistency of the scale was satisfactory (alpha = 0.77). No significant differences were observed between genders (t = 0.51, p = 0.611), and age was corrected by averaging the CRS score. The study of validity evidence showed that education affected the CRS (t = -2.98, p = 0.004, partial eta(2) = 0.07) and there was no significant relationship between the CRS and IQ (r = 0.09, p = 0.33). Occupational attainment and the CRS were not related (F-2,F-116 = 0.11, p = 0.898). In line with previous studies on reserve, heterogeneity was observed in the analyses of relationships between the CRS and cognitive performance. There were significant relationships between CRS score and the Verbal Learning Spanish-Complutense Test last trial (r = 0.24, p = 0.009), sum (r = 0.32, p = 0.000), short-term (r = 0.29, p = 0.002) and long-term memory (r = 0.22, p = 0.018), Matrix Reasoning subtest (r = 0.20, p = 0.027) and Block Design subtest (r = 0.20, p = 0.029). No other neuropsychological variables correlated with the CRS (p > 0.05). The CRS is a reliable instrument that reflects the frequency of participation in brain-stimulating activities across the lifetime. The associations between the CRS and education and neuropsychological performance support validity evidence.	[Leon, Irene; Garcia-Garcia, Juan; Roldan-Tapia, Lola] Univ Almeria, Dept Psychol, Almeria, Spain	Roldan-Tapia, L (corresponding author), Univ Almeria, Dept Psychol, Almeria, Spain.	mdroldan@ual.es	Leon, Irene/AAJ-6829-2020; Garcia-Garcia, Juan/L-7116-2014	Leon, Irene/0000-0002-3558-8831; Garcia-Garcia, Juan/0000-0002-0123-8497; Roldan-Tapia, Maria/0000-0002-7417-8624	Ministry of Economy and Competitiveness (Spain) [PSI2011-26985]; Plan Propio de Investigacion Grant	This work was supported by the Ministry of Economy and Competitiveness (Spain) [PSI2011-26985] and Plan Propio de Investigacion Grant to IL (University of Almeria). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbaraly TN, 2009, NEUROLOGY, V73, P854, DOI 10.1212/WNL.0b013e3181b7849b; Alosco ML, 2012, J CLIN EXP NEUROPSYC, V34, P1, DOI 10.1080/13803395.2011.614596; Apolinario D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060084; Bartres-Faz D, 2011, BRAIN TOPOGR, V24, P340, DOI 10.1007/s10548-011-0195-9; Bastin C, 2012, NEUROIMAGE, V63, P713, DOI 10.1016/j.neuroimage.2012.06.074; Benedet M., 1998, TEST APRENDIZAJE VER; Borenstein AR, 2006, ALZ DIS ASSOC DIS, V20, P63, DOI 10.1097/01.wad.0000201854.62116.d7; Brayne C, 2010, BRAIN, V133, P2210, DOI 10.1093/brain/awq185; Brickman AM, 2011, NEUROBIOL AGING, V32, P1588, DOI 10.1016/j.neurobiolaging.2009.10.013; Carnero-Pardo C, 2007, NEUROLOGIA, V22, P860; Casals-Coll M, 2013, NEUROLOGIA, V28, P33, DOI 10.1016/j.nrl.2012.02.010; Chao S, 2012, NEUROIMAGE, V63, P1542; Chtistensen H, 2009, AM J GERIAT PSYCHIAT, V17, P218, DOI 10.1097/JGP.0b013e3181961a84; Coffey CE, 1999, NEUROLOGY, V53, P189, DOI 10.1212/WNL.53.1.189; de la Serna E, 2013, SCHIZOPHR RES, V143, P125, DOI 10.1016/j.schres.2012.10.026; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Foubert-Samier A, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.09.023; Fratiglioni L, 2007, J ALZHEIMERS DIS, V12, P11; Garcia-Molina A, 2013, MED CLIN-BARCELONA, V140, P527, DOI 10.1016/j.medcli.2012.09.047; Ghaffar O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047206; Golden CJ, 2010, STOOP TEST COLORES P; Instituto Nacional de Estadistica (INE), 2011, CLAS NAC OC CNO; Jones RN, 2011, J INT NEUROPSYCH SOC, V17, P593, DOI 10.1017/S1355617710001748; Kemppainen NM, 2008, ANN NEUROL, V63, P112, DOI 10.1002/ana.21212; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Le Carret N, 2003, DEV NEUROPSYCHOL, V23, P317, DOI 10.1207/S15326942DN2303_1; Lee JM, 2007, CER ORTHO, P187, DOI 10.1007/978-3-7985-1783-7_26; Leon I, 2011, REV NEUROLOGIA, V52, P653, DOI 10.33588/rn.5211.2010704; Liu YY, 2013, J CLIN NEUROSCI, V20, P548, DOI 10.1016/j.jocn.2012.04.020; Lobo A, 1979, Actas Luso Esp Neurol Psiquiatr Cienc Afines, V7, P189; Sanchez JL, 2011, J CLIN EXP NEUROPSYC, V33, P874, DOI 10.1080/13803395.2011.567976; Marioni RE, 2012, J ALZHEIMERS DIS, V28, P223, DOI 10.3233/JAD-2011-110377; Meng XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038268; Mitrushina M., 2005, HDB NORMATIVE DATA N; Nelson HE, 1982, NATL ADULT READING T; Nucci Massimo, 2012, Aging Clin Exp Res, V24, P218, DOI 10.3275/7800; Palomo R, 2013, NEUROLOGIA, V28, P226, DOI 10.1016/j.nrl.2012.03.008; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P413, DOI 10.1093/arclin/acp043; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P395, DOI 10.1093/arclin/acp042; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P371, DOI 10.1093/arclin/acp041; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P321, DOI 10.1093/arclin/acp038; Perneczky R, 2008, DEMENT GERIATR COGN, V26, P475, DOI 10.1159/000167791; Rami L, 2011, REV NEUROLOGIA, V52, P195, DOI 10.33588/rn.5204.2010478; Reed BR, 2011, J INT NEUROPSYCH SOC, V17, P615, DOI 10.1017/S1355617711000014; Rey A, 2009, TEST COPIA FIGURA CO; Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; Roe CM, 2007, NEUROLOGY, V68, P223, DOI 10.1212/01.wnl.0000251303.50459.8a; Rognoni T, 2013, NEUROLOGIA, V28, P73, DOI 10.1016/j.nrl.2012.02.009; Roldan-Tapia L, 2012, APPL NEUROPSYCH-ADUL, V19, P2, DOI 10.1080/09084282.2011.595458; Perez PS, 2009, MED CLIN-BARCELONA, V132, P459, DOI 10.1016/j.medcli.2008.04.012; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Scarmeas N, 2003, ARCH NEUROL-CHICAGO, V60, P359, DOI 10.1001/archneur.60.3.359; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Scarmeas N., 2007, COGNITIVE RESERVE TH, P187; Schwartz CE, 2013, MULT SCLER J, V19, P87, DOI 10.1177/1352458512444914; Sole-Padulles C, 2009, NEUROBIOL AGING, V30, P1114, DOI 10.1016/j.neurobiolaging.2007.10.008; Soto-Anari M, 2013, REV NEUROLOGIA, V56, P79, DOI 10.33588/rn.5602.2012402; Steffener J, 2012, BBA-MOL BASIS DIS, V1822, P467, DOI 10.1016/j.bbadis.2011.09.012; Stern Y, 2005, CEREB CORTEX, V15, P394, DOI 10.1093/cercor/bhh142; Stern Y, 2003, J CLIN EXP NEUROPSYC, V25, P691, DOI 10.1076/jcen.25.5.691.14573; Stern Y, 1999, NEUROLOGY, V53, P1942, DOI 10.1212/WNL.53.9.1942; Stern Y, 2008, CEREB CORTEX, V18, P959, DOI 10.1093/cercor/bhm134; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Tamayo F, 2012, NEUROLOGIA, V27, P319, DOI 10.1016/j.nrl.2011.12.020; Valenzuela M, 2006, PSYCHOL MED, V52, P195; Valenzuela MJ, 2007, PSYCHOL MED, V37, P1015, DOI 10.1017/S003329170600938X; Valenzuela MJ, 2006, PSYCHOL MED, V36, P441, DOI 10.1017/S0033291705006264; Van Dijk KRA, 2008, PSYCHOL AGING, V23, P119, DOI 10.1037/0882-7974.23.1.119; Vemuri P, 2011, BRAIN, V134, P1479, DOI 10.1093/brain/awr049; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Wang HX, 2002, AM J EPIDEMIOL, V155, P1081, DOI 10.1093/aje/155.12.1081; WECHSLER D, 1999, ESCALA INTELIGENCIA, V3; Wilson RS, 2003, J CLIN EXP NEUROPSYC, V25, P634, DOI 10.1076/jcen.25.5.634.14572; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742; Yaffe K, 2011, JAMA-J AM MED ASSOC, V305, P261, DOI 10.1001/jama.2010.1995; Zahodne LB, 2011, J INT NEUROPSYCH SOC, V17, P1039, DOI 10.1017/S1355617711001044	76	30	30	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2014	9	7							e102632	10.1371/journal.pone.0102632			8	Multidisciplinary Sciences	Science & Technology - Other Topics	AM0QO	WOS:000339551100045	25050711	DOAJ Gold, Green Published			2021-06-18	
J	Shay, N; Yeates, KO; Walz, NC; Stancin, T; Taylor, HG; Beebe, DW; Caldwell, CT; Krivitzky, L; Cassedy, A; Wade, SL				Shay, Nicole; Yeates, Keith O.; Walz, Nicolay C.; Stancin, Terry; Taylor, H. Gerry; Beebe, Dean W.; Caldwell, Carolyn T.; Krivitzky, Lauren; Cassedy, Amy; Wade, Shari L.			Sleep Problems and Their Relationship to Cognitive and Behavioral Outcomes in Young Children with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; cognitive ability; preschool; sleep; traumatic brain injury	DISTURBANCES; SYMPTOMS; HYPERACTIVITY; ASSOCIATION; ADOLESCENTS; DISORDERS; MODERATE; RISK	This study examined the effect of traumatic brain injury (TBI) in young children on sleep problems and the relationship of sleep problems to neuropsychological and psychosocial functioning. Participants were drawn from an ongoing longitudinal study of injury in young children recruited from 3 to 6 years of age. They constituted three groups: orthopedic injury (OI; n = 92), complicated mild/moderate TBI (mTBI; n = 55); and severe TBI (sTBI; n = 20). Caregivers completed the Children's Sleep Habits Questionnaire (CSHQ), as well as ratings of behavioral adjustment, adaptive functioning, and everyday executive function at 1, 6, 12, and 18 months postinjury. Retrospective ratings of preinjury sleep and psychosocial functioning were obtained at the initial assessment. Children completed neuropsychological testing at all occasions. Children with complicated mTBI demonstrated more total sleep problems than children with OI at 6 months postinjury, but not at 12 or 18 months. Children with sTBI displayed more bedtime resistance and shorter sleep duration than those with complicated mTBI or OI at several occasions. Across groups, total sleep problems predicted more emotional and behavioral problems and worse everyday executive function as rated by parents across follow-up occasions. In contrast, sleep problems were generally not related to neuropsychological test performance. The results suggest that young children with TBI demonstrate more sleep problems than children with injuries not involving the head. Sleep problems, in turn, significantly increase the risk of poor psychosocial outcomes across time, but are not associated with worse neuropsychological test performance.	[Shay, Nicole] Brown Univ, Dept Psychiat & Human Behav, Warren Alpert Med Sch, Providence, RI 02912 USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith O.] Nationwide Childrens Hosp, Ctr Behav Hlth, Res Inst, Columbus, OH USA; [Walz, Nicolay C.] Cincinnati Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, Cincinnati, OH 45229 USA; [Stancin, Terry; Taylor, H. Gerry] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; [Beebe, Dean W.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Caldwell, Carolyn T.] US Army Northern Reg Med Command, Aberdeen Proving Ground, MD USA; [Krivitzky, Lauren] Childrens Hosp Philadelphia, Dept Child & Adolescent Psychiat, Philadelphia, PA 19104 USA; [Cassedy, Amy] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Cassedy, Amy] Univ Cincinnati, Dept Sociol, McMicken Coll Arts & Sci, Cincinnati, OH USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Dept Phys Med & Rehabil, Cincinnati, OH USA	Yeates, KO (corresponding author), Univ Calgary, Dept Psychol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	kyeates@ucalgary.ca	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER	The research reported here was supported by grant R01 HD42729 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (to Dr. Shari Wade). The authors acknowledge the contributions of Christine Abraham, Andrea Beebe, Lori Bernard, Anne Birnbaum, Beth Bishop, Tammy Matecun, Karen Oberjohn, Elizabeth Roth, and Elizabeth Shaver in data collection and coding. The Cincinnati Children's Medical Center Trauma Registry, Rainbow Pediatric Trauma Center, Rainbow Babies and Children's Hospital, Nationwide Children's Hospital Trauma Program, and MetroHealth Center Department of Pediatrics and Trauma Registry provided assistance with recruitment.	Achenbach T. M., 2000, MANUAL ASEBA PRESCHO; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Ali NJ, 1996, EUR J PEDIATR, V155, P56, DOI 10.1007/BF02115629; Archbold Kristen Hedger, 2004, Biol Res Nurs, V5, P168, DOI 10.1177/1099800403260261; Aronen ET, 2000, J AM ACAD CHILD PSY, V39, P502, DOI 10.1097/00004583-200004000-00020; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P845, DOI 10.1093/jpepsy/jsm003; Beebe DW, 2006, SLEEP, V29, P1115, DOI 10.1093/sleep/29.9.1115; Beebe DW, 2012, CHILD NEUROPSYCHOL, V18, P313, DOI 10.1080/09297049.2011.602014; Beebe DW, 2011, PEDIATR CLIN N AM, V58, P649, DOI 10.1016/j.pcl.2011.03.002; Bourke RS, 2011, SLEEP MED, V12, P222, DOI 10.1016/j.sleep.2010.08.011; Chervin RD, 2002, PEDIATRICS, V109, P449, DOI 10.1542/peds.109.3.449; Elliott C.D., 1990, DIFFERENTIAL ABILITY; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Gioia G., 2000, BEHAV RATING EXECUTI; Gottlieb DJ, 2004, J PEDIATR-US, V145, P458, DOI 10.1016/j.jpeds.2004.05.039; Gregory AM, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200208000-00015; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Johnson EO, 2000, PSYCHIAT RES, V94, P93, DOI 10.1016/S0165-1781(00)00145-1; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kheirandish L, 2006, DEVELOPMENTAL SCI, V9, P388, DOI 10.1111/j.1467-7687.2006.00504.x; Korkman M, 1998, NEPSY DEV NEUROPSYCH; Luginbuehl M, 2009, CHILD ADOL PSYCH CL, V18, P825, DOI 10.1016/j.chc.2009.04.012; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Osorio MB, 2013, PM&R, V5, P554, DOI 10.1016/j.pmrj.2012.11.006; Owens JA, 2000, SLEEP, V23, P1043; Picchietti DL, 1999, MOVEMENT DISORD, V14, P1000, DOI 10.1002/1531-8257(199911)14:6<1000::AID-MDS1014>3.0.CO;2-P; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Spruyt K, 2011, SLEEP MED REV, V15, P19, DOI 10.1016/j.smrv.2010.07.005; Stores G, 2013, DEV MED CHILD NEUROL, V55, P797, DOI 10.1111/dmcn.12163; Sumpter RE, 2013, J INT NEUROPSYCH SOC, V19, P829, DOI 10.1017/S1355617713000465; Taylor H.G., 2008, J INT NEUROPSYCH SOC, V7, P755; TEASDALE G, 1974, LANCET, V2, P81; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Woodcock R.W., 2001, WOODCOCKJOHNSON 3 TE; Yeates K. O., 2010, PEDIAT NEUROPSYCHOLO, P112	41	30	30	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2014	31	14					1305	1312		10.1089/neu.2013.3275			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AN4CA	WOS:000340534000007	24665961	Green Published			2021-06-18	
J	Simard, JM; Pampori, A; Keledjian, K; Tosun, C; Schwartzbauer, G; Ivanova, S; Gerzanich, V				Simard, J. Marc; Pampori, Adam; Keledjian, Kaspar; Tosun, Cigdem; Schwartzbauer, Gary; Ivanova, Svetlana; Gerzanich, Volodymyr			Exposure of the Thorax to a Sublethal Blast Wave Causes a Hydrodynamic Pulse That Leads to Perivenular Inflammation in the Brain	JOURNAL OF NEUROTRAUMA			English	Article						blast-TBI; ED-1; GFAP; perivenular inflammation; Sur1, TNF-alpha	SHEAR-STRESS; INJURY; NEUROTRAUMA; RATS; TRANSCRIPTION; OVERPRESSURE; MECHANISMS; HEMORRHAGE; EXPRESSION; PRESSURE	Traumatic brain injury (TBI) caused by an explosive blast (blast-TBI) is postulated to result, in part, from transvascular transmission to the brain of a hydrodynamic pulse (a.k.a., volumetric blood surge, ballistic pressure wave, hydrostatic shock, or hydraulic shock) induced in major intrathoracic blood vessels. This mechanism of blast-TBI has not been demonstrated directly. We tested the hypothesis that a blast wave impacting the thorax would induce a hydrodynamic pulse that would cause pathological changes in the brain. We constructed a Thorax-Only Blast Injury Apparatus (TOBIA) and a Jugular-Only Blast Injury Apparatus (JOBIA). TOBIA delivered a collimated blast wave to the right lateral thorax of a rat, precluding direct impact on the cranium. JOBIA delivered a blast wave to the fluid-filled port of an extracorporeal intravenous infusion device whose catheter was inserted retrograde into the jugular vein, precluding lung injury. Long Evans rats were subjected to sublethal injury by TOBIA or JOBIA. Blast injury induced by TOBIA was characterized by apnea and diffuse bilateral hemorrhagic injury to the lungs associated with a transient reduction in pulse oximetry signals. Immunolabeling 24 h after injury by TOBIA showed up-regulation of tumor necrosis factor alpha, ED-1, sulfonylurea receptor 1 (Sur1), and glial fibrillary acidic protein in veins or perivenular tissues and microvessels throughout the brain. The perivenular inflammatory effects induced by TOBIA were prevented by ligating the jugular vein and were reproduced using JOBIA. We conclude that blast injury to the thorax leads to perivenular inflammation, Sur1 up-regulation, and reactive astrocytosis resulting from the induction of a hydrodynamic pulse in the vasculature.	[Simard, J. Marc; Pampori, Adam; Keledjian, Kaspar; Tosun, Cigdem; Schwartzbauer, Gary; Ivanova, Svetlana; Gerzanich, Volodymyr] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 South Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu	Tosun, Cigdem/AAG-4026-2020		Veterans Administration (Baltimore, MD) [BX001629]; Department of the Army [W81XWH-08-2-0157]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072501] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001629] Funding Source: NIH RePORTER	The authors are grateful to Dr. Ibolja Cernak for exceedingly informative discussions on mechanisms of blast-TBI. This work was supported by grants (to J.M.S.) from the Veterans Administration (Baltimore, MD; BX001629) and from the Department of the Army (W81XWH-08-2-0157). This article was presented, in part, at the Military Health Systems Research Symposium, Ft. Lauderdale, Florida, August 13-16, 2012.	Abumiya T, 2002, ARTERIOSCL THROM VAS, V22, P907, DOI 10.1161/01.ATV.0000018300.43492.83; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 1995, Magnesium Research, V8, P249; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Clemedson J. C., 1956, PHYSIOL REV, V36, P336; Coupland RM, 1999, BRIT MED J, V319, P410, DOI 10.1136/bmj.319.7207.410; Coupland RM, 1999, BRIT MED J, V319, P407, DOI 10.1136/bmj.319.7207.407; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney M., 2008, SCI EVIDENCE HYDROST; Courtney M, 2011, NEUROSURGERY, V68, pE596, DOI 10.1227/NEU.0b013e3182041992; Davalos D, 2012, SEMIN IMMUNOPATHOL, V34, P43, DOI 10.1007/s00281-011-0290-8; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; Falvo JV, 2010, CURR DIR AUTOIMMUN, V11, P27, DOI 10.1159/000289196; Garai O., 1944, LANCET, V243, P788; Gardner CJ, 2007, CNS SPECTRUMS, V12, P35, DOI 10.1017/S1092852900020502; Ge YL, 2005, AM J NEURORADIOL, V26, P2316; Gerzanich V, 2003, CIRC RES, V93, P805, DOI 10.1161/01.RES.0000097872.69043.A0; GhaziBirry HS, 1997, AM J NEURORADIOL, V18, P219; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Korenaga R, 2001, AM J PHYSIOL-HEART C, V280, pH2214; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; Ortega FJ, 2012, EXP NEUROL, V235, P282, DOI 10.1016/j.expneurol.2012.02.010; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; SHAY H, 1949, ARCH SURG-CHICAGO, V59, P210, DOI 10.1001/archsurg.1949.01240040215004; Tosun C, 2013, STROKE, V44, P3522, DOI 10.1161/STROKEAHA.113.002904; Verstraeten SV, 2010, BBA-BIOMEMBRANES, V1798, P1739, DOI 10.1016/j.bbamem.2010.06.010; Wuerfel J, 2008, BRAIN, V131, P2332, DOI 10.1093/brain/awn171; Yun SS, 2002, J BIOL CHEM, V277, P34808, DOI 10.1074/jbc.M205417200	36	30	31	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2014	31	14					1292	1304		10.1089/neu.2013.3016			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AN4CA	WOS:000340534000006	24673157	Green Published			2021-06-18	
J	Umschweif, G; Liraz-Zaltsman, S; Shabashov, D; Alexandrovich, A; Trembovler, V; Horowitz, M; Shohami, E				Umschweif, Gali; Liraz-Zaltsman, Sigal; Shabashov, Dalia; Alexandrovich, Alexander; Trembovler, Victoria; Horowitz, Michal; Shohami, Esther			Angiotensin Receptor Type 2 Activation Induces Neuroprotection and Neurogenesis After Traumatic Brain Injury	NEUROTHERAPEUTICS			English	Article						Traumatic brain injury; angiotensin receptor type 2; neuroprotection; neurogenesis; CGP42112A; neurotrophins	LONG-TERM POTENTIATION; CLOSED-HEAD INJURY; AT(2) RECEPTOR; NEURITE OUTGROWTH; NEURONAL DIFFERENTIATION; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTOR; CELL-PROLIFERATION; CEREBRAL-ISCHEMIA; NITRIC-OXIDE	Angiotensin II receptor type 2 (AT(2)) agonists have been shown to limit brain ischemic insult and to improve its outcome. The activation of AT(2) was also linked to induced neuronal proliferation and differentiation in vitro. In this study, we examined the therapeutic potential of AT(2) activation following traumatic brain injury (TBI) in mice, a brain pathology that displays ischemia-like secondary damages. The AT(2) agonist CGP42112A was continuously infused immediately after closed head injury (CHI) for 3 days. We have followed the functional recovery of the injured mice for 35 days post-CHI, and evaluated cognitive function, lesion volume, molecular signaling, and neurogenesis at different time points after the impact. We found dose-dependent improvement in functional recovery and cognitive performance after CGP42112A treatment that was accompanied by reduced lesion volume and induced neurogenesis in the neurogenic niches of the brain and also in the injury region. At the cellular/molecular level, CGP42112A induced early activation of neuroprotective kinases protein kinase B (Akt) and extracellular-regulated kinases A1/2 (ERKA1/2), and the neurotrophins nerve growth factor and brain-derived neurotrophic factor; all were blocked by treatment with the AT(2) antagonist PD123319. Our results suggest that AT(2) activation after TBI promotes neuroprotection and neurogenesis, and may be a novel approach for the development of new drugs to treat victims of TBI.	[Umschweif, Gali; Liraz-Zaltsman, Sigal; Shabashov, Dalia; Alexandrovich, Alexander; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel; [Umschweif, Gali; Horowitz, Michal] Hebrew Univ Jerusalem, Environm Physiol Lab, Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel.	esty.shohami@mail.huji.ac.il			Brettler Foundation at the School of Pharmacy; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)	This study was supported, in part, by grants (to ES) from the Brettler Foundation at the School of Pharmacy, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF).	Allen SJ, 2013, PHARMACOL THERAPEUT, V138, P155, DOI 10.1016/j.pharmthera.2013.01.004; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Carrillo-Sepulveda MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061982; Caruso-Neves C, 2005, P NATL ACAD SCI USA, V102, P17513, DOI 10.1073/pnas.0507255102; Chao J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063488; Chao MV, 2006, CLIN SCI, V110, P167, DOI 10.1042/CS20050163; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Cote F, 1998, ENDOCR RES, V24, P403, DOI 10.3109/07435809809032622; Cote F, 1999, J BIOL CHEM, V274, P31686, DOI 10.1074/jbc.274.44.31686; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Fournier NM, 2012, NEUROPHARMACOLOGY, V63, P642, DOI 10.1016/j.neuropharm.2012.04.033; GANTEN D, 1971, SCIENCE, V173, P64, DOI 10.1126/science.173.3991.64; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gendron L, 2003, J MOL ENDOCRINOL, V31, P359, DOI 10.1677/jme.0.0310359; Gendron L, 1999, MOL ENDOCRINOL, V13, P1615, DOI 10.1210/me.13.9.1615; Gendron L, 2002, NEUROENDOCRINOLOGY, V75, P70, DOI 10.1159/000048222; Guimond Marie-Odile, 2012, Front Endocrinol (Lausanne), V3, P164, DOI 10.3389/fendo.2012.00164; Hafko R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069234; Hashikawa-Hobara N, 2012, DIABETES, V61, P925, DOI 10.2337/db11-1468; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; Iwai M, 2004, CIRCULATION, V110, P843, DOI 10.1161/01.CIR.0000138848.58269.80; Jing F, 2012, J CEREBR BLOOD F MET, V32, P248, DOI 10.1038/jcbfm.2011.133; Johren O, 2004, CARDIOVASC RES, V62, P460, DOI 10.1016/j.cardiores.2004.01.011; Kan I, 2011, STEM CELL REV REP, V7, P404, DOI 10.1007/s12015-010-9190-x; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; Laflamme L, 1996, J BIOL CHEM, V271, P22729, DOI 10.1074/jbc.271.37.22729; Lao CL, 2013, GLIA, V61, P475, DOI 10.1002/glia.22449; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lenkei Z, 1996, J COMP NEUROL, V373, P322, DOI 10.1002/(SICI)1096-9861(19960923)373:3<322::AID-CNE2>3.0.CO;2-4; Li J, 2005, FASEB J, V19, P617, DOI 10.1096/fj.04-2960fje; Li NC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5465; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lucius R, 1998, J EXP MED, V188, P661, DOI 10.1084/jem.188.4.661; Ma YH, 2011, BRAIN RES BULL, V86, P441, DOI 10.1016/j.brainresbull.2011.07.007; Macova M, 2009, BRAIN RES, V1250, P130, DOI 10.1016/j.brainres.2008.11.006; Maul B, 2008, J MOL MED, V86, P563, DOI 10.1007/s00109-008-0316-4; McCarthy CA, 2012, HYPERTENSION, V60, P1531, DOI 10.1161/HYPERTENSIONAHA.112.199646; McCarthy CA, 2009, STROKE, V40, P1482, DOI 10.1161/STROKEAHA.108.531509; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; Michel MC, 2013, PHARMACOL REV, V65, P809, DOI 10.1124/pr.112.007278; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mogi M, 2006, HYPERTENSION, V48, P141, DOI 10.1161/01.HYP.0000229648.67883.f9; Mogi M, 2013, GERIATR GERONTOL INT, V13, P13, DOI 10.1111/j.1447-0594.2012.00900.x; Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789; Nakamura K, 2011, MOL CELL NEUROSCI, V46, P498, DOI 10.1016/j.mcn.2010.12.002; Namsolleck P, 2013, NEUROBIOL DIS, V51, P177, DOI 10.1016/j.nbd.2012.11.008; Naruse M, 2002, HYPERTENSION, V40, P28, DOI 10.1161/01.HYP.0000022606.52221.2F; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Okuyama S, 1999, BRAIN RES, V821, P150, DOI 10.1016/S0006-8993(99)01098-7; Paxions G., 1997, MOUSE BRAIN STEREOTA; Plouffe B, 2006, ENDOCRINOLOGY, V147, P4646, DOI 10.1210/en.2005-1315; Porrello ER, 2009, FRONT BIOSCI-LANDMRK, V14, P958, DOI 10.2741/3289; Premer C, 2013, INT J HYPERTENS, V2013, DOI 10.1155/2013/175428; Reinecke K, 2003, FASEB J, V17, P2094, DOI 10.1096/fj.02-1193fje; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Saavedra JM, 2012, CLIN SCI, V123, P567, DOI 10.1042/CS20120078; Saavedra JM, 2011, PSYCHONEUROENDOCRINO, V36, P1, DOI 10.1016/j.psyneuen.2010.10.001; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Siragy HM, 1997, J CLIN INVEST, V100, P264, DOI 10.1172/JCI119531; Skaper SD, 2008, CNS NEUROL DISORD-DR, V7, P46, DOI 10.2174/187152708783885174; Steckelings UM, 2010, J RENIN-ANGIO-ALDO S, V11, P67, DOI 10.1177/1470320309347791; Stroth U, 2000, MOL BRAIN RES, V78, P175, DOI 10.1016/S0169-328X(00)00093-0; Suh H, 2009, ANNU REV CELL DEV BI, V25, P253, DOI 10.1146/annurev.cellbio.042308.113256; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tigerstedt R, 1898, SKAND ARCH PHYSL, V8, P223, DOI DOI 10.1111/J.1748-1716.1898.TB00272.X; Tota S, 2012, PSYCHOPHARMACOLOGY, V222, P185, DOI 10.1007/s00213-012-2639-7; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Umschweif G, 2013, J CEREBR BLOOD F MET, V33, P524, DOI 10.1038/jcbfm.2012.193; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; Walther T, 2002, FASEB J, V16, DOI 10.1096/fj.01-0641com; Wan YQ, 2004, J MED CHEM, V47, P5995, DOI 10.1021/jm049715t; Weishaupt N, 2012, EXP NEUROL, V238, P254, DOI 10.1016/j.expneurol.2012.09.001; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025	84	30	30	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JUL	2014	11	3					665	678		10.1007/s13311-014-0286-x			14	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AN1VR	WOS:000340372400020	24957202	Green Published			2021-06-18	
J	Luedtke, K; Bouchard, SM; Woller, SA; Funk, MK; Aceves, M; Hook, MA				Luedtke, Kelsey; Bouchard, Sioui Maldonado; Woller, Sarah A.; Funk, Mary Katherine; Aceves, Miriam; Hook, Michelle A.			Assessment of Depression in a Rodent Model of Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						contusion; depression; fluoxetine; quality of life; spinal cord injury	PRO-INFLAMMATORY CYTOKINES; TRAUMATIC BRAIN-INJURY; FORCED SWIMMING TEST; MAJOR DEPRESSION; RAT MODEL; FUNCTIONAL RECOVERY; INTERFERON-ALPHA; ANIMAL-MODEL; FLUOXETINE; ACTIVATION	Despite an increased incidence of depression in patients after spinal cord injury (SCI), there is no animal model of depression after SCI. To address this, we used a battery of established tests to assess depression after a rodent contusion injury. Subjects were acclimated to the tasks, and baseline scores were collected before SCI. Testing was conducted on days 9-10 (acute) and 19-20 (chronic) postinjury. To categorize depression, subjects' scores on each behavioral measure were averaged across the acute and chronic stages of injury and subjected to a principal component analysis. This analysis revealed a two-component structure, which explained 72.2% of between-subjects variance. The data were then analyzed with a hierarchical cluster analysis, identifying two clusters that differed significantly on the sucrose preference, open field, social exploration, and burrowing tasks. One cluster (9 of 26 subjects) displayed characteristics of depression. Using these data, a discriminant function analysis was conducted to derive an equation that could classify subjects as "depressed'' on days 9-10. The discriminant function was used in a second experiment examining whether the depression-like symptoms could be reversed with the antidepressant, fluoxetine. Fluoxetine significantly decreased immobility in the forced swim test (FST) in depressed subjects identified with the equation. Subjects that were depressed and treated with saline displayed significantly increased immobility on the FST, relative to not depressed, saline-treated controls. These initial experiments validate our tests of depression, generating a powerful model system for further understanding the relationships between molecular changes induced by SCI and the development of depression.	[Luedtke, Kelsey; Bouchard, Sioui Maldonado; Woller, Sarah A.; Funk, Mary Katherine; Aceves, Miriam; Hook, Michelle A.] Texas A&M Hlth Sci Ctr, Dept Neurosci & Expt Therapeut, Bryan, TX USA	Hook, MA (corresponding author), Texas A&M Univ Hlth Sci Ctr, Dept Neurosci & Expt Therapeut, 8447 State Highway 47, Bryan, TX 77807 USA.	hook@medicine.tamhsc.edu	Hook, Michelle/M-3140-2019	Aceves Rodriguez, Miriam/0000-0002-1778-0213; Woller, Sarah/0000-0001-7767-4845; Hook, Michelle/0000-0002-8709-936X	NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA031197] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 031197] Funding Source: Medline		ABEL EL, 1990, PHYSIOL BEHAV, V48, P233, DOI 10.1016/0031-9384(90)90306-O; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Angst J, 1997, J AFFECT DISORDERS, V45, P31, DOI 10.1016/S0165-0327(97)00057-8; Anisman H, 1996, BRAIN RES, V731, P1; Anisman H, 2005, NEUROSCI BIOBEHAV R, V29, P525, DOI 10.1016/j.neubiorev.2005.03.007; Anisman H, 2005, CURR PHARM DESIGN, V11, P963, DOI 10.2174/1381612053381701; Anisman H, 1999, ADV EXP MED BIOL, V461, P199; Anisman H, 2009, J PSYCHIATR NEUROSCI, V34, P4; BARBEAU H, 1991, BRAIN RES, V546, P250, DOI 10.1016/0006-8993(91)91489-N; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BEATTIE MS, 1992, J NEUROTRAUM, V9, P157, DOI 10.1089/neu.1992.9.157; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Berry A, 2012, PSYCHONEUROENDOCRINO, V37, P762, DOI 10.1016/j.psyneuen.2011.09.007; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; Bombardier CH, 2012, ARCH PHYS MED REHAB, V93, P775, DOI 10.1016/j.apmr.2011.12.020; Brenes JC, 2009, BEHAV BRAIN RES, V198, P199, DOI 10.1016/j.bbr.2008.10.036; Capuron L, 2002, MOL PSYCHIATR, V7, P468, DOI 10.1038/sj.mp.4000995; Christensen MD, 1997, J NEUROTRAUM, V14, P517, DOI 10.1089/neu.1997.14.517; Cristante AF, 2013, SPINAL CORD, V51, P501, DOI 10.1038/sc.2013.18; Cryan JF, 2005, PSYCHOPHARMACOLOGY, V182, P335, DOI 10.1007/s00213-005-0093-5; Cryan JF, 2004, MOL PSYCHIATR, V9, P326, DOI 10.1038/sj.mp.4001457; Davies AL, 2007, ARCH PHYS MED REHAB, V88, P1384, DOI 10.1016/j.apmr.2007.08.004; de Carvalho SAD, 1998, GEN HOSP PSYCHIAT, V20, P353, DOI 10.1016/S0163-8343(98)00047-4; Detloff MR, 2008, EXP NEUROL, V212, P337, DOI 10.1016/j.expneurol.2008.04.009; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Elliott TR, 2004, REHABIL PSYCHOL, V49, P134, DOI 10.1037/0090-5550.49.2.134; Engesser-Cesar C, 2007, NEUROSCIENCE, V144, P1033, DOI 10.1016/j.neuroscience.2006.10.016; Fong AJ, 2005, J NEUROSCI, V25, P11738, DOI 10.1523/JNEUROSCI.1523-05.2005; FRANK RG, 1985, AM J PSYCHIAT, V142, P252; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; Fumagalli F, 2009, NEUROSCIENCE, V159, P936, DOI 10.1016/j.neuroscience.2009.01.030; Garraway SM, 2011, NEUROSCIENCE, V199, P86, DOI 10.1016/j.neuroscience.2011.10.007; Grau JW, 2004, J NEUROTRAUM, V21, P1795, DOI 10.1089/neu.2004.21.1795; Hajebrahimi Z, 2008, NEUROSCI LETT, V441, P261, DOI 10.1016/j.neulet.2008.06.046; Hartkopp A, 1998, ARCH PHYS MED REHAB, V79, P1356, DOI 10.1016/S0003-9993(98)90227-1; Hayes KC, 2002, J NEUROTRAUM, V19, P753, DOI 10.1089/08977150260139129; HILAKIVICLARKE LA, 1990, PHYSIOL BEHAV, V48, P429, DOI 10.1016/0031-9384(90)90339-6; Hollis F, 2011, HORM BEHAV, V59, P331, DOI 10.1016/j.yhbeh.2010.09.005; Hook MA, 2009, J NEUROTRAUM, V26, P741, DOI 10.1089/neu.2008.0710; Huang TL, 2008, J PSYCHIATR RES, V42, P521, DOI 10.1016/j.jpsychires.2007.05.007; Hyun JK, 2009, J NEUROTRAUM, V26, P1773, DOI [10.1089/neu.2007.0485, 10.1089/neu.2007-0485]; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Juruena MF, 2006, PSYCHOPHARMACOLOGY, V189, P225, DOI 10.1007/s00213-006-0555-4; Kalpakjian CZ, 2006, WOMEN HEALTH ISS, V16, P380, DOI 10.1016/j.whi.2006.08.005; Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359; King VR, 2000, EXP NEUROL, V165, P327, DOI 10.1006/exnr.2000.7480; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Krause JS, 2000, ARCH PHYS MED REHAB, V81, P1099, DOI 10.1053/apmr.2000.7167; Krueger H, 2013, SPINAL CORD, V51, P260, DOI 10.1038/sc.2013.3; Lamkin DM, 2011, BRAIN BEHAV IMMUN, V25, P555, DOI 10.1016/j.bbi.2010.12.010; Lee JY, 2012, BRAIN, V135, P2375, DOI 10.1093/brain/aws171; Li N, 2012, BEHAV BRAIN RES, V233, P428, DOI 10.1016/j.bbr.2012.05.035; Liebl DJ, 2001, EXP NEUROL, V167, P15, DOI 10.1006/exnr.2000.7548; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; Maes M, 1999, ADV EXP MED BIOL, V461, P25; Makino M, 2000, PSYCHOPHARMACOLOGY, V148, P106, DOI 10.1007/s002130050031; Manji HK, 2001, NAT MED, V7, P541, DOI 10.1038/87865; MCKINNEY WT, 1969, ARCH GEN PSYCHIAT, V21, P240; Menkes DB, 2000, PSYCHOL MED, V30, P259, DOI 10.1017/S0033291799001774; Migliorini CE, 2009, SPINAL CORD, V47, P783, DOI 10.1038/sc.2009.43; MINKOFF K, 1973, AM J PSYCHIAT, V130, P455; Morikawa O, 1998, EUR J PHARMACOL, V349, P317, DOI 10.1016/S0014-2999(98)00187-3; Pace TWW, 2009, ANN NY ACAD SCI, V1179, P86, DOI 10.1111/j.1749-6632.2009.04984.x; Perona MTG, 2008, BEHAV PHARMACOL, V19, P566, DOI 10.1097/FBP.0b013e32830cd80f; Petit-Demouliere B, 2005, PSYCHOPHARMACOLOGY, V177, P245, DOI 10.1007/s00213-004-2048-7; Popovich PG, 2001, J NEUROTRAUM, V18, P957, DOI 10.1089/089771501750451866; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Pyter LM, 2009, P NATL ACAD SCI USA, V106, P9069, DOI 10.1073/pnas.0811949106; Raison CL, 2011, CURR PSYCHIAT REP, V13, P467, DOI 10.1007/s11920-011-0232-0; Ribotta MGY, 2000, J NEUROSCI, V20, P5144; Scali M, 2013, SCI REP-UK, V3, DOI 10.1038/srep02217; Smith RR, 2006, J NEUROTRAUM, V23, P1654, DOI 10.1089/neu.2006.23.1654; SMITH RS, 1991, MED HYPOTHESES, V35, P298, DOI 10.1016/0306-9877(91)90272-Z; Song C, 1999, NEUROSCIENCE, V88, P823, DOI 10.1016/S0306-4522(98)00271-1; Spradley JM, 2012, PAIN, V153, P1890, DOI 10.1016/j.pain.2012.05.032; Swain MG, 1998, HEPATOLOGY, V28, P6, DOI 10.1002/hep.510280102; Tabachnick BG, 2007, PRINCIPAL COMPONENTS; Vazquez-Palacios G, 2005, PROG NEURO-PSYCHOPH, V29, P39, DOI 10.1016/j.pnpbp.2004.08.008; Wang SH, 2009, J PSYCHOPHARMACOL, V23, P295, DOI 10.1177/0269881108089814; Yang LQ, 2005, J CLIN NEUROSCI, V12, P276, DOI 10.1016/j.jocn.2004.06.011	81	30	33	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 15	2014	31	12					1107	1121		10.1089/neu.2013.3204			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AK5DC	WOS:000338443600348	24564232	Green Published			2021-06-18	
J	Amaranath, JE; Ramanan, M; Reagh, J; Saekang, E; Prasad, N; Chaseling, R; Soundappan, S				Amaranath, Jeevaka E.; Ramanan, Mahesh; Reagh, Jessica; Saekang, Eilen; Prasad, Narayan; Chaseling, Raymond; Soundappan, Sannappa			Epidemiology of traumatic head injury from a major paediatric trauma centre in New South Wales, Australia	ANZ JOURNAL OF SURGERY			English	Article						epidemiology; paediatric; traumatic head injury	BRAIN-INJURY; CANCER-RISKS	Background Traumatic brain injury (TBI) is common and is a leading cause of presentations to emergency departments. Understanding the epidemiology of TBI can aid in improving overall management and identifying opportunities for prevention. Currently, there is a paucity of data on paediatric TBI in NSW. The purpose of this study was to determine the demographics, causes, treatment and outcome of TBI at The Children's Hospital at Westmead (CHW), a large trauma referral paediatric hospital. Methods A retrospective chart review was conducted of patients admitted to CHW emergency from 2006 to 2011 with a TBI. Patients who presented to the emergency department and had a history of TBI with either symptoms of concussion and/or positive computed tomography (CT) findings of head injury were selected. Information regarding demographics, injury pattern, CT findings, treatment and outcome were retrieved. Results Over the 6-year period, there were 1489 presentations at the CHW. Of these, 65% were male and 35% were female. The mean age was 7 years. A total of 93% were classified as mild, 1.5% as moderate and 5.5% as severe. Sports and recreational injuries accounted for 26% of all TBI presentations, while motor vehicle accidents (MVAs) accounted for 77% of all TBI deaths. Sixty-two percent of children underwent a CT brain, and of those, 40% were normal. Conclusion The majority of TBI are mild in nature, with younger children and males at greatest risk. There was a low rate of operative intervention and a high rate of good outcomes. Many injuries may be preventable with the adaptation of better public health education programmes, particularly in very young children and those related to MVAs.	[Amaranath, Jeevaka E.; Reagh, Jessica; Saekang, Eilen; Prasad, Narayan] Childrens Hosp Westmead, Douglas Cohen Dept Paediat Surg, Sydney, NSW, Australia; [Ramanan, Mahesh; Chaseling, Raymond] Childrens Hosp Westmead, Dept Neurosurg, Sydney, NSW, Australia; [Soundappan, Sannappa] Childrens Hosp Westmead, Douglas Cohen Dept Paediat Surg & Trauma, Sydney, NSW, Australia	Amaranath, JE (corresponding author), Unit 7-9-27 Pk Ave, Sydney, NSW 2047, Australia.	jamaranath@optusnet.com.au	Ramanan, Mahesh/H-2523-2012	Ramanan, Mahesh/0000-0003-4509-4015			AAP AAFP, 2009, MIN HEAD INJ CHILDR; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; BASS JL, 1993, PEDIATRICS, V92, P544; BERNEY J, 1994, CHILD NERV SYST, V10, P509, DOI 10.1007/BF00335073; Cooksley D, 2006, TXB PAEDIAT EMERGENC, P245; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Debono P, 2011, ADV CLIN NEUROSCI RE, V10, P30; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; ITIM. NSWIoTaIM, 2009, NSW TRAUM REG PROF S; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kleinerman RA, 2006, PEDIATR RADIOL, V36, P121, DOI 10.1007/s00247-006-0191-5; Lam WH, 1999, PAEDIATR ANAESTH, V9, P377; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; National Health Performance Authority, 2011, EM DEP SERV; NOLAN T, 1992, J PAEDIATR CHILD H, V28, P27, DOI 10.1111/j.1440-1754.1992.tb02613.x; NSW Health, 2010, INF CHILDR AC MAN HE; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Premier & Cabinet NSW Government, 2011, DEM; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Ron E, 2003, HEALTH PHYS, V85, P47, DOI 10.1097/00004032-200307000-00011; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Swaminathan A, 2009, J EMERG MED, V37, P63, DOI 10.1016/j.jemermed.2009.02.003; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thiessen ML, 2006, PEDIATR CLIN N AM, V53, P1, DOI 10.1016/j.pcl.2005.09.004	26	30	31	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1445-1433	1445-2197		ANZ J SURG	ANZ J. Surg.	JUN	2014	84	6					424	428		10.1111/ans.12445			5	Surgery	Surgery	AJ3JB	WOS:000337561300008	24405988	Bronze			2021-06-18	
J	Corser-Jensen, CE; Goodell, DJ; Freund, RK; Serbedzija, P; Murphy, RC; Farias, SE; Dell'Acqua, ML; Frey, LC; Serkova, N; Heidenreich, KA				Corser-Jensen, Chelsea E.; Goodell, Dayton J.; Freund, Ronald K.; Serbedzija, Predrag; Murphy, Robert C.; Farias, Santiago E.; Dell'Acqua, Mark L.; Frey, Lauren C.; Serkova, Natalie; Heidenreich, Kim A.			Blocking leukotriene synthesis attenuates the pathophysiology of traumatic brain injury and associated cognitive deficits	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Neuroinflammation; Leukotrienes; FLAP inhibitor; Hippocampus; Long-term potentiation; Memory and learning; Blood-brain barrier; Edema	FOCAL CEREBRAL-ISCHEMIA; TRANSCELLULAR BIOSYNTHESIS; RECEPTOR-1 ANTAGONIST; ASTHMATIC SUBJECTS; EDEMA FORMATION; GERBIL BRAIN; EXPRESSION; PRANLUKAST; INHIBITORS; PERMEABILITY	Neuroinflammation is a component of secondary injury following traumatic brain injury (TBI) that can persist beyond the acute phase. Leukotrienes are potent, pro-inflammatory lipid mediators generated from membrane phospholipids. In the absence of injury, leukotrienes are undetectable in the brain, but after trauma they are rapidly synthesized by a transcellular event involving infiltrating neutrophils and endogenous brain cells. Here, we investigate the efficacy of MK-886, an inhibitor of 5-lipoxygenase activating protein (FLAP), in blocking leukotriene synthesis, secondary brain damage, synaptic dysfunction, and cognitive impairments after TBI. Male Sprague Dawley rats (9-11 weeks) received either MK-886 or vehicle after they were subjected to unilateral moderate fluid percussion injury (FPI) to assess the potential clinical use of FLAP inhibitors for TBI. MK-886 was also administered before FPI to determine the preventative potential of FLAP inhibitors. MK-886 given before or after injury significantly blocked the production of leukotrienes, measured by reverse-phase liquid chromatography coupled to tandem mass spectrometry (RP LC-MS/MS), and brain edema, measured by T2-weighted magnetic resonance imaging (MRI). MK-886 significantly attenuated blood-brain barrier disruption in the CA1 hippocampal region and deficits in long-term potentiation (LTP) at CA1 hippocampal synapses. The prevention of FPI-induced synaptic dysfunction by MK-886 was accompanied by fewer deficits in post-injury spatial learning and memory performance in the radial arm water maze (RAWM). These results indicate that leukotrienes contribute significantly to secondary brain injury and subsequent cognitive deficits. FLAP inhibitors represent a novel anti-inflammatory approach for treating human TBI that is feasible for both intervention and prevention of brain injury and neurologic deficits. (C) 2014 Elsevier Inc. All rights reserved.	[Corser-Jensen, Chelsea E.; Goodell, Dayton J.; Murphy, Robert C.; Farias, Santiago E.; Dell'Acqua, Mark L.; Heidenreich, Kim A.] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA; [Corser-Jensen, Chelsea E.; Goodell, Dayton J.; Freund, Ronald K.; Serbedzija, Predrag; Murphy, Robert C.; Farias, Santiago E.; Dell'Acqua, Mark L.; Heidenreich, Kim A.] Univ Colorado, Dept Pharmacol, Aurora, CO 80045 USA; [Frey, Lauren C.] Univ Colorado, Dept Neurol, Aurora, CO 80045 USA; [Serkova, Natalie] Univ Colorado, Dept Anesthesiol, Aurora, CO 80045 USA	Heidenreich, KA (corresponding author), Univ Colorado, Anschutz Med Campus,12800 E 19th Ave, Aurora, CO 80045 USA.	kim.heidenreich@ucdenver.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD041697, R01NS040710, GM069338, R21NS079435]; Colorado Brain Injury Program; UC Denver Center for Neuroscience Translational Research Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD041697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM069338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS079435] Funding Source: NIH RePORTER	This study was supported by NIH grants 5T32HD041697 (C.E.C. and D.J.G.), R01NS040710 (M.L.D.), GM069338 (R.C.M.), and R21NS079435 (K.A.H.), the Colorado Brain Injury Program (K.A.H.), and the UC Denver Center for Neuroscience Translational Research Award (K.A.H.). Contents are the authors' sole responsibility and do not necessarily represent official NIH views.	Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Biber N, 2009, BRAIN INJURY, V23, P577, DOI 10.1080/02699050902926317; Boyce JA, 2007, IMMUNOL REV, V217, P168, DOI 10.1111/j.1600-065X.2007.00512.x; Campbell JN, 2012, J NEUROTRAUM, V29, P218, DOI 10.1089/neu.2011.1762; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; Chu LS, 2006, ACTA PHARMACOL SIN, V27, P282, DOI 10.1111/j.1745-7254.2006.00290.x; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Dahlen B, 1997, THORAX, V52, P342, DOI 10.1136/thx.52.4.342; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; Ding Q, 2007, ACTA PHARMACOL SIN, V28, P945, DOI 10.1111/j.1745-7254.2007.00576.x; Evans JF, 2008, TRENDS PHARMACOL SCI, V29, P72, DOI 10.1016/j.tips.2007.11.006; Fang SH, 2006, NEUROSCIENCE, V140, P969, DOI 10.1016/j.neuroscience.2006.02.051; Farias S, 2009, J NEUROTRAUM, V26, P1977, DOI 10.1089/neu.2009.0877; Farias SE, 2007, J NEUROCHEM, V103, P1310, DOI 10.1111/j.1471-4159.2007.04830.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Hartig W, 2013, BRAIN RES, V1498, P69, DOI 10.1016/j.brainres.2012.12.022; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; Kochanek PM, 2009, J NEUROTRAUM, V26, P813, DOI 10.1089/neu.2008.0893; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LOBERG EM, 1991, ACTA NEUROPATHOL, V81, P479, DOI 10.1007/BF00310126; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MINAMISAWA H, 1988, STROKE, V19, P372, DOI 10.1161/01.STR.19.3.372; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; Qian XD, 2006, EUR J PHARMACOL, V549, P35, DOI 10.1016/j.ejphar.2006.07.056; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Voigt C, 2012, NEUROPATH APPL NEURO, V38, P354, DOI 10.1111/j.1365-2990.2011.01211.x; Wang ML, 2006, BIOCHEM BIOPH RES CO, V350, P399, DOI 10.1016/j.bbrc.2006.09.057; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; Yu GL, 2005, BRAIN RES, V1053, P116, DOI 10.1016/j.brainres.2005.06.046; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088	51	30	31	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2014	256						7	16		10.1016/j.expneurol.2014.03.008			10	Neurosciences	Neurosciences & Neurology	AI1VZ	WOS:000336644600002	24681156	Green Accepted			2021-06-18	
J	Griesbach, GS; Tio, DL; Nair, S; Hovda, DA				Griesbach, Grace S.; Tio, Delia L.; Nair, Shyama; Hovda, David A.			Recovery of Stress Response Coincides with Responsiveness to Voluntary Exercise after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain derived neurotrophic factor; corticosterone; exercise; temperature	HIPPOCAMPAL EXCITATORY SYNAPSES; NEUROTROPHIC FACTOR; DENTATE GYRUS; MILD; INCREASES; FATIGUE; CONCUSSION; EXPRESSION; DEPRESSION; SEVERITY	We have recently shown that there is a heightened stress response after a mild traumatic brain injury (TBI) during the first 2 post-injury weeks. This corresponds to the same post-injury period when exercise does not increase brain-derived neurotrophic factor (BDNF) and autonomic dysfunction becomes evident with exercise. Here we determined stress and autonomic responses to voluntary and forced exercise at a post-injury time window when exercise has been found to elicit beneficial effects. Rats underwent a mild fluid percussion injury and were exercised at post-injury days 28-32 and 35-39. Cardiac and temperature autonomic function were evaluated. Hippocampal tissue was obtained immediately after exercise for analysis of BDNF. In contrast to the sub-acute period, corticosterone and adrenocorticotropic hormone responses to exercise were normalized in the TBI group. Irrespective of injury, forced exercise markedly stimulated the corticotrophic axis and did not increase BDNF. BDNF levels were increased with voluntary exercise in all animals. Rats exposed to forced exercise had lower activity levels during periods of non-exercise. This effect was more pronounced in the TBI rats. Cardiac and temperature autonomic responses to delayed exercise also recuperated. Rats with TBI that underwent forced exercise, however, had higher core body temperatures during experimental manipulations, thus suggesting that exposure to a potent stressor facilitates responsiveness to environmental stimulations.	[Griesbach, Grace S.; Nair, Shyama; Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Tio, Delia L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Griesbach, Grace S.; Nair, Shyama; Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Griesbach, GS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957030, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS06190]; UCLA Brain Injury Research Center	We thank Ramin Rajai, Hans Sebastian, and Sam Kazemian for their excellent technical assistance. This research was supported by NIH grant NS06190 to GSG and the UCLA Brain Injury Research Center.	Llompart-Pou JA, 2010, NEUROCRIT CARE, V13, P211, DOI 10.1007/s12028-010-9399-1; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P25, DOI 10.1097/01.HTR.0000308718.88214.bb; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Griesbach GS, 2012, NEUROSCIENCE, V210, P393, DOI 10.1016/j.neuroscience.2012.03.005; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2013, J NEUROTRAUM, V30, P281, DOI 10.1089/neu.2012.2616; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Norrie J, 2010, BRAIN INJURY, V24, P1528, DOI 10.3109/02699052.2010.531687; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; Sutton RL, 2000, NEURAL PLAST, V7, P109, DOI 10.1155/NP.2000.109; Tyler WJ, 2006, J PHYSIOL-LONDON, V574, P787, DOI 10.1113/jphysiol.2006.111310; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001	26	30	30	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					674	682		10.1089/neu.2013.3151			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000009	24151829	Green Published			2021-06-18	
J	Iaccarino, C; Schiavi, P; Picetti, E; Goldoni, M; Cerasti, D; Caspani, M; Servadei, F				Iaccarino, Corrado; Schiavi, Paolo; Picetti, Edoardo; Goldoni, Matteo; Cerasti, Davide; Caspani, Marialuisa; Servadei, Franco			Patients with brain contusions: predictors of outcome and relationship between radiological and clinical evolution	JOURNAL OF NEUROSURGERY			English	Article						cerebral contusion; radiological evolution; outcome; clinical deterioration; traumatic brain injury	HEAD-INJURY; RISK-FACTORS; PROGRESSION; HEMORRHAGE; LESIONS; DETERIORATION; MULTICENTER; MANAGEMENT; HEMATOMA; MODERATE	Object. Traumatic parenchymal mass lesions are common sequelae of traumatic brain injuries (TBIs). They occur in up to 8.2% of all TBI cases and 13%-35% of severe TBI cases, and they account for up to 20% of surgical intracranial lesions. Controversy exists concerning the association between radiological and clinical evolution of brain contusions. The aim of this study was to identify predictors of unfavorable outcome, analyze the evolution of brain contusions, and evaluate specific indications for surgery. Methods. In a retrospective, multicenter study, patients with brain contusions were identified in separate patient cohorts from 11 hospitals over a 4-year period (2008-2011). Data on clinical parameters and course of the contusion were collected. Radiological parameters were registered by using CT images taken at the time of hospital admission and at subsequent follow-up times. Patients who underwent surgical procedures were identified. Outcomes were evaluated 6 months after trauma by using the Glasgow Outcome Scale-Extended. Results. Multivariate analysis revealed the following reliable predictors of unfavorable outcome: 1) increased patient age, 2) lower Glasgow Coma Scale score at first evaluation, 3) clinical deterioration in the first hours after trauma, and 4) onset or increase of midline shift on follow-up CT images. Further multivariate analysis identified the following as statistically significant predictors of clinical deterioration during the first hours after trauma: 1) onset of or increase in midline shift on follow-up CT images (p < 0.001) and 2) increased effacement of basal cisterns on follow-up CT images (p < 0.001). Conclusions. In TBI patients with cerebral contusion, the onset of clinical deterioration is predictably associated with the onset or increase of midline shift and worsened status of basal cisterns but not with hematoma or edema volume increase. A combination of clinical deterioration and increased midline shift/basal cistern compression is the most reasonable indicator for surgery.	[Iaccarino, Corrado; Schiavi, Paolo; Servadei, Franco] Arcispedale Santa Maria Nuova Ist Ricovero & Cura, Reggio Emilia, Italy; [Iaccarino, Corrado; Schiavi, Paolo; Servadei, Franco] Univ Hosp Parma, Neurosurg Neurotraumatol Unit, I-43100 Parma, Italy; [Picetti, Edoardo; Caspani, Marialuisa] Univ Hosp Parma, Intens Care Unit, I-43100 Parma, Italy; [Goldoni, Matteo] Univ Hosp Parma, Dept Biostat, I-43100 Parma, Italy; [Cerasti, Davide] Univ Hosp Parma, Dept Neuroradiol, I-43100 Parma, Italy	Servadei, F (corresponding author), Univ Hosp Parma, Dept Emergency Med, Neurosurg Neurotraumatol Unit, Viale Gramsci 14, I-43100 Parma, Italy.	fservadei@ao.pr.it	Iaccarino, Corrado/ABE-2361-2020; Iaccarino, Corrado/L-3190-2013; Goldoni, Matteo/E-9153-2011	Iaccarino, Corrado/0000-0002-5133-6327; Iaccarino, Corrado/0000-0002-5133-6327; Goldoni, Matteo/0000-0002-1342-3921; Servadei, Franco/0000-0002-3595-3464			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; FABBRI A, 2006, APPROCCIO NEL DEA GE; Fabbri A, 2010, J NEUROL NEUROSUR PS, V81, P1275, DOI 10.1136/jnnp.2009.197467; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Iaccarino C, 2008, TELERADIOLOGY, P181; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Marion DW, 2006, NEUROSURGERY, V58, P655; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Peterson EC, 2011, J TRAUMA, V71, P1588, DOI 10.1097/TA.0b013e31822b791d; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2000, NEUROSURGERY, V46, P70; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; Snoek A, 2013, EUR J EMERG MED, V20, P167, DOI 10.1097/MEJ.0b013e328353d926; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109	37	30	32	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2014	120	4					908	918		10.3171/2013.12.JNS131090			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AD7IZ	WOS:000333438800016	24506250				2021-06-18	
J	Dachir, S; Shabashov, D; Trembovler, V; Alexandrovich, AG; Benowitz, LI; Shohami, E				Dachir, Shlomit; Shabashov, Dalia; Trembovler, Victoria; Alexandrovich, Alexander G.; Benowitz, Larry I.; Shohami, Esther			Inosine improves functional recovery after experimental traumatic brain injury	BRAIN RESEARCH			English	Article						Cortical spinal tract (CST); Novel object recognition test (NORT); Y-maze; Synaptophysin; GAP-43	CLOSED-HEAD-INJURY; SPINAL-CORD; SUBTHALAMIC NUCLEUS; NEUROTROPHIC FACTOR; PARKINSONS-DISEASE; AXON REGENERATION; MEMORY DEFICITS; MOTOR FUNCTION; URIC-ACID; STIMULATION	Despite years of research, no effective therapy is yet available for the treatment of traumatic brain injury (TBI). The most prevalent and debilitating features in survivors of TBI are cognitive deficits and motor dysfunction. A potential therapeutic method for improving the function of patients following TBI would be to restore, at least in part, plasticity to the CNS in a controlled way that would allow for the formation of compensatory circuits. Inosine, a naturally occurring purine nucleoside, has been shown to promote axon collateral growth in the corticospinal tract (CST) following stroke and focal TBI. In the present study, we investigated the effects of inosine on motor and cognitive deficits, CST sprouting, and expression of synaptic proteins in an experimental model of closed head injury (CHI). Treatment with inosine (100 mg/kg i.p. at 1, 24 and 48 h following CHI) improved outcome after TBI, significantly decreasing the neurological severity score (NSS, p <0.04 vs. saline), an aggregate measure of performance on several tasks. It improved non-spatial cognitive performance (object recognition, p<0.016 vs. saline) but had little effect on sensorimotor coordination (rotarod) and spatial cognitive functions (Y-maze). Inosine did not affect CST sprouting in the lumbar spinal cord but did restore levels of the growth-associated protein GAP-43 in the hippocampus, though not in the cerebral cortex. Our results suggest that inosine may improve functional outcome after TBI. (C) 2014 Published by Elsevier B.V.	[Dachir, Shlomit; Shabashov, Dalia; Trembovler, Victoria; Alexandrovich, Alexander G.; Shohami, Esther] Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Dachir, Shlomit] Israel Inst Biol Res, Dept Pharmacol, IL-70450 Ness Ziona, Israel; [Benowitz, Larry I.] Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Benowitz, Larry I.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty.shohami@mail.huji.ac.il			Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)	This study was supported by grants from the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF) to ES and LB.	Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bay E, 2012, ARCH PSYCHIAT NURS, V26, P477, DOI 10.1016/j.apnu.2012.06.002; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Beni SM, 2006, J CEREBR BLOOD F MET, V26, P478, DOI 10.1038/sj.jcbfm.9600209; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Benowitz LI, 1999, P NATL ACAD SCI USA, V96, P13486, DOI 10.1073/pnas.96.23.13486; Benowitz LI, 1998, J BIOL CHEM, V273, P29626, DOI 10.1074/jbc.273.45.29626; Burello L, 2012, EXP NEUROL, V233, P273, DOI 10.1016/j.expneurol.2011.10.016; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conta A. C., 2008, SPINAL CORD, V46, P151; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Daniele A, 2003, J NEUROL NEUROSUR PS, V74, P175, DOI 10.1136/jnnp.74.2.175; Darwish H, 2012, BRAIN INJURY, V26, P1763, DOI [10.3109/02699052.2012.741452, 10.3109/02699052.2011.635362]; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Dellu F, 2000, NEUROBIOL LEARN MEM, V73, P31, DOI 10.1006/nlme.1999.3919; Denny JB, 2006, CURR NEUROPHARMACOL, V4, P293, DOI 10.2174/157015906778520782; Dobkin B.H., 2003, CLIN SCI NEUROLOGIC; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fasano A, 2008, MOVEMENT DISORD, V23, P1289, DOI 10.1002/mds.22116; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Grossman R, 2012, FUTUR NEUROL, V7, P329, DOI 10.2217/FNL.12.25; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hasko G, 2004, TRENDS PHARMACOL SCI, V25, P152, DOI 10.1016/j.tips.2004.01.006; Hiebert GW, 2002, J NEUROSCI RES, V69, P160, DOI 10.1002/jnr.10275; Hirshler Y, 2010, EXP NEUROL, V222, P42, DOI 10.1016/j.expneurol.2009.12.006; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Irwin N, 2006, P NATL ACAD SCI USA, V103, P18320, DOI 10.1073/pnas.0605135103; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Kennedy HS, 2011, LAB ANIMAL, V40, P53, DOI 10.1038/laban0211-53; Ladurelle N, 2000, BRAIN RES, V858, P371, DOI 10.1016/S0006-8993(00)01953-3; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lorber B, 2009, NAT NEUROSCI, V12, P1407, DOI 10.1038/nn.2414; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; NAKAGAWA S, 1973, J NEUROCHEM, V20, P1143, DOI 10.1111/j.1471-4159.1973.tb00084.x; Nielsen MS, 2007, EUR J NEUROL, V14, P132, DOI 10.1111/j.1468-1331.2006.01569.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PARDRIDGE WM, 1994, J PHARMACOL EXP THER, V268, P14; Petrausch B, 2000, J NEUROSCI, V20, P8031; Rekart JL, 2007, LEARN MEMORY, V14, P416, DOI 10.1101/lm.516507; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shen H, 2005, STROKE, V36, P654, DOI 10.1161/01.STR.0000155747.15679.04; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Thau-Zuchman O, 2012, NEUROSCIENCE, V202, P334, DOI 10.1016/j.neuroscience.2011.11.071; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Verrier JD, 2012, J NEUROCHEM, V122, P115, DOI 10.1111/j.1471-4159.2012.07705.x; Viberg H, 2009, INT J DEV NEUROSCI, V27, P423, DOI 10.1016/j.ijdevneu.2009.05.007; WINN HR, 1980, AM J PHYSIOL, V239, pH212; Witt K, 2008, LANCET NEUROL, V7, P605, DOI 10.1016/S1474-4422(08)70114-5; Yamada M, 2011, J ETHNOPHARMACOL, V135, P737, DOI 10.1016/j.jep.2011.04.010; York MK, 2008, J NEUROL NEUROSUR PS, V79, P789, DOI 10.1136/jnnp.2007.118786; Zai LL, 2011, J NEUROSCI, V31, P5977, DOI 10.1523/JNEUROSCI.4498-10.2011; Zai LL, 2009, J NEUROSCI, V29, P8187, DOI 10.1523/JNEUROSCI.0414-09.2009; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zhou LJ, 2003, J NEUROSCI, V23, P1424	66	30	33	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 25	2014	1555						78	88		10.1016/j.brainres.2014.01.044			11	Neurosciences	Neurosciences & Neurology	AF1LS	WOS:000334476000008	24502983				2021-06-18	
J	Bao, L; Chen, D; Ding, L; Ling, WH; Xu, F				Bao, Long; Chen, Du; Ding, Li; Ling, Weihua; Xu, Feng			Fever Burden Is an Independent Predictor for Prognosis of Traumatic Brain Injury	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; BODY-TEMPERATURE; CLINICAL-TRIAL; IMPACT; MORTALITY; OUTCOMES; DESIGN; STROKE; COMA; AGE	Objective: To evaluate fever burden as an independent predictor for prognosis of traumatic brain injury (TBI). Methods: This retrospective study involved 355 TBI patients with Glasgow Coma Scale (GCS) <= 14, who presented at the emergency department of our hospital between November 2010 and October 2012. At 6 months follow-up, patients were divided into 5 groups based on Glasgow Outcome Scale (GOS) and dichotomized to GOS score (high (4 to 5) vs. low (1 to 3)). The relationship between fever burden and GOS was assessed. Results: Fever burden increased as GOS scores decreased from 5 to 2, except for score 1 of GOS, which corresponded to a significant lower fever burden. Following dichotomization, patients in the high GOS group were younger, and showed less abnormal pupil reactivity (P < 0.001), a higher median GCS score (P < 0.001), and a lower median fever burden (P < 0.001), compared with patients in the low GOS group. Univariate logistic regression analysis revealed that poor TBI prognosis was related to age, GCS, pupil reactivity, and fever burden (OR: 1.166 [95% CI: 1.117-1.217] P < 0.0001). Multivariate logistic regression analysis identified fever burden as an independent predictor of poor prognosis after TBI (OR 1.098; 95% CI: 1.031-1.169; P = 0.003). These observations were confirmed by evaluation of the receiver operating characteristic (ROC) curve for fever burden (area under the curve [AUC] 0.73 [95% CI: 0.663-0.760]). Conclusion: Fever burden might be an independent predictor for prognosis of TBI. High fever burden in the early stage of the disease course associated with TBI could increase the risk of poor prognosis.	[Bao, Long; Chen, Du; Ding, Li; Ling, Weihua; Xu, Feng] Soochow Univ, Affiliated Hosp 1, Dept Emergency Med, Suzhou, Peoples R China	Xu, F (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Emergency Med, Suzhou, Peoples R China.	xufengmedsci@163.com	Chen, Du/AAM-8789-2021	Chen, Du/0000-0001-6990-3310			Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Greer DM, 2008, STROKE, V39, P3029, DOI 10.1161/STROKEAHA.108.521583; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Naidech AM, 2008, NEUROSURGERY, V63, P212, DOI 10.1227/01.NEU.0000320453.61270.0F; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Phipps MS, 2011, STROKE, V42, P3357, DOI 10.1161/STROKEAHA.111.621425; Puccio AM, 2009, NEUROCRIT CARE, V11, P82, DOI 10.1007/s12028-009-9213-0; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; TEASDALE G, 1974, LANCET, V2, P81; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577	21	30	32	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2014	9	3							e90956	10.1371/journal.pone.0090956			5	Multidisciplinary Sciences	Science & Technology - Other Topics	AC9JS	WOS:000332851300044	24626046	DOAJ Gold, Green Published			2021-06-18	
J	Wade, SL; Karver, CL; Taylor, HG; Cassedy, A; Stancin, T; Kirkwood, MW; Brown, TM				Wade, Shari L.; Karver, Christine L.; Taylor, H. Gerry; Cassedy, Amy; Stancin, Terry; Kirkwood, Michael W.; Brown, Tanya Maines			Counselor-Assisted Problem Solving Improves Caregiver Efficacy Following Adolescent Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						brain injury; caregiver outcomes; stress; trauma; adolescence	PEDIATRIC TRAUMATIC INJURY; FAMILY INTERVENTION; RANDOMIZED-TRIAL; DIGITAL DIVIDE; TECHNOLOGY USE; INITIAL YEAR; OUTCOMES; CHILDREN; ADAPTATION; BURDEN	Purpose: The purpose of the current study is to examine the efficacy of Counselor-Assisted Problem Solving (CAPS) in improving caregiver adaptation following traumatic brain injury (TBI). Research Method/Design: In a randomized clinical trial comparing CAPS (n = 65), an online problem-solving intervention with accompanying Web-based counseling sessions, with an information-based Internet Resource Comparison (IRC; n = 67) program, participants included families of 12- to17-year-olds who had sustained a TBI in the past 6 months. Linear regression analyses were used to identify main effects and to examine whether caregiver education, race, or prior computer use moderated treatment efficacy. Results: Computer experience moderated postintervention improvements in caregiving self-efficacy following CAPS, Specifically, parents in CAPS with low levels of prior use reporting the greatest improvements. CAPS participants who completed 5 or more sessions reported greater reductions in depression than did the IRC; however, the groups did not differ on global distress. Conclusions/ Implications: Findings support the potential utility of counselor-supported Web-based interventions particularly for individuals with limited computer expertise following adolescent TBI.	[Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Karver, Christine L.] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA; [Karver, Christine L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Dept Pediat, Cleveland, OH USA; [Cassedy, Amy] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Stancin, Terry] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Psychiat, Cleveland, OH 44109 USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; [Brown, Tanya Maines] Mayo Clin, Dept Psychiat, Rochester, MN USA; [Brown, Tanya Maines] Mayo Clin, Dept Psychol, Rochester, MN USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Stancin, Terry/L-7993-2019		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01-MH073764, R01 MH073764] Funding Source: Medline		Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Boothroyd R. A., 1997, PRELIMINARY MANUAL C; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; D'Zurilla T. J., 2006, HDB COGNITIVE BEHAV, P211; Gan C, 2010, BRAIN INJURY, V24, P651, DOI 10.3109/02699051003692142; Glueckauf RL, 2011, CAREGIVING-RES PRACT, P85, DOI 10.1007/978-1-4419-8031-1_7; Jackson LA, 2008, CYBERPSYCHOL BEHAV, V11, P437, DOI 10.1089/cpb.2007.0157; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Lorence Daniel P, 2006, J Med Syst, V30, P241, DOI 10.1007/s10916-005-9003-y; Maruish M.E., 1994, USE PSYCHOL TESTING, P217; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rivera P, 2003, TOP SPINAL CORD INJ, V9, P53, DOI [DOI 10.1310/G82F-BR2R-T69L-3QX8, 10.1310/G82F-BR2R-T69L-3QX8]; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Wade S. L., J HEAD TRAUMA REHABI, P406; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393	27	30	30	0	12	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2014	59	1					1	9		10.1037/a0034911			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	AC7PU	WOS:000332723800001	24611923	Green Accepted			2021-06-18	
J	Sato, S; Kawauchi, S; Okuda, W; Nishidate, I; Nawashiro, H; Tsumatori, G				Sato, Shunichi; Kawauchi, Satoko; Okuda, Wataru; Nishidate, Izumi; Nawashiro, Hiroshi; Tsumatori, Gentaro			Real-Time Optical Diagnosis of the Rat Brain Exposed to a Laser-Induced Shock Wave: Observation of Spreading Depolarization, Vasoconstriction and Hypoxemia-Oligemia	PLOS ONE			English	Article							CLOSED-HEAD-INJURY; CONTROLLED CORTICAL IMPACT; INDUCED STRESS WAVES; FLUID-PERCUSSION MODEL; BLAST OVERPRESSURE; EXPLOSIVE BLAST; INDUCED NEUROTRAUMA; HIPPOCAMPAL SLICE; CEREBRAL-CORTEX; VISUAL-CORTEX	Despite many efforts, the pathophysiology and mechanism of blast-induced traumatic brain injury (bTBI) have not yet been elucidated, partially due to the difficulty of real-time diagnosis and extremely complex factors determining the outcome. In this study, we topically applied a laser-induced shock wave (LISW) to the rat brain through the skull, for which real-time measurements of optical diffuse reflectance and electroencephalogram (EEG) were performed. Even under conditions showing no clear changes in systemic physiological parameters, the brain showed a drastic light scattering change accompanied by EEG suppression, which indicated the occurrence of spreading depression, long-lasting hypoxemia and signal change indicating mitochondrial energy impairment. Under the standard LISW conditions examined, hemorrhage and contusion were not apparent in the cortex. To investigate events associated with spreading depression, measurement of direct current (DC) potential, light scattering imaging and stereomicroscopic observation of blood vessels were also conducted for the brain. After LISW application, we observed a distinct negative shift in the DC potential, which temporally coincided with the transit of a light scattering wave, showing the occurrence of spreading depolarization and concomitant change in light scattering. Blood vessels in the brain surface initially showed vasodilatation for 3-4 min, which was followed by long-lasting vasoconstriction, corresponding to hypoxemia. Computer simulation based on the inverse Monte Carlo method showed that hemoglobin oxygen saturation declined to as low as similar to 35% in the long-term hypoxemic phase. Overall, we found that topical application of a shock wave to the brain caused spreading depolarization/depression and prolonged severe hypoxemia-oligemia, which might lead to pathological conditions in the brain. Although further study is needed, our findings suggest that spreading depolarization/depression is one of the key events determining the outcome in bTBI. Furthermore, a rat exposed to an LISW(s) can be a reliable laboratory animal model for blast injury research.	[Sato, Shunichi; Kawauchi, Satoko] Natl Def Med Coll, Res Inst, Div Biomed Informat Sci, Tokorozawa, Saitama 359, Japan; [Okuda, Wataru; Nishidate, Izumi] Tokyo Univ Agr & Technol, Grad Sch Bioapplicat & Syst Engn, Tokyo, Japan; [Nawashiro, Hiroshi] Tokorozawa Cent Hosp, Div Neurosurg, Tokorozawa, Saitama, Japan; [Tsumatori, Gentaro] Natl Def Med Coll, Dept Def Med, Tokorozawa, Saitama 359, Japan	Sato, S (corresponding author), Natl Def Med Coll, Res Inst, Div Biomed Informat Sci, Tokorozawa, Saitama 359, Japan.	shunsato@ndmc.ac.jp	NISHIDATE, IZUMI/C-8826-2013		Ministry of Defense; General Insurance Association of Japan	This study was supported by the Research Promotion Program for Defense Medicine under the Ministry of Defense and a research grant from The General Insurance Association of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Aizawa K, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3253325; Ando T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051744; ANDREW RD, 1994, NEUROSCIENCE, V62, P371, DOI 10.1016/0306-4522(94)90372-7; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Ba AM, 2002, J NEUROPHYSIOL, V88, P2726, DOI 10.1152/jn.00729.2001; Bahar S, 2000, J NEUROPHYSIOL, V84, P311; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Center for Chemical Process Safety, 1994, GUID EV CHAR VAP CLO, P351; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1996, CHINESE J TRAUMATOL, V12, P28; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chandra N, 2012, SHOCK WAVES, V22, P403, DOI 10.1007/s00193-012-0399-2; Chang JC, 2010, BRAIN, V133, P996, DOI 10.1093/brain/awp338; Chen Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039353; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dreckhahn C, 2012, BRAIN, V135, P853; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Ebersberger A, 2001, ANN NEUROL, V49, P7, DOI 10.1002/1531-8249(200101)49:1<7::AID-ANA4>3.3.CO;2-B; Elsayed NM, 1997, TOXICOLOGY, V121, P81, DOI 10.1016/S0300-483X(97)03657-3; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fischer H, 2013, CRS REP C; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; HANSEN AJ, 1980, ACTA PHYSIOL SCAND, V108, P355, DOI 10.1111/j.1748-1716.1980.tb06544.x; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; Hartings JA, 2008, NEUROL RES, V30, P876, DOI 10.1179/174313208X309739; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; Hatano B, 2011, P SPIE, V7897; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; JAFFIN JH, 1987, J TRAUMA, V27, P349, DOI 10.1097/00005373-198704000-00002; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kawauchi S, 2008, APPL OPTICS, V47, P4164, DOI 10.1364/AO.47.004164; Kawauchi S, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.1.015003; Kawauchi S, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3542046; Kurita A, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3628313; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Leis JA, 2005, GLIA, V50, P407, DOI 10.1002/glia.20145; Leo L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002129; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Manor T, 2008, NEUROL RES, V30, P1075, DOI 10.1179/174313208X346107; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mourant JR, 2003, BIOMEDICAL PHOTONICS; NARAYAN SM, 1995, J CEREBR BLOOD F MET, V15, P754, DOI 10.1038/jcbfm.1995.95; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; Ogura M, 2004, LASER SURG MED, V34, P242, DOI 10.1002/lsm.20024; OKUSKY J, 1982, J COMP NEUROL, V210, P307, DOI 10.1002/cne.902100309; OZAWA Y, 1991, Neurologia Medico-Chirurgica, V31, P685, DOI 10.2176/nmc.31.685; PAINTAL AS, 1969, J PHYSIOL-LONDON, V203, P511, DOI 10.1113/jphysiol.1969.sp008877; PIPER RD, 1991, AM J PHYSIOL, V261, pH96; Polischuk TM, 1998, NEUROBIOL DIS, V4, P423, DOI 10.1006/nbdi.1998.0172; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Sato S, 2011, OPT LETT, V36, P4545, DOI 10.1364/OL.36.004545; Satoh Y, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2128432; Satoh Y, 2010, LASER SURG MED, V42, P313, DOI 10.1002/lsm.20899; Schumacher RN, 1977, 2724 US BALL RES LAB; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; Showstack R., 2013, EOS T AGU, V94, P87; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Somjen GG, 2008, J COMPUT NEUROSCI, V25, P349, DOI 10.1007/s10827-008-0083-9; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; VANDERZEE P, 1993, P SOC PHOTO-OPT INS, V1888, P454, DOI 10.1117/12.154665; VANHARREVELD A, 1956, AM J PHYSIOL, V184, P312; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; Wharton DC, 1966, BIOCH COPPER, P235; Windmuller O, 2005, BRAIN, V128, P2042, DOI 10.1093/brain/awh545; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Zhang FY, 2002, J NEUROSURG, V97, P963, DOI 10.3171/jns.2002.97.4.0963; Zuckerman S, 1940, LANCET, V2, P219	96	30	31	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e82891	10.1371/journal.pone.0082891			15	Multidisciplinary Sciences	Science & Technology - Other Topics	291WL	WOS:000329862500022	24416150	DOAJ Gold, Green Published			2021-06-18	
J	Gouello, G; Hamel, O; Asehnoune, K; Bord, E; Robert, R; Buffenoir, K				Gouello, Gaetane; Hamel, Olivier; Asehnoune, Karim; Bord, Eric; Robert, Roger; Buffenoir, Kevin			Study of the Long-Term Results of Decompressive Craniectomy after Severe Traumatic Brain Injury Based on a Series of 60 Consecutive Cases	SCIENTIFIC WORLD JOURNAL			English	Article							SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; COMPLICATIONS; CRANIOTOMY; EXPERIENCE; ICP	Background. Decompressive craniectomy can be proposed in the management of severe traumatic brain injury. Current studies report mixed results, preventing any clear conclusions on the place of decompressive craniectomy in traumatology. Methods. The objective of this retrospective study was to evaluate the results of all decompressive craniectomies performed between 2005 and 2011 for refractory intracranial hypertension after severe traumatic brain injury. Sixty patients were included. Clinical parameters (Glasgow scale, pupillary examination) and radiological findings (Marshall CT scale) were analysed. Complications, clinical outcome, and early and long-term Glasgow Outcome Scale (GOS) were evaluated after surgery. Finally, the predictive value of preoperative parameters to guide the clinician's decision to perform craniectomy was studied. Results. Craniectomy was unilateral in 58 cases and the mean bone flap area was 100 cm(2). Surgical complications were observed in 6.7% of cases. Mean followup was 30 months and a favourable outcome was obtained in 50% of cases. The initial Glasgow Scale was the only statistically significant predictive factor for long-term outcome. Conclusion. Despite the discordant results in the literature, this study demonstrates that decompressive craniectomy is useful for the management of refractory intracranial hypertension after severe traumatic brain injury.	[Gouello, Gaetane; Hamel, Olivier; Bord, Eric; Robert, Roger; Buffenoir, Kevin] CHU Nantes, Serv Neurotraumatol & Neurochirurg, F-44093 Nantes, France; [Asehnoune, Karim] CHU Nantes, Serv Anesthesie Reanimat Chirurg, F-44093 Nantes, France; [Buffenoir, Kevin] CHU Nantes, INSERM EA3826, F-44093 Nantes, France	Buffenoir, K (corresponding author), CHU Nantes, Serv Neurotraumatol & Neurochirurg, F-44093 Nantes, France.	kevin.buffenoirbillet@chu-nantes.fr	Buffenoir, Kevin/ABD-9003-2020				Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bao YH, 2010, J NEUROTRAUM, V27, P341, DOI 10.1089/neu.2009.1040; Bouvier D, 2012, ANN BIOL CLIN-PARIS, V70, P269, DOI 10.1684/abc.2012.0701; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock MR, 1996, J NEUROTRAUM, V13, P685; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Ecker RD, 2011, J NEUROSURG, V115, P124, DOI 10.3171/2011.2.JNS101490; Faleiro RM, 2008, ARQ NEURO-PSIQUIAT, V66, P369, DOI 10.1590/S0004-282X2008000300017; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Kocher T, 1901, HIRNERSCHUTTERUNG HI, P262; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Romero CM, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Schneider GH, 2002, ACT NEUR S, V81, P77; Tayfur V, 2010, J CRANIOFAC SURG, V21, P1945, DOI 10.1097/SCS.0b013e3181f4ee6a; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Voelbel GT, 2012, NEUROREHABILITATION, V31, P281, DOI 10.3233/NRE-2012-0796; Wen L, 2011, BRAIN INJURY, V25, P1318, DOI 10.3109/02699052.2011.608214; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	32	30	30	0	5	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1537-744X			SCI WORLD J	Sci. World J.		2014									207585	10.1155/2014/207585			10	Multidisciplinary Sciences	Science & Technology - Other Topics	AC5ER	WOS:000332544300001	24719566	DOAJ Gold, Green Published			2021-06-18	
J	Hudak, AM; Peng, LF; de la Plata, CM; Thottakara, J; Moore, C; Harper, C; McColl, R; Babcock, E; Diaz-Arrastia, R				Hudak, Anne M.; Peng, Lifang; de la Plata, Carlos Marquez; Thottakara, John; Moore, Carol; Harper, Caryn; McColl, Roderick; Babcock, Evelyn; Diaz-Arrastia, Ramon			Cytotoxic and vasogenic cerebral oedema in traumatic brain injury: Assessment with FLAIR and DWI imaging	BRAIN INJURY			English	Article						Traumatic brain injury; MRI scan; outcome	APPARENT DIFFUSION-COEFFICIENT; FUNCTIONAL STATUS EXAMINATION; IMPROVES OUTCOME PREDICTION; MAGNETIC-RESONANCE; WHITE-MATTER; T2-WEIGHTED MRI; CELLULAR EDEMA; AXONAL INJURY; ISCHEMIA; ATROPHY	Primary objective: Cerebral oedema is a common complication of traumatic brain injury (TBI). The use of Fluid-Attenuated Inversion Recovery (FLAIR) imaging in combination with Diffusion Weighted Imaging (DWI) has the potential to distinguish between cytotoxic and vasogenic oedema. This study hypothesized a significant relationship between cytotoxic lesion volume and outcome. Research design: This observational study reports on a convenience sample where MRI was obtained for clinical purposes. Methods and procedures: Clinical post-TBI FLAIR and DWI images were analysed. For this study, lesions were defined as primarily cytotoxic oedema if the ratio of FLAIR to DWI lesion volume was comparable, defined as a ratio <2. If the ratio of FLAIR to DWI lesion volume was >= 2, oedema was considered predominantly of vasogenic origin. Main outcomes and results: The sample consisted primarily of males with TBIs whose injury severity ranged from complicated mild to severe. Analysis revealed that both oedema types are common after TBI and both are associated with functional deficits 6 months after injury. Conclusions: Acute MRI may be useful to assess pathology at the tissue after traumatic brain injury. Clinical trials targeting cytotoxic and vasogenic mechanisms of oedema formation may benefit from using DWI and FLAIR MRI as a means to differentiate the predominant oedema type after TBI.	[Hudak, Anne M.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Hudak, Anne M.] Hunter Holmes McGuire VA Med Ctr, Dept PM&R, Richmond, VA 23224 USA; [Peng, Lifang] Univ Texas Rio Grande Valley, Edinburg, TX USA; [de la Plata, Carlos Marquez] Pate Rehabil, Dallas, TX USA; [de la Plata, Carlos Marquez] Univ Texas Dallas, Ctr BrainHlth, Sch Behav & Brain Sci, Dallas, TX 75230 USA; [Thottakara, John] Univ Texas SW Med Ctr Dallas, Dept Phys Med & Rehabil, Dallas, TX 75390 USA; [Moore, Carol; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Harper, Caryn] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [McColl, Roderick; Babcock, Evelyn] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA	Hudak, AM (corresponding author), Hunter Holmes McGuire VA Med Ctr, Dept PM&R, 1201 Broad Rock Blvd, Richmond, VA 23224 USA.	Anne.Hudak@va.gov		Diaz-Arrastia, Ramon/0000-0001-6051-3594; McColl, Roderick/0000-0001-7022-100X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23 HD067553, K23 N5060827, R01 HD48179, U01 HD42652]; Mike Winters Fund; NIDRR [H133A070027]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652, K23HD067553] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	The authors report no conflicts of interest. The present study was supported by NIH K23 HD067553 (Hudak), The Mike Winters Fund (Hudak), NIH K23 N5060827 (Marquez de la Plata), NIH R01 HD48179 (Diaz-Arrastia), NIH U01 HD42652 (Diaz-Arrastia), NIDRR H133A070027 (Diaz-Arrastia).	[Anonymous], MATLAB 7 1 STAT TOOL; [Anonymous], 2008, SAS WIND VERS 9 2 ST; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; BULLOCK R, 1990, ACT NEUR S, V51, P286; Burdette JH, 1999, RADIOLOGY, V212, P333, DOI 10.1148/radiology.212.2.r99au36333; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Doelken M, 2007, DIAGN INTERV RADIOL, V13, P125; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kirkness Catherine J, 2002, J Neurosci Nurs, V34, P134; Kuroiwa T, 1998, STROKE, V29, P859, DOI 10.1161/01.STR.29.4.859; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Rabinstein AA, 2006, NEUROLOGIST, V12, P59, DOI 10.1097/01.nrl.0000186810.62736.f0; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rumpel H, 1997, PEDIATR RES, V42, P54, DOI 10.1203/00006450-199707000-00009; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; Schneider JP, 2006, ROFO-FORTSCHR RONTG, V178, P618, DOI 10.1055/s-2006-926631; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stroop R, 1998, ACT NEUR S, V71, P303; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yankah A C, 1995, J Heart Valve Dis, V4, P40	39	30	32	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	12					1602	1609		10.3109/02699052.2014.936039			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AR6UD	WOS:000343717700012	25058428				2021-06-18	
J	Magone, MT; Kwon, E; Shin, SY				Magone, M. Teresa; Kwon, Ellen; Shin, Soo Y.			Chronic visual dysfunction after blast-induced mild traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						accommodative insufficiency; blast-induced traumatic brain injury; combat-related traumatic brain injury; convergence insufficiency; dismounted injury; eyes; loss of consciousness; mild traumatic brain injury; near vision deficit; photophobia; traumatic brain injury; visual dysfunction	POSTTRAUMATIC-STRESS-DISORDER; POLYTRAUMA NETWORK SITE; DUAL SENSORY IMPAIRMENT; PERSISTENT; SYMPTOMS; VETERANS; MILITARY; SOLDIERS; PROGRAM; VISION	The purpose of this study was to investigate the long-term visual dysfunction in patients after blast-induced mild traumatic brain injury (mbTBI) using a retrospective case series of 31 patients with mbTBI (>12 mo prior) without eye injuries. Time since mbTBI was 50.5 +/- 19.8 mo. Age at the time of injury was 30.0 +/- 8.3 yr. Mean corrected visual acuity was 20/20. Of the patients, 71% (n = 22) experienced loss of consciousness; 68% (n = 15) of patients in this subgroup were dismounted during the blast injury. Overall, 68% (n = 21) of patients had visual complaints. The most common complaints were photophobia (55%) and difficulty with reading (32%). Of all patients, 25% were diagnosed with convergence insufficiency and 23% had accommodative insufficiency. Patients with more than one mbTBI had a higher rate of visual complaints (87.5%). Asymptomatic patients had a significantly longer time (62.5 +/- 6.2 mo) since the mbTBI than symptomatic patients (42.0 +/- 16.4 mo, p < 0.004). Long-term visual dysfunction after mbTBI is common even years after injury despite excellent distance visual acuity and is more frequent if more than one incidence of mbTBI occurred. We recommend obtaining a careful medical history, evaluation of symptoms, and binocular vision assessment during routine eye examinations in this prepresbyopic patient population.	[Magone, M. Teresa; Kwon, Ellen; Shin, Soo Y.] Dept Vet Affairs Med Ctr, Dept Surg, Eye Clin, Washington, DC 20422 USA	Magone, MT (corresponding author), Dept Vet Affairs Med Ctr, Dept Surg, Eye Clin, 50 Irving St NW, Washington, DC 20422 USA.	maria.magone@va.gov		Magone, M. Teresa/0000-0001-6370-6295			Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Armed Forces Health Surveillance Center, 2012, MED SURVEILL MON REP, V19, P19; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Coppola G, 2007, Cephalalgia, V27, P1427, DOI 10.1111/j.1468-2982.2007.01500.x; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; Digre KB, 2012, J NEURO-OPHTHALMOL, V32, P68, DOI 10.1097/WNO.0b013e3182474548; Du T, 2005, BRAIN INJURY, V19, P1125, DOI 10.1080/02699050500149817; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fraunfelder F, 2008, CLIN OCULAR TOXICOLO; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Galor A, 2012, AM J OPHTHALMOL, V154, P340, DOI 10.1016/j.ajo.2012.02.009; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; KENT P R, 1953, Mil Surg, V112, P202; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Military Health System Office of Strategic Communications, 2012, DOD NUMB TRAUM BRAIN; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Scheiman M., 2008, CLIN MANAGEMENT BINO, V3rd; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schrupp LE, 2009, OPTOMETRY, V80, P642, DOI 10.1016/j.optm.2009.04.097; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Trachtman JN, 2010, OPTOMETRY, V81, P240, DOI 10.1016/j.optm.2009.07.017; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wilkins AJ, 2004, EPILEPSIA S1, V45, P17; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Zollman FS, 2011, MANUAL OF TRAUMATIC BRAIN INJURY MANAGEMENT, P1; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	41	30	31	1	14	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2014	51	1					71	80		10.1682/JRRD.2013.01.0008			10	Rehabilitation	Rehabilitation	AF8GB	WOS:000334952600007	24805895	Bronze			2021-06-18	
J	Genovese, RF; Simmons, LP; Ahlers, ST; Maudlin-Jeronimo, E; Dave, JR; Boutte, AM				Genovese, R. F.; Simmons, L. P.; Ahlers, S. T.; Maudlin-Jeronimo, E.; Dave, J. R.; Boutte, A. M.			EFFECTS OF MILD TBI FROM REPEATED BLAST OVERPRESSURE ON THE EXPRESSION AND EXTINCTION OF CONDITIONED FEAR IN RATS	NEUROSCIENCE			English	Article						mTBI; blast overpressure; conditioned fear; PTSD; stress processes; operant conditioning	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; BATTLEFIELD INJURY; PAVLOVIAN FEAR; LONG-TERM; SUPPRESSION; BEHAVIOR; LESIONS; SYSTEM; MEMORY	Mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) are pressing medical issues for the War-lighter. Symptoms of mTBI can overlap with those of PTSD, suggesting the possibility of a causal or mediating role of mTBI in PTSD. To address whether mTBI can exacerbate the neurobiological processes associated with traumatic stress, we evaluated the impact of mTBI from a blast overpressure (BOP) on the expression of a conditioned fear. In the rat, conditioned fear models are used to evaluate the emotional conditioning processes that are known to become dysfunctional in PTSD. Rats were first trained on a variable interval (VI), food maintained, operant conditioning task that established a general measure of performance. Inescapable electric shock (IES) was paired with an audio-visual conditioned stimulus (CS) and followed 1 day later by three daily exposures to BOP (75 kPa). Subsequently, the CS alone was presented once every 7 days for 2 months, beginning 4 days following the last BOP. The CS was presented during the VI sessions allowing a concurrent measure of performance. Treatment groups (n = 10, each group) received IES + BOP, IES + sham-BOP, sham-IES + BOP or shamIES + sham-BOP. As expected, pairing the CS with IES produced a robust conditioned fear that was quantified by a suppression of responding on the VI. BOP significantly decreased the expression of the conditioned fear. No systematic short- or long-term performance deficits were observed on the VI from BOP. These results show that mTBI from BOP can affect the expression of a conditioned fear and suggests that BOP caused a decrease in inhibitory behavioral control. Continued presentation of the CS produced progressively less response suppression in both fear conditioned treatments, consistent with extinction of the conditioned fear. Taken together, these results show that mTBI from BOP can affect the expression of a conditioned fear but not necessarily in a manner that increases the conditioned fear or extends the extinction process. Published by Elsevier Ltd. on behalf of IBRO.	[Genovese, R. F.; Simmons, L. P.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Behav Biol Branch, Silver Spring, MD 20910 USA; [Ahlers, S. T.; Maudlin-Jeronimo, E.] Naval Med Res Ctr, Dept Neurotrauma, Operat & Undersea Med Directorate, Silver Spring, MD USA; [Dave, J. R.; Boutte, A. M.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect & Neuroregenerat Branch, Silver Spring, MD USA	Genovese, RF (corresponding author), Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Behav Biol Branch, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	Raymond.Genovese@US.Army.Mil	Dave, Jitendra R/A-8940-2011		Congressional Directed Medical Research Program [W81XWH-10-2-0091, W81XWH-10-2-0092]; Military Operational Medicine Research Program; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	This work was supported by the Congressional Directed Medical Research Program, (awards W81XWH-10-2-0091 and -0092) and by the Military Operational Medicine Research Program, U.S. Army Medical Research and Materiel Command. The funding sources had no role in the collection, analysis and interpretation of the data or in the decision to submit for publication.	Ahlers ST, 2012, FRONT NEUROL, V3, P1; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Amorapanth P, 1999, LEARN MEMORY, V6, P491, DOI 10.1101/lm.6.5.491; Blechert J, 2007, BEHAV RES THER, V45, P2019, DOI 10.1016/j.brat.2007.02.012; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Defense and Veterans Brain Injury Center Working Group on the Acute Management of Mild Traumatic Brain Injury in Military Operational Settings, 2006, CLIN PRACT GUID REC; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Dimoska-Di Marco A, 2011, J CLIN EXP NEUROPSYC, V33, P471, DOI 10.1080/13803395.2010.533158; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Eagle DM, 2010, NEUROSCI BIOBEHAV R, V34, P50, DOI 10.1016/j.neubiorev.2009.07.003; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Estes WK, 1941, J EXP PSYCHOL, V29, P390, DOI 10.1037/h0062283; Genovese RF, 2006, J TOXICOL ENV HEAL A, V69, P2167, DOI 10.1080/15287390600748153; GENOVESE RF, 1988, LIFE SCI, V43, P571, DOI 10.1016/0024-3205(88)90060-4; GENOVESE RF, 1994, BRAIN RES BULL, V34, P111, DOI 10.1016/0361-9230(94)90006-X; GENOVESE RF, 1992, PHYSIOL BEHAV, V52, P1025, DOI 10.1016/0031-9384(92)90386-G; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GUALTIERI T, 1991, Brain Injury, V5, P219, DOI 10.3109/02699059109008093; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Lee JLC, 2005, BEHAV BRAIN RES, V159, P221, DOI 10.1016/j.bbr.2004.11.003; Long JB, 2010, IFMBE PROC, V32, P26, DOI 10.1007/978-3-642-14998-6_7; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; McDannald MA, 2011, BRAIN RES, V1374, P82, DOI 10.1016/j.brainres.2010.12.050; McDannald MA, 2010, BEHAV BRAIN RES, V211, P111, DOI 10.1016/j.bbr.2010.03.020; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Pickens CL, 2010, NEUROSCIENCE, V169, P1501, DOI 10.1016/j.neuroscience.2010.06.036; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wessa M, 2007, AM J PSYCHIAT, V164, P1684, DOI 10.1176/appi.ajp.2007.07030525	38	30	30	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 19	2013	254						120	129		10.1016/j.neuroscience.2013.09.021			10	Neurosciences	Neurosciences & Neurology	255ZN	WOS:000327279400011	24056195				2021-06-18	
J	Dillahunt-Aspillaga, C; Jorgensen-Smith, T; Ehlke, S; Sosinski, M; Monroe, D; Thor, J				Dillahunt-Aspillaga, Christina; Jorgensen-Smith, Tammy; Ehlke, Sarah; Sosinski, Melanie; Monroe, Douglas; Thor, Jennifer			Traumatic Brain Injury: Unmet Support Needs of Caregivers and Families in Florida	PLOS ONE			English	Article							INDIVIDUALS; VALIDATION; MANAGEMENT; QUALITY; CARERS; PEOPLE; ADULTS; SCALE; LIFE	Sustaining a Traumatic Brain Injury results in familial strain due to the significant impact the injury has upon the role and function of individuals and their families at home and in the community. Using the Stress Process Model of Caregiving, a caregiver needs assessment survey was developed and conducted to better understand the needs of individuals with a Traumatic Brain Injury and their caregivers. Survey results indicate that caregivers experience many challenges including unmet needs in areas of relational supports such as maintaining relationships, long-term emotional and financial support for themselves and the survivor, and the need for a patient or caregiver advocate. Implications for future practice are presented.	[Dillahunt-Aspillaga, Christina; Jorgensen-Smith, Tammy; Thor, Jennifer] Univ S Florida, Dept Rehabil & Mental Hlth Counseling, Tampa, FL 33620 USA; [Monroe, Douglas] Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA; [Ehlke, Sarah] Univ N Carolina, Dept Psychol, Wilmington, NC 28401 USA; [Sosinski, Melanie] Univ S Florida, Dept Social Work, Tampa, FL USA; [Dillahunt-Aspillaga, Christina] Brain Injury Assoc Florida Inc, Tallahassee, FL USA; [Monroe, Douglas] WellFlorida Council Inc, Gainesville, FL USA	Dillahunt-Aspillaga, C (corresponding author), Univ S Florida, Dept Rehabil & Mental Hlth Counseling, Tampa, FL 33620 USA.	cdillahuntas@usf.edu		Dillahunt-Aspillaga, Christina/0000-0002-1231-2023; Jorgensen Smith, Tammy/0000-0001-6769-7269			Arango-Lasprilla JC, 2010, BRAIN INJURY, V24, P1017, DOI 10.3109/02699052.2010.490516; Arciniegas DB, 2008, CRIT CARE CLIN, V24, P737, DOI 10.1016/j.ccc.2008.06.001; Boycott N, 2013, J HEAD TRAUMA REHAB, V28, P106, DOI 10.1097/HTR.0b013e31823fe07e; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Centers for Disease Control and Prevention, 2010, TRAUMATIC BRAIN INJU; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chronister J, 2010, NEUROREHABILITATION, V27, P49, DOI 10.3233/NRE-2010-0580; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; Degeneffe CE, 2011, REHABIL PSYCHOL, V56, P243, DOI 10.1037/a0024465; Family Caregiver Alliance, 2012, FCA FAM CAR ALL NAT; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hassan STS, 2011, J NEPAL MED ASSOC, V50, P53; Hassan STS, 2012, HEALTHMED, V6, P2423; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2010, J HEAD TRAUMA REHAB, V25, P113, DOI 10.1097/HTR.0b013e3181cf0712; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Murray HM, 2006, BRAIN INJURY, V20, P575, DOI 10.1080/02699050600664590; O'Callaghan AM, 2011, INT J SPEECH-LANG PA, V13, P218, DOI 10.3109/17549507.2011.549240; Ramkumar NA, 2010, NEUROREHABILITATION, V27, P105, DOI 10.3233/NRE-2010-0585; Reinhard S, 2008, PATIENT SAFETY QUALI; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Turner BJ, 2011, DISABIL REHABIL, V33, P818, DOI 10.3109/09638288.2010.513422; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; WellFlorida Council Inc, 2012, WHAT IS TRAUM BRAIN; WellFlorida Council Inc, 2007, TRAUM BRAIN INJ STAT; WellFlorida Council Inc, 2010, TBI STAT FLOR; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005	37	30	30	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2013	8	12							e82896	10.1371/journal.pone.0082896			9	Multidisciplinary Sciences	Science & Technology - Other Topics	276GT	WOS:000328737700039	24358236	DOAJ Gold, Green Published			2021-06-18	
J	Vermeij, JD; Aslami, H; Fluiter, K; Roelofs, JJ; van den Bergh, WM; Juffermans, NP; Schultz, MJ; Van der Sluijs, K; van de Beek, D; van Westerloo, DJ				Vermeij, Jan-Dirk; Aslami, Hamid; Fluiter, Kees; Roelofs, Joris J.; van den Bergh, Walter M.; Juffermans, Nicole P.; Schultz, Marcus J.; Van der Sluijs, Koen; van de Beek, Diederik; van Westerloo, David J.			Traumatic Brain Injury in Rats Induces Lung Injury and Systemic Immune Suppression	JOURNAL OF NEUROTRAUMA			English	Article						acute lung injury; immune suppression; neurogenic pulmonary edema; neuroimmunology; traumatic brain injury	INTENSIVE-CARE-UNIT; SEVERE HEAD-INJURY; VAGUS NERVE; PNEUMONIA; STROKE; COMPLICATIONS; INFECTIONS; ACTIVATION; PULMONARY; IMPACT	Traumatic brain injury (TBI) is frequently complicated by acute lung injury, which is predictive for poor outcome. However, it is unclear whether lung injury develops independently or as a result of mechanical ventilation after TBI. Further, TBI is strongly associated with the development of pneumonia, suggesting a specific vulnerability for the development of nosocomial infections in the lung after TBI. In this study, we evaluated whether indeed pulmonary injury and immune suppression develop spontaneously in an animal model of mild TBI (mTBI). TBI was induced in male PVG rats by closed-head trauma using a weight-drop device. Subsequently, we evaluated the effects of this on the lungs as well as on the excitability of the systemic immune system. Finally, we performed an experiment in which TBI was followed by induction of pneumonitis and evaluated whether TBI affects the severity of subsequent pneumonitis induced by intratracheal instillation of heat-killed Staphylococcus aureus. mTBI resulted in significant lung injury, as evidenced by pulmonary edema, protein leakage to the alveolar compartment, and increased concentrations of interleukin-1 and -6 in broncho alveolar lavage fluid (all p<0.05vs. sham-treated animals). Further, after TBI, the release of tumor necrosis factor alpha was decreased when whole blood was stimulated ex vivo (p<0.05 TBI vs. sham), indicating systemic immune suppression. When TBI was followed by pneumonitis, the severity of subsequent pneumonitis was not different in rats previously subjected to TBI or sham treatment (p>0.05), suggesting that systemic immune suppression is not translated toward the pulmonary compartment in this specific model. We here show that during mild experimental TBI, acute pulmonary injury, as well as a decrease in the excitability of the systemic immune system, can be observed.	[Vermeij, Jan-Dirk; Van der Sluijs, Koen; van de Beek, Diederik] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; [Vermeij, Jan-Dirk; Aslami, Hamid; Juffermans, Nicole P.; Schultz, Marcus J.] Univ Amsterdam, Acad Med Ctr, Dept Lab Expt Intens Care & Anesthesiol, NL-1105 AZ Amsterdam, Netherlands; [Fluiter, Kees] Univ Amsterdam, Acad Med Ctr, Dept Neurogenet, NL-1105 AZ Amsterdam, Netherlands; [Roelofs, Joris J.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [van den Bergh, Walter M.] Univ Groningen, Univ Med Ctr Groningen, Dept Intens Care Med, NL-9713 AV Groningen, Netherlands; [van Westerloo, David J.] Leiden Univ, Med Ctr, Dept Intens Care Med, NL-2300 RC Leiden, Netherlands	van Westerloo, DJ (corresponding author), Leiden Univ, Med Ctr, Dept Intens Care Med, POB 9600, NL-2300 RC Leiden, Netherlands.	djvanwesterloo@lumc.nl	Fluiter, Kees/H-2828-2015; van de Beek, Diederik/Y-2713-2019; Schultz, Marcus/AAB-6379-2021	Fluiter, Kees/0000-0003-0898-7260; van de Beek, Diederik/0000-0002-4571-044X; Schultz, Marcus/0000-0003-3969-7792; Roelofs, Joris/0000-0001-9595-6571	European Society of Intensive Care Medicine (ESICM); Dutch Brain Foundation	The study was funded by an unrestricted grant of the European Society of Intensive Care Medicine (ESICM; basic science award to David van Westerloo). Kees Fluiter is supported by the Dutch Brain Foundation. The authors are grateful for the expert technical assistance of Geartsje Jongsma, who provided expert technical assistance with all animal experiments.	Agbaht K, 2007, INTENS CARE MED, V33, P1387, DOI 10.1007/s00134-007-0729-5; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Emsley HCA, 2008, STROKE, V39, pE7, DOI 10.1161/STROKEAHA.107.500447; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Go SL, 2013, CRIT CARE, V17, DOI 10.1186/cc11389; Griffin GD, 2011, MIL MED, V176, P364, DOI 10.7205/MILMED-D-10-00021; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; Heuer JF, 2011, INTENS CARE MED, V37, P1182, DOI 10.1007/s00134-011-2232-2; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; JAREK MJ, 1993, CRIT CARE MED, V21, P543, DOI 10.1097/00003246-199304000-00015; Kemp CD, 2008, AM SURGEON, V74, P866; Kox M, 2012, J NEUROTRAUM, V29, P747, DOI 10.1089/neu.2011.2035; Lou MQ, 2013, CLIN NEUROL NEUROSUR, V115, P904, DOI 10.1016/j.clineuro.2012.09.001; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martino R, 2005, STROKE, V36, P2756, DOI 10.1161/01.STR.0000190056.76543.eb; Mascia L, 2008, MINERVA ANESTESIOL, V74, P325; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Tennant A, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-21; Tracey KJ, 2010, NAT IMMUNOL, V11, P561, DOI 10.1038/ni0710-561; Van Westerloo DJ, 2006, J THROMB HAEMOST, V4, P1997, DOI 10.1111/j.1538-7836.2006.02112.x; Van Westerloo DJ, 2006, GASTROENTEROLOGY, V130, P1822, DOI 10.1053/j.gastro.2006.02.022; van Westerloo DJ, 2005, CRIT CARE MED, V33, P1770, DOI 10.1097/01.CCM.0000172277.41033.F0; van Westerloo DJ, 2005, J INFECT DIS, V191, P2138, DOI 10.1086/430323	29	30	32	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2073	2079		10.1089/neu.2013.3060			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500009	23937270				2021-06-18	
J	Acosta, SA; Diamond, DM; Wolfe, S; Tajiri, N; Shinozuka, K; Ishikawa, H; Hernandez, DG; Sanberg, PR; Kaneko, Y; Borlongan, CV				Acosta, Sandra A.; Diamond, David M.; Wolfe, Steven; Tajiri, Naoki; Shinozuka, Kazutaka; Ishikawa, Hiroto; Hernandez, Diana G.; Sanberg, Paul R.; Kaneko, Yuji; Borlongan, Cesar V.			Influence of Post-Traumatic Stress Disorder on Neuroinflammation and Cell Proliferation in a Rat Model of Traumatic Brain Injury	PLOS ONE			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; MEDIAL TEMPORAL-LOBES; HIPPOCAMPAL VOLUME; ANIMAL-MODEL; MEMORY; PERFORMANCE; SURVIVORS; EXPOSURE; ABSENCE; CORTEX	Long-term consequences of traumatic brain injury (TBI) are closely associated with the development of severe psychiatric disorders, such as post-traumatic stress disorder (PTSD), yet preclinical studies on pathological changes after combined TBI with PTSD are lacking. In the present in vivo study, we assessed chronic neuroinflammation, neuronal cell loss, cell proliferation and neuronal differentiation in specific brain regions of adult Sprague-Dawley male rats following controlled cortical impact model of moderate TBI with or without exposure to PTSD. Eight weeks post-TBI, stereology-based histological analyses revealed no significant differences between sham and PTSD alone treatment across all brain regions examined, whereas significant exacerbation of OX6-positive activated microglial cells in the striatum, thalamus, and cerebral peduncle, but not cerebellum, in animals that received TBI alone and combined TBI-PTSD compared with PTSD alone and sham treatment. Additional immunohistochemical results revealed a significant loss of CA3 pyramidal neurons in the hippocampus of TBI alone and TBI-PTSD compared to PTSD alone and sham treatment. Further examination of neurogenic niches revealed a significant downregulation of Ki67-positive proliferating cells, but not DCX-positive neuronally migrating cells in the neurogenic subgranular zone and subventricular zone for both TBI alone and TBI-PTSD compared to PTSD alone and sham treatment. Comparisons of levels of neuroinflammation and neurogenesis between TBI alone and TBI+PTSD revealed that PTSD did not exacerbate the neuropathological hallmarks of TBI. These results indicate a progressive deterioration of the TBI brain, which, under the conditions of the present approach, was not intensified by PTSD, at least within our time window and within the examined areas of the brain. Although the PTSD manipulation employed here did not exacerbate the pathological effects of TBI, the observed long-term inflammation and suppressed cell proliferation may evolve into more severe neurodegenerative diseases and psychiatric disorders currently being recognized in traumatized TBI patients.	[Acosta, Sandra A.; Tajiri, Naoki; Shinozuka, Kazutaka; Ishikawa, Hiroto; Hernandez, Diana G.; Sanberg, Paul R.; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA; [Diamond, David M.; Wolfe, Steven] James A Haley Vet Affairs Med Ctr, Tampa, FL USA; [Diamond, David M.; Wolfe, Steven] Univ S Florida, Dept Psychol, Ctr Preclin & Clin Res PTSD, Dept Mol Pharmacol & Physiol, Tampa, FL 33620 USA; [Sanberg, Paul R.] Univ S Florida, Off Res & Innovat, Tampa, FL 33620 USA	Borlongan, CV (corresponding author), Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782; Ishikawa, Hiroto/0000-0003-0760-7203; Shinozuka, Kazutaka/0000-0002-6435-4460	USF Veterans Reintegration Research Funds; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0634]	Supported by USF Veterans Reintegration Research Funds and Department of Defense W81XWH-11-1-0634. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bonne O, 2001, AM J PSYCHIAT, V158, P1248, DOI 10.1176/appi.ajp.158.8.1248; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Brown S, 2003, J NEUROPSYCH CLIN N, V15, P367, DOI 10.1176/appi.neuropsych.15.3.367; Carrion VG, 2001, BIOL PSYCHIAT, V50, P943, DOI 10.1016/S0006-3223(01)01218-5; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; De Bellis MD, 1999, BIOL PSYCHIAT, V45, P1271, DOI 10.1016/S0006-3223(99)00045-1; De Bellis MD, 2002, BIOL PSYCHIAT, V52, P1066, DOI 10.1016/S0006-3223(02)01459-2; De Bellis MD, 2001, BIOL PSYCHIAT, V50, P305, DOI 10.1016/S0006-3223(01)01105-2; Diamond DM, 1999, HIPPOCAMPUS, V9, P542, DOI 10.1002/(SICI)1098-1063(1999)9:5<542::AID-HIPO8>3.0.CO;2-N; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fennema-Notestine C, 2002, BIOL PSYCHIAT, V52, P1089, DOI 10.1016/S0006-3223(02)01413-0; Freeman TW, 1998, MAGNET RESON MED, V40, P66, DOI 10.1002/mrm.1910400110; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Golier JA, 2005, PSYCHIAT RES-NEUROIM, V139, P53, DOI 10.1016/j.pscychresns.2005.02.007; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holschneider DP, 2011, J NEUROTRAUM, V28, P1909, DOI 10.1089/neu.2011.1978; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kraus JF, 1993, HEAD INJURY, P1; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; MAYHEW TM, 1991, EXP PHYSIOL, V76, P639, DOI 10.1113/expphysiol.1991.sp003533; Menon PM, 2003, PSYCHIAT RES-NEUROIM, V123, P101, DOI 10.1016/S0925-4927(03)00044-1; Pardini M, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.1; Park CR, 2001, BIOL PSYCHIAT, V50, P994, DOI 10.1016/S0006-3223(01)01255-0; Pederson CL, 2004, J TRAUMA STRESS, V17, P37, DOI 10.1023/B:JOTS.0000014674.84517.46; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Roth TL, 2011, J PSYCHIATR RES, V45, P919, DOI 10.1016/j.jpsychires.2011.01.013; Sapolsky RM, 1999, EXP GERONTOL, V34, P721, DOI 10.1016/S0531-5565(99)00047-9; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Schuff N, 2001, BIOL PSYCHIAT, V50, P952, DOI 10.1016/S0006-3223(01)01245-8; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Strangman GE, 2009, NEUROREHAB NEURAL RE, V23, P226, DOI 10.1177/1545968308324225; Tanielian T, 2008, MG720CCF RAND CORP; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Villarreal G, 2002, CAN J PSYCHIAT, V47, P666; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zoladz P.R., 2010, CULTURE PSY NEUROSCI, V15, P6; Zoladz PR, 2012, PSYCHONEUROENDOCRINO, V37, P1531, DOI 10.1016/j.psyneuen.2012.02.007; Zoladz PR, 2008, STRESS, V11, P259, DOI 10.1080/10253890701768613	53	30	30	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2013	8	12							e81585	10.1371/journal.pone.0081585			10	Multidisciplinary Sciences	Science & Technology - Other Topics	275VD	WOS:000328705200035	24349091	DOAJ Gold, Green Published			2021-06-18	
J	Savigni, DL; Doig, RLO; Szymanski, CR; Bartlett, CA; Lozic, I; Smith, NM; Fitzgerald, M				Savigni, Donna L.; Doig, Ryan L. O'Hare; Szymanski, Charis R.; Bartlett, Carole A.; Lozic, Ivan; Smith, Nicole M.; Fitzgerald, Melinda			Three Ca2+ channel inhibitors in combination limit chronic secondary degeneration following neurotrauma	NEUROPHARMACOLOGY			English	Article						Secondary degeneration; Ca2+ channel inhibitors; Myelin; Myelin compaction; Neurotrauma; Visual system; Node/paranode complex; Oxidative stress	SPINAL-CORD-INJURY; RETINAL GANGLION-CELLS; OPTIC-NERVE; NMDA RECEPTORS; AXONAL DEGENERATION; LIPID-PEROXIDATION; MYELIN; BLOCKER; RATS; OLIGODENDROCYTES	Following neurotrauma, cells beyond the initial trauma site undergo secondary degeneration, with excess Ca2+ a likely trigger for loss of neurons, compact myelin and function. Treatment using inhibitors of specific Ca2+ channels has shown promise in preclinical studies, but clinical trials have been disappointing and combinatorial approaches are needed. We assessed efficacy of multiple combinations of three Ca2+ channel inhibitors at reducing secondary degeneration following partial optic nerve transection in rat. We used lomerizine to inhibit voltage gated Ca2+ channels; oxidised adenosine-triphosphate (oxATP) to inhibit purinergic P2X(7) receptors and/or 2-[7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-1,2,3,4-tetrahydro quinoxalin-1-yl]acetic acid (INQ) to inhibit Ca2+ permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Only the three Ca2+ channel inhibitors delivered in combination significantly preserved visual function, as assessed using the optokinetic nystagmus visual reflex, at 3 months after injury. Preservation of retinal ganglion cells was partial and is unlikely to have accounted for differential effects on function. A range of the Ca2+ channel inhibitor combinations prevented swelling of optic nerve vulnerable to secondary degeneration. Each of the treatments involving lomerizine significantly increased the proportion of axons with normal compact myelin. Nevertheless, limiting decompaction of myelin was not sufficient for preservation of function in our model. Multiple combinations of Ca2+ channel inhibitors reduced formation of atypical node/paranode complexes; outcomes were not associated with preservation of visual function. However, prevention of lengthening of the paranodal gap that was only achieved by treatment with the three Ca2+ channel inhibitors in combination was an important additional effect that likely contributed to the associated preservation of the optokinetic reflex using this combinatorial treatment strategy. (C) 2013 Elsevier Ltd. All rights reserved.	[Savigni, Donna L.; Doig, Ryan L. O'Hare; Szymanski, Charis R.; Bartlett, Carole A.; Lozic, Ivan; Smith, Nicole M.; Fitzgerald, Melinda] Univ Western Australia, Crawley, WA 6009, Australia; [Savigni, Donna L.; Doig, Ryan L. O'Hare; Szymanski, Charis R.; Bartlett, Carole A.; Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Lozic, Ivan; Smith, Nicole M.] Univ Western Australia, Sch Chem & Biochem, Crawley, WA 6009, Australia	Fitzgerald, M (corresponding author), Univ Western Australia, Crawley, WA 6009, Australia.	lindy.fitzgerald@uwa.edu.au	Smith, Nicole/L-2502-2013; Doig, Ryan O'Hare/AAG-7585-2019; Fitzgerald, Melinda/C-4235-2011	Smith, Nicole/0000-0002-5519-8152; Fitzgerald, Melinda/0000-0002-4823-8179; Lozic, Ivan/0000-0001-7441-743X	Neurotrauma Research Program (Western Australia); National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [572550]	This work was supported by the Neurotrauma Research Program (Western Australia) and the National Health and Medical Research Council (NH&MRC, Grant ID: 572550). Our funding sources played no role in the conduct of the research or preparation of this article. We thank Mr. Michael Archer for technical assistance with electron microscopy, Dr K. Swaminathan Iyer for advice regarding synthesis of INQ and Ms Sophie C. Payne for helpful discussions and critical review of the manuscript.	Abdejalil J, 2005, VISION RES, V45, P1439, DOI 10.1016/j.visres.2004.12.015; Araujo IM, 2007, CELL DEATH DIFFER, V14, P1635, DOI 10.1038/sj.cdd.4402171; Arvanian VL, 2009, EXP NEUROL, V216, P471, DOI 10.1016/j.expneurol.2009.01.004; Back SA, 1998, J NEUROSCI, V18, P6241; Beazley LD, 1996, RESTOR NEUROL NEUROS, V10, P95, DOI 10.3233/RNN-1996-10205; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; Bizzozero OA, 2004, NEUROCHEM RES, V29, P1675, DOI 10.1023/B:NERE.0000035802.27087.16; Blair M, 2005, INVEST OPHTH VIS SCI, V46, P884, DOI 10.1167/iovs.04-0731; Buttermore ED, 2011, J NEUROSCI, V31, P8013, DOI 10.1523/JNEUROSCI.1015-11.2011; Calin-Jageman I, 2008, J NEUROCHEM, V105, P573, DOI 10.1111/j.1471-4159.2008.05286.x; Camello-Almaraz MC, 2006, J CELL PHYSIOL, V206, P487, DOI 10.1002/jcp.20498; Choi HB, 2007, J NEUROSCI, V27, P4957, DOI 10.1523/JNEUROSCI.5417-06.2007; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dupree JL, 1998, J NEUROSCI, V18, P1642; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; Franke H, 2004, J NEUROPATH EXP NEUR, V63, P686, DOI 10.1093/jnen/63.7.686; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Fu Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006705; Giaume C, 2007, CELL DEATH DIFFER, V14, P1324, DOI 10.1038/sj.cdd.4402144; Hamilton N, 2008, GLIA, V56, P734, DOI 10.1002/glia.20649; Hara H, 1999, CLIN EXP PHARMACOL P, V26, P870, DOI 10.1046/j.1440-1681.1999.03154.x; Howell OW, 2006, BRAIN, V129, P3173, DOI 10.1093/brain/awl290; Imaizumi T, 1999, BRAIN RES, V817, P84, DOI 10.1016/S0006-8993(98)01214-1; Juurlink BHJ, 1998, GLIA, V22, P371, DOI 10.1002/(SICI)1098-1136(199804)22:4<371::AID-GLIA6>3.0.CO;2-6; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Karim MD, 2006, CURR EYE RES, V31, P273, DOI 10.1080/02713680500536647; Kennedy C., 2007, XPHARM COMPREHENSIVE, P1; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; Klein KU, 2010, BEST PRACT RES-CLIN, V24, P535, DOI 10.1016/j.bpa.2010.10.008; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Lasiene J, 2008, J NEUROSCI, V28, P3887, DOI 10.1523/JNEUROSCI.4756-07.2008; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; Matute C, 1998, P NATL ACAD SCI USA, V95, P10229, DOI 10.1073/pnas.95.17.10229; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; Miller RH, 2007, NAT NEUROSCI, V10, P1351, DOI 10.1038/nn1995; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Payne SC, 2012, INVEST OPHTH VIS SCI, V53, P6093, DOI 10.1167/iovs.12-10080; Payne SC, 2011, J NEUROTRAUM, V28, P1077, DOI 10.1089/neu.2010.1665; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Phokeo V, 2002, J COMP NEUROL, V451, P213, DOI 10.1002/cne.10330; Pitt D, 2010, BRAIN RES, V1309, P146, DOI 10.1016/j.brainres.2009.10.066; Rosenbluth J, 2009, J NEUROSCI RES, V87, P3250, DOI 10.1002/jnr.22013; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Saggu SK, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-97; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Selt M, 2010, BRAIN RES BULL, V81, P467, DOI 10.1016/j.brainresbull.2009.11.004; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; Sykova E, 2008, NEUROCHEM INT, V52, P5, DOI 10.1016/j.neuint.2007.04.007; Syntichaki P, 2003, NAT REV NEUROSCI, V4, P672, DOI 10.1038/nrn1174; Takahashi M, 2002, CNS DRUG REV, V8, P337; Tamaki Y, 2003, INVEST OPHTH VIS SCI, V44, P4864, DOI 10.1167/iovs.02-1173; Toriu N, 2000, EXP EYE RES, V70, P475, DOI 10.1006/exer.1999.0809; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Wells J, 2012, J NEUROSCI RES, V90, P606, DOI 10.1002/jnr.22784; WONG EHF, 1991, ANNU REV PHARMACOL, V31, P401; Yamada H, 2006, BRAIN RES, V1071, P75, DOI 10.1016/j.brainres.2005.11.072; YANAGISAWA K, 1988, J NEUROCHEM, V51, P803, DOI 10.1111/j.1471-4159.1988.tb01815.x	73	30	30	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	DEC	2013	75				SI		380	390		10.1016/j.neuropharm.2013.07.034			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	300UU	WOS:000330490300039	23958451				2021-06-18	
J	Jiang, XF; Huang, Y; Lin, W; Gao, DK; Fei, Z				Jiang, Xiaofan; Huang, Yi; Lin, Wei; Gao, Dakuan; Fei, Zhou			Protective effects of hydrogen sulfide in a rat model of traumatic brain injury via activation of mitochondrial adenosine triphosphate-sensitive potassium channels and reduction of oxidative stress	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Oxidative stress; Hydrogen sulfide; mitoK(ATP) channels	ISCHEMIA-REPERFUSION INJURY; K-ATP CHANNELS; SIGNALING MOLECULE; HEMORRHAGIC-SHOCK; NEURONAL CELLS; IN-VIVO; MICE; IMPACT; MARKERS; SALINE	Background: Hydrogen sulfide (H2S) is considered an important neuromodulator in the central nervous system. We designed the present study to investigate the effects of exogenous H2S in a rat model of traumatic brain injury (TBI) and the mechanism(s) that underlie this effect. Methods: We induced a TBI model by controlled cortical impact injury. We intraperitoneally administered sodium hydrosulfide (NaHS) (an H2S donor) (3 mg/kg) or vehicle alone at 5 min after a TBI operation. We then measured the H2S level, brain edema, blood-brain barrier integrity, neurologic dysfunction, and lesion volume in all animals. Moreover, we assessed the role of mitochondrial adenosine triphosphate-sensitive potassium (mitoK(ATP)) channels by intraperitoneal injection of the selective blocker 5-hydroxydecanoate before NaHS administration. In addition, we detected the levels of oxidative products and the activities of antioxidant enzymes in brain tissue. Results: Administration of NaHS significantly increased the H2S level of brain tissue in TBI-challenged rats. The TBI-challenged animals exhibited significant brain injuries, characterized by an increase of blood-brain barrier permeability, brain edema, and lesion volume, as well as neurologic dysfunction, which were significantly ameliorated by NaHS treatment. However, the protective effects of H2S in TBI could be abolished by the mitoK(ATP)channel blocker 5-hydroxydecanoate. Moreover, we found that NaHS treatment increased endogenous antioxidant enzymatic activities and decreased oxidative product levels in brain tissue of TBI-challenged rats. Conclusions: Exogenous H2S administered at an appropriate dose can exert a protective effect against TBI via activation of mitoK(ATP) channels and reduction of oxidative stress. (C) 2013 Elsevier Inc. All rights reserved.	[Jiang, Xiaofan; Lin, Wei; Gao, Dakuan; Fei, Zhou] Fourth Mil Med Univ, Dept Neurosurg, Xijing Inst Clin Neurosci, Xiing Hosp, Xian 710032, Shaanxi Provinc, Peoples R China; [Huang, Yi] Fourth Mil Med Univ, Dept Anesthesiol, Xiing Hosp, Xian 710032, Shaanxi Provinc, Peoples R China	Fei, Z (corresponding author), Fourth Mil Med Univ, Dept Neurosurg, Xijing Inst Clin Neurosci, Xiing Hosp, Xian 710032, Shaanxi Provinc, Peoples R China.	Tougaozy2011@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81071034]	This work was supported by grant 81071034 from the National Natural Science Foundation of China.	Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Benetti LR, 2013, EUR J PHARMACOL, V698, P463, DOI 10.1016/j.ejphar.2012.11.025; Busija DW, 2004, BRAIN RES REV, V46, P282, DOI 10.1016/j.brainresrev.2004.06.011; Chai W, 2012, J SURG RES, V176, P210, DOI 10.1016/j.jss.2011.07.016; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; Elliott MB, 2009, BRAIN RES, V1305, P183, DOI 10.1016/j.brainres.2009.09.104; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Francis RC, 2011, ANESTHESIOLOGY, V115, P1012, DOI 10.1097/ALN.0b013e31823306cf; Ganster F, 2010, CRIT CARE, V14, DOI 10.1186/cc9257; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Hu LF, 2011, ANTIOXID REDOX SIGN, V15, P405, DOI 10.1089/ars.2010.3517; Ji XT, 2012, J SURG RES, V178, pE9, DOI 10.1016/j.jss.2011.12.038; Johansen D, 2006, BASIC RES CARDIOL, V101, P53, DOI 10.1007/s00395-005-0569-9; Kimura H, 2012, ANTIOXID REDOX SIGN, V17, P45, DOI 10.1089/ars.2011.4345; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kimura Y, 2006, ANTIOXID REDOX SIGN, V8, P661, DOI 10.1089/ars.2006.8.661; Kumar A, 2008, NEONATOLOGY, V94, P96, DOI 10.1159/000116633; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu DD, 2008, CRIT CARE MED, V36, P565, DOI 10.1097/01.CCM.0000299737.24338.5C; Liu YY, 2013, NEUROCHEM INT, V62, P603, DOI 10.1016/j.neuint.2012.12.010; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Peers C, 2012, ANTIOXID REDOX SIGN, V17, P95, DOI 10.1089/ars.2011.4359; Sakamoto M, 2002, NEUROL RES, V24, P301, DOI 10.1179/016164102101199783; Satpute RM, 2009, FOOD CHEM TOXICOL, V47, P2689, DOI 10.1016/j.fct.2009.06.007; Shen XG, 2011, FREE RADICAL BIO MED, V50, P1021, DOI 10.1016/j.freeradbiomed.2011.01.025; Tan BH, 2010, NEUROCHEM INT, V56, P3, DOI 10.1016/j.neuint.2009.08.008; Tang GH, 2005, MOL PHARMACOL, V68, P1757, DOI 10.1124/mol.105.017467; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yang Guangdong, 2011, Expert Rev Clin Pharmacol, V4, P33, DOI 10.1586/ecp.10.131; Yin J, 2013, BRAIN RES, V1491, P188, DOI 10.1016/j.brainres.2012.10.046; Yonezawa D, 2007, TOXICOLOGY, V241, P11, DOI 10.1016/j.tox.2007.07.020; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang MY, 2013, NEUROCHEM RES, V38, P714, DOI 10.1007/s11064-013-0969-4; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077	45	30	31	1	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	OCT	2013	184	2					E27	E35		10.1016/j.jss.2013.03.067			9	Surgery	Surgery	215XE	WOS:000324243500004	23590867				2021-06-18	
J	Mannix, R; Monuteaux, MC; Schutzman, SA; Meehan, WP; Nigrovic, LE; Neuman, MI				Mannix, Rebekah; Monuteaux, Michael C.; Schutzman, Sara A.; Meehan, William P., III; Nigrovic, Lise E.; Neuman, Mark I.			Isolated Skull Fractures: Trends in Management in US Pediatric Emergency Departments	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CHILDREN; INFANTS	Study objective: Previous studies have suggested that children with isolated skull fractures are at low risk of requiring neurosurgical intervention, suggesting that admission to the hospital may not be necessary in many instances. We seek to evaluate current practice for children presenting to the emergency department (ED) for isolated skull fractures in US children's hospitals. Methods: We conducted a retrospective multicenter cross-sectional study of children younger 19 years with a diagnosis of isolated skull fracture who were evaluated in the ED from 2005 to 2011, using the Pediatric Health Information System database. The primary outcome measure was the rate of hospital admission. Secondary outcomes were any neurosurgical procedure during hospitalization, repeated neuroimaging, duration of hospitalization, and cost of care. Results: We identified 3,915 patients with isolated skull fractures, of whom 60% were male patients; 78% were hospitalized. Of hospitalized children, 85% were discharged within 1 day and 95% were discharged within 2 days. During hospitalization, 47 patients received repeated computed tomography imaging and 1 child required a neurosurgical procedure. Hospital costs were more than triple for hospitalized patients compared with patients discharged from the ED ($2,064 versus $619). Conclusion: Most children treated in EDs of US children's hospitals with isolated skull fractures are hospitalized. The rate of neurosurgical intervention is very low. A better understanding of current practice is necessary to assess whether these admissions are warranted or not.	[Mannix, Rebekah; Monuteaux, Michael C.; Schutzman, Sara A.; Meehan, William P., III; Nigrovic, Lise E.; Neuman, Mark I.] Boston Childrens Hosp, Div Emergency Med, Dept Med, Boston, MA USA; [Mannix, Rebekah; Monuteaux, Michael C.; Schutzman, Sara A.; Meehan, William P., III; Nigrovic, Lise E.; Neuman, Mark I.] Harvard Univ, Sch Med, Boston, MA USA; [Meehan, William P., III] Boston Childrens Hosp, Sports Concuss Clin, Div Sports Med, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA	Mannix, R (corresponding author), Boston Childrens Hosp, Div Emergency Med, Dept Med, Boston, MA USA.	rebekah.nnannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020; Monuteaux, Michael C/O-5032-2018	Nigrovic, Lise/0000-0002-6369-3997			Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laskey AL, 2013, J PEDIATR-US, V162, P86, DOI 10.1016/j.jpeds.2012.06.038; Macy ML, 2012, J HOSP MED, V7, P287, DOI 10.1002/jhm.949; Narus Scott P, 2011, AMIA Annu Symp Proc, V2011, P994; Rollins MD, 2011, J PEDIATR SURG, V46, P1342, DOI 10.1016/j.jpedsurg.2010.12.019; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Tieder JS, 2011, PEDIATRICS, V128, P323, DOI 10.1542/peds.2010-2064	10	30	30	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	OCT	2013	62	4					327	331		10.1016/j.annemergmed.2013.02.027			5	Emergency Medicine	Emergency Medicine	229ZZ	WOS:000325307700011	23602429				2021-06-18	
J	Ozen, LJ; Itier, RJ; Preston, FF; Fernandes, MA				Ozen, Lana J.; Itier, Roxane J.; Preston, Frank F.; Fernandes, Myra A.			Long-term working memory deficits after concussion: Electrophysiological evidence	BRAIN INJURY			English	Article						Attention; event-related potential; mild traumatic brain injury; n-back task; P300	TRAUMATIC BRAIN-INJURY; EVENT-RELATED POTENTIALS; HEAD-INJURY; DUAL-TASK; MILD; P300; PERFORMANCE; ATTENTION; QUESTIONNAIRE; METAANALYSIS	Background: Persistent complaints of lingering memory and concentration difficulties are common following a concussion, although the brain basis of these is unknown. Some suggest abnormalities can be found on the P300 event-related potential component, recorded using electroencephalography (EEG), despite unobservable cognitive impairments. Objective: To examine the P300 and cognitive performance following a remote concussion during an n-back task that varies in working memory load. Research design: Seventeen participants with a remote concussion and 17 controls performed a visual n-back task in which working memory demands were systematically increased by manipulating cognitive load. Participants also completed neuropsychological and self-report measures. Results: The concussion group showed a decrease in P300 amplitude compared to controls that was independent of working memory load on the n-back task. While no performance differences were observed between groups, P300 amplitude was negatively correlated with response times at higher loads in both groups. Conclusion: High functioning young adults with a remote concussion may have inefficient recruitment of processing resources for target identification, evident by the attenuated P300. The negative correlations between response time and P300 amplitude suggest that the time necessary to accurately respond to targets increases as the efficiency of allocating processing resources decreases during highly demanding working memory tasks.	[Ozen, Lana J.; Itier, Roxane J.; Preston, Frank F.; Fernandes, Myra A.] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada	Ozen, LJ (corresponding author), St Josephs Care Grp, Res Dept, 580 Algoma North, Thunder Bay, ON P7B 5G4, Canada.	ozenl@tbh.net	Itier, Roxane/AAE-1340-2019	Itier, Roxane/0000-0001-6460-5218	NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); ORF; CFICanada Foundation for Innovation; CRC programCanada Research Chairs	The authors report no conflicts of interest. This work was supported by an NSERC Discovery grant to MAF, an NSERC post-graduate scholarship to LJO and funds from the ORF, CFI and the CRC program to RJI.	Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Carriere JSA, 2008, CONSCIOUS COGN, V17, P835, DOI 10.1016/j.concog.2007.04.008; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gaetz M, 2000, BRAIN INJURY, V14, P1077; ISREAL JB, 1980, PSYCHOPHYSIOLOGY, V17, P259, DOI 10.1111/j.1469-8986.1980.tb00146.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAMER AF, 1985, J EXP PSYCHOL HUMAN, V11, P393, DOI 10.1037/0096-1523.11.4.393; Kraus JCL, 2005, TXB TRAUMATIC BRAIN; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McEvoy LK, 1998, CEREB CORTEX, V8, P563, DOI 10.1093/cercor/8.7.563; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Pare N, 2009, NEUROPSYCHOL REHABIL, V19, P110, DOI 10.1080/09602010802106486; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; REASON JT, 1982, ABSENT MINDED PSYCHO; Reitan RM., 1985, HALSTEAD REITAN NEUR; Repovs G, 2006, NEUROSCIENCE, V139, P5, DOI 10.1016/j.neuroscience.2005.12.061; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Schoenberg MR, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P1, DOI 10.1007/978-0-387-76978-3; Schoning S, 2009, HUM BRAIN MAPP, V30, P2746, DOI 10.1002/hbm.20702; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spielberger CD, 1970, STATE TRAIT ANXIETY; Thurman DJ, 2007, BRAIN INJURY MED; Watter S, 2001, PSYCHOPHYSIOLOGY, V38, P998, DOI 10.1111/1469-8986.3860998; Wechsler D, 1997, WAIS 3 ADM SCORING M; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	45	30	31	0	43	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2013	27	11					1244	1255		10.3109/02699052.2013.804207			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	217YQ	WOS:000324399800003	23875864				2021-06-18	
J	Rogan, C; Fortune, DG; Prentice, G				Rogan, Carol; Fortune, Donal G.; Prentice, Garry			Post-traumatic growth, illness perceptions and coping in people with acquired brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Post-traumatic growth; Acquired brain injury; Illness perceptions; Coping	2-COMPONENT MODEL; HEAD-INJURY; LIFE; REHABILITATION; LONG; PREDICTORS; PSYCHOLOGY; STRATEGIES; RESOURCES; HIV/AIDS	Post-traumatic growth is a process by which an individual who has faced a significantly adverse and life-altering event, can show evidence of an ability meaningfully to construe benefits from such adversity. The purpose of this study was to investigate, in a sample of people with acquired brain injury (ABI), the contribution of illness perceptions, distress, disability, and coping strategies and health to post-traumatic growth. Seventy people with an ABI took part in this cross-sectional investigation, comprising 70% males and 30% females. Traumatic brain injury accounted for the majority of brain injuries (56%), with 31% arising from a cerebrovascular accident and the remaining 13% arising from hypoxia, brain tumours, brain abcesses and encephalitis. The average time since injury was 70.43 months (SD=55.30, range=7-350). Participants completed assessments comprising post-traumatic growth (Post-traumatic Growth Inventory), beliefs about their condition (Illness Perception Questionnaire Revised), coping strategies (Brief COPE), anxiety and depression (Hospital Anxiety and Depression Scale) and functional disability (Functional Independence Measure and Functional Assessment Measure). All participants were accessing post-acute brain injury rehabilitation and support services. Results showed that greater levels of post-traumatic growth were associated with greater use of adaptive coping strategies (r=.597), lower levels of distress (r=-.241) and stronger beliefs about treatment-induced controllability of the effects arising from brain injury (r=.263). Greater use of adaptive coping strategies accounted for the greater proportion of the variance in post-traumatic growth (sr(2)=0.287) and was the only variable found to make a unique and statistically significant contribution to the prediction of growth. Illness perceptions more generally were not significantly associated with growth experiences. This study provides additional evidence of the factors associated with the process of post-traumatic growth, in particular adaptive coping strategies that may help to facilitate growth, although the direction of this relationship requires further empirical investigation. The findings of this study may have implications for professionals providing neurorehabilitation services.	[Rogan, Carol; Fortune, Donal G.] Acquired Brain Injury Ireland, Limerick, Ireland; [Fortune, Donal G.] Univ Limerick, Dept Psychol, Limerick, Ireland; [Prentice, Garry] Dublin Business Sch, Dublin, Ireland	Fortune, DG (corresponding author), Acquired Brain Injury Ireland, OMeara House,Ballinacurra Rd, Limerick, Ireland.	dfortune@abiireland.ie		Rogan, Carol/0000-0003-1510-5334			Ackroyd K, 2011, J CLIN PSYCHOL MED S, V18, P372, DOI 10.1007/s10880-011-9265-0; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Cattelani R, 2010, NEUROPSYCHOL REV, V20, P52, DOI 10.1007/s11065-009-9125-y; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Danoff-Burg S, 2005, J BEHAV MED, V28, P91, DOI 10.1007/s10865-005-2720-3; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; Evans JJ, 2011, BRAIN IMPAIR, V12, P117, DOI 10.1375/brim.12.2.117; Farhall J, 2007, CLIN PSYCHOL REV, V27, P476, DOI 10.1016/j.cpr.2006.12.002; Fortune D., 2005, PSYCHOL HEALTH MED, V10, P44, DOI [10.1080/13548500512331315352, DOI 10.1080/13548500512331315352]; Frazier P, 2001, J CONSULT CLIN PSYCH, V69, P1048, DOI 10.1037//0022-006X.69.6.1048; Frostholm L, 2005, PSYCHOSOM MED, V67, P997, DOI 10.1097/01.psy.0000189164.85653.bc; Gangstad B, 2009, REHABIL PSYCHOL, V54, P69, DOI 10.1037/a0014639; Gillen G, 2006, AM J OCCUP THER, V60, P136, DOI 10.5014/ajot.60.2.136; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Hawley CA, 2008, BRAIN INJURY, V22, P427, DOI 10.1080/02699050802064607; Hefferon K, 2009, BRIT J HEALTH PSYCH, V14, P343, DOI 10.1348/135910708X332936; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jones JM, 2011, PSYCHOL HEALTH, V26, P353, DOI 10.1080/08870440903440699; JOSEPH S, 1993, J TRAUMA STRESS, V6, P271, DOI 10.1007/BF00974121; Joseph S., 2011, **DROPPED REF**; Katz RC, 2001, J BEHAV MED, V24, P561, DOI 10.1023/A:1012939310459; Krpan KM, 2011, J INT NEUROPSYCH SOC, V17, P248, DOI 10.1017/S1355617710001499; Leventhal H., 1980, MED PSYCHOL, V2, P7; Leventhal H., 1997, PERCEPTIONS HLTH ILL, P19; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; Maercker A, 2004, PSYCHOL INQ, V15, P41; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; McGrath JC, 2011, BRAIN IMPAIR, V12, P82, DOI 10.1375/brim.12.2.82; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; Milam JE, 2004, J APPL SOC PSYCHOL, V34, P2353, DOI 10.1111/j.1559-1816.2004.tb01981.x; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Park CL, 2006, J CONSULT CLIN PSYCH, V74, P791, DOI 10.1037/0022-006X.74.5.791; Powell T, 2007, BRAIN INJURY, V21, P31, DOI 10.1080/02699050601106245; Powell T, 2012, DISABIL REHABIL, V34, P1461, DOI 10.3109/09638288.2011.644384; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Seel RT, 2007, J HEAD TRAUMA REHAB, V22, P267, DOI 10.1097/01.HTR.0000290971.56130.c8; Siegel K, 2005, J BEHAV MED, V28, P403, DOI 10.1007/s10865-005-9015-6; Silva J, 2011, BRAIN IMPAIR, V12, P93, DOI 10.1375/brim.12.2.93; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Taylor SE, 2000, AM PSYCHOL, V55, P99, DOI 10.1037//0003-066X.55.1.99; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1007/BF02103658; Tedeschi RG, 1998, POSTTRAUMATIC GROWTH; Thompson RJ, 2010, BEHAV RES THER, V48, P459, DOI 10.1016/j.brat.2010.01.007; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Updegraff JA, 2002, PERS SOC PSYCHOL B, V28, P382, DOI 10.1177/0146167202286009; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zoellner T, 2006, CLIN PSYCHOL REV, V26, P626, DOI 10.1016/j.cpr.2006.01.008	53	30	31	0	54	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	OCT 1	2013	23	5					639	657		10.1080/09602011.2013.799076			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	220UE	WOS:000324611600002	23701407				2021-06-18	
J	Whyte, J; Nakase-Richardson, R				Whyte, John; Nakase-Richardson, Risa			Disorders of Consciousness: Outcomes, Comorbidities, and Care Needs	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Consciousness disorders; Healthcare delivery; Minimally conscious state; Prognosis; Rehabilitation; Systems of care; Vegetative state	VEGETATIVE STATE; REHABILITATION; AWARENESS; RECOVERY	Over the last decade, research on patients with disorders of consciousness (DOC) has suggested that their prognosis for functional recovery early after injury is surprisingly positive, particularly for those with traumatic etiologies; that meaningful recovery proceeds for longer intervals than previously appreciated; and that such individuals are often medically complex and challenging to manage However, access to intensive specialty rehabilitation is limited for most individuals with DOC in the United States. The evolving understanding of DOC calls for a reconsideration of appropriate models of care. This collection of articles provides insight into the functional recovery of individuals with DOC, new tools for assessing prognosis, and the patterns of comorbidity that complicate the recovery process. In addition, models of care from the United States and Europe that attempt to address the needs of patients as well as their caregivers are presented. (c) 2013 by the American Congress of Rehabilitation Medicine	[Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL 33612 USA; [Nakase-Richardson, Risa] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Nakase-Richardson, Risa] Ctr Excellence Maximizing Rehabil Outcomes, Tampa, FL USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	jwhyte@einstein.edu		Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research (NIDRR), US Department of EducationUS Department of Education [H133A070040, H133A120037]	Supported in part by grant nos. H133A070040 and H133A120037 from the National Institute on Disability and Rehabilitation Research (NIDRR), US Department of Education (T. Hart, Principal Investigator). However, the contents do not necessarily represent the policy of the Department of Education, and endorsement by the federal government should not be assumed. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of Veterans Affairs or the US government.No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated.This represents work from the American Congress of Rehabilitation Medicine, Brain Injury-Interdisciplinary Special Interest Group, Disorders of Consciousness Task Force, and NIDRR TBI Model System Program Special Interest Group on Disorders of Consciousness.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; BERUBE J, 2006, MOHONK REPORT DISORD; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; ESTRANEO A, 2010, NEUROLOGY, P75; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Kotchoubey B, 2002, NEWS PHYSIOL SCI, V17, P38; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; *MCKESS INC, 2012, INT LEV CAR CRIT 201; McNamee S, 2012, J HEAD TRAUMA REHAB, V27, P244, DOI 10.1097/HTR.0b013e31825e12c8; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Owen AM, 2008, NAT REV NEUROSCI, V9, P235, DOI 10.1038/nrn2330; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; SCLUIACKERS C, 2009, BMC NEUROL, P9; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; TURGEON AF, 2011, CMAJ, V183, P1563; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0	24	30	31	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1851	1854		10.1016/j.apmr.2013.07.003			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	231TU	WOS:000325442100001	23856152				2021-06-18	
J	Barker-Collo, S; Starkey, N; Theadom, A				Barker-Collo, Suzanne; Starkey, Nicola; Theadom, Alice			Treatment for depression following mild traumatic brain injury in adults: A meta-analysis	BRAIN INJURY			English	Article						Antidepressants; CBT; depression; interventions; Meta-analysis; mild brain injury; TBI; treatment	MAJOR DEPRESSION; HEAD-INJURY; SERTRALINE; EPIDEMIOLOGY; CITALOPRAM; DISORDERS; THERAPY; IMPACT; TRIALS	Primary objective: Development of depression after TBI is linked to poorer outcomes. The aim of this manuscript is to review evidence for the effectiveness of current treatments. Research design: Two meta-analyses were undertaken to examine the effectiveness of both pharmacological and non-pharmacological interventions for depression after mild TBI Method and procedures: PubMed, Medline, PsychInfo, Web of Science and Digital Dissertations were searched and 13 studies located. Meta Analyst Beta 3.13 was used to conduct analyses of pre- vs post-effects then to examine treatment group vs control group effects. Main outcomes and results: Studies using a pre-post design produced an overall effect size of 1.89 (95% CI = 1.20-2.58, p<0.001), suggesting that treatments were effective; however, the overall effect for controlled trials was 0.46 (95% CI = -0.44-1.36, p<0.001), which favoured the control rather than treatment groups. Conclusions: This study highlights the need for additional large well-controlled trials of effective treatments for depression post-TBI.	[Barker-Collo, Suzanne] Univ Auckland, Dept Psychol, Fac Sci, Auckland, New Zealand; [Starkey, Nicola] Univ Waikato, Fac Arts & Social Sci, Sch Psychol, Hamilton, New Zealand; [Theadom, Alice] AUT Univ, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand	Barker-Collo, S (corresponding author), Univ Auckland, Dept Psychol, Tamaki Campus,Private Bag 92019, Auckland, New Zealand.	s.barker-collo@auckland.ac.nz	Starkey, Nicola/AAJ-3795-2020	Starkey, Nicola/0000-0002-4370-8186; Theadom, Alice/0000-0003-0351-6216			Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Baker-Price L, 2003, PERCEPT MOTOR SKILL, V96, P965, DOI 10.2466/PMS.96.3.965-974; BakerPrice LA, 1996, PERCEPT MOTOR SKILL, V83, P491, DOI 10.2466/pms.1996.83.2.491; Borenstein M, 2009, INTRO META ANAL, P69; Borenstein M, 2009, INTRO METAANALYSIS, P53; Borenstein M., 2009, INTRO METAANALYSIS, P139; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; Gaultieri CT, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P411; Grant I, 1987, NEUROBEHAVIOURAL REC; Hedges LV., 1981, J EDUC STAT, V6, P107; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kanetani Kouichi, 2003, Journal of Nippon Medical School, V70, P313; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Lanctot KL, 2010, BRAIN INJURY, V24, P959, DOI 10.3109/02699051003789229; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leonard KL, 2002, COGNITIVE BEHAV INTE; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Price A, 2011, J NEUROL NEUROSUR PS, V82, P914, DOI 10.1136/jnnp.2010.230862; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Robinson RG, 2005, TXB TRAUMATIC BRAIN, P201; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Villar J, 1997, J CLIN EPIDEMIOL, V50, P997, DOI 10.1016/S0895-4356(97)00148-0; Wallace BC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-80; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]	50	30	31	0	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2013	27	10					1124	1133		10.3109/02699052.2013.801513			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	204KW	WOS:000323365200004	23895287	Green Accepted			2021-06-18	
J	Hammeke, TA; McCrea, M; Coats, SM; Verber, MD; Durgerian, S; Flora, K; Olsen, GS; Leo, PD; Gennarelli, TA; Rao, SM				Hammeke, Thomas A.; McCrea, Michael; Coats, Sarah M.; Verber, Matthew D.; Durgerian, Sally; Flora, Kristin; Olsen, Gary S.; Leo, Peter D.; Gennarelli, Thomas A.; Rao, Stephen M.			Acute and Subacute Changes in Neural Activation during the Recovery from Sport-Related Concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						fMRI; Brain activation; Mild TBI; Cognitive compensation; Brain injury; Attention networks	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; WORKING-MEMORY; FUNCTIONAL ABNORMALITIES; NCAA CONCUSSION; ATTENTION; SYMPTOMS; FMRI; METAANALYSIS	To study the natural recovery from sports concussion, 12 concussed high school football athletes and 12 matched uninjured teammates were evaluated with symptom rating scales, tests of postural balance and cognition, and an event-related fMRI study during performance of a load-dependent working memory task at 13 h and 7 weeks following injury. Injured athletes showed the expected postconcussive symptoms and cognitive decline with decreased reaction time (RT) and increased RT variability on a working memory task during the acute period and an apparent full recovery 7 weeks later. Brain activation patterns showed decreased activation of right hemisphere attentional networks in injured athletes relative to controls during the acute period with a reversed pattern of activation (injured > controls) in the same networks at 7 weeks following injury. These changes coincided with a decrease in self-reported postconcussive symptoms and improved cognitive test performance in the injured athletes. Results from this exploratory study suggest that decreased activation of right hemisphere attentional networks mediate the cognitive changes and postconcussion symptoms observed during the acute period following concussion. Conversely, improvement in cognitive functioning and postconcussive symptoms during the subacute period may be mediated by compensatory increases in activation of this same attentional network.	[Hammeke, Thomas A.] Med Coll Wisconsin, Clement J Zablocki VA Med Ctr, Milwaukee, WI 53226 USA; [Hammeke, Thomas A.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA; [McCrea, Michael; Gennarelli, Thomas A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Coats, Sarah M.] St Marys Hosp, Inst Rehabil, Enid, OK USA; [Verber, Matthew D.] Univ N Carolina, Dept Chem, Chapel Hill, NC USA; [Durgerian, Sally; Leo, Peter D.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Flora, Kristin] Franklin Coll, Dept Psychol, Franklin, IN USA; [Olsen, Gary S.] Marshfield Clin Fdn Med Res & Educ, Dept Neuropsychol, Marshfield, WI USA; [Rao, Stephen M.] Cleveland Clin, Neurol Inst, Schey Ctr Cognit Neuroimaging, Cleveland, OH 44106 USA	Hammeke, TA (corresponding author), Clement J Zablocki VA Med Ctr, Bldg 111,Room 3301,5000 W Natl Ave, Milwaukee, WI 53295 USA.	thammeke@mcw.edu	Rao, Stephen M/A-2460-2010	Rao, Stephen M/0000-0002-6463-7460; Durgerian, Sally/0000-0003-3931-9679	National Institutes of Health General Clinical Research CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00058]; National Academy of Neuropsychology; Green Bay Packer Foundation; Herbert Kohl Foundation; National Federation of State High School Associations; Milwaukee Bucks; Waukesha Memorial Hospital Foundation; Waukesha Charities Service Organization; NFL Charities; Medical College of Wisconsin; National Operating Committee on Standards for Athletic Equipment; Michael Emme; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000058] Funding Source: NIH RePORTER	We thank the athletes and their parents who participated in this study and its larger foundational study, the many athletic trainers and technicians who assisted in data collection, and our colleagues who had countless helpful suggestions concerning the study and manuscript. This work was supported in part by National Institutes of Health General Clinical Research Center [M01 RR00058] and grants from National Academy of Neuropsychology, Green Bay Packer Foundation, Herbert Kohl Foundation, National Federation of State High School Associations, Milwaukee Bucks, Waukesha Memorial Hospital Foundation, Waukesha Charities Service Organization, NFL Charities, Medical College of Wisconsin, National Operating Committee on Standards for Athletic Equipment and Michael Emme. The senior author receives income from personal injury medicolegal work, approximately 50% of which is done on behalf of the plaintiff and the same for the defense, and royalties from test publication-the test was not used in this study. The remaining authors have no conflicts of interest or relevant disclosures.	Arrington CM, 2000, J COGNITIVE NEUROSCI, V12, P106, DOI 10.1162/089892900563975; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Corbetta M, 2011, ANNU REV NEUROSCI, V34, P569, DOI 10.1146/annurev-neuro-061010-113731; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Heilman KM, 2012, CLIN NEUROPSYCHOLOGY; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kelly JP, 1997, NEUROLOGY, V48, P581; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; Mesulam M., 2000, PRINCIPLES BEHAV COG; Narayanan NS, 2005, NEUROPSYCHOLOGY, V19, P223, DOI 10.1037/0894-4105.19.2.223; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Sadek Joseph R, 2002, CNS Spectr, V7, P286; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652	31	30	31	0	49	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2013	19	8					863	872		10.1017/S1355617713000702			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	209AQ	WOS:000323725800003	23829951				2021-06-18	
J	Kinnaman, KA; Mannix, RC; Comstock, RD; Meehan, WP				Kinnaman, Karen A.; Mannix, Rebekah C.; Comstock, R. Dawn; Meehan, William P., III			Management strategies and medication use for treating paediatric patients with concussions	ACTA PAEDIATRICA			English	Article						Concussion; Medication management; Paediatric patient	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION; SPORT; PHYSICIANS; KNOWLEDGE; PROVIDERS; MEDICINE	Aim: To assess management strategies for paediatric patients suffering from concussions. Methods: A 17-item questionnaire was distributed to 1305 section members of the American Academy of Pediatrics Sections on Adolescent Health, Sports Medicine and Fitness, Community Pediatrics and School Health. The use of medications, neuropsychological testing, neuroimaging and published guidelines in concussion management was queried. Results: Two hundred and twenty respondents (17%) completed the questionnaire, of which 64% had been an attending for greater than 10 years. A majority of respondents (92%) managed patients with concussions, with 26% treating more than 24 patients per year. Most paediatricians (84%) reported using a published guideline. The majority of respondents (89%) manage the symptoms of concussed patients with medications, most commonly acetaminophen (62%) or nonsteroidal anti-inflammatory medications (54%). The use of prescriptions medications such as tricyclic antidepressants (23%), amantadine (10%) and methylphenidate (8%) was also commonly reported. Paediatricians treating > 16 patients per year with concussion were more likely to prescribe tricyclic antidepressants, stimulants and agents used for sleep disturbance. Conclusion: Paediatricians nationwide routinely use medications when managing patients with concussions. The pharmacological agents used differ according to number of patients treated per year. In addition, most paediatricians use published guidelines in concussion management.	[Kinnaman, Karen A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Kinnaman, Karen A.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Mannix, Rebekah C.; Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah C.] Harvard Univ, Sch Med, Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Comstock, R. Dawn] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Meehan, William P., III] Harvard Univ, Sch Med, Div Sports Med, Boston Childrens Hosp, Boston, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Sports Concuss Clin, Boston Childrens Hosp, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury & Prevent, Waltham, MA USA	Kinnaman, KA (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St,Neville House 2nd Floor, Boston, MA 02115 USA.	kkinnaman@partners.org	Mannix, Rebekah/AAD-8702-2020				Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Francisco GE, 2007, BRAIN INJURY, V21, P1007, DOI 10.1080/02699050701559558; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Giebel S, 2011, J EMERG MED, V41, P649, DOI 10.1016/j.jemermed.2011.03.021; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCarthy Mark, 2010, Conn Med, V74, P485; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Reddy CC, 2012, J HEAD; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Williams SE, 2007, BRAIN INJURY, V21, P885, DOI 10.1080/02699050701553213; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	22	30	30	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	SEP	2013	102	9					E424	E428		10.1111/apa.12315			5	Pediatrics	Pediatrics	193YV	WOS:000322598300010	23750873				2021-06-18	
J	Rochat, L; Beni, C; Annoni, JM; Vuadens, P; Van der Linden, M				Rochat, Lucien; Beni, Catia; Annoni, Jean-Marie; Vuadens, Philippe; Van der Linden, Martial			How Inhibition Relates to Impulsivity after Moderate to Severe Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						TBI; Urgency; UPPS Impulsive Behavior Scale; Executive control; Neurobehavioral symptoms; Cognition	LATENT-VARIABLE ANALYSIS; STOP-SIGNAL PARADIGM; RESPONSE-INHIBITION; ALZHEIMERS-DISEASE; TASKS; MODEL	Impulsive behaviors and poor inhibition performances are frequently described in patients with traumatic brain injury (TBI). However, few studies have examined impulsivity and associated inhibition impairments in these patients. Twenty-eight patients with moderate to severe TBI and 27 matched controls performed a stop-signal task designed to assess prepotent response inhibition (the ability to inhibit a dominant or automatic motor response) in a neutral or emotional context and a recent negative task to assess resistance to proactive interference (the ability to resist the intrusion into memory of information that was previously relevant but has since become irrelevant). Informants of each patient completed a short questionnaire designed to assess impulsivity. Patients showed a significant increase in current urgency, lack of premeditation, and lack of perseverance when retrospectively compared with the preinjury condition. Group comparisons revealed poorer prepotent response inhibition and resistance to proactive interference performances in patients with TBI. Finally, correlation analyses revealed a significant positive correlation between urgency (the tendency to act rashly when distressed) and prepotent response inhibition in patients with TBI. This study sheds new light on the construct of impulsivity after a TBI, its related cognitive mechanisms, and its potential role in problematic behaviors described after a TBI.	[Rochat, Lucien; Beni, Catia; Van der Linden, Martial] Univ Geneva, Cognit Psychopathol & Neuropsychol Unit, CH-1205 Geneva, Switzerland; [Rochat, Lucien; Van der Linden, Martial] Univ Geneva, Swiss Ctr Affect Sci, CH-1205 Geneva, Switzerland; [Annoni, Jean-Marie] Univ Hosp Geneva, Neuropsychol Unit, Geneva, Switzerland; [Annoni, Jean-Marie] Univ Fribourg, Neurol Unit, Dept Med, CH-1700 Fribourg, Switzerland; [Vuadens, Philippe] Clin Romande Readaptat, Sion, Switzerland; [Van der Linden, Martial] Univ Liege, Cognit Psychopathol Unit, B-4000 Liege, Belgium	Rochat, L (corresponding author), Univ Geneva, Cognit Psychopathol & Neuropsychol Unit, 40 Blvd Pont dArve, CH-1205 Geneva, Switzerland.	lucien.rochat@unige.ch		Rochat, Lucien/0000-0002-9992-2720	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [325130_138497]	There are no conflicts of interest. This work has not been published previously either electronically or in print. Prof. J.M. Annoni is supported by the Swiss National Science Foundation (Grant #325130_138497). We thank the four reviewers for their helpful comments.	Bechara A, 2005, CURR OPIN NEUROL, V18, P734, DOI 10.1097/01.wco.0000194141.56429.3c; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Billieux J, 2010, BEHAV RES THER, V48, P1085, DOI 10.1016/j.brat.2010.07.008; CONTENT A, 1990, ANN PSYCHOL, V90, P551; Cyders MA, 2008, PSYCHOL BULL, V134, P807, DOI 10.1037/a0013341; Cyders MA, 2013, ASSESSMENT, V20, P86, DOI 10.1177/1073191111428762; Dimoska-Di Marco A, 2011, J CLIN EXP NEUROPSYC, V33, P471, DOI 10.1080/13803395.2010.533158; Duchek JM, 2009, NEUROPSYCHOLOGY, V23, P746, DOI 10.1037/a0016583; Friedman NP, 2004, J EXP PSYCHOL GEN, V133, P101, DOI 10.1037/0096-3445.133.1.101; Gay P, 2008, ACTA PSYCHOL, V129, P332, DOI 10.1016/j.actpsy.2008.08.010; Goeleven E, 2008, COGNITION EMOTION, V22, P1094, DOI 10.1080/02699930701626582; Hamilton AC, 2005, COGN AFFECT BEHAV NE, V5, P1; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Logan Gordon D., 1994, P189; Lundqvist D., 1998, KAROLINSKA DIRECTED; Miller J, 2003, PERS INDIV DIFFER, V34, P1403, DOI 10.1016/S0191-8869(02)00122-8; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Nee DE, 2007, NEUROIMAGE, V38, P740, DOI 10.1016/j.neuroimage.2007.07.066; Pessoa L, 2009, TRENDS COGN SCI, V13, P160, DOI 10.1016/j.tics.2009.01.006; Philippe G, 2010, J RES PERS, V44, P46, DOI 10.1016/j.jrp.2009.10.003; Phillips ML, 2003, BIOL PSYCHIAT, V54, P515, DOI 10.1016/S0006-3223(03)00171-9; Ponsford J., 2013, TRAUMATIC BRAIN INJU; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rochat L, 2008, ALZ DIS ASSOC DIS, V22, P278, DOI 10.1097/WAD.0b013e318166d692; Rochat L, 2013, CORTEX, V49, P90, DOI 10.1016/j.cortex.2011.08.004; Rochat L, 2011, PSYCHOPATHOLOGY, V44, P158, DOI 10.1159/000322454; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Verbruggen F, 2008, TRENDS COGN SCI, V12, P418, DOI 10.1016/j.tics.2008.07.005; Verbruggen F, 2007, COGNITION EMOTION, V21, P391, DOI 10.1080/02699930600625081; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; WICKENS DD, 1963, J VERB LEARN VERB BE, V2, P440, DOI 10.1016/S0022-5371(63)80045-6; Yoon KL, 2009, J ABNORM PSYCHOL, V118, P223, DOI 10.1037/a0014658	34	30	31	0	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2013	19	8					890	898		10.1017/S1355617713000672			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	209AQ	WOS:000323725800006	23816263				2021-06-18	
J	Hirose, T; Shiozaki, T; Shimizu, K; Mouri, T; Noguchi, K; Ohnishi, M; Shimazu, T				Hirose, Tomoya; Shiozaki, Tadahiko; Shimizu, Kentaro; Mouri, Tomoyoshi; Noguchi, Kazuo; Ohnishi, Mitsuo; Shimazu, Takeshi			The effect of electrical muscle stimulation on the prevention of disuse muscle atrophy in patients with consciousness disturbance in the intensive care unit	JOURNAL OF CRITICAL CARE			English	Article						Electrical muscle stimulation (EMS); Disuse muscle atrophy; Consciousness disturbance; Head injury; Sarcopenia	SKELETAL-MUSCLE; SARCOPENIA; STRENGTH; DIETARY; COPD	Purpose: Disuse atrophy of the lower limbs of patients with consciousness disturbance has often been recognized as "an unavoidable consequence," such that the mechanism was not investigated diligently. In this study, we examined the preventive effects of electrical muscle stimulation (EMS) against disuse atrophy of the lower limbs in patients in coma after stroke or traumatic brain injury in the intensive care unit. Materials and Methods: We evaluated changes in cross-sectional area of lower limb muscles weekly with computed tomography in 6 control group patients and 9 EMS group patients. Electrical muscle stimulation was performed daily from day 7 after admission. We evaluated the anterior thigh muscle compartment, posterior thigh muscle compartment, anterior leg muscle compartment, and posterior leg muscle compartment. Results: In the control group, the decrease in cross-sectional area progressed in all compartments every week (P < .0001). Cross-sectional areas of all compartments at day 14 were significantly decreased in the control group compared with those in the EMS group at day 7 (P < .001). We were able to limit the rate of muscle atrophy as measured in the cross-sectional areas to within 4% during the period of EMS (days 7-42) in 5 patients. The difference between the control and the EMS groups was statistically significant (P < .001). Conclusion: Electrical muscle stimulation is effective in the prevention of disuse muscle atrophy in patients with consciousness disorder. (c) 2013 Elsevier Inc. All rights reserved.	[Hirose, Tomoya; Shiozaki, Tadahiko; Shimizu, Kentaro; Mouri, Tomoyoshi; Noguchi, Kazuo; Ohnishi, Mitsuo; Shimazu, Takeshi] Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, Osaka 5650871, Japan	Hirose, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, 2-15 Yamadaoka Suita, Osaka 5650871, Japan.	htomoya1979@hp-emerg.med.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology in JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [24390401]; Marine and Fire Insurance Association of Japan, Inc.; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24390401] Funding Source: KAKEN	This work was supported by a Grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology in Japan (No. 24390401) and a grant from the Marine and Fire Insurance Association of Japan, Inc. The authors declare no conflict of interest. T.H. carried out data analyses and drafted the manuscript. T.S. conceived the study, analyzed the data, and helped to draft the manuscript. K.S. collected and analyzed the data and helped to draft the manuscript. M.O. analyzed the data and helped to draft the manuscript. T.M. and K.N. collected and analyzed the data. T.S. analyzed the data and helped to draft the manuscript. All authors read and approved the final manuscript.	Babault N, 2007, J STRENGTH COND RES, V21, P431; Banerjee P, 2005, J APPL PHYSIOL, V99, P2307, DOI 10.1152/japplphysiol.00891.2004; Bloomfield SA, 1997, MED SCI SPORT EXER, V29, P197, DOI 10.1097/00005768-199702000-00006; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brower Roy G, 2009, Crit Care Med, V37, pS422, DOI 10.1097/CCM.0b013e3181b6e30a; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Dreyer HC, 2006, J PHYSIOL-LONDON, V576, P613, DOI 10.1113/jphysiol.2006.113175; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Muscaritoli M, 2010, CLIN NUTR, V29, P154, DOI 10.1016/j.clnu.2009.12.004; Nuhr MJ, 2004, EUR HEART J, V25, P136, DOI 10.1016/j.ehj.2003.09.027; Paddon-Jones D, 2009, CURR OPIN CLIN NUTR, V12, P86, DOI 10.1097/MCO.0b013e32831cef8b; Vivodtzev I, 2006, CHEST, V129, P1540, DOI 10.1378/chest.129.6.1540; Waters DL, 2010, CLIN INTERV AGING, V5, P259, DOI 10.2147/CIA.S6920; Witham MD, 2008, AGE AGEING, V37, P363, DOI 10.1093/ageing/afn124; Zanotti E, 2003, CHEST, V124, P292, DOI 10.1378/chest.124.1.292	16	30	33	0	20	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441			J CRIT CARE	J. Crit. Care	AUG	2013	28	4							536.e1	10.1016/j.jcrc.2013.02.010			7	Critical Care Medicine	General & Internal Medicine	181UQ	WOS:000321694900043	23561945				2021-06-18	
J	Labombarda, F; Ghoumari, AT; Liere, P; De Nicola, AE; Schumacher, M; Guennoun, R				Labombarda, Florencia; Ghoumari, Abdel Tvloumen; Liere, Philippe; De Nicola, Alejandro E.; Schumacher, Michael; Guennoun, Rachida			Neuroprotection by steroids after neurotrauma in organotypic spinal cord cultures: A key role for progesterone receptors and steroidal modulators of GABA(A) receptors	NEUROPHARMACOLOGY			English	Article						Progesterone; Allopregnanolone; Progesterone receptor; GABA(A) receptors; Organotypic slice cultures; Spinal cord	MYELIN BASIC-PROTEIN; NEUROACTIVE STEROIDS; COGNITIVE DEFICITS; SLICE CULTURES; CELL-DEATH; ALLOPREGNANOLONE; NEUROSTEROIDS; EXPRESSION; INJURY; NEUROPATHY	Progesterone is neuroprotective after spinal cord injury, however its mechanism of action remains unexplored. Here we used organotypic spinal cord slice cultures from 3 weeks-old mice to evaluate the mechanisms of neuroprotection by progesterone and its 5 alpha-reduced metabolites. In vitro spinal cord injury, using a weight drop model, induced a decrease in the number of motoneurons. This was correlated with an increase in the number of dying cells (PI+ cells) and in LDH release. Addition of 10 mu M of progesterone, 5 alpha-dihydroprogesterone (5 alpha-DHP) or allopregnanolone (3 alpha, 5 alpha-tetrahydroprogesterone) to the medium at the time of injury rescued the spinal cord slices from the effects of damage. Progesterone prevented membrane cell damage, motoneuron loss and cell death. These effects were not due to its bioconversion to 5 alpha-DHP nor to allopregnanolone, as supported by the finasteride, an inhibitor of 5 alpha-reductase enzymes, and by the absence of 5 alpha-reduced progesterone metabolites in the slices analyzed by gas chromatography mass spectrometry. The neuroprotective effects of progesterone required PR as they could not be observed in slices from homozygous knockout PR-/- mice. Allopregnanolone treatment was also neuroprotective. Its effects were not due to its bioconversion back to 5 alpha-DHP, which can activate gene transcription via PR, because they were still observed in slices from knockout PR-/- mice. Allopregnanolone effects involved GABA(A) receptors, as they were inhibited by the selective GABA(A) receptor antagonist Gabazine, in both PR+/+ and PR-/- mice. Altogether, these findings identify both PR and GABA(A) receptors as important targets for neuroprotection by progestagens after spinal cord injury. (C) 2013 Elsevier Ltd. All rights reserved.	[Labombarda, Florencia; Ghoumari, Abdel Tvloumen; Liere, Philippe; Schumacher, Michael; Guennoun, Rachida] INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; [Labombarda, Florencia; Ghoumari, Abdel Tvloumen; Liere, Philippe; Schumacher, Michael; Guennoun, Rachida] Univ Paris 11, F-94276 Le Kremlin Bicetre, France; [Labombarda, Florencia; De Nicola, Alejandro E.] Univ Buenos Aires, Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1053 Buenos Aires, DF, Argentina; [Labombarda, Florencia; De Nicola, Alejandro E.] Univ Buenos Aires, Dept Human Biochem, RA-1053 Buenos Aires, DF, Argentina	Guennoun, R (corresponding author), INSERM, UMR 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	flabo@dna.uba.ar; abdel.ghoumari@inserm.fr; philippe.liere@inserm.fr; alejandrodenicola@gmail.com; michael.schumacher@inserm.fr; rachida.guennoun@inserm.fr	Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371	AFMAssociation Francaise contre les Myopathies [RAE06031LLA]; Government of France (INSERM/CONICET); Government of Argentina (INSERM/CONICET); INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission; "la Fondation pour la Recherche Medicale" (FRM)Fondation pour la Recherche Medicale	This work was partly supported by funds from AFM (RAE06031LLA) and a cooperative program between the Governments of France and Argentina (INSERM/CONICET). F.L. was supported by INSERM and by a post-doctoral research fellowship from "la Fondation pour la Recherche Medicale" (FRM). We are grateful to Dr J. Lydon for providing heterozygous breeder pairs of PRlacz mice to establish the colony in our animal facility. We thank the excellent technical assistance of B. Delespierre for mice genotyping; and B. Eychenne, A. Pianos and A. Cambourg for steroid measurements by GC/MS.	Abe K, 2000, NEUROSCI RES, V38, P325, DOI 10.1016/S0168-0102(00)00188-7; Ardeshiri A, 2006, EUR J NEUROSCI, V24, P2567, DOI 10.1111/j.1460-9568.2006.05142.x; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; BURKE RE, 1977, J NEUROPHYSIOL, V40, P667; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Diaz Brinton R., 2011, HORMONES NEURODEGENE, P287; Dingledine R, 1999, PHARMACOL REV, V51, P7; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibson CL, 2009, NEUROSCIENTIST, V15, P324, DOI 10.1177/1073858409333069; Goletiani NV, 2007, EXP CLIN PSYCHOPHARM, V15, P427, DOI 10.1037/1064-1297.15.5.427; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Gwak YS, 2011, CURR PAIN HEADACHE R, V15, P215, DOI 10.1007/s11916-011-0186-2; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Ishihara Y, 2013, J STEROID BIOCHEM, V135, P1, DOI 10.1016/j.jsbmb.2012.12.013; Ismail PM, 2002, MOL ENDOCRINOL, V16, P2475, DOI 10.1210/me.2002-0169; Keller AF, 2004, J NEUROSCI, V24, P907, DOI 10.1523/JNEUROSCI.4642-03.2004; KERKUT GA, 1995, PROG NEUROBIOL, V46, P1, DOI 10.1016/0301-0082(94)00055-M; Krassioukov AV, 2002, BRAIN RES PROTOC, V10, P60, DOI 10.1016/S1385-299X(02)00180-0; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Liere P, 2000, J CHROMATOGR B, V739, P301, DOI 10.1016/S0378-4347(99)00563-0; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034; Mehta AK, 1999, BRAIN RES REV, V29, P196, DOI 10.1016/S0165-0173(98)00052-6; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Melcangi RC, 2006, J MOL NEUROSCI, V28, P1, DOI 10.1385/JMN:28:1:1; Melcangi RC, 2010, HORM BEHAV, V57, P2, DOI 10.1016/j.yhbeh.2009.06.001; Patte-Mensah C, 2006, J MOL NEUROSCI, V28, P17, DOI 10.1385/JMN:28:1:17; Patte-Mensah C, 2008, BRAIN RES REV, V57, P454, DOI 10.1016/j.brainresrev.2007.05.007; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rupprecht R, 1996, EUR J PHARMACOL, V303, P227, DOI 10.1016/0014-2999(96)00036-2; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Singh C, 2012, NEUROBIOL AGING, V33, P1493, DOI 10.1016/j.neurobiolaging.2011.06.008; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; STEINER TJ, 1972, J PHYSIOL-LONDON, V222, pP123; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Ueno S, 1997, J NEUROSCI, V17, P625; Vos CMP, 2000, EXP NEUROL, V163, P324, DOI 10.1006/exnr.2000.7388; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	63	30	33	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	AUG	2013	71						46	55		10.1016/j.neuropharm.2013.03.010			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	164QI	WOS:000320424200006	23542439				2021-06-18	
J	Shandera-Ochsner, AL; Berry, DTR; Harp, JP; Edmundson, M; Graue, LO; Roach, A; High, WM				Shandera-Ochsner, Anne L.; Berry, David T. R.; Harp, Jordan P.; Edmundson, Maryanne; Graue, Lili O.; Roach, Abbey; High, Walter M., Jr.			Neuropsychological Effects of Self-Reported Deployment-Related Mild TBI and Current PTSD in OIF/OEF Veterans	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild TBI; PTSD; Veterans; Concussion; Assessment	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; CONCUSSION SYMPTOMS QUESTIONNAIRE; VIETNAM COMBAT VETERANS; MINOR HEAD-INJURY; PSYCHOMETRIC PROPERTIES; POSTCONCUSSIONAL-SYNDROME; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; PROCESSING SPEED	Current combat veterans are exposed to many incidents that may result in mild traumatic brain injury (mTBI) and/or posttraumatic stress disorder (PTSD). While there is literature on the neuropsychological consequences of PTSD only (PTSD-o) and mTBI alone (mTBI-o), less has been done to explore their combined (mTBI+PTSD) effect. The goal of this study was to determine whether Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) veterans with mTBI+PTSD have poorer cognitive and psychological outcomes than veterans with PTSD-o, mTBI-o, or combat exposure-only. The final sample included 20 OIF/OEF veterans with histories of self-reported deployment mTBI (mTBI-o), 19 with current PTSD (PTSD-o), 21 with PTSD and self-reported mTBI (mTBI+PTSD), and 21 combat controls (CC) (no PTSD and no reported mTBI). Groups were formed using structured interviews for mTBI and PTSD. All participants underwent comprehensive neuropsychological testing, including neurocognitive and psychiatric feigning tests. Results of cognitive tests revealed significant differences in performance in the mTBI+PTSD and PTSD-o groups relative to mTBI-o and CC. Consistent with previous PTSD literature, significant differences were found on executive (switching) tasks, verbal fluency, and verbal memory. Effect sizes tended to be large in both groups with PTSD. Thus, PTSD seems to be an important variable affecting neuropsychological profiles in the post-deployment time period. Consistent with literature on civilian mTBI, the current study did not find evidence that combat-related mTBI in and of itself contributes to objective cognitive impairment in the late stage of injury.	[Shandera-Ochsner, Anne L.; Berry, David T. R.; Harp, Jordan P.; Edmundson, Maryanne] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA; [Graue, Lili O.; Roach, Abbey; High, Walter M., Jr.] Lexington VA Med Ctr, Lexington, KY USA; [High, Walter M., Jr.] Univ Kentucky, Dept Phys Med & Rehabil, Lexington, KY USA	High, WM (corresponding author), Cardinal Hill Rehabil Hosp, 2050 Versailles Rd, Lexington, KY 40504 USA.	walter.high@uky.edu			Health Services Administration of the Department of Veterans Affairs [VA ORD HSRD SDR 08-377]	This material is based upon work supported in part by grant number VA ORD HSR&D SDR 08-377 from the Health Services Administration of the Department of Veterans Affairs. The views expressed in this publication do not represent the views of the Department of Veterans Affairs or the United States Government. The authors gratefully acknowledge Frederick Schmitt, Ph.D., Shonna Jenkins, M.S., Randal Schleenbaker, M.D., and Ian Abney for their valuable insight and assistance with this project. This manuscript is based on a dissertation submitted by Anne L. Shandera-Ochsner in partial fulfillment of the requirements for a doctoral degree in clinical psychology at the University of Kentucky. David T.R. Berry holds the copyright to the Letter Memory Test. All proceeds from the Letter Memory Test are donated to the Harris Psychological Services Center at the University of Kentucky	Barrett DH, 1996, AM J PSYCHIAT, V153, P1492; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Beckham JC, 1998, J TRAUMA STRESS, V11, P811, DOI 10.1023/A:1024409903617; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Brady KT, 1997, J CLIN PSYCHIAT, V58, P12; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Breslau N, 2006, ARCH GEN PSYCHIAT, V63, P1238, DOI 10.1001/archpsyc.63.11.1238; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CLIFF N, 1993, PSYCHOL BULL, V114, P494, DOI 10.1037/0033-2909.114.3.494; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Conners C., 2000, CONNERS CONTINUOUS P; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Geuze E, 2009, DEPRESS ANXIETY, V26, P7, DOI 10.1002/da.20476; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Hart J, 2008, J NEUROPSYCH CLIN N, V20, P309, DOI 10.1176/appi.neuropsych.20.3.309; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Herman D., 1993, ANN CONV INT SOC TRA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; Jenkins MA, 2000, CLIN NEUROPSYCHOL, V14, P7, DOI 10.1076/1385-4046(200002)14:1;1-8;FT007; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; MCNALLY RJ, 1995, AM J PSYCHIAT, V152, P936; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Miller H.A., 2000, DEV MILLERS FORENSIC; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Morel KR, 1998, J PERS ASSESS, V70, P299, DOI 10.1207/s15327752jpa7002_8; Myers JL., 2003, RES DESIGN STAT ANAL; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Polusny MA, 2011, PSYCHOL MED, V41, P687, DOI 10.1017/S0033291710002047; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Psychological Corporation, 2001, WECHSL TEST AD READ; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vargha A, 2000, J EDUC BEHAV STAT, V25, P101, DOI 10.2307/1165329; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Walter KH, 2010, J TRAUMA STRESS, V23, P292, DOI 10.1002/jts.20506; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed	73	30	30	0	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG 1	2013	27	6					881	907		10.1080/13854046.2013.802017			27	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	197RA	WOS:000322867100001	23755991				2021-06-18	
J	Cheadle, GA; Costantini, TW; Lopez, N; Bansal, V; Eliceiri, BP; Coimbra, R				Cheadle, Gerald A.; Costantini, Todd W.; Lopez, Nicole; Bansal, Vishal; Eliceiri, Brian P.; Coimbra, Raul			Enteric Glia Cells Attenuate Cytomix-Induced Intestinal Epithelial Barrier Breakdown	PLOS ONE			English	Article							NERVE-STIMULATION PROTECTS; TIGHT JUNCTION STRUCTURE; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; S-NITROSYLATION; BURN-INJURY; PERMEABILITY; GUT; KINASE; ACTIVATION	Background: Intestinal barrier failure may lead to systemic inflammation and distant organ injury in patients following severe injury. Enteric glia cells (EGCs) have been shown to play an important role in maintaining gut barrier integrity through secretion of S-Nitrosoglutathione (GSNO). We have recently shown than Vagal Nerve Stimulation (VNS) increases EGC activation, which was associated with improved gut barrier integrity. Thus, we sought to further study the mechanism by which EGCs prevent intestinal barrier breakdown utilizing an in vitro model. We postulated that EGCs, through the secretion of GSNO, would improve intestinal barrier function through improved expression and localization of intestinal tight junction proteins. Methods: Epithelial cells were co-cultured with EGCs or incubated with GSNO and exposed to Cytomix (TNF-alpha, INF-gamma, IL-1 beta) for 24 hours. Barrier function was assessed by permeability to 4kDa FITC-Dextran. Changes in tight junction proteins ZO-1, occludin, and phospho-MLC (P-MLC) were assessed by immunohistochemistry and immunoblot. Key Results: Co-culture of Cytomix-stimulated epithelial monolayers with EGCs prevented increases in permeability and improved expression and localization of occludin, ZO-1, and P-MLC. Further, treatment of epithelial monolayers with GSNO also prevented Cytomix-induced increases in permeability and exhibited a similar improvement in expression and localization of occludin, ZO-1, and P-MLC. Conclusions & Inferences: The addition of EGCs, or their secreted mediator GSNO, prevents epithelial barrier failure after injury and improved expression of tight junction proteins. Thus, therapies that increase EGC activation, such as VNS, may be a novel strategy to limit barrier failure in patients following severe injury.	[Cheadle, Gerald A.; Costantini, Todd W.; Lopez, Nicole; Bansal, Vishal; Eliceiri, Brian P.; Coimbra, Raul] Univ Calif San Diego Hlth Sci, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA USA	Coimbra, R (corresponding author), Univ Calif San Diego Hlth Sci, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Eliceiri, Brian/0000-0003-1811-1916; Lopez, Nicole/0000-0002-4807-7360; Costantini, Todd/0000-0002-0215-5327	American Association for the Surgery of Trauma (AAST) Research and Education Foundation Scholarship	This work was supported by the American Association for the Surgery of Trauma (AAST) Research and Education Foundation Scholarship (TWC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Sadi R, 2008, J IMMUNOL, V180, P5653, DOI 10.4049/jimmunol.180.8.5653; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Boivin MA, 2007, AM J PHYSIOL-GASTR L, V292, pG590, DOI 10.1152/ajpgi.00252.2006; Borovikova LV, 2000, NATURE, V405, P458; Chavez AM, 1999, CRIT CARE MED, V27, P2246, DOI 10.1097/00003246-199910000-00030; Conlin VS, 2009, AM J PHYSIOL-GASTR L, V297, pG735, DOI 10.1152/ajpgi.90551.2008; Costantini TW, 2012, AM J PATHOL, V181, P478, DOI 10.1016/j.ajpath.2012.04.005; Costantini TW, 2010, AM J PHYSIOL-GASTR L, V299, pG1308, DOI 10.1152/ajpgi.00156.2010; Costantini TW, 2010, J TRAUMA, V68, P1349, DOI 10.1097/TA.0b013e3181dccea0; Costantini TW, 2009, J TRAUMA, V67, P1162, DOI 10.1097/TA.0b013e3181ba3577; Costantini TW, 2009, SHOCK, V31, P416, DOI 10.1097/SHK.0b013e3181863080; Costantini TW, 2009, J TRAUMA, V66, P17, DOI 10.1097/TA.0b013e318191bb1f; Costantini TW, 2009, LIFE SCI, V84, P18, DOI 10.1016/j.lfs.2008.10.007; Deitch EA, 2004, CRIT CARE MED, V32, P533, DOI 10.1097/01.CCM.0000109773.00644.F4; Flamant M, 2011, GUT, V60, P473, DOI 10.1136/gut.2010.229237; Hollander D, 2003, J Physiol Pharmacol, V54 Suppl 4, P183; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Krzyzaniak M, 2011, J TRAUMA, V70, P1168, DOI 10.1097/TA.0b013e318216f754; Krzyzaniak MJ, 2011, SURGERY, V150, P379, DOI 10.1016/j.surg.2011.06.008; MacEachern SJ, 2011, J PHYSIOL-LONDON, V589, P3333, DOI 10.1113/jphysiol.2011.207902; MADARA JL, 1987, AM J PHYSIOL, V253, pC854; Marshall HE, 2004, P NATL ACAD SCI USA, V101, P8841, DOI 10.1073/pnas.0403034101; Musch MW, 2006, AM J PHYSIOL-GASTR L, V290, pG222, DOI 10.1152/ajpgi.00301.2005; Neunlist M, 2008, J INTERN MED, V263, P577, DOI 10.1111/j.1365-2796.2008.01963.x; Neunlist M, 2007, AM J PHYSIOL-GASTR L, V292, pG231, DOI 10.1152/ajpgi.00276.2005; Neunlist M, 2003, AM J PHYSIOL-GASTR L, V285, pG1028, DOI 10.1152/ajpgi.00066.2003; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Ruhl A, 2004, NEUROGASTROENT MOTIL, V16, P44, DOI 10.1111/j.1743-3150.2004.00474.x; Samonte VA, 2004, CRIT CARE MED, V32, P2267, DOI 10.1097/01.CCM.0000145579.66001.05; Savidge TC, 2007, LAB INVEST, V87, P731, DOI 10.1038/labinvest.3700600; Savidge TC, 2007, GASTROENTEROLOGY, V132, P1344, DOI 10.1053/j.gastro.2007.01.051; Shen L, 2006, J CELL SCI, V119, P2095, DOI 10.1242/jcs.02915; Shiou SR, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.154625; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Van Landeghem L, 2011, AM J PHYSIOL-GASTR L, V300, pG976, DOI 10.1152/ajpgi.00427.2010; Van Landeghem L, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-507; Wang Q, 2008, SHOCK, V29, P531, DOI 10.1097/SHK.0b013e318150737f	40	30	31	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2013	8	7							e69042	10.1371/journal.pone.0069042			11	Multidisciplinary Sciences	Science & Technology - Other Topics	175ZH	WOS:000321271900045	23840906	DOAJ Gold, Green Published			2021-06-18	
J	Zhang, D; Hu, Y; Sun, Q; Zhao, J; Cong, Z; Liu, H; Zhou, M; Li, K; Hang, C				Zhang, D.; Hu, Y.; Sun, Q.; Zhao, J.; Cong, Z.; Liu, H.; Zhou, M.; Li, K.; Hang, C.			INHIBITION OF TRANSFORMING GROWTH FACTOR BETA-ACTIVATED KINASE 1 CONFERS NEUROPROTECTION AFTER TRAUMATIC BRAIN INJURY IN RATS	NEUROSCIENCE			English	Article						TAK1; traumatic brain injury; 5Z-7-oxozeaenol; NF-kappa B; AP-1; inflammation	NF-KAPPA-B; CONTROLLED CORTICAL IMPACT; CEREBRAL-CORTEX; UP-REGULATION; TAK1; EXPRESSION; AP-1; INFLAMMATION; CONTUSION; SUPPRESSION	The transforming growth factor beta-activated kinase 1 (TAK1), a member of the Mitogen-activated protein kinase kinase kinase family, is characterized as a key regulator in inflammatory and apoptosis signaling pathways. The aim of the present study was to evaluate the role of the TAK1 pathway in experimental traumatic brain injury (TBI) in rats. Adult male Sprague Dawley rats were subjected to TBI using a modified Feeney's weight-drop model. The time course showed that a significant increase of TAK1 and p-TAK1 expression in the cortex after TBI. Moreover, TBI induced TAK1 redistribution both in neurons and astrocytes of the lesion boundary zone. The effects of specific inhibition of the TAK1 pathway by 5Z-7-oxozeaenol (OZ, intracerebroventricular injection at 10 min post-trauma) on histopathological and behavioral outcomes in rats were assessed at 24 h post injury. The number of TUNEL-positive stained cells was diminished and neuronal survival and neurological function were improved with OZ treatment. Biochemically, the high dose of OZ significantly reduced the levels of TAK1 and p-TAK1, further decreased nuclear factor-kappa B and activator protein 1 activities and the release of inflammatory cytokines. In addition, we found that both 10 min and 3 h post-trauma OZ therapies could markedly improve neurological function and neuronal survival after long-term survival. These results revealed that the TAK1 pathway is activated after experimental TBI and the inhibitor OZ affords significant neuro- protection and amelioration of neurobehavioral deficits after experimental TBI, suggesting a potential rationale for manipulating this pathway in clinical practice. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Zhang, D.; Hu, Y.; Sun, Q.; Zhao, J.; Cong, Z.; Zhou, M.; Hang, C.] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Li, K.] Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing 210093, Jiangsu, Peoples R China; [Hang, C.] Southern Med Univ Guangzhou, Sch Med, Dept Neurosurg, Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China	Li, K (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	likuanyu@nju.edu.cn; hang_neurosurger-y@163.com	Li, Kuanyu/AAL-2051-2020	Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170]; Nature Science Foundation of the Jiangsu Province, China [BK2010459]	We would like to thank Dr. Zong Zhuang, Jiawei Wang and Lin Zhu for their technical assistance. This study was supported by the National Natural Science Foundation, China (No. 81171170) and the Nature Science Foundation of the Jiangsu Province, China (BK2010459).	Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Bersudsky Y, 1997, J NEURAL TRANSM, V104, P943, DOI 10.1007/BF01285562; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Dai WJ, 1999, STROKE, V30, P2391, DOI 10.1161/01.STR.30.11.2391; Dey N, 2011, VIROLOGY, V418, P93, DOI 10.1016/j.virol.2011.07.007; Hailer NP, 2005, EUR J NEUROSCI, V21, P2347, DOI 10.1111/j.1460-9568.2005.04067.x; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hou DX, 2007, BIOCHEM PHARMACOL, V74, P742, DOI 10.1016/j.bcp.2007.06.006; Kajino-Sakamoto R, 2008, J IMMUNOL, V181, P1143, DOI 10.4049/jimmunol.181.2.1143; Lee AK, 2003, BRIT J PHARMACOL, V139, P11, DOI 10.1038/sj.bjp.0705231; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Ma FY, 2011, AM J PHYSIOL-RENAL, V300, pF1410, DOI 10.1152/ajprenal.00018.2011; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Neubert M, 2011, CELL DEATH DIFFER, V18, P1521, DOI 10.1038/cdd.2011.29; Nijboer CH, 2009, STROKE, V40, P3362, DOI 10.1161/STROKEAHA.109.560250; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Safina A, 2008, ONCOGENE, V27, P1198, DOI 10.1038/sj.onc.1210768; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Serkkola E, 2005, EUR J BIOCHEM, V213, P243; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Wang JW, 2012, BRAIN RES, V1464, P73, DOI 10.1016/j.brainres.2012.05.014; White BJ, 2012, EXP NEUROL, V237, P238, DOI 10.1016/j.expneurol.2012.05.019; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Zhuang Z, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-47; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	43	30	30	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 15	2013	238						209	217		10.1016/j.neuroscience.2013.02.022			9	Neurosciences	Neurosciences & Neurology	141SH	WOS:000318746300019	23485590				2021-06-18	
J	Kaiboriboon, K; Bakaki, PM; Lhatoo, SD; Koroukian, S				Kaiboriboon, Kitti; Bakaki, Paul M.; Lhatoo, Samden D.; Koroukian, Siran			Incidence and prevalence of treated epilepsy among poor health and low-income Americans	NEUROLOGY			English	Article							POPULATION-BASED COHORT; SELF-REPORTED EPILEPSY; NEW-YORK-CITY; LONG-TERM; UNPROVOKED SEIZURES; RISK-FACTOR; ADULTS; COMMUNITY; CARE; ORGANIZATIONS	Objectives: To determine the incidence and prevalence of treated epilepsy in an adult Medicaid population. Methods: We performed a retrospective, dynamic cohort analysis using Ohio Medicaid claims data between 1992 and 2006. Individuals aged 18-64 years were identified as prevalent cases if they had >= 2 claims of epilepsy (ICD-9-CM: 345.xx) or >= 3 claims of convulsion (ICD-9-CM: 780.3 or 780.39) and >= 2 claims of antiepileptic drugs. Incident cases were required to have no epilepsy or convulsion claims for >5 years before epilepsy diagnosis. Subjects were determined as having preexisting disability and/or comorbid conditions, including brain tumor, depression, developmental disorders, migraine, schizophrenia, stroke, and traumatic brain injury, when at least one of these conditions occurred before epilepsy onset. Results: There were 9,056 prevalent cases of treated epilepsy in 1992-2006 and 1,608 incident cases in 1997-2006. The prevalence was 13.2/1,000 (95% confidence interval, 13.0-13.5/1,000). The incidence was 362/100,000 person-years (95% confidence interval, 344-379/100,000 person-years). The incidence and prevalence were significantly higher in men, in older people, in blacks, and in people with preexisting disability and/or comorbid conditions. The most common preexisting conditions in epilepsy subjects were depression, developmental disorders, and stroke, whereas people with brain tumor, traumatic brain injury, and stroke had the higher risk of developing epilepsy. Conclusions: The Medicaid population has a high incidence and prevalence of epilepsy, in an order of magnitude greater than that reported in the US general population. This indigent population carries a disproportionate amount of the epilepsy burden and deserves more attention for its health care needs and support services. Neurology (R) 2013; 80: 1942-1949	[Kaiboriboon, Kitti; Lhatoo, Samden D.] Univ Hosp Case Med Ctr, Dept Neurol, Epilepsy Ctr, Cleveland, OH USA; [Bakaki, Paul M.; Koroukian, Siran] Case Western Reserve Univ, Dept Epidemiol & Biostat, Clin & Translat Sci Collaborat, Populat Hlth & Outcomes Res Core, Cleveland, OH 44106 USA	Kaiboriboon, K (corresponding author), Univ Hosp Case Med Ctr, Dept Neurol, Epilepsy Ctr, Cleveland, OH USA.	Kitti.Kaiboriboon@UHhospitals.org	Lhatoo, Samden/L-7341-2019		Epilepsy Foundation; Case Western Reserve University/Cleveland Clinic CTSA from the National Center for Research Resources (NCRR), a component of the NIH [UL1 RR024989]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024989] Funding Source: NIH RePORTER	K.K. and P. M. B. are supported by the Epilepsy Foundation. This study was also supported in part by the Case Western Reserve University/Cleveland Clinic CTSA grant number UL1 RR024989 from the National Center for Research Resources (NCRR), a component of the NIH and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.	ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Annegers JF, 1999, EPILEPSIA, V40, P502, DOI 10.1111/j.1528-1157.1999.tb00748.x; Banerjee PN, 2009, EPILEPSY RES, V85, P31, DOI 10.1016/j.eplepsyres.2009.03.003; Benn EKT, 2008, EPILEPSIA, V49, P1431, DOI 10.1111/j.1528-1167.2008.01564.x; Chen CC, 2012, EPILEPSIA, V53, P283, DOI 10.1111/j.1528-1167.2011.03332.x; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Edwards T, 2008, LANCET NEUROL, V7, P50, DOI 10.1016/S1474-4422(07)70292-2; Elias R, MEDICAID RESOURCE BO; Ellis ER, MEDICAID ENROLLMENT; Fisher B, 2012, EPILEPSY BEHAV, V24, P488, DOI 10.1016/j.yebeh.2012.06.006; Gibson TB, 2009, MIL MED, V174, P936, DOI 10.7205/MILMED-D-03-7808; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Heaney DC, 2002, BMJ-BRIT MED J, V325, P1013, DOI 10.1136/bmj.325.7371.1013; Hesdorffer DC, 2005, EPILEPSIA, V46, P1297, DOI 10.1111/j.1528-1167.2005.10705.x; Hildebrand J, 2005, NEUROLOGY, V65, P212, DOI 10.1212/01.wnl.0000168903.09277.8f; Holden E Wayne, 2005, Dis Manag, V8, P1, DOI 10.1089/dis.2005.8.1; Holden EW, 2005, EPILEPSIA, V46, P311, DOI 10.1111/j.0013-9580.2005.30604.x; Kaiser Commission on Medicaid and the Uninsured, MED PROGR GLANC; Kelvin EA, 2007, EPILEPSY RES, V77, P141, DOI 10.1016/j.eplepsyres.2007.09.012; Kobau Rosemarie, 2008, Morbidity and Mortality Weekly Report, V57, P1; Kobau R, 2007, EPILEPSIA, V48, P1904, DOI 10.1111/j.1528-1167.2007.01161.x; Kobau Rosemarie, 2012, Morbidity and Mortality Weekly Report, V61, P909; Kroner BL, 2013, EPILEPSY RES, V103, P279, DOI 10.1016/j.eplepsyres.2012.07.005; Lhatoo SD, 2001, ANN NEUROL, V49, P336; Lossius MI, 2005, EPILEPSIA, V46, P1246, DOI 10.1111/j.1528-1167.2005.57904.x; MEIERKORD H, 1991, NEUROLOGY, V41, P1643, DOI 10.1212/WNL.41.10.1643; Ngugi AK, 2011, NEUROLOGY, V77, P1005, DOI 10.1212/WNL.0b013e31822cfc90; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; O'Malley KJ, 2005, HEALTH SERV RES, V40, P1620, DOI 10.1111/j.1475-6773.2005.00444.x; Ottman R, 1996, ANN NEUROL, V39, P442, DOI 10.1002/ana.410390406; Reuber M, 2003, EPILEPSY BEHAV, V4, P205, DOI 10.1016/S1525-5050(03)00104-5; Seiber EE, 2011, MEDICARE MEDICAID RE, V1, pE1; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; Winawer MR, 2010, NEUROLOGY, V74, P1166, DOI 10.1212/WNL.0b013e3181d90065	35	30	30	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	MAY	2013	80	21					1942	1949		10.1212/WNL.0b013e318293e1b4			8	Clinical Neurology	Neurosciences & Neurology	149PJ	WOS:000319332900011	23616158	Green Published			2021-06-18	
J	Teel, EF; Register-Mihalik, JK; Blackburn, JT; Guskiewicz, KM				Teel, Elizabeth F.; Register-Mihalik, Johna K.; Blackburn, J. Troy; Guskiewicz, Kevin M.			Balance and cognitive performance during a dual-task: Preliminary implications for use in concussion assessment	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Concussion; Dual-task; Reliability; Attention; Cognition	SENSORY ORGANIZATION TEST; SPORTS-RELATED CONCUSSION; POSTURAL CONTROL; RELIABILITY; ATTENTION; DEFICITS; FOCUS	Objectives: To determine the reliability and effects of a dual-task paradigm on balance and cognitive function compared to a single-task paradigm. Design: Repeated measures. Methods: Healthy participants (n=23) completed a variation of the Sensory Organization Test and the incongruent Stroop test individually (single-task) and concurrently (dual-task) during two testing sessions. Results: The Sensory Organization Test and incongruent Stroop test had moderate to high reliability (1.00 >ICC2,k >0.60) under the dual-task conditions. Reaction time was significantly longer (t(21) = -2.54, p = 0.019) under the dual-task conditions, while balance scores under one of the four conditions of the Sensory Organization Test (sway floor/fixed wall) were statistically better (t(22) = -3.03, p = 0.006) under the dual-task conditions. However, this difference in balance scores may not be clinically meaningful. Conclusions: These findings illustrate that the Sensory Organization Test and incongruent Stroop task can be reliably incorporated into a dual-task assessment paradigm. The slowed reaction time under the dual-task paradigm indicates that the dual-task provided an additional cost to cognitive function. Dual-task concussion assessment paradigms involving these two tasks are psychometrically appropriate as well as more representative of actual sporting situations. However, more research should be conducted in a concussed population to further validate this claim. (C) 2012 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Teel, Elizabeth F.; Register-Mihalik, Johna K.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27515 USA; [Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, Raleigh, NC USA; [Blackburn, J. Troy] Univ N Carolina, Neuromuscular Res Lab, Dept Exercise & Sport Sci, Chapel Hill, NC USA	Register-Mihalik, JK (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27515 USA.	jmihalik@wakemed.org		Register-Mihalik, Johna/0000-0002-4229-4743; Teel, Elizabeth/0000-0002-2846-5884; Guskiewicz, Kevin/0000-0002-8682-2130			Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Dault MC, 2001, GAIT POSTURE, V14, P248, DOI 10.1016/S0966-6362(01)00130-8; Dickin DC, 2007, CLIN J SPORT MED, V17, P109, DOI 10.1097/JSM.0b013e31803bf647; Dickin DC, 2010, CLIN J SPORT MED, V20, P278, DOI 10.1097/JSM.0b013e3181e8f8b1; Franzen M D, 1987, Arch Clin Neuropsychol, V2, P265, DOI 10.1016/0887-6177(87)90014-X; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hunter MC, 2001, GAIT POSTURE, V13, P41, DOI 10.1016/S0966-6362(00)00089-8; Monsell S, 2003, MEM COGNITION, V31, P327, DOI 10.3758/BF03194391; Neurocom, 1991, EQ SYST DAT INT MAN; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Resch JE, 2011, J ATHL TRAINING, V46, P170, DOI 10.4085/1062-6050-46.2.170; Siegrist M, 1995, PERCEPT MOTOR SKILL, V81, P1295, DOI 10.2466/pms.1995.81.3f.1295; Spierer DK, 2011, J STRENGTH COND RES, V25, P1134, DOI 10.1519/JSC.0b013e3181d09e4c; Strauss GP, 2005, ASSESSMENT, V12, P330, DOI 10.1177/1073191105276375; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003; Wulf G, 1999, RES Q EXERCISE SPORT, V70, P120, DOI 10.1080/02701367.1999.10608029; Wulf G, 2003, Q J EXP PSYCHOL-A, V56, P1191, DOI 10.1080/02724980343000062	22	30	30	0	23	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAY	2013	16	3					190	194		10.1016/j.jsams.2012.09.007			5	Sport Sciences	Sport Sciences	142WH	WOS:000318827800003	23092651				2021-06-18	
J	Dai, SS; Wang, H; Yang, N; An, JH; Li, W; Ning, YL; Zhu, PF; Chen, JF; Zhou, YG				Dai, Shuang-Shuang; Wang, Hao; Yang, Nan; An, Jian-Hong; Li, Wei; Ning, Ya-Lei; Zhu, Pei-Fang; Chen, Jiang-Fan; Zhou, Yuan-Guo			Plasma glutamate-modulated interaction of A(2A)R and mGluR5 on BMDCs aggravates traumatic brain injury-induced acute lung injury	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; CORTICAL IMPACT MODEL; COUPLED RECEPTOR DIMERIZATION; CENTRAL-NERVOUS-SYSTEM; BONE-MARROW-CELLS; INFLAMMATORY RESPONSE; PULMONARY-EDEMA; ADENOSINE A2A; AMINO-ACIDS; HEAD-INJURY	The bone marrow-derived cell (BMDC)-associated inflammatory response plays a key role in the development of acute lung injury (ALI). Activation of adenosine A(2A) receptor (A(2A)R) is generally considered to be antiinflammatory, inhibiting BMDC activities to protect against ALI. However, in the present study, we found that in a mouse model of neurogenic ALI induced by severe traumatic brain injury (TBI), BMDC A(2A)R exerted a proinflammatory effect, aggravating lung damage. This is in contrast to the antiinflammatory effect observed in the mouse oleic acid-induced ALI model (a nonneurogenic ALI model.) Moreover, the A(2A)R agonist CGS21680 aggravated, whereas the antagonist ZM241385 attenuated, the severe TBI-induced lung inflammatory damage in mice. Further investigation of white blood cells isolated from patients or mouse TBI models and of cultured human or mouse neutrophils demonstrated that elevated plasma glutamate after severe TBI induced interaction between A(2A)R and the metabotropic glutamate receptor 5 (mGluR5) to increase phospholipase C-protein kinase C signaling, which mediated the proinflammatory effect of A(2A)R. These results are in striking contrast to the well-known antiinflammatory and protective role of A(2A)R in nonneurogenic ALI and indicate different therapeutic strategies should be used for nonneurogenic and neurogenic ALI treatment when targeting A(2A)R.	[Dai, Shuang-Shuang] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400042, Peoples R China; [Dai, Shuang-Shuang; Yang, Nan; An, Jian-Hong; Li, Wei; Ning, Ya-Lei; Zhu, Pei-Fang; Zhou, Yuan-Guo] Third Mil Med Univ, Ctr Mol Biol, State Key Lab Trauma Burn & Combined Injury, Chongqing 400042, Peoples R China; [Wang, Hao] Third Mil Med Univ, Dept Neurosurg, Inst Surg Res, Chongqing 400042, Peoples R China; [Wang, Hao] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China; [Chen, Jiang-Fan] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA	Zhou, YG (corresponding author), Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400042, Peoples R China.	ygzhou@tmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30900587, 81172817, 31171022]; Natural Science Foundation of Chongqing, ChinaNatural Science Foundation of Chongqing [CSTC2009BB5317]; Science Foundation of Third Military Medical University	This work was supported by grants from the National Natural Science Foundation of China (nos. 30900587, 81172817, and 31171022), the Natural Science Foundation of Chongqing, China (no. CSTC2009BB5317), and the Science Foundation of Third Military Medical University (to S.-S. Dai).	Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8; Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137; Aliprandi A, 2005, J CEREBR BLOOD F MET, V25, P513, DOI 10.1038/sj.jcbfm.9600039; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Azoulay E, 2002, CRIT CARE MED, V30, P781, DOI 10.1097/00003246-200204000-00010; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Baughman RP, 1996, AM J RESP CRIT CARE, V154, P76, DOI 10.1164/ajrccm.154.1.8680703; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Brown RM, 2012, INT J NEUROPSYCHOPH, V15, P995, DOI 10.1017/S146114571100126X; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cheng ZJ, 2003, J BIOL CHEM, V278, P52972, DOI 10.1074/jbc.M310090200; Chung LP, 2009, J CLIN ENDOCR METAB, V94, P3038, DOI 10.1210/jc.2009-0778; Ciruela F, 2001, DRUG DEVELOP RES, V52, P316, DOI 10.1002/ddr.1129; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Dai SS, 2010, J NEUROCHEM, V113, P1536, DOI 10.1111/j.1471-4159.2010.06716.x; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; DETTBARN CL, 1989, HEART LUNG, V18, P583; Donadieu E, 2007, ACTA HISTOCHEM, V109, P177, DOI 10.1016/j.acthis.2007.01.004; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; Ferre S, 2002, P NATL ACAD SCI USA, V99, P11940, DOI 10.1073/pnas.172393799; Fredholm BB, 2007, PROG NEUROBIOL, V83, P263, DOI 10.1016/j.pneurobio.2007.07.005; FULTON RL, 1975, SURG GYNECOL OBSTET, V140, P179; Gill SS, 2001, TOXICOL PATHOL, V29, P208, DOI 10.1080/019262301317052486; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Graham DB, 2007, J CLIN INVEST, V117, P3445, DOI 10.1172/JCI32729; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Hasko G, 2006, CRIT CARE MED, V34, P1119, DOI 10.1097/01.CCM.0000206467.19509.C6; Hawkins RA, 2006, J NUTR, V136, p218S, DOI 10.1093/jn/136.1.218S; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HENSON PM, 1975, J CLIN INVEST, V56, P1053, DOI 10.1172/JCI108152; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Jin W, 2009, EXP BIOL MED, V234, P181, DOI 10.3181/0807-RM-232; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003; Keita M, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-3; Lee WJ, 1998, AM J PHYSIOL-CELL PH, V274, pC1101; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Liu Xiang-Cheng, 2010, Zhonghua Wai Ke Za Zhi, V48, P1050; Liu Xue-Yun, 2010, Shengli Xuebao, V62, P219; MACKERSIE RC, 1983, J TRAUMA, V23, P968, DOI 10.1097/00005373-198311000-00002; Magalhaes MAO, 2007, J LEUKOCYTE BIOL, V82, P559, DOI 10.1189/jlb.0207126; Mascia L, 2008, MINERVA ANESTESIOL, V74, P325; Nakajima T, 2010, J IMMUNOL, V184, P5835, DOI 10.4049/jimmunol.0903238; Nishi A, 2003, P NATL ACAD SCI USA, V100, P1322, DOI 10.1073/pnas.0237126100; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Pacheco R, 2006, J IMMUNOL, V177, P6695, DOI 10.4049/jimmunol.177.10.6695; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Parekh D, 2011, CLIN MED, V11, P615, DOI 10.7861/clinmedicine.11-6-615; Pinto-Duarte A, 2005, J NEUROCHEM, V93, P595, DOI 10.1111/j.1471-4159.2005.03071.x; Qian F, 2012, AM J PHYSIOL-LUNG C, V302, pL866, DOI 10.1152/ajplung.00277.2011; Reutershan J, 2004, CRIT CARE, V8, P453, DOI 10.1186/cc2881; Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Said SI, 1996, P NATL ACAD SCI USA, V93, P4688, DOI 10.1073/pnas.93.10.4688; Schepp CP, 2008, CRIT CARE, V12, DOI 10.1186/cc6990; Schroder H, 2009, NEUROPHARMACOLOGY, V56, P768, DOI 10.1016/j.neuropharm.2008.12.010; Sharma AK, 2010, J THORAC CARDIOV SUR, V139, P474, DOI 10.1016/j.jtcvs.2009.08.033; Shen L, 2007, ACTA PHARMACOL SIN, V28, P392, DOI 10.1111/j.1745-7254.2007.00511.x; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7; Xu T, 2006, AM J RESP CRIT CARE, V174, P1011, DOI 10.1164/rccm.200511-1751OC; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103; Zlotnik A, 2010, ANESTH ANALG, V111, P1497, DOI 10.1213/ANE.0b013e3181fc0112	73	30	34	0	32	ROCKEFELLER UNIV PRESS	NEW YORK	950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA	0022-1007	1540-9538		J EXP MED	J. Exp. Med.	APR 8	2013	210	4					839	851		10.1084/jem.20122196			13	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	121ZP	WOS:000317284900016	23478188	Green Published, Other Gold			2021-06-18	
J	Leonardi, M; Sattin, D; Raggi, A				Leonardi, Matilde; Sattin, Davide; Raggi, Alberto		Italian Natl Consortium Functionin	An Italian population study on 600 persons in vegetative state and minimally conscious state	BRAIN INJURY			English	Article						Vegetative state; minimally conscious state; anatomical therapeutic chemical classification system; pain; children	TRAUMATIC BRAIN-INJURY; PLACEBO-CONTROLLED TRIAL; LIFE EXPECTANCY; CLINICAL CHARACTERISTICS; RECOVERY; CHILDREN; OUTCOMES; COMA; REHABILITATION; PREVALENCE	Objective: To describes socio-demographic and clinical features of adults and children in vegetative state (VS) and minimally conscious state (MCS). Design: Observational cross-sectional study. Methods: Demographic, aetiological and clinical data were collected, together with patients' management procedures. Mann-Whitney U-test was used for continuous variables and chi-squared test for categorical variables. Results: Six hundred patients (69.7% in VS; 6% children) were enrolled. No difference regarding age at enrolment, age at acute event and disease duration was observed between VS and MCS. Disease duration was superior to 10 years for 3.3% of the whole sample and 64.3-77% of cases had a non-traumatic aetiology. Mean number of drugs per adult patient was four and decreased consistently with increased disease duration. Discussion: Patients with VS and MCS were similar for age at acute event and at enrolment, both over 50 years, as well as for the frequency of non-traumatic aetiology. Disease duration was similar for both conditions and 2.6% of VS and 4.8% of MCS patients survived for more than 10 years. Finally care and treatment needs are similar and not related to diagnosis.	[Leonardi, Matilde; Sattin, Davide; Raggi, Alberto; Italian Natl Consortium Functionin] Neurol Inst C Besta IRCCS Fdn, Neurol Publ Hlth & Disabil Unit, I-20133 Milan, Italy	Leonardi, M (corresponding author), Neurol Inst C Besta IRCCS Fdn, Neurol Publ Hlth & Disabil Unit, Via Celoria 11, I-20133 Milan, Italy.	leonardi@istituto-besta.it	Raggi, Alberto/K-5787-2016; Sattin, Davide/K-5963-2016; leonardi, matilde/J-9997-2018; Sattin, Davide/AAX-4083-2020	Raggi, Alberto/0000-0002-7433-7779; Sattin, Davide/0000-0001-7736-4337; leonardi, matilde/0000-0003-0552-8923; Sattin, Davide/0000-0001-7736-4337	Italian Centre for Disease Control and Prevention (Centro Nazionale per la Prevenzione ed il Controllo delle Malattie - 2009), Ministry of Health, Italy	The authors report no conflicts of interest. The study was supported by a Grant of the Italian Centre for Disease Control and Prevention (Centro Nazionale per la Prevenzione ed il Controllo delle Malattie - 2009), Ministry of Health, Italy.	[Anonymous], 2003, Clin Med (Lond), V3, P249; Ashford S, 2000, Physiother Res Int, V5, P202, DOI 10.1002/pri.199; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Ashwal S, 2005, NEUROPSYCHOL REHABIL, V15, P190, DOI 10.1080/09602010443000281; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Avesani R, 2006, BRAIN INJURY, V20, P333, DOI 10.1080/02699050500487605; Beaumont JG, 2005, NEUROPSYCHOL REHABIL, V15, P184, DOI 10.1080/09602010443000489; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Demertzi A, 2009, PROG BRAIN RES, V177, P329, DOI 10.1016/S0079-6123(09)17722-1; Di Carlo A, 2003, CEREBROVASC DIS, V16, P141, DOI 10.1159/000070594; DUBROJA I, 1995, J NEUROL NEUROSUR PS, V58, P465, DOI 10.1136/jnnp.58.4.465; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Fantini MP, 2010, BRAIN INJURY, V24, P620, DOI 10.3109/02699051003652831; Fins JJ, 2007, ARCH NEUROL-CHICAGO, V64, P1400, DOI 10.1001/archneur.64.10.1400; Georgiopoulos M, 2010, STEREOT FUNCT NEUROS, V88, P199, DOI 10.1159/000314354; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2005, PROG BRAIN RES, V150, P381, DOI 10.1016/S0079-6123(05)50027-X; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; International Organization for Standardization, 2002, TECHN AIDS PERS DIS; Jennett B, 2002, J NEUROL NEUROSUR PS, V73, P355, DOI 10.1136/jnnp.73.4.355; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kassubek J, 2003, J NEUROL SCI, V212, P85, DOI 10.1016/S0022-510X(03)00106-0; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Krimchansky BZ, 1999, BRAIN INJURY, V13, P899; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2009, PROG BRAIN RES, V177, pXIII, DOI 10.1016/S0079-6123(09)17736-1; Leong B, 2002, BRAIN INJURY, V16, P169, DOI 10.1080/02699050110103292; Leong B, 2002, BRAIN INJURY, V16, P217, DOI 10.1080/02699050110103283; Lin LC, 2008, J CLIN NURS, V17, P861, DOI 10.1111/j.1365-2702.2006.01883.x; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Machado C, 2011, CAN J NEUROL SCI, V38, P341, DOI 10.1017/S0317167100011562; McMahon MA, 2009, AM J PHYS MED REHAB, V88, P525, DOI 10.1097/PHM.0b013e3181a5ade3; Ministry of Health of Italy, 2009, REP TECHN SCI COMM V; MULLER U, 1994, PROG NEURO-PSYCHOPH, V18, P1103, DOI 10.1016/0278-5846(94)90114-7; Ng YS, 2005, NEUROREHABILITATION, V20, P97; O'Neil-Pirozzi TM, 2003, BRAIN INJURY, V17, P389, DOI 10.1080/0269905031000070251; Oliveira L, 2011, BRAIN INJURY, V25, P315, DOI 10.3109/02699052.2011.556103; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Pistoia F, 2010, CNS DRUGS, V24, P625, DOI 10.2165/11535940-000000000-00000; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; Sacco S, 2011, BRAIN INJURY, V25, P488, DOI 10.3109/02699052.2011.558043; Saout V., 2010, Annals of Physical and Rehabilitation Medicine, V53, P96, DOI 10.1016/j.rehab.2010.01.002; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Schnakers C, 2012, AAPS J, V14, P437, DOI 10.1208/s12248-012-9346-5; Schnakers C, 2000, CURRENT OPINION NEUR, V20, P620; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Snyman N, 2010, NEUROPEDIATRICS, V41, P223, DOI 10.1055/s-0030-1269893; Stepan C, 2004, EUR J NEUROL, V11, P461, DOI 10.1111/j.1468-1331.2004.00817.x; Stocchetti N, 2010, MINERVA ANESTESIOL, V76, P1052; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 2000, PEDIATR NEUROL, V23, P312, DOI 10.1016/S0887-8994(00)00194-6; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tan M, 2011, BRIT J NEUROSURG, V25, P2, DOI 10.3109/02688697.2010.522745; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Weeks DL, 2011, ARCH PHYS MED REHAB, V92, P683, DOI 10.1016/j.apmr.2010.12.026; *WHO, 2002, INT CLASS DIS 9 REV; WHO Collaborating Centre for Drug Statistics Methodology, 2012, AN THER CHEM ATC CLA; Wilson FC, 2002, NEUROREHABILITATION, V17, P231; Wittenberg GF, 2009, DEV MED CHILD NEUROL, V51, P130, DOI 10.1111/j.1469-8749.2009.03425.x	68	30	32	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2013	27	4					473	484		10.3109/02699052.2012.750758			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	117LG	WOS:000316954300012	23472633				2021-06-18	
J	Siopi, E; Llufriu-Daben, G; Cho, AH; Vidal-Lletjos, S; Plotkine, M; Marchand-Leroux, C; Jafarian-Tehranr, M				Siopi, Eleni; Llufriu-Daben, Gemma; Cho, Angelo H.; Vidal-Lletjos, Sandra; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehranr, Mehrnaz			Etazolate, an alpha-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice	NEUROPHARMACOLOGY			English	Article						Traumatic brain injury; sAPP alpha; Etazolate; Neuroprotection; Neuroinflammation; Functional outcome	AMYLOID-PRECURSOR-PROTEIN; SPINAL-CORD-INJURY; LONG-TERM POTENTIATION; CLOSED-HEAD INJURY; MOUSE MODEL; COGNITIVE IMPAIRMENT; HIPPOCAMPAL-NEURONS; SAPP-ALPHA; CLINICAL NEUROPSYCHOLOGY; OLFACTORY DYSFUNCTION	Traumatic brain injury (TBI) evokes an intense neuroinflammatory reaction that is essentially mediated by activated microglia and that has been reported to act as a secondary injury mechanism that further promotes neuronal death. It involves the excessive production of inflammatory cytokines and the diminution of neuroprotective and neurotrophic factors, such as the soluble form alpha of the amyloid precursor protein (sAPP alpha), generated by the activity of alpha-secretases. Hence, the aim of this study was to examine the effects of etazolate, an alpha-secretase activator, on acute and belated post-TBI consequences. The mouse model of TBI by mechanical percussion was used and injured mice received either the vehicle or etazolate at the dose of 1, 3 or 10 mg/kg at 2 h post-TBI. Neurological score, cerebral edema, IL-1 beta and sAPP alpha levels, microglial activation and lesion size were evaluated from 6 to 24 h post-TBI. Spontaneous locomotor activity was evaluated from 48 h to 12 weeks post-TBI, memory function at 5 weeks and olfactory bulb lesions at 13 weeks post-TBI. A single administration of etazolate exerted a dose-dependent anti-inflammatory and anti-oedematous effect accompanied by lasting memory improvement, reduction of locomotor hyperactivity and olfactory bulb tissue protection, with a therapeutic window of at least 2 h. These effects were associated with the restoration of the levels of the sAPP alpha protein post-TBI. Taken together, these results highlight for the first time the therapeutic interest of an alpha-secretase activator in TBI. (C) 2012 Elsevier Ltd. All rights reserved.	[Siopi, Eleni; Llufriu-Daben, Gemma; Cho, Angelo H.; Vidal-Lletjos, Sandra; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehranr, Mehrnaz] Univ Paris 05, Lab Pharmacol Circulat Cerebrale EA 4475, Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, F-75006 Paris, France	Jafarian-Tehranr, M (corresponding author), Univ Paris 05, CNRS UMR 8194, Sorbonne Paris Cite, UFR Biomed, 45 Rue St Peres, F-75006 Paris, France.	mehrnaz.jafarian@parisdescartes.fr	MARCHAND-LEROUX, Catherine/L-7453-2017; Vidal-Lletjos, Sandra/AAC-7312-2020	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Vidal-Lletjos, Sandra/0000-0003-0629-9165; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856	Fondation des Gueules cassees	We would like to thank the non-profitable organisation "Fondation des Gueules cassees" for financially supporting this work (grants to ES and MJT).	Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; Anderson JJ, 1999, NEUROSCIENCE, V93, P1409, DOI 10.1016/S0306-4522(99)00244-4; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Avramovich Y, 2002, J BIOL CHEM, V277, P31466, DOI 10.1074/jbc.M201308200; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; BARNES DM, 1983, J NEUROSCI, V3, P762; Bell KFS, 2008, NEUROBIOL AGING, V29, P554, DOI 10.1016/j.neurobiolaging.2006.11.004; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Corrigan F, 2012, NEUROSCI LETT, V515, P50, DOI 10.1016/j.neulet.2012.03.017; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Doty RL, 2001, ANNU REV PSYCHOL, V52, P423, DOI 10.1146/annurev.psych.52.1.423; Drott J, 2010, EUR J PHARMACOL, V634, P95, DOI 10.1016/j.ejphar.2010.02.036; Emilien G, 1996, ACTA NEUROL BELG, V96, P89; Fortin A, 2010, BRAIN INJURY, V24, P27, DOI 10.3109/02699050903446815; Frierl M.A., 2009, NAT PROTOC, V4, P1328; Fujii M, 2002, AURIS NASUS LARYNX, V29, P35, DOI 10.1016/S0385-8146(01)00118-3; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Girgis H., BRAIN RES IN PRESS; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hannila SS, 2008, EXP NEUROL, V209, P321, DOI 10.1016/j.expneurol.2007.06.020; Haxel BR, 2008, J HEAD TRAUMA REHAB, V23, P407, DOI 10.1097/01.HTR.0000341437.59627.ec; Hein AM, 2010, BRAIN BEHAV IMMUN, V24, P243, DOI 10.1016/j.bbi.2009.10.002; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; Kang HM, 2010, NEUROREPORT, V21, P179, DOI 10.1097/WNR.0b013e328334884c; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kondo K, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-147; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lesne S, 2005, J NEUROSCI, V25, P9367, DOI 10.1523/JNEUROSCI.0849-05.2005; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Marcade M, 2008, J NEUROCHEM, V106, P392, DOI 10.1111/j.1471-4159.2008.05396.x; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Moore AH, 2009, NEUROSCIENCE, V164, P1484, DOI 10.1016/j.neuroscience.2009.08.073; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; Mucignat-Caretta C, 2006, PHYSIOL BEHAV, V89, P637, DOI 10.1016/j.physbeh.2006.08.003; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Ohsawa I, 1997, BIOCHEM BIOPH RES CO, V236, P59, DOI 10.1006/bbrc.1997.6903; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Taylor CJ, 2008, NEUROBIOL DIS, V31, P250, DOI 10.1016/j.nbd.2008.04.011; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Treiber C, 2004, J BIOL CHEM, V279, P51958, DOI 10.1074/jbc.M407410200; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vellas B, 2011, CURR ALZHEIMER RES, V8, P203, DOI 10.2174/156720511795256053; Viggiano D, 2008, BEHAV BRAIN RES, V194, P1, DOI 10.1016/j.bbr.2008.06.033; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang P, 1997, BIOCHEM BIOPH RES CO, V234, P320, DOI 10.1006/bbrc.1997.6636; Whitaker CM, 2008, NEUROSCI LETT, V438, P200, DOI 10.1016/j.neulet.2008.03.087; Whiting PJ, 1997, J NEUROSCI, V17, P5027; Wu AP, 2008, AM J RHINOL, V22, P606, DOI 10.2500/ajr.2008.22.3238; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; YAMAMOTO K, 1994, J NEUROBIOL, V25, P585, DOI 10.1002/neu.480250510; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Zueger A, 2005, NEUROSCI LETT, V374, P142, DOI 10.1016/j.neulet.2004.10.040	85	30	33	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2013	67						183	192		10.1016/j.neuropharm.2012.11.009			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	097ME	WOS:000315477400021	23178198				2021-06-18	
J	Sibley, KM; Straus, SE; Inness, EL; Salbach, NM; Jaglal, SB				Sibley, Kathryn M.; Straus, Sharon E.; Inness, Elizabeth L.; Salbach, Nancy M.; Jaglal, Susan B.			Clinical balance assessment: perceptions of commonly-used standardized measures and current practices among physiotherapists in Ontario, Canada	IMPLEMENTATION SCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; PHYSICAL-THERAPISTS; BEHAVIOR-CHANGE; KNOWLEDGE TRANSLATION; OLDER-PEOPLE; STROKE; CONSENSUS; EXERCISE; MOBILITY; FALLS	Background: Balance impairment is common in multiple clinical populations, and comprehensive assessment is important for identifying impairments, planning individualized treatment programs, and evaluating change over time. However, little information is available regarding whether clinicians who treat balance are satisfied with existing assessment tools. In 2010 we conducted a cross-sectional survey of balance assessment practices among physiotherapists in Ontario, Canada, and reported on the use of standardized balance measures (Sibley et al. 2011 Physical Therapy; 91: 1583-91). The purpose of this study was to analyse additional survey data and i) evaluate satisfaction with current balance assessment practices and standardized measures among physiotherapists who treat adult or geriatric populations with balance impairment, and ii) identify factors associated with satisfaction. Methods: The questionnaire was distributed to 1000 practicing physiotherapists. This analysis focuses on questions in which respondents were asked to rate their general perceptions about balance assessment, the perceived utility of individual standardized balance measures, whether they wanted to improve balance assessment practices, and why. Data were summarized with descriptive statistics and utility of individual measures was compared across clinical practice areas (orthopaedic, neurological, geriatric or general rehabilitation). Results: The questionnaire was completed by 369 respondents, of which 43.4% of respondents agreed that existing standardized measures of balance meet their needs. In ratings of individual measures, the Single Leg Stance test and Berg Balance Scale were perceived as useful for clinical decision-making and evaluating change over time by over 70% of respondents, and the Timed Up-and-Go test was perceived as useful for decision-making by 56.9% of respondents and useful for evaluating change over time by 62.9% of respondents, but there were significant differences across practice groups. Seventy-nine percent of respondents wanted to improve their assessments, identifying individual, environmental and measure-specific barriers. The most common barriers were lack of time and knowledge. Conclusions: This study offers new information on issues affecting the evaluation of balance in clinical settings from a broad sample of physiotherapists. Continued work to address barriers by specific practice area will be critical for the success of any intervention attempting to implement optimal balance assessment practices in the clinical setting.	[Sibley, Kathryn M.; Inness, Elizabeth L.; Salbach, Nancy M.; Jaglal, Susan B.] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada; [Sibley, Kathryn M.; Salbach, Nancy M.; Jaglal, Susan B.] Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada; [Straus, Sharon E.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Straus, Sharon E.] Univ Toronto, Fac Med, Toronto, ON, Canada; [Inness, Elizabeth L.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada	Jaglal, SB (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada.	susan.jaglal@utoronto.ca		Inness, Elizabeth L./0000-0002-9217-4619; Jaglal, Susan/0000-0002-2930-1443	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Toronto Rehabilitation Institute-University Health Network; Provincial Rehabilitation Research Program from the Ministry of Health and Long Term Care in Ontario	KMS is supported by a Fellowship from the Canadian Institutes of Health Research and the Toronto Rehabilitation Institute-University Health Network. SBJ holds the Toronto Rehabilitation Institute Chair in Rehabilitation Research at the University of Toronto. SES holds a Canada Research Chair in Knowledge Translation and Quality of Care. We thank the College of Physiotherapists of Ontario for providing the mailing list. We acknowledge the support of the Toronto Rehabilitation Institute-University Health Network who receives funding under the Provincial Rehabilitation Research Program from the Ministry of Health and Long Term Care in Ontario.	An MJ, 2011, J NEUROSCI NURS, V43, P298, DOI 10.1097/JNN.0b013e318234ea24; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BERG K, 1989, Physiotherapy Canada, V41, P304; Birken SA, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-28; Dillman D.A., 2000, MAIL INTERNET SURVEY; Flansbjer UB, 2012, PM&R, V4, P165, DOI 10.1016/j.pmrj.2011.11.004; FREGLY AR, 1968, AEROSPACE MED, V39, P277; French SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-38; Gillespie LD, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD14007146.pub14651853, DOI 10.1002/14651858.CD14007146.PUB14651853]; Graham ID, 2006, J CONTIN EDUC HEALTH, V26, P13, DOI 10.1002/chp.47; Grimshaw JM, 2001, MED CARE, V39, pII2; Horak FB, 2006, AGE AGEING, V35, P7, DOI 10.1093/ageing/afl077; Horak FB, 2009, PHYS THER, V89, P484, DOI 10.2522/ptj.20080071; Howe JA, 2006, CLIN REHABIL, V20, P885, DOI 10.1177/0269215506072183; Howe TE, 2011, COCHRANE DB SYST REV, V11, DOI [10.1002/14651858.CD14004963.pub14651853, DOI 10.1002/14651858.CD14004963.PUB14651853]; Howe TE, 2011, AGE AGEING, V40, P532, DOI 10.1093/ageing/afr082; Jacobs JV, 2006, J NEUROL, V253, P1404, DOI 10.1007/s00415-006-0224-x; Kay TM, 2001, PHYSIOTHER CAN, V53, P281; Kay TM, 2001, PHYSIOTHER CAN, V53, P268; Maki BE, 1997, PHYS THER, V77, P488, DOI 10.1093/ptj/77.5.488; MAKI BE, 2001, CONTROL POSTURE GAIT, P126; McGinnis Patricia Q., 2010, Physiotherapy Theory and Practice, V26, P358, DOI 10.3109/09593980903219050; McGinnis PQ, 2009, PHYS THER, V89, P233, DOI 10.2522/ptj.20080131; McGlynn M, 2007, PHYSIOTHER CAN, V59, P241, DOI DOI 10.3138/ptc.59.4.241; Menon A, 2009, J REHABIL MED, V41, P1024, DOI 10.2340/16501977-0451; Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155; Nilsen P, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-53; Pardasaney PK, 2012, PHYS THER, V92, P388, DOI 10.2522/ptj.20100398; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Pollock CL, 2011, CLIN REHABIL, V25, P693, DOI 10.1177/0269215510397394; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; Rose DJ, 2006, ARCH PHYS MED REHAB, V87, P1478, DOI 10.1016/j.apmr.2006.07.263; Salbach NM, 2007, PHYS THER, V87, P1284, DOI 10.2522/ptj.20070040; Salbach NM, 2011, J REHABIL MED, V43, P543, DOI 10.2340/16501977-0820; Salbach NM, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-77; Scott SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-70; Sherrington Catherine, 2011, N S W Public Health Bull, V22, P78, DOI 10.1071/NB10056; Shumway-Cook A, 2007, MOTOR CONTROL TRANSL; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Sibley KM, 2011, PHYS THER, V91, P1583, DOI 10.2522/ptj.20110063; Silva A, 2012, BRAZ J PHYS THER, V16, P1; Straus SE, 2009, KNOWLEDGE TRANSLATIO; Straus SE, 2005, EVIDENCE BASED MEDIC; Sturnieks DL, 2004, J RHEUMATOL, V31, P2272; Tinetti ME, 2010, JAMA-J AM MED ASSOC, V303, P258, DOI 10.1001/jama.2009.2024; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; Tyson SF, 2006, PHYS THER, V86, P30, DOI 10.1093/ptj/86.1.30	47	30	30	0	16	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1748-5908			IMPLEMENT SCI	Implement. Sci.	MAR 20	2013	8								33	10.1186/1748-5908-8-33			8	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	137EQ	WOS:000318418700001	23510277	DOAJ Gold, Green Published			2021-06-18	
J	Fitrolaki, DM; Dimitriou, H; Kalmanti, M; Briassoulis, G				Fitrolaki, Diana-Michaela; Dimitriou, Helen; Kalmanti, Maria; Briassoulis, George			CD64-Neutrophil expression and stress metabolic patterns in early sepsis and severe traumatic brain injury in children	BMC PEDIATRICS			English	Article						Metabolic pattern; Glucose; Lipoproteins; CD64; CD11b; Neutrophils; Sepsis; Traumatic brain injury	NEUTROPHIL CD64 EXPRESSION; HIGH-DENSITY-LIPOPROTEIN; CYTOKINE PRODUCTION; LIPIDS; RISK; HYPERGLYCEMIA; ACTIVATION; MORTALITY; MONOCYTES; INFECTION	Background: Critical illness constitutes a serious derangement of metabolism. The aim of our study was to compare acute phase metabolic patterns in children with sepsis (S) or severe sepsis/septic shock (SS) to those with severe traumatic brain injury (TBI) and healthy controls (C) and to evaluate their relations to neutrophil, lymphocyte and monocyte expressions of CD64 and CD11b. Methods: Sixty children were enrolled in the study. Forty-five children with systemic inflammatory response syndrome (SIRS) were classified into three groups: TBI (n = 15), S (n = 15), and SS (n = 15). C consisted of 15 non-SIRS patients undergoing screening tests for minor elective surgery. Blood samples were collected within 6 hours after admission for flow cytometry of neutrophil, lymphocyte and monocyte expression of CD64 and CD11b (n = 60). Procalcitonin (PCT), C-reactive protein (CRP), glucose, triglycerides (TG), total cholesterol (TC), high (HDL) or low-density-lipoproteins (LDL) were also determined in all groups, and repeated on day 2 and 3 in the 3 SIRS groups (n = 150). Results: CRP, PCT and TG (p < 0.01) were significantly increased in S and SS compared to TBI and C; glucose did not differ among critically ill groups. Significantly lower were the levels of TC, LDL, and HDL in septic groups compared to C and to moderate changes in TBI (p < 0.0001) but only LDL differed between S and SS (p < 0.02). Among septic patients, PCT levels declined significantly (p < 0.02) with time, followed by parallel decrease of HDL (p < 0.03) and increase of TG (p < 0.02) in the SS group. Neutrophil CD64 (nCD64) expression was higher in patients with SS (81.2%) and S (78.8%) as compared to those with TBI (5.5%) or C (0.9%, p < 0.0001). nCD64 was positively related with CRP, PCT, glucose, and TG (p < 0.01) and negatively with TC, LDL, and HDL (p < 0.0001), but not with severity of illness, hematologic indices, length of stay or mechanical ventilation duration. Conclusions: In sepsis, the early stress-metabolic pattern is characterized by a high (nCD64, glucose, TG) - low (TC, HDL, LDL) combination in contrast to the moderate pattern of TBI in which only glucose increases combined with a moderate cholesterol - lipoprotein decrease. These early metabolic patterns persist the first 3 days of acute illness and are associated with the acute phase CD64 expression on neutrophils.	[Fitrolaki, Diana-Michaela; Briassoulis, George] Univ Hosp Herakl, Pediat Intens Care Unit, Iraklion 71110, Crete, Greece; [Dimitriou, Helen; Kalmanti, Maria] Univ Crete, Sch Med, Dept Pediat Hematol Oncol, Iraklion, Greece	Briassoulis, G (corresponding author), Univ Hosp Herakl, Pediat Intens Care Unit, Iraklion 71110, Crete, Greece.	ggbriass@otenet.gr			European Union (European Social Fund (ESF))European Social Fund (ESF); Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF)-Research Funding Program: THALES	This research has been co-financed by the European Union (European Social Fund (ESF)) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF)-Research Funding Program: THALES. We thank all the nurses, doctors, and biologists who contributed to this study.	ALVAREZ C, 1986, CLIN CHEM, V32, P142; Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Barlage S, 2009, INTENS CARE MED, V35, P1877, DOI 10.1007/s00134-009-1609-y; Beekman JA, 2008, IMMUNOL LETT, V116, P149, DOI 10.1016/j.imlet.2007.12.003; Briassoulis G, 2005, INTENS CARE MED, V31, P851, DOI 10.1007/s00134-005-2631-3; Briassoulis G, 2006, PEDIATR CRIT CARE ME, V7, P56, DOI 10.1097/01.PCC.0000192339.44871.26; Briassoulis G, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/354047; Brunialti MKC, 2006, SHOCK, V25, P351, DOI 10.1097/01.shk.0000217815.57727.29; Cardelli P, 2008, INT J IMMUNOPATH PH, V21, P43, DOI 10.1177/039463200802100106; Davis BH, 2005, EXPERT REV MOL DIAGN, V5, P193, DOI 10.1586/14737159.5.2.193; Davis BH, 2006, ARCH PATHOL LAB MED, V130, P654; Dhar A, 2011, CURR OPIN PEDIATR, V23, P269, DOI 10.1097/MOP.0b013e3283464b3e; Dunham CM, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-42; Genel F, 2012, WORLD J PEDIATR, V8, P72, DOI 10.1007/s12519-011-0304-6; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Gordon BR, 2001, CRIT CARE MED, V29, P1563, DOI 10.1097/00003246-200108000-00011; Gros A, 2012, INTENS CARE MED, V38, P445, DOI 10.1007/s00134-012-2483-6; Groselj-Grenc M, 2009, INTENS CARE MED, V35, P1950, DOI 10.1007/s00134-009-1637-7; Groselj-Grenc M, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/202646; Gruher M, 2009, SWISS MED WKLY, V139, P166, DOI smw-12494; Gullo J. D., 2011, J CRIT CARE; Harris HW, 2002, CRIT CARE MED, V30, P23, DOI 10.1097/00003246-200201000-00004; Herra CM, 1996, J MED MICROBIOL, V44, P135, DOI 10.1099/00222615-44-2-135; Hsu KH, 2011, RESPIROLOGY, V16, P152, DOI 10.1111/j.1440-1843.2010.01876.x; HUBSCH AP, 1995, J LAB CLIN MED, V126, P548; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; Kosuge Masami, 2004, J Cardiol, V43, P251; Kumaraswamy SB, 2012, CRIT CARE, V16, DOI 10.1186/cc11305; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Li L, 2004, CIRC RES, V95, P877, DOI 10.1161/01.RES.0000147309.54227.42; Livaditi O, 2006, CYTOKINE, V36, P283, DOI 10.1016/j.cyto.2007.02.007; LopesVirella MF, 1997, ATHEROSCLEROSIS, V135, P161, DOI 10.1016/S0021-9150(97)00157-3; Luthold S, 2007, EUR J CLIN INVEST, V37, P573, DOI 10.1111/j.1365-2362.2007.01826.x; Mesotten D, 2004, J CLIN ENDOCR METAB, V89, P219, DOI 10.1210/jc.2003-030760; Nakae H, 1996, RES COMMUN MOL PATH, V91, P329; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Pussinen PJ, 2011, DIABETES CARE, V34, P392, DOI 10.2337/dc10-1676; Qureshi SS, 2001, CLIN EXP IMMUNOL, V125, P258, DOI 10.1046/j.1365-2249.2001.01596.x; RuchaudSparagano MH, 1997, BRIT J HAEMATOL, V98, P612, DOI 10.1046/j.1365-2141.1997.2523070.x; Russwurm S, 2002, SHOCK, V17, P263, DOI 10.1097/00024382-200204000-00004; Streimish I, 2012, PEDIATR INFECT DIS J, V31, P777, DOI 10.1097/INF.0b013e318256fb07; van Leeuwen HJ, 2003, CRIT CARE MED, V31, P1359, DOI 10.1097/01.CCM.0000059724.08290.51; Verhoeven JJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10006; Weinschenk NP, 2000, J PEDIATR-US, V137, P345, DOI 10.1067/mpd.2000.107846; Wolf Z, 2007, CYTOM PART A, V71A, P486, DOI 10.1002/cyto.a.20403; Wolfe RR, 2000, WORLD J SURG, V24, P639, DOI 10.1007/s002689910105; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; Zhang L, 2009, ATHEROSCLEROSIS, V206, P298, DOI 10.1016/j.atherosclerosis.2008.12.043	49	30	33	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2431			BMC PEDIATR	BMC Pediatr.	MAR 1	2013	13								31	10.1186/1471-2431-13-31			10	Pediatrics	Pediatrics	104KO	WOS:000315992000001	23452299	DOAJ Gold, Green Published			2021-06-18	
J	Kozlowski, AJ; Pretz, CR; Dams-O'Connor, K; Kreider, S; Whiteneck, G				Kozlowski, Allan J.; Pretz, Christopher R.; Dams-O'Connor, Kristen; Kreider, Scott; Whiteneck, Gale			An Introduction to Applying Individual Growth Curve Models to Evaluate Change in Rehabilitation: A National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems Report	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Longitudinal studies; Regression analysis; Rehabilitation; Treatment outcome	SPINAL-CORD-INJURY; LIFE SATISFACTION; LONGITUDINAL DATA; MULTILEVEL MODELS; PREDICTORS	The abundance of time-dependent information contained in the Spinal Cord Injury and the Traumatic Brain Injury Model Systems National Databases, and the increased prevalence of repeated-measures designs in clinical trials highlight the need for more powerful longitudinal analytic methodologies in rehabilitation research. This article describes the particularly versatile analytic technique of individual growth curve (IGC) analysis. A defining characteristic of IGC analysis is that change in outcome such as functional recovery can be described at both the patient and group levels, such that it is possible to contrast 1 patient with other patients, subgroups of patients, or a group as a whole. Other appealing characteristics of IGC analysis include its flexibility in describing how outcomes progress over time (whether in linear, curvilinear, cyclical, or other fashion), its ability to accommodate covariates at multiple levels of analyses to better describe change, and its ability to accommodate cases with partially missing outcome data. These features make IGC analysis an ideal tool for investigating longitudinal outcome data and to better equip researchers and clinicians to explore a multitude of hypotheses. The goal of this special communication is to familiarize the rehabilitation community with IGC analysis and encourage the use of this sophisticated research tool to better understand temporal change in outcomes. Archives of Physical Medicine and Rehabilitation 2013;94:589-96 (C) 2013 by the American Congress of Rehabilitation Medicine	[Kozlowski, Allan J.] Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA; [Kozlowski, Allan J.] Northwestern Univ, Feinberg Med Sch, Ctr Healthcare Studies, Chicago, IL 60611 USA; [Pretz, Christopher R.; Kreider, Scott; Whiteneck, Gale] Craig Hosp, Englewood, CO USA; [Pretz, Christopher R.; Kreider, Scott; Whiteneck, Gale] Traumat Brain Injury Natl Stat & Data Ctr, Englewood, CO USA; [Dams-O'Connor, Kristen] Mt Sinai Sch Med, New York, NY USA	Kozlowski, AJ (corresponding author), Rehabil Inst Chicago, 345 E Ontario St, Chicago, IL 60611 USA.	akozlowski@ric.org			National Institute on Disability and Rehabilitation Research through the Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes [H133B090024]; Traumatic Brain Injury Model Systems National Data and Statistical Center [H133A110006]	Supported by the National Institute on Disability and Rehabilitation Research through the Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes (grant no. H133B090024), and the Traumatic Brain Injury Model Systems National Data and Statistical Center (grant no. H133A110006).	[Anonymous], 2012, HLM 7 STAT SOFTW HIE; [Anonymous], 2012, STAT AN STAT SOFTW; [Anonymous], 2012, MPLUS STAT SOFTW; Barker GM, 2010, ANN THORAC SURG, V89, P843, DOI 10.1016/j.athoracsur.2009.11.048; Benton A, 1989, MULTILINGUAL APHASIA; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Chan L, 1997, NEW ENGL J MED, V337, P978, DOI 10.1056/NEJM199710023371406; Chen YY, 2008, ARCH PHYS MED REHAB, V89, P2285, DOI 10.1016/j.apmr.2008.06.008; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; DUNLOP DD, 1994, AM STAT, V48, P299, DOI 10.2307/2684838; Fitzmaurice G, 2011, APPL LONGITUDINAL AN; Hedeker D., 2006, LONGITUDINAL DATA AN; IBM, 2012, SPSS STAT VERS 20; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Liu SW, 2012, PSYCHOL METHODS, V17, P15, DOI 10.1037/a0026971; Putzke JD, 2002, ARCH PHYS MED REHAB, V83, P555, DOI 10.1053/apmr.2002.31173; Rabe-Hesketh S., 2012, MULTILEVEL LONGITUDI, VII; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; ROGOSA DR, 1985, PSYCHOMETRIKA, V50, P203, DOI 10.1007/BF02294247; ROGOSA DR, 1982, PSYCHOL BULL, V90, P726; SAS Institute, 2012, SAS STAT SOFTW VERS; Singer J.D., 2003, APPL LONGITUDINAL DA; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Skrondal A, 2012, MULTILEVEL LONGITUDI, VI; Spreen O., 1998, COMPENDIUM NEUROPSYC; van Leeuwen CM, 2011, ARCH PHYS MED REHAB, V92, P207, DOI 10.1016/j.apmr.2010.10.011; Warschausky S, 2001, ARCH PHYS MED REHAB, V82, P329, DOI 10.1053/apmr.2001.21510	28	30	30	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2013	94	3					589	596		10.1016/j.apmr.2012.08.199			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	106PZ	WOS:000316158500026	22902887				2021-06-18	
J	Quigley, MR; Chew, BG; Swartz, CE; Wilberger, JE				Quigley, Matthew R.; Chew, Brandon G.; Swartz, Christopher E.; Wilberger, Jack E.			The clinical significance of isolated traumatic subarachnoid hemorrhage	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Head injury; traumatic subarachnoid hemorrhage; outcome	HEAD COMPUTED-TOMOGRAPHY; BRAIN-INJURY; CT; MANAGEMENT	BACKGROUND: Mild traumatic brain injury is a clinical diagnosis predicated on a patient's neurologic status and encompasses a variety of pathologies on computed tomography. We wondered whether isolated traumatic subarachnoid hemorrhage (iSAH) without other intracranial pathologic diagnosis is a more benign form of minor head injury that does not warrant extensive (and expensive) observation and follow-up. METHODS: This is a retrospective review of patients identified prospectively via a trauma registry during a period of 7 years, who had the computed tomographic finding of iSAH on admission scan and a Glasgow Coma Scale (GCS) score of 13 or greater. RESULTS: There were 478 patients identified, with a mean age 61 years, and 223 were male. Median Injury Severity Score (ISS) was 10 (range, 9-48), and the distribution was 415, 54, and 12 for those with GCS score of 15, 14, and 13, respectively. In-hospital follow-up imaging in nine patients demonstrated increased pathologic findings, but subsequent imaging showed stable or decreasing blood, and none experienced a neurologic decline or underwent a neurosurgical procedure. Among those with no other injuries (ISS = 9, n = 118) patients spent a mean of 2.0 (95% confidence interval, 1.1-2.9) days in intensive care unit and 4.9 (95% confidence interval, 3.9-6.0) days in hospital. The likelihood of discharge home was significantly related to age (p < 0.0001), ISS (p < 0.01), and admission GCS (p < 0.01) (stepwise logistic regression), but not progression of SAH. At 6-week follow-up, one patient (0.2%) developed bilateral chronic subdurals requiring drainage, without neurologic sequela. CONCLUSION: In this largest reported series to date of iSAH in the setting of mild traumatic brain injury, the finding seems to be benign and can likely be managed without routine follow-up imaging or intensive care unit admission in the absence of other significant trauma. (J Trauma Acute Care Surg. 2013;74: 581-584. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Quigley, Matthew R.; Chew, Brandon G.; Swartz, Christopher E.; Wilberger, Jack E.] Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA	Quigley, MR (corresponding author), 420 East North Ave,Suite 302, Pittsburgh, PA 15215 USA.	q@mattquigley.com			Department of Neurosurgery, Allegheny General Hospital	Financial support was provided by Department of Neurosurgery, Allegheny General Hospital, and by a generous donation from the Lee Solomon Memorial Fund.	Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Fainardi E, 2004, ACTA NEUROCHIR, V146, P257, DOI 10.1007/s00701-003-0207-y; Falimirski ME, 2003, J TRAUMA, V55, P1, DOI 10.1097/01.TA.0000071295.67263.A2; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Levy AS, 2011, J TRAUMA, V71, P1199, DOI 10.1097/TA.0b013e31822067fc; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Thomas BW, 2010, J AM COLL SURGEONS, V210, P824, DOI 10.1016/j.jamcollsurg.2009.12.039; Thomas BW, 2010, J AM COLL SURGEONS, V210, P831; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092	14	30	30	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2013	74	2					581	584		10.1097/TA.0b013e31827d6088			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	108UH	WOS:000316321200049	23354254				2021-06-18	
J	Adelson, PD; Fellows-Mayle, W; Kochanek, PM; Dixon, CE				Adelson, P. David; Fellows-Mayle, Wendy; Kochanek, Patrick M.; Dixon, C. Edward			Morris water maze function and histologic characterization of two age-at-injury experimental models of controlled cortical impact in the immature rat	CHILDS NERVOUS SYSTEM			English	Article						Age; Animal studies; Models of injury; Pediatric brain injury; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; COGNITIVE DEFICITS; SPATIAL NAVIGATION; MEMORY; MATURATION; ADULT; NEURODEGENERATION; HYPOTHERMIA; EXPRESSION	Controlled cortical impact (CCI) is commonly used in adult animals to study focal traumatic brain injury (TBI). Our study aims to further study injury mechanisms in children and variable models of pathology in the developing brain. Develop a focal injury model of experimental TBI in the immature, postnatal days (PND) 7 and 17 rats that underwent a CCI at varying depths of deflection, 1.5-2.5 mm compared with sham and then tested using the Morris water maze (MWM) beginning on post-injury day (PID) 11. Histopathologic analysis was performed at PID 1 and 28. In PND 7, the 1.75- and 2.0-mm deflections (diameter (d) = 3 mm; velocity = 4 m/s; and duration = 500 ms) resulted in significant MWM deficits while the 1.5-mm injury did not produce MWM deficits vs. sham controls. In PND 17, all injury levels resulted in significant MWM deficits vs. sham controls with a graded response; the 1.5-mm deflection (d = 6 mm; velocity = 4 m/s; and duration = 500 ms) produced significantly less deficits as compared WITH the 2.0- and 2.5-mm injuries. Histologically, a graded injury response was also seen in both ages at injury with cortical and more severe injuries, hippocampal damage. Cortical contusion volume increased in most injury severities from PID 1 to 28 in both ages at injury while hippocampal volumes subsequently decreased. CCI in PND 7 and 17 rat results in significant MWM deficits and cortical histopathology providing two different and unique experimental models of TBI in immature rats that may be useful in further investigations into the mechanisms and treatments of pediatric TBI.	[Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Fellows-Mayle, Wendy; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurosurg, Childrens Hosp Pittsburgh, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA	Adelson, PD (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, 1919 E Thomas Rd,Bldg B,4th Floor, Phoenix, AZ 85016 USA.	dadelson@phoenixchildrens.com	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH RO1 NS42298, NIH RO1 NS 30318, NS 38087]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038087, R01NS042298] Funding Source: NIH RePORTER	The authors wish to thank the National Institute of Health for its support for PDA (NIH RO1 NS42298) and PMK (NIH RO1 NS 30318 and NS 38087). The authors also wish to thank Ms. Christina Casanova for her help in the manuscript preparation.	Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Adelson PD, 1999, EXP TOXICOL PATHOL, V51, P130; Armstead WM, 1998, J NEUROTRAUM, V15, P721, DOI 10.1089/neu.1998.15.721; BACHEVALIER J, 1993, HIPPOCAMPUS, V3, P191; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clark RSB, 1997, J NEUROSCI, V17, P9172; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fink Ericka L, 2004, Pediatr Crit Care Med, V5, P139, DOI 10.1097/01.PCC.0000112376.29903.8F; Frielingsdorf H, 2006, BEHAV BRAIN RES, V168, P37, DOI 10.1016/j.bbr.2005.10.008; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kraemer PJ, 1996, BRAIN RES BULL, V39, P17, DOI 10.1016/0361-9230(95)02028-4; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; KRAUS JF, 1987, HEAD INJURY, P1; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MOSER E, 1993, SCIENCE, V259, P1324, DOI 10.1126/science.8446900; NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83; NEHLIG A, 1988, J NEUROSCI, V8, P2321; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; SCHENK F, 1989, J NEUROSCI METH, V26, P249, DOI 10.1016/0165-0270(89)90123-4; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Stevenson K. L., 2000, Journal of Neurotrauma, V17, P944; SUTHERLAND RJ, 1982, J COMP PHYSIOL PSYCH, V96, P563, DOI 10.1037/h0077914	65	30	32	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	JAN	2013	29	1					43	53		10.1007/s00381-012-1932-4			11	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	064JN	WOS:000313071200006	23089934				2021-06-18	
J	Carre, E; Ogier, M; Boret, H; Montcriol, A; Bourdon, L; Risso, JJ				Carre, Emilie; Ogier, Michael; Boret, Henry; Montcriol, Ambroise; Bourdon, Lionel; Risso, Jean-Jacques			Metabolic crisis in severely head-injured patients: is ischemia just the tip of the iceberg?	FRONTIERS IN NEUROLOGY			English	Article						metabolic crisis; ischemia; head injury; multimodal monitoring; intracerebral microdialysis	TRAUMATIC BRAIN-INJURY; PENTOSE-PHOSPHATE PATHWAY; ENERGY-METABOLISM; CEREBRAL METABOLISM; LACTATE/PYRUVATE RATIO; INTRACRANIAL-PRESSURE; OXIDATIVE-METABOLISM; GLUCOSE; LACTATE; MICRODIALYSIS	Ischemia and metabolic crisis are frequent post-traumatic secondary brain insults that negatively influence outcome. Clinicians commonly mix up these two types of insults, mainly because high lactate/pyruvate ratio (LPR) is the common marker for both ischemia and metabolic crisis. However, LPR elevations during ischemia and metabolic crisis reflect two different energetic imbalances: ischemia (Type 1 LPR elevations with low oxygenation) is characterized by a drastic deprivation of energetic substrates, whereas metabolic crisis (Type 2 LPR elevations with normal or high oxygenation) is associated with profound mitochondrial dysfunction but normal supply of energetic substrates. The discrimination between ischemia and metabolic crisis is crucial because conventional recommendations against ischemia may be detrimental for patients with metabolic crisis. Multimodal monitoring, including microdialysis and brain tissue oxygen monitoring, allows such discrimination, but these techniques are not easily accessible to all head-injured patients. Thus, a new "gold standard" and adapted medical education are required to optimize the management of patients with metabolic crisis.	[Carre, Emilie; Ogier, Michael; Bourdon, Lionel; Risso, Jean-Jacques] Inst Rech Biomed Armees, Unit Traumatol, BP 73, F-91223 Bretigny Sur Orge, France; [Boret, Henry; Montcriol, Ambroise] Hop Instruct Armees St Anne, Intens Care Unit, F-83800 Toulon, France	Carre, E (corresponding author), Inst Rech Biomed Armees, Unit Traumatol, BP 73, F-91223 Bretigny Sur Orge, France.	emilie_carre@hotmail.com					Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik-Olson BL, 2010, J NEUROTRAUM, V27, P2191, DOI 10.1089/neu.2010.1508; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bor-Seng-Shu E, 2010, J NEUROSURG, V112, P1351, DOI 10.3171/2009.10.JNS091426; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cerdan S, 2006, NEUROCHEM INT, V48, P523, DOI 10.1016/j.neuint.2005.12.036; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Diedler J, 2010, NEUROCRIT CARE, V12, P313, DOI 10.1007/s12028-010-9350-5; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Grewer C, 2008, IUBMB LIFE, V60, P609, DOI 10.1002/iub.98; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2008, CRIT CARE MED, V36, P2952, DOI 10.1097/CCM.0b013e3181872178; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kramer AH, 2011, NEUROCRIT CARE, V14, P329, DOI 10.1007/s12028-011-9530-y; Larach DB, 2011, NEUROCRIT CARE, V15, P609, DOI 10.1007/s12028-011-9517-8; LINDQUIST JL, 1942, SURG GYNECOL OBSTET, V75, P28; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P793, DOI 10.1111/aas.12092; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Soustiel JF, 2011, PHARM RES-DORDR, V28, P2945, DOI 10.1007/s11095-011-0463-0; Soustiel JF, 2010, NEUROTHERAPEUTICS, V7, P13, DOI 10.1016/j.nurt.2009.11.001; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wang X, 2007, BRAIN RES, V1132, P1, DOI 10.1016/j.brainres.2006.11.032; Ward MJ, 2012, NEUROCRIT CARE, V16, P232, DOI 10.1007/s12028-011-9644-2; Wender R, 2000, J NEUROSCI, V20, P6804, DOI 10.1523/JNEUROSCI.20-18-06804.2000; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	47	30	31	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								146	10.3389/fneur.2013.00146			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QT	WOS:000209629000145	24130548	DOAJ Gold, Green Published			2021-06-18	
J	Mioni, G; Stablum, F; Cantagallo, A				Mioni, Giovanna; Stablum, Franca; Cantagallo, Anna			Time discrimination in traumatic brain injury patients	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Time discrimination; Attention; Working memory; Speed of processing	DURATION-DISCRIMINATION; PROSPECTIVE MEMORY; FRONTAL-LOBE; ATTENTION; PERCEPTION; ERPS; REPRESENTATION; PERFORMANCE; ACTIVATION; MECHANISMS	Time management skills are required for most daily activities. Traumatic brain injury (TBI) patients often present with cognitive dysfunction, but few studies have investigated temporal impairment. The aim of the present study was to assess temporal abilities in TBI patients using a time discrimination task. Twenty-seven TBI patients (ages = 18-60 years) and 27 controls (ages = 20-60 years) were asked to discriminate between two time intervals presented sequentially. The standard intervals were 500 ms or 1,300 ms long followed by a comparison stimulus that was 25% shorter or longer than the standard one. Participants were also asked to perform two tasks to assess attention, speed-of-processing (the Stroop task), and working memory (the n-back task) abilities. The TBI patients were less accurate than the controls on the time discrimination task and showed greater time-order error effects. In fact, TBI patients pressed the short key more times when the standard time interval was 500 ms and the long key more times when the standard interval was 1,300 ms. Significant correlations were found between time discrimination, working memory, and speed of processing in both TBI and controls when the standard time interval was 1,300 ms. Attention appeared to be involved in different ways in the two groups. Working memory and speed of processing were involved in time processing only in TBI patients when the standard time interval was 500 ms. These data lend additional support to the notion that two different systems are responsible for elaborating time durations shorter or longer than a second.	[Mioni, Giovanna; Stablum, Franca] Univ Padua, Dipartimento Psicol Gen, I-35131 Padua, Italy; [Cantagallo, Anna] BrainCare Srl, Padua, Italy	Mioni, G (corresponding author), Univ Padua, Dipartimento Psicol Gen, Via Venezia 8, I-35131 Padua, Italy.	giovanna.mioni@unipd.it		mioni, Giovanna/0000-0002-1212-4591; Stablum, Franca/0000-0003-0123-5090			Aharon Peretz J., 2007, HUMAN FRONTAL LOBES, P540; Anderson JW, 2011, NEUROPSYCHOLOGY, V25, P36, DOI 10.1037/a0020333; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Block, 1996, TIME INTERNAL CLOCKS, V115, P143, DOI DOI 10.1016/S0166-4115(96)80057-4; Block R.A., 1990, COGNITIVE MODELS PSY, P59; Block R.A., 1990, COGNITIVE MODELS PSY; Block RA, 1996, TIME AND MIND, P171; Block RA, 1998, PSYCHOL AGING, V13, P584, DOI 10.1037/0882-7974.13.4.584; Block RA, 2006, TIMING THE FUTURE: THE CASE FOR A TIME-BASED PROSPECTIVE MEMORY, P25, DOI 10.1142/9789812707123_0002; Boelen DHE, 2009, NEUROPSYCHOL REHABIL, V19, P625, DOI 10.1080/09602010802613853; Buhusi CV, 2005, NAT REV NEUROSCI, V6, P755, DOI 10.1038/nrn1764; Casini L, 1999, NEUROPSYCHOLOGY, V13, P10, DOI 10.1037/0894-4105.13.1.10; CASINI L, 1992, NATO ADV SCI INST SE, V66, P177; CHURCH RM, 1984, ANN NY ACAD SCI, V423, P566, DOI 10.1111/j.1749-6632.1984.tb23459.x; Del Missier F, 2010, THINK REASONING, V16, P69, DOI 10.1080/13546781003630117; Fleming J, 2008, J INT NEUROPSYCH SOC, V14, P823, DOI 10.1017/S1355617708080971; FRAISSE P, 1984, ANNU REV PSYCHOL, V35, P1, DOI 10.1146/annurev.ps.35.020184.000245; GIBBON J, 1991, LEARN MOTIV, V22, P3, DOI 10.1016/0023-9690(91)90015-Z; Gontier E, 2007, BRAIN RES, V1170, P79, DOI 10.1016/j.brainres.2007.07.022; Gontier E, 2009, NEUROPSYCHOLOGY, V23, P668, DOI 10.1037/a0015757; GRONDIN S, 1992, NATO ADV SCI INST SE, V66, P119; Grondin S, 2010, ATTEN PERCEPT PSYCHO, V72, P561, DOI 10.3758/APP.72.3.561; Grondin S, 2009, PERCEPTION, V38, P1542, DOI 10.1068/p6359; Hagen C, 1979, REHABILITATION HEAD; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Handy TC, 2003, NEUROPSYCHOLOGIA, V41, P1461, DOI 10.1016/S0028-3932(03)00093-9; Harrington DL, 1998, J NEUROSCI, V18, P1085; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hellstrom A, 2004, ACTA PSYCHOL, V116, P1, DOI 10.1016/j.actpsy.2003.11.003; HELLSTROM A, 1985, PSYCHOL BULL, V97, P35, DOI 10.1037/0033-2909.97.1.35; Ivry RB, 2004, CURR OPIN NEUROBIOL, V14, P225, DOI 10.1016/j.conb.2004.03.013; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Le Dantec C, 2007, ACTA PSYCHOL, V125, P85, DOI 10.1016/j.actpsy.2006.07.003; Lewis PA, 2003, NEUROPSYCHOLOGIA, V41, P1583, DOI 10.1016/S0028-3932(03)00118-0; Lewis PA, 2003, CURR OPIN NEUROBIOL, V13, P250, DOI 10.1016/S0959-4388(03)00036-9; Macar F, 2002, EXP BRAIN RES, V142, P475, DOI 10.1007/s00221-001-0953-0; Macmillan N. A., 2005, DETECTION THEORY USE; Mangels JA, 1998, COGNITIVE BRAIN RES, V7, P15, DOI 10.1016/S0926-6410(98)00005-6; Meck WH, 1996, COGNITIVE BRAIN RES, V3, P227, DOI 10.1016/0926-6410(96)00009-2; MEYERS CA, 1992, NEUROPSY NEUROPSY BE, V5, P28; Mioni G, 2012, J INT NEUROPSYCH SOC, V18, P697, DOI 10.1017/S1355617712000306; Moscovitch Morris, 1995, P1341; Nichelli P, 1996, NEUROPSYCHOLOGIA, V34, P863, DOI 10.1016/0028-3932(96)00001-2; Nichelli P, 1995, ANN NY ACAD SCI, V769, P183, DOI 10.1111/j.1749-6632.1995.tb38139.x; Oshio KI, 2006, EUR J NEUROSCI, V23, P2779, DOI 10.1111/j.1460-9568.2006.04781.x; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Paul I, 2003, J CLIN NEUROPHYSIOL, V20, P351, DOI 10.1097/00004691-200309000-00007; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Picton TW, 2006, NEUROPSYCHOLOGIA, V44, P1195, DOI 10.1016/j.neuropsychologia.2005.10.002; Pouthas V, 2004, ACTA NEUROBIOL EXP, V64, P367; Rammsayer TH, 2001, Q J EXP PSYCHOL-B, V54, P247, DOI 10.1080/02724990143000036; Rammsayer TH, 2001, EUR J COGN PSYCHOL, V13, P549, DOI 10.1080/09541440042000322; Rubia K, 2004, ACTA NEUROBIOL EXP, V64, P329; Rubia K, 1999, PERCEPT MOTOR SKILL, V89, P1237, DOI 10.2466/PMS.89.7.1237-1258; Rubia K, 2006, TIMING THE FUTURE: THE CASE FOR A TIME-BASED PROSPECTIVE MEMORY, P213, DOI 10.1142/9789812707123_0009; Schmitter-Edgecombe M, 2008, J CLIN EXP NEUROPSYC, V30, P212, DOI 10.1080/13803390701363803; Shimamura Arthur P., 1995, P803; Smith A, 2003, NEUROIMAGE, V20, P344, DOI 10.1016/S1053-8119(03)00337-9; TEASDALE G, 1974, LANCET, V2, P81; TREISMAN M, 1963, PSYCHOL MONOGR, V77, P1, DOI 10.1037/h0093864; Wiener M, 2010, NEUROPSYCHOLOGIA, V48, P3967, DOI 10.1016/j.neuropsychologia.2010.09.014; Zakay D, 2004, ACTA NEUROBIOL EXP, V64, P319	64	30	30	1	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JAN 1	2013	35	1					90	102		10.1080/13803395.2012.755151			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	189YL	WOS:000322304100010	23259647				2021-06-18	
J	Gosselin, N; Bottari, C; Chen, JK; Huntgeburth, SC; De Beaumont, L; Petrides, M; Cheung, B; Ptito, A				Gosselin, Nadia; Bottari, Carolina; Chen, Jen-Kai; Huntgeburth, Sonja Christina; De Beaumont, Louis; Petrides, Michael; Cheung, Bob; Ptito, Alain			Evaluating the cognitive consequences of mild traumatic brain injury and concussion by using electrophysiology	NEUROSURGICAL FOCUS			English	Article						concussion; mild traumatic brain injury; event-related potential; working memory; electroencephalography	SPORTS-RELATED CONCUSSION; EVENT-RELATED POTENTIALS; POSTCONCUSSIVE SYNDROME; PREFRONTAL CORTEX; FRONTAL-CORTEX; RISK-FACTORS; SYMPTOMS; ABNORMALITIES; DEFICITS; MRI	Object. Mild traumatic brain injury (MTBI), often referred to as concussion when it occurs in sports, produces persistent cognitive problems in at least 15% of patients. Unfortunately, conventional neuropsychological tests usually yield results within normal limits in this population. The main objective of this event-related potential (ERP) study was to understand brain functioning during the performance of a working memory (WM) task in patients who have sustained an MTBI, mostly due to motor vehicle accident or sports concussion. This study also aimed for a better understanding of the association between brain functioning as measured with ERP, behavioral performance on the WM task, postconcussion symptoms, type of injury (that is, sports concussion vs other types), and time since the injury. Methods. Forty-four patients with MTBI (7.6 +/- 8.4 months postinjury) were tested on a visual WM task with simultaneous recording of ERP, and were compared with 40 control volunteers who were their equivalent for age and sex. Amplitude and latency of frontal (N200 and N350) and parietal (P200 and P300) ERP waves were measured and were compared between groups. Correlation analyses were also performed between ERP characteristics, clinical variables, and behavioral performance. Results. A significant group difference was found for behavioral performance on the WM task, in which the MTBI group had a lower percentage of correct answers than the control group (p < 0.05). The patients with MTBI also had smaller amplitudes of both frontal N350 and parietal P300 ERP components when compared with control volunteers (p < 0.05). No changes were found for latency of ERP components. Smaller ERP amplitudes were associated with slower reaction times and worse accuracy on the WM task among patients with MTBI (p < 0.05). Types of injury (that is, sports concussion vs other mechanisms) were not associated with different ERP characteristics. Conclusions. Abnormal ERP results are observed in patients after MTBI or sports concussion, even for those in the nonacute stage after their injury. Current standard clinical evaluations most often fail to detect cerebral dysfunction after MTBI, even when patients or athletes report symptoms. Clinicians should be aware that patients with MTBI, including sports concussion, probably have underlying mild but persistent cerebral dysfunctions that require further investigation. (http://thejns.org/doi/abs/10.3171/2012.10.FOCUS12253)	[Gosselin, Nadia; De Beaumont, Louis] Hop Sacre Coeur, Res Ctr, Montreal, PQ H4J 1C5, Canada; [Gosselin, Nadia] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada; [Bottari, Carolina] Univ Montreal, Sch Rehabil, Montreal, PQ, Canada; [Chen, Jen-Kai; Huntgeburth, Sonja Christina; Petrides, Michael; Ptito, Alain] Montreal Neurol Hosp & Inst, Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; [Huntgeburth, Sonja Christina; Petrides, Michael; Ptito, Alain] McGill Univ, Dept Psychol, Montreal, PQ H3A 2B4, Canada; [Ptito, Alain] McGill Univ, Montreal Gen Hosp, Ctr Hlth, Montreal, PQ H3A 2B4, Canada; [De Beaumont, Louis] Univ Quebec Trois Rivieres, Dept Psychol, Toronto, ON, Canada; [Cheung, Bob] Def Res & Dev Canada, Toronto, ON, Canada	Ptito, A (corresponding author), McGill Univ, Montreal Neurol Inst, Cognit Neurosci Unit, Neuropsychol Dept, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.ptito@mcgill.ca			Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MOP-64271]; Defence Research & Development Canada (DRDC-CR) [DRDC-CR W7711-088134/001/TOR]; Fonds pour la Recherche du Quebec-Sante	This study was supported by the Canadian Institutes of Health Research (CIHR operating grant MOP-64271 to A. P. and M. P., and fellowships to N.G. and C. B.); by the Defence Research & Development Canada (DRDC-CR W7711-088134/001/TOR-contract to A. P.); and by the Fonds pour la Recherche du Quebec-Sante (fellowship to N.G. and J.K.C.). No competing financial interests exist.	Ally BA, 2007, NEUROIMAGE, V35, P378, DOI [10.1016/j.neuroimage.2006.11.023, 10.1016/j.neuroimage.2006.12.023]; Barch DM, 2012, TRENDS COGN SCI, V16, P27, DOI 10.1016/j.tics.2011.11.015; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bigler ED, 2009, J HEAD TRAUMA REHAB, V24, P76, DOI 10.1097/HTR.0b013e31819c2190; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bottari C, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/837301; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Champod AS, 2007, P NATL ACAD SCI USA, V104, P14837, DOI 10.1073/pnas.0607101104; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Erez ABH, 2009, AM J OCCUP THER, V63, P634; Gosselin N, 2012, J NEUROTRAUMA; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Hamilton JP, 2012, AM J PSYCHIAT, V169, P693, DOI 10.1176/appi.ajp.2012.11071105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Petrides M, 2005, PHILOS T ROY SOC B, V360, P781, DOI 10.1098/rstb.2005.1631; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; PETRIDES M, 1995, J NEUROSCI, V15, P359; Polich John, 2004, Phys Med Rehabil Clin N Am, V15, P133, DOI 10.1016/S1047-9651(03)00109-8; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Tremblay S, 2012, CEREB CORTEX; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298	49	30	30	1	53	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E7	10.3171/2012.10.FOCUS12253			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500008	23199430				2021-06-18	
J	Terry, DP; Faraco, CC; Smith, D; Diddams, MJ; Puente, AN; Miller, LS				Terry, Douglas P.; Faraco, Carlos C.; Smith, Devin; Diddams, Max J.; Puente, Antonio N.; Miller, L. Stephen			Lack of long-term fMRI differences after multiple sports-related concussions	BRAIN INJURY			English	Article						FMRI; concussion; TBI; mild TBI; MTBI; Stroop; OSPAN; operation span	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; MINOR HEAD-INJURY; WORKING-MEMORY; RECURRENT CONCUSSION; POSTCONCUSSION SYNDROME; FUNCTIONAL ACTIVATION; RESPONSE-INHIBITION; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX	Introduction: Mild traumatic brain injury (mTBI) or concussion has been acutely associated with several cognitive symptoms, including deficits in response inhibition, working memory and motor performance. The pervasiveness of these cognitive symptoms has been more controversial. The effects of multiple concussions on neuropsychological functioning and brain activation following at least 6-months post-mTBI were examined. Methods: Twenty right-handed male athletes with a history of at least two concussions and 20 age/pre-morbid IQ/athletic-experience matched controls underwent neuropsychological assessment and fMRI scanning where they performed versions of a colour-word Stroop interference task, an operation-span working memory task and a finger-tapping task. Results: The Attention index score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was lower for the concussion group, but only at liberal statistical threshold. Total RBANS score approached statistical significance. Reaction time during neurobehavioural tasks was similar across groups, but accuracy was reduced in the concussed group on the working memory task. Despite expected activation patterns within each group, there were no group differences in neural activation on any functional tasks using either whole-brain or ROI-specific analyses at liberal statistical thresholds. Conclusion: There were minimal differences between the two closely matched groups. Results point to the relative plasticity of younger adults' cognitive abilities following concussion.	[Terry, Douglas P.; Faraco, Carlos C.; Smith, Devin; Miller, L. Stephen] Univ Georgia, BioImaging Res Ctr, Athens, GA 30602 USA; [Terry, Douglas P.; Faraco, Carlos C.; Puente, Antonio N.; Miller, L. Stephen] Univ Georgia, Dept Psychol, Athens, GA 30602 USA; [Smith, Devin] Georgia Hlth Sci Univ, Med Coll Georgia, Augusta, GA USA; [Diddams, Max J.] Carleton Coll, Dept Neurosci, Northfield, MN 55057 USA	Miller, LS (corresponding author), Univ Georgia, BioImaging Res Ctr, Coverdell Room 119B, Athens, GA 30602 USA.	lsmiller@uga.edu					Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Aron AR, 2005, BIOL PSYCHIAT, V57, P1285, DOI 10.1016/j.biopsych.2004.10.026; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Cabeza R, 1997, J NEUROSCI, V17, P391; *CDCP, 2007, MORTALITY MORBIDITY, V0056; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Desmond JE, 2002, J NEUROSCI METH, V118, P115, DOI 10.1016/S0165-0270(02)00121-8; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dimoska-Di Marco A, 2011, J CLIN EXP NEUROPSYC, V33, P471, DOI 10.1080/13803395.2010.533158; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; EVANS RW, 1992, NEUROL CLIN, V10, P815; Faraco CC, 2011, NEUROIMAGE, V55, P773, DOI 10.1016/j.neuroimage.2010.12.033; Fletcher PC, 1998, ARCH GEN PSYCHIAT, V55, P1001, DOI 10.1001/archpsyc.55.11.1001; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Jang SH, 2002, AM J PHYS MED REHAB, V81, P844, DOI 10.1097/00002060-200211000-00007; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; KAWASHIMA R, 1994, BRAIN RES, V663, P251, DOI 10.1016/0006-8993(94)91270-X; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kondo H, 2004, NEUROIMAGE, V21, P2, DOI 10.1016/j.neuroimage.2003.09.046; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mani TM, 2007, NEUROCASE, V13, P229, DOI 10.1080/13554790701594862; Mani TM, 2007, BRAIN INJURY, V21, P1155, DOI 10.1080/02699050701687367; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Oztekin I, 2009, J COGNITIVE NEUROSCI, V21, P581, DOI 10.1162/jocn.2008.21016; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wager TD, 2005, NEUROIMAGE, V27, P323, DOI 10.1016/j.neuroimage.2005.01.054; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Yoo SS, 2005, INT J NEUROSCI, V115, P55, DOI 10.1080/00207450490512650	77	30	30	1	64	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1684	1696		10.3109/02699052.2012.722259			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700014	23163249				2021-06-18	
J	Yin, LL; Ye, SS; Chen, Z; Zeng, YY				Yin, Lele; Ye, Shasha; Chen, Zhen; Zeng, Yaoying			Rapamycin Preconditioning Attenuates Transient Focal Cerebral Ischemia/Reperfusion Injury in Mice	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						2, 3, 5-Triphenyltetrazoluim Chloride staining (TTC staining); apoptosis, preconditioning, rapamycin, transient focal ischemic/reperfusion	FACTOR-KAPPA-B; ARTERY OCCLUSION; ISCHEMIC TOLERANCE; BRAIN; APOPTOSIS; PROTECTS; NEURONS; FK506; INHIBITION; MODELS	Rapamycin, an mTOR inhibitor and immunosuppressive agent in clinic, has protective effects on traumatic brain injury and neurodegenerative diseases. But, its effects on transient focal ischemia/reperfusion disease are not very clear. In this study, we examined the effects of rapamycin preconditioning on mice treated with middle cerebral artery occlusion/reperfusion operation (MCAO/R). We found that the rapamycin preconditioning by intrahippocampal injection 20 hr before MCAO/R significantly improved the survival rate and longevity of mice. It also decreased the neurological deficit score, infracted areas and brain edema. In addition, rapamycin preconditioning decreased the production of NF-kappa B, TNF-alpha, and Bax, but not Bcl-2, an antiapoptotic protein in the ischemic area. From these results, we may conclude that rapamycin preconditioning attenuate transient focal cerebral ischemia/reperfusion injury and inhibits apoptosis induced by MCAO/R in mice.	[Yin, Lele; Ye, Shasha; Chen, Zhen; Zeng, Yaoying] Jinan Univ, Inst Tissue Transplantat & Immunol, Guangzhou 510632, Guangdong, Peoples R China; [Yin, Lele] Jinan Univ, Affiliated Hosp 1, Guangzhou 510632, Guangdong, Peoples R China	Zeng, YY (corresponding author), Jinan Univ, Inst Tissue Transplantat & Immunol, Guangzhou 510632, Guangdong, Peoples R China.	tzengyy@jnu.edu.cn			Major Project of Chinese National Programs for Fundamental Research [2004CB720100, 2006CB504200]; Science and Technology Development Program of Guangdong Province [2010A080407005]	This study was supported by the Major Project of Chinese National Programs for Fundamental Research (No. 2004CB720100 and No. 2006CB504200) and Science and Technology Development Program of Guangdong Province (No. 2010A080407005).	Alyea EP, 2008, BIOL BLOOD MARROW TR, V14, P920, DOI 10.1016/j.bbmt.2008.05.024; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bochelen D, 1999, J PHARMACOL EXP THER, V288, P653; Boersma MC, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.16pe7; Chauhan A, 2011, BEHAV BRAIN RES, V225, P603, DOI 10.1016/j.bbr.2011.08.035; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Ferrer I, 2003, NEUROPATH APPL NEURO, V29, P472, DOI 10.1046/j.1365-2990.2003.00485.x; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hata R, 1998, J CEREBR BLOOD F MET, V18, P367, DOI 10.1097/00004647-199804000-00004; Herber DL, 2006, GLIA, V53, P382, DOI 10.1002/glia.20272; Hua F, 2009, BRAIN RES, V1262, P100, DOI 10.1016/j.brainres.2009.01.018; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Li JS, 2009, NEUROSCIENCE, V159, P1309, DOI 10.1016/j.neuroscience.2009.01.011; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Malagelada C, 2010, J NEUROSCI, V30, P1166, DOI 10.1523/JNEUROSCI.3944-09.2010; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Noh WC, 2004, CLIN CANCER RES, V10, P1013, DOI 10.1158/1078-0432.CCR-03-0043; O'Neill MJ, 2001, CURR PROTEC NEUROSCI, P961; Parker EM, 2000, NEUROPHARMACOLOGY, V39, P1913, DOI 10.1016/S0028-3908(00)00028-9; Puisieux F, 2004, BRAIN RES, V1027, P30, DOI 10.1016/j.brainres.2004.08.067; Rangamani P, 2007, BIOTECHNOL BIOENG, V97, P1216, DOI 10.1002/bit.21307; Ridder DA, 2009, NEUROSCIENCE, V158, P995, DOI 10.1016/j.neuroscience.2008.07.007; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Santos RX, 2011, J NEUROCHEM, V117, P927, DOI 10.1111/j.1471-4159.2011.07262.x; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Stagliano NE, 1999, J CEREBR BLOOD F MET, V19, P757, DOI 10.1097/00004647-199907000-00005; Stephenson D, 2000, J CEREBR BLOOD F MET, V20, P592, DOI 10.1097/00004647-200003000-00017; Trendelenburg G, 2005, GLIA, V50, P307, DOI 10.1002/glia.20204; Zhang HL, 2008, J NEUROSCI RES, V86, P1132, DOI 10.1002/jnr.21569; Zhang XJ, 2004, CAN J ANAESTH, V51, P258, DOI 10.1007/BF03019107	35	30	34	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0020-7454	1563-5279		INT J NEUROSCI	Int. J. Neurosci.	DEC	2012	122	12					748	756		10.3109/00207454.2012.721827			9	Neurosciences	Neurosciences & Neurology	034QV	WOS:000310888900009	22901235				2021-06-18	
J	Henkin, RI; Schultz, M; Minnick-Poppe, L				Henkin, Robert I.; Schultz, Michael; Minnick-Poppe, Laura			Intranasal Theophylline Treatment of Hyposmia and Hypogeusia A Pilot Study	ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY			English	Article							NASAL MUCUS; PARKINSONS-DISEASE; PAROTID-SALIVA; ETIOLOGIC RELATIONSHIPS; OLFACTORY DYSFUNCTION; CYCLIC-NUCLEOTIDES; SMELL DYSFUNCTION; TASTE; BLOOD; TRANSPORT	Objective: To determine whether intranasal theophylline methylpropyl paraben can correct hyposmia and hypogeusia. Design: We performed an open-label pilot study in patients with hyposmia and hypogeusia under the following 3 conditions: (1) before treatment, (2) after oral theophylline anhydrous treatment, and (3) after intranasal theophylline treatment. Under each condition, we performed subjective evaluations of taste and smell functions, quantitative measurements of taste (gustometry) and smell (olfactometry), and measurements of serum theophylline level and body weight. Setting: The Taste and Smell Clinic in Washington, DC. Patients: Ten patients with hyposmia and hypogeusia clinically related to the effects of viral illness, allergic rhinitis, traumatic brain injury, congenital hyposmia, and other chronic disease processes were selected. Interventions: Oral theophylline anhydrous, 200 to 800 mg/d for 2 to 12 months, was administered to each patient. This treatment was discontinued for 3 weeks to 4 months when intranasal theophylline methylpropyl paraben, 20 mu g/d in each naris, was administered for 4 weeks. Main Outcome Measures: At termination of each condition, taste and smell function was determined subjectively, by means of gustometry and olfactometry, with measurement of serum theophylline levels and body weight. Results: Oral theophylline treatment improved taste and smell acuity in 6 patients after 2 to 12 months of treatment. Intranasal theophylline treatment improved taste and smell acuity in 8 patients after 4 weeks, with improvement greater than after oral administration. No adverse effects accompanied intranasal drug use. Body weight increased with each treatment but was greater after intranasal than after oral administration. Conclusions: Intranasal theophylline treatment is safer and more effective in improving hyposmia and hypogeusia than oral theophylline anhydrous treatment. Arch Otolaryngol Head Neck Surg. 2012;138(11):1064-1070	[Henkin, Robert I.] Taste & Smell Clin, Ctr Mol Nutr & Sensory Disorders, Washington, DC 20016 USA; [Schultz, Michael] Fdn Care, Earth City, MO USA; [Minnick-Poppe, Laura] St Louis Coll Pharm, St Louis, MO USA	Henkin, RI (corresponding author), Taste & Smell Clin, Ctr Mol Nutr & Sensory Disorders, 5125 MacArthur Blvd NW,Ste 20, Washington, DC 20016 USA.	doc@tasteandsmell.com					Al Suleimani YM, 2007, PHARMACOL THERAPEUT, V114, P233, DOI 10.1016/j.pharmthera.2007.01.012; ANSARI KA, 1976, EUR NEUROL, V14, P138, DOI 10.1159/000114736; Banks WA, 2004, EUR J PHARMACOL, V490, P5, DOI 10.1016/j.ejphar.2004.02.040; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579; Briner HR, 2003, CLIN OTOLARYNGOL, V28, P417, DOI 10.1046/j.1365-2273.2003.00735.x; Bush A, 2009, NEW ENGL J MED, V360, P409, DOI 10.1056/NEJMe0808951; Chow HHS, 1999, J PHARM SCI, V88, P754; CHURCH JA, 1978, ANN ALLERGY, V40, P105; CONSTANTINESCU CS, 1994, J NEUROL NEUROSUR PS, V57, P1011, DOI 10.1136/jnnp.57.8.1011; Cullen MM, 1999, MED CLIN N AM, V83, P57, DOI 10.1016/S0025-7125(05)70087-0; Dahlin M, 2000, PHARMACEUT RES, V17, P737, DOI 10.1023/A:1007542618378; Dahlin M, 2001, EUR J PHARM SCI, V14, P75, DOI 10.1016/S0928-0987(01)00151-8; Dahlin M, 2000, INT J PHARM, V195, P197, DOI 10.1016/S0378-5173(99)00392-0; DJUKANOVIC R, 1995, EUR RESPIR J, V8, P831; Dorman DC, 2002, J TOXICOL ENV HEAL A, V65, P1493, DOI 10.1080/00984100290071630; Doty RL, 1997, CHEM SENSES, V22, P565, DOI 10.1093/chemse/22.5.565; DOTY RL, 1992, J NEUROL NEUROSUR PS, V55, P138, DOI 10.1136/jnnp.55.2.138; Doty RL, 1997, NEW ENGL J MED, V336, P1918, DOI 10.1056/NEJM199706263362617; English GM, 1993, OTOLARYNGOLOGY, V2, P1; EVANS J, 1992, FUND APPL TOXICOL, V19, P275, DOI 10.1016/0272-0590(92)90161-A; FJELLESTADPAULSEN A, 1987, ARCH DIS CHILD, V62, P674, DOI 10.1136/adc.62.7.674; Gudziol V, 2009, ARCH OTOLARYNGOL, V135, P291, DOI 10.1001/archoto.2008.524; Harris R, 2006, AM J RHINOL, V20, P101, DOI 10.1177/194589240602000119; Henkin R, 2004, ENCY NEUROSCIENCE, P2010; Henkin RI, 2008, CLIN INVEST MED, V31, pE78; Henkin RI, 2008, CLIN INVEST MED, V31, pE71; Henkin RI, 2010, NUTRITION, V26, P624, DOI 10.1016/j.nut.2009.08.003; Henkin R. I., 2011, HDB GROWTH GROWTH MO, VII, P1417; Henkin RI, 2006, J INVEST MED, V54, pS378; HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006; Henkin RI, 2003, NUTRITION, V19, P1013, DOI 10.1016/j.nut.2003.08.006; Henkin RI, 2002, J COMPUT ASSIST TOMO, V26, P39, DOI 10.1097/00004728-200201000-00008; HENKIN RI, 1967, LANCET, V2, P1268; HENKIN RI, 1971, LANCET, V1, P823; HENKIN RI, 1984, BIOL TRACE ELEM RES, V6, P263, DOI 10.1007/BF02917511; HENKIN RI, 1975, ANN OTO RHINOL LARYN, V84, P672, DOI 10.1177/000348947508400519; Henkin RI, 1996, FASEB J, V10, P3900; HENKIN RI, 1976, SCI FDN OTOLARYNGOLO, P469; Henkin RI, 1981, OLFACTORY REV, V1, P1; Henkin RI, 2000, AM J RHINOL, V14, pA; Henkin RI, 2007, AM J MED SCI, V334, P431, DOI 10.1097/MAJ.0b013e3180de4d97; Henkin RI, 2012, ARCH ORAL BIOL, V57, P670, DOI 10.1016/j.archoralbio.2012.01.004; Henkin RI, 2012, J CLIN PATHOL, V65, P447, DOI 10.1136/jclinpath-2012-200698; Henkin RI, 2012, THER DRUG MONIT, V34, P217, DOI 10.1097/FTD.0b013e3182492a20; Henkin RI, 2011, NAT BIOTECHNOL, V29, P480, DOI 10.1038/nbt.1866; Henkin RI, 2011, AM J MED SCI, V341, P17, DOI 10.1097/MAJ.0b013e3181f1fdc8; Henkin RI, 2009, AM J MED SCI, V337, P396, DOI 10.1097/MAJ.0b013e3181914a97; Henkin RI, 2009, METABOLISM, V58, P1717, DOI 10.1016/j.metabol.2009.05.027; HODGES RE, 1978, AM J CLIN NUTR, V31, P876; Hummel T, 2005, J NEURAL TRANSM, V112, P669, DOI 10.1007/s00702-004-0207-y; Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022539; JORGENSEN M B, 1961, Acta Otolaryngol, V53, P539, DOI 10.3109/00016486109126521; Kastin AJ, 2006, ENDOCRINOLOGY, V147, P2086, DOI 10.1210/en.2006-0208; KESSLAK JP, 1988, NEUROBIOL AGING, V9, P399, DOI 10.1016/S0197-4580(88)80087-3; Kubek MJ, 2001, BLOOD BRAIN BARRIER, P331; LAW JS, 1986, BIOCHEM MED METAB B, V36, P118, DOI 10.1016/0885-4505(86)90115-5; Liberini P, 2000, J NEUROL, V247, P88, DOI 10.1007/PL00007803; Mattsson LA, 2000, AM J OBSTET GYNECOL, V182, P545, DOI 10.1067/mob.2000.104843; Moberg PJ, 1997, INT J NEUROSCI, V89, P133, DOI 10.3109/00207459708988468; Moharram R, 2004, FASEB J, V18, pA201; Ozben T, 2004, NATO SCI SERIES 1, V358; PARDRIDGE WM, 1985, J NEUROCHEM, V44, P1771, DOI 10.1111/j.1471-4159.1985.tb07167.x; Putcha L, 1996, J PHARM SCI, V85, P899, DOI 10.1021/js950327b; REINHARDT RR, 1994, ENDOCRINOLOGY, V135, P1753, DOI 10.1210/en.135.5.1753; SARKAR MA, 1992, PHARM RES-DORDR, V9, P1, DOI 10.1023/A:1018911206646; SCHECHTER PJ, 1974, J NEUROL NEUROSUR PS, V37, P802, DOI 10.1136/jnnp.37.7.802; SCHIFFMAN SS, 1983, NEW ENGL J MED, V308, P1337; Serby MJ, 2001, AM J PSYCHIAT, V158, P1534, DOI 10.1176/appi.ajp.158.9.1534; Syrett N, 2003, NEUROLOGY, V61, pS27, DOI 10.1212/WNL.61.8_suppl_4.S27; THORNE RG, 1995, BRAIN RES, V692, P278, DOI 10.1016/0006-8993(95)00637-6; Tissingh G, 2001, MOVEMENT DISORD, V16, P41, DOI 10.1002/1531-8257(200101)16:1<41::AID-MDS1017>3.0.CO;2-M; WARNER MD, 1986, BIOL PSYCHIAT, V21, P116, DOI 10.1016/0006-3223(86)90013-2; Watelet JB, 2009, DRUG METAB REV, V41, P301, DOI 10.1080/10837450902891204; WEINBERGER M, 1978, J PEDIATR-US, V92, P1, DOI 10.1016/S0022-3476(78)80058-4; Zheng YQ, 2004, WORLD J GASTROENTERO, V10, P3165; ZIAI F, 1978, ARCH INTERN MED, V138, P1382, DOI 10.1001/archinte.138.9.1382; Zivadinov R, 1999, J NEUROL SCI, V168, P127, DOI 10.1016/S0022-510X(99)00189-6	78	30	31	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0886-4470	1538-361X		ARCH OTOLARYNGOL	Arch. Otolaryngol. Head Neck Surg.	NOV	2012	138	11					1064	1070		10.1001/2013.jamaoto.342			7	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	055FH	WOS:000312400100010	23165381				2021-06-18	
J	Davis, MT; Loyd, AM; Shen, HYH; Mulroy, MH; Nightingale, RW; Myers, BS; Bass, CD				Davis, Matthew T.; Loyd, Andre M.; Shen, Han-yu Henry; Mulroy, Maura H.; Nightingale, Roger W.; Myers, Barry S.; Bass, Cameron Dale			The mechanical and morphological properties of 6 year-old cranial bone	JOURNAL OF BIOMECHANICS			English	Article						Bone; Cranial bone; Pediatric; Biomechanics; Strength; Skull; Mechanical properties; Injury; Structure	TRAUMATIC BRAIN-INJURY; DYNAMIC RESPONSE; INFANT SKULL; HEAD; SUTURE	Traumatic Brain Injury (TBI) is a leading cause of mortality and morbidity for children in the United States. The unavailability of pediatric cadavers makes it difficult to study and characterize the mechanical behavior of the pediatric skull. Computer based finite element modeling could provide valuable insights, but the utility of these models depends upon the accuracy of cranial material property inputs. In this study, 47 samples from one six year-old human cranium were tested to failure via four point bending to study the effects of strain rate and the structure of skull bone on modulus of elasticity and failure properties for both cranial bone and suture. The results show that strain rate does not have a statistically meaningful effect on the mechanical properties of the six year-old skull over the range of strain rates studied (average low rate of 0.045 s(-1), average medium rate of 0.44 s(-1), and an average high rate of 2.2 s(-1)), but that these properties do depend on the growth patterns and morphology of the skull. The thickness of the bone was found to vary with structure. The bending stiffness (per unit width) for tri-layer bone (12.32 +/- 5.18 Nm(2)/m) was significantly higher than that of cortical bone and sutures (5.58 +/- 1.46 Nm(2)/m and 3.70 +/- 1.88 Nm(2)/m respectively). The modulus of elasticity was 9.87 +/- 1.24 GPa for cranial cortical bone and 1.10 +/- 0.53 GPa for sutures. The effective elastic modulus of tri-layer bone was 3.69 +/- 0.92 GPa. Accurate models of the pediatric skull should account for the differences amongst these three distinct tissues in the six year-old skull. (C) 2012 Elsevier Ltd. All rights reserved.	[Davis, Matthew T.; Loyd, Andre M.; Shen, Han-yu Henry; Mulroy, Maura H.; Nightingale, Roger W.; Myers, Barry S.; Bass, Cameron Dale] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA	Nightingale, RW (corresponding author), Duke Univ, Dept Biomed Engn, Box 90281, Durham, NC 27708 USA.	rwn@duke.edu	Nightingale, Roger W/D-2872-2011				Baumer T.G., 2009, J BIOMECHANICAL ENG, V131; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Camacho DLA, 2001, J BIOMECH ENG-T ASME, V123, P432, DOI 10.1115/1.1389086; CARTER DR, 1976, SCIENCE, V194, P1174, DOI 10.1126/science.996549; Coats B., 2007, THESIS U PENNSYLVANI; Coats B, 2007, STAPP CAR CRASH JO, V51, P1; Coats B, 2006, J NEUROTRAUM, V23, P1222, DOI 10.1089/neu.2006.23.1222; Cohen M.M.J., 2000, EVALUATION MANAGEMEN; Desantis Klinich Kathleen, 2002, Stapp Car Crash J, V46, P165; DUTERLOO HS, 1970, AM J ANAT, V127, P357, DOI 10.1002/aja.1001270403; Evans F.G., 1956, J APPL PHYSIOL, V10, P493; Guan FJ, 2011, ANN BIOMED ENG, V39, P85, DOI 10.1007/s10439-010-0125-0; Hibbeler, 2003, BENDING MECH MAT, P324; James HE, 1999, ACT NEUR S, V73, P85; KRIEWALL TJ, 1981, J BIOMECH, V14, P73, DOI 10.1016/0021-9290(81)90166-4; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; MCELHANEY JH, 1966, J APPL PHYSIOL, V21, P1231; MCPHERSON GK, 1980, J BIOMECH, V13, P17, DOI 10.1016/0021-9290(80)90004-4; MCPHERSON GK, 1980, J BIOMECH, V13, P9, DOI 10.1016/0021-9290(80)90003-2; Mulroy M.H., 2011, EVALUATION PEDIAT SK; Nightingale R.W., 1997, P 41 STAPP CAR CRASH, V41, P451; Prange Michael T, 2004, Stapp Car Crash J, V48, P279; Roberts V.L., 1968, ACCIDENT PATHOLOGY; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8	27	30	35	1	30	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	OCT 11	2012	45	15					2493	2498		10.1016/j.jbiomech.2012.07.001			6	Biophysics; Engineering, Biomedical	Biophysics; Engineering	024KE	WOS:000310107300002	22939291				2021-06-18	
J	Lafrenaye, AD; McGinn, MJ; Povlishock, JT				Lafrenaye, Audrey D.; McGinn, Melissa J.; Povlishock, John T.			Increased intracranial pressure after diffuse traumatic brain injury exacerbates neuronal somatic membrane poration but not axonal injury: evidence for primary intracranial pressure-induced neuronal perturbation	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						animal models; basic science; brain trauma; cathepsin-B; intracranial pressure; membrane poration	CATHEPSIN-B; MECHANICAL STRETCH; CEREBRAL-ISCHEMIA; HEMORRHAGIC-SHOCK; DEATH; CELLS; PERMEABILITY; RELEASE; IMPACT	Increased intracranial pressure (ICP) associated with traumatic brain injury (TBI) is linked to increased morbidity. Although our understanding of the pathobiology of TBI has expanded, questions remain regarding the specific neuronal somatic and axonal damaging consequences of elevated ICP, independent of its impact on cerebral perfusion pressure (CPP). To investigate this, Fischer rats were subjected to moderate TBI. Measurements of ICP revealed two distinct responses to injury. One population exhibited transient increases in ICP that returned to baseline levels acutely, while the other displayed persistent ICP elevation (>20 mm Hg). Utilizing these populations, the effect of elevated ICP on neuronal pathology associated with diffuse TBI was analyzed at 6 hours after TBI. No difference in axonal injury was observed, however, rats exhibiting persistently elevated ICP postinjury revealed a doubling of neurons with chronic membrane poration compared with rats exhibiting only transient increases in ICP. Elevated postinjury ICP was not associated with a concurrent increase in DNA damage; however, traditional histological assessments did reveal increased neuronal damage, potentially associated with redistribution of cathepsin-B from the lysosomal compartment into the cytosol. These findings indicate that persistently increased ICP, without deleterious alteration of CPP, exacerbates neuronal plasmalemmal perturbation that could precipitate persistent neuronal impairment and ultimate neuronal death. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1919-1932; doi:10.1038/jcbfm.2012.95; published online 11 July 2012	[Lafrenaye, Audrey D.; McGinn, Melissa J.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 045824, NS 047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS045824] Funding Source: NIH RePORTER	This study is supported by NIH grants NS 045824 and NS 047463.	Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ellis RC, 2005, EXP NEUROL, V193, P19, DOI 10.1016/j.expneurol.2004.11.034; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Hill IE, 1997, BRAIN RES, V751, P206, DOI 10.1016/S0006-8993(96)01403-5; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc M, 2010, NEUROBIOL DIS, V40, P293, DOI 10.1016/j.nbd.2010.06.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; LAPLACA MC, 2009, EMBC 2009 ANN INT C, P1113; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Mollanji R, 2001, AM J PHYSIOL-REG I, V280, pR1573; Nagai A, 2005, BRAIN RES, V1066, P120, DOI 10.1016/j.brainres.2005.10.063; Nagra G, 2006, AM J PHYSIOL-REG I, V291, pR1383, DOI 10.1152/ajpregu.00235.2006; Navarro JC, 2012, J NEUROTRAUM, V29, P322, DOI 10.1089/neu.2011.1979; Oberle C, 2010, CELL DEATH DIFFER, V17, P1167, DOI 10.1038/cdd.2009.214; Pratt MR, 2009, CHEM BIOL, V16, P1001, DOI 10.1016/j.chembiol.2009.07.011; Reid WM, 2010, J NEUROTRAUM, V27, P1243, DOI 10.1089/neu.2010.1270; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Wang JY, 2011, J NEUROPATH EXP NEUR, V70, P314, DOI 10.1097/NEN.0b013e31821352bd; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yacoub A, 2006, MOL PHARMACOL, V70, P589, DOI 10.1124/mol.106.025007; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Yoshida M, 2002, ACTA NEUROPATHOL, V104, P267, DOI 10.1007/s00401-002-0554-4; Zhang HL, 2009, J IMMUNOL, V182, P6993, DOI 10.4049/jimmunol.0802502	40	30	30	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2012	32	10					1919	1932		10.1038/jcbfm.2012.95			14	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	014KY	WOS:000309375800010	22781336	Green Published, Bronze			2021-06-18	
J	Samson, AL; Knaupp, AS; Sashindranath, M; Borg, RJ; Au, AEL; Cops, EJ; Saunders, HM; Cody, SH; McLean, CA; Nowell, CJ; Hughes, VA; Bottomley, SP; Medcalf, RL				Samson, Andre L.; Knaupp, Anja S.; Sashindranath, Maithili; Borg, Rachael J.; Au, Amanda E. -L.; Cops, Elisa J.; Saunders, Helen M.; Cody, Stephen H.; McLean, Catriona A.; Nowell, Cameron J.; Hughes, Victoria A.; Bottomley, Stephen P.; Medcalf, Robert L.			Nucleocytoplasmic Coagulation: An Injury-Induced Aggregation Event that Disulfide Crosslinks Proteins and Facilitates Their Removal by Plasmin	CELL REPORTS			English	Article							ALZHEIMERS-DISEASE; OXIDATIVE STRESS; BINDING-PROTEIN; BOND FORMATION; BRAIN-INJURY; A-BETA; ACTIVATOR; STIMULATION; ISCHEMIA; IDENTIFICATION	Cellular injury causes a myriad of processes that affect proteostasis. We describe nucleocytoplasmic coagulation (NCC), an intracellular disulfide-dependent protein crosslinking event occurring upon late-stage cell death that orchestrates the proteolytic removal of misfolded proteins. In vitro and in vivo models of neuronal injury show that NCC involves conversion of soluble intracellular proteins, including tubulin, into insoluble oligomers. These oligomers, also seen in human brain tissue following neurotrauma, act as a cofactor and substrate for the plasminogen-activating system. In plasminogen(-/-) mice, levels of misfolded beta-tubulin were elevated and its clearance delayed following neurotrauma, demonstrating a requirement for plasminogen in the removal of NCC constituents. While additional in vivo studies will further dissect this phenomenon, our study clearly shows that NCC, a process analogous to the formation of thrombi, generates an aggregated protein scaffold that limits release of cellular components and recruits clearance mechanisms to the site of injury.	[Samson, Andre L.; Sashindranath, Maithili; Borg, Rachael J.; Au, Amanda E. -L.; Cops, Elisa J.; Medcalf, Robert L.] Monash Univ, AMREP, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; [Cody, Stephen H.] Monash Univ, AMREP, Monash Microimaging, Melbourne, Vic 3004, Australia; [Samson, Andre L.; Knaupp, Anja S.; Saunders, Helen M.; Hughes, Victoria A.; Bottomley, Stephen P.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; [McLean, Catriona A.] Alfred Hosp, Dept Pathol, Melbourne, Vic 3004, Australia; [Nowell, Cameron J.] Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Parkville Branch, Parkville, Vic 3050, Australia	Borg, RJ (corresponding author), Monash Univ, AMREP, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia.	andre.samson@monash.edu; robert.medcalf@monash.edu	Medcalf, Robert L/E-9632-2011; Sashindranath, Maithili/AAI-7408-2021	Sashindranath, Maithili/0000-0002-9712-4784; Knaupp, Anja/0000-0003-0493-7872; Samson, Andre/0000-0002-0637-2716; Nowell, Cameron/0000-0002-8662-9840	Victorian Brain Bank Network; Mental Health Research Institute; The Alfred; National Trauma Research Institute; Victorian Forensic Institute of Medicine; Victorian Neurotrauma Initiative; TAC; Australia's NHMRCNational Health and Medical Research Council of Australia; NH&MRC of AustraliaNational Health and Medical Research Council of Australia; Monash University Faculty of Medicine, Nursing and Health Sciences Strategic Grant; Australian Postgraduate AwardAustralian Government; Faculty Postgraduate Scholarship	We thank Professor Charles G. Glabe for kindly providing the conformation-specific antibodies. Tissues were received from the Neurotrauma Tissue/Fluid Bank, supported by the Victorian Brain Bank Network, Mental Health Research Institute, The Alfred, National Trauma Research Institute, and Victorian Forensic Institute of Medicine and funded by Victorian Neurotrauma Initiative, the TAC, and Australia's NH&MRC. We thank Monash Biomedical Proteomic facility for peptide mass fingerprinting and Dr. Kris Hall for assistance with image processing. We thank the Burnet Institute (Victoria, Australia) for use of the Zeiss Cell Observer system. We acknowledge Mr. Be'eri Niego and Dr. Amy Robertson for constructive comments. This study was supported by grants awarded to A.L.S., S.P.B., and R.L.M. by the NH&MRC of Australia, by a Monash University Faculty of Medicine, Nursing and Health Sciences Strategic Grant awarded to A.L.S. and by an Australian Postgraduate Award and Faculty Postgraduate Scholarship awarded to A.E.-L.A. and R.J.B., respectively.	Bergemalm D, 2010, J NEUROCHEM, V114, P408, DOI 10.1111/j.1471-4159.2010.06753.x; Brennan JP, 2004, J BIOL CHEM, V279, P41352, DOI 10.1074/jbc.M403827200; Brown A. W., 1972, THROMB HAEMOSTASIS, V16, P59; Cumming RC, 2005, FASEB J, V19, P2060, DOI 10.1096/fj.05-4195fje; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Fernandez-Monreal M, 2004, MOL CELL NEUROSCI, V25, P594, DOI 10.1016/j.mcn.2003.11.002; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Gebbink MFBG, 2011, J THROMB HAEMOST, V9, P174, DOI 10.1111/j.1538-7836.2011.04278.x; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; Hu BR, 2001, J CEREBR BLOOD F MET, V21, P865, DOI 10.1097/00004647-200107000-00012; Huang JS, 2009, BRAIN RES, V1279, P1, DOI 10.1016/j.brainres.2009.05.011; Jacobsen JS, 2008, P NATL ACAD SCI USA, V105, P8754, DOI 10.1073/pnas.0710823105; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; KINGSTON IB, 1995, NAT MED, V1, P138; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kranenburg O, 2002, CURR BIOL, V12, P1833, DOI 10.1016/S0960-9822(02)01224-1; Kuhn DM, 2011, J NEUROCHEM, V116, P426, DOI 10.1111/j.1471-4159.2010.07123.x; Ledesma MD, 2000, EMBO REP, V1, P530; Lia LJ, 2004, J BIOL CHEM, V279, P37061, DOI 10.1074/jbc.M403672200; Longstaff C, 2011, BLOOD, V117, P661, DOI 10.1182/blood-2010-06-290338; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Maas C, 2008, AMYLOID, V15, P166, DOI 10.1080/13506120802193498; Nakajima H, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M704199200; Nakajima H, 2009, J BIOL CHEM, V284, P34331, DOI 10.1074/jbc.M109.027698; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; RADCLIFFE R, 1981, ARCH BIOCHEM BIOPHYS, V211, P750, DOI 10.1016/0003-9861(81)90512-9; Roussel BD, 2009, BRAIN, V132, P2219, DOI 10.1093/brain/awp162; Samson AL, 2008, J NEUROCHEM, V107, P1091, DOI 10.1111/j.1471-4159.2008.05687.x; Samson AL, 2009, BLOOD, V114, P1937, DOI 10.1182/blood-2009-02-203448; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Sui HX, 2010, STRUCTURE, V18, P1022, DOI 10.1016/j.str.2010.05.010; Sultana R, 2009, ACTA NEUROPATHOL, V118, P131, DOI 10.1007/s00401-009-0517-0; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wang Q, 2005, FASEB J, V19, P869, DOI 10.1096/fj.04-3210fje	40	30	30	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	OCT	2012	2	4					889	901		10.1016/j.celrep.2012.08.026			13	Cell Biology	Cell Biology	083IA	WOS:000314455600020	23041318	DOAJ Gold			2021-06-18	
J	Jiang, Y; Brody, DL				Jiang, Yong; Brody, David L.			Administration of COG1410 Reduces Axonal Amyloid Precursor Protein Immunoreactivity and Microglial Activation after Controlled Cortical Impact in Mice	JOURNAL OF NEUROTRAUMA			English	Article						COG1410; controlled cortical impact injury; microglia; neuroprotection; traumatic axonal injury	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; CYCLOSPORINE-A; WHITE-MATTER; MIMETIC PEPTIDES; APOE; DAMAGE; MODEL	Traumatic axonal injury (TAI) accounts for at least 35% of the morbidity and mortality in traumatic brain injury (TBI) patients without space-occupying lesions. It is also believed to be a key determinant of adverse outcomes such as cognitive dysfunction across the spectrum of TBI severity. Previous studies have shown that COG1410, a synthetic peptide derived from the apolipoprotein E (apoE) receptor binding region, has anti-inflammatory effects after experimental TBI, with improvements in cognitive recovery. However, the effects of COG1410 on axonal injury following TBI are not known. The current study evaluated the effects of 1 mg/kg daily COG1410 versus saline administered intravenously starting 30 min after controlled cortical impact (CCI) injury on pericontusional TAI in young, wild-type C57BL6/J male mice. We found that COG1410 did not affect the number of amyloid precursor protein (APP)-immunoreactive axonal varicosities in the pericontusional corpus callosum and external capsule at 24 h, but reduced APP-immunoreactive varicosities by 31% at 3 days (p = 0.0023), and 36% at 7 days (p = 0.0009). COG1410 significantly reduced the number of Iba1-positive cells with activated microglial morphology at all three time points by 21-30%. There was no effect of COG1410 on pericontusional white matter volume or silver staining at any time point. This indicates a possible effect of COG1410 on delayed but not immediate TAI. Future studies are needed to investigate the underlying mechanisms, therapeutic time window, and physiological implications of this effect.	[Jiang, Yong; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Jiang, Yong] Luzhou Med Coll, Affiliated Hosp, Dept Neurosurg, Luzhou, Peoples R China; [Brody, David L.] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81000528, 30973087]; Foundation for Sci & Tech Research Project of Sichuan Province [2009JY0126]; Project Foundation of Health Bureau of Sichuan Province [090217]; Project Foundation of Sichuan Province Education Committee [08zb049]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065069]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065069] Funding Source: NIH RePORTER	This work was supported by the National Natural Science Foundation of China (grants 81000528 and 30973087), the Foundation for Sci & Tech Research Project of Sichuan Province (grant 2009JY0126), the Project Foundation of Health Bureau of Sichuan Province (grant 090217), the Project Foundation of Sichuan Province Education Committee (grant 08zb049), and the NIH (grant NS065069). We thank Thomas Esparza, Rachel Bennett, and Hien Tran for technical assistance, and Dr. David Holtzman for the use of his stereology system. We thank Cognosci Inc. for providing COG1410. None of the authors has a financial interest in Cognosci Inc.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Fujita M, 2011, J NEUROTRAUM, V28, P1209, DOI 10.1089/neu.2011.1852; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oda Y, 2011, J CEREBR BLOOD F MET, V31, P1143, DOI 10.1038/jcbfm.2010.208; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sun XC, 2008, CHIN J TRAUMATOL, V11, P247, DOI 10.1016/S1008-1275(08)60051-6; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tukhovskaya EA, 2009, J NEUROSCI RES, V87, P677, DOI 10.1002/jnr.21874; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	70	30	39	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	13					2332	2341		10.1089/neu.2012.2362			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000PU	WOS:000308399900009	22676717	Green Published			2021-06-18	
J	Sanchez-Porras, R; Santos, E; Czosnyka, M; Zheng, Z; Unterberg, AW; Sakowitz, OW				Sanchez-Porras, Renan; Santos, Edgar; Czosnyka, Marek; Zheng, Zelong; Unterberg, Andreas W.; Sakowitz, Oliver W.			'Long' pressure reactivity index (L-PRx) as a measure of autoregulation correlates with outcome in traumatic brain injury patients	ACTA NEUROCHIRURGICA			English	Article						Cerebral autoregulation; Low-frequency pressure reactivity index; Microdialysis; Neuromonitoring; Outcome; Pressure reactivity index; Traumatic brain injury	CEREBRAL VASOMOTOR REACTIVITY; CEREBROVASCULAR AUTOREGULATION; PERFUSION-PRESSURE; MICRODIALYSIS; CHEMISTRY	Cerebral autoregulation and, consequently, cerebrovascular pressure reactivity, can be disturbed after traumatic brain injury (TBI). Continuous monitoring of autoregulation has shown its clinical importance as an independent predictor of neurological outcome. The cerebral pressure reactivity index (PRx) reflects that changes in seconds of cerebrovascular reactivity have prognostic significance. Using an alternative algorithm similar to PRx, we investigate whether the utilization of lower-frequency changes of the order of minutes of mean arterial blood pressure (MAP) and intracranial pressure (ICP) could have a prognostic value in TBI patients. Head-injured patients requiring continued advanced multimodal monitoring, including hemodynamic, ICP and microdialysis (MD) monitoring, were analyzed retrospectively. A low-frequency sample pressure reactivity index (L-PRx) was calculated, using 20-min averages of MAP and ICP data as a linear Pearson's correlation. The mean values per patient were correlated to outcome at 6 months after injury. Differences of monitoring parameters between non-survivors and survivors were compared. A total of 29 patients (mean age 37.2 years, 26 males) suffering from TBI were monitored for a mean of 109.6 h (16-236 h, SD +/- 60.4). Mean L-PRx was found to be of 0.1 (-0.2 to 0.6, SD +/- 0.20), six patients presented impaired (> 0.2) values. The averaged L-PRx correlated significantly with ICP (r = 0.467, p = 0.011) and 6-month outcome (r = -0.556, p = 0.002). Significant statistical differences were found in L-PRx, cerebral perfusion pressure (CPP), lactate, and lactate-pyruvate ratio when comparing patients who died (n = 5) and patients who survived. L-PRx correlates with the 6-month outcome in TBI patients. Very slow changes of MAP and ICP may contain important autoregulation information. L-PRx may be an alternative algorithm for the estimation of cerebral autoregulation and clinical prognosis.	[Sanchez-Porras, Renan] Heidelberg Univ, Dept Neurosurg, D-69120 Heidelberg, Germany; [Sanchez-Porras, Renan; Santos, Edgar; Zheng, Zelong; Unterberg, Andreas W.; Sakowitz, Oliver W.] Univ Heidelberg Hosp, Dept Neurosurg, Heidelberg, Germany; [Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Neurosurg Unit, Dept Clin Neurosci, Cambridge CB2 2QQ, England	Sanchez-Porras, R (corresponding author), Heidelberg Univ, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Renan.Sanchez-Porras@med.uni-heidelberg.de		Sanchez-Porras, Renan/0000-0002-9084-8114; Santos, Edgar/0000-0002-8976-5549	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G9439390] Funding Source: Medline		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chan MTV, 2005, ACT NEUR S, V95, P113; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Hejcl A, 2011, Cent Eur Neurosurg, V72, P1, DOI 10.1055/s-0031-1275745; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Low D, 2009, J NEUROTRAUM, V26, P1177, DOI [10.1089/neu.2008.0841, 10.1089/neu.2008-0841]; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Santos E, 2012, ACTA NEUROCHIRURGI S, P363; Santos E, 2011, ACTA NEUROCHIR, V153, P2189, DOI 10.1007/s00701-011-1148-5; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STRANDGAARD S, 1984, STROKE, V15, P413, DOI 10.1161/01.STR.15.3.413; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; White H, 2008, ANESTH ANALG, V107, P979, DOI 10.1213/ane.0b013e31817e7b1a; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	24	30	30	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	SEP	2012	154	9					1575	1581		10.1007/s00701-012-1423-0			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	994UF	WOS:000307957500006	22743796				2021-06-18	
J	Taub, E				Taub, Edward			The Behavior-Analytic Origins of Constraint-Induced Movement Therapy: An Example of Behavioral Neurorehabilitation	BEHAVIOR ANALYST			English	Article						CI therapy; CI movement therapy; Cl aphasia therapy; stroke; central nervous system injury; neurorehabilitation; behavior analysis	FOCAL HAND DYSTONIA; PHANTOM-LIMB PAIN; UPPER-EXTREMITY; CORTICAL REORGANIZATION; MOTOR RECOVERY; MONKEYS; APHASIA; STROKE; BRAIN; DEAFFERENTATION	Constraint-induced (CI) therapy is a term given to a family of efficacious neurorehabilitation treatments including to date: upper extremity Cl movement therapy, lower extremity CI movement therapy, pediatric CI therapy, and Cl aphasia therapy. The purpose of this article is to outline the behavior analysis origins of Cl therapy and the ways in which its procedures incorporate behavior analysis methods and principles. The intervention is founded on the concept of learned nonuse, a mechanism now empirically demonstrated to exist, which occurs after many different types of damage to the central nervous system (CNS). It results from the dramatic alteration of the contingencies of reinforcement that results from substantial CNS damage and leads to a greater deficit than is warranted by the actual damage sustained. CI therapy produces a countervailing alteration in the contingencies of reinforcement. The intervention has been used successfully to substantially improve motor deficits after stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, with cerebral palsy in a pediatric population, and for language impairment in poststroke aphasia. The protocol of Cl therapy consists primarily of standard behavior-analytic methods. It produces a marked plastic brain change that is correlated with its therapeutic effect, and therefore provides an example of the way in which behavior change can contribute to a profound remodeling of the brain. CI therapy may be viewed as an example of behavioral neurorehabilitation.	Univ Alabama Birmingham, Birmingham, AL 35294 USA	Taub, E (corresponding author), Univ Alabama Birmingham, 1530 3rd Ave S,CPM 712, Birmingham, AL 35294 USA.	etaub@uab.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD034273] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD034273] Funding Source: NIH RePORTER		Azrin N. H., 1966, OPERANT BEHAVIOR ARE, P380; Bauder H, 1999, PSYCHOPHYSIOLOGY, V36, pS31; Bhogal SK, 2003, STROKE, V34, P987, DOI 10.1161/01.STR.0000062343.64383.D0; Candia V, 1999, LANCET, V353, P42, DOI 10.1016/S0140-6736(05)74865-0; Candia V, 2002, ARCH PHYS MED REHAB, V83, P1342, DOI 10.1053/apmr.2002.35094; Catania A.C., 1998, LEARNING, Vinterim 4th; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DeBow SB, 2003, STROKE, V34, P1021, DOI 10.1161/01.STR.0000063374.89732.9F; Dettmers C, 2005, ARCH PHYS MED REHAB, V86, P204, DOI 10.1016/j.apmr.2004.05.007; Draganski B, 2006, NEUROIMAGE, V31, P951, DOI 10.1016/j.neuroimage.2006.01.018; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; Estes W. K., 1944, PSYCHOL MONOGR, V57; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Gauthier LV, 2008, STROKE, V39, P1520, DOI 10.1161/STROKEAHA.107.502229; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82; Kirmess M, 2010, APHASIOLOGY, V24, P725, DOI 10.1080/02687030903437682; KNAPP H D, 1959, Trans Am Neurol Assoc, V84, P185; KNAPP HD, 1963, EXP NEUROL, V7, P305, DOI 10.1016/0014-4886(63)90077-3; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Kunkel A, 1999, ARCH PHYS MED REHAB, V80, P624, DOI 10.1016/S0003-9993(99)90163-6; LASSEK AM, 1953, J NEUROPATH EXP NEUR, V12, P83, DOI 10.1097/00005072-195301000-00008; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Maher LM, 2006, J INT NEUROPSYCH SOC, V12, P843, DOI 10.1017/S1355617706061029; Mark VW, 2008, MULT SCLER J, V14, P992, DOI 10.1177/1352458508090223; Mark V. W., 2008, ARCH PHYS MED REHAB, V89, pE5; Meinzer M, 2007, NEUROREHABILITATION, V22, P311; Meinzer M, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-20; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; MORGAN WG, 1974, BEHAV THER, V5, P271, DOI 10.1016/S0005-7894(74)80144-9; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Panyan M.V., 1980, USE SHAPING; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; PULVERMULLER F, 1993, COGNITION, V48, P139, DOI 10.1016/0010-0277(93)90028-T; Pulvermuller F., 1990, APHASISCHE KOMMUNIKA; Raymer AM, 2008, J SPEECH LANG HEAR R, V51, pS259, DOI 10.1044/1092-4388(2008/020); Shaw S. E., 2003, J NEUROL PHYS THER, V27, P180, DOI [10.1682/JRRD.2005.06.0094, DOI 10.1682/JRRD.2005.06.0094]; Sherrington CS, 1910, BRAIN, V33, P1, DOI 10.1093/brain/33.1.1; Sherrington CS., 1894, P ROY SOC LONDON, V57, P481, DOI DOI 10.1098/RSP1.1894.0179; Skinner B. F., 1968, TECHNOLOGY TEACHING; Skinner BF, 1938, BEHAV ORGANISMS; Sterr A, 2002, ARCH PHYS MED REHAB, V83, P1374, DOI 10.1053/apmr.2002.35108; TAUB E, 1966, SCIENCE, V151, P593, DOI 10.1126/science.151.3710.593; TAUB E, 1975, EXP NEUROL, V46, P178, DOI 10.1016/0014-4886(75)90040-0; Taub E, 2006, Eura Medicophys, V42, P241; Taub E, 2006, STROKE, V37, P1045, DOI 10.1161/01.STR.0000206463.66461.97; TAUB E, 1977, ANN NY ACAD SCI, V290, P348, DOI 10.1111/j.1749-6632.1977.tb39737.x; Taub E, 2004, PEDIATRICS, V113, P305, DOI 10.1542/peds.113.2.305; TAUB E, 1973, SCIENCE, V181, P959, DOI 10.1126/science.181.4103.959; TAUB E, 1975, BIOL PSYCHIAT, V10, P609; TAUB E, 1963, J COMP PHYSIOL PSYCH, V56, P1012, DOI 10.1037/h0048315; Taub E, 1976, Exerc Sport Sci Rev, V4, P335; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; TAUB E, 1978, EXP NEUROL, V58, P1, DOI 10.1016/0014-4886(78)90116-4; Taub E, 1999, J REHABIL RES DEV, V36, P237; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; Taub E., 2008, GUIDE PHYS THERAPY P, P232; Taub E., 2006, CI THERAPY YOUNG CHI; Taub E., 2002, KLIN FORSCH, V8, P48; Taub E., 2009, HDB NEUROSCIENCE BEH, P1296; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; Taub E, 1968, NEUROPSYCHOL SPATIAL, P173; Taub Edward, 2007, Dev Neurorehabil, V10, P3, DOI 10.1080/13638490601151836; Taub E, 2011, J CHILD NEUROL, V26, P1163, DOI 10.1177/0883073811408423; TIMBERLAKE W, 1993, J EXP ANAL BEHAV, V60, P105, DOI 10.1901/jeab.1993.60-105; TWITCHELL TE, 1954, J NEUROPHYSIOL, V17, P239; Uswatte G, 2006, NEUROLOGY, V67, P1189, DOI 10.1212/01.wnl.0000238164.90657.c2; Uswatte G, 1997, REHABIL PSYCHOL, V42, P139; Uswatte G, 2005, STROKE, V36, P2493, DOI 10.1161/01.STR.0000185928.90848.2e; Uswatte G., 1997, ARCH PHYS MED REHAB, V78, P396; Uswatte G., 1998, IN M PROGR COGN REH; Uswatte G, 2006, NEUROREHABILITATION, V21, P147; van der Lee JH, 1999, ARCH PHYS MED REHAB, V80, P1606, DOI 10.1016/S0003-9993(99)90339-8; Weiss T, 1999, NEUROSCI LETT, V272, P131, DOI 10.1016/S0304-3940(99)00595-9; Wittenberg GF, 2003, NEUROREHAB NEURAL RE, V17, P48, DOI 10.1177/0888439002250456; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	78	30	32	0	18	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0738-6729	2196-8918		BEHAV ANALYST	Behav. Anal.	FAL	2012	35	2					155	178		10.1007/BF03392276			24	Psychology, Clinical	Psychology	050IY	WOS:000312048200003	23449867	Green Published			2021-06-18	
J	Wall, PLH				Wall, Pamela L. (Herbig)			Posttraumatic Stress Disorder and Traumatic Brain Injury in Current Military Populations: A Critical Analysis	JOURNAL OF THE AMERICAN PSYCHIATRIC NURSES ASSOCIATION			English	Article						posttraumatic stress disorder; PTSD; traumatic brain injury; TBI; postconcussive syndrome; veteran; military	PERSISTENT POSTCONCUSSIVE SYMPTOMS; NATIONAL-GUARD SOLDIERS; SERVICE MEMBERS; VETERANS; BLAST; PTSD; IRAQ; AFGHANISTAN; PREVALENCE; WAR	BACKGROUND: The use of unconventional weaponry combined with decreased mortality rates and servicemembers being exposed to intense ground combat during multiple deployments has increased the risk of servicemembers living with the consequences of traumatic brain injuries (TBI) and combat operational stress. OBJECTIVE: The purpose of this article is to perform a critical analysis of the literature to identify current rates of comorbid posttraumatic stress disorder (PTSD) and TBI in military and veteran populations who have served in Iraq or Afghanistan and their combined effects on persistent postconcussive symptoms. DESIGN: A search of the literature with military and veteran populations published after 2001 in Pubmed, OVID/Medline, Cochran Database, Embase, Scopus, CINAHL, and PsychInfo was conducted using keywords. RESULTS: Twenty studies met inclusion criteria. The literature search yielded mixed results for rates of PTSD, TBI, and comorbid conditions. CONCLUSIONS: There is some evidence that comorbid PTSD and TBI result in greater reports of postconcussive symptomology than either condition alone. Limitations include lack of consistency of measurements, sampling biases, and lack of experimental design, and these warrant further exploration. Future research is needed to decrease variability in study findings and elucidate relationships between these disorders and their effects on persistent postconcussive symptomology.	[Wall, Pamela L. (Herbig)] Univ Penn, Philadelphia, PA 19104 USA	Wall, PLH (corresponding author), 2nd Marine Corps Div, Div Psychiat, PSC Box 20003, Camp Lejuene, NC 28542 USA.	luvridley@aol.com			Jonas Center for Nursing excellence	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the author received an educational grant from the Jonas Center for Nursing excellence to support PhD program.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Centers for Disease Control and Prevention, 1975, INT CLASS DIS; Centers for Disease Control and Prevention, 1990, INT CLASS DIS 10 REV; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Defense and Veterans Brain Injury Center, 2011, MIL ACUT CONC EV INF; Department of Defense & Department of Veterans Affairs, 2009, CLIN PRACT GUID MAN; Department of Veterans Affairs, 2011, VA EL HOM; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Institute of Medicine, 2009, GULF WAR HLTH, V7; Iversen AC, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-31; Iverson A. C., 2008, PSYCHOL MED, V38, P1; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Ivins BJ, 2010, NEUROREHABILITATION, V26, P199, DOI 10.3233/NRE-2010-0556; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kim PY, 2010, PSYCHIAT SERV, V61, P582, DOI 10.1176/ps.2010.61.6.582; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Mclay RN, 2008, AM J PSYCHIAT, V165, P775, DOI 10.1176/appi.ajp.2008.07121960; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Phillips CJ, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-52; Polit DF, 2008, NURSING RES GENERATI; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Romesser J, 2011, MIL MED, V176, P246, DOI 10.7205/MILMED-D-10-00056; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Sandweiss DA, 2011, ARCH GEN PSYCHIAT, V68, P496, DOI 10.1001/archgenpsychiatry.2011.44; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Shen YC, 2010, MIL MED, V175, P763, DOI 10.7205/MILMED-D-10-00086; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Southwick SM, 1997, AM J PSYCHIAT, V154, P173; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Suri H, 2009, REV EDUC RES, V79, P395, DOI 10.3102/0034654308326349; Tan M., 2009, ARMYTIMES; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thomas B H, 2004, Worldviews Evid Based Nurs, V1, P176, DOI 10.1111/j.1524-475X.2004.04006.x; U.S. Department of Defense Statistical Information and Analysis Division, 2011, US MIL CAS OIF OEF C; U.S. Department of Defense Statistical Information and Analysis Division, 2010, US MIL CAS OIF OEF C; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Veterans Administration, 2012, TSGLI SCHED LOSS; Vogt D, 2011, PSYCHIAT SERV, V62, P135, DOI 10.1176/ps.62.2.pss6202_0135; Wallace D, 2009, AUSTRALAS PSYCHIATRY, V17, P218, DOI 10.1080/10398560902878679; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837	62	30	30	1	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1078-3903	1532-5725		J AM PSYCHIAT NURSES	J. Am. Psych. Nurses Assoc.	SEP-OCT	2012	18	5					278	298		10.1177/1078390312460578			21	Nursing; Psychiatry	Nursing; Psychiatry	V32PO	WOS:000208963300003	23053745				2021-06-18	
J	Davis, LC; Sherer, M; Sander, AM; Bogner, JA; Corrigan, JD; Dijkers, MP; Hanks, RA; Bergquist, TF; Seel, RT				Davis, Lynne C.; Sherer, Mark; Sander, Angelle M.; Bogner, Jennifer A.; Corrigan, John D.; Dijkers, Marcel P.; Hanks, Robin A.; Bergquist, Thomas F.; Seel, Ronald T.			Preinjury Predictors of Life Satisfaction at 1 Year After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Outcome assessment (health care); Personal satisfaction; Quality of life; Rehabilitation; Treatment outcome	QUALITY-OF-LIFE; 1ST 5 YEARS; SOCIAL COMMUNICATION-SKILLS; IMPAIRED SELF-AWARENESS; REHABILITATION OUTCOMES; SPINAL-CORD; NEIGHBORHOOD CHARACTERISTICS; SUBSTANCE-ABUSE; DEPRESSION; DISABILITY	Davis LC, Sherer M, Sander AM, Bogner JA, Corrigan JD, Dijkers MP, Hanks RA, Bergquist TF, Seel RT. Preinjury predictors of life satisfaction at 1 year after traumatic brain injury. Arch Phys Med Rehabil 2012;93:1324-30. Objective: To investigate the predictive value of preinjury factors for satisfaction with life (SWL) at 1-year posttraumatic brain injury (TBI). Design: Secondary analysis of prospective, longitudinal registry using data collected during inpatient rehabilitation and at 1-year post-TBI. Setting: Fifteen specialized brain injury units providing acute rehabilitation care as part of the Traumatic Brain Injury Model Systems (TBIMS) program. Participants: Community-dwelling persons (N = 444) with moderate to severe TBI aged 16 to 64 years enrolled in the TBIMS program between October 2007 and October 2008 with 1-year follow-up data. Interventions: Not applicable. Main Outcome Measure: Satisfaction With Life Scale (SWLS). Results: Hierarchical stepwise linear regression revealed that injury-related and demographic variables did not contribute significantly to the explained variance in SWLS scores. In contrast, the preinjury functioning (education, productivity/employment) and preinjury condition (psychiatric and substance use problems, severe sensory dysfunction, learning problems, prior TBI) blocks each contributed significantly to the explained variance in SWLS scores. Preinjury functioning accounted for 2.9% of the variance and preinjury conditions for 3.8%. Conclusions: Although their contributions are small, preinjury functioning and preinjury conditions are important to consider in the prediction of SWL post-TBI. Educational level and history of psychiatric and other premorbid difficulties are particularly important for clinicians to consider when implementing or developing interventions for persons with moderate to severe TBI.	[Davis, Lynne C.; Sherer, Mark; Sander, Angelle M.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sander, Angelle M.] Harris Cty Hosp Dist, Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX USA; [Bogner, Jennifer A.; Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Hanks, Robin A.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med, Rochester, MN USA; [Seel, Ronald T.] Crawford Res Inst, Shepherd Ctr, Atlanta, GA USA	Davis, LC (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd,Ste 907, Houston, TX 77019 USA.	lynne.davis@memorialhermann.org; lynne.davis@memorialhermann.org	Corrigan, John D./E-2921-2011; Bogner, Jennifer/E-2773-2011; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [HI33A080044, HI33B090023, HI33A070029, HI33A070033]	Supported by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. HI33A080044, HI33B090023, HI33A070029, and HI33A070033).	Arango-Lasprilla JC, 2008, BRAIN INJURY, V22, P565, DOI 10.1080/02699050802172004; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Argyle M., 1999, WELL BEING FDN HEDON, P353, DOI DOI 10.7758/9781610443258.22; Barclay-Goddard R, 2011, ARCH PHYS MED REHAB, V92, P1762, DOI 10.1016/j.apmr.2011.06.013; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2011, J HEAD TRAUMA REHABI; Corrigan JA, 2008, ARCH PHYS MED REHAB, V89, P912, DOI 10.1016/j.apmr.2007.12.027; Corrigan JD, 2012, ARCH PHYS MED REHAB, V93, P1350, DOI 10.1016/j.apmr.2012.04.028; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Diener E, 2006, AM PSYCHOL, V61, P305, DOI 10.1037/0003-066X.61.4.305; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diener E., 1999, WELL BEING FDN HEDON, P213; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Frederick S., 1999, HEDONIC PSYCHOL SCI, P302; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Harker WF, 2002, INT J REHABIL RES, V25, P93, DOI 10.1097/00004356-200206000-00003; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hicken BL, 2002, J REHABIL RES DEV, V39, P359; Jacobsson LJ, 2011, NEUROPSYCHOL REHABIL, V21, P383, DOI 10.1080/09602011.2011.566711; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Johnson CL, 2010, REHABIL PSYCHOL, V55, P180, DOI 10.1037/a0019480; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Myers DG, 2000, AM PSYCHOL, V55, P56, DOI 10.1037/0003-066X.55.1.56; Pavot W, 2009, SOC INDIC RES SER, V39, P101, DOI 10.1007/978-90-481-2354-4_5; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; Saban KL, 2011, J WOMENS HEALTH, V20, P179, DOI 10.1089/jwh.2010.2334; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Uniform Data System for Medical Rehabilitation, 1997, GUID UN DAT SET MED; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Waldron-Perrine B, 2011, REHABIL PSYCHOL, V56, P107, DOI 10.1037/a0023552; Warren L, 1996, J REHABIL RES DEV, V33, P404; Willer B., 1993, BRAIN INJURY REHABIL, P355; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540	62	30	30	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1324	1330		10.1016/j.apmr.2012.02.036			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700005	22840830				2021-06-18	
J	Gatson, JW; Liu, MM; Abdelfattah, K; Wigginton, JG; Smith, S; Wolf, S; Simpkins, JW; Minei, JP				Gatson, Joshua W.; Liu, Ming-Mei; Abdelfattah, Kareem; Wigginton, Jane G.; Smith, Scott; Wolf, Steven; Simpkins, James W.; Minei, Joseph P.			Estrone Is Neuroprotective in Rats after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain-derived neurotrophic factor; estrone; extracellular signal-regulated kinase (ERK); traumatic brain injury	AMYLOID PRECURSOR PROTEIN; SPINAL-CORD-INJURY; CEREBRAL-ARTERY OCCLUSION; RECEPTOR-BETA AGONIST; APOPTOTIC CELL-DEATH; PRIMARY CULTURES; CORTICAL CULTURES; INDUCED TOXICITY; UP-REGULATION; ADULT-RAT	In various animal and human studies, early administration of 17 beta-estradiol, a strong antioxidant, anti-inflammatory, and anti-apoptotic agent, significantly decreases the severity of injury in the brain associated with cell death. Estrone, the predominant estrogen in postmenopausal women, has been shown to be a promising neuroprotective agent. The overall goal of this project was to determine if estrone mitigates secondary injury following traumatic brain injury (TBI) in rats. Male rats were given either placebo (corn oil) or estrone (0.5 mg/kg) at 30 min after severe TBI. Using a controlled cortical impact device in rats that underwent a craniotomy, the right parietal cortex was injured using the impactor tip. Non-injured control and sham animals were also included. At 72 h following injury, the animals were perfused intracardially with 0.9% saline followed by 10% phosphate-buffered formalin. The whole brain was removed, sliced, and stained for TUNEL-positive cells. Estrone decreased cortical lesion volume (p < 0.01) and neuronal injury (p < 0.001), and it reduced cerebral cortical levels of TUNEL-positive staining (p < 0.0001), and decreased numbers of TUNEL-positive cells in the corpus callosum (p < 0.03). We assessed the levels of beta-amyloid in the injured animals and found that estrone significantly decreased the cortical levels of beta-amyloid after brain injury. Cortical levels of phospho-ERK1/2 were significantly ( p < 0.01) increased by estrone. This increase was associated with an increase in phospho-CREB levels (p < 0.021), and brain-derived neurotrophic factor (BDNF) expression (p < 0.0006). In conclusion, estrone given acutely after injury increases the signaling of protective pathways such as the ERK1/2 and BDNF pathways, decreases ischemic secondary injury, and decreases apoptotic-mediated cell death. These results suggest that estrone may afford protection to those suffering from TBI.	[Gatson, Joshua W.; Liu, Ming-Mei; Abdelfattah, Kareem; Wigginton, Jane G.; Smith, Scott; Wolf, Steven; Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dept Surg, D FW Ctr Resuscitat Res, Dallas, TX 75390 USA; [Simpkins, James W.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Univ N Texas Hlth Sci Ctr, Dallas, TX 75390 USA	Gatson, JW (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, D FW Ctr Resuscitat Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joshua.gatson@utsw.edu		Wigginton, Jane/0000-0002-8561-3492; Wolf, Steven/0000-0003-2972-3440	Department of Surgery, Division of Burn/Trauma/Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG027956, P01AG022550] Funding Source: NIH RePORTER	The authors would like to thank Martha Romero for technical assistance with the animal perfusion protocol and use of the fluorescence microscope. We would also like to acknowledge Dr. John Shelton for assisting with the slicing of the brains for immunohistochemical analysis and acquiring photomicrographs of the coronal brain slices. This work was supported by the Department of Surgery, Division of Burn/Trauma/Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas.	ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Bae YH, 2000, J KOREAN MED SCI, V15, P327, DOI 10.3346/jkms.2000.15.3.327; Bekinschtein P, 2008, P NATL ACAD SCI USA, V105, P2711, DOI 10.1073/pnas.0711863105; Bhavnani BR, 2003, J SOC GYNECOL INVEST, V10, P302, DOI 10.1016/S1071-5576(03)00087-X; Blair IA, 2010, STEROIDS, V75, P297, DOI 10.1016/j.steroids.2010.01.012; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Cirigliano M, 2007, J WOMENS HEALTH, V16, P600, DOI 10.1089/jwh.2006.0311; Conti AC, 1998, J NEUROSCI, V18, P5663; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Ferrer I, 2001, ACTA NEUROPATHOL, V101, P229; Gatson JW, 2011, ENDOCRINOLOGY, V152, P207, DOI 10.1210/en.2010-0724; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kajta M, 2005, J PHYSIOL PHARMACOL, V56, P233; Kajta M, 2004, NEUROSCIENCE, V123, P515, DOI 10.1016/j.neuroscience.2003.09.005; Kajta M, 2002, POL J PHARMACOL, V54, P727; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Knoferl MW, 2000, ARCH SURG-CHICAGO, V135, P425, DOI 10.1001/archsurg.135.4.425; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; Merchenthaler I, 2003, ANN NY ACAD SCI, V1007, P89, DOI 10.1196/annals.1286.009; Mizushima Y, 2000, ANN SURG, V232, P673, DOI 10.1097/00000658-200011000-00009; Nakamura T, 2005, J NEUROSURG, V103, P97, DOI 10.3171/jns.2005.103.1.0097; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Palacios B, 1998, J CARDIOVASC PHARM, V31, P479, DOI 10.1097/00005344-199804000-00001; Perez E, 2005, BRAIN RES, V1038, P216, DOI 10.1016/j.brainres.2005.01.026; Pierce JES, 1996, J NEUROSCI, V16, P1083; Regan RF, 1997, BRAIN RES, V764, P133, DOI 10.1016/S0006-8993(97)00437-X; RINK A, 1995, AM J PATHOL, V147, P1575; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sener G, 2005, J SURG RES, V128, P70, DOI 10.1016/j.jss.2005.02.019; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shughrue PJ, 2003, NEUROSCIENCE, V116, P851, DOI 10.1016/S0306-4522(02)00790-X; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Su C, 2011, J NEUROSCI RES, V89, P1542, DOI 10.1002/jnr.22683; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Szalay L, 2005, AM J PHYSIOL-HEART C, V289, pH92, DOI 10.1152/ajpheart.01247.2004; Tomasevic G, 2010, J NEUROSCI RES, V88, P3414, DOI 10.1002/jnr.22491; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamada K, 2003, J PHARMACOL SCI, V91, P267; Yang SH, 2003, ANN NY ACAD SCI, V1007, P101, DOI 10.1196/annals.1286.010; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yu HP, 2006, AM J PHYSIOL-LUNG C, V290, pL1004, DOI 10.1152/ajplung.00504.2005; Yu HP, 2006, J MOL CELL CARDIOL, V40, P185, DOI 10.1016/j.yjmcc.2005.10.001; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	69	30	31	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2209	2219		10.1089/neu.2011.2274			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900008	22435710	Green Published			2021-06-18	
J	Kirk, KA; Shoykhet, M; Jeong, JH; Tyler-Kabara, EC; Henderson, MJ; Bell, MJ; Fink, EL				Kirk, Katherine A.; Shoykhet, Michael; Jeong, Jong H.; Tyler-Kabara, Elizabeth C.; Henderson, Maryanne J.; Bell, Michael J.; Fink, Ericka L.			Dysautonomia after pediatric brain injury	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							PAROXYSMAL SYMPATHETIC HYPERACTIVITY; AUTONOMIC DYSFUNCTION; CHILDREN; REHABILITATION	Aim Dysautonomia after brain injury is a diagnosis based on fever, tachypnea, hypertension, tachycardia, diaphoresis, and/or dystonia. It occurs in 8 to 33% of adults with brain injury and is associated with poor outcome. We hypothesized that children with brain injury with dysautonomia have worse outcomes and prolonged rehabilitation, and sought to determine the prevalence of dysautonomia in children and to characterize its clinical features. Method We developed a database of children (n=249, 154 males, 95 females; mean [SD] age 11 years 10 months [5y 7mo]) with traumatic brain injury, cardiac arrest, stroke, infection of the central nervous system, or brain neoplasm admitted for rehabilitation to The Childrens Institute of Pittsburgh between 2002 and 2009. Dysautonomia diagnosis, injury type, clinical signs, length of stay, and Functional Independence Measure for Children (WeeFIM) testing were extracted from medical records, and analysed for differences between groups with and without dysautonomia. Results Dysautonomia occurred in 13% of children with brain injury (95% confidence interval 9.318.0%), occurring in 10% after traumatic brain injury and 31% after cardiac arrest. The combination of hypertension, diaphoresis, and dystonia best predicted a diagnosis of dysautonomia (area under the curve=0.92). Children with dysautonomia had longer stays, worse WeeFIM scores, and improved less on the scores motor component (all p=0.001). Interpretation Dysautonomia is common in children with brain injury and is associated with prolonged rehabilitation. Prospective study and standardized diagnostic approaches are needed to maximize outcomes.	[Kirk, Katherine A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Shoykhet, Michael] Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, Div Pediat Crit Care Med, St Louis, MO 63110 USA; [Jeong, Jong H.] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA; [Tyler-Kabara, Elizabeth C.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; [Henderson, Maryanne J.] Childrens Inst Pittsburgh, Pittsburgh, PA USA; [Bell, Michael J.; Fink, Ericka L.] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA USA; [Bell, Michael J.; Fink, Ericka L.] Univ Pittsburgh, Med Ctr, Dept Pediat, Pittsburgh, PA USA; [Bell, Michael J.; Fink, Ericka L.] Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Fink, EL (corresponding author), UPMC, Childrens Hosp Pittsburgh, 4401 Penn Ave,2nd Floor, Pittsburgh, PA 15224 USA.	finkel@ccm.upmc.edu	Tyler-Kabara, Elizabeth/H-4930-2013	Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Hill, Katherine/0000-0002-9824-7268; Fink, Ericka/0000-0002-3683-4571; Jeong, Jong/0000-0003-0596-2201	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1K23NS065132]; University of Pittsburgh School of MedicineUniversity of Pittsburgh; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS065132] Funding Source: NIH RePORTER	We thank Sharon Dorogy, Pat Wotherspoon, Ron Reeher, and Christopher Joseph from The Children's Institute for assistance in data collection and medical record access. We acknowledge our funding sources, National Institutes of Health grant 1K23NS065132 and University of Pittsburgh School of Medicine Dean's Summer Research Program.	Azaula M, 2000, ARCH PHYS MED REHAB, V81, P307, DOI 10.1053/apmr.2000.0810307; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 2008, SEMIN NEUROL, V28, P716, DOI 10.1055/s-0028-1105971; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Chelly H, 2011, J TRAUMA, V71, P838, DOI 10.1097/TA.0b013e3182127baa; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Francois B, 2001, J TRAUMA, V50, P158, DOI 10.1097/00005373-200101000-00035; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; Kim CT, 2010, PM&R, V2, pS3, DOI 10.1016/j.pmrj.2009.12.004; Kliegman RM, 2007, NELSON TXB PEDIAT; Krach LE, 1997, J NEUROL REHABIL, V11, P41; Lemke Denise M, 2004, J Neurosci Nurs, V36, P4; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; Mehta NM, 2008, JPEN-PARENTER ENTER, V32, P281, DOI 10.1177/0148607108316196; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Rodriguez N, 2006, REV NEUROLOGIA, V43, P143, DOI 10.33588/rn.4303.2004453	25	30	32	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	AUG	2012	54	8					759	764		10.1111/j.1469-8749.2012.04322.x			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	971TV	WOS:000306227700021	22712762	Green Accepted, Bronze			2021-06-18	
J	Saadeh, Y; Gohil, K; Bill, C; Smith, C; Morrison, C; Mosher, B; Schneider, P; Stevens, P; Kepros, JP				Saadeh, Yamaan; Gohil, Kartik; Bill, Charles; Smith, Curtis; Morrison, Chet; Mosher, Benjamin; Schneider, Paul; Stevens, Penny; Kepros, John P.			Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Thromboembolism prophylaxis; intracranial hemorrhage; traumatic brain injury	DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; VENA-CAVA FILTERS; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; PULMONARY-EMBOLISM; PRACTICE PATTERNS; AAST MULTICENTER; PREVENTION; EPIDEMIOLOGY; POPULATION	BACKGROUND: Venous thromboembolism (VTE) continues to be an important complication for patients with trauma, including patients with intracranial hemorrhage. We implemented a protocol starting chemical prophylaxis 24 hours after the absence of progression of hemorrhage on computed tomography (CT) to increase consistency with the use of chemical venous thromboembolic prophylaxis in this population. The objective of this study was to review the protocol of VTE prophylaxis for patients with traumatic brain injury at our institution to determine whether it has been effective and safe in preventing VTE without increasing intracranial hemorrhage. METHODS: A retrospective case series was conducted to study 205 patients with intracranial hemorrhage admitted to a Level I trauma center during a 24-month period. These patients were reviewed with respect to type of intracranial injury, need for surgery, injury severity, time to initiation of chemical prophylaxis, and progression of injury on brain CT. Patients with a hospital length of stay less than 3 days or nonstable CT were excluded in the analysis of administration of chemical prophylaxis. Time to chemical prophylaxis in relation to absence of progression on brain CT was examined as well as the subsequent risk of progression of hemorrhage and risk of VTE events. The overall rate of venous thromboembolism was compared with that of matched historical controls. RESULTS: All patients received mechanical prophylaxis in the form of sequential compression devices. One hundred sixty-two intracranial hemorrhages were identified in 122 patients who met the study's inclusion criteria. Of this group of patients who did not have progression of hemorrhage on follow-up CT, 76.2% received chemical prophylaxis during their hospitalization. No patients had progression of intracranial hemorrhage after initiation of chemical VTE prophylaxis, and no patients developed VTE. This represents a decrease of VTE from previous years. No other complications related to chemical VTE prophylaxis were identified. CONCLUSION: A protocol based on an early use of chemical venous thromboembolic prophylaxis after the absence of progression of tramatic intracranial hemorrhage does not result in increased progression of intracranial hemorrhage and reduced the rate of venous thromboembolic events at our institution. (J Trauma Acute Care Surg. 2012;73:426-430. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Gohil, Kartik; Morrison, Chet; Mosher, Benjamin; Schneider, Paul; Kepros, John P.] Michigan State Univ, Sparrow Hosp, Dept Surg, Lansing, MI 48912 USA; [Saadeh, Yamaan] Michigan State Univ, Sparrow Hosp, Coll Human Med, Lansing, MI 48912 USA; [Bill, Charles; Smith, Curtis; Morrison, Chet; Mosher, Benjamin; Schneider, Paul; Stevens, Penny; Kepros, John P.] Sparrow Hlth Syst, Lansing, MI USA	Kepros, JP (corresponding author), Michigan State Univ, Dept Surg, 1200 Michigan Ave,Suite 655, Lansing, MI 48912 USA.	John.Kepros@hc.msu.edu					Anderson FA, 2010, AM J MED, V123, P1099, DOI 10.1016/j.amjmed.2010.07.011; [Anonymous], 2005, BLOOD, V106, p5a; [Anonymous], 2008, SURG GEN CALL ACT DE; BOEER A, 1991, J NEUROL NEUROSUR PS, V54, P466, DOI 10.1136/jnnp.54.5.466; Brandt MM, 2007, AM J SURG, V193, P383; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Ekeh AP, 2010, J TRAUMA, V68, P912, DOI 10.1097/TA.0b013e3181b21cad; Heit JA, 2006, J THROMB THROMBOLYS, V21, P23, DOI 10.1007/s11239-006-5572-y; Helling TS, 2009, J TRAUMA, V67, P1293, DOI 10.1097/TA.0b013e3181b0637a; Ho KM, 2011, CHEST, V140, P1436, DOI 10.1378/chest.11-1444; Karmy-Jones R, 2007, J TRAUMA, V62, P17, DOI 10.1097/TA.0b013e31802dd72a; Kiphuth IC, 2009, CEREBROVASC DIS, V27, P146, DOI 10.1159/000177923; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Mahan CE, 2011, THROMB HAEMOSTASIS, V106, P405, DOI 10.1160/TH11-02-0132; Malinoski D, 2011, INJURY          1101; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; O'Carroll CB, 2011, NEUROLOGIST, V17, P232, DOI 10.1097/NRL.0b013e318222d6c0; Orken DN, 2009, NEUROLOGIST, V15, P329, DOI 10.1097/NRL.0b013e3181a93bac; Rogers FB, 1997, J TRAUMA, V5, P142; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; Shackford SR, 2007, J TRAUMA, V62, P24; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Spyropoulos AC, 2009, THROMB HAEMOSTASIS, V102, P951, DOI 10.1160/TH09-02-0073; Toker S, 2011, THROMBOSIS, DOI DOI 10.1155/2011/505373; White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66	26	30	31	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2012	73	2					426	430		10.1097/TA.0b013e31825a758b			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	992VG	WOS:000307807400032	22846950				2021-06-18	
J	Schoch, KM; Evans, HN; Brelsfoard, JM; Madathil, SK; Takano, J; Saido, TC; Saatman, KE				Schoch, Kathleen M.; Evans, Heather N.; Brelsfoard, Jennifer M.; Madathil, Sindhu K.; Takano, Jiro; Saido, Takaomi C.; Saatman, Kathryn E.			Calpastatin overexpression limits calpain-mediated proteolysis and behavioral deficits following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Cognition; Controlled cortical impact; Neuroprotection; Spectrin; Transgenic	CONTROLLED CORTICAL IMPACT; LONG-TERM POTENTIATION; SPINAL-CORD-INJURY; INHIBITOR MDL-28170; ALPHA-SPECTRIN; NEURONAL DEGENERATION; MOLECULAR-MECHANISMS; COGNITIVE DEFICITS; CEREBRAL-ISCHEMIA; AXONAL INJURY	Traumatic brain injury (TBI) results in abrupt, initial cell damage leading to delayed neuronal death. The calcium-activated proteases, calpains, are known to contribute to this secondary neurodegenerative cascade. Although the specific inhibitor of calpains, calpastatin, is present within neurons, normal levels of calpastatin are unable to fully prevent the damaging proteolytic activity of calpains after injury. In this study, increased calpastatin expression was achieved using transgenic mice that overexpress the human calpastatin (hCAST) construct under control of a calcium-calmodulin-dependent kinase II alpha promoter. Naive hCAST transgenic mice exhibited enhanced neuronal calpastatin expression and significantly reduced protease activity. Acute calpain-mediated spectrin proteolysis in the cortex and hippocampus induced by controlled cortical impact brain injury was significantly attenuated in calpastatin overexpressing mice. Aspects of posttraumatic motor and cognitive behavioral deficits were also lessened in hCAST transgenic mice compared to their wildtype littermates. However, volumetric analyses of neocortical contusion revealed no histological neuroprotection at either acute or long-term time points. Partial hippocampal neuroprotection observed at a moderate injury severity was lost after severe TBI. This study underscores the effectiveness of calpastatin overexpression in reducing calpain-mediated proteolysis and behavioral impairment after TB!, supporting the therapeutic potential for calpain inhibition. In addition, the reduction in spectrin proteolysis without accompanied neocortical neuroprotection suggests the involvement of other factors that are critical for neuronal survival after contusion brain injury. (C) 2012 Elsevier Inc. All rights reserved.	[Schoch, Kathleen M.; Evans, Heather N.; Brelsfoard, Jennifer M.; Madathil, Sindhu K.; Saatman, Kathryn E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY 40536 USA; [Schoch, Kathleen M.; Evans, Heather N.; Brelsfoard, Jennifer M.; Madathil, Sindhu K.; Saatman, Kathryn E.] Univ Kentucky, Dept Physiol, Coll Med, Lexington, KY 40536 USA; [Takano, Jiro; Saido, Takaomi C.] RIKEN Brain Sci Inst RIKEN BSI, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan	Saatman, KE (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, B473 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.	kmscho6@uky.edu; evansh1@nku.edu; jmplea2@uky.edu; Sindhu.KM@uky.edu; jtakano@brain.riken.jp; saido@brain.riken.jp; k.saatman@uky.edu	Saido, Takaomi C/N-5472-2015; Madathil, Sindhu K/E-9407-2012; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F31 NS071804, P01 NS058484, P30 NS051220]; KSCHIRT [6-12]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, F31NS071804, P01NS058484] Funding Source: NIH RePORTER	This work was funded by NIH F31 NS071804 (KMS), NIH P01 NS058484, P30 NS051220 and KSCHIRT 6-12 (KES).	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Aikman J, 2006, DEV NEUROSCI-BASEL, V28, P457, DOI 10.1159/000094171; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Bertaina-Anglade V., 2006, Journal of Pharmacological and Toxicological Methods, V54, P99, DOI 10.1016/j.vascn.2006.04.001; Bevers MB, 2010, EXP NEUROL, V224, P170, DOI 10.1016/j.expneurol.2010.03.007; Bevers MB, 2009, J NEUROCHEM, V108, P1237, DOI 10.1111/j.1471-4159.2008.05860.x; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Chidlow G, 2009, EXP EYE RES, V88, P426, DOI 10.1016/j.exer.2008.10.015; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Couto LA, 2004, J NEUROSCI RES, V77, P410, DOI 10.1002/jnr.20170; CRAWFORD C, 1993, BIOCHEM J, V296, P135, DOI 10.1042/bj2960135; Croall DE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-218; DELCERRO S, 1990, BRAIN RES, V530, P91; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; DENNY JB, 1990, BRAIN RES, V534, P317, DOI 10.1016/0006-8993(90)90148-5; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas B, 2004, BRAIN RES, V1024, P150, DOI 10.1016/j.brainres.2004.07.059; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Grammer M, 2005, NEUROBIOL LEARN MEM, V84, P222, DOI 10.1016/j.nlm.2005.07.007; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hanna RA, 2008, NATURE, V456, P409, DOI 10.1038/nature07451; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Hassen GW, 2008, BRAIN RES, V1236, P206, DOI 10.1016/j.brainres.2008.07.124; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Institute of Laboratory Animal Resources (U.S.), 2011, NIH PUBL; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koumura A, 2008, NEUROSCIENCE, V157, P309, DOI 10.1016/j.neuroscience.2008.09.007; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Mellgren RL, 2009, BBA-MOL CELL RES, V1793, P1886, DOI 10.1016/j.bbamcr.2009.09.013; Moldoveanu T, 2008, NATURE, V456, P404, DOI 10.1038/nature07353; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MULLER D, 1995, SYNAPSE, V19, P37, DOI 10.1002/syn.890190106; Nakajima R, 2008, MOL BRAIN, V1, DOI 10.1186/1756-6606-1-7; Naseer MI, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-20; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, J NEUROTRAUM, V16, P1, DOI 10.1089/neu.1999.16.1; Oshitari T, 2008, BRIT J OPHTHALMOL, V92, P552, DOI 10.1136/bjo.2007.132308; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Parr T, 2004, ARCH BIOCHEM BIOPHYS, V427, P8, DOI 10.1016/j.abb.2004.04.001; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Rao MV, 2008, J NEUROSCI, V28, P12241, DOI 10.1523/JNEUROSCI.4119-08.2008; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Serrano GE, 2011, J NEUROSCI, V31, P14850, DOI 10.1523/JNEUROSCI.3922-11.2011; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sorimachi H, 2011, P JPN ACAD B-PHYS, V87, P287, DOI 10.2183/pjab.87.287; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; SUZUKI T, 1992, BIOCHEM BIOPH RES CO, V189, P1515, DOI 10.1016/0006-291X(92)90247-I; Takano J, 1999, BIOCHEM BIOPH RES CO, V260, P339, DOI 10.1006/bbrc.1999.0903; Takano J, 2000, J BIOCHEM, V128, P83, DOI 10.1093/oxfordjournals.jbchem.a022733; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thompson SN, 2010, J NEUROTRAUM, V27, P2233, DOI 10.1089/neu.2010.1474; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yu CG, 2008, J NEUROTRAUM, V25, P833, DOI 10.1089/neu.2007.0490; Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4	81	30	31	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2012	236	2					371	382		10.1016/j.expneurol.2012.04.022			12	Neurosciences	Neurosciences & Neurology	976YI	WOS:000306622900019	22572592	Green Accepted			2021-06-18	
J	Huang, YH; Deng, YH; Lee, TC; Chen, WF				Huang, Yu-Hua; Deng, Yu-Han; Lee, Tao-Chen; Chen, Wu-Fu			Rotterdam Computed Tomography Score as a Prognosticator in Head-Injured Patients Undergoing Decompressive Craniectomy	NEUROSURGERY			English	Article						Decompressive craniectomy; Glasgow Outcome Scale; Prognosis; Rotterdam CT score; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; CLASSIFICATION; MULTICENTER; MANAGEMENT; SEVERITY; SCALE; COMA	BACKGROUND: The Rotterdam computed tomography (CT) score was developed for prognostic purposes in traumatic brain injury (TBI). OBJECTIVE: To examine the prognostic discrimination and prediction of the Rotterdam CT score in the case of patients undergoing decompressive craniectomy (DC) for TBI. METHODS: The CT scans with the worst findings before DC were scored according to the Rotterdam CT classification. Mortality and Glasgow Outcome Scale score at the end of follow-up were used as outcome measures. Unfavorable and favorable outcomes were defined by a Glasgow Outcome Scale score of 1 to 3 and 4 to 5, respectively. We used binary logistic and proportional odds regression for prognostic analyses. RESULTS: The relationship between the Rotterdam CT score and prognosis was quantified, and higher scores indicated worse patient outcomes. Univariate analysis showed that the Rotterdam CT score was significantly associated with mortality (odds ratio: 3.117, 95% confidence interval: 1.867-5.386; P < .001) and unfavorable outcomes (odds ratio: 2.612, 95% confidence interval: 1.733-3.939; P < .001). After adjustment for published outcome predictors of TBI in multivariate regression, the Rotterdam CT score remained an independent predictor of unfavorable outcomes (odds ratio: 1.830, 95% confidence interval: 1.043-3.212; P = .035). CONCLUSION: For head-injured patients undergoing DC, the Rotterdam CT score provides great prognostic discrimination and is an independent predictor of unfavorable outcomes. We suggest that the Rotterdam CT score be included as a prognosticator in the overall assessment of clinical condition of TBI patients before DC.	[Huang, Yu-Hua; Deng, Yu-Han; Lee, Tao-Chen; Chen, Wu-Fu] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung, Taiwan	Huang, YH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, 123 Ta Pei Rd, Niao Sung Hsiang, Kaohsiung Hsien, Taiwan.	newlupin2001@yahoo.com.tw					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170	21	30	34	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2012	71	1					80	85		10.1227/NEU.0b013e3182517aa1			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	961RX	WOS:000305487000019	22382208				2021-06-18	
J	Kenning, TJ; Gooch, MR; Gandhi, RH; Shaikh, MP; Boulos, AS; German, JW				Kenning, Tyler J.; Gooch, M. Reid; Gandhi, Ravi H.; Shaikh, M. Parvez; Boulos, Alan S.; German, John W.			Cranial decompression for the treatment of malignant intracranial hypertension after ischemic cerebral infarction: decompressive craniectomy and hinge craniotomy	JOURNAL OF NEUROSURGERY			English	Article						craniectomy; hinge craniotomy; cerebral decompression; intracranial hypertension; malignant cerebral infarction; traumatic brain injury	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; ARTERY INFARCTION; STROKE SURVIVORS; HEMICRANIECTOMY; COMPLICATIONS; DETERMINANTS; MULTICENTER; CAREGIVERS; SURGERY	Object. Recent randomized trials have demonstrated a positive role (improved survival) in patients treated with cranial decompression for malignant cerebral infarction. However, many variables regarding operative decompression in this setting remain to be determined. Hinge craniotomy is an alternative to decompressive craniectomy, but its role in space-occupying cerebral infarctions has not been delineated. The objective of this study was to compare the authors' experiences with these 2 procedures in the management of space-occupying cerebral infarctions to determine the efficacy of each. Methods. The authors conducted a retrospective review of 28 cases involving patients who underwent cranial decompression (hinge craniotomy in 9 cases, decompressive craniectomy in 19) for treatment of malignant intracranial hypertension after ischemic cerebral infarction. Results. No significant differences were identified in baseline demographics, neurological examination, or Rotterdam score between the hinge craniotomy and decompressive craniectomy groups. Both treatments resulted in adequate control of intracranial pressure (ICP). The need for reoperation for persistent intracranial hypertension and duration of mechanical ventilation and intensive care unit stay were similar. Hospital survival was significantly higher in the decompressive craniectomy group (89% vs 56%), whereas long-term functional outcome was better in the hinge craniotomy group. Cranial defect size was comparable in the 2 groups. Postoperative imaging revealed a higher rate of subarachnoid hemorrhage, contusion/hematoma progression, and subdural effusions/hygromas after decompressive craniectomy. The requirement for cranial revision in survivors was higher for patients undergoing decompressive craniectomy (100%) than those undergoing hinge craniotomy (20%). Conclusions. Hinge craniotomy appears to be at least as good as decompressive craniectomy in providing postoperative ICP control at a similar therapeutic index. Although the in-hospital mortality was higher in patients treated with hinge craniotomy, that procedure resulted in superior long-term functional outcomes and may help limit postoperative complications. (http://thejns.org/doi/abs/10.3171/2012.2.JNS111772)	[Kenning, Tyler J.] Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Gooch, M. Reid; Gandhi, Ravi H.; Shaikh, M. Parvez; Boulos, Alan S.; German, John W.] Albany Med Ctr, Div Neurosurg, Albany, NY USA	Kenning, TJ (corresponding author), Thomas Jefferson Univ Hosp, Dept Neurosurg, 909 Walnut St,2nd Floor, Philadelphia, PA 19107 USA.	tyler.kenning@jeffersonhospital.org					Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Benejam B, 2009, J NEUROL, V256, P1126, DOI 10.1007/s00415-009-5083-9; BONITA R, 1988, STROKE, V19, P1497, DOI 10.1161/01.STR.19.12.1497; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Foerch C, 2004, J NEUROSURG, V101, P248, DOI 10.3171/jns.2004.101.2.0248; Goettler CE, 2007, J TRAUMA, V62, P777, DOI 10.1097/TA.0b013e31802ee55e; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Green Theresa L, 2010, Can J Neurosci Nurs, V32, P24; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; JENNETT B, 1975, LANCET, V1, P480; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kenning TJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0960; Ko K, 2007, NEUROSURGERY, V60, P255, DOI 10.1227/01.NEU.0000255380.64969.81; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; McCullagh E, 2005, STROKE, V36, P2181, DOI 10.1161/01.STR.0000181755.23914.53; Nakagawa K, 2010, NEUROCRIT CARE, V13, P118, DOI 10.1007/s12028-010-9340-7; Rigby H, 2009, INT J STROKE, V4, P152, DOI 10.1111/j.1747-4949.2009.00287.x; Saban KL, 2010, J NEUROSCI NURS, V42, P128, DOI 10.1097/JNN.0b013e3181d4a3ee; Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Su TM, 2011, J TRAUMA, V71, P833, DOI 10.1097/TA.0b013e31821b092a; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Wang HK, 2010, INJURY	26	30	31	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUN	2012	116	6					1289	1298		10.3171/2012.2.JNS111772			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	945RP	WOS:000304294000023	22462506				2021-06-18	
J	Byom, LJ; Turkstra, L				Byom, Lindsey J.; Turkstra, Lyn			Effects of social cognitive demand on Theory of Mind in conversations of adults with traumatic brain injury	INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS			English	Article						communication; brain injury; social cognition; language; mentalizing; discourse	HEAD-INJURY; EMOTION RECOGNITION; NARRATIVE DISCOURSE; ELICITATION TASK; SELF; ADOLESCENTS; LANGUAGE; DEFICITS; GENDER; SKILLS	Background: A requisite skill for successful conversation is the ability to adjust one's language according to contextual factors. Aims: This study examined one aspect of language use in context-the use of mental-state terms, i.e. words that communicate thoughts, beliefs or feelings-in conversations between adult males with and without traumatic brain injury (TBI) and familiar partners. Methods & Procedures: Participants were five males in the chronic stage of recovery following severe TBI and five male peers matched for age, conversing with friends. Conversational context was manipulated using conversation starters that were designed to induce differing levels of self-disclosure or intimacy, with the expectation that mental-state term use would increase when participants talked about more intimate topics. Outcomes & Results: Participants in both groups used more mental-state terms in more intimate conversations; however, adults with TBI did not increase their mental-state term use to the same extent as matched peers. Adults with TBI also used a significantly different pattern of mental-state term types across intimacy levels as compared with peers. Conclusions & Implications: These quantitative and qualitative differences may contribute to social conversation problems of adults with TBI.	[Byom, Lindsey J.; Turkstra, Lyn] Univ Wisconsin, Madison, WI 53706 USA	Byom, LJ (corresponding author), Univ Wisconsin, 1975Willow Dr, Madison, WI 53706 USA.	ljfrederixon@wisc.edu	Byom, Lindsey/AAC-5095-2019	Byom, Lindsey/0000-0002-2457-1735	Wisconsin Alumni Research Foundation; Walker Foundation; NIDCDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [T32DC005359]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [T32DC005359] Funding Source: NIH RePORTER	This work was supported in part by funds from the Wisconsin Alumni Research Foundation and the Walker Foundation, as well as from a training fellowship to the first author from the University of Wisconsin-Madison Department of Communicative Disorders Interdisciplinary training grant NIDCD T32DC005359. The authors acknowledge Sara Brehm's assistance with data collection; and thank Laura Mork, Jacqueline Johnson and Danielle Schneider for their assistance with data analysis. The authors report no conflict of interest associated with this work. Declaration of Interest: The authors report no conflict of interest and only the authors are responsible for the content and writing of this paper.	Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Adrian JE, 2005, J CHILD LANG, V32, P673, DOI 10.1017/S0305000905006963; Bach LJ, 2006, BRAIN COGNITION, V60, P196; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Bosacki SL, 2000, J EDUC PSYCHOL, V92, P709, DOI 10.1037//0022-0663.92.4.709; BRETHERTON I, 1982, DEV PSYCHOL, V18, P906, DOI 10.1037/0012-1649.18.6.906; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Charlton RA, 2009, PSYCHOL AGING, V24, P338, DOI 10.1037/a0015225; Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Frith CD, 1999, SCIENCE, V286, P1692, DOI 10.1126/science.286.5445.1692; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Heatherton TF, 2000, J PERS SOC PSYCHOL, V78, P725, DOI 10.1037/0022-3514.78.4.725; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Kaufman A. S., 2004, K BIT2 KAUFMAN BRIEF; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; MACCOBY EE, 1988, DEV PSYCHOL, V24, P755, DOI 10.1037/0012-1649.24.6.755; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Miller CA, 2006, AM J SPEECH-LANG PAT, V15, P142, DOI 10.1044/1058-0360(2006/014); MILLER JF, 1994, SALT GUIDE STANDARD; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Peterson CC, 2006, BRIT J DEV PSYCHOL, V24, P151, DOI 10.1348/026151005X60022; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Samson D, 2007, NEUROPSYCHOLOGIA, V45, P2561, DOI 10.1016/j.neuropsychologia.2007.03.013; Scott CM, 2000, J SPEECH LANG HEAR R, V43, P324, DOI 10.1044/jslhr.4302.324; Sedikides C, 1998, J PERS SOC PSYCHOL, V74, P378, DOI 10.1037/0022-3514.74.2.378; Sedikides C., 1999, REPRESENT R SOC PSYC, V23, P1; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Stronach ST, 2008, APHASIOLOGY, V22, P1054, DOI 10.1080/02687030701632187; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Thorndike E.L., 1920, HARPERS MAGAZINE, V140, P227, DOI DOI 10.1234/12345678; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Vohs KD, 2004, SOC COGNITION, V22, P168, DOI 10.1521/soco.22.1.168.30983; Walker S, 2005, J GENET PSYCHOL, V166, P297, DOI 10.3200/GNTP.166.3.297-312; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	62	30	30	0	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1368-2822	1460-6984		INT J LANG COMM DIS	Int. J. Lang. Commun. Disord.	MAY-JUN	2012	47	3					310	321		10.1111/j.1460-6984.2011.00102.x			12	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	927WT	WOS:000302941900007	22512516	Green Accepted			2021-06-18	
J	Shin, SS; Verstynen, T; Pathak, S; Jarbo, K; Hricik, AJ; Maserati, M; Beers, SR; Puccio, AM; Boada, FE; Okonkwo, DO; Schneider, W				Shin, Samuel S.; Verstynen, Timothy; Pathak, Sudhir; Jarbo, Kevin; Hricik, Allison J.; Maserati, Megan; Beers, Sue R.; Puccio, Ava M.; Boada, Fernando E.; Okonkwo, David O.; Schneider, Walter			High-definition fiber tracking for assessment of neurological deficit in a case of traumatic brain injury: finding, visualizing, and interpreting small sites of damage	JOURNAL OF NEUROSURGERY			English	Article						axonal injury; diffusion tensor imaging; traumatic brain injury; high-definition fiber tracking	DIFFUSE AXONAL INJURY	For patients with traumatic brain injury (TBI), current clinical imaging methods generally do not provide highly detailed information about the location of axonal injury, severity of injury, or expected recovery. In a case of severe TB!, the authors applied a novel high-definition fiber tracking (HDFT) to directly visualize and quantify the degree of axonal fiber damage and predict functional deficits due to traumatic axonal injury and loss of cortical projections. This 32-year-old man sustained a severe TBI. Computed tomography and MRI revealed an area of hemorrhage in the basal ganglia with mass effect, but no specific information on the location of axonal injury could be obtained from these studies. Examinations of the patient at Week 3 and Week 8 after TBI revealed motor weaknesses of the left extremities. Four months postinjury, 257-direction diffusion spectrum imaging and HDFT analysis was performed to evaluate the degree of axonal damage in the motor pathway and quantify asymmetries in the left and right axonal pathways. High-definition fiber tracking was used to follow corticospinal and corona radiata pathways from the cortical surface to the midbrain and quantify projections from motor areas. Axonal damage was then localized by assessing the number of descending fibers at the level of the cortex, internal capsule, and midbrain. The motor deficit apparent in the clinical examinations correlated with the axonal losses visualized using HDFT. Fiber loss estimates at 4 months postinjury accurately predicted the nature of the motor deficits (severe, focal left-hand weakness) when other standard clinical imaging modalities did not. A repeat scan at 10 months postinjury, when edema and hemorrhage had receded, replicated the fiber loss. Using HDFT, the authors accurately identified the presence and location of damage to the underlying white matter in this patient with TBI. Detailed information of injury provided by this novel technique holds future potential for precise neuroimaging assessment of TBI. (http://thejns.org/doi/abs/10.3171/2012.1.JNS111282)	[Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, UPMC Presbyterian, Pittsburgh, PA 15213 USA; [Boada, Fernando E.; Schneider, Walter] Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA 15213 USA; [Beers, Sue R.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA; [Verstynen, Timothy; Pathak, Sudhir; Jarbo, Kevin; Schneider, Walter] Univ Pittsburgh, Ctr Learning Res & Dev, Pittsburgh, PA 15213 USA	Okonkwo, DO (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, UPMC Presbyterian, Suite B-400,200 Lothrop St, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu		Jarbo, Kevin/0000-0002-6356-0916	Defense Advanced Research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [D09PC75271]	Funding for this study was provided through a Defense Advanced Research Projects Agency (DARPA) contract (D09PC75271). The views, opinions, and/or findings contained in this paper are those of the authors and should not be interpreted as representing the official views or policies, either expressed or implied, of DARPA or the United States Department of Defense. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Fernandez-Miranda JC, 2010, J NEUROSURG, V113, P990, DOI 10.3171/2009.10.JNS09933; Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Jbabdi S, 2011, BRAIN CONNECT, V1, P169, DOI 10.1089/brain.2011.0033; Lee SK, 2005, RADIOGRAPHICS, V25, P53, DOI 10.1148/rg.251045085; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Verstynen T, 2011, J NEUROPHYSIOL, V105, P336, DOI 10.1152/jn.00698.2010; Yamada K, 2003, RADIOLOGY, V227, P295, DOI 10.1148/radiol.2271020313; Yokoyama K, 2008, AM J NEURORADIOL, V29, P1159, DOI 10.3174/ajnr.A1001	18	30	30	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2012	116	5					1062	1069		10.3171/2012.1.JNS111282			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	929TO	WOS:000303088800022	22381003				2021-06-18	
J	Robertson, CS; Cherian, L; Shah, M; Garcia, R; Navarro, JC; Grill, RJ; Hand, CC; Tian, TS; Hannay, HJ				Robertson, Claudia S.; Cherian, Leela; Shah, Mahek; Garcia, Robert; Navarro, Jovany Cruz; Grill, Raymond J.; Hand, Carla Cerami; Tian, Tian Siva; Hannay, H. Julia			Neuroprotection with an Erythropoietin Mimetic Peptide (pHBSP) in a Model of Mild Traumatic Brain Injury Complicated by Hemorrhagic Shock	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; head trauma; ischemia; secondary insult; traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; CONTROLLED CORTICAL IMPACT; CRITICALLY-ILL PATIENTS; TISSUE-PLASMINOGEN ACTIVATOR; FOCAL CEREBRAL-ISCHEMIA; CARBAMYLATED ERYTHROPOIETIN; ENHANCES NEUROGENESIS; NEURONAL APOPTOSIS; BLOOD-FLOW; IN-VITRO	Pyroglutamate helix B surface peptide (pHBSP) is an 11 amino acid peptide, designed to interact with a novel cell surface receptor, composed of the classical erythropoietin (EPO) receptor disulfide linked to the beta common receptor. pHBSP has the cytoprotective effects of EPO without stimulating erythropoiesis. Effects on early cerebral hemodynamics and neurological outcome at 2 weeks post-injury were compared in a rat model of mild cortical impact injury (3m/sec, 2.5 mm deformation) followed by 50 min of hemorrhagic hypotension (MAP 40 mm Hg for 50 min). Rats were randomly assigned to receive 5000 U/kg of EPO, 30 mu g/kg of pHBSP, or an inactive substance every 12 h for 3 days, starting at the end of resuscitation from the hemorrhagic hypotension, which was 110 min post-injury. Both treatments reduced contusion volume at 2 weeks post-injury, from 20.8 +/- 2.8 mm(3) in the control groups to 7.7 +/- 2.0 mm(3) in the EPO-treated group and 5.9 +/- 1.5 mm(3) in the pHBSP-treated group (p = 0.001). Both agents improved recovery of cerebral blood flow in the injured brain following resuscitation, and resulted in more rapid recovery of performance on beam balancing and beam walking tests. These studies suggest that pHBSP has neuroprotective effects similar to EPO in this model of combined brain injury and hypotension. pHBSP may be more useful in the clinical situation because there is less risk of thrombotic adverse effects.	[Robertson, Claudia S.; Cherian, Leela; Shah, Mahek; Garcia, Robert; Navarro, Jovany Cruz] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX USA; [Hand, Carla Cerami] Univ N Carolina, Dept Epidemiol, Gillisngs Sch Global Publ Hlth, Chapel Hill, NC USA; [Tian, Tian Siva] Univ Houston, Dept Psychol, Houston, TX USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.edu		Hannay, H. Julia/0000-0001-7023-912X; Cerami, Carla/0000-0002-7634-0955	U.S. ArmyUnited States Department of Defense [W81XWH-08-2-0132, W81XWH-08-2-0150]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS077964] Funding Source: NIH RePORTER	This work was funded by U.S. Army Award numbers W81XWH-08-2-0132 (C.S.R.) and W81XWH-08-2-0150 (R.J.G.). Araim Pharmaceuticals, Ossining, NY, USA supplied the pHBSP for the study.	Adembri C, 2008, CRIT CARE MED, V36, P975, DOI 10.1097/CCM.0B013E3181644343; Ahmet I, 2011, MOL MED, V17, P194, DOI 10.2119/molmed.2010.00235; Brines M, 2008, J INTERN MED, V264, P405, DOI 10.1111/j.1365-2796.2008.02024.x; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Corwin HL, 2002, JAMA-J AM MED ASSOC, V288, P2827, DOI 10.1001/jama.288.22.2827; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Dicato M, 2008, ONCOLOGIST, V13, P11, DOI 10.1634/theoncologist.13-S3-11; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Elliott S, 1997, BLOOD, V89, P493, DOI 10.1182/blood.V89.2.493; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2001, J Neurosurg Sci, V45, P7; Jia LF, 2010, STROKE, V41, P2071, DOI 10.1161/STROKEAHA.110.586198; King VR, 2007, EUR J NEUROSCI, V26, P90, DOI 10.1111/j.1460-9568.2007.05635.x; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mann C, 2008, EXP NEUROL, V211, P34, DOI 10.1016/j.expneurol.2007.12.013; Marti HH, 2000, NEWS PHYSIOL SCI, V15, P225; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Napolitano LM, 2008, J TRAUMA, V65, P285, DOI 10.1097/TA.0b013e31817f2c6e; Pinzon A, 2008, EXP NEUROL, V213, P129, DOI 10.1016/j.expneurol.2008.05.018; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Ueba H, 2010, P NATL ACAD SCI USA, V107, P14357, DOI 10.1073/pnas.1003019107; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Zarychanski R, 2007, CAN MED ASSOC J, V177, P725, DOI 10.1503/cmaj.071055; Zechariah A, 2010, STROKE, V41, P1008, DOI 10.1161/STROKEAHA.109.574418	44	30	32	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1156	1166		10.1089/neu.2011.1827			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100016	21545288	Green Published			2021-06-18	
J	Salonia, R; Bell, MJ; Kochanek, PM; Berger, RP				Salonia, Rosanne; Bell, Michael J.; Kochanek, Patrick M.; Berger, Rachel P.			The Utility of Near Infrared Spectroscopy in Detecting Intracranial Hemorrhage in Children	JOURNAL OF NEUROTRAUMA			English	Article						abusive head trauma; children; intracranial hemorrhage; near infrared spectroscopy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; BIOMARKERS; MANAGEMENT; HEMATOMAS; DIAGNOSIS; SERUM	A prospective case-control study was conducted in a tertiary care pediatric intensive care unit (PICU) to evaluate the use of near infrared spectroscopy (NIRS) for the detection of intracranial hemorrhage (ICH) in children. Subjects 0-14 years of age who had a computed tomography (CT) scan of the head performed as part of clinical care were eligible for enrollment. The children were stratified into two groups based on whether the CT was normal or abnormal. Children in the abnormal imaging cohort were further divided into those with ICH and those with other abnormalities of the brain parenchyma (contusions, diffuse axonal injury [DAI], or cerebral edema) or fractures. NIRS measurements were performed on all subjects within 24 h of head CT. The NIRS operator was blinded to the presence or absence of ICH. NIRS measurements were performed in eight different scalp locations (four bilaterally). A total of 103 measurements were made. The optical density (OD) was automatically calculated by comparing the reflected and diffused optical signal. A Delta OD>0.2 between hemispheres in any scalp location was considered abnormal. NIRS was performed in a total of 28 subjects: 7 had normal imaging and 21 had abnormal imaging. Of those with abnormal imaging, 12 had ICH. The sensitivity and specificity of NIRS at detecting ICH was 1.0 and 0.8, respectively. The positive and negative predictive values were 0.8 and 1.0, respectively. In conclusion, NIRS correctly identified all cases of ICH in this pilot study. Our preliminary results suggest that NIRS may be beneficial in the evaluation of a child with possible ICH.	[Salonia, Rosanne; Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Dept Crit Care Med, Sch Med, Pittsburgh, PA 15224 USA; [Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Dept Pediat, Sch Med, Pittsburgh, PA 15224 USA; [Bell, Michael J.] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Dept Neurol Surg, Sch Med, Pittsburgh, PA 15224 USA; [Salonia, Rosanne; Bell, Michael J.; Kochanek, Patrick M.; Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Safar Ctr Resuscitat Res, Sch Med, Pittsburgh, PA 15224 USA	Salonia, R (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Dept Crit Care Med, Sch Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	saloniar@upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD040686-09, NS30318]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health 5T32HD040686-09 (to R.S. and P.M.K.), NS30318 (to P.M.K.), and the National Heart, Lung, and Blood Institute T32HL007820 (to R.S. and M.R.P.).	Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; *CDCP, 2000, NAT CTR INJ PREV CON; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; Coren ME, 1998, PEDIATR PULM, V26, P389, DOI 10.1002/(SICI)1099-0496(199812)26:6<389::AID-PPUL3>3.0.CO;2-6; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Francis SV, 2005, J CLIN NEUROSCI, V12, P291, DOI 10.1016/j.jocn.2004.06.009; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; GOPINATH SP, 1993, J NEUROSURG, V79, P43, DOI 10.3171/jns.1993.79.1.0043; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Kahraman S, 2006, J TRAUMA, V61, P1480, DOI 10.1097/01.ta.0000197616.10279.48; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Robertson C S, 1997, J Biomed Opt, V2, P31, DOI 10.1117/12.261680; Robertson CS, 2010, J NEUROTRAUM, V27, P1597, DOI 10.1089/neu.2010.1340; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P591, DOI 10.1089/neu.1995.12.591; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; VEYRAC C, 1990, PEDIATR RADIOL, V20, P236, DOI 10.1007/BF02019655; Zhang Q, 2000, J BIOMED OPT, V5, P206, DOI 10.1117/1.429988	24	30	30	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1047	1053		10.1089/neu.2011.1890			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100003	22098538	Green Published			2021-06-18	
J	Gutierrez-Colina, AM; Topjian, AA; Dlugos, DJ; Abend, NS				Gutierrez-Colina, Ana M.; Topjian, Alexis A.; Dlugos, Dennis J.; Abend, Nicholas S.			Electroencephalogram Monitoring in Critically Ill Children: Indications and Strategies	PEDIATRIC NEUROLOGY			English	Article							INTENSIVE-CARE-UNIT; NONCONVULSIVE STATUS EPILEPTICUS; HYPOTHERMIC CIRCULATORY ARREST; TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; NEONATAL SEIZURES; EEG; PREDICTORS	Continuous electroencephalographic monitoring often detects nonconvulsive seizures in critically ill children, but it is resource-intense and has not been demonstrated to improve outcomes. As institutions develop clinical pathways for monitoring, they should consider how seemingly minor variations may exert substantial impacts on resource utilization and cost. In our 1-month prospective observational study, each patient in a 45-bed pediatric intensive care unit was screened for potential monitoring indications. We screened 247 patients. Minor differences in monitoring indications would exert substantial impact on resource utilization. We then calculated the number of monitoring days required each month, based on two strategies that differed in monitoring duration. The prolonged-targeted and brief-targeted strategies would have required 106 and 33 monitoring days, respectively. Based on nonconvulsive seizure occurrence data, these strategies would detect 0.14, and 0.43 patients with seizures per monitoring day performed, respectively. A brief-targeted strategy provides a high yield for nonconvulsive seizure identification, but would fail to diagnose some patients with seizures. (C) 2012 Elsevier Inc. All rights reserved.	[Gutierrez-Colina, Ana M.; Dlugos, Dennis J.; Abend, Nicholas S.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Topjian, Alexis A.] Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care Med, Philadelphia, PA 19104 USA; [Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Abend, NS (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, 3501 Civ Ctr Blvd,Colket Translat Res Bldg,10th F, Philadelphia, PA 19104 USA.	abend@email.chop.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS049453]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS076550, K12NS049453] Funding Source: NIH RePORTER	N.S.A. received support from a National Institutes of Health Neurological Sciences Academic Development Award (NS049453).	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Alehan FK, 2001, J CHILD NEUROL, V16, P484, DOI 10.1177/088307380101600704; BELLINGER DC, 1995, NEW ENGL J MED, V332, P549, DOI 10.1056/NEJM199503023320901; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Chock VY, 2006, J PERINATOL, V26, P237, DOI 10.1038/sj.jp.7211459; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Clancy RR, 2005, EPILEPSIA, V46, P84, DOI 10.1111/j.0013-9580.2005.22504.x; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Gaynor JW, 2005, J THORAC CARDIOV SUR, V130, P1278, DOI 10.1016/j.jtcvs.2005.02.065; Helmers SL, 1997, ELECTROEN CLIN NEURO, V102, P27, DOI 10.1016/S0013-4694(96)95079-8; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506; McCoy B, 2011, EPILEPSIA, V52, P1973, DOI 10.1111/j.1528-1167.2011.03291.x; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pisani F, 2007, NEUROLOGY, V69, P2177, DOI 10.1212/01.wnl.0000295674.34193.9e; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; Young GB, 1996, NEUROLOGY, V47, P83	31	30	30	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAR	2012	46	3					158	161		10.1016/j.pediatrneurol.2011.12.009			4	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	902JU	WOS:000301035200004	22353290	Green Accepted			2021-06-18	
J	Rosi, S; Belarbi, K; Ferguson, RA; Fishman, K; Obenaus, A; Raber, J; Fike, JR				Rosi, Susanna; Belarbi, Karim; Ferguson, Ryan A.; Fishman, Kelly; Obenaus, Andre; Raber, Jacob; Fike, John R.			Trauma-induced alterations in cognition and Arc expression are reduced by previous exposure to 56Fe irradiation	HIPPOCAMPUS			English	Article						hippocampus; traumatic brain injury; immediate early gene; radiation	CENTRAL-NERVOUS-SYSTEM; RADIATION-INDUCED CHANGES; NEURAL PRECURSOR CELLS; EARLY GENE ARC; HIPPOCAMPAL NEUROGENESIS; BRAIN-INJURY; CRANIAL IRRADIATION; DENTATE GYRUS; ENVIRONMENTAL ENRICHMENT; ADULT NEUROGENESIS	Exposure to ionizing irradiation may affect brain functions directly, but may also change tissue sensitivity to a secondary insult such as trauma, stroke, or degenerative disease. To determine if a low dose of particulate irradiation sensitizes the brain to a subsequent injury, C56BL6 mice were exposed to brain only irradiation with 0.5 Gy of 56Fe ions. Two months later, unilateral traumatic brain injury was induced using a controlled cortical impact system. Three weeks after trauma, animals received multiple BrdU injections and 30 days later were tested for cognitive performance in the Morris water maze. All animals were able to locate the visible and hidden platform during training; however, treatment effects were seen when spatial memory retention was assessed in the probe trial (no platform). Although sham and irradiated animals showed spatial memory retention, mice that received trauma alone did not. When trauma was preceded by irradiation, performance in the water maze was not different from sham-treated animals, suggesting that low-dose irradiation had a protective effect in the context of a subsequent traumatic injury. Measures of hippocampal neurogenesis showed that combined injury did not induce any changes greater that those seen after trauma or radiation alone. After trauma, there was a significant decrease in the percentage of neurons expressing the behaviorally induced immediate early gene Arc in both hemispheres, without associated neuronal loss. After combined injury there were no differences relative to sham-treated mice. Our results suggest that combined injury resulted in decreased alterations of our endpoints compared to trauma alone. Although the underlying mechanisms are not yet known, these results resemble a preconditioning, adaptive, or inducible-like protective response, where a sublethal or potentially injurious stimulus (i.e., irradiation) induces tolerance to a subsequent and potentially more damaging insult (trauma). (c) 2010 Wiley Periodicals, Inc.	[Rosi, Susanna; Belarbi, Karim; Ferguson, Ryan A.; Fishman, Kelly; Fike, John R.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Rosi, Susanna; Belarbi, Karim; Ferguson, Ryan A.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94110 USA; [Rosi, Susanna; Fike, John R.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Obenaus, Andre] Loma Linda Univ, Dept Radiat Med, Loma Linda, CA 92350 USA; [Obenaus, Andre] Loma Linda Univ, Dept Radiol, Loma Linda, CA 92350 USA; [Obenaus, Andre] Loma Linda Univ, Dept Biophys & Bioengn, Loma Linda, CA 92350 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Div Neurosci ONPRC, Portland, OR 97201 USA; [Fike, John R.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94110 USA	Rosi, S (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Brain & Spinal Injury Ctr, 1001 Potrero Av, San Francisco, CA 94110 USA.	rosis@ptrehab.ucsf.edu	belarbi, karim/G-4467-2013; belarbi, karim/T-9461-2018	belarbi, karim/0000-0002-0027-1172	NASANational Aeronautics & Space Administration (NASA); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NNJ05HE33G, NNJ04HC90G, R01CA133216, R21AI080531]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA133216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21AI080531] Funding Source: NIH RePORTER	Grant sponsors: NASA, NIH; Grant numbers: NNJ05HE33G, NNJ04HC90G, R01CA133216, R21AI080531.	Abayomi OK, 1996, ACTA ONCOL, V35, P659, DOI 10.3109/02841869609083995; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Benice TS, 2006, NEUROSCIENCE, V137, P413, DOI 10.1016/j.neuroscience.2005.08.029; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; Cadet J, 2009, MOL NEUROBIOL, V39, P50, DOI 10.1007/s12035-009-8051-6; Cannon JR, 2006, BRAIN RES, V1116, P177, DOI 10.1016/j.brainres.2006.07.094; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Drew Michael R., 2007, CNS & Neurological Disorders-Drug Targets, V6, P205, DOI 10.2174/187152707780619353; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Fan Y, 2007, EUR J NEUROSCI, V25, P38, DOI 10.1111/j.1460-9568.2006.05269.x; Fike JR, 2007, NEUROSURG CLIN N AM, V18, P115, DOI 10.1016/j.nec.2006.10.010; Fike JR, 2009, SEMIN RADIAT ONCOL, V19, P122, DOI 10.1016/j.semradonc.2008.12.003; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Gouras Gunnar, 2006, Current Alzheimer Research, V3, P3, DOI 10.2174/156720506775697151; Guzowski JF, 2001, J NEUROSCI, V21, P5089, DOI 10.1523/JNEUROSCI.21-14-05089.2001; Guzowski JF, 1999, NAT NEUROSCI, V2, P1120, DOI 10.1038/16046; Guzowski JF, 2000, J NEUROSCI, V20, P3993; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Jones NM, 2008, PEDIATR RES, V63, P620, DOI 10.1203/PDR.0b013e31816d9117; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kirino T, 2002, J CEREBR BLOOD F MET, V22, P1283, DOI 10.1097/01.WCB.0000040942.89393.88; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu X, 2006, CANCER RES, V66, P1052, DOI 10.1158/0008-5472.CAN-05-3459; Mizumatsu S, 2003, CANCER RES, V63, P4021; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Obrenovitch TP, 2008, PHYSIOL REV, V88, P211, DOI 10.1152/physrev.00039.2006; Parent JM, 2002, EPILEPSY RES, V50, P179, DOI 10.1016/S0920-1211(02)00078-5; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Raber J, 2009, HIPPOCAMPUS IN PRESS; Ramirez-Amaya V, 2005, J NEUROSCI, V25, P1761, DOI 10.1523/JNEUROSCI.4342-04.2005; Ramirez-Amaya V, 2006, J NEUROSCI, V26, P12237, DOI 10.1523/JNEUROSCI.2195-06.2006; Rola R, 2005, RADIAT RES, V164, P556, DOI 10.1667/RR3412.1; Rola R, 2004, RADIAT RES, V162, P442, DOI 10.1667/RR3234; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Rola R, 2008, RADIAT RES, V169, P626, DOI 10.1667/RR1263.1; Rola R, 2007, FREE RADICAL BIO MED, V42, P1133, DOI 10.1016/j.freeradbiomed.2007.01.020; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; ROMAN DD, 1995, INT J RADIAT ONCOL, V31, P983, DOI 10.1016/0360-3016(94)00550-8; Rosi S, 2006, NEUROSCIENCE, V142, P1303, DOI 10.1016/j.neuroscience.2006.08.017; Rosi S, 2005, J NEUROSCI, V25, P723, DOI 10.1523/JNEUROSCI.4469-04.2005; Rosi S, 2009, BRAIN, V132, P2464, DOI 10.1093/brain/awp148; Rosi S, 2008, CANCER RES, V68, P9763, DOI 10.1158/0008-5472.CAN-08-1861; Shi L, 2006, RADIAT RES, V166, P892, DOI 10.1667/RR0588.1; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; SWANSON LW, 1978, J COMP NEUROL, V181, P681, DOI 10.1002/cne.901810402; Tofilon PJ, 2000, RADIAT RES, V153, P357, DOI 10.1667/0033-7587(2000)153[0357:TROTCN]2.0.CO;2; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Villasana L., 2008, Radiatsionnaya Biologiya Radioekologiya, V48, P167; Villasana L, 2006, RADIAT RES, V166, P883, DOI 10.1667/RR0642.1; Whishaw IQ, 1996, HIPPOCAMPUS, V6, P513, DOI 10.1002/(SICI)1098-1063(1996)6:5<513::AID-HIPO4>3.0.CO;2-J; Zeitlin C, 1998, RADIAT RES, V149, P560, DOI 10.2307/3579902	62	30	31	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1050-9631			HIPPOCAMPUS	Hippocampus	MAR	2012	22	3					544	554		10.1002/hipo.20920			11	Neurosciences	Neurosciences & Neurology	897VJ	WOS:000300686900015	21192069	Green Accepted			2021-06-18	
J	Dawish, H; Mahmood, A; Schallert, T; Chopp, M; Therrien, B				Dawish, Hala; Mahmood, Asim; Schallert, Timothy; Chopp, Michael; Therrien, Barbara			Mild traumatic brain injury (MTBI) leads to spatial learning deficits	BRAIN INJURY			English	Article						Hippocampus; synaptophysin; Morris water maze	CONTROLLED CORTICAL IMPACT; HEAD-INJURY; WORKING-MEMORY; AXONAL INJURY; TERM-MEMORY; RATS; HIPPOCAMPUS; ACQUISITION; CONSEQUENCES; ATORVASTATIN	Primary objective: The aim of this study was to investigate the effect of mild and severe TBI on young male Wistar rats' spatial learning. Research design: Randomized repeated measure experimental design was used to examine spatial learning in three independent animal groups. Methods and procedures: Twenty-four (severe n = 9, mild n = 8, sham n = 7) male rats were included in the study. Animals received controlled mild (1.5 mm), severe (2.5 mm) cortical impact injury or sham surgery. Spatial learning was assessed daily using a modified Morris water maze test, 20 days post-trauma, for 5 consecutive days. Percentage time travelled within each quadrant and escape latency were calculated. All animals' hippocampal brain regions were examined post-injury using neuron (MAP2) and pre-synaptic protein (Synaptophysin) biomarkers. Main outcomes and results: It took the animals with mild injury until day 3 to reach the platform; and animals with mild and severe injury spent significantly less time in the target quadrant than the sham. The hippocampal neuron numbers differed proportionately between animals with severe and mild injury, but the percentage of synaptophysin density was significantly less in the dentate gyrus of both animals with mild and severe injury than sham group. Conclusion: Persistent spatial learning deficits exist after mild TBI; these deficits appear equivalent to deficits exhibited after a more severe injury.	[Dawish, Hala] Amer Univ Beirut, Fac Med, Sch Nursing, New York, NY 10017 USA; [Mahmood, Asim; Chopp, Michael] Henry Ford Hlth Syst, Detroit, MI USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Therrien, Barbara] Univ Michigan, Med Surg Nursing Dept, Ann Arbor, MI 48109 USA	Dawish, H (corresponding author), Amer Univ Beirut, Fac Med, Sch Nursing, 3 Dag Hammerskjold Plaza,8th Floor, New York, NY 10017 USA.	hd30@aub.edu.lb		Darwish, Hala/0000-0001-5744-6466	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 NS042345, RO1 NS04225905, RO1 NS 05228001, T32 NR 007074, F31 NR009741]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31NR009741, T32NR007074] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS042345, R01 NS04225905, R01 NS 05228001] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32 NR007074, F31 NR009741, T32 NR 007074] Funding Source: Medline	This work was conducted at Henry Ford Hospital and funded from the National Institutes of Health P01 NS042345, RO1 NS04225905, RO1 NS 05228001, T32 NR 007074 and F31 NR009741. The authors report no conflicts of interest.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Aubry M, 2002, BRIT J SPORT MED, V36, P888; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bonanomi D, 2007, BIOCHEM J, V404, P525, DOI 10.1042/BJ20061907; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chin-Cheng Y, 2007, J TRAUMA, V62, P657; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002; Clark RE, 2005, HIPPOCAMPUS, V15, P260, DOI 10.1002/hipo.20056; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fontaine-Lenoir V, 2006, P NATL ACAD SCI USA, V103, P4711, DOI 10.1073/pnas.0600113103; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hartley T, 2007, HIPPOCAMPUS, V17, P34, DOI 10.1002/hipo.20240; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lee I, 2003, BEHAV NEUROSCI, V117, P1044, DOI 10.1037/0735-7044.117.5.1044; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Ludin A, 2006, BRAIN INJURY, V20, P799; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Martin SJ, 2007, CELL MOL LIFE SCI, V64, P401, DOI 10.1007/s00018-007-6336-3; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Ramirez-Amaya V, 2001, J NEUROSCI, V21, P7340; Rekart JL, 2007, LEARN MEMORY, V14, P416, DOI 10.1101/lm.516507; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shrager Y, 2007, P NATL ACAD SCI USA, V104, P2961, DOI 10.1073/pnas.0611233104; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Swanson KL, 1999, LITTER LINGERIE ILL, P13; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Umile EM, 1998, BRAIN INJURY, V12, P577; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Whiting MD, 2006, J NEUROTRAUM, V23, P1529, DOI 10.1089/neu.2006.23.1529; Zec RF, 2001, J CLIN EXP NEUROPSYC, V23, P671, DOI 10.1076/jcen.23.5.671.1247	48	30	30	0	5	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2012	26	2					151	165		10.3109/02699052.2011.635362			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	897NP	WOS:000300658200004	22360521	Green Accepted			2021-06-18	
